subgraph_triples,perturbed_subgraph_triples,perturbation_log,similarity,subgraph_hash,perturbed_subgraph_hash,original_response,perturbed_response
"[{'source_node': {'name': 'tpmpa'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'gamma-aminobutyric acid receptor subunit rho-1'}}, {'source_node': {'name': 'tpmpa'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'gamma-aminobutyric acid receptor subunit rho-2'}}, {'source_node': {'name': 'tpmpa'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'gamma-aminobutyric acid receptor subunit rho-3'}}, {'source_node': {'name': 'gamma-aminobutyric acid receptor subunit rho-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GABRR1'}}]","[{'source_node': {'name': 'gamma-aminobutyric acid receptor subunit rho-2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GABRR1'}}, {'source_node': {'name': 'tpmpa'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'gamma-aminobutyric acid receptor subunit rho-2'}}, {'source_node': {'name': 'tpmpa'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'gamma-aminobutyric acid receptor subunit rho-3'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:1721', 'target': 'GENE:27637', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'PROTEIN:1137', 'target': None, 'metadata': {'node_id': '1137', 'node_type': 'PROTEIN', 'display_name': 'gamma-aminobutyric acid receptor subunit rho-1'}}]",0.6666666666666667,5121e9fb73a7411c6c92411123052d21,3ddd7a3f9d72c57c963cc18d2780a6cc,"['The drug TPMPA targets three different subunits of the gamma-aminobutyric acid receptor, specifically the gamma-aminobutyric acid receptor subunit rho-1, subunit rho-2, and subunit rho-3. It is interesting to note that the subunit rho-1 is actually a gene product of GABRR1.', ""The compound TPMPA has several targets including gamma-aminobutyric acid receptor subunit rho-1, gamma-aminobutyric acid receptor subunit rho-2, and gamma-aminobutyric acid receptor subunit rho-3. It's worth noting that gamma-aminobutyric acid receptor subunit rho-1 is a gene product of GABRR1."", 'The drug TPMPA targets several subunits of the gamma-aminobutyric acid receptor such as the gamma-aminobutyric acid receptor subunit rho-1, subunit rho-2, and subunit rho-3. Among these, the gamma-aminobutyric acid receptor subunit rho-1 is a gene product of GABRR1.', 'The drug TPMPA has several targets, including the gamma-aminobutyric acid receptor subunit rho-1, rho-2, and rho-3. The gamma-aminobutyric acid receptor subunit rho-1 is a gene product of GABRR1.', 'The drug TPMPA has multiple targets which include: gamma-aminobutyric acid receptor subunit rho-1, gamma-aminobutyric acid receptor subunit rho-2, and gamma-aminobutyric acid receptor subunit rho-3. Interestingly, the gamma-aminobutyric acid receptor subunit rho-1 is a gene product of GABRR1.']","['The drug Tpmpa exerts its effect by targeting gamma-aminobutyric acid receptor subunit rho-2 and gamma-aminobutyric acid receptor subunit rho-3. Interestingly, the gamma-aminobutyric acid receptor subunit rho-2 is a gene product of GABRR1. Hence, there exists a clear and crucial connection between the drug Tpmpa, receptor subunits and the gene GABRR1.', 'The compound TPMPA targets both the gamma-aminobutyric acid receptor subunit rho-2 and rho-3. Interestingly, the gamma-aminobutyric acid receptor subunit rho-2 is a gene product of GABRR1.', 'The gamma-aminobutyric acid receptor subunit rho-2 is the gene product of GABRR1. This receptor protein becomes a target for the drug TPMPA. Meanwhile, TPMPA also targets another protein, the gamma-aminobutyric acid receptor subunit rho-3. Thus, TPMPA plays a role in modulating the functions of these two important receptor proteins in the nervous system.', 'The gamma-aminobutyric acid receptor subunit rho-2 is a gene product of GABRR1. The drug TPMPA targets this receptor alongside another potential target, gamma-aminobutyric acid receptor subunit rho-3.', 'The drug TPMPA, targets the gamma-aminobutyric acid receptor subunit rho-2 and gamma-aminobutyric acid receptor subunit rho-3, with the former being a gene product of GABRR1.']"
"[{'source_node': {'name': 'mu-type opioid receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'OPRM1'}}, {'source_node': {'name': 'v1003'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kappa-type opioid receptor'}}, {'source_node': {'name': 'v1003'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mu-type opioid receptor'}}, {'source_node': {'name': 'OPRM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Peptide ligand-binding receptors'}}, {'source_node': {'name': 'kappa-type opioid receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'OPRK1'}}]","[{'source_node': {'name': 'mu-type opioid receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'OPRM1'}}, {'source_node': {'name': 'v1003'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kappa-type opioid receptor'}}, {'source_node': {'name': 'v1003'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mu-type opioid receptor'}}, {'source_node': {'name': 'v1003'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'OPRM1'}}, {'source_node': {'name': 'OPRM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Peptide ligand-binding receptors'}}, {'source_node': {'name': 'kappa-type opioid receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'OPRK1'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:4735', 'target': 'GENE:30403', 'metadata': {'predicate': 'is_affecting'}}]",0.9090909090909092,278395f6cfb73252a6aa2cc9c5d0f4cb,492bd7bde0313b85ef379ee8b2786b70,"['The mu-type opioid receptor is a gene product of OPRM1. It, along with the kappa-type opioid receptor which is a gene product of OPRK1, are targeted by the drug v1003. OPRM1 is known to act within the pathway of peptide ligand-binding receptors.', 'The drug v1003 targets two specific opioid receptors, namely the kappa-type opioid receptor and the mu-type opioid receptor. Interestingly, these two receptors are gene products of OPRK1 and OPRM1 respectively. The OPRM1 gene, in particular, also acts within the context of peptide ligand-binding receptors.']",[]
"[{'source_node': {'name': 'betibeglogene autotemcel'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'alpha globin'}}, {'source_node': {'name': 'betibeglogene autotemcel'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hydroxyurea'}}, {'source_node': {'name': 'betibeglogene autotemcel'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ibalizumab'}}, {'source_node': {'name': 'hydroxyurea'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Neoplasms'}}, {'source_node': {'name': 'hydroxyurea'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Rash maculo-papular'}}]","[{'source_node': {'name': 'betibeglogene autotemcel'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'alpha globin'}}, {'source_node': {'name': 'hydroxyurea'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Neoplasms'}}, {'source_node': {'name': 'hydroxyurea'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Rash maculo-papular'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:13931', 'target': 'COMPOUND:988', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:10582', 'target': None, 'metadata': {'node_id': '10582', 'node_type': 'COMPOUND', 'display_name': 'ibalizumab'}}]",0.7272727272727273,fef1e94ffb42ba7d445e6f3eee2a84da,c577778ef8eb891e933ee03b34c37680,"['Betibeglogene autotemcel, a therapeutic agent, has an affinity towards the alpha globin protein. This molecule interestingly displays the impact of lessening the effectiveness of hydroxyurea and ibalizumab. Hydroxyurea, a drug with wide implications in the medical field, is primarily indicated for treating various types of Neoplasms. However, side effects can occur with the use of hydroxyurea. Among them, the occurrence of a Rash maculo-papular, a skin condition characterized by raised lesions, is notable.', 'The drug betibeglogene autotemcel targets alpha globin and is known to decrease the efficacy of hydroxyurea and ibalizumab. On one hand, hydroxyurea is commonly indicated for the treatment of Neoplasms. However, it should be noted that a significant side effect of using hydroxyurea is the occurrence of a maculo-papular rash. Hence, the interaction between betibeglogene autotemcel and these other drugs and indications ought to be considered when making therapeutic decisions.', 'The drug betibeglogene autotemcel targets alpha globin and is known to decrease the efficacy of both hydroxyurea and ibalizumab. Hydroxyurea is often indicated for the treatment of neoplasms but can have side effects such as a maculo-papular rash.', 'The drug Betibeglogene Autotemcel targets alpha globin and has been observed to decrease the efficacy of both Hydroxyurea and Ibalizumab. Hydroxyurea, other than its noted indication for treating Neoplasms, has a known side effect which includes developing a rash maculo-papular.', 'The drug Betibeglogene Autotemcel targets Alpha Globin and appears to decrease the efficacy of certain other drugs, including Hydroxyurea and Ibalizumab. Interestingly, Hydroxyurea is typically indicated for the treatment of various neoplasms, but it comes with potential side effects such as a maculo-papular rash. This interconnected web of relationships provides valuable insights into possible drug interactions and side effects.']","['The drug betibeglogene autotemcel targets alpha globin. On the other hand, hydroxyurea, a medication known for its therapeutic indications in treating Neoplasms may have side effects such as causing a rash maculo-papular to occur in some patients.', 'The drug betibeglogene autotemcel specifically targets alpha globin. Additionally, hydroxyurea is a medication that is indicated for various Neoplasms. One of the known side effects of hydroxyurea is the development of a maculo-papular rash.', 'The drug Betibeglogene Autotemcel targets alpha globin, aiding in the management of related genetic disorders. In contrast, Hydroxyurea has an indication for Neoplasms. While Hydroxyurea is effective, it may have side effects, including Rash Maculo-Papular, which must be managed carefully.', 'The drug betibeglogene autotemcel notably has alpha globin as its target. On a related note, another drug, hydroxyurea, has been indicated for the treatment of Neoplasms. However, one must be cautious as the use of hydroxyurea may have a side effect causing a condition known as rash maculo-papular.']"
"[{'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15B'}}, {'source_node': {'name': 'lysine-specific demethylase 4a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KDM4A'}}, {'source_node': {'name': 'dibenzoylmethane'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arachidonate 15-lipoxygenase'}}, {'source_node': {'name': 'dibenzoylmethane'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lysine-specific demethylase 4a'}}, {'source_node': {'name': 'dibenzoylmethane'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'transcription factor ap-1'}}]","[{'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': 'lysine-specific demethylase 4a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KDM4A'}}, {'source_node': {'name': 'lysine-specific demethylase 4a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': 'dibenzoylmethane'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lysine-specific demethylase 4a'}}, {'source_node': {'name': 'dibenzoylmethane'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'transcription factor ap-1'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:47064', 'target': 'PROTEIN:2703', 'metadata': None}, {'type': 'edge_addition', 'source': 'PROTEIN:860', 'target': 'GENE:27539', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'GENE:27539', 'target': None, 'metadata': {'node_id': '27539', 'node_type': 'GENE', 'display_name': 'ALOX15B'}}, {'type': 'edge_addition', 'source': 'PROTEIN:6193', 'target': 'GENE:27532', 'metadata': {'predicate': 'gene_product_of'}}]",0.6923076923076923,74ce18a7fb6ad45ead5fbf87c3037a0d,8c3087ba84a75189fc1a6e0c29e02c2b,"['The compound dibenzoylmethane targets several biological entities including arachidonate 15-lipoxygenase and lysine-specific demethylase 4a, as well as the transcription factor ap-1. Arachidonate 15-lipoxygenase is a gene product of both ALOX15 and ALOX15B. Furthermore, lysine-specific demethylase 4a is produced by the KDM4A gene.', 'Arachidonate 15-lipoxygenase is the gene product of ALOX15, as well as ALOX15B, which implicates a significant relationship between these genes and their product. Similarly, lysine-specific demethylase 4a is the gene product of KDM4A, demonstrating a crucial gene-product link for this enzyme. The compound Dibenzoylmethane plays an important role in this biological network by targeting not only arachidonate 15-lipoxygenase and lysine-specific demethylase 4a but also the transcription factor AP-1. These targets suggest potential pathways through which Dibenzoylmethane may exert its biological effects.', 'The drug dibenzoylmethane targets several entities including arachidonate 15-lipoxygenase and lysine-specific demethylase 4a. Interestingly, arachidonate 15-lipoxygenase is the gene product of both ALOX15 and ALOX15B. Similarly, lysine-specific demethylase 4a is the gene product of KDM4A. In addition to these targets, dibenzoylmethane also interacts with the transcription factor ap-1.', 'Arachidonate 15-lipoxygenase is a gene product of both ALOX15 and ALOX15B, and similarly, lysine-specific demethylase 4a is a gene product of KDM4A. Dibenzoylmethane, a potent compound, targets several biomolecules including arachidonate 15-lipoxygenase, lysine-specific demethylase 4a, and the transcription factor ap-1. The latter is known for its integral role in cellular functions and development.', 'Arachidonate 15-lipoxygenase is a gene product of ALOX15 and ALOX15B, whereas Lysine-specific demethylase 4a is a gene product of KDM4A. The drug Dibenzoylmethane targets several proteins, including Arachidonate 15-lipoxygenase and Lysine-specific demethylase 4a, as well as the Transcription factor AP-1.']","['Arachidonate 15-lipoxygenase and lysine-specific demethylase 4a are both gene products of ALOX15. The latter is also a gene product of KDM4A. The substance dibenzoylmethane has several targets including lysine-specific demethylase 4a and the transcription factor ap-1.', 'The enzyme Arachidonate 15-lipoxygenase is a gene product of ALOX15, whereas Lysine-specific demethylase 4a is a gene product of both ALOX15 and KDM4A. The drug Dibenzoylmethane targets both Lysine-specific demethylase 4a and the Transcription factor AP-1. This reveals a complex interplay between these drugs, enzymes and their corresponding genes.', 'The enzymes arachidonate 15-lipoxygenase and lysine-specific demethylase 4a are gene products of the genes ALOX15 and KDM4A respectively. It is notable, however, that lysine-specific demethylase 4a is also a gene product of ALOX15. The compound dibenzoylmethane, on the other hand, interacts with lysine-specific demethylase 4a and transcription factor AP-1 as its targets. Therefore, both enzymes and factors influence various cellular mechanisms, and studying these interactions may yield insights into drug discovery and development processes.', 'The enzymes arachidonate 15-lipoxygenase and lysine-specific demethylase 4a are gene products of ALOX15 and KDM4A respectively. Interestingly, lysine-specific demethylase 4a is also a gene product of ALOX15. The compound dibenzoylmethane has certain targets in the body, these include lysine-specific demethylase 4a and transcription factor ap-1.', 'Arachidonate 15-lipoxygenase is a gene product of ALOX15, and similarly, lysine-specific demethylase 4a is a gene product of both KDM4A and ALOX15. The drug dibenzoylmethane targets lysine-specific demethylase 4a as well as transcription factor AP-1. This indicates a complex interaction between these entities at the genetic and molecular level where ALOX15 and KDM4A are coding for enzymes that are then targeted by dibenzoylmethane, suggesting potential pharmacological implications. It also highlights the dual role of the lysine-specific demethylase 4a enzyme in this process.']"
"[{'source_node': {'name': 'TPM2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'nemaline myopathy 4'}}, {'source_node': {'name': 'TPM2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'childhood-onset nemaline myopathy'}}, {'source_node': {'name': 'TPM2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'myopathy'}}, {'source_node': {'name': 'nemaline myopathy 4'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'facial diplegia'}}, {'source_node': {'name': 'childhood-onset nemaline myopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'scapular winging'}}, {'source_node': {'name': 'childhood-onset nemaline myopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'feeding difficulties'}}, {'source_node': {'name': 'childhood-onset nemaline myopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'polyhydramnios'}}]","[{'source_node': {'name': 'TPM2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'nemaline myopathy 4'}}, {'source_node': {'name': 'TPM2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'childhood-onset nemaline myopathy'}}, {'source_node': {'name': 'TPM2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'myopathy'}}, {'source_node': {'name': 'nemaline myopathy 4'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'facial diplegia'}}, {'source_node': {'name': 'childhood-onset nemaline myopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'scapular winging'}}, {'source_node': {'name': 'childhood-onset nemaline myopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'feeding difficulties'}}, {'source_node': {'name': 'childhood-onset nemaline myopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'facial diplegia'}}]","[{'type': 'edge_addition', 'source': 'DISEASE:3679', 'target': 'PHENOTYPE:1022', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:1145', 'target': None, 'metadata': {'node_id': '1145', 'node_type': 'PHENOTYPE', 'display_name': 'polyhydramnios'}}]",0.8,1f9a9bcd8c62517da2b98cd752f13b45,3d0be7eca3d1294b51df600618380ae0,"['The gene TPM2 triggers several conditions, such as nemaline myopathy 4, childhood-onset nemaline myopathy, and myopathy. Nemaline myopathy 4 exhibits symptoms like facial diplegia. On the other hand, childhood-onset nemaline myopathy is characterized by scapular winging, difficulties in feeding, and polyhydramnios.', 'The gene TPM2 is implicated in several health conditions. It is known to cause nemaline myopathy 4, childhood-onset nemaline myopathy and other forms of myopathy. Notably, these conditions each present specific symptoms. Nemaline myopathy 4 is characterized by facial diplegia. Childhood-onset nemaline myopathy often demonstrates symptoms including scapular winging and feeding difficulties and is often diagnosed in the presence of polyhydramnios. Each of these complex conditions and their associated phenotypes can be traced back to the causative gene, TPM2.', 'The gene TPM2 is known to cause several conditions, including Nemaline Myopathy 4, Childhood-Onset Nemaline Myopathy, and simply Myopathy. Nemaline Myopathy 4 is characterized by the specific phenotype of facial diplegia. Likewise, Childhood-Onset Nemaline Myopathy has several distinctive phenotypes associated with it. These include scapular winging, feeding difficulties, and polyhydramnios which refers to an excessive amount of amniotic fluid around a baby in the womb.', 'The gene TPM2 causes several conditions such as nemaline myopathy 4, childhood-onset nemaline myopathy, and myopathy. Nemaline myopathy 4 exhibits phenotypes like facial diplegia. The childhood-onset nemaline myopathy, on the other hand, manifests symptoms including scapular winging, feeding difficulties, and polyhydramnios.', 'The gene TPM2 is known to cause several conditions including nemaline myopathy 4, childhood-onset nemaline myopathy, and myopathy. Nemaline myopathy 4 is characterized by symptoms such as facial diplegia. On the other hand, childhood-onset nemaline myopathy leads to multiple physiological changes, such as scapular winging, feeding difficulties, and conditions such as polyhydramnios.']","['The gene TPM2 is associated with causing several conditions, including nemaline myopathy 4, childhood-onset nemaline myopathy, and myopathy. Nemaline myopathy 4 manifests a phenotype of facial diplegia. On the other hand, childhood-onset nemaline myopathy exhibits multiple phenotypes including scapular winging, feeding difficulties, and facial diplegia.', 'The gene TPM2 is known to cause several conditions, including nemaline myopathy 4, childhood-onset nemaline myopathy, and myopathy. Specifically, nemaline myopathy 4 is characterized by symptoms such as facial diplegia. Similarly, childhood-onset nemaline myopathy is associated with a range of symptoms including scapular winging, feeding difficulties, and facial diplegia.', 'The gene TPM2 is known to cause various conditions such as nemaline myopathy 4, childhood-onset nemaline myopathy, and myopathy. Specifically, nemaline myopathy 4 is characterized by the phenotype of facial diplegia. Likewise, childhood-onset nemaline myopathy presents symptoms such as scapular winging, feeding difficulties, and facial diplegia.', 'The gene TPM2 is known to cause various conditions including nemaline myopathy 4, childhood-onset nemaline myopathy, and a generic myopathy. Each of these conditions exhibits specific phenotypes. For example, nemaline myopathy 4 might exhibit a phenotype named facial diplegia. On the other hand, one suffering from childhood-onset nemaline myopathy might experience a range of symptoms including scapular winging, feeding difficulties, and facial diplegia.', 'The gene TPM2 has shown to cause multiple conditions, including nemaline myopathy 4, childhood-onset nemaline myopathy, and a more generalized form of myopathy. Nemaline myopathy 4 specifically has the phenotype of facial diplegia, a condition characterised by symmetrical paralysis affecting the facial muscles. \n\nOn the other hand, childhood-onset nemaline myopathy has multiple phenotypes, such as scapular winging, feeding difficulties, and once again, facial diplegia. Scapular winging is a condition in which the shoulder blades stick out from the back, while feeding difficulties in children have a range of implications including reduced weight and delayed development. As with nemaline myopathy 4, childhood-onset nemaline myopathy involves facial diplegia as well, indicating a potential cross-link between these two conditions in the involvement of TPM2.']"
"[{'source_node': {'name': 'artepillin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hop-92'}}, {'source_node': {'name': 'artepillin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'snb-19'}}]","[{'source_node': {'name': 'artepillin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hop-92'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5632', 'target': None, 'metadata': {'node_id': '5632', 'node_type': 'PROTEIN', 'display_name': 'snb-19'}}]",0.6,5f555d0f8a51c5be53574567c4d60439,a5ee86b289b15d4d18bb3e4feb9bc511,"['Artepillin, a specific compound, targets two different elements; HOP-92 and SNB-19.', 'Artepillin, a compound with several biological activities, is known to target multiple proteins, such as HOP-92 and SNB-19. This interaction helps further elucidate its mode of action and potential therapeutic uses.', 'Artepillin, a compound known for its medicinal properties, targets two distinct proteins called HOP-92 and SNB-19.', 'The compound artepillin targets two proteins, HOP-92 and SNB-19.', 'The compound artepillin has been identified to target both HOP-92 and SNB-19.']","['The compound artepillin has been identified to target the protein hop-92.', 'Artepillin has a target known as hop-92.']"
"[{'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR1'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': 'ESR1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ovarian tumor domain proteases'}}, {'source_node': {'name': 'ligustrazine hydrochloride'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'estrogen receptor alpha'}}]","[{'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR1'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': 'ESR1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ovarian tumor domain proteases'}}, {'source_node': {'name': 'ligustrazine hydrochloride'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'estrogen receptor alpha'}}, {'source_node': {'name': 'ligustrazine hydrochloride'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'VHL'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:38852', 'target': 'GENE:33509', 'metadata': {'predicate': 'is_affecting'}}]",0.8888888888888888,6dbf380cfcfbe870caab58a06a401a1c,5d8b4a7ebb997c6dd2baafce264b2422,"['The drug ligustrazine hydrochloride targets estrogen receptor alpha, a protein which is a gene product of both ESR1 and VHL. In particular, ESR1 is known to act within the pathway of ovarian tumor domain proteases.', 'The compound ligustrazine hydrochloride targets estrogen receptor alpha, which is a gene product of both ESR1 and VHL. Particularly, ESR1 acts within the pathway of ovarian tumor domain proteases.', 'The drug Ligustrazine Hydrochloride targets the Estrogen Receptor Alpha which is a gene product of both ESR1 and VHL. Notably, ESR1 itself acts within the pathway of Ovarian tumor domain proteases that may play a key role in tumorigenesis and cancer progression.']","['Estrogen receptor alpha is a gene product of both ESR1 and VHL. The drug ligustrazine hydrochloride targets this estrogen receptor alpha and is known to affect VHL. Additionally, ESR1, the gene that produces this receptor, acts within the pathway of ovarian tumor domain proteases.', 'Estrogen receptor alpha is a key gene product of ESR1 and VHL. When it comes to involvement in cellular processes, ESR1 features prominently by acting within the ovarian tumor domain proteases. The drug ligustrazine hydrochloride targets the estrogen receptor alpha, exerting its effects. Notably, ligustrazine hydrochloride also affects VHL.', 'Estrogen receptor alpha is a gene product of the genes ESR1 and VHL. ESR1, in particular, acts within the functional context of ovarian tumor domain proteases. Ligustrazine hydrochloride, a type of medicinal compound, targets the estrogen receptor alpha and is also known to affect the gene VHL.']"
"[{'source_node': {'name': 'ornithine carbamoyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'OTC'}}, {'source_node': {'name': 'n-(phosphonoacetyl)-l-ornithine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ornithine carbamoyltransferase'}}, {'source_node': {'name': 'OTC'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'ornithine transcarbamylase deficiency'}}, {'source_node': {'name': 'OTC'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Mitochondrial protein import'}}, {'source_node': {'name': 'OTC'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Urea cycle'}}]","[{'source_node': {'name': 'ornithine carbamoyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'OTC'}}, {'source_node': {'name': 'OTC'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'ornithine transcarbamylase deficiency'}}, {'source_node': {'name': 'OTC'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Mitochondrial protein import'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:326', 'target': None, 'metadata': {'node_id': '326', 'node_type': 'PATHWAY', 'display_name': 'Urea cycle'}}, {'type': 'node_removal', 'source': 'COMPOUND:1907', 'target': None, 'metadata': {'node_id': '1907', 'node_type': 'COMPOUND', 'display_name': 'n-(phosphonoacetyl)-l-ornithine'}}]",0.6363636363636364,49537fa673b61455525e75956b8257be,e0b926ae230a0f8e685b46594daecea1,"['The enzyme ornithine carbamoyltransferase is a gene product of OTC. This enzyme is the target of the drug n-(phosphonoacetyl)-l-ornithine. The gene OTC has roles within several biological processes, namely mitochondrial protein import and the urea cycle. Additionally, abnormalities in OTC can cause a medical condition known as ornithine transcarbamylase deficiency.', 'Ornithine carbamoyltransferase is the gene product of OTC. The drug, N-(phosphonoacetyl)-L-ornithine, targets ornithine carbamoyltransferase. OTC is associated with causing a condition known as ornithine transcarbamylase deficiency. Additionally, OTC operates within several biological pathways, including the mitochondrial protein import and urea cycle pathways.', 'Ornithine carbamoyltransferase is a product of the gene OTC and is targeted by the compound n-(phosphonoacetyl)-l-ornithine. OTC plays a crucial role in two biological processes, namely mitochondrial protein import and the urea cycle. Furthermore, any mutation or dysfunction in the OTC gene is known to cause a medical condition called ornithine transcarbamylase deficiency.', 'The enzyme ornithine carbamoyltransferase is a gene product of OTC. This OTC gene is known to act within a couple of essential pathways such as mitochondrial protein import and urea cycle. Furthermore, abnormalities in OTC can often lead to a condition called ornithine transcarbamylase deficiency. The compound N-(phosphonoacetyl)-L-ornithine specifically targets the enzyme ornithine carbamoyltransferase.', 'Ornithine carbamoyltransferase is a gene product of OTC, a gene that plays a role within the Urea cycle and the process of Mitochondrial protein import. Notably, when malfunctions occur in the OTC gene, it could lead to the condition known as ornithine transcarbamylase deficiency. Furthermore, evidence shows that the compound known as n-(phosphonoacetyl)-l-ornithine targets ornithine carbamoyltransferase, which provides valuable insights into the functions and implications of these biological entities.']","['Ornithine carbamoyltransferase is a gene product of OTC. This OTC gene not only causes a condition known as ornithine transcarbamylase deficiency but also operates within the pathway of mitochondrial protein import.', 'The enzyme ornithine carbamoyltransferase is a gene product of OTC, which acts within a process called mitochondrial protein import. Abnormal function of OTC has been linked to the cause of a metabolic disorder known as ornithine transcarbamylase deficiency.', 'The enzyme ornithine carbamoyltransferase is a gene product of OTC. Mutations in the OTC gene are known to cause a condition known as ornithine transcarbamylase deficiency. Furthermore, OTC acts within the process of mitochondrial protein import.']"
"[{'source_node': {'name': 'azimilide'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the arrhythmogenic activities '}}, {'source_node': {'name': 'azimilide'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'azimilide'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' bradycardia '}}]","[{'source_node': {'name': 'azimilide'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' bradycardia '}}]","[{'type': 'node_removal', 'source': 'EFFECT:5', 'target': None, 'metadata': {'node_id': '5', 'node_type': 'EFFECT', 'display_name': ' adverse effects '}}, {'type': 'node_removal', 'source': 'ACTIVITY:46', 'target': None, 'metadata': {'node_id': '46', 'node_type': 'ACTIVITY', 'display_name': ' the arrhythmogenic activities '}}]",0.4285714285714286,b0d73895d0a5c69f0239beacc477e94d,9cf85aa95727edd7f30b102e88d5c4bb,[],[]
"[{'source_node': {'name': 'tamirin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'transcription factor p65'}}, {'source_node': {'name': 'ependymoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'distal muscle weakness'}}, {'source_node': {'name': 'ependymoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'dysesthesia'}}, {'source_node': {'name': 'ependymoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'neoplasm of the lung'}}, {'source_node': {'name': 'RELA'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'mucocutaneous ulceration'}}, {'source_node': {'name': 'RELA'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'ependymoma'}}, {'source_node': {'name': 'RELA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Senescence-Associated Secretory Phenotype (SASP)'}}, {'source_node': {'name': 'transcription factor p65'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RELA'}}]","[{'source_node': {'name': 'tamirin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'transcription factor p65'}}, {'source_node': {'name': 'tamirin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'RELA'}}, {'source_node': {'name': 'ependymoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'distal muscle weakness'}}, {'source_node': {'name': 'ependymoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'neoplasm of the lung'}}, {'source_node': {'name': 'RELA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Senescence-Associated Secretory Phenotype (SASP)'}}, {'source_node': {'name': 'transcription factor p65'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RELA'}}, {'source_node': {'name': 'mucocutaneous ulceration'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'distal muscle weakness'}}, {'source_node': {'name': 'mucocutaneous ulceration'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'neoplasm of the lung'}}]","[{'type': 'edge_addition', 'source': 'DISEASE:17185', 'target': 'PHENOTYPE:1786', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_deletion', 'source': 'GENE:32288', 'target': 'DISEASE:5498', 'metadata': None}, {'type': 'node_removal', 'source': 'PHENOTYPE:8919', 'target': None, 'metadata': {'node_id': '8919', 'node_type': 'PHENOTYPE', 'display_name': 'dysesthesia'}}, {'type': 'edge_addition', 'source': 'COMPOUND:88644', 'target': 'GENE:32288', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'DISEASE:17185', 'target': 'PHENOTYPE:10976', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_deletion', 'source': 'GENE:32288', 'target': 'DISEASE:17185', 'metadata': None}]",0.5882352941176471,91778050146c5ae10f17fbb5189c8e74,09ca0cbe374ea3e58846c0a605275af4,[],[]
"[{'source_node': {'name': 'CXCR1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Chemokine receptors bind chemokines'}}, {'source_node': {'name': 'CXCR1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (i) signalling events'}}, {'source_node': {'name': 'CXCR1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}, {'source_node': {'name': 'c-x-c chemokine receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CXCR1'}}]","[{'source_node': {'name': 'CXCR1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (i) signalling events'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:3', 'target': None, 'metadata': {'node_id': '3', 'node_type': 'PATHWAY', 'display_name': 'Neutrophil degranulation'}}, {'type': 'node_removal', 'source': 'PROTEIN:1527', 'target': None, 'metadata': {'node_id': '1527', 'node_type': 'PROTEIN', 'display_name': 'c-x-c chemokine receptor type 1'}}, {'type': 'node_removal', 'source': 'PATHWAY:707', 'target': None, 'metadata': {'node_id': '707', 'node_type': 'PATHWAY', 'display_name': 'Chemokine receptors bind chemokines'}}]",0.3333333333333333,c69a09a377f0611b301f210911782c54,b4602ef33f6e9a8611b1e967afa758c9,[],['The gene CXCR1 operates within the context of G alpha (i) signalling events.']
"[{'source_node': {'name': 'enzalutamide'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' methemoglobinemia '}}, {'source_node': {'name': 'enzalutamide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'finerenone'}}, {'source_node': {'name': 'enzalutamide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'olutasidenib'}}, {'source_node': {'name': 'finerenone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'meptazinol'}}]","[{'source_node': {'name': 'meptazinol'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' methemoglobinemia '}}, {'source_node': {'name': 'enzalutamide'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' methemoglobinemia '}}, {'source_node': {'name': 'enzalutamide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'finerenone'}}, {'source_node': {'name': 'enzalutamide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'meptazinol'}}, {'source_node': {'name': 'finerenone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'meptazinol'}}, {'source_node': {'name': 'finerenone'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' methemoglobinemia '}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:7851', 'target': 'COMPOUND:11330', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:13586', 'target': None, 'metadata': {'node_id': '13586', 'node_type': 'COMPOUND', 'display_name': 'olutasidenib'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11330', 'target': 'EFFECT:8', 'metadata': {'predicate': 'increase_effect'}}, {'type': 'edge_addition', 'source': 'COMPOUND:13513', 'target': 'EFFECT:8', 'metadata': {'predicate': 'has_effect'}}]",0.4444444444444444,583a50fc1f44eeca12b49a85acd3c286,9a323e80d6f5a19b4f0c164c20addbca,[],[]
"[{'source_node': {'name': 'cytochrome p450 19a1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP19A1'}}, {'source_node': {'name': 'fusarentin 6-methyl ether'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 19a1'}}, {'source_node': {'name': 'fusarentin 6-methyl ether'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}, {'source_node': {'name': 'fusarentin 6-methyl ether'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'xanthine dehydrogenase/oxidase'}}, {'source_node': {'name': 'xanthine dehydrogenase/oxidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'XDH'}}, {'source_node': {'name': 'XDH'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Purine catabolism'}}]","[{'source_node': {'name': 'cytochrome p450 19a1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP19A1'}}, {'source_node': {'name': 'fusarentin 6-methyl ether'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 19a1'}}, {'source_node': {'name': 'fusarentin 6-methyl ether'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}, {'source_node': {'name': 'fusarentin 6-methyl ether'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'xanthine dehydrogenase/oxidase'}}, {'source_node': {'name': 'fusarentin 6-methyl ether'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'XDH'}}, {'source_node': {'name': 'fusarentin 6-methyl ether'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'CYP19A1'}}, {'source_node': {'name': 'xanthine dehydrogenase/oxidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'XDH'}}, {'source_node': {'name': 'XDH'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Purine catabolism'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:48482', 'target': 'GENE:33551', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'COMPOUND:48482', 'target': 'GENE:26347', 'metadata': {'predicate': 'is_affecting'}}]",0.8461538461538461,b369b7ae96c828b0d39c3612a8530c76,d1c0d66be09839ac0d8718634988f8d9,"['Cytochrome p450 19a1, a gene product of CYP19A1, is targeted by the fusarentin 6-methyl ether. This compound also targets the HL-60 cellular component and the enzyme xanthine dehydrogenase/oxidase. Interestingly, xanthine dehydrogenase/oxidase is a gene product of XDH that partakes within the purine catabolism pathway.']",[]
"[{'source_node': {'name': 'ifetroban'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'ifetroban'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' bleeding and hemorrhage '}}]","[{'source_node': {'name': 'ifetroban'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}]","[{'type': 'node_removal', 'source': 'EFFECT:1', 'target': None, 'metadata': {'node_id': '1', 'node_type': 'EFFECT', 'display_name': ' bleeding and hemorrhage '}}]",0.6,fe9bfe1bb93efe8c8c011488818e1791,d0f8ee2cbc8fa94ddfea5453dbcb3389,[],[]
"[{'source_node': {'name': 'aldo-keto reductase family 1 member c4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AKR1C4'}}, {'source_node': {'name': 'aldo-keto reductase family 1 member c3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AKR1C3'}}, {'source_node': {'name': 'drupanin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-116'}}, {'source_node': {'name': 'drupanin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'aldo-keto reductase family 1 member c3'}}, {'source_node': {'name': 'drupanin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'aldo-keto reductase family 1 member c4'}}, {'source_node': {'name': 'AKR1C4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Retinoid metabolism and transport'}}]","[{'source_node': {'name': 'aldo-keto reductase family 1 member c4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AKR1C4'}}, {'source_node': {'name': 'AKR1C3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Retinoid metabolism and transport'}}, {'source_node': {'name': 'aldo-keto reductase family 1 member c3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AKR1C3'}}, {'source_node': {'name': 'aldo-keto reductase family 1 member c3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AKR1C4'}}, {'source_node': {'name': 'drupanin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-116'}}, {'source_node': {'name': 'drupanin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'aldo-keto reductase family 1 member c4'}}, {'source_node': {'name': 'drupanin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'AKR1C4'}}, {'source_node': {'name': 'AKR1C4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Retinoid metabolism and transport'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:52538', 'target': 'GENE:25288', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:563', 'target': 'GENE:25288', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:52538', 'target': 'PROTEIN:563', 'metadata': None}, {'type': 'edge_addition', 'source': 'GENE:34740', 'target': 'PATHWAY:234', 'metadata': {'predicate': 'acts_within'}}]",0.6923076923076923,7fafafbe5f8b3b765c005a97e2d55296,aaeddacdd9fd5323fb9fb4638f60f064,"['The molecules aldo-keto reductase family 1 member c3 and aldo-keto reductase family 1 member c4 are gene products of AKR1C3 and AKR1C4 respectively. Further, the substance drupanin targets three entities, one of them being the HCT-116. The other two targeted entities are the aldo-keto reductase family 1 member c3 and the aldo-keto reductase family 1 member c4 mentioned earlier. In addition, the gene AKR1C4, which produces the aldo-keto reductase family 1 member c4, also acts within the pathway of retinoid metabolism and transport.', 'The drug drupanin targets multiple elements including hct-116 and two distinctive gene products; aldo-keto reductase family 1 member c3 and c4. Of interest, aldo-keto reductase family 1 member c3 is a gene product of AKR1C3, while aldo-keto reductase family 1 member c4 is a gene product of AKR1C4. AKR1C4, in particular, functions within the context of retinoid metabolism and transport.', 'The substances known as aldo-keto reductase family 1 member c3 and aldo-keto reductase family 1 member c4 are gene products of AKR1C3 and AKR1C4, respectively. The drug named drupanin targets these aldo-keto reductases along with another entity, hct-116. Furthermore, it is noted that AKR1C4 acts within the pathway responsible for retinoid metabolism and transport.', 'The genes aldo-keto reductase family 1 member c3 and aldo-keto reductase family 1 member c4 are gene products of AKR1C3 and AKR1C4 respectively. The drug drupanin targets both these genes along with hct-116. Furthermore, AKR1C4 acts within a pathway known as retinoid metabolism and transport.', 'The aldo-keto reductase family 1 member c4 and aldo-keto reductase family 1 member c3 are the gene products of AKR1C4 and AKR1C3 respectively. Moreover, the compound drupanin targets each of these members along with targeting a subtype of colorectal cancer cells known as hct-116. It is particularly noteworthy that AKR1C4 actively participates within the process concerning retinoid metabolism and transport.']",[]
"[{'source_node': {'name': 'mitochondrial complex iv deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ataxia'}}, {'source_node': {'name': 'mitochondrial complex iv deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypertension'}}, {'source_node': {'name': 'COX8A'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'mitochondrial complex iv deficiency'}}, {'source_node': {'name': 'COX8A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'TP53 Regulates Metabolic Genes'}}, {'source_node': {'name': 'COX8A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Respiratory electron transport'}}, {'source_node': {'name': 'cytochrome c oxidase subunit 8a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'COX8A'}}]","[{'source_node': {'name': 'mitochondrial complex iv deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ataxia'}}, {'source_node': {'name': 'mitochondrial complex iv deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypertension'}}, {'source_node': {'name': 'COX8A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'TP53 Regulates Metabolic Genes'}}, {'source_node': {'name': 'COX8A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Respiratory electron transport'}}]","[{'type': 'edge_deletion', 'source': 'GENE:25931', 'target': 'DISEASE:10172', 'metadata': None}, {'type': 'node_removal', 'source': 'PROTEIN:2686', 'target': None, 'metadata': {'node_id': '2686', 'node_type': 'PROTEIN', 'display_name': 'cytochrome c oxidase subunit 8a'}}]",0.7692307692307692,32e1a8f66f5240a770522ae16fe32851,727cf84d7afac02b3db9a18dcca4d720,"['The gene cytochrome c oxidase subunit 8a is a product of the gene COX8A which operates within two pathways: TP53 regulates metabolic genes and respiratory electron transport. Furthermore, mutations in the gene COX8A can cause a condition known as mitochondrial complex IV deficiency. This condition typically presents with various symptoms such as ataxia and hypertension.']",[]
"[{'source_node': {'name': 'calcium silicate'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the excretion rate '}}, {'source_node': {'name': 'calcium silicate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'polyethylene glycol'}}, {'source_node': {'name': 'calcium silicate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sulfate ion'}}]","[{'source_node': {'name': 'polyethylene glycol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sulfate ion'}}, {'source_node': {'name': 'polyethylene glycol'}, 'relation': {'name': 'increase_activity'}, 'target_node': {'name': ' the excretion rate '}}, {'source_node': {'name': 'polyethylene glycol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'calcium silicate'}}, {'source_node': {'name': 'calcium silicate'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the excretion rate '}}, {'source_node': {'name': 'calcium silicate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'polyethylene glycol'}}, {'source_node': {'name': 'calcium silicate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sulfate ion'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:8222', 'target': 'COMPOUND:12283', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:8222', 'target': 'ACTIVITY:7', 'metadata': {'predicate': 'increase_activity'}}, {'type': 'edge_addition', 'source': 'COMPOUND:8222', 'target': 'COMPOUND:11676', 'metadata': {'predicate': 'increase_efficacy'}}]",0.5714285714285714,36c93ee5293e61079b12f53388611fa4,f5f7dba5239ef4dff9a4a73d02516072,[],[]
"[{'source_node': {'name': 'abiraterone'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'abiraterone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'spironolactone'}}, {'source_node': {'name': 'abiraterone'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'aldo-keto reductase family 1 member c3'}}]","[{'source_node': {'name': 'spironolactone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'abiraterone'}}, {'source_node': {'name': 'abiraterone'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'abiraterone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'spironolactone'}}, {'source_node': {'name': 'abiraterone'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'aldo-keto reductase family 1 member c3'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:409', 'target': 'COMPOUND:5250', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.8571428571428572,a7ea67494ec58f625d96fff450d81504,0ecc9641e2415bf98cca52a7f68a37ef,[],[]
"[{'source_node': {'name': 'immunodeficiency 54'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'respiratory insufficiency'}}, {'source_node': {'name': 'immunodeficiency 54'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'respiratory failure'}}, {'source_node': {'name': 'immunodeficiency 54'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'recurrent respiratory infections'}}]","[{'source_node': {'name': 'immunodeficiency 54'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'respiratory insufficiency'}}, {'source_node': {'name': 'immunodeficiency 54'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'recurrent respiratory infections'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:2084', 'target': None, 'metadata': {'node_id': '2084', 'node_type': 'PHENOTYPE', 'display_name': 'respiratory failure'}}]",0.7142857142857143,11115a1ef9fcdb9dc5ef3c56cebde829,8943a02317fc57202da4710048fd1d32,[],[]
"[{'source_node': {'name': '1-biphenyl-2-ylmethanamine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dipeptidyl peptidase 4'}}, {'source_node': {'name': 'dipeptidyl peptidase 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DPP4'}}]","[{'source_node': {'name': '1-biphenyl-2-ylmethanamine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dipeptidyl peptidase 4'}}, {'source_node': {'name': '1-biphenyl-2-ylmethanamine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'DPP4'}}, {'source_node': {'name': 'dipeptidyl peptidase 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DPP4'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:6442', 'target': 'GENE:26567', 'metadata': {'predicate': 'is_affecting'}}]",0.8,f92e5738695b28f0238eb9b1d36ac385,816a2546741f1bd108ef237540286dd2,"['The compound 1-biphenyl-2-ylmethanamine has a known target in dipeptidyl peptidase 4, which in turn is a gene product of DPP4.', 'The drug 1-biphenyl-2-ylmethanamine has a target, which is the protein known as dipeptidyl peptidase 4. Further, dipeptidyl peptidase 4 is actually the gene product of the gene called DPP4.', 'The chemical compound 1-biphenyl-2-ylmethanamine targets dipeptidyl peptidase 4. Notably, dipeptidyl peptidase 4 is the gene product of DPP4.', 'The drug 1-biphenyl-2-ylmethanamine has a specific target, which is dipeptidyl peptidase 4. Dipeptidyl peptidase 4 is recognised as the gene product of DPP4.', 'The drug 1-biphenyl-2-ylmethanamine targets dipeptidyl peptidase 4, which is a gene product of DPP4.']","['The drug 1-biphenyl-2-ylmethanamine has been found to target dipeptidyl peptidase 4, a gene product of DPP4. Moreover, 1-biphenyl-2-ylmethanamine is also known to affect the DPP4 gene itself.', 'The compound 1-biphenyl-2-ylmethanamine has a specific target which is dipeptidyl peptidase 4, and it also affects the gene DPP4. Importantly, dipeptidyl peptidase 4 is a gene product of DPP4.']"
"[{'source_node': {'name': 'aristolochic acid ii'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cyclin-dependent kinase 2'}}, {'source_node': {'name': 'CDK2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Senescence-Associated Secretory Phenotype (SASP)'}}, {'source_node': {'name': 'CDK2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cyclin A:Cdk2-associated events at S phase entry'}}, {'source_node': {'name': 'CDK2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'PTK6 Regulates Cell Cycle'}}, {'source_node': {'name': 'cyclin-dependent kinase 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CDK2'}}]","[{'source_node': {'name': 'CDK2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Senescence-Associated Secretory Phenotype (SASP)'}}, {'source_node': {'name': 'cyclin-dependent kinase 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CDK2'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:65364', 'target': None, 'metadata': {'node_id': '65364', 'node_type': 'COMPOUND', 'display_name': 'aristolochic acid ii'}}, {'type': 'node_removal', 'source': 'PATHWAY:342', 'target': None, 'metadata': {'node_id': '342', 'node_type': 'PATHWAY', 'display_name': 'PTK6 Regulates Cell Cycle'}}, {'type': 'node_removal', 'source': 'PATHWAY:30', 'target': None, 'metadata': {'node_id': '30', 'node_type': 'PATHWAY', 'display_name': 'Cyclin A:Cdk2-associated events at S phase entry'}}]",0.4545454545454546,95c1e1edcca84f665934d6e42461420c,cc463a427997bf8b4d52387573af0737,[],[]
"[{'source_node': {'name': 'cytochrome p450 19a1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP19A1'}}, {'source_node': {'name': 'abyssinone ii'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 19a1'}}, {'source_node': {'name': 'abyssinone ii'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosinase'}}, {'source_node': {'name': 'abyssinone ii'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'CYP19A1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'aromatase deficiency'}}, {'source_node': {'name': 'CYP19A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Estrogen biosynthesis'}}, {'source_node': {'name': 'CYP19A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Endogenous sterols'}}, {'source_node': {'name': 'tyrosinase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TYR'}}]","[{'source_node': {'name': 'cytochrome p450 19a1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP19A1'}}, {'source_node': {'name': 'abyssinone ii'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 19a1'}}, {'source_node': {'name': 'abyssinone ii'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'CYP19A1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'aromatase deficiency'}}, {'source_node': {'name': 'CYP19A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Estrogen biosynthesis'}}, {'source_node': {'name': 'CYP19A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Endogenous sterols'}}, {'source_node': {'name': 'tyrosinase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TYR'}}, {'source_node': {'name': 'tyrosinase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP19A1'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:655', 'target': 'GENE:26347', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:37434', 'target': 'PROTEIN:655', 'metadata': None}]",0.8823529411764706,cae993804755e0a8fe8573b76e4e85a1,cf1c3e40d0ee98ec1ee66113bd1da8b3,"['Cytochrome P450 19A1, which acts as the gene product of CYP19A1, is targeted by Abyssinone II. This compound also targets Tyrosinase and A549. Furthering its role, CYP19A1 not only causes a condition known as Aromatase deficiency, but actively engages within the Estrogen biosynthesis and Endogenous sterols pathways as well. Tyrosinase is also connected, as it is the gene product of TYR.', 'The drug Abyssinone II targets several entities like the Cytochrome P450 19A1, Tyrosinase, and A549. Tyrosinase is a gene product of TYR, while Cytochrome P450 19A1 is a gene product of CYP19A1. Interestingly, CYP19A1 can cause a condition known as Aromatase Deficiency. It also acts within various pathways such as Estrogen biosynthesis and Endogenous sterols.']",[]
"[{'source_node': {'name': 'translocator protein'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TSPO'}}, {'source_node': {'name': 'ACAT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Utilization of Ketone Bodies'}}, {'source_node': {'name': 'acetyl-coa acetyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACAT2'}}, {'source_node': {'name': 'acetyl-coa acetyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACAT1'}}, {'source_node': {'name': 'TSPO'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pregnenolone biosynthesis'}}, {'source_node': {'name': 'cannabidiol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'acetyl-coa acetyltransferase'}}, {'source_node': {'name': 'cannabidiol'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the serotonergic activities '}}, {'source_node': {'name': 'cannabidiol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'translocator protein'}}]","[{'source_node': {'name': 'translocator protein'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TSPO'}}, {'source_node': {'name': 'TSPO'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pregnenolone biosynthesis'}}, {'source_node': {'name': 'TSPO'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Utilization of Ketone Bodies'}}, {'source_node': {'name': 'cannabidiol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'acetyl-coa acetyltransferase'}}, {'source_node': {'name': 'cannabidiol'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the serotonergic activities '}}, {'source_node': {'name': 'cannabidiol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'translocator protein'}}]","[{'type': 'node_removal', 'source': 'GENE:29578', 'target': None, 'metadata': {'node_id': '29578', 'node_type': 'GENE', 'display_name': 'ACAT2'}}, {'type': 'edge_addition', 'source': 'GENE:33242', 'target': 'PATHWAY:1837', 'metadata': {'predicate': 'acts_within'}}, {'type': 'node_removal', 'source': 'GENE:29444', 'target': None, 'metadata': {'node_id': '29444', 'node_type': 'GENE', 'display_name': 'ACAT1'}}]",0.6470588235294117,a77436fcc270179e78179e89f5b2d0f2,dfaaca64ab91387d50a4caa3ffb8e049,[],[]
"[{'source_node': {'name': '\\n'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'k562'}}, {'source_node': {'name': '\\n'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tankyrase-1'}}, {'source_node': {'name': '\\n'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cyclin-dependent kinase 5 activator 1'}}, {'source_node': {'name': 'cyclin-dependent kinase 5 activator 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CDK5R1'}}, {'source_node': {'name': 'CDK5R1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Activated NTRK2 signals through CDK5'}}]","[{'source_node': {'name': 'cyclin-dependent kinase 5 activator 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CDK5R1'}}, {'source_node': {'name': 'CDK5R1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Activated NTRK2 signals through CDK5'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:85076', 'target': None, 'metadata': {'node_id': '85076', 'node_type': 'COMPOUND', 'display_name': '\\n'}}]",0.4545454545454546,1205f59e00d1b7e92d2b25aaebca7d54,1a4e8cf229f72ff49eb7e9960dbe5c53,[],['The gene Cyclin-dependent kinase 5 activator 1 is a product of the CDK5R1 gene. This CDK5R1 gene acts within the pathway of activated NTRK2 signals through CDK5.']
"[{'source_node': {'name': 'cytochrome p450 19a1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP19A1'}}, {'source_node': {'name': 'tyrosinase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TYR'}}, {'source_node': {'name': ""(2s)-5,7,2',4'-tetrahydroxyflavanone""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 19a1'}}, {'source_node': {'name': ""(2s)-5,7,2',4'-tetrahydroxyflavanone""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosinase'}}, {'source_node': {'name': 'CYP19A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Endogenous sterols'}}]","[{'source_node': {'name': 'cytochrome p450 19a1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP19A1'}}, {'source_node': {'name': 'tyrosinase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TYR'}}, {'source_node': {'name': ""(2s)-5,7,2',4'-tetrahydroxyflavanone""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 19a1'}}, {'source_node': {'name': ""(2s)-5,7,2',4'-tetrahydroxyflavanone""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosinase'}}, {'source_node': {'name': ""(2s)-5,7,2',4'-tetrahydroxyflavanone""}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'CYP19A1'}}, {'source_node': {'name': ""(2s)-5,7,2',4'-tetrahydroxyflavanone""}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'TYR'}}, {'source_node': {'name': 'CYP19A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Endogenous sterols'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:51289', 'target': 'GENE:26347', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'COMPOUND:51289', 'target': 'GENE:33417', 'metadata': {'predicate': 'is_affecting'}}]",0.8181818181818181,f5d95804ad2110ee4661f3c84ef141bb,79346637ae0e30ff37f3510de6561260,[],[]
"[{'source_node': {'name': 'nephrotic syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'sensorineural hearing impairment'}}, {'source_node': {'name': 'nephrotic syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'high palate'}}, {'source_node': {'name': 'nephrotic syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypercholesterolemia'}}, {'source_node': {'name': 'NPHS1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'nephrotic syndrome'}}, {'source_node': {'name': 'NPHS1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'genetic steroid-resistant nephrotic syndrome'}}]","[{'source_node': {'name': 'nephrotic syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'sensorineural hearing impairment'}}, {'source_node': {'name': 'nephrotic syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypercholesterolemia'}}, {'source_node': {'name': 'NPHS1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'genetic steroid-resistant nephrotic syndrome'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:184', 'target': None, 'metadata': {'node_id': '184', 'node_type': 'PHENOTYPE', 'display_name': 'high palate'}}, {'type': 'edge_deletion', 'source': 'GENE:30325', 'target': 'DISEASE:15399', 'metadata': None}]",0.7272727272727273,327f6e0eedf2f792a8965bd29868fb54,193e2a9466064d9458cff8f65c6cfd45,"['The gene NPHS1 is a causative factor for conditions such as nephrotic syndrome and genetic steroid-resistant nephrotic syndrome. Nephrotic syndrome is a disease noted for a variety of phenotypes including sensorineural hearing impairment, the presence of a high palate and hypercholesterolemia.', 'Nephrotic syndrome, a condition triggered by the gene NPHS1, features various phenotypes including sensorineural hearing impairment, a high palate, and hypercholesterolemia. The same gene, NPHS1, is also responsible for causing another condition known as the genetic steroid-resistant nephrotic syndrome.', 'Nephrotic syndrome, a condition caused by the NPHS1 gene, is characterized by a range of phenotypes including sensorineural hearing impairment, a high palate, and hypercholesterolemia. Furthermore, the NPHS1 gene also causes a special type of this disorder known as genetic steroid-resistant nephrotic syndrome.', 'Nephrotic syndrome, a condition caused by the gene NPHS1, is characterized by several phenotypes such as sensorineural hearing impairment, the presence of a high palate, and hypercholesterolemia. It is worth noting that the NPHS1 gene is also linked with the cause of another condition named genetic steroid-resistant nephrotic syndrome.', 'The gene NPHS1 has been identified to cause two conditions: nephrotic syndrome and a genetic condition resistant to steroid treatment known as genetic steroid-resistant nephrotic syndrome. Nephrotic syndrome exhibits several phenotypes which include sensorineural hearing impairment, a high palate, and hypercholesterolemia.']","['Nephrotic syndrome is a condition that has phenotypes such as sensorineural hearing impairment and hypercholesterolemia. Interestingly, the gene NPHS1 is known to cause genetic steroid-resistant nephrotic syndrome, a form of the disease that is inherently resistant to typical treatment methods.']"
"[{'source_node': {'name': 'ganoderic acid e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepg2'}}, {'source_node': {'name': 'ganoderic acid e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'raji'}}, {'source_node': {'name': 'ganoderic acid e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cholinesterase'}}]","[{'source_node': {'name': 'ganoderic acid e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepg2'}}, {'source_node': {'name': 'ganoderic acid e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'raji'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:276', 'target': None, 'metadata': {'node_id': '276', 'node_type': 'PROTEIN', 'display_name': 'cholinesterase'}}]",0.7142857142857143,595b97939c3d21e1fcdcc7b560a15051,9443ea6047dc089ced12db95e7d9f2c5,"['Ganoderic acid E, a well-known compound, has multiple targets. These include HepG2, a liver cancer cell line, Raji, a lymphoma cell line and the essential enzyme, cholinesterase. It is indeed intriguing to observe such a broad spectrum of targets impacted by a single compound.', 'Ganoderic acid E, a known bioactive compound, notably targets various biological entities including HepG2, a liver cancer cell line, Raji, a lymphoma cell line, and cholinesterase, an essential enzyme in neural function.', 'Ganoderic Acid E is known to target several entities such as HepG2, a prominent liver cancer cell line, Raji, a cell line derived from human lymphoblasts, and cholinesterase, an important enzyme in the nervous system. This indicates that the bioactive compound Ganoderic Acid E possesses diverse potential targets within biological systems and could be relevant for the treatment of diverse medical conditions.']","['Ganoderic acid E is a bioactive compound that targets various cell lines, such as HepG2 and Raji.', 'Ganoderic acid E, a biomolecule of interest, is known to target two specific cell lines: HepG2 and Raji.', 'Ganoderic acid E, a bioactive compound, targets two different cells: HepG2, a human liver cancer cell line, and Raji, a human lymphoma cell line.', 'The compound Ganoderic acid E has been identified to target two cells, specifically HepG2 and Raji.', 'The compound Ganoderic Acid E has been found to target two specific cell lines, HepG2 and Raji.']"
"[{'source_node': {'name': 'angelman syndrome due to a point mutation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'dysphagia'}}, {'source_node': {'name': 'UBE3A'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'angelman syndrome'}}, {'source_node': {'name': 'UBE3A'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'angelman syndrome due to a point mutation'}}, {'source_node': {'name': 'UBE3A'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': '15q11q13 microduplication syndrome'}}, {'source_node': {'name': 'angelman syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'protruding tongue'}}, {'source_node': {'name': 'angelman syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'optic atrophy'}}, {'source_node': {'name': 'angelman syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'precocious puberty in females'}}]","[{'source_node': {'name': 'angelman syndrome due to a point mutation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'dysphagia'}}, {'source_node': {'name': 'UBE3A'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'angelman syndrome due to a point mutation'}}, {'source_node': {'name': 'UBE3A'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': '15q11q13 microduplication syndrome'}}, {'source_node': {'name': 'angelman syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'protruding tongue'}}, {'source_node': {'name': 'angelman syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'optic atrophy'}}, {'source_node': {'name': 'angelman syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'precocious puberty in females'}}, {'source_node': {'name': 'angelman syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'dysphagia'}}]","[{'type': 'edge_addition', 'source': 'DISEASE:188', 'target': 'PHENOTYPE:1475', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_deletion', 'source': 'GENE:33448', 'target': 'DISEASE:188', 'metadata': None}]",0.8666666666666667,44b00bacf5c71becf05e8b4a24566048,41bdee6b1a20d4c6ff9acb9f45b5e3b7,"['The gene UBE3A causes several conditions such as Angelman Syndrome, Angelman Syndrome due to a point mutation, and 15q11q13 microduplication syndrome. It is interesting to note that Angelman Syndrome and its variant due to a point mutation exhibit certain phenotypical characteristics. For example, Angelman Syndrome is often characterized by symptoms like protruding tongue, optic atrophy, and precocious puberty in females. Specifically pertaining to the variant type, Angelman Syndrome due to a point mutation, one predominant phenotype observed is dysphagia. Therefore, mutations in the UBE3A gene can lead to various conditions with diverse phenotypical manifestations.', 'The gene UBE3A is known to cause several conditions, namely Angelman syndrome, Angelman syndrome due to a point mutation, and 15q11q13 microduplication syndrome. Angelman syndrome presents a range of phenotypic symptoms, such as a protruding tongue, optic atrophy, and precocious puberty in females. Additionally, Angelman syndrome due to a point mutation can result in dysphagia.', 'The gene UBE3A causes several conditions including Angelman syndrome, Angelman syndrome due to a point mutation, and 15q11q13 microduplication syndrome. Angelman syndrome is manifested with various symptoms such as protruding tongue, optic atrophy, and precocious puberty in females. The Angelman syndrome due to a point mutation specifically exhibits dysphagia among its observed phenotypes.', 'The gene UBE3A is known to cause several conditions, including Angelman syndrome, Angelman syndrome due to a point mutation, and 15q11q13 microduplication syndrome. These conditions display varying phenotypes. For example, Angelman syndrome is typically characterized by symptoms such as a protruding tongue, optic atrophy, and precocious puberty in females. Additionally, Angelman syndrome due to a point mutation often presents with dysphagia.', 'The gene UBE3A is associated with several conditions including Angelman syndrome, Angelman syndrome due to a point mutation, and 15q11q13 microduplication syndrome. Angelman syndrome, whether caused by a point mutation or not, exhibits a range of phenotypic characteristics such as a protruding tongue, optic atrophy, and precocious puberty in females. In addition to these features, dysphagia, a condition characterized by difficulty in swallowing, is particularly associated with Angelman syndrome due to a point mutation.']","['The gene UBE3A is known to cause several conditions including Angelman syndrome due to a point mutation and the 15q11q13 microduplication syndrome. Angelman syndrome due to a point mutation is characterized by the symptom of dysphagia. The broader category of Angelman syndrome is associated with a number of phenotypes, including a protruding tongue, optic atrophy, precocious puberty in females, and also dysphagia.']"
"[{'source_node': {'name': 'egaptivon pegol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'peginterferon alfa-2b'}}, {'source_node': {'name': 'egaptivon pegol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pegademase'}}, {'source_node': {'name': 'egaptivon pegol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'propylene glycol'}}, {'source_node': {'name': 'peginterferon alfa-2b'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'anthrax immune globulin human'}}, {'source_node': {'name': 'peginterferon alfa-2b'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'interleukin 6'}}, {'source_node': {'name': 'peginterferon alfa-2b'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'vitamin d receptor'}}]","[{'source_node': {'name': 'egaptivon pegol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pegademase'}}, {'source_node': {'name': 'egaptivon pegol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'propylene glycol'}}, {'source_node': {'name': 'egaptivon pegol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'anthrax immune globulin human'}}, {'source_node': {'name': 'peginterferon alfa-2b'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'anthrax immune globulin human'}}, {'source_node': {'name': 'peginterferon alfa-2b'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'interleukin 6'}}, {'source_node': {'name': 'peginterferon alfa-2b'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'propylene glycol'}}, {'source_node': {'name': 'propylene glycol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pegademase'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:4875', 'target': 'COMPOUND:21', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:4875', 'target': 'COMPOUND:7998', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:21', 'target': 'COMPOUND:1750', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1750', 'target': 'COMPOUND:59', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'GENE:23279', 'target': None, 'metadata': {'node_id': '23279', 'node_type': 'GENE', 'display_name': 'vitamin d receptor'}}]",0.5384615384615384,ac4eed67c6f104e0425e6b36900518cf,3f41252f743fe2212b8108b299b8c0cd,"['Egaptivon pegol is a drug known to decrease the efficacy of several other substances, including peginterferon alfa-2b, pegademase and propylene glycol. Peginterferon alfa-2b, once effected by egaptivon pegol, also shows a decrease in efficacy over anthrax immune globulin human. Furthermore, peginterferon alfa-2b also affects the interleukin 6 and the vitamin d receptor in the body. This intricate network of interconnected effects underscores the complex dynamics of drug interactions and their potential impact on therapeutic outcomes.', 'The drug Egaptivon Pegol is noted to decrease the efficacy of several other substances including Peginterferon Alfa-2b, Pegademase, and Propylene Glycol. The specific implications of these interactions vary significantly. For instance, Peginterferon Alfa-2b not only has its efficacy decreased by Egaptivon Pegol but also decreases the efficacy of Anthrax immune globulin human. Additionally, Peginterferon Alfa-2b interacts with certain biological substances, affecting the function of Interleukin 6 and the Vitamin D receptor. Understanding these complex relationships is critical in the context of drug interactions and the potential impacts on treatment outcomes.', ""Egaptivon pegol, a pharmaceutical drug, is known to decrease the efficacy of several other medications, namely, peginterferon alfa-2b, pegademase, and propylene glycol. The drug peginterferon alfa-2b, whose efficacy is reduced by egaptivon pegol, also exhibits a decrease in efficacy when combined with anthrax immune globulin human. Further, peginterferon alfa-2b is found to affect levels of interleukin 6 and the function of the vitamin d receptor. Therefore, it's important to consider these potential interactions when prescribing egaptivon pegol or peginterferon alfa-2b to ensure appropriate medicinal effects."", 'Egaptivon pegol is a drug that is reported to decrease the efficacy of several other compounds including peginterferon alfa-2b, pegademase, and propylene glycol. Particularly, peginterferon alfa-2b is also noted to reduce the efficacy of anthrax immune globulin human. Moreover, peginterferon alfa-2b is seen to influence certain biological factors like interleukin 6 and the vitamin D receptor.', 'The drug Egaptivon Pegol is known to decrease the efficacy of several other drugs including Peginterferon Alfa-2b, Pegademase, and Propylene Glycol. Peginterferon Alfa-2b itself, aside from its interactions with Egaptivon Pegol, has the ability to hinder the efficacy of Anthrax Immune Globulin Human. This drug also interacts with other biological substances, affecting Interleukin 6 and Vitamin D receptor. These complex interaction networks highlight the intricate ways in which drugs and biological substances can affect each other.']","['The drug egaptivon pegol is noteworthy for its ability to decrease the efficacy of several other substances. These include pegademase, propylene glycol, and anthrax immune globulin human. Similarly, the drug peginterferon alfa-2b also decreases the efficacy of anthrax immune globulin human. Beyond this shared characteristic, both drugs exhibit further interaction with other substances. Peginterferon alfa-2b significantly impacts the function of interleukin 6 and enhances the efficacy of propylene glycol while propylene glycol, in turn, increases the efficacy of pegademase. These complex interactions illuminated through these triples underline the intricate interplay between various drugs and substances within the body.\n', 'Egaptivon pegol, a medication, is known to decrease the efficacy of several other compounds, including pegademase, propylene glycol, and anthrax immune globulin human. Interestingly, another drug called peginterferon alfa-2b follows a similar route by decreasing the efficacy of anthrax immune globulin human; however, it increases the efficacy of propylene glycol. Therefore, propylene glycol seems to increase the efficacy of pegademase in turn. Moreover, peginterferon alfa-2b affects the biological entity known as interleukin 6, indicating that these compounds influence a variety of biochemical interactions.', ""Egaptivon pegol, a bioactive compound, is known to decrease the efficacy of several substances including pegademase, propylene glycol, and anthrax immune globulin human. Another substance, peginterferon alfa-2b, also decreased the efficacy of anthrax immune globulin human. Yet, it has an opposite effect on propylene glycol, where it actually increases its efficacy. It's worth noting that peginterferon alfa-2b is impacting the functionality of interleukin 6. Interestingly, propylene glycol, which has interactions with both egaptivon pegol and peginterferon alfa-2b, is known to increase the efficacy of pegademase."", ""Egaptivon pegol is a drug known to decrease the efficacy of other medical substances, including pegademase, propylene glycol, and anthrax immune globulin human. Interestingly, another drug, peginterferon alfa-2b, shares this characteristic with egaptivon pegol, as it also reduces the efficacy of anthrax immune globulin human. However, peginterferon alfa-2b also influences the body in other ways; it impacts the function of interleukin 6 and, unlike egaptivon pegol, it actually serves to enhance the efficacy of propylene glycol. Demonstrating the interplay of substances within the body, propylene glycol in turn also boosts the efficacy of pegademase. It's important to consider such interactions to avoid potential drug conflicts and to maximize the efficacy of treatments."", 'The drug, egaptivon pegol, has been found to decreased the efficacy of various other substances, including pegademase, propylene glycol, and anthrax immune globulin human. On the other hand, another drug, peginterferon alfa-2b, exhibits mixed effects. It decreases the efficacy of anthrax immune globulin human, but has contrasting effects on interleukin 6 and propylene glycol with the former affected by the drug, while the latter sees an increased efficacy due to peginterferon alfa-2b. Interestingly, propylene glycol also has an efficiency-enhancing effect on pegademase. Therefore, physicians should be cautious when co-administering these drugs, to avoid threats to patient safety and to maximize the efficacy of treatments.']"
"[{'source_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TDP1'}}, {'source_node': {'name': 'umbelliprenin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}}, {'source_node': {'name': 'umbelliprenin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-mel-28'}}, {'source_node': {'name': 'umbelliprenin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'geminin'}}]","[{'source_node': {'name': 'sk-mel-28'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TDP1'}}, {'source_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TDP1'}}, {'source_node': {'name': 'umbelliprenin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}}, {'source_node': {'name': 'umbelliprenin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-mel-28'}}, {'source_node': {'name': 'umbelliprenin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'geminin'}}, {'source_node': {'name': 'umbelliprenin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'TDP1'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:4998', 'target': 'GENE:31610', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'COMPOUND:39999', 'target': 'GENE:31610', 'metadata': {'predicate': 'is_affecting'}}]",0.7777777777777778,8cd75de3b3657e140e90b0c5fd96cc14,dafb1af9ac790ebfe76e4f54eb3b6ff8,"[""Umbelliprenin, a therapeutic compound, targets several entities within the body including Tyrosyl-DNA phosphodiesterase 1, SK-MEL-28, and Geminin. It is interesting to note that Tyrosyl-DNA phosphodiesterase 1 is a gene product of the gene TDP1. This interconnected network of interactions plays a significant role in the effectiveness and impact of Umbelliprenin's therapeutic actions."", ""Tyrosyl-DNA phosphodiesterase 1, which is a gene product of TDP1, acts as a target for the chemical compound Umbelliprenin. It's interesting to note that Umbelliprenin also targets SK-MEL-28 and Geminin."", 'The compound umbelliprenin targets a variety of entities, including tyrosyl-DNA phosphodiesterase 1, SK-MEL-28, and geminin. Interestingly, tyrosyl-DNA phosphodiesterase 1 is a gene product of TDP1, which indicates a possible genomic influence of umbelliprenin.', 'The compound umbelliprenin targets several things, including the protein tyrosyl-DNA phosphodiesterase 1 and SK-MEL-28, a melanoma cell line, as well as geminin, a protein involved in DNA replication. It is interesting to note that tyrosyl-DNA phosphodiesterase 1 is a gene product of TDP1.', 'The drug Umbelliprenin has several targets including tyrosyl-DNA phosphodiesterase 1, SK-MEL-28, and geminin. Notably, tyrosyl-DNA phosphodiesterase 1 is a gene product of TDP1.']","['The drug Umbelliprenin has multiple targets which include tyrosyl-DNA phosphodiesterase 1, sk-mel-28, and geminin. Additionally, Umbelliprenin is known to affect TDP1. Both tyrosyl-DNA phosphodiesterase 1 and sk-mel-28 are gene products of TDP1.', 'The drug Umbelliprenin targets multiple entities including sk-mel-28, which is a gene product of TDP1. Another target of Umbelliprenin is tyrosyl-DNA phosphodiesterase 1, also termed as a gene product of TDP1. Furthermore, Umbelliprenin not only targets geminin but it also affects the overall functioning of TDP1.', 'The compound umbelliprenin presents several interactions within the biological system. Primarily, it targets three entities: the sk-mel-28, a gene product of TDP1; the enzyme tyrosyl-DNA phosphodiesterase 1, which is another gene product of TDP1; and additionally, geminin. Furthermore, umbelliprenin also affects TDP1 directly.', 'The compound umbelliprenin is known to target several entities, including tyrosyl-DNA phosphodiesterase 1, SK-MEL-28, and geminin. Interestingly, both tyrosyl-DNA phosphodiesterase 1 and SK-MEL-28 share a common origin as they are both gene products of TDP1. Additionally, TDP1 is affected by the presence of umbelliprenin, demonstrating a complex web of relationships and interactions among these entities.', 'SK-MEL-28, a gene product of TDP1, functions similarly to tyrosyl-DNA phosphodiesterase 1, which is also a gene product of TDP1. It is significant to note that these two entities are targets of umbelliprenin, along with geminin. Furthermore, umbelliprenin is found to significantly affect the functioning of TDP1.']"
"[{'source_node': {'name': 'dyskinesia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'anxiety'}}, {'source_node': {'name': 'dyskinesia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'dilated cardiomyopathy'}}, {'source_node': {'name': 'dyskinesia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'tremor'}}]","[{'source_node': {'name': 'dyskinesia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'dilated cardiomyopathy'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:576', 'target': None, 'metadata': {'node_id': '576', 'node_type': 'PHENOTYPE', 'display_name': 'anxiety'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:1011', 'target': None, 'metadata': {'node_id': '1011', 'node_type': 'PHENOTYPE', 'display_name': 'tremor'}}]",0.4285714285714286,d0b73806f5ecb8fa61727b25040ee038,f027533bc4be70e614b96695209b0f0c,[],[]
"[{'source_node': {'name': 'grassystatin c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cathepsin d'}}, {'source_node': {'name': 'grassystatin c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cathepsin e'}}]","[{'source_node': {'name': 'grassystatin c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cathepsin d'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:6298', 'target': None, 'metadata': {'node_id': '6298', 'node_type': 'PROTEIN', 'display_name': 'cathepsin e'}}]",0.6,3a091b5d812f45db45d38269eaf501de,81fd884d12886ad98571e69851924c89,"['Grassystatin C, a bioactive compound, targets two specific enzymes in the body - Cathepsin D and Cathepsin E.', 'Grassystatin C is a substance that targets two key proteins, Cathepsin D and Cathepsin E.', 'The compound Grassystatin C targets both Cathepsin D and Cathepsin E.', 'The drug Grassystatin C targets both Cathepsin D and Cathepsin E.', 'The compound Grassystatin C targets both Cathepsin D and Cathepsin E.']","['The compound Grassystatin C has the protein Cathepsin D as its target.', 'The compound grassystatin C is known to target the enzyme cathepsin D.', 'The compound Grassystatin C has Cathepsin D as its target.']"
"[{'source_node': {'name': 'insulin-like growth factor 1 receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'IGF1R'}}, {'source_node': {'name': 'somatrem'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'insulin-like growth factor 1 receptor'}}, {'source_node': {'name': 'somatrem'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hypoglycemic activities '}}, {'source_node': {'name': 'somatrem'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'macimorelin'}}, {'source_node': {'name': 'macimorelin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'insulin glulisine'}}, {'source_node': {'name': 'macimorelin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'suxibuzone'}}, {'source_node': {'name': 'macimorelin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'benzilone'}}, {'source_node': {'name': 'IGF1R'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'SHC-related events triggered by IGF1R'}}]","[{'source_node': {'name': 'insulin-like growth factor 1 receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'IGF1R'}}, {'source_node': {'name': 'somatrem'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'insulin-like growth factor 1 receptor'}}, {'source_node': {'name': 'macimorelin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'insulin glulisine'}}, {'source_node': {'name': 'macimorelin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'suxibuzone'}}, {'source_node': {'name': 'macimorelin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'benzilone'}}, {'source_node': {'name': 'suxibuzone'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'IGF1R'}}, {'source_node': {'name': 'IGF1R'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'SHC-related events triggered by IGF1R'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:8038', 'target': 'COMPOUND:10944', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:11090', 'target': 'GENE:29135', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'ACTIVITY:12', 'target': None, 'metadata': {'node_id': '12', 'node_type': 'ACTIVITY', 'display_name': ' the hypoglycemic activities '}}]",0.7647058823529411,b29cb39e6ab9558c117f3170a449608b,4af725bbec909cfee744d89b779cfa6d,[],"[""The insulin-like growth factor 1 receptor acts as a gene product of the IGF1R gene, and is targeted by the drug somatrem. Notably, IGF1R also acts within a pathway known as the SHC-related events triggered by IGF1R.\n\nIGF1R's activities can be affected by the drug suxibuzone which, alongside insulin glulisine and benzilone, has its efficacy decreased by the drug macimorelin. This particular interaction between different drugs and their target receptor demonstrates the complexity of biochemical processes within the body.""]"
"[{'source_node': {'name': '7-oxodehydroabietinol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lovo'}}, {'source_node': {'name': '7-oxodehydroabietinol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}, {'source_node': {'name': '7-oxodehydroabietinol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'jurkat'}}]","[{'source_node': {'name': '7-oxodehydroabietinol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}, {'source_node': {'name': '7-oxodehydroabietinol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'jurkat'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4950', 'target': None, 'metadata': {'node_id': '4950', 'node_type': 'PROTEIN', 'display_name': 'lovo'}}]",0.7142857142857143,2b41e3c39985e717ba943a98f55208b1,9c4b47d1581eeb4d1e8b4682f3c32011,"['The compound 7-oxodehydroabietinol targets several cell lines including LoVo, HeLa and Jurkat. By doing so, 7-oxodehydroabietinol presents potential uses in therapeutic research and treatments.', 'The compound 7-oxodehydroabietinol has several target cells, including LoVo, HeLa, and Jurkat cells.', 'The compound 7-oxodehydroabietinol has been found to target various cell lines, such as LoVo, HeLa, and Jurkat.', 'The compound 7-oxodehydroabietinol has several targets, including LoVo, HeLa, and Jurkat cell lines.', 'The compound 7-oxodehydroabietinol has targets in several cell lines, namely LoVo, HeLa, and Jurkat.']","['The compound 7-oxodehydroabietinol has been identified to target two different cell lines, notably HeLa and Jurkat.', 'The compound 7-oxodehydroabietinol has targeted effects on both Hela and Jurkat cell lines.', 'The compound 7-oxodehydroabietinol has been observed to target two different cells lines, namely HeLa and Jurkat.', 'The compound 7-oxodehydroabietinol has been found to target two different cell types, specifically Hela and Jurkat cells.', 'The compound 7-oxodehydroabietinol has targets on different cell types, specifically the Hela and Jurkat cells.']"
"[{'source_node': {'name': 'glycocholic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'chlormadinone'}}, {'source_node': {'name': 'glycocholic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'quingestanol'}}]","[{'source_node': {'name': 'chlormadinone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'glycocholic acid'}}, {'source_node': {'name': 'glycocholic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'chlormadinone'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:11532', 'target': None, 'metadata': {'node_id': '11532', 'node_type': 'COMPOUND', 'display_name': 'quingestanol'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11379', 'target': 'COMPOUND:2541', 'metadata': {'predicate': 'increase_efficacy'}}]",0.4,354406c6c7260c2e89e018a61aa40f3d,8d31dce8f66e04d28476b1b15b312781,"['Glycocholic acid, a bile acid, has been found to decrease the efficacy of certain drugs, notably chlormadinone and quingestanol. This indicates that the presence of glycocholic acid could potentially affect the therapeutic effectiveness of these drugs.', 'The substance glycocholic acid has been found to decrease the efficacy of certain medications, including chlormadinone and quingestanol. It is crucial to take this into consideration in medicinal therapy regimes involving these drugs to ensure an optimal impact.', 'Glycocholic acid has been observed to decrease the efficacy of certain drugs, notably chlormadinone and quingestanol.', 'The presence of glycocholic acid has been found to decrease the efficacy of certain medications, including chlormadinone and quingestanol.', 'Glycocholic acid decreases the efficacy of certain substances, including chlormadinone and quingestanol.']","['The drug chlormadinone is known to increase the efficacy of glycocholic acid. However, interestingly, this interaction appears to be one-sided as glycocholic acid in turn decreases the efficacy of chlormadinone.', 'The drug chlormadinone has been found to increase the efficacy of glycocholic acid. In a surprising reciprocal relationship, glycocholic acid itself can decrease the efficacy of chlormadinone.', ""Chlormadinone increases the efficacy of glycocholic acid treatment. However, it's important to note that glycocholic acid, in turn, can decrease the efficacy of chlormadinone. This suggests a complex interaction between the two substances where the benefits of one component can potentially be limited by the other."", 'The drug chlormadinone has been found to increase the efficacy of glycocholic acid. However, interestingly, glycocholic acid in return may decrease the efficacy of chlormadinone. This suggests a complex interplay between chlormadinone and glycocholic acid which warrants further investigation.', 'The drug chlormadinone can increase the efficacy of glycocholic acid. Surprisingly, glycocholic acid itself has an inverse effect and can decrease the efficacy of chlormadinone.']"
"[{'source_node': {'name': 'bitolterol'}, 'relation': {'name': 'increase_activity'}, 'target_node': {'name': ' the hypokalemic activities '}}, {'source_node': {'name': 'bitolterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'terazosin'}}, {'source_node': {'name': 'bitolterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bunazosin'}}, {'source_node': {'name': 'bunazosin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'salmeterol'}}, {'source_node': {'name': 'bunazosin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'levonordefrin'}}, {'source_node': {'name': 'bunazosin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hexoprenaline'}}, {'source_node': {'name': 'terazosin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'morniflumate'}}, {'source_node': {'name': 'terazosin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Loss of consciousness'}}]","[{'source_node': {'name': 'bitolterol'}, 'relation': {'name': 'decrease_activity'}, 'target_node': {'name': ' the hypokalemic activities '}}, {'source_node': {'name': 'hexoprenaline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bitolterol'}}, {'source_node': {'name': 'bunazosin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'levonordefrin'}}, {'source_node': {'name': 'bunazosin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hexoprenaline'}}, {'source_node': {'name': 'terazosin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'morniflumate'}}, {'source_node': {'name': 'terazosin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Loss of consciousness'}}, {'source_node': {'name': 'terazosin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'hexoprenaline'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:921', 'target': 'COMPOUND:8220', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:884', 'target': 'COMPOUND:1142', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:921', 'target': None, 'metadata': {'node_id': '921', 'node_type': 'COMPOUND', 'display_name': 'salmeterol'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:884', 'target': 'COMPOUND:10134', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:7904', 'target': 'COMPOUND:884', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_replacement', 'source': 'COMPOUND:884', 'target': 'ACTIVITY:38', 'metadata': {'predicate': 'decrease_activity'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1142', 'target': 'COMPOUND:7904', 'metadata': {'predicate': 'increase_efficacy'}}]",0.5882352941176471,318da299e4d0a0950f51d2a6623449f9,e7816889384bd097970d147fc76101b2,[],[]
"[{'source_node': {'name': 'spastic paraplegia 79'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'neurodegeneration'}}, {'source_node': {'name': 'spastic paraplegia 79'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'intellectual disability'}}]","[{'source_node': {'name': 'spastic paraplegia 79'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'neurodegeneration'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:950', 'target': None, 'metadata': {'node_id': '950', 'node_type': 'PHENOTYPE', 'display_name': 'intellectual disability'}}]",0.6,4e3b5c5ba8db9cdb4865cded9f46ee22,dd006d047ecb77f3c98de10649e7021c,"['Spastic paraplegia 79, a medical condition, has notable phenotypes including neurodegeneration and intellectual disability.', 'Spastic paraplegia 79 is a condition characterized by a variety of phenotypes, including neurodegeneration and intellectual disability.', 'Spastic paraplegia 79 is a condition that manifests with symptoms such as neurodegeneration and intellectual disability.', 'Spastic paraplegia 79, a neurological disorder, is characterized by certain phenotypes including neurodegeneration and intellectual disability.', 'Spastic paraplegia 79, a complex neurological condition, exhibits phenotypes such as neurodegeneration and intellectual disability.']",[]
"[{'source_node': {'name': 'icomucret'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}}, {'source_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'APEX1'}}]","[{'source_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'APEX1'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:61128', 'target': None, 'metadata': {'node_id': '61128', 'node_type': 'COMPOUND', 'display_name': 'icomucret'}}]",0.6,58fd36dc21e44c5135daa4fd675f948e,d972e718146b484c1aa84ee6894d9ad1,"['The drug Icomucret targets the DNA-(apurinic or apyrimidinic site) lyase. This enzyme is a gene product of APEX1.\n', 'The drug Icomucret targets the DNA-(apurinic or apyrimidinic site) lyase, which is a gene product of APEX1.', 'The drug Icomucret has DNA-(apurinic or apyrimidinic site) lyase as its target. It is noteworthy that DNA-(apurinic or apyrimidinic site) lyase is the gene product of APEX1.', 'The drug Icomucret targets the DNA-(apurinic or apyrimidinic site) lyase. This lyase is a gene product of APEX1.', 'The drug Icomucret has DNA-(apurinic or apyrimidinic site) lyase as its target. Interestingly, DNA-(apurinic or apyrimidinic site) lyase is a gene product of APEX1.']","['The enzyme known as DNA-(apurinic or apyrimidinic site) lyase is a gene product of APEX1.', 'The enzyme known as DNA-(apurinic or apyrimidinic site) lyase is a gene product of APEX1.']"
"[{'source_node': {'name': 'ADCYAP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'NGF-independant TRKA activation'}}, {'source_node': {'name': 'ADCYAP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (s) signalling events'}}]","[{'source_node': {'name': 'ADCYAP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'NGF-independant TRKA activation'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:424', 'target': None, 'metadata': {'node_id': '424', 'node_type': 'PATHWAY', 'display_name': 'G alpha (s) signalling events'}}]",0.6,2c351f85e09904997438a7060d8dc212,f26379bf381091462568e3717f6fb59f,[],[]
"[{'source_node': {'name': 'cholesteryl ester transfer protein'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'death'}}, {'source_node': {'name': 'cholesteryl ester transfer protein'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hyperlipidemias'}}]","[{'source_node': {'name': 'cholesteryl ester transfer protein'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'death'}}]","[{'type': 'node_removal', 'source': 'DISEASE:1514', 'target': None, 'metadata': {'node_id': '1514', 'node_type': 'DISEASE', 'display_name': 'hyperlipidemias'}}]",0.6,57d74642122797ebbc45df8ab9fcffb9,600715f0a4fef0fcb509d46507dd5956,"['The cholesteryl ester transfer protein has been associated with causing conditions such as hyperlipidemias and even death.', 'The cholesteryl ester transfer protein has been implicated in several conditions. It can cause hyperlipidemias, and in some severe cases, it has even been associated with death.', 'The cholesteryl ester transfer protein has been identified as a causative entity for two different conditions. This protein plays a role in provoking hyperlipidemias, a condition characterized by abnormally high levels of lipids in the blood. Furthermore, it also induces broader and more severe effects such as death.', 'The protein known as cholesteryl ester transfer protein is shown to cause several conditions, including death and hyperlipidemias.', 'The cholesteryl ester transfer protein has been identified as a cause of two different conditions - death and hyperlipidemias. This protein proves the interconnectedness of biochemical processes and health conditions.']",[]
"[{'source_node': {'name': 'EGLN1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'erythrocytosis'}}, {'source_node': {'name': 'erythrocytosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'increased red blood cell mass'}}, {'source_node': {'name': 'erythrocytosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypotension'}}]","[{'source_node': {'name': 'erythrocytosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'increased red blood cell mass'}}]","[{'type': 'node_removal', 'source': 'GENE:31185', 'target': None, 'metadata': {'node_id': '31185', 'node_type': 'GENE', 'display_name': 'EGLN1'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:1892', 'target': None, 'metadata': {'node_id': '1892', 'node_type': 'PHENOTYPE', 'display_name': 'hypotension'}}]",0.4285714285714286,ec126754ee3cab61ef7218670a169dc5,c88dc4ac9ab70e6ecd0105e4a85cc1ba,[],[]
"[{'source_node': {'name': 'MMP9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Signaling by SCF-KIT'}}, {'source_node': {'name': 'MMP9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Collagen degradation'}}, {'source_node': {'name': 'MMP9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Degradation of the extracellular matrix'}}]","[{'source_node': {'name': 'MMP9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Signaling by SCF-KIT'}}, {'source_node': {'name': 'MMP9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Collagen degradation'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:254', 'target': None, 'metadata': {'node_id': '254', 'node_type': 'PATHWAY', 'display_name': 'Degradation of the extracellular matrix'}}]",0.7142857142857143,c6ce2499bbf225fbf71cba4d26395d9f,3e00bc603f7fe1b1935e8c87e73d0611,"['The gene MMP9 acts within several biological processes such as signaling by SCF-KIT, collagen degradation, and degradation of the extracellular matrix.', 'The gene MMP9 operates within several pathways. It plays a role in the signaling by SCF-KIT pathway, is involved in the process of collagen degradation, and also contributes to the degradation of the extracellular matrix.', 'The protein MMP9 exhibits its function within several biochemical processes, including the signaling by SCF-KIT, collagen degradation, and the degradation of the extracellular matrix.']",['The protein MMP9 serves an integral role within the signaling by SCF-KIT pathway and is also involved in the process of collagen degradation.']
"[{'source_node': {'name': 'EIF3M'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Translation initiation complex formation'}}, {'source_node': {'name': 'EIF3M'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Formation of a pool of free 40S subunits'}}, {'source_node': {'name': 'EIF3M'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ribosomal scanning and start codon recognition'}}]","[{'source_node': {'name': 'EIF3M'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Formation of a pool of free 40S subunits'}}, {'source_node': {'name': 'EIF3M'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ribosomal scanning and start codon recognition'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:666', 'target': None, 'metadata': {'node_id': '666', 'node_type': 'PATHWAY', 'display_name': 'Translation initiation complex formation'}}]",0.7142857142857143,21c4a40fdb11a10a6fbd731e74beb094,a6b5a373e9fdaecda3674b610502b05a,"['The protein EIF3M is involved in several molecular pathways. Firstly, it acts within the formation of the translation initiation complex, a crucial step in the beginning of protein synthesis. Additionally, EIF3M plays a role in the formation of a pool of free 40S subunits, which are essential components of the cellular machinery for protein synthesis. Moreover, this protein participates in ribosomal scanning and start codon recognition, key processes in the identification and initiation of protein synthesis from the correct starting point within a messenger RNA molecule.', 'The gene EIF3M is involved in several biological processes. It acts within the formation of the translation initiation complex, a critical early step in protein synthesis. Furthermore, it has a role in the formation of a pool of free 40S subunits, which are integral components of the ribosome. Lastly, EIF3M also acts within the process of ribosomal scanning and start codon recognition, an essential step in determining the reading frame for translation.', 'The gene EIF3M is involved in several important cellular processes. It acts within the process of translation initiation complex formation, which is critical for protein synthesis. Additionally, EIF3M takes part in the formation of a pool of free 40S subunits, which are building blocks of the ribosome. Finally, the gene is also a necessary component in the process of ribosomal scanning and start codon recognition, a step that is essential for correct protein synthesis.', 'The gene EIF3M plays a significant role in several biochemical processes. It acts within the translation initiation complex formation pathway, a critical process necessary for protein synthesis. Furthermore, EIF3M is implicated in the formation of a pool of free 40S subunits, which also plays a key role in the initiation of protein translation. Importantly, EIF3M also has a role in the phase of ribosomal scanning and start codon recognition, which is critical in determining the reading frame for translation.', 'The gene EIF3M acts within several biological pathways. It is involved in the formation of the translation initiation complex, plays a role in the formation of a pool of free 40S subunits, and facilitates ribosomal scanning and start codon recognition.']","['The gene EIF3M performs its function within several biological processes. One of these includes the formation of a pool of free 40S subunits. Additionally, EIF3M is known to act within the process of ribosomal scanning and start codon recognition.', 'The gene EIF3M has various roles within critical biological processes. Notably, it acts within the formation of a pool of free 40S subunits, which is crucial in protein synthesis. Additionally, this gene also participates in ribosomal scanning and start codon recognition, contributing to the accuracy of protein translation.', 'The gene EIF3M has a crucial role within the process known as the formation of a pool of free 40S subunits. Furthermore, it also acts within the pathway governing ribosomal scanning and start codon recognition.', ""The gene EIF3M is involved in two significant cellular processes namely - the formation of a pool of free 40S subunits and ribosomal scanning and start codon recognition. The gene's role in these processes underlines its importance in the overall cellular machinery and its functionality."", 'The gene EIF3M plays a role in the formation of a pool of free 40S subunits and also acts within the pathway of ribosomal scanning and start codon recognition.']"
"[{'source_node': {'name': 'carbonic anhydrase 9'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA9'}}, {'source_node': {'name': 'carbonic anhydrase 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA2'}}, {'source_node': {'name': 'CA9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Reversible hydration of carbon dioxide'}}, {'source_node': {'name': '7-hydroxy-8-acetylcoumarin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'carbonic anhydrase 9'}}, {'source_node': {'name': '7-hydroxy-8-acetylcoumarin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'carbonic anhydrase 2'}}]","[{'source_node': {'name': 'CA2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Reversible hydration of carbon dioxide'}}, {'source_node': {'name': 'carbonic anhydrase 9'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA9'}}, {'source_node': {'name': 'CA9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Reversible hydration of carbon dioxide'}}, {'source_node': {'name': '7-hydroxy-8-acetylcoumarin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'carbonic anhydrase 9'}}]","[{'type': 'edge_addition', 'source': 'GENE:33598', 'target': 'PATHWAY:994', 'metadata': {'predicate': 'acts_within'}}, {'type': 'edge_addition', 'source': 'PROTEIN:889', 'target': 'GENE:33613', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:62805', 'target': 'PROTEIN:889', 'metadata': None}, {'type': 'node_removal', 'source': 'PROTEIN:889', 'target': None, 'metadata': {'node_id': '889', 'node_type': 'PROTEIN', 'display_name': 'carbonic anhydrase 2'}}]",0.6363636363636364,8ffd886c30ef3e118174f2be56b2fa61,4e9baa86cfcff41f5aa0d4d19a1267e1,"['Carbonic anhydrase 9 and carbonic anhydrase 2 are both gene products of CA9 and CA2 genes respectively. The CA9 gene also acts within the process of reversible hydration of carbon dioxide. Furthermore, the compound 7-hydroxy-8-acetylcoumarin has carbonic anhydrase 9 and carbonic anhydrase 2 as its targets.', 'Carbonic Anhydrase 9 and Carbonic Anhydrase 2 are gene products of CA9 and CA2, respectively. Particularly, CA9 is involved in the reversible hydration of carbon dioxide pathway. Interesting to note is that 7-hydroxy-8-acetylcoumarin, a compound, targets both Carbonic Anhydrase 9 and Carbonic Anhydrase 2.', 'Carbonic anhydrase 9 and carbonic anhydrase 2 are gene products of CA9 and CA2 respectively. Interestingly, CA9 acts within the pathway of reversible hydration of carbon dioxide. Furthermore, 7-hydroxy-8-acetylcoumarin, a potent compound, targets both carbonic anhydrase 9 and carbonic anhydrase 2 potentially impacting these processes.', 'Carbonic anhydrase 9 is a gene product of CA9, and carbonic anhydrase 2 is a gene product of CA2. Notably, CA9 acts within the pathway of reversible hydration of carbon dioxide. In the pharmacological context, the compound 7-hydroxy-8-acetylcoumarin targets both carbonic anhydrase 9 and carbonic anhydrase 2.']","['The gene protein CA2 acts within a biological process known as the reversible hydration of carbon dioxide. Similarly, the gene CA9 also participates in the reversible hydration of carbon dioxide. Carbonic anhydrase 9 is a gene product of CA9 and is targeted by a compound known as 7-hydroxy-8-acetylcoumarin.', 'The enzyme CA2 acts within the reversible hydration of carbon dioxide pathway. This enzymatic process is also facilitated by CA9, a gene product of carbonic anhydrase 9. Furthermore, the drug 7-hydroxy-8-acetylcoumarin specifically targets carbonic anhydrase 9, aiding the function of both CA2 and CA9 within the carbon dioxide hydration process.']"
"[{'source_node': {'name': '1,6-do-o-galloyl-beta-d-glucose'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}, {'source_node': {'name': '1,6-do-o-galloyl-beta-d-glucose'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'synaptojanin-2'}}, {'source_node': {'name': '1,6-do-o-galloyl-beta-d-glucose'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'synaptojanin-1'}}, {'source_node': {'name': 'SYNJ1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'young-onset parkinson disease'}}, {'source_node': {'name': 'synaptojanin-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SYNJ1'}}, {'source_node': {'name': 'SYNJ2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of PIPs at the plasma membrane'}}, {'source_node': {'name': 'SYNJ2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Clathrin-mediated endocytosis'}}, {'source_node': {'name': 'synaptojanin-2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SYNJ2'}}]","[{'source_node': {'name': '1,6-do-o-galloyl-beta-d-glucose'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}, {'source_node': {'name': '1,6-do-o-galloyl-beta-d-glucose'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'synaptojanin-2'}}, {'source_node': {'name': 'SYNJ2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of PIPs at the plasma membrane'}}, {'source_node': {'name': 'SYNJ2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Clathrin-mediated endocytosis'}}, {'source_node': {'name': 'SYNJ2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'young-onset parkinson disease'}}, {'source_node': {'name': 'synaptojanin-2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SYNJ2'}}]","[{'type': 'edge_addition', 'source': 'GENE:34932', 'target': 'DISEASE:4290', 'metadata': {'predicate': 'causes_condition'}}, {'type': 'node_removal', 'source': 'PROTEIN:6489', 'target': None, 'metadata': {'node_id': '6489', 'node_type': 'PROTEIN', 'display_name': 'synaptojanin-1'}}, {'type': 'node_removal', 'source': 'GENE:34918', 'target': None, 'metadata': {'node_id': '34918', 'node_type': 'GENE', 'display_name': 'SYNJ1'}}]",0.6470588235294117,edd240c23a0a466a9633f1258cb837a6,bc2681d9fe43290570e36ade6f34e7fc,"[""The compound 1,6-do-o-galloyl-beta-d-glucose targets three entities: one known as kb, and two proteins known as synaptojanin-1 and synaptojanin-2. Synaptojanin-1 is a gene product of SYNJ1, which interestingly, is linked to a condition known as young-onset Parkinson's disease. On the other hand, synaptojanin-2 is a gene product of SYNJ2, a gene that plays critical roles in two biological processes, synthesis of PIPs at the plasma membrane and clathrin-mediated endocytosis.""]","['The drug 1,6-do-o-galloyl-beta-d-glucose targets both kb and synaptojanin-2. Synaptojanin-2 is the gene product of SYNJ2. SYNJ2 acts within two pathways: the synthesis of PIPs at the plasma membrane and clathrin-mediated endocytosis. Interestingly, SYNJ2 can cause a condition known as young-onset parkinson disease.', 'The compound 1,6-do-o-galloyl-beta-d-glucose targets both KB and Synaptojanin-2. Synaptojanin-2 is, in fact, a gene product of SYNJ2. SYNJ2, on its part, operates within multiple pathways such as the synthesis of PIPs at the plasma membrane and clathrin-mediated endocytosis. Notably, SYNJ2 is implicated in causing Young-onset Parkinson disease.', ""The compound 1,6-do-o-galloyl-beta-d-glucose has known target interactions with both kb and synaptojanin-2. Interestingly, synaptojanin-2 is the gene product of SYNJ2. Furthermore, SYNJ2 acts within some critical biological processes, such as the synthesis of PIPs at the plasma membrane and clathrin-mediated endocytosis. It is noteworthy to mention that mutations in SYNJ2 have been linked to causes of young-onset Parkinson's disease."", 'The compound 1,6-do-o-galloyl-beta-d-glucose targets KB and Synaptojanin-2. Synaptojanin-2 is a gene product of SYNJ2, a gene which plays a crucial role in several pathways. Specifically, SYNJ2 acts within the synthesis of PIPs at the plasma membrane and is also involved in clathrin-mediated endocytosis. Importantly, the malfunction or alteration of SYNJ2 can cause young-onset Parkinson disease.', 'The compound, 1,6-do-o-galloyl-beta-d-glucose, exhibits its effect by targeting two significant entities: kb and synaptojanin-2. Interestingly, synaptojanin-2 is derived as a gene product from SYNJ2. SYNJ2, in turn, is acting within two biological processes, which are the synthesis of PIPs at the plasma membrane and clathrin-mediated endocytosis. Moreover, studies have suggested that SYNJ2 is directly involved in causing a condition known as young-onset Parkinson disease.']"
"[{'source_node': {'name': 'cycloguanil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '(6s)-5,6,7,8-tetrahydrofolic acid'}}, {'source_node': {'name': 'cycloguanil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'triglu-5-formyl-tetrahydrofolate'}}, {'source_node': {'name': 'cycloguanil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'levoleucovorin'}}, {'source_node': {'name': 'levoleucovorin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'levoleucovorin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nolatrexed'}}]","[{'source_node': {'name': 'cycloguanil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '(6s)-5,6,7,8-tetrahydrofolic acid'}}, {'source_node': {'name': 'cycloguanil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'triglu-5-formyl-tetrahydrofolate'}}, {'source_node': {'name': 'nolatrexed'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'triglu-5-formyl-tetrahydrofolate'}}, {'source_node': {'name': 'levoleucovorin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'levoleucovorin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nolatrexed'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:10789', 'target': 'COMPOUND:1959', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:12464', 'target': 'COMPOUND:9519', 'metadata': None}]",0.8181818181818181,6d725d3625e23f0ca5357e1dcf26cae5,dd038be94b10b8e44fe8e010cf6afd6e,[],[]
"[{'source_node': {'name': 'PROC'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'thrombophilia'}}, {'source_node': {'name': 'PROC'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Common Pathway of Fibrin Clot Formation'}}, {'source_node': {'name': 'cupric chloride'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'vitamin k-dependent protein c'}}, {'source_node': {'name': 'cupric chloride'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cystatin-b'}}, {'source_node': {'name': 'vitamin k-dependent protein c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PROC'}}, {'source_node': {'name': 'cystatin-b'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CSTB'}}, {'source_node': {'name': 'CSTB'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'epilepsy'}}, {'source_node': {'name': 'CSTB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}]","[{'source_node': {'name': 'PROC'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'thrombophilia'}}, {'source_node': {'name': 'PROC'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Common Pathway of Fibrin Clot Formation'}}, {'source_node': {'name': 'PROC'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}, {'source_node': {'name': 'cupric chloride'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'vitamin k-dependent protein c'}}, {'source_node': {'name': 'vitamin k-dependent protein c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PROC'}}, {'source_node': {'name': 'vitamin k-dependent protein c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CSTB'}}, {'source_node': {'name': 'cystatin-b'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CSTB'}}, {'source_node': {'name': 'cystatin-b'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PROC'}}, {'source_node': {'name': 'CSTB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}, {'source_node': {'name': 'CSTB'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'thrombophilia'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:4372', 'target': 'GENE:31725', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'GENE:31725', 'target': 'PATHWAY:3', 'metadata': {'predicate': 'acts_within'}}, {'type': 'node_removal', 'source': 'DISEASE:15008', 'target': None, 'metadata': {'node_id': '15008', 'node_type': 'DISEASE', 'display_name': 'epilepsy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:8070', 'target': 'PROTEIN:4372', 'metadata': None}, {'type': 'edge_addition', 'source': 'GENE:26144', 'target': 'DISEASE:14831', 'metadata': {'predicate': 'causes_condition'}}, {'type': 'edge_addition', 'source': 'PROTEIN:697', 'target': 'GENE:26144', 'metadata': {'predicate': 'gene_product_of'}}]",0.5882352941176471,a8b37d6edae448a1110d41006f0da6e3,2159dc25e0103284992308f96706dcb1,"['The gene PROC, which acts within the common pathway of fibrin clot formation, is responsible for causing a condition known as thrombophilia. Cupric chloride, a chemical compound, targets two specific entities, Vitamin K-dependent protein C and cystatin-B, both notable within biological processes. Vitamin K-dependent protein C is a gene product of PROC, which as mentioned earlier, plays a role in causing thrombophilia. Cystatin-B, on the other hand, is a gene product of CSTB. CSTB also plays a role in causing a condition, specifically epilepsy, and is active within a process known as neutrophil degranulation.', 'The gene PROC, which causes a condition known as thrombophilia, acts within the common pathway of fibrin clot formation. The drug cupric chloride targets two proteins: vitamin k-dependent protein c and cystatin-b. Vitamin k-dependent protein c is a gene product of PROC. Meanwhile, cystatin-b is a gene product of CSTB. CSTB not only causes a condition termed as epilepsy but it also acts within a process referred to as neutrophil degranulation.', 'The gene PROC is known to cause a condition known as thrombophilia and acts within the common pathway of fibrin clot formation. A compound called cupric chloride targets two proteins: vitamin K-dependent protein C and cystatin-b. These proteins are gene products of PROC and CSTB respectively. While PROC is involved in causing thrombophilia, CSTB leads to epilepsy and acts within the biological process of neutrophil degranulation.', 'The gene PROC, which operates within the common pathway of fibrin clot formation, can lead to a condition known as thrombophilia. The drug Cupric Chloride targets two important proteins, which include vitamin k-dependent protein c and cystatin-b. The vitamin k-dependent protein c is a gene product of PROC, while cystatin-b is a gene product of CSTB. The gene CSTB has been affiliated with the cause of epilepsy and is also known to act within the process of neutrophil degranulation.']","[""The gene PROC is known to play an active role within both the common pathway of fibrin clot formation and neutrophil degranulation. Interestingly, PROC also leads to a condition known as thrombophilia. Vitamins also play a role in this complex network; for instance, the vitamin k-dependent protein C is a product of PROC, and it is targeted by the drug cupric chloride. It's worth noting that vitamin k-dependent protein C is also a product of CSTB. \n\nThis leads us to another gene, CSTB, which acts within the neutrophil degranulation path as well. Additionally, CSTB contributes to the condition called thrombophilia. Furthermore, cystatin-B, another product of this system, is generated from both CSTB and PROC. Thus, PROC, CSTB, various proteins, and even some drugs like cupric chloride intricately interact within these pathways and the conditions they cause.""]"
"[{'source_node': {'name': 'chondroitin sulfate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'vascular endothelial growth factor a'}}, {'source_node': {'name': 'chondroitin sulfate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'c-c motif chemokine 2'}}, {'source_node': {'name': 'chondroitin sulfate'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the anticoagulant activities '}}]","[{'source_node': {'name': 'chondroitin sulfate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'vascular endothelial growth factor a'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:1560', 'target': None, 'metadata': {'node_id': '1560', 'node_type': 'PROTEIN', 'display_name': 'c-c motif chemokine 2'}}, {'type': 'node_removal', 'source': 'ACTIVITY:1', 'target': None, 'metadata': {'node_id': '1', 'node_type': 'ACTIVITY', 'display_name': ' the anticoagulant activities '}}]",0.4285714285714286,d0bfc4d36d8ea610c550a5847ce67451,74f6dee375bb305b6169ccb65b954bac,[],['Chondroitin sulfate targets the vascular endothelial growth factor A.']
"[{'source_node': {'name': 'cardiac valvular dysplasia 2'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'congenital onset'}}, {'source_node': {'name': 'cardiac valvular dysplasia 2'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'chest pain'}}]","[{'source_node': {'name': 'cardiac valvular dysplasia 2'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'congenital onset'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:11177', 'target': None, 'metadata': {'node_id': '11177', 'node_type': 'PHENOTYPE', 'display_name': 'chest pain'}}]",0.6,bf04158ecda1f550e8b36d96960e6cf8,fff753b826de1d8adaf73e6e65374938,[],[]
"[{'source_node': {'name': 'emetonium iodide'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' urinary retention '}}, {'source_node': {'name': 'emetonium iodide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tretamine'}}]","[{'source_node': {'name': 'tretamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'emetonium iodide'}}, {'source_node': {'name': 'emetonium iodide'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' urinary retention '}}, {'source_node': {'name': 'emetonium iodide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tretamine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:11865', 'target': 'COMPOUND:11616', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.8,f5d5c41b0452becb3377d1f4dca023f5,c1c4734024eadc08edb93e652c76ef8a,[],[]
"[{'source_node': {'name': 'lecithin retinol acyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'LRAT'}}, {'source_node': {'name': 'LRAT'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'leber congenital amaurosis 14'}}, {'source_node': {'name': 'LRAT'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'leber congenital amaurosis'}}, {'source_node': {'name': 'LRAT'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Retinoid metabolism and transport'}}]","[{'source_node': {'name': 'LRAT'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'leber congenital amaurosis 14'}}, {'source_node': {'name': 'LRAT'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'leber congenital amaurosis'}}, {'source_node': {'name': 'LRAT'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Retinoid metabolism and transport'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:672', 'target': None, 'metadata': {'node_id': '672', 'node_type': 'PROTEIN', 'display_name': 'lecithin retinol acyltransferase'}}]",0.7777777777777778,c0dc01784fd781a4b603cef4e3fc4b92,294bf669d42319a883b12153c15441f5,"['Lecithin retinol acyltransferase is a gene product of LRAT, which operates within the pathway of retinoid metabolism and transport. LRAT is known to cause conditions like Leber congenital amaurosis 14 and Leber congenital amaurosis.', 'Lecithin retinol acyltransferase is the gene product of LRAT. LRAT acts within the pathway of retinoid metabolism and transport. Interestingly, LRAT is known to cause conditions such as Leber congenital amaurosis and Leber congenital amaurosis 14.', 'The enzyme, lecithin retinol acyltransferase, is a gene product of LRAT. LRAT is known to act within the pathway of retinoid metabolism and transport. Additionally, LRAT is associated with causing certain medical conditions such as Leber congenital amaurosis 14 and Leber congenital amaurosis.']","['The gene LRAT, which operates within the pathway of retinoid metabolism and transport, is known to cause two related conditions: Leber congenital amaurosis 14 and Leber congenital amaurosis.', 'The gene LRAT, which acts within the retinoid metabolism and transport pathway, has been associated with causing both Leber Congenital Amaurosis 14 and the more broadly defined condition of Leber Congenital Amaurosis.', 'The gene LRAT, which acts within the retinoid metabolism and transport pathway, is known to be responsible for causing conditions such as Leber Congenital Amaurosis 14 and Leber Congenital Amaurosis.', 'The gene LRAT, which functions within the pathway of retinoid metabolism and transport, is known to cause certain conditions. These include Leber congenital amaurosis and a subtype known as Leber congenital amaurosis 14.', 'The gene LRAT, which plays a critical role in the Retinoid metabolism and transport, is known to cause two conditions: Leber congenital amaurosis and Leber congenital amaurosis 14.']"
"[{'source_node': {'name': 'apolizumab'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the thrombogenic activities '}}, {'source_node': {'name': 'apolizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imlifidase'}}]","[{'source_node': {'name': 'apolizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imlifidase'}}]","[{'type': 'node_removal', 'source': 'ACTIVITY:2', 'target': None, 'metadata': {'node_id': '2', 'node_type': 'ACTIVITY', 'display_name': ' the thrombogenic activities '}}]",0.6,d2f7b07b075768f8f7f40734cd0dc1c8,011eb0cabb7f6b5f4eaf55ff2036bf83,[],"['The drug apolizumab may reduce the efficacy of another drug named imlifidase.', 'The drug apolizumab can decrease the efficacy of imlifidase.', 'The drug apolizumab can decrease the efficacy of another drug, imlifidase.', 'The drug apolizumab has been observed to decrease the efficacy of another medication, imlifidase.', 'The drug apolizumab is known to decrease the efficacy of another drug known as imlifidase.']"
"[{'source_node': {'name': 'methoserpidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'kebuzone'}}, {'source_node': {'name': 'methoserpidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dexibuprofen'}}, {'source_node': {'name': 'methoserpidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bumadizone'}}, {'source_node': {'name': 'phentolamine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'hydroflumethiazide'}}, {'source_node': {'name': 'parecoxib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phentolamine'}}, {'source_node': {'name': 'parecoxib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methoserpidine'}}, {'source_node': {'name': 'parecoxib'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Alanine aminotransferase increased'}}]","[{'source_node': {'name': 'methoserpidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'kebuzone'}}, {'source_node': {'name': 'methoserpidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dexibuprofen'}}, {'source_node': {'name': 'methoserpidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bumadizone'}}, {'source_node': {'name': 'phentolamine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'hydroflumethiazide'}}, {'source_node': {'name': 'phentolamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'kebuzone'}}, {'source_node': {'name': 'parecoxib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phentolamine'}}, {'source_node': {'name': 'parecoxib'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Alanine aminotransferase increased'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:677', 'target': 'COMPOUND:7887', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:7426', 'target': 'COMPOUND:11479', 'metadata': None}]",0.8666666666666667,44249b9a3a7f8cd0c3529008d7cbdd75,48bcd59371cca120a00fadf8f375e3b5,[],[]
"[{'source_node': {'name': 'wolf-hirschhorn syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cleft palate'}}, {'source_node': {'name': 'PIGG'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'mental retardation'}}, {'source_node': {'name': 'PIGG'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'wolf-hirschhorn syndrome'}}, {'source_node': {'name': 'PIGG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of glycosylphosphatidylinositol (GPI)'}}, {'source_node': {'name': 'mental retardation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'attention deficit hyperactivity disorder'}}, {'source_node': {'name': 'mental retardation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'global developmental delay'}}, {'source_node': {'name': 'mental retardation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of the nose'}}]","[{'source_node': {'name': 'wolf-hirschhorn syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cleft palate'}}, {'source_node': {'name': 'PIGG'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'wolf-hirschhorn syndrome'}}, {'source_node': {'name': 'PIGG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of glycosylphosphatidylinositol (GPI)'}}, {'source_node': {'name': 'mental retardation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'attention deficit hyperactivity disorder'}}, {'source_node': {'name': 'mental retardation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'global developmental delay'}}, {'source_node': {'name': 'mental retardation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cleft palate'}}]","[{'type': 'edge_addition', 'source': 'DISEASE:4510', 'target': 'PHENOTYPE:151', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_deletion', 'source': 'GENE:31252', 'target': 'DISEASE:4510', 'metadata': None}, {'type': 'node_removal', 'source': 'PHENOTYPE:289', 'target': None, 'metadata': {'node_id': '289', 'node_type': 'PHENOTYPE', 'display_name': 'abnormality of the nose'}}]",0.7333333333333334,6d222f0d5e60d478c48af3d05754ee47,f0efbf42908bb4f68e08ac8461c94148,"['The gene PIGG acts within the process of synthesis of glycosylphosphatidylinositol (GPI) and causes certain conditions such as mental retardation and Wolf-Hirschhorn syndrome. Mental retardation is a disorder characterized by a variety of phenotypes including attention deficit hyperactivity disorder, global developmental delay, and abnormality of the nose. On the other hand, Wolf-Hirschhorn syndrome is a genetic disorder which may have a phenotype of cleft palate.', 'The gene PIGG, which is involved in the synthesis of glycosylphosphatidylinositol (GPI), causes several conditions including mental retardation and Wolf-Hirschhorn syndrome. Mental retardation presents with various phenotypes such as attention deficit hyperactivity disorder, global developmental delay, and abnormalities of the nose. Additionally, Wolf-Hirschhorn syndrome, another condition caused by the PIGG gene, manifests with phenotypes such as a cleft palate.', 'The gene PIGG, which acts within the pathway of synthesis of glycosylphosphatidylinositol (GPI), is known to cause several conditions including mental retardation and Wolf-Hirschhorn syndrome. Mental retardation is characterized by various phenotypes inclusive of attention deficit hyperactivity disorder, global developmental delay and abnormality of the nose. Wolf-Hirschhorn syndrome, another condition caused by PIGG, manifests one of its phenotypes as a cleft palate.']","['Wolf-Hirschhorn syndrome, caused by the gene PIGG, exhibits the phenotype of having a cleft palate. The gene PIGG acts within the pathway of synthesis of glycosylphosphatidylinositol (GPI). \n\nOn the other hand, mental retardation, another form of neurodevelopmental disorder, is clinically characterized by multiple phenotypes including attention deficit hyperactivity disorder, global developmental delay, and a similar symptom as Wolf-Hirschhorn syndrome, which is the occurrence of a cleft palate.']"
"[{'source_node': {'name': 'lofexidine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'botulinum toxin type b'}}, {'source_node': {'name': 'lofexidine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'acetazolamide'}}, {'source_node': {'name': 'lofexidine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'levobupivacaine'}}, {'source_node': {'name': 'cerlapirdine'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' neuropsychiatric effects '}}, {'source_node': {'name': 'cerlapirdine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pregabalin'}}, {'source_node': {'name': 'cerlapirdine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'lofexidine'}}]","[{'source_node': {'name': 'lofexidine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'acetazolamide'}}, {'source_node': {'name': 'lofexidine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'levobupivacaine'}}, {'source_node': {'name': 'lofexidine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pregabalin'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:10133', 'target': 'COMPOUND:4653', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:4653', 'target': 'COMPOUND:220', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:40', 'target': None, 'metadata': {'node_id': '40', 'node_type': 'COMPOUND', 'display_name': 'botulinum toxin type b'}}, {'type': 'node_removal', 'source': 'COMPOUND:10133', 'target': None, 'metadata': {'node_id': '10133', 'node_type': 'COMPOUND', 'display_name': 'cerlapirdine'}}]",0.4615384615384615,28a48ff958c2e3d7c8d68bb54f66d62f,7dedc34f74efaa87753e9b0e9185a591,[],"['The drug Lofexidine is known to increase the efficacy of multiple medications such as Acetazolamide, Levobupivacaine and Pregabalin.', 'Lofexidine is a medication that is known to increase the efficacy of several other drugs. Specifically, it promotes the effectiveness of acetazolamide, levobupivacaine, and pregabalin.', 'The drug lofexidine has been shown to increase the efficacy of multiple pharmaceutical substances including acetazolamide, levobupivacaine, and pregabalin. This suggests potential interaction mechanisms where co-administration with lofexidine could enhance therapeutic effects.', 'The drug Lofexidine is known to increase the efficacy of Acetazolamide, Levobupivacaine and Pregabalin. This means that these drugs are more effective in their ability to treat conditions when used in conjunction with Lofexidine.', 'The drug Lofexidine is known to enhance the efficacy of several other drugs, including Acetazolamide, Levobupivacaine, and Pregabalin.']"
"[{'source_node': {'name': 'trilostane'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' methemoglobinemia '}}, {'source_node': {'name': 'trilostane'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methanesulfonyl fluoride'}}, {'source_node': {'name': 'trilostane'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mifamurtide'}}, {'source_node': {'name': 'gallamine triethiodide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trilostane'}}, {'source_node': {'name': 'gallamine triethiodide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'apramycin'}}, {'source_node': {'name': 'gallamine triethiodide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'glycerin'}}]","[{'source_node': {'name': 'trilostane'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' methemoglobinemia '}}, {'source_node': {'name': 'trilostane'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methanesulfonyl fluoride'}}, {'source_node': {'name': 'trilostane'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mifamurtide'}}, {'source_node': {'name': 'apramycin'}, 'relation': {'name': 'decrease_effect'}, 'target_node': {'name': ' methemoglobinemia '}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:471', 'target': 'COMPOUND:1088', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:4347', 'target': 'COMPOUND:8342', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:471', 'target': None, 'metadata': {'node_id': '471', 'node_type': 'COMPOUND', 'display_name': 'gallamine triethiodide'}}, {'type': 'edge_addition', 'source': 'COMPOUND:4347', 'target': 'EFFECT:8', 'metadata': {'predicate': 'decrease_effect'}}, {'type': 'node_removal', 'source': 'COMPOUND:8342', 'target': None, 'metadata': {'node_id': '8342', 'node_type': 'COMPOUND', 'display_name': 'glycerin'}}]",0.5384615384615384,a6a0cac68b6a2227edede88a0e11f4a3,f75f97c37b50b3c9693be3e14ff97f59,[],[]
"[{'source_node': {'name': 'melevodopa'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mesoridazine'}}, {'source_node': {'name': 'melevodopa'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'quetiapine'}}, {'source_node': {'name': 'melevodopa'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'aripiprazole lauroxil'}}, {'source_node': {'name': 'mesoridazine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the anticholinergic activities '}}]","[{'source_node': {'name': 'melevodopa'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mesoridazine'}}, {'source_node': {'name': 'melevodopa'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'aripiprazole lauroxil'}}, {'source_node': {'name': 'mesoridazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'aripiprazole lauroxil'}}, {'source_node': {'name': 'mesoridazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'melevodopa'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:1204', 'target': None, 'metadata': {'node_id': '1204', 'node_type': 'COMPOUND', 'display_name': 'quetiapine'}}, {'type': 'node_removal', 'source': 'ACTIVITY:43', 'target': None, 'metadata': {'node_id': '43', 'node_type': 'ACTIVITY', 'display_name': ' the anticholinergic activities '}}, {'type': 'edge_addition', 'source': 'COMPOUND:916', 'target': 'COMPOUND:12009', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:916', 'target': 'COMPOUND:11169', 'metadata': {'predicate': 'increase_efficacy'}}]",0.3333333333333333,12260fd0168065195065653237ef3764,0215e5e7b58426f5206dd7a98bbd0596,[],"[""The drug melevodopa has been shown to decrease the efficacy of both mesoridazine and aripiprazole lauroxil. Interestingly, mesoridazine also reduces the efficacy of aripiprazole lauroxil. However, this interaction isn't one-directional as mesoridazine actually increases the efficacy of melevodopa. These complex interactions exemplify the intricate balance needed when administering multitherapies involving these drugs."", 'The drug melevodopa is known to decrease the efficacy of both mesoridazine and aripiprazole lauroxil. Interestingly, mesoridazine also decreases the efficacy of aripiprazole lauroxil but increases the efficacy of melevodopa. This intricate relationship could have implications in drug interaction studies and dosing considerations for patients on these medications.', 'The drug melevodopa is known to decrease the efficacy of both mesoridazine and aripiprazole lauroxil. Interestingly, mesoridazine itself also reduces the efficacy of aripiprazole lauroxil, but contrary to this, it increases the efficacy of melevodopa. Thus, there is a complex relationship in the interactions of these drugs where the effects are not consistently inhibitory or enhancing.', 'The drug melevodopa is known to reduce the efficacy of other drugs like mesoridazine and aripiprazole lauroxil. Interestingly, mesoridazine also decreases the effectiveness of aripiprazole lauroxil, but it has an inverse effect on melevodopa, actually increasing its efficacy.', 'The drug Melevodopa holds the capacity to decrease the efficacy of both Mesoridazine and Aripiprazole Lauroxil. Interestingly, while Melevodopa diminishes the effectiveness of Mesoridazine, it is conversely proposed that Mesoridazine can potentially amplify the efficacy of Melevodopa. Mesoridazine also shares a similar relationship with Aripiprazole Lauroxil in that it lessens the efficacy of the latter. These interactions highlight the interconnected and complex relationships that drugs can have with one another and their potential implications on patient treatment strategies.']"
"[{'source_node': {'name': 'solifenacin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'linaclotide'}}, {'source_node': {'name': 'solifenacin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Dry eye'}}, {'source_node': {'name': 'solifenacin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Ileus'}}, {'source_node': {'name': 'linaclotide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'codeine'}}, {'source_node': {'name': 'linaclotide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'umeclidinium'}}]","[{'source_node': {'name': 'umeclidinium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'linaclotide'}}, {'source_node': {'name': 'solifenacin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Dry eye'}}, {'source_node': {'name': 'solifenacin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Ileus'}}, {'source_node': {'name': 'linaclotide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'umeclidinium'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:1520', 'target': 'COMPOUND:7842', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:8016', 'target': 'COMPOUND:7842', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:308', 'target': None, 'metadata': {'node_id': '308', 'node_type': 'COMPOUND', 'display_name': 'codeine'}}]",0.6363636363636364,62f5e74276e4ae41762804687de628c9,819d5f6871304ef78217cc53b6b21b29,"['The drug solifenacin has been reported to decrease the efficacy of linaclotide, another pharmaceutical compound. Furthermore, solifenacin has been associated with a variety of side effects including dry eye and ileus. On the other hand, the drug linaclotide can also decrease the effectiveness of other medications such as codeine and umeclidinium.', 'Solifenacin is a drug that can have various impacts including decreasing the efficacy of linaclotide. Additionally, solifenacin can lead to side effects such as dry eye and ileus. On the other hand, linaclotide, which is impacted by solifenacin, can also decrease the efficacy of codeine and umeclidinium. Thus careful management of these interactions must be considered in the course of treatment.', 'Solifenacin, a commonly prescribed medication, has been known to decrease the efficacy of linaclotide and has side effects such as dry eye and ileus. Similarly, linaclotide may also decrease the efficacy of other drugs like codeine and umeclidinium. It is important to monitor these interactions and side effects to ensure the best possible patient outcomes.', 'The drug solifenacin is associated with certain side effects including dry eye and ileus. Additionally, it has been noted to decrease the efficacy of another drug, linaclotide. In turn, linaclotide is also associated with a reduction in efficacy of certain medications, specifically codeine and umeclidinium.', 'The medication Solifenacin has been associated with various side effects, including Dry Eye and Ileus. Additionally, it has been found to decrease the efficacy of the drug Linaclotide. In turn, Linaclotide also appears to decrease the efficacy of Codeine and Umeclidinium, thereby impacting their therapeutic benefits.']","[""The drugs Umeclidinium and Linaclotide interact in a way that decreases each other's efficacy. Meanwhile, another drug, Solifenacin, is observed to have side effects, including dry eye and ileus."", 'The drug umeclidinium may decrease the efficacy of another medication, linaclotide. Similarly, linaclotide also has the potential to adversely affect the efficacy of umeclidinium. On another note, solifenacin, a different drug, has been reported to cause side effects such as Dry eye and Ileus.', 'The drug Umeclidinium is known to decrease the efficacy of another medication, Linaclotide. On a related note, the drug Solifenacin can have various side effects, including Dry eye and Ileus. Interestingly, the efficacy of Umeclidinium can also be decreased by Linaclotide. Thus, patients taking these combinations of drugs should be closely monitored for these potential interactions and side effects.', 'The drug umeclidinium decreases the efficacy of another drug called linaclotide. Similarly, linaclotide also hampers the efficacy of umeclidinium. On a related note, solifenacin, a different drug, has been observed to have certain side effects. Consuming solifenacin could lead to dry eye and ileus.', 'The drug Umeclidinium has been found to decrease the efficacy of Linaclotide. Additionally, it has also been observed that Solifenacin can produce side effects such as dry eye and ileus. Interestingly, Linaclotide in turn is known to decrease the efficacy of Umeclidinium, suggesting a potential reciprocal interaction between these drugs.']"
"[{'source_node': {'name': 'carbaryl'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dipyridamole'}}, {'source_node': {'name': 'dipyridamole'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cefoperazone'}}, {'source_node': {'name': 'dipyridamole'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ceftolozane'}}, {'source_node': {'name': 'dipyridamole'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'factor xiii (human)'}}, {'source_node': {'name': 'factor xiii (human)'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'drotrecogin alfa'}}, {'source_node': {'name': 'cefoperazone'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the excretion rate '}}, {'source_node': {'name': 'cefoperazone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cangrelor'}}, {'source_node': {'name': 'cefoperazone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'monteplase'}}]","[{'source_node': {'name': 'carbaryl'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dipyridamole'}}, {'source_node': {'name': 'dipyridamole'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'factor xiii (human)'}}, {'source_node': {'name': 'cefoperazone'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the excretion rate '}}, {'source_node': {'name': 'cefoperazone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cangrelor'}}, {'source_node': {'name': 'cefoperazone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'monteplase'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:7991', 'target': None, 'metadata': {'node_id': '7991', 'node_type': 'COMPOUND', 'display_name': 'ceftolozane'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:958', 'target': 'COMPOUND:1289', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:53', 'target': None, 'metadata': {'node_id': '53', 'node_type': 'COMPOUND', 'display_name': 'drotrecogin alfa'}}]",0.7058823529411764,a801703fc07aeacbd214e140c494a4fe,f25f91af49cbf5a6a8f1c59f5d237cfa,[],[]
"[{'source_node': {'name': 'g protein subunit beta 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'liver cirrhosis'}}, {'source_node': {'name': 'g protein subunit beta 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'tachycardia'}}, {'source_node': {'name': 'g protein subunit beta 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'schizophrenia'}}, {'source_node': {'name': 'schizophrenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hallucinations'}}, {'source_node': {'name': 'schizophrenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'social and occupational deterioration'}}]","[{'source_node': {'name': 'tachycardia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hallucinations'}}, {'source_node': {'name': 'liver cirrhosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hallucinations'}}, {'source_node': {'name': 'liver cirrhosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'social and occupational deterioration'}}, {'source_node': {'name': 'g protein subunit beta 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'liver cirrhosis'}}, {'source_node': {'name': 'g protein subunit beta 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'tachycardia'}}, {'source_node': {'name': 'schizophrenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hallucinations'}}, {'source_node': {'name': 'schizophrenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'social and occupational deterioration'}}]","[{'type': 'edge_deletion', 'source': 'GENE:7276', 'target': 'DISEASE:13792', 'metadata': None}, {'type': 'edge_addition', 'source': 'DISEASE:1863', 'target': 'PHENOTYPE:575', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_addition', 'source': 'DISEASE:3113', 'target': 'PHENOTYPE:575', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_addition', 'source': 'DISEASE:1863', 'target': 'PHENOTYPE:4576', 'metadata': {'predicate': 'has_phenotype'}}]",0.6363636363636364,e2e92da86e86860c3ba8d7e829ef3c83,58424f62ead62aceac9ec5481071e3a7,"['The gene known as G protein subunit beta 3 has been identified as a causal factor in several conditions including liver cirrhosis, tachycardia, and schizophrenia. Among these conditions, schizophrenia is characterized by certain phenotypes like hallucinations and social and occupational deterioration.', 'The G protein subunit beta 3 is implicated in causing a number of conditions, including liver cirrhosis, tachycardia, and schizophrenia. In particular, schizophrenia manifests through various phenotypes such as hallucinations and a noticeable social and occupational deterioration.', 'The gene referred to as G protein subunit beta 3 holds significant roles in causing various conditions such as liver cirrhosis and tachycardia. Notably, it also causes schizophrenia, a complex psychological disorder characterized by phenotypes such as hallucinations and a pronounced social and occupational deterioration.', 'The G protein subunit beta 3 is implicated in causing several conditions including liver cirrhosis, tachycardia and schizophrenia. Schizophrenia, a complex psychiatric disorder, is characterised by symptoms that include hallucinations as well as social and occupational deterioration.']","['Tachycardia, a rapid heart rate condition caused by the G protein subunit beta 3, is often characterized by hallucinations. The same hallucinations are also associated with liver cirrhosis, a disease also caused by the G protein subunit beta 3. This liver disease not only brings about hallucinations but also leads to social and occupational deterioration. Interestingly, hallucinations and social and occupational deterioration are also phenotypes frequently observed in patients with schizophrenia.', 'The gene G protein subunit beta 3 has been documented to cause two health conditions: tachycardia and liver cirrhosis. Notably, tachycardia is characterised by symptoms such as hallucinations, while liver cirrhosis has phenotypes which include social and occupational deterioration in addition to hallucinations. These symptoms of hallucinations are also observed in schizophrenia, another condition characterised by social and occupational deterioration.', 'The gene known as G protein subunit beta 3 plays a key role in causing both tachycardia and liver cirrhosis. Tachycardia, a condition characterized by an abnormally high heart rate, has a phenotype that includes experience of hallucinations. Similarly, liver cirrhosis, a progressive disease that leads to scarring of the liver, also manifests the hallucinations phenotype but additionally exhibits social and occupational deterioration as part of its symptoms. The psychiatric disorder schizophrenia too, has both hallucinations as well as social and occupational deterioration as phenotypes.\n', 'The G protein subunit beta 3 is responsible for causing conditions such as liver cirrhosis and tachycardia. Liver cirrhosis often leads to symptoms including hallucinations and social and occupational deterioration. On the other hand, tachycardia, a condition characterized by an abnormally rapid heart rate, is also associated with hallucinations. More so, hallucinations and social and occupational deterioration are often found in conditions like schizophrenia as well.', 'The G protein subunit beta 3 is implicated in causing several conditions including tachycardia and liver cirrhosis. Tachycardia, characterized by a rapid heart rate, often presents hallucinations as an associated symptom. Moreover, liver cirrhosis, a progressive disease characterized by liver damage, is also known to have hallucinations and social and occupational deterioration associated with its course. Additionally, schizophrenia, a severe mental disorder, manifests in both hallucinations and social and occupational deterioration.']"
"[{'source_node': {'name': 'enibomal'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'desflurane'}}, {'source_node': {'name': 'enibomal'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'gamma-hydroxybutyric acid'}}, {'source_node': {'name': 'enibomal'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'medical cannabis'}}, {'source_node': {'name': 'desflurane'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Electrocardiogram T wave inversion'}}, {'source_node': {'name': 'medical cannabis'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glycine receptor (alpha-1/beta)'}}, {'source_node': {'name': 'medical cannabis'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'fatty-acid amide hydrolase 1'}}, {'source_node': {'name': 'medical cannabis'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' Tachycardia '}}]","[{'source_node': {'name': 'enibomal'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'desflurane'}}, {'source_node': {'name': 'enibomal'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'gamma-hydroxybutyric acid'}}, {'source_node': {'name': 'desflurane'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Electrocardiogram T wave inversion'}}, {'source_node': {'name': 'medical cannabis'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glycine receptor (alpha-1/beta)'}}, {'source_node': {'name': 'medical cannabis'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'fatty-acid amide hydrolase 1'}}, {'source_node': {'name': 'medical cannabis'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' Tachycardia '}}, {'source_node': {'name': 'medical cannabis'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Electrocardiogram T wave inversion'}}, {'source_node': {'name': 'medical cannabis'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'desflurane'}}, {'source_node': {'name': 'gamma-hydroxybutyric acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'desflurane'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:11087', 'target': 'COMPOUND:11846', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:11846', 'target': 'SIDE_EFFECT:2712', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1378', 'target': 'COMPOUND:1169', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11846', 'target': 'COMPOUND:1169', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.7333333333333334,fb6f579692ab8e5a68511f20eddedf6c,429cb0648e92d3623e151391dd96184a,[],[]
"[{'source_node': {'name': 'VHL'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hereditary pheochromocytoma-paraganglioma'}}, {'source_node': {'name': 'VHL'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'sporadic pheochromocytoma/secreting paraganglioma'}}, {'source_node': {'name': 'VHL'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RHOBTB3 ATPase cycle'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR1'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': 'dehydro-alpha-curcumene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'estrogen receptor alpha'}}]","[{'source_node': {'name': 'VHL'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'sporadic pheochromocytoma/secreting paraganglioma'}}, {'source_node': {'name': 'VHL'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RHOBTB3 ATPase cycle'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR1'}}]","[{'type': 'edge_deletion', 'source': 'PROTEIN:943', 'target': 'GENE:33509', 'metadata': None}, {'type': 'node_removal', 'source': 'DISEASE:9694', 'target': None, 'metadata': {'node_id': '9694', 'node_type': 'DISEASE', 'display_name': 'hereditary pheochromocytoma-paraganglioma'}}, {'type': 'node_removal', 'source': 'COMPOUND:57183', 'target': None, 'metadata': {'node_id': '57183', 'node_type': 'COMPOUND', 'display_name': 'dehydro-alpha-curcumene'}}]",0.6153846153846154,1f3a8d9f0ce356bba8e9b2da98ab8464,e8110663ce7efde125329ad37a86a0ea,"['The gene VHL is known to cause conditions such as hereditary pheochromocytoma-paraganglioma and sporadic pheochromocytoma/secreting paraganglioma. Additionally, VHL acts within the RHOBTB3 ATPase cycle. An interesting link can be made to estrogen receptor alpha, which is a gene product of both ESR1 and VHL. Interestingly, dehydro-alpha-curcumene has been recognized as having estrogen receptor alpha as a target.', 'The gene VHL operates within the RHOBTB3 ATPase cycle and has been implicated in causing both hereditary pheochromocytoma-paraganglioma and sporadic pheochromocytoma/secreting paraganglioma. On another note, estrogen receptor alpha is a gene product of not only ESR1 but also VHL. Furthermore, it has been found that the compound dehydro-alpha-curcumene has a target in the estrogen receptor alpha.', 'The gene VHL acts within the RHOBTB3 ATPase cycle and causes two conditions: hereditary pheochromocytoma-paraganglioma and sporadic pheochromocytoma/secreting paraganglioma. On the other hand, the estrogen receptor alpha, which is a gene product of both ESR1 and VHL, is a target of the drug dehydro-alpha-curcumene.', 'The compound dehydro-alpha-curcumene targets estrogen receptor alpha. This receptor is a gene product of both ESR1 and VHL. VHL is a gene that acts within the RHOBTB3 ATPase cycle and is known to cause multiple conditions, including hereditary pheochromocytoma-paraganglioma and sporadic pheochromocytoma/secreting paraganglioma.', 'The gene VHL, which acts within the RHOBTB3 ATPase cycle, has been found to cause multiple conditions including hereditary pheochromocytoma-paraganglioma and sporadic pheochromocytoma/secreting paraganglioma. In addition, the protein estrogen receptor alpha, which is a product of both the ESR1 and VHL genes, is targeted by the compound dehydro-alpha-curcumene.']","['The gene VHL is implicated in causing a condition known as sporadic pheochromocytoma/secreting paraganglioma. Furthermore, VHL takes part in the RHOBTB3 ATPase cycle. Additionally, the gene product of ESR1 is known to be the estrogen receptor alpha.', 'The VHL gene, which functions as part of the RHOBTB3 ATPase cycle, can cause sporadic pheochromocytoma/secreting paraganglioma. Furthermore, estrogen receptor alpha is a gene product of the ESR1 gene.', 'The gene VHL, which functions within the RHOBTB3 ATPase cycle, is known to cause a condition called sporadic pheochromocytoma/secreting paraganglioma. Meanwhile, the estrogen receptor alpha is a gene product of ESR1.', 'The gene VHL, involved in the RHOBTB3 ATPase cycle, has been identified as a cause of the condition known as sporadic pheochromocytoma/secreting paraganglioma. Another gene, estrogen receptor alpha, is noted to be a product of the gene ESR1.', 'The gene VHL, that acts within the RHOBTB3 ATPase cycle, causes the condition sporadic pheochromocytoma/secreting paraganglioma. Additionally, the estrogen receptor alpha is a gene product of ESR1.']"
"[{'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15B'}}, {'source_node': {'name': 'ALDH1A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Fructose catabolism'}}, {'source_node': {'name': 'ALDH1A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ethanol oxidation'}}, {'source_node': {'name': 'geranyl acetate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'retinal dehydrogenase 1'}}, {'source_node': {'name': 'geranyl acetate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arachidonate 15-lipoxygenase'}}, {'source_node': {'name': 'geranyl acetate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lymphoblastoid cells'}}, {'source_node': {'name': 'retinal dehydrogenase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALDH1A1'}}]","[{'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15B'}}, {'source_node': {'name': 'ALDH1A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Fructose catabolism'}}, {'source_node': {'name': 'ALDH1A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ethanol oxidation'}}, {'source_node': {'name': 'lymphoblastoid cells'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': 'geranyl acetate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lymphoblastoid cells'}}, {'source_node': {'name': 'retinal dehydrogenase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:74659', 'target': 'PROTEIN:2703', 'metadata': None}, {'type': 'edge_addition', 'source': 'PROTEIN:5610', 'target': 'GENE:27532', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'PROTEIN:579', 'target': 'GENE:27532', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:74659', 'target': 'PROTEIN:579', 'metadata': None}, {'type': 'edge_deletion', 'source': 'PROTEIN:579', 'target': 'GENE:26863', 'metadata': None}]",0.7058823529411764,e7086a53a3d1d1326b16ca3e5218c6c4,517de7f8b60bd5e6d9e2d921367f1d6a,"['The enzyme arachidonate 15-lipoxygenase is a gene product of both ALOX15 and ALOX15B. This enzyme is targeted by the organic compound geranyl acetate, which also targets retinal dehydrogenase 1 and lymphoblastoid cells. Retinal dehydrogenase 1 is a gene product of ALDH1A1, which acts within both the fructose catabolism and ethanol oxidation pathways.', 'The enzymes arachidonate 15-lipoxygenase are gene products of both ALOX15 and ALOX15B. The substance geranyl acetate interacts with these enzymes as well as with retinal dehydrogenase 1 and lymphoblastoid cells. Specifically, retinal dehydrogenase 1 is the gene product of ALDH1A1 which acts within two metabolic pathways, namely fructose catabolism and ethanol oxidation.', 'The enzyme arachidonate 15-lipoxygenase is a gene product of both ALOX15 and ALOX15B. This enzyme, along with retinal dehydrogenase 1, a gene product of the ALDH1A1 gene, is targeted by geranyl acetate, a commonly used fragrant compound. Additionally, ALDH1A1 is seen acting within various metabolic pathways, including fructose catabolism and ethanol oxidation. Interestingly, geranyl acetate is known to target not only specific enzymes but also biological groups such as lymphoblastoid cells.', 'The enzyme arachidonate 15-lipoxygenase, a gene product of both ALOX15 and ALOX15B, is targeted by the compound geranyl acetate. Geranyl Acetate also targets retinal dehydrogenase 1 and lymphoblastoid cells. Speaking of retinal dehydrogenase 1, it is the gene product of ALDH1A1. ALDH1A1 plays roles in several pathways, including fructose catabolism and ethanol oxidation.', 'The enzyme arachidonate 15-lipoxygenase is a gene product of both ALOX15 and ALOX15B. This enzyme is also a target of the substance geranyl acetate. The same substance, geranyl acetate, also targets retinal dehydrogenase 1 and lymphoblastoid cells. Furthermore, retinal dehydrogenase 1 is a gene product of ALDH1A1. Interestingly, ALDH1A1 acts within several metabolic pathways, including the fructose catabolism and ethanol oxidation pathways.']",[]
"[{'source_node': {'name': 'IFNA6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Interferon alpha/beta signaling'}}, {'source_node': {'name': 'IFNA6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'TRAF6 mediated IRF7 activation'}}]","[{'source_node': {'name': 'IFNA6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Interferon alpha/beta signaling'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:61', 'target': None, 'metadata': {'node_id': '61', 'node_type': 'PATHWAY', 'display_name': 'TRAF6 mediated IRF7 activation'}}]",0.6,229363ae07f7d6871d79fdf8db2cb2f3,0acf85e08cc1abc5a545103d10724aa3,[],[]
"[{'source_node': {'name': 'rivoglitazone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'tolbutamide'}}, {'source_node': {'name': 'rivoglitazone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'sulfaguanidine'}}]","[{'source_node': {'name': 'sulfaguanidine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'rivoglitazone'}}, {'source_node': {'name': 'rivoglitazone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'sulfaguanidine'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:1104', 'target': None, 'metadata': {'node_id': '1104', 'node_type': 'COMPOUND', 'display_name': 'tolbutamide'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11573', 'target': 'COMPOUND:8135', 'metadata': {'predicate': 'increase_efficacy'}}]",0.4,5aab2b5b589ad65d045b36c1f08fc970,f4461c65dc10fc2136225a2c7c8dab96,"['Rivoglitazone, a drug commonly used in medical practice, has been observed to increase the efficacy of certain other medications. Specifically, it enhances the effectiveness of Tolbutamide, and also of Sulfaguanidine. Therefore, in a medical scenario requiring reduced resistance and maximized drug impact, Rivoglitazone can be considered as an adjunct medication to improve treatment outcomes.', 'The drug Rivoglitazone has been shown to increase the efficacy of both Tolbutamide and Sulfaguanidine.', 'The drug rivoglitazone has been found to increase the efficacy of not only tolbutamide but also sulfaguanidine, thereby enhancing their therapeutic impact.', 'The drug Rivoglitazone is known to increase the efficacy of both Tolbutamide and Sulfaguanidine.', 'The drug Rivoglitazone has been observed to increase the efficacy of both Tolbutamide and Sulfaguanidine.']","['The drug sulfaguanidine is known to increase the efficacy of rivoglitazone. Upon reciprocal analysis, it was also observed that rivoglitazone in turn increases the efficacy of sulfaguanidine, indicating a potentially synergistic relationship between the two drugs.', 'The drug sulfaguanidine has been shown to increase the efficacy of another medication, rivoglitazone. Interestingly, this relationship is reciprocated, as rivoglitazone also augments the efficacy of sulfaguanidine.', 'The drug Sulfaguanidine is known to increase the efficacy of another medication called Rivoglitazone. Interestingly, Rivoglitazone also reciprocally enhances the efficacy of Sulfaguanidine.', 'The drug sulfaguanidine can increase the efficacy of rivoglitazone and interestingly, rivoglitazone can also increase the efficacy of sulfaguanidine. These drugs seem to enhance the effectiveness of each other.', 'The drug sulfaguanidine is known to increase the efficacy of rivoglitazone. Conversely, rivoglitazone also enhances the efficacy of sulfaguanidine. Therefore, these two drugs seem to have a synergistic relationship, each boosting the effectiveness of the other.']"
"[{'source_node': {'name': 'udp-glucuronosyltransferase 1-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'UGT1A1'}}, {'source_node': {'name': 'alpha-terpineol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'udp-glucuronosyltransferase 1-1'}}, {'source_node': {'name': 'alpha-terpineol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'udp-glucuronosyltransferase 1a4'}}, {'source_node': {'name': 'UGT1A4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glucuronidation'}}, {'source_node': {'name': 'UGT1A4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Aspirin ADME'}}, {'source_node': {'name': 'udp-glucuronosyltransferase 1a4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'UGT1A4'}}]","[{'source_node': {'name': 'udp-glucuronosyltransferase 1-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'UGT1A1'}}, {'source_node': {'name': 'alpha-terpineol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'udp-glucuronosyltransferase 1-1'}}, {'source_node': {'name': 'UGT1A4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glucuronidation'}}, {'source_node': {'name': 'UGT1A4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Aspirin ADME'}}, {'source_node': {'name': 'UGT1A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glucuronidation'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:6330', 'target': None, 'metadata': {'node_id': '6330', 'node_type': 'PROTEIN', 'display_name': 'udp-glucuronosyltransferase 1a4'}}, {'type': 'edge_addition', 'source': 'GENE:31198', 'target': 'PATHWAY:825', 'metadata': {'predicate': 'acts_within'}}]",0.6923076923076923,eb85cd3f989ec30421f48de27ca8d6ee,199b8fb2e48d87dd6a9bb0653cecadab,"['The drug alpha-terpineol targets two enzymes: udp-glucuronosyltransferase 1-1 and udp-glucuronosyltransferase 1a4. The udp-glucuronosyltransferase 1-1 is a gene product of UGT1A1. On the other hand, udp-glucuronosyltransferase 1a4 is a gene product of UGT1A4. UGT1A4 acts within several metabolic pathways, notably Glucuronidation and Aspirin ADME.']","['The drug alpha-terpineol has a target known as udp-glucuronosyltransferase 1-1, which is produced by the gene UGT1A1. Interestingly, UGT1A1 acts within a process known as Glucuronidation, a major pathway in drug metabolism. Similarly, UGT1A4, another gene, also plays a role in the Glucuronidation process, as well as within the Aspirin ADME (absorption, distribution, metabolism, and excretion) pathway.', 'The compound alpha-terpineol targets the enzyme UDP-glucuronosyltransferase 1-1, which is a gene product of UGT1A1. The gene UGT1A4 acts within different pathways including glucuronidation and aspirin ADME. Notably, UGT1A1 also participates in the glucuronidation pathway, highlighting the interconnectivity of this system.', 'The compound alpha-terpineol targets udp-glucuronosyltransferase 1-1, a gene product of UGT1A1. UGT1A1 and UGT1A4 are both operational within the glucuronidation pathway. Moreover, UGT1A4 also acts within Aspirin ADME.']"
"[{'source_node': {'name': 'balsalazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cyclothiazide'}}, {'source_node': {'name': 'balsalazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sitaxentan'}}, {'source_node': {'name': 'balsalazide'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Dizziness'}}, {'source_node': {'name': 'sitaxentan'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'icosapent'}}, {'source_node': {'name': 'sitaxentan'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Faecal incontinence'}}, {'source_node': {'name': 'sitaxentan'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Uterine leiomyoma'}}]","[{'source_node': {'name': 'balsalazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cyclothiazide'}}, {'source_node': {'name': 'balsalazide'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Dizziness'}}, {'source_node': {'name': 'balsalazide'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Faecal incontinence'}}, {'source_node': {'name': 'sitaxentan'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Faecal incontinence'}}, {'source_node': {'name': 'sitaxentan'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Uterine leiomyoma'}}, {'source_node': {'name': 'sitaxentan'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cyclothiazide'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:997', 'target': 'COMPOUND:5502', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:5502', 'target': 'COMPOUND:592', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:997', 'target': 'SIDE_EFFECT:1329', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'node_removal', 'source': 'COMPOUND:150', 'target': None, 'metadata': {'node_id': '150', 'node_type': 'COMPOUND', 'display_name': 'icosapent'}}]",0.6153846153846154,52c8aef5df439b7bcfc9e277f48532bb,606d75e9b3f0313a293b3258bab8e7c1,"['Balsalazide is a drug that has shown to decrease the efficacy of both cyclothiazide and sitaxentan. Moreover, this drug is also known to potentially cause a side effect of dizziness. On the other hand, sitaxentan that also has its efficacy decreased by balsalazide, is known to decrease the efficacy of another drug, icosapent. Additionally, sitaxentan treatment can lead to side effects like faecal incontinence and uterine leiomyoma.', 'The application of the drug balsalazide has been shown to decrease the efficacy of both cyclothiazide and sitaxentan. Furthermore, balsalazide usage has side effects, one of which includes dizziness. However, sitaxentan acts similarly and decreases the efficacy of the drug icosapent and comes with its own array of side effects. Notable among these are faecal incontinence and uterine leiomyoma. Hence, careful consideration is required when combining these drugs for therapeutic reasons.', 'The drug balsalazide has been noted to decrease the efficacy of other medications, such as cyclothiazide and sitaxentan. Additionally, people using balsalazide may experience the side effect of dizziness. Similar to balsalazide, sitaxentan also reduces the effectiveness of icosapent when used concurrently. There are also potential side effects including faecal incontinence and uterine leiomyoma associated with the use of sitaxentan.', 'The drug balsalazide can potentially decrease the efficacy of other drugs such as cyclothiazide and sitaxentan. As a side effect, balsalazide can cause dizziness. Similarly, sitaxentan might decrease the efficacy of the medication icosapent. Some reported side effects of using sitaxentan include faecal incontinence as well as uterine leiomyoma.', 'The drug balsalazide is known to decrease the efficacy of both cyclothiazide and sitaxentan and can have a side effect such as dizziness. On the other hand, sitaxentan also reduces the efficacy of icosapent and may cause side effects like faecal incontinence and uterine leiomyoma.']","['The medication balsalazide can decrease the efficacy of another drug, cyclothiazide. Additionally, balsalazide has several side effects including dizziness and faecal incontinence. Faecal incontinence is also a side effect of the drug sitaxentan, which can also decrease the effectiveness of cyclothiazide. Sitexentan, like balsalazide, has multiple side effects, and in this case, another example is the development of uterine leiomyoma.', 'The drug balsalazide has several notable effects, such as decreased efficacy when taken with cyclothiazide. In terms of side effects, balsalazide can cause dizziness and faecal incontinence. Similarly, the medication sitaxentan also has a couple of side effects. Like balsalazide, sitaxentan can cause faecal incontinence. Another side effect associated with sitaxentan is uterine leiomyoma, a type of benign tumor. Additionally, the efficacy of cyclothiazide is diminished when it is taken along with sitaxentan.', 'The drug balsalazide has the potential to decrease the efficacy of cyclothiazide. It also has several side effects, which may include dizziness and faecal incontinence. Similarly, the drug sitaxentan can potentially decrease the efficacy of cyclothiazide. Side effects of sitaxentan may include faecal incontinence and the development of uterine leiomyoma.', 'Balsalazide is a drug that has been found to decrease the efficacy of another drug, cyclothiazide. Additionally, use of balsalazide may lead to certain side effects such as dizziness and faecal incontinence. Another drug, sitaxentan, has been linked to similar side effects, including faecal incontinence and development of uterine leiomyoma. Like balsalazide, use of sitaxentan may also result in decreased efficacy of cyclothiazide. Therefore, caregivers and patients should consider these relationships and potential side effects when considering treatment options with these drugs.', 'The drug balsalazide can decrease the efficacy of another drug, cyclothiazide. Moreover, balsalazide has been associated with side effects such as dizziness and faecal incontinence. Sitaxentan, another drug, also contributes to side effects such as faecal incontinence and uterine leiomyoma. Similar to balsalazide, sitaxentan also has a tendency to decrease the efficacy of cyclothiazide.']"
"[{'source_node': {'name': 'macimorelin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'insulin lispro'}}, {'source_node': {'name': 'macimorelin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'promethazine'}}, {'source_node': {'name': 'macimorelin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'floctafenine'}}, {'source_node': {'name': 'insulin lispro'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'etacrynic acid'}}, {'source_node': {'name': 'insulin lispro'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'practolol'}}, {'source_node': {'name': 'insulin lispro'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'sitafloxacin'}}, {'source_node': {'name': 'floctafenine'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' nephrotoxicity '}}, {'source_node': {'name': 'floctafenine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methoserpidine'}}]","[{'source_node': {'name': 'macimorelin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'promethazine'}}, {'source_node': {'name': 'insulin lispro'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'etacrynic acid'}}, {'source_node': {'name': 'insulin lispro'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'practolol'}}, {'source_node': {'name': 'insulin lispro'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'sitafloxacin'}}, {'source_node': {'name': 'floctafenine'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' nephrotoxicity '}}, {'source_node': {'name': 'floctafenine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methoserpidine'}}, {'source_node': {'name': 'floctafenine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'etacrynic acid'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:7922', 'target': 'COMPOUND:886', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:10944', 'target': 'COMPOUND:7922', 'metadata': None}, {'type': 'edge_deletion', 'source': 'COMPOUND:10944', 'target': 'COMPOUND:44', 'metadata': None}]",0.8235294117647058,3469b4fa2b45a18ebfec74f5015b1890,b6ad39038c27df530a7799967357d736,[],[]
"[{'source_node': {'name': 'erystagallin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}, {'source_node': {'name': 'erystagallin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'erystagallin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mda-mb-231'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}]","[{'source_node': {'name': 'erystagallin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}, {'source_node': {'name': 'erystagallin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'erystagallin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mda-mb-231'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:5851', 'target': 'GENE:32076', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'PROTEIN:5850', 'target': 'GENE:32076', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'GENE:32076', 'target': None, 'metadata': {'node_id': '32076', 'node_type': 'GENE', 'display_name': 'PTPN1'}}]",0.7777777777777778,54eaabf414c8c6045401c88246dd73c1,f8ced859970ec2488c3113b169b7ec21,"['The compound Erystagallin A targets both the MCF7 and MDA-MB-231, with specific activity towards the tyrosine-protein phosphatase non-receptor type 1, which is a gene product of PTPN1.', ""The compound erystagallin A has several targets, including the tyrosine-protein phosphatase non-receptor type 1, the mcf7, and the mda-mb-231. It's interesting to note that the tyrosine-protein phosphatase non-receptor type 1 is actually the gene product of PTPN1."", 'The compound Erystagallin A targets several entities including the tyrosine-protein phosphatase non-receptor type 1, as well as MCF7 and MDA-MB-231 cells. Interestingly, the tyrosine-protein phosphatase non-receptor type 1 is a gene product of PTPN1.', ""Erystagallin A targets multiple entities including the tyrosine-protein phosphatase non-receptor type 1, as well as two cell lines named MCF7 and MDA-MB-231. It's also important to note that the tyrosine-protein phosphatase non-receptor type 1 is a gene product of PTPN1."", 'Erystagallin A, a medical drug, targets several sites including tyrosine-protein phosphatase non-receptor type 1, MCF7, and MDA-MB-231. Tyrosine-protein phosphatase non-receptor type 1 is a gene product of PTPN1.']","['The compound erystagallin A has been identified to target multiple entities including the tyrosine-protein phosphatase non-receptor type 1, MCF7 and MDA-MB-231.', 'The compound erystagallin A targets several entities, including the tyrosine-protein phosphatase non-receptor type 1, as well as two cell lines; MCF7 and MDA-MB-231.', 'The compound erystagallin A targets several molecules, including tyrosine-protein phosphatase non-receptor type 1, and two types of cancer cells, specifically MCF7 and MDA-MB-231.', 'The compound erystagallin A acts by targeting several entities. This includes the tyrosine-protein phosphatase non-receptor type 1, a key player in cellular processes. Additionally, it targets the MCF7 and MDA-MB-231, two cells lines commonly utilized in breast cancer research.', 'The compound erystagallin A has been identified as having multiple targets, including the tyrosine-protein phosphatase non-receptor type 1, as well as two cancer cell lines known as MCF7 and MDA-MB-231.']"
"[{'source_node': {'name': 'folate receptor 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pleural mesothelioma'}}, {'source_node': {'name': 'folate receptor 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'carcinoma'}}, {'source_node': {'name': 'pleural mesothelioma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hepatomegaly'}}, {'source_node': {'name': 'pleural mesothelioma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'fourth cranial nerve palsy'}}, {'source_node': {'name': 'pleural mesothelioma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormal cardiovascular system physiology'}}]","[{'source_node': {'name': 'folate receptor 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'carcinoma'}}, {'source_node': {'name': 'carcinoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hepatomegaly'}}]","[{'type': 'edge_addition', 'source': 'DISEASE:477', 'target': 'PHENOTYPE:7442', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:4537', 'target': None, 'metadata': {'node_id': '4537', 'node_type': 'PHENOTYPE', 'display_name': 'fourth cranial nerve palsy'}}, {'type': 'edge_addition', 'source': 'DISEASE:477', 'target': 'PHENOTYPE:1650', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'node_removal', 'source': 'DISEASE:2020', 'target': None, 'metadata': {'node_id': '2020', 'node_type': 'DISEASE', 'display_name': 'pleural mesothelioma'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:7442', 'target': None, 'metadata': {'node_id': '7442', 'node_type': 'PHENOTYPE', 'display_name': 'abnormal cardiovascular system physiology'}}]",0.3636363636363636,a57eef3d9c31cbf864bc0489ab1906d5,82e391e89e82223ca7740d21e1aed25b,"['Folate receptor 3, a critical part of cell functions, has been linked to causing several serious conditions like pleural mesothelioma and carcinoma. The condition pleural mesothelioma typically presents with several notable symptoms or phenotypes. These include hepatomegaly, which refers to an enlarged liver, fourth cranial nerve palsy that affects eye movement, and abnormal cardiovascular system physiology which could involve any number of heart or blood vessel irregularities. The genomic effects of folate receptor 3 are complex, and its impact on health and disease continues to be an area of active research.', 'Folate receptor 3, a key receptor in cell biology, is known to cause conditions such as pleural mesothelioma and carcinoma. Pleural mesothelioma in particular is characterized by several phenotypes including hepatomegaly, fourth cranial nerve palsy and abnormal cardiovascular system physiology.', 'Folate receptor 3 has been identified as a factor causing several conditions, including pleural mesothelioma and carcinoma. Pleural mesothelioma, in particular, exhibits a distinct set of phenotypic traits. These traits include hepatomegaly, or the abnormal enlargement of the liver; fourth cranial nerve palsy, which leads to an impaired ability to move the eye; and an abnormal cardiovascular system physiology, which causes irregularities in the heart and blood vessels. These findings deepen our understanding of the interactions and effects of folate receptor 3 on these diseases.', 'The protein folate receptor 3 has been associated with causing two forms of cancer, pleural mesothelioma and carcinoma. Notably, pleural mesothelioma is characterized by various phenotypes such as hepatomegaly (abnormally large liver), fourth cranial nerve palsy, and abnormal cardiovascular system physiology.', 'Folate receptor 3 is known to cause several diseases, namely pleural mesothelioma and carcinoma. Pleural mesothelioma has various phenotypes including hepatomegaly, fourth cranial nerve palsy, and abnormal cardiovascular system physiology.']",[]
"[{'source_node': {'name': 'antidesmone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}, {'source_node': {'name': 'antidesmone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'antidesmone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}]","[{'source_node': {'name': 'antidesmone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'antidesmone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4994', 'target': None, 'metadata': {'node_id': '4994', 'node_type': 'PROTEIN', 'display_name': 'hela'}}]",0.7142857142857143,c236f7d9c3f44d1e37cfc2fa138111a2,7fdba9586c73430f237b4f7e3fe8a4af,"['The chemical compound antidesmone has been found to target a variety of different cells, including Hela, A549, and KB cells.', 'Antidesmone is a compound that targets several cells including Hela, A549, and KB.', 'The drug Antidesmone targets several types of cells, including the Hela, A549, and KB cells.', 'The compound Antidesmone has been identified as targeting multiple cells, including Hela, A549, and KB cells.', 'The drug Antidesmone has been identified to target several types of cells including HeLa, A549, and KB.']","['The compound antidesmone has the ability to target both A549 and KB, showcasing its potential biomedical applications in research.', 'The substance antidesmone targets two cell lines, namely A549 and KB.', 'The drug Antidesmone has been shown to target both A549 and KB cells.', 'The drug Antidesmone is shown to target two specific cell lines: A549 and KB.', 'The compound Antidesmone targets two different cell lines: A549 and KB.']"
"[{'source_node': {'name': 'napapuin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'napapuin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'k562'}}, {'source_node': {'name': 'napapuin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ovcar-8'}}]","[{'source_node': {'name': 'napapuin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ovcar-8'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5849', 'target': None, 'metadata': {'node_id': '5849', 'node_type': 'PROTEIN', 'display_name': 'a549'}}, {'type': 'node_removal', 'source': 'PROTEIN:4947', 'target': None, 'metadata': {'node_id': '4947', 'node_type': 'PROTEIN', 'display_name': 'k562'}}]",0.4285714285714286,8a1b26e538c2806011e88c9ed232d0db,f16e76120c4477ab601f2d31a742206c,"['The compound Napapuin B has several targets, including A549, K562, and OVCAR-8.', 'The compound Napapuin B is known to target several cell lines including A549, K562, and OVCAR-8.', 'The compound Napapuin B has been observed to target various cell lines including A549, K562, and OVCAR-8.', 'The substance Napapuin B targets several entities, including the A549, K562 and OVCAR-8 cells.', 'The compound Napapuin B has been shown to target multiple cells including A549, K562, and OVCAR-8.']",[]
"[{'source_node': {'name': 'rosmaquinone b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'rosmaquinone b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hep-2'}}, {'source_node': {'name': 'rosmaquinone b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}]","[{'source_node': {'name': 'rosmaquinone b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'rosmaquinone b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4953', 'target': None, 'metadata': {'node_id': '4953', 'node_type': 'PROTEIN', 'display_name': 'hep-2'}}]",0.7142857142857143,90e629e69b9006b2bb4b8b0fd3f4abd9,ab01270327684cdff8e91fe424fd4383,"['The compound rosmaquinone B has been found to target several cell lines, including A549, Hep-2 and HeLa.', 'The compound Rosmaquinone B targets several cell lines including A549, Hep-2, and Hela.', 'The compound Rosmaquinone B has been identified to target several cell lines, including A549, Hep-2, and Hela.', 'The compound Rosmaquinone B is noted for having biological targets on different cellular structures, specifically A549, Hep-2, and HeLa cells.', 'The compound Rosmaquinone B has multiple targets including A549, Hep-2 and Hela cells.']","['The drug Rosmaquinone B is designed with specific targets in mind, including A549 and HeLa.', 'The compound rosmaquinone b targets both A549 and Hela cells.', 'The compound Rosmaquinone B is known to target both A549 and HeLa cells.', 'Rosmaquinone B, a pharmacologically active compound, has been identified to target both the A549 and HeLa cell lines. This indicates its potential in influencing cell mechanisms or intracellular pathways in these specific types of cells.', 'The compound Rosmaquinone B has been identified as a target for both A549 and Hela cell lines.']"
"[{'source_node': {'name': 'GBA1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'gaucher disease'}}, {'source_node': {'name': 'GBA1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glycosphingolipid metabolism'}}, {'source_node': {'name': 'glucosylceramidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GBA1'}}, {'source_node': {'name': 'demethylencecalin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'demethylencecalin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}, {'source_node': {'name': 'demethylencecalin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucosylceramidase'}}]","[{'source_node': {'name': 'GBA1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'gaucher disease'}}, {'source_node': {'name': 'GBA1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glycosphingolipid metabolism'}}, {'source_node': {'name': 'glucosylceramidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GBA1'}}, {'source_node': {'name': 'demethylencecalin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucosylceramidase'}}, {'source_node': {'name': 'demethylencecalin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'GBA1'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5851', 'target': None, 'metadata': {'node_id': '5851', 'node_type': 'PROTEIN', 'display_name': 'mcf7'}}, {'type': 'edge_addition', 'source': 'COMPOUND:24288', 'target': 'GENE:27886', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'PROTEIN:4976', 'target': None, 'metadata': {'node_id': '4976', 'node_type': 'PROTEIN', 'display_name': 'ht-29'}}]",0.6153846153846154,f64c77cfd28739cf7df1718e7cff14cc,b995668ebcc3ac9fb0658fc8c96146f0,"['The gene GBA1, which acts within the pathway of glycosphingolipid metabolism, causes Gaucher disease. Glucosylceramidase is a gene product of GBA1. Additionally, Demethylencecalin, a medication, targets glucosylceramidase as well as MCF7 and HT-29, both of which are types of cancer cells.', 'The gene GBA1 is involved in Glycosphingolipid metabolism and is known to cause Gaucher disease. Glucosylceramidase is a gene product of GBA1. Demethylencecalin, a drug, targets various entities including glucosylceramidase, MCF7, and HT-29 cells. Therefore, the interconnections between these entities offer potential therapeutic approaches for the management of Gaucher disease.', 'The gene GBA1, which acts within the pathway of glycosphingolipid metabolism, is known to cause Gaucher disease. Glucosylceramidase, a gene product of GBA1, is a biochemical target of the drug demethylencecalin. Interestingly, demethylencecalin also targets other entities, such as mcf7 and ht-29, indicating its wide acting mechanism.']","['The GBA1 gene, which causes Gaucher disease, acts within the Glycosphingolipid metabolism pathway. Glucosylceramidase is a gene product of GBA1. The compound demethylencecalin targets glucosylceramidase and affects the function of GBA1.']"
"[{'source_node': {'name': 'naphthalen-1-amine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'udp-glucuronosyltransferase 1-6'}}, {'source_node': {'name': 'naphthalen-1-amine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'androgen receptor'}}, {'source_node': {'name': 'naphthalen-1-amine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'transcription factor ap-1'}}, {'source_node': {'name': 'androgen receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AR'}}, {'source_node': {'name': 'transcription factor ap-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'JUN'}}, {'source_node': {'name': 'udp-glucuronosyltransferase 1-6'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'UGT1A6'}}, {'source_node': {'name': 'UGT1A6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Paracetamol ADME'}}]","[{'source_node': {'name': 'AR'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Paracetamol ADME'}}, {'source_node': {'name': 'naphthalen-1-amine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'udp-glucuronosyltransferase 1-6'}}, {'source_node': {'name': 'naphthalen-1-amine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'androgen receptor'}}, {'source_node': {'name': 'androgen receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AR'}}, {'source_node': {'name': 'transcription factor ap-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'JUN'}}, {'source_node': {'name': 'transcription factor ap-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AR'}}, {'source_node': {'name': 'udp-glucuronosyltransferase 1-6'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'UGT1A6'}}, {'source_node': {'name': 'udp-glucuronosyltransferase 1-6'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AR'}}, {'source_node': {'name': 'UGT1A6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Paracetamol ADME'}}]","[{'type': 'edge_addition', 'source': 'GENE:29295', 'target': 'PATHWAY:5', 'metadata': {'predicate': 'acts_within'}}, {'type': 'edge_addition', 'source': 'PROTEIN:860', 'target': 'GENE:29295', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:16515', 'target': 'PROTEIN:860', 'metadata': None}, {'type': 'edge_addition', 'source': 'PROTEIN:6320', 'target': 'GENE:29295', 'metadata': {'predicate': 'gene_product_of'}}]",0.7333333333333334,ec0050e8d89870c7e4fd292fdee43a43,65fdbaee681daae618d40b87b28493c2,[],[]
"[{'source_node': {'name': 'dihydrotachysterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cortisone acetate'}}, {'source_node': {'name': 'dihydrotachysterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methylprednisolone aceponate'}}, {'source_node': {'name': 'dihydrotachysterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluocortolone caproate'}}]","[{'source_node': {'name': 'dihydrotachysterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cortisone acetate'}}, {'source_node': {'name': 'dihydrotachysterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methylprednisolone aceponate'}}, {'source_node': {'name': 'dihydrotachysterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluocortolone caproate'}}, {'source_node': {'name': 'fluocortolone caproate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'cortisone acetate'}}, {'source_node': {'name': 'cortisone acetate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'dihydrotachysterol'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1327', 'target': 'COMPOUND:1050', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:13236', 'target': 'COMPOUND:1327', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7142857142857143,dfd715db87b0ca2477cd95a73ee0a988,bb0ef2c257d4994c236ea930f2056dc2,"['Dihydrotachysterol, a type of vitamin D, is known to decrease the efficacy of several drugs. Specifically, it can potentially reduce the effectiveness of cortisone acetate, methylprednisolone aceponate, and fluocortolone caproate. These interactions need to be considered when these drugs are used in combination therapies.', 'Dihydrotachysterol, a form of vitamin D, may decrease the efficacy of several drugs. Specifically, it can reduce the effectiveness of cortisone acetate, methylprednisolone aceponate, and fluocortolone caproate. Hence, caution is required when using these drugs in conjunction with dihydrotachysterol.', 'The substance dihydrotachysterol can decrease the efficacy of several medicinal compounds. Specifically, it can affect cortisone acetate, methylprednisolone aceponate, and fluocortolone caproate, leading to potentially diminished therapeutic effects.', 'The compound dihydrotachysterol is known to decrease the efficacy of several drugs, including cortisone acetate, methylprednisolone aceponate, and fluocortolone caproate.', 'The drug dihydrotachysterol is known to decrease the efficacy of several other drugs including cortisone acetate, methylprednisolone aceponate, and fluocortolone caproate. This interaction could potential affect therapeutic outcomes and may be important to consider in patient treatment plans.']","['Dihydrotachysterol, a form of medication, has been observed to decrease the efficacy of several drugs, including cortisone acetate, methylprednisolone aceponate and fluocortolone caproate. Interestingly, it seems there is a complex interplay between these substances that also features effects in the opposite direction. Fluocortolone caproate can potentially increase the efficacy of cortisone acetate, which, in turn, can bolster the efficacy of dihydrotachysterol. This intricate relationship may pose challenges and opportunities in managing their therapeutic use.', 'Dihydrotachysterol is a medication that is observed to decrease the efficacy of cortisone acetate, methylprednisolone aceponate, and fluocortolone caproate. Interestingly, fluocortolone caproate, in spite of its efficacy being decreased by dihydrotachysterol, increases the efficacy of cortisone acetate. In turn, cortisone acetate, which has its efficacy reduced by dihydrotachysterol, paradoxically also enhances the efficacy of dihydrotachysterol itself. This illustrates a complex interplay of drug efficacy modulations, highlighting the significance of considering these interactions in prescribing medications.', ""The drug Dihydrotachysterol is known to decrease the efficacy of several drugs including Cortisone Acetate and Methylprednisolone Aceponate. Interestingly, it also has been observed to decrease the efficacy of Fluocortolone Caproate. However, the relationship between Dihydrotachysterol and Cortisone Acetate doesn't just stop there. There is a reciprocal effect where the presence of Fluocortolone Caproate can increase the efficacy of Cortisone Acetate. And, in certain instances, Cortisone Acetate can increase the efficacy of Dihydrotachysterol. The complex interplay between these drugs suggest a potentially intricate balance in their combined use."", 'The drug dihydrotachysterol is known to decrease the efficacy of several other medications including cortisone acetate and methylprednisolone aceponate. Interestingly, it also works to lower the efficacy of fluocortolone caproate. However, in a twisting turn of events, fluocortolone caproate enhances the efficacy of cortisone acetate, which in turn, reciprocates this effect by increasing the efficacy of dihydrotachysterol. This interplay of efficacy modification forms a complex network of drug interactions.', 'The drug dihydrotachysterol is known to decrease the efficacy of cortisone acetate, methylprednisolone aceponate, and fluocortolone caproate. Meanwhile, it is observed that the efficacy of cortisone acetate may be increased by fluocortolone caproate. Interestingly, cortisone acetate also increases the efficacy of dihydrotachysterol.']"
"[{'source_node': {'name': 'methylcellulose'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methantheline'}}, {'source_node': {'name': 'methylcellulose'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carvedilol'}}, {'source_node': {'name': 'methylcellulose'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fenpiverinium'}}, {'source_node': {'name': 'nalbuphine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trichlormethiazide'}}, {'source_node': {'name': 'nalbuphine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methylcellulose'}}, {'source_node': {'name': 'nalbuphine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Shock'}}, {'source_node': {'name': 'trichlormethiazide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'hydralazine'}}]","[{'source_node': {'name': 'methylcellulose'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methantheline'}}, {'source_node': {'name': 'methylcellulose'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carvedilol'}}, {'source_node': {'name': 'methylcellulose'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Shock'}}, {'source_node': {'name': 'nalbuphine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trichlormethiazide'}}, {'source_node': {'name': 'nalbuphine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Shock'}}, {'source_node': {'name': 'trichlormethiazide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'hydralazine'}}, {'source_node': {'name': 'hydralazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methylcellulose'}}, {'source_node': {'name': 'fenpiverinium'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'hydralazine'}}, {'source_node': {'name': 'fenpiverinium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nalbuphine'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:827', 'target': 'COMPOUND:9224', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:11606', 'target': 'COMPOUND:1254', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11606', 'target': 'COMPOUND:827', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1254', 'target': 'COMPOUND:9224', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:9224', 'target': 'SIDE_EFFECT:177', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:9224', 'target': 'COMPOUND:11606', 'metadata': None}]",0.6,2ec35ec8c7f11e559f5b7f63d6e0432f,5a80312ea881b62c69becb744d7461c6,"['The drug methylcellulose has been found to decrease the efficacy of various other medications including methantheline, carvedilol, and fenpiverinium. On the other hand, nalbuphine, another pharmaceutical agent, exhibits a reduced efficacy when combined with trichlormethiazide or methylcellulose. It is important to note that nalbuphine may have a side effect of inducing shock. Interestingly, trichlormethiazide, which interactions negatively with nalbuphine, actually increases the efficacy of hydralazine. Therefore, caution must be exercised while co-administering these medications due to their diverse interactions.', 'In the realm of pharmacology, methylcellulose is known to decrease the efficacy of several pharmaceuticals, namely methantheline, carvedilol, and fenpiverinium. Similarly, nalbuphine exhibits properties that lessen the efficacy of other substances such as trichlormethiazide and methylcellulose. It is noteworthy to mention that nalbuphine has been reported to have a side effect: It may induce Shock. On the other hand, trichlormethiazide demonstrates the ability to enhance the effectiveness of hydralazine. These complex interactions illustrate the intricate nature of pharmacological interactions and their potential impacts on treatment efficacy.', ""The drug methylcellulose has been found to decrease the efficacy of multiple medications including methantheline, carvedilol, and fenpiverinium. Interestingly, nalbuphine, another pharmaceutical substance, has a similar effect, reducing the efficacy of trichlormethiazide and also methylcellulose. However, it's worth noting that nalbuphine has a recorded side effect of causing shock. On a different note, trichlormethiazide has the capacity to increase the efficacy of hydralazine, adding another dimension to the intricate network of drug interactions."", ""The compound methylcellulose has been observed to decrease the efficacy of several drugs including methantheline, carvedilol, and fenpiverinium. In a similar manner, the medication nalbuphine has been demonstrated to lower the efficacy of both trichlormethiazide and methylcellulose. This same medication, nalbuphine, has also been associated with side effects, one of which is Shock. What's interesting is that trichlormethiazide, a drug whose efficacy can be reduced by nalbuphine, has the ability to increase the efficacy of hydralazine. These findings, therefore, point towards complex interactions existing amidst these mentioned medicinal entities."", 'Methylcellulose, a common thickening agent, has shown to decrease efficacy of several drugs like methantheline, carvedilol, and fenpiverinium. Similarly, nalbuphine, an opioid analgesic drug, has also indicated to decrease the efficacy of trichlormethiazide and methylcellulose. However, a notable side effect of nalbuphine appears to be Shock. Interestingly, while the efficacy of trichlormethiazide decreases with certain drugs, its efficacy increases when interacts with hydralazine, a medication used to treat high blood pressure and heart failure. This intricate web of drug interactions serves as a crucial reminder of potential impacts on drug efficacy.']","['The drug methylcellulose has multiple interactions with other medications. It is known to decrease the efficacy of both methantheline and carvedilol. Moreover, methylcellulose has a side effect of inducing shock, a critical condition that needs immediate treatment.\n\nMoving on to the action of nalbuphine, a medicine that also decreases the efficacy of another drug known as trichlormethiazide. Interestingly, nalbuphine shares a common side effect with methylcellulose, which is the occurrence of shock.\n\nTrichlormethiazide, on the other hand, is known to increase the efficacy of hydralazine. In reverse, hydralazine decreases the efficacy of methylcellulose when they are taken together. \n\nFenpiverinium contributes to this interconnected mechanism by increasing the efficacy of hydralazine, but it also decreases the efficacy of nalbuphine. These interactions prove the complexity and delicate balance of pharmaceutical compounds in medical treatments.', ""Methylcellulose decreases the efficacy of both methantheline and carvedilol, and it has a side effect of causing shock. Similarly, nalbuphine also decreases the efficacy of trichlormethiazide and also has the side effect of causing shock. Yet, trichlormethiazide increases the efficacy of hydralazine. However, this increased efficacy can be offset as hydralazine has the effect of decreasing the efficacy of methylcellulose. Fenpiverinium plays a dual role, as it boosts the efficacy of hydralazine while decreasing the efficacy of nalbuphine. It's implications on the balance between these medications and their related conditions need to be well accounted for in pharmacological applications.""]"
"[{'source_node': {'name': '(12e,20z,18s)-8-hydroxyvariabilin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glycine receptor subunit alpha-2'}}, {'source_node': {'name': '(12e,20z,18s)-8-hydroxyvariabilin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}, {'source_node': {'name': '(12e,20z,18s)-8-hydroxyvariabilin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 't-cell protein-tyrosine phosphatase'}}, {'source_node': {'name': 'glycine receptor subunit alpha-2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GLRA2'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}, {'source_node': {'name': 't-cell protein-tyrosine phosphatase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN2'}}]","[{'source_node': {'name': '(12e,20z,18s)-8-hydroxyvariabilin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'GLRA2'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN2'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:1921', 'target': 'GENE:32080', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:70397', 'target': 'PROTEIN:1921', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:70397', 'target': 'GENE:28157', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'PROTEIN:5888', 'target': None, 'metadata': {'node_id': '5888', 'node_type': 'PROTEIN', 'display_name': 't-cell protein-tyrosine phosphatase'}}, {'type': 'node_removal', 'source': 'PROTEIN:490', 'target': None, 'metadata': {'node_id': '490', 'node_type': 'PROTEIN', 'display_name': 'glycine receptor subunit alpha-2'}}]",0.3076923076923077,abcafe816c31d890c0d72544934cfe1c,bdc6554ddab4d233f23dbb53fe7e665b,"['The compound known as (12e,20z,18s)-8-hydroxyvariabilin has several targets. It interacts with the glycine receptor subunit alpha-2, tyrosine-protein phosphatase non-receptor type 1, and t-cell protein-tyrosine phosphatase. These target proteins are gene products of the corresponding genes. Specifically, the glycine receptor subunit alpha-2 is a gene product of GLRA2, tyrosine-protein phosphatase non-receptor type 1 is a gene product of PTPN1, and t-cell protein-tyrosine phosphatase is a gene product of PTPN2.', 'The compound (12e,20z,18s)-8-hydroxyvariabilin has several molecular targets. These include the glycine receptor subunit alpha-2, which is a gene product of GLRA2, tyrosine-protein phosphatase non-receptor type 1, a product of the PTPN1 gene, and the t-cell protein-tyrosine phosphatase, produced by the PTPN2 gene.', 'The substance known as (12e,20z,18s)-8-hydroxyvariabilin has several targets including the glycine receptor subunit alpha-2, the tyrosine-protein phosphatase non-receptor type 1, and the T-cell protein-tyrosine phosphatase. Further investigation into these targets reveals distinct gene products. The glycine receptor subunit alpha-2 is the gene product of GLRA2. Similarly, the tyrosine-protein phosphatase non-receptor type 1 and the T-cell protein-tyrosine phosphatase are gene products of PTPN1 and PTPN2 respectively.', 'The chemical compound, (12e,20z,18s)-8-hydroxyvariabilin, exhibits its functions by targeting a number of proteins. These include the glycine receptor subunit alpha-2, tyrosine-protein phosphatase non-receptor type 1, and t-cell protein-tyrosine phosphatase. Interestingly, each of these proteins are the gene products of specific genes. The glycine receptor subunit alpha-2 is a gene product of GLRA2. On the other hand, the tyrosine-protein phosphatase non-receptor type 1 and the t-cell protein-tyrosine phosphatase are gene products of PTPN1 and PTPN2 respectively.', 'The compound (12e,20z,18s)-8-hydroxyvariabilin targets several proteins, including the glycine receptor subunit alpha-2, tyrosine-protein phosphatase non-receptor type 1, and t-cell protein-tyrosine phosphatase. These proteins are all gene products of different genes. Glycine receptor subunit alpha-2 is a gene product of GLRA2 gene, tyrosine-protein phosphatase non-receptor type 1 is a gene product of PTPN1 gene, and t-cell protein-tyrosine phosphatase is a gene product of PTPN2 gene.']","['The compound (12e,20z,18s)-8-hydroxyvariabilin is affecting GLRA2. On the other hand, tyrosine-protein phosphatase non-receptor type 1, which is known to be a gene product of both PTPN1 and PTPN2 genes.', 'The compound (12e,20z,18s)-8-hydroxyvariabilin affects the GLRA2 gene. Tyrosine-protein phosphatase non-receptor type 1, a product of two genes, PTPN1 and PTPN2, also plays a critical role in this biochemical system.', 'The compound (12e,20z,18s)-8-hydroxyvariabilin affects the GLRA2 gene. In addition, the gene products of the PTPN1 and PTPN2 genes are both tyrosine-protein phosphatase non-receptor type 1 enzymes.']"
"[{'source_node': {'name': 'camrelizumab'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the thrombogenic activities '}}, {'source_node': {'name': 'camrelizumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'camrelizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imlifidase'}}]","[{'source_node': {'name': 'camrelizumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'camrelizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imlifidase'}}]","[{'type': 'node_removal', 'source': 'ACTIVITY:2', 'target': None, 'metadata': {'node_id': '2', 'node_type': 'ACTIVITY', 'display_name': ' the thrombogenic activities '}}]",0.7142857142857143,23b1aacc6e440575e095d84303d4b07a,d36c0c3978e50ae19b56b41787590566,[],[]
"[{'source_node': {'name': 'MRPL20'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Mitochondrial translation initiation'}}, {'source_node': {'name': 'MRPL20'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Mitochondrial translation elongation'}}, {'source_node': {'name': 'MRPL20'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Mitochondrial translation termination'}}]","[{'source_node': {'name': 'MRPL20'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Mitochondrial translation termination'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:256', 'target': None, 'metadata': {'node_id': '256', 'node_type': 'PATHWAY', 'display_name': 'Mitochondrial translation elongation'}}, {'type': 'node_removal', 'source': 'PATHWAY:466', 'target': None, 'metadata': {'node_id': '466', 'node_type': 'PATHWAY', 'display_name': 'Mitochondrial translation initiation'}}]",0.4285714285714286,c7769bef40f84d7f430f3c48f1e0779c,bda9ded20ab914f14a064e9bd0971356,[],"['The gene MRPL20 functions within the process of mitochondrial translation termination.', 'The gene MRPL20 is known to act within the pathway of mitochondrial translation termination.', 'The gene MRPL20 acts within the pathway of mitochondrial translation termination.']"
"[{'source_node': {'name': 'oxane-2,3,4,5-tetrol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'geminin'}}, {'source_node': {'name': 'oxane-2,3,4,5-tetrol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'isocitrate dehydrogenase [nadp] cytoplasmic'}}]","[{'source_node': {'name': 'oxane-2,3,4,5-tetrol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'geminin'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:1917', 'target': None, 'metadata': {'node_id': '1917', 'node_type': 'PROTEIN', 'display_name': 'isocitrate dehydrogenase [nadp] cytoplasmic'}}]",0.6,8060e7046604db46e2c2b009c0c73778,c49c0d4039d30618dad6f7ecbf7c357e,"['The compound oxane-2,3,4,5-tetrol has been identified as having multiple targets, including the protein geminin and the enzyme isocitrate dehydrogenase [nadp] cytoplasmic.', 'The compound oxane-2,3,4,5-tetrol is known to target both geminin and isocitrate dehydrogenase [nadp] cytoplasmic enzymes.', 'The compound oxane-2,3,4,5-tetrol targets both geminin and isocitrate dehydrogenase [nadp] cytoplasmic in certain biological interactions.', 'The drug oxane-2,3,4,5-tetrol targets two different enzymes: geminin and isocitrate dehydrogenase [nadp] cytoplasmic, potentially affecting their normal functions within the organism.', 'The compound oxane-2,3,4,5-tetrol targets two distinct entities: one being geminin, a protein crucial to DNA replication, and the other being the cytoplasmic isocitrate dehydrogenase [NADP], which is an essential enzyme involved in cellular metabolism.']","['The compound oxane-2,3,4,5-tetrol has geminin as its target.']"
"[{'source_node': {'name': 'betamethasone'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' infection '}}, {'source_node': {'name': 'betamethasone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'isoflurophate'}}, {'source_node': {'name': 'betamethasone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rabies immune globulin'}}, {'source_node': {'name': 'isoflurophate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cholinesterase'}}, {'source_node': {'name': 'isoflurophate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imipramine'}}, {'source_node': {'name': 'isoflurophate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'meclizine'}}, {'source_node': {'name': 'rabies immune globulin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methotrexate'}}, {'source_node': {'name': 'rabies immune globulin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'apremilast'}}]","[{'source_node': {'name': 'betamethasone'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' infection '}}, {'source_node': {'name': 'isoflurophate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cholinesterase'}}, {'source_node': {'name': 'isoflurophate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imipramine'}}, {'source_node': {'name': 'isoflurophate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'meclizine'}}, {'source_node': {'name': 'methotrexate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'meclizine'}}, {'source_node': {'name': 'rabies immune globulin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methotrexate'}}, {'source_node': {'name': 'rabies immune globulin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'apremilast'}}, {'source_node': {'name': 'rabies immune globulin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'meclizine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:549', 'target': 'COMPOUND:721', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:431', 'target': 'COMPOUND:662', 'metadata': None}, {'type': 'edge_deletion', 'source': 'COMPOUND:431', 'target': 'COMPOUND:9526', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:9526', 'target': 'COMPOUND:721', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.7647058823529411,ae6ede0047dca939c8ddb3a3c47115df,d19057aa36b20588b4089b03baa5cef9,[],[]
"[{'source_node': {'name': 'tankyrase-2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TNKS2'}}, {'source_node': {'name': 'carbonic anhydrase 12'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA12'}}, {'source_node': {'name': '2-hydroxyquinoline'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': '72 kda type iv collagenase'}}, {'source_node': {'name': '2-hydroxyquinoline'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'carbonic anhydrase 12'}}, {'source_node': {'name': '2-hydroxyquinoline'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tankyrase-2'}}, {'source_node': {'name': '72 kda type iv collagenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MMP2'}}]","[{'source_node': {'name': 'tankyrase-2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TNKS2'}}, {'source_node': {'name': 'tankyrase-2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA12'}}, {'source_node': {'name': 'carbonic anhydrase 12'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA12'}}, {'source_node': {'name': '72 kda type iv collagenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MMP2'}}, {'source_node': {'name': '72 kda type iv collagenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA12'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:4462', 'target': 'GENE:29960', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'COMPOUND:4462', 'target': None, 'metadata': {'node_id': '4462', 'node_type': 'COMPOUND', 'display_name': '2-hydroxyquinoline'}}, {'type': 'edge_addition', 'source': 'PROTEIN:5942', 'target': 'GENE:33626', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'PROTEIN:1383', 'target': 'GENE:33626', 'metadata': {'predicate': 'gene_product_of'}}]",0.5384615384615384,efd97e54f7a6cfb3a9ec53c18061b664,527dec8a246e41b24c21052c6682e989,"['Tankyrase-2 and Carbonic Anhydrase 12 are gene products of TNKS2 and CA12 respectively. These two proteins are targeted by 2-Hydroxyquinoline, a therapeutic agent. This compound also targets 72 kDa type IV collagenase, which is a gene product of MMP2. This evidences the broad spectrum activity of 2-hydroxyquinoline, which targets multiple proteins involved in various biological processes and diseases.', 'Tankyrase-2 and carbonic anhydrase 12 are gene products of TNKS2 and CA12 respectively. Tankyrase-2 and carbonic anhydrase 12, along with 72 kDa type IV collagenase, are the targets of 2-hydroxyquinoline, which is a drug. Furthermore, the 72 kDa type IV collagenase is the gene product of MMP2.', 'The compound 2-hydroxyquinoline targets several proteins including 72 kda type IV collagenase, carbonic anhydrase 12, and tankyrase-2. Each of these proteins is the gene product of a distinct gene. Specifically, 72 kda type IV collagenase is a gene product of MMP2, tankyrase-2 is a gene product of TNKS2, and carbonic anhydrase 12 is a gene product of CA12.', 'The protein tankyrase-2, is a gene product of TNKS2, and carbonic anhydrase 12 is a gene product of CA12. Both proteins are targeted by the molecule 2-hydroxyquinoline. Similarly, the protein 72 kDa type IV collagenase, which is also a gene product of MMP2, is another target of 2-hydroxyquinoline.', 'Tankyrase-2, which is a gene product of TNKS2, and Carbonic Anhydrase 12, which is a gene product of CA12, are both targets of the drug 2-hydroxyquinoline. This drug also targets the 72 kDa type IV Collagenase, a gene product of MMP2.']","['Tankyrase-2, a gene product of TNKS2 and CA12, and carbonic anhydrase 12, which is also a gene product of CA12, act within these respective genes. Furthermore, 72 kDa Type IV Collagenase, a gene product of other key genes namely MMP2 and CA12, is also involved in the genetic interplay.']"
"[{'source_node': {'name': 'carfecillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lynestrenol'}}, {'source_node': {'name': 'carfecillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'quingestanol'}}]","[{'source_node': {'name': 'carfecillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'quingestanol'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:10371', 'target': None, 'metadata': {'node_id': '10371', 'node_type': 'COMPOUND', 'display_name': 'lynestrenol'}}]",0.6,44a8c868ec55ca14262a409843113128,6b75fb4b6bb6f07ef79e6e007a3e0b03,"['The drug Carfecillin has been found to decrease the efficacy of both Lynestrenol and Quingestanol.', 'The drug Carfecillin is known to decrease the efficacy of both Lynestrenol and Quingestanol.', 'The drug carfecillin has been known to decrease the efficacy of certain other drugs. Specifically, it reduces the effectiveness of both lynestrenol and quingestanol.', 'The drug Carfecillin has been found to decrease the efficacy of both Lynestrenol and Quingestanol. This implies that the usage of Carfecillin may reduce the effectiveness of these drugs.', ""The drug Carfecillin is known to decrease the efficacy of both Lynestrenol and Quingestanol. It's important to take this into account when taking these drugs concurrently, as Carfecillin could potentially inhibit the intended effects of Lynestrenol and Quingestanol.""]","['The drug carfecillin has been found to decrease the efficacy of quingestanol.', 'The efficacy of quingestanol is decreased by the drug carfecillin.']"
"[{'source_node': {'name': 'dexrazoxane'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ingn 225'}}, {'source_node': {'name': 'dexrazoxane'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Dry mouth'}}, {'source_node': {'name': 'dexrazoxane'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Injection site reaction'}}, {'source_node': {'name': 'clofarabine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Haemoglobin'}}, {'source_node': {'name': 'ingn 225'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'interferon gamma-1b'}}, {'source_node': {'name': 'ingn 225'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clofarabine'}}, {'source_node': {'name': 'ingn 225'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fludarabine'}}]","[{'source_node': {'name': 'dexrazoxane'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Dry mouth'}}, {'source_node': {'name': 'dexrazoxane'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Injection site reaction'}}, {'source_node': {'name': 'clofarabine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Haemoglobin'}}, {'source_node': {'name': 'ingn 225'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'interferon gamma-1b'}}, {'source_node': {'name': 'ingn 225'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clofarabine'}}, {'source_node': {'name': 'ingn 225'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fludarabine'}}, {'source_node': {'name': 'fludarabine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'interferon gamma-1b'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:369', 'target': 'COMPOUND:4962', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:1053', 'target': 'COMPOUND:32', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.8666666666666667,5c5e9033640ca94878119aaaae1162d3,2cb2a5f5f390789a0b5a427f06bf3b34,[],[]
"[{'source_node': {'name': 'mersalyl'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nalbuphine'}}, {'source_node': {'name': 'mersalyl'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bezitramide'}}]","[{'source_node': {'name': 'mersalyl'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nalbuphine'}}, {'source_node': {'name': 'nalbuphine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'mersalyl'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:1395', 'target': None, 'metadata': {'node_id': '1395', 'node_type': 'COMPOUND', 'display_name': 'bezitramide'}}, {'type': 'edge_addition', 'source': 'COMPOUND:827', 'target': 'COMPOUND:8271', 'metadata': {'predicate': 'increase_efficacy'}}]",0.4,dbaf0c7c09cfaa8045fb00f4a36de951,bcf3bf1e04b3401683c8d125f563ff54,"['The drug Mersalyl is known to decrease the efficacy of both Nalbuphine and Bezitramide. Therefore, caution should be taken when co-administering Mersalyl with these drugs as it could potentially reduce their therapeutic effects.', 'The drug Mersalyl is known to decrease the efficacy of both Nalbuphine and Bezitramide.', 'The drug mersalyl is known to decrease the efficacy of both nalbuphine and bezitramide.', 'The drug Mersalyl is known to decrease the efficacy of other drugs, specifically Nalbuphine and Bezitramide.', 'The drug Mersalyl is known to decrease the efficacy of both Nalbuphine and Bezitramide. Therefore, concurrent usage of Mersalyl with these medications should be reconsidered.']","['The drug Mersalyl is known to decrease the efficacy of Nalbuphine. Conversely, Nalbuphine has been observed to increase the efficacy of Mersalyl.', 'The drug Mersalyl is known to decrease the efficacy of Nalbuphine. On the other hand, it appears that Nalbuphine increases the efficacy of Mersalyl. This illustrates a complex interaction between these two substances.', 'The drug Mersalyl is known to decrease the efficacy of Nalbuphine. However, in return, Nalbuphine is observed to increase the efficacy of Mersalyl.', 'The drug Mersalyl is known to decrease the efficacy of Nalbuphine. Conversely, Nalbuphine is found to increase the efficacy of Mersalyl.', 'The drug Mersalyl is known to decrease the efficacy of Nalbuphine. Surprisingly, Nalbuphine, on the other hand, can increase the efficacy of Mersalyl.']"
"[{'source_node': {'name': 'simfibrate'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'simfibrate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tauroursodeoxycholic acid'}}, {'source_node': {'name': 'simfibrate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dehydrocholic acid'}}, {'source_node': {'name': 'tauroursodeoxycholic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'chlormadinone'}}, {'source_node': {'name': 'tauroursodeoxycholic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sodium/bile acid cotransporter'}}]","[{'source_node': {'name': 'chlormadinone'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'simfibrate'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'simfibrate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tauroursodeoxycholic acid'}}, {'source_node': {'name': 'simfibrate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dehydrocholic acid'}}, {'source_node': {'name': 'tauroursodeoxycholic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'chlormadinone'}}, {'source_node': {'name': 'tauroursodeoxycholic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sodium/bile acid cotransporter'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:11379', 'target': 'EFFECT:5', 'metadata': {'predicate': 'increase_effect'}}]",0.9090909090909092,054546d178b02a770a6bb0df9896b525,951d022f2bf52253014eab3dadeeb12d,[],[]
"[{'source_node': {'name': 'coagulation factor viia recombinant human'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'alteplase'}}, {'source_node': {'name': 'coagulation factor viia recombinant human'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ferulic acid'}}, {'source_node': {'name': 'semuloparin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'coagulation factor viia recombinant human'}}, {'source_node': {'name': 'semuloparin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'platelet activating factor'}}, {'source_node': {'name': 'semuloparin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'plazomicin'}}]","[{'source_node': {'name': 'plazomicin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'alteplase'}}, {'source_node': {'name': 'coagulation factor viia recombinant human'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'alteplase'}}, {'source_node': {'name': 'coagulation factor viia recombinant human'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ferulic acid'}}, {'source_node': {'name': 'semuloparin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'coagulation factor viia recombinant human'}}, {'source_node': {'name': 'semuloparin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'platelet activating factor'}}, {'source_node': {'name': 'semuloparin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'plazomicin'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:10501', 'target': 'COMPOUND:9', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.9090909090909092,66b188a3259d68af7ac9b9e8e406f63b,ce7d68f519f5945a3656384e015ee0c4,"['The drug Coagulation Factor VIIa Recombinant Human has been known to decrease the efficacy of Alteplase and Ferulic Acid. On the other hand, the use of Semuloparin can decrease the efficacy of Coagulation Factor VIIa Recombinant Human, Platelet Activating Factor, and Plazomicin. Thus, care should be taken when using these substances concurrently.', 'The drug coagulation factor VIIa recombinant human has been shown to decrease the efficacy of both alteplase and ferulic acid. Meanwhile, semuloparin, another drug, decreases the efficacy of coagulation factor VIIa recombinant human alongside platelet activating factor and plazomicin. This means that coadministration of these drugs can lead to less effective treatment outcomes, providing essential information for prescribing and medicine management.', 'Coagulation Factor VIIa Recombinant Human, a drug used to aid clotting, is noted to decrease the efficacy of Alteplase, a medication used to breakdown blood clots, and Ferulic Acid, a chemical commonly used in skincare. Additionally, the medication Semuloparin, used to prevent blood clots in knee or hip surgery patients, has been found to decrease the efficacy of Coagulation Factor VIIa Recombinant Human. Interestingly, Semuloparin also reduces the efficacy of Platelet Activating Factor and Plazomicin, an antibiotic drug that fights bacteria in the body.', 'The drug coagulation factor VIIa recombinant human has been noted to decrease the efficacy of both alteplase and ferulic acid. However, it is essential to highlight that semuloparin may decrease the efficacy of coagulation factor VIIa recombinant human. Additionally, semuloparin also has the potential to limit the efficacy of platelet activating factor and plazomicin.', 'The drug coagulation factor VIIa recombinant human decreases the efficacy of both alteplase and ferulic acid. Meanwhile, semuloparin has a therapeutic effect, which could decrease the efficacy of coagulation factor VIIa recombinant human, platelet activating factor and plazomicin. Therefore, care should be taken when administering these medications in combination, as the decreased efficacy could potentially impact the effectiveness of treatment.']","['The relationship among a series of substances and their efficacy in relation to each other unfolds as follows. Plazomicin decreases the efficacy of alteplase. Meanwhile, coagulation factor VIIa recombinant human also reduces the efficacy of alteplase, in addition to decreasing the efficacy of ferulic acid. On another front, semuloparin diminishes the efficacy of three separate entities: coagulation factor VIIa recombinant human, platelet activating factor, and plazomicin. Therefore, these interactions should be taken into account when considering the administration and effectiveness of these substances in various treatments.', 'The efficacy of various chemical compounds and drugs is interdependent. For instance, plazomicin and the coagulation factor VIIa recombinant human both decrease the efficacy of alteplase. Similarly, the coagulation factor VIIa recombinant human has a diminishing impact on the efficacy of ferulic acid. Likewise, semuloparin negatively affects the efficacy of the coagulation factor VIIa recombinant human and plazomicin. In addition, it has the same reducing effect on the platelet activating factor. This shows the complex interactions and relationships in drug efficacy.', 'The drug Plazomicin and Coagulation Factor VIIa recombinant human are both known to decrease the efficacy of Alteplase. Furthermore, Coagulation Factor VIIa recombinant human also reduces the efficacy of Ferulic Acid. Semuloparin has a similar diminishing effect on the Coagulation Factor VIIa recombinant human, Platelet Activating Factor, and Plazomicin, further decreasing their efficacy. These interactions suggest that caution should be exercised when these drugs are co-administered, considering their potential to negatively affect each others efficacy.', 'The drug plazomicin and the coagulation factor viia recombinant human both decrease the efficacy of alteplase. Furthermore, coagulation factor viia recombinant human also decreases the efficacy of ferulic acid. Meanwhile, semuloparin, a type of anticoagulant, decreases the efficacy of coagulation factor viia recombinant human, platelet activating factor, and plazomicin. This interplay of drug efficacies emphasizes the need for careful consideration when combining treatments.', 'The drug plazomicin is known to decrease the efficacy of alteplase. Similarly, coagulation factor VIIa recombinant human also diminishes the effectiveness of alteplase and ferulic acid. In an interconnected chain of interactions, the drug semuloparin has been observed to decrease the efficacy of coagulation factor VIIa recombinant human, platelet activating factor, and plazomicin. These reduction in efficacies underlines key interactions and potential complications in co-administered drug regimens.']"
"[{'source_node': {'name': 'menthyl salicylate'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' bleeding and hemorrhage '}}, {'source_node': {'name': 'menthyl salicylate'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'menthyl salicylate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'manidipine'}}, {'source_node': {'name': 'manidipine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'abafungin'}}, {'source_node': {'name': 'manidipine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'aceclofenac'}}, {'source_node': {'name': 'manidipine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pentaerithrityl'}}, {'source_node': {'name': 'aceclofenac'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' hyperkalemia '}}]","[{'source_node': {'name': 'manidipine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'abafungin'}}, {'source_node': {'name': 'manidipine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'aceclofenac'}}, {'source_node': {'name': 'manidipine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pentaerithrityl'}}, {'source_node': {'name': 'abafungin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'aceclofenac'}}]","[{'type': 'node_removal', 'source': 'EFFECT:51', 'target': None, 'metadata': {'node_id': '51', 'node_type': 'EFFECT', 'display_name': ' hyperkalemia '}}, {'type': 'edge_deletion', 'source': 'COMPOUND:9202', 'target': 'COMPOUND:8173', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:9202', 'target': None, 'metadata': {'node_id': '9202', 'node_type': 'COMPOUND', 'display_name': 'menthyl salicylate'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5563', 'target': 'COMPOUND:5786', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.4,7476fe8ee76772e5bc4ba10b4e9186ad,dddbf1e14bcf8ca12856b040652497a9,[],"['Manidipine, a commonly used drug, has a dual impact on other medication. It increases the efficacy of the antifungal drug, abafungin. However, it decreases the efficacy of two other drugs: the anti-inflammatory drug aceclofenac and pentaerithrityl, a vasodilator typically used for angina. Interestingly, abafungin also has an impact on aceclofenac, as it too is known to decrease its efficacy.', 'The drug Manidipine is known to increase the efficacy of Abafungin. Conversely, it decreases the efficacy of other medications, such as Aceclofenac and Pentaerithrityl. Interestingly, Abafungin also shows a decrease in efficacy when combined with Aceclofenac.', 'The drug Manidipine has varying effects on the efficacy of other drugs. Notably, it increases the efficacy of Abafungin, a powerful antifungal medication. However, it decreases the efficacy of Aceclofenac, a non-steroidal anti-inflammatory drug (NSAID), as well as Pentaerithrityl, a type of medicinal alcohol. Interestingly, Abafungin also decreases the efficacy of Aceclofenac, suggesting a possible trending interaction between these three medications. Thus, careful consideration needs to be given when co-administering these drugs.', 'The drug manidipine demonstrates diverse interactions with other medications. Specifically, it increases the efficacy of the antifungal agent abafungin, while conversely decreasing the efficacy of aceclofenac, an anti-inflammatory used for pain management, and pentaerithrityl, a common component in medicines. Interestingly, abafungin independently shows a negative interaction with aceclofenac as well, reducing its efficacy. Such complex interactions highlight the importance of careful assessment of drug combinations in patient treatment plans.', ""Manidipine, a pharmaceutical drug, has shown to increase the efficacy of another drug, Abafungin. However, it's been observed that its efficacy decreases when in combination with Aceclofenac and Pentaerithrityl. Additionally, Abafungin, otherwise enhanced by Manidipine, also exhibits decreased efficacy when combined with Aceclofenac. This information is important for devising efficient and safe drug therapeutic strategies.""]"
"[{'source_node': {'name': 'gamma-aminobutyric acid receptor subunit gamma-2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GABRG2'}}, {'source_node': {'name': 'arachidonate 12-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX12'}}, {'source_node': {'name': '2,6-dibromophenol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'gamma-aminobutyric acid receptor subunit gamma-2'}}, {'source_node': {'name': '2,6-dibromophenol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arachidonate 12-lipoxygenase'}}, {'source_node': {'name': '2,6-dibromophenol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arachidonate 15-lipoxygenase'}}]","[{'source_node': {'name': 'gamma-aminobutyric acid receptor subunit gamma-2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GABRG2'}}, {'source_node': {'name': '2,6-dibromophenol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arachidonate 12-lipoxygenase'}}, {'source_node': {'name': '2,6-dibromophenol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arachidonate 15-lipoxygenase'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:1106', 'target': 'GENE:27499', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:43122', 'target': 'PROTEIN:1106', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:27499', 'target': None, 'metadata': {'node_id': '27499', 'node_type': 'GENE', 'display_name': 'ALOX12'}}]",0.7272727272727273,d88a8ec38db9c2fb7a83972b7c79ed4a,7162c3177c438fa49a576cce00b787cf,"['The compound 2,6-dibromophenol targets several entities, including the gamma-aminobutyric acid receptor subunit gamma-2 and arachidonate 12-lipoxygenase. Notably, the gamma-aminobutyric acid receptor subunit gamma-2 is a gene product of GABRG2 while arachidonate 12-lipoxygenase is a gene product of ALOX12. In addition, 2,6-dibromophenol also targets arachidonate 15-lipoxygenase.', 'The drug 2,6-dibromophenol targets several entities including gamma-aminobutyric acid receptor subunit gamma-2, arachidonate 12-lipoxygenase, and arachidonate 15-lipoxygenase. Interestingly, the gamma-aminobutyric acid receptor subunit gamma-2 is a gene product of GABRG2 and similarly, arachidonate 12-lipoxygenase is a gene product of ALOX12.', 'The compound 2,6-dibromophenol targets several entities, including the gamma-aminobutyric acid receptor subunit gamma-2, arachidonate 12-lipoxygenase, and arachidonate 15-lipoxygenase. Of note, gamma-aminobutyric acid receptor subunit gamma-2 is a gene product of GABRG2 and arachidonate 12-lipoxygenase is a gene product of ALOX12.', 'The compound 2,6-dibromophenol is known to target several key molecules, including the gamma-aminobutyric acid receptor subunit gamma-2 and arachidonate 12-lipoxygenase. The gamma-aminobutyric acid receptor subunit gamma-2 is a gene product of GABRG2. Similarly, arachidonate 12-lipoxygenase is the gene product of ALOX12. Lastly, another key target of 2,6-dibromophenol is arachidonate 15-lipoxygenase. These interactions highlight the nuanced network within which 2,6-dibromophenol operates.', 'The compound 2,6-dibromophenol targets multiple other compounds, namely gamma-aminobutyric acid receptor subunit gamma-2 and arachidonate 12-lipoxygenase, as well as arachidonate 15-lipoxygenase. The gamma-aminobutyric acid receptor subunit gamma-2 is a gene product of GABRG2, while arachidonate 12-lipoxygenase is produced by the gene ALOX12.']","['The drug 2,6-dibromophenol acts by primarily targeting two proteins, arachidonate 12-lipoxygenase and arachidonate 15-lipoxygenase. On the other hand, we have the gamma-aminobutyric acid receptor subunit gamma-2, an important receptor in the central nervous system, which is a gene product of GABRG2.', 'The protein gamma-aminobutyric acid receptor subunit gamma-2 is a gene product of GABRG2. On the other hand, the compound 2,6-dibromophenol specifically targets two enzymes: arachidonate 12-lipoxygenase and arachidonate 15-lipoxygenase.', 'The gamma-aminobutyric acid receptor subunit gamma-2 is a gene product of GABRG2. Meanwhile, the chemical compound 2,6-dibromophenol targets both arachidonate 12-lipoxygenase and arachidonate 15-lipoxygenase.', 'The protein known as gamma-aminobutyric acid receptor subunit gamma-2 is a gene product of GABRG2. Concurrently, the compound 2,6-dibromophenol demonstrates target abilities towards two different enzymes, namely arachidonate 12-lipoxygenase and arachidonate 15-lipoxygenase.', 'The drug 2,6-dibromophenol acts by targeting two enzymes: arachidonate 12-lipoxygenase and arachidonate 15-lipoxygenase. In a separate process, the gamma-aminobutyric acid receptor subunit gamma-2 is identified as the gene product of the gene GABRG2.']"
"[{'source_node': {'name': 'gosogliptin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'norfloxacin'}}, {'source_node': {'name': 'gosogliptin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'chlorsulfaquinoxaline'}}, {'source_node': {'name': 'clorexolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carfentanil'}}, {'source_node': {'name': 'clorexolone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'gosogliptin'}}, {'source_node': {'name': 'clorexolone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'netoglitazone'}}]","[{'source_node': {'name': 'gosogliptin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'norfloxacin'}}, {'source_node': {'name': 'gosogliptin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'chlorsulfaquinoxaline'}}, {'source_node': {'name': 'clorexolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carfentanil'}}, {'source_node': {'name': 'clorexolone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'netoglitazone'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:11465', 'target': 'COMPOUND:7372', 'metadata': None}]",0.9090909090909092,6ec404ba448a1cc80edfe1ac105f58c1,1213fb1f0a1887009cd8ffd3a4c64432,"['The drug Gosogliptin is known to increase the efficacy of Norfloxacin and Chlorsulfaquinoxaline. On the other hand, Clorexolone, another drug, has a mixed effect on different substances. Whilst it decreases the efficacy of Carfentanil, a highly potent synthetic opioid, it increases the efficacy of Gosogliptin and Netoglitazone.', 'The drug Gosogliptin is known to increase the efficacy of Norfloxacin and Chlorsulfaquinoxaline. On the other hand, Clorexolone is observed to decrease the efficacy of Carfentanil. Interestingly, Clorexolone can also increase the efficacy of Gosogliptin and Netoglitazone. This indicates a complex interplay of effects among these medications.', 'The drug gosogliptin is known to increase the efficacy of norfloxacin and chlorsulfaquinoxaline. On the other hand, the drug clorexolone seems to have varying effects on different drugs, where it increases the efficacy of gosogliptin and netoglitazone but decreases the efficacy of carfentanil.', 'The drug Gosogliptin is known to increase the efficacy of both Norfloxacin and Chlorsulfaquinoxaline. On the other hand, Clorexolone has a dual effect. It has been found to decrease the efficacy of Carfentanil, but interestingly increases the efficacy of Gosogliptin and Netoglitazone.', ""The drug Gosogliptin is noted to increase the efficacy of both Norfloxacin and Chlorsulfaquinoxaline. Similarly, Clorexolone has been found to enhance the efficacy of Gosogliptin and Netoglitazone. However, it's important to note that Clorexolone may decrease the efficacy of Carfentanil. Thus, these drug interactions should be considered in medical practice to optimize therapeutic effect.""]","['The drug Gosogliptin is known to increase the efficacy of other drugs, specifically Norfloxacin and Chlorsulfaquinoxaline. In contrast, Clorexolone generally decreases the efficacy of Carfentanil. However, an interesting point to note is that it increases the efficacy of another drug, Netoglitazone.', 'The drug gosogliptin is known to increase the efficacy of various other medications, notably norfloxacin and chlorsulfaquinoxaline. On the other hand, clorexolone, another medication, has a two-sided effect: it enhances the efficacy of netoglitazone, yet decreases that of carfentanil. These interactions reflect the complex network of medication interactions that can potentially influence treatment outcomes.', 'The drug Gosogliptin is known to increase the efficacy of both Norfloxacin and Chlorsulfaquinoxaline, making them more effective in their roles. On the other hand, Clorexolone, another drug, has a dual effect: it is shown to decrease the efficacy of Carfentanil, potentially rendering it less effective in its therapeutic use, while simultaneously it increases the efficacy of Netoglitazone, boosting its therapeutic potency.', 'Gosogliptin, a medication, is known to increase the efficacy of two other drugs - Norfloxacin, an antibiotic, and Chlorsulfaquinoxaline, a sulfonamide. On the other hand, Clorexolone exhibits contrasting activity. It has been observed to decrease the efficacy of Carfentanil, an extremely potent opioid, while improving the effectiveness of Netoglitazone, an antidiabetic drug.', 'The medication Gosogliptin has been found to increase the efficacy of other drugs like Norfloxacin and Chlorsulfaquinoxaline. Conversely, Clorexolone has a different effect: it decreases the efficacy of Carfentanil, but interestingly, it increases the efficacy of Netoglitazone. These differing effects highlight the importance of understanding the interactions between different medications.']"
"[{'source_node': {'name': 'topsentolide b3'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'topsentolide b3'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-mel-2'}}, {'source_node': {'name': 'topsentolide b3'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-15'}}]","[{'source_node': {'name': 'topsentolide b3'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4980', 'target': None, 'metadata': {'node_id': '4980', 'node_type': 'PROTEIN', 'display_name': 'sk-mel-2'}}, {'type': 'node_removal', 'source': 'PROTEIN:4982', 'target': None, 'metadata': {'node_id': '4982', 'node_type': 'PROTEIN', 'display_name': 'hct-15'}}]",0.4285714285714286,b930e490de324c8a217499620bac088d,16fb6e01cbfa5e3f90d94e8fb9e9fdff,"['The drug Topsentolide B3 has multiple targets, including A549, SK-MEL-2, and HCT-15.', 'The compound Topsentolide B3 has been shown to target several cell lines, including A549, SK-MEL-2, and HCT-15.', 'Topsentolide B3 is a compound that has been shown to target multiple types of cells, including A549, SK-MEL-2, and HCT-15.', 'The compound Topsentolide B3 has been shown to target multiple cell lines including A549, SK-MEL-2 and HCT-15.', 'Topsentolide B3, a compound of interest, has been observed to target several cellular targets including A549, SK-MEL-2 and HCT-15.']",[]
"[{'source_node': {'name': 'piroxicam'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'piroxicam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nitrendipine'}}, {'source_node': {'name': 'piroxicam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bietaserpine'}}]","[{'source_node': {'name': 'bietaserpine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'piroxicam'}}, {'source_node': {'name': 'piroxicam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bietaserpine'}}]","[{'type': 'node_removal', 'source': 'EFFECT:5', 'target': None, 'metadata': {'node_id': '5', 'node_type': 'EFFECT', 'display_name': ' adverse effects '}}, {'type': 'node_removal', 'source': 'COMPOUND:1034', 'target': None, 'metadata': {'node_id': '1034', 'node_type': 'COMPOUND', 'display_name': 'nitrendipine'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11425', 'target': 'COMPOUND:540', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.2857142857142857,1281fc2188813c07e48d3eb96e9d1f34,6d65ca7e7e6886e84bcbbae79c42d61a,[],"['The drug bietaserpine has been found to decrease the efficacy of another drug, piroxicam. In a reciprocal manner, piroxicam also decreases the efficacy of bietaserpine. Thus caution should be exercised when concurrently administering these two medications.', 'The drug Bietaserpine has been found to decrease the efficacy of another medication known as Piroxicam. Conversely, Piroxicam also decreases the efficacy of Bietaserpine. This indicates a complex interplay where each drug lessens the effectiveness of the other.', 'The drug bietaserpine decreases the efficacy of another medication named piroxicam, and interestingly, piroxicam also similarly reduces the efficacy of bietaserpine. This suggests a mutual interaction where the effectiveness of each drug may be compromised by the other.', ""The drug bietaserpine is known to decrease the efficacy of piroxicam. Conversely, piroxicam also has the same effect on bietaserpine, meaning it decreases the efficacy of bietaserpine. Both drugs therefore appear to mutually impact each other's effectiveness."", ""The use of Bietaserpine, a widely used drug, has been found to decrease the efficacy of Piroxicam. In a similar manner, the use of Piroxicam can also affect and significantly decrease the efficacy of Bietaserpine. Thus, it can be seen that these two medications have a reciprocally diminishing effect on each other's effectiveness.""]"
"[{'source_node': {'name': 'daclizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'allogeneic processed thymus tissue'}}, {'source_node': {'name': 'daclizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'famtozinameran'}}]","[{'source_node': {'name': 'famtozinameran'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'allogeneic processed thymus tissue'}}, {'source_node': {'name': 'daclizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'allogeneic processed thymus tissue'}}, {'source_node': {'name': 'daclizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'famtozinameran'}}, {'source_node': {'name': 'allogeneic processed thymus tissue'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'daclizumab'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:14040', 'target': 'COMPOUND:13820', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:13820', 'target': 'COMPOUND:103', 'metadata': {'predicate': 'increase_efficacy'}}]",0.6,2fa18b8ae748962cfafe74c3aa5b8e26,76204a4fb9d00cc45ece7a84e91e6baa,"['The drug Daclizumab has been shown to decrease the efficacy of both allogeneic processed thymus tissue and the vaccine Famtozinameran. Therefore, caution is recommended when using these therapies together in clinical settings.', 'The drug Daclizumab is known to decrease the efficacy of both allogeneic processed thymus tissue and the vaccine famtozinameran. Therefore, it is important to consider the interactions of daclizumab with these substances when used in treatment plans.', 'Daclizumab, a therapeutic agent, is known to decrease the efficacy of other treatments such as allogeneic processed thymus tissue and famtozinameran. This indicates that when daclizumab and either of these treatments are used concurrently, the effectiveness of the latter may be compromised.', 'The drug daclizumab has been found to decrease the efficacy of both allogeneic processed thymus tissue and famtozinameran. This highlights potential therapeutic challenges with the simultaneous use of these drugs.', 'The drug Daclizumab is known to decrease the efficacy of both allogeneic processed thymus tissue and Famtozinameran. Specifically, the effectiveness of these substances may be compromised when used in conjunction with Daclizumab. It is crucial to consider these interactions to ensure the effectiveness of the treatments.']","['The medication Famtozinameran is known to increase the efficacy of allogeneic processed thymus tissue. However, the drug Daclizumab, when used, is known to decrease the efficacy of both, allogeneic processed thymus tissue and Famtozinameran. Interestingly, the effectiveness of Daclizumab itself can be enhanced by the use of allogeneic processed thymus tissue.', 'The drug famtozinameran is known to increase the efficacy of allogeneic processed thymus tissue. On the other hand, daclizumab relates to this scenario in two ways. First, daclizumab appears to decrease the efficacy of allogeneic processed thymus tissue, and second, it also reduces the efficacy of famtozinameran. Interestingly, in a reversed trend, the allogeneic processed thymus tissue is found to increase the efficacy of daclizumab, illustrating a complex interplay between these biological factors.', 'Famtozinameran is reported to increase the efficacy of allogeneic processed thymus tissue. However, the use of daclizumab tends to decrease the efficacy of both allogeneic processed thymus tissue and famtozinameran. Interestingly, this effect is somewhat offset as allogeneic processed thymus tissue tends to increase the efficacy of daclizumab. As such, these elements can interact in intricate ways, highlighting the complexity of their associated biological processes.', 'Famtozinameran and allogeneic processed thymus tissue have an interesting interconnected relationship with their effectiveness. Famtozinameran, a drug, is known to increase the efficacy of allogeneic processed thymus tissue. However, it appears that these relationships are not insulated and are affected by daclizumab. Daclizumab, another medication, decreases the efficacy of both allogeneic processed thymus tissue and famtozinameran. Interestingly, the efficacy of daclizumab itself is increased by the presence of allogeneic processed thymus tissue. Thus, the efficacy and effectiveness of these three pharmaceutical substances seem intertwined in a complex web.', 'Famtozinameran, a potential therapeutic, has been shown to increase the efficacy of allogeneic processed thymus tissue, a kind of therapeutic tissue. However, another drug, daclizumab, appears to decrease the efficacy of both allogeneic processed thymus tissue and famtozinameran. Interestingly, it has been observed that allogeneic processed thymus tissue can reciprocally escalate the efficacy of daclizumab, indicating a complex interaction between these bioactive substances.']"
"[{'source_node': {'name': 'trichothecinol a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}, {'source_node': {'name': 'trichothecinol a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'trichothecinol a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}]","[{'source_node': {'name': 'trichothecinol a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5858', 'target': None, 'metadata': {'node_id': '5858', 'node_type': 'PROTEIN', 'display_name': 'kb'}}, {'type': 'node_removal', 'source': 'PROTEIN:5851', 'target': None, 'metadata': {'node_id': '5851', 'node_type': 'PROTEIN', 'display_name': 'mcf7'}}]",0.4285714285714286,aed3ca158ac7cdcca9dbfabf9b449fd8,dd5c5e4858b4510eda69f05496086a1e,"['The compound trichothecinol a exhibits targeting activity towards KB, A549, and MCF7 cells.', 'Trichothecinol A is a compound that targets multiple entities, including KB, A549, and MCF7. These targets suggest a broad applicability and potential in cellular studies.', 'Trichothecinol A is a drug that has multiple targets, including KB, A549, and MCF7 cells.', 'The compound Trichothecinol A has multiple targets including KB, A549, and MCF7 cells.', 'The compound Trichothecinol A has been found to target multiple entities such as KB, A549, and MCF7.']",[]
"[{'source_node': {'name': 'hemoglobin e disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'splenomegaly'}}, {'source_node': {'name': 'hemoglobin e disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'drug-sensitive hemolytic anemia'}}, {'source_node': {'name': 'hemoglobin e disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'miscarriage'}}]","[{'source_node': {'name': 'hemoglobin e disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'drug-sensitive hemolytic anemia'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1271', 'target': None, 'metadata': {'node_id': '1271', 'node_type': 'PHENOTYPE', 'display_name': 'splenomegaly'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:3577', 'target': None, 'metadata': {'node_id': '3577', 'node_type': 'PHENOTYPE', 'display_name': 'miscarriage'}}]",0.4285714285714286,e47b0693e51d2c68e915385faf51505e,1d1225704a76b97d349e94dd02e8c50c,"['Hemoglobin E disease, a prevalent genetic disorder, exhibits several phenotypic traits. Notable amongst these are splenomegaly, an abnormal enlargement of the spleen, drug-sensitive hemolytic anemia, which often characterizes an adverse reaction to certain medications leading to rapid destruction of red blood cells, and a higher risk of miscarriage.', 'Hemoglobin E disease, a medical condition, presents several symptoms, or phenotypes, among its afflicted patients. Notably, such phenotypes include splenomegaly, which is an abnormal enlargement of the spleen, and drug-sensitive hemolytic anemia, a condition where red blood cells are destroyed and removed from the bloodstream more rapidly than they can be produced. In some severe cases, individuals suffering from Hemoglobin E disease may also experience miscarriages.', 'Hemoglobin E disease is a condition characterized by several distinct phenotypes. It often leads to splenomegaly, which is the abnormal enlargement of the spleen. Additionally, it is associated with drug-sensitive hemolytic anemia, a condition where red blood cells are destroyed faster than they can be produced, particularly under the influence of certain medications. Furthermore, hemoglobin E disease can also result in miscarriages, suggesting its significant impact on reproductive health.', 'Hemoglobin E disease is a health condition that manifests with several phenotypes including splenomegaly, drug-sensitive hemolytic anemia, and has been linked with miscarriages.', 'Hemoglobin E disease, a condition known for its array of phenotypes, often results in splenomegaly or drug-sensitive hemolytic anemia in patients. Additionally, it has also been associated with increasing the likelihood of miscarriage.']",[]
"[{'source_node': {'name': 'acrylamide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lymphoblastoid cells'}}, {'source_node': {'name': 'acrylamide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glyceraldehyde-3-phosphate dehydrogenase'}}, {'source_node': {'name': 'acrylamide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'fibroblast growth factor receptor 4'}}, {'source_node': {'name': 'fibroblast growth factor receptor 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FGFR4'}}]","[{'source_node': {'name': 'glyceraldehyde-3-phosphate dehydrogenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FGFR4'}}, {'source_node': {'name': 'acrylamide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lymphoblastoid cells'}}, {'source_node': {'name': 'acrylamide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glyceraldehyde-3-phosphate dehydrogenase'}}, {'source_node': {'name': 'acrylamide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'fibroblast growth factor receptor 4'}}, {'source_node': {'name': 'acrylamide'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'FGFR4'}}, {'source_node': {'name': 'lymphoblastoid cells'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FGFR4'}}, {'source_node': {'name': 'fibroblast growth factor receptor 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FGFR4'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:580', 'target': 'GENE:27048', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'COMPOUND:62585', 'target': 'GENE:27048', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:5610', 'target': 'GENE:27048', 'metadata': {'predicate': 'gene_product_of'}}]",0.6666666666666667,48d90d0eafdfc4c4e3280c3c6f96cb44,1491a0836c060bcdbd7728ddc0346381,"['Acrylamide, a compound that is used in many industrial processes, targets several cellular components including lymphoblastoid cells and the enzyme glyceraldehyde-3-phosphate dehydrogenase. It also targets a specific protein known as fibroblast growth factor receptor 4, which is an encoded product of the FGFR4 gene.', 'The chemical compound acrylamide has been identified to target several cellular components including lymphoblastoid cells, glyceraldehyde-3-phosphate dehydrogenase, and the fibroblast growth factor receptor 4. Interestingly, this latter receptor is known to be a gene product of FGFR4.', 'The compound acrylamide targets several things, including lymphoblastoid cells and the enzyme glyceraldehyde-3-phosphate dehydrogenase, but also the fibroblast growth factor receptor 4, which is a gene product of FGFR4.', 'The compound acrylamide specifically targets several entities including lymphoblastoid cells, glyceraldehyde-3-phosphate dehydrogenase, and the fibroblast growth factor receptor 4. Furthermore, it is worth noting that the fibroblast growth factor receptor 4 is a gene product of FGFR4.', 'The chemical substance acrylamide is known to target several entities including lymphoblastoid cells, glyceraldehyde-3-phosphate dehydrogenase, and fibroblast growth factor receptor 4. Notably, fibroblast growth factor receptor 4 is a gene product of FGFR4.']","['The substance acrylamide does not only target lymphoblastoid cells, but also both glyceraldehyde-3-phosphate dehydrogenase and fibroblast growth factor receptor 4. Glyceraldehyde-3-phosphate dehydrogenase is a gene product of FGFR4. Similarly, both lymphoblastoid cells and fibroblast growth factor receptor 4 are gene products of FGFR4. In addition, acrylamide also affects FGFR4 directly.']"
"[{'source_node': {'name': 'casticin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'col2'}}, {'source_node': {'name': 'casticin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}, {'source_node': {'name': 'casticin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}]","[{'source_node': {'name': 'casticin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5008', 'target': None, 'metadata': {'node_id': '5008', 'node_type': 'PROTEIN', 'display_name': 'col2'}}, {'type': 'node_removal', 'source': 'PROTEIN:5858', 'target': None, 'metadata': {'node_id': '5858', 'node_type': 'PROTEIN', 'display_name': 'kb'}}]",0.4285714285714286,6e5abf0f7d06cbf86872ab626c670f7b,234b93e7f2dd429261a101756c7bdd47,"['The drug casticin targets several entities including COL2, Kb and HL-60.', 'The compound casticin has been identified to target multiple entities including col2, kb, and hl-60.', 'The compound casticin has several targets, including Col2, Kb, and Hl-60.', 'The compound casticin is known to target several elements, including COL2, KB, and HL-60.', 'The compound casticin is known to target multiple entities, namely col2, kb, and hl-60.']",[]
"[{'source_node': {'name': 'autosomal recessive spastic paraplegia type 54'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'high palate'}}, {'source_node': {'name': 'autosomal recessive spastic paraplegia type 54'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'periventricular leukomalacia'}}, {'source_node': {'name': 'DDHD2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'spastic paraplegia 54'}}, {'source_node': {'name': 'DDHD2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'autosomal recessive spastic paraplegia type 54'}}, {'source_node': {'name': 'DDHD2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of PA'}}]","[{'source_node': {'name': 'autosomal recessive spastic paraplegia type 54'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'high palate'}}, {'source_node': {'name': 'autosomal recessive spastic paraplegia type 54'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'periventricular leukomalacia'}}, {'source_node': {'name': 'DDHD2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of PA'}}]","[{'type': 'node_removal', 'source': 'DISEASE:15544', 'target': None, 'metadata': {'node_id': '15544', 'node_type': 'DISEASE', 'display_name': 'spastic paraplegia 54'}}, {'type': 'edge_deletion', 'source': 'GENE:27275', 'target': 'DISEASE:7864', 'metadata': None}]",0.7272727272727273,6364a018414d1e523328e1c33c28efb0,e8ad7f770f130435b9f06dccfd78ba90,[],[]
"[{'source_node': {'name': 'cis-n-feruloyltyramine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'cis-n-feruloyltyramine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-mel-2'}}, {'source_node': {'name': 'cis-n-feruloyltyramine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-15'}}]","[{'source_node': {'name': 'cis-n-feruloyltyramine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-15'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4980', 'target': None, 'metadata': {'node_id': '4980', 'node_type': 'PROTEIN', 'display_name': 'sk-mel-2'}}, {'type': 'node_removal', 'source': 'PROTEIN:5849', 'target': None, 'metadata': {'node_id': '5849', 'node_type': 'PROTEIN', 'display_name': 'a549'}}]",0.4285714285714286,9966bd2de8b344c299911216e66b3fb8,15c6b7e189e8f89ac8c17b2ce2c8abe3,"['The compound cis-n-feruloyltyramine has been identified as a potential target in numerous types of pathologies. It specifically targets the A549, SK-MEL-2, and HCT-15 cell lines, highlighting its potential for therapeutic interventions.', 'The compound cis-n-feruloyltyramine targets various cells including the A549, SK-MEL-2, and HCT-15 cells.', 'The compound cis-n-feruloyltyramine has been identified as a target for various cell lines including a549, sk-mel-2, and hct-15.', 'The compound cis-N-feruloyltyramine targets several cell lines including A549, SK-MEL-2, and HCT-15.', 'The compound cis-n-feruloyltyramine has been identified as having several targets. Among them are A549, SK-MEL-2, and HCT-15.']",[]
"[{'source_node': {'name': 'sveinsson chorioretinal atrophy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'astigmatism'}}, {'source_node': {'name': 'sveinsson chorioretinal atrophy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'peripapillary chorioretinal atrophy'}}, {'source_node': {'name': 'sveinsson chorioretinal atrophy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autosomal dominant inheritance'}}]","[{'source_node': {'name': 'sveinsson chorioretinal atrophy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'astigmatism'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:5045', 'target': None, 'metadata': {'node_id': '5045', 'node_type': 'PHENOTYPE', 'display_name': 'peripapillary chorioretinal atrophy'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:5', 'target': None, 'metadata': {'node_id': '5', 'node_type': 'PHENOTYPE', 'display_name': 'autosomal dominant inheritance'}}]",0.4285714285714286,59abc5be73f8d736a459972c1f0fb23f,59d954a809710e489f5616052bf752ad,"['Sveinsson chorioretinal atrophy, a rare genetic disorder, exhibits several phenotypes including astigmatism, peripapillary chorioretinal atrophy - a pathological condition where the retina thins near the optic nerve, as well as autosomal dominant inheritance - a pattern of inheritance where an affected individual has one copy of a mutant gene and one normal gene on a pair of autosomal chromosomes.']",[]
"[{'source_node': {'name': 'PLCE1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'nephrotic syndrome'}}, {'source_node': {'name': 'PLCE1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'genetic steroid-resistant nephrotic syndrome'}}, {'source_node': {'name': 'PLCE1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of IP3 and IP4 in the cytosol'}}]","[{'source_node': {'name': 'PLCE1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'nephrotic syndrome'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1018', 'target': None, 'metadata': {'node_id': '1018', 'node_type': 'PATHWAY', 'display_name': 'Synthesis of IP3 and IP4 in the cytosol'}}, {'type': 'node_removal', 'source': 'DISEASE:7112', 'target': None, 'metadata': {'node_id': '7112', 'node_type': 'DISEASE', 'display_name': 'genetic steroid-resistant nephrotic syndrome'}}]",0.4285714285714286,129e049eaeeb9de63cf271c0061627b5,e8e72f7f0bb9a49335d4ff4d46c10766,"['The gene PLCE1 is known to cause certain health conditions such as nephrotic syndrome and genetic steroid-resistant nephrotic syndrome. Furthermore, it is found to act within the pathway responsible for the synthesis of IP3 and IP4 in the cytosol.']",[]
"[{'source_node': {'name': 'mesalazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'torasemide'}}, {'source_node': {'name': 'mesalazine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Glomerulonephritis minimal lesion'}}, {'source_node': {'name': 'mesalazine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Cough increased'}}, {'source_node': {'name': 'torasemide'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Shunt thrombosis'}}]","[{'source_node': {'name': 'mesalazine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Glomerulonephritis minimal lesion'}}, {'source_node': {'name': 'mesalazine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Cough increased'}}, {'source_node': {'name': 'torasemide'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Shunt thrombosis'}}, {'source_node': {'name': 'torasemide'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Glomerulonephritis minimal lesion'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:204', 'target': 'SIDE_EFFECT:2645', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:234', 'target': 'COMPOUND:204', 'metadata': None}]",0.7777777777777778,be72e1a558614ef5316957b99379f99a,ede52b32731b02f1551a4f216753a94b,[],[]
"[{'source_node': {'name': 'symplostatin 6'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'neutrophil elastase'}}, {'source_node': {'name': 'neutrophil elastase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ELANE'}}]","[{'source_node': {'name': 'symplostatin 6'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'neutrophil elastase'}}, {'source_node': {'name': 'symplostatin 6'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'ELANE'}}, {'source_node': {'name': 'neutrophil elastase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ELANE'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:67168', 'target': 'GENE:26709', 'metadata': {'predicate': 'is_affecting'}}]",0.8,31a12820a9d776ce5fbd0333595b292c,6b510569e991d12702369fc7deacaac6,"['The compound symplostatin 6 is known to interact with, and target, the enzyme known as neutrophil elastase. This enzyme, in turn, is a gene product of ELANE.', 'The drug Symplostatin 6 targets a protein called Neutrophil Elastase, which is a gene product of the ELANE gene.', 'The drug symplostatin 6 has a target known as neutrophil elastase, which interestingly, is a gene product of ELANE.', 'The compound symplostatin 6 targets neutrophil elastase, which is a gene product of ELANE.', 'The marine natural product, symplostatin 6, has been identified to target neutrophil elastase. Intriguingly, this neutrophil elastase is a gene product of ELANE.']","['The drug Symplostatin 6 targets neutrophil elastase and affects the ELANE gene. Notably, neutrophil elastase itself is a gene product of ELANE.']"
"[{'source_node': {'name': 'NUP88'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Transport of the SLBP independent Mature mRNA'}}, {'source_node': {'name': 'NUP88'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'SUMOylation of chromatin organization proteins'}}, {'source_node': {'name': 'NUP88'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'tRNA processing in the nucleus'}}]","[{'source_node': {'name': 'NUP88'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'tRNA processing in the nucleus'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:348', 'target': None, 'metadata': {'node_id': '348', 'node_type': 'PATHWAY', 'display_name': 'Transport of the SLBP independent Mature mRNA'}}, {'type': 'node_removal', 'source': 'PATHWAY:181', 'target': None, 'metadata': {'node_id': '181', 'node_type': 'PATHWAY', 'display_name': 'SUMOylation of chromatin organization proteins'}}]",0.4285714285714286,c24229609c08b39fcfd4091c108095dc,35af75d05bf13a80cce5fa8210082f49,"['The protein NUP88 plays a role in several cellular pathways. Firstly, it acts within the pathway for the transport of the SLBP independent mature mRNA. Secondly, NUP88 is involved in the SUMOylation of chromatin organization proteins. Lastly, NUP88 also participates in tRNA processing in the nucleus.', 'The gene NUP88 performs various actions in several processes. It acts within the mechanism for the transport of the SLBP independent mature mRNA. It also plays a role in the pathway of SUMOylation of chromatin organization proteins. Additionally, it contributes to the process of tRNA processing in the nucleus.', 'The protein NUP88 is involved in several biochemical pathways. It acts within the transport of the SLBP independent mature mRNA, a critical process for gene expression from DNA to protein. Furthermore, NUP88 plays a role in the SUMOylation of chromatin organization proteins, which controls cellular activities like transcription and DNA repair. The protein also participates in tRNA processing in the nucleus, another vital step in protein synthesis. These activities highlight the central role NUP88 plays in influencing genetic outcomes.']",[]
"[{'source_node': {'name': 'coenzyme a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'pantothenate kinase'}}, {'source_node': {'name': 'coenzyme a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'acyl-coa-binding protein'}}, {'source_node': {'name': 'coenzyme a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': ""gentamicin 3'-acetyltransferase""}}]","[{'source_node': {'name': 'coenzyme a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'acyl-coa-binding protein'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:2211', 'target': None, 'metadata': {'node_id': '2211', 'node_type': 'PROTEIN', 'display_name': ""gentamicin 3'-acetyltransferase""}}, {'type': 'node_removal', 'source': 'PROTEIN:1972', 'target': None, 'metadata': {'node_id': '1972', 'node_type': 'PROTEIN', 'display_name': 'pantothenate kinase'}}]",0.4285714285714286,92696008ff6c08786fb30f40b8966344,659f1bc2c9d31b24b4a4056fda3fa4ae,"[""The molecule coenzyme A targets several key reactions in the body. It specifically interacts with pantothenate kinase, a crucial enzyme involved in coenzyme A biosynthesis. Additionally, it targets acyl-CoA-binding protein, a protein involved in fatty acid metabolism. Coenzyme A also interacts with gentamicin 3'-acetyltransferase, an enzyme responsible for bacterial resistance to the antibiotic gentamicin."", ""Coenzyme A targets several molecules including pantothenate kinase, acyl-coA-binding protein, and gentamicin 3'-acetyltransferase. These various targets exhibit the diverse interaction profile of coenzyme A within biochemical processes."", ""Coenzyme A is a critical molecule that targets several proteins including pantothenate kinase, acyl-CoA-binding protein, and gentamicin 3'-acetyltransferase in the body. These interactions play a crucial role in various metabolic processes and can influence response to certain drugs.\n"", ""The molecule coenzyme A targets several proteins including pantothenate kinase, acyl-coA-binding protein, and gentamicin 3'-acetyltransferase."", ""The molecule coenzyme A has distinct targets including the enzymes pantothenate kinase and gentamicin 3'-acetyltransferase, as well as the protein, acyl-CoA-binding protein.""]","['The molecule coenzyme A commonly targets the acyl-CoA-binding protein in various biological processes.', 'The molecule coenzyme A has acyl-CoA-binding protein as a target.', 'The molecule coenzyme A targets the acyl-CoA-binding protein.', 'The molecule coenzyme A has the acyl-CoA-binding protein as its target.', 'The molecule Coenzyme A has a target interaction with the Acyl-CoA-binding protein.']"
"[{'source_node': {'name': 'ketotifen'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histamine h1 receptor'}}, {'source_node': {'name': 'ketotifen'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'norepinephrine'}}, {'source_node': {'name': 'ketotifen'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'ephedrine'}}, {'source_node': {'name': 'ephedrine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the neuromuscular blocking activities '}}, {'source_node': {'name': 'ephedrine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'ritodrine'}}, {'source_node': {'name': 'ephedrine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'sequifenadine'}}, {'source_node': {'name': 'norepinephrine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'betahistine'}}]","[{'source_node': {'name': 'ketotifen'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histamine h1 receptor'}}, {'source_node': {'name': 'ketotifen'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'norepinephrine'}}, {'source_node': {'name': 'ephedrine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'ritodrine'}}, {'source_node': {'name': 'ephedrine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'sequifenadine'}}, {'source_node': {'name': 'sequifenadine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'ephedrine'}}, {'source_node': {'name': 'norepinephrine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'betahistine'}}]","[{'type': 'node_removal', 'source': 'ACTIVITY:13', 'target': None, 'metadata': {'node_id': '13', 'node_type': 'ACTIVITY', 'display_name': ' the neuromuscular blocking activities '}}, {'type': 'edge_deletion', 'source': 'COMPOUND:903', 'target': 'COMPOUND:1317', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:11416', 'target': 'COMPOUND:1317', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7333333333333334,bca53afc4ebb6c77636c3056cc54e671,9c2798eec842f4cd97b9be451fbebb60,[],"[""Ketotifen, a drug commonly used in the treatment of allergies, has been found to have a couple of significant interactions. Firstly, it targets the histamine h1 receptor, effectively reducing the effect of histamines in allergic reactions. Secondly, Ketotifen has been known to increase the efficacy of norepinephrine. \n\nIn a related note, Ephedrine, another drug clinically used for its stimulant properties, demonstrates its effectiveness by increasing the efficacy of ritodrine and sequifenadine. Interestingly, Sequifenadine reciprocates Ephedrine's action by elevating its effectiveness as well.\n\nOn another hand, norepinephrine, part of adrenergic neurotransmitters, has a noted interaction with betahistine, where the efficacy of betahistine is decreased with the presence of norepinephrine. Therefore, these interrelationships should be taken into account when prescribing and using these medications concurrently."", 'Ketotifen is a drug that has a target, specifically the histamine H1 receptor. Moreover, it is known to increase the efficacy of norepinephrine. Here, a complex network of interactions is observed  Ephedrine, an amine, increases the efficacy of both ritodrine, a uterine relaxant, and sequifenadine, which in turn also increases the efficacy of ephedrine. Yet, these interactions are affected by norepinephrine, which interestingly decreases the efficacy of betahistine. Thus, this diverse spectrum of interactions and efficacies shape the nuanced pharmacological landscape of these compounds.', 'The drug Ketotifen has a targeted effect on the histamine H1 receptor and has been shown to increase the efficacy of norepinephrine, another trending drug. Along the same efficacy-increasing pathway, Ephedrine, yet another pharmaceutical drug, seems to boost the efficiency of both Ritodrine and Sequifenadine. Interestingly, the relationship between Ephedrine and Sequifenadine is mutual, as Sequifenadine also potentiates the action of Ephedrine. However, norepinephrine, previously described as benefiting from Ketotifen, appears to decrease the efficacy of the drug Betahistine, forming an intricate interactive network of drug actions and reactions.', 'The drug Ketotifen targets the Histamine H1 Receptor and also increases the efficacy of Norepinephrine. Ephedrine, on the other hand, can boost the efficacy of both Ritodrine and Sequifenadine. Interestingly, Sequifenadine in turn amplifies the efficacy of Ephedrine. However, it is worth noting that Norepinephrine decreases the efficacy of the drug Betahistine.', 'The drug Ketotifen has been identified to target the histamine H1 receptor, and interestingly, it also has a role in increasing the efficacy of norepinephrine. The substance known as Ephedrine also shares a similar function in increasing the efficacy of Ritodrine and Sequifenadine. In a reciprocal interaction, Sequifenadine is also understood to escalate the effectiveness of Ephedrine. On the other hand, contrary to this process of enhancement, norepinephrine has shown a negative correlation with Betahistine, where it decreases its efficacy.']"
"[{'source_node': {'name': 't988 c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-8'}}, {'source_node': {'name': 't988 c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'bgc-823'}}]","[{'source_node': {'name': 't988 c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'bgc-823'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5005', 'target': None, 'metadata': {'node_id': '5005', 'node_type': 'PROTEIN', 'display_name': 'hct-8'}}]",0.6,70fae6eae23c4ba4b2640e0462da72dc,8fd6b37a15b3939203bf800b4d658b4f,"['The compound T988 C has the ability to target two specific cells, namely HCT-8 and BGC-823.', 'The drug T988 C targets both HCT-8 and BGC-823.', 'The compound T988 C has been identified to target two entities - HCT-8 and BGC-823.', 'The drug T988 C is known to target multiple entities, including HCT-8 and BGC-823.', 'The compound T988 C has been identified to target two separate entities, namely HCT-8 and BGC-823.']",[]
"[{'source_node': {'name': 'lymecycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'picosulfuric acid'}}, {'source_node': {'name': 'lymecycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carfecillin'}}, {'source_node': {'name': 'lymecycline'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Vaginal inflammation'}}]","[{'source_node': {'name': 'lymecycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'picosulfuric acid'}}, {'source_node': {'name': 'lymecycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carfecillin'}}, {'source_node': {'name': 'lymecycline'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Vaginal inflammation'}}, {'source_node': {'name': 'carfecillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lymecycline'}}, {'source_node': {'name': 'carfecillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'picosulfuric acid'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:11357', 'target': 'COMPOUND:246', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11357', 'target': 'COMPOUND:8203', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.7142857142857143,13baf5ce289c7395db482b1d0865693f,30b7ba97315a4484354c0e2d2a1b7ce4,"['The drug lymecycline has been found to decrease the efficacy of both picosulfuric acid and carfecillin. Additionally, one of the noted side effects of lymecycline is vaginal inflammation.', 'The drug lymecycline decreases the efficacy of both picosulfuric acid and carfecillin. Moreover, usage of lymecycline may also lead to a side effect of vaginal inflammation.', 'The drug lymecycline is known to decrease the efficacy of both picosulfuric acid and carfecillin. Additionally, lymecycline may have the side effect of causing vaginal inflammation.', 'The drug lymecycline has been found to decrease the efficacy of both picosulfuric acid and carfecillin. Additionally, the use of lymecycline has been associated with the side effect of vaginal inflammation.', 'The antibiotic drug lymecycline is known to decrease the efficacy of certain substances such as picosulfuric acid and carfecillin. Additionally, a noted side effect of lymecycline is that it can cause vaginal inflammation.']","['The drug lymecycline has been known to decrease the efficacy of both picosulfuric acid and carfecillin. On the other hand, carfecillin also plays a role in decreasing the effectiveness of picosulfuric acid and lymecycline itself. Moreover, vaginal inflammation is a recognized side effect of lymecylline consumption. Thus, it is crucial to take these interactions into consideration when co-administering these drugs.', 'The antibiotic lymecycline has been found to decrease the efficacy of picosulfuric acid and carfecillin when administered together. Interestingly, a reciprocal relationship is observed with carfecillin as well, where it has shown to decrease the potency of lymecycline and picosulfuric acid. Additionally, one of the known side effects of lymecycline is vaginal inflammation. Therefore, careful consideration should be given when prescribing these medications simultaneously.', 'Lymecycline, an antibiotic, is known to decrease the efficacy of certain medications, including picosulfuric acid and carfecillin. It should be noted that lymecycline might have a side effect, causing vaginal inflammation. Strikingly, carfecillin also reduces the efficacy of both lymecycline and picosulfuric acid. Therefore, prescribers should be aware of these potential drug interactions when using these drugs in concurrent therapy.', 'The drug lymecycline, which is known to have the side effect of causing vaginal inflammation, has been observed to decrease the efficacy of several other drugs. These include picosulfuric acid and carfecillin. Interestingly, other drugs, such as carfecillin, have also been found to decrease the efficacy of lymecycline and picosulfuric acid. Therefore, clinicians should exercise caution when considering drug combinations involving lymecycline, carfecillin and picosulfuric acid to avoid unintended reduction in drug efficacy.', ""Lymecycline, a commonly used antibiotic, decreases the efficacy of two medications: picosulfuric acid and carfecillin. Interestingly, carfecillin also decreases the efficacy of lymecycline and picosulfuric acid, suggesting a complex interplay between these three drugs. Additionally, lymecycline has been associated with certain side effects, such as vaginal inflammation. Therefore, when prescribing these medications, healthcare professionals should consider the patient's complete medication profile for optimal treatment efficacy.""]"
"[{'source_node': {'name': 'citric acid'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Hyperkalaemia'}}, {'source_node': {'name': 'citric acid'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Nausea'}}, {'source_node': {'name': 'citric acid'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Stomach cramps'}}]","[{'source_node': {'name': 'citric acid'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Hyperkalaemia'}}, {'source_node': {'name': 'citric acid'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Nausea'}}]","[{'type': 'node_removal', 'source': 'SIDE_EFFECT:580', 'target': None, 'metadata': {'node_id': '580', 'node_type': 'SIDE_EFFECT', 'display_name': 'Stomach cramps'}}]",0.7142857142857143,8eef2a21bf2ca70e28b78a2a089d9e94,43c1b2fda328993188b00ddbe2392bf6,"['Citric acid, a common food additive and preservative, can have several side effects including hyperkalaemia, nausea, and stomach cramps.', 'Citric acid, a common additive in foods and beverages, has been associated with several side effects, including hyperkalaemia, nausea, and stomach cramps.', ""Citric acid has side effects such as hyperkalaemia, nausea, and stomach cramps. It's important to take these into consideration when consuming or using products that contain citric acid."", 'The substance citric acid has several known side effects including hyperkalaemia, nausea, and stomach cramps.', 'Citric acid, a common food and beverage additive, has been found to have several side effects. These include Hyperkalaemia, a condition that results in an elevated potassium level in your blood. It can also cause Nausea and produce Stomach cramps, contributing to a sense of discomfort or pain in the abdominal area. It is important to monitor for these side effects when consuming products containing citric acid.']","['The compound citric acid is known to induce certain side effects, specifically causing conditions like hyperkalaemia and nausea.', 'Citric acid, a common food additive, is known to have side effects including Hyperkalaemia, which is characterized by an abnormally high potassium level in the blood, and Nausea, a sensation of discomfort typically in the upper stomach.', 'Citric acid, a common food additive known for its sour taste, has several side effects. These include hyperkalaemia, which is an elevated level of potassium in the blood, and nausea which is a feeling of sickness with an inclination to vomit.', 'Citric acid has been known to cause side effects such as Hyperkalaemia and Nausea.', 'Citric acid, a common additive used in food and beverages, is known to occasionally cause side effects such as hyperkalaemia and nausea in some individuals.']"
"[{'source_node': {'name': 'GNG5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (z) signalling events'}}, {'source_node': {'name': 'GNG5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Thromboxane signalling through TP receptor'}}, {'source_node': {'name': 'GNG5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Extra-nuclear estrogen signaling'}}]","[{'source_node': {'name': 'GNG5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (z) signalling events'}}, {'source_node': {'name': 'GNG5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Thromboxane signalling through TP receptor'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:782', 'target': None, 'metadata': {'node_id': '782', 'node_type': 'PATHWAY', 'display_name': 'Extra-nuclear estrogen signaling'}}]",0.7142857142857143,862e0fcc1f6222f968f5157e44338781,12dd3d152d70d182d4fbb875efafcc18,"['The gene GNG5 is active within several pathways. These include the G alpha (z) signaling events, thromboxane signaling through TP receptor and also in extra-nuclear estrogen signaling.', 'The gene GNG5 plays a significant role within multiple molecular pathways. These include G alpha (z) signalling events, thromboxane signalling through TP receptor, as well as extra-nuclear estrogen signaling.', 'The gene GNG5 is involved in various signalling events. Specifically, it acts within the G alpha (z) signalling events, influences thromboxane signalling through TP receptor, and participates in extra-nuclear estrogen signaling.', 'The gene GNG5 is involved in a variety of signaling events. Specifically, it acts within G alpha (z) signaling events, thromboxane signaling through TP receptor, and also contributes to extra-nuclear estrogen signaling. These intricate interactions highlight the diverse roles that GNG5 plays within cellular pathways.']","['The gene GNG5 operates within multiple signal pathways. It acts within the G alpha (z) signalling events and also within the Thromboxane signalling through TP receptor.', 'The gene GNG5 is involved in several processes and acts within distinct pathways. Specifically, it plays an important role in G alpha (z) signalling events as well as thromboxane signalling through the TP receptor. These pathways are critical for various cellular and physiological responses.', 'The gene GNG5 participates in several key signalling events. These include the G alpha (z) signalling events and the thromboxane signalling through the TP receptor.']"
"[{'source_node': {'name': 'potassium lactate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'verapamil'}}, {'source_node': {'name': 'potassium lactate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'levorphanol'}}, {'source_node': {'name': 'potassium lactate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methadyl acetate'}}]","[{'source_node': {'name': 'potassium lactate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'verapamil'}}, {'source_node': {'name': 'potassium lactate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'levorphanol'}}, {'source_node': {'name': 'levorphanol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'potassium lactate'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:837', 'target': 'COMPOUND:8349', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:837', 'target': 'COMPOUND:1371', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:1371', 'target': None, 'metadata': {'node_id': '1371', 'node_type': 'COMPOUND', 'display_name': 'methadyl acetate'}}]",0.5714285714285714,a886b7737d5ef3a28251ca417724b232,9ef2148369e252cc0a59e698eaa134a8,"['The substance potassium lactate is known to decrease the efficacy of several drugs. Specifically, it reduces the effectiveness of verapamil, levorphanol, and methadyl acetate. Users of these medications should therefore be cautious when consuming products containing potassium lactate to avoid potential interference with their therapeutic outcomes.', 'Potassium lactate can decrease the efficacy of several medications. For instance, its interactions with drugs such as verapamil, levorphanol, and methadyl acetate have been reported. Thus, when these medications are administered, the presence of potassium lactate could potentially attenuate their therapeutic effects.', 'Potassium lactate has the ability to decrease the efficacy of multiple pharmaceutical substances. Notably, it can impact drugs such as verapamil, levorphanol, and methadyl acetate, potentially reducing their therapeutic benefits. Therefore, care should be taken when combining potassium lactate with these particular drugs.', 'The use of potassium lactate has been found to decrease the efficacy of several medicines including verapamil, levorphanol, and methadyl acetate. Hence, caution should be taken when prescribing or using these medications alongside potassium lactate.', 'The use of potassium lactate has been found to decrease the efficacy of several drugs. Specifically, the effectiveness of verapamil, levorphanol, and methadyl acetate are all reduced when combined with potassium lactate. Consequently, caution is advised when administering these drugs in conjunction with potassium lactate.']","[""The drug potassium lactate can decrease the efficacy of both verapamil as well as levorphanol. Interestingly, it's also noted that levorphanol can in turn decrease the efficacy of potassium lactate. This reciprocative relationship indicates their interplay in a pharmaceutical context."", 'The compound potassium lactate has the ability to decrease the efficacy of both verapamil and levorphanol. Interestingly, levorphanol also reciprocates the interaction and is found to reduce the efficacy of potassium lactate.', 'The administration of potassium lactate has been documented to decrease the efficacy of certain substances such as verapamil and levorphanol. Conversely, levorphanol also decreases the efficacy of potassium lactate, suggesting a mutual interaction whereby both compounds can influence the effectiveness of each other.', 'Potassium lactate has been noted for its ability to decrease the efficacy of the drugs verapamil and levorphanol. Interestingly, the use of levorphanol also has a reciprocal effect, decreasing the efficacy of potassium lactate.', 'The compound potassium lactate can decrease the efficacy of both verapamil, a medication used for treating high blood pressure, and levorphanol, an opioid medication. Interestingly, levorphanol also decreases the efficacy of potassium lactate. Therefore, caution should be taken when these components are used in combination.']"
"[{'source_node': {'name': 'sid17403365'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'atpase family aaa domain-containing protein 5'}}, {'source_node': {'name': 'sid17403365'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'alpha-galactosidase a'}}, {'source_node': {'name': 'sid17403365'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'amine oxidase [flavin-containing] b'}}]","[{'source_node': {'name': 'sid17403365'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'atpase family aaa domain-containing protein 5'}}, {'source_node': {'name': 'sid17403365'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'alpha-galactosidase a'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:784', 'target': None, 'metadata': {'node_id': '784', 'node_type': 'PROTEIN', 'display_name': 'amine oxidase [flavin-containing] b'}}]",0.7142857142857143,3683f81fe810f7442a2268db73579b81,6d0b6439c7a9b9c17cb4aa1d7264f7f5,"['The compound sid17403365 targets several proteins including ATPase family AAA domain-containing protein 5, alpha-galactosidase A, and amine oxidase [flavin-containing] B.', 'The substance sid17403365 targets several entities including the ATPase family AAA domain-containing protein 5, alpha-galactosidase A, and amine oxidase [flavin-containing] B.', 'The substance known as sid17403365 targets several proteins including ATPase family AAA domain-containing protein 5, alpha-galactosidase A, and amine oxidase [flavin-containing] B.', 'The compound sid17403365 targets three different components: the ATPase family AAA domain-containing protein 5, alpha-galactosidase A, and amine oxidase [flavin-containing] B.', 'The biochemical entity labeled sid17403365 interacts with several cellular targets. It engages with ATPase family AAA domain-containing protein 5, targets Alpha-galactosidase A, and further has active communication with Amine oxidase [flavin-containing] B.']","['The molecule sid17403365 targets two distinct proteins: ATPase family AAA domain-containing protein 5 and alpha-galactosidase A.', 'The compound sid17403365 has multiple biological targets which include ATPase family AAA domain-containing protein 5 and Alpha-galactosidase A.', 'The compound sid17403365 has multiple targets including the ATPase family AAA domain-containing protein 5 and Alpha-galactosidase A.', 'The compound sid17403365 has multiple targets including the ATPase family AAA domain-containing protein 5 and the enzyme alpha-galactosidase A.', 'The compound sid17403365 has been identified as having a target effect on two specific proteins: ATPase family AAA domain-containing protein 5 and alpha-galactosidase A. These molecular interactions suggest potential novel therapeutic avenues for diseases associated with the affected proteins.']"
"[{'source_node': {'name': 'neobulgarone e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'k562'}}, {'source_node': {'name': 'neobulgarone e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'jurkat'}}, {'source_node': {'name': 'neobulgarone e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'u-937'}}]","[{'source_node': {'name': 'neobulgarone e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'u-937'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4947', 'target': None, 'metadata': {'node_id': '4947', 'node_type': 'PROTEIN', 'display_name': 'k562'}}, {'type': 'node_removal', 'source': 'PROTEIN:4983', 'target': None, 'metadata': {'node_id': '4983', 'node_type': 'PROTEIN', 'display_name': 'jurkat'}}]",0.4285714285714286,2af3653aa48f4989cc698953a6ba01d5,c0b352ed61704e61cc4c181397fee419,"['The compound Neobulgarone E has several targets including K562, Jurkat, and U-937.', 'The compound known as Neobulgarone E has been identified as having several targets, including K562, Jurkat, and U-937 cell lines.', 'Neobulgarone E, a known bioactive compound, has targets in several cell lines which include K562, Jurkat and U-937.', 'The substance Neobulgarone E targets three different types of cells: K562, Jurkat, and U-937.', 'The compound Neobulgarone E has multiple targets including the K562, Jurkat, and U-937 cell lines.']",[]
"[{'source_node': {'name': 'spg7 matrix aaa peptidase subunit'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'cardiotoxicity'}}, {'source_node': {'name': 'spg7 matrix aaa peptidase subunit'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neoplasms'}}, {'source_node': {'name': 'spg7 matrix aaa peptidase subunit'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'prostatic neoplasms'}}]","[{'source_node': {'name': 'spg7 matrix aaa peptidase subunit'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'cardiotoxicity'}}, {'source_node': {'name': 'spg7 matrix aaa peptidase subunit'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neoplasms'}}]","[{'type': 'node_removal', 'source': 'DISEASE:2674', 'target': None, 'metadata': {'node_id': '2674', 'node_type': 'DISEASE', 'display_name': 'prostatic neoplasms'}}]",0.7142857142857143,9669b45a12720e8bf88466a69d75d1c0,a35c51a5d90e150295c511399c6bac29,"['The SPG7 matrix AAA peptidase subunit is known to cause several conditions including cardiotoxicity, neoplasms, and specifically, prostatic neoplasms.', 'The SPG7 Matrix AAA Peptidase Subunit is known to cause several conditions. Specifically, it has been linked to cardiotoxicity, a broad spectrum of neoplasms, and specifically, prostatic neoplasms.', 'The SPG7 matrix AAA peptidase subunit is known to cause multiple conditions. One of the associated conditions is cardiotoxicity, a harmful effect on the heart. Moreover, it is also responsible for the onset of neoplasms, abnormal and excessive growth of tissue, commonly related to cancer. Additionally, this peptidase subunit has a particularly significant impact in leading to prostatic neoplasms, a type of cancer that affects the prostate gland.', 'The SPG7 matrix AAA peptidase subunit is known to cause several conditions, including cardiotoxicity, a variety of neoplasms, and more specifically, prostatic neoplasms.', 'The protein known as SPG7 Matrix AAA Peptidase Subunit is responsible for causing certain medical conditions. Included among these are cardiotoxicity, a range of neoplasms, and specifically, prostatic neoplasms.']","['The SPG7 matrix AAA peptidase subunit has been found to cause several conditions, including cardiotoxicity and different types of neoplasms.', 'The SPG7 Matrix AAA Peptidase subunit is known to cause several conditions such as cardiotoxicity and neoplasms.', 'The SPG7 matrix AAA peptidase subunit is known to cause several conditions including cardiotoxicity and neoplasms.', 'The protein known as SPG7 matrix AAA peptidase subunit is known to cause various conditions, notably cardiotoxicity and neoplasms.', 'The SPG7 matrix AAA peptidase subunit has been identified as a cause of several conditions, including cardiotoxicity and various neoplasms.']"
"[{'source_node': {'name': 'interstitial collagenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MMP1'}}, {'source_node': {'name': 'lawsone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'coumarin'}}, {'source_node': {'name': 'lawsone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'diphenadione'}}, {'source_node': {'name': 'lawsone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'interstitial collagenase'}}, {'source_node': {'name': 'diphenadione'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'garenoxacin'}}, {'source_node': {'name': 'diphenadione'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hydroxyprogesterone caproate'}}, {'source_node': {'name': 'diphenadione'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'coagulation factor x human'}}]","[{'source_node': {'name': 'interstitial collagenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MMP1'}}, {'source_node': {'name': 'lawsone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'coumarin'}}, {'source_node': {'name': 'lawsone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'diphenadione'}}, {'source_node': {'name': 'lawsone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'interstitial collagenase'}}, {'source_node': {'name': 'diphenadione'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hydroxyprogesterone caproate'}}, {'source_node': {'name': 'diphenadione'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'MMP1'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:11015', 'target': 'COMPOUND:4461', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11203', 'target': 'GENE:29959', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'COMPOUND:5425', 'target': None, 'metadata': {'node_id': '5425', 'node_type': 'COMPOUND', 'display_name': 'garenoxacin'}}, {'type': 'node_removal', 'source': 'COMPOUND:11015', 'target': None, 'metadata': {'node_id': '11015', 'node_type': 'COMPOUND', 'display_name': 'coagulation factor x human'}}]",0.6666666666666667,bb72abb0d7a0765954c127d5eb4da536,c7f88208d502a9a64199c1177652c775,"['The enzyme interstitial collagenase is a product of the MMP1 gene. Lawsone is a compound that enhances the efficacy of both coumarin and diphenadione. Furthermore, lawsone also targets interstitial collagenase. On the other hand, diphenadione not only enhances the efficacy of garenoxacin but decreases the efficacy of both hydroxyprogesterone caproate and coagulation factor x human.', 'The enzyme interstitial collagenase is a gene product of MMP1 and is a target of the compound lawsone. This compound, lawsone, is known to increase the efficacy of other compounds such as coumarin and diphenadione. The latter, diphenadione, plays a dual role by not only enhancing the efficacy of garenoxacin but also by reducing the efficacy of hydroxyprogesterone caproate and the coagulation factor X human.', 'Interstitial collagenase is a gene product of MMP1. This is important because the compound lawsone not only targets interstitial collagenase, but it also increases the efficacy of both coumarin and diphenadione. Diphenadione in turn has complex interactions with various other substances. It enhances the efficacy of garenoxacin while decreasing the effectiveness of hydroxyprogesterone caproate and human coagulation factor X. In summary, these intricate interactions all revolve around the central roles of lawsone and diphenadione, highlighting the intricate nature of biochemical pathways.', 'The enzyme interstitial collagenase is a gene product of MMP1. This collagenase enzyme is targeted by Lawsone, a compound known to enhance the efficacy of coumarin and diphenadione. Diphenadione, in turn, not only promotes the efficacy of the antibacterial agent, garenoxacin, but also reduces the efficacy of both hydroxyprogesterone caproate, a synthetic progestin used in obstetric treatments, and coagulation factor X human, a significant protein in the blood coagulation process. This intricate network of biochemical relationships demonstrates the complex interplay between these substances.', 'Interstitial collagenase is a gene product of MMP1. It is also a target of the compound lawsone, which is known to increase the efficacy of both coumarin and diphenadione. Notably, diphenadione is effective in increasing the efficacy of garenoxacin, while simultaneously decreasing the efficacy of hydroxyprogesterone caproate and coagulation factor x human. Thus, lawsone and diphenadione have significant interconnected roles in affecting the efficacies of various compounds.']","[""Interstitial collagenase, a gene product of MMP1, can be targeted by the compound lawsone. Lawsone, on its part, has been found to increase the efficacy of certain substances: namely coumarin and diphenadione. However, it's intriguing to note that diphenadione can decrease the efficacy of hydroxyprogesterone caproate. Furthermore, diphenadione appears to affect the functions of MMP1 in some way, suggesting an interlinked network of biological interactions and effects."", 'Interstitial collagenase is a gene product of MMP1. The compound lawsone has been observed to target interstitial collagenase and subsequently increase the efficacy of the drugs coumarin and diphenadione. Interestingly, diphenadione is found to decrease the efficacy of hydroxyprogesterone caproate and also affect MMP1, providing an intriguing interconnectedness of these biological entities and their behaviors.', 'The compound lawsone has multiple interactions within the body. It is known to increase the efficacy of both coumarin and diphenadione, trending towards an amplification of their effects. Intriguingly, lawsone also targets a gene product called interstitial collagenase. This molecule, from a biological perspective, is a product of the gene MMP1. On the other hand, diphenadione does not only interact with lawsone but also affects MMP1 and decreases the efficacy of hydroxyprogesterone caproate, a female hormone. This intricate network of interactions suggests a complex role and importance for these substances in biological systems.', 'Interstitial Collagenase is a gene product of MMP1. The compound Lawsone not only targets this collagenase but also has been found to increase the efficacy of both Coumarin and Diphenadione. Interestingly, Diphenadione appears to play a further role in decreasing the efficacy of Hydroxyprogesterone Caproate and affecting MMP1 directly.', 'Interstitial collagenase, a gene product of MMP1, is a target of lawsone. This compound, other than targeting interstitial collagenase, is also known to increase the efficacy of both coumarin and diphenadione. Interestingly, while lawsone favors diphenadione, diphenadione itself has a reducing effect on the efficacy of hydroxyprogesterone caproate. Additionally, diphenadione is known to affect MMP1, the gene responsible for interstitial collagenase.']"
"[{'source_node': {'name': 'GRM5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (q) signalling events'}}, {'source_node': {'name': 'GRM5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neurexins and neuroligins'}}, {'source_node': {'name': 'metabotropic glutamate receptor 5'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GRM5'}}]","[{'source_node': {'name': 'GRM5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (q) signalling events'}}, {'source_node': {'name': 'GRM5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neurexins and neuroligins'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:1310', 'target': None, 'metadata': {'node_id': '1310', 'node_type': 'PROTEIN', 'display_name': 'metabotropic glutamate receptor 5'}}]",0.7142857142857143,9174061313f88d9007605c63d1ca4305,8f0ee8e7717cc653437eabf5a3e75250,[],[]
"[{'source_node': {'name': 'ACTB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RHO GTPases Activate WASPs and WAVEs'}}, {'source_node': {'name': 'ACTB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'DNA Damage Recognition in GG-NER'}}, {'source_node': {'name': 'ACTB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'FCGR3A-mediated phagocytosis'}}, {'source_node': {'name': 'actin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACTG1'}}, {'source_node': {'name': 'actin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACTA1'}}, {'source_node': {'name': 'actin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACTB'}}, {'source_node': {'name': 'tmr'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'actin'}}]","[{'source_node': {'name': 'ACTB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RHO GTPases Activate WASPs and WAVEs'}}, {'source_node': {'name': 'ACTB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'DNA Damage Recognition in GG-NER'}}, {'source_node': {'name': 'actin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACTG1'}}, {'source_node': {'name': 'actin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACTA1'}}, {'source_node': {'name': 'tmr'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'actin'}}, {'source_node': {'name': 'tmr'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'ACTA1'}}, {'source_node': {'name': 'ACTG1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RHO GTPases Activate WASPs and WAVEs'}}]","[{'type': 'edge_deletion', 'source': 'PROTEIN:2662', 'target': 'GENE:32309', 'metadata': None}, {'type': 'edge_addition', 'source': 'GENE:33274', 'target': 'PATHWAY:52', 'metadata': {'predicate': 'acts_within'}}, {'type': 'node_removal', 'source': 'PATHWAY:56', 'target': None, 'metadata': {'node_id': '56', 'node_type': 'PATHWAY', 'display_name': 'FCGR3A-mediated phagocytosis'}}, {'type': 'edge_addition', 'source': 'COMPOUND:3671', 'target': 'GENE:32124', 'metadata': {'predicate': 'is_affecting'}}]",0.6666666666666667,e4ce7503bb3b822031d5aa36fa15d282,66daef214d558364c3a08dc9e6822d92,[],[]
"[{'source_node': {'name': 'AR'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'androgen insensitivity syndrome'}}, {'source_node': {'name': 'pulegone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'androgen receptor'}}, {'source_node': {'name': 'pulegone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear factor nf-kappa-b p105 subunit'}}, {'source_node': {'name': 'nuclear factor nf-kappa-b p105 subunit'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NFKB1'}}, {'source_node': {'name': 'androgen receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AR'}}]","[{'source_node': {'name': 'pulegone'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'NFKB1'}}, {'source_node': {'name': 'androgen receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AR'}}, {'source_node': {'name': 'androgen receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NFKB1'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:64235', 'target': 'GENE:30277', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:946', 'target': 'GENE:30277', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:64235', 'target': 'PROTEIN:946', 'metadata': None}, {'type': 'node_removal', 'source': 'DISEASE:167', 'target': None, 'metadata': {'node_id': '167', 'node_type': 'DISEASE', 'display_name': 'androgen insensitivity syndrome'}}, {'type': 'node_removal', 'source': 'PROTEIN:1408', 'target': None, 'metadata': {'node_id': '1408', 'node_type': 'PROTEIN', 'display_name': 'nuclear factor nf-kappa-b p105 subunit'}}]",0.2727272727272727,3cec373f2c154e6df67f35e184a65a15,b811df874d660e2177fd14eb9d14abbc,"['The drug pulegone targets both the androgen receptor and the nuclear factor nf-kappa-b p105 subunit. The androgen receptor is a gene product of AR, which causes a condition known as androgen insensitivity syndrome. Similarly, the nuclear factor nf-kappa-b p105 subunit is a gene product of NFKB1.', 'The compound pulegone targets both the androgen receptor and the nuclear factor NF-kappa-B p105 subunit. The androgen receptor is a gene product of AR, which is known to cause androgen insensitivity syndrome, a condition characterized by a partial or complete inability of cells to respond to androgens. On the other hand, the nuclear factor NF-kappa-B p105 subunit is a gene product of NFKB1.', 'The drug pulegone targets the androgen receptor as well as the nuclear factor nf-kappa-b p105 subunit. The nuclear factor nf-kappa-b p105 subunit is a gene product of NFKB1. The androgen receptor, on the other hand, is a gene product of AR, which is known to cause androgen insensitivity syndrome.', 'The compound Pulegone targets multiple proteins such as the androgen receptor and the nuclear factor nf-kappa-b p105 subunit. Notably, the androgen receptor is a gene product of AR, which causes androgen insensitivity syndrome. Additionally, the nuclear factor nf-kappa-b p105 subunit is a gene product of NFKB1.', 'The compound pulegone targets both the androgen receptor and the nuclear factor nf-kappa-b p105 subunit in its mode of action. The androgen receptor is a gene product of AR which, when mutated, can cause a condition known as androgen insensitivity syndrome. Similarly, nuclear factor nf-kappa-b p105 subunit is a gene product of NFKB1.']",[]
"[{'source_node': {'name': ""2'-o-demethylbidwillol b""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}, {'source_node': {'name': ""2'-o-demethylbidwillol b""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': ""2'-o-demethylbidwillol b""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear factor erythroid 2-related factor 2'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}]","[{'source_node': {'name': 'mcf7'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}, {'source_node': {'name': ""2'-o-demethylbidwillol b""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5907', 'target': None, 'metadata': {'node_id': '5907', 'node_type': 'PROTEIN', 'display_name': 'nuclear factor erythroid 2-related factor 2'}}, {'type': 'edge_addition', 'source': 'PROTEIN:5851', 'target': 'GENE:32076', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'PROTEIN:1921', 'target': None, 'metadata': {'node_id': '1921', 'node_type': 'PROTEIN', 'display_name': 'tyrosine-protein phosphatase non-receptor type 1'}}]",0.4444444444444444,7b4cbbea3cc529343d9e5ed4a5871b59,bba7e523d66b42611a0d268c7f9aa00a,"[""The compound 2'-O-demethylbidwillol B has multiple targets, including the tyrosine-protein phosphatase non-receptor type 1, MCF7, and the nuclear factor erythroid 2-related factor 2. Among these, the tyrosine-protein phosphatase non-receptor type 1 is a gene product of PTPN1."", ""The compound 2'-O-demethylbidwillol B targets several entities: tyrosine-protein phosphatase non-receptor type 1, MCF7, and nuclear factor erythroid 2-related factor 2. Furthermore, it is noteworthy to mention that the tyrosine-protein phosphatase non-receptor type 1 is a gene product of PTPN1."", ""The compound 2'-O-demethylbidwillol B targets multiple entities including the tyrosine-protein phosphatase non-receptor type 1, MCF7, and nuclear factor erythroid 2-related factor 2. It is noteworthy to mention that tyrosine-protein phosphatase non-receptor type 1 is a gene product of PTPN1."", ""The compound 2'-O-demethylbidwillol B has multiple targets. It targets tyrosine-protein phosphatase non-receptor type 1, which is the gene product of PTPN1. It also targets MCF7, and nuclear factor erythroid 2-related factor 2, expanding its spectrum of activity."", ""The chemical compound 2'-O-demethylbidwillol B targets multiple entities, including the tyrosine-protein phosphatase non-receptor type 1, MCF7, and the nuclear factor erythroid 2-related factor 2. Interestingly, the tyrosine-protein phosphatase non-receptor type 1 is also a gene product of PTPN1.""]","[""The compound 2'-O-Demethylbidwillol B targets MCF7, which is a gene product of PTPN1."", ""The compound 2'-O-demethylbidwillol B targets MCF7, which is a gene product of the gene PTPN1."", ""The gene product MCF7 is a result of the PTPN1 gene. Significantly, it is targeted by the compound 2'-O-demethylbidwillol B."", ""The drug 2'-O-demethylbidwillol B targets the protein MCF7, which is a gene product of the PTPN1 gene.""]"
"[{'source_node': {'name': 'esmolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'deoxyepinephrine'}}, {'source_node': {'name': 'esmolol'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Fatigue'}}, {'source_node': {'name': 'esmolol'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Rigors'}}, {'source_node': {'name': 'hexoprenaline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'esmolol'}}, {'source_node': {'name': 'hexoprenaline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'brexpiprazole'}}, {'source_node': {'name': 'hexoprenaline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'talinolol'}}]","[{'source_node': {'name': 'esmolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'deoxyepinephrine'}}, {'source_node': {'name': 'esmolol'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Fatigue'}}, {'source_node': {'name': 'esmolol'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Rigors'}}, {'source_node': {'name': 'deoxyepinephrine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'talinolol'}}, {'source_node': {'name': 'talinolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'hexoprenaline'}}, {'source_node': {'name': 'hexoprenaline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'talinolol'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:7904', 'target': 'COMPOUND:177', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:11759', 'target': 'COMPOUND:9686', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:8067', 'target': None, 'metadata': {'node_id': '8067', 'node_type': 'COMPOUND', 'display_name': 'brexpiprazole'}}, {'type': 'edge_addition', 'source': 'COMPOUND:9686', 'target': 'COMPOUND:7904', 'metadata': {'predicate': 'increase_efficacy'}}]",0.6153846153846154,a9e94798ac4de6e4a191cfcd78345ad2,b8f83d9d2c8d5ee2530916b10305647f,"['The drug esmolol is known to increase the efficacy of deoxyepinephrine but it has some side effects such as fatigue and rigors. On the other hand, hexoprenaline decreases the efficacy of esmolol, brexpiprazole, and talinolol. Therefore, precautions should be taken when these drugs are used concurrently.', 'The drug esmolol has been found to have multiple interactions and effects. Interestingly, it is known to increase the efficacy of deoxyepinephrine, an important mechanism in its medicinal use. However, patients on esmolol should be made aware of certain side effects such as fatigue and rigors, which are often associated with its use. Conversely, the drug hexoprenaline, has been shown to decrease the efficacy of esmolol - a point of caution for patients on both medications. In addition, hexoprenaline is also reported to reduce the effectiveness of other drugs such as brexpiprazole and talinolol. In a pharmaceutical context, this interconnected web of drug interactions is critical for understanding optimal treatment plans and anticipating potential side effects or decreased efficacy due to drug-drug interactions.', 'Esmolol is a drug known to increase the efficacy of deoxyepinephrine. However, it can produce side effects such as fatigue and rigors. Conversely, interactions with another drug, hexoprenaline, can decrease the efficacy of esmolol. Furthermore, it should be noted that hexoprenaline can also decrease the efficacy of additional drugs including brexpiprazole and talinolol.', 'The drug esmolol has been shown to increase the efficacy of deoxyepinephrine. However, use of esmolol can have side effects including fatigue and rigors. Additionally, another drug, hexoprenaline, may potentially decrease the efficacy of esmolol. Interestingly, hexoprenaline has also been reported to decrease the efficacy of other drugs like brexpiprazole and talinolol. It is important for health care professionals to consider these interactions and potential side effects when providing treatment options for patients.', 'The drug esmolol is known to increase the efficacy of deoxyepinephrine. However, one must be cautious as esmolol is associated with certain side effects such as rigors and fatigue. Hexoprenaline, on the other hand, can decrease the efficacy of esmolol. This is not only limited to esmolol, as other drugs like brexpiprazole and talinolol also have their efficacy reduced when taken with hexoprenaline.']","['The drug esmolol is known to increase the efficacy of deoxyepinephrine and also has some side effects such as fatigue and rigors. Deoxyepinephrine in turn enhances the efficacy of talinolol. Interestingly, talinolol is not only known to increase the efficacy of hexoprenaline, but hexoprenaline can also decrease the efficacy of talinolol.', 'The drug esmolol is noted to increase the efficacy of deoxyepinephrine which, in turn, also increases the efficacy of talinolol. Interestingly, talinolol further enhances the efficacy of hexoprenaline. However, hexoprenaline appears to decrease the efficacy of talinolol, creating a reciprocal interaction between these two drugs. It is important to note that esmolol has been reported to cause side effects including fatigue and rigors.', ""The drug esmolol enhances the efficacy of deoxyepinephrine, but can also have side effects, which could include fatigue and rigors. Interestingly, deoxyepinephrine increases the effectiveness of another drug, talinolol. To further complicate matters, talinolol, in turn, heightens the efficacy of hexoprenaline, a drug that paradoxically decreases talinolol's potency, completing a complex web of pharmacological interactions."", 'The drug esmolol is known to increase the efficacy of deoxyepinephrine, while also having side effects such as fatigue and rigors. Interestingly, deoxyepinephrine also increases the efficacy of talinolol, a drug which in turn boosts the effectiveness of hexoprenaline. However, an intriguing relationship is observed as hexoprenaline, despite its boosted efficacy, is found to decrease the effectiveness of talinolol. Thus, an intertwined cycle of pharmacological interactions exists among these drugs.', ""The drug esmolol is known to increase the efficacy of another drug called deoxyepinephrine. Interestingly, deoxyepinephrine is also found to enhance the efficacy of talinolol. This chain of drug interaction continues as talinolol increases the efficacy of hexoprenaline. However, it's important to note that hexoprenaline, in return, decreases the efficacy of talinolol.\n\nMoreover, administration of esmolol may result in certain side effects. These can include ailments like fatigue and rigors. Therefore, while considering the use of these drugs, the balance between their benefits and potential side effects should be closely monitored.""]"
"[{'source_node': {'name': '3-(gamma,gamma-dimethylallyl)resveratrol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prostaglandin g/h synthase 2'}}, {'source_node': {'name': 'prostaglandin g/h synthase 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTGS2'}}, {'source_node': {'name': 'PTGS2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of 15-eicosatetraenoic acid derivatives'}}]","[{'source_node': {'name': '3-(gamma,gamma-dimethylallyl)resveratrol'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'PTGS2'}}, {'source_node': {'name': 'PTGS2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of 15-eicosatetraenoic acid derivatives'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:27029', 'target': 'GENE:31977', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'PROTEIN:511', 'target': None, 'metadata': {'node_id': '511', 'node_type': 'PROTEIN', 'display_name': 'prostaglandin g/h synthase 2'}}]",0.4285714285714286,c40b035c42a0b42943de167b57a6edf7,16d07b35a5a680896a6b8656a2eb8872,"['The drug 3-(gamma,gamma-dimethylallyl)resveratrol targets prostaglandin g/h synthase 2. This protein is a gene product of PTGS2 which operates within the process of synthesis of 15-eicosatetraenoic acid derivatives.', 'The compound 3-(gamma,gamma-dimethylallyl)resveratrol targets prostaglandin g/h synthase 2, a gene product of PTGS2. This PTGS2 gene acts within the synthesis of 15-eicosatetraenoic acid derivatives pathway.', 'The compound 3-(gamma,gamma-dimethylallyl)resveratrol targets the protein prostaglandin g/h synthase 2, which is a gene product of PTGS2. The PTGS2 gene functions within the pathway for the synthesis of 15-eicosatetraenoic acid derivatives.', 'The drug 3-(gamma,gamma-dimethylallyl)resveratrol targets prostaglandin g/h synthase 2. This prostaglandin g/h synthase 2 is a gene product of PTGS2. Importantly, PTGS2 acts within the pathway of synthesis of 15-eicosatetraenoic acid derivatives.', 'The compound 3-(gamma,gamma-dimethylallyl)resveratrol is known to target prostaglandin g/h synthase 2. This enzyme is a product of the PTGS2 gene, which plays a role within the synthesis of 15-eicosatetraenoic acid derivatives process.']",[]
"[{'source_node': {'name': 'indobufen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'chlorothiazide'}}, {'source_node': {'name': 'indobufen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'felodipine'}}, {'source_node': {'name': 'indobufen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dinoprost'}}, {'source_node': {'name': 'chlorothiazide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'nitrendipine'}}, {'source_node': {'name': 'chlorothiazide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'rilmenidine'}}]","[{'source_node': {'name': 'nitrendipine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rilmenidine'}}, {'source_node': {'name': 'indobufen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'chlorothiazide'}}, {'source_node': {'name': 'indobufen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'felodipine'}}, {'source_node': {'name': 'indobufen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dinoprost'}}, {'source_node': {'name': 'chlorothiazide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'nitrendipine'}}, {'source_node': {'name': 'chlorothiazide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'rilmenidine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1034', 'target': 'COMPOUND:9654', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.9090909090909092,feecdfe252eb86c63e3640b056c41625,848d8d8d2f24a12bb83674539a1fb85f,"['The drug Indobufen is known to decrease the efficacy of several other drugs, including Chlorothiazide, Felodipine, and Dinoprost. Furthermore, it has been observed that Chlorothiazide interestingly heightens the efficacy of certain medications such as Nitrendipine and Rilmenidine.', 'Indobufen, a potent drug, has been shown to decrease the efficacy of chlorothiazide, felodipine, and dinoprost. Interestingly, while indobufen decreases the efficacy of chlorothiazide, chlorothiazide itself is capable of increasing the efficacy of other drugs such as nitrendipine and rilmenidine. Therefore, caution should be exercised while choosing a drug combination that involves these molecules due to their interacting nature.', 'The drug indobufen is known to decrease the efficacy of several other drugs, including chlorothiazide, felodipine, and dinoprost. Interestingly, chlorothiazide has been found to increase the efficacy of other drugs such as nitrendipine and rilmenidine. Thus, when considering medication interactions, the use of indobufen in conjunction with these other drugs should be carefully monitored.', 'The drug indobufen has been observed to decrease the efficacy of several other drugs, including chlorothiazide, felodipine, and dinoprost. Interestingly, while indobufen can decrease the efficacy of chlorothiazide, this drug, in turn, can increase the efficacy of other medications, such as nitrendipine and rilmenidine. The dynamic interaction between these different drugs highlights the complexity of pharmaceutical treatments and the importance of considering drug interactions in medical practice.', 'Indobufen, an antiplatelet agent, has been found to diminish the efficacy of multiple drugs, such as chlorothiazide, felodipine, and dinoprost. Interestingly, chlorothiazide - a medication lowered in efficiency by indobufen - can actually increase therapeutic efficacy of certain drugs such as nitrendipine and rilmenidine. Thus, the interaction between these substances should be considered in treatment plans to avoid counterproductive effects.']","['The drug Nitrendipine is known to decrease the efficacy of Rilmenidine. Similarly, Indobufen has the effect of decreasing the efficacy of several other drugs including Chlorothiazide, Felodipine, and Dinoprost. However, in a contrasting interaction, Chlorothiazide can increase the efficacy of both Nitrendipine and Rilmenidine.', 'The efficacy of several drugs can be influenced by the use of other specific drug compounds. For instance, the potency of rilmenidine can be decreased by nitrendipine. Additionally, indobufen is known to lower the effectiveness of drugs such as chlorothiazide, felodipine, and dinoprost. Interestingly, chlorothiazide can also increase the efficacy of other medications. It has been observed to boost the effect of nitrendipine and rilmenidine, for example. These intersections of drug influences underscore the importance of a comprehensive understanding of pharmacology and its nuanced interactions.', 'The drug Nitrendipine is known to decrease the efficacy of Rilmenidine. Additionally, Indobufen could reduce the effectiveness of medications like Chlorothiazide, Felodipine, and Dinoprost. Interestingly, Chlorothiazide has been found to promote the efficacy of Nitrendipine and Rilmenidine.', 'The drug Nitrendipine is known to decrease the efficacy of Rilmenidine. Similarly, Indobufen also decreases the efficacy of several drugs such as Chlorothiazide, Felodipine and Dinoprost. However, Chlorothiazide reciprocally increases the efficacy of Nitrendipine and Rilmenidine. Therefore, careful consideration should be given when prescribing combinations of these drugs.', 'The drug nitrendipine is known to decrease the efficacy of rilmenidine. Similarly, indobufen has been reported to reduce the efficacy of various drugs including chlorothiazide, felodipine and dinoprost. Interestingly, chlorothiazide can increase the efficacy of not only nitrendipine but also rilmenidine. This information highlights the complex interactions between drugs and the need to consider these effects when prescribing medications.']"
"[{'source_node': {'name': 'H2AC21'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'HDACs deacetylate histones'}}, {'source_node': {'name': 'H2AC21'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'HATs acetylate histones'}}, {'source_node': {'name': 'H2AC21'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Metalloprotease DUBs'}}]","[{'source_node': {'name': 'H2AC21'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'HATs acetylate histones'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:534', 'target': None, 'metadata': {'node_id': '534', 'node_type': 'PATHWAY', 'display_name': 'HDACs deacetylate histones'}}, {'type': 'node_removal', 'source': 'PATHWAY:433', 'target': None, 'metadata': {'node_id': '433', 'node_type': 'PATHWAY', 'display_name': 'Metalloprotease DUBs'}}]",0.4285714285714286,6dc72ed8d9fe30ace515cd3c457efb76,d94701c5907b14d82ef40823acaed446,"['The gene H2AC21 operates within several pathways. It acts within the process where HDACs deacetylate histones and the opposing process where HATs acetylate histones. Furthermore, it also contributes to the function of Metalloprotease DUBs.', 'The gene H2AC21 operates within several enzymatic processes, including the pathways where HDACs deacetylate histones, where HATs acetylate histones, and within the process involving Metalloprotease DUBs.', 'The protein H2AC21 acts within multiple biological pathways. Notably, it plays a role in the process where HDACs deacetylate histones and similarly where HATs acetylate histones. Furthermore, H2AC21 is also found to act within the Metalloprotease DUBs pathway.', 'The gene H2AC21 is notably active within various interactions and pathways. It acts within the HDACs deacetylate histones and HATs acetylate histones processes, respectively influencing the removal and addition of acetyl groups to histone proteins for gene regulation. Furthermore, H2AC21 also plays a role within the Metalloprotease DUBs process, emphasising its importance in multiple biological pathways.']","['The gene H2AC21 functions within the pathway where HATs acetylate histones.', 'The gene H2AC21 operates within the pathway where HATs acetylate histones.', 'The gene H2AC21 is known to act within the pathway where HATs acetylate histones.']"
"[{'source_node': {'name': 'TP53'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Transcriptional Regulation by VENTX'}}, {'source_node': {'name': 'dimethyl hexanedioate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucocorticoid receptor'}}, {'source_node': {'name': 'dimethyl hexanedioate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cellular tumor antigen p53'}}, {'source_node': {'name': 'dimethyl hexanedioate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear factor erythroid 2-related factor 2'}}, {'source_node': {'name': 'glucocorticoid receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR3C1'}}, {'source_node': {'name': 'cellular tumor antigen p53'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TP53'}}]","[{'source_node': {'name': 'dimethyl hexanedioate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucocorticoid receptor'}}, {'source_node': {'name': 'dimethyl hexanedioate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear factor erythroid 2-related factor 2'}}, {'source_node': {'name': 'glucocorticoid receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR3C1'}}, {'source_node': {'name': 'NR3C1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Transcriptional Regulation by VENTX'}}, {'source_node': {'name': 'cellular tumor antigen p53'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR3C1'}}]","[{'type': 'edge_addition', 'source': 'GENE:28425', 'target': 'PATHWAY:539', 'metadata': {'predicate': 'acts_within'}}, {'type': 'edge_addition', 'source': 'PROTEIN:1498', 'target': 'GENE:28425', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:81391', 'target': 'PROTEIN:1498', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:33312', 'target': None, 'metadata': {'node_id': '33312', 'node_type': 'GENE', 'display_name': 'TP53'}}]",0.6153846153846154,a55ff7f406a7caf3654946d9b1f240c9,9e3983cad53f8a9e9ce15d9e9b7ac3e1,[],"['The compound dimethyl hexanedioate targets a variety of structures, including the glucocorticoid receptor and the nuclear factor erythroid 2-related factor 2. Interestingly, the glucocorticoid receptor is a gene product of NR3C1, a gene which also acts within the pathway of transcriptional regulation by VENTX. Furthermore, another intriguing gene product of NR3C1 is the cellular tumor antigen p53, adding more depth to the complexity of the interactions involved.']"
"[{'source_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'death'}}, {'source_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'insomnia'}}, {'source_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'serotonin syndrome'}}, {'source_node': {'name': 'acetaminophen / codeine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}}, {'source_node': {'name': 'acetaminophen / codeine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'glucose-6-phosphate dehydrogenase'}}]","[{'source_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'death'}}, {'source_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'insomnia'}}, {'source_node': {'name': 'glucose-6-phosphate dehydrogenase'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'death'}}, {'source_node': {'name': 'acetaminophen / codeine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}}, {'source_node': {'name': 'acetaminophen / codeine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'glucose-6-phosphate dehydrogenase'}}]","[{'type': 'edge_addition', 'source': 'GENE:6821', 'target': 'DISEASE:764', 'metadata': {'predicate': 'causes_condition'}}, {'type': 'node_removal', 'source': 'DISEASE:2917', 'target': None, 'metadata': {'node_id': '2917', 'node_type': 'DISEASE', 'display_name': 'serotonin syndrome'}}]",0.7272727272727273,981691c7e7cf75a5fc56ca6e3df3a9af,f8f1bace611f3ba5db228332a7e11588,"['The enzyme known as cytochrome p450 family 2 subfamily d member 6 is known to cause several conditions such as death, insomnia, and serotonin syndrome. Furthermore, this enzyme is affected by the drug combination of acetaminophen / codeine. Interestingly, this drug also affects another enzyme called glucose-6-phosphate dehydrogenase, suggesting a complex interaction network.', 'The enzyme Cytochrome P450 Family 2 Subfamily D Member 6, which is affected by the drug Acetaminophen/Codeine, can cause several conditions including death, insomnia, and serotonin syndrome. The same drug, Acetaminophen/Codeine, is also affecting another enzyme called Glucose-6-Phosphate Dehydrogenase.', 'The enzyme cytochrome P450 family 2 subfamily D member 6 can cause several conditions including death, insomnia and serotonin syndrome. Interestingly, this enzyme is affected by the drug acetaminophen/codeine. Also, it is noteworthy that this drug impacts another enzyme, glucose-6-phosphate dehydrogenase.', 'The enzyme cytochrome p450 family 2 subfamily d member 6, which is affected by the drug combination of acetaminophen / codeine, can cause several conditions such as death, insomnia and serotonin syndrome. Interestingly, acetaminophen / codeine is also known to affect another enzyme, glucose-6-phosphate dehydrogenase.']",[]
"[{'source_node': {'name': 'wilsonol f'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'wilsonol f'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'wilsonol f'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}]","[{'source_node': {'name': 'wilsonol f'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'wilsonol f'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5851', 'target': None, 'metadata': {'node_id': '5851', 'node_type': 'PROTEIN', 'display_name': 'mcf7'}}]",0.7142857142857143,63756cce0c2aa919a28bdb63458ab2b3,befb853208a052e11fc268627b77fc83,"['The compound Wilsonol F has been identified as a target for several types of cells, including MCF7, A549, and HL-60. It appears that these specific cells are directly impacted by Wilsonol F.', 'The compound Wilsonol F has been identified to target several cells; specifically, it targets MCF7, A549, and HL-60 cells.', 'The compound Wilsonol F has several targets, including the MCF7 and A549 cell lines, as well as the HL-60 leukemic cell line.', 'The compound Wilsonol F targets multiple cell lines, specifically MCF7, A549, and HL-60.', 'The substance Wilsonol F is known to target several cell lines including MCF7, A549, and HL-60.']","['The compound Wilsonol F is known to target both A549 and HL-60.', 'The compound Wilsonol F has targets in multiple cells, including A549 and HL-60.', 'The compound Wilsonol F has been identified to target two types of cells, A549 and HL-60.', 'The compound Wilsonol F targets two kinds of cells: A549 and HL-60.', 'Wilsonol F, a chemical compound, has been identified to target two types of human cell lines- A549 and HL-60, which are commonly utilized in various biomedical researches.']"
"[{'source_node': {'name': 'difluocortolone'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the neutropenic activities '}}, {'source_node': {'name': 'difluocortolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pev3a'}}, {'source_node': {'name': 'difluocortolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '1alpha-hydroxyvitamin d5'}}]","[{'source_node': {'name': '1alpha-hydroxyvitamin d5'}, 'relation': {'name': 'increase_activity'}, 'target_node': {'name': ' the neutropenic activities '}}, {'source_node': {'name': 'difluocortolone'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the neutropenic activities '}}, {'source_node': {'name': 'difluocortolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pev3a'}}, {'source_node': {'name': 'difluocortolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '1alpha-hydroxyvitamin d5'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:10965', 'target': 'ACTIVITY:4', 'metadata': {'predicate': 'increase_activity'}}]",0.8571428571428572,bae5bfbdd095d01f9c64987eae25b753,5787c73918abfae1e5b6dbb6bc91b134,[],[]
"[{'source_node': {'name': 'NDUFC2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'mitochondrial complex i deficiency'}}, {'source_node': {'name': 'NDUFC2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}, {'source_node': {'name': 'nadh dehydrogenase [ubiquinone] 1 subunit c2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NDUFC2'}}]","[{'source_node': {'name': 'NDUFC2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'mitochondrial complex i deficiency'}}, {'source_node': {'name': 'nadh dehydrogenase [ubiquinone] 1 subunit c2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NDUFC2'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:3', 'target': None, 'metadata': {'node_id': '3', 'node_type': 'PATHWAY', 'display_name': 'Neutrophil degranulation'}}]",0.7142857142857143,4a761c62871ca1ede20030dc27b68981,1844d8625b6adb3a01c14cabfa652639,"['The gene NDUFC2, which acts within the process of neutrophil degranulation, causes a condition known as mitochondrial complex I deficiency. Furthermore, NADH dehydrogenase [ubiquinone] 1 subunit c2 is a gene product of NDUFC2.']","['The gene product of NADH dehydrogenase [ubiquinone] 1 subunit c2, known as NDUFC2, has been identified to cause a medical condition referred to as mitochondrial complex I deficiency.', 'The gene NADH dehydrogenase [ubiquinone] 1 subunit c2 is a gene product of NDUFC2 which is known to cause a condition known as mitochondrial complex I deficiency.', 'The gene NADH dehydrogenase [ubiquinone] 1 subunit c2, which is a product of the gene NDUFC2, has been identified to cause a condition known as mitochondrial complex I deficiency.', 'The NDUFC2 gene, which is the product of the gene nadh dehydrogenase [ubiquinone] 1 subunit c2, is known to cause a condition known as mitochondrial complex i deficiency.']"
"[{'source_node': {'name': 'topotecan'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'measles virus vaccine live attenuated'}}, {'source_node': {'name': 'topotecan'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vi polysaccharide vaccine'}}]","[{'source_node': {'name': 'measles virus vaccine live attenuated'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'typhoid vi polysaccharide vaccine'}}, {'source_node': {'name': 'measles virus vaccine live attenuated'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'topotecan'}}, {'source_node': {'name': 'topotecan'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'measles virus vaccine live attenuated'}}, {'source_node': {'name': 'topotecan'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vi polysaccharide vaccine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:8423', 'target': 'COMPOUND:8860', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:8423', 'target': 'COMPOUND:1012', 'metadata': {'predicate': 'increase_efficacy'}}]",0.6,800acf7046fa24d7843d63cf2bcf0eb4,2f24004dc643a7a00e5880fe2a2920f0,"['The drug topotecan is known to decrease the efficacy of certain vaccines, including the measles virus vaccine live attenuated and the typhoid vi polysaccharide vaccine. Consequently, this may impact the effectiveness of these vaccines in combating the respective diseases.', 'The drug Topotecan is known to decrease the efficacy of certain vaccines, including the measles virus vaccine live attenuated and the typhoid vi polysaccharide vaccine. Thus, it is important to consider the potential interactions between this medication and these vaccines in the context of patient care and disease prevention.', 'The drug Topotecan has been found to decrease the efficacy of both measles virus vaccine live attenuated and typhoid vi polysaccharide vaccine. Thus, care should be taken when considering vaccination schedules for individuals undergoing treatment with this drug.']","['Administration of the measles virus vaccine live attenuated has been shown to increase the efficacy of both the typhoid vi polysaccharide vaccine and the anticancer drug topotecan. Interestingly, topotecan in turn has been noted to potentially decrease the efficacy of the measles virus vaccine live attenuated, as well as the typhoid vi polysaccharide vaccine. This interplay stresses the importance of considering drug and vaccine interactions in treatment strategies.', 'The measles virus vaccine live attenuated has been found to increase the efficacy of both the typhoid vi polysaccharide vaccine and the drug topotecan. However, it should be noted that topotecan simultaneously decreases the efficacy of the measles virus vaccine live attenuated and the typhoid vi polysaccharide vaccine. This forms a complex interplay of pharmaceutical effects that should be carefully considered in medical approaches.', ""The measles virus vaccine live attenuated, a common immunization, increases the efficacy of both the typhoid vi polysaccharide vaccine and a chemotherapy drug known as topotecan. However, it's noteworthy that topotecan reciprocally decreases the efficacy of the measles virus vaccine live attenuated as well as the typhoid vi polysaccharide vaccine, creating an intricate interplay among these treatments."", 'The measles virus vaccine live attenuated is known to increase the efficacy of both the typhoid vi polysaccharide vaccine and topotecan. However, it is interesting to note that topotecan may in turn decrease the efficacy of the measles virus vaccine live attenuated, as well as that of the typhoid vi polysaccharide vaccine. This highlights the complex interplay between these medical substances and underscores the importance of careful consideration when co-administering them.', 'Administration of the measles virus vaccine live attenuated is known to enhance the efficacy of the typhoid vi polysaccharide vaccine and an oncology drug, topotecan. Interestingly, while the measles vaccine enhances the performance of these two, topotecan in reverse decreases the efficacy of both the measles virus vaccine live attenuated and the typhoid vi polysaccharide vaccine.']"
"[{'source_node': {'name': 'ethylene glycol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hsc-2'}}, {'source_node': {'name': 'ethylene glycol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucocorticoid receptor'}}, {'source_node': {'name': 'ethylene glycol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor delta'}}, {'source_node': {'name': 'glucocorticoid receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR3C1'}}, {'source_node': {'name': 'peroxisome proliferator-activated receptor delta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PPARD'}}]","[{'source_node': {'name': 'ethylene glycol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hsc-2'}}, {'source_node': {'name': 'ethylene glycol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucocorticoid receptor'}}, {'source_node': {'name': 'ethylene glycol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor delta'}}, {'source_node': {'name': 'ethylene glycol'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'NR3C1'}}, {'source_node': {'name': 'ethylene glycol'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'PPARD'}}, {'source_node': {'name': 'glucocorticoid receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR3C1'}}, {'source_node': {'name': 'peroxisome proliferator-activated receptor delta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PPARD'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:24011', 'target': 'GENE:28425', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'COMPOUND:24011', 'target': 'GENE:31201', 'metadata': {'predicate': 'is_affecting'}}]",0.8181818181818181,5ffea8019c9c8b2dbd2875392bd7042c,f84d75741a9060b99cce15be381e5325,"['The compound ethylene glycol has multiple targets which include hsc-2, the glucocorticoid receptor, and the peroxisome proliferator-activated receptor delta. Interestingly, the glucocorticoid receptor is a gene product of the NR3C1 gene, and the peroxisome proliferator-activated receptor delta is a product of the PPARD gene.', 'Ethylene glycol, a chemical compound commonly used in many industrial applications, has been found to target various cellular components. These include HSC-2, a human oral squamous cell carcinoma cell line, the glucocorticoid receptor, and the peroxisome proliferator-activated receptor delta. Notably, these two receptors are gene products of NR3C1 and PPARD respectively.', 'The compound ethylene glycol targets several molecules including hsc-2, the glucocorticoid receptor, and the peroxisome proliferator-activated receptor delta. Here, the glucocorticoid receptor is a gene product of NR3C1, and likewise, peroxisome proliferator-activated receptor delta is a product of the PPARD gene.', 'Ethylene glycol, a commonly used industrial compound, has several biological targets. It interacts with HSC-2, a crucial protein in the body. Additionally, the compound targets the glucocorticoid receptor, a protein product of the NR3C1 gene. Ethylene glycol is also known to target the peroxisome proliferator-activated receptor delta. This receptor is a gene product of PPARD, underscoring the myriad ways in which this compound can interact with and potentially affect bodily processes.', 'The chemical compound ethylene glycol targets multiple elements including the cell line HSC-2 and two distinct receptors: the glucocorticoid receptor and the peroxisome proliferator-activated receptor delta. Interestingly, these two receptors are the gene products of specific genes. The glucocorticoid receptor is produced by the NR3C1 gene, while the peroxisome proliferator-activated receptor delta is the product of the PPARD gene.']","[""Ethylene glycol, a versatile compound utilized in a multitude of applications, has been identified to interact with several specific targets such as HSC-2, glucocorticoid receptor, and peroxisome proliferator-activated receptor delta. It is also known to affect the biological processes linked with genes NR3C1 and PPARD.\n\nFurther investigation into these connections reveal that glucocorticoid receptor, one of ethylene glycol's targets, is actually a gene product of NR3C1, a gene which ethylene glycol is known to affect. Similarly, peroxisome proliferator-activated receptor delta, another target of ethylene glycol, is generated from the gene PPARD, which is also affected by ethylene glycol. This highlights the complex intricacies of biological interactions and how a single compound such as ethylene glycol can have multiple routes of interaction within biological systems.""]"
"[{'source_node': {'name': 'cleft palate-lateral synechia syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'narrow mouth'}}, {'source_node': {'name': 'cleft palate-lateral synechia syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'full cheeks'}}, {'source_node': {'name': 'cleft palate-lateral synechia syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'blepharophimosis'}}]","[{'source_node': {'name': 'cleft palate-lateral synechia syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'narrow mouth'}}, {'source_node': {'name': 'cleft palate-lateral synechia syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'blepharophimosis'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:242', 'target': None, 'metadata': {'node_id': '242', 'node_type': 'PHENOTYPE', 'display_name': 'full cheeks'}}]",0.7142857142857143,45615a2b0aaa3187eb3315379a72699a,c2a925f989c0eb16231cff0fd666ef03,"['Cleft palate-lateral synechia syndrome, a medical condition, is characterized by several phenotypes including a narrow mouth, full cheeks, and a distinct eye condition known as blepharophimosis.', ""The disease known as cleft palate-lateral synechia syndrome manifests phenotypes such as a narrow mouth, full cheeks, and blepharophimosis, which refers to an abnormal narrowing of the eye's opening.""]",[]
"[{'source_node': {'name': 'muricin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'muricin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': '1a9'}}]","[{'source_node': {'name': 'muricin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': '1a9'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5849', 'target': None, 'metadata': {'node_id': '5849', 'node_type': 'PROTEIN', 'display_name': 'a549'}}]",0.6,ea678f15d3f11ce10a1e49210fbe808f,14bf6b70b78ca0db7e4fa84a6f2cf8ce,"['The compound Muricin A has been identified as having two primary targets, specifically the A549 and 1A9 cell lines.', 'The compound Muricin A has been identified to target two specific entities, A549 and 1A9.', 'The compound Muricin A is known to target multiple cell lines including A549 and 1A9.', 'The compound Muricin A has been identified to target two separate entities, namely A549 and 1A9.', 'The substance called Muricin A has been shown to target cells named A549 and 1A9. These interactions indicate potential therapeutic or research significance of Muricin A on these specific cells.']","['The drug Muricin A has a noted target, which is 1A9.']"
"[{'source_node': {'name': 'epothilone d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tubulin beta-3 chain'}}, {'source_node': {'name': 'epothilone d'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'estetrol'}}, {'source_node': {'name': 'epothilone d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h226'}}, {'source_node': {'name': 'tubulin beta-3 chain'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TUBB3'}}]","[{'source_node': {'name': 'epothilone d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tubulin beta-3 chain'}}, {'source_node': {'name': 'epothilone d'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'estetrol'}}, {'source_node': {'name': 'epothilone d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h226'}}, {'source_node': {'name': 'nci-h226'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TUBB3'}}, {'source_node': {'name': 'estetrol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tubulin beta-3 chain'}}, {'source_node': {'name': 'tubulin beta-3 chain'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TUBB3'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:5668', 'target': 'GENE:24861', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'COMPOUND:10139', 'target': 'PROTEIN:2072', 'metadata': {'predicate': 'has_target'}}]",0.7777777777777778,656a086d74ad06a4d36e6db79f13f62e,41b79182092785050067989ea39ba9f4,"['Epothilone D is a drug that targets multiple entities: it interacts with the tubulin beta-3 chain, a product of the TUBB3 gene, and also with NCI-H226. Interestingly, this drug is known to decrease the efficacy of Estetrol.', 'The drug, Epothilone D, has been found to target several components, including the Tubulin beta-3 chain and NCI-H226. This Tubulin beta-3 chain is a gene product of the gene known as TUBB3. In an interesting interaction, it has also been discovered that Epothilone D decreases the efficacy of another drug, Estetrol.', 'The drug Epothilone D has several targets including the Tubulin Beta-3 Chain and NCI-H226, a specific type of human lung cancer cells. Interestingly, the Tubulin Beta-3 Chain is a gene product of TUBB3. However, it is crucial to note that Epothilone D may decrease the efficacy of another drug called Estetrol.', 'Epothilone D, a drug known for its active effects, is particularly targeted towards the Tubulin Beta-3 Chain and NCI-H226, two crucial entities within the biological sector. Interestingly, this potent drug has been shown to decrease the efficacy of estetrol. To provide more context, the Tubulin Beta-3 Chain, which is influenced by Epothilone D, is in fact, a gene product of TUBB3.', 'The drug Epothilone D has targets such as the Tubulin Beta-3 Chain and NCI-H226. Interestingly, the Tubulin Beta-3 Chain is a gene product of TUBB3. However, it is important to note that the efficacy of Epothilone D decreases when it interacts with Estetrol.']","['The drug epothilone D is known to target both the tubulin beta-3 chain and the nci-h226 molecules. Interestingly, both tubulin beta-3 chain and nci-h226 are indeed gene products of TUBB3. Furthermore, epothilone D has been found to decrease the efficacy of the drug estetrol. In a related finding, estetrol itself also targets tubulin beta-3 chain. This intricate web of relationships between these entities can have crucial implications in our understanding of drug interactions and their downstream effects on target molecules.', ""Epothilone D is a drug that targets several entities including the Tubulin Beta-3 Chain and NCI-H226. Notably, NCI-H226 is a gene product of TUBB3. Interestingly, Epothilone D, has been found to decrease the efficacy of another drug, Estetrol, which also targets the Tubulin Beta-3 Chain. Similar to NCI-H226, the Tubulin Beta-3 Chain is a gene product of TUBB3. Therefore, both Epothilone D and Estetrol may affect processes involving the Tubulin Beta-3 Chain and its parent gene TUBB3, but Epothilone D could potentially affect Estetrol's ability to do so."", 'The drug epothilone d has been shown to target multiple entities such as the tubulin beta-3 chain and NCI-H226, a gene product of TUBB3. Furthermore, the drug epothilone d decreases the efficacy of another drug, estetrol. Interestingly, estetrol targets the same tubulin beta-3 chain that epothilone d does. The tubulin beta-3 chain is also known to be a gene product of TUBB3.', 'The drug Epothilone D targets multiple entities including the Tubulin beta-3 chain, and NCI-H226, which is a gene product of TUBB3. Interestingly, Epothilone D has been observed to decrease the efficacy of another drug, Estetrol. Additionally, Estetrol also targets the Tubulin beta-3 chain, a gene product of TUBB3. Therefore, it could be inferred that both Epothilone D and Estetrol are indirectly related to the gene TUBB3 via their shared target, the Tubulin beta-3 chain.', 'Epothilone D, a potent anticancer agent, targets therapeutic molecules such as the tubulin beta-3 chain and nci-h226. Notably, nci-h226 is the gene product of TUBB3. Simultaneously, this drug has the capacity to decrease the efficacy of estetrol, another therapeutic agent. Fascinatingly, estetrol also targets the tubulin beta-3 chain, which is a gene product of TUBB3. Therefore, we could conclude that both epothilone D and estetrol potentially share a common target in their action mechanism which could possibly lead to competitive interactions.']"
"[{'source_node': {'name': 'cyclin-dependent kinase 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CDK2'}}, {'source_node': {'name': 'aristolactam i'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cyclin-dependent kinase 2'}}]","[{'source_node': {'name': 'aristolactam i'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cyclin-dependent kinase 2'}}]","[{'type': 'node_removal', 'source': 'GENE:24733', 'target': None, 'metadata': {'node_id': '24733', 'node_type': 'GENE', 'display_name': 'CDK2'}}]",0.6,5a0da130d6c55ced43123d6bb0e32f54,f1cf98dda712b8bc13c0efdb4a62d619,[],"['The compound aristolactam I has a known interaction with a target, specifically the enzyme cyclin-dependent kinase 2.', 'The compound aristolactam I has cyclin-dependent kinase 2 as its target.']"
"[{'source_node': {'name': 'TSHR'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hyperthyroidism'}}, {'source_node': {'name': 'TSHR'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'thyroid hypoplasia'}}, {'source_node': {'name': 'TSHR'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hypothyroidism due to tsh receptor mutations'}}, {'source_node': {'name': 'phloretin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'thyrotropin receptor'}}, {'source_node': {'name': 'phloretin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'microtubule-associated protein tau'}}, {'source_node': {'name': 'phloretin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hek293'}}, {'source_node': {'name': 'microtubule-associated protein tau'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MAPT'}}, {'source_node': {'name': 'thyrotropin receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TSHR'}}]","[{'source_node': {'name': 'TSHR'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hyperthyroidism'}}, {'source_node': {'name': 'TSHR'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'thyroid hypoplasia'}}, {'source_node': {'name': 'TSHR'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hypothyroidism due to tsh receptor mutations'}}, {'source_node': {'name': 'phloretin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'thyrotropin receptor'}}, {'source_node': {'name': 'phloretin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'microtubule-associated protein tau'}}, {'source_node': {'name': 'microtubule-associated protein tau'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MAPT'}}, {'source_node': {'name': 'microtubule-associated protein tau'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TSHR'}}, {'source_node': {'name': 'thyrotropin receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TSHR'}}, {'source_node': {'name': 'MAPT'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'thyroid hypoplasia'}}, {'source_node': {'name': 'MAPT'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hyperthyroidism'}}]","[{'type': 'edge_addition', 'source': 'GENE:29856', 'target': 'DISEASE:12151', 'metadata': {'predicate': 'causes_condition'}}, {'type': 'edge_addition', 'source': 'GENE:29856', 'target': 'DISEASE:13544', 'metadata': {'predicate': 'causes_condition'}}, {'type': 'node_removal', 'source': 'PROTEIN:5833', 'target': None, 'metadata': {'node_id': '5833', 'node_type': 'PROTEIN', 'display_name': 'hek293'}}, {'type': 'edge_addition', 'source': 'PROTEIN:1148', 'target': 'GENE:33362', 'metadata': {'predicate': 'gene_product_of'}}]",0.7058823529411764,1c6827b8150550829d4073c7c3e0cf43,8378309b0c7fff16b79a0df56bc40955,"['The gene TSHR is associated with the cause of several conditions including hyperthyroidism, thyroid hypoplasia, and hypothyroidism due to TSH receptor mutations. The drug phloretin targets multiple proteins, such as the thyrotropin receptor, microtubule-associated protein tau and HEK293. Worth noting is that the thyrotropin receptor is a gene product of TSHR. Similarly, the microtubule-associated protein tau is a gene product of MAPT. Thus, the connections between these genes, drug and conditions create an intricate network of consequences on health.']","['The gene TSHR is known to cause several conditions, including hyperthyroidism, thyroid hypoplasia, and hypothyroidism due to TSH receptor mutations. On the other hand, the drug phloretin targets two proteins: the thyrotropin receptor and the microtubule-associated protein tau. The latter is a gene product of two known genes, namely the MAPT and TSHR genes. Similar to the TSHR gene, the MAPT gene is also associated with the conditions hyperthyroidism and thyroid hypoplasia. Furthermore, the thyrotropin receptor is also a gene product of the TSHR gene, creating a network of interrelated elements impacting thyroid health and associated conditions.']"
"[{'source_node': {'name': 'pinazepam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'uric acid'}}, {'source_node': {'name': 'etamiphylline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pinazepam'}}, {'source_node': {'name': 'etamiphylline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cinazepam'}}, {'source_node': {'name': 'etamiphylline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bentazepam'}}, {'source_node': {'name': 'cinazepam'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' neuropsychiatric effects '}}, {'source_node': {'name': 'cinazepam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'guanine'}}, {'source_node': {'name': 'cinazepam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '9-deazaguanine'}}]","[{'source_node': {'name': 'pinazepam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'uric acid'}}, {'source_node': {'name': '9-deazaguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pinazepam'}}, {'source_node': {'name': '9-deazaguanine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'uric acid'}}, {'source_node': {'name': 'etamiphylline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pinazepam'}}, {'source_node': {'name': 'etamiphylline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cinazepam'}}, {'source_node': {'name': 'etamiphylline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bentazepam'}}, {'source_node': {'name': 'cinazepam'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' neuropsychiatric effects '}}, {'source_node': {'name': 'cinazepam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'guanine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:4099', 'target': 'COMPOUND:11191', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:4099', 'target': 'COMPOUND:7805', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:12417', 'target': 'COMPOUND:4099', 'metadata': None}]",0.8,25855888d997681eb0f928e3840cd649,cc7b1b12d6211030d6b9472adf6a29c7,[],[]
"[{'source_node': {'name': 'PCM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of PLK1 Activity at G2/M Transition'}}, {'source_node': {'name': 'PCM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Loss of Nlp from mitotic centrosomes'}}, {'source_node': {'name': 'PCM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'AURKA Activation by TPX2'}}]","[{'source_node': {'name': 'PCM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of PLK1 Activity at G2/M Transition'}}, {'source_node': {'name': 'PCM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'AURKA Activation by TPX2'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:288', 'target': None, 'metadata': {'node_id': '288', 'node_type': 'PATHWAY', 'display_name': 'Loss of Nlp from mitotic centrosomes'}}]",0.7142857142857143,ed913f305807e52323973c60881d9e0f,528c1d1c54297cb68c69a027e8902348,[],"['The gene PCM1 takes part in various biological pathways - it acts within the regulation of PLK1 activity during the G2/M transition, and also has a role within AURKA activation by TPX2.', 'The gene PCM1 is involved in several crucial processes. It acts within the regulation of PLK1 activity at G2/M transition and also contributes to AURKA activation by TPX2. These interactions illustrate the key roles that PCM1 plays in cellular regulation.']"
"[{'source_node': {'name': 'CSF1R'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Transcriptional Regulation by VENTX'}}, {'source_node': {'name': 'CSF1R'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Signaling by CSF1 (M-CSF) in myeloid cells'}}]","[{'source_node': {'name': 'CSF1R'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Transcriptional Regulation by VENTX'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1185', 'target': None, 'metadata': {'node_id': '1185', 'node_type': 'PATHWAY', 'display_name': 'Signaling by CSF1 (M-CSF) in myeloid cells'}}]",0.6,35205040454be5eb4428cb6be432a925,b30ef5d22ada0448f84ccfe2d1fad19c,"['The gene CSF1R acts within different biological processes, participating in transcriptional regulation by VENTX as well as signaling by CSF1 (M-CSF) in myeloid cells.']",[]
"[{'source_node': {'name': 'DZIP1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'mitral valve prolapse'}}, {'source_node': {'name': 'DZIP1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'spermatogenic failure 47'}}, {'source_node': {'name': 'DZIP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': ""Hedgehog 'on' state""}}]","[{'source_node': {'name': 'DZIP1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'mitral valve prolapse'}}, {'source_node': {'name': 'DZIP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': ""Hedgehog 'on' state""}}]","[{'type': 'node_removal', 'source': 'DISEASE:17676', 'target': None, 'metadata': {'node_id': '17676', 'node_type': 'DISEASE', 'display_name': 'spermatogenic failure 47'}}]",0.7142857142857143,a4eddac3a784ce1bacbd6d69760f4998,24bc83ae27d76658009732fa1c6b5887,[],[]
"[{'source_node': {'name': 'chaparrinone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}, {'source_node': {'name': 'chaparrinone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'k562'}}, {'source_node': {'name': 'chaparrinone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepg2'}}]","[{'source_node': {'name': 'chaparrinone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'k562'}}, {'source_node': {'name': 'chaparrinone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepg2'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4951', 'target': None, 'metadata': {'node_id': '4951', 'node_type': 'PROTEIN', 'display_name': 'hl-60'}}]",0.7142857142857143,819f0474e84a920e0a3caaab221a2f88,cded50ab95773420f545bfc44f0a2b64,"['The drug Chaparrinone has several targets, including HL-60, K562, and HepG2 cells.', 'The compound chaparrinone targets multiple cells such as HL-60, K562, and HepG2.', 'The compound chaparrinone has been observed to target several cell lines including HL-60, K562, and HepG2.', 'The substance Chaparrinone targets several entities, including HL-60, K562 and HepG2.', 'The compound Chaparrinone has been shown to target multiple entities including HL-60, K562, and HepG2.']","['Chaparrinone is a compound that targets two different elements; K562 and HepG2.', 'The compound chaparrinone has been identified to target two entities - K562 and HepG2.', 'The drug Chaparrinone is known to target multiple entities, including the K562 and HepG2.', 'The compound chaparrinone has been identified to target two separate entities, namely K562 and HepG2.', 'Chaparrinone, a known compound, targets two distinct entities: K562 and HepG2. These represent different cells or tissues which the compound interacts with as part of its function or potential therapeutic action.']"
"[{'source_node': {'name': 'geminin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GMNN'}}, {'source_node': {'name': 'sulochrin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lysine-specific demethylase 4a'}}, {'source_node': {'name': 'sulochrin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'geminin'}}, {'source_node': {'name': 'sulochrin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}}, {'source_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TDP1'}}, {'source_node': {'name': 'lysine-specific demethylase 4a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KDM4A'}}]","[{'source_node': {'name': 'geminin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GMNN'}}, {'source_node': {'name': 'geminin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TDP1'}}, {'source_node': {'name': 'sulochrin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lysine-specific demethylase 4a'}}, {'source_node': {'name': 'sulochrin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}}, {'source_node': {'name': 'sulochrin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'TDP1'}}, {'source_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TDP1'}}, {'source_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KDM4A'}}, {'source_node': {'name': 'lysine-specific demethylase 4a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KDM4A'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:43963', 'target': 'GENE:31610', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:6169', 'target': 'GENE:35605', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'PROTEIN:5869', 'target': 'GENE:31610', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:43963', 'target': 'PROTEIN:5869', 'metadata': None}]",0.6923076923076923,a3b6300958a80f77b785747c93d68da9,10957bd8db3ed2322f7f61b415a103c1,"['Geminin, a gene product of GMNN, and Tyrosyl-DNA phosphodiesterase 1, a gene product of TDP1, are both targets of the drug Sulochrin. Sulochrin also targets the lysine-specific demethylase 4A, a gene product of KDM4A. Therefore, the interactions of Sulochrin with these proteins may be significant in the context of biological processes and disease.', 'The protein geminin, which is a gene product of GMNN, is one of the targets of the compound sulochrin. In addition to geminin, sulochrin also targets lysine-specific demethylase 4a and tyrosyl-DNA phosphodiesterase 1. The enzyme tyrosyl-DNA phosphodiesterase 1 is a gene product of TDP1, and lysine-specific demethylase 4a is a gene product of KDM4A.', 'Geminin is a product of the gene GMNN and serves as one of the target points for the compound Sulochrin. Sulochrin also targets two other elements, the lysine-specific demethylase 4a, which is a product of the gene KDM4A, and tyrosyl-DNA phosphodiesterase 1, a gene product of TDP1. Thus, Sulochrin interacts with a variety of gene products, highlighting its comprehensive influence within biological systems.', 'The molecule sulochrin is known to target several key biological entities. It targets geminin, an important mechanism involved in DNA replication, which is a gene product of GMNN. Sulochrin also targets lysine-specific demethylase 4a, a protein associated with gene expression regulation and is a product of the gene KDM4A. Additionally, sulochrin has a target in tyrosyl-DNA phosphodiesterase 1, a DNA repair enzyme that is a gene product of TDP1.', 'The protein geminin, which is a gene product of GMNN, is targeted by Sulochrin, a bioactive compound. In addition, Sulochrin also targets other proteins like lysine-specific demethylase 4a, which is a gene product of KDM4A, and tyrosyl-DNA phosphodiesterase 1, a gene product of TDP1. Therefore, Sulochrin has a wide range of targets, suggesting a broad spectrum of biological activities.']","['Geminin, which is a gene product of both GMNN and TDP1, plays a role in the complex biology of our cells. Another molecule named Sulochrin interacts with several targets within the body. Among these are lysine-specific demethylase 4a and tyrosyl-DNA phosphodiesterase 1. Additionally, Sulochrin is known to influence the function of TDP1. Interestingly, tyrosyl-DNA phosphodiesterase 1 is a gene product of both TDP1 and KDM4A. Similarly, lysine-specific demethylase 4a is also a gene product of KDM4A. The intertwining nature of these relationships illustrates the complex interplay of genes and molecules within the body.', 'Geminin is a gene product of both GMNN and TDP1. On the other hand, Sulochrin targets lysine-specific demethylase 4a and tyrosyl-DNA phosphodiesterase 1. Further, sulochrin is known to affect TDP1. Tyrosyl-DNA phosphodiesterase 1 too is a gene product of TDP1, and interestingly, it is also a gene product of KDM4A. Finally, lysine-specific demethylase 4a is a gene product of KDM4A. These intricate relationships between these entities further illuminate the remarkable web of interactions at the molecular level in the biological world.', 'The protein geminin is a gene product of GMNN and TDP1. There also exists a substance called sulochrin, which has various targets. These include lysine-specific demethylase 4a and tyrosyl-dna phosphodiesterase 1. Moreover, sulochrin also affects TDP1. The enzyme tyrosyl-dna phosphodiesterase 1 is a gene product of both TDP1 and KDM4A. On the other hand, lysine-specific demethylase 4a is a gene product of KDM4A.', 'Geminin is known to be a gene product of both GMNN and TDP1. On the other hand, sulochrin has multiple targets, including lysine-specific demethylase 4a and tyrosyl-dna phosphodiesterase 1. Interestingly, sulochrin also affects TDP1. Tyrosyl-dna phosphodiesterase 1 itself is a gene product of both TDP1 and KDM4A. Similarly, lysine-specific demethylase 4a is a gene product of KDM4A. Thus, a complex network of gene products and biological interactions are articulated by these relations.', 'Geminin is a gene product of both GMNN and TDP1. Sulochrin, on the other hand, has various targets including lysine-specific demethylase 4a and tyrosyl-dna phosphodiesterase 1. It is interesting to note that sulochrin affects TDP1, which is associated with the gene product geminin. The protein tyrosyl-dna phosphodiesterase 1 is a gene product of both TDP1 and KDM4A, linking sulochrin, TDP1 and geminin directly. Furthermore, lysine-specific demethylase 4a, another target of sulochrin, is a gene product of KDM4A, bringing KDM4A into the interconnected relationship. This interconnectedness presents a complex interaction of genes and proteins influenced by sulochrin.']"
"[{'source_node': {'name': 'CLCF1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'cold-induced sweating syndrome 2'}}, {'source_node': {'name': 'CLCF1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'crisponi/cold-induced sweating syndrome 1'}}, {'source_node': {'name': 'CLCF1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'IL-6-type cytokine receptor ligand interactions'}}, {'source_node': {'name': 'crisponi/cold-induced sweating syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'short palm'}}]","[{'source_node': {'name': 'CLCF1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'cold-induced sweating syndrome 2'}}, {'source_node': {'name': 'CLCF1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'crisponi/cold-induced sweating syndrome 1'}}, {'source_node': {'name': 'crisponi/cold-induced sweating syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'short palm'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1115', 'target': None, 'metadata': {'node_id': '1115', 'node_type': 'PATHWAY', 'display_name': 'IL-6-type cytokine receptor ligand interactions'}}]",0.7777777777777778,0ebbde0cef762f25f82fede618d8c84d,6b08c75363adc40418d5f3586362121d,"['The gene CLCF1 is known to act within the pathway of IL-6-type cytokine receptor ligand interactions. It is also documented with causing certain conditions, two of which are crisponi/cold-induced sweating syndrome 1 and cold-induced sweating syndrome 2. Notably, short palm has been identified as a phenotype present in those affected by crisponi/cold-induced sweating syndrome 1.', 'The gene CLCF1, which is known to act within IL-6-type cytokine receptor ligand interactions, is associated with certain medical conditions. Specifically, it is known to cause crisponi/cold-induced sweating syndrome 1 and cold-induced sweating syndrome 2. Interestingly, one distinctive phenotype of crisponi/cold-induced sweating syndrome 1 is the presence of short palms.', 'The gene CLCF1, which is involved in the IL-6-type cytokine receptor ligand interactions, is linked to a number of conditions. For example, CLCF1 is known to cause both cold-induced sweating syndrome 2 and Crisponi/cold-induced sweating syndrome 1. The latter is characterized by specific symptoms such as a short palm.', ""The protein CLCF1 plays an essential role within the IL-6-type cytokine receptor ligand interactions. It's also associated with causing two distinct conditions - Cold-induced sweating syndrome 2 and Crisponi/Cold-induced sweating syndrome 1. Notably, individuals with Crisponi/Cold-induced sweating syndrome 1 often exhibit a phenotype characterized by a short palm."", 'The gene CLCF1, which acts within the IL-6-type cytokine receptor ligand interactions pathway, has been known to cause several conditions. These include cold-induced sweating syndrome 2 and crisponi/cold-induced sweating syndrome 1, which is a condition characterised by phenotypes such as a short palm.']","['The gene CLCF1 is known to cause two conditions, cold-induced sweating syndrome 2 and crisponi/cold-induced sweating syndrome 1. Notably, the latter condition is also associated with the phenotypic characteristic of having a short palm.', 'The gene CLCF1 has been identified as the causative agent for two medical conditions: cold-induced sweating syndrome 2 and crisponi/cold-induced sweating syndrome 1. Crisponi/cold-induced sweating syndrome 1 is typified by a notable phenotype feature - short palm.', 'The gene CLCF1 is found to cause various conditions such as the cold-induced sweating syndrome 2 and crisponi/cold-induced sweating syndrome 1. Notably, the latter syndrome is characterized by the phenotype of having a short palm.', 'The cardiokine protein CLCF1 is responsible for causing several conditions including cold-induced sweating syndrome 2 and crisponi/cold-induced sweating syndrome 1. Notably, the symptom of having a short palm is a diagnostic phenotype of crisponi/cold-induced sweating syndrome 1.', 'The gene CLCF1 is associated with causing several conditions, namely cold-induced sweating syndrome 2 and crisponi/cold-induced sweating syndrome 1. Crisponi/cold-induced sweating syndrome 1, in particular, is characterized by a particular phenotype marked by short palms.']"
"[{'source_node': {'name': 'hydroxyethylpromethazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'protokylol'}}, {'source_node': {'name': 'hydroxyethylpromethazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'deoxyepinephrine'}}]","[{'source_node': {'name': 'hydroxyethylpromethazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'deoxyepinephrine'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:5857', 'target': None, 'metadata': {'node_id': '5857', 'node_type': 'COMPOUND', 'display_name': 'protokylol'}}]",0.6,2b53f55eaf1c541160880ef06d6452bd,a37b2d4cce6229fad7ea81aae4507dec,"['The drug hydroxyethylpromethazine is known to increase the efficacy of both protokylol and deoxyepinephrine.', 'The drug hydroxyethylpromethazine has been found to increase the efficacy of both protokylol and deoxyepinephrine.', 'The drug hydroxyethylpromethazine is known to increase the efficacy of both protokylol and deoxyepinephrine. This suggests that hydroxyethylpromethazine may be useful in therapies where these two drugs are involved, as it could potentially enhance their effectiveness.', 'The medication hydroxyethylpromethazine is known to increase the efficacy of both protokylol and deoxyepinephrine.', 'The drug hydroxyethylpromethazine has been found to increase efficacy of two other drugs, namely protokylol and deoxyepinephrine.']","['The drug hydroxyethylpromethazine has been found to increase the efficacy of deoxyepinephrine.', 'The drug hydroxyethylpromethazine is known to increase the efficacy of deoxyepinephrine.', 'The drug hydroxyethylpromethazine is known to increase the efficacy of deoxyepinephrine.', 'The drug hydroxyethylpromethazine is known to increase the efficacy of deoxyepinephrine.']"
"[{'source_node': {'name': 'fluticasone furoate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rabies virus inactivated antigen'}}, {'source_node': {'name': 'modified vaccinia ankara'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pentostatin'}}, {'source_node': {'name': 'modified vaccinia ankara'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluticasone furoate'}}, {'source_node': {'name': 'modified vaccinia ankara'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'baricitinib'}}]","[{'source_node': {'name': 'rabies virus inactivated antigen'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'baricitinib'}}, {'source_node': {'name': 'fluticasone furoate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rabies virus inactivated antigen'}}, {'source_node': {'name': 'fluticasone furoate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'baricitinib'}}, {'source_node': {'name': 'modified vaccinia ankara'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pentostatin'}}, {'source_node': {'name': 'modified vaccinia ankara'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluticasone furoate'}}, {'source_node': {'name': 'modified vaccinia ankara'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'baricitinib'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:8395', 'target': 'COMPOUND:9732', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:7858', 'target': 'COMPOUND:9732', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.7777777777777778,5f8fa75c713ee4a7b4a599b394b88670,598b0b35cf1cc4c85afcead9afc5863c,"[""The drug fluticasone furoate has been observed to decrease the efficacy of the rabies virus inactivated antigen. Similarly, the modified vaccinia ankara, a type of vaccine, has been reported to reduce the effectiveness of several substances such as pentostatin, fluticasone furoate, and baricitinib. This indicates that careful consideration is needed when these substances are used in combination, as they may negatively impact one another's functioning."", 'The drug fluticasone furoate is known to decrease the efficacy of the rabies virus inactivated antigen. Concurrently, modified vaccinia ankara, another type of vaccine, is known to diminish the effectiveness of several other treatments, such as pentostatin and baricitinib. Interestingly, this vaccine also affects fluticasone furoate by reducing its efficacy. This indicates a potential complex interaction among these agents which may need to be considered when designing treatment plans.', 'The drug fluticasone furoate is noted to decrease the efficacy of the rabies virus inactivated antigen. Moreover, the use of modified vaccinia ankara, a recombinant viral vaccine, has been found to decrease the efficacy of several drugs including pentostatin, fluticasone furoate, and baricitinib. These interactions highlight the need for careful consideration when combining these treatments.', 'The drug Fluticasone Furoate is known to decrease the efficacy of Rabies Virus Inactivated Antigen. Similarly, Modified Vaccinia Ankara, a treatment option, also decreases the efficacy of several medications including Pentostatin, Fluticasone Furoate, and Baricitinib. This highlights the importance of considering the interactions between these agents when developing therapeutic strategies.']","['The efficacy of baricitinib, a drug used for treating inflammatory diseases, is influenced by several other drugs and antigens. Notably, the rabies virus inactivated antigen is known to increase the efficacy of baricitinib, potentially enhancing its therapeutic effect. However, fluticasone furoate, a corticosteroid used to control symptoms of asthma and other lung diseases, tends to decrease the efficacy of both baricitinib and the rabies virus inactivated antigen. This implies that patients on these treatments need to be cautious when using fluticasone furoate. In a similar vein, modified vaccinia ankara, a type of vaccine vector, seems to have a negative impact too. It decreases the efficacy of not just baricitinib and fluticasone furoate, but also pentostatin, a chemotherapy drug. The interplay of these substances underlines the complexity of drug interactions and the need for continued research for the understanding of these effects.', 'The rabies virus inactivated antigen is found to increase the efficacy of baricitinib. However, the presence of fluticasone furoate can decrease the efficacy of both the rabies virus inactivated antigen and baricitinib. Meanwhile, modified vaccinia ankara, a viral vaccine, also decreases the efficacy of several substances. It diminishes the efficacy of pentostatin, fluticasone furoate, and baricitinib. Hence, when determining treatment plans, it would be essential to consider these interactions to maximize efficacy.', 'The efficacy of different drugs can be influenced by other substances. For example, the inactivated antigen of the rabies virus enhances the effectiveness of the drug Baricitinib. However, Fluticasone Furoate, a potent glucocorticoid, can reduce the efficacy of the rabies virus inactivated antigen as well as Baricitinib itself. Moreover, Modified Vaccinia Ankara, a highly attenuated strain of vaccinia virus, decreases the efficacy of several drugs including Pentostatin, Fluticasone Furoate and Baricitinib. Therefore, one must be cautious about the interactions of these drugs and substances in clinical treatments.', 'The efficacy of several drugs can be influenced by various pharmaceuticals and microorganisms. For instance, the rabies virus inactivated antigen is known to increase the efficacy of baricitinib. Meanwhile, fluticasone furoate has been observed to decrease the efficacy of the rabies virus inactivated antigen and baricitinib. Additionally, the modified vaccinia ankara, a type of vaccine, is reported to have a diminishing effect on the efficacy of several medicines including pentostatin, fluticasone furoate, and baricitinib. These relationships underline the intricacy of drug interactions and the role of various factors in determining their effectiveness.', 'The rabies virus inactivated antigen is known to increase the efficacy of the drug Baricitinib. However, the presence of Fluticasone Furoate can decrease the efficacy of both the rabies virus inactivated antigen and Baricitinib. In the same vein, the Modified Vaccinia Ankara reduces the effectiveness of several medications including Pentostatin, Fluticasone Furoate, and Baricitinib. Thus, these interactions between various antigens, viruses, and medications can significantly impact drug effectiveness.']"
"[{'source_node': {'name': 'sucutinirane e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}, {'source_node': {'name': 'sucutinirane e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'sucutinirane e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-116'}}]","[{'source_node': {'name': 'sucutinirane e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5656', 'target': None, 'metadata': {'node_id': '5656', 'node_type': 'PROTEIN', 'display_name': 'hct-116'}}, {'type': 'node_removal', 'source': 'PROTEIN:4951', 'target': None, 'metadata': {'node_id': '4951', 'node_type': 'PROTEIN', 'display_name': 'hl-60'}}]",0.4285714285714286,b4ecd984c559dee740009291cc3d5693,181809134aa85e17d27b1ecafab86913,"['Sucutinirane E is a compound that targets several entities including HL-60, MCF7 and HCT-116.', 'The compound Sucutinirane E is known to target multiple cell lines, including HL-60, MCF7, and HCT-116.', 'The compound Sucutinirane E targets multiple cells including HL-60, MCF7, and HCT-116.', 'The compound Sucutinirane E has been identified to target multiple cell lines. It demonstrates activity against HL-60, MCF7, and HCT-116 cell lines.', 'The compound Sucutinirane E has several cellular targets, specifically HL-60, MCF7, and HCT-116 cells.']",[]
"[{'source_node': {'name': '(5s)-5-hydroxyacetylcaespitol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}, {'source_node': {'name': '(5s)-5-hydroxyacetylcaespitol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a-431'}}]","[{'source_node': {'name': '(5s)-5-hydroxyacetylcaespitol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5841', 'target': None, 'metadata': {'node_id': '5841', 'node_type': 'PROTEIN', 'display_name': 'a-431'}}]",0.6,49b4ea7aa04193989d1969fa423b137b,ce191295516039e939ad43084625107b,"['The drug (5S)-5-hydroxyacetylcaespitol has targets on both HT-29 and A-431 cells.', 'The drug (5S)-5-hydroxyacetylcaespitol targets both HT-29 and A-431.', 'The compound (5S)-5-hydroxyacetylcaespitol has been found to target both HT-29 and A-431 cells. This suggests a possible therapeutic potential in cellular conditions where these cell lines are prevalent.', 'The compound (5S)-5-hydroxyacetylcaespitol targets two cell lines: HT-29 and A-431.', 'The compound (5S)-5-hydroxyacetylcaespitol targets both the HT-29 and the A-431 cell lines.']",['The compound (5S)-5-hydroxyacetylcaespitol has a target interaction with HT-29.']
"[{'source_node': {'name': 'GLP1R'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (s) signalling events'}}, {'source_node': {'name': 'glucagon-like peptide 1 receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GLP1R'}}, {'source_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TDP1'}}, {'source_node': {'name': 'TDP1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'spinocerebellar ataxia'}}, {'source_node': {'name': 'TDP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nonhomologous End-Joining (NHEJ)'}}, {'source_node': {'name': 'isoliquiritigenin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ataxin-2'}}, {'source_node': {'name': 'isoliquiritigenin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucagon-like peptide 1 receptor'}}, {'source_node': {'name': 'isoliquiritigenin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}}]","[{'source_node': {'name': 'GLP1R'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (s) signalling events'}}, {'source_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GLP1R'}}, {'source_node': {'name': 'isoliquiritigenin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ataxin-2'}}, {'source_node': {'name': 'isoliquiritigenin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}}, {'source_node': {'name': 'isoliquiritigenin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'GLP1R'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:85', 'target': 'GENE:31610', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'PATHWAY:270', 'target': None, 'metadata': {'node_id': '270', 'node_type': 'PATHWAY', 'display_name': 'Nonhomologous End-Joining (NHEJ)'}}, {'type': 'edge_addition', 'source': 'PROTEIN:6169', 'target': 'GENE:28155', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:3095', 'target': 'PROTEIN:85', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:31610', 'target': None, 'metadata': {'node_id': '31610', 'node_type': 'GENE', 'display_name': 'TDP1'}}, {'type': 'node_removal', 'source': 'PROTEIN:85', 'target': None, 'metadata': {'node_id': '85', 'node_type': 'PROTEIN', 'display_name': 'glucagon-like peptide 1 receptor'}}, {'type': 'edge_addition', 'source': 'COMPOUND:3095', 'target': 'GENE:28155', 'metadata': {'predicate': 'is_affecting'}}]",0.4117647058823529,d1c98efc46bda4f3a9fdf06e11fb748b,8f494e320be1ea7a8a50e783e32596fd,[],"['The substance isoliquiritigenin has multiple biological targets, interacting with both ataxin-2 and tyrosyl-DNA phosphodiesterase 1. Interestingly, this tyrosyl-DNA phosphodiesterase 1 is a gene product of GLP1R. As a receptor, GLP1R operates within the complex system of G alpha (s) signalling events. Isoliquiritigenin also does affect GLP1R, further suggesting the interconnected roles of these entities in cellular processes.']"
"[{'source_node': {'name': 'AKT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Constitutive Signaling by AKT1 E17K in Cancer'}}, {'source_node': {'name': 'AKT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RUNX2 regulates genes involved in cell migration'}}, {'source_node': {'name': 'perifosine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'rac-alpha serine/threonine-protein kinase'}}, {'source_node': {'name': 'perifosine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mitogen-activated protein kinase 1'}}, {'source_node': {'name': 'rac-alpha serine/threonine-protein kinase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AKT1'}}]","[{'source_node': {'name': 'AKT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Constitutive Signaling by AKT1 E17K in Cancer'}}, {'source_node': {'name': 'AKT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RUNX2 regulates genes involved in cell migration'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:5710', 'target': 'GENE:26810', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'PROTEIN:1615', 'target': None, 'metadata': {'node_id': '1615', 'node_type': 'PROTEIN', 'display_name': 'mitogen-activated protein kinase 1'}}, {'type': 'node_removal', 'source': 'COMPOUND:5710', 'target': None, 'metadata': {'node_id': '5710', 'node_type': 'COMPOUND', 'display_name': 'perifosine'}}, {'type': 'node_removal', 'source': 'PROTEIN:718', 'target': None, 'metadata': {'node_id': '718', 'node_type': 'PROTEIN', 'display_name': 'rac-alpha serine/threonine-protein kinase'}}]",0.4545454545454546,87236ad811d5e149025fd9f0f17cb033,740f9b0a21fddb381dd509b997767b6f,[],"['The gene AKT1 is involved in multiple pathways such as constitutive signaling by AKT1 E17K in cancer and it also acts within a pathway where RUNX2 regulates genes involved in cell migration.', 'The gene AKT1 is active within several pathways, namely the pathway involving constitutive signaling by AKT1 E17K in cancer as well as the one where RUNX2 regulates genes that are involved in cell migration.']"
"[{'source_node': {'name': 'brilaroxazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'selegiline'}}, {'source_node': {'name': 'brilaroxazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mazaticol'}}, {'source_node': {'name': 'brilaroxazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dexpramipexole'}}]","[{'source_node': {'name': 'mazaticol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'selegiline'}}, {'source_node': {'name': 'mazaticol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'brilaroxazine'}}, {'source_node': {'name': 'brilaroxazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'selegiline'}}, {'source_node': {'name': 'brilaroxazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mazaticol'}}, {'source_node': {'name': 'brilaroxazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dexpramipexole'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:11301', 'target': 'COMPOUND:1019', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11301', 'target': 'COMPOUND:8161', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7142857142857143,908cc3678df54c780e2ff1ce992f8c93,5137b8c0441dc8b6262d241d142beaae,"['Brilaroxazine, a medication, has been found to decrease the efficacy of several other drugs. Notably, the effectiveness of selegiline, mazaticol, and dexpramipexole are all diminished when combined with brilaroxazine. This knowledge is instrumental for physicians when they consider various treatment options and potential drug interactions.', 'The medication brilaroxazine is known to decrease the efficacy of several other drugs, including selegiline, mazaticol, and dexpramipexole. Hence, caution should be exercised when these drugs are administered in combination.', 'The drug brilaroxazine has been shown to decrease the efficacy of several other medications, including selegiline, mazaticol, and dexpramipexole. This suggests that care must be taken when administering brilaroxazine concurrently with these drugs, as it may undermine their therapeutic effects.', 'The drug Brilaroxazine is known to decrease the efficacy of several other medications including Selegiline, Mazaticol, and Dexpramipexole. This suggests that there might be potential drug interactions if these medicines are administered together. Therefore, caution might be needed when combining therapies.', 'The drug brilaroxazine is known to decrease the efficacy of several other drugs including selegiline, mazaticol, and dexpramipexole. This means that the effectiveness of these drugs may be reduced when used concurrently with brilaroxazine.']","['The drug Mazaticol is known to increase the efficacy of both Selegiline and Brilaroxazine. Interestingly, this increased efficacy is not mutual, as Brilaroxazine actually decreases the efficacy of both Selegiline and Mazaticol. Furthermore, Brilaroxazine is also observed to decrease the efficacy of Dexpramipexole. The complex interplay of these drugs suggests a delicate balance of therapeutic benefits and potential drug interactions that could impact patient treatment outcomes.', 'The drug Mazaticol is known to increase the efficacy of two other drugs, Selegiline and Brilaroxazine. Interestingly, Brilaroxazine appears to have a complex interaction pattern. It can decrease the efficacy of Selegiline and Mazaticol, thus potentially affecting their overall performance. Moreover, the effectiveness of another drug, Dexpramipexole, might also be reduced when combined with Brilaroxazine. Therefore, these interactions, particularly those involving Mazaticol and Brilaroxazine, must be carefully considered in pharmaceutical planning and patient treatment strategies.', 'Mazaticol, as a drug, works to increase the efficacy of both selegiline and brilaroxazine. However, a complex interaction exists amongst these drugs. Brilaroxazine, while enhanced by Mazaticol, actually decreases the effectiveness of both Mazaticol and selegiline. Furthermore, brilaroxazine also reduces the efficacy of another drug, dexpramipexole. This intricate relationship underscores the necessity of careful management when combining these therapeutics.', 'The drug mazaticol is known to increase the efficacy of both selegiline and brilaroxazine. However, it is interesting to note that brilaroxazine, while enhanced by mazaticol, in turn, decreases the efficacy of selegiline and mazaticol itself. Brilaroxazine also reduces the effectiveness of dexpramipexole. Thus, one must handle these interactions carefully when co-administering these drugs.', ""The drug Mazaticol enhances the efficacy of other drugs such as Selegiline and Brilaroxazine. Interestingly, while Brilaroxazine's efficacy is increased by Mazaticol, it conversely decreases the efficacy of Selegiline and Mazaticol itself. Additionally, Dexpramipexole, another drug, has its efficacy decreased when Brilaroxazine is present.""]"
"[{'source_node': {'name': ""adenosine 5'-[gamma-thio]triphosphate""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'adp-ribosyl cyclase 2'}}, {'source_node': {'name': ""adenosine 5'-[gamma-thio]triphosphate""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'phosphoribosylglycinamide formyltransferase 2'}}, {'source_node': {'name': ""adenosine 5'-[gamma-thio]triphosphate""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'serine/threonine-protein kinase pknb'}}, {'source_node': {'name': 'BST1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nicotinate metabolism'}}, {'source_node': {'name': 'adp-ribosyl cyclase 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'BST1'}}]","[{'source_node': {'name': ""adenosine 5'-[gamma-thio]triphosphate""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'adp-ribosyl cyclase 2'}}, {'source_node': {'name': ""adenosine 5'-[gamma-thio]triphosphate""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'serine/threonine-protein kinase pknb'}}]","[{'type': 'node_removal', 'source': 'GENE:33107', 'target': None, 'metadata': {'node_id': '33107', 'node_type': 'GENE', 'display_name': 'BST1'}}, {'type': 'node_removal', 'source': 'PROTEIN:2386', 'target': None, 'metadata': {'node_id': '2386', 'node_type': 'PROTEIN', 'display_name': 'phosphoribosylglycinamide formyltransferase 2'}}]",0.4545454545454546,72b2069e762cfe03cb4a4c1014e2a729,780daf92e4402960cab6fe30a20c6756,"[""Adenosine 5'-[gamma-thio]triphosphate, a notable compound, targets various molecules including ADP-ribosyl cyclase 2, phosphoribosylglycinamide formyltransferase 2, and the serine/threonine-protein kinase pknb. ADP-ribosyl cyclase 2, interestingly, is a gene product of BST1. BST1 itself acts within the pathway of nicotinate metabolism, demonstrating intricate interplay between these compounds and biological pathways."", ""The compound adenosine 5'-[gamma-thio]triphosphate is known to interact with multiple targets including adp-ribosyl cyclase 2, phosphoribosylglycinamide formyltransferase 2, and serine/threonine-protein kinase pknb. In a related chain of relationships, adp-ribosyl cyclase 2 is identified as a gene product of BST1. Furthermore, BST1 functions within the nicotinate metabolism. This illustrates the interconnected relationships between these biological entities and pathways."", ""The chemical compound adenosine 5'-[gamma-thio]triphosphate successfully targets three distinct proteins: adp-ribosyl cyclase 2, phosphoribosylglycinamide formyltransferase 2, and serine/threonine-protein kinase pknb. Furthermore, adp-ribosyl cyclase 2, is a gene product of BST1. Importantly, BST1 also plays a role within the nicotinate metabolism pathway. This suggests a possible interconnected network between these components."", ""The enzyme adenosine 5'-[gamma-thio]triphosphate targets several proteins including adp-ribosyl cyclase 2, phosphoribosylglycinamide formyltransferase 2, and serine/threonine-protein kinase pknb. Specifically, the protein adp-ribosyl cyclase 2 is a gene product of BST1. Furthermore, BST1 acts within the process of nicotinate metabolism."", ""The molecule adenosine 5'-[gamma-thio]triphosphate targets several proteins including the adp-ribosyl cyclase 2, phosphoribosylglycinamide formyltransferase 2 and serine/threonine-protein kinase pknb. Interestingly, the protein adp-ribosyl cyclase 2 is a gene product of BST1. Importantly, BST1 also acts within the nicotinate metabolism pathway, which is crucial in how our body breaks down and utilizes nutrients.""]","[""The molecule adenosine 5'-[gamma-thio]triphosphate targets multiple elements, including the ADP-ribosyl cyclase 2 and the serine/threonine-protein kinase pknb."", ""The compound adenosine 5'-[gamma-thio]triphosphate has two known targets. These include the protein ADP-ribosyl cyclase 2 and the enzyme serine/threonine-protein kinase pknb."", ""The compound adenosine 5'-[gamma-thio]triphosphate targets both the adp-ribosyl cyclase 2 and the serine/threonine-protein kinase pknb."", ""The compound adenosine 5'-[gamma-thio]triphosphate acts on two key targets: adp-ribosyl cyclase 2 and serine/threonine-protein kinase pknb."", ""The chemical compound adenosine 5'-[gamma-thio]triphosphate has multiple targets in cellular processes. It specifically targets both the adp-ribosyl cyclase 2 enzyme and the serine/threonine-protein kinase pknb, influencing their activities within the cell.""]"
"[{'source_node': {'name': 'sensory ataxic neuropathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cataract'}}, {'source_node': {'name': 'sensory ataxic neuropathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'frequent falls'}}, {'source_node': {'name': 'TWNK'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'sensory ataxic neuropathy'}}, {'source_node': {'name': 'TWNK'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'perrault syndrome 5'}}]","[{'source_node': {'name': 'sensory ataxic neuropathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cataract'}}, {'source_node': {'name': 'sensory ataxic neuropathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'frequent falls'}}, {'source_node': {'name': 'TWNK'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'perrault syndrome 5'}}]","[{'type': 'edge_deletion', 'source': 'GENE:31774', 'target': 'DISEASE:14303', 'metadata': None}]",0.8888888888888888,c6fa26790b320ac9530fca09ea19a980,324d810f3e99c1c747e72ea53552b10d,"['The gene TWNK is known to cause several conditions including sensory ataxic neuropathy and Perrault Syndrome 5. Notably, sensory ataxic neuropathy is characterized by distinctive phenotypes such as cataract and a tendency for frequent falls.', 'The gene TWNK is implicated in causing several conditions, including sensory ataxic neuropathy and Perrault Syndrome 5. Sensory ataxic neuropathy is a disease characterized by symptoms such as cataract and frequent falls.']",[]
"[{'source_node': {'name': 'epirizole'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' nephrotoxicity '}}, {'source_node': {'name': 'epirizole'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'guanabenz'}}, {'source_node': {'name': 'epirizole'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pargyline'}}, {'source_node': {'name': 'pargyline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'salicylamide'}}]","[{'source_node': {'name': 'salicylamide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pargyline'}}, {'source_node': {'name': 'pargyline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'salicylamide'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:7936', 'target': 'COMPOUND:7764', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:7936', 'target': None, 'metadata': {'node_id': '7936', 'node_type': 'COMPOUND', 'display_name': 'epirizole'}}, {'type': 'edge_addition', 'source': 'COMPOUND:7764', 'target': 'COMPOUND:1553', 'metadata': {'predicate': 'increase_efficacy'}}]",0.2222222222222222,87858c39c3afd72a29c0af92c6d9ad07,7afa12273bff0d563b844532032fbf53,[],"['The drug salicylamide is known to increase the efficacy of another drug, pargyline. Interestingly, pargyline in turn can decrease the efficacy of salicylamide, suggesting a complex interplay between these two drugs.\n', ""The drug Salicylamide has been shown to increase the efficacy of Pargyline. However, it's interesting to note that Pargyline reciprocally decreases the efficacy of Salicylamide. This unique interaction highlights the complex nature of drug interactions and their potential implications for treatment regimens."", ""The drug Salicylamide is known to increase the efficacy of another drug, Pargyline. However, it's noteworthy that Pargyline, in turn, can decrease the efficacy of Salicylamide. Therefore, their combined use should be managed carefully to achieve the optimal therapeutic effect."", 'Salicylamide has been found to increase the efficacy of pargyline. Conversely, pargyline is also known to decrease the efficacy of salicylamide. The interaction between these two drugs suggests a complex relationship impacting their mutual effectiveness.', 'Salicylamide, a type of drug, is known to increase the efficacy of another drug called Pargyline. However, interestingly, when taking Pargyline, it has been observed to decrease the effectiveness of Salicylamide. This suggests a complex, reciprocal relationship between these two drugs.']"
"[{'source_node': {'name': 'GLA'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'fabry disease'}}, {'source_node': {'name': 'GLA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glycosphingolipid metabolism'}}, {'source_node': {'name': 'alpha-galactosidase a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GLA'}}, {'source_node': {'name': '2,5-dideoxy-2,5-imino-d-altritol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucosylceramidase'}}, {'source_node': {'name': '2,5-dideoxy-2,5-imino-d-altritol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'alpha-galactosidase a'}}, {'source_node': {'name': 'glucosylceramidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GBA1'}}]","[{'source_node': {'name': 'GLA'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'fabry disease'}}, {'source_node': {'name': 'GLA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glycosphingolipid metabolism'}}, {'source_node': {'name': 'alpha-galactosidase a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GLA'}}, {'source_node': {'name': '2,5-dideoxy-2,5-imino-d-altritol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucosylceramidase'}}, {'source_node': {'name': '2,5-dideoxy-2,5-imino-d-altritol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'alpha-galactosidase a'}}, {'source_node': {'name': '2,5-dideoxy-2,5-imino-d-altritol'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'GBA1'}}, {'source_node': {'name': 'glucosylceramidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GBA1'}}, {'source_node': {'name': 'glucosylceramidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GLA'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:2870', 'target': 'GENE:28079', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'COMPOUND:82291', 'target': 'GENE:27886', 'metadata': {'predicate': 'is_affecting'}}]",0.8461538461538461,dfadcb7fa6671ab5650653bca3815742,f512a81e8126307f9163e1e8a06beef2,"[""The enzyme alpha-galactosidase A, which is a gene product of GLA, plays a role in Glycosphingolipid metabolism. It's important to note that aberrations in GLA can lead to Fabry disease. Furthermore, the compound 2,5-dideoxy-2,5-imino-d-altritol targets two enzymes: glucosylceramidase and alpha-galactosidase A. Glucosylceramidase is a gene product of GBA1. This interconnected network of genes, enzymes, and compounds underline critical interactions in our biological systems.""]",[]
"[{'source_node': {'name': 'weill-marchesani syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'pulmonic stenosis'}}, {'source_node': {'name': 'ADAMTS10'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'weill-marchesani syndrome'}}, {'source_node': {'name': 'ADAMTS10'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Defective B3GALTL causes PpS'}}, {'source_node': {'name': 'ADAMTS10'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'O-glycosylation of TSR domain-containing proteins'}}]","[{'source_node': {'name': 'weill-marchesani syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'pulmonic stenosis'}}]","[{'type': 'node_removal', 'source': 'GENE:34156', 'target': None, 'metadata': {'node_id': '34156', 'node_type': 'GENE', 'display_name': 'ADAMTS10'}}]",0.3333333333333333,308072db02a899fc695ce366abcc0443,a75797760078a0a9018bd5f73321dbcc,"['The gene ADAMTS10, which functions within the pathways of Defective B3GALTL causes PpS and O-glycosylation of TSR domain-containing proteins, is known to cause Weill-Marchesani syndrome. Notably, Weill-Marchesani syndrome is characterized by the presence of certain clinical features, such as pulmonic stenosis.', 'The gene ADAMTS10, which acts within the pathways of Defective B3GALTL causing PpS and the O-glycosylation of TSR domain-containing proteins, is identified as the cause of Weill-Marchesani syndrome. This syndrome exhibits various phenotypes including pulmonic stenosis among others.']",[]
"[{'source_node': {'name': 'multiple sulfatase deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'rapid neurologic deterioration'}}, {'source_node': {'name': 'multiple sulfatase deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ichthyosis'}}]","[{'source_node': {'name': 'multiple sulfatase deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'rapid neurologic deterioration'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:5109', 'target': None, 'metadata': {'node_id': '5109', 'node_type': 'PHENOTYPE', 'display_name': 'ichthyosis'}}]",0.6,137a7461998387d7e359ba97d6786425,ea12a6788dd843693691ef864d941643,[],[]
"[{'source_node': {'name': 'ACHE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of PC'}}, {'source_node': {'name': 'ACHE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis, secretion, and deacylation of Ghrelin'}}, {'source_node': {'name': 'acetylcholinesterase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACHE'}}, {'source_node': {'name': 'amine oxidase [flavin-containing] b'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MAOB'}}, {'source_node': {'name': 'corymbiferin 1-o-glucoside'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'acetylcholinesterase'}}, {'source_node': {'name': 'corymbiferin 1-o-glucoside'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'amine oxidase [flavin-containing] b'}}]","[{'source_node': {'name': 'ACHE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of PC'}}, {'source_node': {'name': 'ACHE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis, secretion, and deacylation of Ghrelin'}}, {'source_node': {'name': 'MAOB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of PC'}}, {'source_node': {'name': 'acetylcholinesterase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACHE'}}, {'source_node': {'name': 'amine oxidase [flavin-containing] b'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MAOB'}}, {'source_node': {'name': 'corymbiferin 1-o-glucoside'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'acetylcholinesterase'}}, {'source_node': {'name': 'corymbiferin 1-o-glucoside'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'amine oxidase [flavin-containing] b'}}, {'source_node': {'name': 'corymbiferin 1-o-glucoside'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'MAOB'}}, {'source_node': {'name': 'corymbiferin 1-o-glucoside'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'ACHE'}}]","[{'type': 'edge_addition', 'source': 'GENE:29855', 'target': 'PATHWAY:606', 'metadata': {'predicate': 'acts_within'}}, {'type': 'edge_addition', 'source': 'COMPOUND:70554', 'target': 'GENE:29855', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'COMPOUND:70554', 'target': 'GENE:29952', 'metadata': {'predicate': 'is_affecting'}}]",0.7692307692307692,d74263439139ba9f9d5c16ee80c3467f,7a94f79f575721208cae6e475ef5e308,[],[]
"[{'source_node': {'name': 'velaglucerase alfa'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucosylceramidase'}}, {'source_node': {'name': 'velaglucerase alfa'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'glucosylceramidase beta'}}, {'source_node': {'name': 'GBA1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'dementia'}}, {'source_node': {'name': 'GBA1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hereditary late-onset parkinson disease'}}, {'source_node': {'name': 'glucosylceramidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GBA1'}}]","[{'source_node': {'name': 'velaglucerase alfa'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucosylceramidase'}}, {'source_node': {'name': 'GBA1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'dementia'}}, {'source_node': {'name': 'GBA1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hereditary late-onset parkinson disease'}}, {'source_node': {'name': 'glucosylceramidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GBA1'}}]","[{'type': 'node_removal', 'source': 'GENE:6985', 'target': None, 'metadata': {'node_id': '6985', 'node_type': 'GENE', 'display_name': 'glucosylceramidase beta'}}]",0.8181818181818181,e57ebf3ffb7c1af3e103e89692e2614f,d9bfca40142f15efdfd37a9e8a7d7456,"[""The substance velaglucerase alfa has been found to target glucosylceramidase and is also affecting its beta isoform, glucosylceramidase beta. Interestingly, glucosylceramidase is a gene product of GBA1. This gene GBA1 is known to cause several conditions including dementia and hereditary late-onset Parkinson's disease.""]","['The drug Velaglucerase Alfa targets glucosylceramidase, which is a gene product of the GBA1 gene. This GBA1 gene, with its relation to glucosylceramidase, is known to cause conditions such as dementia and hereditary late-onset Parkinson disease.', ""The drug Velaglucerase alfa targets the glucosylceramidase enzyme, which is a gene product of the GBA1 gene. The GBA1 gene is linked with causing several conditions including dementia and hereditary late-onset Parkinson's disease."", 'The drug Velaglucerase alfa targets glucosylceramidase, a gene product of GBA1. Interestingly, the GBA1 gene is known to cause conditions such as dementia and hereditary late-onset parkinson disease.', 'The drug Velaglucerase Alfa targets glucosylceramidase, which is a gene product of GBA1. The gene GBA1 is known to cause several conditions, such as dementia and hereditary late-onset Parkinson disease.', ""The drug Velaglucerase Alfa targets the Glucosylceramidase, which is a gene product of GBA1. It's notable that GBA1 is known to cause conditions such as dementia and hereditary late-onset Parkinson disease.""]"
"[{'source_node': {'name': 'imagabalin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' sedation '}}, {'source_node': {'name': 'imagabalin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'yohimbine'}}, {'source_node': {'name': 'imagabalin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'lofexidine'}}, {'source_node': {'name': 'yohimbine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prolactin-releasing peptide receptor'}}, {'source_node': {'name': 'yohimbine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}}]","[{'source_node': {'name': 'imagabalin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' sedation '}}, {'source_node': {'name': 'imagabalin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'yohimbine'}}, {'source_node': {'name': 'imagabalin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'lofexidine'}}, {'source_node': {'name': 'imagabalin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}}, {'source_node': {'name': 'imagabalin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prolactin-releasing peptide receptor'}}, {'source_node': {'name': 'yohimbine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prolactin-releasing peptide receptor'}}, {'source_node': {'name': 'yohimbine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}}, {'source_node': {'name': 'yohimbine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imagabalin'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1333', 'target': 'COMPOUND:10014', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:10014', 'target': 'GENE:4352', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'COMPOUND:10014', 'target': 'PROTEIN:6207', 'metadata': {'predicate': 'has_target'}}]",0.7272727272727273,c43a0fd4c9b6a3546e4a3285c83739f6,b1004c044482906f01640fe9e8de5b54,[],[]
"[{'source_node': {'name': 'bryant-li-bhoj neurodevelopmental syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'microcephaly'}}, {'source_node': {'name': 'bryant-li-bhoj neurodevelopmental syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'joint laxity'}}, {'source_node': {'name': 'bryant-li-bhoj neurodevelopmental syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'deep philtrum'}}]","[{'source_node': {'name': 'bryant-li-bhoj neurodevelopmental syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'joint laxity'}}, {'source_node': {'name': 'bryant-li-bhoj neurodevelopmental syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'deep philtrum'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:211', 'target': None, 'metadata': {'node_id': '211', 'node_type': 'PHENOTYPE', 'display_name': 'microcephaly'}}]",0.7142857142857143,7e5024981bffd048010e35643d19e7f9,8c48e4c542b6a247cb32361a7615a576,"['Bryant-Li-Bhoj Neurodevelopmental Syndrome 1 is associated with several phenotypes. Some of these consist of microcephaly, a condition characterized by a smaller than normal head size, joint laxity, referring to joints that are looser or more flexible than normal, as well as deep philtrum which is a more pronounced groove between the nose and the upper lip.', 'Bryant-Li-Bhoj neurodevelopmental syndrome 1 is a condition that has several phenotypes, including microcephaly, joint laxity, and a deep philtrum.', 'Bryant-Li-Bhoj Neurodevelopmental Syndrome 1, a complex condition, manifests several characteristic symptoms including microcephaly, joint laxity, and a distinct deep philtrum.', 'Bryant-Li-Bhoj Neurodevelopmental Syndrome 1 has several associated phenotypes, including microcephaly, joint laxity, and a deep philtrum. These physical manifestations are characteristic to individuals diagnosed with this syndrome.', 'Bryant-Li-Bhoj neurodevelopmental syndrome 1 is characterized by several phenotypes including microcephaly, joint laxity, and the presence of a deep philtrum.']","['Bryant-Li-Bhoj Neurodevelopmental Syndrome 1 is a medical condition that demonstrates various physical characteristics such as joint laxity and a deep philtrum.', 'Bryant-Li-Bhoj Neurodevelopmental Syndrome 1, a rare genetic disorder, is characterized by several phenotypic traits including joint laxity and a deep philtrum.', 'Bryant-Li-Bhoj Neurodevelopmental Syndrome 1 is a condition which has several phenotypic traits including joint laxity and a distinguishing deep philtrum.']"
"[{'source_node': {'name': 'deacetylnimbin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}, {'source_node': {'name': 'deacetylnimbin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'deacetylnimbin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-br-3'}}]","[{'source_node': {'name': 'deacetylnimbin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-br-3'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4951', 'target': None, 'metadata': {'node_id': '4951', 'node_type': 'PROTEIN', 'display_name': 'hl-60'}}, {'type': 'node_removal', 'source': 'PROTEIN:5849', 'target': None, 'metadata': {'node_id': '5849', 'node_type': 'PROTEIN', 'display_name': 'a549'}}]",0.4285714285714286,8ba6a216884dbe9221bed71880c97172,7dc7e9b550cf253221544b734fc0a138,"['Deacetylnimbin, a notable compound often studied for its medical properties, has been identified to target several specific cell lines. These include HL-60, a cell line used primarily in the research of leukemia, as well as A549 and SK-BR-3, which are often utilized in lung and breast cancer studies, respectively.', 'The compound deacetylnimbin acts on several cellular targets, including HL-60, A549, and SK-BR-3.', 'The compound deacetylnimbin targets various cells including HL-60, A549, and SK-BR-3.', 'The compound deacetylnimbin has several biological targets, including HL-60, a human promyelocytic leukemia cell line, A549, a human lung carcinoma cell line, and SK-BR-3, a human breast cancer cell line.', 'The compound deacetylnimbin has been found to target various cell lines. These include HL-60, A549, and SK-BR-3.']",[]
"[{'source_node': {'name': 'propatyl nitrate'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hypotensive and vasodilatory activities '}}, {'source_node': {'name': 'propatyl nitrate'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hypotensive activities '}}, {'source_node': {'name': 'propatyl nitrate'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}]","[{'source_node': {'name': 'propatyl nitrate'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hypotensive and vasodilatory activities '}}]","[{'type': 'node_removal', 'source': 'ACTIVITY:17', 'target': None, 'metadata': {'node_id': '17', 'node_type': 'ACTIVITY', 'display_name': ' the hypotensive activities '}}, {'type': 'node_removal', 'source': 'EFFECT:5', 'target': None, 'metadata': {'node_id': '5', 'node_type': 'EFFECT', 'display_name': ' adverse effects '}}]",0.4285714285714286,95094ebbb09ead5548a06565f7c2435b,91f3e2cc5b1090258ca87dd0f8cda86f,[],[]
"[{'source_node': {'name': 'LETM1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neurodegeneration'}}, {'source_node': {'name': 'LETM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Mitochondrial calcium ion transport'}}]","[{'source_node': {'name': 'LETM1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neurodegeneration'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:582', 'target': None, 'metadata': {'node_id': '582', 'node_type': 'PATHWAY', 'display_name': 'Mitochondrial calcium ion transport'}}]",0.6,2c64b745e6136c1280d8c03400206a8b,de4a01f195355de7a9b62b3c7daba29c,"['The gene LETM1, which is operational within the mitochondrial calcium ion transport process, is known to cause a condition leading to neurodegeneration.', 'The gene LETM1, which is involved in mitochondrial calcium ion transport, has been found to cause neurodegeneration.', 'The gene LETM1, which functions within the mitochondrial calcium ion transport pathway, is known to cause the condition of neurodegeneration.', 'The protein coded by the LETM1 gene acts within the pathway responsible for mitochondrial calcium ion transport. Additionally, changes or alterations in LETM1 have been observed to cause neurodegeneration, a broad term referring to the progressive loss of structure or function of neurons.', 'The gene LETM1, which is involved in the process of mitochondrial calcium ion transport, is known to cause a condition known as neurodegeneration.']",['The gene LETM1 is known to cause a condition known as neurodegeneration.']
"[{'source_node': {'name': 'alacrima'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'feeding difficulties'}}, {'source_node': {'name': 'GMPPA'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'alacrima'}}, {'source_node': {'name': 'GMPPA'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'triple a syndrome'}}, {'source_node': {'name': 'GMPPA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of GDP-mannose'}}, {'source_node': {'name': 'triple a syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'microcephaly'}}, {'source_node': {'name': 'triple a syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of the calf musculature'}}, {'source_node': {'name': 'triple a syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'developmental regression'}}]","[{'source_node': {'name': 'alacrima'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'feeding difficulties'}}, {'source_node': {'name': 'GMPPA'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'alacrima'}}, {'source_node': {'name': 'GMPPA'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'triple a syndrome'}}, {'source_node': {'name': 'triple a syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'developmental regression'}}, {'source_node': {'name': 'triple a syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'feeding difficulties'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1070', 'target': None, 'metadata': {'node_id': '1070', 'node_type': 'PHENOTYPE', 'display_name': 'abnormality of the calf musculature'}}, {'type': 'edge_addition', 'source': 'DISEASE:4482', 'target': 'PHENOTYPE:8363', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'node_removal', 'source': 'PATHWAY:1733', 'target': None, 'metadata': {'node_id': '1733', 'node_type': 'PATHWAY', 'display_name': 'Synthesis of GDP-mannose'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:211', 'target': None, 'metadata': {'node_id': '211', 'node_type': 'PHENOTYPE', 'display_name': 'microcephaly'}}]",0.5333333333333333,ce006ec02893f902793b687f6570ec06,595a9a2e7f78715e0098f98cbf2b6b00,[],"['The gene GMPPA causes a condition known as alacrima, which presents a phenotype of feeding difficulties. Furthermore, GMPPA is also responsible for a condition called triple A syndrome. Notably, this syndrome is characterized by distinctive phenotypes such as feeding difficulties and developmental regression.', 'GMPPA, a gene, is known to be associated with the conditions of alacrima and triple A syndrome. Alacrima is characterized by a distinct phenotype, primarily involving feeding difficulties. Similarly, triple A syndrome also displays a phenotype that encompasses developmental regression and feeding difficulties. This clearly establishes the critical roles GMPPA plays in these conditions characterized by such diverse symptoms.', 'The GMPPA gene is known to cause certain conditions such as alacrima and triple A syndrome. Alacrima is a condition characterized by phenotypes such as feeding difficulties. On the other hand, triple A syndrome is a condition characterized by phenotypes like developmental regression and feeding difficulties.', 'The gene GMPPA is linked to a number of conditions including alacrima and triple a syndrome. Specifically, alacrima, which results in feeding difficulties, is caused by mutations in the GMPPA gene. Triple a syndrome, another condition associated with GMPPA, is characterized by symptoms such as developmental regression and feeding difficulties.', 'The gene GMPPA is known to cause conditions such as alacrima, and triple a syndrome. Alacrima is characterized by specific phenotypes including feeding difficulties. Triple a syndrome is also associated with several symptoms, notable among them are feeding difficulties and developmental regression.']"
"[{'source_node': {'name': 'MMP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Basigin interactions'}}, {'source_node': {'name': 'methylamino-phenylalanyl-leucyl-hydroxamic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'interstitial collagenase'}}, {'source_node': {'name': 'methylamino-phenylalanyl-leucyl-hydroxamic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'neutrophil collagenase'}}, {'source_node': {'name': 'neutrophil collagenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MMP8'}}, {'source_node': {'name': 'interstitial collagenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MMP1'}}]","[{'source_node': {'name': 'MMP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Basigin interactions'}}, {'source_node': {'name': 'methylamino-phenylalanyl-leucyl-hydroxamic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'interstitial collagenase'}}, {'source_node': {'name': 'methylamino-phenylalanyl-leucyl-hydroxamic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'neutrophil collagenase'}}, {'source_node': {'name': 'methylamino-phenylalanyl-leucyl-hydroxamic acid'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'MMP1'}}, {'source_node': {'name': 'interstitial collagenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MMP1'}}]","[{'type': 'node_removal', 'source': 'GENE:29963', 'target': None, 'metadata': {'node_id': '29963', 'node_type': 'GENE', 'display_name': 'MMP8'}}, {'type': 'edge_addition', 'source': 'COMPOUND:7393', 'target': 'GENE:29959', 'metadata': {'predicate': 'is_affecting'}}]",0.7272727272727273,870a820ae77706dca438e8b7649aadd1,878760c138c2aa15b1eea3e079fc1953,"['The gene MMP1 is known to act within the biochemical pathway of Basigin interactions. The compound methylamino-phenylalanyl-leucyl-hydroxamic acid has two notable targets: interstitial collagenase and neutrophil collagenase. Notably, interstitial collagenase is a gene product of MMP1, whereas neutrophil collagenase is a gene product of MMP8. This connects the targets of the compound to the original gene, MMP1, thorough the medium of Basigin interactions.', 'The drug methylamino-phenylalanyl-leucyl-hydroxamic acid has multiple targets, including interstitial collagenase and neutrophil collagenase. Interestingly, these targets are gene products of MMP1 and MMP8, respectively. MMP1, in particular, has been implicated to act within the Basigin interactions pathway.', 'The gene MMP1 is involved in the basigin interactions pathway, while the compound methylamino-phenylalanyl-leucyl-hydroxamic acid targets both interstitial collagenase and neutrophil collagenase. These two collagenases are gene products of MMP1 and MMP8 respectively.']",[]
"[{'source_node': {'name': 'metolazone'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' hypotension '}}, {'source_node': {'name': 'metolazone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phenformin'}}, {'source_node': {'name': 'metolazone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lofentanil'}}, {'source_node': {'name': 'phenformin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'timolol'}}]","[{'source_node': {'name': 'lofentanil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'timolol'}}, {'source_node': {'name': 'metolazone'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' hypotension '}}, {'source_node': {'name': 'metolazone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phenformin'}}, {'source_node': {'name': 'metolazone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lofentanil'}}, {'source_node': {'name': 'phenformin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'timolol'}}, {'source_node': {'name': 'phenformin'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' hypotension '}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:897', 'target': 'EFFECT:36', 'metadata': {'predicate': 'increase_effect'}}, {'type': 'edge_addition', 'source': 'COMPOUND:8110', 'target': 'COMPOUND:362', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.7777777777777778,d74d50a3319212fc5021f40d777326a9,d0f45aa04b80a8a937f8fcb044ebac79,[],[]
"[{'source_node': {'name': 'vitamin b12-unresponsive methylmalonic acidemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'renal insufficiency'}}, {'source_node': {'name': 'vitamin b12-unresponsive methylmalonic acidemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cardiomyopathy'}}, {'source_node': {'name': 'vitamin b12-unresponsive methylmalonic acidemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'anemia'}}]","[{'source_node': {'name': 'vitamin b12-unresponsive methylmalonic acidemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'renal insufficiency'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1383', 'target': None, 'metadata': {'node_id': '1383', 'node_type': 'PHENOTYPE', 'display_name': 'anemia'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:1190', 'target': None, 'metadata': {'node_id': '1190', 'node_type': 'PHENOTYPE', 'display_name': 'cardiomyopathy'}}]",0.4285714285714286,1ee79eefac51f2ccca31b5e1636d900e,0410d7167cd0a74d36a626ca5dfe6b6e,"['Vitamin B12-unresponsive methylmalonic acidemia, a metabolic disorder, presents several symptoms or phenotypes such as renal insufficiency, cardiomyopathy and anemia.', 'Vitamin B12-unresponsive methylmalonic acidemia is a condition that expresses several phenotypes. This includes renal insufficiency, cardiomyopathy, and anemia.', 'Vitamin B12-unresponsive methylmalonic acidemia is a condition that presents several distinct phenotypes, including renal insufficiency, cardiomyopathy, and anemia.', 'The condition known as vitamin B12-unresponsive methylmalonic acidemia manifests with several symptoms or phenotypes. These phenotypes include renal insufficiency, cardiomyopathy, and anemia. Each of these symptoms plays a key role in the overall manifestation and diagnosis of the disease.', 'Vitamin B12-unresponsive methylmalonic acidemia is a condition that presents with several associated phenotypes, including renal insufficiency, cardiomyopathy, and anemia.']",['The disease called vitamin B12-unresponsive methylmalonic acidemia exhibits the phenotype of renal insufficiency.']
"[{'source_node': {'name': 'etacrynic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prelamin-a/c'}}, {'source_node': {'name': 'etacrynic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'werner syndrome atp-dependent helicase'}}, {'source_node': {'name': 'etacrynic acid'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Vision blurred'}}]","[{'source_node': {'name': 'etacrynic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'werner syndrome atp-dependent helicase'}}, {'source_node': {'name': 'etacrynic acid'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Vision blurred'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:6154', 'target': None, 'metadata': {'node_id': '6154', 'node_type': 'PROTEIN', 'display_name': 'prelamin-a/c'}}]",0.7142857142857143,e79b3e48d4278cd85709174ded33b7a9,bb8a9e3da1801aadc13ca7f2cc4a66ff,"['The drug etacrynic acid has multiple targets in the body, including prelamin-a/c and the Werner syndrome ATP-dependent helicase. However, one of its noted side effects is blurred vision.', ""The drug Etacrynic Acid targets both Prelamin-A/C and Werner Syndrome ATP-dependent Helicase. However, it's important to note that Etacrynic Acid may also have the side effect of causing blurred vision."", 'The drug etacrynic acid targets multiple proteins, which include prelamin-a/c and Werner syndrome ATP-dependent helicase. However, it should be noted that usage of etacrynic acid may have the side effect of blurred vision.', 'The medication etacrynic acid has multiple targets, including prelamin-a/c and the Werner syndrome ATP-dependent helicase. Additionally, a known side effect of etacrynic acid is blurred vision.', 'The drug etacrynic acid has several targets, including prelamin-A/C and the Werner syndrome ATP-dependent helicase. However, a side effect of etacrynic acid usage can be blurred vision.']","['The drug etacrynic acid targets an enzyme known as the Werner Syndrome ATP-dependent helicase. However, a notable side effect of etacrynic acid is blurred vision.', 'The drug Etacrynic acid has been found to target the Werner syndrome ATP-dependent helicase. However, one known side effect of Etacrynic acid is blurred vision.', 'The drug Etacrynic acid has several interactions within the body. It targets a specific protein known as the Werner syndrome ATP-dependent helicase. However, it should be noted that the use of this drug can also have the side effect of causing blurred vision.', 'The drug Etacrynic acid targets the Werner syndrome ATP-dependent helicase. However, a noted side effect of Etacrynic acid is blurred vision.', 'The drug Etacrynic Acid not only targets the Werner Syndrome ATP-dependent helicase but also has a known side effect of blurred vision.']"
"[{'source_node': {'name': 'FN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Extracellular matrix organization'}}, {'source_node': {'name': 'FN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Syndecan interactions'}}, {'source_node': {'name': 'FN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Signaling downstream of RAS mutants'}}]","[{'source_node': {'name': 'FN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Extracellular matrix organization'}}, {'source_node': {'name': 'FN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Signaling downstream of RAS mutants'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1123', 'target': None, 'metadata': {'node_id': '1123', 'node_type': 'PATHWAY', 'display_name': 'Syndecan interactions'}}]",0.7142857142857143,4d45a03fc903ea365b037c0f3bfdc598,0e91d13051971c00793bfb3971798d2a,"['FN1 is a gene that acts within several biological pathways. These include the extracellular matrix organization, interactions with syndecans, and downstream signaling of RAS mutants.', 'The gene FN1 participates in various processes. For instance, it acts within the organization of the extracellular matrix. It also plays a role in the interactions of syndecans. In addition, FN1 has been found to engage in signaling downstream of RAS mutants.', 'The gene FN1 has a role in several pathways. It is known to act within the organization of the extracellular matrix, take part in syndecan interactions, and also has a role in the signaling downstream of RAS mutants.']","['The gene FN1 acts within two different biological processes; it acts within both the extracellular matrix organization and signaling downstream of RAS mutants.', 'The gene FN1 plays a role in both extracellular matrix organization and signaling downstream of RAS mutants.', 'The gene FN1 is involved in the organization of the extracellular matrix, and also acts within the pathway of signaling downstream of RAS mutants.', 'The gene FN1 has a critical role in various cellular pathways. It has been identified to act within the extracellular matrix organization and is also involved in signaling downstream of RAS mutants.', 'The gene FN1 is found to act within several pathways. It plays a role in the organization of the extracellular matrix and is involved in signaling downstream of RAS mutants.']"
"[{'source_node': {'name': 'isolated complex i deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'microcephaly'}}, {'source_node': {'name': 'isolated complex i deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'diabetes mellitus'}}, {'source_node': {'name': 'isolated complex i deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'feeding difficulties'}}, {'source_node': {'name': 'NDUFB9'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'isolated complex i deficiency'}}, {'source_node': {'name': 'NDUFB9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Respiratory electron transport'}}, {'source_node': {'name': 'NDUFB9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Complex I biogenesis'}}]","[{'source_node': {'name': 'isolated complex i deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'microcephaly'}}, {'source_node': {'name': 'isolated complex i deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'diabetes mellitus'}}, {'source_node': {'name': 'isolated complex i deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'feeding difficulties'}}, {'source_node': {'name': 'NDUFB9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Respiratory electron transport'}}, {'source_node': {'name': 'NDUFB9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Complex I biogenesis'}}]","[{'type': 'edge_deletion', 'source': 'GENE:30233', 'target': 'DISEASE:3740', 'metadata': None}]",0.9230769230769232,0634b119b6d04ba444944f3fe618b33d,f1254dac26a98a4688d1162134a5c399,"['Isolated complex I deficiency, a condition caused by the gene NDUFB9, can be characterized by several phenotypes including microcephaly, diabetes mellitus, and feeding difficulties. It is worth noting that NDUFB9 acts within two biological processes, respiratory electron transport and Complex I biogenesis that are crucial for the proper functioning of cells.', 'The gene NDUFB9 is implicated in Respiratory electron transport and Complex I biogenesis. It is known to cause a condition characterized as isolated complex I deficiency. Notably, this condition is associated with several phenotypes including microcephaly, diabetes mellitus, and feeding difficulties.', 'The gene NDUFB9, which acts within the respiratory electron transport and complex I biogenesis pathways, is known to cause isolated complex I deficiency. This condition is characterized by a number of phenotypes, including microcephaly, diabetes mellitus, and feeding difficulties.', 'The gene NDUFB9 plays a crucial role in both the Respiratory Electron Transport and Complex I Biogenesis pathways. An anomaly or malfunction in NDUFB9 can cause a condition known as Isolated Complex I Deficiency. This condition presents phenotypes such as microcephaly, diabetes mellitus, and feeding difficulties.', 'Isolated Complex I deficiency, a condition caused by the NDUFB9 gene, can manifest a trio of phenotypes that include microcephaly, diabetes mellitus, and feeding difficulties. It should be noted that this gene is a key actor within the respiratory electron transport and Complex I biogenesis pathways.']","['Isolated Complex I Deficiency, a medical condition, has several notable symptoms or phenotypes, which include microcephaly, diabetes mellitus, and feeding difficulties. Understanding the biological underpinnings of this disease can provide insight into its phenotypic expressions. For instance, the NDUFB9 gene is known to act within two vital biological pathways - the Respiratory electron transport and Complex I biogenesis. Therefore, interactions and malfunctions within these pathways may contribute to the manifestation of the phenotypes associated with Isolated Complex I Deficiency.']"
"[{'source_node': {'name': 'laxiflorin j'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'k562'}}, {'source_node': {'name': 'laxiflorin j'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'laxiflorin j'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 't-24'}}]","[{'source_node': {'name': 'laxiflorin j'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'laxiflorin j'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 't-24'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4947', 'target': None, 'metadata': {'node_id': '4947', 'node_type': 'PROTEIN', 'display_name': 'k562'}}]",0.7142857142857143,2a4897890d67effa53ff27d9d2ca659f,4bba9faadc98f2b7e9662eaa4df792b6,"['The compound Laxiflorin J is identified to have multiple targets which include K562, A549 and T-24 cell lines.', 'The compound known as Laxiflorin J has been identified as having multiple targets. These targets include K562, A549, and T-24.', 'The drug, Laxiflorin J, targets several entities, including K562, A549, and T-24.', 'The substance laxiflorin J is found to target several cells including K562, A549, and T-24.', 'The compound Laxiflorin J has multiple targets including the cell lines K562, A549, and T-24.']","['The compound Laxiflorin J has been found to target both A549 and T-24 cells.', 'The compound Laxiflorin J is known to target both A549 and T-24 cell lines.', 'The drug laxiflorin J targets both A549 and T-24.', 'The compound Laxiflorin J is known to target both A549 and T-24 cells.', 'The compound known as Laxiflorin J has been shown to target A549 and T-24.']"
"[{'source_node': {'name': 'congenital contractures of the limbs and face'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'seizure'}}, {'source_node': {'name': 'congenital contractures of the limbs and face'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': '11 pairs of ribs'}}, {'source_node': {'name': 'congenital contractures of the limbs and face'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cerebral atrophy'}}]","[{'source_node': {'name': 'congenital contractures of the limbs and face'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'seizure'}}, {'source_node': {'name': 'congenital contractures of the limbs and face'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cerebral atrophy'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:686', 'target': None, 'metadata': {'node_id': '686', 'node_type': 'PHENOTYPE', 'display_name': '11 pairs of ribs'}}]",0.7142857142857143,bcdd75d919dc41282543817f24812a81,27eb4d64db6d3f25309507e5b99e41ae,"['Congenital contractures of the limbs and face, a condition manifested by symptoms such as seizures, the presence of 11 pairs of ribs instead of the usual 12, and cerebral atrophy.', 'The disorder known as congenital contractures of the limbs and face has several phenotypic characteristics. Patients with this condition often experience seizures and cerebral atrophy, and it is also typical for them to have 11 pairs of ribs, which is one less than the standard number in humans.', 'Congenital contractures of the limbs and face, a medical condition, presents several phenotypes which include seizures, the possession of 11 pairs of ribs and cerebral atrophy.', 'Congenital contractures of the limbs and face is a condition that presents various phenotypes such as seizures, having 11 pairs of ribs, and cerebral atrophy.']",[]
"[{'source_node': {'name': 'neural tube defects'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'absence of the sacrum'}}, {'source_node': {'name': 'FUZ'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neural tube defects'}}, {'source_node': {'name': 'FUZ'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'caudal regression syndrome'}}, {'source_node': {'name': 'FUZ'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': ""Hedgehog 'off' state""}}, {'source_node': {'name': 'caudal regression syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cryptorchidism'}}, {'source_node': {'name': 'caudal regression syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ambiguous genitalia'}}, {'source_node': {'name': 'caudal regression syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'arrhinencephaly'}}]","[{'source_node': {'name': 'neural tube defects'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'absence of the sacrum'}}, {'source_node': {'name': 'caudal regression syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cryptorchidism'}}, {'source_node': {'name': 'caudal regression syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ambiguous genitalia'}}, {'source_node': {'name': 'caudal regression syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'arrhinencephaly'}}]","[{'type': 'edge_deletion', 'source': 'GENE:33977', 'target': 'DISEASE:4275', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:33977', 'target': None, 'metadata': {'node_id': '33977', 'node_type': 'GENE', 'display_name': 'FUZ'}}]",0.6666666666666667,823c80beffc582f1bd84b10bf2a8d129,2e4cbf79dfcff0e49fdf652dc74efe23,[],"['Neural tube defects have a phenotype characterized by the absence of the sacrum. Caudal regression syndrome, on the other hand, presents with phenotypes such as cryptorchidism, ambiguous genitalia and arrhinencephaly.', 'Neural tube defects, a group of congenital anomalies of the central nervous system, have a phenotype characterized by the absence of the sacrum. Another condition, caudal regression syndrome, is characterized by several phenotypes, such as cryptorchidism, ambiguous genitalia, and arrhinencephaly.', 'Neural tube defects represent a group of disorders characterized by certain phenotypes, such as the absence of the sacrum. Another condition, known as caudal regression syndrome, can display a range of phenotypes like cryptorchidism, ambiguous genitalia, and arrhinencephaly. Each of these phenotypes represents a unique aspect of these particular forms of developmental disorders.', 'The neural tube defects are characterized by the absence of the sacrum. On the other hand, caudal regression syndrome presents with various phenotypes including cryptorchidism, ambiguous genitalia, and arrhinencephaly.']"
"[{'source_node': {'name': 'PLA2G1B'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Acyl chain remodelling of PC'}}, {'source_node': {'name': 'PLA2G1B'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Acyl chain remodelling of PE'}}, {'source_node': {'name': 'PLA2G1B'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of PA'}}, {'source_node': {'name': 'phospholipase a2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PLA2G2A'}}, {'source_node': {'name': 'phospholipase a2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PLA2G1B'}}, {'source_node': {'name': 'sarcophine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'phospholipase a2'}}, {'source_node': {'name': 'sarcophine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}, {'source_node': {'name': 'sarcophine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}]","[{'source_node': {'name': 'PLA2G1B'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Acyl chain remodelling of PC'}}, {'source_node': {'name': 'PLA2G1B'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Acyl chain remodelling of PE'}}, {'source_node': {'name': 'PLA2G1B'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of PA'}}, {'source_node': {'name': 'phospholipase a2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PLA2G2A'}}, {'source_node': {'name': 'sarcophine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'phospholipase a2'}}, {'source_node': {'name': 'sarcophine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}, {'source_node': {'name': 'sarcophine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}]","[{'type': 'edge_deletion', 'source': 'PROTEIN:1047', 'target': 'GENE:30995', 'metadata': None}]",0.9411764705882352,628d2474fca456061cd5232b912756a2,8182d00aac0af26c6166cc074748a179,[],[]
"[{'source_node': {'name': 'tregalizumab'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the thrombogenic activities '}}, {'source_node': {'name': 'tregalizumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'tregalizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imlifidase'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'erenumab'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'loncastuximab tesirine'}}]","[{'source_node': {'name': 'tregalizumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'erenumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imlifidase'}}, {'source_node': {'name': 'erenumab'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'loncastuximab tesirine'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'erenumab'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'loncastuximab tesirine'}}]","[{'type': 'node_removal', 'source': 'ACTIVITY:2', 'target': None, 'metadata': {'node_id': '2', 'node_type': 'ACTIVITY', 'display_name': ' the thrombogenic activities '}}, {'type': 'edge_deletion', 'source': 'COMPOUND:10943', 'target': 'COMPOUND:12843', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:11871', 'target': 'COMPOUND:12843', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11871', 'target': 'COMPOUND:13551', 'metadata': {'predicate': 'increase_efficacy'}}]",0.5454545454545454,f2c818e7235c1e0d0875d7ed170c5887,f907da84cb73f0c32ec34fb320a571c4,[],[]
"[{'source_node': {'name': 'PRIM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Activation of the pre-replicative complex'}}, {'source_node': {'name': 'PRIM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Polymerase switching'}}, {'source_node': {'name': 'PRIM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Defective pyroptosis'}}]","[{'source_node': {'name': 'PRIM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Defective pyroptosis'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:336', 'target': None, 'metadata': {'node_id': '336', 'node_type': 'PATHWAY', 'display_name': 'Activation of the pre-replicative complex'}}, {'type': 'node_removal', 'source': 'PATHWAY:808', 'target': None, 'metadata': {'node_id': '808', 'node_type': 'PATHWAY', 'display_name': 'Polymerase switching'}}]",0.4285714285714286,fb0542ba96d0229d9bababadfb53945c,d7716f52dd81a26bd1fc51831b2cb87d,"['The gene PRIM1 is involved in several processes. It acts within the activation of the pre-replicative complex and is crucial in the process of polymerase switching. Interestingly, PRIM1 is also found to act within defective pyroptosis, suggesting a diverse role in multiple cell processes.', 'The gene PRIM1 plays a significant role in various paths in cellular processes. It acts within the mechanism for the activation of the pre-replicative complex which sets the stage for DNA replication. Furthermore, PRIM1 also involves in the process of polymerase switching, a critical event in DNA replication and repair. Interestingly, PRIM1 also acts within the process of defective pyroptosis, enabling us to understand better its influence on programmed cell death.', 'The gene PRIM1 has a role in several processes including the activation of the pre-replicative complex, polymerase switching, and even in defective pyroptosis.']",[]
"[{'source_node': {'name': 'olfactory receptor family 4 subfamily d member 6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neutropenia'}}, {'source_node': {'name': 'olfactory receptor family 4 subfamily d member 6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'carcinoma'}}]","[{'source_node': {'name': 'olfactory receptor family 4 subfamily d member 6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'carcinoma'}}]","[{'type': 'node_removal', 'source': 'DISEASE:14592', 'target': None, 'metadata': {'node_id': '14592', 'node_type': 'DISEASE', 'display_name': 'neutropenia'}}]",0.6,7a63dd897a14d1aedf48de677fcc5fb7,9f9ab9ab8aa62b66fcc3ebc8db4b811e,"['The gene, olfactory receptor family 4 subfamily d member 6, is associated with causing certain conditions, notably neutropenia and carcinoma.', 'The gene known as olfactory receptor family 4 subfamily d member 6 plays a significant role in the causation of several conditions. Notably, it instigates the occurrence of neutropenia, as well as carcinoma, providing a link between these conditions and the workings of this specific olfactory receptor.', 'The olfactory receptor family 4 subfamily D member 6, a complex protein structure, is known to cause certain health conditions. It is linked to neutropenia, a condition characterized by abnormally low levels of white blood cells, and also contributes to the development of carcinoma, a type of cancer.', 'The gene known as olfactory receptor family 4 subfamily d member 6 is implicated in causing several conditions, including neutropenia and carcinoma.', 'The gene known as olfactory receptor family 4 subfamily d member 6 is known to cause certain conditions, namely neutropenia and carcinoma.']",[]
"[{'source_node': {'name': 'TINF2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Telomere C-strand synthesis initiation'}}, {'source_node': {'name': 'TINF2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'DNA Damage/Telomere Stress Induced Senescence'}}, {'source_node': {'name': 'TINF2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Inhibition of DNA recombination at telomere'}}]","[{'source_node': {'name': 'TINF2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'DNA Damage/Telomere Stress Induced Senescence'}}, {'source_node': {'name': 'TINF2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Inhibition of DNA recombination at telomere'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:81', 'target': None, 'metadata': {'node_id': '81', 'node_type': 'PATHWAY', 'display_name': 'Telomere C-strand synthesis initiation'}}]",0.7142857142857143,9cd716d0c5f26dd3dcf58d95d96de880,fa81389a5856afeee186665ea13e2c0c,[],"['The gene TINF2 operates within two distinct pathways. The first is the DNA Damage/Telomere Stress Induced Senescence pathway which handles cellular aging and genetic stability. The second is the pathway for the Inhibition of DNA recombination at telomeres which prevents unwanted genetic combinations at the ends of our chromosomes. These pathways highlight the essential role of TINF2 in maintaining genetic fidelity and longevity.', 'The gene TINF2 participates in two crucial pathways: the DNA Damage/Telomere Stress Induced Senescence and inhibition of DNA recombination at the telomere.', 'The gene TINF2 acts within two significant pathways: the DNA Damage/Telomere Stress Induced Senescence and the inhibition of DNA recombination at the telomere.', 'The gene TINF2 plays a role in several processes such as the DNA damage/telomere stress induced senescence and the inhibition of DNA recombination at the telomere.', 'The gene TINF2 is involved in various processes, notably the DNA damage/telomere stress induced senescence and the inhibition of DNA recombination at the telomere.']"
"[{'source_node': {'name': 'cephalosporin analog'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'amobarbital'}}, {'source_node': {'name': 'cephalosporin analog'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pheneturide'}}, {'source_node': {'name': 'cephalosporin c'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methohexital'}}, {'source_node': {'name': 'cephalosporin c'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'paramethadione'}}, {'source_node': {'name': 'cephalosporin c'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tramiprosate'}}, {'source_node': {'name': 'valpromide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cephalosporin analog'}}, {'source_node': {'name': 'valpromide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cephalosporin c'}}, {'source_node': {'name': 'valpromide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phenothiazine'}}]","[{'source_node': {'name': 'cephalosporin analog'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'amobarbital'}}, {'source_node': {'name': 'cephalosporin analog'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pheneturide'}}, {'source_node': {'name': 'cephalosporin c'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methohexital'}}, {'source_node': {'name': 'cephalosporin c'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'paramethadione'}}, {'source_node': {'name': 'cephalosporin c'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tramiprosate'}}, {'source_node': {'name': 'valpromide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phenothiazine'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:3921', 'target': 'COMPOUND:3123', 'metadata': None}, {'type': 'edge_deletion', 'source': 'COMPOUND:3921', 'target': 'COMPOUND:2027', 'metadata': None}]",0.8823529411764706,3bcf43fe5f43404bffb21d3d1fc9d237,f1a518f7d393c32a3243c85132a47b25,"['The use of cephalosporin analog and cephalosporin c can decrease the efficacy of several other drugs. Specifically, the cephalosporin analog has been found to impact the effectiveness of drugs such as amobarbital and pheneturide. Similarly, cephalosporin c diminishes the efficacy of methohexital, paramethadione, and tramiprosate. On the other hand, when valpromide is administered, it decreases the effectiveness of drugs like cephalosporin analog, cephalosporin c, and phenothiazine. Therefore, it is vital to consider these interactions when prescribing and using these medications.', 'The drug cephalosporin analog decreases the efficacy of both amobarbital and pheneturide. Similarly, cephalosporin c, another drug, decreases the efficacy of methohexital, paramethadione, and tramiprosate. On the other hand, valpromide, another medication, decreases the efficacy of cephalosporin analog, cephalosporin c, and phenothiazine. All these interactions should be taken into consideration while prescribing these medications together.', 'The drug cephalosporin analog is known to decrease the efficacy of both amobarbital and pheneturide. Similarly, another variant, cephalosporin c, can diminish the effectiveness of methohexital, paramethadione, and tramiprosate. On the other hand, valpromide, a different drug, decreases the efficacy of not only cephalosporin analog but also cephalosporin c and phenothiazine. Hence, care must be taken when these drugs are used in combination, as their effectiveness can be compromised.', 'The drug cephalosporin analog has the effect of decreasing the efficacy of both amobarbital and pheneturide. Similarly, cephalosporin c also decreases the efficacy of methohexital, paramethadione, and tramiprosate. Valpromide, another drug, can reduce the effectiveness of cephalosporin analog, cephalosporin c, and phenothiazine. Thus, the interaction and co-administration of these drugs, and potentially other medications in the cephalosporin class, need to be carefully considered.', 'The efficacy of several drugs is known to be decreased by other compounds. Cephalosporin analog, for example, is capable of diminishing the effectiveness of both amobarbital and pheneturide. Cephalosporin C shares this characteristic as well, as it can decrease the efficacy of methohexital, paramethadione, and tramiprosate. Interestingly, this property is not unique to cephalosporins. Valpromide, another drug, also has this effect on cephalosporin analog and cephalosporin C. Furthermore, valpromide can decrease the efficacy of phenothiazine, another medication. Therefore, careful consideration must be given when these drugs are prescribed together to avoid potential negative impacts on treatment outcomes.']","['Cephalosporin analog and Cephalosporin C, both types of antibiotics, are known to decrease the efficacy of certain drugs. For instance, Cephalosporin analog can reduce the effectiveness of Amobarbital and Pheneturide. Similarly, Cephalosporin C compromises the efficacy of Methohexital, Paramethadione, and Tramiprosate. Additionally, the drug Valpromide decreases the efficacy of Phenothiazine, a medication typically used to treat psychological disorders.', ""The pharmaceutical compounds, cephalosporin analog and cephalosporin C, have been found to decrease the efficacy of certain medications. Cephalosporin analog notably decreases the effectiveness of both amobarbital and pheneturide. Meanwhile, cephalosporin C similarly impacts the efficacy of methohexital, paramethadione, and tramiprosate. It's important to note these interactions, as co-administration could diminish the desired therapeutic effect of these medications. An unrelated compound, valpromide, also has the potential to decrease the effectiveness of phenothiazine. As a result, further research and careful drug administration planning is necessary to ensure patient safety and optimal treatment effectiveness. \n"", 'The use of certain drugs, such as a cephalosporin analog, can decrease the efficacy of other medicines, like amobarbital and pheneturide. Similarly, cephalosporin C, another variant of the drug, has been found to reduce the effectivity of methohexital, paramethadione, and tramiprosate. In addition to these, valpromide, yet another medication, could potentially weaken the impact of phenothiazine. Therefore, careful consideration must be taken when these drugs are prescribed together to ensure optimal treatment outcomes.', 'The cephalosporin analog, a type of antibiotic, is known to decrease the efficacy of certain drugs such as amobarbital and pheneturide. Another related compound, cephalosporin C, also displays a similar effect on drugs including methohexital, paramethadione, and tramiprosate, reducing their effectiveness. Furthermore, the medication valpromide has been found to lower the efficacy of the drug phenothiazine. This shows the potential interactions and impacts these substances have on each other and highlights the importance of considering drug interactions in pharmaceutical and medical fields.', 'The use of therapeutic drugs, such as cephalosporin analog and cephalosporin C, can sometimes lead to decreased efficacy of a number of other medications. The cephalosporin analog, for instance, is known to decrease the efficacy of both amobarbital and pheneturide. Similarly, cephalosporin C can reduce the effectiveness of methohexital, paramethadione, and tramiprosate. Moreover, valpromide is also noted to weaken the therapeutic purpose of phenothiazine. These interactions between drugs emphasize the importance of understanding the complex interactions in pharmacotherapy.']"
"[{'source_node': {'name': '3-hydroxy-3-methylglutaryl-coenzyme a reductase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HMGCR'}}, {'source_node': {'name': 'HMGCR'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cholesterol biosynthesis'}}, {'source_node': {'name': 'HMGCR'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'PPARA activates gene expression'}}, {'source_node': {'name': 'HMGCR'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Activation of gene expression by SREBF (SREBP)'}}]","[{'source_node': {'name': '3-hydroxy-3-methylglutaryl-coenzyme a reductase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HMGCR'}}, {'source_node': {'name': 'HMGCR'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cholesterol biosynthesis'}}, {'source_node': {'name': 'HMGCR'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Activation of gene expression by SREBF (SREBP)'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:39', 'target': None, 'metadata': {'node_id': '39', 'node_type': 'PATHWAY', 'display_name': 'PPARA activates gene expression'}}]",0.7777777777777778,3f77dbc7185d418bd619b18b1dfff20e,2882df2c921e44189559220333711b7b,"['The enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase is a gene product of HMGCR. The HMGCR gene is active within several processes such as cholesterol biosynthesis and the activation of gene expression by SREBF (SREBP). Additionally, HMGCR is involved in the process by which PPARA activates gene expression.', 'The enzyme 3-hydroxy-3-methylglutaryl-coenzyme a reductase is a gene product of HMGCR. This gene is known to act within several pathways including cholesterol biosynthesis, PPARA activated gene expression, and the activation of gene expression by SREBF (SREBP).']","['The enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase is the gene product of HMGCR. HMGCR actively participates in crucial pathways such as cholesterol biosynthesis and the activation of gene expression by SREBF (SREBP).', 'The enzyme 3-hydroxy-3-methylglutaryl-coenzyme a reductase is a gene product of HMGCR. This gene HMGCR acts within multiple biological pathways: it is involved in cholesterol biosynthesis and it also plays a crucial role in the activation of gene expression by SREBF (SREBP).', 'The enzyme 3-hydroxy-3-methylglutaryl-coenzyme a reductase is a gene product of HMGCR. This gene is particularly active within two crucial biochemical pathways: cholesterol biosynthesis and activation of gene expression by SREBF (SREBP).']"
"[{'source_node': {'name': 'bevacizumab'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'thymidine phosphorylase'}}, {'source_node': {'name': 'bevacizumab'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'hypertension'}}]","[{'source_node': {'name': 'bevacizumab'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'thymidine phosphorylase'}}]","[{'type': 'edge_addition', 'source': 'GENE:22794', 'target': 'DISEASE:13810', 'metadata': {'predicate': 'causes_condition'}}, {'type': 'node_removal', 'source': 'DISEASE:13810', 'target': None, 'metadata': {'node_id': '13810', 'node_type': 'DISEASE', 'display_name': 'hypertension'}}]",0.6,5ac81e96abe602f0e4c1ac9bfb648a67,4a12189ad466ac75d31a5b2c83e4e2cb,"['Bevacizumab is known to affect the function of an enzyme called thymidine phosphorylase. In addition to this, Bevacizumab is also a substance that has been used in the treatment of hypertension.', 'The drug Bevacizumab has several impacts on the body including affecting the enzyme thymidine phosphorylase. Additionally, Bevacizumab is recognized as a substance that treats hypertension, a common cardiovascular condition.', 'The drug Bevacizumab is affecting the activity of an enzyme known as thymidine phosphorylase. Furthermore, Bevacizumab is a substance that effectively treats hypertension, a common yet serious medical condition characterized by chronically elevated blood pressure.']",[]
"[{'source_node': {'name': 'gallium nitrate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'modified vaccinia ankara'}}, {'source_node': {'name': 'gallium nitrate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'moderna covid-19 vaccine'}}]","[{'source_node': {'name': 'gallium nitrate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'moderna covid-19 vaccine'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:13015', 'target': None, 'metadata': {'node_id': '13015', 'node_type': 'COMPOUND', 'display_name': 'modified vaccinia ankara'}}]",0.6,9691ab897eb653ddf932885e7cb29969,c17de881b3408be60f83b20c8c3a6d93,"['The drug Gallium Nitrate is observed to decrease the efficacy of both the Modified Vaccinia Ankara and the Moderna covid-19 vaccine. This suggests the importance of careful consideration when co-administering gallium nitrate in conjunction with these vaccines.', 'The drug gallium nitrate can decrease the efficacy of some vaccines such as the modified vaccinia Ankara and the Moderna COVID-19 vaccine.', 'Gallium nitrate, a commonly used substance, has been found to decrease the efficacy of certain vaccines. Particularly, it negatively impacts the potency of both Modified Vaccinia Ankara and the Moderna COVID-19 vaccine, leading to a reduction in their overall effectiveness.', 'Gallium nitrate has been found to decrease the efficacy of different vaccines. This not only includes the Modified Vaccinia Ankara but also extends to the Moderna COVID-19 vaccine.', 'The drug Gallium nitrate has been observed to decrease the efficacy of certain vaccines. In particular, it has been shown to reduce the effectiveness of both the Modified Vaccinia Ankara and the Moderna COVID-19 vaccine. Consequently, this factor should be considered when handling vaccinations in individuals using Gallium nitrate.']","['The drug gallium nitrate has been found to decrease the efficacy of the Moderna COVID-19 vaccine.', 'The drug gallium nitrate is known to decrease the efficacy of the Moderna COVID-19 vaccine.', 'The drug gallium nitrate may decrease the efficacy of the Moderna COVID-19 vaccine.', 'The drug gallium nitrate may potentially decrease the efficacy of the Moderna COVID-19 vaccine.', 'The efficacy of the Moderna COVID-19 vaccine may be decreased by Gallium Nitrate.']"
"[{'source_node': {'name': '12,16-dihydroxy-8,11,13-abietatrien-3-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-116'}}, {'source_node': {'name': '12,16-dihydroxy-8,11,13-abietatrien-3-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}]","[{'source_node': {'name': '12,16-dihydroxy-8,11,13-abietatrien-3-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5656', 'target': None, 'metadata': {'node_id': '5656', 'node_type': 'PROTEIN', 'display_name': 'hct-116'}}]",0.6,0178d3eb47fe10f58eb8c6b93983b5d3,148fb6d7d30e16a47767a486733fdbf3,"['The compound 12,16-dihydroxy-8,11,13-abietatrien-3-one targets two different cell lines: HCT-116 and HL-60.', 'The compound 12,16-dihydroxy-8,11,13-abietatrien-3-one has been identified to target HCT-116 and HL-60 cell lines.', 'The compound 12,16-dihydroxy-8,11,13-abietatrien-3-one is known to target two different entities: the HCT-116 and HL-60 cell lines.', 'The compound 12,16-dihydroxy-8,11,13-abietatrien-3-one targets both HCT-116 and HL-60.', 'The compound 12,16-dihydroxy-8,11,13-abietatrien-3-one has demonstrated efficacy against multiple targets, including the HCT-116 and HL-60 cell lines.']","['The compound 12,16-dihydroxy-8,11,13-abietatrien-3-one targets HL-60.', 'The compound 12,16-dihydroxy-8,11,13-abietatrien-3-one has the target of HL-60, a human cell line often used in scientific research.', 'The compound 12,16-dihydroxy-8,11,13-abietatrien-3-one has HL-60, a human leukemia cell line, as a target.', 'The compound 12,16-dihydroxy-8,11,13-abietatrien-3-one has HL-60, a human leukemia cell line, as its target.', 'The compound 12,16-dihydroxy-8,11,13-abietatrien-3-one has the cancer cell line HL-60 as its target.']"
"[{'source_node': {'name': 'xamoterol'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' Tachycardia '}}, {'source_node': {'name': 'xamoterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'penbutolol'}}, {'source_node': {'name': 'xamoterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'niguldipine'}}]","[{'source_node': {'name': 'xamoterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'penbutolol'}}]","[{'type': 'node_removal', 'source': 'EFFECT:90', 'target': None, 'metadata': {'node_id': '90', 'node_type': 'EFFECT', 'display_name': ' Tachycardia '}}, {'type': 'node_removal', 'source': 'COMPOUND:8174', 'target': None, 'metadata': {'node_id': '8174', 'node_type': 'COMPOUND', 'display_name': 'niguldipine'}}]",0.4285714285714286,bf3e107262e5da09e6959699567628a3,ecedd21f31e6d1b144aa72889ce966e3,[],"['The drug xamoterol is known to decrease the efficacy of penbutolol.', 'The drug xamoterol is known to decrease the efficacy of penbutolol.', 'The drug xamoterol is known to decrease the efficacy of penbutolol.', 'The drug xamoterol is known to decrease the efficacy of penbutolol.', 'The drug Xamoterol has been found to decrease the efficacy of another medication known as Penbutolol.']"
"[{'source_node': {'name': 'malonyl-coa-acyl carrier protein transacylase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MCAT'}}, {'source_node': {'name': 'MCAT'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Mitochondrial Fatty Acid Beta-Oxidation'}}]","[{'source_node': {'name': 'malonyl-coa-acyl carrier protein transacylase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MCAT'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:644', 'target': None, 'metadata': {'node_id': '644', 'node_type': 'PATHWAY', 'display_name': 'Mitochondrial Fatty Acid Beta-Oxidation'}}]",0.6,393eb56e0a776fc78ce08e178bb2e2bd,dd4414b366cbc7a7a3aa34599c5ab14d,"['Malonyl-CoA-acyl carrier protein transacylase is the gene product of MCAT, which acts within the mitochondrial fatty acid beta-oxidation pathway.', 'The enzyme malonyl-coa-acyl carrier protein transacylase is a gene product of MCAT. Furthermore, MCAT acts within the process of mitochondrial fatty acid beta-oxidation.', 'The enzyme malonyl-coa-acyl carrier protein transacylase is a gene product of MCAT. Furthermore, MCAT operates within the process of mitochondrial fatty acid beta-oxidation.', 'The protein malonyl-coa-acyl carrier protein transacylase is a gene product of MCAT. This gene participates and functions within the pathway of mitochondrial fatty acid beta-oxidation.', 'Malonyl-CoA-acyl carrier protein transacylase is a gene product of MCAT which, in turn, acts within the mitochondrial fatty acid beta-oxidation.']",['The enzyme malonyl-CoA-acyl carrier protein transacylase is a gene product of the gene MCAT.']
"[{'source_node': {'name': 'THRB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nuclear Receptor transcription pathway'}}, {'source_node': {'name': 'eprotirome'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'thyroid hormone receptor alpha'}}, {'source_node': {'name': 'eprotirome'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'thyroid hormone receptor beta'}}, {'source_node': {'name': 'thyroid hormone receptor beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'THRB'}}]","[{'source_node': {'name': 'eprotirome'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'thyroid hormone receptor alpha'}}, {'source_node': {'name': 'eprotirome'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'thyroid hormone receptor beta'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:983', 'target': 'GENE:33248', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'PATHWAY:42', 'target': None, 'metadata': {'node_id': '42', 'node_type': 'PATHWAY', 'display_name': 'Nuclear Receptor transcription pathway'}}, {'type': 'node_removal', 'source': 'GENE:33248', 'target': None, 'metadata': {'node_id': '33248', 'node_type': 'GENE', 'display_name': 'THRB'}}]",0.5555555555555556,01a60ab3d0191cfe12e2dd760b72e3db,570ad220da9bbd5c20096328084e372d,"['The gene THRB acts within the nuclear receptor transcription pathway. The drug eprotirome targets two specific receptors, thyroid hormone receptor alpha and thyroid hormone receptor beta. Intriguingly, the thyroid hormone receptor beta is a gene product of THRB.']","['The drug eprotirome targets both the thyroid hormone receptor alpha and the thyroid hormone receptor beta.', 'Eprotirome, a pharmaceutical compound, targets two specific receptors: thyroid hormone receptor alpha and thyroid hormone receptor beta.', 'The drug eprotirome targets both the thyroid hormone receptor alpha and thyroid hormone receptor beta.', 'The drug eprotirome targets both the thyroid hormone receptor alpha and the thyroid hormone receptor beta.', 'The drug eprotirome has dual targets: it targets both the thyroid hormone receptor alpha and the thyroid hormone receptor beta.']"
"[{'source_node': {'name': 'tyrianthin 8'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}, {'source_node': {'name': 'tyrianthin 8'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ovcar-5'}}, {'source_node': {'name': 'tyrianthin 8'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-15'}}]","[{'source_node': {'name': 'tyrianthin 8'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ovcar-5'}}, {'source_node': {'name': 'tyrianthin 8'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-15'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5858', 'target': None, 'metadata': {'node_id': '5858', 'node_type': 'PROTEIN', 'display_name': 'kb'}}]",0.7142857142857143,b40ea4a03d213fad95ecc9ddd2bf49f9,0caca1cf13d239ddadfbf34400af1122,"['The drug Tyrianthin 8 targets multiple entities including KB, OVCAR-5, and HCT-15.', 'Tyrianthin 8, a compound of interest in scientific research, has multiple targets. These targets include KB, OVCAR-5, and HCT-15, all of which are various types of cells commonly used in laboratory experiments.', 'Tyrianthin 8 is a pharmacological compound that has several biological targets, including KB, OVCAR-5, and HCT-15.', 'Tyrianthin 8 is a compound that has multiple targets, including KB, OVCAR-5, and HCT-15.', 'The compound Tyrianthin 8 targets several different entities, specifically KB, OVCAR-5, and HCT-15.']","['The drug Tyrianthin 8 has multiple targets, including both OVCAR-5 and HCT-15.', 'Tyrianthin 8 is a substance that targets two different entities, specifically the OVCAR-5 and HCT-15.', 'The compound Tyrianthin 8 has been identified to target various cell lines, including OVCAR-5 and HCT-15.', 'The drug Tyrianthin 8 has two notable targets: OVCAR-5 and HCT-15.', 'The compound Tyrianthin 8 displays a targeted effect on both the OVCAR-5 and HCT-15 cell lines.']"
"[{'source_node': {'name': 'ABCC4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Platelet degranulation '}}, {'source_node': {'name': 'ABCC4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Azathioprine ADME'}}, {'source_node': {'name': 'ABCC4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Paracetamol ADME'}}]","[{'source_node': {'name': 'ABCC4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Platelet degranulation '}}, {'source_node': {'name': 'ABCC4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Paracetamol ADME'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:197', 'target': None, 'metadata': {'node_id': '197', 'node_type': 'PATHWAY', 'display_name': 'Azathioprine ADME'}}]",0.7142857142857143,ed3f1244848a0207d481235cdd5761cc,37778c9ef8ca27657d3e6a9475944a49,"['The gene ABCC4 has been identified as playing a key role across multiple pathways. In particular, it acts within the process of platelet degranulation, as well as both the Azathioprine ADME and Paracetamol ADME metabolic pathways.', 'The gene ABCC4 operates within several mechanisms. It plays a role in processes such as platelet degranulation, handling of Azathioprine within the body (a process referred to as Azathioprine ADME), and also the metabolism and elimination of Paracetamol, also known as Paracetamol ADME.']","['The gene ABCC4 plays a role in several biological processes, including platelet degranulation and Paracetamol ADME.']"
"[{'source_node': {'name': 'neuronal acetylcholine receptor subunit alpha-3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CHRNA3'}}, {'source_node': {'name': 'CHRNA3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'bladder dysfunction'}}, {'source_node': {'name': 'cyfusine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'neuronal acetylcholine receptor subunit alpha-3'}}, {'source_node': {'name': 'bladder dysfunction'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'orthostatic hypotension'}}, {'source_node': {'name': 'bladder dysfunction'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'failure to thrive'}}, {'source_node': {'name': 'bladder dysfunction'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'gastroesophageal reflux'}}]","[{'source_node': {'name': 'neuronal acetylcholine receptor subunit alpha-3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CHRNA3'}}, {'source_node': {'name': 'CHRNA3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'bladder dysfunction'}}, {'source_node': {'name': 'cyfusine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'neuronal acetylcholine receptor subunit alpha-3'}}, {'source_node': {'name': 'bladder dysfunction'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'orthostatic hypotension'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1115', 'target': None, 'metadata': {'node_id': '1115', 'node_type': 'PHENOTYPE', 'display_name': 'failure to thrive'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:1479', 'target': None, 'metadata': {'node_id': '1479', 'node_type': 'PHENOTYPE', 'display_name': 'gastroesophageal reflux'}}]",0.6923076923076923,311f4332b5e9f8b097fb50a49d877971,c1aac06fb863c75395acbada09472a71,"['The neuronal acetylcholine receptor subunit alpha-3 is a gene product of CHRNA3, which is known to cause bladder dysfunction. This bladder dysfunction is characterized by various phenotypes including orthostatic hypotension, failure to thrive, and gastroesophageal reflux. Furthermore, the drug cyfusine targets the neuronal acetylcholine receptor subunit alpha-3.', 'The drug cyfusine targets the neuronal acetylcholine receptor subunit alpha-3, a gene product of CHRNA3. Notably, CHRNA3 has been identified as a gene that can cause bladder dysfunction, a condition associated with several phenotypes, including orthostatic hypotension, failure to thrive, and gastroesophageal reflux.', 'The protein known as neuronal acetylcholine receptor subunit alpha-3, is a gene product of CHRNA3. This gene is implicated in causing bladder dysfunction, which is characterized by several symptoms including orthostatic hypotension, failure to thrive, and gastroesophageal reflux. Cyfusine, a drug under investigation, targets this specific protein potentially offering a novel therapeutic approach to address bladder dysfunction and its associated symptoms.', 'The drug Cyfusine targets the neuronal acetylcholine receptor subunit alpha-3, which is a gene product of CHRNA3. The gene CHRNA3 is associated with certain conditions such as bladder dysfunction. This particular condition displays several symptoms including orthostatic hypotension, failure to thrive, and gastroesophageal reflux.', 'The neuronal acetylcholine receptor subunit alpha-3, which is a gene product of CHRNA3, is targeted by the drug Cyfusine. CHRNA3 is also known to cause a condition called bladder dysfunction characterized by multiple symptoms such as orthostatic hypotension, failure to thrive, and gastroesophageal reflux. Thus, it seems pharmaceutical substances like Cyfusine that interact with this receptor might have implications for individuals suffering from bladder dysfunction and its various symptoms.']","['The drug cyfusine targets the neuronal acetylcholine receptor subunit alpha-3, which is a gene product of CHRNA3. CHRNA3 is known to cause bladder dysfunction which can further develop conditions like orthostatic hypotension.', 'The drug Cyfusine targets the neuronal acetylcholine receptor subunit alpha-3, which is a gene product of CHRNA3. The gene CHRNA3 is linked to the condition bladder dysfunction and may be a critical factor that causes it. Notably, bladder dysfunction exhibits the phenotype of orthostatic hypotension.', 'The gene product neuronal acetylcholine receptor subunit alpha-3 is derived from its parent gene CHRNA3. Dysfunctions within the CHRNA3 gene may lead to conditions such as bladder dysfunction. Furthermore, the medication cyfusine has been identified as having a target interaction with the neuronal acetylcholine receptor subunit alpha-3. Bladder dysfunction, often associated with this gene, presents with several clinical symptoms, one of which includes orthostatic hypotension.', 'The drug Cyfusine targets the Neuronal Acetylcholine Receptor Subunit Alpha-3. This receptor is a gene product of CHRNA3, which has been linked to causing bladder dysfunction. Additionally, bladder dysfunction, as a condition, is characterized by orthostatic hypotension.', 'The neuronal acetylcholine receptor subunit alpha-3, which is a gene product of CHRNA3, is targeted by the drug Cyfusine. Mutations in the CHRNA3 gene have been known to cause bladder dysfunction, a condition which can present with symptoms such as orthostatic hypotension.']"
"[{'source_node': {'name': 'hemoglobin subunit alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HBA1'}}, {'source_node': {'name': 'hemoglobin subunit alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HBA2'}}, {'source_node': {'name': 'HBA1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'erythrocytosis 7'}}, {'source_node': {'name': 'HBA1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cytoprotection by HMOX1'}}, {'source_node': {'name': 'ferrous sulfate anhydrous'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hemoglobin subunit alpha'}}, {'source_node': {'name': 'ferrous sulfate anhydrous'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'transferrin receptor'}}, {'source_node': {'name': 'ferrous sulfate anhydrous'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the nephrotoxic activities '}}]","[{'source_node': {'name': 'hemoglobin subunit alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HBA2'}}, {'source_node': {'name': 'HBA1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'erythrocytosis 7'}}, {'source_node': {'name': 'HBA1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cytoprotection by HMOX1'}}, {'source_node': {'name': 'HBA2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cytoprotection by HMOX1'}}, {'source_node': {'name': 'ferrous sulfate anhydrous'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hemoglobin subunit alpha'}}, {'source_node': {'name': 'ferrous sulfate anhydrous'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'transferrin receptor'}}, {'source_node': {'name': 'ferrous sulfate anhydrous'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the nephrotoxic activities '}}]","[{'type': 'edge_deletion', 'source': 'PROTEIN:1454', 'target': 'GENE:28624', 'metadata': None}, {'type': 'edge_addition', 'source': 'GENE:28625', 'target': 'PATHWAY:302', 'metadata': {'predicate': 'acts_within'}}]",0.8666666666666667,2ade2a7159eb1ce88450b49d69fbb970,856d2d0638b4991eab29c15977db190d,[],[]
"[{'source_node': {'name': 'eplivanserin'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' neuropsychiatric effects '}}, {'source_node': {'name': 'eplivanserin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'lofexidine'}}]","[{'source_node': {'name': 'eplivanserin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'lofexidine'}}]","[{'type': 'node_removal', 'source': 'EFFECT:41', 'target': None, 'metadata': {'node_id': '41', 'node_type': 'EFFECT', 'display_name': ' neuropsychiatric effects '}}]",0.6,4963ea382d98dce52f0a65fcc27995e5,d1fe3e53b8f930f24e82dd462d5eff2b,[],"['The drug Eplivanserin has been shown to increase the efficacy of Lofexidine.', 'The drug eplivanserin has been shown to increase the efficacy of another medication, lofexidine.', 'The drug eplivanserin has been found to increase the efficacy of lofexidine.']"
"[{'source_node': {'name': 'phorbol 12-myristate 13-acetate diester'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'u-937'}}, {'source_node': {'name': 'phorbol 12-myristate 13-acetate diester'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'snu-387'}}, {'source_node': {'name': 'phorbol 12-myristate 13-acetate diester'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}}, {'source_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'APEX1'}}]","[{'source_node': {'name': 'phorbol 12-myristate 13-acetate diester'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'u-937'}}, {'source_node': {'name': 'phorbol 12-myristate 13-acetate diester'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'snu-387'}}, {'source_node': {'name': 'u-937'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'APEX1'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:5724', 'target': 'GENE:28904', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'PROTEIN:3751', 'target': None, 'metadata': {'node_id': '3751', 'node_type': 'PROTEIN', 'display_name': 'dna-(apurinic or apyrimidinic site) lyase'}}]",0.6666666666666667,1ec791c71f0340c995f178511f805a2b,ee370e6f21e98cbe3a09f0cf74b9b499,"['The compound phorbol 12-myristate 13-acetate diester is known to target several entities, including U-937, SNU-387, and DNA-(apurinic or apyrimidinic site) lyase. Notably, DNA-(apurinic or apyrimidinic site) lyase is the gene product of APEX1.', 'Phorbol 12-myristate 13-acetate diester is a compound that targets multiple entities including U-937 and SNU-387. Interestingly, it also targets DNA-(apurinic or apyrimidinic site) lyase, which is a gene product of APEX1.', 'Phorbol 12-myristate 13-acetate diester is a substance that has multiple targets, including U-937, SNU-387 as well as the enzyme DNA-(apurinic or apyrimidinic site) lyase. Interestingly, DNA-(apurinic or apyrimidinic site) lyase is a gene product of APEX1.', 'The compound phorbol 12-myristate 13-acetate diester targets multiple entities, including U-937, SNU-387, and the enzyme known as DNA-(apurinic or apyrimidinic site) lyase. This particular enzyme is a gene product of APEX1.', 'The compound Phorbol 12-myristate 13-acetate diester has multiple targets, including U-937, SNU-387, and the protein DNA-(apurinic or apyrimidinic site) lyase. Notably, this DNA-(apurinic or apyrimidinic site) lyase is a gene product of APEX1.']","['The compound phorbol 12-myristate 13-acetate diester targets both U-937 and SNU-387. Interestingly, U-937 is actually a gene product of APEX1.', 'The compound phorbol 12-myristate 13-acetate diester targets both U-937 and SNU-387. Interestingly, U-937 is a gene product of APEX1.', 'The compound phorbol 12-myristate 13-acetate diester targets both the U-937 and SNU-387. Notably, U-937 is a gene product of APEX1.', 'The drug phorbol 12-myristate 13-acetate diester targets both U-937 and SNU-387. Moreover, U-937 is a gene product of APEX1.', 'The phorbol 12-myristate 13-acetate diester is known to target both U-937 and SNU-387. Notably, U-937 is a gene product of APEX1.']"
"[{'source_node': {'name': 'vadastuximab talirine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the thrombogenic activities '}}, {'source_node': {'name': 'vadastuximab talirine'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'vadastuximab talirine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imlifidase'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'daclizumab'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nimotuzumab'}}]","[{'source_node': {'name': 'vadastuximab talirine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the thrombogenic activities '}}, {'source_node': {'name': 'vadastuximab talirine'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}]","[{'type': 'node_removal', 'source': 'COMPOUND:12843', 'target': None, 'metadata': {'node_id': '12843', 'node_type': 'COMPOUND', 'display_name': 'imlifidase'}}]",0.4545454545454546,9781c90904f148679fa5047cb3a1e81f,d09b906e3bcf2ef2deb3506e7c9120d5,[],[]
"[{'source_node': {'name': 'sulfaethoxypyridazine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the excretion rate '}}, {'source_node': {'name': 'sulfaethoxypyridazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pramlintide'}}, {'source_node': {'name': 'sulfaethoxypyridazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'voglibose'}}]","[{'source_node': {'name': 'sulfaethoxypyridazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pramlintide'}}, {'source_node': {'name': 'sulfaethoxypyridazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'voglibose'}}]","[{'type': 'node_removal', 'source': 'ACTIVITY:7', 'target': None, 'metadata': {'node_id': '7', 'node_type': 'ACTIVITY', 'display_name': ' the excretion rate '}}]",0.7142857142857143,fb6f652eda7b961b79fefac4a2fa6d80,f6ceb3524151dc74a978daafc724172e,[],"['The drug sulfaethoxypyridazine is known to increase the efficacy of both pramlintide and voglibose.', 'The drug sulfaethoxypyridazine is observed to increase the efficacy of pramlintide and voglibose.', 'The drug Sulfaethoxypyridazine is known to increase the efficacy of both Pramlintide and Voglibose. This suggests that co-administration of Sulfaethoxypyridazine could potentially enhance the therapeutic effects of these drugs.', 'The drug sulfaethoxypyridazine has been found to increase the efficacy of both pramlintide and voglibose.', 'The drug sulfaethoxypyridazine has been noted to increase the efficacy of both pramlintide and voglibose.']"
"[{'source_node': {'name': 'solute carrier family 14 member 2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hypertension'}}, {'source_node': {'name': 'solute carrier family 14 member 2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'coronary artery disease'}}, {'source_node': {'name': 'coronary artery disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'obesity'}}]","[{'source_node': {'name': 'coronary artery disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'obesity'}}]","[{'type': 'node_removal', 'source': 'GENE:19113', 'target': None, 'metadata': {'node_id': '19113', 'node_type': 'GENE', 'display_name': 'solute carrier family 14 member 2'}}]",0.4285714285714286,adcef4e1365bca9dc9df2e0b4363832b,f5a067f0ac11c22e5ee0f53768249efb,"['The gene known as solute carrier family 14 member 2 is known to cause several medical conditions including hypertension and coronary artery disease. Notably, one of the phenotypes associated with coronary artery disease is obesity.', ""The gene known as solute carrier family 14 member 2 has been found to cause certain conditions including hypertension and coronary artery disease. Furthermore, it's important to note that coronary artery disease is characterized by a phenotype of obesity."", 'The gene Solute Carrier Family 14 Member 2 causes various conditions such as hypertension and coronary artery disease. Interestingly, obesity, which can act as a risk factor, has also been identified as a phenotype of coronary artery disease.', ""The gene solute carrier family 14 member 2 has been found to cause two prominent conditions: hypertension and coronary artery disease. Importantly, it's noteworthy that coronary artery disease, often influenced by this gene, is associated with the phenotype of obesity."", 'The protein known as solute carrier family 14 member 2 is implicated in causing certain conditions such as hypertension and coronary artery disease. Notably, coronary artery disease is characterized by a phenotype that includes obesity.']",['Coronary artery disease is a condition that has obesity as one of its potential phenotypes.']
"[{'source_node': {'name': 'diethylpropion'}, 'relation': {'name': 'decrease_activity'}, 'target_node': {'name': ' effectiveness '}}, {'source_node': {'name': 'diethylpropion'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Tension'}}]","[{'source_node': {'name': 'diethylpropion'}, 'relation': {'name': 'increase_activity'}, 'target_node': {'name': ' effectiveness '}}]","[{'type': 'edge_replacement', 'source': 'COMPOUND:920', 'target': 'ACTIVITY:6', 'metadata': {'predicate': 'increase_activity'}}, {'type': 'node_removal', 'source': 'SIDE_EFFECT:101', 'target': None, 'metadata': {'node_id': '101', 'node_type': 'SIDE_EFFECT', 'display_name': 'Tension'}}]",0.4,c8b329fbad84f14fa00d98b3dcb9549d,efe457eca72d4f8073622e35ce179776,[],[]
"[{'source_node': {'name': 'RELN'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'lissencephaly 2'}}, {'source_node': {'name': 'RELN'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'epilepsy'}}, {'source_node': {'name': 'RELN'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Reelin signalling pathway'}}, {'source_node': {'name': 'epilepsy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'focal aware seizure'}}, {'source_node': {'name': 'epilepsy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'difficulty standing'}}]","[{'source_node': {'name': 'lissencephaly 2'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'focal aware seizure'}}, {'source_node': {'name': 'RELN'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'lissencephaly 2'}}, {'source_node': {'name': 'RELN'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Reelin signalling pathway'}}, {'source_node': {'name': 'epilepsy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'focal aware seizure'}}, {'source_node': {'name': 'epilepsy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'difficulty standing'}}]","[{'type': 'edge_deletion', 'source': 'GENE:31754', 'target': 'DISEASE:15008', 'metadata': None}, {'type': 'edge_addition', 'source': 'DISEASE:10970', 'target': 'PHENOTYPE:1722', 'metadata': {'predicate': 'has_phenotype'}}]",0.8181818181818181,404911dc6170515384fd591ef227df6d,d9247a77d36d6c5d19dc241fac1cb993,"['The gene RELN, which acts within the Reelin signalling pathway, causes specific medical conditions including lissencephaly 2 and epilepsy. Notably, epilepsy, which is caused by RELN, exhibits an array of phenotypes such as difficulty standing and focal aware seizures.', 'The gene RELN acts within the Reelin signalling pathway and it is associated with the causation of two conditions, lissencephaly 2 and epilepsy. Epilepsy features certain phenotypes, including the occurrence of focal aware seizures and difficulty standing.', 'The gene RELN, which acts within the Reelin signalling pathway, is known to cause both lissencephaly 2 and epilepsy. Epilepsy, as a condition, is associated with various phenotypes such as experiencing focal aware seizures and experiencing difficulty standing.', 'The gene RELN, which functions within the Reelin signalling pathway, is known to cause several conditions like lissencephaly 2 and epilepsy. Epilepsy is characterized by symptoms such as focal aware seizures and difficulty standing.', 'The gene RELN plays a key role within the reelin signalling pathway and is known to cause several medical conditions, including lissencephaly 2 and epilepsy. Epilepsy, a condition induced by RELN, exhibits various symptoms such as difficulty standing and focal aware seizures.']","['The gene RELN, which acts within the Reelin signalling pathway, causes a condition known as lissencephaly 2. This condition has a phenotype manifestation of focal aware seizures. Also, epilepsy, another neurological disorder, shares this symptom of focal aware seizures, along with another phenotype of difficulty standing.', 'The gene RELN, which is involved in the Reelin signalling pathway, causes the condition known as lissencephaly 2. This condition is characterized by several phenotypes including focal aware seizures. Similarly, epilepsy, another neurological condition, also exhibits the phenotypes of focal aware seizures and difficulty standing.', 'The gene RELN is involved in the Reelin signalling pathway and is known to cause lissencephaly 2, a condition which often presents with a unique phenotype of focal aware seizures. Interestingly, these seizures are also a symptom of another neurological condition named epilepsy. Moreover, individuals living with epilepsy often face challenges such as difficulty in standing.', 'The gene RELN, which is active within the Reelin signalling pathway, is known to cause the condition known as lissencephaly 2. This disease presents with various symptoms, including focal aware seizures, a phenotype it shares with epilepsy, another neurological disorder. Additionally, epilepsy exhibits the phenotype of difficulty standing, further complicating the condition.', 'The gene RELN, that acts within the Reelin signalling pathway, is known to cause a condition called lissencephaly 2. This condition exhibits a phenotype called focal aware seizure, which is also a common phenotype of epilepsy. Epilepsy, on the other hand, is also characterized by another phenotype - difficulty standing.']"
"[{'source_node': {'name': 'cefcapene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fibrinolysin'}}, {'source_node': {'name': 'cefcapene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'picosulfuric acid'}}, {'source_node': {'name': 'betrixaban'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'coagulation factor vii human'}}, {'source_node': {'name': 'betrixaban'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'kallidinogenase'}}, {'source_node': {'name': 'betrixaban'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cefcapene'}}]","[{'source_node': {'name': 'cefcapene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fibrinolysin'}}, {'source_node': {'name': 'cefcapene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'picosulfuric acid'}}, {'source_node': {'name': 'betrixaban'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'coagulation factor vii human'}}, {'source_node': {'name': 'betrixaban'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'kallidinogenase'}}, {'source_node': {'name': 'betrixaban'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'fibrinolysin'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:10265', 'target': 'COMPOUND:11313', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:10265', 'target': 'COMPOUND:4914', 'metadata': {'predicate': 'increase_efficacy'}}]",0.8181818181818181,da49b62bebec6501b6e7fa5abb53bf56,dd726534881dcd4d80466a758243cfc3,"['The drug cefcapene is observed to potentially decrease the efficacy of both fibrinolysin and picosulfuric acid. Similarly, another drug named betrixaban also has similar effects on different molecules. It is known to decrease the efficacy of coagulation factor VII human, kallidinogenase, and even cefcapene itself. This shows a complex interplay between cefcapene and betrixaban in influencing the efficacy of multiple substances within the body.', 'The antibiotics, cefcapene, has been found to decrease the efficacy of fibrinolysin and picosulfuric acid. Simultaneously, betrixaban, an anticoagulant, is reported to decrease the efficacy of coagulation factor VII human, kallidinogenase, and also cefcapene. Therefore, caution should be applied when these drugs are administered together as their therapeutic effects might be compromised.', 'The drug cefcapene tends to decrease the efficacy of fibrinolysin and picosulfuric acid. Similarly, betrixaban, another pharmaceutical agent, curbs the effectiveness of coagulation factor VII human, kallidinogenase, and also cefcapene. Therefore, while taking these medications, one should be alert to their potential interactions and effects.', 'The drug cefcapene has been found to decrease the efficacy of fibrinolysin and picosulfuric acid. In a similar manner, the drug betrixaban also decreases the efficacy of several entities, including coagulation factor vii human, kallidinogenase, and interestingly, cefcapene as well. Thus, care should be exercised when co-administering these substances.', ""The drug Cefcapene has the potential to decrease the efficacy of both Fibrinolysin and Picosulfuric Acid. Similarly, the drug Betrixaban can decrease the efficacy of Coagulation Factor VII Human and Kallidinogenase. Furthermore, it's interesting to note that Betrixaban can also reduce the efficacy of Cefcapene, suggesting potential drug interaction considerations.""]","['The drug Cefcapene is known to decrease the efficacy of fibrinolysin and picosulfuric acid. Similarly, the drug Betrixaban reduces the effectiveness of coagulation factor VII human and kallidinogenase. Interestingly, Betrixaban has the opposite effect on fibrinolysin, where it actually increases its efficacy.', 'The drug cefcapene has been observed to decrease the efficacy of fibrinolysin and picosulfuric acid. Similarly, betrixaban also affects various substances; it decreases the efficacy of coagulation factor VII human and kallidinogenase but interestingly, it increases the efficacy of fibrinolysin.', 'The antimicrobial drug Cefcapene is known to decrease the efficacy of Fibrinolysin and Picosulfuric acid. On the other hand, Betrixaban, an anticoagulant medication, has been shown to decrease the efficacy of Coagulation Factor VII Human and Kallidinogenase while it increases the efficacy of Fibrinolysin.', 'The drug Cefcapene is known to decrease the efficacy of both Fibrinolysin and Picosulfuric acid. Similarly, Betrixaban has been found to decrease the efficacy of Coagulation factor VII human and Kallidinogenase. However, it is worth noting that Betrixaban can actually increase the efficacy of Fibrinolysin.', 'The drug cefcapene is known to decrease the efficacy of fibrinolysin and picosulfuric acid. In a similar manner, the drug betrixaban also decreases the efficacy of coagulation factor VII human and kallidinogenase. Interestingly, while betrixaban decreases the efficacy of some substances, it increases the efficacy of fibrinolysin.']"
"[{'source_node': {'name': 'acrosin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACR'}}, {'source_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'APEX1'}}, {'source_node': {'name': 'l-xylopyranose'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'xylose isomerase'}}, {'source_node': {'name': 'l-xylopyranose'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'acrosin'}}, {'source_node': {'name': 'l-xylopyranose'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}}]","[{'source_node': {'name': 'acrosin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACR'}}, {'source_node': {'name': 'xylose isomerase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACR'}}, {'source_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'APEX1'}}, {'source_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACR'}}, {'source_node': {'name': 'l-xylopyranose'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'xylose isomerase'}}, {'source_node': {'name': 'l-xylopyranose'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'acrosin'}}, {'source_node': {'name': 'l-xylopyranose'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'APEX1'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:3751', 'target': 'GENE:30341', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'COMPOUND:3679', 'target': 'GENE:28904', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:290', 'target': 'GENE:30341', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:3679', 'target': 'PROTEIN:3751', 'metadata': None}]",0.6363636363636364,b3869de4bdaf9b16bbefc50fd991af4d,c31dcea32c7bc10d0cfe792c9811ac26,"['Acrosin is a gene product of ACR, and DNA-(apurinic or apyrimidinic site) lyase is a gene product of APEX1. The molecule L-xylopyranose has several targets, including xylose isomerase, acrosin, and DNA-(apurinic or apyrimidinic site) lyase. This shows the complex interaction and impact of L-xylopyranose within the genetic and enzymatic landscape.', 'The protein acrosin is a gene product of ACR while the protein DNA-(apurinic or apyrimidinic site) lyase is a gene product of APEX1. Meanwhile, the compound L-xylopyranose has multiple biological targets including the enzymes xylose isomerase, acrosin, and DNA-(apurinic or apyrimidinic site) lyase.', 'The molecule acrosin is a gene product of ACR, and DNA-(apurinic or apyrimidinic site) lyase is produced by the APEX1 gene. Additionally, the compound L-xylopyranose interacts with several targets, including xylose isomerase, acrosin, and DNA-(apurinic or apyrimidinic site) lyase.', 'Acrosin, a gene product of ACR, along with DNA-(apurinic or apyrimidinic site) lyase, a gene product of APEX1, is targeted by L-xylopyranose. Additionally, L-xylopyranose also targets xylose isomerase. Thus, L-xylopyranose plays a significant role in biologically regulating these targets.', 'The bioactive compound L-xylopyranose interacts with several biological entities, including xylose isomerase and enzymes namely acrosin and DNA-(apurinic or apyrimidinic site) lyase. Acrosin is a gene product of ACR, while DNA-(apurinic or apyrimidinic site) lyase is a gene product of APEX1.']","['In the given knowledge graph, we see several relationships among biological entities. Acrosin and xylose isomerase are both gene products of ACR. Similarly, DNA-(apurinic or apyrimidinic site) lyase is a gene product of both APEX1 and ACR. Furthermore, the compound l-xylopyranose targets both acrosin and xylose isomerase. Meanwhile, the APEX1 gene is affected by l-xylopyranose. Therefore, there appears to be a web of interconnections among these proteins and the genes that produce them, while l-xylopyranose impacts several targets in this network.', 'The enzymes acrosin and xylose isomerase are both gene products of ACR, while the enzyme known as dna-(apurinic or apyrimidinic site) lyase is a gene product of both ACR and APEX1. An important compound, l-xylopyranose, targets both xylose isomerase and acrosin, and, interestingly, it affects the enzymatic activity of APEX1.']"
"[{'source_node': {'name': 'testosterone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'nitrofurantoin'}}, {'source_node': {'name': 'testosterone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Paresthesia generalized'}}, {'source_node': {'name': 'testosterone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Blood prolactin increased'}}, {'source_node': {'name': 'nitrofurantoin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Psychotic disorder'}}]","[{'source_node': {'name': 'testosterone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Paresthesia generalized'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:683', 'target': 'SIDE_EFFECT:2489', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'node_removal', 'source': 'COMPOUND:683', 'target': None, 'metadata': {'node_id': '683', 'node_type': 'COMPOUND', 'display_name': 'nitrofurantoin'}}, {'type': 'node_removal', 'source': 'SIDE_EFFECT:2489', 'target': None, 'metadata': {'node_id': '2489', 'node_type': 'SIDE_EFFECT', 'display_name': 'Blood prolactin increased'}}]",0.3333333333333333,71cbabffd561d913be13da88a64de64a,2fbe80e28ee87d08ac681710b77f891e,[],['The hormone testosterone has been reported to have the side effect of generalized paresthesia.']
"[{'source_node': {'name': 'dacetuzumab'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the thrombogenic activities '}}, {'source_node': {'name': 'dacetuzumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'dacetuzumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imlifidase'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'durvalumab'}}]","[{'source_node': {'name': 'dacetuzumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'dacetuzumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imlifidase'}}, {'source_node': {'name': 'dacetuzumab'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'durvalumab'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'durvalumab'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:10478', 'target': 'COMPOUND:9633', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'ACTIVITY:2', 'target': None, 'metadata': {'node_id': '2', 'node_type': 'ACTIVITY', 'display_name': ' the thrombogenic activities '}}]",0.6666666666666667,c3381268091a98609fdcc12b416c0b74,3b731c762751efde54bb9123e45e61f2,[],[]
"[{'source_node': {'name': 'BAX'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pyroptosis'}}, {'source_node': {'name': 'BAX'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Transcriptional regulation by RUNX2'}}, {'source_node': {'name': 'BAX'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'NTRK3 as a dependence receptor'}}]","[{'source_node': {'name': 'BAX'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Transcriptional regulation by RUNX2'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1637', 'target': None, 'metadata': {'node_id': '1637', 'node_type': 'PATHWAY', 'display_name': 'NTRK3 as a dependence receptor'}}, {'type': 'node_removal', 'source': 'PATHWAY:161', 'target': None, 'metadata': {'node_id': '161', 'node_type': 'PATHWAY', 'display_name': 'Pyroptosis'}}]",0.4285714285714286,cd0157e99004150e0543ddee3b53217c,5f923401002d908071a00affb8b2459f,[],['The gene BAX is known to act within the pathway of transcriptional regulation by RUNX2.']
"[{'source_node': {'name': 'atp binding cassette subfamily b member 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'arrhythmias'}}, {'source_node': {'name': 'atp binding cassette subfamily b member 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'systemic lupus erythematosus'}}, {'source_node': {'name': 'atp binding cassette subfamily b member 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'tuberculosis'}}]","[{'source_node': {'name': 'atp binding cassette subfamily b member 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'arrhythmias'}}, {'source_node': {'name': 'atp binding cassette subfamily b member 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'systemic lupus erythematosus'}}]","[{'type': 'node_removal', 'source': 'DISEASE:3239', 'target': None, 'metadata': {'node_id': '3239', 'node_type': 'DISEASE', 'display_name': 'tuberculosis'}}]",0.7142857142857143,b278bad9434d85e443057702f61d8858,c76cd8a156fe333911dc474a6166e9dd,"['The ATP binding cassette subfamily B member 1 is known to cause several conditions. Some of these include arrhythmias, systemic lupus erythematosus, and tuberculosis.', 'The ATP binding cassette subfamily B member 1 is linked to several health conditions. Specifically, it leads to a condition known as arrhythmias, causes systemic lupus erythematosus, a chronic autoimmune disease, and is also responsible for developing tuberculosis, a highly infectious disease primarily affecting the lungs.', 'The protein ATP binding cassette subfamily B member 1 is known to cause several conditions. Specifically, it has been implicated in the development of arrhythmias, which are disruptions in the regular rhythm of the heart. Interestingly, this protein is also associated with triggering systemic lupus erythematosus, an autoimmune disease in which the immune system mistakenly attacks healthy cells and tissues. Lastly, ATP binding cassette subfamily B member 1 has also been implicated in causing tuberculosis, an infectious disease generally affecting the lungs.', 'The ATP binding cassette subfamily B member 1 has been found to cause several conditions, including arrhythmias, systemic lupus erythematosus, and tuberculosis.']","['The gene ATP binding cassette subfamily B member 1 has been found to cause several health conditions, most notably arrhythmias and systemic lupus erythematosus.', 'The ATP binding cassette subfamily B member 1, a vital protein, has been closely linked to causing certain conditions. Notably, it has been found to instigate arrhythmias, an irregularity in heart rhythm, as well as systemic lupus erythematosus, a chronic autoimmune disease that can affect practically any part of the body.', 'The ATP binding cassette subfamily B member 1 is associated with certain conditions. It can cause arrhythmias, a group of conditions characterized by an irregular heart rhythm. This protein can also lead to the development of systemic lupus erythematosus, a chronic autoimmune disease that can affect various parts of the body including skin, joints, kidneys, brain, and other organs.', 'The ATP binding cassette subfamily B member 1, a type of protein, is known to cause various conditions, including arrhythmias and systemic lupus erythematosus.', '""The gene known as ATP binding cassette subfamily B member 1 is known to cause several conditions including arrhythmias and systemic lupus erythematosus.']"
"[{'source_node': {'name': 'ATP6AP2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'congenital disorder of glycosylation'}}, {'source_node': {'name': 'ATP6AP2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'parkinsonism with spasticity'}}, {'source_node': {'name': 'ATP6AP2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Metabolism of Angiotensinogen to Angiotensins'}}]","[{'source_node': {'name': 'ATP6AP2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'congenital disorder of glycosylation'}}]","[{'type': 'node_removal', 'source': 'DISEASE:15796', 'target': None, 'metadata': {'node_id': '15796', 'node_type': 'DISEASE', 'display_name': 'parkinsonism with spasticity'}}, {'type': 'node_removal', 'source': 'PATHWAY:321', 'target': None, 'metadata': {'node_id': '321', 'node_type': 'PATHWAY', 'display_name': 'Metabolism of Angiotensinogen to Angiotensins'}}]",0.4285714285714286,978ef3f06f44b92b31e4a2a04ea20740,283e5bd7e0abfc5b569b62ff716e7822,"['The gene ATP6AP2 has been found to cause several conditions, including both congenital disorder of glycosylation and parkinsonism with spasticity. In addition, it is involved in the pathway referred to as the metabolism of Angiotensinogen to Angiotensins.', 'The gene ATP6AP2 plays a significant role in the metabolism of Angiotensinogen to Angiotensins. Furthermore, abnormalities in ATP6AP2 often result in severe health conditions, including a congenital disorder of glycosylation and parkinsonism with spasticity.', 'The gene ATP6AP2 is associated with several health conditions and biological processes. Specifically, defects in ATP6AP2 are known to cause conditions like congenital disorder of glycosylation and parkinsonism with spasticity. Furthermore, this gene also participates in a particular bodily process, specifically the metabolism of angiotensinogen to angiotensins.', 'The gene ATP6AP2, active within the metabolism of angiotensinogen to angiotensins pathway, is known to cause multiple conditions. These conditions include congenital disorder of glycosylation and parkinsonism with spasticity.', 'The gene ATP6AP2, which acts within the metabolism of angiotensinogen to angiotensins, causes several conditions. Notably, it has been connected to the congenital disorder of glycosylation and to Parkinsonism with spasticity.']",[]
"[{'source_node': {'name': 'senior-loken syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'elevated circulating creatinine concentration'}}, {'source_node': {'name': 'senior-loken syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ataxia'}}, {'source_node': {'name': 'senior-loken syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of bone mineral density'}}, {'source_node': {'name': 'NPHP1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'senior-loken syndrome 1'}}, {'source_node': {'name': 'NPHP1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'bardet-biedl syndrome'}}, {'source_node': {'name': 'NPHP1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'joubert syndrome with renal defect'}}, {'source_node': {'name': 'bardet-biedl syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'generalized hirsutism'}}, {'source_node': {'name': 'bardet-biedl syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'skeletal muscle atrophy'}}]","[{'source_node': {'name': 'joubert syndrome with renal defect'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'elevated circulating creatinine concentration'}}, {'source_node': {'name': 'senior-loken syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'elevated circulating creatinine concentration'}}, {'source_node': {'name': 'senior-loken syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ataxia'}}, {'source_node': {'name': 'senior-loken syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of bone mineral density'}}, {'source_node': {'name': 'senior-loken syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'skeletal muscle atrophy'}}, {'source_node': {'name': 'NPHP1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'joubert syndrome with renal defect'}}, {'source_node': {'name': 'bardet-biedl syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'generalized hirsutism'}}, {'source_node': {'name': 'bardet-biedl syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'skeletal muscle atrophy'}}, {'source_node': {'name': 'bardet-biedl syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of bone mineral density'}}]","[{'type': 'edge_deletion', 'source': 'GENE:30324', 'target': 'DISEASE:6699', 'metadata': None}, {'type': 'edge_deletion', 'source': 'GENE:30324', 'target': 'DISEASE:326', 'metadata': None}, {'type': 'edge_addition', 'source': 'DISEASE:326', 'target': 'PHENOTYPE:3040', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_addition', 'source': 'DISEASE:7367', 'target': 'PHENOTYPE:2354', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_addition', 'source': 'DISEASE:6699', 'target': 'PHENOTYPE:2308', 'metadata': {'predicate': 'has_phenotype'}}]",0.7058823529411764,1dea3f8be03ed98d9254a5b14cb6e074,b5a7047d885f490528277c23f39bdc72,"['The gene NPHP1 is known to cause several conditions including Senior-Loken syndrome 1, Bardet-Biedl syndrome, and Joubert syndrome with a renal defect. Each of these syndromes has specific phenotypes associated with them. For example, Senior-Loken syndrome 1 is characterized by an elevated circulating creatinine concentration, ataxia, and an abnormality of bone mineral density. On the other hand, those suffering from Bardet-Biedl syndrome often exhibit generalized hirsutism and skeletal muscle atrophy.', 'The gene NPHP1 can cause multiple conditions including Senior-Loken Syndrome 1, Bardet-Biedl Syndrome, and Joubert Syndrome with renal defect. Interestingly, each of these conditions presents with unique symptoms. Senior-Loken Syndrome 1 is characterized by phenotypes such as elevated circulating creatinine concentration, ataxia, and abnormality of bone mineral density. Meanwhile, Bardet-Biedl Syndrome often manifests generalized hirsutism and skeletal muscle atrophy.', 'The gene NPHP1 has been identified as a causative factor behind several conditions. Notably, it causes Senior-Loken Syndrome 1, a condition that encompasses various phenotypes including elevated circulating creatinine concentration, ataxia, and abnormalities in bone mineral density. Additionally, NPHP1 is responsible for Bardet-Biedl Syndrome, which is characterized by a broad spectrum of symptoms such as generalized hirsutism and skeletal muscle atrophy. NPHP1 also causes Joubert Syndrome with a renal defect, demonstrating its significant influence on the development of various health conditions.', 'Senior-Loken Syndrome 1 exhibits multiple clinical phenotypes including an elevated circulating creatinine concentration, ataxia, as well as abnormalities of bone mineral density. This condition, along with Bardet-Biedl syndrome and Joubert syndrome with a renal defect, are caused by genetic mutations in the NPHP1 gene. Bardet-Biedl syndrome additionally manifests itself through clinical phenotypes such as generalized hirsutism and skeletal muscle atrophy.', 'The gene NPHP1 is associated with various conditions like Senior-Loken Syndrome 1, Bardet-Biedl Syndrome, and Joubert Syndrome with renal defect. Senior-Loken Syndrome 1 causes some distinct phenotypes including elevated circulating creatinine concentration, ataxia, and abnormality of bone mineral density. On the other hand, Bardet-Biedl Syndrome is characterised by unique phenotypes like generalized hirsutism and skeletal muscle atrophy.']","['Joubert syndrome with renal defect and Senior-Loken Syndrome 1 are two conditions that both have the phenotype of elevated circulating creatinine concentration. The former condition is caused by the NPHP1 gene. Senior-Loken Syndrome 1 also shows other phenotypes such as ataxia, abnormality of bone mineral density, and skeletal muscle atrophy.\n\nAnother condition, Bardet-Biedl Syndrome, also exhibits the phenotypes of skeletal muscle atrophy and abnormality of bone mineral density, comparable to Senior-Loken Syndrome 1. Moreover, Bardet-Biedl Syndrome possesses the additional phenotype of generalized hirsutism.', 'The genetic disorder Joubert syndrome with renal defect, which is caused by the gene NPHP1, is characterized by an elevated circulating creatinine concentration. Similarly, Senior-Loken syndrome 1 also shows an elevated circulating creatinine concentration along with other symptoms such as ataxia, skeletal muscle atrophy, and abnormalities in bone mineral density. Another disorder, Bardet-Biedl syndrome, shares a couple of symptoms with Senior-Loken syndrome 1, namely skeletal muscle atrophy and abnormal bone mineral density, but also includes an unusual phenotype of generalized hirsutism.']"
"[{'source_node': {'name': 'caspase-8'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CASP8'}}, {'source_node': {'name': 'an-9'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'apoptosis regulator bcl-2'}}, {'source_node': {'name': 'an-9'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'caspase-8'}}]","[{'source_node': {'name': 'an-9'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'apoptosis regulator bcl-2'}}, {'source_node': {'name': 'an-9'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'caspase-8'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:4781', 'target': 'GENE:34383', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:1554', 'target': 'GENE:34383', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'GENE:34383', 'target': None, 'metadata': {'node_id': '34383', 'node_type': 'GENE', 'display_name': 'CASP8'}}]",0.7142857142857143,dfb4aaf43a48483bf3e71309ca588907,bc3c3f598dba6477f1ede1aa1518b7da,"['The protein caspase-8, which is a gene product of CASP8, is targeted by the drug an-9. It is important to mention that an-9 also targets the protein known as apoptosis regulator bcl-2.']","['The compound AN-9 targets multiple proteins, specifically the apoptosis regulator BCL-2 and caspase-8.', 'The compound AN-9 targets two significant cellular components: the apoptosis regulator Bcl-2 and caspase-8.', 'The compound AN-9 targets both the apoptosis regulator Bcl-2 and caspase-8, playing an important role in regulating cell death mechanisms.', 'The compound AN-9 has been observed to target both apoptosis regulator BCL-2 and caspase-8.', 'The drug AN-9 lists the apoptosis regulator BCL-2 and caspase-8 among its primary targets.']"
"[{'source_node': {'name': 'TSG101'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Membrane binding and targetting of GAG proteins'}}, {'source_node': {'name': 'TSG101'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'HCMV Late Events'}}, {'source_node': {'name': 'TSG101'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Late endosomal microautophagy'}}]","[{'source_node': {'name': 'TSG101'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'HCMV Late Events'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:72', 'target': None, 'metadata': {'node_id': '72', 'node_type': 'PATHWAY', 'display_name': 'Late endosomal microautophagy'}}, {'type': 'node_removal', 'source': 'PATHWAY:1155', 'target': None, 'metadata': {'node_id': '1155', 'node_type': 'PATHWAY', 'display_name': 'Membrane binding and targetting of GAG proteins'}}]",0.4285714285714286,d91b48405206fa4ceea75aa944220441,225c2b99b6bbd754b25ca045a86e4c97,[],[]
"[{'source_node': {'name': 'KIFAP3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Intraflagellar transport'}}, {'source_node': {'name': 'KIFAP3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'COPI-dependent Golgi-to-ER retrograde traffic'}}, {'source_node': {'name': 'KIFAP3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Kinesins'}}]","[{'source_node': {'name': 'KIFAP3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Intraflagellar transport'}}, {'source_node': {'name': 'KIFAP3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'COPI-dependent Golgi-to-ER retrograde traffic'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:283', 'target': None, 'metadata': {'node_id': '283', 'node_type': 'PATHWAY', 'display_name': 'Kinesins'}}]",0.7142857142857143,3a635bb8787b8ac1e0eaa1ef4df512a5,2338d08257a9123dc7795a935527a4bf,"['The protein KIFAP3 is involved in several cellular transport and trafficking processes such as intraflagellar transport, COPI-dependent Golgi-to-ER retrograde traffic, and it is also a component of the kinesins, a class of motor proteins.', 'The protein KIFAP3 acts within several biological processes including intraflagellar transport, COPI-dependent Golgi-to-ER retrograde traffic, and function as one of the kinesins.', 'The KIFAP3 gene is involved in several biological processes such as the intraflagellar transport, the COPI-dependent Golgi-to-ER retrograde traffic, and acting within a group of motor proteins known as kinesins.', 'The gene KIFAP3 is involved in several processes. It acts within the mechanism of intraflagellar transport, contributes to the COPI-dependent Golgi-to-ER retrograde traffic, and operates within the group of proteins known as kinesins.', ""The protein KIFAP3 plays a significant role within several biochemical processes. It is vital in the intraflagellar transport, a mechanism responsible for the movement of proteins inside the flagella and cilia of cells. Furthermore, KIFAP3 is also implicated in the COPI-dependent Golgi-to-ER retrograde traffic, a cellular process that ensures the delivery of proteins from the Golgi apparatus back to the endoplasmic reticulum. Lastly, it's worth noting that KIFAP3 acts within kinesins, which are a class of motor proteins that move along microtubule filaments in cells.""]",[]
"[{'source_node': {'name': 'sodium cation'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'magnesium sulfate'}}, {'source_node': {'name': 'sodium cation'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fentanyl'}}, {'source_node': {'name': 'sodium cation'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'darodipine'}}, {'source_node': {'name': 'fentanyl'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'magnesium'}}, {'source_node': {'name': 'fentanyl'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 2 subfamily b member 6'}}]","[{'source_node': {'name': 'fentanyl'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'magnesium'}}, {'source_node': {'name': 'fentanyl'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 2 subfamily b member 6'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:12253', 'target': 'COMPOUND:796', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:12253', 'target': None, 'metadata': {'node_id': '12253', 'node_type': 'COMPOUND', 'display_name': 'sodium cation'}}]",0.4545454545454546,394963f2a607d640dfa968f45c91f92c,f184f488f18acbc5b3f30c52f3dd0490,"['The sodium cation decreases the efficacy of several compounds including magnesium sulfate, fentanyl, and darodipine. Meanwhile, fentanyl, a powerful opioid analgesic, not only has its efficacy decreased by sodium cations but also reduces the efficiency of magnesium. Additionally, fentanyl affects the activity of the enzyme Cytochrome P450 family 2 subfamily B member 6, a crucial component in drug metabolism.', 'The presence of sodium cation is known to decrease the efficacy of several substances such as magnesium sulfate, fentanyl and darodipine. Interestingly, fentanyl itself can decrease the efficacy of magnesium and it is also known to affect the cytochrome P450 family 2 subfamily B member 6 enzyme.', 'The presence of sodium cation is known to decrease the efficacy of several substances including magnesium sulfate, fentanyl, and darodipine. Interestingly, fentanyl, a potent opioid, also exhibits a similar behaviour by decreasing the efficacy of magnesium. Moreover, it affects the cytochrome p450 family 2 subfamily b member 6, a crucial enzyme involved in drug metabolism.', 'Sodium cation is reported to decrease the efficacy of multiple agents including magnesium sulfate, fentanyl, and darodipine. Interestingly, fentanyl, one of the agents affected by sodium cation, is also known to decrease the efficacy of magnesium. Furthermore, fentanyl has an impact on the cytochrome p450 family 2 subfamily b member 6, which is an important component of drug metabolism. Therefore, careful consideration should be taken when administering these compounds concurrently.', 'The presence of sodium cation decreases the efficacy of several substances: magnesium sulfate, fentanyl, and darodipine. Concurrently, fentanyl also reduces the efficacy of magnesium, indicating a complex interplay between these substances. Additionally, fentanyl affects the activity of the enzyme known as cytochrome P450 family 2 subfamily B member 6. Therefore, the interaction between sodium cation, fentanyl, darodipine, and magnesium in the body may have significant implications in biological processes and in medicine. Therefore, it is crucial to consider the presence of these substances when conducting health-related assessments and physiological research.']","['The drug Fentanyl has various interactions within the body. It is reported to decrease the efficacy of Magnesium, creating a potential risk for patients with low Magnesium levels. It also exerts effects on metabolic reactions by affecting the function of the enzyme, Cytochrome P450 Family 2 Subfamily B Member 6. This interaction can potentially alter the metabolism and effectiveness of other drugs within the body.']"
"[{'source_node': {'name': 'filaminast'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': ""camp-specific 3',5'-cyclic phosphodiesterase 4b""}}, {'source_node': {'name': ""camp-specific 3',5'-cyclic phosphodiesterase 4b""}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PDE4B'}}]","[{'source_node': {'name': 'filaminast'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': ""camp-specific 3',5'-cyclic phosphodiesterase 4b""}}, {'source_node': {'name': 'filaminast'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'PDE4B'}}, {'source_node': {'name': ""camp-specific 3',5'-cyclic phosphodiesterase 4b""}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PDE4B'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:2513', 'target': 'GENE:30736', 'metadata': {'predicate': 'is_affecting'}}]",0.8,786b6fd3d4f4a01c1ebf6b48129b9038,f35804fad6e1a7111422da6ece0e2c19,[],[]
"[{'source_node': {'name': 'PTGS2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nicotinamide salvaging'}}, {'source_node': {'name': 'PTGS2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Interleukin-10 signaling'}}, {'source_node': {'name': '3-alpha-acetoxy-7,24-diene-tirucallic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prostaglandin e synthase'}}, {'source_node': {'name': '3-alpha-acetoxy-7,24-diene-tirucallic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prostaglandin g/h synthase 2'}}, {'source_node': {'name': 'prostaglandin g/h synthase 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTGS2'}}]","[{'source_node': {'name': 'PTGS2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Interleukin-10 signaling'}}, {'source_node': {'name': '3-alpha-acetoxy-7,24-diene-tirucallic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prostaglandin g/h synthase 2'}}, {'source_node': {'name': '3-alpha-acetoxy-7,24-diene-tirucallic acid'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'PTGS2'}}, {'source_node': {'name': 'prostaglandin g/h synthase 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTGS2'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:67997', 'target': 'GENE:31977', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'PATHWAY:311', 'target': None, 'metadata': {'node_id': '311', 'node_type': 'PATHWAY', 'display_name': 'Nicotinamide salvaging'}}, {'type': 'node_removal', 'source': 'PROTEIN:6334', 'target': None, 'metadata': {'node_id': '6334', 'node_type': 'PROTEIN', 'display_name': 'prostaglandin e synthase'}}]",0.5454545454545454,0289b855514bb3afe792618586cd5879,0a303f419cea25da068c1fc08320a6b5,"['The gene PTGS2 acts within several biological pathways such as the Nicotinamide salvaging and Interleukin-10 signaling. This gene is also identified as the gene product of prostaglandin g/h synthase 2, which indeed is a target of the compound 3-alpha-acetoxy-7,24-diene-tirucallic acid. Additionally, this compound also targets another molecule, prostaglandin e synthase, which plays a significant role in biological processes.', 'The gene PTGS2 is known to act within several biological pathways, including the Nicotinamide salvaging and Interleukin-10 signaling. Furthermore, this PTGS2 gene is the known product of the prostaglandin g/h synthase 2 gene. Interestingly, the substance, 3-alpha-acetoxy-7,24-diene-tirucallic acid, has been identified to target not only this prostaglandin g/h synthase 2 but also the prostaglandin e synthase.', ""The gene PTGS2 plays an active role within the Nicotinamide salvaging and Interleukin-10 signaling pathways. Furthermore, the molecule 3-alpha-acetoxy-7,24-diene-tirucallic acid targets two enzymatic proteins: prostaglandin e synthase and prostaglandin g/h synthase 2. It's essential to note that prostaglandin g/h synthase 2 is a gene product of PTGS2."", 'The gene PTGS2, which functions within the nicotinamide salvaging and interleukin-10 signaling pathways, codes for the protein prostaglandin G/H synthase 2. This protein is one of the targets of 3-alpha-acetoxy-7,24-diene-tirucallic acid, a compound which also targets prostaglandin E synthase.', 'The gene PTGS2, also known as cyclooxygenase-2, acts within the pathways of nicotinamide salvaging and interleukin-10 signaling. This gene is the product of the prostaglandin g/h synthase 2 protein, which is a target of the compound 3-alpha-acetoxy-7,24-diene-tirucallic acid. This compound also targets the prostaglandin e synthase, revealing a complex network of interactions within the body.']",[]
"[{'source_node': {'name': 'etilevodopa'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hypertensive activities '}}, {'source_node': {'name': 'etilevodopa'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sertindole'}}, {'source_node': {'name': 'azaperone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carbidopa'}}, {'source_node': {'name': 'azaperone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'biperiden'}}, {'source_node': {'name': 'azaperone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'etilevodopa'}}]","[{'source_node': {'name': 'carbidopa'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'biperiden'}}, {'source_node': {'name': 'etilevodopa'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hypertensive activities '}}, {'source_node': {'name': 'etilevodopa'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sertindole'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:9348', 'target': 'ACTIVITY:15', 'metadata': {'predicate': 'decrease_activity'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:9348', 'target': 'COMPOUND:5646', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:180', 'target': 'COMPOUND:793', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:9348', 'target': None, 'metadata': {'node_id': '9348', 'node_type': 'COMPOUND', 'display_name': 'azaperone'}}]",0.6363636363636364,e9235d3061da49961b9311358a0a5428,9670f5a1a54286ab194867bfe8ae3c98,[],[]
"[{'source_node': {'name': 'lissencephaly 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hearing impairment'}}, {'source_node': {'name': 'lissencephaly 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cataract'}}, {'source_node': {'name': 'lissencephaly 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'global developmental delay'}}]","[{'source_node': {'name': 'lissencephaly 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hearing impairment'}}, {'source_node': {'name': 'lissencephaly 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'global developmental delay'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:396', 'target': None, 'metadata': {'node_id': '396', 'node_type': 'PHENOTYPE', 'display_name': 'cataract'}}]",0.7142857142857143,5f59f0dc1e81a5035a20fb29b64ff15d,1b7a2d45fe024d839c1fbc4f19e79514,"['Lissencephaly 5 is a disorder associated with several phenotypes such as hearing impairment and cataract. Additionally, individuals with Lissencephaly 5 often show a distinct pattern of global developmental delay.', 'Lissencephaly 5, a neurological condition, has various phenotypes - the prominent symptoms include hearing impairment, cataract, and global developmental delay.', 'Lissencephaly 5, a neurodevelopmental disorder, has several distinct phenotypes associated with it. These phenotypes include hearing impairment and cataract, both of which afflict the sensory organs, as well as global developmental delay, which is a broader indicator of reduced physical and intellectual growth.', 'Lissencephaly 5 is a medical condition that exhibits several phenotypes including hearing impairment, cataract, and global developmental delay.', 'Lissencephaly 5 is a condition that exhibits several phenotypes including hearing impairment, cataract, and global developmental delay.']","['Lissencephaly 5 is a condition associated with various phenotypes such as hearing impairment and global developmental delay.', 'Lissencephaly 5 is a condition that presents various phenotypes such as hearing impairment and global developmental delay.', 'Lissencephaly 5, a neurological condition, presents with several phenotypes including hearing impairment and global developmental delay.', 'Lissencephaly 5 is a complex neurological condition associated with various phenotypes. Notably, individuals diagnosed with this condition often display hearing impairment and global developmental delay.', 'Lissencephaly 5, a neurological disorder, has phenotypes that include hearing impairment and global developmental delay.']"
"[{'source_node': {'name': 'neocitrullamon'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mefloquine'}}, {'source_node': {'name': 'neocitrullamon'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'centella asiatica'}}, {'source_node': {'name': 'evening primrose oil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phenobarbital'}}, {'source_node': {'name': 'evening primrose oil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'valpromide'}}, {'source_node': {'name': 'evening primrose oil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'neocitrullamon'}}]","[{'source_node': {'name': 'centella asiatica'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'evening primrose oil'}}, {'source_node': {'name': 'centella asiatica'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phenobarbital'}}, {'source_node': {'name': 'neocitrullamon'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mefloquine'}}, {'source_node': {'name': 'neocitrullamon'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'centella asiatica'}}, {'source_node': {'name': 'neocitrullamon'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'valpromide'}}, {'source_node': {'name': 'evening primrose oil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phenobarbital'}}, {'source_node': {'name': 'evening primrose oil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'valpromide'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:11251', 'target': 'COMPOUND:3921', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:9331', 'target': 'COMPOUND:11251', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:12077', 'target': 'COMPOUND:9331', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:12077', 'target': 'COMPOUND:1154', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.6363636363636364,e0bf28bf4d5a7dfb3fd64541b509b3fa,44cb7d976191abb5e18528a19e379cd7,"['Neocitrullamon is reported to decrease the efficacy of several substances such as mefloquine and centella asiatica. On the other hand, evening primrose oil can impact the effectiveness of medications such as phenobarbital and valpromide. Interestingly, evening primrose oil also reduces the efficacy of neocitrullamon, creating a complex interplay between these agents. Care should be taken when using these substances concurrently because of their interactive effects.', 'Neocitrullamon and evening primrose oil have been noted to decrease the efficacy of certain substances. Neocitrullamon has shown to lessen the potency of both mefloquine, an antimalarial medication, and centella asiatica, a medicinal plant used in the treatment of various conditions. Similarly, the effectiveness of several compounds - phenobarbital, a medication used primarily to treat seizures; valpromide, an antiepileptic drug; and neocitrullamon itself - are decreased when combined with evening primrose oil.', 'Neocitrullamon, a compound, is known to decrease the efficacy of certain substances such as mefloquine, a medication, and centella asiatica, a plant extract. On the other hand, evening primrose oil, another compound, could reduce the effectiveness of medications like phenobarbital and valpromide. Interestingly, evening primrose oil also decreases the efficacy of neocitrullamon.', 'Neocitrullamon is a compound that has been found to decrease the efficacy of certain substances, notably mefloquine and Centella asiatica. Similarly, Evening Primrose Oil also displays this negative interaction with substances such as phenobarbital, valpromide, and interestingly, neocitrullamon itself. Therefore, caution needs to be taken when considering combined usage of these compounds.', 'The substance neocitrullamon has been found to decrease the efficacy of both mefloquine, an anti-malarial drug, and Centella asiatica, a medicinal plant often used in traditional medicines. On the other hand, evening primrose oil is known to decrease the efficacy of several substances, including the anticonvulsant drugs phenobarbital and valpromide, as well as neocitrullamon itself. In practice, this suggests a possible interaction between these substances, which could impact their overall effectiveness.']","['Centella Asiatica is known to increase the efficacy of Evening Primrose Oil but at the same time it decreases the efficacy of Phenobarbital. On the other hand, Neocitrullamon, another substance, decreases the efficacy of several agents including Centella Asiatica, Mefloquine, and Valpromide. Interestingly, Evening Primrose Oil, despite its improved efficacy by Centella Asiatica, also decreases the efficacy of Phenobarbital and Valpromide. This intertwined series of interactions reflects the complex nature of efficacy modulation between these substances.', 'Centella Asiatica, a medicinal herb, acts by altering the efficacy of other substances. For instance, it has been observed to increase the efficacy of Evening Primrose Oil, making it more effective. However, it simultaneously decreases the efficacy of Phenobarbital, decreasing its effectiveness. \n\nNeocitrullamon, on the other hand, acts largely by reducing efficacy. It has been found to decrease the effectiveness of Mefloquine, Centella Asiatica and Valpromide. \n\nLastly, Evening Primrose Oil, an herbal supplement, also has interactions that reduce efficacy, specifically decreasing the effectiveness of both Phenobarbital and Valpromide. Overall, these findings suggest complex interactions between these various agents in the body and underscore the need to consider these interactions when using or prescribing them.', 'Centella Asiatica has been observed to increase the efficacy of Evening Primrose Oil and decrease the efficacy of Phenobarbital. Interestingly, Neocitrullamon decreases the efficacy of Mefloquine, Centella Asiatica, and Valpromide. Evening Primrose Oil also shows a decrease in effectiveness when interacting with both Phenobarbital and Valpromide. These interactive effects need to be taken into account for optimizing the usage of these medicinal compounds.', 'The herb Centella Asiatica exhibits divergent properties, where it heightens the efficacy of Evening Primrose Oil, while reducing the effectiveness of the drug Phenobarbital. Another pharmaceutical entity, Neocitrullamon, also has various effects where it substantially decreases the efficacy of multiple substances including Mefloquine, Centella Asiatica, and Valpromide. Furthermore, Evening Primrose Oil induces a similar effect by lessening the efficacy of Phenobarbital and Valpromide. Overall, this describes the myriad interactions and impacts these substances have within the network of pharmaceutical activity.', 'Centella Asiatica, a medicinal herb, has been found to increase the efficacy of Evening Primrose Oil, which is often used in herbal remedies. However, it should be noted that the same Centella Asiatica can decrease the efficacy of Phenobarbital, a medication used to treat seizures. Similarly, Neocitrullamon, an acidic compound, decreases the efficacy of a number of substances, such as Mefloquine (used to prevent and treat malaria), Centella Asiatica itself, and Valpromide, a mood-stabilizing drug. Lastly, Evening Primrose Oil, while enhanced by Centella Asiatica, decreases the efficacy of both Phenobarbital and Valpromide. Thus, potential interactions should be considered before combining these substances in treatment approaches.']"
"[{'source_node': {'name': '2,3,4,7-tetramethoxyphenanthrene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': '2,3,4,7-tetramethoxyphenanthrene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': '2,3,4,7-tetramethoxyphenanthrene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}]","[{'source_node': {'name': '2,3,4,7-tetramethoxyphenanthrene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': '2,3,4,7-tetramethoxyphenanthrene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5851', 'target': None, 'metadata': {'node_id': '5851', 'node_type': 'PROTEIN', 'display_name': 'mcf7'}}]",0.7142857142857143,7b67ef9d3d94341d39804f3e05049e00,2d147ca3a955653755cd20228755d072,"['The compound 2,3,4,7-tetramethoxyphenanthrene displays targeted action towards several cell lines which include A549, MCF7 and HT-29.', 'The compound 2,3,4,7-tetramethoxyphenanthrene targets different cell lines including A549, MCF7, and HT-29.', 'The compound 2,3,4,7-tetramethoxyphenanthrene has been identified to target several cell lines which include A549, MCF7, and HT-29.', 'The compound 2,3,4,7-tetramethoxyphenanthrene has multiple targets. It affects A549, MCF7 and HT-29, which are distinct cell lines used in scientific research.', 'The compound 2,3,4,7-tetramethoxyphenanthrene has been identified to target several cell lines including A549, MCF7 and HT-29.']","['The compound 2,3,4,7-tetramethoxyphenanthrene has two known targets: a549 and ht-29.', 'The substance 2,3,4,7-tetramethoxyphenanthrene has two key targets: A549 and HT-29.', 'The compound 2,3,4,7-tetramethoxyphenanthrene has a couple of specific targets, including A549 and HT-29.', 'The compound 2,3,4,7-tetramethoxyphenanthrene targets both the A549 and HT-29 cell lines.', 'The compound 2,3,4,7-tetramethoxyphenanthrene has been identified to target two cell lines: A549 and HT-29.']"
"[{'source_node': {'name': 'dexniguldipine'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' hypertension '}}, {'source_node': {'name': 'dexniguldipine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cimicoxib'}}, {'source_node': {'name': 'oxyphenisatin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lercanidipine'}}, {'source_node': {'name': 'oxyphenisatin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'thiopental'}}, {'source_node': {'name': 'oxyphenisatin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dexniguldipine'}}]","[{'source_node': {'name': 'dexniguldipine'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' hypertension '}}, {'source_node': {'name': 'oxyphenisatin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'thiopental'}}, {'source_node': {'name': 'oxyphenisatin'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' hypertension '}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:4539', 'target': 'COMPOUND:11898', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:514', 'target': None, 'metadata': {'node_id': '514', 'node_type': 'COMPOUND', 'display_name': 'lercanidipine'}}, {'type': 'edge_addition', 'source': 'COMPOUND:4539', 'target': 'EFFECT:31', 'metadata': {'predicate': 'increase_effect'}}, {'type': 'node_removal', 'source': 'COMPOUND:4773', 'target': None, 'metadata': {'node_id': '4773', 'node_type': 'COMPOUND', 'display_name': 'cimicoxib'}}]",0.4545454545454546,a2979a7435fdf4b67af8334439f6d230,ff1e85f3d9d90c7f07b0be574a0878c6,[],[]
"[{'source_node': {'name': 'tyrosinemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypophosphatemic rickets'}}, {'source_node': {'name': 'tyrosinemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'melena'}}, {'source_node': {'name': 'HPD'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'tyrosinemia'}}, {'source_node': {'name': 'HPD'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hawkinsinuria'}}, {'source_node': {'name': 'HPD'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Tyrosine catabolism'}}]","[{'source_node': {'name': 'tyrosinemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'melena'}}]","[{'type': 'edge_deletion', 'source': 'GENE:28886', 'target': 'DISEASE:7208', 'metadata': None}, {'type': 'node_removal', 'source': 'PHENOTYPE:3353', 'target': None, 'metadata': {'node_id': '3353', 'node_type': 'PHENOTYPE', 'display_name': 'hypophosphatemic rickets'}}, {'type': 'node_removal', 'source': 'PATHWAY:1459', 'target': None, 'metadata': {'node_id': '1459', 'node_type': 'PATHWAY', 'display_name': 'Tyrosine catabolism'}}, {'type': 'node_removal', 'source': 'GENE:28886', 'target': None, 'metadata': {'node_id': '28886', 'node_type': 'GENE', 'display_name': 'HPD'}}]",0.2727272727272727,a13d5eb6158d68f46d7450876a44ac78,6f4e7013fa4ccadea268fcbd2a49419e,"['The gene HPD, functioning within the tyrosine catabolism pathway, is known to cause conditions such as tyrosinemia and hawkinsinuria. Furthermore, tyrosinemia presents with distinctive phenotypes such as hypophosphatemic rickets and melena.', 'Tyrosinemia, a condition caused by the gene HPD, is characterized by various symptoms including hypophosphatemic rickets and melena. Notably, this gene not only causes tyrosinemia but is also responsible for hawkinsinuria. Importantly, HPD acts within the pathway of tyrosine catabolism, adding to our understanding of the biological processes contributing to these disease conditions.', 'The gene HPD, which acts within the pathway of tyrosine catabolism, has been shown to cause two conditions: tyrosinemia and hawkinsinuria. Tyrosinemia is associated with specific phenotypes such as hypophosphatemic rickets and melena.', 'The gene HPD, which acts within the Tyrosine catabolism pathway, is known to cause conditions like tyrosinemia and hawkinsinuria. Tyrosinemia, in particular, has phenotypes such as hypophosphatemic rickets and melena.', 'The gene HPD, which is involved in the tyrosine catabolism pathway, can cause several conditions including tyrosinemia and hawkinsinuria. Tyrosinemia itself is associated with various phenotypes such as hypophosphatemic rickets and melena.']",[]
"[{'source_node': {'name': 'RAPGEF3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Integrin signaling'}}, {'source_node': {'name': 'RAPGEF3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Rap1 signalling'}}, {'source_node': {'name': 'RAPGEF3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of insulin secretion'}}]","[{'source_node': {'name': 'RAPGEF3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Integrin signaling'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:299', 'target': None, 'metadata': {'node_id': '299', 'node_type': 'PATHWAY', 'display_name': 'Rap1 signalling'}}, {'type': 'node_removal', 'source': 'PATHWAY:630', 'target': None, 'metadata': {'node_id': '630', 'node_type': 'PATHWAY', 'display_name': 'Regulation of insulin secretion'}}]",0.4285714285714286,58e76f989b6926b36d94951841bd9583,83f559d789a35000cad6346178884dbd,"['The gene RAPGEF3 plays a crucial role in several pathways. It acts within the pathway of Integrin signaling and is involved in Rap1 signalling. Additionally, it plays a part in the regulation of insulin secretion, contributing to the regulation of glucose levels in the body.', 'The gene RAPGEF3 is an active participant within several cellular pathways, specifically integrin signaling, Rap1 signalling and the regulation of insulin secretion.', 'The gene RAPGEF3 plays a significant role in various paths including integrin signaling, Rap1 signalling, and the regulation of insulin secretion.', 'The gene RAPGEF3 plays a key role in a variety of cellular processes, as it acts within pathways such as integrin signaling, Rap1 signalling, and regulation of insulin secretion.', 'The gene RAPGEF3 is involved in various pathways. It plays a significant role in integrin signalling, Rap1 signalling, as well as in the regulation of insulin secretion.']",['The gene RAPGEF3 operates within the context of integrin signaling.']
"[{'source_node': {'name': 'ranibizumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'ranibizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imlifidase'}}, {'source_node': {'name': 'ranibizumab'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'ldl receptor related protein 5'}}]","[{'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_effect'}, 'target_node': {'name': ' adverse effects '}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:12843', 'target': 'EFFECT:5', 'metadata': {'predicate': 'decrease_effect'}}, {'type': 'node_removal', 'source': 'COMPOUND:1249', 'target': None, 'metadata': {'node_id': '1249', 'node_type': 'COMPOUND', 'display_name': 'ranibizumab'}}]",0.1428571428571429,4816a6f4df106dc62694ca3d941899f6,355d4aaf096df2c8b4d41e864e031d0c,[],[]
"[{'source_node': {'name': 'KIF11'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'microcephaly with or without chorioretinopathy'}}, {'source_node': {'name': 'KIF11'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'MHC class II antigen presentation'}}, {'source_node': {'name': 'KIF11'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'COPI-dependent Golgi-to-ER retrograde traffic'}}, {'source_node': {'name': 'microcephaly with or without chorioretinopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'retinal fold'}}, {'source_node': {'name': 'microcephaly with or without chorioretinopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'optic atrophy'}}]","[{'source_node': {'name': 'KIF11'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'COPI-dependent Golgi-to-ER retrograde traffic'}}, {'source_node': {'name': 'microcephaly with or without chorioretinopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'optic atrophy'}}]","[{'type': 'edge_deletion', 'source': 'GENE:29472', 'target': 'DISEASE:5956', 'metadata': None}, {'type': 'node_removal', 'source': 'PHENOTYPE:5097', 'target': None, 'metadata': {'node_id': '5097', 'node_type': 'PHENOTYPE', 'display_name': 'retinal fold'}}, {'type': 'node_removal', 'source': 'PATHWAY:175', 'target': None, 'metadata': {'node_id': '175', 'node_type': 'PATHWAY', 'display_name': 'MHC class II antigen presentation'}}]",0.5454545454545454,b32295255b0543a413c7ed658f0840ea,d061285062445ba495850226ec702f68,"['The gene KIF11 functions within the pathways of MHC class II antigen presentation and COPI-dependent Golgi-to-ER retrograde traffic. Interestingly, KIF11 is known to cause a condition known as microcephaly with or without chorioretinopathy. This condition is characterized by specific phenotypes such as retinal fold and optic atrophy.', 'The gene KIF11 acts within the MHC class II antigen presentation and the COPI-dependent Golgi-to-ER retrograde traffic pathways. Notably, KIF11 is known to cause a condition known as microcephaly with or without chorioretinopathy. This condition is characterized by phenotypic features like retinal fold and optic atrophy.', 'The protein KIF11 is known to act within two different pathways: MHC class II antigen presentation and COPI-dependent Golgi-to-ER retrograde traffic. It is also noted that this protein causes a condition known as microcephaly with or without chorioretinopathy. This condition attributes to two significant phenotypes: retinal fold and optic atrophy.', 'The gene KIF11, which participates in MHC class II antigen presentation and COPI-dependent Golgi-to-ER retrograde traffic pathways, is known to cause a condition known as microcephaly with or without chorioretinopathy. This condition is characterized by phenotypes such as retinal fold and optic atrophy.', 'The gene KIF11 acts within several pathways, including MHC class II antigen presentation and COPI-dependent Golgi-to-ER retrograde traffic. The activity of this gene directly causes a condition known as microcephaly with or without chorioretinopathy. This condition is characterized by distinct phenotypes including retinal folds and optic atrophy.']","['The protein KIF11 is involved in the process of COPI-dependent Golgi-to-ER retrograde traffic. A disorder known as microcephaly with or without chorioretinopathy exhibits phenotypes which include optic atrophy.', 'The gene KIF11 operates within the pathway of COPI-dependent Golgi-to-ER retrograde traffic. A condition called Microcephaly with or without chorioretinopathy, where the brain does not fully develop, has a phenotype associated with it known as optic atrophy.', 'The gene KIF11 acts within the pathway of COPI-dependent Golgi-to-ER retrograde traffic. On the other hand, the condition known as microcephaly with or without chorioretinopathy has an associated phenotype of optic atrophy.']"
"[{'source_node': {'name': 'tyrosinase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TYR'}}, {'source_node': {'name': 'glyasperin c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosinase'}}, {'source_node': {'name': 'TYR'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'albinism'}}]","[{'source_node': {'name': 'TYR'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'albinism'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:655', 'target': None, 'metadata': {'node_id': '655', 'node_type': 'PROTEIN', 'display_name': 'tyrosinase'}}]",0.4285714285714286,84737826437681c9a8bf2afba2cac138,93b1c776903fcb68c4df5bbd76c2a8f6,"['Glyasperin C, a compound noted for its biological effects, targets tyrosinase, an enzyme. This enzyme is a gene product of TYR. Notably, the TYR gene is associated with causing the condition of albinism.', 'Tyrosinase is a gene product of the gene TYR and it is targeted by the compound Glyasperin C. Additionally, the gene TYR is known to cause a condition called albinism.', 'The enzyme tyrosinase, which is a gene product of TYR, is targeted by glyasperin C. Notably, mutations in the TYR gene are known to cause the condition known as albinism.', 'Tyrosinase is a gene product of TYR and is a target of the compound glyasperin c. Additionally, TYR is known to cause the condition albinism.', 'Tyrosinase is a gene product of TYR and is targeted by the drug Glyasperin C. Notably, TYR is known to cause the condition of albinism.']",[]
"[{'source_node': {'name': 'senna leaf'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'talbutal'}}, {'source_node': {'name': 'senna leaf'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'doxepin'}}, {'source_node': {'name': 'senna leaf'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pizotifen'}}, {'source_node': {'name': 'talbutal'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'gamma-aminobutyric acid receptor subunit alpha-1'}}, {'source_node': {'name': 'talbutal'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'isoflurophate'}}, {'source_node': {'name': 'talbutal'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bambuterol'}}, {'source_node': {'name': 'doxepin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Diplopia'}}]","[{'source_node': {'name': 'pizotifen'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'senna leaf'}}, {'source_node': {'name': 'senna leaf'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pizotifen'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:13275', 'target': 'COMPOUND:296', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:1122', 'target': None, 'metadata': {'node_id': '1122', 'node_type': 'COMPOUND', 'display_name': 'doxepin'}}, {'type': 'edge_addition', 'source': 'COMPOUND:662', 'target': 'COMPOUND:296', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:296', 'target': None, 'metadata': {'node_id': '296', 'node_type': 'COMPOUND', 'display_name': 'talbutal'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5419', 'target': 'COMPOUND:13275', 'metadata': {'predicate': 'increase_efficacy'}}]",0.1333333333333333,107101b47f88c5984bfdb05aae3eaaff,a0b0c59e004386a09a6f36e235468549,[],"['The drug pizotifen has been found to increase the efficacy of senna leaf. However, interestingly, senna leaf has been noted to decrease the efficacy of pizotifen. This indicates a complex interactive relationship between the two.', 'Pizotifen is known to increase the efficacy of senna leaf. However, it should also be noted that senna leaf may conversely decrease the efficacy of Pizotifen, creating a complex interaction between the two.', ""The medication pizotifen has been found to increase the efficacy of senna leaf. However, it's notable that the efficacy of pizotifen is reciprocally decreased by the use of senna leaf."", 'The drug Pizotifen is known to increase the efficacy of Senna Leaf. Interestingly, in a reciprocal interaction, Senna Leaf also has the ability to decrease the efficacy of Pizotifen.', 'The medication pizotifen is known to increase the efficacy of another medicinal plant known as senna leaf. Interestingly, senna leaf in turn decreases the efficacy of pizotifen. Therefore, care must be taken when administering these two substances together.']"
"[{'source_node': {'name': 'PPP2R5E'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Separation of Sister Chromatids'}}, {'source_node': {'name': 'PPP2R5E'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'APC truncation mutants have impaired AXIN binding'}}, {'source_node': {'name': 'PPP2R5E'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling'}}]","[{'source_node': {'name': 'PPP2R5E'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Separation of Sister Chromatids'}}, {'source_node': {'name': 'PPP2R5E'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'APC truncation mutants have impaired AXIN binding'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:820', 'target': None, 'metadata': {'node_id': '820', 'node_type': 'PATHWAY', 'display_name': 'PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling'}}]",0.7142857142857143,db5219b74f4179f95c44ca2fdf2d617e,f336786124c6fb58c319ea09d6ff2bba,[],[]
"[{'source_node': {'name': 'CYB5A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Vitamin C (ascorbate) metabolism'}}, {'source_node': {'name': 'chromous sulfate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome b5'}}, {'source_node': {'name': 'chromous sulfate'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the excretion rate '}}, {'source_node': {'name': 'cytochrome b5'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYB5A'}}]","[{'source_node': {'name': 'CYB5A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Vitamin C (ascorbate) metabolism'}}, {'source_node': {'name': 'chromous sulfate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome b5'}}, {'source_node': {'name': 'chromous sulfate'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the excretion rate '}}, {'source_node': {'name': 'chromous sulfate'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'CYB5A'}}, {'source_node': {'name': 'cytochrome b5'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYB5A'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:12267', 'target': 'GENE:26261', 'metadata': {'predicate': 'is_affecting'}}]",0.8888888888888888,c4cc6ee600d00af38f5ec42dfb130ece,a227e75b81aa794bf60c26a7d53251f6,[],[]
"[{'source_node': {'name': 'sotos syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'pedal edema'}}, {'source_node': {'name': 'sotos syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypodontia'}}]","[{'source_node': {'name': 'sotos syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'pedal edema'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:522', 'target': None, 'metadata': {'node_id': '522', 'node_type': 'PHENOTYPE', 'display_name': 'hypodontia'}}]",0.6,cf5137d70c58db6f8979ace6b265bffd,b341028c69a0ae9afeeb70ce974de33a,[],[]
"[{'source_node': {'name': 'DRD1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Dopamine receptors'}}, {'source_node': {'name': 'DRD1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (s) signalling events'}}]","[{'source_node': {'name': 'DRD1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (s) signalling events'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1356', 'target': None, 'metadata': {'node_id': '1356', 'node_type': 'PATHWAY', 'display_name': 'Dopamine receptors'}}]",0.6,515e15a84ae14f9a7ab8c61bf0897039,cea5032c646b6b47d6fb23606f9fbc37,"['The gene DRD1 is active within multiple processes, specifically within both dopamine receptors and G alpha (s) signalling events.', 'The gene DRD1 operates within various biological domains, functioning in processes such as dopamine receptors and G alpha (s) signalling events.', 'The gene DRD1 plays a significant role in certain biological pathways, specifically acting within the dopamine receptors and G alpha (s) signalling events.', 'The gene DRD1 plays a functional role in two crucial signaling processes. Firstly, DRD1 acts within the framework of dopamine receptors, which play a pivotal role in the neuronal signals associated with reward-motivated behavior. Secondly, it interacts with G alpha (s) signalling events, a crucial step in transmitting signals from many hormones, neurotransmitters and other signaling factors.', 'The gene DRD1 acts within multiple signaling pathways, including dopamine receptors and G alpha (s) signalling events. These pathways illustrate the complex ways in which DRD1 modulates and is modulated by various biological systems.']","['The gene DRD1 plays a role within the G alpha (s) signaling events pathway.', 'The gene DRD1 operates within the context of G alpha (s) signalling events.']"
"[{'source_node': {'name': 'muscimol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'gamma-aminobutyric acid receptor subunit alpha-1'}}, {'source_node': {'name': 'muscimol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'gamma-aminobutyric acid receptor subunit gamma-2'}}]","[{'source_node': {'name': 'muscimol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'gamma-aminobutyric acid receptor subunit alpha-1'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:1106', 'target': None, 'metadata': {'node_id': '1106', 'node_type': 'PROTEIN', 'display_name': 'gamma-aminobutyric acid receptor subunit gamma-2'}}]",0.6,26d8a1a1e1153e3a827c69476e376f88,5683a39d44823b8369bea0c1d79bd8ee,"['The drug Muscimol targets two specific receptors: the gamma-aminobutyric acid receptor subunit alpha-1 and the gamma-aminobutyric acid receptor subunit gamma-2.', 'The molecule muscimol is known to target two specific gamma-aminobutyric acid receptor subunits: alpha-1 and gamma-2.', 'The compound muscimol targets two different receptors: the gamma-aminobutyric acid receptor subunit alpha-1 and the gamma-aminobutyric acid receptor subunit gamma-2.', 'The substance named muscimol targets two specific receptors: the gamma-aminobutyric acid receptor subunit alpha-1 and the gamma-aminobutyric acid receptor subunit gamma-2.', 'The drug muscimol targets two primary receptors, the gamma-aminobutyric acid receptor subunit alpha-1 and the gamma-aminobutyric acid receptor subunit gamma-2.']","['The drug Muscimol has a target in the gamma-aminobutyric acid receptor subunit alpha-1.', 'The compound Muscimol has the gamma-aminobutyric acid receptor subunit alpha-1 as its target.']"
"[{'source_node': {'name': '3-carbamimidamido-1,1-diphenylurea'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prothrombin'}}, {'source_node': {'name': 'prothrombin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'F2'}}]","[{'source_node': {'name': '3-carbamimidamido-1,1-diphenylurea'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prothrombin'}}, {'source_node': {'name': '3-carbamimidamido-1,1-diphenylurea'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'F2'}}, {'source_node': {'name': 'prothrombin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'F2'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:6157', 'target': 'GENE:26852', 'metadata': {'predicate': 'is_affecting'}}]",0.8,27c6810255531b0d99f2f5326b1b914a,bf6ccd0632a81ee19ba1077bc187ee49,"['The drug 3-carbamimidamido-1,1-diphenylurea targets prothrombin, which interestingly, is the gene product of F2.', 'The drug 3-carbamimidamido-1,1-diphenylurea has been identified to target prothrombin. Interestingly, prothrombin is a gene product of F2.', 'The drug 3-carbamimidamido-1,1-diphenylurea acts against prothrombin, which is a gene product of the gene F2.', 'The drug 3-carbamimidamido-1,1-diphenylurea has a specific target, which is the protein known as prothrombin. This prothrombin is a gene product of F2.', 'The drug 3-carbamimidamido-1,1-diphenylurea has prothrombin as its target. Prothrombin is a gene product of F2.']",[]
"[{'source_node': {'name': 'zerumin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 't-cell protein-tyrosine phosphatase'}}, {'source_node': {'name': 'zerumin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}, {'source_node': {'name': 't-cell protein-tyrosine phosphatase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN2'}}]","[{'source_node': {'name': 'zerumin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}, {'source_node': {'name': 't-cell protein-tyrosine phosphatase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN2'}}, {'source_node': {'name': 't-cell protein-tyrosine phosphatase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:5888', 'target': 'GENE:32076', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:84725', 'target': 'PROTEIN:5888', 'metadata': None}]",0.7777777777777778,65fb8bedeba84d358c9418d004f60cf6,e5bb98c0220673ebfff0eec6d61a57cf,"['The drug Zerumin A targets two specific proteins, T-cell protein-tyrosine phosphatase and tyrosine-protein phosphatase non-receptor type 1. Interestingly, these proteins are gene products of PTPN2 and PTPN1, respectively.', 'The compound Zerumin A targets both T-cell protein-tyrosine phosphatase and Tyrosine-protein phosphatase non-receptor type 1. It should be noted that T-cell protein-tyrosine phosphatase is the gene product of PTPN2, whereas Tyrosine-protein phosphatase non-receptor type 1 is the gene product of PTPN1.', 'Zerumin A is a compound known to target two distinct proteins - T-cell protein-tyrosine phosphatase and tyrosine-protein phosphatase non-receptor type 1. Interestingly, both these proteins are different gene products. T-cell protein-tyrosine phosphatase is a gene product of PTPN2 while tyrosine-protein phosphatase non-receptor type 1 is a gene product of PTPN1. Hence, through its targets, Zerumin A could potentially mediate interactions with the PTPN1 and PTPN2 genes.', 'The compound zerumin A targets two different proteins: t-cell protein-tyrosine phosphatase and tyrosine-protein phosphatase non-receptor type 1. The former is a gene product of PTPN2, while the latter is produced by the gene PTPN1.', 'The drug Zerumin A has two main targets - the T-cell protein-tyrosine phosphatase and the Tyrosine-protein phosphatase non-receptor type 1. Interestingly, the T-cell protein-tyrosine phosphatase is a gene product of PTPN2, while the Tyrosine-protein phosphatase non-receptor type 1 is a gene product of PTPN1.']","['The drug Zerumin A has been identified to target tyrosine-protein phosphatase non-receptor type 1, which is a gene product of PTPN1. In addition, T-cell protein-tyrosine phosphatase has been linked to the genes PTPN1 and PTPN2, indicating that this protein is a gene product of both. This highlights the interconnected relationship between these genes and proteins in biological processes.', 'The drug Zerumin A targets the Tyrosine-Protein Phosphatase Non-Receptor Type 1, which is a gene product of PTPN1. In addition, the T-Cell Protein-Tyrosine Phosphatase is another gene product of PTPN1, as well as PTPN2.', 'Zerumin A targets the tyrosine-protein phosphatase non-receptor type 1, which is a gene product of PTPN1. Interestingly, the t-cell protein-tyrosine phosphatase is a gene product of both PTPN1 and PTPN2.', 'The compound Zerumin A targets a particular protein, the tyrosine-protein phosphatase non-receptor type 1. Interestingly, this protein is a gene product of PTPN1. Additionally, the T-cell protein-tyrosine phosphatase, which is known to be a gene product of both PTPN1 and PTPN2 genes, also plays a significant role in cellular processes.', 'The drug Zerumin A has been found to target Tyrosine-Protein Phosphatase Non-Receptor Type 1, which is a gene product of PTPN1. Interestingly, PTPN1 is also responsible for producing the T-cell Protein-Tyrosine Phosphatase. Moreover, T-cell Protein-Tyrosine Phosphatase is not solely a product of PTPN1, but is also associated with PTPN2. Therefore, a complex interaction network exists involving Zerumin A, two protein-tyrosine phosphatases and their corresponding genes, PTPN1 and PTPN2.']"
"[{'source_node': {'name': 'elenoside'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'uo-31'}}, {'source_node': {'name': 'elenoside'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h23'}}]","[{'source_node': {'name': 'elenoside'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'uo-31'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5618', 'target': None, 'metadata': {'node_id': '5618', 'node_type': 'PROTEIN', 'display_name': 'nci-h23'}}]",0.6,aeef159ae2b1467c325bea80635ef43b,c1fca5d719716614502d45b58a064e11,"['The compound elenoside is known to target both UO-31 and NCI-H23.', 'The compound elenoside has targets including both uo-31 and nci-h23.', 'Elenoside, a compound of interest, primarily targets both UO-31 and NCI-H23. These targeted entities could serve as potential pathways for further scientific investigation on the effects of Elenoside.', 'The compound elenoside targets two entities, UO-31 and NCI-H23.', 'The compound elenoside has been identified to target both UO-31 and NCI-H23.']",['The compound elenoside has a target known as uo-31.']
"[{'source_node': {'name': 'remurin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}, {'source_node': {'name': 'remurin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hsc-2'}}, {'source_node': {'name': 'remurin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hsc-3'}}]","[{'source_node': {'name': 'remurin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5438', 'target': None, 'metadata': {'node_id': '5438', 'node_type': 'PROTEIN', 'display_name': 'hsc-3'}}, {'type': 'node_removal', 'source': 'PROTEIN:5860', 'target': None, 'metadata': {'node_id': '5860', 'node_type': 'PROTEIN', 'display_name': 'hsc-2'}}]",0.4285714285714286,6ebba3f53179edc16cb46bec160f0395,4041eac53acdb62f5779b50961ee8361,"['The compound Remurin B targets several entities including the HL-60 cell line, as well as HSC-2 and HSC-3 cell types.', 'The compound Remurin B has several notable biological targets. These include the HL-60 cell line, HSC-2 cells, and HSC-3 cells.', 'The compound Remurin B has been observed to target several entities such as HL-60, HSC-2, and HSC-3.', 'Remurin B is a compound known for its multiple biological targets. It has an affinity for HL-60, HSC-2, and HSC-3 cell lines, potentially having effects on various biological processes involving these cells.', 'Remurin B, a pharmacological substance, has multiple targets including HL-60, a human promyelocytic leukemia cell line, as well as HSC-2 and HSC-3, two human oral cancer cell lines.']",['The drug Remurin B has been noted to specifically target the HL-60 cell line.']
"[{'source_node': {'name': '4-bromo-2,5-dimethoxyamphetamine'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' serotonin syndrome '}}, {'source_node': {'name': '4-bromo-2,5-dimethoxyamphetamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'propranolol'}}, {'source_node': {'name': '4-bromo-2,5-dimethoxyamphetamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dutasteride'}}, {'source_node': {'name': 'landiolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dexmedetomidine'}}, {'source_node': {'name': 'landiolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methyldopa'}}, {'source_node': {'name': 'landiolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '4-bromo-2,5-dimethoxyamphetamine'}}, {'source_node': {'name': 'methyldopa'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'zaltoprofen'}}]","[{'source_node': {'name': '4-bromo-2,5-dimethoxyamphetamine'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' serotonin syndrome '}}, {'source_node': {'name': '4-bromo-2,5-dimethoxyamphetamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'propranolol'}}, {'source_node': {'name': '4-bromo-2,5-dimethoxyamphetamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dutasteride'}}, {'source_node': {'name': 'landiolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methyldopa'}}, {'source_node': {'name': 'methyldopa'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'zaltoprofen'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:10118', 'target': 'COMPOUND:1420', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:619', 'target': None, 'metadata': {'node_id': '619', 'node_type': 'COMPOUND', 'display_name': 'dexmedetomidine'}}]",0.8,0e541b3831aabc9c83136bd5f56f84db,e19bc635802d287c1ef1fd7084b6630d,[],[]
"[{'source_node': {'name': 'trimethobenzamide'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' CNS depression '}}, {'source_node': {'name': 'trimethobenzamide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pregabalin'}}, {'source_node': {'name': 'trimethobenzamide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'racepinephrine'}}, {'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'tandospirone'}}, {'source_node': {'name': 'racepinephrine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bisoprolol'}}, {'source_node': {'name': 'racepinephrine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phentolamine'}}, {'source_node': {'name': 'racepinephrine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pseudoephedrine'}}]","[{'source_node': {'name': 'trimethobenzamide'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' CNS depression '}}, {'source_node': {'name': 'trimethobenzamide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pseudoephedrine'}}, {'source_node': {'name': 'pseudoephedrine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phentolamine'}}, {'source_node': {'name': 'racepinephrine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phentolamine'}}, {'source_node': {'name': 'racepinephrine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pseudoephedrine'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:220', 'target': None, 'metadata': {'node_id': '220', 'node_type': 'COMPOUND', 'display_name': 'pregabalin'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:648', 'target': 'COMPOUND:9136', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:835', 'target': 'COMPOUND:677', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:648', 'target': 'COMPOUND:835', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:598', 'target': None, 'metadata': {'node_id': '598', 'node_type': 'COMPOUND', 'display_name': 'bisoprolol'}}]",0.4,a0c59127bbc84a29d4f203433f7ae5d8,8d516f8c4e4e6d16e65a00743d8c7f9a,[],[]
"[{'source_node': {'name': 'OPRK1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Peptide ligand-binding receptors'}}, {'source_node': {'name': 'OPRK1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (i) signalling events'}}, {'source_node': {'name': 'OPRK1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'MECP2 regulates neuronal receptors and channels'}}]","[{'source_node': {'name': 'OPRK1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'MECP2 regulates neuronal receptors and channels'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:109', 'target': None, 'metadata': {'node_id': '109', 'node_type': 'PATHWAY', 'display_name': 'G alpha (i) signalling events'}}, {'type': 'node_removal', 'source': 'PATHWAY:253', 'target': None, 'metadata': {'node_id': '253', 'node_type': 'PATHWAY', 'display_name': 'Peptide ligand-binding receptors'}}]",0.4285714285714286,e1b34e3bd653685e5f8445fb57c63a6a,b33bd8dd26d5282a95a8cb164454b72a,"['The gene OPRK1 is involved in multiple molecular pathways. It acts within peptide ligand-binding receptors and G alpha (i) signalling events. Additionally, OPRK1 also plays a significant role in the mechanism where MECP2 regulates neuronal receptors and channels.', 'The gene OPRK1 performs actions within multiple pathways. These include the pathway of peptide ligand-binding receptors, the pathway of G alpha (i) signalling events, and the pathway where MECP2 regulates neuronal receptors and channels.']",[]
"[{'source_node': {'name': 'ascididemin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}, {'source_node': {'name': 'ascididemin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h322m'}}, {'source_node': {'name': 'ascididemin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'caki-1'}}]","[{'source_node': {'name': 'ascididemin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}, {'source_node': {'name': 'ascididemin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h322m'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5590', 'target': None, 'metadata': {'node_id': '5590', 'node_type': 'PROTEIN', 'display_name': 'caki-1'}}]",0.7142857142857143,e54b67943aa8e7462c7c763e07bc0701,236b84391ef7902d72e3d35fb0479231,"['Ascididemin, a marine derived compound, shows bioactive properties where it targets several cell lines which include HL-60, NCI-H322M and CAKI-1. Observations suggest it could be a potential therapeutic agent.', 'The compound Ascididemin is noted for having multiple targets. It has an affinity for HL-60, NCI-H322M, and CAKI-1, which are all particular cell lines. Therefore, Ascididemin might be potentially utilized in therapies that target these cell lines.', 'Ascididemin, an active compound used widely in the pharmaceutical sector, has several targets. It specifically targets HL-60, NCI-H322M, and CAKI-1. These are clinically relevant receptor targets that play pivotal roles in many cellular processes.', 'Ascididemin, a known pharmacological compound, has several biological targets including HL-60, a human promyelocytic leukemia cell, the NCI-H322M, a part of human lung cancer cell lines, and CAKI-1, a cell line active in kidney cancer research.', 'The compound Ascididemin targets several entities including HL-60, NCI-H322M, and CAKI-1.']","['The drug Ascididemin is known to target both HL-60, a human leukemia cell line, and NCI-H322M, a human lung cancer cell line.', 'The drug Ascididemin has been shown to target both HL-60, a human leukemia cell line, and NCI-H322M, a human lung cancer cell line.', ""The compound Ascididemin targets both HL-60 and NCI-H322M. These targets are likely part of the drug's mechanism of action and its potential therapeutic effects."", 'The compound ascididemin targets both HL-60 and NCI-H322M.', 'The drug Ascididemin targets both HL-60 and NCI-H322M.']"
"[{'source_node': {'name': 'hydroxyprogesterone caproate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carbenicillin'}}, {'source_node': {'name': 'hydroxyprogesterone caproate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'beraprost'}}]","[{'source_node': {'name': 'hydroxyprogesterone caproate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carbenicillin'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:4896', 'target': 'COMPOUND:5837', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:4896', 'target': None, 'metadata': {'node_id': '4896', 'node_type': 'COMPOUND', 'display_name': 'beraprost'}}]",0.6,1dcddbb5f541abc71d5550712951f48a,69b9ca2c8eddfbaa655b17d2b09e5e71,"['The drug hydroxyprogesterone caproate has been shown to decrease the efficacy of both carbenicillin and beraprost. This could potentially lead to decreased treatment success when these drugs are used simultaneously in a medical regimen.', 'The drug hydroxyprogesterone caproate is known to decrease the efficacy of both carbenicillin and beraprost when used concurrently or mixed together. This might caution against their simultaneous use to avoid an undesirable impact on treatment outcomes.', 'The drug hydroxyprogesterone caproate has been shown to decrease the efficacy of carbenicillin and beraprost. This interaction should be kept in mind when prescribing these medications together.', 'The drug hydroxyprogesterone caproate is found to decrease the efficacy of certain medicines, notably carbenicillin and beraprost. This suggests that care should be taken when these substances are prescribed concurrently with hydroxyprogesterone caproate.', 'The drug hydroxyprogesterone caproate can decrease the efficacy of several other drugs, including carbenicillin and beraprost.']","['The drug hydroxyprogesterone caproate is known to decrease the efficacy of another medication called carbenicillin.', 'The use of the drug hydroxyprogesterone caproate could potentially decrease the efficacy of carbenicillin.', 'The drug hydroxyprogesterone caproate is observed to decrease the efficacy of carbenicillin.', 'The drug hydroxyprogesterone caproate has been found to decrease the efficacy of carbenicillin.', 'The drug hydroxyprogesterone caproate may decrease the efficacy of carbenicillin.']"
"[{'source_node': {'name': 'motesanib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '3,5-diiodotyrosine'}}, {'source_node': {'name': 'motesanib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dibromotyrosine'}}, {'source_node': {'name': 'motesanib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'protirelin'}}]","[{'source_node': {'name': '3,5-diiodotyrosine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dibromotyrosine'}}, {'source_node': {'name': '3,5-diiodotyrosine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'motesanib'}}, {'source_node': {'name': 'motesanib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '3,5-diiodotyrosine'}}, {'source_node': {'name': 'motesanib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dibromotyrosine'}}, {'source_node': {'name': 'motesanib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'protirelin'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:3181', 'target': 'COMPOUND:6658', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:3181', 'target': 'COMPOUND:5131', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.7142857142857143,3a45a92267123432b2d4ad7de4efa20a,74d5b725778182c59d8799f46e5386ff,"['The drug motesanib has been found to decrease the efficacy of several other substances, including 3,5-diiodotyrosine, dibromotyrosine, and protirelin.', 'The drug Motesanib is known to decrease the efficacy of several substances including 3,5-diiodotyrosine, dibromotyrosine, and protirelin.', 'The drug motesanib is found to decrease the efficacy of 3,5-diiodotyrosine, dibromotyrosine, and protirelin. This means that the presence of motesanib might impact the function or effectiveness of these substances.', ""The drug motesanib is known to decrease the efficacy of several substances including 3,5-diiodotyrosine, dibromotyrosine, and protirelin. It's important to note this potential interaction when considering treatment options."", 'The drug Motesanib is known to decrease the efficacy of several substances, including 3,5-diiodotyrosine, dibromotyrosine, and protirelin.']","['3,5-diiodotyrosine has been known to decrease the efficacy of both dibromotyrosine and motesanib. In a similar vein, motesanib has also been observed to lower the efficacy of 3,5-diiodotyrosine, dibromotyrosine, and protirelin. This reciprocal relationship indicates a complex interaction between these compounds.', 'The compound 3,5-diiodotyrosine has been found to decrease the efficacy of dibromotyrosine and motesanib. Motesanib, in turn, decreases the efficacy of 3,5-diiodotyrosine, dibromotyrosine, and protirelin. This suggests a complex interaction network among these substances where their respective efficacies can be influenced by one another.', ""The drug 3,5-diiodotyrosine is found to decrease the efficacy of both dibromotyrosine and motesanib. Meanwhile, motesanib not only decreases the efficacy of 3,5-diiodotyrosine but also that of dibromotyrosine, and protirelin. This presents a complex relationship where 3,5-diiodotyrosine and motesanib seemingly decrease each other's efficacy, potentially affecting the outcome when administered together or in sequence. The efficacy of dibromotyrosine could also be compromised when used alongside either 3,5-diiodotyrosine or motesanib. Further, motesanib seems to affect the efficacy of protirelin as well. These interactions should be highly considered when developing and administrating treatment plans involving any of these substances."", 'The compound 3,5-diiodotyrosine is associated with a reduction in efficacy of both dibromotyrosine and motesanib. In turn, motesanib also reduces the efficacy of 3,5-diiodotyrosine and dibromotyrosine as well as protirelin. This suggests a complex bi-directional interaction and potential antagonistic effects between these compounds.', 'The substance 3,5-diiodotyrosine decreases the efficacy of both dibromotyrosine and motesanib. Interestingly, a mutual relationship forms as motesanib also reduces the efficacy of 3,5-diiodotyrosine and dibromotyrosine, as well as protirelin. This complex interplay suggests intricate functional associations between these substances.']"
"[{'source_node': {'name': 'coagulation factor x'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'F10'}}, {'source_node': {'name': 'kappadione'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prothrombin'}}, {'source_node': {'name': 'kappadione'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'coagulation factor vii'}}, {'source_node': {'name': 'kappadione'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'coagulation factor x'}}, {'source_node': {'name': 'coagulation factor vii'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'F7'}}]","[{'source_node': {'name': 'coagulation factor x'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'F10'}}, {'source_node': {'name': 'coagulation factor x'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'F7'}}, {'source_node': {'name': 'coagulation factor vii'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'F7'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:44', 'target': 'GENE:26859', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:8265', 'target': 'PROTEIN:44', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:8265', 'target': None, 'metadata': {'node_id': '8265', 'node_type': 'COMPOUND', 'display_name': 'kappadione'}}]",0.4545454545454546,26e536a66254bc76fbb006889eab331f,79eea018d2c71e569861d343c5b1d34b,"['The pharmaceutical agent Kappadione targets several specific factors involved in the coagulation process which include Prothrombin, Coagulation Factor VII, and Coagulation Factor X. Digging deeper into their origins, the Coagulation Factor X is the gene product of F10, while the Coagulation Factor VII is the gene product of F7.', 'The drug kappadione targets key components involved in blood coagulation including prothrombin, and coagulation factors VII and X. Interestingly, coagulation factor VII is in fact a gene product of F7, and similarly, coagulation factor X is a product of the F10 gene.', ""The drug Kappadione has the capability to target three specific factors: prothrombin, coagulation factor VII, and coagulation factor X. It's particularly interesting to note that coagulation factor VII is a gene product of F7, while coagulation factor X is a gene product of F10. As such, through targeting these factors, Kappadione can indirectly influence the genetic outcomes of F7 and F10."", 'Coagulation Factor X, which happens to be a gene product of F10, is targeted by Kappadione. Similarly, Kappadione also targets Coagulation Factor VII, which is a gene product of F7, and Prothrombin. This shows how Kappadione interacts with various aspects of the blood coagulation process through targeting multiple coagulation factors.', 'The drug Kappadione has proven to engage with several targets, specifically Prothrombin, Coagulation Factor VII, and Coagulation Factor X. Further examination reveals that Coagulation Factor VII and Coagulation Factor X are gene products of F7 and F10, respectively.']","['Coagulation factor X is a gene product of both F10 and F7, while coagulation factor VII is a gene product of F7. These relationships play a significant role in understanding the genetic underpinning of certain clotting disorders.', 'The protein known as coagulation factor X is a gene product of both F10 and F7. Similarly, coagulation factor VII is also a gene product of F7.', 'The protein coagulation factor X is a gene product of both F10 and F7. Similarly, coagulation factor VII is also a gene product of F7.', 'Coagulation factor X and coagulation factor VII are both gene products of F7, while coagulation factor X is also a gene product of F10.', 'Coagulation Factor X is a gene product of both F10 and F7. Similarly, Coagulation Factor VII also exists as a gene product of F7.']"
"[{'source_node': {'name': 'aguerin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'aguerin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'aguerin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'colo 320'}}]","[{'source_node': {'name': 'aguerin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'aguerin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5570', 'target': None, 'metadata': {'node_id': '5570', 'node_type': 'PROTEIN', 'display_name': 'colo 320'}}]",0.7142857142857143,91611bf40fa8cbc2cfd5716047065cb9,15d7a19a9ab6326a93c2f1bebd8c1ad2,"['The drug Aguerin B has several targets, including A549, MCF7, and Colo 320 cells.', 'The compound Aguerin B is known to target several cell lines including A549, MCF7, and Colo 320.', 'The drug Aguerin B has been observed to target various cell lines including A549, MCF7, and Colo 320.', 'The compound Aguerin B targets several cells lines, including A549, MCF7, and Colo 320.', 'The drug Aguerin B has been shown to target multiple cancer cell lines, including A549, MCF7, and Colo 320.']","['The compound Aguerin B has been identified as having two primary targets, specifically the A549 and MCF7 cell lines.', 'The compound Aguerin B has A549 and MCF7 as its targets.', 'The drug Aguerin B is known to target multiple cell lines including A549 and MCF7.', 'The compound Aguerin B has been identified to target two separate entities, namely A549 and MCF7.', 'The drug Aguerin B has been found to target two distinct cell lines: A549 and MCF7.']"
"[{'source_node': {'name': 'VHL'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neddylation'}}, {'source_node': {'name': 'estrogen receptor beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR2'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR1'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': '6-hydroxy-2-phenethyl-chromen-4-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'estrogen receptor alpha'}}, {'source_node': {'name': '6-hydroxy-2-phenethyl-chromen-4-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'estrogen receptor beta'}}]","[{'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': '6-hydroxy-2-phenethyl-chromen-4-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'estrogen receptor alpha'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:942', 'target': 'GENE:33509', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'GENE:26824', 'target': None, 'metadata': {'node_id': '26824', 'node_type': 'GENE', 'display_name': 'ESR2'}}, {'type': 'node_removal', 'source': 'PATHWAY:119', 'target': None, 'metadata': {'node_id': '119', 'node_type': 'PATHWAY', 'display_name': 'Neddylation'}}, {'type': 'node_removal', 'source': 'PROTEIN:942', 'target': None, 'metadata': {'node_id': '942', 'node_type': 'PROTEIN', 'display_name': 'estrogen receptor beta'}}, {'type': 'node_removal', 'source': 'GENE:26821', 'target': None, 'metadata': {'node_id': '26821', 'node_type': 'GENE', 'display_name': 'ESR1'}}]",0.3846153846153846,8dbe7f280f86926f7873edbee56818b4,b505133f6934786631eb390d1dd2fe3c,"['The compound 6-hydroxy-2-phenethyl-chromen-4-one serves as a targeted solution to address estrogen receptor alpha and beta, which are gene products of ESR1 and ESR2 respectively. Furthermore, the estrogen receptor alpha is also a gene product of VHL. Notably, the gene VHL acts within the biological process known as neddylation.']","['The drug 6-hydroxy-2-phenethyl-chromen-4-one has a target, which is estrogen receptor alpha. Notably, the estrogen receptor alpha is a gene product of VHL.', 'The compound 6-hydroxy-2-phenethyl-chromen-4-one has a target known as the estrogen receptor alpha, which is a gene product of the VHL gene.', 'The compound 6-hydroxy-2-phenethyl-chromen-4-one targets the estrogen receptor alpha, which is a gene product of VHL.', 'The estrogen receptor alpha, which is a gene product of VHL, is also targeted by 6-hydroxy-2-phenethyl-chromen-4-one. This demonstrates a complex interplay of genes and compounds.', 'The drug 6-hydroxy-2-phenethyl-chromen-4-one targets the estrogen receptor alpha. This receptor is a gene product of VHL.']"
"[{'source_node': {'name': 'MARCHF6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'epilepsy'}}, {'source_node': {'name': 'MARCHF6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'benign adult familial myoclonic epilepsy'}}, {'source_node': {'name': 'MARCHF6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'ER Quality Control Compartment (ERQC)'}}, {'source_node': {'name': 'benign adult familial myoclonic epilepsy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'headache'}}]","[{'source_node': {'name': 'MARCHF6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'epilepsy'}}, {'source_node': {'name': 'MARCHF6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'benign adult familial myoclonic epilepsy'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1699', 'target': None, 'metadata': {'node_id': '1699', 'node_type': 'PHENOTYPE', 'display_name': 'headache'}}, {'type': 'node_removal', 'source': 'PATHWAY:426', 'target': None, 'metadata': {'node_id': '426', 'node_type': 'PATHWAY', 'display_name': 'ER Quality Control Compartment (ERQC)'}}]",0.5555555555555556,5b0be3e6333ca405c24993d2117f7112,f97793802eb4e2b13b491c8c9419cd46,[],"['The gene MARCHF6 is known to cause several conditions including epilepsy and benign adult familial myoclonic epilepsy.', 'The gene MARCHF6 is implicated in causing several conditions such as epilepsy and benign adult familial myoclonic epilepsy.', 'The gene MARCHF6 is known to cause several conditions - it has been associated with epilepsy as well as benign adult familial myoclonic epilepsy.', 'The gene MARCHF6 is known to cause several conditions, including epilepsy and benign adult familial myoclonic epilepsy.', 'The gene MARCHF6 is associated with causing several conditions, including epilepsy and benign adult familial myoclonic epilepsy.']"
"[{'source_node': {'name': 'demecolcinone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'demecolcinone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h460'}}, {'source_node': {'name': 'demecolcinone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sf-268'}}]","[{'source_node': {'name': 'demecolcinone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sf-268'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5660', 'target': None, 'metadata': {'node_id': '5660', 'node_type': 'PROTEIN', 'display_name': 'nci-h460'}}, {'type': 'node_removal', 'source': 'PROTEIN:5851', 'target': None, 'metadata': {'node_id': '5851', 'node_type': 'PROTEIN', 'display_name': 'mcf7'}}]",0.4285714285714286,6eec9bc7446e2bceb475500e7c537c5b,c0334b177e3783e5f9f30b0d71facbcb,"['The drug demecolcinone has multiple targets including MCF7, NCI-H460, and SF-268. It appears to be effective in targeting these specific cells and tissues, which are commonly studied in biomedical research.', 'The drug known as demecolcinone targets several cell lines including MCF7, NCI-H460, and SF-268.', 'The drug, demecolcinone, targets several cellular entities, including MCF7, NCI-H460 and SF-268.', 'The drug demecolcinone targets multiple cancer cell lines. These include MCF7, NCI-H460, and SF-268.', 'The drug demecolcinone prominently targets cancer cells such as MCF7, NCI-H460, and SF-268.']",['The drug demecolcinone has a target known as sf-268.']
"[{'source_node': {'name': 'F2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Defective F8 cleavage by thrombin'}}, {'source_node': {'name': 'd-phenylalanyl-n-benzyl-l-prolinamide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prothrombin'}}, {'source_node': {'name': 'prothrombin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'F2'}}]","[{'source_node': {'name': 'd-phenylalanyl-n-benzyl-l-prolinamide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prothrombin'}}, {'source_node': {'name': 'd-phenylalanyl-n-benzyl-l-prolinamide'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'F2'}}, {'source_node': {'name': 'prothrombin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'F2'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1440', 'target': None, 'metadata': {'node_id': '1440', 'node_type': 'PATHWAY', 'display_name': 'Defective F8 cleavage by thrombin'}}, {'type': 'edge_addition', 'source': 'COMPOUND:6180', 'target': 'GENE:26852', 'metadata': {'predicate': 'is_affecting'}}]",0.5714285714285714,352f4bd4ab0d8401158560dae20cae05,18fb542125e13c3dea695aa33d3411e9,"['The gene F2, which acts within the defective F8 cleavage by thrombin pathway, produces prothrombin. This prothrombin then becomes the target of the drug D-phenylalanyl-N-benzyl-L-prolinamide.', 'The gene F2, which acts within the pathway of defective F8 cleavage by thrombin, is the gene product of prothrombin. This prothrombin is targeted by the drug d-phenylalanyl-n-benzyl-l-prolinamide.', 'The drug D-phenylalanyl-N-benzyl-L-prolinamide targets prothrombin, which is the gene product of F2. Interestingly, F2 also acts within the pathway responsible for defective F8 cleavage by thrombin.', 'The gene F2, which behaves within the process of defective F8 cleavage by thrombin, produces the gene product prothrombin. Interestingly, prothrombin is targeted by the drug d-phenylalanyl-n-benzyl-l-prolinamide.', 'The gene F2 functions within the process of defective F8 cleavage by thrombin. Prothrombin is a gene product of F2 and is targeted by the drug D-phenylalanyl-N-benzyl-L-prolinamide.']",[]
"[{'source_node': {'name': '4,(23)-dihydro-nyctanthic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prostaglandin e synthase'}}, {'source_node': {'name': '4,(23)-dihydro-nyctanthic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prostaglandin g/h synthase 2'}}, {'source_node': {'name': 'PTGS2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Interleukin-10 signaling'}}, {'source_node': {'name': 'prostaglandin g/h synthase 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTGS2'}}]","[{'source_node': {'name': '4,(23)-dihydro-nyctanthic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prostaglandin e synthase'}}, {'source_node': {'name': '4,(23)-dihydro-nyctanthic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prostaglandin g/h synthase 2'}}, {'source_node': {'name': '4,(23)-dihydro-nyctanthic acid'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'PTGS2'}}, {'source_node': {'name': 'PTGS2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Interleukin-10 signaling'}}, {'source_node': {'name': 'prostaglandin g/h synthase 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTGS2'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:68000', 'target': 'GENE:31977', 'metadata': {'predicate': 'is_affecting'}}]",0.8888888888888888,9a955b05de9db052eb25387fe6fd4845,cc5f67de52109c438bcabf91c8a37dcd,"['The compound 4,(23)-dihydro-nyctanthic acid targets two different proteins: prostaglandin e synthase and prostaglandin g/h synthase 2. The latter, prostaglandin g/h synthase 2, is noted to be the gene product of PTGS2. In turn, PTGS2 acts within the pathway of Interleukin-10 signaling.', ""The compound 4,(23)-dihydro-nyctanthic acid acts by targeting both prostaglandin e synthase and prostaglandin g/h synthase 2. It's important to note that prostaglandin g/h synthase 2 is the gene product of PTGS2. Furthermore, PTGS2 operates within the pathway of Interleukin-10 signaling.""]","['The compound 4,(23)-dihydro-nyctanthic acid targets prostaglandin e synthase and prostaglandin g/h synthase 2, both of which are critical enzymes involved in the production of prostaglandins. Notably, prostaglandin g/h synthase 2 is a gene product of PTGS2. Furthermore, 4,(23)-dihydro-nyctanthic acid is also affecting PTGS2, which in turn acts within the context of interleukin-10 signaling, a critical pathway in immune response regulation.']"
"[{'source_node': {'name': '13-epient-manoyl oxide 18-oic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': '13-epient-manoyl oxide 18-oic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-mel-2'}}, {'source_node': {'name': '13-epient-manoyl oxide 18-oic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'xf498'}}]","[{'source_node': {'name': '13-epient-manoyl oxide 18-oic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': '13-epient-manoyl oxide 18-oic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-mel-2'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5784', 'target': None, 'metadata': {'node_id': '5784', 'node_type': 'PROTEIN', 'display_name': 'xf498'}}]",0.7142857142857143,643fd3aeb9fed1c166029af051f869a7,1360705814530d64bcc12df031a1b2b3,"['The compound 13-epient-manoyl oxide 18-oic acid has multiple targets, which include A549, SK-MEL-2, and XF498.', 'The compound 13-epient-manoyl oxide 18-oic acid targets various cell lines including a549, sk-mel-2, and xf498.', 'The compound 13-epient-manoyl oxide 18-oic acid has multiple targets. This includes A549, a human lung carcinoma cell line, SK-MEL-2, a human melanoma cell line, and XF498, a cancer cell line. These targets suggest the compound may have applications in cancer treatment research.', 'The compound 13-epient-manoyl oxide 18-oic acid has multiple targets including A549, SK-MEL-2, and XF498.', 'The drug 13-epient-manoyl oxide 18-oic acid targets several cancer cell lines, including A549, SK-MEL-2, and XF498.']","['The compound, 13-epient-manoyl oxide 18-oic acid, has been identified to have two distinct targets: A549 and SK-MEL-2.', 'The compound 13-epient-manoyl oxide 18-oic acid is known to target both A549 and SK-MEL-2 cells.', 'The compound 13-epient-manoyl oxide 18-oic acid is known to target A549, a human lung cancer cell line. Additionally, the same compound also targets SK-MEL-2, a cell line derived from malignant melanoma.', 'The compound 13-epient-manoyl oxide 18-oic acid has been found to target two distinct cell lines, namely A549 and SK-MEL-2.', 'The compound 13-epient-manoyl oxide 18-oic acid targets two specific cells; A549 and SK-MEL-2.']"
"[{'source_node': {'name': 'beta-mercaptolactate cysteine disulfiduria'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of the ureter'}}, {'source_node': {'name': 'beta-mercaptolactate cysteine disulfiduria'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'umbilical hernia'}}, {'source_node': {'name': 'beta-mercaptolactate cysteine disulfiduria'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'atrial septal defect'}}]","[{'source_node': {'name': 'beta-mercaptolactate cysteine disulfiduria'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'umbilical hernia'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1184', 'target': None, 'metadata': {'node_id': '1184', 'node_type': 'PHENOTYPE', 'display_name': 'atrial septal defect'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:64', 'target': None, 'metadata': {'node_id': '64', 'node_type': 'PHENOTYPE', 'display_name': 'abnormality of the ureter'}}]",0.4285714285714286,27c8f1192c0b49925735b499cd109187,4dac0da16e98f25cc44b95b9ef615d60,"['Beta-mercaptolactate cysteine disulfiduria is characterized by several phenotypic traits. These include abnormalities of the ureter, the presence of an umbilical hernia, and an atrial septal defect, which is a hole in the wall that separates the top two chambers of the heart.', 'Beta-mercaptolactate cysteine disulfiduria, a rare disorder, is characterized by several phenotypes, including an abnormality of the ureter, an umbilical hernia, and an atrial septal defect.', 'Beta-mercaptolactate cysteine disulfiduria, a rare metabolic disorder, presents several phenotypes including an abnormality of the ureter, an umbilical hernia, and an atrial septal defect.', 'Beta-mercaptolactate cysteine disulfiduria, a rare metabolic condition, manifests several physical phenotype characteristics including abnormalities of the ureter, presence of an umbilical hernia, and atrial septal defect.', 'Beta-mercaptolactate cysteine disulfiduria, a medical condition, manifests several phenotypes including abnormalities of the ureter, presence of an umbilical hernia, and an atrial septal defect in the heart.']",[]
"[{'source_node': {'name': 'ethylmorphine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'etacrynic acid'}}, {'source_node': {'name': 'ethylmorphine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'efonidipine'}}, {'source_node': {'name': 'ethylmorphine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cyclopenthiazide'}}, {'source_node': {'name': 'etacrynic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bisegliptin'}}]","[{'source_node': {'name': 'efonidipine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cyclopenthiazide'}}, {'source_node': {'name': 'etacrynic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bisegliptin'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:8170', 'target': 'COMPOUND:11383', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1402', 'target': 'COMPOUND:5403', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:1402', 'target': None, 'metadata': {'node_id': '1402', 'node_type': 'COMPOUND', 'display_name': 'ethylmorphine'}}]",0.5555555555555556,aa11034ef35cc502efe9e4d735bc607e,97ea3279c6ef172dca9b268278b008dc,"['Ethylmorphine, a well-known drug, is considered to have a decreasing efficacy on several other drugs, including etacrynic acid, efonidipine, and cyclopenthiazide. Among these, etacrynic acid, when used, is known to lessen the efficacy of another drug, bisegliptin.', ""The drug ethylmorphine is known to decrease the efficacy of several other medicinal compounds including etacrynic acid, efonidipine, and cyclopenthiazide. Notably, it is also observed that etacrynic acid can decrease the efficacy of bisegliptin. It's important in patient care to be aware of these interactions to prevent reduced effectiveness of the drugs."", 'The drug Ethylmorphine has been found to decrease the efficacy of several other medications, including Etacrynic Acid, Efonidipine, and Cyclopenthiazide. Interestingly, Etacrynic Acid has a similar effect on Bisegliptin, reducing its efficacy as well.', 'The drug ethylmorphine has been found to decrease the efficacy of several other medications. These include etacrynic acid, efonidipine, and cyclopenthiazide. Interestingly, etacrynic acid has a similar effect on the drug bisegliptin, meaning that ethylmorphine and etacrynic acid both decrease the efficacy of certain drugs.', ""The drug ethylmorphine has been found to decrease the efficacy of several other drugs including etacrynic acid, efonidipine, and cyclopenthiazide. It's worth noting that etacrynic acid, in turn, is known to also decrease the efficacy of bisegliptin.""]","['The drug efonidipine is known to decrease the efficacy of another drug, cyclopenthiazide. Similarly, etacrynic acid also reduces the effectiveness of bisegliptin.', 'Efonidipine has been noted to decrease the efficacy of cyclopenthiazide. Similarly, the drug etacrynic acid is known to reduce the potency of bisegliptin.', 'Efonidipine, a commonly used medication, can decrease the efficacy of cyclopenthiazide when they are taken concurrently. This could potentially impact the treatment outcome for patients who are on these therapies. The efficacy of bisegliptin, another medication, tends to decrease when taken in combination with etacrynic acid. This information is significant in pharmacology as it contributes to understanding drug-drug interactions and optimizing therapeutic strategies.', 'The drug efonidipine is known to decrease the efficacy of another drug, cyclopenthiazide.  Similarly, etacrynic acid has been observed to negatively affect the efficacy of bisegliptin. Therefore, caution should be applied when considering combination therapies with these pairs of drugs.', 'The effectiveness of certain medications can be impacted when used in conjunction with others. For example, the drug efonidipine has been found to decrease the efficacy of cyclopenthiazide. Similarly, the administration of etacrynic acid can lessen the effectiveness of bisegliptin. Care should be taken when prescribing these combinations to ensure optimal patient outcomes.']"
"[{'source_node': {'name': 'CAB39'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Energy dependent regulation of mTOR by LKB1-AMPK'}}, {'source_node': {'name': 'CAB39'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}]","[{'source_node': {'name': 'CAB39'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:568', 'target': None, 'metadata': {'node_id': '568', 'node_type': 'PATHWAY', 'display_name': 'Energy dependent regulation of mTOR by LKB1-AMPK'}}]",0.6,09785d55cb75a89d8fc146fb40d1dfc8,e5e386aa3d845fb259a13f5a45c49042,"['The gene CAB39 acts within several pathways including the energy dependent regulation of mTOR by LKB1-AMPK and is also involved in neutrophil degranulation.', 'The gene CAB39 operates within several pathways, specifically the energy-dependent regulation of mTOR by LKB1-AMPK. In addition, CAB39 also acts within the process of neutrophil degranulation.']",[]
"[{'source_node': {'name': 'ginsenoside f5'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}, {'source_node': {'name': 'ginsenoside f5'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna topoisomerase 1'}}, {'source_node': {'name': 'ginsenoside f5'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'u-251'}}, {'source_node': {'name': 'dna topoisomerase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TOP1'}}]","[{'source_node': {'name': 'hl-60'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TOP1'}}, {'source_node': {'name': 'u-251'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TOP1'}}, {'source_node': {'name': 'ginsenoside f5'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}, {'source_node': {'name': 'ginsenoside f5'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna topoisomerase 1'}}, {'source_node': {'name': 'ginsenoside f5'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'u-251'}}, {'source_node': {'name': 'dna topoisomerase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TOP1'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:4951', 'target': 'GENE:33308', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'PROTEIN:5629', 'target': 'GENE:33308', 'metadata': {'predicate': 'gene_product_of'}}]",0.7777777777777778,72237997149e7e5f77a7153725760cde,afa2022b5e1b7d013f36f3266ee05e96,"[""The compound Ginsenoside F5 targets several components such as HL-60, DNA topoisomerase 1, and U-251. Furthermore, it's interesting to note that DNA topoisomerase 1 is a gene product of TOP1."", 'Ginsenoside F5, a known compound, has several targets including dna topoisomerase 1, hl-60 and U-251. Notably, dna topoisomerase 1 is the gene product of TOP1, linking these biochemical interactions together.', 'The compound Ginsenoside F5 targets multiple entities, including HL-60, DNA Topoisomerase 1, and U-251. Notably, DNA Topoisomerase 1 is a gene product of TOP1.', 'Ginsenoside F5 is a potent agent with multiple targets. Specifically, it has been shown to target the HL-60, a cancer cell line, the U-251, another cancer cell line, and DNA Topoisomerase 1, a crucial enzyme for DNA transaction. Interestingly, DNA Topoisomerase 1 is also a gene product of the gene TOP1.', 'The compound Ginsenoside F5 has been found to have numerous specific targets. Notably, it targets HL-60, U-251, and DNA topoisomerase 1. Interestingly, DNA topoisomerase 1 is a known gene product of TOP1. The wide range of target interactions highlights the multi-functional potential of Ginsenoside F5.']","['The HL-60 and U-251 are both gene products of TOP1. Ginsenoside F5, a medicinal compound, targets both HL-60 and U-251, alongside DNA topoisomerase 1 which also happens to be a gene product of TOP1. This implies a potential importance of the TOP1 gene in the effectiveness of Ginsenoside F5.', 'Both HL-60 and U-251 are gene products of TOP1. The drug Ginsenoside F5 targets not only DNA topoisomerase 1, but also these two gene products, HL-60 and U-251. DNA topoisomerase 1 is itself a gene product of TOP1, thereby creating a complex interplay of genetic interactions.', 'HL-60 and U-251 are both gene products of TOP1. Ginsenoside F5 targets these two gene products along with DNA topoisomerase 1. Interestingly, DNA topoisomerase 1 is also a gene product of TOP1. This shows a complex interplay between the compounds, gene products, and the TOP1 gene.', 'HL-60 and U-251 are both gene products of TOP1. The compound ginsenoside F5 targets both HL-60 and U-251. Additionally, ginsenoside F5 also has DNA topoisomerase 1 as one of its targets. DNA topoisomerase 1 is also a gene product of TOP1.', 'HL-60 and U-251 are both gene products of TOP1. Ginsenoside F5 targets both HL-60 and U-251, as well as DNA Topoisomerase 1. Notably, DNA Topoisomerase 1 is also a gene product of TOP1.']"
"[{'source_node': {'name': 'acetylcholinesterase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACHE'}}, {'source_node': {'name': 'ganodermanondiol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'acetylcholinesterase'}}, {'source_node': {'name': 'ganodermanondiol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cholinesterase'}}, {'source_node': {'name': 'ganodermanondiol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}]","[{'source_node': {'name': 'hela'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACHE'}}, {'source_node': {'name': 'acetylcholinesterase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACHE'}}, {'source_node': {'name': 'cholinesterase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACHE'}}, {'source_node': {'name': 'ganodermanondiol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'acetylcholinesterase'}}, {'source_node': {'name': 'ganodermanondiol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cholinesterase'}}, {'source_node': {'name': 'ganodermanondiol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:276', 'target': 'GENE:29952', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'PROTEIN:4994', 'target': 'GENE:29952', 'metadata': {'predicate': 'gene_product_of'}}]",0.7777777777777778,df2aa2823ad2ae2d5128297148b4afb7,c29fecf8da1fef08cbcdd6ddd5e6b372,"['Acetylcholinesterase is a gene product of ACHE. Ganodermanondiol, a biologically active compound, has several targets including acetylcholinesterase, another class of enzymes known as cholinesterase, and a type of cell known as hela.', 'Ganodermanondiol is a compound that targets several protein entities, including the acetylcholinesterase, cholinesterase, and hela. Notably, acetylcholinesterase is the gene product of the ACHE gene, hence, indirectly linking ganodermanondiol to the ACHE gene via functional interaction.', 'The compound ganodermanondiol has multiple targets including acetylcholinesterase, cholinesterase, and hela. Acetylcholinesterase is a gene product of the gene named ACHE.']","['The compound ganodermanondiol targets three different entities: acetylcholinesterase, cholinesterase, and hela. Interestingly, all three of these targets are gene products of the ACHE gene. Specifically, the hela cell line is a product of this gene, along with acetylcholinesterase and cholinesterase. Therefore, ganodermanondiol seems to exert its effects largely through the influence on the gene products of ACHE.']"
"[{'source_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'progression-free survival'}}, {'source_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hypotension'}}]","[{'source_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hypotension'}}]","[{'type': 'node_removal', 'source': 'DISEASE:2664', 'target': None, 'metadata': {'node_id': '2664', 'node_type': 'DISEASE', 'display_name': 'progression-free survival'}}]",0.6,63bcac356bf5a56eac3fed356933a22e,ee541db3450582c82f68032c721b8674,"['The enzyme Cytochrome P450 Family 2 Subfamily D Member 6 has been linked to several medical conditions. Specifically, it plays a role in causing progression-free survival and hypotension.', 'The enzyme Cytochrome P450 family 2 subfamily D member 6 has been found to cause several conditions, including progression-free survival and hypotension.', 'The gene known as cytochrome p450 family 2 subfamily d member 6 is associated with causing varying conditions. Specifically, it is responsible for conditions such as progression-free survival and hypotension.', 'The gene, cytochrome p450 family 2 subfamily d member 6 is associated with both progression-free survival and hypotension, as it has been found to influence these conditions.', 'The enzyme, cytochrome p450 family 2 subfamily d member 6, has a significant impact in causing certain conditions such as progression-free survival and hypotension.']","['The enzyme cytochrome P450 family 2 subfamily D member 6 is known to cause the medical condition hypotension.', 'The enzyme cytochrome P450 family 2 subfamily D member 6 is known to cause a condition known as hypotension.']"
"[{'source_node': {'name': 'HNF1A'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'renal cell carcinoma'}}, {'source_node': {'name': 'hepatocyte nuclear factor 1-alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HNF1A'}}]","[{'source_node': {'name': 'HNF1A'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'renal cell carcinoma'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:3585', 'target': None, 'metadata': {'node_id': '3585', 'node_type': 'PROTEIN', 'display_name': 'hepatocyte nuclear factor 1-alpha'}}]",0.6,358f5d77a0539113f24b9990f34b2fc1,3fff3ae10d6cc2c177fc64c5745a1fe6,"['Hepatocyte nuclear factor 1-alpha, which is the gene product of HNF1A, is linked to the cause of renal cell carcinoma.', 'Hepatocyte Nuclear Factor 1-alpha, which is a gene product of HNF1A, has been known to cause a condition named renal cell carcinoma.', 'The Hepatocyte Nuclear Factor 1-Alpha, which is the gene product of HNF1A, is involved in causing the condition known as renal cell carcinoma.']","['The gene HNF1A can cause a condition known as renal cell carcinoma.', 'The gene HNF1A is known to cause a condition known as renal cell carcinoma.', 'The gene HNF1A is responsible for causing the condition known as renal cell carcinoma.', 'The gene HNF1A is known to cause the condition known as renal cell carcinoma.']"
"[{'source_node': {'name': 'barbexaclone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ganciclovir'}}, {'source_node': {'name': 'barbexaclone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imipenem'}}, {'source_node': {'name': 'barbexaclone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cephalosporin c'}}]","[{'source_node': {'name': 'imipenem'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'barbexaclone'}}, {'source_node': {'name': 'barbexaclone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ganciclovir'}}, {'source_node': {'name': 'barbexaclone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imipenem'}}, {'source_node': {'name': 'barbexaclone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cephalosporin c'}}, {'source_node': {'name': 'ganciclovir'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imipenem'}}, {'source_node': {'name': 'ganciclovir'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'barbexaclone'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:987', 'target': 'COMPOUND:1526', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:987', 'target': 'COMPOUND:7946', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1526', 'target': 'COMPOUND:7946', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.5714285714285714,75cf9655ff85f9d289d4e001eb5771fd,dd1d772624415784795b3246ffd07aa3,"['The drug Barbexaclone is known to decrease the efficacy of several other drugs including Ganciclovir, Imipenem and Cephalosporin C. This suggests that interactions between Barbexaclone and these drugs may reduce their overall effectiveness.', 'The drug Barbexaclone is reported to decrease the efficacy of several other medications including Ganciclovir, Imipenem, and Cephalosporin C. This interference with therapeutic effectiveness is an important consideration in multi-drug therapies.', 'The drug Barbexaclone has been found to decrease the efficacy of a few other drugs including Ganciclovir, Imipenem, and Cephalosporin C.', 'Barbexaclone, a therapeutic drug, demonstrates actions that decrease the efficacy of several other drugs. Notably, Barbexaclone lessens the effectiveness of ganciclovir, an antiviral medication; imipenem, a powerful broad-spectrum antibiotic; and cephalosporin C, another commonly used antibiotic.', 'Barbexaclone, a medication, is known to decrease the efficacy of several other drugs. Notably, it curtails the effectiveness of Ganciclovir, an antiviral medication, Imipenem, a broad-spectrum antibiotic, and Cephalosporin C, a class of advanced-generation antibiotic.']","['The use of the antibiotic Imipenem is known to decrease the efficacy of the antiepileptic drug Barbexaclone. Similarly, Barbexaclone decreases the efficacy of not only Imipenem, but also of Ganciclovir, an antiviral drug, and Cephalosporin C, another type of antibiotic. Interestingly, while Barbexaclone reduces the effectiveness of these treatment regimens, the efficacy of Barbexaclone itself is seen to increase when combined with Ganciclovir. Meanwhile, Ganciclovir also has the ability to decrease the efficacy of Imipenem. Hence, these findings suggest a complex interplay of drug interactions that require careful management to achieve optimal therapeutic results.', 'Imipenem, a broad-spectrum antibiotic, has been found to decrease the efficacy of barbexaclone, an antiepileptic drug. However, the relationship appears to be mutual as barbexaclone has a similar effect on imipenem, decreasing its effectiveness as well. Additionally, barbexaclone also reduces the efficacy of ganciclovir, an antiviral medication, and cephalosporin c, a type of antibiotic. Interestingly, ganciclovir has a dual effect on the efficacy of imipenem and barbexaclone. It reduces the efficacy of imipenem, but in contrast, it increases the efficacy of barbexaclone. This intricate network of drug-drug interactions highlights the importance of considering potential medication interactions when prescribing regimens for patients.', ""The drug imipenem has been found to decrease the efficacy of barbexaclone, an effect that is reciprocated as barbexaclone also decreases the efficacy of imipenem. Furthermore, barbexaclone also has the same effect on ganciclovir and cephalosporin c, reducing their effectiveness. Interestingly, while ganciclovir's efficacy is hindered by barbexaclone, it in turn lessens the functionality of imipenem but remarkably increases the efficacy of barbexaclone. These complex interaction dynamics highlight the intricate relationships between these drugs."", 'The drug Imipenem has been identified to decrease the efficacy of Barbexaclone, which then reduces the appearance of its effect when used with other drugs such as Ganciclovir and Cephalosporin C. Interestingly, Barbexaclone also depresses the efficacy of Imipenem, showing a complex reciprocal interaction. On the other hand, Ganciclovir, while also diminishing the efficacy of Imipenem, intriguingly, heightens the efficacy of Barbexaclone, presenting yet another layer to this drug interaction network.', 'Imipenem is a potent antibiotic that unfortunately decreases the efficacy of Barbexaclone, an antiepileptic drug. Conversely, the use of Barbexaclone leads to a decrease in the efficacy of various drugs, including not just Imipenem but also Ganciclovir, an antiviral used for herpes, and Cephalosporin C, another antibiotic. Interestingly, while Barbexaclone reduces the effectiveness of Ganciclovir, the converse is not true - Ganciclovir actually enhances the efficacy of Barbexaclone, suggesting a complex, non-linear interaction between these drugs. However, Ganciclovir also has a negative impact on the efficacy of Imipenem, reinforcing the necessity for careful monitoring and dosage adjustments when these medications are used in combination treatments.']"
"[{'source_node': {'name': '1,3,8-tri-o-methylemodin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'neutrophil elastase'}}, {'source_node': {'name': '1,3,8-tri-o-methylemodin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'estrogen receptor alpha'}}, {'source_node': {'name': '1,3,8-tri-o-methylemodin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}, {'source_node': {'name': 'ELANE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Activation of Matrix Metalloproteinases'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR1'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': 'neutrophil elastase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ELANE'}}]","[{'source_node': {'name': '1,3,8-tri-o-methylemodin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'neutrophil elastase'}}, {'source_node': {'name': '1,3,8-tri-o-methylemodin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}, {'source_node': {'name': '1,3,8-tri-o-methylemodin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'ELANE'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR1'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': 'neutrophil elastase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ELANE'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:27401', 'target': 'PROTEIN:943', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:27401', 'target': 'GENE:26709', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'PATHWAY:907', 'target': None, 'metadata': {'node_id': '907', 'node_type': 'PATHWAY', 'display_name': 'Activation of Matrix Metalloproteinases'}}]",0.7333333333333334,17ea3f6a7da1df750e55e4fa94a68aba,6d12140eba3acd231ddc23ff979c6876,"[""1,3,8-tri-o-methylemodin is a compound that has been shown to target multiple entities including neutrophil elastase, estrogen receptor alpha, and hl-60. It's interesting to note that neutrophil elastase and estrogen receptor alpha are gene products of ELANE and ESR1, respectively, but estrogen receptor alpha is also a product of the VHL gene. Meanwhile, the ELANE gene further acts within the activation of matrix metalloproteinases pathway, adding another layer to the complex interactions occurring within the body due to the influence of this single compound.""]","['The substance 1,3,8-tri-o-methylemodin has several targets including neutrophil elastase and HL-60. Additionally, it is affecting the ELANE gene from which neutrophil elastase is a gene product. Estrogen receptor alpha, on the other hand, is a gene product of both the ESR1 and VHL genes.', 'The compound 1,3,8-tri-o-methylemodin has two targets: neutrophil elastase and hl-60. This compound further influences ELANE. Neutrophil elastase is a gene product of ELANE. Another key entity, the estrogen receptor alpha, is a gene product of two genes: ESR1 and VHL.']"
"[{'source_node': {'name': 'l-709,587'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peptidyl-prolyl cis-trans isomerase fkbp1a'}}, {'source_node': {'name': 'FKBP1A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'TGF-beta receptor signaling activates SMADs'}}, {'source_node': {'name': 'peptidyl-prolyl cis-trans isomerase fkbp1a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FKBP1A'}}]","[{'source_node': {'name': 'l-709,587'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'FKBP1A'}}, {'source_node': {'name': 'FKBP1A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'TGF-beta receptor signaling activates SMADs'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:3407', 'target': 'GENE:27057', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'PROTEIN:1060', 'target': None, 'metadata': {'node_id': '1060', 'node_type': 'PROTEIN', 'display_name': 'peptidyl-prolyl cis-trans isomerase fkbp1a'}}]",0.4285714285714286,9dc733564e15676f9850064dfcfca2bd,354bd6a7d41e5553c95774a3616296b9,"['The drug L-709,587 targets peptidyl-prolyl cis-trans isomerase FKBP1A, which is a gene product of FKBP1A. Furthermore, FKBP1A actively functions within the TGF-beta receptor signaling that activates SMADs pathway.']",[]
"[{'source_node': {'name': 'tyrothricin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trihexyphenidyl'}}, {'source_node': {'name': 'tyrothricin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'aripiprazole'}}, {'source_node': {'name': 'tyrothricin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluocortolone pivalate'}}]","[{'source_node': {'name': 'tyrothricin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trihexyphenidyl'}}, {'source_node': {'name': 'tyrothricin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'aripiprazole'}}, {'source_node': {'name': 'tyrothricin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluocortolone pivalate'}}, {'source_node': {'name': 'aripiprazole'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'tyrothricin'}}, {'source_node': {'name': 'aripiprazole'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'fluocortolone pivalate'}}, {'source_node': {'name': 'fluocortolone pivalate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trihexyphenidyl'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:13212', 'target': 'COMPOUND:365', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1218', 'target': 'COMPOUND:11354', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1218', 'target': 'COMPOUND:13212', 'metadata': {'predicate': 'increase_efficacy'}}]",0.5714285714285714,0014c116bf7affcb3491e270f5dd3404,8baaaf746b99c227514246f3e3123fd5,"[""Tyrothricin is a drug that may decrease the efficacy of several other medications. For instance, it has been found to lessen the effectiveness of trihexyphenidyl, aripiprazole, and fluocortolone pivalate. It's crucial for healthcare professionals and patients to be aware of such interactions to avoid potential treatment complications."", 'Tyrothricin is a compound that has been observed to decrease the efficacy of several other substances, including trihexyphenidyl, aripiprazole, and fluocortolone pivalate.', 'The medication tyrothricin is known to decrease the efficacy of several other drugs. Specifically, it reduces the effectiveness of trihexyphenidyl and aripiprazole. Furthermore, it also diminishes the efficacy of fluocortolone pivalate.', ""The drug tyrothricin is known to reduce the efficacy of several other drugs including trihexyphenidyl, aripiprazole, and fluocortolone pivalate. It's necessary to note this interaction before prescribing these drugs in conjunction with tyrothricin, to avoid a reduced efficacy of the treatment."", 'Tyrothricin, a widely used antibiotic, has been found to decrease the efficacy of several drugs. Particularly, it reduces the effectiveness of trihexyphenidyl, an antiparkinsonian drug, and aripiprazole, used in the treatment of various mental health conditions. Furthermore, tyrothricin also hampers the performance of fluocortolone pivalate, a potent corticosteroid used for a host of skin disorders, thereby diminishing its potential therapeutic benefits.']","[""Tyrothricin is a drug known to decrease the efficacy of a few other drugs including trihexyphenidyl, aripiprazole and fluocortolone pivalate. Interestingly, while tyrothricin reduces the efficacy of aripiprazole, there's a reciprocal relationship as aripiprazole is known to increase the efficacy of tyrothricin. Aripiprazole also increases the potency of fluocortolone pivalate. However, fluocortolone pivalate appears to have a diminishing effect on the efficacy of trihexyphenidyl. This intricate network of drug interactions underlines the importance of understanding the pharmacodynamics when prescribing multiple medications."", 'Tyrothricin is known to decrease the efficacy of several drugs including trihexyphenidyl, aripiprazole, and fluocortolone pivalate. Interestingly, aripiprazole has the property of increasing the efficacy of tyrothricin and fluocortolone pivalate. Yet, it should also be noted that fluocortolone pivalate can decrease the efficacy of trihexyphenidyl. Therefore, these drugs have a complex interaction network regarding their efficacy.', 'The drug Tyrothricin is implicated in several interactions impacting the efficacy of multiple other drugs. For instance, it has been observed to decrease the efficacy of Trihexyphenidyl, Aripiprazole, and Fluocortolone pivalate. Interestingly, while Tyrothricin has a reductive effect on Aripiprazole, the reverse is also true, with Aripiprazole actually serving to increase the efficacy of Tyrothricin. Aripiprazole demonstrates a similar pattern with Fluocortolone pivalate, enhancing its efficacy. However, in a contrasting interaction, Fluocortolone pivalate decreases the efficacy of Trihexyphenidyl. These complex dynamics highlight the intricate and sometimes contradictory relationships drug interactions can exhibit.', 'Tyrothricin is a drug known to decrease the efficacy of multiple medications including trihexyphenidyl, aripiprazole, and fluocortolone pivalate. A unique interplay exists between these drugs. On one hand, tyrothricin reduces the effectiveness of aripiprazole while on another hand, aripiprazole is reported to increase the efficacy of tyrothricin. Furthermore, aripiprazole also enhances the effectiveness of fluocortolone pivalate. However, fluocortolone pivalate has been found to decrease the efficacy of trihexyphenidyl. These complex relationships highlight the importance of considering drug interactions in pharmacological treatments.', 'The antibiotic drug Tyrothricin is found to decrease the efficacy of other drugs like Trihexyphenidyl, Aripiprazole, and Fluocortolone Pivalate. On the other hand, the drug Aripiprazole is known to boost the efficacy of Tyrothricin and Fluocortolone Pivalate. Interestingly, Fluocortolone Pivalate, a powerful corticosteroid, exhibits a diminishing effect on the efficacy of Trihexyphenidyl.']"
"[{'source_node': {'name': 'brexucabtagene autoleucel'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'b-lymphocyte antigen cd19'}}, {'source_node': {'name': 'brexucabtagene autoleucel'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' Thrombosis '}}, {'source_node': {'name': 'brexucabtagene autoleucel'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' methemoglobinemia '}}, {'source_node': {'name': 'b-lymphocyte antigen cd19'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CD19'}}, {'source_node': {'name': 'CD19'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'immunodeficiency'}}, {'source_node': {'name': 'CD19'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'PIP3 activates AKT signaling'}}]","[{'source_node': {'name': 'CD19'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'immunodeficiency'}}, {'source_node': {'name': 'CD19'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'PIP3 activates AKT signaling'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:3903', 'target': None, 'metadata': {'node_id': '3903', 'node_type': 'PROTEIN', 'display_name': 'b-lymphocyte antigen cd19'}}, {'type': 'node_removal', 'source': 'COMPOUND:13189', 'target': None, 'metadata': {'node_id': '13189', 'node_type': 'COMPOUND', 'display_name': 'brexucabtagene autoleucel'}}]",0.3846153846153846,0268cf2c523f2f0c8e116ecf57cef35f,647e7ed1a64bc6f7dc05e1eb6eb36b3c,[],"[""The gene CD19 is instrumental in various biological processes and functions. For instance, it causes a condition known as immunodeficiency. Immunodeficiency is a state where the immune system's ability to fight infectious diseases is compromised or entirely absent. Additionally, CD19 is an active component within a molecular pathway known as PIP3 activates AKT signaling. This signaling pathway is crucial for numerous cellular processes, including cell survival, growth, proliferation, metabolism, and migration.""]"
"[{'source_node': {'name': 'flap endonuclease 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FEN1'}}, {'source_node': {'name': 'dl-anabasine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'neuronal acetylcholine receptor subunit alpha-4'}}, {'source_node': {'name': 'dl-anabasine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna polymerase beta'}}, {'source_node': {'name': 'dl-anabasine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'flap endonuclease 1'}}, {'source_node': {'name': 'POLB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ub-specific processing proteases'}}, {'source_node': {'name': 'dna polymerase beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'POLB'}}, {'source_node': {'name': 'neuronal acetylcholine receptor subunit alpha-4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CHRNA4'}}]","[{'source_node': {'name': 'flap endonuclease 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FEN1'}}, {'source_node': {'name': 'FEN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ub-specific processing proteases'}}, {'source_node': {'name': 'dl-anabasine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'neuronal acetylcholine receptor subunit alpha-4'}}, {'source_node': {'name': 'dl-anabasine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna polymerase beta'}}, {'source_node': {'name': 'dl-anabasine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'flap endonuclease 1'}}, {'source_node': {'name': 'POLB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ub-specific processing proteases'}}, {'source_node': {'name': 'dna polymerase beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'POLB'}}, {'source_node': {'name': 'dna polymerase beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FEN1'}}, {'source_node': {'name': 'neuronal acetylcholine receptor subunit alpha-4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CHRNA4'}}]","[{'type': 'edge_addition', 'source': 'GENE:27020', 'target': 'PATHWAY:115', 'metadata': {'predicate': 'acts_within'}}, {'type': 'edge_addition', 'source': 'PROTEIN:1519', 'target': 'GENE:27020', 'metadata': {'predicate': 'gene_product_of'}}]",0.8666666666666667,595b3b75bea6576aeca04bbdefd71a36,53936493bf02833b3ab5ff3aa3588389,"['The molecule dl-anabasine targets several entities including the neuronal acetylcholine receptor subunit alpha-4, DNA polymerase beta, and flap endonuclease 1. The former is a gene product of CHRNA4. DNA polymerase beta is a gene product of POLB which functions within the pathway of Ub-specific processing proteases. Lastly, flap endonuclease 1 is a gene product of FEN1.', 'The compounds dl-anabasine has multiple targets including the neuronal acetylcholine receptor subunit alpha-4, DNA polymerase beta, and flap endonuclease 1. Interestingly, the neuronal acetylcholine receptor subunit alpha-4 is the gene product of the CHRNA4 gene. Moreover, DNA polymerase beta is the gene product of the POLB gene, which acts within the pathway of Ub-specific processing proteases. Lastly, flap endonuclease 1 is the gene product of the FEN1 gene. These compounds and gene interactions indicate complex mechanisms of action in biological systems.', 'The drug dl-anabasine has several targets: the neuronal acetylcholine receptor subunit alpha-4, dna polymerase beta, and flap endonuclease 1. The neuronal acetylcholine receptor subunit alpha-4 is a gene product of CHRNA4. Dna polymerase beta is not only a target of dl-anabasine but is also the gene product of POLB. POLB acts within the Ub-specific processing proteases pathway. As for flap endonuclease 1, it plays a significant role in this complex relationship as it is both a target of dl-anabasine and the gene product of FEN1.', 'The compound dl-anabasine targets several elements including the neuronal acetylcholine receptor subunit alpha-4, dna polymerase beta, and flap endonuclease 1. The flap endonuclease 1 is a gene product of FEN1. On the other hand, the dna polymerase beta is an end product of the gene POLB, which also acts within the Ub-specific processing proteases. Additionally, the neuronal acetylcholine receptor subunit alpha-4 is a gene product of CHRNA4.', 'Flap endonuclease 1, which is a gene product of FEN1, is one of the targets of the dl-anabasine. In addition to the flap endonuclease 1, neuronal acetylcholine receptor subunit alpha-4 and dna polymerase beta are also targeted by dl-anabasine. DNA polymerase beta is found to be a gene product of POLB. It is worth mentioning that POLB is known to act within the pathway of Ub-specific processing proteases. Moreover, the neuronal acetylcholine receptor subunit alpha-4 is a gene product of CHRNA4. Through this intricate network of relationships, dl-anabasine affects the functioning of various biological entities and pathways.']",[]
"[{'source_node': {'name': 'plakortolide j'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'du-145'}}, {'source_node': {'name': 'plakortolide j'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a2058'}}]","[{'source_node': {'name': 'plakortolide j'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a2058'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5857', 'target': None, 'metadata': {'node_id': '5857', 'node_type': 'PROTEIN', 'display_name': 'du-145'}}]",0.6,64bac4dd07e5ed0319a3014206508429,2bd17f3d3786390500f43c204cea4d2a,"['Plakortolide J, a bioactive compound, is known to interact with, or target, two cancer cell lines, DU-145 and A2058.', 'The compound plakortolide J targets both DU-145 and A2058.', 'The compound Plakortolide J operates by targeting two cells: DU-145 and A2058.', 'The compound Plakortolide J has been identified to target both DU-145 and A2058, which are important in scientific studies and researches.', 'The compound Plakortolide J targets both DU-145 and A2058.']",[]
"[{'source_node': {'name': 'magnesium sulfate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'meclizine'}}, {'source_node': {'name': 'magnesium sulfate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'idalopirdine'}}, {'source_node': {'name': 'magnesium sulfate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'piritramide'}}, {'source_node': {'name': 'benzyl alcohol'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' methemoglobinemia '}}, {'source_node': {'name': 'benzyl alcohol'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' sedation '}}, {'source_node': {'name': 'benzyl alcohol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'magnesium sulfate'}}, {'source_node': {'name': 'idalopirdine'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'idalopirdine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pregabalin'}}]","[{'source_node': {'name': 'magnesium sulfate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'meclizine'}}, {'source_node': {'name': 'magnesium sulfate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'piritramide'}}, {'source_node': {'name': 'benzyl alcohol'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' methemoglobinemia '}}, {'source_node': {'name': 'benzyl alcohol'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' sedation '}}, {'source_node': {'name': 'idalopirdine'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:5818', 'target': 'COMPOUND:639', 'metadata': None}, {'type': 'edge_deletion', 'source': 'COMPOUND:639', 'target': 'COMPOUND:9868', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:220', 'target': None, 'metadata': {'node_id': '220', 'node_type': 'COMPOUND', 'display_name': 'pregabalin'}}]",0.7647058823529411,6717692996a2c7e149c982963cdd79c7,4c18cc955ef5a9307a33f0d6743182bc,[],[]
"[{'source_node': {'name': 'perflutren'}, 'relation': {'name': 'increase_activity'}, 'target_node': {'name': ' the QTc-prolonging activities '}}, {'source_node': {'name': 'perflutren'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' bradycardia '}}, {'source_node': {'name': 'perflutren'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' adverse effects '}}]","[{'source_node': {'name': 'perflutren'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' bradycardia '}}, {'source_node': {'name': 'perflutren'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'perflutren'}, 'relation': {'name': 'decrease_activity'}, 'target_node': {'name': ' the QTc-prolonging activities '}}]","[{'type': 'edge_replacement', 'source': 'COMPOUND:542', 'target': 'ACTIVITY:5', 'metadata': {'predicate': 'decrease_activity'}}]",0.8571428571428572,cab2019345e8ca02ac78725402309ad0,bcde11e34af10964fd43dd2a03842c88,[],[]
"[{'source_node': {'name': 'schisandrin c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'snu-638'}}, {'source_node': {'name': 'schisandrin c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 't47d'}}]","[{'source_node': {'name': 'schisandrin c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'snu-638'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5659', 'target': None, 'metadata': {'node_id': '5659', 'node_type': 'PROTEIN', 'display_name': 't47d'}}]",0.6,8f52808b089724d41d12a51ab0a39281,7577a85842e457c091260e5dd3599723,"['The compound Schisandrin C has multiple targets, including SNU-638 and T47D.', 'The compound schisandrin C is known to have targets such as SNU-638 and T47D.', 'The compound Schisandrin C has been found to target two different entities: SNU-638 and T47D.', 'The drug Schisandrin C targets both SNU-638 and T47D.', 'The compound Schisandrin C has been identified to target two specific entities, namely SNU-638 and T47D.']","['The compound Schisandrin C has been identified to target SNU-638.', 'The compound schisandrin C has been found to target SNU-638.']"
"[{'source_node': {'name': 'arenaran a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'arenaran a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}]","[{'source_node': {'name': 'arenaran a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5849', 'target': None, 'metadata': {'node_id': '5849', 'node_type': 'PROTEIN', 'display_name': 'a549'}}]",0.6,56776dab548f7f5f810348f8953bc032,182f90ab146b9661a0e96f27720f0d32,"['The compound Arenaran A targets two different types of cells - A549 and HT-29.', 'The drug Arenaran A has been found to target two human cancer cell lines - A549 and HT-29.', 'The compound Arenaran A targets two different cell lines, specifically A549 and HT-29.', 'The chemical compound Arenaran A has been identified to target multiple entities including A549 and HT-29.', 'The compound Arenaran A is noted to target multiple cells, including A549 and HT-29.']",['The compound Arenaran A has been identified to target HT-29.']
"[{'source_node': {'name': 'anthrax vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fludrocortisone'}}, {'source_node': {'name': 'taribavirin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'anthrax vaccine'}}, {'source_node': {'name': 'taribavirin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vaccine live'}}, {'source_node': {'name': 'taribavirin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'vibrio cholerae cvd 103-hgr strain live antigen'}}, {'source_node': {'name': 'vibrio cholerae cvd 103-hgr strain live antigen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'aldesleukin'}}, {'source_node': {'name': 'vibrio cholerae cvd 103-hgr strain live antigen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ceftolozane'}}, {'source_node': {'name': 'vibrio cholerae cvd 103-hgr strain live antigen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tiamulin'}}]","[{'source_node': {'name': 'anthrax vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fludrocortisone'}}, {'source_node': {'name': 'taribavirin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'anthrax vaccine'}}, {'source_node': {'name': 'taribavirin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vaccine live'}}, {'source_node': {'name': 'fludrocortisone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'tiamulin'}}, {'source_node': {'name': 'vibrio cholerae cvd 103-hgr strain live antigen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ceftolozane'}}, {'source_node': {'name': 'vibrio cholerae cvd 103-hgr strain live antigen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tiamulin'}}, {'source_node': {'name': 'vibrio cholerae cvd 103-hgr strain live antigen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fludrocortisone'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:672', 'target': 'COMPOUND:39', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:5572', 'target': 'COMPOUND:12210', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:9074', 'target': 'COMPOUND:39', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:12210', 'target': 'COMPOUND:672', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:672', 'target': 'COMPOUND:9424', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:39', 'target': None, 'metadata': {'node_id': '39', 'node_type': 'COMPOUND', 'display_name': 'aldesleukin'}}]",0.6666666666666667,3c6dc4e6356ee20024b404974d59033e,c9d5cd4647fef62487d427de167e97d7,"[""The anthrax vaccine, when administered, decreases the efficacy of the drug fludrocortisone. This vaccine's potency can also be decreased by the drug taribavirin. The latter not only decreases the effectiveness of the anthrax vaccine but also hinders the efficacy of the typhoid vaccine live and the Vibrio cholerae cvd 103-hgr strain live antigen. However, the decreased efficacy is not a one-way relationship as the vibrio cholerae cvd 103-hgr strain live antigen has been found to reduce the efficiency of the immunomodulatory drug aldesleukin, the antibiotic ceftolozane, and the veterinary antibiotic tiamulin."", 'The administration of the anthrax vaccine has been found to decrease the efficacy of the drug fludrocortisone, and interestingly, the drug taribavirin also decreases the effectiveness of this anthrax vaccine. Studies have also highlighted that taribavirin decreases the efficiency of not only the anthrax vaccine but the typhoid vaccine live and the vibrio cholerae cvd 103-hgr strain live antigen as well. This same live antigen of vibrio cholerae cvd 103-hgr strain is also known to decrease the efficacy of certain drugs including aldesleukin, ceftolozane, and tiamulin. Taken together, these findings underline the complex network of interactions between various vaccines and pharmaceuticals, emphasizing the need for vigilant care in drug administration.']","[""The anthrax vaccine is known to decrease the efficacy of fludrocortisone, a crucial hormonal drug. On the other hand, this vaccine's effectiveness itself can be reduced by the drug taribavirin. Interestingly, taribavirin also decreases the efficacy of the live typhoid vaccine. Interestingly, fludrocortisone, whose effectiveness is reduced by the anthrax vaccine, also plays a role in increasing the efficacy of tiamulin, an antibiotic used in animals. Furthermore, the live antigen of Vibrio cholerae cvd 103-hgr strain decreases the efficacy of ceftolozane, a potent antibiotic, and tiamulin. This strain also impacts the efficacy of fludrocortisone, thereby revealing a complex network of efficacy interaction among various pharmaceutical substances."", 'The anthrax vaccine has been observed to decrease the efficacy of fludrocortisone. Coincidentally, the same vaccine also has its efficacy decreased when used in conjunction with a drug called taribavirin. Tariabvirin, on the other hand, has been found to reduce the efficacy of the typhoid vaccine live. In clinical trials, fludrocortisone has demonstrated an increased efficacy when combined with another drug, tiamulin.\n\nMeanwhile, the Vibrio cholerae cvd 103-hgr strain live antigen has been found to decrease the efficacy of ceftolozane, tiamulin, and fludrocortisone. These connections imply a complex interaction network among these drugs, vaccines, and biological entities. Further studies are likely needed to untangle the web of interactions and their implications on the treatment efficacy.', 'The anthrax vaccine can decrease the efficacy of fludrocortisone, a drug which is known to increase the efficacy of tiamulin. On the other hand, taribavirin can decrease the efficacy of the anthrax vaccine as well as the typhoid vaccine live. Interestingly, the Vibrio cholerae CVD 103-HGR strain live antigen can also have an impact on drug efficacy. This antigen can decrease the efficacy of ceftolozane, tiamulin, and fludrocortisone.', 'The anthrax vaccine has been found to decrease the efficacy of the drug fludrocortisone. Interestingly, another drug called taribavirin can also decrease the efficacy of the anthrax vaccine. Beyond its effect on the anthrax vaccine, taribavirin has the same diminishing impact on the typhoid vaccine live. On the other hand, the drug fludrocortisone has been shown to increase the efficacy of tiamulin. Coincidentally, the vibrio cholerae cvd 103-hgr strain live antigen can decrease the efficacy of three drugs: ceftolozane, tiamulin, and fludrocortisone.']"
"[{'source_node': {'name': 'cytochrome p450 2a6'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP2A6'}}, {'source_node': {'name': '1,2-dimethylnaphthalene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 1a2'}}, {'source_node': {'name': '1,2-dimethylnaphthalene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 2a6'}}, {'source_node': {'name': '1,2-dimethylnaphthalene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lymphoblastoid cells'}}, {'source_node': {'name': 'cytochrome p450 1a2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP1A2'}}]","[{'source_node': {'name': 'cytochrome p450 2a6'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP2A6'}}, {'source_node': {'name': 'cytochrome p450 2a6'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP1A2'}}, {'source_node': {'name': 'lymphoblastoid cells'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP1A2'}}, {'source_node': {'name': '1,2-dimethylnaphthalene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 1a2'}}, {'source_node': {'name': '1,2-dimethylnaphthalene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lymphoblastoid cells'}}, {'source_node': {'name': '1,2-dimethylnaphthalene'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'CYP2A6'}}, {'source_node': {'name': 'cytochrome p450 1a2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP1A2'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:5610', 'target': 'GENE:26285', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'COMPOUND:25533', 'target': 'GENE:26290', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:3690', 'target': 'GENE:26285', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:25533', 'target': 'PROTEIN:3690', 'metadata': None}]",0.6363636363636364,f98ffafa7cbce0ce3ef603f8d59dd824,cdb8e921f99d80606fe71ef6798f02e7,"['The compound 1,2-dimethylnaphthalene targets several entities, including cytochrome p450 1a2, cytochrome p450 2a6, and lymphoblastoid cells. Cytochrome p450 1a2 and cytochrome p450 2a6 are gene products. Particularly, cytochrome p450 1a2 is a gene product of CYP1A2 and cytochrome p450 2a6 is a gene product of CYP2A6. This highlights a complex web of interactions driven by 1,2-dimethylnaphthalene involving multiple target entities.', 'The compound 1,2-dimethylnaphthalene targets several entities including cytochrome p450 1a2, cytochrome p450 2a6, and lymphoblastoid cells. Cytochrome p450 1a2 is the gene product of CYP1A2, while cytochrome p450 2a6 is a product of the gene CYP2A6.', 'The compound 1,2-dimethylnaphthalene targets several molecules which include cytochrome p450 1a2, cytochrome p450 2a6, and lymphoblastoid cells. Notably, cytochrome p450 2a6 is also a gene product of CYP2A6, re-confirming its role in the pathway. Similarly, cytochrome p450 1a2 is a gene product of CYP1A2, highlighting its involvement in similar biological processes.', 'Cytochrome p450 2a6 and cytochrome p450 1a2 are gene products of CYP2A6 and CYP1A2 respectively. The compound known as 1,2-dimethylnaphthalene targets these two cytochromes as well as lymphoblastoid cells.', ""The compound 1,2-dimethylnaphthalene has targets including cytochrome p450 1a2 and cytochrome p450 2a6, as well as lymphoblastoid cells. It's interesting to note that cytochrome p450 1a2 is a gene product of CYP1A2, where as cytochrome p450 2a6 is a gene product of CYP2A6.""]","['The compound 1,2-dimethylnaphthalene targets both the cytochrome p450 1a2 and lymphoblastoid cells. Furthermore, it has an affecting interaction with the CYP2A6 gene. Cytochrome p450 1a2 is a product of the gene CYP1A2. On the other hand, lymphoblastoid cells are products of the CYP1A2 gene. Also, cytochrome p450 2a6, which happens to be a product of both CYP2A6 and CYP1A2 genes, plays significant roles in these interactions. These associations suggest a convoluted genetic landscape involving multiple genes and their products with the potential to be influenced by the compound 1,2-dimethylnaphthalene.']"
"[{'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15B'}}, {'source_node': {'name': 'igernellin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arachidonate 15-lipoxygenase'}}]","[{'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15B'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:73919', 'target': None, 'metadata': {'node_id': '73919', 'node_type': 'COMPOUND', 'display_name': 'igernellin'}}]",0.7142857142857143,1c49d7352d7dacb5bcf018bb277bca0d,a2749c2a81c4462c1d7f00f33dca60f6,"['The drug igernellin targets arachidonate 15-lipoxygenase, which is a gene product of both ALOX15 and ALOX15B.', 'The drug igernellin targets the enzyme arachidonate 15-lipoxygenase, which is the gene product of both ALOX15 and ALOX15B.', 'The drug igernellin targets arachidonate 15-lipoxygenase, which is a gene product of both ALOX15 and ALOX15B.', 'The drug igernellin targets arachidonate 15-lipoxygenase, a molecule that is a gene product of both ALOX15 and ALOX15B.', 'The enzyme arachidonate 15-lipoxygenase, a gene product of both ALOX15 and ALOX15B, is targeted by the drug igernellin.']","['The enzyme arachidonate 15-lipoxygenase is a gene product of both ALOX15 and ALOX15B.', 'The enzyme arachidonate 15-lipoxygenase is a gene product of both ALOX15 and ALOX15B.', 'The enzyme arachidonate 15-lipoxygenase is a gene product of both ALOX15 and ALOX15B.', 'The enzyme arachidonate 15-lipoxygenase is a gene product of both ALOX15 and ALOX15B.', 'The enzyme arachidonate 15-lipoxygenase is the gene product of both ALOX15 and ALOX15B.']"
"[{'source_node': {'name': 'dl-methylephedrine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bisoprolol'}}, {'source_node': {'name': 'dl-methylephedrine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nebivolol'}}]","[{'source_node': {'name': 'dl-methylephedrine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bisoprolol'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:4577', 'target': None, 'metadata': {'node_id': '4577', 'node_type': 'COMPOUND', 'display_name': 'nebivolol'}}]",0.6,3a80ba34c00dd132469d03d26206ff67,95d3729714099f78af9fa8a5e7db6dde,"['The drug dl-methylephedrine is known to decrease the efficacy of both bisoprolol and nebivolol.', 'The compound dl-methylephedrine is observed to decrease the efficacy of certain medications such as bisoprolol and nebivolol.', 'The drug called dl-methylephedrine is reported to decrease the efficacy of two cardioselective 1-adrenergic blocking agents: bisoprolol and nebivolol. This suggests caution in their co-administration, as dl-methylephedrine might affect the therapeutic outcomes of these heart medications.', 'The drug dl-methylephedrine interacts with certain medications, decreasing the efficacy of drugs such as bisoprolol and nebivolol.', 'The drug dl-methylephedrine is known to decrease the efficacy of several other drugs, specifically bisoprolol and nebivolol.']",['The drug dl-methylephedrine is known to decrease the efficacy of bisoprolol.']
"[{'source_node': {'name': 'clocortolone acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'donepezil'}}, {'source_node': {'name': 'clocortolone acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'seocalcitol'}}, {'source_node': {'name': 'ketamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'aldosterone'}}, {'source_node': {'name': 'ketamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clocortolone acetate'}}, {'source_node': {'name': 'ketamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'prednisolone acetate'}}]","[{'source_node': {'name': 'donepezil'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'seocalcitol'}}, {'source_node': {'name': 'clocortolone acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'donepezil'}}, {'source_node': {'name': 'clocortolone acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'seocalcitol'}}, {'source_node': {'name': 'ketamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'aldosterone'}}, {'source_node': {'name': 'ketamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'prednisolone acetate'}}, {'source_node': {'name': 'ketamine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'seocalcitol'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:1201', 'target': 'COMPOUND:12358', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:826', 'target': 'COMPOUND:4008', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1201', 'target': 'COMPOUND:4008', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7272727272727273,5da75f18b1950e5397dac3e2adb29e89,eb7f45c327691ceb57ac3634ed866fcc,"['The drug clocortolone acetate has been observed to decrease the efficacy of both donepezil and seocalcitol. Meanwhile, ketamine, a common anesthetic, can impact the effectiveness of several substances, notably decreasing the efficacy of aldosterone, clocortolone acetate, and prednisolone acetate. This evidence demonstrates the intricate interactions between these drugs which could significantly alter their therapeutic impacts.', 'The efficacy of several drugs can be decreased by others. In this context, clocortolone acetate is known to decrease the efficacy of donepezil and seocalcitol. Similarly, the drug ketamine is reported to reduce the efficiency of aldosterone, clocortolone acetate, and prednisolone acetate. Hence, these drug interactions should be considered carefully in medical treatments.', 'The administration of certain drugs such as clocortolone acetate and ketamine have been found to decrease the efficacy of other medications. For instance, clocortolone acetate is reported to reduce the effectiveness of donepezil and seocalcitol. Ketamine, on the other hand, negatively impacts the efficacy of aldosterone, clocortolone acetate, and prednisolone acetate. This presents potential areas of concern in drug management therapy and requires careful consideration when administrating multi-drug treatments.', 'Clocortolone acetate, a medication, is known to decrease the efficacy of other drugs, specifically donepezil and seocalcitol. Meanwhile, the drug ketamine also has similar effects as it can decrease the efficacy of a variety of compounds including aldosterone, clocortolone acetate itself, and prednisolone acetate. Thus, it is essential to consider these interactions whilst administering these medications simultaneously.', 'The drug Clocortolone Acetate has been found to decrease the efficacy of both Donepezil and Seocalcitol. Similarly, Ketamine, a well-known anaesthetic, reduces the efficacy of Aldosterone, Clocortolone Acetate, and Prednisolone Acetate. Hence interactions between these drugs should be considered in any therapeutic plan.']","['Donepezil plays a significant role in increasing the efficacy of seocalcitol, a drug widely used in certain health conditions. On the other hand, clocortolone acetate decreases the efficacy of both donepezil and seocalcitol, leading to possible drug interaction. Meanwhile, ketamine, a well-known anesthetic, decreases the efficacy of aldosterone and prednisolone acetate, but interestingly, it increases the efficacy of seocalcitol. These findings highlight the crucial role of understanding the drug interactions and their potential influence on treatment outcomes.', 'The drug donepezil enhances the effectiveness of seocalcitol. However, its potency is reduced by clocortolone acetate, a substance that also diminishes the efficacy of seocalcitol. Meanwhile, ketamine, another drug, downgrades the efficiency of both aldosterone and prednisolone acetate, whilst concurrently escalating the efficacy of seocalcitol.', 'The drug donepezil is known to amplify the efficacy of seocalcitol. However, the drug clocortolone acetate negatively influences the effectiveness of both donepezil and seocalcitol. On the other hand, ketamine has a complex role. It tends to decrease the effectiveness of aldosterone and prednisolone acetate, yet interestingly, it enhances the efficacy of seocalcitol.', 'In the complex web of pharmaceutical interactions, several intriguing relationships are observed. The drug Donepezil, for instance, increases the efficacy of Seocalcitol. However, Clocortolone Acetate appears to play a dampening role in this process, decreasing the efficacy of both Donepezil and Seocalcitol separately. \n\nSimilarly, the drug Ketamine also reveals a bifaceted role. While it reduces the efficacy of both Aldosterone and Prednisolone Acetate, contrary to the dampening activity seen with Clocortolone Acetate, Ketamine astonishingly increases the efficacy of Seocalcitol. These interconnected interactions underline the complexity and specificity of pharmaceutical effects in various contexts.', ""Donepezil can increase the efficiency of seocalcitol, a known therapeutic agent. However, its efficacy can be decreased when used with clocortolone acetate. Interestingly, this compound, clocortolone acetate, can also decrease the efficacy of seocalcitol directly. Another drug, ketamine, could decrease the efficacy of several compounds such as aldosterone and prednisolone acetate. But unlike it's effect on these compounds, ketamine may actually increase the efficacy of seocalcitol.""]"
"[{'source_node': {'name': '(2,4-cis and trans)-mosinone a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': '(2,4-cis and trans)-mosinone a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a498'}}]","[{'source_node': {'name': '(2,4-cis and trans)-mosinone a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a498'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5851', 'target': None, 'metadata': {'node_id': '5851', 'node_type': 'PROTEIN', 'display_name': 'mcf7'}}]",0.6,209e3cba61462146410736505d0a7078,825295a6411d8f95d6c2b49795e9df7c,"['The drug (2,4-cis and trans)-mosinone A has two targets, both of which are cancer cell lines, MCF7 and A498.', 'The compound (2,4-cis and trans)-mosinone A has targets including MCF7 and A498.', 'The compound (2,4-cis and trans)-mosinone A displays activity against several targets including two cancer cell lines, MCF7 and A498.', 'The drug, (2,4-cis and trans)-mosinone A, targets both MCF7 and A498.', 'The compound (2,4-cis and trans)-mosinone A targets both MCF7 and A498 cell lines.']",[]
"[{'source_node': {'name': 'oteseconazole'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'agmatine'}}, {'source_node': {'name': 'oteseconazole'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'darodipine'}}, {'source_node': {'name': 'oteseconazole'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'dexverapamil'}}, {'source_node': {'name': 'dexverapamil'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}]","[{'source_node': {'name': 'oteseconazole'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'agmatine'}}, {'source_node': {'name': 'oteseconazole'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'dexverapamil'}}, {'source_node': {'name': 'dexverapamil'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}]","[{'type': 'node_removal', 'source': 'COMPOUND:8169', 'target': None, 'metadata': {'node_id': '8169', 'node_type': 'COMPOUND', 'display_name': 'darodipine'}}]",0.7777777777777778,9e7afef35690e87911b87a18cb3024e4,d138d33b078f7092ec54d87e6ba2b496,[],[]
"[{'source_node': {'name': 'glycogen phosphorylase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PYGB'}}, {'source_node': {'name': 'glycogen phosphorylase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PYGM'}}, {'source_node': {'name': 'melibiose'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glycogen phosphorylase'}}]","[{'source_node': {'name': 'glycogen phosphorylase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PYGM'}}, {'source_node': {'name': 'melibiose'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glycogen phosphorylase'}}, {'source_node': {'name': 'melibiose'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'PYGM'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:87308', 'target': 'GENE:32154', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'GENE:32152', 'target': None, 'metadata': {'node_id': '32152', 'node_type': 'GENE', 'display_name': 'PYGB'}}]",0.5714285714285714,a762057d1cbcfc251f143cd7099f4a2b,7207b058e794f68fd00115b172951c77,"['The enzyme glycogen phosphorylase, which is a gene product of both PYGB and PYGM genes, has been identified as a target of the compound melibiose.', 'The enzyme glycogen phosphorylase, which acts as a target for melibiose, is expressed as a gene product of two genes, PYGB and PYGM.', 'Glycogen phosphorylase, a gene product of both PYGB and PYGM, is targeted by the sugar compound melibiose.', 'The enzyme glycogen phosphorylase, which is a gene product of both PYGB and PYGM, is targeted by the carbohydrate compound melibiose.', 'The enzyme glycogen phosphorylase, which is a gene product of both PYGB and PYGM, is targeted by the disaccharide, melibiose.']","['The compound melibiose affects the PYGM gene, which is responsible for the production of the enzyme glycogen phosphorylase. Notably, glycogen phosphorylase is also a target of melibiose.', 'Glycogen phosphorylase, which is a gene product of PYGM, can be targeted by melibiose. Additionally, melibiose is known to affect PYGM.', 'The compound melibiose interacts with the gene product of PYGM, known as glycogen phosphorylase. Concurrently, melibiose itself is known to affect PYGM.', 'The compound melibiose targets glycogen phosphorylase, which is a gene product of PYGM. Additionally, the presence of melibiose can affect the PYGM gene.']"
"[{'source_node': {'name': 'roquefortine c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mda-mb-231'}}, {'source_node': {'name': 'roquefortine c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf-10a'}}]","[{'source_node': {'name': 'roquefortine c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf-10a'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5850', 'target': None, 'metadata': {'node_id': '5850', 'node_type': 'PROTEIN', 'display_name': 'mda-mb-231'}}]",0.6,500cbe8d6d48db871a61848edd04faa9,9a9215ea9b9c6fbf713fa2fcf94a1d21,"['The compound Roquefortine C has been identified as targeting two specific cell lines, MDA-MB-231 and MCF-10A.', 'Roquefortine C, a bioactive compound, has multiple targets including MDA-MB-231 and MCF-10A, both of which are human cell lines used for biomedical research.', 'The compound Roquefortine C is known to target two cellular entities, MDA-MB-231 and MCF-10A.', 'The compound Roquefortine C has been found to target two specific cell lines, MDA-MB-231 and MCF-10A.', 'The compound Roquefortine C has the ability to target two cell lines, namely MDA-MB-231 and MCF-10A.']","['The compound Roquefortine C has the cellular entity MCF-10A as its target.', 'Roquefortine C is a compound that has as its target MCF-10A, which is a type of non-tumorigenic human mammary epithelial cell line.']"
"[{'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Nail disorder'}}, {'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Hypomagnesaemia'}}, {'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Bone pain'}}, {'source_node': {'name': 'thyrotropin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'insulin argine'}}, {'source_node': {'name': 'thyrotropin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'infigratinib'}}, {'source_node': {'name': 'indalpine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the fluid retaining and vasopressor activities '}}, {'source_node': {'name': 'indalpine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pregabalin'}}, {'source_node': {'name': 'indalpine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'thyrotropin'}}]","[{'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Nail disorder'}}, {'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Hypomagnesaemia'}}, {'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Bone pain'}}, {'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'infigratinib'}}, {'source_node': {'name': 'indalpine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the fluid retaining and vasopressor activities '}}, {'source_node': {'name': 'indalpine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'infigratinib'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:220', 'target': 'COMPOUND:9801', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:12847', 'target': None, 'metadata': {'node_id': '12847', 'node_type': 'COMPOUND', 'display_name': 'thyrotropin'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:7900', 'target': 'COMPOUND:220', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:7900', 'target': 'COMPOUND:9801', 'metadata': {'predicate': 'increase_efficacy'}}]",0.5294117647058824,4d3b301c628974adce5fd6252cd485b3,e4a8ab38f928512b9aeb057b961e3d9c,[],[]
"[{'source_node': {'name': 'danazol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'teneligliptin'}}, {'source_node': {'name': 'danazol'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Diabetic'}}, {'source_node': {'name': 'danazol'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Pancreatitis'}}, {'source_node': {'name': 'simeprevir'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'interferon lambda 3'}}, {'source_node': {'name': 'simeprevir'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'hepatitis c'}}, {'source_node': {'name': 'teneligliptin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'leuprolide'}}, {'source_node': {'name': 'teneligliptin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'simeprevir'}}, {'source_node': {'name': 'teneligliptin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'bucindolol'}}]","[{'source_node': {'name': 'danazol'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Diabetic'}}, {'source_node': {'name': 'danazol'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Pancreatitis'}}, {'source_node': {'name': 'simeprevir'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'interferon lambda 3'}}, {'source_node': {'name': 'simeprevir'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'hepatitis c'}}, {'source_node': {'name': 'teneligliptin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'leuprolide'}}, {'source_node': {'name': 'teneligliptin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'bucindolol'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:1345', 'target': 'COMPOUND:9861', 'metadata': None}, {'type': 'edge_deletion', 'source': 'COMPOUND:9861', 'target': 'COMPOUND:5515', 'metadata': None}]",0.8823529411764706,dabb8ab01e852ab5d5847748eb88d5ce,a60d6cc42bb3af363208f1a404dcbd49,"[""Danazol is a drug which has multiple impacts. It decreases the efficacy of another drug called teneligliptin, which is known to have a decreased efficacy when interacting with leuprolide but an increased efficacy when interacting with both simeprevir and bucindolol. Interestingly, danazol itself also has an indication for treating diabetics, despite its effect on teneligliptin. However, it's not devoid of side effects and has been linked to pancreatitis.\n\nOn the other hand, simeprevir, which also has its efficacy increased by teneligliptin, has been identified as a substance that treats hepatitis C. Notably, it also affects the protein interferon lambda 3. Clearly, the interactions among these drugs are complex and multi-layered, suggesting a need for careful consideration in prescription decisions."", 'The drug Danazol has been indicated for use in Diabetic patients while demonstrated to decrease the efficacy of the medication Teneligliptin. Furthermore, usage of Danazol has also been associated with the side effect of Pancreatitis. Teneligliptin itself, apart from having its effectiveness reduced by Danazol, has been reported to decrease the efficacy of another medication known as Leuprolide. However, its interaction with other drugs such as Simeprevir and Bucindolol shows enhanced efficacy. Simeprevir, on the other hand, treats Hepatitis C and its effectiveness can be influenced positively by Teneligliptin. Moreover, this drug has shown impact on Interferon lambda 3.']","['The drug Danazol has indications for treating Diabetic patients, however, it has been noted to have a side effect of Pancreatitis. As for Simeprevir, it operates by affecting interferon lambda 3 and is known as a substance that treats Hepatitis C. On the other hand, Teneligliptin is another significant drug; it decreases the efficacy of Leuprolide and conversely, increases the efficacy of Bucindolol.']"
"[{'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'xylazine'}}, {'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Leukaemoid reaction'}}, {'source_node': {'name': 'dibromotyrosine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tolazamide'}}, {'source_node': {'name': 'dibromotyrosine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'escitalopram'}}, {'source_node': {'name': 'dibromotyrosine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ritanserin'}}, {'source_node': {'name': 'seproxetine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pregabalin'}}, {'source_node': {'name': 'seproxetine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'levothyroxine'}}, {'source_node': {'name': 'seproxetine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dibromotyrosine'}}]","[{'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Leukaemoid reaction'}}, {'source_node': {'name': 'escitalopram'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'seproxetine'}}, {'source_node': {'name': 'dibromotyrosine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tolazamide'}}, {'source_node': {'name': 'dibromotyrosine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'escitalopram'}}, {'source_node': {'name': 'dibromotyrosine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ritanserin'}}, {'source_node': {'name': 'xylazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'tolazamide'}}, {'source_node': {'name': 'xylazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'levothyroxine'}}, {'source_node': {'name': 'seproxetine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'levothyroxine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1155', 'target': 'COMPOUND:5781', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:9432', 'target': 'COMPOUND:822', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:5781', 'target': 'COMPOUND:220', 'metadata': None}, {'type': 'edge_deletion', 'source': 'COMPOUND:5781', 'target': 'COMPOUND:6658', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:9432', 'target': 'COMPOUND:439', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:220', 'target': 'COMPOUND:9432', 'metadata': None}]",0.6470588235294117,cfc64551fb1bcc1f80d06a3051e8a3b7,1aa4255e792e21edd9a266326c340a72,"[""Pregabalin is known to increase the efficacy of xylazine, but it also has a side effect that can result in a leukaemoid reaction. Additionally, the effectiveness of pregabalin is enhanced by seproxetine. However, it's important to note that seproxetine also decreases the efficacy of levothyroxine and dibromotyrosine. Speaking of dibromotyrosine, it has been observed to lessen the effectivity of a number of medications such as tolazamide, escitalopram, and ritanserin."", ""The drug pregabalin has shown to increase the efficacy of xylazine and seproxetine also enhances the efficacy of pregabalin. However, it's important to note that use of pregabalin may have side effects, one of which could be a leukaemoid reaction. On the other hand, dibromotyrosine is known to decrease the efficacy of several medications including tolazamide, escitalopram and ritanserin. Moreover, seproxetine also has a reducing effect on the efficacy of levothyroxine and dibromotyrosine. Therefore, the interactions between these drugs should be taken into account in a clinical setting to avoid decrease in efficacy or adverse reactions."", 'The drug pregabalin increases the efficacy of xylazine and has a known side effect of causing a Leukaemoid reaction. Meanwhile, dibromotyrosine decreases the efficacy of several drugs including tolazamide, escitalopram, and ritanserin. On the other hand, seproxetine is known to enhance the efficacy of pregabalin but reduces the efficacy of levothyroxine and dibromotyrosine.', 'The drug pregabalin has been shown to increase the efficacy of xylazine and also have a side effect known as a leukaemoid reaction. Interestingly, seproxetine also increases the efficacy of pregabalin. However, it appears that seproxetine can decrease the efficacy of two drugs: levothyroxine and dibromotyrosine. Furthermore, dibromotyrosine itself is known to decrease the efficacy of several different medications: tolazamide, escitalopram, and ritanserin.', 'The drug Pregabalin is found to increase the efficacy of Xylazine and is also associated with a possible side effect known as Leukaemoid reaction. On the other hand, the drug Dibromotyrosine is known to decrease the efficacy of the drugs Tolazamide, Escitalopram and Ritanserin. Seproxetine also influences these drug interactions, enhancing the efficacy of Pregabalin, while reducing the efficacy of both Levothyroxine and Dibromotyrosine.']","['The drugs escitalopram and pregabalin display diverse effects; escitalopram increases the efficacy of the drug seproxetine, while pregabalin has been associated with the side effect of prompting a leukaemoid reaction. On the other hand, dibromotyrosine has a reducing action, as it decreases the efficacy of a number of drugs including tolazamide, escitalopram, and ritanserin. Interestingly, the drug xylazine exerts a contrasting effect, demonstrating an increase in the efficacy of drugs such as tolazamide and levothyroxine. Yet, the relationship between seproxetine and levothyroxine is antagonistic in nature, with seproxetine acting to decrease the efficacy of levothyroxine.', 'The drug pregabalin has a side effect known as Leukaemoid reaction. It has been observed that escitalopram can increase the efficacy of seproxetine. On the other hand, dibromotyrosine is known to decrease the efficacy of several drugs, including tolazamide, escitalopram, and ritanserin. Interestingly, xylazine seems to enhance the efficacy of both tolazamide and levothyroxine. However, in relation to levothyroxine, its efficacy is decreased when combined with seproxetine.', 'The drug Pregabalin is associated with the side effect known as a Leukaemoid reaction. The efficacy of Seproxetine can be increased through use of Escitalopram, while conversely Seproxetine, when administered, decreases the efficacy of Levothyroxine. Similarly, the use of Dibromotyrosine is found to decrease the efficacy of multiple drugs such as Tolazamide, Escitalopram and Ritanserin. Xylazine, on the other hand, has a contrasting effect and is known to increase the efficacy of Tolazamide and Levothyroxine. These intricate interplays between different drugs underscore the complexity of pharmacology and its influence on drug efficacy.', 'The use of the drug Pregabalin can have a side effect known as a Leukaemoid reaction. On the other hand, when combined, Escitalopram tends to increase the efficacy of Seproxetine. Dibromotyrosine, another drug, can decrease the efficacy of multiple medications including Tolazamide, Escitalopram, and Ritanserin. Meanwhile, Xylazine has been found to increase the efficacy of both Tolazamide and Levothyroxine. However, the effectiveness of Levothyroxine might get reduced when combined with Seproxetine.', 'The drug Pregabalin can potentially cause side effects, such as triggering a leukaemoid reaction. Meanwhile, other pharmaceutical interactions can occur between various drugs, like how Escitalopram can increase the efficacy of Seproxetine.\n\nHowever, certain substances can decrease drug efficacy. For instance, Dibromotyrosine can decrease the efficacy of Tolazamide, Escitalopram, and Ritanserin. That being said, another compound called Xylazine can actually increase the efficacy of drugs like Tolazamide and Levothyroxine, though the specific mechanisms may vary. Interestingly, Seproxetine, which was highlighted earlier to have its efficacy compounded by Escitalopram, is also found to reduce the efficacy of the hormone supplement, Levothyroxine.']"
"[{'source_node': {'name': 'RPS8'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Selenocysteine synthesis'}}, {'source_node': {'name': 'RPS8'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Formation of a pool of free 40S subunits'}}, {'source_node': {'name': 'RPS8'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'SARS-CoV-1 modulates host translation machinery'}}]","[{'source_node': {'name': 'RPS8'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Selenocysteine synthesis'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1196', 'target': None, 'metadata': {'node_id': '1196', 'node_type': 'PATHWAY', 'display_name': 'SARS-CoV-1 modulates host translation machinery'}}, {'type': 'node_removal', 'source': 'PATHWAY:667', 'target': None, 'metadata': {'node_id': '667', 'node_type': 'PATHWAY', 'display_name': 'Formation of a pool of free 40S subunits'}}]",0.4285714285714286,5abbf9ac0ea58124fe29052aa4bc9c5f,dbd1beec3ce349f04fb469cd25ac04ec,"['The gene RPS8 is involved in several biological processes. Firstly, it plays a key role in selenocysteine synthesis. Furthermore, it is pivotal in the formation of a pool of free 40S subunits. Lastly, this gene also acts within the mechanisms through which SARS-CoV-1 modulates host translation machinery.']",[]
"[{'source_node': {'name': 'sacrotride a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'sacrotride a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-mel-2'}}, {'source_node': {'name': 'sacrotride a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}]","[{'source_node': {'name': 'sacrotride a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4980', 'target': None, 'metadata': {'node_id': '4980', 'node_type': 'PROTEIN', 'display_name': 'sk-mel-2'}}, {'type': 'node_removal', 'source': 'PROTEIN:4976', 'target': None, 'metadata': {'node_id': '4976', 'node_type': 'PROTEIN', 'display_name': 'ht-29'}}]",0.4285714285714286,cdc955d485ec34c0e9cc1b6db4c70a32,ee57bc58c9bb7136e8a9bab17b9558c4,"['The drug Sacrotride A has been identified to target several cell lines, including A549, SK-MEL-2, and HT-29.', 'The drug Sacrotride A has been found to target several cell lines, including A549, SK-MEL-2, and HT-29.', 'The drug Sacrotride A is known to target A549, SK-MEL-2, and HT-29, which are all different cell lines commonly used in biomedical research.', 'The substance Sacrotride A is found to target several cells including A549, SK-MEL-2, and HT-29.', 'The drug Sacrotride A has multiple targets, including A549, SK-MEL-2, and HT-29.']",['The drug Sacrotride A has the cellular A549 as its target.']
"[{'source_node': {'name': 'KCNN3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'zimmermann-laband syndrome 3'}}, {'source_node': {'name': 'KCNN3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'zimmermann-laband syndrome 1'}}, {'source_node': {'name': 'KCNN3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ca2+ activated K+ channels'}}]","[{'source_node': {'name': 'KCNN3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'zimmermann-laband syndrome 3'}}, {'source_node': {'name': 'KCNN3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ca2+ activated K+ channels'}}]","[{'type': 'node_removal', 'source': 'DISEASE:6567', 'target': None, 'metadata': {'node_id': '6567', 'node_type': 'DISEASE', 'display_name': 'zimmermann-laband syndrome 1'}}]",0.7142857142857143,c213f87e5e5740ebb201e75690a68f2e,559044b248f1399f509bd6eba0bb42a9,"['The gene KCNN3 is identified to act within Ca2+ activated K+ channels and it is found to cause certain conditions such as Zimmermann-Laband Syndrome 1 and Zimmermann-Laband Syndrome 3.', 'The gene KCNN3, which functions within Ca2+ activated K+ channels, is known to cause two variants of an inherited condition: Zimmermann-Laband syndrome 1 and Zimmermann-Laband syndrome 3.', 'The gene KCNN3 has been identified to cause multiple conditions such as Zimmermann-Laband Syndrome 3 and Zimmermann-Laband Syndrome 1. Interestingly, this gene also operates within the pathway of Ca2+ activated K+ channels.', 'The KCNN3 gene, which operates within Ca2+ activated K+ channels, is known to cause two distinct conditions: Zimmermann-Laband Syndrome 3 and Zimmermann-Laband Syndrome 1.', 'The gene KCNN3 has been found to cause both Zimmermann-Laband Syndrome 1 and 3. Additionally, KCNN3 is known to act within Ca2+ activated K+ channels, playing a potentially critical role in the pathogenesis of these disorders.']","['The gene KCNN3, functioning within the Ca2+ activated K+ channels, is a known cause of Zimmermann-Laband syndrome 3.', 'The KCNN3 gene, which acts within the functionality of Ca2+ activated K+ channels, is known to cause Zimmermann-Laband Syndrome 3.', 'The gene KCNN3, which acts within the pathway of Ca2+ activated K+ channels, is known to cause Zimmermann-Laband Syndrome 3.', 'The gene KCNN3, which acts within the Ca2+ activated K+ channels, is known to cause a condition known as Zimmermann-Laband syndrome 3.']"
"[{'source_node': {'name': 'aldo-keto reductase family 1 member c3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AKR1C3'}}, {'source_node': {'name': 'aldose reductase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AKR1B1'}}, {'source_node': {'name': 'drupanin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}, {'source_node': {'name': 'drupanin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'aldose reductase'}}, {'source_node': {'name': 'drupanin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'aldo-keto reductase family 1 member c3'}}]","[{'source_node': {'name': 'aldose reductase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AKR1B1'}}, {'source_node': {'name': 'hela'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AKR1B1'}}, {'source_node': {'name': 'drupanin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}, {'source_node': {'name': 'drupanin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'aldose reductase'}}, {'source_node': {'name': 'drupanin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'aldo-keto reductase family 1 member c3'}}]","[{'type': 'node_removal', 'source': 'GENE:34740', 'target': None, 'metadata': {'node_id': '34740', 'node_type': 'GENE', 'display_name': 'AKR1C3'}}, {'type': 'edge_addition', 'source': 'PROTEIN:4994', 'target': 'GENE:27202', 'metadata': {'predicate': 'gene_product_of'}}]",0.7272727272727273,cab246da8d55a5714014d2d115681768,8a32cd25b6e5e7a8e89ae1216cc5e8d0,"['The drug Drupanin has multiple targets, including the aldo-keto reductase family 1 member C3, aldose reductase, and HeLa; the first two of which are gene products of AKR1C3 and AKR1B1, respectively.', 'The molecule Drupanin has multiple targets, which include Hela, Aldose reductase, and Aldo-keto reductase family 1 member C3. Aldo-Keto reductase family 1 member C3 and Aldose reductase are notable as they are gene products of AKR1C3 and AKR1B1 respectively.', 'The molecule drupanin has several targets, including HeLa, a type of human cell line, and two proteins: aldose reductase and aldo-keto reductase family 1 member c3. Notably, aldose reductase is the gene product of AKR1B1, while aldo-keto reductase family 1 member c3 is the gene product of AKR1C3.', 'The drug Drupanin targets several entities, including the Hela, a cell derived from a cancer tumor, and two enzymes, Aldose Reductase and Aldo-keto Reductase Family 1 Member C3. Both of these enzymes are gene products - Aldose Reductase is a gene product of AKR1B1, while Aldo-Keto Reductase Family 1 Member C3 is a gene product of AKR1C3.', 'Aldo-keto reductase family 1 member c3 and aldose reductase are gene products of AKR1C3 and AKR1B1 respectively. The substance drupanin targets multiple substances including the specific cell line, hela, as well as aldose reductase and aldo-keto reductase family 1 member c3.']","['The enzyme aldose reductase and HeLa (a cell line used in medical research) are both products of the gene AKR1B1. An organic compound called Drupanin targets aldose reductase, HeLa and another enzyme known as aldo-keto reductase family 1 member c3 for its action.', 'The drug Drupanin has multiple targets including the HeLa cell line and Aldose Reductase enzyme. Both HeLa and Aldose Reductase are gene products of AKR1B1. Additionally, Drupanin targets another enzyme named Aldo-Keto Reductase Family 1 Member C3.', 'The drug Drupanin targets several entities including Hela, aldose reductase, and aldo-keto reductase family 1 member c3. Interestingly, both Hela and aldose reductase are gene products of AKR1B1.', 'The drug known as drupanin has multiple targets including hela, aldose reductase, and also aldo-keto reductase family 1 member c3. This aldose reductase is in fact a gene product of AKR1B1. Interestingly, hela is also a gene product of AKR1B1. Therefore, it seems that drupanin could indirectly impact the function of AKR1B1 through its targets.', '""Aldose reductase and Hela, both gene products of AKR1B1, are targeted by the compound Drupanin. Drupanin additionally targets a member of the aldo-keto reductase family 1 member c3. Hence, Drupanin, by targeting different proteins, engages in biochemical interactions that might have significant physiological consequences.']"
"[{'source_node': {'name': 'combretastatin a-2'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}, {'source_node': {'name': 'combretastatin a-2'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'bxpc-3'}}]","[{'source_node': {'name': 'combretastatin a-2'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4939', 'target': None, 'metadata': {'node_id': '4939', 'node_type': 'PROTEIN', 'display_name': 'bxpc-3'}}]",0.6,f963b91cd62970d9eeadb5cb19990003,78ffe6a317ae9d2588d256714242535e,"['The drug combretastatin a-2 is targeted at two different types of cancer cells, namely HT-29 and BxPC-3.', 'The drug Combretastatin A-2 has been found to target two cell lines, specifically HT-29 and BxPC-3.', 'The drug known as Combretastatin A-2 has multiple targets, particularly the HT-29 and BXPC-3 cells.', 'Combretastatin A-2, a potent medicinal compound, is known to target several cell lines. Specifically, it has been observed to target both HT-29 and BXPC-3, which are critical in advancing our understanding of human diseases at a cellular level.', 'The drug Combretastatin A-2 has been found to target two specific cancer cell lines, namely HT-29 and BXPC-3.']",[]
"[{'source_node': {'name': 'VRK1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pontocerebellar hypoplasia type 1a'}}, {'source_node': {'name': 'VRK1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nuclear Envelope Breakdown'}}, {'source_node': {'name': 'VRK1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Initiation of Nuclear Envelope (NE) Reformation'}}, {'source_node': {'name': 'serine/threonine-protein kinase vrk1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VRK1'}}]","[{'source_node': {'name': 'VRK1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pontocerebellar hypoplasia type 1a'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:6532', 'target': None, 'metadata': {'node_id': '6532', 'node_type': 'PROTEIN', 'display_name': 'serine/threonine-protein kinase vrk1'}}, {'type': 'node_removal', 'source': 'PATHWAY:1406', 'target': None, 'metadata': {'node_id': '1406', 'node_type': 'PATHWAY', 'display_name': 'Nuclear Envelope Breakdown'}}, {'type': 'node_removal', 'source': 'PATHWAY:1407', 'target': None, 'metadata': {'node_id': '1407', 'node_type': 'PATHWAY', 'display_name': 'Initiation of Nuclear Envelope (NE) Reformation'}}]",0.3333333333333333,928c4bef4fe47c4c3eeeb3c97cbc8516,dd892c51781d88ef7d3759cd37078c5a,[],"['The gene VRK1 is known to cause a condition known as pontocerebellar hypoplasia type 1a.', 'The gene VRK1 has been identified to cause the condition known as pontocerebellar hypoplasia type 1a.']"
"[{'source_node': {'name': '6-pentylpyran-2-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tk-10'}}, {'source_node': {'name': '6-pentylpyran-2-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h226'}}, {'source_node': {'name': '6-pentylpyran-2-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-mel-28'}}]","[{'source_node': {'name': '6-pentylpyran-2-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-mel-28'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5668', 'target': None, 'metadata': {'node_id': '5668', 'node_type': 'PROTEIN', 'display_name': 'nci-h226'}}, {'type': 'node_removal', 'source': 'PROTEIN:5633', 'target': None, 'metadata': {'node_id': '5633', 'node_type': 'PROTEIN', 'display_name': 'tk-10'}}]",0.4285714285714286,bc5659e78542e44f6da0f9ae609d9bd9,9798105e9ffd0aecb5328a0df308360e,"['The compound 6-pentylpyran-2-one has multiple targets, including TK-10, NCI-H226, and SK-MEL-28.', 'The compound 6-pentylpyran-2-one acts by targeting various cells such as TK-10, NCI-H226, and SK-MEL-28.', 'The biochemical compound 6-pentylpyran-2-one has been identified to target multiple entities, specifically TK-10, NCI-H226, and SK-MEL-28.', 'The compound 6-pentylpyran-2-one has been identified to target various cellular entities such as TK-10, NCI-H226 and SK-MEL-28.', 'The compound 6-pentylpyran-2-one has several targets. It is known to focus on TK-10, NCI-H226, and SK-MEL-28.']",[]
"[{'source_node': {'name': 'primidone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'magnesium cation'}}, {'source_node': {'name': 'sodium bisulfite'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cisplatin'}}, {'source_node': {'name': 'thymidylate synthetase'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'gastroesophageal cancer'}}, {'source_node': {'name': 'thymidylate synthetase'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'adenocarcinoma'}}, {'source_node': {'name': 'thymidylate synthetase'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'progression-free survival'}}, {'source_node': {'name': 'cisplatin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'primidone'}}, {'source_node': {'name': 'cisplatin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'thymidylate synthetase'}}, {'source_node': {'name': 'cisplatin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Myalgia'}}]","[{'source_node': {'name': 'thymidylate synthetase'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'gastroesophageal cancer'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:501', 'target': 'COMPOUND:1326', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:1326', 'target': None, 'metadata': {'node_id': '1326', 'node_type': 'COMPOUND', 'display_name': 'magnesium cation'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:501', 'target': 'GENE:22795', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:501', 'target': None, 'metadata': {'node_id': '501', 'node_type': 'COMPOUND', 'display_name': 'cisplatin'}}, {'type': 'node_removal', 'source': 'DISEASE:65', 'target': None, 'metadata': {'node_id': '65', 'node_type': 'DISEASE', 'display_name': 'adenocarcinoma'}}, {'type': 'node_removal', 'source': 'DISEASE:2664', 'target': None, 'metadata': {'node_id': '2664', 'node_type': 'DISEASE', 'display_name': 'progression-free survival'}}]",0.1764705882352941,7ae5292a823b190acb31d19c7844e7be,28d79d423487adbb0c052d0ef5dc8a6d,[],[]
"[{'source_node': {'name': 'ethyl 3-methylbutanoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor delta'}}, {'source_node': {'name': 'peroxisome proliferator-activated receptor delta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PPARD'}}]","[{'source_node': {'name': 'peroxisome proliferator-activated receptor delta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PPARD'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:35944', 'target': None, 'metadata': {'node_id': '35944', 'node_type': 'COMPOUND', 'display_name': 'ethyl 3-methylbutanoate'}}]",0.6,fa1e8eed37a89ba2e42e683c4db86c4a,de7f81cf426af382c71da7f3a8e59b38,"['The compound ethyl 3-methylbutanoate targets the peroxisome proliferator-activated receptor delta, which is the gene product of PPARD.', 'The chemical compound ethyl 3-methylbutanoate has been identified to target the peroxisome proliferator-activated receptor delta. This receptor is a gene product of PPARD.', 'The compound ethyl 3-methylbutanoate acts on a specific target, the peroxisome proliferator-activated receptor delta. It is noteworthy that this receptor is the gene product of PPARD.', 'The compound ethyl 3-methylbutanoate has a target in the peroxisome proliferator-activated receptor delta. This receptor is a gene product of PPARD.', 'The compound ethyl 3-methylbutanoate has been shown to target the peroxisome proliferator-activated receptor delta. This receptor is the gene product of the PPARD gene.']","['The gene product of PPARD is peroxisome proliferator-activated receptor delta.', 'The gene peroxisome proliferator-activated receptor delta is a product of the gene PPARD.']"
"[{'source_node': {'name': 'insulin receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'INSR'}}, {'source_node': {'name': 'kw-2450 free base'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'insulin receptor'}}, {'source_node': {'name': 'kw-2450 free base'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'insulin-like growth factor 1 receptor'}}]","[{'source_node': {'name': 'kw-2450 free base'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'insulin-like growth factor 1 receptor'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:62', 'target': 'GENE:29277', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'GENE:29277', 'target': None, 'metadata': {'node_id': '29277', 'node_type': 'GENE', 'display_name': 'INSR'}}, {'type': 'node_removal', 'source': 'PROTEIN:61', 'target': None, 'metadata': {'node_id': '61', 'node_type': 'PROTEIN', 'display_name': 'insulin receptor'}}]",0.4285714285714286,ad04c12d5189367ed96d89a6ca55ef05,0c4f448f8fc7593db1724d7eeec01484,"['The drug KW-2450 free base targets both the insulin receptor and the insulin-like growth factor 1 receptor. The insulin receptor itself is the gene product of INSR.', 'Insulin receptor is a gene product of INSR. This receptor is a target of the drug KW-2450 free base, which also targets the insulin-like growth factor 1 receptor.', ""The drug KW-2450 free base has been shown to target both the insulin receptor and the insulin-like growth factor 1 receptor. It's noteworthy that the insulin receptor is the gene product of INSR."", 'Kw-2450 free base, a compound in pharmacology, is known to target the insulin receptor and insulin-like growth factor 1 receptor. The insulin receptor is the gene product of INSR.', 'The drug KW-2450 free base specifically targets both the insulin receptor and the insulin-like growth factor 1 receptor. Importantly, the insulin receptor is a gene product of INSR.']",[]
"[{'source_node': {'name': 'amenamevir'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rubella virus vaccine'}}, {'source_node': {'name': 'amenamevir'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'varicella zoster vaccine (live/attenuated)'}}, {'source_node': {'name': 'amenamevir'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'vibrio cholerae cvd 103-hgr strain live antigen'}}, {'source_node': {'name': 'rubella virus vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oseltamivir acid'}}]","[{'source_node': {'name': 'oseltamivir acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'vibrio cholerae cvd 103-hgr strain live antigen'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:9620', 'target': 'COMPOUND:2458', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:2458', 'target': 'COMPOUND:12210', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:9620', 'target': None, 'metadata': {'node_id': '9620', 'node_type': 'COMPOUND', 'display_name': 'amenamevir'}}, {'type': 'node_removal', 'source': 'COMPOUND:8425', 'target': None, 'metadata': {'node_id': '8425', 'node_type': 'COMPOUND', 'display_name': 'rubella virus vaccine'}}]",0.2222222222222222,5d891310fd0b5630abd65f1c6c255c67,311743d2c0503fecddb707ea4efe1094,"['The drug amenamevir is known to decrease the efficacy of several vaccines, including the rubella virus vaccine, the varicella zoster vaccine (live/attenuated), and the vibrio cholerae cvd 103-hgr strain live antigen. Interestingly, the rubella virus vaccine also decreases the efficacy of another drug, oseltamivir acid.', 'The drug Amenamevir has been shown to decrease the efficacy of several vaccines including the Rubella virus vaccine, Varicella zoster vaccine (live/attenuated), and the Vibrio cholerae CVD 103-HgR strain live antigen. Furthermore, the Rubella virus vaccine decreases the efficacy of Oseltamivir acid, a common antiviral medication.', 'The drug amenamevir has been observed to decrease the efficacy of several vaccines and drugs. Specifically, it diminishes the effectiveness of the rubella virus vaccine, varicella zoster vaccine (live/attenuated), and the vibrio cholerae cvd 103-hgr strain live antigen. Interestingly, it was also found that the rubella virus vaccine, in turn, decreases the efficacy of the drug oseltamivir acid. This interconnected effect raises important considerations in pharmacology and immunization strategies.']","['The efficacy of Vibrio cholerae CVD 103-Hgr strain live antigen is decreased by oseltamivir acid.', 'The efficacy of Vibrio cholerae CVD 103-HGR strain live antigen is decreased by the drug Oseltamivir acid.', 'The efficacy of Vibrio cholerae CVD 103-Hgr strain live antigen decreases when subjected to Oseltamivir acid.', 'The efficacy of the Vibrio cholerae CVD 103-HGR strain live antigen is decreased by Oseltamivir acid.', 'The efficacy of the Vibrio cholerae CVD 103-HGR strain live antigen is decreased by Oseltamivir acid.']"
"[{'source_node': {'name': 'apraclonidine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Constipation'}}, {'source_node': {'name': 'apraclonidine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Headache'}}]","[{'source_node': {'name': 'apraclonidine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Headache'}}]","[{'type': 'node_removal', 'source': 'SIDE_EFFECT:17', 'target': None, 'metadata': {'node_id': '17', 'node_type': 'SIDE_EFFECT', 'display_name': 'Constipation'}}]",0.6,c2e952fd99b288911c1334b65962988e,5910819b032babdf463e2b18442da2f2,"['The drug apraclonidine is known to have several side effects, two of which include constipation and headache.', 'The drug apraclonidine has several potential side effects, including constipation and headaches.', 'The drug apraclonidine has been associated with certain side effects, notably constipation and headaches.', 'The drug apraclonidine can have side effects including constipation and headache.', 'The drug apraclonidine has been associated with certain side effects such as constipation and headaches.']",['The drug apraclonidine can have the side effect of causing headaches.']
"[{'source_node': {'name': 'dopamine receptor d3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'opioid-related disorders'}}, {'source_node': {'name': 'dopamine receptor d3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'parkinson disease'}}, {'source_node': {'name': 'dopamine receptor d3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'alcoholism'}}, {'source_node': {'name': 'parkinson disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'dystonia'}}, {'source_node': {'name': 'parkinson disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hallucinations'}}]","[{'source_node': {'name': 'dopamine receptor d3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'opioid-related disorders'}}, {'source_node': {'name': 'dopamine receptor d3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'alcoholism'}}, {'source_node': {'name': 'opioid-related disorders'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hallucinations'}}, {'source_node': {'name': 'parkinson disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'dystonia'}}, {'source_node': {'name': 'parkinson disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hallucinations'}}]","[{'type': 'edge_deletion', 'source': 'GENE:5056', 'target': 'DISEASE:15314', 'metadata': None}, {'type': 'edge_addition', 'source': 'DISEASE:2320', 'target': 'PHENOTYPE:575', 'metadata': {'predicate': 'has_phenotype'}}]",0.8181818181818181,6cd0bbc2f895e7d54e680aae50e0b2c1,aac321b08e0732a2ec51ca83b5976e8e,"['The dopamine receptor D3 is known to cause several conditions including opioid-related disorders, Parkinson disease, and alcoholism. Interestingly, Parkinson disease itself is characterized by several symptoms, such as dystonia and hallucinations. This suggests a potential link between the dopamine receptor D3 and these symptoms through its role in causing Parkinson disease.', 'The Dopamine Receptor D3 is attributed to causing several conditions including opioid-related disorders, Parkinson Disease, and alcoholism. Notably, Parkinson Disease itself can manifest in several phenotypes, such as dystonia and hallucinations.', 'The dopamine receptor D3 is known to cause several conditions, including opioid-related disorders, Parkinson disease, and alcoholism. Particularly, Parkinson disease, triggered by the same receptor, exhibits phenotypes such as dystonia and hallucinations.', 'The dopamine receptor D3 is associated with causing a range of conditions, including opioid-related disorders, Parkinson disease, and alcoholism. Specifically, Parkinson disease, a condition caused by the dopamine receptor D3, is characterized by certain phenotypes such as dystonia and hallucinations.', 'The dopamine receptor D3 has been implicated in causing various conditions, notably among them being opioid-related disorders, Parkinson disease, and alcoholism. Parkinson disease, a condition caused by alterations in the dopamine receptor D3, is characterized by particular phenotypes such as dystonia and hallucinations.']","['The dopamine receptor D3, with its causative roles in various conditions, including opioid-related disorders and alcoholism, has been significantly linked to certain phenotypes. For instance, opioid-related disorders have been known to elicit hallucinations. Concurrently, Parkinson disease is another condition that manifests symptoms such as dystonia and hallucinations.', 'Abnormal activities within the dopamine receptor D3 may lead to conditions such as opioid-related disorders and alcoholism. Opioid-related disorders can manifest specific phenotypes like hallucinations. Similarly, Parkinson disease can also result in phenotypes like hallucinations and dystonia. Therefore, individuals affected by opioid-related disorders or Parkinson disease could potentially exhibit hallucinatory symptoms.', ""The dopamine receptor D3 can lead to multiple conditions such as opioid-related disorders and alcoholism. Interestingly, these disorders present themselves with various phenotypes. For instance, opioid-related disorders are often characterized by the presence of hallucinations. Similarly, Parkinson's disease, another neurological condition, also frequently exhibits symptoms like hallucinations and dystonia."", 'The dopamine receptor D3 is known to cause conditions such as opioid-related disorders and alcoholism. Opioid-related disorders have phenotypes that include symptoms such as hallucinations. In addition, Parkinson disease, another neurological disorder, shares hallucinations as a common symptom, along with other phenotypic characteristics such as dystonia.', 'The dopamine receptor D3 has a significant impact on health, notably causing conditions such as opioid-related disorders and alcoholism. Opioid-related disorders, in turn, manifest with distinctive phenotypes including hallucinations. In a similar vein, Parkinson disease, another neurological condition, is characterized by phenotypes like dystonia and hallucinations.']"
"[{'source_node': {'name': 'annomuricin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'annomuricin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'annomuricin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}]","[{'source_node': {'name': 'annomuricin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5849', 'target': None, 'metadata': {'node_id': '5849', 'node_type': 'PROTEIN', 'display_name': 'a549'}}, {'type': 'node_removal', 'source': 'PROTEIN:4976', 'target': None, 'metadata': {'node_id': '4976', 'node_type': 'PROTEIN', 'display_name': 'ht-29'}}]",0.4285714285714286,fe6d8f923b5ca6dd1e1a193dfab9c3c9,9cb052b5e80fd8dc4f6e3c0e7f36cac3,"['The compound Annomuricin A has been found to target several cells, including A549, MCF7 and HT-29.', 'The compound Annomuricin A targets several cell lines including A549, MCF7, as well as HT-29.', 'The compound Annomuricin A has several targets which include A549, MCF7, and HT-29.', 'The compound Annomuricin A has multiple targets. It has been found to interact with A549, MCF7, and HT-29 cell lines.', 'The compound Annomuricin A has been identified as a target in a range of cancer cell lines, namely A549, MCF7, and HT-29.']",[]
"[{'source_node': {'name': 'pyrroloquinoline quinone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'quinohemoprotein ethanol dehydrogenase type-1'}}, {'source_node': {'name': 'pyrroloquinoline quinone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'quinoprotein glucose dehydrogenase b'}}, {'source_node': {'name': 'pyrroloquinoline quinone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'quinoprotein ethanol dehydrogenase'}}]","[{'source_node': {'name': 'pyrroloquinoline quinone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'quinohemoprotein ethanol dehydrogenase type-1'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:2967', 'target': None, 'metadata': {'node_id': '2967', 'node_type': 'PROTEIN', 'display_name': 'quinoprotein ethanol dehydrogenase'}}, {'type': 'node_removal', 'source': 'PROTEIN:2482', 'target': None, 'metadata': {'node_id': '2482', 'node_type': 'PROTEIN', 'display_name': 'quinoprotein glucose dehydrogenase b'}}]",0.4285714285714286,7a4f6090377d2841afffc667b2af4c09,fec93e4e801549be0c827c3b24cc346b,"['The compound pyrroloquinoline quinone has multiple targets. These include quinohemoprotein ethanol dehydrogenase type-1, quinoprotein glucose dehydrogenase b, and quinoprotein ethanol dehydrogenase. By interacting with these targets, pyrroloquinoline quinone plays a critical role in a variety of biochemical processes.', 'The compound pyrroloquinoline quinone specifically targets several important proteins. These include quinohemoprotein ethanol dehydrogenase type-1, quinoprotein glucose dehydrogenase b, as well as quinoprotein ethanol dehydrogenase.', 'The compound pyrroloquinoline quinone is known to target several enzymes, including quinohemoprotein ethanol dehydrogenase type-1, quinoprotein glucose dehydrogenase b and quinoprotein ethanol dehydrogenase. Thus, it plays a critical role in mediating interactions with these substrates.', 'The compound pyrroloquinoline quinone specifically targets three enzymes: quinohemoprotein ethanol dehydrogenase type-1, quinoprotein glucose dehydrogenase b, and quinoprotein ethanol dehydrogenase.', 'The compound known as pyrroloquinoline quinone targets several elements, including quinohemoprotein ethanol dehydrogenase type-1, quinoprotein glucose dehydrogenase b, and quinoprotein ethanol dehydrogenase.']","['The compound pyrroloquinoline quinone has a target interaction with quinohemoprotein ethanol dehydrogenase type-1.', 'The compound pyrroloquinoline quinone targets the protein known as quinohemoprotein ethanol dehydrogenase type-1.']"
"[{'source_node': {'name': 'MIF'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'systemic-onset juvenile idiopathic arthritis'}}, {'source_node': {'name': 'MIF'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cell surface interactions at the vascular wall'}}, {'source_node': {'name': 'MIF'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}, {'source_node': {'name': 'macrophage migration inhibitory factor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MIF'}}, {'source_node': {'name': 'systemic-onset juvenile idiopathic arthritis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'pleural effusion'}}]","[{'source_node': {'name': 'MIF'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cell surface interactions at the vascular wall'}}, {'source_node': {'name': 'MIF'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}]","[{'type': 'node_removal', 'source': 'DISEASE:11585', 'target': None, 'metadata': {'node_id': '11585', 'node_type': 'DISEASE', 'display_name': 'systemic-onset juvenile idiopathic arthritis'}}, {'type': 'node_removal', 'source': 'PROTEIN:2079', 'target': None, 'metadata': {'node_id': '2079', 'node_type': 'PROTEIN', 'display_name': 'macrophage migration inhibitory factor'}}]",0.4545454545454546,1dd3b8475f687ec60e88ee9e1748aede,123afc09870af507852682e4d4f08391,"['The gene MIF, which is a product of the macrophage migration inhibitory factor, is known to act within several pathways, notably the cell surface interactions at the vascular wall and the process of neutrophil degranulation. Furthermore, MIF is reported to cause systemic-onset juvenile idiopathic arthritis - an affliction that often manifests with symptoms such as pleural effusion.']","['The molecule MIF operates within various biological processes, functioning in processes such as cell surface interactions at the vascular wall and neutrophil degranulation.', 'The molecule MIF plays a role in several biological processes, including cell surface interactions at the vascular wall and the process of neutrophil degranulation.', 'The protein MIF functions within various biological processes such as cell surface interactions at the vascular wall and the process of neutrophil degranulation.', 'The protein MIF plays a functional role in two crucial processes: cell surface interactions at the vascular wall and neutrophil degranulation.', 'The molecule MIF takes part in several cellular processes such as cell surface interactions at the vascular wall and neutrophil degranulation.']"
"[{'source_node': {'name': 'POT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cleavage of the damaged pyrimidine '}}, {'source_node': {'name': 'POT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Telomere C-strand (Lagging Strand) Synthesis'}}, {'source_node': {'name': 'POT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'DNA Damage/Telomere Stress Induced Senescence'}}]","[{'source_node': {'name': 'POT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cleavage of the damaged pyrimidine '}}, {'source_node': {'name': 'POT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Telomere C-strand (Lagging Strand) Synthesis'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:263', 'target': None, 'metadata': {'node_id': '263', 'node_type': 'PATHWAY', 'display_name': 'DNA Damage/Telomere Stress Induced Senescence'}}]",0.7142857142857143,159f10006a48a093d84f108ad400ea43,307c5337bc19a87b873cfbbaf7c5e1fd,[],[]
"[{'source_node': {'name': 'epoxypholamin d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ovcar-3'}}, {'source_node': {'name': 'epoxypholamin d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'panc-1'}}]","[{'source_node': {'name': 'epoxypholamin d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ovcar-3'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5707', 'target': None, 'metadata': {'node_id': '5707', 'node_type': 'PROTEIN', 'display_name': 'panc-1'}}]",0.6,52bd711afbf83369628d870d272d1750,0e3f68ea1d67b22bd38ef90dfd7177ac,"['The compound epoxypholamin D is known to target and interact with both OVCAR-3 and PANC-1, demonstrating its potential use in therapeutic interventions.', 'The drug Epoxypholamin D has been found to target several different cell lines, including both OVCAR-3 and PANC-1.', 'The drug Epoxypholamin D has been shown to target both OVCAR-3 and PANC-1.', 'The drug epoxypholamin D has specific targets, including OVCAR-3 and PANC-1 cells.', 'The drug Epoxypholamin D is known to target the OVCAR-3 and PANC-1 cells.']",[]
"[{'source_node': {'name': 'CEACAM6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'cystic fibrosis'}}, {'source_node': {'name': 'CEACAM6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}]","[{'source_node': {'name': 'CEACAM6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}]","[{'type': 'node_removal', 'source': 'DISEASE:749', 'target': None, 'metadata': {'node_id': '749', 'node_type': 'DISEASE', 'display_name': 'cystic fibrosis'}}]",0.6,40c78bd27140780d53575acf7c378f04,f739b3f23790b72fc7d014118b0fffdd,"['The gene CEACAM6, which acts within the process of neutrophil degranulation, is known to cause the condition cystic fibrosis.', 'The gene CEACAM6, functioning within the neutrophil degranulation process, is a known cause of the medical condition known as cystic fibrosis.', 'The gene known as CEACAM6 participates in the process of neutrophil degranulation and is responsible for causing a medical condition known as cystic fibrosis.', 'The gene CEACAM6, which plays a role in the process of neutrophil degranulation, is involved in causing the genetic disorder known as cystic fibrosis.', 'The gene CEACAM6, which acts within the pathway of neutrophil degranulation, is known to cause the condition cystic fibrosis.']","['The gene CEACAM6 is involved in the process of neutrophil degranulation.', 'The gene CEACAM6 is known to act within the process of neutrophil degranulation.']"
"[{'source_node': {'name': 'colorectal cancer'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'adenomatous colonic polyposis'}}, {'source_node': {'name': 'colorectal cancer'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autosomal dominant inheritance'}}, {'source_node': {'name': 'colorectal cancer'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'carcinoma'}}, {'source_node': {'name': 'fibroblast growth factor receptor 3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FGFR3'}}, {'source_node': {'name': 'FGFR3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'achondroplasia'}}, {'source_node': {'name': 'FGFR3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'colorectal cancer'}}, {'source_node': {'name': 'FGFR3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Signaling by FGFR3 fusions in cancer'}}, {'source_node': {'name': 'achondroplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'respiratory distress'}}]","[{'source_node': {'name': 'colorectal cancer'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'adenomatous colonic polyposis'}}, {'source_node': {'name': 'colorectal cancer'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autosomal dominant inheritance'}}, {'source_node': {'name': 'colorectal cancer'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'carcinoma'}}, {'source_node': {'name': 'colorectal cancer'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'respiratory distress'}}, {'source_node': {'name': 'FGFR3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'achondroplasia'}}, {'source_node': {'name': 'FGFR3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'colorectal cancer'}}, {'source_node': {'name': 'FGFR3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Signaling by FGFR3 fusions in cancer'}}, {'source_node': {'name': 'achondroplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'respiratory distress'}}, {'source_node': {'name': 'achondroplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'adenomatous colonic polyposis'}}]","[{'type': 'edge_addition', 'source': 'DISEASE:13720', 'target': 'PHENOTYPE:1544', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'node_removal', 'source': 'PROTEIN:3759', 'target': None, 'metadata': {'node_id': '3759', 'node_type': 'PROTEIN', 'display_name': 'fibroblast growth factor receptor 3'}}, {'type': 'edge_addition', 'source': 'DISEASE:23', 'target': 'PHENOTYPE:3541', 'metadata': {'predicate': 'has_phenotype'}}]",0.7647058823529411,485fff29d9805a25f130b71f82416de9,43ae6123914be8db88c6b3694844ed9b,[],[]
"[{'source_node': {'name': 'COL14A1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'punctate palmoplantar keratoderma type 1'}}, {'source_node': {'name': 'COL14A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Collagen degradation'}}, {'source_node': {'name': 'COL14A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Collagen chain trimerization'}}, {'source_node': {'name': 'punctate palmoplantar keratoderma type 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'pain'}}, {'source_node': {'name': 'punctate palmoplantar keratoderma type 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'brain neoplasm'}}]","[{'source_node': {'name': 'COL14A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Collagen degradation'}}, {'source_node': {'name': 'COL14A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Collagen chain trimerization'}}]","[{'type': 'edge_deletion', 'source': 'GENE:33472', 'target': 'DISEASE:11651', 'metadata': None}, {'type': 'node_removal', 'source': 'DISEASE:11651', 'target': None, 'metadata': {'node_id': '11651', 'node_type': 'DISEASE', 'display_name': 'punctate palmoplantar keratoderma type 1'}}]",0.4545454545454546,4a3d16c5c6e2e4a2ab7e8aa3d7fe7ac1,c76c5fd6fb94d854b0bb034288776e75,"['The gene COL14A1 acts within several processes, including the degradation of collagen and the trimerization of collagen chains. This gene is also linked to the causation of a specific medical condition known as punctate palmoplantar keratoderma type 1. This condition is characterized by specific phenotypes such as pain and the development of brain neoplasms.', 'The gene COL14A1, which participates in the process of collagen degradation and collagen chain trimerization, is known to cause the condition Punctate Palmoplantar Keratoderma type 1. This condition is characterized by various symptoms such as pain and the presence of a brain neoplasm.', 'The gene COL14A1, which is known to cause punctate palmoplantar keratoderma type 1, partakes in the biological processes of collagen degradation and collagen chain trimerization within cells. Interesting to note, punctate palmoplantar keratoderma type 1 presents with phenotypes including pain and the potential for brain neoplasm.', 'The gene COL14A1, which participates in the processes of collagen degradation and collagen chain trimerization, is known to cause punctate palmoplantar keratoderma type 1. This condition is characterized by certain phenotypes such as pain and the development of brain neoplasms.', 'The gene COL14A1, involved in the degradation of collagen and also in collagen chain trimerization, is known to cause punctate palmoplantar keratoderma type 1, a condition with symptoms like pain and brain neoplasm.']","['The gene COL14A1 acts within multiple processes, specifically collagen degradation and collagen chain trimerization.', 'The gene COL14A1 is involved in the processes of collagen degradation and collagen chain trimerization.', 'The gene COL14A1 plays a role within multiple cellular processes, including collagen degradation and the trimerization of collagen chains.', 'The protein COL14A1 acts within several biochemical processes, such as the degradation of collagen and the trimerization of collagen chains.', 'The gene COL14A1 is known to act within several pathways, including the collagen degradation and the collagen chain trimerization pathways.']"
"[{'source_node': {'name': ""3'-hydroxyphloretin""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosinase'}}, {'source_node': {'name': 'tyrosinase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TYR'}}, {'source_node': {'name': 'TYR'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'oculocutaneous albinism type 1b'}}]","[{'source_node': {'name': 'tyrosinase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TYR'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:39633', 'target': None, 'metadata': {'node_id': '39633', 'node_type': 'COMPOUND', 'display_name': ""3'-hydroxyphloretin""}}, {'type': 'node_removal', 'source': 'DISEASE:11415', 'target': None, 'metadata': {'node_id': '11415', 'node_type': 'DISEASE', 'display_name': 'oculocutaneous albinism type 1b'}}]",0.4285714285714286,3caab1d4da18fdd992f37729b6085e01,968626cd37cded875a07e76c9ebe31b1,"[""The compound 3'-hydroxyphloretin targets tyrosinase, which is a gene product of the TYR gene. Importantly, mutations within the TYR gene are known to cause a condition known as oculocutaneous albinism type 1b."", ""The compound 3'-hydroxyphloretin has as its target tyrosinase. Tyrosinase is a gene product of TYR, which leads to a condition known as oculocutaneous albinism type 1b."", ""The compound 3'-hydroxyphloretin targets tyrosinase, which is the gene product of TYR. Notably, TYR is known to cause oculocutaneous albinism type 1b, a skin and eye condition."", ""The compound 3'-hydroxyphloretin targets tyrosinase, an enzyme that is the gene product of TYR. Mutations in the TYR gene are known to cause a condition named oculocutaneous albinism type 1b."", ""The compound 3'-hydroxyphloretin has a target of tyrosinase. This tyrosinase is a gene product of TYR. Mutations or malfunction of TYR are known to cause a condition known as oculocutaneous albinism type 1b.""]",[]
"[{'source_node': {'name': 'oopodin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}, {'source_node': {'name': 'oopodin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'k562'}}]","[{'source_node': {'name': 'oopodin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'k562'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5858', 'target': None, 'metadata': {'node_id': '5858', 'node_type': 'PROTEIN', 'display_name': 'kb'}}]",0.6,5716810f12659b9e4e79ce158ec8c3e2,dd1c87b67d4fc2209f554e14ea1e94d0,"['The drug Oopodin has two known targets, namely KB and K562.', 'The drug Oopodin has specific targets, these being KB and K562.', 'The drug oopodin targets two different entities: kb and k562.', 'The drug Oopodin has been identified to target both the KB and K562 cells.', 'The compound oopodin is known to target two specific entities: Kb and K562.']",[]
"[{'source_node': {'name': 'noonan syndrome 13'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'epicanthus'}}, {'source_node': {'name': 'noonan syndrome 13'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'almond-shaped palpebral fissure'}}, {'source_node': {'name': 'noonan syndrome 13'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'pointed chin'}}]","[{'source_node': {'name': 'noonan syndrome 13'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'pointed chin'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:5006', 'target': None, 'metadata': {'node_id': '5006', 'node_type': 'PHENOTYPE', 'display_name': 'almond-shaped palpebral fissure'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:235', 'target': None, 'metadata': {'node_id': '235', 'node_type': 'PHENOTYPE', 'display_name': 'epicanthus'}}]",0.4285714285714286,5f5e3fa49947d52a7ed6699ceb448958,dfb4e77b8e030b0c5e1c043432865ff3,"['Noonan syndrome 13, a genetic disorder, presents with various phenotypes, notably an epicanthus, almond-shaped palpebral fissures, and a pointed chin.', 'Noonan Syndrome 13, a rare genetic disorder, exhibits several distinctive physical phenotypes such as an epicanthus, almond-shaped palpebral fissure, and a pointed chin.', 'Noonan Syndrome 13 is a health condition characterized by several distinct phenotypic features. These include the presence of an epicanthus, almond-shaped palpebral fissure, and a pointed chin.']",[]
"[{'source_node': {'name': 'retinitis pigmentosa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'nyctalopia'}}, {'source_node': {'name': 'retinitis pigmentosa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hyperreflexia'}}, {'source_node': {'name': 'retinitis pigmentosa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'type ii diabetes mellitus'}}, {'source_node': {'name': 'CA4'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'retinitis pigmentosa'}}, {'source_node': {'name': 'CA4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Reversible hydration of carbon dioxide'}}]","[{'source_node': {'name': 'retinitis pigmentosa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'nyctalopia'}}, {'source_node': {'name': 'retinitis pigmentosa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hyperreflexia'}}, {'source_node': {'name': 'retinitis pigmentosa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'type ii diabetes mellitus'}}, {'source_node': {'name': 'CA4'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'retinitis pigmentosa'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:994', 'target': None, 'metadata': {'node_id': '994', 'node_type': 'PATHWAY', 'display_name': 'Reversible hydration of carbon dioxide'}}]",0.8181818181818181,ef67c8d77aea91d245af33f9be592512,40d5f0342c5f961451f7a2042d8b4dd4,"['Retinitis pigmentosa, a condition caused by the gene CA4, which acts within the pathway of reversible hydration of carbon dioxide, presents with several clinical findings, including nyctalopia, hyperreflexia and even type II diabetes mellitus.', 'Retinitis pigmentosa, a condition caused by the gene CA4, is associated with several symptoms including nyctalopia, hyperreflexia, and even type II diabetes mellitus. Interestingly, the CA4 gene acts within the pathway responsible for the reversible hydration of carbon dioxide.', 'Retinitis pigmentosa is a genetic disorder caused by the gene CA4, which also operates within a biological pathway known as the reversible hydration of carbon dioxide. This condition is characterized by several associated phenotypes including nyctalopia (night blindness), hyperreflexia (an abnormally high motor response), and a propensity towards type II diabetes mellitus.', 'The CA4 gene, which acts within the pathway of reversible hydration of carbon dioxide, is known to cause retinitis pigmentosa, a disease that has various phenotypes including nyctalopia, hyperreflexia, and type II diabetes mellitus.', 'Retinitis pigmentosa, a disease caused by an irregularity in the gene CA4, is known to exhibit several symptoms including nyctalopia, hyperreflexia, and even type II diabetes mellitus. The gene CA4 not only plays a role in causing retinitis pigmentosa but also acts within the pathway responsible for the reversible hydration of carbon dioxide.']","['Retinitis pigmentosa, a condition known to be caused by the CA4 gene, carries several phenotypes including nyctalopia, hyperreflexia and type II diabetes mellitus.', 'The gene CA4 is known to cause retinitis pigmentosa, a condition that presents several symptoms such as nyctalopia (night blindness), hyperreflexia (overactive reflexes), and even type II diabetes mellitus.']"
"[{'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' weight gain and edema formation '}}, {'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'butobarbital'}}, {'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Cardiomegaly'}}, {'source_node': {'name': 'difenoxin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' sedation '}}, {'source_node': {'name': 'difenoxin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pregabalin'}}, {'source_node': {'name': 'difenoxin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'magnesium sulfate'}}]","[{'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' weight gain and edema formation '}}, {'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'butobarbital'}}, {'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Cardiomegaly'}}, {'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' sedation '}}, {'source_node': {'name': 'difenoxin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' sedation '}}, {'source_node': {'name': 'difenoxin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'magnesium sulfate'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:1436', 'target': 'COMPOUND:220', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:220', 'target': 'EFFECT:39', 'metadata': {'predicate': 'increase_effect'}}]",0.8461538461538461,069b824c5ea541e0167221daf548e622,01130de66c18a285bb50ff0a1ba4162c,[],[]
"[{'source_node': {'name': 'homocystinuria-megaloblastic anemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'poor coordination'}}, {'source_node': {'name': 'homocystinuria-megaloblastic anemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hearing impairment'}}, {'source_node': {'name': 'homocystinuria-megaloblastic anemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'lower limb hypertonia'}}]","[{'source_node': {'name': 'homocystinuria-megaloblastic anemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hearing impairment'}}, {'source_node': {'name': 'homocystinuria-megaloblastic anemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'lower limb hypertonia'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1737', 'target': None, 'metadata': {'node_id': '1737', 'node_type': 'PHENOTYPE', 'display_name': 'poor coordination'}}]",0.7142857142857143,874ea500eed16531ed87f7d0f2b225d0,4a57d398f2f62d8889704d3e2961d68d,"['The condition known as homocystinuria-megaloblastic anemia is characterized by multiple phenotypes. Among those are poor coordination, hearing impairment, and lower limb hypertonia. These variations in symptomatology shed light on the array of ways this condition can affect individuals.', 'Homocystinuria-megaloblastic anemia, a genetic disorder, exhibits several phenotypes including poor coordination, hearing impairment, and lower limb hypertonia.', 'Homocystinuria-megaloblastic anemia, a medical condition, manifests phenotypes such as poor coordination, hearing impairment, and lower limb hypertonia.', 'Homocystinuria-Megaloblastic Anemia is a disease that expresses several phenotypes. One of the characteristics of this disease is poor coordination, which can significantly hamper daily activities. Another is hearing impairment, which can lead to difficulties in communication and potential social isolation. Furthermore, a patient with Homocystinuria-Megaloblastic Anemia may also exhibit a condition known as lower limb hypertonia, which reflects an increase in muscle tension in the lower extremities.', 'Homocystinuria-megaloblastic anemia is a medical condition characterized by several phenotypes. These include poor coordination, hearing impairment, and lower limb hypertonia. These are all physical manifestations or signs that allow healthcare professionals to recognize and diagnose this particular disorder.']","['Homocystinuria-megaloblastic anemia is a condition that has various phenotypes including hearing impairment and lower limb hypertonia.', 'Homocystinuria-megaloblastic anemia, a certain condition, has phenotypes including hearing impairment and lower limb hypertonia.', '""Homocystinuria-megaloblastic anemia is a condition that is characterized by several phenotypes, including hearing impairment and lower limb hypertonia.', 'Homocystinuria-megaloblastic anemia, a complex disorder, has phenotype manifestations including hearing impairment and lower limb hypertonia.', 'Homocystinuria-megaloblastic anemia is a condition that manifests with certain phenotypes, including hearing impairment and lower limb hypertonia.']"
"[{'source_node': {'name': 'landiolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'glucagon'}}, {'source_node': {'name': 'landiolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'calcium acetate'}}, {'source_node': {'name': 'landiolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'guanabenz'}}, {'source_node': {'name': 'ritobegron'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the analgesic activities '}}, {'source_node': {'name': 'ritobegron'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tamsulosin'}}, {'source_node': {'name': 'ritobegron'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'landiolol'}}, {'source_node': {'name': 'tamsulosin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'plasma'}}]","[{'source_node': {'name': 'landiolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'glucagon'}}, {'source_node': {'name': 'landiolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'calcium acetate'}}, {'source_node': {'name': 'landiolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'guanabenz'}}, {'source_node': {'name': 'ritobegron'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the analgesic activities '}}, {'source_node': {'name': 'ritobegron'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tamsulosin'}}, {'source_node': {'name': 'tamsulosin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'plasma'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:9990', 'target': 'COMPOUND:10118', 'metadata': None}]",0.9333333333333332,a3b84fccbaba8acd3aef313af1f03b2b,d7d0eb87e4696dfff41b41d51631be0f,[],[]
"[{'source_node': {'name': 'HDAC2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'p75NTR negatively regulates cell cycle via SC1'}}, {'source_node': {'name': 'HDAC2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Notch-HLH transcription pathway'}}, {'source_node': {'name': 'HDAC2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'STAT3 nuclear events downstream of ALK signaling'}}]","[{'source_node': {'name': 'HDAC2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'STAT3 nuclear events downstream of ALK signaling'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:67', 'target': None, 'metadata': {'node_id': '67', 'node_type': 'PATHWAY', 'display_name': 'Notch-HLH transcription pathway'}}, {'type': 'node_removal', 'source': 'PATHWAY:947', 'target': None, 'metadata': {'node_id': '947', 'node_type': 'PATHWAY', 'display_name': 'p75NTR negatively regulates cell cycle via SC1'}}]",0.4285714285714286,f726f7d950a8df74bee56cac338bd575,32ae4f41944dbc8c9130eb7001beb916,[],[]
"[{'source_node': {'name': 'ethenzamide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'remikiren'}}, {'source_node': {'name': 'ethenzamide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'unoprostone'}}, {'source_node': {'name': 'ethenzamide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dasiglucagon'}}, {'source_node': {'name': 'remikiren'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hypotensive activities '}}, {'source_node': {'name': 'remikiren'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'bendroflumethiazide'}}, {'source_node': {'name': 'dasiglucagon'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucagon receptor'}}, {'source_node': {'name': 'dasiglucagon'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cimicoxib'}}, {'source_node': {'name': 'dasiglucagon'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lonazolac'}}]","[{'source_node': {'name': 'unoprostone'}, 'relation': {'name': 'decrease_activity'}, 'target_node': {'name': ' the hypotensive activities '}}, {'source_node': {'name': 'unoprostone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cimicoxib'}}, {'source_node': {'name': 'ethenzamide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'unoprostone'}}, {'source_node': {'name': 'ethenzamide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dasiglucagon'}}, {'source_node': {'name': 'remikiren'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hypotensive activities '}}, {'source_node': {'name': 'remikiren'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'bendroflumethiazide'}}, {'source_node': {'name': 'dasiglucagon'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucagon receptor'}}, {'source_node': {'name': 'dasiglucagon'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cimicoxib'}}, {'source_node': {'name': 'dasiglucagon'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lonazolac'}}, {'source_node': {'name': 'bendroflumethiazide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'remikiren'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:5868', 'target': 'ACTIVITY:17', 'metadata': {'predicate': 'decrease_activity'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5868', 'target': 'COMPOUND:4773', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:424', 'target': 'COMPOUND:202', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:11395', 'target': 'COMPOUND:202', 'metadata': None}]",0.7647058823529411,f4d357f029887f2b662714fe945a7224,e59d79276e92cd6d9de0c5cde7f38285,[],[]
"[{'source_node': {'name': 'ciclesonide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methanesulfonyl fluoride'}}, {'source_node': {'name': 'ciclesonide'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Pain in extremity'}}, {'source_node': {'name': 'ciclesonide'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Obstructive airways disorder'}}, {'source_node': {'name': 'liotrix'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'calcium glucoheptonate'}}, {'source_node': {'name': 'liotrix'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'ciclesonide'}}, {'source_node': {'name': 'liotrix'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'epimestrol'}}]","[{'source_node': {'name': 'ciclesonide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methanesulfonyl fluoride'}}, {'source_node': {'name': 'ciclesonide'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Pain in extremity'}}, {'source_node': {'name': 'ciclesonide'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Obstructive airways disorder'}}, {'source_node': {'name': 'liotrix'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'calcium glucoheptonate'}}, {'source_node': {'name': 'liotrix'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'epimestrol'}}, {'source_node': {'name': 'liotrix'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Obstructive airways disorder'}}, {'source_node': {'name': 'liotrix'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'methanesulfonyl fluoride'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:1513', 'target': 'COMPOUND:1349', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:1513', 'target': 'SIDE_EFFECT:541', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1513', 'target': 'COMPOUND:10928', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7692307692307692,358a89676caab5dc5b627670238e7d39,5596f3c8cd8f75a809f1a34d51d2239e,"['The medication ciclesonide decreases the efficacy of methanesulfonyl fluoride and can result in side effects like pain in the extremities and obstructive airways disorder. Meanwhile, liotrix, a separate agent, has a complex output: it can increase the efficacy of ciclesonide but decrease that of both calcium glucoheptonate and epimestrol, playing a significant role in modifying drug interactions.', 'The drug ciclesonide can decrease the efficacy of methanesulfonyl fluoride, while it may also result in side effects such as pain in extremities and obstructive airways disorder. Another drug, liotrix, can decrease the efficacy of calcium glucoheptonate and epimestrol, while it is also known to increase the efficacy of ciclesonide. These relationships reveal complex interactions between the drugs and their potential impacts on different health conditions.', ""When the drug Ciclesonide is used, it can decrease the efficacy of Methanesulfonyl Fluoride. Furthermore, this drug has been associated with side effects such as pain in extremities and obstructive airways disorder. Similarly, Liotrix, another drug has a varied effect on different substances. It decreases the efficacy of Calcium Glucoheptonate and Epimestrol, while interestingly, it increases the efficacy of Ciclesonide. Therefore, application of these drugs need to be carefully monitored and adjusted according to the patient's needs."", ""The drug ciclesonide has been observed to decrease the efficacy of methanesulfonyl fluoride while, at the same time, it may result in side effects such as pain in the extremity and obstructive airways disorder. On the other hand, this drug's efficacy is increased by another drug, liotrix. However, liotrix itself has its limitations as it decreases the effectiveness of calcium glucoheptonate and epimestrol."", ""The drug Ciclesonide is reported to decrease the efficacy of Methanesulfonyl Fluoride. Furthermore, it has been linked to certain side effects including pain in the extremity and obstructive airways disorder. Conversely, Liotrix, another drug, has been observed to enhance the efficacy of Ciclesonide. However, it's important to note that Liotrix can hinder the effectiveness of certain substances including Calcium Glucoheptonate and Epimestrol. These interactions among drugs and their potential side effects should be taken into consideration in the context of patient health and treatment planning.""]","['The drug ciclesonide is known to decrease the efficacy of methanesulfonyl fluoride. Furthermore, it has been associated with certain side effects including pain in the extremity and an obstructive airways disorder. On the other hand, the drug liotrix tends to decrease the efficacy of both calcium glucoheptonate and epimestrol, while paradoxically increasing the efficacy of methanesulfonyl fluoride. Just like ciclesonide, liotrix has been found to cause an obstructive airways disorder as a side effect.', 'Ciclesonide, a commonly used drug, has been known to decrease the efficacy of methanesulfonyl fluoride, and also produce side effects including pain in extremities and obstructive airways disorder. Similarly, liotrix is another drug which decreases the efficacy of calcium glucoheptonate and epimestrol, but unexpectedly increases the efficacy of methanesulfonyl fluoride. Notably, liotrix has also been observed to induce obstructive airways disorder as a side effect.', 'The drugs, ciclesonide and liotrix, exhibit various interactions and side effects. Ciclesonide is known to decrease the efficacy of methanesulfonyl fluoride and also potentially contributes to side effects such as pain in the extremity and obstructive airways disorder. On the other hand, liotrix can decrease the efficacy of calcium glucoheptonate and epimestrol, but it is also known to increase the efficacy of methanesulfonyl fluoride. One common side effect exhibited by both ciclesonide and liotrix is obstructive airways disorder.', 'The drug ciclesonide is known to decrease the efficacy of methanesulfonyl fluoride and can have side effects such as pain in extremities and obstructive airways disorder. Similarly, the drug liotrix has been found to decrease the efficacy of calcium glucoheptonate and epimestrol. There could also be side effects such as obstructive airways disorder associated with liotrix. In a contrasting scenario, liotrix may actually increase the efficacy of methanesulfonyl fluoride.', 'The drug ciclesonide has been documented to decrease the efficacy of methanesulfonyl fluoride. Additionally, ciclesonide usage has been linked to some side effects such as pain in extremity and obstructive airways disorder. Similarly, the drug liotrix is known to reduce the efficacy of calcium glucoheptonate and epimestrol. Interestingly, liotrix also contributes to obstructive airways disorder, similar to ciclesonide. However, in the case of methanesulfonyl fluoride, liotrix works in an opposite way of ciclesonide and actually increases its efficacy.']"
"[{'source_node': {'name': 'KDELR3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'XBP1(S) activates chaperone genes'}}, {'source_node': {'name': 'KDELR3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'COPI-dependent Golgi-to-ER retrograde traffic'}}]","[{'source_node': {'name': 'KDELR3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'XBP1(S) activates chaperone genes'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:126', 'target': None, 'metadata': {'node_id': '126', 'node_type': 'PATHWAY', 'display_name': 'COPI-dependent Golgi-to-ER retrograde traffic'}}]",0.6,11be893be8a3342850c5c52fbf0ef1b5,1fb253fd101054d498615d24b2821f98,"['The gene KDELR3 functions within two pathways: it is part of the process where XBP1(S) activates chaperone genes and is also involved in COPI-dependent Golgi-to-ER retrograde traffic.', 'The gene KDELR3 operates within various pathways including the pathway in which XBP1(S) activates chaperone genes. This gene also acts within the pathway managing COPI-dependent Golgi-to-ER retrograde traffic.', 'The gene KDELR3 plays a role in several biological processes. It acts within the pathway where XBP1(S) activates chaperone genes. Additionally, KDELR3 acts within the process of COPI-dependent Golgi-to-ER retrograde traffic.']",[]
"[{'source_node': {'name': 'dehydroconiferyl alcohol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepg2'}}, {'source_node': {'name': 'dehydroconiferyl alcohol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hep 3b2'}}]","[{'source_node': {'name': 'dehydroconiferyl alcohol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hep 3b2'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5817', 'target': None, 'metadata': {'node_id': '5817', 'node_type': 'PROTEIN', 'display_name': 'hepg2'}}]",0.6,649696d16d6b9a451311a2330e23206d,ddad4d7e49fe344d22962ffa249c239a,"['The compound dehydroconiferyl alcohol has been found to target several cell types, including both hepG2 and hep 3B2 cells.', 'The compound known as Dehydroconiferyl Alcohol has been found to target various cells including HepG2 and Hep 3B2.', 'The compound dehydroconiferyl alcohol targets two distinct elements, HepG2 and Hep 3B2.', 'The substance dehydroconiferyl alcohol targets both the HepG2 and Hep 3B2.', 'The compound Dehydroconiferyl Alcohol targets both HepG2 and Hep 3B2 cells.']","['The compound dehydroconiferyl alcohol has hep 3b2 as its target.', 'The compound dehydroconiferyl alcohol has a target interaction with hep 3b2.']"
"[{'source_node': {'name': 'cenobamate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pentazocine'}}, {'source_node': {'name': 'cenobamate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'azatadine'}}, {'source_node': {'name': 'dibenzepin'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the vasopressor activities '}}, {'source_node': {'name': 'dibenzepin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'lofexidine'}}, {'source_node': {'name': 'dibenzepin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cenobamate'}}, {'source_node': {'name': 'lofexidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'diclofenac'}}, {'source_node': {'name': 'lofexidine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'guanfacine'}}, {'source_node': {'name': 'lofexidine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'procarbazine'}}]","[{'source_node': {'name': 'pentazocine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'guanfacine'}}, {'source_node': {'name': 'dibenzepin'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the vasopressor activities '}}, {'source_node': {'name': 'lofexidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'diclofenac'}}, {'source_node': {'name': 'lofexidine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'guanfacine'}}, {'source_node': {'name': 'lofexidine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'procarbazine'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:11083', 'target': 'COMPOUND:4653', 'metadata': None}, {'type': 'edge_deletion', 'source': 'COMPOUND:11083', 'target': 'COMPOUND:5401', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:638', 'target': 'COMPOUND:1001', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:5401', 'target': None, 'metadata': {'node_id': '5401', 'node_type': 'COMPOUND', 'display_name': 'cenobamate'}}]",0.5882352941176471,79beb3c0951db76289a2afe7c9469bb3,9c4975b69e0f2f86f9e79929441828b7,[],[]
"[{'source_node': {'name': 'transcription factor p65'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RELA'}}, {'source_node': {'name': '3-oxoguaia-4,11(13)-dien-12,8beta-olide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'transcription factor p65'}}, {'source_node': {'name': 'RELA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'FCERI mediated NF-kB activation'}}, {'source_node': {'name': 'RELA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'PKMTs methylate histone lysines'}}, {'source_node': {'name': 'RELA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'TAK1-dependent IKK and NF-kappa-B activation  '}}]","[{'source_node': {'name': 'transcription factor p65'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RELA'}}, {'source_node': {'name': '3-oxoguaia-4,11(13)-dien-12,8beta-olide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'transcription factor p65'}}, {'source_node': {'name': '3-oxoguaia-4,11(13)-dien-12,8beta-olide'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'RELA'}}, {'source_node': {'name': 'RELA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'FCERI mediated NF-kB activation'}}, {'source_node': {'name': 'RELA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'PKMTs methylate histone lysines'}}, {'source_node': {'name': 'RELA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'TAK1-dependent IKK and NF-kappa-B activation  '}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:84570', 'target': 'GENE:32288', 'metadata': {'predicate': 'is_affecting'}}]",0.9090909090909092,4ccdbe8ac143b785a8633e316cad0d32,a3dba753f9d22f86d8dd1574f7c8abd1,[],[]
"[{'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR1'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': 'oxybenzone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'progesterone receptor'}}, {'source_node': {'name': 'oxybenzone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'estrogen receptor alpha'}}, {'source_node': {'name': 'oxybenzone'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the excretion rate '}}, {'source_node': {'name': 'progesterone receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PGR'}}]","[{'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR1'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': 'oxybenzone'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the excretion rate '}}, {'source_node': {'name': 'progesterone receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PGR'}}, {'source_node': {'name': 'progesterone receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:1007', 'target': 'GENE:33509', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:1366', 'target': 'PROTEIN:943', 'metadata': None}, {'type': 'edge_deletion', 'source': 'COMPOUND:1366', 'target': 'PROTEIN:1007', 'metadata': None}]",0.7692307692307692,f95d2b7d2830465581bd093c92c0ec36,44093b55b11468ff0769606bb35e332f,[],[]
"[{'source_node': {'name': 'harpagide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a2780'}}, {'source_node': {'name': 'harpagide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sw1573'}}, {'source_node': {'name': 'harpagide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'angiotensin-converting enzyme'}}]","[{'source_node': {'name': 'harpagide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a2780'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:766', 'target': None, 'metadata': {'node_id': '766', 'node_type': 'PROTEIN', 'display_name': 'angiotensin-converting enzyme'}}, {'type': 'node_removal', 'source': 'PROTEIN:4990', 'target': None, 'metadata': {'node_id': '4990', 'node_type': 'PROTEIN', 'display_name': 'sw1573'}}]",0.4285714285714286,9f89bbc429ea33e80cdc3540ce0b8943,438bd317417778aa63ae86e0c60647aa,"['The compound Harpagide has been found to target several proteins and cell lines. Specifically, it targets A2780 and SW1573 cell lines, and exerts an effect on the angiotensin-converting enzyme.', 'The compound harpagide has been identified to target several entities including the A2780, SW1573, and the angiotensin-converting enzyme.', 'The substance harpagide is noted for having biological targets that include cellular structures such as A2780 and SW1573, as well as the prominent protein known as angiotensin-converting enzyme.', ""The compound harpagide has several targets. It targets the A2780 and SW1573 cell lines, as well as the angiotensin-converting enzyme which plays an important role in the cardiovascular system. This highlights harpagide's potential for broad therapeutic applications."", 'Harpagide, a pharmacologically active compound, has been shown to selectively target a variety of cellular targets. This includes the cancer cell lines A2780 and SW1573, in addition to the angiotensin-converting enzyme.']",[]
"[{'source_node': {'name': 'melagatran'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'p-coumaric acid'}}, {'source_node': {'name': 'melagatran'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'eftrenonacog alfa'}}, {'source_node': {'name': 'melagatran'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cefozopran'}}]","[{'source_node': {'name': 'p-coumaric acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'melagatran'}}, {'source_node': {'name': 'melagatran'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'p-coumaric acid'}}, {'source_node': {'name': 'melagatran'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'eftrenonacog alfa'}}, {'source_node': {'name': 'melagatran'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cefozopran'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:3827', 'target': 'COMPOUND:11464', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.8571428571428572,bfdc5a2564a2bb5f8db8f3b0b953ab00,991c6adfdf47209d38c20a61c3aa940f,"['The drug Melagatran is reported to decrease the efficacy of p-coumaric acid, eftrenonacog alfa, and cefozopran. This suggests that if Melagatran is administered concurrently with these substances, their medicinal impact could be significantly reduced.', 'The drug, melagatran, has been observed to decrease the efficacy of several substances including p-coumaric acid, eftrenonacog alfa, and cefozopran. Thus, caution should be exercised when co-administering these substances with melagatran to prevent potential sub-optimal therapeutic outcomes.', 'Melagatran, an anticoagulant medication, is known to reduce the efficacy of several different substances. Specifically, the effectiveness of p-coumaric acid, eftrenonacog alfa, and cefozopran is decreased when they interact with melagatran.', 'Melagatran, a drug, is known to decrease the efficacy of p-coumaric acid, eftrenonacog alfa, and cefozopran. Therefore, it should be noted that potential therapeutic effects of these three substances may be reduced when used in combination with melagatran.', 'Melagatran, a drug used to prevent blood clots, has been shown to decrease the efficacy of multiple substances. These include p-coumaric acid, a phenolic acid known for its antioxidant properties, eftrenonacog alfa, a recombinant factor IX Fc fusion protein used to control and prevent bleeding in individuals with hemophilia B, and cefozopran, a fourth-generation cephalosporin. Therefore, co-administration of Melagatran with these substances should be done with caution.']","['P-coumaric acid is known to decrease the efficacy of melagatran, a relationship that is reciprocal as melagatran also decreases the efficacy of p-coumaric acid. Furthermore, melagatran can potentially reduce the efficacy of two other substances, namely eftrenonacog alfa and cefozopran. It is therefore crucial to note these interactions to avoid diminished therapeutic effects.', 'The compound p-coumaric acid is known to decrease the efficacy of the drug melagatran. Interestingly, melagatran also lessens the efficacy of p-coumaric acid, creating a bi-directional interaction between the two substances. Additionally, melagatran is seen to decrease the efficacy of other medicines such as eftrenonacog alfa and cefozopran.', 'P-coumaric acid and melagatran have a reciprocal effect in which they both decrease the efficacy of each other. Moreover, the drug melagatran also lessens the effectiveness of eftrenonacog alfa and cefozopran. This might suggest potential implications in drug interactions and effectiveness.', ""The compound p-coumaric acid decreases the efficacy of the drug melagatran. Conversely, melagatran also reduces the effectiveness of p-coumaric acid. This interaction is similar to melagatran's effect on other substances like eftrenonacog alfa and cefozopran, where it also diminishes their efficacy."", 'The substance called p-coumaric acid appears to decrease the efficacy of the drug melagatran. Conversely, melagatran also reduces the efficacy of p-coumaric acid. Besides, this particular drug, melagatran, seems to impede the effectualness of other substances such as eftrenonacog alfa and cefozopran as well. It suggests that the interplay between these compounds could affect the pharmacological outcomes leading to variations in the treatment responses.']"
"[{'source_node': {'name': 'probable global transcription activator snf2l2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SMARCA2'}}, {'source_node': {'name': 'SMARCA2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'nicolaides-baraitser syndrome'}}, {'source_node': {'name': 'SMARCA2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RMTs methylate histone arginines'}}, {'source_node': {'name': 'nicolaides-baraitser syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'accelerated skeletal maturation'}}, {'source_node': {'name': 'nicolaides-baraitser syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hernia'}}]","[{'source_node': {'name': 'probable global transcription activator snf2l2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SMARCA2'}}, {'source_node': {'name': 'SMARCA2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RMTs methylate histone arginines'}}, {'source_node': {'name': 'nicolaides-baraitser syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'accelerated skeletal maturation'}}, {'source_node': {'name': 'nicolaides-baraitser syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hernia'}}]","[{'type': 'edge_deletion', 'source': 'GENE:32925', 'target': 'DISEASE:6984', 'metadata': None}]",0.9090909090909092,de9bebd32902c3ad09916d1ad3bc0ca0,aacaa12a404a7dbaf2dc05fd7beae30d,"['The gene SMARCA2, which acts within the pathway where RMTs methylate histone arginines, is responsible for producing the probable global transcription activator SNF2L2. A mutation in this gene can cause Nicolaides-Baraitser syndrome. This syndrome is characterized by an array of symptoms including accelerated skeletal maturation and hernia.', 'The probable global transcription activator snf2l2 is a gene product of SMARCA2, a gene that acts within the pathway where RMTs methylate histone arginines. Furthermore, mutations in SMARCA2 are responsible for causing Nicolaides-Baraitser syndrome. This syndrome is characterized by an accelerated skeletal maturation and also has the phenotype of hernia.']","['The protein known as probable global transcription activator snf2l2 is a gene product of SMARCA2, with SMARCA2 acting within a pathway that focuses on how RMTs methylate histone arginines. On another note, an unusual genetic disorder called Nicolaides-Baraitser syndrome exhibits phenotypes such as accelerated skeletal maturation and hernia.', 'The global transcription activator known as probable global transcription activator snf2l2 is a gene product of SMARCA2. SMARCA2 acts within the pathway wherein RMTs methylate histone arginines. Inclusive in the different manifestations of Nicolaides-Baraitser syndrome, a disease with phenotypes like accelerated skeletal maturation and hernia, are these gene and pathway interactions.']"
"[{'source_node': {'name': 'FBP1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'fructose-1,6-bisphosphatase deficiency'}}, {'source_node': {'name': 'FBP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Gluconeogenesis'}}, {'source_node': {'name': 'fructose-1,6-bisphosphatase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FBP1'}}]","[{'source_node': {'name': 'fructose-1,6-bisphosphatase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FBP1'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:325', 'target': None, 'metadata': {'node_id': '325', 'node_type': 'PATHWAY', 'display_name': 'Gluconeogenesis'}}, {'type': 'node_removal', 'source': 'DISEASE:4017', 'target': None, 'metadata': {'node_id': '4017', 'node_type': 'DISEASE', 'display_name': 'fructose-1,6-bisphosphatase deficiency'}}]",0.4285714285714286,166777ab7423e36c42b521b6bc05ea3e,4b8129552d211e33559d4a5373d76d69,"['The gene known as FBP1, which functions within the gluconeogenesis pathway, can cause a condition known as fructose-1,6-bisphosphatase deficiency. Furthermore, FBP1 is the gene product of fructose-1,6-bisphosphatase 1.', 'The gene FBP1, acting within the gluconeogenesis pathway, causes a condition known as fructose-1,6-bisphosphatase deficiency. This protein, fructose-1,6-bisphosphatase 1, is also a gene product of FBP1.', 'The gene FBP1, which acts within the gluconeogenesis pathway and is responsible for producing the protein fructose-1,6-bisphosphatase 1, can cause a condition known as fructose-1,6-bisphosphatase deficiency.', 'The gene FBP1, which functions within the Gluconeogenesis pathway, has been linked to causing the medical condition known as fructose-1,6-bisphosphatase deficiency. Additionally, fructose-1,6-bisphosphatase 1 is a gene product of FBP1.', 'The gene FBP1, which acts within the pathway of gluconeogenesis, can cause a condition known as fructose-1,6-bisphosphatase deficiency. Additionally, fructose-1,6-bisphosphatase 1 is a gene product of FBP1.']","['Fructose-1,6-bisphosphatase 1 is a gene product of FBP1.']"
"[{'source_node': {'name': 'bonannione a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a2780'}}, {'source_node': {'name': 'bonannione a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'u-266'}}, {'source_node': {'name': 'bonannione a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'thp-1'}}]","[{'source_node': {'name': 'bonannione a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a2780'}}, {'source_node': {'name': 'bonannione a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'u-266'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5083', 'target': None, 'metadata': {'node_id': '5083', 'node_type': 'PROTEIN', 'display_name': 'thp-1'}}]",0.7142857142857143,7f5bd6d85ef0c562dafa81eda2f04fbe,391fbed97511d7342b72ac8527cbf2fc,"['The drug Bonannione A is known to target several entities. These include A2780, U-266, and THP-1.', 'The drug Bonannione A has shown promise in targeting multiple cell lines such as A2780, U-266, and THP-1.', 'The drug Bonannione A has multiple targets including A2780, U-266, and THP-1.', 'The compound Bonannione A has been found to target multiple entities, including A2780, U-266, and THP-1.', 'Bonannione A, a bioactive compound, has multiple targets including A2780, U-266, and THP-1. These targets may represent varying cell lines that the compound has an effect on, offering potential therapeutic relevance and opportunities for further research.']","['The compound Bonannione A has been identified to target multiple cells, specifically A2780 and U-266.', 'The drug Bonannione A has been shown to target two different entities: A2780 and U-266.', 'The compound Bonannione A has targets that include both A2780 and U-266 cells.', 'The drug Bonannione A is known to target both A2780 and U-266.', 'Bonannione A is a compound that targets both A2780 and U-266.']"
"[{'source_node': {'name': 'sibiriquinone a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ags'}}, {'source_node': {'name': 'sibiriquinone a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hep 3b2'}}]","[{'source_node': {'name': 'sibiriquinone a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hep 3b2'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5072', 'target': None, 'metadata': {'node_id': '5072', 'node_type': 'PROTEIN', 'display_name': 'ags'}}]",0.6,1c3617cdafc5f2adfce5d6f5e1284b06,446096822c42b0c1262f86891b9cafbd,"['The compound Sibiriquinone A is known to target AGS and HEP 3B2.', 'The compound Sibiriquinone A targets two different entities, specifically AGS and HEP 3B2.', 'The molecule Sibiriquinone A targets both AGS and Hep 3B2.', '""Sibiriquinone A has two notable targets: AGS and HEP 3B2. This indicates that Sibiriquinone A interacts with both those components in its functional activity.', 'The compound Sibiriquinone A is known to target both AGS and HEP 3B2.']","['The compound Sibiriquinone A has a targeted interaction with Hep 3B2.', 'The compound Sibiriquinone A has been identified to target Hep 3B2.', 'The drug Sibiriquinone A has been found to target the Hep 3B2.']"
"[{'source_node': {'name': 'visceral myopathy 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'vesicoureteral reflux'}}, {'source_node': {'name': 'visceral myopathy 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abdominal distention'}}, {'source_node': {'name': 'visceral myopathy 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'urinary retention'}}]","[{'source_node': {'name': 'visceral myopathy 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'vesicoureteral reflux'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:2363', 'target': None, 'metadata': {'node_id': '2363', 'node_type': 'PHENOTYPE', 'display_name': 'abdominal distention'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:15', 'target': None, 'metadata': {'node_id': '15', 'node_type': 'PHENOTYPE', 'display_name': 'urinary retention'}}]",0.4285714285714286,7bbc4608ea1414128dc256e3ee8288fb,0d01a6cc86d0e6ce841eb88dd6351023,"['Visceral Myopathy 1, a gastrointestinal disorder, manifests various symptoms or phenotypes such as vesicoureteral reflux, a condition where urine flows backwards from the bladder into the kidneys; abdominal distention, characterized by swelling or enlargement of the abdomen; and urinary retention, a condition where the patient is unable to completely empty the bladder.', 'The disease visceral myopathy 1 presents several clinical manifestations such as vesicoureteral reflux, abdominal distention and urinary retention.']",[]
"[{'source_node': {'name': '7,9-dimethylguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cinolazepam'}}, {'source_node': {'name': '7,9-dimethylguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cinazepam'}}, {'source_node': {'name': '7,9-dimethylguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bentazepam'}}, {'source_node': {'name': 'cinazepam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '7-deazaguanine'}}, {'source_node': {'name': 'cinazepam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'theodrenaline'}}, {'source_node': {'name': 'cinazepam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'etamiphylline'}}]","[{'source_node': {'name': 'theodrenaline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'etamiphylline'}}, {'source_node': {'name': 'theodrenaline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': '7,9-dimethylguanine'}}, {'source_node': {'name': '7,9-dimethylguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cinolazepam'}}, {'source_node': {'name': '7,9-dimethylguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cinazepam'}}, {'source_node': {'name': '7,9-dimethylguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bentazepam'}}, {'source_node': {'name': 'cinazepam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '7-deazaguanine'}}, {'source_node': {'name': 'cinazepam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'theodrenaline'}}, {'source_node': {'name': 'cinazepam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'etamiphylline'}}, {'source_node': {'name': 'cinazepam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '7,9-dimethylguanine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:12417', 'target': 'COMPOUND:1876', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:10801', 'target': 'COMPOUND:11441', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:10801', 'target': 'COMPOUND:1876', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7692307692307692,d8430bd0b43237dabe0c3c1f712c557a,8ce7d07b24ec574004300cbf85887ace,"['7,9-dimethylguanine, a chemical compound, has a role in the decreasing efficacy of several drugs, including cinolazepam, cinazepam, and bentazepam, meaning it minimizes their intended effects. Interestingly, cinazepam itself can also reduce the efficacy of other substances. It lowers the activity of 7-deazaguanine and two drugs, theodrenaline and etamiphylline. Therefore, the interplay between these entities and the influence of 7,9-dimethylguanine and cinazepam should be taken into account when considering the pharmacological implications and treatment outcomes.']","['Theodrenaline is a drug that has been found to increase the efficacy of both etamiphylline and 7,9-dimethylguanine. However, the compound 7,9-dimethylguanine, while its efficacy is increased by theodrenaline, interestingly decreases the efficacy of several benzodiazepine class drugs: cinolazepam, cinazepam and bentazepam. Further, cinazepam not only has its efficacy decreased by 7,9-dimethylguanine but also decreases the efficacy of several other compounds including 7-deazaguanine, theodrenaline, etamiphylline and even 7,9-dimethylguanine itself. This forms a complexity of interactions that has implications for therapeutic applications and warrants cautious consideration when these drugs are prescribed together.', ""The drug Theodrenaline is known to increase the efficacy of both Etamiphylline and 7,9-Dimethylguanine. It's interesting to note that 7,9-Dimethylguanine not only has its effectiveness boosted by Theodrenaline, but it also decreases the efficacy of several other drugs. These include Cinolazepam, Cinazepam, and Bentazepam. Cinazepam, in particular, has a complex interaction graph. Its efficiency is reduced by 7,9-Dimethylguanine but at the same time, it decreases the efficiency of 7-Deazaguanine, Theodrenaline, Etamiphylline and reverts back to reduce the efficacy of 7,9-Dimethylguanine. This intricate web of relationships illustrates how drug interactions can be complex and multi-directional, involving the increase and decrease of efficacy between different compounds."", 'The drug theodrenaline has been found to increase the efficacy of other drugs such as etamiphylline and 7,9-dimethylguanine. However, while theodrenaline enhances the effectiveness of 7,9-dimethylguanine, the latter has been shown to decrease the efficacy of a range of substances including cinolazepam, cinazepam, and bentazepam. Moreover, the drug cinazepam also reduces the efficacy of several other substances, including 7-deazaguanine, theodrenaline, etamiphylline, and 7,9-dimethylguanine. Overall, this interplay between different substances suggests a complex network of interactions that can influence the effectiveness of various treatment regimens.', 'Theodrenaline is known to increase the efficacy of both etamiphylline and 7,9-dimethylguanine. However, 7,9-dimethylguanine has been observed to decrease the efficacy of multiple compounds including cinolazepam, cinazepam, and bentazepam. Similarly, cinazepam also reduces the effectiveness of several components like 7-deazaguanine, theodrenaline, etamiphylline, and 7,9-dimethylguanine. This intricate web of interaction highlights the complexity of dynamics between these compounds.', ""The drug Theodrenaline has been shown to increase the efficacy of both Etamiphylline and 7,9-Dimethylguanine. However, it's interesting to note that 7,9-Dimethylguanine, while enhanced by Theodrenaline, decreases the efficacy of several drugs including Cinolazepam, Cinazepam, and Bentazepam. Furthermore, the decrease in efficacy is mutual. Cinazepam not only is less effective due to 7,9-Dimethylguanine but also lessens the effect of 7-Deazaguanine, the initial enhancer, Theodrenaline, Etamiphylline, and retracts back to decrease the efficacy of 7,9-Dimethylguanine itself. This intricate web of interactions highlights the complexity of drug interactions and the importance of considering all drug compounds and their potential interactions.""]"
"[{'source_node': {'name': 'sarecycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mezlocillin'}}, {'source_node': {'name': 'sarecycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ticarcillin'}}]","[{'source_node': {'name': 'ticarcillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sarecycline'}}, {'source_node': {'name': 'sarecycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ticarcillin'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:931', 'target': None, 'metadata': {'node_id': '931', 'node_type': 'COMPOUND', 'display_name': 'mezlocillin'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1535', 'target': 'COMPOUND:9945', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.4,374942464b3dec8b2c071141832b65d0,f8e6b0981747942c986238007eacb9e1,"['Sarecycline, a commonly used antibiotic, has been found to decrease the efficacy of other antibiotics such as mezlocillin and ticarcillin. This implies that when sarecycline is administered concurrently with these drugs, it may reduce their effectiveness to treat infections. Therefore, caution should be exercised while prescribing these combinations.', 'The drug sarecycline has been known to decrease the efficacy of certain antibiotics including mezlocillin and ticarcillin. This interaction might impact the effectiveness of these drugs when used in combination with sarecycline.', 'The drug sarecycline has been found to decrease the efficacy of both mezlocillin and ticarcillin. This indicates a potential interaction that could impede desired treatment outcomes when these medications are used together.', 'The drug sarecycline is known to decrease the efficacy of both mezlocillin and ticarcillin. Therefore, caution should be exercised when co-administering these drugs.', 'The drug sarecycline is known to decrease the efficacy of both mezlocillin and ticarcillin.']","[""The efficacy of the antibiotic Ticarcillin decreases when used in conjunction with another antibiotic, Sarecycline. Interestingly, the relationship is reciprocal, as Sarecycline's efficacy also decreases when administered alongside Ticarcillin."", 'The drug ticarcillin is known to decrease the efficacy of sarecycline. However, it is also important to note that sarecycline, in turn, reciprocates this effect by diminishing the potency of ticarcillin.', ""The drug Ticarcillin has been known to decrease the efficacy of Sarecycline treatment. However, it's also notable to understand that Sarecycline reciprocally reduces the effectiveness of the Ticarcillin drug."", 'Ticarcillin and Sarecycline, two medicinal drugs, have a unique interplay. Ticarcillin decreases the efficacy of Sarecycline, while conversely, Sarecycline also decreases the efficiency of Ticarcillin. Thus, their co-administration could lead to a reduction in their individual effectiveness.', 'The drug Ticarcillin can decrease the effectiveness of Sarecycline, and likewise, Sarecycline can reduce the efficacy of Ticarcillin. This reciprocal relationship might influence the therapeutic outcomes when these drugs are administered concurrently.']"
"[{'source_node': {'name': 'emylcamate'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'emylcamate'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' CNS depression '}}, {'source_node': {'name': 'emylcamate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pregabalin'}}, {'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'nabilone'}}, {'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Decreased appetite'}}, {'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Panic attack'}}]","[{'source_node': {'name': 'emylcamate'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'emylcamate'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' CNS depression '}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:11422', 'target': 'SIDE_EFFECT:7', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'node_removal', 'source': 'COMPOUND:220', 'target': None, 'metadata': {'node_id': '220', 'node_type': 'COMPOUND', 'display_name': 'pregabalin'}}, {'type': 'node_removal', 'source': 'SIDE_EFFECT:7', 'target': None, 'metadata': {'node_id': '7', 'node_type': 'SIDE_EFFECT', 'display_name': 'Decreased appetite'}}]",0.3846153846153846,794fcab4be7d693af97ed90e426734d4,6854e8e99f134eff6b7481bedc8fe32d,[],[]
"[{'source_node': {'name': 'hydromorphone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nalbuphine'}}, {'source_node': {'name': 'hydromorphone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Alcohol abuse'}}, {'source_node': {'name': 'hydromorphone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Asthenia'}}, {'source_node': {'name': 'nalbuphine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methadyl acetate'}}, {'source_node': {'name': 'nalbuphine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sodium phosphate'}}, {'source_node': {'name': 'nalbuphine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oxyphenisatin acetate'}}]","[{'source_node': {'name': 'nalbuphine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methadyl acetate'}}, {'source_node': {'name': 'nalbuphine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sodium phosphate'}}, {'source_node': {'name': 'nalbuphine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oxyphenisatin acetate'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:317', 'target': 'COMPOUND:827', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:1371', 'target': 'SIDE_EFFECT:1495', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'node_removal', 'source': 'COMPOUND:317', 'target': None, 'metadata': {'node_id': '317', 'node_type': 'COMPOUND', 'display_name': 'hydromorphone'}}, {'type': 'edge_addition', 'source': 'COMPOUND:12333', 'target': 'SIDE_EFFECT:1495', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'node_removal', 'source': 'SIDE_EFFECT:1495', 'target': None, 'metadata': {'node_id': '1495', 'node_type': 'SIDE_EFFECT', 'display_name': 'Alcohol abuse'}}]",0.5384615384615384,222c27cb42473fcb6874cf85709914d3,dd95d2e33201c1955dff6ef775a0ff4a,"['The opioid medication Hydromorphone has been found to decrease the efficacy of another pain medication, Nalbuphine. In addition, Hydromorphone can have side effects like alcohol abuse and asthenia, which is a condition characterized by abnormal physical weakness or lack of energy. On the other hand, Nalbuphine can reduce the efficacy of Methadyl Acetate, a synthetic opioid used to treat opioid dependence. It also decreases the effectiveness of Sodium Phosphate, a medication used for bowel preparation before colonoscopy, and Oxyphenisatin Acetate, a type of laxative.', 'The drug hydromorphone has been noted to decrease the efficacy of nalbuphine. Furthermore, hydromorphone can also lead to side effects such as alcohol abuse and asthenia. On the other side, nalbuphine can decrease the efficacy of several other drugs including methadyl acetate, sodium phosphate, and oxyphenisatin acetate.', 'The opioid drug hydromorphone can decrease the efficacy of nalbuphine. At the same time, the use of hydromorphone may lead to certain side effects, such as alcohol abuse and asthenia. Furthermore, nalbuphine, which could have its effectiveness reduced by hydromorphone, can similarly decrease the efficacy of several other substances, like methadyl acetate, sodium phosphate, and oxyphenisatin acetate. Thus, caution must be observed when combining these substances in the course of treatments or therapies.', 'The drug hydromorphone has been shown to decrease the efficacy of another drug, nalbuphine. Furthermore, use of hydromorphone has also been linked to side effects such as alcohol abuse and asthenia. Meanwhile, nalbuphine, on the other hand, has been found to reduce the effectiveness of several other drugs including methadyl acetate, sodium phosphate, and oxyphenisatin acetate.']","['Nalbuphine is a drug that has been observed to decrease the efficacy of several other substances. These include methadyl acetate, sodium phosphate, and oxyphenisatin acetate. Therefore, it is important to consider potential interactions when nalbuphine is administered alongside these substances.', ""Nalbuphine is a pharmaceutical drug that has been observed to decrease the efficacy of several other compounds, namely methadyl acetate, sodium phosphate, and oxyphenisatin acetate. Therefore, when using nalbuphine, it is crucial to take this into consideration, especially if these compounds are included in an individual's therapy regimen."", 'The drug nalbuphine is found to decrease the efficacy of multiple substances including methadyl acetate, sodium phosphate, and oxyphenisatin acetate. Therefore, caution is suggested when these substances are used in combination with nalbuphine.', 'Nalbuphine, a commonly used drug, is known to decrease the efficacy of several other substances. These include methadyl acetate, sodium phosphate, and oxyphenisatin acetate. Consequently, co-administration of nalbuphine with these substances might potentially lead to reduced therapeutic effects.', 'The drug nalbuphine has been shown to decrease the efficacy of several other compounds. These include methadyl acetate, sodium phosphate, and oxyphenisatin acetate. Therefore, care should be taken when administering nalbuphine alongside these substances due to potential interaction effects.']"
"[{'source_node': {'name': 'major histocompatibility complex'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'lung neoplasms'}}, {'source_node': {'name': 'major histocompatibility complex'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neoplasms'}}, {'source_node': {'name': 'major histocompatibility complex'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'erythema multiforme nos'}}, {'source_node': {'name': 'flupirtine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the excretion rate '}}, {'source_node': {'name': 'flupirtine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'major histocompatibility complex'}}, {'source_node': {'name': 'flupirtine'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'drug-induced liver injury'}}]","[{'source_node': {'name': 'major histocompatibility complex'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'lung neoplasms'}}, {'source_node': {'name': 'major histocompatibility complex'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neoplasms'}}, {'source_node': {'name': 'major histocompatibility complex'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'erythema multiforme nos'}}, {'source_node': {'name': 'major histocompatibility complex'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'drug-induced liver injury'}}, {'source_node': {'name': 'flupirtine'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'drug-induced liver injury'}}, {'source_node': {'name': 'flupirtine'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'neoplasms'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:5697', 'target': 'GENE:8028', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:5697', 'target': 'DISEASE:2199', 'metadata': {'predicate': 'is_substance_that_treats'}}, {'type': 'node_removal', 'source': 'ACTIVITY:7', 'target': None, 'metadata': {'node_id': '7', 'node_type': 'ACTIVITY', 'display_name': ' the excretion rate '}}, {'type': 'edge_addition', 'source': 'GENE:8028', 'target': 'DISEASE:898', 'metadata': {'predicate': 'causes_condition'}}]",0.6153846153846154,0bf6887f52e687f7508ab3a0563fa2c3,6926e8672572d1dcfe79c98ab8e0841a,[],"['The major histocompatibility complex is known to cause various conditions such as lung neoplasms, neoplasms in general, erythema multiforme nos, and drug-induced liver injury. Furthermore, flupirtine is a substance that treats conditions triggered by the major histocompatibility complex, specifically drug-induced liver injury and neoplasms.', 'The major histocompatibility complex is known to cause several conditions including lung neoplasms, neoplasms in general, erythema multiforme nos, and drug-induced liver injury. Interestingly, flupirtine, a substance known for its therapeutic properties, is used to treat certain conditions caused by the major histocompatibility complex such as drug-induced liver injury and neoplasms.', ""The major histocompatibility complex, a key part of the immune system, is known to cause various conditions such as lung neoplasms, neoplasms, erythema multiforme nos, and drug-induced liver injury. Interestingly, flupirtine is a substance used to treat some of these conditions, including drug-induced liver injury and neoplasms. This knowledge could be important for understanding the complex paths of disease treatment and the immune system's role in certain conditions.\n"", 'The Major Histocompatibility Complex, a key component in our immune system, is known to cause several conditions, including lung neoplasms, other types of neoplasms, erythema multiforme nos, and drug-induced liver injury. Interestingly, the drug Flupirtine can be used to treat drug-induced liver injury and neoplasms, suggesting a potential method of counteracting some of the negative effects caused by the Major Histocompatibility Complex.', 'The major histocompatibility complex, a critical component in the immune system, is known to cause various conditions including lung neoplasms, neoplasms in general, erythema multiforme NOS and drug-induced liver injury. Interestingly, the drug flupirtine can treat drug-induced liver injury, a condition that the major histocompatibility complex can cause. Additionally, flupirtine can be used to treat neoplasms, which is another condition associated with the major histocompatibility complex.']"
"[{'source_node': {'name': 'taiwanin e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hek293'}}, {'source_node': {'name': 'taiwanin e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}]","[{'source_node': {'name': 'taiwanin e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5833', 'target': None, 'metadata': {'node_id': '5833', 'node_type': 'PROTEIN', 'display_name': 'hek293'}}]",0.6,eeb641875cab9a3a51ecf7907372a124,bcfc421dca70cd8bc8baf52d579d0893,"['Taiwanin E targets two cell lines, namely HEK293 and KB.']",[]
"[{'source_node': {'name': 'CXCR4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Binding and entry of HIV virion'}}, {'source_node': {'name': 'CXCR4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (i) signalling events'}}, {'source_node': {'name': 'CXCR4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Formation of definitive endoderm'}}, {'source_node': {'name': 'c-x-c chemokine receptor type 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CXCR4'}}]","[{'source_node': {'name': 'CXCR4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Binding and entry of HIV virion'}}, {'source_node': {'name': 'CXCR4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Formation of definitive endoderm'}}, {'source_node': {'name': 'c-x-c chemokine receptor type 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CXCR4'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:109', 'target': None, 'metadata': {'node_id': '109', 'node_type': 'PATHWAY', 'display_name': 'G alpha (i) signalling events'}}]",0.7777777777777778,207ccc1383d513276b2ae416424b1fec,dcaa3f189297fb51b0f4cd4ce8622125,"['The gene CXCR4 functions within several biological processes, namely the binding and entry of the HIV virion, G alpha (i) signalling events, as well as the formation of definitive endoderm. Importantly, it is worth noting that c-x-c chemokine receptor type 4 is a gene product of CXCR4.', 'The gene product of c-x-c chemokine receptor type 4, known as CXCR4, acts within various biological pathways. These include the binding and entry of the HIV virion, processes involving G alpha (i) signalling events, and the formation of definitive endoderm.']","['The gene c-x-c chemokine receptor type 4 is a product of the gene CXCR4. This gene actively operates within various biological processes including the binding and entry of the HIV virion and the formation of definitive endoderm.', 'The gene known as c-x-c chemokine receptor type 4 is a product of the gene CXCR4. CXCR4 is involved in several biological pathways. It acts within the process of definitive endoderm formation, and plays a crucial role in the binding and entry of HIV virions.']"
"[{'source_node': {'name': 'vedolizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vi polysaccharide vaccine'}}, {'source_node': {'name': 'landogrozumab'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the thrombogenic activities '}}, {'source_node': {'name': 'landogrozumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'landogrozumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imlifidase'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'matuzumab'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'vedolizumab'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'gantenerumab'}}]","[{'source_node': {'name': 'landogrozumab'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the thrombogenic activities '}}, {'source_node': {'name': 'landogrozumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'matuzumab'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'gantenerumab'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'matuzumab'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'gantenerumab'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:8860', 'target': None, 'metadata': {'node_id': '8860', 'node_type': 'COMPOUND', 'display_name': 'typhoid vi polysaccharide vaccine'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:9777', 'target': 'COMPOUND:12843', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:4779', 'target': 'COMPOUND:9944', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:7975', 'target': None, 'metadata': {'node_id': '7975', 'node_type': 'COMPOUND', 'display_name': 'vedolizumab'}}]",0.6,ebb21f587226702ec5800025e6f23bbb,871ee5fe9ee0bcfa24c35d70eb2c50b5,[],[]
"[{'source_node': {'name': 'pachydermoperiostosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hepatomegaly'}}, {'source_node': {'name': 'pachydermoperiostosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'avascular necrosis'}}]","[{'source_node': {'name': 'pachydermoperiostosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hepatomegaly'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:7310', 'target': None, 'metadata': {'node_id': '7310', 'node_type': 'PHENOTYPE', 'display_name': 'avascular necrosis'}}]",0.6,7c50ef2fe179ca3d21ae0fbf94cb1c1a,e5e95244ca3199827b6c40eb4d6335e9,[],[]
"[{'source_node': {'name': '4-(5-bromo-1h-indol-2-yl)pyrimidin-2-amine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cyclin-dependent kinase 1/cyclin b'}}, {'source_node': {'name': '4-(5-bromo-1h-indol-2-yl)pyrimidin-2-amine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'camp-dependent protein kinase (pka)'}}, {'source_node': {'name': '4-(5-bromo-1h-indol-2-yl)pyrimidin-2-amine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glycogen synthase kinase-3 beta'}}, {'source_node': {'name': 'glycogen synthase kinase-3 beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GSK3B'}}, {'source_node': {'name': 'cyclin-dependent kinase 1/cyclin b'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CCNB2'}}, {'source_node': {'name': 'GSK3B'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of RUNX2 expression and activity'}}]","[{'source_node': {'name': '4-(5-bromo-1h-indol-2-yl)pyrimidin-2-amine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cyclin-dependent kinase 1/cyclin b'}}, {'source_node': {'name': '4-(5-bromo-1h-indol-2-yl)pyrimidin-2-amine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'camp-dependent protein kinase (pka)'}}, {'source_node': {'name': '4-(5-bromo-1h-indol-2-yl)pyrimidin-2-amine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glycogen synthase kinase-3 beta'}}, {'source_node': {'name': 'glycogen synthase kinase-3 beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GSK3B'}}, {'source_node': {'name': 'CCNB2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of RUNX2 expression and activity'}}, {'source_node': {'name': 'cyclin-dependent kinase 1/cyclin b'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CCNB2'}}, {'source_node': {'name': 'GSK3B'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of RUNX2 expression and activity'}}]","[{'type': 'edge_addition', 'source': 'GENE:35171', 'target': 'PATHWAY:404', 'metadata': {'predicate': 'acts_within'}}]",0.9230769230769232,947997be45bc975771550794590fdaa0,6ea44cd2858b45ac0ddba9a98435128a,"['The compound 4-(5-bromo-1h-indol-2-yl)pyrimidin-2-amine has multiple targets including the cyclin-dependent kinase 1/cyclin B, camp-dependent protein kinase (PKA), and glycogen synthase kinase-3 beta. Interestingly, glycogen synthase kinase-3 beta is a gene product of GSK3B, which acts within the regulation of RUNX2 expression and activity. Meanwhile, the cyclin-dependent kinase 1/cyclin B, another target of the compound, is the gene product of CCNB2.', ""The drug named 4-(5-bromo-1h-indol-2-yl)pyrimidin-2-amine targets several enzymes, including cyclin-dependent kinase 1/cyclin B, camp-dependent protein kinase (PKA), and glycogen synthase kinase-3 beta. The cyclin-dependent kinase 1/cyclin B is a gene product of CCNB2. The glycogen synthase kinase-3 beta is associated with the GSK3B gene. Also, it's worthy to mention that GSK3B is known to act within the regulation of RUNX2 expression and activity pathway."", 'The molecule 4-(5-bromo-1h-indol-2-yl)pyrimidin-2-amine is known to target several key proteins including cyclin-dependent kinase 1/cyclin b, camp-dependent protein kinase (PKA), and glycogen synthase kinase-3 beta. These proteins are products of specific genes. For instance, cyclin-dependent kinase 1/cyclin b is a gene product of CCNB2, while glycogen synthase kinase-3 beta is produced by the GSK3B gene. It is notable that GSK3B also plays a role within a specific cellular process, known as the regulation of RUNX2 expression and activity.']","['The drug 4-(5-bromo-1h-indol-2-yl)pyrimidin-2-amine focuses its actions on particular targets such as the cyclin-dependent kinase 1/cyclin b, the camp-dependent protein kinase (pka), and the glycogen synthase kinase-3 beta. These targets have significant roles, where glycogen synthase kinase-3 beta is a gene product of GSK3B and symbolically, cyclin-dependent kinase 1/cyclin b, which is produced by the gene known as CCNB2. Both GSK3B and CCNB2 take part within the regulation of RUNX2 expression and activity.', 'The compound 4-(5-bromo-1h-indol-2-yl)pyrimidin-2-amine is highly interactive as it targets multiple entities such as the cyclin-dependent kinase 1/cyclin b and the glycogen synthase kinase-3 beta. Interestingly, these targeted entities are gene products of various genes. For instance, glycogen synthase kinase-3 beta is a gene product of GSK3B. Strikingly, cyclin-dependent kinase 1/cyclin b is a gene product of CCNB2, which also acts within the regulation of RUNX2 expression and activity. Along the same line, GSK3B also actively participates within the regulation of RUNX2 expression and activity, bringing about a complex interplay of actions and interactions. Additionally, 4-(5-bromo-1h-indol-2-yl)pyrimidin-2-amine also targets the camp-dependent protein kinase (pka), further increasing its complexity of interactions.', 'The compound 4-(5-bromo-1h-indol-2-yl)pyrimidin-2-amine targets several enzymes including the cyclin-dependent kinase 1/cyclin b, the glycogen synthase kinase-3 beta, and the cAMP-dependent protein kinase (PKA). Interestingly, cyclin-dependent kinase 1/cyclin b is a gene product of CCNB2, which actively functions within the regulation of RUNX2 expression and activity. Similarly, glycogen synthase kinase-3 beta is generated by the gene GSK3B, which also contributes to the same regulatory process as CCNB2. Through these connections, we can discern the intricate network dynamics governed by these biological elements.', ""The drug 4-(5-bromo-1h-indol-2-yl)pyrimidin-2-amine targets three major proteins: the cyclin-dependent kinase 1/cyclin B, cAMP-dependent protein kinase (PKA), and the glycogen synthase kinase-3 beta. The latter is actually a gene product of the GSK3B gene. Interestingly, GSK3B also operates within the regulation of RUNX2 expression and activity, indicating a complex interaction network within the cell. On the other hand, the cyclin-dependent kinase 1/cyclin B, also a target of 4-(5-bromo-1h-indol-2-yl)pyrimidin-2-amine, is a gene product of CCNB2. This gene also works within the regulation of RUNX2 expression and activity. This reveals a potential for studying the combined influence of GSK3B and CCNB2 on RUNX2 expression and activity along with the drug's effects on these relations."", 'The compound 4-(5-bromo-1h-indol-2-yl)pyrimidin-2-amine is known to target several proteins. These include cyclin-dependent kinase 1/cyclin b, cAMP-dependent protein kinase (PKA), and glycogen synthase kinase-3 beta. Interestingly, glycogen synthase kinase-3 beta is the gene product of GSK3B, and cyclin-dependent kinase 1/cyclin b is the gene product of CCNB2. Both GSK3B and CCNB2 act within the regulation of RUNX2 expression and activity pathway, suggesting a potential regulatory mechanism involving these two proteins in this pathway.']"
"[{'source_node': {'name': 'TBXAS1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'ghosal hematodiaphyseal dysplasia'}}, {'source_node': {'name': 'TBXAS1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Eicosanoids'}}, {'source_node': {'name': 'TBXAS1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Defective TBXAS1 causes GHDD'}}, {'source_node': {'name': 'ghosal hematodiaphyseal dysplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'leukopenia'}}, {'source_node': {'name': 'ghosal hematodiaphyseal dysplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of speech or vocalization'}}]","[{'source_node': {'name': 'TBXAS1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Defective TBXAS1 causes GHDD'}}]","[{'type': 'edge_deletion', 'source': 'GENE:33169', 'target': 'DISEASE:5197', 'metadata': None}, {'type': 'node_removal', 'source': 'PHENOTYPE:1364', 'target': None, 'metadata': {'node_id': '1364', 'node_type': 'PHENOTYPE', 'display_name': 'leukopenia'}}, {'type': 'node_removal', 'source': 'PATHWAY:1015', 'target': None, 'metadata': {'node_id': '1015', 'node_type': 'PATHWAY', 'display_name': 'Eicosanoids'}}, {'type': 'node_removal', 'source': 'DISEASE:5197', 'target': None, 'metadata': {'node_id': '5197', 'node_type': 'DISEASE', 'display_name': 'ghosal hematodiaphyseal dysplasia'}}]",0.2727272727272727,b47d4b3e5279d5ce5dac72b939ef3f75,e16aa82a6a7131aef0ffe82f08429d18,"['The gene TBXAS1 is instrumental in various pathways including Defective TBXAS1 causes GHDD and Eicosanoids. However, it is noted that this gene also causes Ghosal hematodiaphyseal dysplasia, a condition characterized by symptoms such as leukopenia and abnormalities in speech or vocalization.', 'The gene TBXAS1 plays a crucial role in both the Eicosanoids and Defective TBXAS1 causes GHDD pathways. Interestingly, TBXAS1 has been identified as a cause of ghosal hematodiaphyseal dysplasia, a medical condition that is characterized by specific phenotypes including leukopenia and abnormality of speech or vocalization.']",[]
"[{'source_node': {'name': 'dimetindene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lactulose'}}, {'source_node': {'name': 'dimetindene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'procainamide'}}]","[{'source_node': {'name': 'dimetindene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'procainamide'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:567', 'target': None, 'metadata': {'node_id': '567', 'node_type': 'COMPOUND', 'display_name': 'lactulose'}}]",0.6,4d7278c09894411afea7f5391c2efab3,74f91c74d5c2a91eaa335e9236a67b69,"['The drug dimetindene is known to decrease the efficacy of both lactulose and procainamide.', 'The medication Dimetindene has been shown to decrease the efficacy of both Lactulose and Procainamide. This implies that the therapeutic benefits of these drugs may be reduced when administered concurrently with Dimetindene.', 'The drug dimetindene is known to decrease the efficacy of both lactulose and procainamide.', 'The efficacy of both lactulose and procainamide is known to be decreased by dimetindene.', 'The drug Dimetindene is known to decrease efficacy of other drugs it interacts with. This includes the drugs lactulose and procainamide, whose effectiveness is lessened when used concurrently with Dimetindene.']","['The drug dimetindene may decrease the efficacy of another medication known as procainamide.', 'The efficacy of procainamide is decreased by the drug dimetindene.', 'The drug dimetindene is known to decrease the efficacy of another medication, procainamide.']"
"[{'source_node': {'name': 'cytochrome p450 19a1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP19A1'}}, {'source_node': {'name': 'gancaonin p'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 19a1'}}, {'source_node': {'name': 'CYP19A1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'aromatase excess syndrome'}}]","[{'source_node': {'name': 'CYP19A1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'aromatase excess syndrome'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:25489', 'target': None, 'metadata': {'node_id': '25489', 'node_type': 'COMPOUND', 'display_name': 'gancaonin p'}}, {'type': 'node_removal', 'source': 'PROTEIN:796', 'target': None, 'metadata': {'node_id': '796', 'node_type': 'PROTEIN', 'display_name': 'cytochrome p450 19a1'}}]",0.4285714285714286,519ac1c42ade728ff65d4349fdb27fe3,a0248cfbdbb8a5681fb7fbaefb31095b,"['The compound Gancaonin P has a target known as Cytochrome P450 19A1. This Cytochrome P450 19A1 is the gene product of CYP19A1, which is known to cause a condition called Aromatase Excess Syndrome.', 'The compound gancaonin p has cytochrome p450 19a1 as its target. This cytochrome is a gene product of CYP19A1, a gene which, when dysregulated, can cause a medical condition known as aromatase excess syndrome.', ""Gancaonin P, a drug compound, has as its target the protein known as cytochrome p450 19A1. This protein is a gene product of the CYP19A1 gene. It's worth noting that the CYP19A1 gene is linked to causing a rare disorder known as aromatase excess syndrome."", 'Gancaonin P is a compound that targets the protein Cytochrome P450 19A1. This protein is a gene product of CYP19A1. Notably, mutations in the CYP19A1 gene can lead to a medical condition known as aromatase excess syndrome.', 'Cytochrome P450 19A1, which is the gene product of CYP19A1, is targeted by the substance known as gancaonin P. Furthermore, CYP19A1 is known to cause a condition called Aromatase Excess Syndrome.']","['The gene CYP19A1 is known to cause a condition known as aromatase excess syndrome.', 'The gene CYP19A1 is known to cause a condition known as aromatase excess syndrome.', 'The gene CYP19A1 is known to cause a condition known as aromatase excess syndrome.', 'The gene CYP19A1 is known to cause a condition known as aromatase excess syndrome.', 'The gene CYP19A1 is known to cause a condition known as aromatase excess syndrome.']"
"[{'source_node': {'name': 'bleeding disorder'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'epistaxis'}}, {'source_node': {'name': 'bleeding disorder'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autosomal recessive inheritance'}}, {'source_node': {'name': 'bleeding disorder'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'anemia'}}, {'source_node': {'name': 'P2RY12'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'bleeding disorder'}}, {'source_node': {'name': 'P2RY12'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'ADP signalling through P2Y purinoceptor 12'}}, {'source_node': {'name': 'P2RY12'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (i) signalling events'}}]","[{'source_node': {'name': 'bleeding disorder'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autosomal recessive inheritance'}}, {'source_node': {'name': 'bleeding disorder'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'anemia'}}, {'source_node': {'name': 'P2RY12'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'ADP signalling through P2Y purinoceptor 12'}}, {'source_node': {'name': 'P2RY12'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (i) signalling events'}}]","[{'type': 'edge_deletion', 'source': 'GENE:32763', 'target': 'DISEASE:17720', 'metadata': None}, {'type': 'node_removal', 'source': 'PHENOTYPE:326', 'target': None, 'metadata': {'node_id': '326', 'node_type': 'PHENOTYPE', 'display_name': 'epistaxis'}}]",0.7692307692307692,a339fd0d09cd83e1928bdc92d123dfad,20e45e66bcb7397412aa24a9fed1ec18,"['Bleeding disorder, a condition caused by P2RY12 gene, is characterized by various phenotypes such as epistaxis, autosomal recessive inheritance, and anemia. The gene P2RY12 plays a role within two vital pathways viz., ADP signalling through P2Y purinoceptor 12 and G alpha (i) signalling events.', 'The gene P2RY12, which operates within the pathways of ADP signalling through P2Y purinoceptor 12 and G alpha (i) signalling events, is known to cause a bleeding disorder. This disorder is often identifiable by several phenotypic characteristics, such as epistaxis, autosomal recessive inheritance and anemia.', 'The gene P2RY12, which is involved in both ADP signalling through P2Y purinoceptor 12 and G alpha (i) signalling events, is known to cause a bleeding disorder. This disorder manifests various symptoms including epistaxis, autosomal recessive inheritance, and anemia.', 'Bleeding disorder is a condition that is caused by the gene P2RY12. This gene acts within two key pathways: ADP signaling through P2Y purinoceptor 12 and G alpha (i) signaling events. The bleeding disorder may reveal itself through several phenotypes, including epistaxis, a symptom characterized by nosebleeds, autosomal recessive inheritance, and even anemia.', 'The gene P2RY12, that operates within the ADP signalling through P2Y purinoceptor 12 pathway as well as the G alpha (i) signalling events, is known to cause a bleeding disorder. This condition is identified by several phenotypes, such as epistaxis (nosebleeds), autosomal recessive inheritance, and anemia.']",[]
"[{'source_node': {'name': '(r)-3-hydroxybutanoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna polymerase iota'}}, {'source_node': {'name': '(r)-3-hydroxybutanoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'geminin'}}]","[{'source_node': {'name': '(r)-3-hydroxybutanoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna polymerase iota'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5869', 'target': None, 'metadata': {'node_id': '5869', 'node_type': 'PROTEIN', 'display_name': 'geminin'}}]",0.6,61c0234f06adb276ecec485909fd7761,06ba623c2afd5d4fc04869eeb432ee72,"['The compound, (R)-3-hydroxybutanoate, targets two specific elements: DNA polymerase iota and geminin.', 'The compound (R)-3-hydroxybutanoate targets both DNA Polymerase Iota and Geminin.', 'The compound (R)-3-hydroxybutanoate has two major targets. First, it targets DNA polymerase iota, an enzyme crucial for DNA synthesis. Second, it targets geminin, a protein that prevents DNA replication. By doing so, it can influence cellular processes involving these two key proteins.', 'The compound (R)-3-hydroxybutanoate targets both DNA polymerase iota and geminin.', 'The compound (R)-3-hydroxybutanoate targets both DNA polymerase iota and geminin.']","['The compound (R)-3-hydroxybutanoate has DNA polymerase iota as its target.', 'The compound (R)-3-hydroxybutanoate targets the DNA polymerase iota.', 'The compound (R)-3-hydroxybutanoate has DNA polymerase iota as a target.', 'The compound (R)-3-Hydroxybutanoate has DNA polymerase iota as its target.', 'The molecule (R)-3-Hydroxybutanoate targets the enzyme known as DNA polymerase iota.']"
"[{'source_node': {'name': '9-deoxygoniopypyrone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': '9-deoxygoniopypyrone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': '9-deoxygoniopypyrone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}]","[{'source_node': {'name': '9-deoxygoniopypyrone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5849', 'target': None, 'metadata': {'node_id': '5849', 'node_type': 'PROTEIN', 'display_name': 'a549'}}, {'type': 'node_removal', 'source': 'PROTEIN:5851', 'target': None, 'metadata': {'node_id': '5851', 'node_type': 'PROTEIN', 'display_name': 'mcf7'}}]",0.4285714285714286,f459912393eeebc3914ce43bbb3364f7,7df0f3abd0e43cb97c4dd5cc958a64f0,"['The compound 9-deoxygoniopypyrone has been found to target multiple cell lines including A549, MCF7, and HT-29.', 'The compound 9-deoxygoniopypyrone has been identified to target a variety of cell lines including A549, MCF7, and HT-29.', 'The compound 9-deoxygoniopypyrone has been observed to target multiple cell lines which include A549, MCF7 and HT-29.', 'The compound 9-deoxygoniopypyrone has several targets including A549, MCF7 and HT-29.', 'The compound 9-deoxygoniopypyrone has been identified to target multiple cell lines, including A549, MCF7, and HT-29.']",[]
"[{'source_node': {'name': 'cerebral dysgenesis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'proteinuria'}}, {'source_node': {'name': 'cerebral dysgenesis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of the dentition'}}]","[{'source_node': {'name': 'cerebral dysgenesis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of the dentition'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:84', 'target': None, 'metadata': {'node_id': '84', 'node_type': 'PHENOTYPE', 'display_name': 'proteinuria'}}]",0.6,58ab7e1bf466411d9909edd07e954530,1ea758f9b118ff37b748f4cc1bbdcd94,"['Cerebral dysgenesis, a neurological condition, is associated with various phenotypes such as proteinuria, a condition characterized by excessive proteins in urine, and abnormalities in dentition, which refers to the development and arrangement of teeth.', 'Cerebral dysgenesis is a condition that presents with certain phenotypes, notably proteinuria and abnormalities of the dentition.', 'Cerebral dysgenesis is a condition that presents various phenotypes, including proteinuria and abnormalities of the dentition.', 'Cerebral dysgenesis, a neurological condition, manifests phenotypes like proteinuria, an abnormal presence of proteins in urine, and abnormalities of the dentition which refers to irregularities in tooth formation or arrangement.', 'Cerebral dysgenesis is a neurological condition that can present with multiple phenotypes, including proteinuria, which is an excess of serum proteins in the urine, and abnormalities of the dentition that can affect the structure and formation of teeth.']",[]
"[{'source_node': {'name': 'hetacillin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'gallamine triethiodide'}}, {'source_node': {'name': 'hetacillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trestolone'}}, {'source_node': {'name': 'hetacillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'norelgestromin'}}]","[{'source_node': {'name': 'hetacillin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'gallamine triethiodide'}}, {'source_node': {'name': 'hetacillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trestolone'}}, {'source_node': {'name': 'hetacillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'norelgestromin'}}, {'source_node': {'name': 'gallamine triethiodide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'hetacillin'}}, {'source_node': {'name': 'norelgestromin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'hetacillin'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:471', 'target': 'COMPOUND:723', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5764', 'target': 'COMPOUND:723', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7142857142857143,92f9342545261c97e55542bf91a6f7be,1903990180d6fe312c3bc3de28b23fbf,"['The drug Hetacillin is known to interact in different ways with other drugs. Specifically, it has been found to increase the efficacy of Gallamine Triethiodide. However, it seems to have the opposite effect on two other substances, Trestolone and Norelgestromin, where it has been reported to decrease their efficacy. These interactions highlight the complex relationships that can exist between different drugs.', 'Hetacillin, a drug known to interact with various other substances, has been found to increase the efficacy of gallamine triethiodide. Interestingly, it was also found to decrease the efficacy of both trestolone and norelgestromin, a notable finding given the differing therapeutic uses of these two drugs.', 'The drug Hetacillin is reported to increase the efficacy of Gallamine Triethiodide. However, it decreases the efficacy of Trestolone and Norelgestromin.', 'The drug hetacillin is known to increase the efficacy of gallamine triethiodide. However, it is also found to decrease the efficacy of both trestolone and norelgestromin.', 'The drug Hetacillin has a varied range of interactions. On one hand, it is known to increase the efficacy of Gallamine Triethiodide. However, it also has the capacity to decrease the efficacy of two other substances called Trestolone and Norelgestromin.']","[""The drug Hetacillin has been found to increase the efficacy of Gallamine Triethiodide and simultaneously decrease the efficacy of both Trestolone and Norelgestromin. Interestingly, the efficacy of Hetacillin itself is improved by not only Gallamine Triethiodide but also Norelgestromin. This intricate interplay among these drugs depicts the complicated nature of bioactive substances and their influence on each other's actions. Such knowledge is crucial for understanding drug interactions and side effects, which can help ensure safe and effective pharmacotherapy."", 'The antibiotic Hetacillin has been implicated in a number of complex biochemical interactions with other drugs. Specifically, its administration has been shown to increase the efficacy of Gallamine Triethiodide, while simultaneously decreasing the efficacy of both Trestolone and Norelgestromin. Intriguingly, the activity of Hetacillin can be further modulated by other drugs. Evidence suggests that both Gallamine Triethiodide and Norelgestromin can in turn increase the efficacy of Hetacillin, forming a sophisticated network of pharmacological interactions.', 'The drug hetacillin has complex interactions with other drugs. Specifically, hetacillin is known to increase the efficacy of gallamine triethiodide, while simultaneously decreasing the efficacy of both trestolone and norelgestromin. Interestingly, this relationship is bidirectional for gallamine triethiodide and norelgestromin, as they also increase the efficacy of hetacillin. However, such effect is not observed with trestolone.', 'The drug, Hetacillin, has been observed to increase the efficacy of Gallamine Triethiodide and at the same time, it also decreases the efficacy of both Trestolone and Norelgestromin. Interestingly, this relationship is mutual with Gallamine Triethiodide and Norelgestromin, as both these drugs were also seen to increase the efficacy of Hetacillin. The understanding of these interactions can potentially guide precise drug administrations.', 'Hetacillin, a broad-spectrum penicillin antibiotic, is known to increase the efficacy of gallamine triethiodide, a neuromuscular-blocking drug, but it decreases the efficacy of both trestolone and norelgestromin. Interestingly, gallamine triethiodide and norelgestromin both reciprocate by increasing the efficacy of hetacillin. However, it is important to note that the efficacy of trestolone, a synthetic androgen, remains unaffected by hetacillin. Understanding interactions like these can be incredibly important for medical practitioners to ensure optimal drug performance.']"
"[{'source_node': {'name': 'MBD5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'mental retardation'}}, {'source_node': {'name': 'MBD5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': '2q23.1 microdeletion syndrome'}}, {'source_node': {'name': 'MBD5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'UCH proteinases'}}, {'source_node': {'name': '2q23.1 microdeletion syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypoplasia of penis'}}]","[{'source_node': {'name': '2q23.1 microdeletion syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypoplasia of penis'}}]","[{'type': 'node_removal', 'source': 'GENE:31611', 'target': None, 'metadata': {'node_id': '31611', 'node_type': 'GENE', 'display_name': 'MBD5'}}]",0.3333333333333333,71c6a20e8a87ab456583b7321fee62b0,c84380a59edb5ec485257f66b924a6e5,[],"['The genetic condition known as 2q23.1 microdeletion syndrome has a phenotype associated with it, specifically the hypoplasia of the penis.']"
"[{'source_node': {'name': 'allicin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'etonogestrel'}}, {'source_node': {'name': 'allicin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clozapine'}}, {'source_node': {'name': 'allicin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'flumequine'}}, {'source_node': {'name': 'etonogestrel'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Breast pain female'}}]","[{'source_node': {'name': 'allicin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'etonogestrel'}}, {'source_node': {'name': 'allicin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'flumequine'}}, {'source_node': {'name': 'etonogestrel'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Breast pain female'}}, {'source_node': {'name': 'flumequine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'etonogestrel'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:352', 'target': None, 'metadata': {'node_id': '352', 'node_type': 'COMPOUND', 'display_name': 'clozapine'}}, {'type': 'edge_addition', 'source': 'COMPOUND:7918', 'target': 'COMPOUND:284', 'metadata': {'predicate': 'increase_efficacy'}}]",0.6666666666666667,395ba62258574316f80a3766feb14dbc,a92b817e4ee7c1fcd0bc8c658d32e651,[],[]
"[{'source_node': {'name': 'hepatocyte nuclear factor 4 alpha'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'nephrotoxicity'}}, {'source_node': {'name': 'hepatocyte nuclear factor 4 alpha'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'epilepsy'}}, {'source_node': {'name': 'hepatocyte nuclear factor 4 alpha'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hemorrhage'}}, {'source_node': {'name': 'epilepsy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'delayed cns myelination'}}, {'source_node': {'name': 'epilepsy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'long neck'}}, {'source_node': {'name': 'epilepsy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'eeg with generalized sharp slow waves'}}]","[{'source_node': {'name': 'hemorrhage'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'long neck'}}, {'source_node': {'name': 'epilepsy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'delayed cns myelination'}}, {'source_node': {'name': 'epilepsy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'long neck'}}, {'source_node': {'name': 'epilepsy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'eeg with generalized sharp slow waves'}}]","[{'type': 'edge_deletion', 'source': 'GENE:8123', 'target': 'DISEASE:15008', 'metadata': None}, {'type': 'edge_addition', 'source': 'DISEASE:1396', 'target': 'PHENOTYPE:358', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'node_removal', 'source': 'GENE:8123', 'target': None, 'metadata': {'node_id': '8123', 'node_type': 'GENE', 'display_name': 'hepatocyte nuclear factor 4 alpha'}}]",0.5384615384615384,2f8a5df58002949347e924ce747cd4d2,2b6625d680a75e0074e85160c781685b,"['Hepatocyte nuclear factor 4 alpha, a key player in certain health conditions, is known to cause nephrotoxicity, epilepsy, and hemorrhage. Specifically, it has been observed that epilepsy, one of the conditions that hepatocyte nuclear factor 4 alpha can cause, is associated with specific phenotypic characteristics. These include delayed cns myelination, a long neck, and an eeg with generalized sharp slow waves.', 'The protein, Hepatocyte Nuclear Factor 4 Alpha, is known to cause several health conditions including Nephrotoxicity, Epilepsy, and Hemorrhage. Notably, Epilepsy, one of the conditions caused by Hepatocyte Nuclear Factor 4 Alpha, exhibits various phenotypes such as Delayed CNS Myelination, Long Neck, and EEG with Generalized Sharp Slow Waves.']",[]
"[{'source_node': {'name': 'uncoupling protein 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'schizophrenia'}}, {'source_node': {'name': 'schizophrenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hallucinations'}}, {'source_node': {'name': 'schizophrenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'social and occupational deterioration'}}, {'source_node': {'name': 'schizophrenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'delusions'}}]","[{'source_node': {'name': 'schizophrenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'social and occupational deterioration'}}, {'source_node': {'name': 'schizophrenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'delusions'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:575', 'target': None, 'metadata': {'node_id': '575', 'node_type': 'PHENOTYPE', 'display_name': 'hallucinations'}}, {'type': 'node_removal', 'source': 'GENE:22955', 'target': None, 'metadata': {'node_id': '22955', 'node_type': 'GENE', 'display_name': 'uncoupling protein 3'}}]",0.5555555555555556,25ee219d33d43c916f7cb050fbc5faf9,79bd836e42e518f66f82f501dc4ea667,"['The pathophysiology of schizophrenia, a disorder characterized by hallucinations, social and occupational deterioration, and delusions, can be mapped to the gene uncoupling protein 3. This gene is known to cause the condition that manifests these symptomologies.', 'The Uncoupling Protein 3 has been associated with causing schizophrenia, a mental disorder characterized by several symptoms. These symptoms include, but are not limited to, hallucinations, delusions, as well as social and occupational deterioration.']","['Schizophrenia, a complex psychiatric disorder, has several distinctive phenotypes, including social and occupational deterioration and delusions.', 'The mental health disorder known as schizophrenia is associated with several symptoms such as social and occupational deterioration and delusions.', ""Schizophrenia is a mental disorder that exhibits various phenotypes, including social and occupational deterioration and delusions. The presence of these symptoms may not only affect a person's ability to function in their everyday life but also challenge their perception of reality."", 'Schizophrenia, a complex mental health disorder, manifests certain phenotypes, including social and occupational deterioration as well as delusions. These various symptoms characterize the multi-faceted nature of this disease.', 'Schizophrenia is a complex mental disorder that manifests in various phenotypes such as social and occupational deterioration and delusions. These disabling symptoms significantly impact the daily functioning and quality of life of individuals affected by this condition.']"
"[{'source_node': {'name': '1-benzylimidazole'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'propylhexedrine'}}, {'source_node': {'name': '1-benzylimidazole'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mephedrone'}}, {'source_node': {'name': '1-benzylimidazole'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'racephedrine'}}, {'source_node': {'name': 'mephedrone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'profenamine'}}, {'source_node': {'name': 'mephedrone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'propranolol'}}, {'source_node': {'name': 'mephedrone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'quinidine'}}]","[{'source_node': {'name': '1-benzylimidazole'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'propylhexedrine'}}, {'source_node': {'name': '1-benzylimidazole'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'racephedrine'}}, {'source_node': {'name': '1-benzylimidazole'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'quinidine'}}, {'source_node': {'name': 'profenamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'propylhexedrine'}}, {'source_node': {'name': 'mephedrone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'profenamine'}}, {'source_node': {'name': 'mephedrone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'propranolol'}}, {'source_node': {'name': 'mephedrone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'quinidine'}}, {'source_node': {'name': 'mephedrone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'propylhexedrine'}}, {'source_node': {'name': 'propylhexedrine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'racephedrine'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:4306', 'target': 'COMPOUND:10976', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:380', 'target': 'COMPOUND:5765', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:10976', 'target': 'COMPOUND:5765', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:4306', 'target': 'COMPOUND:891', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5765', 'target': 'COMPOUND:12453', 'metadata': {'predicate': 'increase_efficacy'}}]",0.6153846153846154,09ae5ed48762a66f2ff8b6621d759062,0d8c4496b2e09923d8b198d175b5854a,"['The drug 1-benzylimidazole is shown to decrease the efficacy of propylhexedrine, mephedrone, and racephedrine. Additionally, mephedrone, whose efficiency is reduced by 1-benzylimidazole, further decreases the efficacy of other drugs including profenamine, propranolol, and quinidine. These interactions highlight complex efficacy interdependencies in drug combinations involving 1-benzylimidazole and mephedrone.', 'The agent 1-benzylimidazole has been found to decrease the efficacy of propylhexedrine, mephedrone, and racephedrine. Furthermore, mephedrone, when its effectiveness is lessened by 1-benzylimidazole, also shows decreased efficacy when interacting with drugs such as profenamine, propranolol, and quinidine. The implication of these findings on clinical drug usage and treatment regimens warrants further investigation.', 'The compound 1-benzylimidazole is known to decrease the efficacy of various substances like propylhexedrine, mephedrone, and racephedrine. Additionally, mephedrone also has a similar effect, reducing the efficacy of profenamine, propranolol, and quinidine. This suggests complex interactions between these compounds and potentially broad implications for their use in medicinal contexts.', 'The drug 1-benzylimidazole is noted to decrease the efficacy of several substances, including propylhexedrine, mephedrone, and racephedrine. Additionally, mephedrone itself can also decrease the efficacy of other substances, such as profenamine, propranolol, and quinidine. Therefore, it is crucial to consider these interactions when administering these drugs in a clinical setting to avoid potential adverse effects or decreased therapeutic efficiency.', 'The drug 1-benzylimidazole has been found to decrease the efficacy of several substances including propylhexedrine, mephedrone, and racephedrine. Interestingly, mephedrone not only has its efficacy decreased by 1-benzylimidazole, but it also decreases the efficacy of other substances such as profenamine, propranolol, and quinidine.']","[""The drug 1-benzylimidazole decreases the efficacy of propylhexedrine, racephedrine, and quinidine. Similarly, profenamine also has an effect on propylhexedrine, reducing its efficacy. In addition, mephedrone decreases the efficacy of profenamine, propranolol, and quinidine. Interestingly, mephedrone increases the efficacy of propylhexedrine, which in turn, boosts the efficacy of racephedrine. Clearly, these drugs show complex, interconnected influences on each other's performance."", 'The compound 1-benzylimidazole decreases the effectiveness of several drugs, including propylhexedrine, racephedrine, and quinidine. Similarly, the drug profenamine is also known to decrease the efficacy of propylhexedrine. \n\nMephedrone, another notable compound, affects several drugs: it decreases the effectiveness of profenamine, propranolol, and quinidine. Intriguingly, in the case of propylhexedrine, mephedrone actually increases its efficacy. Furthermore, propylhexedrine, in turn, enhances the efficacy of racephedrine. \n\nThese interactions indicate complex relationships between various compounds and drugs influencing their therapeutic effectiveness.', 'The drug 1-benzylimidazole is known to decrease the efficacy of several other drugs including propylhexedrine, racephedrine, and quinidine. Similarly, profenamine, another medication, also decreases the effectiveness of propylhexedrine, which is enhanced by mephedrone. Moreover, mephedrone appears to have a varied effect on different drugs since it decreases the efficacy of profenamine, propranolol, and quinidine, while increasing the efficacy of propylhexedrine. In the interconnected dynamics of these drugs, propylhexedrine also plays a role in increasing the efficacy of racephedrine.', 'The drug 1-benzylimidazole decreases the efficacy of propylhexedrine, racephedrine and quinidine. Similarly, profenamine reduces the efficacy of propylhexedrine. Mephedrone also has an impact on several drugs: it decreases the efficacy of profenamine, propranolol and quinidine, but interestingly, it increases the efficacy of propylhexedrine. Propylhexedrine, in turn, enhances the efficacy of racephedrine.', 'The drug 1-benzylimidazole is known to decrease the efficacy of propylhexedrine, racephedrine, and quinidine. Similarly, the drug profenamine also has an impact on the efficacy of propylhexedrine, decreasing it significantly. Another drug, mephedrone, has complex interactions with multiple other medications. It decreases the efficacy of profenamine, propranolol, and quinidine, but interestingly, it increases the efficacy of propylhexedrine. Furthermore, propylhexedrine, in turn, enhances the efficacy of racephedrine, forming a complex network of drug interactions and efficacy changes. These interactions shed light on the need for careful consideration when combining these specific medications.']"
"[{'source_node': {'name': 'steganone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ovcar-3'}}, {'source_node': {'name': 'steganone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'colo 205'}}]","[{'source_node': {'name': 'steganone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'colo 205'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5625', 'target': None, 'metadata': {'node_id': '5625', 'node_type': 'PROTEIN', 'display_name': 'ovcar-3'}}]",0.6,e13578b47ac9a49dc13be5bb62657275,9d626f6dcdbfcf520cdf76c87bf051f4,"['The compound steganone is known to target both OVCAR-3 and COLO 205 cells.', 'Steganone, a compound of interest in scientific research, is known to target multiple cells, specifically the OVCAR-3 and COLO 205 cells.', 'The compound Steganone has been identified to target multiple entities, namely OVCAR-3 and COLO 205.', 'The compound Steganone targets two kinds of cells: OVCAR-3 and COLO 205.', 'The compound Steganone has been identified as targeting both OVCAR-3 and COLO 205 cells.']",[]
"[{'source_node': {'name': 'michellamine a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cem-ss'}}, {'source_node': {'name': 'michellamine a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'c8166'}}, {'source_node': {'name': 'michellamine a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ccrf-cem'}}]","[{'source_node': {'name': 'michellamine a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'c8166'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5601', 'target': None, 'metadata': {'node_id': '5601', 'node_type': 'PROTEIN', 'display_name': 'cem-ss'}}, {'type': 'node_removal', 'source': 'PROTEIN:5667', 'target': None, 'metadata': {'node_id': '5667', 'node_type': 'PROTEIN', 'display_name': 'ccrf-cem'}}]",0.4285714285714286,af33e0cb79f2bbfa987b62af6707f334,4a8f7b8039b97bda1f20f846ddd022b0,"['Michellamine A, a compound of interest in medical research, has been identified to target various cell lines in its mechanism of action. These targeted cell lines are known as CEM-SS, C8166, and CCRF-CEM.', 'The drug Michellamine A is known to target several cell lines including CEM-SS, C8166, and CCRF-CEM.', 'The drug Michellamine A targets multiple entities including CEM-SS, C8166 and CCRF-CEM.', 'The substance Michellamine A targets several entities including CEM-SS, C8166, and CCRF-CEM.', 'The drug Michellamine A targets several entities, including the CEM-SS and C8166 cell lines, as well as CCRF-CEM.']","['The drug Michellamine A has been identified to target C8166.', 'The compound Michellamine A has a specific target, known as C8166.', 'The drug Michellamine A has C8166 as its target.', 'The drug Michellamine A has been identified to target the protein C8166.']"
"[{'source_node': {'name': 'trichlormethiazide'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hypotensive activities '}}, {'source_node': {'name': 'trichlormethiazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'glimepiride'}}, {'source_node': {'name': 'trichlormethiazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oxycodone'}}, {'source_node': {'name': 'etacrynic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dpdpe'}}, {'source_node': {'name': 'methadyl acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'etacrynic acid'}}, {'source_node': {'name': 'methadyl acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trichlormethiazide'}}, {'source_node': {'name': 'methadyl acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mebutizide'}}]","[{'source_node': {'name': 'trichlormethiazide'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hypotensive activities '}}, {'source_node': {'name': 'trichlormethiazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'glimepiride'}}, {'source_node': {'name': 'trichlormethiazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oxycodone'}}, {'source_node': {'name': 'trichlormethiazide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'dpdpe'}}, {'source_node': {'name': 'etacrynic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dpdpe'}}, {'source_node': {'name': 'mebutizide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'dpdpe'}}, {'source_node': {'name': 'dpdpe'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oxycodone'}}, {'source_node': {'name': 'methadyl acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'etacrynic acid'}}, {'source_node': {'name': 'methadyl acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mebutizide'}}, {'source_node': {'name': 'methadyl acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dpdpe'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:11284', 'target': 'COMPOUND:7815', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:7815', 'target': 'COMPOUND:485', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1004', 'target': 'COMPOUND:7815', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:1371', 'target': 'COMPOUND:1004', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:1371', 'target': 'COMPOUND:7815', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.6666666666666667,765d4981db658e9da9d67060b9c40f67,12d19cd7299e9e95813e5138a5a4e78e,[],[]
"[{'source_node': {'name': 'NAMPT'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nicotinamide salvaging'}}, {'source_node': {'name': 'NAMPT'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'NPAS4 regulates expression of target genes'}}, {'source_node': {'name': 'nicotinamide phosphoribosyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NAMPT'}}, {'source_node': {'name': 'chs-828'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nicotinamide phosphoribosyltransferase'}}]","[{'source_node': {'name': 'NAMPT'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nicotinamide salvaging'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:3807', 'target': None, 'metadata': {'node_id': '3807', 'node_type': 'PROTEIN', 'display_name': 'nicotinamide phosphoribosyltransferase'}}, {'type': 'node_removal', 'source': 'PATHWAY:312', 'target': None, 'metadata': {'node_id': '312', 'node_type': 'PATHWAY', 'display_name': 'NPAS4 regulates expression of target genes'}}]",0.3333333333333333,aac563ddd9c2c1db4e35d6f23728f1ce,975102d7f55c9b59ba08089117a78ddc,[],"['The protein NAMPT operates within the process of Nicotinamide salvaging.', 'The gene NAMPT acts within the process of nicotinamide salvaging.']"
"[{'source_node': {'name': 'VAMP8'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'ER-Phagosome pathway'}}, {'source_node': {'name': 'VAMP8'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'trans-Golgi Network Vesicle Budding'}}, {'source_node': {'name': 'VAMP8'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}]","[{'source_node': {'name': 'VAMP8'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'trans-Golgi Network Vesicle Budding'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:367', 'target': None, 'metadata': {'node_id': '367', 'node_type': 'PATHWAY', 'display_name': 'ER-Phagosome pathway'}}, {'type': 'node_removal', 'source': 'PATHWAY:3', 'target': None, 'metadata': {'node_id': '3', 'node_type': 'PATHWAY', 'display_name': 'Neutrophil degranulation'}}]",0.4285714285714286,31d86f12dba6d63174c2019a92037dad,a5921782b36fd0cb77a2cc3d76feb285,"['The gene VAMP8 plays a role in several cellular pathways. It acts within the ER-phagosome pathway, contributes to the process of trans-Golgi network vesicle budding, and is also involved in neutrophil degranulation.', 'The gene VAMP8 operates within several pathways, including the ER-phagosome pathway and the trans-Golgi network vesicle budding. Additionally, it plays a key role in the process of neutrophil degranulation.', 'The gene VAMP8 is involved in multiple pathways, such as the ER-Phagosome pathway, the trans-Golgi network vesicle budding, and neutrophil degranulation.', 'The gene VAMP8 interacts within several cellular procedures, such as the ER-Phagosome pathway, Trans-Golgi Network Vesicle Budding, and Neutrophil degranulation.', 'The protein VAMP8 is involved in several cellular processes, such as the ER-Phagosome pathway, trans-Golgi Network Vesicle Budding, and Neutrophil degranulation.']","['The protein VAMP8 operates within the process of trans-Golgi network vesicle budding.', 'The gene VAMP8 is involved in the process of Trans-Golgi Network Vesicle Budding.', 'The gene VAMP8 is known to function within the process of trans-Golgi network vesicle budding.', 'The gene VAMP8 operates within the pathway of trans-Golgi network vesicle budding.', 'The gene VAMP8 is known to act within the process of trans-Golgi network vesicle budding.']"
"[{'source_node': {'name': 'seizures'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'short stature'}}, {'source_node': {'name': 'seizures'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'inability to walk'}}]","[{'source_node': {'name': 'seizures'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'inability to walk'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:3016', 'target': None, 'metadata': {'node_id': '3016', 'node_type': 'PHENOTYPE', 'display_name': 'short stature'}}]",0.6,1493a25128ea2ade81820ab8517ec23e,edd0a8a3c9b77a1aaf6ff5e1936b092c,"['The condition of seizures presents with multiple phenotypes, including a short stature and an inability to walk.', 'Seizures, a neurological condition, can present with multiple phenotype characteristics. This includes short stature and an inability to walk. These are some of the physical manifestations that range in severity amongst individuals suffering from seizures.', 'Seizures, a neurological condition, can exhibit several phenotypes such as short stature and an inability to walk.', 'The condition of seizures has several associated phenotypes, including short stature and an inability to walk. These physical manifestations or characteristics are frequently seen in individuals suffering from this neurological disorder.', 'Seizures, a neurological condition, often present certain phenotypes, such as short stature and the inability to walk, impacting the physical capabilities of the affected individuals.']",[]
"[{'source_node': {'name': 'fibroblast growth factor receptor 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FGFR2'}}, {'source_node': {'name': 'sappanene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'proto-oncogene tyrosine-protein kinase src'}}, {'source_node': {'name': 'sappanene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'fibroblast growth factor receptor 1'}}, {'source_node': {'name': 'sappanene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'fibroblast growth factor receptor 2'}}, {'source_node': {'name': 'fibroblast growth factor receptor 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FGFR1'}}, {'source_node': {'name': 'proto-oncogene tyrosine-protein kinase src'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SRC'}}]","[{'source_node': {'name': 'fibroblast growth factor receptor 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FGFR2'}}, {'source_node': {'name': 'fibroblast growth factor receptor 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SRC'}}, {'source_node': {'name': 'sappanene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'proto-oncogene tyrosine-protein kinase src'}}, {'source_node': {'name': 'sappanene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'fibroblast growth factor receptor 1'}}, {'source_node': {'name': 'fibroblast growth factor receptor 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FGFR2'}}, {'source_node': {'name': 'proto-oncogene tyrosine-protein kinase src'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SRC'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:80', 'target': 'GENE:33030', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:51055', 'target': 'PROTEIN:80', 'metadata': None}, {'type': 'edge_addition', 'source': 'PROTEIN:80', 'target': 'GENE:27044', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'GENE:27044', 'target': None, 'metadata': {'node_id': '27044', 'node_type': 'GENE', 'display_name': 'FGFR1'}}, {'type': 'edge_addition', 'source': 'PROTEIN:81', 'target': 'GENE:27047', 'metadata': {'predicate': 'gene_product_of'}}]",0.6153846153846154,6060c8ab7e8c8ca4ef9d72efadc283fe,799ef85415401e89e8755966d453ccf8,"['The compound sappanene exhibits notable interactions within the body; it specifically targets multiple proteins including proto-oncogene tyrosine-protein kinase src and fibroblast growth factor receptors 1 and 2. These proteins are gene products of their respective genes; FGFR1 is the gene product of fibroblast growth factor receptor 1, FGFR2 is the gene product of fibroblast growth factor receptor 2, and SRC is the gene product of proto-oncogene tyrosine-protein kinase src.', 'Fibroblast growth factor receptor 2, which is a gene product of FGFR2, along with fibroblast growth factor receptor 1, a gene product of FGFR1, and proto-oncogene tyrosine-protein kinase src, a gene product of SRC, are all targets of the compound sappanene.', 'Fibroblast growth factor receptor 2 and fibroblast growth factor receptor 1 are both targeted by the compound sappanene. These receptors are, in fact, gene products of FGFR2 and FGFR1, respectively. Sappanene also targets the proto-oncogene tyrosine-protein kinase src, which is a gene product of SRC.', 'Fibroblast growth factor receptor 2 and fibroblast growth factor receptor 1 are both gene products of FGFR2 and FGFR1 respectively. These receptors, in conjunction with the proto-oncogene tyrosine-protein kinase src, which is a gene product of SRC, are targeted by the compound sappanene. Therefore, sappanene plays a pivotal role in interacting with crucial growth factor receptors and kinase proteins that could impact various cellular pathways and functions.', 'The therapeutic agent, sappanene, is known to target various proteins including the proto-oncogene tyrosine-protein kinase src, fibroblast growth factor receptor 1, and fibroblast growth factor receptor 2. These targeted proteins are gene products of their respective genes, SRC, FGFR1, and FGFR2. Further knowledge of these protein-gene relationships can lead to more precise therapies in combating various diseases and conditions.']","['Fibroblast growth factor receptor 2 and fibroblast growth factor receptor 1 are both gene products of FGFR2. Interestingly, fibroblast growth factor receptor 2 is also a gene product of SRC. On another note, the substance known as sappanene targets both the proto-oncogene tyrosine-protein kinase src and fibroblast growth factor receptor 1. It is noteworthy to mention that proto-oncogene tyrosine-protein kinase src is a gene product of SRC.']"
"[{'source_node': {'name': 'mephedrone'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' hypertension '}}, {'source_node': {'name': 'mephedrone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'prazosin'}}, {'source_node': {'name': 'mephedrone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tolazoline'}}]","[{'source_node': {'name': 'mephedrone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'prazosin'}}, {'source_node': {'name': 'mephedrone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tolazoline'}}]","[{'type': 'node_removal', 'source': 'EFFECT:31', 'target': None, 'metadata': {'node_id': '31', 'node_type': 'EFFECT', 'display_name': ' hypertension '}}]",0.7142857142857143,6d1852acdeb61e318099e6e59bc69554,0ae8283b8bc4a24a58aa5e6959941aa7,[],"['Mephedrone is a substance known to decrease the efficacy of certain drugs. Specifically, it has been found to reduce the effectiveness of prazosin and tolazoline. This information could be particularly important for health professionals when considering drug interactions.', 'The drug Mephedrone is known to decrease the efficacy of both Prazosin and Tolazoline.', 'Mephedrone, a synthetic stimulant drug, has been found to decrease the efficacy of certain medications, including prazosin, an alpha-blocker used to treat high blood pressure, and tolazoline, a vasodilator. These impacts can potentially affect the treatment outcomes for patients using these drugs.', 'The substance Mephedrone is known to decrease the efficacy of certain substances. Specifically, it diminishes the effectiveness of both Prazosin and Tolazoline.', 'The drug mephedrone is known to decrease the efficacy of both prazosin and tolazoline.']"
"[{'source_node': {'name': 'ribosomal protein s6 kinase alpha 5'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RPS6KA5'}}, {'source_node': {'name': 'RPS6KA5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'ERK/MAPK targets'}}, {'source_node': {'name': 'RPS6KA5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Recycling pathway of L1'}}, {'source_node': {'name': 'RPS6KA5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'CD209 (DC-SIGN) signaling'}}]","[{'source_node': {'name': 'RPS6KA5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'CD209 (DC-SIGN) signaling'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5918', 'target': None, 'metadata': {'node_id': '5918', 'node_type': 'PROTEIN', 'display_name': 'ribosomal protein s6 kinase alpha 5'}}, {'type': 'node_removal', 'source': 'PATHWAY:596', 'target': None, 'metadata': {'node_id': '596', 'node_type': 'PATHWAY', 'display_name': 'Recycling pathway of L1'}}, {'type': 'node_removal', 'source': 'PATHWAY:1207', 'target': None, 'metadata': {'node_id': '1207', 'node_type': 'PATHWAY', 'display_name': 'ERK/MAPK targets'}}]",0.3333333333333333,a0985ec32939d262f022a8a918f393b5,c9dc0e276fa053e6a287662d27da3061,"['The Ribosomal protein s6 kinase alpha 5 is a gene product of RPS6KA5. Interestingly, RPS6KA5 acts within several pathways such as ERK/MAPK targets, the recycling pathway of L1, as well as CD209 (DC-SIGN) signaling. This sheds light on the various roles it could play in biological processes.', 'The ribosomal protein s6 kinase alpha 5 is a gene product of the gene RPS6KA5. This particular gene, RPS6KA5, is known to act within several pathways including ERK/MAPK targets, the recycling pathway of L1, and CD209 (DC-SIGN) signaling.']",[]
"[{'source_node': {'name': 'SLC24A4'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'amelogenesis imperfecta'}}, {'source_node': {'name': 'SLC24A4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Sodium/Calcium exchangers'}}]","[{'source_node': {'name': 'SLC24A4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Sodium/Calcium exchangers'}}]","[{'type': 'node_removal', 'source': 'DISEASE:16044', 'target': None, 'metadata': {'node_id': '16044', 'node_type': 'DISEASE', 'display_name': 'amelogenesis imperfecta'}}]",0.6,f844aaa1eecdb340542417758f718e33,c234f02597500d3fb007ab710a5aba90,"['The gene SLC24A4, which acts within the realm of Sodium/Calcium exchangers, has been identified as a causative factor of amelogenesis imperfecta, a condition that severely impairs tooth enamel formation.\n', 'The gene SLC24A4, which acts within the Sodium/Calcium exchangers pathway, has been identified as a cause of amelogenesis imperfecta, a condition characterized by abnormal formation of the enamel.']","['The gene SLC24A4 functions within the pathway of sodium/calcium exchangers.', 'The gene SLC24A4 functions within the pathway of sodium/calcium exchangers.', 'The gene SLC24A4 operates within the Sodium/Calcium exchangers pathway.', 'The gene SLC24A4 functions within the pathway of sodium/calcium exchangers.', 'The gene SLC24A4 acts within the pathway of sodium/calcium exchangers.']"
"[{'source_node': {'name': 'jeavons syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormal head movements'}}, {'source_node': {'name': 'jeavons syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'eeg with spike-wave complexes'}}, {'source_node': {'name': 'jeavons syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'interictal epileptiform activity'}}]","[{'source_node': {'name': 'jeavons syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'interictal epileptiform activity'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1785', 'target': None, 'metadata': {'node_id': '1785', 'node_type': 'PHENOTYPE', 'display_name': 'abnormal head movements'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:7276', 'target': None, 'metadata': {'node_id': '7276', 'node_type': 'PHENOTYPE', 'display_name': 'eeg with spike-wave complexes'}}]",0.4285714285714286,1bb5eaf1028da276423e3f7ca35992dd,98fec4feb976f73efed3a30ddfa876a4,"['The neurological condition known as Jeavons syndrome is characterized by a collection of specific symptoms or phenotypes which include abnormal head movements and both EEGs with spike-wave complexes as well as interictal epileptiform activity.', 'Jeavons syndrome is a condition that manifests certain phenotypes, including abnormal head movements, EEG with spike-wave complexes and interictal epileptiform activity. These symptoms challenge patients suffering from this syndrome by directly influencing their movement and neurological functioning.']",[]
"[{'source_node': {'name': 'ulipristal'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bivalirudin'}}, {'source_node': {'name': 'tenecteplase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ceftriaxone'}}, {'source_node': {'name': 'tenecteplase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ulipristal'}}, {'source_node': {'name': 'tenecteplase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ceftezole'}}]","[{'source_node': {'name': 'bivalirudin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'ceftriaxone'}}, {'source_node': {'name': 'ulipristal'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bivalirudin'}}, {'source_node': {'name': 'tenecteplase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ceftriaxone'}}, {'source_node': {'name': 'tenecteplase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ulipristal'}}, {'source_node': {'name': 'tenecteplase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ceftezole'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:6', 'target': 'COMPOUND:1192', 'metadata': {'predicate': 'increase_efficacy'}}]",0.8888888888888888,0fa2feed25600f1e515938b2674a51c5,9186c2dbd25f0e27e396f061380635a4,"['Ulipristal, a medication often used in emergency contraception, has been found to decrease the efficacy of Bivalirudin, a direct thrombin inhibitor with anticoagulant effects. Similarly, the thrombolytic agent Tenecteplase is known to lessen the effectiveness of a few other medications. For instance, it decreases the efficacy of Ceftriaxone and Ceftezole, both of which are antibacterial agents. In addition, Tenecteplase also decreases the efficacy of Ulipristal. Thereby, careful consideration should be given while co-administering these drugs.', 'The administration of certain drugs affects the efficacy of others - for instance, ulipristal decreases the efficacy of bivalirudin. The medication tenecteplase also has a similar effect, as it reduces the efficacy of ceftriaxone, ulipristal, and ceftezole. Users of these drugs should take note, as the reduced efficacy may influence treatment outcomes.', 'The drug ulipristal is known to decrease the efficacy of bivalirudin. Meanwhile, tenecteplase, another drug, has the capability to decrease the efficacy of several other drugs such as ceftriaxone, ulipristal, and ceftezole. Thus, caution is advised when these drugs are combined in treatment strategies.', 'The drug Ulipristal is known to decrease the efficacy of Bivalirudin. Additionally, Tenecteplase, another drug, has the ability to decrease the efficacy of multiple medications, notably Ceftriaxone, Ulipristal, and Ceftezole. Hence, it becomes critical to consider these interactions while administering these medications simultaneously.', 'The active ingredient, ulipristal, can decrease the efficacy of the anticoagulant drug, bivalirudin. On a similar note, the thrombolytic drug, tenecteplase, is known to decrease the efficacy of various medications. Its effects have been particularly noted in decreasing the efficacy of the antibiotic, ceftriaxone, and the cephalosporin antibiotic, ceftezole. Interestingly, tenecteplase is also reported to decrease the efficacy of ulipristal.']","['The efficacy of certain drugs can be influenced when used in conjunction with other drugs. For instance, bivalirudin is known to increase the efficacy of ceftriaxone. However, the presence of ulipristal can decrease the efficacy of bivalirudin. Also, tenecteplase has been found to decrease the efficacy of ceftriaxone, ulipristal, and ceftezole. Consequently, careful consideration must be given when administering these combinations in a clinical setting.', ""The efficacy of certain drugs can be influenced by the presence of others. In the case of bivalirudin, it has been found to increase the efficacy of ceftriaxone. On the other hand, it's worth noting that ulipristal can decrease the efficacy of bivalirudin. Similarly, tenecteplase has multiple interactions, with it being known to decrease the efficacy of not just one, but three separate drugs; ceftriaxone, ulipristal and ceftezole. These interactions raise implications for treatment plans that involve a combination of these drugs."", 'The drug Bivalirudin is known to increase the efficacy of Ceftriaxone. However, this effect can be diminished as the drug Ulipristal decreases the efficacy of Bivalirudin. Moreover, the drug Tenecteplase has an adverse effect on several drugs. Notably, it decreases the efficacy of Ceftriaxone, Ulipristal, and Ceftezole. This intricate interplay of drugs and their effects makes the choice of concurrent drug administration critical to accomplishing the desired therapeutic effect.', ""In the vast realm of pharmacology, several drugs can influence each other's efficacy. For instance, bivalirudin is known to boost the efficacy of ceftriaxone. However, this enhanced effect of bivalirudin on ceftriaxone could get undermined by ulipristal, as ulipristal brings down the efficacy of bivalirudin. Another drug, tenecteplase, exhibits a similar negative effect on several medications. Specifically, it lessens the efficacy of ceftriaxone, ulipristal, and ceftezole. Therefore, understanding such interactions among drugs is crucial in the field of drug development and clinical practice."", '""Bivalirudin increases the efficacy of ceftriaxone, while ulipristal, on the other hand, decreases the efficacy of bivalirudin. Another drug, tenecteplase, reduces the efficacy of ceftriaxone, ulipristal, and ceftezole. Thus, the interplay of these drugs can greatly impact outcomes and careful management of their interaction is crucial in treatment strategies.']"
"[{'source_node': {'name': 'keratoendotheliitis fugax hereditaria'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'epiphora'}}, {'source_node': {'name': 'keratoendotheliitis fugax hereditaria'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'young adult onset'}}, {'source_node': {'name': 'keratoendotheliitis fugax hereditaria'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'epiretinal membrane'}}]","[{'source_node': {'name': 'keratoendotheliitis fugax hereditaria'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'epiphora'}}, {'source_node': {'name': 'keratoendotheliitis fugax hereditaria'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'epiretinal membrane'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:7865', 'target': None, 'metadata': {'node_id': '7865', 'node_type': 'PHENOTYPE', 'display_name': 'young adult onset'}}]",0.7142857142857143,852fd4ea651c8ac49b0ed37df037e8bd,31a75b31763458444ea2848e733d6cdf,"['The disease known as keratoendotheliitis fugax hereditaria presents several symptoms or phenotypes. These range from epiphora, a condition characterized by an overflow of tears due to an obstruction of the tear duct, to issues impacting the retina, such as an epiretinal membrane, which is a thin sheet of fibrous tissue that can develop on the surface of the retina and cause a variety of visual impairments. Furthermore, the onset of this disease often occurs during early adulthood, noted as a young adult onset.', 'Keratoendotheliitis fugax hereditaria, a hereditary eye condition, has several characteristic phenotypes. This includes a young adult onset, the formation of an epiretinal membrane, and the symptom of epiphora, which is the excessive tearing of the eyes.']","['Keratoendotheliitis fugax hereditaria, a rare genetic condition, is characterized by certain phenotypes such as epiphora, or tearing often caused by excessive production or reduced drainage of tears, and epiretinal membrane, which is the formation of a thin layer of fibrous tissue over the retina.', 'Keratoendotheliitis fugax hereditaria, a genetic condition, presents with several phenotypes or observable characteristics. Notably, it results in epiphora, a condition marked by an overflow of tears onto the face, and epiretinal membrane, a disorder which causes a transparent layer of fibrous tissue to develop over the retinal surface.', 'Keratoendotheliitis fugax hereditaria, a rare eye condition, exhibits certain phenotypes, which include the accumulation of an epiretinal membrane and the symptom of epiphora, characterized by an excessive tearing of the eyes.', 'Keratoendotheliitis fugax hereditaria, a specific type of eye condition, presents with certain phenotypes like epiphora and epiretinal membrane.', 'The condition known as keratoendotheliitis fugax hereditaria is characterized by several phenotypes, notably epiphora and the formation of an epiretinal membrane.']"
"[{'source_node': {'name': 'macrathoin f'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': '72 kda type iv collagenase'}}, {'source_node': {'name': 'macrathoin f'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'matrix metalloproteinase-9'}}, {'source_node': {'name': 'macrathoin f'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'collagenase 3'}}, {'source_node': {'name': 'collagenase 3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MMP13'}}, {'source_node': {'name': '72 kda type iv collagenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MMP2'}}]","[{'source_node': {'name': 'macrathoin f'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': '72 kda type iv collagenase'}}, {'source_node': {'name': 'macrathoin f'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'matrix metalloproteinase-9'}}, {'source_node': {'name': 'macrathoin f'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'MMP13'}}, {'source_node': {'name': 'collagenase 3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MMP13'}}, {'source_node': {'name': 'collagenase 3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MMP2'}}, {'source_node': {'name': '72 kda type iv collagenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MMP2'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:64662', 'target': 'GENE:29970', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:1389', 'target': 'GENE:29960', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:64662', 'target': 'PROTEIN:1389', 'metadata': None}]",0.7272727272727273,99b25f8a13fd98d28fa1d7b67f1bd548,3023348590ff9efc480d4390008f8ac9,"['Macrathoin F, a pharmaceutical compound, targets a range of proteins, namely, the 72 kDa type IV collagenase, matrix metalloproteinase-9, and collagenase 3. Each of these proteins is the gene product of a specific gene. Specifically, the 72 kDa type IV collagenase is a product of the MMP2 gene, whereas collagenase 3 emerges from the MMP13 gene.', 'The drug Macrathoin F targets various proteins including 72 kda type IV collagenase, matrix metalloproteinase-9, and collagenase 3. It is interesting to note that collagenase 3 is a gene product of MMP13 while 72 kda type IV collagenase is a gene product of MMP2.', 'The drug Macrathoin F targets several proteins including 72 kDa type IV collagenase, matrix metalloproteinase-9 and collagenase 3. Interestingly, collagenase 3 is a gene product of MMP13 while the 72 kDa type IV collagenase is a gene product of MMP2.', 'The compound macrathoin f targets several enzymes including 72 kda type iv collagenase, matrix metalloproteinase-9, and collagenase 3. Interestingly, collagenase 3 is a gene product of MMP13, while the 72 kda type iv collagenase results from the genetic expression of MMP2.', 'The drug Macrathoin F targets several proteins including 72 kDa type IV collagenase, Matrix Metalloproteinase-9, and Collagenase 3. These proteins are gene products of different genes; for example, 72 kDa type IV collagenase is a gene product of MMP2, and Collagenase 3 is a gene product of MMP13.']","['The compound Macrathoin F has been shown to target several proteins such as the 72 kDa Type IV Collagenase and Matrix Metalloproteinase-9, and it also affects MMP13. The 72 kDa Type IV Collagenase, in turn, is a gene product of MMP2. Notably, Collagenase 3, another gene product of MMP2, also happens to be a gene product of MMP13.', 'Macrathoin F is a compound that has targets such as 72 kda type IV collagenase and matrix metalloproteinase-9. In addition, Macrathoin F is known to affect MMP13. To further elaborate, 72 kda type IV collagenase is a gene product of MMP2. On the other hand, Collagenase 3, a gene product of both MMP13 and MMP2, plays a role in these paths. Therefore, both 72 kda type IV collagenase and Collagenase 3 exhibit a connectivity linking back to MMP2.', ""The compound macrathoin f has been found to target the 72 kda type iv collagenase as well as the matrix metalloproteinase-9. Moreover, macrathoin f is affecting the molecule MMP13. In another connection, collagenase 3 is identified as the gene product of MMP13, and it also emanates from the MMP2 gene. Lastly, there is an association between the 72 kda type iv collagenase and the MMP2 gene, where the former is a product of the latter's gene expression.""]"
"[{'source_node': {'name': 'interleukin-1 receptor-associated kinase 3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'IRAK3'}}, {'source_node': {'name': 'IRAK3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Interleukin-1 signaling'}}]","[{'source_node': {'name': 'interleukin-1 receptor-associated kinase 3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'IRAK3'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:407', 'target': None, 'metadata': {'node_id': '407', 'node_type': 'PATHWAY', 'display_name': 'Interleukin-1 signaling'}}]",0.6,997f86c2ef16a3cbf0639ba1c44195a9,fcf8d933abd7517baa72bc06ac6f7288,"['Interleukin-1 receptor-associated kinase 3 is a gene product of IRAK3. This IRAK3 molecule further acts within the pathway of Interleukin-1 signaling.', 'Interleukin-1 receptor-associated kinase 3 is a gene product of IRAK3. IRAK3, in turn, operates within the domain of Interleukin-1 signaling.', 'Interleukin-1 receptor-associated kinase 3 is a gene product of IRAK3. This gene, IRAK3, functions within the pathway known as interleukin-1 signaling.']",[]
"[{'source_node': {'name': 'ALOX15B'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of 15-eicosatetraenoic acid derivatives'}}, {'source_node': {'name': '(2e)-3-(2-oct-1-yn-1-ylphenyl)acrylic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arachidonate 15-lipoxygenase'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15B'}}, {'source_node': {'name': 'ALOX15'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of 12-eicosatetraenoic acid derivatives'}}, {'source_node': {'name': 'ALOX15'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Biosynthesis of DHA-derived SPMs'}}, {'source_node': {'name': 'ALOX15'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Biosynthesis of E-series 18(R)-resolvins'}}]","[{'source_node': {'name': '(2e)-3-(2-oct-1-yn-1-ylphenyl)acrylic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arachidonate 15-lipoxygenase'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15B'}}, {'source_node': {'name': 'ALOX15'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of 12-eicosatetraenoic acid derivatives'}}, {'source_node': {'name': 'ALOX15'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Biosynthesis of E-series 18(R)-resolvins'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1595', 'target': None, 'metadata': {'node_id': '1595', 'node_type': 'PATHWAY', 'display_name': 'Biosynthesis of DHA-derived SPMs'}}, {'type': 'edge_deletion', 'source': 'PROTEIN:2703', 'target': 'GENE:27532', 'metadata': None}, {'type': 'node_removal', 'source': 'PATHWAY:1607', 'target': None, 'metadata': {'node_id': '1607', 'node_type': 'PATHWAY', 'display_name': 'Synthesis of 15-eicosatetraenoic acid derivatives'}}]",0.6666666666666667,a488d35377ed2c6c97ae11aa9597b54f,567d6df65094ec0cef2e7949a4efc6d2,"['The gene ALOX15B is known to act within a biological process known as the synthesis of 15-eicosatetraenoic acid derivatives. Meanwhile, the drug known as (2e)-3-(2-oct-1-yn-1-ylphenyl)acrylic acid is seen to target a protein called arachidonate 15-lipoxygenase. Intriguingly, this protein has been evidently revealed as a gene product of both ALOX15 and ALOX15B. Moreover, the ALOX15 gene not only acts within the pathway involving the synthesis of 12-eicosatetraenoic acid derivatives, but also plays a significant role in the biosynthesis of DHA-derived SPMs and E-series 18(R)-resolvins, further revealing its multifaceted functions within the cell.', 'The gene ALOX15B acts within the pathway of synthesis of 15-eicosatetraenoic acid derivatives. Meanwhile, the drug (2e)-3-(2-oct-1-yn-1-ylphenyl)acrylic acid targets arachidonate 15-lipoxygenase, which is a gene product of both ALOX15 and ALOX15B.\n\nThe ALOX15 gene also has essential roles in several other pathways. It is involved in the synthesis of 12-eicosatetraenoic acid derivatives, the biosynthesis of DHA-derived SPMs, and the biosynthesis of E-series 18(R)-resolvins.', 'The gene ALOX15B is involved in the synthesis of 15-eicosatetraenoic acid derivatives. The drug, (2e)-3-(2-oct-1-yn-1-ylphenyl)acrylic acid, has as its target the protein product of this gene known as arachidonate 15-lipoxygenase. This protein is not only a product of ALOX15B, but also of the ALOX15 gene. The role of ALOX15 is quite extensive as it acts within multiple pathways including the synthesis of 12-eicosatetraenoic acid derivatives, the biosynthesis of DHA-derived SPMs, and the biosynthesis of E-series 18(R)-resolvins. This gene-protein-system shows the intricate nature of how genes interact within and are influenced by various biochemical pathways.', 'The gene ALOX15B acts within the synthesis of 15-eicosatetraenoic acid derivatives, while the drug (2e)-3-(2-oct-1-yn-1-ylphenyl)acrylic acid targets arachidonate 15-lipoxygenase. This enzyme is a gene product of both ALOX15B and ALOX15. Furthermore, ALOX15 is active within several pathways including the synthesis of 12-eicosatetraenoic acid derivatives, the biosynthesis of DHA-derived SPMs, and the biosynthesis of E-series 18(R)-resolvins.']","['The compound (2e)-3-(2-oct-1-yn-1-ylphenyl)acrylic acid has a target interaction with arachidonate 15-lipoxygenase. This enzyme is a gene product of ALOX15B. The gene ALOX15 is notable for participating in various biochemical pathways such as the synthesis of 12-eicosatetraenoic acid derivatives and the biosynthesis of E-series 18(R)-resolvins.', 'The compound (2e)-3-(2-oct-1-yn-1-ylphenyl)acrylic acid targets arachidonate 15-lipoxygenase, which is a gene product of ALOX15B. In turn, ALOX15 is involved in several biological pathways. Notably, ALOX15 participates in the synthesis of 12-eicosatetraenoic acid derivatives as well as the biosynthesis of E-series 18(R)-resolvins.', 'The compound known as (2e)-3-(2-oct-1-yn-1-ylphenyl)acrylic acid targets arachidonate 15-lipoxygenase, which is a gene product of ALOX15B. Additionally, ALOX15, which could be confused with ALOX15B, is involved in distinct biological pathways such as the synthesis of 12-eicosatetraenoic acid derivatives and the biosynthesis of E-series 18(R)-resolvins.', 'The compound (2e)-3-(2-oct-1-yn-1-ylphenyl)acrylic acid has a target, which is arachidonate 15-lipoxygenase. Arachidonate 15-lipoxygenase is a gene product of ALOX15B. The gene ALOX15 is involved in various biological pathways such as the synthesis of 12-eicosatetraenoic acid derivatives and it also plays a role in the biosynthesis of E-series 18(R)-resolvins.', 'The molecule known as (2e)-3-(2-oct-1-yn-1-ylphenyl)acrylic acid has a target known as arachidonate 15-lipoxygenase. This macromolecule is a product of the ALOX15B gene. ALOX15, another gene closely related to ALOX15B, acts within several pathways including the synthesis of 12-eicosatetraenoic acid derivatives and the biosynthesis of E-series 18(R)-resolvins.']"
"[{'source_node': {'name': 'glutathione s-transferase a2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GSTA2'}}, {'source_node': {'name': 'GSTA2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glutathione conjugation'}}, {'source_node': {'name': 'GSTA2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Azathioprine ADME'}}]","[{'source_node': {'name': 'glutathione s-transferase a2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GSTA2'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:570', 'target': None, 'metadata': {'node_id': '570', 'node_type': 'PATHWAY', 'display_name': 'Glutathione conjugation'}}, {'type': 'node_removal', 'source': 'PATHWAY:197', 'target': None, 'metadata': {'node_id': '197', 'node_type': 'PATHWAY', 'display_name': 'Azathioprine ADME'}}]",0.4285714285714286,5813d76a9cd6e6df6d574a3c7e8cebd9,de7b5c9e61464db33df3ccf2e6f0337f,"['The protein glutathione s-transferase a2 is a gene product of GSTA2. This particular gene operates within multiple pathways including glutathione conjugation and Azathioprine ADME.', 'Glutathione S-transferase A2 is a gene product of GSTA2. This gene, GSTA2, acts within several chemical processes, namely Glutathione conjugation and Azathioprine ADME.', 'The enzyme glutathione S-transferase A2 is a product of the GSTA2 gene. This gene behaves within two significant pathways: the firstly, glutathione conjugation and secondly, Azathioprine ADME, which is crucial in drug metabolism.', 'Glutathione S-transferase A2 is a gene product of GSTA2, which participates in various pathways, including glutathione conjugation and azathioprine ADME.']","['The enzyme glutathione S-transferase A2 is the gene product of GSTA2.', 'The enzyme glutathione s-transferase a2 is a gene product of GSTA2.']"
"[{'source_node': {'name': 'glutaminase kidney isoform'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GLS'}}, {'source_node': {'name': 'hydroxytoluic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'retinal dehydrogenase 1'}}, {'source_node': {'name': 'hydroxytoluic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'neutrophil collagenase'}}, {'source_node': {'name': 'hydroxytoluic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glutaminase kidney isoform'}}, {'source_node': {'name': 'retinal dehydrogenase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALDH1A1'}}]","[{'source_node': {'name': 'glutaminase kidney isoform'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GLS'}}, {'source_node': {'name': 'neutrophil collagenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GLS'}}, {'source_node': {'name': 'hydroxytoluic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'retinal dehydrogenase 1'}}, {'source_node': {'name': 'hydroxytoluic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'neutrophil collagenase'}}, {'source_node': {'name': 'hydroxytoluic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glutaminase kidney isoform'}}, {'source_node': {'name': 'hydroxytoluic acid'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'ALDH1A1'}}, {'source_node': {'name': 'retinal dehydrogenase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALDH1A1'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:1386', 'target': 'GENE:28162', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'COMPOUND:35477', 'target': 'GENE:26863', 'metadata': {'predicate': 'is_affecting'}}]",0.8181818181818181,c5dbb06b0a7f8254463e829718f2a7f3,efbcf235bf5cc235171e346c4abf2790,"['The compound hydroxytoluic acid exhibits targeted activity against several entities, namely retinal dehydrogenase 1, neutrophil collagenase, and the glutaminase kidney isoform. Interestingly, these targets are gene products of distinct genes. Retinal dehydrogenase 1 is the gene product of ALDH1A1, while the glutaminase kidney isoform is the gene product of GLS.', 'The enzyme called glutaminase kidney isoform is noteworthy for being a gene product of GLS. This enzyme is one of the targets of hydroxytoluic acid, a compound that also targets other proteins, such as retinal dehydrogenase 1 and neutrophil collagenase. Intriguingly, retinal dehydrogenase 1 is a gene product of ALDH1A1, adding to the interconnectedness of these pathways.', 'The substance hydroxytoluic acid has various targets, interacting with retinal dehydrogenase 1, neutrophil collagenase, and glutaminase kidney isoform. The retinal dehydrogenase 1 is a gene product of ALDH1A1, while the glutaminase kidney isoform is a product of the GLS gene.', 'The drug hydroxytoluic acid has multiple targets, including retinal dehydrogenase 1, neutrophil collagenase, and glutaminase kidney isoform. Interestingly, the glutaminase kidney isoform is a gene product of GLS, and retinal dehydrogenase 1 is a gene product of ALDH1A1. This suggests complex underlying biochemistry with these interactions.', 'The drug hydroxytoluic acid targets several entities, including retinal dehydrogenase 1, neutrophil collagenase, and the glutaminase kidney isoform. Interestingly, retinal dehydrogenase 1 is a gene product of ALDH1A1, and the glutaminase kidney isoform is a gene product of GLS.']","['The compound hydroxytoluic acid targets several proteins. These proteins include the glutaminase kidney isoform, neutrophil collagenase and retinal dehydrogenase 1. Both neutrophil collagenase and glutaminase kidney isoform are gene products of GLS, a gene that plays notable roles in our body. In addition, the retinal dehydrogenase 1 is a gene product of ALDH1A1. Notably, hydroxytoluic acid is also affecting ALDH1A1, revealing an intricate interaction network within the cellular system.', 'The drug hydroxytoluic acid has multiple targets including retinal dehydrogenase 1, neutrophil collagenase, and glutaminase kidney isoform. These targets are significant because retinal dehydrogenase 1 and neutrophil collagenase are gene products of ALDH1A1 and GLS respectively and glutaminase kidney isoform is a gene product of GLS. In addition, hydroxytoluic acid is known to affect ALDH1A1, further emphasizing its potential therapeutic applications.', 'The drug hydroxytoluic acid has multiple targets including retinal dehydrogenase 1, neutrophil collagenase, and glutaminase kidney isoform. Retinal dehydrogenase 1 and neutrophil collagenase are gene products of ALDH1A1 and GLS respectively, while glutaminase kidney isoform is a gene product of GLS. In addition, hydroxytoluic acid also affects the activity of ALDH1A1.']"
"[{'source_node': {'name': 'remogliflozin etabonate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'levobetaxolol'}}, {'source_node': {'name': 'remogliflozin etabonate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'phthalylsulfathiazole'}}, {'source_node': {'name': 'remogliflozin etabonate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'mitapivat'}}, {'source_node': {'name': 'phthalylsulfathiazole'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'chlorpropamide'}}, {'source_node': {'name': 'phthalylsulfathiazole'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'anagliptin'}}]","[{'source_node': {'name': 'phthalylsulfathiazole'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'chlorpropamide'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:10809', 'target': None, 'metadata': {'node_id': '10809', 'node_type': 'COMPOUND', 'display_name': 'remogliflozin etabonate'}}, {'type': 'node_removal', 'source': 'COMPOUND:10317', 'target': None, 'metadata': {'node_id': '10317', 'node_type': 'COMPOUND', 'display_name': 'anagliptin'}}]",0.2727272727272727,df64870021c49cb86aac446fd5c8e8e6,554aee461c3bf8c1a0f08fbf6d5b2f15,"['Remogliflozin etabonate is known to increase the efficacy of several drugs including levobetaxolol, phthalylsulfathiazole, and mitapivat. Notably, phthalylsulfathiazole also plays an important role in enhancing the effectiveness of drugs such as chlorpropamide and anagliptin.', 'The medication Remogliflozin Etabonate has been seen to increase the efficacy of several other drugs including Levobetaxolol, Phthalylsulfathiazole, and Mitapivat. Interestingly, Phthalylsulfathiazole also seems to boost the efficiency of both Chlorpropamide and Anagliptin.', 'The drug Remogliflozin Etabonate is known to increase the efficacy of Levobetaxolol, Phthalylsulfathiazole, and Mitapivat. Furthermore, Phthalylsulfathiazole itself also enhances the efficacy of Chlorpropamide and Anagliptin. These interactions could potentially be utilized in the development of more effective combination therapies.', ""Remogliflozin etabonate plays a significant role in enhancing the efficacy of multiple substances, such as levobetaxolol, phthalylsulfathiazole, and mitapivat. Notably, phthalylsulfathiazole, one of remogliflozin etabonate's targets, also has a similar effect by increasing the effectiveness of both chlorpropamide and anagliptin."", 'The drug remogliflozin etabonate has been observed to enhance the efficacy of several other substances such as levobetaxolol, phthalylsulfathiazole and mitapivat. In an analogous manner, phthalylsulfathiazole itself has been noted to increase the effectiveness of chlorpropamide and anagliptin.']","['The drug Phthalylsulfathiazole has been shown to increase the efficacy of Chlorpropamide.', 'The drug phthalylsulfathiazole is known to increase the efficacy of chlorpropamide.', 'The drug phthalylsulfathiazole has been shown to increase the efficacy of chlorpropamide.', 'The drug phthalylsulfathiazole is known to increase the efficacy of another medication called chlorpropamide.', 'The drug phthalylsulfathiazole is known to increase the efficacy of chlorpropamide.']"
"[{'source_node': {'name': 'ALOX12'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of Hepoxilins (HX) and Trioxilins (TrX)'}}, {'source_node': {'name': 'ALOX12'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Biosynthesis of Lipoxins (LX)'}}, {'source_node': {'name': 'ALOX12'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Biosynthesis of DHA-derived SPMs'}}]","[{'source_node': {'name': 'ALOX12'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of Hepoxilins (HX) and Trioxilins (TrX)'}}, {'source_node': {'name': 'ALOX12'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Biosynthesis of Lipoxins (LX)'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1595', 'target': None, 'metadata': {'node_id': '1595', 'node_type': 'PATHWAY', 'display_name': 'Biosynthesis of DHA-derived SPMs'}}]",0.7142857142857143,aa58fb503acd5ee9123acc7c6ec01fac,bb805039bc3f2c7e62f1f396671a6b0d,"['The gene ALOX12 plays a role within several biochemical pathways. It acts within the synthesis of Hepoxilins (HX) and Trioxilins (TrX), Biosynthesis of Lipoxins (LX), and also in the Biosynthesis of DHA-derived SPMs.']",[]
"[{'source_node': {'name': 'nemaline myopathy 11'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'first degree atrioventricular block'}}, {'source_node': {'name': 'nemaline myopathy 11'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'scapular winging'}}, {'source_node': {'name': 'nemaline myopathy 11'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'childhood onset'}}]","[{'source_node': {'name': 'nemaline myopathy 11'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'first degree atrioventricular block'}}, {'source_node': {'name': 'nemaline myopathy 11'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'scapular winging'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:7866', 'target': None, 'metadata': {'node_id': '7866', 'node_type': 'PHENOTYPE', 'display_name': 'childhood onset'}}]",0.7142857142857143,ba9b91aca00f4a7e2e219d9830a86b4f,a59595b0fe4493b7edda7bf9325f52e2,[],"['Nemaline myopathy 11 is a medical condition that exhibits multiple phenotypes including first degree atrioventricular block and scapular winging.', 'Nemaline myopathy 11 is a condition that has certain unique phenotypes. These include a first degree atrioventricular block and scapular winging. These specific phenotypes give us key insights into the physiological outcomes of this muscular disorder.', 'Nemaline myopathy 11, a muscle disorder, manifests various symptoms including a first degree atrioventricular block and scapular winging.', 'Nemaline myopathy 11 is a disorder associated with distinct phenotypes such as first degree atrioventricular block and scapular winging.']"
"[{'source_node': {'name': 'fruticoside a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'smmc-7721'}}, {'source_node': {'name': 'fruticoside a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'fruticoside a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sw480'}}]","[{'source_node': {'name': 'fruticoside a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sw480'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5826', 'target': None, 'metadata': {'node_id': '5826', 'node_type': 'PROTEIN', 'display_name': 'smmc-7721'}}, {'type': 'node_removal', 'source': 'PROTEIN:5851', 'target': None, 'metadata': {'node_id': '5851', 'node_type': 'PROTEIN', 'display_name': 'mcf7'}}]",0.4285714285714286,646245e3d4c5d3aea2efebf96ae4642e,49e4e2c509a169940e3843168f4d0b06,"['The compound Fruticoside A has been identified to target several cell lines, including SMMC-7721, MCF7, and SW480.', 'Fruticoside A is notable for having multiple targets which notably includes SMMC-7721, MCF7 and SW480.', 'The substance Fruticoside A is found to target several cells including SMMC-7721, MCF7, and SW480.', 'Fruticoside A is a compound that has been identified as a target in a range of entities including SMMC-7721, MCF7, and SW480. The designation of Fruticoside A as a target signifies its importance in influencing the functionality of these entities.', 'Fruticoside A is a compound that targets a variety of entities, including SMMC-7721, MCF7, and SW480.']",['The drug Fruticoside A has the cellular line known as SW480 as its target.']
"[{'source_node': {'name': 'guselkumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pev3a'}}, {'source_node': {'name': 'guselkumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rindopepimut'}}, {'source_node': {'name': 'guselkumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nuvaxovid'}}]","[{'source_node': {'name': 'guselkumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pev3a'}}, {'source_node': {'name': 'guselkumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rindopepimut'}}, {'source_node': {'name': 'guselkumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nuvaxovid'}}, {'source_node': {'name': 'rindopepimut'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'guselkumab'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:4989', 'target': 'COMPOUND:9749', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.8571428571428572,45b2efb3b16b1a18a608141b90f7b158,116fd2cfb4d0ff60fe92a35174fbf7b0,"['The drug Guselkumab has been found to decrease the efficacy of several other substances, including PEV3A, Rindopepimut, and Nuvaxovid. This means that the effects of these substances may not be as strong when Guselkumab is present.', 'The medication Guselkumab is known to decrease the efficacy of several other pharmaceuticals, including Pev3a, Rindopepimut, and Nuvaxovid. This is particularly important to consider when prescribing simultaneous treatments, as drug interaction can significantly influence therapeutic outcome.', 'The drug Guselkumab exhibits decreased efficacy when it interacts with Pev3a, Rindopepimut, and Nuvaxovid.', 'The drug Guselkumab has been observed to decrease the efficacy of several substances including Pev3a, Rindopepimut, and Nuvaxovid. Extra caution might be required when these substances are administered concurrently with Guselkumab due to this observed interaction.', 'The drug Guselkumab is known to decrease the efficacy of several other treatments including Pev3a, Rindopepimut, and Nuvaxovid. Therefore, it should be used with caution when patients are also receiving these additional treatments to avoid suboptimal results.']","['The drug Guselkumab has been observed to decrease the efficacy of several other therapeutic agents including Pev3a, Rindopepimut, and Nuvaxovid. Interestingly, it is also been noted that Rindopepimut reciprocally decreases the efficacy of Guselkumab. Therefore, care should be taken when considering drug combinations involving these agents.', ""The drug Guselkumab adversely affects the efficacy of several medical interventions, including Pev3a, Rindopepimut, and Nuvaxovid. Interestingly, it's not a one way effect as Rindopepimut also decreases the efficacy of Guselkumab. This intricate interplay could potentially impact the treatment strategies where these drug dosages need to be carefully controlled."", 'The medication Guselkumab has been observed to decrease the efficacy of several other drugs, including Pev3a, Rindopepimut, and Nuvaxovid. Interestingly, this influence is reciprocal with Rindopepimut, as it also negatively impacts the effectiveness of Guselkumab.', 'The drug Guselkumab is known to decrease the efficacy of several others including Pev3a, Rindopepimut and Nuvaxovid. Interestingly, Rindopepimut also appears to decrease the efficacy of Guselkumab, suggesting a complex interaction between these drugs.', 'The drug Guselkumab is known to decrease the efficacy of multiple substances including Pev3a, Rindopepimut, and Nuvaxovid. Interestingly, Rindopepimut also diminishes the efficacy of Guselkumab in return, suggesting a complex interplay between these substances.']"
"[{'source_node': {'name': 'retinal arteries'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'visual loss'}}, {'source_node': {'name': 'COL4A1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'retinal arteries'}}, {'source_node': {'name': 'COL4A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Extracellular matrix organization'}}, {'source_node': {'name': 'COL4A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Scavenging by Class A Receptors'}}]","[{'source_node': {'name': 'retinal arteries'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'visual loss'}}, {'source_node': {'name': 'COL4A1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'retinal arteries'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1068', 'target': None, 'metadata': {'node_id': '1068', 'node_type': 'PATHWAY', 'display_name': 'Scavenging by Class A Receptors'}}, {'type': 'node_removal', 'source': 'PATHWAY:1118', 'target': None, 'metadata': {'node_id': '1118', 'node_type': 'PATHWAY', 'display_name': 'Extracellular matrix organization'}}]",0.5555555555555556,bb90f6a72d20cf410b7a91de4f46055d,2cd66cdf63c17d23f9626cdb609a2248,"['The gene COL4A1, which plays a vital role in both the Extracellular Matrix Organization and Scavenging by Class A Receptors pathways, is known to cause conditions that afflict the retinal arteries. One such affliction of the retinal arteries is visual loss, representing a key phenotype for these conditions.']","['The gene COL4A1 has been identified as a causative agent for conditions affecting the retinal arteries. Changes to the retinal arteries can lead to a variety of phenotypes, including visual loss.']"
"[{'source_node': {'name': 'fibrinolysin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'triamcinolone'}}, {'source_node': {'name': 'fibrinolysin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rusalatide acetate'}}, {'source_node': {'name': 'fibrinolysin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'anti-inhibitor coagulant complex'}}, {'source_node': {'name': 'anti-inhibitor coagulant complex'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'coagulation factor v'}}, {'source_node': {'name': 'anti-inhibitor coagulant complex'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'streptokinase'}}, {'source_node': {'name': 'anti-inhibitor coagulant complex'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'beraprost'}}, {'source_node': {'name': 'triamcinolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '4-hydroxycoumarin'}}]","[{'source_node': {'name': 'fibrinolysin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'triamcinolone'}}, {'source_node': {'name': 'fibrinolysin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rusalatide acetate'}}, {'source_node': {'name': 'fibrinolysin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': '4-hydroxycoumarin'}}, {'source_node': {'name': 'beraprost'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'coagulation factor v'}}, {'source_node': {'name': 'anti-inhibitor coagulant complex'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'coagulation factor v'}}, {'source_node': {'name': 'anti-inhibitor coagulant complex'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'streptokinase'}}, {'source_node': {'name': 'anti-inhibitor coagulant complex'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'beraprost'}}, {'source_node': {'name': 'triamcinolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '4-hydroxycoumarin'}}, {'source_node': {'name': '4-hydroxycoumarin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'triamcinolone'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:4914', 'target': 'COMPOUND:11018', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:4896', 'target': 'PROTEIN:103', 'metadata': {'predicate': 'has_target'}}, {'type': 'edge_addition', 'source': 'COMPOUND:3214', 'target': 'COMPOUND:606', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:4914', 'target': 'COMPOUND:3214', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7333333333333334,62bfaf2797998e65f91d351a7022aa6f,90c7638edf328bf6e588193536c9641f,[],"[""The enzymatic protein Fibrinolysin has been observed to decrease the efficacy of the drugs Triamcinolone and Rusalatide Acetate. Conversely, Fibrinolysin can increase the efficacy of the anticoagulant 4-Hydroxycoumarin. Further in the context of coagulation pathway, the drug Beraprost and the Anti-inhibitor Coagulant Complex both act upon the same target, namely the Coagulation Factor V. Notably, the Anti-inhibitor Coagulant Complex has been found to decrease the efficacy of both Streptokinase and Beraprost. Looking specifically at Triamcinolone and 4-Hydroxycoumarin, a decrease in Triamcinolone's efficacy has been documented to promote an increase in the effectiveness of 4-Hydroxycoumarin. This seemingly inverse relationship is mirrored when the efficacy of 4-Hydroxycoumarin is increased, leading to a corresponding increase in the effectiveness of Triamcinolone."", 'Fibrinolysin decreases the efficacy of both triamcinolone and rusalatide acetate, but interestingly, it increases the efficacy of 4-hydroxycoumarin. Coincidentally, the drug triamcinolone also causes a decrease in the efficacy of 4-hydroxycoumarin, which means we have a complex relationship between these substances. The anti-inhibitor coagulant complex is another key player in this web of interactions; it targets coagulation factor Va target shared with beraprostand decreases the efficacy of both streptokinase and beraprost. Finally, the molecule 4-hydroxycoumarin shows an increase in efficacy when interacting with triamcinolone, adding yet another layer of complexity to this intricate network of relationships and interactions.']"
"[{'source_node': {'name': 'efalizumab'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the neutropenic activities '}}, {'source_node': {'name': 'efalizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ingn 225'}}, {'source_node': {'name': 'efalizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vi polysaccharide vaccine'}}]","[{'source_node': {'name': 'ingn 225'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'efalizumab'}}, {'source_node': {'name': 'ingn 225'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'typhoid vi polysaccharide vaccine'}}, {'source_node': {'name': 'efalizumab'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the neutropenic activities '}}, {'source_node': {'name': 'efalizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ingn 225'}}, {'source_node': {'name': 'efalizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vi polysaccharide vaccine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:4962', 'target': 'COMPOUND:89', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:4962', 'target': 'COMPOUND:8860', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7142857142857143,de9dc818b8fab5701ea862a076c3f9ea,50ac213e4435a4eafa58e2bb5c911c04,[],[]
"[{'source_node': {'name': 'cytochrome p450 family 3 subfamily a member 5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'discontinuation'}}, {'source_node': {'name': 'cytochrome p450 family 3 subfamily a member 5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'carotid artery diseases'}}, {'source_node': {'name': 's-eddp'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 3 subfamily a member 5'}}, {'source_node': {'name': 's-eddp'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'udp glucuronosyltransferase family 2 member b7'}}, {'source_node': {'name': 's-eddp'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'opioid-related disorders'}}]","[{'source_node': {'name': 'cytochrome p450 family 3 subfamily a member 5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'discontinuation'}}, {'source_node': {'name': 'cytochrome p450 family 3 subfamily a member 5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'carotid artery diseases'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:90699', 'target': 'GENE:4368', 'metadata': None}, {'type': 'node_removal', 'source': 'DISEASE:2320', 'target': None, 'metadata': {'node_id': '2320', 'node_type': 'DISEASE', 'display_name': 'opioid-related disorders'}}, {'type': 'node_removal', 'source': 'COMPOUND:90699', 'target': None, 'metadata': {'node_id': '90699', 'node_type': 'COMPOUND', 'display_name': 's-eddp'}}]",0.4545454545454546,b558518b97155b012b83bb6473540a48,194ce97559c9e226a59fc1a8dc598601,"['The substance S-EDDP is known to affect the protein Cytochrome P450 Family 3 Subfamily A Member 5 and UDP glucuronosyltransferase family 2 member B7. Abnormal function or alterations in the Cytochrome P450 Family 3 Subfamily A Member 5 can cause conditions such as discontinuation and carotid artery diseases. Additionally, S-EDDP is also known to treat opioid-related disorders.', 'The molecule S-EDDP is known to be affecting two proteins: cytochrome p450 family 3 subfamily a member 5 and UDP glucuronosyltransferase family 2 member b7. Interestingly, it turns out that the protein cytochrome p450 family 3 subfamily a member 5 causes some health conditions such as discontinuation and carotid artery diseases. Furthermore, S-EDDP also acts as a substance that treats opioid-related disorders.', 'The compound known as S-EDDP exhibits an interesting web of interactions and effects. Initially, it affects the genetic entity cytochrome p450 family 3 subfamily a member 5, which interestingly enough plays a role in the occurrence of the conditions carotid artery diseases and discontinuation. In addition to this, S-EDDP also influences the function of udp glucuronosyltransferase family 2 member b7. Remarkably, it is also recognized as a substance that can be used in the treatment of opioid-related disorders.', 'The drug S-EDDP is known to affect several enzymes including cytochrome p450 family 3 subfamily a member 5 and UDP glucuronosyltransferase family 2 member b7. An effect on cytochrome p450 family 3 subfamily a member 5 can lead to certain conditions such as discontinuation and carotid artery diseases. Moreover, S-EDDP is recognized for its therapeutic effect in treating opioid-related disorders.']","['The Cytochrome P450 family 3 subfamily A member 5 is known to cause certain conditions, including discontinuation and carotid artery diseases.']"
"[{'source_node': {'name': 'lonazolac'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'debrisoquine'}}, {'source_node': {'name': 'lonazolac'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'xipamide'}}]","[{'source_node': {'name': 'lonazolac'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'debrisoquine'}}, {'source_node': {'name': 'lonazolac'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'xipamide'}}, {'source_node': {'name': 'debrisoquine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'lonazolac'}}, {'source_node': {'name': 'xipamide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'lonazolac'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:11650', 'target': 'COMPOUND:11286', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:4556', 'target': 'COMPOUND:11286', 'metadata': {'predicate': 'increase_efficacy'}}]",0.6,a6e89a69973d31dcbdfef5b226017ece,12a64b1ec4a3bb3007d48d8d651521c6,"['The drug lonazolac is known to decrease the efficacy of both debrisoquine and xipamide. This could potentially interfere with the therapeutic outcomes if these drugs are administered concurrently.', 'The drug Lonazolac has been implicated in decreasing the efficacy of both Debrisoquine and Xipamide. This interaction needs to be closely monitored to prevent potential therapy failure.', 'The drug Lonazolac is known to decrease the efficacy of both Debrisoquine and Xipamide. This interaction might impact the effectiveness of these drugs when used in combination with Lonazolac.', 'The drug Lonazolac is known to decrease the efficacy of both Debrisoquine and Xipamide. This means that the usage of Lonazolac could potentially lead to less effective treatments when used in conjunction with these drugs. Thus, careful consideration should be given when prescribing these drugs together.', 'Lonazolac, a type of medication, is known to decrease the efficacy of other drugs like debrisoquine and xipamide. This means taking lonazolac in conjunction with these drugs may result in a less effective treatment.']","['The drug Lonazolac decreases the efficacy of both Debrisoquine and Xipamide. Intriguingly, when administered alongside Lonazolac, both Debrisoquine and Xipamide have been observed to show an increase in the efficacy of Lonazolac itself, thereby creating a complex interplay of drug interactions.', 'The drug Lonazolac is known to decrease the efficacy of Debrisoquine and Xipamide. Conversely, Debrisoquine and Xipamide have effects that increase the efficacy of Lonazolac. Hence, there is a complicated dynamic between these drugs and their effectiveness can be influenced by each other.', 'Lonazolac, a non-steroidal anti-inflammatory drug, has a unique interaction with both debrisoquine and xipamide, its co-administered drugs. Lonazolac decreases the efficacy of debrisoquine, a potent antihypertensive agent and xipamide, a diuretic used primarily for the treatment of hypertension. Yet, interestingly, both debrisoquine and xipamide reciprocate by increasing the efficacy of lonazolac thereby establishing a trending towards balanced drug activity.', ""The drug lonazolac is known to decrease the efficacy of both debrisoquine and xipamide. However, it's worth noting that debrisoquine and xipamide, when administered, can reciprocally increase the efficacy of lonazolac."", 'Lonazolac, a potent drug, is known to decrease the efficacy of debrisoquine and xipamide. Surprisingly, despite this interaction, both debrisoquine and xipamide in turn are observed to increase the efficacy of lonazolac. This complex interplay suggests a reciprocal relationship among these drugs, potentially influencing their overall therapeutic impact.']"
"[{'source_node': {'name': 'rupatadine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'levonordefrin'}}, {'source_node': {'name': 'rupatadine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'protokylol'}}]","[{'source_node': {'name': 'rupatadine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'protokylol'}}, {'source_node': {'name': 'protokylol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'rupatadine'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:5758', 'target': None, 'metadata': {'node_id': '5758', 'node_type': 'COMPOUND', 'display_name': 'levonordefrin'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5857', 'target': 'COMPOUND:9536', 'metadata': {'predicate': 'increase_efficacy'}}]",0.4,b05c951de01826c6c03b34c7be8d27b8,6bd95afb9801d71d3d5e06943128f7bf,"['The drug rupatadine is known to increase the efficacy of both levonordefrin and protokylol.', 'The drug Rupatadine has been shown to increase the efficacy of both Levonordefrin and Protokylol.', 'Rupatadine, a type of medication, is known to increase the efficacy of other drugs like levonordefrin and protokylol. This ability suggests beneficial synergistic effects when rupatadine is used in conjunction with these drugs.', 'The drug rupatadine is known to increase the efficacy of both levonordefrin and protokylol.', 'The drug Rupatadine is known to increase the efficacy of both Levonordefrin and Protokylol.']","['The drug Rupatadine is known to increase the efficacy of Protokylol. Interestingly, this relationship is reciprocal as Protokylol also enhances the effectiveness of Rupatadine.', 'The drug Rupatadine is known to increase the efficacy of Protokylol, and interestingly, this interaction is reciprocal, as Protokylol also enhances the effectiveness of Rupatadine.', 'The drug Rupatadine is known to increase the efficacy of Protokylol, and interestingly, Protokylol reciprocates by also increasing the efficacy of Rupatadine. This suggests a mutual synergy between the two drugs.', 'The drug Rupatadine has been shown to increase the efficacy of Protokylol, and interestingly, Protokylol also reciprocates this effect, enhancing the effectiveness of Rupatadine.', 'The drug Rupatadine is known to increase the efficacy of Protokylol. Conversely, Protokylol also enhances the effectiveness of Rupatadine, showcasing their synergistic relationship.']"
"[{'source_node': {'name': 'lavendustin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'menin/histone-lysine n-methyltransferase mll'}}, {'source_node': {'name': 'lavendustin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'vitamin d3 receptor'}}, {'source_node': {'name': 'lavendustin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'regulator of g-protein signaling 4'}}, {'source_node': {'name': 'vitamin d3 receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VDR'}}, {'source_node': {'name': 'RGS4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (i) signalling events'}}, {'source_node': {'name': 'RGS4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (z) signalling events'}}, {'source_node': {'name': 'regulator of g-protein signaling 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RGS4'}}]","[{'source_node': {'name': 'menin/histone-lysine n-methyltransferase mll'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RGS4'}}, {'source_node': {'name': 'lavendustin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'menin/histone-lysine n-methyltransferase mll'}}, {'source_node': {'name': 'lavendustin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'vitamin d3 receptor'}}, {'source_node': {'name': 'lavendustin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'regulator of g-protein signaling 4'}}, {'source_node': {'name': 'lavendustin b'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'VDR'}}, {'source_node': {'name': 'vitamin d3 receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VDR'}}, {'source_node': {'name': 'RGS4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (i) signalling events'}}, {'source_node': {'name': 'RGS4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (z) signalling events'}}, {'source_node': {'name': 'VDR'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (i) signalling events'}}, {'source_node': {'name': 'VDR'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (z) signalling events'}}, {'source_node': {'name': 'regulator of g-protein signaling 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RGS4'}}]","[{'type': 'edge_addition', 'source': 'GENE:33504', 'target': 'PATHWAY:109', 'metadata': {'predicate': 'acts_within'}}, {'type': 'edge_addition', 'source': 'PROTEIN:6378', 'target': 'GENE:32308', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'GENE:33504', 'target': 'PATHWAY:535', 'metadata': {'predicate': 'acts_within'}}, {'type': 'edge_addition', 'source': 'COMPOUND:13831', 'target': 'GENE:33504', 'metadata': {'predicate': 'is_affecting'}}]",0.7333333333333334,afb17c64e313c2657225a880017b4c57,32ee3ff988063ab113e07aa493d3a046,"['The compound lavendustin b is known to target a variety of molecules. These include the menin/histone-lysine n-methyltransferase mll, the vitamin d3 receptor, and the regulator of g-protein signaling 4. The vitamin D3 receptor is a gene product of a gene known as VDR. On the other hand, the regulator of g-protein signaling 4 is a gene product of the RGS4 gene, which actively engages within the G alpha (i) signalling events and G alpha (z) signalling events.', ""The drug Lavendustin B has several targets, including the Menin/Histone-lysine N-methyltransferase MLL, Vitamin D3 receptor, and the Regulator of G-protein signaling 4. It's noted that the Vitamin D3 receptor is a gene product of VDR. Furthermore, the Regulator of G-protein signaling 4, which is also a target of Lavendustin B, is the gene product of RGS4. RGS4 is actively involved in various signaling events, specifically the G alpha (i) and the G alpha (z) signaling events.""]",[]
"[{'source_node': {'name': 'potassium citrate'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the diuretic activities '}}, {'source_node': {'name': 'potassium citrate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'demeclocycline'}}, {'source_node': {'name': 'potassium citrate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dihydrocodeine'}}]","[{'source_node': {'name': 'demeclocycline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'potassium citrate'}}, {'source_node': {'name': 'dihydrocodeine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'potassium citrate'}}, {'source_node': {'name': 'potassium citrate'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the diuretic activities '}}, {'source_node': {'name': 'potassium citrate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'demeclocycline'}}, {'source_node': {'name': 'potassium citrate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dihydrocodeine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:604', 'target': 'COMPOUND:8065', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1481', 'target': 'COMPOUND:8065', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7142857142857143,38743d7d59ba431a26a5fe0e16d6d0c3,8d7aec33d0abde0b3a7459c29d431765,[],[]
"[{'source_node': {'name': 'sulfameter'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'mitiglinide'}}, {'source_node': {'name': 'sulfameter'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'aica ribonucleotide'}}, {'source_node': {'name': 'sulfameter'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vaccine'}}]","[{'source_node': {'name': 'sulfameter'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'mitiglinide'}}, {'source_node': {'name': 'sulfameter'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'aica ribonucleotide'}}, {'source_node': {'name': 'sulfameter'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vaccine'}}, {'source_node': {'name': 'typhoid vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'aica ribonucleotide'}}, {'source_node': {'name': 'typhoid vaccine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'mitiglinide'}}, {'source_node': {'name': 'typhoid vaccine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'sulfameter'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:11858', 'target': 'COMPOUND:1620', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11858', 'target': 'COMPOUND:1232', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11858', 'target': 'COMPOUND:5863', 'metadata': {'predicate': 'increase_efficacy'}}]",0.5714285714285714,72955716bfda04b8f62efe250da3f6f7,8058ffd6613866703b016e9fd0035cea,"['The drug sulfameter is known to increase the efficacy of mitiglinide and aica ribonucleotide. However, it should be noted that sulfameter may decrease the efficacy of the typhoid vaccine.', 'The drug sulfameter is reported to increase the efficacy of both mitiglinide and AICA ribonucleotide. However, its usage has been demonstrated to decrease the efficacy of the typhoid vaccine.', 'The drug Sulfameter has been found to increase the efficacy of both Mitiglinide and the AICA ribonucleotide. Interestingly, Sulfameter appears to decrease the efficacy of the Typhoid vaccine.', 'The medication sulfameter has been shown to enhance the efficacy of both mitiglinide and AICA ribonucleotide. However, its important to note that the same medication, sulfameter, is found to notably decrease the efficacy of the typhoid vaccine.\n', ""The drug Sulfameter is known to increase the efficacy of both Mitiglinide and AICA Ribonucleotide. However, it's important to note that Sulfameter can decrease the efficacy of the Typhoid Vaccine.""]","['The drug Sulfameter is known to increase the efficacy of both Mitiglinide and AICA ribonucleotide. However, it is also noted to decrease the efficacy of the Typhoid vaccine. On the other hand, the Typhoid vaccine itself has a complex role in this network of interactions. It decreases the efficacy of AICA ribonucleotide, and paradoxically, it also enhances the efficacy of Sulfameter, the drug which decreases its own efficacy. Furthermore, the Typhoid vaccine elevates the effectiveness of Mitiglinide.', 'The drug Sulfameter is known to increase the efficacy of both Mitiglinide and AICA ribonucleotide. However, it seems to decrease the efficacy of the Typhoid Vaccine. Interestingly, the Typhoid Vaccine has a reciprocal impact on these substances as well. It increases the efficacy of Sulfameter and Mitiglinide but significantly decreases the efficacy of AICA ribonucleotide. Further research is needed to understand this complex web of drug interactions.', 'The drug Sulfameter has demonstrated to increase the efficacy of both Mitiglinide and AICA Ribonucleotide, thereby enhancing their therapeutic effectiveness. However, it is important to note that Sulfameter tends to decrease the efficacy of the Typhoid Vaccine, which in turn also reduces the efficacy of AICA Ribonucleotide. Interestingly, the efficacy of Mitiglinide and Sulfameter is increased when combined with the Typhoid Vaccine. These complex interactions highlight the intricate ways in which drug efficacy can be modulated and the need for a comprehensive understanding when considering drug combinations.', 'Sulfameter is known to increase the efficacy of other medications, namely mitiglinide and aica ribonucleotide. However, while sulfameter can enhance the effects of aica ribonucleotide, typhoid vaccine surprisingly exhibits the opposite effect, decreasing the efficacy of aica ribonucleotide. On the other hand, sulfameter decreases the efficacy of typhoid vaccine. Intriguingly, the typhoid vaccine can both decrease and increase efficacy in various situations: while it enhances the effects of sulfameter and mitiglinide, it decreases the efficacy of aica ribonucleotide. The complex interactions of these compounds underscore the intricate nature of drug interactions and their impacts on efficacy.', 'Sulfameter, a drug which is typically used as an antibiotic or antimalarial, has been found to increase the efficacy of both mitiglinide, a drug used to treat diabetes, and AICA ribonucleotide, a compound involved in cellular metabolism. However, it is worth noting that sulfameter also decreases the efficacy of the typhoid vaccine, an important consideration for those traveling to regions where typhoid is prevalent. Intriguingly, this relationship is reciprocal, as the typhoid vaccine also decreases the efficacy of the AICA ribonucleotide but increases the efficacy of mitiglinide and sulfameter. This unique interplay between drugs has potential implications for disease management and drug dosage considerations.']"
"[{'source_node': {'name': 'warburg micro syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'seizure'}}, {'source_node': {'name': 'TBC1D20'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'warburg micro syndrome 4'}}, {'source_node': {'name': 'TBC1D20'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'warburg micro syndrome 1'}}, {'source_node': {'name': 'TBC1D20'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'COPII-mediated vesicle transport'}}]","[{'source_node': {'name': 'warburg micro syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'seizure'}}, {'source_node': {'name': 'TBC1D20'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'warburg micro syndrome 4'}}, {'source_node': {'name': 'TBC1D20'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'warburg micro syndrome 1'}}, {'source_node': {'name': 'TBC1D20'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'COPII-mediated vesicle transport'}}, {'source_node': {'name': 'warburg micro syndrome 4'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'seizure'}}]","[{'type': 'edge_addition', 'source': 'DISEASE:15967', 'target': 'PHENOTYPE:951', 'metadata': {'predicate': 'has_phenotype'}}]",0.8888888888888888,d0fc9349ecbd966e8bf4137fca638e7f,4a880a1b8e951cb5c5191b21506c1585,"['The gene TBC1D20, which acts within the COPII-mediated vesicle transport pathway, is linked to several conditions, specifically Warburg Micro Syndrome 1 and 4. Warburg Micro Syndrome 1 is known to have seizures as a phenotype. Therefore, a malfunction in the TBC1D20 gene can potentially indirectly cause seizures.', 'The gene TBC1D20, which is a key participant in the COPII-mediated vesicle transport process, is associated with triggering numerous conditions, one of them being Warburg Micro Syndrome 1, a disease that manifests a symptom of seizures. In addition to causing Warburg Micro Syndrome 1, the TBC1D20 gene also brings about Warburg Micro Syndrome 4.', 'The gene TBC1D20, which is actively involved in the COPII-mediated vesicle transport, is responsible for causing both warburg micro syndrome 4 and warburg micro syndrome 1. Interestingly, warburg micro syndrome 1 is notably characterized by the presence of seizures as a major phenotypic manifestation.', 'The gene TBC1D20 has a unique role as it acts within the COPII-mediated vesicle transport process. It is known to cause several conditions, including Warburg Micro Syndrome 4 and Warburg Micro Syndrome 1. Interestingly, Warburg Micro Syndrome 1 exhibits the phenotype of seizures.', 'The gene TBC1D20, which acts within the COPII-mediated vesicle transport pathway, is known to cause two conditions: Warburg Micro Syndrome 1 and Warburg Micro Syndrome 4. Notably, Warburg Micro Syndrome 1 is characterized by the presence of seizures.']","['The gene TBC1D20, which is involved in the COPII-mediated vesicle transport pathway, is linked to the causation of two conditions - Warburg micro syndrome 1 and Warburg micro syndrome 4. Notably, both these conditions present the symptom of seizures.', 'The gene TBC1D20, which acts within the COPII-mediated vesicle transport pathway, is associated with causing both Warburg Micro Syndrome 1 and Warburg Micro Syndrome 4. Notably, both of these conditions exhibit the phenotype of seizures.', 'The gene TBC1D20, which is instrumental within the COPII-mediated vesicle transport pathway, leads to both warburg micro syndrome 1 and warburg micro syndrome 4. These conditions manifest with distinct phenotypes which include seizures amongst other symptoms.', 'The gene TBC1D20, which functions within the pathway of COPII-mediated vesicle transport, is known to cause two specific medical conditions: Warburg Micro Syndrome 1 and Warburg Micro Syndrome 4. Interestingly, both these syndromes share a common phenotype, characterized by the occurrence of seizures.', 'The gene TBC1D20, which acts within the COPII-mediated vesicle transport pathway, has been discovered as the root cause of two conditions namely Warburg micro syndrome 1 and Warburg micro syndrome 4. It has been observed that both Warburg micro syndrome 1 and Warburg micro syndrome 4 result in similar phenotypes such as seizures.']"
"[{'source_node': {'name': 'POLI'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Translesion synthesis by POLI'}}, {'source_node': {'name': 'dna polymerase iota'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'POLI'}}, {'source_node': {'name': 'cinchonidine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepg2'}}, {'source_node': {'name': 'cinchonidine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna polymerase iota'}}, {'source_node': {'name': 'cinchonidine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'wi-38'}}]","[{'source_node': {'name': 'POLI'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Translesion synthesis by POLI'}}, {'source_node': {'name': 'wi-38'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'POLI'}}, {'source_node': {'name': 'dna polymerase iota'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'POLI'}}, {'source_node': {'name': 'cinchonidine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna polymerase iota'}}, {'source_node': {'name': 'cinchonidine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'wi-38'}}, {'source_node': {'name': 'cinchonidine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'POLI'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5817', 'target': None, 'metadata': {'node_id': '5817', 'node_type': 'PROTEIN', 'display_name': 'hepg2'}}, {'type': 'edge_addition', 'source': 'COMPOUND:13864', 'target': 'GENE:25358', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:4974', 'target': 'GENE:25358', 'metadata': {'predicate': 'gene_product_of'}}]",0.6363636363636364,1938c3d2b4e4fc54e0fce53c22c73082,56ab18e4ac2a62a658f528ac895b951a,[],"['The gene POLI is a key player in the process of Translesion synthesis by POLI, further, the entities Wi-38 and DNA polymerase iota are gene products of POLI. The substance cinchonidine specifically targets both Wi-38 and DNA polymerase iota and also directly affects the functioning of POLI.']"
"[{'source_node': {'name': 'GLP1R'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (s) signalling events'}}, {'source_node': {'name': 'GLP1R'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glucagon-type ligand receptors'}}, {'source_node': {'name': 'geminin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GMNN'}}, {'source_node': {'name': 'glucagon-like peptide 1 receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GLP1R'}}, {'source_node': {'name': 'arteannuin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'geminin'}}, {'source_node': {'name': 'arteannuin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ataxin-2'}}, {'source_node': {'name': 'arteannuin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucagon-like peptide 1 receptor'}}]","[{'source_node': {'name': 'GLP1R'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glucagon-type ligand receptors'}}, {'source_node': {'name': 'geminin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GMNN'}}, {'source_node': {'name': 'geminin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GLP1R'}}, {'source_node': {'name': 'glucagon-like peptide 1 receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GLP1R'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:424', 'target': None, 'metadata': {'node_id': '424', 'node_type': 'PATHWAY', 'display_name': 'G alpha (s) signalling events'}}, {'type': 'node_removal', 'source': 'COMPOUND:83048', 'target': None, 'metadata': {'node_id': '83048', 'node_type': 'COMPOUND', 'display_name': 'arteannuin b'}}, {'type': 'edge_addition', 'source': 'PROTEIN:5869', 'target': 'GENE:28155', 'metadata': {'predicate': 'gene_product_of'}}]",0.4666666666666667,90a97c4c0f9d13f68f85a46f80dbc675,780ee34fa89c85f505ed4448c0db7cbe,"['The gene product of GLP1R, known as glucagon-like peptide 1 receptor, is targeted by the drug arteannuin b. Moreover, GLP1R is involved in cellular pathways such as G alpha (s) signalling events and also part of the group classified as Glucagon-type ligand receptors. It is noteworthy that arteannuin b also targets other proteins, such as geminin and ataxin-2. Geminin is a gene product of the gene GMNN.']",[]
"[{'source_node': {'name': 'cra_10972'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'trypsin-1'}}, {'source_node': {'name': 'trypsin-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PRSS1'}}, {'source_node': {'name': 'PRSS1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Activation of Matrix Metalloproteinases'}}, {'source_node': {'name': 'PRSS1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Uptake of dietary cobalamins into enterocytes'}}]","[{'source_node': {'name': 'cra_10972'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'trypsin-1'}}]","[{'type': 'node_removal', 'source': 'GENE:31747', 'target': None, 'metadata': {'node_id': '31747', 'node_type': 'GENE', 'display_name': 'PRSS1'}}]",0.3333333333333333,f6a77da929c65df4b949f4f1f89b4c94,8c37e824a7f47f437c8a521b29adf65b,"['The compound cra_10972 targets trypsin-1, which is a gene product of PRSS1. PRSS1 functions within several pathways, specifically within the Activation of Matrix Metalloproteinases pathway, and the Uptake of dietary cobalamins into enterocytes.', 'The compound Cra_10972 targets Trypsin-1, which is a gene product of PRSS1. PRSS1 plays important roles in multiple biological pathways such as the Activation of Matrix Metalloproteinases, as well as the process of Uptake of Dietary Cobalamins into Enterocytes.', 'Cra_10972, an entity of interest, targets trypsin-1. Trypsin-1 is a gene product of PRSS1, a gene that is vital to certain processes within the body, as it acts within many biochemical pathways, such as the activation of matrix metalloproteinases and the uptake of dietary cobalamins into enterocytes. This illustrates how genes, their products, and their actions within cellular processes can create complex, interconnected biological networks.', 'The compound cra_10972 has a target, trypsin-1, which is the gene product of PRSS1. PRSS1 acts within two important pathways, namely the activation of matrix metalloproteinases and the uptake of dietary cobalamins into enterocytes.', 'The compound cra_10972 has trypsin-1 as its target. Trypsin-1 is a gene product of PRSS1. Furthermore, PRSS1 is involved in two significant biological processes; it acts within the activation of matrix metalloproteinases pathway, and it also functions in the pathway responsible for the uptake of dietary cobalamins into enterocytes.']",['The compound cra_10972 has trypsin-1 as its target.']
"[{'source_node': {'name': 'azathioprine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pipecuronium'}}, {'source_node': {'name': 'azathioprine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ethyl biscoumacetate'}}, {'source_node': {'name': 'azathioprine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Hepatitis B'}}]","[{'source_node': {'name': 'pipecuronium'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Hepatitis B'}}, {'source_node': {'name': 'azathioprine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pipecuronium'}}, {'source_node': {'name': 'azathioprine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ethyl biscoumacetate'}}, {'source_node': {'name': 'azathioprine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Hepatitis B'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1296', 'target': 'SIDE_EFFECT:1457', 'metadata': {'predicate': 'has_side_effect'}}]",0.8571428571428572,e6d601df0615495a95dfe8d56bca8758,676db73cd4183ef1052ec63a3c97d268,"['The drug azathioprine has been found to decrease the efficacy of both pipecuronium and ethyl biscoumacetate. Furthermore, usage of azathioprine has been associated with the side effect of Hepatitis B.', 'The drug azathioprine is known to decrease the efficacy of both pipecuronium and ethyl biscoumacetate. Furthermore, use of azathioprine also has a reported side effect of Hepatitis B.', 'The drug Azathioprine has been observed to decrease the efficacy of substances like Pipecuronium and Ethyl Biscoumacetate. Furthermore, the usage of Azathioprine also poses a potential side effect, wherein the person may become susceptible to Hepatitis B.', 'The drug Azathioprine has been observed to decrease the efficacy of both Pipecuronium and Ethyl Biscoumacetate. Additionally, the use of Azathioprine might also lead to a side effect such as Hepatitis B.', 'The medication Azathioprine has several interactions and side effects. It decreases the efficacy of both Pipecuronium and Ethyl Biscoumacetate. Furthermore, Hepatitis B has been reported as a possible side effect of Azathioprine.']","['The drug pipecuronium can have a side effect, such as Hepatitis B. Notably, the efficacy of pipecuronium, along with ethyl biscoumacetate, is known to be decreased when used in conjunction with the drug azathioprine. Interestingly, similar to pipecuronium, azathioprine usage can also result in Hepatitis B as a side effect.', 'The drug pipecuronium has been known to cause Hepatitis B as a side effect. Interestingly, the drug azathioprine has been found to decrease the efficacy of pipecuronium. Azathioprine also affects the efficacy of ethyl biscoumacetate, another drug. However, much like pipecuronium, azathioprine itself also has a side effect of potentially causing Hepatitis B. This forms a complex interplay of pharmaceutical effects and side effects.', ""The drug Pipecuronium has been associated with side effects such as Hepatitis B. Additionally, the efficacy of Pipecuronium can be decreased by the administration of Azathioprine. It's worth noting that Azathioprine also decreases the efficacy of Ethyl Biscoumacetate and has its own side effects, including Hepatitis B."", 'The drug pipecuronium, used in medical treatments, has a known side effect, being hepatitis B. However, the efficacy of pipecuronium can be decreased by azathioprine, another pharmaceutical drug. Interestingly, azathioprine not only reduces the efficacy of pipecuronium but also impacts ethyl biscoumacetate in a similar fashion. Furthermore, azathioprine is also associated with hepatitis B as a side effect, a commonality it shares with pipecuronium. Thus, patients receiving any of these medicinal compounds need to be monitored for potential signs of hepatitis B.', 'The drug pipecuronium has been known to have side effects such as Hepatitis B. Interestingly, the drug azathioprine has been shown to decrease the efficacy of pipecuronium. Additionally, azathioprine affects the efficacy of another drug, ethyl biscoumacetate, by reducing its effectiveness. To add further complexity, azathioprine itself may also have side effects, which includes the potential to cause Hepatitis B.']"
"[{'source_node': {'name': 'DEFB125'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Beta defensins'}}, {'source_node': {'name': 'DEFB125'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Defensins'}}]","[{'source_node': {'name': 'DEFB125'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Beta defensins'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:78', 'target': None, 'metadata': {'node_id': '78', 'node_type': 'PATHWAY', 'display_name': 'Defensins'}}]",0.6,3d1930996985173d9cbdc8de11afd812,4407e6b0d5cde1a3d4a4a25e287a8292,"['The gene DEFB125 is known to function within two biological pathways, specifically those known as beta defensins and defensins.', 'The gene DEFB125 operates within both the beta defensins and the broader defensins pathways.']",['The gene DEFB125 plays a role within the pathway of beta defensins.']
"[{'source_node': {'name': 'sodium/glucose cotransporter 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SLC5A1'}}, {'source_node': {'name': 'sodium/glucose cotransporter 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SLC5A2'}}, {'source_node': {'name': 'SLC5A1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'glucose/galactose malabsorption'}}, {'source_node': {'name': 'alstiphyllanine b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}, {'source_node': {'name': 'alstiphyllanine b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sodium/glucose cotransporter 1'}}, {'source_node': {'name': 'alstiphyllanine b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sodium/glucose cotransporter 2'}}]","[{'source_node': {'name': 'sodium/glucose cotransporter 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SLC5A1'}}]","[{'type': 'node_removal', 'source': 'DISEASE:10606', 'target': None, 'metadata': {'node_id': '10606', 'node_type': 'DISEASE', 'display_name': 'glucose/galactose malabsorption'}}, {'type': 'edge_addition', 'source': 'PROTEIN:4994', 'target': 'GENE:32847', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'GENE:32847', 'target': None, 'metadata': {'node_id': '32847', 'node_type': 'GENE', 'display_name': 'SLC5A2'}}, {'type': 'node_removal', 'source': 'PROTEIN:4994', 'target': None, 'metadata': {'node_id': '4994', 'node_type': 'PROTEIN', 'display_name': 'hela'}}, {'type': 'node_removal', 'source': 'COMPOUND:72351', 'target': None, 'metadata': {'node_id': '72351', 'node_type': 'COMPOUND', 'display_name': 'alstiphyllanine b'}}]",0.2307692307692307,00feaf173039eb00863ed0725e1c4982,21e55a32d909b559a3662defc2980594,[],[]
"[{'source_node': {'name': 'citropten'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histone acetyltransferase kat2a'}}, {'source_node': {'name': 'citropten'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'atpase family aaa domain-containing protein 5'}}, {'source_node': {'name': 'citropten'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sphingomyelin phosphodiesterase'}}, {'source_node': {'name': 'KAT2A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'HATs acetylate histones'}}, {'source_node': {'name': 'sphingomyelin phosphodiesterase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SMPD1'}}, {'source_node': {'name': 'histone acetyltransferase kat2a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KAT2A'}}]","[{'source_node': {'name': 'citropten'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histone acetyltransferase kat2a'}}, {'source_node': {'name': 'citropten'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'atpase family aaa domain-containing protein 5'}}, {'source_node': {'name': 'citropten'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'KAT2A'}}, {'source_node': {'name': 'KAT2A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'HATs acetylate histones'}}, {'source_node': {'name': 'sphingomyelin phosphodiesterase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SMPD1'}}, {'source_node': {'name': 'sphingomyelin phosphodiesterase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KAT2A'}}, {'source_node': {'name': 'histone acetyltransferase kat2a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KAT2A'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:1093', 'target': 'GENE:27912', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:51700', 'target': 'PROTEIN:1093', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:51700', 'target': 'GENE:27912', 'metadata': {'predicate': 'is_affecting'}}]",0.7692307692307692,ac18c32e8b69b82e974b965f24fe6c22,9cc2e80fe9966e0a2ca983753efb1347,[],[]
"[{'source_node': {'name': 'acetyl-coa acetyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACAT2'}}, {'source_node': {'name': 'acetyl-coa acetyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACAT1'}}, {'source_node': {'name': 'ACAT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Utilization of Ketone Bodies'}}, {'source_node': {'name': 'pantothenyl-aminoethanol-acetate pivalic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'acetyl-coa acetyltransferase'}}, {'source_node': {'name': 'ACAT2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'acetyl-coa acetyltransferase-2 deficiency'}}, {'source_node': {'name': 'ACAT2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cholesterol biosynthesis'}}]","[{'source_node': {'name': 'ACAT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Utilization of Ketone Bodies'}}, {'source_node': {'name': 'ACAT2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'acetyl-coa acetyltransferase-2 deficiency'}}, {'source_node': {'name': 'ACAT2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cholesterol biosynthesis'}}]","[{'type': 'edge_deletion', 'source': 'PROTEIN:1407', 'target': 'GENE:29578', 'metadata': None}, {'type': 'node_removal', 'source': 'PROTEIN:1407', 'target': None, 'metadata': {'node_id': '1407', 'node_type': 'PROTEIN', 'display_name': 'acetyl-coa acetyltransferase'}}]",0.6153846153846154,746369224791629fa8841aeeb8592d7a,635bb26def1c72bd63b349bec5246ab1,[],"['The ACAT1 gene operates within the pathway for the utilization of ketone bodies. On the other hand, ACAT2 not only contributes to cholesterol biosynthesis but it can also cause a medical condition known as acetyl-CoA acetyltransferase-2 deficiency.', 'The gene ACAT1 acts within the pathway of ketone bodies utilization. Another gene, ACAT2, not only operates within the cholesterol biosynthesis pathway, but it also causes a condition known as acetyl-coa acetyltransferase-2 deficiency.', 'The genes ACAT1 and ACAT2 function within specific biochemical reactions and cause certain conditions. To be precise, ACAT1 operates within the pathway for the utilization of ketone bodies. On the other hand, ACAT2 acts within cholesterol biosynthesis and contributes to a rare condition known as acetyl-CoA acetyltransferase-2 deficiency.', 'ACAT1 is a gene that acts within the pathway for the utilization of ketone bodies. Another gene, ACAT2, is known for two key roles. Firstly, it can cause a medical condition known as acetyl-CoA acetyltransferase-2 deficiency. Secondly, it acts within the pathway responsible for cholesterol biosynthesis.', 'The gene ACAT1 is found to act within the pathway of ketone bodies utilization. On the other hand, ACAT2 is involved in the process of cholesterol biosynthesis and its abnormal activity is known to cause a condition called acetyl-CoA acetyltransferase-2 deficiency.']"
"[{'source_node': {'name': 'epanolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'acarbose'}}, {'source_node': {'name': 'epanolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'tolbutamide'}}, {'source_node': {'name': 'calnexin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CANX'}}, {'source_node': {'name': 'metoprolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'isometheptene'}}, {'source_node': {'name': 'metoprolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'insulin degludec'}}, {'source_node': {'name': 'calcium phosphate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'calnexin'}}, {'source_node': {'name': 'calcium phosphate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'metoprolol'}}, {'source_node': {'name': 'calcium phosphate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'epanolol'}}]","[{'source_node': {'name': 'epanolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'acarbose'}}, {'source_node': {'name': 'epanolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'isometheptene'}}, {'source_node': {'name': 'epanolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'insulin degludec'}}, {'source_node': {'name': 'calnexin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CANX'}}, {'source_node': {'name': 'metoprolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'isometheptene'}}, {'source_node': {'name': 'metoprolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'insulin degludec'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:9324', 'target': 'COMPOUND:254', 'metadata': None}, {'type': 'edge_deletion', 'source': 'COMPOUND:9324', 'target': 'COMPOUND:11604', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:1104', 'target': None, 'metadata': {'node_id': '1104', 'node_type': 'COMPOUND', 'display_name': 'tolbutamide'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11604', 'target': 'COMPOUND:5757', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:9324', 'target': None, 'metadata': {'node_id': '9324', 'node_type': 'COMPOUND', 'display_name': 'calcium phosphate'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11604', 'target': 'COMPOUND:8388', 'metadata': {'predicate': 'increase_efficacy'}}]",0.5294117647058824,f32917b1741caa0cc63c541cd02fb0d6,cc51b206897822199d61098221d6c11f,"[""Epanolol, a type of drug, is known to increase the efficacy of both Acarbose and Tolbutamide. Meanwhile, a protein called Calnexin is part of the gene product of CANX. Additionally, Metoprolol, another drug, can decrease the efficiency of Isometheptene but it demonstrates to increase the efficacy of Insulin Degludec. Conversely, Calcium Phosphate targets Calnexin but alarmingly decreases the efficacy of both Metoprolol and Epanolol. It's crucial to keep these interactions in mind while prescribing these drugs."", 'Epanolol is a drug that increases the efficacy of both acarbose and tolbutamide. On the other hand, calcium phosphate decreases the efficacy of epanolol and has a target in the protein calnexin. Calnexin is a gene product of CANX. Calcium phosphate also decreases the efficacy of metoprolol. Despite this, metoprolol increases the efficacy of insulin degludec but reduces the efficacy of isometheptene. These interlinked actions reflect the complex drug interactions in medical treatments.', 'The drug epanolol increases the efficacy of both acarbose and tolbutamide. Importantly, calcium phosphate targets calnexin, a gene product of CANX, and constrains the efficacy of epanolol and metoprolol, indicating its modulatory role on their function. On the other hand, metoprolol not only exhibits decreased effectiveness in the presence of calcium phosphate and isometheptene, but its efficacy also increases when interacting with insulin degludec. This complex interplay presents a need for careful drug management in therapeutic regimens.', 'Epanolol, a pharmacological substance, is known to increase the efficacy of medications such as acarbose and tolbutamide. In contrast, metoprolol, another drug, plays a role in both decreasing and increasing the efficacy of certain medications. While it reduces the efficacy of isometheptene, it enhances the effectiveness of insulin degludec. \n\nOn another note, calcium phosphate, a common compound, has been identified to target calnexin, a protein that is a gene product of a gene known as CANX. However, calcium phosphate also possesses the ability to decrease the efficacy of certain medications, including metoprolol and epanolol. Thus, understanding the interplay of these substances will give us better insight into their roles in medical applications.']","[""The drug Epanolol is noted to increase the efficacy of several other drugs, namely Acarbose, Isometheptene and Insulin Degludec. Similarly, Metoprolol is also found to increase the efficacy of Insulin Degludec, whilst decreasing that of Isometheptene. It's interesting to note that Calnexin is the gene product of CANX, providing another layer of information on biological interactions."", 'The drug epanolol has been observed to increase the efficacy of several other drugs such as acarbose, isometheptene, and insulin degludec, thereby enhancing their therapeutic effectiveness. However, another drug called metoprolol shows a contrasting effect. It has been reported to decrease the efficacy of isometheptene while simultaneously increasing the efficacy of insulin degludec. On the other hand, calnexin, a protein, is identified as a gene product of a gene symbol, named CANX.', 'The use of the drug Epanolol has been found to increase the efficacy of several other medications, including Acarbose, Isometheptene, and Insulin Degludec. However, it is important to note that the drug Metoprolol, while it does enhance the effectiveness of Insulin Degludec, has been found to decrease the efficacy of Isometheptene. On a different note, Calnexin is identified as a gene product of CANX.', ""The drug Epanolol is known to increase the efficiency of several other drugs such as Acarbose, Isometheptene and Insulin Degludec. On the other hand, Metoprolol, another drug, tends to decrease the efficacy of Isometheptene but interestingly, it increases the efficacy of Insulin Degludec. Adding to this understanding, it's useful to note that Calnexin, a protein complex, is actually a gene product of CANX."", 'The drug Epanolol is known to increase the efficacy of several other substances, namely Acarbose, Isometheptene, and Insulin Degludec. Interestingly, Metoprolol, another drug, is found to increase the efficacy of Insulin Degludec, yet decreases the efficacy of Isometheptene. On a related note, Calnexin, a molecular chaperone, is identified as a gene product of the gene known as CANX.']"
"[{'source_node': {'name': 'mequitazine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the arrhythmogenic activities '}}, {'source_node': {'name': 'mequitazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hyaluronidase (ovine)'}}, {'source_node': {'name': 'mequitazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pitolisant'}}, {'source_node': {'name': 'pitolisant'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' bradycardia '}}, {'source_node': {'name': 'pitolisant'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pheniramine'}}, {'source_node': {'name': 'hyaluronidase (ovine)'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dimetindene'}}, {'source_node': {'name': 'hyaluronidase (ovine)'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'deptropine'}}, {'source_node': {'name': 'hyaluronidase (ovine)'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'estradiol acetate'}}]","[{'source_node': {'name': 'pheniramine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mequitazine'}}, {'source_node': {'name': 'pheniramine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pitolisant'}}, {'source_node': {'name': 'mequitazine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the arrhythmogenic activities '}}, {'source_node': {'name': 'mequitazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hyaluronidase (ovine)'}}, {'source_node': {'name': 'mequitazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pitolisant'}}, {'source_node': {'name': 'mequitazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'estradiol acetate'}}, {'source_node': {'name': 'pitolisant'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' bradycardia '}}, {'source_node': {'name': 'pitolisant'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pheniramine'}}, {'source_node': {'name': 'pitolisant'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'mequitazine'}}, {'source_node': {'name': 'estradiol acetate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pitolisant'}}, {'source_node': {'name': 'hyaluronidase (ovine)'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dimetindene'}}, {'source_node': {'name': 'hyaluronidase (ovine)'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'deptropine'}}, {'source_node': {'name': 'hyaluronidase (ovine)'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'estradiol acetate'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1547', 'target': 'COMPOUND:1051', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11791', 'target': 'COMPOUND:9561', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1051', 'target': 'COMPOUND:11791', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:9561', 'target': 'COMPOUND:1051', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1547', 'target': 'COMPOUND:9561', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7058823529411764,b55b78ed3c2d14b7be48713311ef8aa6,cf6ea14f21d58a9b7049027fb22f4d7a,[],[]
"[{'source_node': {'name': 'edulirin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lu1'}}, {'source_node': {'name': 'edulirin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lncap'}}, {'source_node': {'name': 'edulirin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'huvec'}}]","[{'source_node': {'name': 'edulirin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lu1'}}, {'source_node': {'name': 'edulirin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'huvec'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5854', 'target': None, 'metadata': {'node_id': '5854', 'node_type': 'PROTEIN', 'display_name': 'lncap'}}]",0.7142857142857143,8acb86040cab5fe1db69efabccf4c0f0,32a9c26ff77b2d24fa969fb9906dc322,"['The compound Edulirin A has several cellular targets, including LU1, LNCaP, and HUVEC.', 'The drug Edulirin A has several notable targets including LU1, LNCaP, and HUVEC.', 'The drug Edulirin A has multiple targets, including LU1, LNCaP, and HUVEC.', 'The chemical compound Edulirin A has several cellular targets, which include the LU1, LNCaP, and HUVEC cells.', 'The compound Edulirin A targets multiple entities including LU1, LNCAP, and HUVEC.']","['The compound Edulirin A has been identified to target both LU1 and HUVEC in its biological activity.', 'The drug Edulirin A is designed with a dual-target nature, homing in on and interacting with LU1 and HUVEC.', 'The compound Edulirin A is known to target both LU1 and HUVEC.', 'The compound Edulirin A targets both LU1 and HUVEC.', 'The compound Edulirin A targets both LU1 and HUVEC.']"
"[{'source_node': {'name': 'GH1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'growth hormone deficiency'}}, {'source_node': {'name': 'GH1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pituitary dwarfism iv'}}, {'source_node': {'name': 'GH1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Growth hormone receptor signaling'}}, {'source_node': {'name': 'pituitary dwarfism iv'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'pituitary dwarfism'}}, {'source_node': {'name': 'pituitary dwarfism iv'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of metabolism/homeostasis'}}, {'source_node': {'name': 'pituitary dwarfism iv'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'growth delay'}}]","[{'source_node': {'name': 'growth hormone deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of metabolism/homeostasis'}}, {'source_node': {'name': 'GH1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'growth hormone deficiency'}}, {'source_node': {'name': 'GH1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pituitary dwarfism iv'}}, {'source_node': {'name': 'pituitary dwarfism iv'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'pituitary dwarfism'}}, {'source_node': {'name': 'pituitary dwarfism iv'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of metabolism/homeostasis'}}, {'source_node': {'name': 'pituitary dwarfism iv'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'growth delay'}}]","[{'type': 'edge_addition', 'source': 'DISEASE:13921', 'target': 'PHENOTYPE:1408', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'node_removal', 'source': 'PATHWAY:1054', 'target': None, 'metadata': {'node_id': '1054', 'node_type': 'PATHWAY', 'display_name': 'Growth hormone receptor signaling'}}]",0.7692307692307692,105b58fdf61df1ea1a830945a3de6806,42b4ad25269062f32d95108158079b5f,[],"['The gene GH1 is responsible for causing two conditions, growth hormone deficiency and pituitary dwarfism IV. These two conditions manifest different phenotypes. Growth hormone deficiency is characterized by an abnormality of metabolism/homeostasis. Pituitary dwarfism IV, on the other hand, is characterized by pituitary dwarfism, growth delay, and abnormalities in metabolism/homeostasis.', 'The gene GH1 plays a significant role in a couple of health conditions. It causes the condition known as growth hormone deficiency, which is associated with an abnormality in metabolism and homeostasis. GH1 also causes a condition known as pituitary dwarfism iv. This condition shows multiple phenotypes such as pituitary dwarfism, abnormality of metabolism/homeostasis, and growth delay.']"
"[{'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR1'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': 'compound 19'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'estrogen receptor alpha'}}, {'source_node': {'name': 'compound 19'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}]","[{'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': 'compound 19'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}, {'source_node': {'name': 'compound 19'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'VHL'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:2471', 'target': 'PROTEIN:943', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:26821', 'target': None, 'metadata': {'node_id': '26821', 'node_type': 'GENE', 'display_name': 'ESR1'}}, {'type': 'edge_addition', 'source': 'COMPOUND:2471', 'target': 'GENE:33509', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:1921', 'target': 'GENE:33509', 'metadata': {'predicate': 'gene_product_of'}}]",0.4444444444444444,a1427dd29a5ad38080d78b543276f8d3,6c435e2dfc2747ceda05e159a0d0727c,"['The drug compound 19 targets two significant entities: estrogen receptor alpha and tyrosine-protein phosphatase non-receptor type 1. Intriguingly, estrogen receptor alpha is the gene product of two specific genes: ESR1 and VHL. This illustrates a multifaceted interaction between drugs and the genetic underpinnings of physiological processes.', 'Estrogen receptor alpha, which is a gene product of both ESR1 and VHL, is targeted by compound 19. This compound also targets another important entity, the tyrosine-protein phosphatase non-receptor type 1.', 'The drug Compound 19 has been identified to target several crucial proteins, such as estrogen receptor alpha and tyrosine-protein phosphatase non-receptor type 1. Notably, estrogen receptor alpha is the gene product of both ESR1 and VHL genes. This intricate network suggests a potentially multifaceted mechanism of action for Compound 19.', 'The drug known as compound 19 targets numerous entities such as the estrogen receptor alpha and the tyrosine-protein phosphatase non-receptor type 1. On the other hand, the estrogen receptor alpha is a gene product of two separate genes: ESR1 and VHL. This shows the interconnected nature of these genes, proteins, and compound 19.', 'The molecule compound 19 targets two proteins, notably the estrogen receptor alpha and the tyrosine-protein phosphatase non-receptor type 1. Interesting to note, estrogen receptor alpha happens to be the gene product of both ESR1 and VHL.']","['The substances estrogen receptor alpha and tyrosine-protein phosphatase non-receptor type 1 are both gene products of the VHL gene. Interestingly, the compound known as Compound 19 has a dual role as it targets the tyrosine-protein phosphatase non-receptor type 1 and also affects the function of the VHL gene itself.', 'Estrogen receptor alpha and tyrosine-protein phosphatase non-receptor type 1 are both gene products of VHL. Compound 19, interestingly, targets tyrosine-protein phosphatase non-receptor type 1 and also affects VHL. This reflects a series of intricate relationships where compound 19 indirectly interacts with the products of VHL gene.', 'Estrogen receptor alpha and tyrosine-protein phosphatase non-receptor type 1 are both gene products of VHL. Interestingly, a substance known as compound 19 has been found to target the tyrosine-protein phosphatase non-receptor type 1. Moreover, compound 19 appears to affect VHL directly.', 'Estrogen receptor alpha and tyrosine-protein phosphatase non-receptor type 1 are both gene products of VHL. Compound 19, on the other hand, targets tyrosine-protein phosphatase non-receptor type 1 specifically and also affects the function of the VHL gene.']"
"[{'source_node': {'name': '45,x/46,xy mixed gonadal dysgenesis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'epispadias'}}, {'source_node': {'name': '45,x/46,xy mixed gonadal dysgenesis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'developmental glaucoma'}}, {'source_node': {'name': '45,x/46,xy mixed gonadal dysgenesis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ovarian serous cystadenoma'}}]","[{'source_node': {'name': '45,x/46,xy mixed gonadal dysgenesis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'developmental glaucoma'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:36', 'target': None, 'metadata': {'node_id': '36', 'node_type': 'PHENOTYPE', 'display_name': 'epispadias'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:9270', 'target': None, 'metadata': {'node_id': '9270', 'node_type': 'PHENOTYPE', 'display_name': 'ovarian serous cystadenoma'}}]",0.4285714285714286,5708f32b25fabc4b96eec4bb35ce90e7,70db673a197f63553e41e17390e0828f,"['The condition known as 45,x/46,xy mixed gonadal dysgenesis presents with several phenotypes such as epispadias, developmental glaucoma, and ovarian serous cystadenoma.', 'The condition known as 45,X/46,XY mixed gonadal dysgenesis displays symptoms including epispadias and developmental glaucoma. Interestingly, it also has the phenotype of ovarian serous cystadenoma.', 'The condition 45,x/46,xy mixed gonadal dysgenesis is associated with several phenotypes including epispadias, developmental glaucoma and ovarian serous cystadenoma.', 'The condition 45,X/46,XY mixed gonadal dysgenesis is associated with several distinctive phenotypes including epispadias, developmental glaucoma, and is characterized by an increased predisposition for developing ovarian serous cystadenoma.', 'The condition known as 45,X/46,XY mixed gonadal dysgenesis manifests certain phenotypes, such as epispadias, developmental glaucoma, and ovarian serous cystadenoma.']","['The condition known as 45,X/46,XY mixed gonadal dysgenesis is associated with certain phenotypic features, among which is developmental glaucoma.']"
"[{'source_node': {'name': 'sulfathiourea'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'saxagliptin'}}, {'source_node': {'name': 'sulfathiourea'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'linagliptin'}}, {'source_node': {'name': 'sulfathiourea'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'remogliflozin etabonate'}}, {'source_node': {'name': 'linagliptin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dipeptidyl peptidase 4'}}, {'source_node': {'name': 'linagliptin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' angioedema '}}, {'source_node': {'name': 'linagliptin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'vorinostat'}}]","[{'source_node': {'name': 'sulfathiourea'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'saxagliptin'}}, {'source_node': {'name': 'sulfathiourea'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'linagliptin'}}, {'source_node': {'name': 'sulfathiourea'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'remogliflozin etabonate'}}, {'source_node': {'name': 'linagliptin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dipeptidyl peptidase 4'}}, {'source_node': {'name': 'linagliptin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' angioedema '}}]","[{'type': 'node_removal', 'source': 'COMPOUND:2407', 'target': None, 'metadata': {'node_id': '2407', 'node_type': 'COMPOUND', 'display_name': 'vorinostat'}}]",0.8461538461538461,8cd530d2980ddac57226ba2e6bbd085f,7f72ae504e1ef3a364b2358722b2c39f,[],[]
"[{'source_node': {'name': 'sengers syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypotonia'}}, {'source_node': {'name': 'sengers syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'developmental cataract'}}, {'source_node': {'name': 'sengers syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'myopia'}}]","[{'source_node': {'name': 'sengers syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypotonia'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:397', 'target': None, 'metadata': {'node_id': '397', 'node_type': 'PHENOTYPE', 'display_name': 'developmental cataract'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:419', 'target': None, 'metadata': {'node_id': '419', 'node_type': 'PHENOTYPE', 'display_name': 'myopia'}}]",0.4285714285714286,dee49aa024ab592686acce8dd07f6354,2cc011e4b3208adeb31b44ca280eba76,"['Sengers syndrome is a condition that has several phenotypical presentations, including hypotonia, which is reduced muscle strength, developmental cataract, an eye condition manifesting in the early stages of life, and myopia, commonly known as near-sightedness.', 'The condition known as Sengers syndrome is characterized by several phenotypes including hypotonia, developmental cataract, and myopia.', 'Sengers syndrome is an ailment prominently recognized for having phenotypes such as hypotonia, developmental cataract, and myopia.', 'Sengers syndrome is a condition characterized by several symptoms. Notably, it exhibits phenotypes such as hypotonia, which refers to decreased muscle tension, myopia or nearsightedness, and developmental cataract, a clouding in the lens of the eye that develops early in life.']",[]
"[{'source_node': {'name': 'KIF12'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'cholestasis'}}, {'source_node': {'name': 'KIF12'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'COPI-dependent Golgi-to-ER retrograde traffic'}}, {'source_node': {'name': 'KIF12'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Kinesins'}}, {'source_node': {'name': 'cholestasis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'fever'}}, {'source_node': {'name': 'cholestasis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'jaundice'}}, {'source_node': {'name': 'cholestasis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'portal hypertension'}}]","[{'source_node': {'name': 'KIF12'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Kinesins'}}, {'source_node': {'name': 'cholestasis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'fever'}}, {'source_node': {'name': 'cholestasis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'portal hypertension'}}]","[{'type': 'edge_deletion', 'source': 'GENE:25433', 'target': 'DISEASE:18159', 'metadata': None}, {'type': 'node_removal', 'source': 'PHENOTYPE:743', 'target': None, 'metadata': {'node_id': '743', 'node_type': 'PHENOTYPE', 'display_name': 'jaundice'}}, {'type': 'node_removal', 'source': 'PATHWAY:126', 'target': None, 'metadata': {'node_id': '126', 'node_type': 'PATHWAY', 'display_name': 'COPI-dependent Golgi-to-ER retrograde traffic'}}]",0.6153846153846154,4477c20741dd35c9a2a9a23c8b2f9745,49f84355f58f2764372a24513556ec65,"['The gene KIF12 has been identified to cause cholestasis, a condition characterized by fever, jaundice, and portal hypertension. This gene acts within two specific pathways: the COPI-dependent Golgi-to-ER retrograde traffic and also within the family of kinesins.', 'The gene KIF12, which is known to act within multiple pathways including the COPI-dependent Golgi-to-ER retrograde traffic and other Kinesins, has been identified as a causal factor for cholestasis. This condition of cholestasis presents several phenotypic characteristics such as fever, jaundice, and portal hypertension.', 'The protein KIF12 plays an important role in the COPI-dependent Golgi-to-ER retrograde traffic as well as in the group of proteins known as Kinesins. This protein is also known to cause a condition named cholestasis. This condition, cholestasis, is associated with certain phenotypes such as fever, jaundice, and portal hypertension.', 'The gene KIF12, which acts within several biological processes such as the COPI-dependent Golgi-to-ER retrograde traffic and a group of proteins known as Kinesins, is known to cause a condition known as cholestasis. Cholestasis is characterized by symptoms including fever, jaundice, and portal hypertension.', 'The gene KIF12, which acts within both the COPI-dependent Golgi-to-ER retrograde traffic pathway and the group of proteins known as kinesins, is known to cause the condition cholestasis. This condition is characterized by symptoms such as fever, jaundice, and portal hypertension.']","['The gene KIF12 functions within the context of kinesins, a family of proteins. Concurrently, cholestasis is a condition that demonstrates several phenotypes such as fever and portal hypertension.', ""The protein KIF12 is known to act within the kinesins, a superfamily of motor proteins. In a different realm of the biological sphere, there's a condition called cholestasis that presents symptoms such as fever and portal hypertension."", 'The gene KIF12 is known to function within the family of motor proteins known as kinesins. In a different context, cholestasis, a liver condition, is identified by several phenotypes including fever and portal hypertension.']"
"[{'source_node': {'name': 'ovarian dysgenesis 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'gonadal dysgenesis'}}, {'source_node': {'name': 'ovarian dysgenesis 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of metabolism/homeostasis'}}, {'source_node': {'name': 'ovarian dysgenesis 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ataxia'}}, {'source_node': {'name': 'spermatogenic failure 2'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormal circulating testosterone concentration'}}, {'source_node': {'name': 'MSH4'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'spermatogenic failure 2'}}, {'source_node': {'name': 'MSH4'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'premature ovarian failure 20'}}, {'source_node': {'name': 'MSH4'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'ovarian dysgenesis 1'}}]","[{'source_node': {'name': 'ovarian dysgenesis 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'gonadal dysgenesis'}}, {'source_node': {'name': 'ovarian dysgenesis 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of metabolism/homeostasis'}}, {'source_node': {'name': 'ovarian dysgenesis 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ataxia'}}, {'source_node': {'name': 'ovarian dysgenesis 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormal circulating testosterone concentration'}}, {'source_node': {'name': 'spermatogenic failure 2'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormal circulating testosterone concentration'}}]","[{'type': 'edge_deletion', 'source': 'GENE:30054', 'target': 'DISEASE:4362', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:30054', 'target': None, 'metadata': {'node_id': '30054', 'node_type': 'GENE', 'display_name': 'MSH4'}}, {'type': 'edge_addition', 'source': 'DISEASE:4362', 'target': 'PHENOTYPE:9383', 'metadata': {'predicate': 'has_phenotype'}}]",0.6,47fd1a3ae8e668f8fe30810ffc3ca7a2,81d09336df51e3b3072093e6d044a490,"['The gene MSH4 is associated with several diseases including spermatogenic failure 2, premature ovarian failure 20, and ovarian dysgenesis 1. Ovarian dysgenesis 1 manifests in a variety of ways including gonadal dysgenesis, an abnormality in metabolism/homeostasis, and ataxia. Furthermore, spermatogenic failure 2 results in an abnormal circulating testosterone concentration.', 'The condition ovarian dysgenesis 1, which has phenotypes including gonadal dysgenesis, abnormalities of metabolism/homeostasis, and ataxia, is caused by the gene MSH4. Also, this gene is responsible for causing another condition known as spermatogenic failure 2, which is phenotypically characterized by abnormal circulating testosterone concentration. Adding to the list of conditions, the MSH4 gene also triggers premature ovarian failure 20. All these disorders showcase the crucial role that MSH4 plays in maintaining normal reproductive and metabolic health.']","['The genetic condition known as ovarian dysgenesis 1 exhibits several phenotypic characteristics including gonadal dysgenesis, abnormalities of metabolism/homeostasis, ataxia, and abnormal circulating testosterone concentration. Another condition, spermatogenic failure 2, also presents with abnormal circulating testosterone concentration as one of its observable traits.', 'The condition ovarian dysgenesis 1 is characterized by several phenotypes including gonadal dysgenesis, an abnormality of metabolism/homeostasis, ataxia, as well as an abnormal circulating testosterone concentration. It is worth noting that spermatogenic failure 2, another condition, also results in an abnormal circulating testosterone concentration.']"
"[{'source_node': {'name': 'cortisone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tacrine'}}, {'source_node': {'name': 'fluorometholone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sipuleucel-t'}}, {'source_node': {'name': 'fluorometholone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rabies immune globulin'}}, {'source_node': {'name': 'fluorometholone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vaccine'}}, {'source_node': {'name': 'ergocalciferol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluorometholone'}}, {'source_node': {'name': 'ergocalciferol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cortisone'}}, {'source_node': {'name': 'ergocalciferol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'u-87 mg'}}]","[{'source_node': {'name': 'cortisone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tacrine'}}, {'source_node': {'name': 'cortisone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'ergocalciferol'}}, {'source_node': {'name': 'fluorometholone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sipuleucel-t'}}, {'source_node': {'name': 'fluorometholone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rabies immune globulin'}}, {'source_node': {'name': 'fluorometholone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vaccine'}}, {'source_node': {'name': 'ergocalciferol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cortisone'}}, {'source_node': {'name': 'ergocalciferol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'u-87 mg'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:144', 'target': 'COMPOUND:314', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:12387', 'target': 'COMPOUND:144', 'metadata': {'predicate': 'increase_efficacy'}}]",0.8666666666666667,2b97a5dc1a89e2065c27e98fa2e94799,6fa998ed5ab5b5063a70cfd2d81f5b09,"[""The drug cortisone does decrease the efficacy of another drug known as tacrine, revealing a potential interaction. Additionally, the drug fluorometholone has been documented to decrease the efficacy of several medications including sipuleucel-t, rabies immune globulin, and typhoid vaccine. Similarly, ergocalciferol, another drug, has been recorded to decrease the efficacy of both fluorometholone and cortisone. It's also interesting to note that ergocalciferol has been found to have a target in u-87 mg, indicating a possible therapeutic application."", ""The drug ergocalciferol has been found to decrease the efficacy of several other drugs like cortisone and fluorometholone. Interestingly, cortisone could potentially reduce the efficacy of tacrine, while, fluorometholone might decrease the efficacy of several drugs and vaccines, including sipuleucel-t, rabies immune globulin, and even the typhoid vaccine. Furthermore, ergocalciferol has a target known as u-87 mg, which may denote another layer of interaction in the drug's mode of action."", 'The drug cortisone has been found to decrease the efficacy of tacrine, while fluorometholone, on the other hand, reduces the efficacy of various therapeutic agents including sipuleucel-t, rabies immune globulin, and typhoid vaccine. Moreover, it has been observed that the drug ergocalciferol can potentially inhibit the efficacy of both cortisone and fluorometholone. Interestingly, ergocalciferol also acts upon a target identified as u-87 mg. Therefore, these drug interactions should be taken into consideration when developing a comprehensive therapeutic regimen.', ""The drug cortisone has been observed to decrease the efficacy of tacrine. Similarly, the use of fluorometholone could potentially decrease the efficacy of several medications including sipuleucel-T, typhoid vaccine, and rabies immune globulin. The vitamin, ergocalciferol, is also known to decrease the efficacy of both cortisone and fluorometholone. Interestingly, ergocalciferol specifically targets U-87 MG, a type of human primary glioblastoma cell line, and may disrupt its activity. Therefore, when weighing a treatment plan, it's essential to consider these medicine interactions to prevent unintended reduced efficacy."", ""The efficacy of various drugs and substances can be reduced by the presence of others. For instance, cortisone decreases the efficacy of tacrine, a disease-modifying antirheumatic drug used to treat Alzheimer's. Similarly, the corticosteroid fluorometholone exhibits a decrease in its efficacy in the presence of several other pharmaceuticals. These include sipuleucel-t, an immunotherapy drug used in certain types of prostate cancer, rabies immune globulin used post-exposure to rabies, and the typhoid vaccine. \n\nAdding another layer to these relationships, the Vitamin D supplement ergocalciferol further diminishes the efficacy of both cortisone and fluorometholone. Interestingly, in addition to these effects, ergocalciferol has a target on a specific brain cancer cell line known as U-87 MG. Therefore, the interactions between these substances and drugs could have significant implications for those taking multiple treatments or those allergic to any of these.""]","['The drug cortisone has been observed to decrease the efficacy of tacrine, but enhance the efficacy of ergocalciferol. Conversely, ergocalciferol may decrease the efficacy of cortisone and has a target in U-87 MG, a well-known human glioma cell line often used in cancer research. On the other hand, fluorometholone, another medication, can potentially diminish the efficacy of sipuleucel-T, rabies immune globulin and the typhoid vaccine. This information highlights the importance of understanding complex drug interactions before defining a treatment plan.', 'The drug cortisone has been found to decrease the efficacy of tacrine while increasing the efficacy of ergocalciferol. On the other hand, ergocalciferol decreases the efficacy of cortisone and targets a cell line named U-87 MG. Another drug, fluorometholone, is also known to decrease the efficacy of several vaccines and treatments, including sipuleucel-t, rabies immune globulin, and the typhoid vaccine.', ""The compounds cortisone and fluorometholone have been observed to decrease the effectiveness of several other substances. Cortisone specifically diminishes the efficacy of tacrine, while simultaneously enhancing the efficacy of ergocalciferol. Conversely, ergocalciferol is known to reduce the efficacy of cortisone, and interestingly has the cell line U-87 MG as a known target.\n\nOn the other hand, fluorometholone decreases the efficacy of sipuleucel-T, rabies immune globulin, and the typhoid vaccine. Thus, it's critical to cautiously interpret these interactions when considering the combined administration of these specific substances in medical treatments."", 'Cortisone, a medication often used to treat a range of conditions such as allergies and arthritis, has been shown to decrease the efficacy of the drug tacrine. On the other hand, it has been found to increase the efficacy of another drug, ergocalciferol. This relationship, however, is not mutual, as ergocalciferol tends to decrease the efficacy of cortisone. Interestingly, ergocalciferol also has a targeted effect on a strain of human cells known as U-87 MG. \n\nIn a similar vein, another drug, fluorometholone, has been observed to decrease the efficacy of several drugs and vaccines. These include sipuleucel-T, a prostate cancer treatment; rabies immune globulin, used in response to potential rabies exposure; and the typhoid vaccine, which protects against typhoid fever. This suggests that the actions of certain medications, such as cortisone and fluorometholone, can have unprecedented effects on the performance of other treatments, highlighting the importance of understanding drug interactions.']"
"[{'source_node': {'name': 'camylofin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'magnesium oxide'}}, {'source_node': {'name': 'camylofin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lactitol'}}, {'source_node': {'name': 'camylofin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'senna leaf'}}]","[{'source_node': {'name': 'camylofin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'magnesium oxide'}}, {'source_node': {'name': 'camylofin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'senna leaf'}}, {'source_node': {'name': 'senna leaf'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'magnesium oxide'}}, {'source_node': {'name': 'senna leaf'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'camylofin'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:10815', 'target': None, 'metadata': {'node_id': '10815', 'node_type': 'COMPOUND', 'display_name': 'lactitol'}}, {'type': 'edge_addition', 'source': 'COMPOUND:13275', 'target': 'COMPOUND:1325', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:13275', 'target': 'COMPOUND:11585', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.4285714285714286,247f6b2e45d566e2f87a20b4787fbd37,d8e5263e572f87fc2ed146ead708170f,"['Camylofin, a well-known medication, can decrease the efficacy of several other substances. It particularly affects the performance of magnesium oxide, lactitol, and senna leaf. The relationships imply that if these substances are used alongside camylofin, they may not perform to their optimal efficiency.', 'Camylofin is a drug that is known to decrease the efficacy of several other substances, including magnesium oxide, lactitol, and senna leaf. This means that the effectiveness of these substances may be reduced when used concurrently with Camylofin.', 'The drug Camylofin is known to decrease the efficacy of several other substances, including Magnesium Oxide, Lactitol, and Senna Leaf. As such, care should be taken when administering these substances concurrently with Camylofin to ensure therapeutic effectiveness.', 'The drug Camylofin is known to decrease the efficacy of several other compounds. It impacts the function of Magnesium Oxide, makes Lactitol less effective and also reduces the beneficial impacts of the Senna Leaf.', ""The drug Camylofin is known to decrease the efficacy of several other substances, namely Magnesium Oxide, Lactitol, and Senna Leaf. It's important to be aware of these interactions when considering the administration of these substances in tandem with Camylofin.""]","['Camylofin is known to decrease the efficacy of both magnesium oxide and senna leaf. Interestingly, senna leaf has been found to both decrease the efficacy of camylofin and increase the efficacy of magnesium oxide. This forms a complex interplay between these drugs, highlighting the importance of careful consideration when they are used in combination.', 'Camylofin, a commonly used drug, has been observed to decrease the efficacy of both magnesium oxide and senna leaf. Intriguingly, senna leaf appears to have a complex interaction with both of these substances. It has been reported to increase the efficacy of magnesium oxide, while at the same time decreasing the efficacy of camylofin. This intricate dynamic of interactions sheds light on the interconnected nature of these substances in our therapeutic arsenal.', 'Camylofin, a well-known drug, has been found to decrease the efficacy of magnesium oxide and senna leaf. Surprisingly, senna leaf plays a dual role in this equation, as it not only increases the efficacy of magnesium oxide, but also decreases the efficacy of Camylofin in a complex interplay of medicinal activity.']"
"[{'source_node': {'name': 'rad52 homolog'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hypertension'}}, {'source_node': {'name': 'rad52 homolog'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'ovarian neoplasms'}}, {'source_node': {'name': 'rad52 homolog'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'essential hypertension'}}, {'source_node': {'name': 'hypertension'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'elevated diastolic blood pressure'}}, {'source_node': {'name': 'hypertension'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'elevated mean arterial pressure'}}, {'source_node': {'name': 'hypertension'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'elevated systolic blood pressure'}}]","[{'source_node': {'name': 'hypertension'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'elevated mean arterial pressure'}}, {'source_node': {'name': 'hypertension'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'elevated systolic blood pressure'}}]","[{'type': 'edge_addition', 'source': 'DISEASE:1069', 'target': 'PHENOTYPE:3470', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'node_removal', 'source': 'DISEASE:2379', 'target': None, 'metadata': {'node_id': '2379', 'node_type': 'DISEASE', 'display_name': 'ovarian neoplasms'}}, {'type': 'edge_deletion', 'source': 'GENE:17041', 'target': 'DISEASE:13810', 'metadata': None}, {'type': 'node_removal', 'source': 'DISEASE:1069', 'target': None, 'metadata': {'node_id': '1069', 'node_type': 'DISEASE', 'display_name': 'essential hypertension'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:3470', 'target': None, 'metadata': {'node_id': '3470', 'node_type': 'PHENOTYPE', 'display_name': 'elevated diastolic blood pressure'}}]",0.3846153846153846,1445d308334dc668b078f6c688cf0022,77be7bc97ad83039a93112ee8f101efd,"['The Rad52 homolog is notable for causing several conditions including hypertension and ovarian neoplasms. Moreover, it is also implicated in causing essential hypertension. Hypertension, a medical condition caused by the Rad52 homolog, manifests phenotypically as elevated diastolic blood pressure, elevated mean arterial pressure, and elevated systolic blood pressure.', 'The rad52 homolog is known to cause several conditions including hypertension, ovarian neoplasms, and essential hypertension. Hypertension, in particular, has multiple phenotypes, such as elevated diastolic blood pressure, elevated systolic blood pressure and the critical condition of elevated mean arterial pressure.', 'The Rad52 homolog gene is known to cause multiple conditions including hypertension, essential hypertension, and ovarian neoplasms. Hypertension, in particular, is characterized by several phenotypes such as elevated diastolic blood pressure, elevated mean arterial pressure, and elevated systolic blood pressure.', 'The rad52 homolog, a gene known for its role in DNA recombination and repair, causes several conditions including hypertension, ovarian neoplasms, and essential hypertension. Hypertension, a condition resulting from the rad52 homolog, is characterized by phenotypes such as elevated diastolic blood pressure, elevated mean arterial pressure, and elevated systolic blood pressure.']","['Hypertension, a medical condition, manifests multiple phenotypes including an elevated mean arterial pressure and an elevated systolic blood pressure.']"
"[{'source_node': {'name': 'reversin 121'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'p-glycoprotein 1'}}, {'source_node': {'name': 'p-glycoprotein 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ABCB1'}}, {'source_node': {'name': 'inflammatory bowel disease 13'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'inflammation of the large intestine'}}, {'source_node': {'name': 'ABCB1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'inflammatory bowel disease 13'}}, {'source_node': {'name': 'ABCB1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'ABC-family proteins mediated transport'}}, {'source_node': {'name': 'ABCB1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Prednisone ADME'}}]","[{'source_node': {'name': 'reversin 121'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'p-glycoprotein 1'}}, {'source_node': {'name': 'p-glycoprotein 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ABCB1'}}, {'source_node': {'name': 'inflammatory bowel disease 13'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'inflammation of the large intestine'}}, {'source_node': {'name': 'ABCB1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'inflammatory bowel disease 13'}}, {'source_node': {'name': 'ABCB1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Prednisone ADME'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:196', 'target': None, 'metadata': {'node_id': '196', 'node_type': 'PATHWAY', 'display_name': 'ABC-family proteins mediated transport'}}]",0.8461538461538461,622a4edef244396540fd2e1b4cfcb325,a52808fa1c80791b13bb72da91828088,"['Reversin 121 is a drug that targets p-glycoprotein 1, which is a gene product of ABCB1. ABCB1 is involved in various biological pathways including ABC-family proteins mediated transport and Prednisone ADME. Furthermore, ABCB1 is known to cause a form of inflammatory bowel disease known as inflammatory bowel disease 13. This disease is characterized by inflammation of the large intestine.', 'The compound Reversin 121 has p-glycoprotein 1 as its target. This protein is the gene product of ABCB1. This ABCB1 gene plays a role in certain biological pathways like ABC-family proteins mediated transport and Prednisone ADME. Interestingly, ABCB1 is linked to causing a condition known as inflammatory bowel disease 13, which is characterized by inflammation of the large intestine.']","['The compound Reversin 121 has a biological target of P-glycoprotein 1, a gene product of ABCB1. This gene not only acts within Prednisone ADME, a pharmacological pathway involved in metabolism, but it also causes a condition known as inflammatory bowel disease 13. This disease, in turn, has been phenotypically characterized by inflammation of the large intestine.']"
"[{'source_node': {'name': 'previtamin d(3)'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mometasone furoate'}}, {'source_node': {'name': 'previtamin d(3)'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'prednisolone phosphate'}}, {'source_node': {'name': 'previtamin d(3)'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluocortolone caproate'}}, {'source_node': {'name': 'prednisolone phosphate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sulpiride'}}, {'source_node': {'name': 'prednisolone phosphate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'gallamine triethiodide'}}, {'source_node': {'name': 'fluocortolone caproate'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the anticoagulant activities '}}, {'source_node': {'name': 'fluocortolone caproate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cisplatin'}}, {'source_node': {'name': 'fluocortolone caproate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '1alpha-hydroxyvitamin d5'}}]","[{'source_node': {'name': 'previtamin d(3)'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mometasone furoate'}}, {'source_node': {'name': 'prednisolone phosphate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sulpiride'}}, {'source_node': {'name': 'prednisolone phosphate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'gallamine triethiodide'}}, {'source_node': {'name': '1alpha-hydroxyvitamin d5'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'previtamin d(3)'}}, {'source_node': {'name': 'cisplatin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'sulpiride'}}, {'source_node': {'name': 'fluocortolone caproate'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the anticoagulant activities '}}, {'source_node': {'name': 'fluocortolone caproate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cisplatin'}}, {'source_node': {'name': 'fluocortolone caproate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '1alpha-hydroxyvitamin d5'}}, {'source_node': {'name': 'sulpiride'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'prednisolone phosphate'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:13120', 'target': 'COMPOUND:12337', 'metadata': None}, {'type': 'edge_deletion', 'source': 'COMPOUND:13120', 'target': 'COMPOUND:13236', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:379', 'target': 'COMPOUND:12337', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:501', 'target': 'COMPOUND:379', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:10965', 'target': 'COMPOUND:13120', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7058823529411764,a336ba18f3ebc9a32e192ab8f8731995,08effa488ce5b6be2650ab3476012681,[],[]
"[{'source_node': {'name': 'beta-secretase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'BACE1'}}, {'source_node': {'name': 'marmesin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'beta-secretase 1'}}, {'source_node': {'name': 'marmesin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'marmesin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'source_node': {'name': 'marmesin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'type': 'node_removal', 'source': 'GENE:27458', 'target': None, 'metadata': {'node_id': '27458', 'node_type': 'GENE', 'display_name': 'BACE1'}}, {'type': 'node_removal', 'source': 'PROTEIN:5851', 'target': None, 'metadata': {'node_id': '5851', 'node_type': 'PROTEIN', 'display_name': 'mcf7'}}, {'type': 'node_removal', 'source': 'PROTEIN:2463', 'target': None, 'metadata': {'node_id': '2463', 'node_type': 'PROTEIN', 'display_name': 'beta-secretase 1'}}]",0.3333333333333333,97b8bf81486e99c4991b79784e1f9b2a,de775df999ebf030a33088952b1282c7,"['The compound named marmesin targets several entities including beta-secretase 1, mcf7, and a549. Notably, beta-secretase 1 is a gene product of the BACE1 gene.', 'Beta-secretase 1, which is a gene product of BACE1, is targeted by the drug marmesin. Notably, marmesin also targets mcf7 and a549, indicating its multi-targeted approach.', 'Beta-secretase 1, a gene product of the BACE1 gene, is a known target of marmesin. Interestingly, marmesin also targets cells such as mcf7 and a549, suggesting a complex network of interlinked processes at work.', 'Beta-secretase 1, a gene product of BACE1, is targeted by the compound marmesin. This compound also targets other entities such as mcf7 and a549. This interaction suggests that marmesin may have extensive biological effects given its ability to target multiple entities.', 'The compound marmesin targets several entities, including beta-secretase 1, MCF7, and A549. Of these, beta-secretase 1 is particularly noteworthy as it is a gene product of BACE1.']",[]
"[{'source_node': {'name': 'AR'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'complete androgen insensitivity syndrome'}}, {'source_node': {'name': 'androgen receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AR'}}, {'source_node': {'name': 'vitamin d3 receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VDR'}}, {'source_node': {'name': 'glucocorticoid receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR3C1'}}, {'source_node': {'name': 'thiophene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucocorticoid receptor'}}, {'source_node': {'name': 'thiophene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'vitamin d3 receptor'}}, {'source_node': {'name': 'thiophene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'androgen receptor'}}]","[{'source_node': {'name': 'androgen receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AR'}}, {'source_node': {'name': 'thiophene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'androgen receptor'}}, {'source_node': {'name': 'thiophene'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'AR'}}]","[{'type': 'edge_addition', 'source': 'GENE:28425', 'target': 'DISEASE:12480', 'metadata': {'predicate': 'causes_condition'}}, {'type': 'node_removal', 'source': 'PROTEIN:770', 'target': None, 'metadata': {'node_id': '770', 'node_type': 'PROTEIN', 'display_name': 'glucocorticoid receptor'}}, {'type': 'node_removal', 'source': 'PROTEIN:370', 'target': None, 'metadata': {'node_id': '370', 'node_type': 'PROTEIN', 'display_name': 'vitamin d3 receptor'}}, {'type': 'node_removal', 'source': 'DISEASE:12480', 'target': None, 'metadata': {'node_id': '12480', 'node_type': 'DISEASE', 'display_name': 'complete androgen insensitivity syndrome'}}, {'type': 'edge_addition', 'source': 'COMPOUND:16431', 'target': 'GENE:29295', 'metadata': {'predicate': 'is_affecting'}}]",0.2666666666666667,4de2fc3f037bfc724fd7dc6cd13b7c1c,bc6e74059f49a933b9c5c720c1c201c5,"['The compound thiophene has several targets including the androgen receptor, vitamin D3 receptor, and glucocorticoid receptor. The androgen receptor that thiophene targets is a gene product of AR, which is known to cause the condition known as complete androgen insensitivity syndrome. Additionally, the vitamin D3 receptor is a gene product of VDR, and the targeted glucocorticoid receptor is a gene product of NR3C1.', 'The compound thiophene has multiple targets including the androgen receptor, vitamin D3 receptor, and glucocorticoid receptor. These receptors, in turn, are gene products of AR, VDR, and NR3C1 respectively. Remarkably, AR is responsible for causing the complete androgen insensitivity syndrome.', 'The drug Thiophene interacts by having targets such as the Glucocorticoid Receptor, the Vitamin D3 Receptor, and the Androgen Receptor. The Glucocorticoid Receptor is a gene product of NR3C1. Similarly, the Vitamin D3 Receptor is a gene product of VDR. The Androgen Receptor, which is part of the gene product of AR, plays an important role in causing Complete Androgen Insensitivity Syndrome.', ""The androgen receptor, which is a gene product of AR, is targeted by the compound thiophene. Similarly, thiophene also targets the glucocorticoid receptor and vitamin D3 receptor, which are gene products of NR3C1 and VDR, respectively. It's interesting to note that AR is responsible for causing a condition known as complete androgen insensitivity syndrome."", 'The androgen receptor is a product of the gene AR, which is known to cause a condition known as complete androgen insensitivity syndrome. This receptor, along with the vitamin D3 receptor and glucocorticoid receptor, are all targeted by thiophene. These latter receptors are respectively gene products of VDR and NR3C1.']","['The chemical compound thiophene targets the androgen receptor, a gene product of the gene AR. Thiophene also affects the functioning of the AR gene.']"
"[{'source_node': {'name': 'levonordefrin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'periciazine'}}, {'source_node': {'name': 'astemizole'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'norepinephrine'}}, {'source_node': {'name': 'astemizole'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'levonordefrin'}}, {'source_node': {'name': 'astemizole'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'protokylol'}}, {'source_node': {'name': 'norepinephrine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}}, {'source_node': {'name': 'norepinephrine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'adrenoceptor alpha 2b'}}, {'source_node': {'name': 'norepinephrine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Anxiety'}}]","[{'source_node': {'name': 'levonordefrin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'periciazine'}}, {'source_node': {'name': 'periciazine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'adrenoceptor alpha 2b'}}, {'source_node': {'name': 'astemizole'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'norepinephrine'}}, {'source_node': {'name': 'astemizole'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'levonordefrin'}}, {'source_node': {'name': 'astemizole'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'protokylol'}}, {'source_node': {'name': 'astemizole'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}}, {'source_node': {'name': 'norepinephrine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}}, {'source_node': {'name': 'norepinephrine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'adrenoceptor alpha 2b'}}, {'source_node': {'name': 'norepinephrine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Anxiety'}}, {'source_node': {'name': 'norepinephrine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'astemizole'}}, {'source_node': {'name': 'protokylol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'levonordefrin'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:357', 'target': 'COMPOUND:623', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5857', 'target': 'COMPOUND:5758', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:623', 'target': 'PROTEIN:3751', 'metadata': {'predicate': 'has_target'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1536', 'target': 'GENE:428', 'metadata': {'predicate': 'is_affecting'}}]",0.7333333333333334,891b3bfc894f836b5ce8784215e3275d,8b1a7e303fd78ac1713faf6fa30baf6a,"[""Levonordefrin has been observed to decrease the efficacy of periciazine. Interestingly, astemizole shows a contrasting behavior where it increases the efficacy of several other agents such as norepinephrine, levonordefrin, and protokylol. Moreover, norepinephrine plays an important role in the biological system by targeting DNA-(apurinic or apyrimidinic site) lyase and affecting the adrenoceptor alpha 2b. However, it is worth noting that norepinephrine's effects are not always positive, as it has been linked to side effects such as anxiety."", 'The drug levonordefrin is known to decrease the efficacy of periciazine. Interestingly, the drug astemizole has been found to increase the efficacy of several compounds including levonordefrin, norepinephrine, and protokylol. In the body, norepinephrine has multiple effects. Firstly, it acts as a target for the enzyme known as DNA-(apurinic or apyrimidinic site) lyase. Moreover, it affects the adrenoceptor alpha 2b, and it has been linked with certain side effects such as anxiety.', 'The drug Levonordefrin decreases the efficacy of Periciazine. In contrast, Astemizole increases the efficacy of several substances, including Levonordefrin, Norepinephrine, and Protokylol. Interestingly, Norepinephrine targets the DNA-(apurinic or apyrimidinic site) lyase and affects the adrenoceptor alpha 2b. An essential side effect to consider when using Norepinephrine is the potential for Anxiety.', 'Levonordefrin is a substance that decreases the efficacy of periciazine. On the other hand, we have Astemizole, which increases the efficacy of several other substances including norepinephrine, levonordefrin, and protokylol. Specifically, norepinephrine has various impacts; it targets DNA-(apurinic or apyrimidinic site) lyase, it affects the adrenoceptor alpha 2b, and it is associated with the side effect of causing anxiety in certain circumstances.']","['The drug levonordefrin is known to decrease the efficacy of another drug, periciazine, which in turn affects the function of adrenoceptor alpha 2b, a receptor involved in the regulation of neurotransmitters. Concurrently, astemizole, another drug, is found to increase the efficacy of norepinephrine, levonordefrin, and protokylol. Both astemizole and norepinephrine target the enzyme, dna-(apurinic or apyrimidinic site) lyase, and norepinephrine also influences the function of adrenoceptor alpha 2b. However, it is important to consider that norepinephrine can cause side effects such as anxiety and can also decrease the efficacy of astemizole. On a different note, protokylol is shown to increase the efficacy of levonordefrin. This intricate web of interactions between these drugs and biological entities indicates the complexity of pharmaceutical treatment and its impacts on the human body at the molecular level.', ""The drug Levonordefrin has been noted to decrease the efficacy of Periciazine, a medication that significantly affects the adrenoceptor alpha 2b. In a related manner, Astemizole increases the efficacy of several compounds such as Norepinephrine, Levonordefrin, and Protokylol. Both Astemizole and Norepinephrine have a common target - the dna-(apurinic or apyrimidinic site) lyase. Norepinephrine also impacts the adrenoceptor alpha 2b and has a side effect associated with anxiety. Astemizole's efficacy, interestingly, decreases under the influence of Norepinephrine. In return, Protokylol increases the efficacy of Levonordefrin, closing the circular interaction among these substances."", 'Levonordefrin is a drug that has been noted to decrease the efficacy of periciazine. Interestingly, periciazine is a drug that affecting the adrenoceptor alpha 2b. A different drug, astemizole, increases the efficacy of several elements, including norepinephrine, levonordefrin, and protokylol. Additionally, astemizole has a particular target: the dna-(apurinic or apyrimidinic site) lyase. In correlation, norepinephrine also has dna-(apurinic or apyrimidinic site) lyase as a target. Interestingly, norepinephrine is noted for affecting adrenoceptor alpha 2b. However, this comes with side effects, one of them being anxiety. An interesting interaction can be found where norepinephrine decreases the efficacy of astemizole. Lastly, it is noted how protokylol is known to increase the efficacy of levonordefrin. Altogether, these elements form a complex web of interactions and impacts on each other in ways one might not initially predict.']"
"[{'source_node': {'name': 'risperidone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Arrhythmia'}}, {'source_node': {'name': 'risperidone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Bronchospasm'}}, {'source_node': {'name': 'risperidone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Stevens-Johnson syndrome'}}, {'source_node': {'name': 'oxprenolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pramlintide'}}, {'source_node': {'name': 'oxprenolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'chlorphentermine'}}, {'source_node': {'name': 'etilefrine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'risperidone'}}, {'source_node': {'name': 'etilefrine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oxprenolol'}}, {'source_node': {'name': 'etilefrine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bufuralol'}}]","[{'source_node': {'name': 'risperidone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Arrhythmia'}}, {'source_node': {'name': 'risperidone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Stevens-Johnson syndrome'}}, {'source_node': {'name': 'oxprenolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pramlintide'}}, {'source_node': {'name': 'oxprenolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'chlorphentermine'}}, {'source_node': {'name': 'oxprenolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'etilefrine'}}, {'source_node': {'name': 'etilefrine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'risperidone'}}, {'source_node': {'name': 'etilefrine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oxprenolol'}}, {'source_node': {'name': 'etilefrine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bufuralol'}}, {'source_node': {'name': 'bufuralol'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Stevens-Johnson syndrome'}}]","[{'type': 'node_removal', 'source': 'SIDE_EFFECT:192', 'target': None, 'metadata': {'node_id': '192', 'node_type': 'SIDE_EFFECT', 'display_name': 'Bronchospasm'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1510', 'target': 'COMPOUND:7930', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5776', 'target': 'SIDE_EFFECT:736', 'metadata': {'predicate': 'has_side_effect'}}]",0.7647058823529411,f2a63e6434c8483cf82e1a1769bcebe6,c49a2227a49567036a9ad396ccd99355,"['The drug Risperidone, known to have side effects such as Arrhythmia, Bronchospasm, and the potentially serious Stevens-Johnson syndrome, has its efficacy decreased by the drug Etilefrine. On the other hand, Oxprenolol, another drug negatively impacted by Etilefrine, is shown to increase the efficacy of Pramlintide while decreasing the efficacy of Chlorphentermine. Lastly, Etilefrine also decreases the efficacy of Bufuralol.', ""The drug Risperidone has been associated with a number of side effects, such as Arrhythmia, Bronchospasm, and even severe reactions like Stevens-Johnson syndrome. The drug Etilefrine, on the other hand, has been observed to decrease the efficacy of several medications, including Risperidone, Oxprenolol and Bufuralol. Interestingly, while Oxprenolol's efficacy might be decreased by Etilefrine, it also has shown to increase the efficacy of another drug, Pramlintide. However, Oxprenolol conversely decreases the efficacy of Chlorphentermine."", 'Risperidone, a antipsychotic drug, has been noted to have several side effects including arrhythmia, bronchospasm, and Stevens-Johnson syndrome, a serious skin disorder. On the other hand, the drug oxprenolol has been observed to increase the efficacy of pramlintide and decrease the efficacy of chlorphentermine. Lastly, etilefrine, a cardiovascular drug, is noted to reduce the efficacy of several drugs including risperidone, oxprenolol, and bufuralol. Consideration of these interactions and side effects is crucial in the successful management of clinical treatments.\n', 'The drug risperidone has been noted to have several side effects including arrhythmia, bronchospasm, and even Stevens-Johnson syndrome. More so, its efficacy could be affected by other drugs. For instance, etilefrine has been found to decrease the efficacy of risperidone.\n\nOn the other hand, oxprenolol, another drug, interacts with different drugs in different ways. It is observed to increase the efficacy of pramlintide while decreasing the efficacy of chlorphentermine. However, similar to risperidone, the efficacy of oxprenolol is also decreased by etilefrine.\n\nFurthermore, etilefrine does not only impact risperidone and oxprenolol. It has also been found to decrease the efficacy of bufuralol, a beta-adrenoreceptor blocking drug. These interactions underline the complex nature of pharmacological interactions and the implications they can have on treatment efficacy.']","['Risperidone is a drug known for having side effects which include Arrhythmia and Stevens-Johnson syndrome. In the complex web of drug interactions, oxprenolol works to increase the efficacy of pramlintide, while concurrently decreasing the efficacy of chlorphentermine. Interestingly, oxprenolol also increases the efficacy of the drug etilefrine. This interactive play continues, with etilefrine seen to decrease the efficacy of a few drugs including risperidone, oxprenolol and bufuralol. Incidentally, bufuralol has also been reported to cause Stevens-Johnson syndrome as a side effect. These intricate interactions depict the connected and complex nature of drug dynamics.', 'Risperidone is a medication that unfortunately has been found to cause side effects including both Arrhythmia and Stevens-Johnson syndrome. In a complex web of pharmacological interactions, researchers have discovered that oxprenolol can boost the effectiveness of another drug called pramlintide while it diminishes the efficacy of chlorphentermine. Intriguingly, oxprenolol also increases the efficacy of etilefrine. \n\nEtilefrine, on the other hand, was found to decrease the potency of several drugs including risperidone, oxprenolol, and bufuralol. Further complicating matters, bufuralol, like risperidone, has also been linked to the most unfortunate side effect of Stevens-Johnson syndrome. One must carefully consider these complex drug interactions and side effects when prescribing and dosing these medications.', 'The drug risperidone has potential side effects such as arrhythmia and Stevens-Johnson syndrome. Another drug, oxprenolol, is known to increase the efficacy of pramlintide and etilefrine but decrease the efficacy of chlorphentermine. Meanwhile, etilefrine decreases the efficacy of risperidone, oxprenolol, and bufuralol; and bufuralol also has a potential side effect of causing Stevens-Johnson syndrome. The complex interplay of these drugs requires careful consideration due to these interactions and potential side effects.', 'The drug risperidone has been observed to have several side effects, including the onset of arrhythmia as well as Stevens-Johnson syndrome. Another drug, oxprenolol, has been noticed to increase the efficacy of pramlintide and etilefrine, while decreasing the efficacy of chlorphentermine. Interestingly, the activity of etilefrine has been found to decrease the efficacy of risperidone, oxprenolol and bufuralol. It should be noted that the drug bufuralol has also been associated with Stevens-Johnson syndrome, the same side effect as risperidone. These findings highlight the complex and intricate interactions within and between drug treatments.', ""The drug risperidone has been reported to have side effects such as arrhythmia and Stevens-Johnson syndrome. In terms of drug interactions, oxprenolol has been found to increase the efficacy of pramlintide and etilefrine but decrease that of chlorphentermine. It's important to note however, that the increased efficacy of etilefrine can decrease the efficacy of risperidone, oxprenolol and bufuralol. Bufuralol, similar to risperidone, has also been linked to the side effect of Stevens-Johnson syndrome. Thus, careful consideration should be given when administering these drugs together.""]"
"[{'source_node': {'name': 'phaeocaulisin f'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}, {'source_node': {'name': 'PTPN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Integrin signaling'}}]","[{'source_node': {'name': 'PTPN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Integrin signaling'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:1921', 'target': None, 'metadata': {'node_id': '1921', 'node_type': 'PROTEIN', 'display_name': 'tyrosine-protein phosphatase non-receptor type 1'}}]",0.4285714285714286,ca69c97d3dbbf980a15261923b8435f1,635b243fc005037c3cb33fd00201c524,"['The compound phaeocaulisin f has a target interaction with the tyrosine-protein phosphatase non-receptor type 1. This protein is a gene product of PTPN1, which interestingly, also acts within the pathway of integrin signaling.']",[]
"[{'source_node': {'name': 'lysinuric protein intolerance'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'coma'}}, {'source_node': {'name': 'lysinuric protein intolerance'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypofibrinogenemia'}}, {'source_node': {'name': 'lysinuric protein intolerance'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'antinuclear antibody positivity'}}]","[{'source_node': {'name': 'lysinuric protein intolerance'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'coma'}}, {'source_node': {'name': 'lysinuric protein intolerance'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypofibrinogenemia'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:2517', 'target': None, 'metadata': {'node_id': '2517', 'node_type': 'PHENOTYPE', 'display_name': 'antinuclear antibody positivity'}}]",0.7142857142857143,794eb32f2e0cc398635aa0f505889f2f,65df3a041702301948d737c5b381dba4,[],[]
"[{'source_node': {'name': 'ursodeoxycholic acid'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' bleeding and bruising '}}, {'source_node': {'name': 'ursodeoxycholic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bezafibrate'}}, {'source_node': {'name': 'ursodeoxycholic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'gestrinone'}}, {'source_node': {'name': 'gemfibrozil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ursodeoxycholic acid'}}, {'source_node': {'name': 'gemfibrozil'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Hypertriglyceridemia'}}, {'source_node': {'name': 'gemfibrozil'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Atrial fibrillation'}}]","[{'source_node': {'name': 'ursodeoxycholic acid'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' bleeding and bruising '}}, {'source_node': {'name': 'ursodeoxycholic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bezafibrate'}}, {'source_node': {'name': 'ursodeoxycholic acid'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'gemfibrozil'}}, {'source_node': {'name': 'gemfibrozil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ursodeoxycholic acid'}}, {'source_node': {'name': 'gemfibrozil'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Hypertriglyceridemia'}}, {'source_node': {'name': 'gemfibrozil'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Atrial fibrillation'}}, {'source_node': {'name': 'bezafibrate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'gemfibrozil'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1515', 'target': 'COMPOUND:1221', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:9540', 'target': None, 'metadata': {'node_id': '9540', 'node_type': 'COMPOUND', 'display_name': 'gestrinone'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1334', 'target': 'COMPOUND:1221', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.6923076923076923,40c1473f1754e05afd7acd35ef326bf3,f4233082f41a84d803f1c749595955fb,[],[]
"[{'source_node': {'name': 'adrenocortical carcinoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of urine homeostasis'}}, {'source_node': {'name': 'ZNRF3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'adrenocortical carcinoma'}}, {'source_node': {'name': 'ZNRF3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of FZD by ubiquitination'}}]","[{'source_node': {'name': 'ZNRF3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'adrenocortical carcinoma'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:2241', 'target': None, 'metadata': {'node_id': '2241', 'node_type': 'PHENOTYPE', 'display_name': 'abnormality of urine homeostasis'}}, {'type': 'node_removal', 'source': 'PATHWAY:1698', 'target': None, 'metadata': {'node_id': '1698', 'node_type': 'PATHWAY', 'display_name': 'Regulation of FZD by ubiquitination'}}]",0.4285714285714286,9a7440ee4fc3afb4472906c3d4a4cff0,28ad2bcbde3d055f24e57c3dfb91a022,"['The gene ZNRF3, which operates within the regulation of FZD by ubiquitination, causes a condition known as adrenocortical carcinoma. This particular carcinoma is characterized by an abnormality of urine homeostasis.', 'The gene ZNRF3, which plays a role in the process of regulation of FZD by ubiquitination, can cause adrenocortical carcinoma, a disease that can lead to an abnormality of urine homeostasis.', 'The gene ZNRF3 is known to act within the regulation of FZD by ubiquitination pathway, and it has been identified as a cause of adrenocortical carcinoma. This type of carcinoma is characterized by abnormality of urine homeostasis.']","['The gene ZNRF3 is known to cause a condition called adrenocortical carcinoma.', 'The gene ZNRF3 is known to cause a specific condition known as adrenocortical carcinoma.']"
"[{'source_node': {'name': 'ACHE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neurotransmitter clearance'}}, {'source_node': {'name': 'buxalongifolamidine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'acetylcholinesterase'}}, {'source_node': {'name': 'acetylcholinesterase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACHE'}}]","[{'source_node': {'name': 'buxalongifolamidine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'acetylcholinesterase'}}]","[{'type': 'node_removal', 'source': 'GENE:29952', 'target': None, 'metadata': {'node_id': '29952', 'node_type': 'GENE', 'display_name': 'ACHE'}}]",0.4285714285714286,7a345fa216442cf43f80a37c7dfb1cef,fd7c794964fd72806ef3b88bc948bbe9,"['Buxalongifolamidine is a drug that targets acetylcholinesterase, which is a gene product of the ACHE gene. Furthermore, ACHE acts within the path of neurotransmitter clearance.', 'The gene ACHE plays a crucial role within the neurotransmitter clearance process. This gene is the producer of acetylcholinesterase, which happens to be a target for buxalongifolamidine, a known substance.']","['The compound buxalongifolamidine has a target interaction with the enzyme acetylcholinesterase.', 'The drug buxalongifolamidine has acetylcholinesterase as its target.', 'The drug buxalongifolamidine is known to target acetylcholinesterase.', 'The compound buxalongifolamidine has a target relationship with the protein acetylcholinesterase.', 'The compound buxalongifolamidine acts on the target known as acetylcholinesterase.']"
"[{'source_node': {'name': 'retinitis pigmentosa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'constriction of peripheral visual field'}}, {'source_node': {'name': 'retinitis pigmentosa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'nyctalopia'}}, {'source_node': {'name': 'retinitis pigmentosa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'type ii diabetes mellitus'}}, {'source_node': {'name': 'AGBL5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'retinitis pigmentosa 75'}}, {'source_node': {'name': 'AGBL5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'retinitis pigmentosa'}}]","[{'source_node': {'name': 'retinitis pigmentosa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'constriction of peripheral visual field'}}, {'source_node': {'name': 'retinitis pigmentosa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'nyctalopia'}}, {'source_node': {'name': 'retinitis pigmentosa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'type ii diabetes mellitus'}}, {'source_node': {'name': 'AGBL5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'retinitis pigmentosa 75'}}]","[{'type': 'edge_deletion', 'source': 'GENE:32350', 'target': 'DISEASE:2810', 'metadata': None}]",0.9090909090909092,77e559ae8695474ea848ad058ff562f1,3e24e614f13158e6a7c4bfaccda67232,[],"['Retinitis pigmentosa, a degenerative eye disease that usually appears in adulthood, is known for exhibiting various phenotypes, including constriction of the peripheral visual field, nyctalopia (night blindness), and a potential connection to Type II diabetes mellitus. Interestingly, the gene AGBL5 has been found to cause a specific form of this disease, known as retinitis pigmentosa 75.', 'Retinitis pigmentosa is a condition that exhibits several phenotypes including constriction of peripheral visual field, nyctalopia, and surprisingly, type II diabetes mellitus. In particular, retinitis pigmentosa 75 is a subtype of this condition which can be caused by the gene AGBL5.', 'Retinitis pigmentosa is associated with multiple phenotypes including constriction of peripheral visual field, nyctalopia, and type II diabetes mellitus. In addition, AGBL5 is a gene that causes a specific type of this condition known as retinitis pigmentosa 75.', ""Retinitis pigmentosa presents with various clinical phenotypes, including constriction of the peripheral visual field, nyctalopia and even comorbid type II diabetes mellitus. It's noteworthy that a specific variety of this condition, termed retinitis pigmentosa 75, has been proven to be caused by the gene AGBL5."", 'Retinitis pigmentosa, a vision disorder, has several notable phenotypes including the constriction of the peripheral visual field, nyctalopia, and an increased risk of developing type II diabetes mellitus. Additionally, the AGBL5 gene has been identified as a causative factor in a specific variant of this disorder termed retinitis pigmentosa 75.']"
"[{'source_node': {'name': 'CIB2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'usher syndrome'}}, {'source_node': {'name': 'CIB2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'deafness'}}, {'source_node': {'name': 'CIB2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'usher syndrome type 1'}}, {'source_node': {'name': 'deafness'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'myopia'}}, {'source_node': {'name': 'usher syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'rod-cone dystrophy'}}, {'source_node': {'name': 'usher syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'congenital sensorineural hearing impairment'}}, {'source_node': {'name': 'usher syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'anxiety'}}]","[{'source_node': {'name': 'CIB2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'usher syndrome'}}, {'source_node': {'name': 'CIB2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'deafness'}}, {'source_node': {'name': 'CIB2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'usher syndrome type 1'}}, {'source_node': {'name': 'deafness'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'myopia'}}, {'source_node': {'name': 'deafness'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'congenital sensorineural hearing impairment'}}, {'source_node': {'name': 'usher syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'rod-cone dystrophy'}}, {'source_node': {'name': 'usher syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'congenital sensorineural hearing impairment'}}, {'source_node': {'name': 'usher syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'anxiety'}}]","[{'type': 'edge_addition', 'source': 'DISEASE:14711', 'target': 'PHENOTYPE:5390', 'metadata': {'predicate': 'has_phenotype'}}]",0.9333333333333332,17afed5877f24adfc4996d1ec7857c5a,6ccb4609ce933d9d57ecbfe81d9de6ee,"['The gene CIB2 is known to cause several conditions including Usher Syndrome, deafness, and Usher Syndrome Type 1. Deafness, one of the conditions induced by CIB2, exhibits several phenotypes including myopia. Additionally, Usher Syndrome, another condition caused by CIB2, is characterized by various symptoms including rod-cone dystrophy, congenital sensorineural hearing impairment, and anxiety.', 'The gene CIB2 is a known cause of several conditions including Usher syndrome, Usher syndrome type 1, and deafness. These conditions, in turn, present with specific phenotypes. For instance, deafness can manifest as myopia, while Usher syndrome often results in phenotypes such as rod-cone dystrophy, congenital sensorineural hearing impairment, and anxiety.', 'The gene CIB2 has been linked to multiple conditions including usher syndrome, deafness, and usher syndrome type 1. Deafness, a condition caused by CIB2, is characterized by myopia, among other symptoms. Similarly, usher syndrome, also caused by the same gene, is associated with various phenotypes such as rod-cone dystrophy, congenital sensorineural hearing impairment, and even anxiety. This evidence suggests a role for the gene CIB2 in various sensory and neurological processes and disorders.', 'The gene CIB2 is known to cause several conditions, including deafness, Usher syndrome, and a particular form of Usher syndrome known as Usher syndrome type 1. Deafness, caused by CIB2, can result in the phenotype of myopia. Usher syndrome, another condition caused by CIB2, can manifest in a variety of phenotypes, such as rod-cone dystrophy, congenital sensorineural hearing impairment, and anxiety.', 'The gene CIB2 is known to cause several conditions including deafness and Usher syndrome, as well as a specific variant, Usher syndrome type 1. These conditions exhibit various manifestations. Deafness often presents with a phenotype of myopia, while Usher syndrome is characterised by symptoms such as rod-cone dystrophy, congenital sensorineural hearing impairment, and even anxiety in some cases.']","['The gene CIB2 is known to cause multiple health conditions, including Usher syndrome, deafness, and Usher syndrome type 1. Usher syndrome exhibits several phenotypes, such as rod-cone dystrophy, congenital sensorineural hearing impairment, and even anxiety. Similarly, deafness also carries phenotypes that include myopia and congenital sensorineural hearing impairment. Thus, these conditions present a diverse array of symptoms, all stemming from the role of the CIB2 gene.', 'The gene CIB2 is known to cause multiple conditions including Usher syndrome, deafness and specifically Usher syndrome type 1. Usher syndrome is characterized by symptoms such as rod-cone dystrophy, congenital sensorineural hearing impairment and even anxiety. On the other hand, deafness is also associated with symptoms like myopia and congenital sensorineural hearing impairment.', 'The gene CIB2 is known to cause several conditions including Usher syndrome, deafness, and Usher syndrome type 1. These conditions often present with various phenotypes. For instance, deafness might be accompanied by myopia or congenital sensorineural hearing impairment. On the other hand, Usher syndrome, a genetic disorder affecting both hearing and vision, is typically characterized by rod-cone dystrophy, congenital sensorineural hearing impairment, and occasionally anxiety.', 'The gene CIB2 can cause several conditions such as Usher syndrome, deafness, and Usher syndrome type 1. Deafness, a condition caused by CIB2, is characterized by certain phenotypes like myopia and congenital sensorineural hearing impairment. In addition, Usher syndrome, another condition attributable to CIB2, is marked by conditions like rod-cone dystrophy, congenital sensorineural hearing impairment, and anxiety.', 'The gene CIB2 is responsible for causing several conditions such as Usher syndrome, deafness, and Usher syndrome type 1. These conditions are linked to distinct symptoms which are categorized as their phenotypes. Deafness might exhibit characteristics such as myopia or congenital sensorineural hearing impairment. Similarly, Usher syndrome shows phenotypes such as rod-cone dystrophy, congenital sensorineural hearing impairment, and even anxiety.']"
"[{'source_node': {'name': 'classic hodgkin lymphoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ataxia'}}, {'source_node': {'name': 'classic hodgkin lymphoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'splenomegaly'}}, {'source_node': {'name': 'classic hodgkin lymphoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'respiratory insufficiency'}}]","[{'source_node': {'name': 'classic hodgkin lymphoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'splenomegaly'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:952', 'target': None, 'metadata': {'node_id': '952', 'node_type': 'PHENOTYPE', 'display_name': 'ataxia'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:1541', 'target': None, 'metadata': {'node_id': '1541', 'node_type': 'PHENOTYPE', 'display_name': 'respiratory insufficiency'}}]",0.4285714285714286,f30b6f0b8c3b031b613c483f9c97e093,e646034051b1e6c4e34d40106843e8c8,"['Classic Hodgkin lymphoma, a medical condition, has various phenotypes, notably including ataxia, splenomegaly, and respiratory insufficiency. Ataxia presents as a failure of muscle control in the arms and legs resulting in lack of balance and coordination. Splenomegaly, on the other hand, results in the enlargement of the spleen while respiratory insufficiency refers to the reduced ability of the lungs to function properly. Therefore, a patient with Classic Hodgkin lymphoma could manifest symptoms ranging from coordination problems, an enlarged spleen, to a difficulty in breathing due to the ineffective operation of the lungs.', ""Classic Hodgkin Lymphoma, a type of cancer, is characterized by a variety of phenotypes including ataxia, which is a lack of muscle control or coordination, splenomegaly, which is an abnormal enlargement of the spleen, and respiratory insufficiency, a condition in which the body's respiratory system cannot properly intake oxygen or release carbon dioxide."", 'Classic Hodgkin Lymphoma is a disease that manifests with various phenotypes such as ataxia, an impairment affecting coordination, and splenomegaly which is an abnormal enlargement of the spleen. Another significant phenotype associated with Classic Hodgkin Lymphoma is respiratory insufficiency, a state in which the respiratory system fails in one or both of its gas exchange functions.', 'Classic Hodgkin lymphoma, a type of cancer, presents several clinical manifestations or phenotypes, including ataxia, which is a loss of full control of bodily movements, splenomegaly which refers to having an enlarged spleen, and respiratory insufficiency, causing breathing difficulties.', 'Classic Hodgkin lymphoma, a type of cancer, can result in various physiological manifestations or phenotypes. Patients suffering from it may experience ataxia, a condition characterized by the loss of control of bodily movements. They might also suffer from splenomegaly which entails an abnormal enlargement of the spleen. Moreover, classic Hodgkin lymphoma can cause respiratory insufficiency, a serious medical condition where the lungs fail to adequately oxygenate the blood or remove carbon dioxide from it.']",[]
"[{'source_node': {'name': 'ACHE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neurotransmitter clearance'}}, {'source_node': {'name': 'ACHE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of PC'}}, {'source_node': {'name': 'ACHE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis, secretion, and deacylation of Ghrelin'}}, {'source_node': {'name': 'beta-l-fucose'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'acetylcholinesterase'}}, {'source_node': {'name': 'beta-l-fucose'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'alpha-l-fucosidase'}}, {'source_node': {'name': 'acetylcholinesterase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACHE'}}]","[{'source_node': {'name': 'ACHE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neurotransmitter clearance'}}, {'source_node': {'name': 'ACHE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of PC'}}, {'source_node': {'name': 'ACHE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis, secretion, and deacylation of Ghrelin'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:3093', 'target': 'GENE:29952', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'PROTEIN:273', 'target': None, 'metadata': {'node_id': '273', 'node_type': 'PROTEIN', 'display_name': 'acetylcholinesterase'}}, {'type': 'edge_addition', 'source': 'PROTEIN:3028', 'target': 'GENE:29952', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'PROTEIN:3028', 'target': None, 'metadata': {'node_id': '3028', 'node_type': 'PROTEIN', 'display_name': 'alpha-l-fucosidase'}}, {'type': 'node_removal', 'source': 'COMPOUND:3093', 'target': None, 'metadata': {'node_id': '3093', 'node_type': 'COMPOUND', 'display_name': 'beta-l-fucose'}}]",0.5384615384615384,9bc99979eec81d5d5c24801c258128d8,ce0137242ad6918d98c520221ab6b9d9,[],"['The ACHE gene plays several roles; it acts within neurotransmitter clearance, synthesis of PC, and in the process of synthesis, secretion, and deacylation of Ghrelin.', 'The gene ACHE plays a crucial role in several processes such as neurotransmitter clearance, synthesis of PC, and the synthesis, secretion, and deacylation of Ghrelin.']"
"[{'source_node': {'name': 'GGT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glutathione synthesis and recycling'}}, {'source_node': {'name': 'GGT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Aflatoxin activation and detoxification'}}, {'source_node': {'name': 'GGT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Paracetamol ADME'}}]","[{'source_node': {'name': 'GGT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glutathione synthesis and recycling'}}, {'source_node': {'name': 'GGT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Aflatoxin activation and detoxification'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:5', 'target': None, 'metadata': {'node_id': '5', 'node_type': 'PATHWAY', 'display_name': 'Paracetamol ADME'}}]",0.7142857142857143,17141080465b1cdc3ad38d33b4c111ff,12127e3cc9ce3dea9cf46259837f8473,[],"['The gene GGT1 acts within two key processes, namely glutathione synthesis and recycling, as well as aflatoxin activation and detoxification.', 'The gene GGT1 operates within multiple pathways. Specifically, it acts within the process of glutathione synthesis and recycling. Furthermore, GGT1 is involved in aflatoxin activation and detoxification. This shows the critical role GGT1 plays in these biological pathways.', 'The gene GGT1 actively functions within two pathways: glutathione synthesis and recycling, as well as aflatoxin activation and detoxification.', 'The gene GGT1 participates in several biological processes, including the pathway of glutathione synthesis and recycling, as well as the activation and detoxification of aflatoxins.', 'The gene GGT1 plays a role in several biochemical pathways, including the synthesis and recycling of glutathione, as well as the activation and detoxification of Aflatoxin.']"
"[{'source_node': {'name': 'alcohol dehydrogenase 1c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ADH1C'}}, {'source_node': {'name': 'ADH1C'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'parkinson disease'}}, {'source_node': {'name': 'ADH1C'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'alcohol dependence'}}, {'source_node': {'name': 'ADH1C'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RA biosynthesis pathway'}}, {'source_node': {'name': 'parkinson disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'juvenile onset'}}, {'source_node': {'name': '3-butylthiolane 1-oxide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'alcohol dehydrogenase 1c'}}]","[{'source_node': {'name': 'alcohol dehydrogenase 1c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ADH1C'}}, {'source_node': {'name': 'ADH1C'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'parkinson disease'}}, {'source_node': {'name': 'ADH1C'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'alcohol dependence'}}, {'source_node': {'name': 'ADH1C'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RA biosynthesis pathway'}}, {'source_node': {'name': 'parkinson disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'juvenile onset'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:2706', 'target': 'DISEASE:13710', 'metadata': {'predicate': 'is_substance_that_treats'}}, {'type': 'node_removal', 'source': 'COMPOUND:2706', 'target': None, 'metadata': {'node_id': '2706', 'node_type': 'COMPOUND', 'display_name': '3-butylthiolane 1-oxide'}}]",0.8461538461538461,d9ae2ac3fffa423d5c99c8b472798886,1ee116ca14458f1f4546b7dbfbfaf558,"['The enzyme alcohol dehydrogenase 1c is a gene product of ADH1C. Notably, ADH1C has been implicated in causing conditions such as Parkinson disease, which can have a juvenile onset, and alcohol dependence. Furthermore, it acts within the RA biosynthesis pathway. The compound 3-butylthiolane 1-oxide has been found to target the enzyme alcohol dehydrogenase 1c.', ""When the drug 3-butylthiolane 1-oxide targets the protein known as alcohol dehydrogenase 1c, it's actually interacting with the product of the gene ADH1C. This gene, ADH1C, is not only involved in the RA biosynthesis pathway, but it also has a crucial role in causing two health conditions - Parkinson disease and alcohol dependence. Further knowledge reveals that one notable phenotype of Parkinson disease is its juvenile onset."", 'Alcohol dehydrogenase 1c is a gene product of ADH1C. ADH1C is responsible for causing conditions such as Parkinson disease and alcohol dependence. Furthermore, ADH1C acts within the RA biosynthesis pathway. Parkinson disease, stemming from ADH1C, can have the phenotype of juvenile onset. The drug 3-butylthiolane 1-oxide specifically targets alcohol dehydrogenase 1c.']","['Alcohol dehydrogenase 1c is a gene product of ADH1C. ADH1C, which acts within the RA biosynthesis pathway, has an established connection to both alcohol dependence and Parkinson disease. Interestingly, this form of Parkinson disease is often characterized by a juvenile onset.', 'Alcohol dehydrogenase 1c is a gene product of ADH1C. ADH1C relates to several conditions and pathways including causing conditions like Parkinson disease and alcohol dependence, as well as acting within the RA biosynthesis pathway. Notably, Parkinson disease typically presents with a phenotype of juvenile onset.', 'The enzyme called alcohol dehydrogenase 1c is a gene product of ADH1C. This gene, ADH1C, acts within the RA biosynthesis pathway and it is implicated in causing conditions such as Parkinson disease and alcohol dependence. Furthermore, Parkinson disease, caused by ADH1C, can be characterized by a phenotype, specifically juvenile onset.']"
"[{'source_node': {'name': 'geminin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GMNN'}}, {'source_node': {'name': '6-(2-methylbut-3-en-2-yl)furo[3,2-g]chromen-7-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucosylceramidase'}}, {'source_node': {'name': '6-(2-methylbut-3-en-2-yl)furo[3,2-g]chromen-7-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lysine-specific demethylase 4a'}}, {'source_node': {'name': '6-(2-methylbut-3-en-2-yl)furo[3,2-g]chromen-7-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'geminin'}}, {'source_node': {'name': 'glucosylceramidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GBA1'}}]","[{'source_node': {'name': 'geminin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GMNN'}}, {'source_node': {'name': '6-(2-methylbut-3-en-2-yl)furo[3,2-g]chromen-7-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucosylceramidase'}}, {'source_node': {'name': '6-(2-methylbut-3-en-2-yl)furo[3,2-g]chromen-7-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lysine-specific demethylase 4a'}}, {'source_node': {'name': '6-(2-methylbut-3-en-2-yl)furo[3,2-g]chromen-7-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'geminin'}}, {'source_node': {'name': 'glucosylceramidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GMNN'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:6193', 'target': 'GENE:27886', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'GENE:27886', 'target': None, 'metadata': {'node_id': '27886', 'node_type': 'GENE', 'display_name': 'GBA1'}}, {'type': 'edge_addition', 'source': 'PROTEIN:2870', 'target': 'GENE:30558', 'metadata': {'predicate': 'gene_product_of'}}]",0.7272727272727273,495349e98050a512647eccfa57ab2650,f2b0b4951cd6b50b981f130fbfd012fd,"['The protein geminin, which is a gene product of GMNN, is targeted by the drug 6-(2-methylbut-3-en-2-yl)furo[3,2-g]chromen-7-one. Intriguingly, the same drug also targets glucosylceramidase and lysine-specific demethylase 4a. Glucosylceramidase is a gene product of the notable GBA1 gene.', ""Geminin, a gene product of GMNN, is targeted by 6-(2-methylbut-3-en-2-yl)furo[3,2-g]chromen-7-one along with glucosylceramidase and lysine-specific demethylase 4a. Interestingly, glucosylceramidase is a gene product of GBA1. Therefore, this diverse spectrum of interactome implicates a potentially complex pharmacological and physiological scenario through 6-(2-methylbut-3-en-2-yl)furo[3,2-g]chromen-7-one's targets comprising of both proteins and the intermediate gene products."", 'The protein geminin, a gene product of GMNN, is known to interact with 6-(2-methylbut-3-en-2-yl)furo[3,2-g]chromen-7-one, a molecule which also targets glucosylceramidase and lysine-specific demethylase 4a. The targeted glucosylceramidase is a gene product of GBA1. Thus, the molecule and the targeted proteins establish a complex interplay in the biochemical system.', 'Geminin, a protein, is a product of the GMNN gene. The compound 6-(2-methylbut-3-en-2-yl)furo[3,2-g]chromen-7-one interacts with several targets in the biological system, such as geminin, glucosylceramidase, and lysine-specific demethylase 4a. It is worth noting that glucosylceramidase is synonymous with a gene product of GBA1.', 'Geminin, a protein, is a gene product of GMNN. The drug, 6-(2-methylbut-3-en-2-yl)furo[3,2-g]chromen-7-one, targets several cellular components including geminin, glucosylceramidase, and lysine-specific demethylase 4a. It is worth mentioning that glucosylceramidase is a gene product of the GBA1 gene.']","['The protein Geminin, a product of the GMNN gene, is a target of the drug 6-(2-methylbut-3-en-2-yl)furo[3,2-g]chromen-7-one. Intriguingly, the same drug also targets glucosylceramidase and lysine-specific demethylase 4a. The former, glucosylceramidase, is another gene product of GMNN. Therefore, it appears that GMNN gene products play a significant role in the action of the drug 6-(2-methylbut-3-en-2-yl)furo[3,2-g]chromen-7-one.', 'Geminin is known to be the gene product of GMNN. Similarly, glucosylceramidase is also a gene product of GMNN. The compound 6-(2-methylbut-3-en-2-yl)furo[3,2-g]chromen-7-one has been found to target several entities including glucosylceramidase, geminin and lysine-specific demethylase 4a. Therefore, we can establish a link between the GMNN gene product and these targeted proteins.', 'Geminin, a protein product of the GMNN gene, plays a critical role in cell function and is a target of the drug 6-(2-methylbut-3-en-2-yl)furo[3,2-g]chromen-7-one. This drug also interacts with other protein targets, specifically glucosylceramidase and lysine-specific demethylase 4a. Interestingly, glucosylceramidase is another gene product of the GMNN gene, further highlighting the complex biological interplay between these proteins and the drug.', 'The protein geminin, which is a product of the GMNN gene, is a target for the compound 6-(2-methylbut-3-en-2-yl)furo[3,2-g]chromen-7-one. The same compound also has other targets including glucosylceramidase and lysine-specific demethylase 4a. Intriguingly, the glucosylceramidase enzyme is also a gene product of the GMNN gene. This highlights an intricate and potentially crucial relationship between these biochemically significant entities.', 'The protein geminin, is a gene product of GMNN, and is targeted by a specific compound known as 6-(2-methylbut-3-en-2-yl)furo[3,2-g]chromen-7-one. This compound also targets other proteins such as lysine-specific demethylase 4a and glucosylceramidase. It is noteworthy that glucosylceramidase is also a gene product of GMNN, which indicates their interconnected roles in biological pathways.']"
"[{'source_node': {'name': 'methylestrenolone'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the anticoagulant activities '}}, {'source_node': {'name': 'methylestrenolone'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' thromboembolism '}}, {'source_node': {'name': 'methylestrenolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ulipristal'}}]","[{'source_node': {'name': 'methylestrenolone'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' thromboembolism '}}, {'source_node': {'name': 'methylestrenolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ulipristal'}}]","[{'type': 'node_removal', 'source': 'ACTIVITY:1', 'target': None, 'metadata': {'node_id': '1', 'node_type': 'ACTIVITY', 'display_name': ' the anticoagulant activities '}}]",0.7142857142857143,09aef5469d06394687b6c1cb186651d2,444dd12989fa98088aa5d89eaf310f34,[],[]
"[{'source_node': {'name': 'xerophilusin f'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'k562'}}, {'source_node': {'name': 'xerophilusin f'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mkn-45'}}, {'source_node': {'name': 'xerophilusin f'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepg2'}}]","[{'source_node': {'name': 'xerophilusin f'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mkn-45'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4947', 'target': None, 'metadata': {'node_id': '4947', 'node_type': 'PROTEIN', 'display_name': 'k562'}}, {'type': 'node_removal', 'source': 'PROTEIN:5817', 'target': None, 'metadata': {'node_id': '5817', 'node_type': 'PROTEIN', 'display_name': 'hepg2'}}]",0.4285714285714286,5bb334827e77643ee55cdfbbc7939fd1,ee31f145262b2a71a7797cf5420006da,"['Xerophilusin F is a drug that has multiple targets, including K562, MKN-45 and HepG2.', 'The compound Xerophilusin F has been identified as having multiple targets, including K562, MKN-45, and HepG2.', 'The compound Xerophilusin F targets several entities, including K562, MKN-45, and HepG2. This signifies that Xerophilusin F interacts with these cells, which is significant in understanding its mechanism of action.', 'Xerophilusin F is a compound known to target several cellular entities. Its targets include K562, MKN-45, and HepG2 cells. The mechanism of action of Xerophilusin F on these targets is an active area of research.', 'The compound Xerophilusin F has several biological targets, including K562, MKN-45, and HEPG2.']","['The drug Xerophilusin F has been identified to have the target MKN-45.', 'The compound Xerophilusin F has MKN-45 as its target.']"
"[{'source_node': {'name': 'robenacoxib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'isradipine'}}, {'source_node': {'name': 'robenacoxib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'chlorthalidone'}}, {'source_node': {'name': 'prostalene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sulfasalazine'}}, {'source_node': {'name': 'prostalene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oxaprozin'}}, {'source_node': {'name': 'prostalene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'robenacoxib'}}, {'source_node': {'name': 'sulfasalazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'doxazosin'}}, {'source_node': {'name': 'sulfasalazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dexibuprofen'}}, {'source_node': {'name': 'sulfasalazine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Petechiae'}}]","[{'source_node': {'name': 'chlorthalidone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'isradipine'}}, {'source_node': {'name': 'robenacoxib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'isradipine'}}, {'source_node': {'name': 'robenacoxib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'chlorthalidone'}}, {'source_node': {'name': 'prostalene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oxaprozin'}}, {'source_node': {'name': 'prostalene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'doxazosin'}}, {'source_node': {'name': 'sulfasalazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'doxazosin'}}, {'source_node': {'name': 'sulfasalazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dexibuprofen'}}, {'source_node': {'name': 'sulfasalazine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Petechiae'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:9411', 'target': 'COMPOUND:9412', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:300', 'target': 'COMPOUND:260', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:9411', 'target': 'COMPOUND:576', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:9411', 'target': 'COMPOUND:778', 'metadata': None}]",0.7647058823529411,ab7405478ffc440fea7251545927a4d5,1616bb761a0338d30cf79afecb41e711,"['Robenacoxib, a nonsteroidal anti-inflammatory drug, can decrease the efficacy of certain drugs such as isradipine and chlorthalidone, which are primarily used for treating high blood pressure. Meanwhile, prostalene, another nonsteroidal anti-inflammatory drug, tends to decrease the effectiveness of numerous medications, including sulfasalazine, oxaprozin, and also robenacoxib itself. This can potentially influence the therapeutic course. Furthermore, sulfasalazine, which is commonly used for treating inflammatory bowel disease, not only decreases the efficacy of doxazosin and dexibuprofen, but also leads to a side effect known as petechiae, which involves red or purple spots on the skin resulting from small bleeding vessels. Therefore, careful consideration of medication combinations is required in the above-mentioned cases to maximize the therapeutic effect and minimize side effects.', 'The drugs Robenacoxib, Prostalene, and Sulfasalazine have particular interactions that decrease the efficacy of other medications. Specifically, Robenacoxib diminishes the efficiency of Isradipine and Chlorthalidone. Similarly, Prostalene has been observed to decrease the efficacy of Sulfasalazine, Oxaprozin, and Robenacoxib. In addition to these interactions, Sulfasalazine has not only been noted to lessen the influence of Doxazosin and Dexibuprofen, but it also has a known side effect of causing Petechiae.', ""Robenacoxib, a drug, is known to decrease the efficacy of multiple other drugs including isradipine and chlorthalidone. In a similar manner, prostalene also reduces the effectiveness of several drugs, such as sulfasalazine, oxaprozin, and interestingly, robenacoxib itself. It's crucial to note that sulfasalazine, in addition to having its efficiency decreased by prostalene, can also lower the efficacy of drugs like doxazosin and dexibuprofen. Furthermore, use of sulfasalazine has been associated with the side effect of developing Petechiae, which are tiny, circular non-raised patches that appear on the skin due to bleeding. These inter-drug relations emphasize the importance of careful management and regular monitoring when these medicines are used in combination."", ""The drug Robenacoxib is noted to decrease the efficacy of other medications, such as Isradipine and Chlorthalidone. Similarly, Prostalene has been shown to reduce the effectiveness of drugs such as Sulfasalazine, Oxaprozin, and even Robenacoxib itself. It has also been noted that Sulfasalazine not only has its efficacy decreased by the use of Prostalene but also diminishes the effectiveness of medications like Doxazosin and Dexibuprofen. In terms of side effects, Sulfasalazine is also associated with conditions like Petechiae. It's crucial to consider these interactions and side effects when using these medications in a clinical setting."", ""The drug robenacoxib has been observed to decrease the efficacy of two different drugs: isradipine and chlorthalidone. Similarly, another drug called prostalene also decreases the efficacy of sulfasalazine, oxaprozin, and robenacoxib. \n\nSulfasalazine, the target of prostalene's efficacy-reducing impact, interestingly, has a dual impact on other drugs as well. It decreases the efficacy of doxazosin and dexibuprofen. Furthermore, use of sulfasalazine is associated with a side effect called Petechiae. \n\nThe overall implication of these drug interactions is that care must be taken when prescribing these drugs together, as their combined use could lead to lowered efficacy and potential side effects.""]","['Several drug interactions and side effects can be identified from recent clinical studies. Chlorthalidone has been found to increase the efficacy of isradipine. However, robenacoxib may decrease the efficacy of both isradipine and chlorthalidone. \n\nAdditionally, prostalene, a newly studied drug, appeared to decrease the efficacy of both oxaprozin and doxazosin. In relation to doxazosin, sulfasalazine has also been found to reduce its efficacy. Furthermore, sulfasalazine not only diminishes the effectiveness of dexibuprofen but also has been linked to petechiae as a possible side effect. \n\nThese findings highlight the importance of understanding and identifying potential drug interactions and side effects when managing patient care.', 'The drug chlorthalidone is known to increase the efficacy of isradipine. However, the efficacy of isradipine may be reduced by robenacoxib. Interestingly, robenacoxib also has the potential to decrease the efficacy of chlorthalidine. In other drug interactions, prostalene has been reported to reduce the efficacy of oxaprozin and doxazosin. Similarly, the drug sulfasalazine can decrease the efficacy of both doxazosin and dexibuprofen. It is worth noting that one of the potential side effects of sulfasalazine is the development of Petechiae.', 'In the complex world of pharmaceuticals, chlorthalidone is known to increase the efficacy of isradipine. However, the presence of robenacoxib can decrease the efficacy of both chlorthalidone and isradipine.\n\nIn another case, the drug prostalene is reported to decrease the efficacy of both oxaprozin and doxazosin. Interestingly, a similar effect on doxazosin is also seen with sulfasalazine, which reportedly decreases its efficacy as well as that of dexibuprofen. Furthermore, the use of sulfasalazine has been linked to a side effect known as Petechiae, characterized by small, red, flat spots appearing on the skin.', 'The efficacy of certain drugs can be modified by the presence of other drugs in the system. For instance, the drug Chlorthalidone increases the efficacy of Isradipine, one of the key treatments for high blood pressure. Conversely, Robenacoxib, a non-steroidal anti-inflammatory drug, reduces the efficacy of both Isradipine and Chlorthalidone. \n\nFurthermore, the drug Prostalene decreases the efficacy of both Oxaprozin, an anti-inflammatory drug, and Doxazosin, a medication used to treat high blood pressure and urinary retention associated with benign prostatic hyperplasia. Additionally, Sulfasalazine, often used for rheumatoid arthritis and ulcerative colitis, decreases the efficacy of Doxazosin and Dexibuprofen, another non-steroidal anti-inflammatory drug. In some patients, Sulfasalazine has been known to cause a side effect known as Petechiae, which is a condition characterized by pinpoint, round spots that appear on the skin as a result of bleeding.', 'Chlorthalidone is known to increase the efficacy of isradipine, while robenacoxib tends to decrease the efficacy of both isradipine and chlorthalidone. In another set of interactions, prostalene decreases the efficacy of both oxaprozin and doxazosin. Speaking of doxazosin, its efficacy is also reduced by sulfasalazine. This drug, sulfasalazine, has a similar diminishing effect on the efficacy of dexibuprofen. Interestingly, the use of sulfasalazine may also result in a side effect known as Petechiae, which involves the appearance of small purplish spots on the skin.']"
"[{'source_node': {'name': 'COA6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'mitochondrial complex iv deficiency'}}, {'source_node': {'name': 'COA6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Mitochondrial protein import'}}]","[{'source_node': {'name': 'COA6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Mitochondrial protein import'}}]","[{'type': 'node_removal', 'source': 'DISEASE:10172', 'target': None, 'metadata': {'node_id': '10172', 'node_type': 'DISEASE', 'display_name': 'mitochondrial complex iv deficiency'}}]",0.6,479f4d4ffe8df47899513294acbc5526,1a22e7aa99ebfc99635bf4f221da8d42,"['The gene COA6, which is involved in the process of mitochondrial protein import, is known to cause a condition known as mitochondrial complex IV deficiency.', 'The gene COA6 contributes to the condition known as mitochondrial complex IV deficiency. Furthermore, it functions within the process of mitochondrial protein import.', 'The gene COA6, which plays a role in mitochondrial protein import, is known to cause a condition known as mitochondrial complex IV deficiency.', 'The gene COA6 causes a condition known as mitochondrial complex IV deficiency. This gene also acts within a pathway known as mitochondrial protein import.', 'The gene COA6, which is known to act within the process of mitochondrial protein import, is also recognized as a cause of mitochondrial complex iv deficiency, a critical metabolic condition.']","['The gene COA6 functions within the process of mitochondrial protein import.', 'The gene COA6 is known to act within the pathway of mitochondrial protein import.', 'The gene COA6 acts within the pathway of mitochondrial protein import.']"
"[{'source_node': {'name': 'furosemide'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' gouty arthritis '}}, {'source_node': {'name': 'furosemide'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 11 subfamily b member 2'}}, {'source_node': {'name': 'normethadone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'furosemide'}}, {'source_node': {'name': 'normethadone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'potassium cation'}}, {'source_node': {'name': 'normethadone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'magnesium cation'}}]","[{'source_node': {'name': 'potassium cation'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' gouty arthritis '}}, {'source_node': {'name': 'furosemide'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' gouty arthritis '}}, {'source_node': {'name': 'furosemide'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 11 subfamily b member 2'}}, {'source_node': {'name': 'normethadone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'potassium cation'}}, {'source_node': {'name': 'normethadone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'magnesium cation'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:9532', 'target': 'COMPOUND:680', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:1302', 'target': 'EFFECT:55', 'metadata': {'predicate': 'has_effect'}}]",0.8181818181818181,7c3c392413b5c9a1e5e4010f0558f1bf,90c9598f1b06a9114f3a8110e605b16f,[],[]
"[{'source_node': {'name': 'TP53'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hepatocellular carcinoma'}}, {'source_node': {'name': 'TP53'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'SUMOylation of transcription factors'}}, {'source_node': {'name': 'TP53'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pyroptosis'}}, {'source_node': {'name': 'cellular tumor antigen p53'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TP53'}}]","[{'source_node': {'name': 'TP53'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hepatocellular carcinoma'}}, {'source_node': {'name': 'TP53'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'SUMOylation of transcription factors'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:161', 'target': None, 'metadata': {'node_id': '161', 'node_type': 'PATHWAY', 'display_name': 'Pyroptosis'}}, {'type': 'node_removal', 'source': 'PROTEIN:1498', 'target': None, 'metadata': {'node_id': '1498', 'node_type': 'PROTEIN', 'display_name': 'cellular tumor antigen p53'}}]",0.5555555555555556,b2a8cd925a27d6c7be496b4c04dc5ea2,94abde60985b210fd25f5552d04c8ac5,"['The gene TP53, which acts within the SUMOylation of transcription factors pathway and Pyroptosis pathway, is a causal factor of hepatocellular carcinoma. In addition, the gene product of TP53 is the cellular tumor antigen p53.', 'The TP53 gene has been identified as a key player in several biological processes and disease mechanisms. It acts within the SUMOylation of transcription factors and also within the process of pyroptosis, demonstrating its substantial role in moderating cellular activity. It should also be noted that mutation or alteration in TP53 can lead to severe health conditions, including hepatocellular carcinoma, a prevalent form of liver cancer. Furthermore, the cellular tumor antigen p53 is a prominent gene product of TP53, highlighting the interconnection and functional relationship between these genomic components.']","['The gene TP53, which is active within the process of SUMOylation of transcription factors, is known to cause the condition known as hepatocellular carcinoma.', 'The gene TP53, which causes the condition hepatocellular carcinoma, also acts within the biological process of transcription factors SUMOylation.', 'The gene TP53, which is known to act within the SUMOylation of transcription factors pathway, has been identified as a causal factor in the development of hepatocellular carcinoma.', 'The gene TP53, which functions within the SUMOylation of transcription factors pathway, is known to cause the condition hepatocellular carcinoma.', 'The gene TP53, which acts within the pathway of transcription factors SUMOylation, is known to cause a condition known as hepatocellular carcinoma.']"
"[{'source_node': {'name': 'soybean oil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'vorapaxar'}}, {'source_node': {'name': 'soybean oil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tioclomarol'}}]","[{'source_node': {'name': 'soybean oil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'vorapaxar'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:11303', 'target': None, 'metadata': {'node_id': '11303', 'node_type': 'COMPOUND', 'display_name': 'tioclomarol'}}]",0.6,81cbd27594f70799884a3ae01f6d5b78,37d844d4ccb7d264434ec52f80d22941,"['The consumption of soybean oil has been found to decrease the efficacy of certain medications such as Vorapaxar and Tioclomarol. This implies that individuals taking these drugs should be cautioned against the use of products containing soybean oil.', 'The consumption of soybean oil has been found to decrease the efficacy of certain drugs such as vorapaxar and tioclomarol. Individuals who are on these medications should perhaps avoid or limit their soybean oil intake to maintain the effectiveness of their treatment.', 'The consumption of soybean oil may decrease the efficacy of certain medications. Specifically, it has been noted to reduce the effectiveness of Vorapaxar and Tioclomarol.', 'Soybean oil has been found to decrease the efficacy of certain drugs, including vorapaxar and tioclomarol.', 'Consumption of soybean oil can decrease the efficacy of certain medications, namely vorapaxar and tioclomarol. This reduction in efficacy may necessitate a modification in the dosage or frequency of these medications.']","['The efficacy of the drug Vorapaxar is decreased when it interacts with Soybean Oil.', 'The efficacy of the drug Vorapaxar is known to be decreased by Soybean Oil.', 'The efficacy of the drug Vorapaxar is known to be decreased by Soybean oil.', 'Consumption of soybean oil may decrease the efficacy of the drug vorapaxar.']"
"[{'source_node': {'name': 'p-glycoprotein 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ABCB1'}}, {'source_node': {'name': 'tabernine a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'p-glycoprotein 1'}}, {'source_node': {'name': 'ABCB1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'inflammatory bowel disease 13'}}, {'source_node': {'name': 'ABCB1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'ABC-family proteins mediated transport'}}, {'source_node': {'name': 'ABCB1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Atorvastatin ADME'}}]","[{'source_node': {'name': 'tabernine a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'p-glycoprotein 1'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:196', 'target': None, 'metadata': {'node_id': '196', 'node_type': 'PATHWAY', 'display_name': 'ABC-family proteins mediated transport'}}, {'type': 'node_removal', 'source': 'GENE:30941', 'target': None, 'metadata': {'node_id': '30941', 'node_type': 'GENE', 'display_name': 'ABCB1'}}]",0.2727272727272727,2917fc1d6a00eab39c56d4f6fd0a4389,0e350cdb8782068c227e9abaaee5feb2,"['The drug tabernine a targets p-glycoprotein 1, which is a gene product of ABCB1. ABCB1 is known to cause inflammatory bowel disease 13 and operates within two important pathways: ABC-family proteins mediated transport and atorvastatin ADME.', 'P-glycoprotein 1 is a gene product of ABCB1, which further acts within several pathways including the transport mediated by ABC-family proteins and Atorvastatin ADME. ABCB1 is also known to be a causative agent for the condition inflammatory bowel disease 13. A compound named tabernine a targets p-glycoprotein 1 in its action mechanism.']","['The compound known as Tabernine A is observed to have P-glycoprotein 1 as its target.', 'The compound Tabernine A is known to target a specific protein, P-Glycoprotein 1.', 'The compound Tabernine A is known to have an effect on the target protein, P-glycoprotein 1.', 'The compound Tabernine A is known to target P-glycoprotein 1.', 'The drug Tabernine A has been identified to target P-glycoprotein 1.']"
"[{'source_node': {'name': 'SDC4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'HS-GAG degradation'}}, {'source_node': {'name': 'SDC4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Syndecan interactions'}}, {'source_node': {'name': 'SDC4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Defective B3GAT3 causes JDSSDHD'}}]","[{'source_node': {'name': 'SDC4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Syndecan interactions'}}, {'source_node': {'name': 'SDC4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Defective B3GAT3 causes JDSSDHD'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:227', 'target': None, 'metadata': {'node_id': '227', 'node_type': 'PATHWAY', 'display_name': 'HS-GAG degradation'}}]",0.7142857142857143,b2f094660ea2470369dcb04fd13118bc,327d0aefe774a47536df0d1cd35b0d6b,[],[]
"[{'source_node': {'name': 'thymic stromal lymphopoietin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TSLP'}}, {'source_node': {'name': 'TSLP'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Interleukin-7 signaling'}}]","[{'source_node': {'name': 'TSLP'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Interleukin-7 signaling'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4891', 'target': None, 'metadata': {'node_id': '4891', 'node_type': 'PROTEIN', 'display_name': 'thymic stromal lymphopoietin'}}]",0.6,f185b3c1c6e76d13b6d1566a5c319ba5,1d624f597eb34af72898754a624e94fd,['The protein thymic stromal lymphopoietin is a gene product of TSLP. This gene TSLP acts within the pathway of Interleukin-7 signaling.'],[]
"[{'source_node': {'name': 'bohring-opitz syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'short toe'}}, {'source_node': {'name': 'ASXL1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'bohring-opitz syndrome'}}, {'source_node': {'name': 'ASXL1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'myelodysplastic syndrome'}}, {'source_node': {'name': 'ASXL1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'UCH proteinases'}}]","[{'source_node': {'name': 'bohring-opitz syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'short toe'}}, {'source_node': {'name': 'myelodysplastic syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'short toe'}}, {'source_node': {'name': 'ASXL1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'bohring-opitz syndrome'}}, {'source_node': {'name': 'ASXL1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'myelodysplastic syndrome'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:397', 'target': None, 'metadata': {'node_id': '397', 'node_type': 'PATHWAY', 'display_name': 'UCH proteinases'}}, {'type': 'edge_addition', 'source': 'DISEASE:2144', 'target': 'PHENOTYPE:1327', 'metadata': {'predicate': 'has_phenotype'}}]",0.6666666666666667,62bcf42864596f96039963248a8b7f92,d46d525a8caf46f9d9ab3c2dde25071f,"['The gene ASXL1 operates within the pathway of UCH proteinases and it is known to cause several conditions, including Bohring-Opitz syndrome and Myelodysplastic syndrome. Bohring-Opitz syndrome is characterized by several phenotypes, one of which is a short toe.']","['The gene ASXL1 is known to cause certain conditions, such as Bohring-Opitz Syndrome and Myelodysplastic Syndrome. Interestingly, both these conditions are characterized by the phenotype with specific bodily features, such as a short toe.', 'Bohring-Opitz syndrome and myelodysplastic syndrome are both conditions that exhibit the phenotype of having short toes. The gene ASXL1 plays a pivotal role in causing these conditions. Thus, it is apparent that the ASXL1 gene is a leading factor in the development of Bohring-Opitz syndrome and myelodysplastic syndrome, both of which are characterized by the physical manifestation of short toes.', 'The gene ASXL1 is known to cause both Bohring-Opitz syndrome and Myelodysplastic syndrome. Intriguingly, both these conditions share a common phenotype of having a short toe.', 'The gene ASXL1 is responsible for causing two conditions: Bohring-Opitz syndrome and Myelodysplastic syndrome. Interestingly, both these syndromes have a common phenotype characterized by having a short toe.', 'Bohring-Opitz Syndrome and Myelodysplastic Syndrome share a common phenotype of having short toes. Both medical conditions are caused by the gene ASXL1. Specifically, the mutation of ASXL1 causes Bohring-Opitz Syndrome and Myelodysplastic Syndrome, diseases characterized by certain physical anomalies, including short toes.']"
"[{'source_node': {'name': 'developmental and epileptic encephalopathy 6b'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypertelorism'}}, {'source_node': {'name': 'developmental and epileptic encephalopathy 6b'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'spasmus nutans'}}, {'source_node': {'name': 'developmental and epileptic encephalopathy 6b'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'high forehead'}}]","[{'source_node': {'name': 'developmental and epileptic encephalopathy 6b'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'spasmus nutans'}}, {'source_node': {'name': 'developmental and epileptic encephalopathy 6b'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'high forehead'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:256', 'target': None, 'metadata': {'node_id': '256', 'node_type': 'PHENOTYPE', 'display_name': 'hypertelorism'}}]",0.7142857142857143,007ace5876ab0fecaf9e6e19704033f5,564e62106f22517444a6ce89fb5c9fb6,"['Developmental and epileptic encephalopathy 6b is a condition characterized by several phenotypes including hypertelorism, spasmus nutans and a high forehead.', 'Developmental and epileptic encephalopathy 6b is a disorder which is characterized by several phenotypes, including hypertelorism, spasmus nutans, and a high forehead.', 'Developmental and epileptic encephalopathy 6b is a condition that has several phenotypic manifestations including hypertelorism, which refers to an unusually wide space between the eyes, spasmus nutans, a disorder in infants causing quick, uncontrolled eye movement and head bobbing, and a high forehead, indicating a larger than average distance between the eyebrows and the hairline.', 'Developmental and epileptic encephalopathy 6b is a condition that presents several phenotypes including hypertelorism, which is an increased distance between the eyes, along with spasmus nutans, an irregular movement disorder observed in early infancy. Additionally, a high forehead is another physical manifestation associated with developmental and epileptic encephalopathy 6b.', 'The disease developmental and epileptic encephalopathy 6b manifests itself with various distinct phenotypes such as hypertelorism, spasmus nutans, and a high forehead.']","['Developmental and epileptic encephalopathy 6b, a complex neurological condition, exhibits certain phenotypes, which include the rare disorder known as spasmus nutans and physical attributes such as a high forehead.']"
"[{'source_node': {'name': 'LAMA5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'bent bone dysplasia syndrome 2'}}, {'source_node': {'name': 'LAMA5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Degradation of the extracellular matrix'}}, {'source_node': {'name': 'LAMA5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Interleukin-4 and Interleukin-13 signaling'}}]","[{'source_node': {'name': 'LAMA5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'bent bone dysplasia syndrome 2'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:254', 'target': None, 'metadata': {'node_id': '254', 'node_type': 'PATHWAY', 'display_name': 'Degradation of the extracellular matrix'}}, {'type': 'node_removal', 'source': 'PATHWAY:496', 'target': None, 'metadata': {'node_id': '496', 'node_type': 'PATHWAY', 'display_name': 'Interleukin-4 and Interleukin-13 signaling'}}]",0.4285714285714286,cfbbbd0bea8107e57c7d715b91e3b95e,a766076946b8d91eb5426a097f28054f,"['The gene LAMA5 plays a significant role within two specific pathways: degradation of the extracellular matrix, and interleukin-4 and interleukin-13 signaling. Notably, a malfunction or mutation in LAMA5 is known to cause the condition known as Bent Bone Dysplasia Syndrome 2.', 'The gene LAMA5, known to act within the pathways of degradation of the extracellular matrix and Interleukin-4 and Interleukin-13 signaling, notably causes Bent Bone Dysplasia Syndrome 2. This highlights the potential role of these pathways in the manifestation and progression of this condition.', 'The gene LAMA5, known to cause Bent Bone Dysplasia Syndrome 2, operates within two significant pathways. These pathways are the degradation of the extracellular matrix and the interleukin-4 and interleukin-13 signaling. These contributions provide insight into the crucial role LAMA5 plays in cellular functionality and disease pathology.', 'The gene LAMA5, which functions within the degradation of the extracellular matrix pathway as well as the interleukin-4 and interleukin-13 signaling pathway, is known to cause the condition known as bent bone dysplasia syndrome 2.']","['The gene LAMA5 is known to cause a condition known as bent bone dysplasia syndrome 2.', 'The gene LAMA5 has been identified to cause a condition known as Bent Bone Dysplasia Syndrome 2.', 'The gene LAMA5 is known to cause a condition known as bent bone dysplasia syndrome 2.']"
"[{'source_node': {'name': 'lysyl oxidase homolog 3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'LOXL3'}}, {'source_node': {'name': 'LOXL3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Crosslinking of collagen fibrils'}}]","[{'source_node': {'name': 'LOXL3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Crosslinking of collagen fibrils'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:6772', 'target': None, 'metadata': {'node_id': '6772', 'node_type': 'PROTEIN', 'display_name': 'lysyl oxidase homolog 3'}}]",0.6,b99f892cc62fb909e4e8228b179944c2,7867615bee4b8212071cd6a1bcb51c80,"['Lysyl oxidase homolog 3 is a gene product of LOXL3, which acts within the pathway responsible for the crosslinking of collagen fibrils.', 'Lysyl oxidase homolog 3 is a gene product of LOXL3, which in turn acts within the pathway involving the crosslinking of collagen fibrils.', 'Lysyl oxidase homolog 3 is a gene product of LOXL3, which acts within the pathway responsible for the crosslinking of collagen fibrils.']","['The enzyme LOXL3 plays a role within the process of crosslinking collagen fibrils.', 'The gene LOXL3 operates within the process of crosslinking of collagen fibrils.']"
"[{'source_node': {'name': 'aprataxin and pnkp like factor'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'progression-free survival'}}, {'source_node': {'name': 'aprataxin and pnkp like factor'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'overall survival'}}, {'source_node': {'name': 'aprataxin and pnkp like factor'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'carcinoma'}}]","[{'source_node': {'name': 'aprataxin and pnkp like factor'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'progression-free survival'}}, {'source_node': {'name': 'aprataxin and pnkp like factor'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'carcinoma'}}]","[{'type': 'node_removal', 'source': 'DISEASE:2380', 'target': None, 'metadata': {'node_id': '2380', 'node_type': 'DISEASE', 'display_name': 'overall survival'}}]",0.7142857142857143,bc65447625c69ceac709c7c9aafdedaf,230c45b3e523053fd591dce1fa8bdb65,[],"['The gene known as aprataxin and pnkp like factor is associated with causing certain conditions. Specifically, it contributes both to progression-free survival and the development of carcinoma.', 'The protein, aprataxin and pnkp like factor, is known to cause two conditions: carcinoma and progression-free survival. This means that higher or lower activity levels of this protein could potentially result in the development of carcinoma or may influence progression-free survival in patients.', 'The gene known as Aprataxin and PNKP like factor is known to cause conditions such as progression-free survival and carcinoma.']"
"[{'source_node': {'name': 'tesaglitazar'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor alpha'}}, {'source_node': {'name': 'tesaglitazar'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor gamma'}}, {'source_node': {'name': 'peroxisome proliferator-activated receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PPARA'}}, {'source_node': {'name': 'peroxisome proliferator-activated receptor gamma'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PPARG'}}, {'source_node': {'name': 'PPARG'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'lipodystrophy'}}, {'source_node': {'name': 'PPARG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'PPARA activates gene expression'}}, {'source_node': {'name': 'PPARG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'MECP2 regulates transcription factors'}}]","[{'source_node': {'name': 'tesaglitazar'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor alpha'}}, {'source_node': {'name': 'tesaglitazar'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor gamma'}}, {'source_node': {'name': 'tesaglitazar'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'lipodystrophy'}}, {'source_node': {'name': 'peroxisome proliferator-activated receptor gamma'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PPARG'}}, {'source_node': {'name': 'PPARG'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'lipodystrophy'}}, {'source_node': {'name': 'PPARG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'PPARA activates gene expression'}}, {'source_node': {'name': 'PPARG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'MECP2 regulates transcription factors'}}]","[{'type': 'edge_addition', 'source': 'GENE:31196', 'target': 'PATHWAY:1167', 'metadata': {'predicate': 'acts_within'}}, {'type': 'edge_addition', 'source': 'GENE:31196', 'target': 'DISEASE:14867', 'metadata': {'predicate': 'causes_condition'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5647', 'target': 'GENE:31196', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5647', 'target': 'DISEASE:14867', 'metadata': {'predicate': 'is_substance_that_treats'}}, {'type': 'node_removal', 'source': 'GENE:31196', 'target': None, 'metadata': {'node_id': '31196', 'node_type': 'GENE', 'display_name': 'PPARA'}}]",0.8,3013b69fd82282c4bccc4933e3fd8e03,8ab6fb90f343bb2e28408231ca0abd33,"['The drug tesaglitazar targets both peroxisome proliferator-activated receptor alpha and peroxisome proliferator-activated receptor gamma. The peroxisome proliferator-activated receptor alpha is a gene product of PPARA while peroxisome proliferator-activated receptor gamma is a gene product of PPARG. It is known that PPARG causes lipodystrophy, a medical condition. Additionally, PPARG plays a significant role in several pathways, including the pathway wherein PPARA activates gene expression and the pathway where MECP2 regulates transcription factors.']","['The drug Tesaglitazar is known to target both the peroxisome proliferator-activated receptor alpha and peroxisome proliferator-activated receptor gamma. It is also a therapeutic substance for the disease lipodystrophy. Interestingly, the peroxisome proliferator-activated receptor gamma is a gene product of PPARG. PPARG has been identified as an entity that causes the condition lipodystrophy and has also been observed acting within two pathways: PPARA activates gene expression and MECP2 regulates transcription factors.']"
"[{'source_node': {'name': 'GNB2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G-protein activation'}}, {'source_node': {'name': 'GNB2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Thromboxane signalling through TP receptor'}}, {'source_node': {'name': 'GNB2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G beta:gamma signalling through BTK'}}]","[{'source_node': {'name': 'GNB2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G-protein activation'}}, {'source_node': {'name': 'GNB2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G beta:gamma signalling through BTK'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:760', 'target': None, 'metadata': {'node_id': '760', 'node_type': 'PATHWAY', 'display_name': 'Thromboxane signalling through TP receptor'}}]",0.7142857142857143,a96a17c2c59becb2e8b036f85e0856b0,0e981d3a4c4e422ed4504612eb93ee91,[],"['The gene GNB2 operates within multiple processes, specifically G-protein activation and G beta:gamma signalling through BTK.']"
"[{'source_node': {'name': 'deacetoxyvinzolidine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'calmodulin'}}, {'source_node': {'name': 'calmodulin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CALM1'}}, {'source_node': {'name': 'calmodulin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CALM2'}}, {'source_node': {'name': 'calmodulin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CALM3'}}, {'source_node': {'name': 'CALM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Activation of RAC1 downstream of NMDARs'}}]","[{'source_node': {'name': 'deacetoxyvinzolidine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'calmodulin'}}, {'source_node': {'name': 'CALM3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Activation of RAC1 downstream of NMDARs'}}, {'source_node': {'name': 'calmodulin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CALM2'}}, {'source_node': {'name': 'calmodulin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CALM3'}}, {'source_node': {'name': 'CALM2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Activation of RAC1 downstream of NMDARs'}}]","[{'type': 'edge_addition', 'source': 'GENE:34054', 'target': 'PATHWAY:751', 'metadata': {'predicate': 'acts_within'}}, {'type': 'node_removal', 'source': 'GENE:33953', 'target': None, 'metadata': {'node_id': '33953', 'node_type': 'GENE', 'display_name': 'CALM1'}}, {'type': 'edge_addition', 'source': 'GENE:34030', 'target': 'PATHWAY:751', 'metadata': {'predicate': 'acts_within'}}]",0.6363636363636364,6fa55db668dcaab87fe711ca1ca3d467,81f2eb810a592aff43f264123ee60a11,"['The compound deacetoxyvinzolidine targets calmodulin, a gene product of CALM1, CALM2, and CALM3. The gene CALM1 acts within the pathway of Activation of RAC1 downstream of NMDARs.', 'The molecule deacetoxyvinzolidine has a target called calmodulin. Calmodulin, in an interesting twist, is a gene product of not one, but three different genes: CALM1, CALM2, and CALM3. Further to this, CALM1 is known to act within a specific cellular pathway, namely the activation of RAC1 downstream of NMDARs.', 'The compound deacetoxyvinzolidine targets calmodulin, which is a gene product of CALM1, CALM2, and CALM3. Notably, CALM1 operates within a pathway known as Activation of RAC1 downstream of NMDARs.', 'The drug called Deacetoxyvinzolidine targets a protein called Calmodulin. This protein is a gene product of three genes - CALM1, CALM2, and CALM3. Among these, CALM1 is known to act within a biochemical pathway, specifically the activation of RAC1 downstream of NMDARs.', 'The drug deacetoxyvinzolidine has calmodulin as its target. Calmodulin is a gene product of three genes: CALM1, CALM2, and CALM3. Among these, CALM1 acts within a specific pathway known as activation of RAC1 downstream of NMDARs.']","['The drug deacetoxyvinzolidine targets a protein called calmodulin. Calmodulin is a gene product of both CALM2 and CALM3, indicating the significant role it plays within a biological context. Interestingly, both CALM2 and CALM3 are known to act within the pathway for the activation of RAC1 downstream of NMDARs, showcasing an inner connected network of biochemical reactions.', 'The drug deacetoxyvinzolidine has a target known as calmodulin. This calmodulin is a gene product of both CALM2 and CALM3. Both CALM2 and CALM3 act within a pathway known as activation of RAC1 downstream of NMDARs.', 'Deacetoxyvinzolidine is a substance that targets calmodulin, which is a gene product of both CALM2 and CALM3. Both of these genes function within the context of the activation of RAC1 downstream of NMDARs pathway. In other words, Calmodulin which is targeted by Deacetoxyvinzolidine is an output of the genes CALM2 and CALM3, and these genes contribute their actions to the activation of RAC1 downstream of NMDARs.', 'The drug deacetoxyvinzolidine targets calmodulin, a protein that is a gene product of CALM2 and CALM3. Both CALM2 and CALM3 are active within the pathway of activation of RAC1 downstream of NMDARs.', ""The chemical compound deacetoxyvinzolidine has a target interaction with the protein calmodulin. Calmodulin is a gene product of both CALM2 and CALM3. These genes play an active role within the biochemical pathway known as activation of RAC1 downstream of NMDARs, a crucial process in numerous regulatory interactions within an organism's cells.""]"
"[{'source_node': {'name': 'cephalostatin 11'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'cephalostatin 11'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h460'}}, {'source_node': {'name': 'cephalostatin 11'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'du-145'}}]","[{'source_node': {'name': 'cephalostatin 11'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h460'}}, {'source_node': {'name': 'cephalostatin 11'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'du-145'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5851', 'target': None, 'metadata': {'node_id': '5851', 'node_type': 'PROTEIN', 'display_name': 'mcf7'}}]",0.7142857142857143,f814663c3d717b1bf507553e7edd6beb,012b584185c27a4a74d74de97f793b93,"['Cephalostatin 11, a potent anticancer compound, has been found to target several cancer cell lines. These include MCF7, an estrogen-receptor positive breast cancer line; NCI-H460, a large cell lung cancer line; and DU-145, a prostate cancer cell line. These findings suggest a broad spectrum of activity for cephalostatin 11 across various cancer types.', 'Cephalostatin 11, a potent bioactive compound, has been identified as having multiple targets. These include MCF7, which is a common breast cancer cell line; NCI-H460, a type of lung cancer cell line; and DU-145, a cell line associated with prostate cancer.', 'The drug Cephalostatin 11 has been found to target several cells, including MCF7, NCI-H460, and DU-145. The targeting action of this drug can specifically affect these cells, making it an intriguing substance for further research and potential therapeutic applications.', 'The drug cephalostatin 11 has been found to target multiple entities such as mcf7, nci-h460, and du-145.', 'The drug cephalostatin 11 targets several entities including the MCF7, NCI-H460, and DU-145.']","['The compound cephalostatin 11 targets two different types of human cells: NCI-H460 and DU-145.', 'The drug Cephalostatin 11 has been identified as targeting two specific cells, NCI-H460 and DU-145.', 'The drug, cephalostatin 11, targets two distinct elements, namely, NCI-H460 and DU-145.']"
"[{'source_node': {'name': 'torasemide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'indapamide'}}, {'source_node': {'name': 'torasemide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dextromoramide'}}]","[{'source_node': {'name': 'torasemide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'indapamide'}}, {'source_node': {'name': 'torasemide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dextromoramide'}}, {'source_node': {'name': 'dextromoramide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'torasemide'}}, {'source_node': {'name': 'indapamide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'dextromoramide'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1459', 'target': 'COMPOUND:204', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:791', 'target': 'COMPOUND:1459', 'metadata': {'predicate': 'increase_efficacy'}}]",0.6,4bb2b5d7c45ca6ec34307a32a305dce1,6722fa634d55d564e115ac03f500634b,"['The drug torasemide is known to increase the efficacy of another drug, indapamide. However, it has the opposite effect on dextromoramide, where it decreases its efficacy.', ""The medication Torasemide has been shown to increase the efficacy of Indapamide. However, it's also been noted to decrease the efficacy of Dextromoramide."", 'The drug Torasemide is known to increase the efficacy of Indapamide treatment while it may potentially decrease the efficacy when used in conjunction with Dextromoramide. This interaction should be kept in mind when prescribing medication regimens.', 'The drug Torasemide is known to increase the efficacy of Indapamide. However, it should be noted that Torasemide also has the ability to reduce the efficacy of Dextromoramide.', 'The drug Torasemide is known to increase the efficacy of Indapamide. On the other hand, it decreases the efficacy of Dextromoramide.']","[""The pharmaceutical drug Torasemide is known to increase the efficacy of Indapamide and conversely decrease the efficacy of Dextromoramide. Interesting enough, Dextromoramide also decreases the efficacy of Torasemide. On the other hand, Indapamide works to bolster the efficacy of Dextromoramide. It's important to understand each of these relationships and potential interactions when prescribing and administering these medications."", 'The drug torasemide has been found to increase the efficacy of indapamide, while simultaneously reducing the efficacy of dextromoramide. Interestingly, dextromoramide also lessens the efficacy of torasemide. Indapamide, on the other hand, enhances the efficacy of dextromoramide. This complex interplay suggests a dynamically balanced drug interaction network among torasemide, indapamide, and dextromoramide.', 'The drug Torasemide is known to increase the efficacy of Indapamide while simultaneously decreasing the efficacy of Dextromoramide. This is not a one-way street, however, as Dextromoramide in turn also decreases the efficacy of Torasemide. Intriguingly, Indapamide is seen to increase the efficacy of Dextromoramide. These relationships highlight the complex and multidimensional interactions of these drugs.', 'The drug Torasemide has active interactions with two other drugs, namely Indapamide and Dextromoramide. It is observed that Torasemide tends to increase the efficacy of Indapamide, making it more effective in its function. However, Torasemide has an inverse effect on Dextromoramide by decreasing its efficacy. Similarly, Dextromoramide also decreases the efficacy of Torasemide, thereby showing a reciprocal relationship. On the contrary, it is observed that the drug Indapamide increases the efficacy of Dextromoramide. Therefore, the dynamics of the interaction between these three drugs, Torasemide, Indapamide, and Dextromoramide, show a unique pattern of interconnections in terms of efficacy modulation.', 'The use of the drug Torasemide increases the efficacy of another medication, Indapamide. However, Torasemide has a contrasting effect on Dextromoramide, where it decreases its efficacy. Conversely, Dextromoramide also diminishes the efficacy of Torasemide. Interestingly, Indapamide, on the other hand, boosts the efficacy of Dextromoramide.']"
"[{'source_node': {'name': 'ganoderic acid h'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'bel-7402'}}, {'source_node': {'name': 'ganoderic acid h'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}, {'source_node': {'name': 'ganoderic acid h'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepg2'}}]","[{'source_node': {'name': 'ganoderic acid h'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'bel-7402'}}, {'source_node': {'name': 'ganoderic acid h'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5817', 'target': None, 'metadata': {'node_id': '5817', 'node_type': 'PROTEIN', 'display_name': 'hepg2'}}]",0.7142857142857143,ea2ff0c31985c9c7c3996888ab0696e7,52cf15d7c6397c6617b5c29715f35a85,"['Ganoderic Acid H, a known agent with health properties, has been identified to target multiple cell lines, including BEL-7402, HeLa, and HepG2. These cell lines, used in research frequently, provide important insights into the biochemical and pharmacological effects of Ganoderic Acid H. This information could potentially lead to novel therapeutic applications in the medical field.', 'Ganoderic Acid H is known to target several types of cells. These include, but are not limited to, Bel-7402, a commonly used human liver cancer cell line, HeLa, the oldest and most commonly used human cell line, and HepG2, a perpetual cell line which was derived from the liver tissue of a human male.', 'The compound Ganoderic Acid H has several targets including the Bel-7402, Hela, and HepG2 cell lines.', 'Ganoderic Acid H is a compound that has been identified as a target for several cancer cells. Specifically, it targets the BEL-7402 strain of cells, which is a strain of human liver cancer cells. In addition, Ganoderic Acid H also targets HeLa cells, named after the patient from whom they were originally derived and are the first immortal human cells ever grown in culture. Another significant target of Ganoderic Acid H are HepG2 cells, a particular strain of liver carcinoma cells. This discovery further accentuates the potential role of Ganoderic Acid H in cancer cell targeting and treatment strategies.', 'The compound, Ganoderic acid H, has multiple targets, including the BEL-7402, HeLa, and HepG2 cell lines.']","['Ganoderic acid H, a known bioactive compound, has been found to target several cell lines. Specifically, it targets the BEL-7402 and HeLa cell lines, which are often used in biomedical research.', 'The compound Ganoderic Acid H targets two different entities, including Bel-7402 and HeLa.', 'The compound Ganoderic Acid H targets both Bel-7402 and HeLa cells.', 'The compound Ganoderic Acid H targets two distinct cells: BEL-7402 and Hela.', 'The bioactive compound Ganoderic acid H targets both BEL-7402 and HeLa cell lines.']"
"[{'source_node': {'name': 'infliximab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pev3a'}}, {'source_node': {'name': 'infliximab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'astrazeneca covid-19 vaccine'}}, {'source_node': {'name': 'infliximab'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'interleukin 2 receptor subunit alpha'}}, {'source_node': {'name': 'astrazeneca covid-19 vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'golimumab'}}, {'source_node': {'name': 'astrazeneca covid-19 vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluticasone furoate'}}]","[{'source_node': {'name': 'infliximab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pev3a'}}, {'source_node': {'name': 'infliximab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluticasone furoate'}}, {'source_node': {'name': 'astrazeneca covid-19 vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'golimumab'}}, {'source_node': {'name': 'astrazeneca covid-19 vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluticasone furoate'}}, {'source_node': {'name': 'astrazeneca covid-19 vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pev3a'}}]","[{'type': 'node_removal', 'source': 'GENE:9095', 'target': None, 'metadata': {'node_id': '9095', 'node_type': 'GENE', 'display_name': 'interleukin 2 receptor subunit alpha'}}, {'type': 'edge_addition', 'source': 'COMPOUND:62', 'target': 'COMPOUND:7858', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:62', 'target': 'COMPOUND:13152', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:13152', 'target': 'COMPOUND:4822', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.5454545454545454,6ada09b1825d4c2c3ba899a71cf7c481,d05ac61ebe764f7ba137eb150b2d1656,"['Infliximab, a biochemical drug, is known to decrease the efficacy of both Pev3a and the AstraZeneca COVID-19 vaccine. Moreover, it is affecting the Interleukin 2 receptor subunit alpha. Similarly, the AstraZeneca COVID-19 vaccine is found to decrease the efficacy of Golimumab and Fluticasone furoate. Therefore, the effectivity of these entities can be compromised when used in conjunction with Infliximab and the AstraZeneca COVID-19 vaccine.', 'Infliximab, a pharmaceutical agent, decreases the efficacy of both Pev3a and the AstraZeneca COVID-19 vaccine. Furthermore, Infliximab also affects the interleukin 2 receptor subunit alpha. Interestingly, the AstraZeneca COVID-19 vaccine has been found to decrease the efficacy of both Golimumab, a monoclonal antibody, and Fluticasone Furoate, a corticosteroid often used in the management of asthma.', 'The drug Infliximab decreases the efficacy of both PEV3A and the AstraZeneca COVID-19 vaccine. It also affects the interleukin 2 receptor subunit alpha, indicating a potential immunomodulatory role. On the other hand, the AstraZeneca COVID-19 vaccine has also been found to decrease the efficacy of the drugs Golimumab and Fluticasone Furoate. Therapeutic combinations involving these agents might require careful management to ensure optimal treatment outcomes.']","['The drugs infliximab and the AstraZeneca COVID-19 vaccine have each been reported to decrease the efficacy of a group of other medications. Specifically, infliximab diminishes the effectiveness of both Pev3a and Fluticasone furoate. Similarly, the AstraZeneca COVID-19 vaccine has been observed to decrease the efficacy of Golimumab, Fluticasone furoate and Pev3a. This implies potential drug interactions that may need to be considered in clinical practice.', 'The drug infliximab is known to decrease the efficacy of both pev3a and fluticasone furoate. Similarly, the AstraZeneca COVID-19 vaccine also reduces the effectiveness of golimumab, fluticasone furoate, and pev3a. This is critically important information for patients who may be on these drugs, as it could impact their treatment plans and outcomes.', 'Infliximab, a therapeutic drug, is known to decrease the efficacy of both PEV3A and Fluticasone Furoate. Similarly, the AstraZeneca Covid-19 vaccine has been reported to lower the effectiveness of Golimumab, Fluticasone Furoate, and PEV3A. It is important to consider the interactions between these entities when administering treatments in a clinical setting.', 'The drug Infliximab has been shown to decrease the efficacy of both Pev3a and Fluticasone furoate. Similarly, the AstraZeneca COVID-19 vaccine has also been identified to reduce the performance of Golimumab, Fluticasone furoate, and Pev3a. This suggests certain interactions between these drugs and the vaccine might affect their expected therapeutic outcomes.', 'The drug infliximab is known to decrease the efficacy of both pev3a and fluticasone furoate. In a similar vein, the AstraZeneca COVID-19 vaccine also exhibits a decrease in efficacy when administered in conjunction with either golimumab, fluticasone furoate, or pev3a.']"
"[{'source_node': {'name': 'cembrene_a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}, {'source_node': {'name': 'cembrene_a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}, {'source_node': {'name': 'cembrene_a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'phospholipase a2'}}, {'source_node': {'name': 'PLA2G1B'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Acyl chain remodelling of PC'}}, {'source_node': {'name': 'phospholipase a2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PLA2G2A'}}, {'source_node': {'name': 'phospholipase a2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PLA2G1B'}}]","[{'source_node': {'name': 'PLA2G2A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Acyl chain remodelling of PC'}}, {'source_node': {'name': 'cembrene_a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}, {'source_node': {'name': 'cembrene_a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}, {'source_node': {'name': 'PLA2G1B'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Acyl chain remodelling of PC'}}, {'source_node': {'name': 'phospholipase a2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PLA2G2A'}}, {'source_node': {'name': 'phospholipase a2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PLA2G1B'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:87873', 'target': 'PROTEIN:1047', 'metadata': None}, {'type': 'edge_addition', 'source': 'GENE:30996', 'target': 'PATHWAY:82', 'metadata': {'predicate': 'acts_within'}}]",0.8461538461538461,df7caa39524274bb0c31fb414a629561,a8961fdccb096adc813241d72895cde7,"['Cembrene_A is a compound with multiple targets, including HT-29, KB, and phospholipase a2. As a target, phospholipase a2 is particularly notable, as it is the gene product of both PLA2G2A and PLA2G1B. Importantly, PLA2G1B also acts within the acyl chain remodelling of PC pathway, highlighting the complex interplay between these various biochemical entities.']","['The genes PLA2G2A and PLA2G1B both act within the acyl chain remodelling of PC pathway. Notably, phospholipase a2 is the gene product of both PLA2G2A and PLA2G1B. In addition to this, the substance cembrene_a has been found to target the two targets: HT-29 and KB.']"
"[{'source_node': {'name': 'cetiedil'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the vasodilatory activities '}}, {'source_node': {'name': 'cetiedil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'patent blue'}}, {'source_node': {'name': 'patent blue'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'molsidomine'}}]","[{'source_node': {'name': 'cetiedil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'patent blue'}}, {'source_node': {'name': 'cetiedil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'molsidomine'}}, {'source_node': {'name': 'patent blue'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'molsidomine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:11600', 'target': 'COMPOUND:8217', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'ACTIVITY:37', 'target': None, 'metadata': {'node_id': '37', 'node_type': 'ACTIVITY', 'display_name': ' the vasodilatory activities '}}]",0.5714285714285714,92a417c6bedb9760781412fce690535b,721eb4eb1af184bdcc892968b1cd1063,[],"['The drug cetiedil is known to decrease the efficacy of both patent blue and molsidomine. It is also noteworthy that patent blue, when introduced into the system, can lessen the effectiveness of molsidomine.', ""The drug cetiedil has been observed to decrease the efficacy of both patent blue and molsidomine. Additionally, it's worth noting that patent blue can also decrease the efficacy of molsidomine."", 'The drug cetiedil is reported to decrease the efficacy of both patent blue and molsidomine. Interestingly, the patent blue dye also appears to reduce the efficacy of molsidomine, establishing a web of interaction wherein the efficacy of each substance is impacted by the others.', 'The drug cetiedil is known to decrease the efficacy of both patent blue and molsidomine. Interestingly, patent blue also reduces the efficacy of molsidomine.', ""The medication Cetiedil has been found to decrease the efficacy of both Patent Blue and Molsidomine. In turn, the use of Patent Blue can also diminish the effectiveness of Molsidomine. Therefore, it's crucial to consider potential interaction effects when co-administering these medicines.""]"
"[{'source_node': {'name': 'englitazone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'teprotumumab'}}, {'source_node': {'name': 'estetrol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rolitetracycline'}}, {'source_node': {'name': 'estetrol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'epofolate'}}, {'source_node': {'name': 'estetrol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'englitazone'}}]","[{'source_node': {'name': 'englitazone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'teprotumumab'}}, {'source_node': {'name': 'estetrol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'epofolate'}}, {'source_node': {'name': 'estetrol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'englitazone'}}, {'source_node': {'name': 'estetrol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'teprotumumab'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:10139', 'target': 'COMPOUND:5542', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:1274', 'target': None, 'metadata': {'node_id': '1274', 'node_type': 'COMPOUND', 'display_name': 'rolitetracycline'}}]",0.6666666666666667,140e4714894505c13b66717453f541f9,5acb59a6ab4a1db4cf33d6c543347989,"['The drug englitazone can decrease the efficacy of the treatment teprotumumab. Similarly, the drug estetrol has the potential to attenuate the therapeutic effects of multiple drugs, with specific examples including rolitetracycline, epofolate, and also englitazone.', 'Englitazone, a pharmacological agent is known to decrease the efficacy of Teprotumumab, a medicament used to treat several disorders. Similary, another medicinal compound, Estetrol, has been observed to reduce the potency of several treatments including Rolitetracycline, Epofolate and Englitazone. This suggests that the administration of these drugs together could potentially limit the therapeutic effects of each other.', 'Englitazone is known to decrease the efficacy of the drug Teprotumumab. Furthermore, Estetrol has been identified to decrease the efficacy of several medications including Rolitetracycline, Epofolate, and Englitazone. Therefore, these combinations should potentially be avoided in medicinal treatments.', 'The drug Englitazone has been found to decrease the efficacy of another drug, Teprotumumab. Similarly, Estetrol, another medication, has been associated with reduced efficacy of three different medications: Rolitetracycline, Epofolate, and Englitazone. Therefore, these simultaneous uses should be avoided where possible to maintain the therapeutic outcomes of the drugs.', 'The drug englitazone has been found to decrease the efficacy of teprotumumab. Concurrently, the use of estetrol can lead to reduced efficacy of several medicines such as rolitetracycline, epofolate and even englitazone. Therefore, it is important to consider these interactions when co-administering these drugs.']","['The drug Englitazone is known to decrease the efficacy of Teprotumumab. Similarly, Estetrol has been found to decrease the efficacy of both Epofolate and Englitazone. However, interestingly, research has shown that Estetrol can increase the efficacy of Teprotumumab.', 'Englitazone is known to decrease the efficacy of teprotumumab. Additionally, the drug estetrol has a dual role; it can decrease the efficacy of both epofolate and englitazone, but interestingly, it can increase the efficacy of teprotumumab.', 'Englitazone is a drug that has been found to decrease the efficacy of teprotumumab. Similarly, estetrol, another drug, can lessen the efficiency of both epofolate and englitazone. Interestingly, whilst estetrol decreases the efficacy of these two drugs, it can increase the efficacy of teprotumumab.', 'Englitazone is a drug that has been found to decrease the efficacy of teprotumumab. On the other hand, estetrol, another medication, has been shown to both decrease the efficacy of epofolate and englitazone, while interestingly, estetrol increases the efficacy of teprotumumab. This indicates complex interactions between these medications, which could influence their overall effect.', 'Englitazone is noted to decrease the efficacy of teprotumumab, a targeted treatment. Concurrently, the use of estetrol can lead to a decrease in the efficacy of both epofolate and englitazone. However, it is interesting to note that estetrol has the opposite effect on teprotumumab, wherein it actually increases its efficacy. Thus, the interaction of these drugs may lead to varying outcomes depending on the specific therapeutic combination.']"
"[{'source_node': {'name': 'murucoidin iv'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}, {'source_node': {'name': 'murucoidin iv'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}, {'source_node': {'name': 'murucoidin iv'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hep-2'}}]","[{'source_node': {'name': 'murucoidin iv'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}, {'source_node': {'name': 'murucoidin iv'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hep-2'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5858', 'target': None, 'metadata': {'node_id': '5858', 'node_type': 'PROTEIN', 'display_name': 'kb'}}]",0.7142857142857143,5cc845ba65c5734d967b12d8d3c9a8d0,d070f223577033138143e800dbfede3a,"['The drug Murucoidin IV has shown to have multiple biological targets. It has an affinity for HeLa, a human cervix carcinoma cell line, and also for KB, which is a particular kind of human mouth epidermoid carcinoma cell line. Additionally, Murucoidin IV also targets Hep-2, a human tissue cultured cells that are widely used for research purposes. This interaction of the drug with diverse cell types indicates the broadness of its biological action.', 'The compound Murucoidin IV has several targets including HeLa, KB and Hep-2.', 'The compound Murucoidin IV has been shown to target various entities, specifically Hela, KB, and Hep-2.', 'Murucoidin IV has multiple targets including HeLa, KB, and HEP-2 cells.', 'Murucoidin IV has several targets, including HeLa, KB, and Hep-2.']","['Murucoidin IV has been identified to target cells, specifically HeLa and Hep-2.', 'The compound Murucoidin IV targets both HeLa and HEP-2 cells.', 'The compound Murucoidin IV targets both HeLa and Hep-2 cells.', 'The drug Murucoidin IV has been found to target HeLa, a type of human cancer cell line, as well as Hep-2, another cell line often used in scientific research.', 'The compound Murucoidin IV targets two distinct cell lines, specifically, HeLa and Hep-2.']"
"[{'source_node': {'name': 'nn344'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'leuprolide'}}, {'source_node': {'name': 'estrone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'gliclazide'}}, {'source_node': {'name': 'estrone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nn344'}}, {'source_node': {'name': 'estrone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}}]","[{'source_node': {'name': 'gliclazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'estrone'}}, {'source_node': {'name': 'estrone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'gliclazide'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:4793', 'target': None, 'metadata': {'node_id': '4793', 'node_type': 'COMPOUND', 'display_name': 'nn344'}}, {'type': 'node_removal', 'source': 'PROTEIN:6169', 'target': None, 'metadata': {'node_id': '6169', 'node_type': 'PROTEIN', 'display_name': 'tyrosyl-dna phosphodiesterase 1'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1100', 'target': 'COMPOUND:641', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.2222222222222222,313fbcf5370a507fd6248784f1df464f,c81588f959b6c83e22d4273fadc6021c,"['The compounds NN344 and Estrone have been identified to potentially decrease the efficacy of certain medications. For instance, NN344 is known to hinder the effectiveness of Leuprolide, a hormone therapy drug. Similarly, Estrone can reduce the effectiveness of Gliclazide, a drug used in the treatment of type 2 diabetes. Furthermore, Estrone is also capable of decreasing the efficacy of NN344. In addition to its inhibitory activity, Estrone also targets a specific enzyme named Tyrosyl-DNA phosphodiesterase 1, which plays a key role in DNA repair processes.', 'The drug NN344 decreases the efficacy of leuprolide. Similarly, estrone has a role in reducing the potency of gliclazide and NN344. Furthermore, estrone also targets enzyme tyrosyl-DNA phosphodiesterase 1. Thus, these compounds interact in an intricate manner, influencing the efficacy and target specificity of each other.', ""The interaction of nn344 decreases the efficacy of the drug leuprolide. Similarly, estrone, a form of estrogen, also has the capacity to decrease the effectiveness of drugs, including gliclazide and nn344. Additionally, it's noteworthy to point out that estrone targets a specific enzyme known as tyrosyl-DNA phosphodiesterase 1."", 'The compound NN344 is known to decrease the efficacy of the drug leuprolide. Similarly, estrone, a form of estrogen, has been found to decrease the efficacy of both the drug gliclazide and the compound NN344. Additionally, estrone has a biochemical interaction with the enzyme known as tyrosyl-DNA phosphodiesterase 1.', 'In certain biochemical interactions, different components can influence each other negatively. Take for instance, the component nn344 that significantly decreases the efficacy of the drug leuprolide. Similarly, estrone, a steroid compound, is known to lessen the efficacy of both gliclazide, an antidiabetic drug, as well as nn344. Furthermore, estrone targets a specific enzyme known as the tyrosyl-dna phosphodiesterase 1, which is crucial in DNA repair processes.']","['The drug Gliclazide is known to decrease the efficacy of Estrone. Conversely, Estrone also diminishes the effectiveness of Gliclazide.', 'The drug Gliclazide and the hormone Estrone have a complex interaction where each substance decreases the efficacy of the other.', 'The drug gliclazide is known to decrease the efficacy of estrone. Interestingly, the reverse is also true, in that estrone similarly has been found to reduce the efficacy of gliclazide.', ""The drug Gliclazide is known to decrease the efficacy of Estrone. In turn, Estrone also diminishes the effectiveness of Gliclazide. This indicates a reciprocal interaction where both drugs decrease each other's efficacy."", 'The drug Gliclazide has been shown to decrease the efficacy of the hormone Estrone, and interestingly, Estrone also reciprocally decreases the efficacy of Gliclazide.']"
"[{'source_node': {'name': 'nabilone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Irritability'}}, {'source_node': {'name': 'nabilone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Tachycardia'}}, {'source_node': {'name': 'nabilone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Agitation'}}]","[{'source_node': {'name': 'nabilone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Irritability'}}, {'source_node': {'name': 'nabilone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Tachycardia'}}]","[{'type': 'node_removal', 'source': 'SIDE_EFFECT:285', 'target': None, 'metadata': {'node_id': '285', 'node_type': 'SIDE_EFFECT', 'display_name': 'Agitation'}}]",0.7142857142857143,2c0f1209bbc8e7d4370f64cf6bcbdb17,a42cd4024d721b00f0321f50caee7043,"['The drug Nabilone is noted to have several side effects. Users often report high levels of irritability and agitation after consumption. Additionally, it has also been marked with the stimulant side effect of tachycardia, resulting in abnormally rapid heart rates.', 'The drug Nabilone is known to produce several side effects including irritability, tachycardia, and agitation.', 'The drug nabilone is known to have certain side effects including inducing irritability, causing an abnormally rapid heart rate known as tachycardia, and leading to an increased propensity for agitation.', 'The drug Nabilone is known to have several side effects, including irritability, tachycardia, and agitation.', 'The drug Nabilone is known to have several side effects. Among these are irritability, tachycardia, and agitation.']","['The medication Nabilone is known to have several side effects, which include irritability and tachycardia.', 'The drug Nabilone has several potential side effects, which includes causing irritability and inducing tachycardia.', 'The drug Nabilone, known for its potential side effects, may cause irritability and tachycardia in some patients.', 'The drug nabilone, often used for therapeutic purposes, has some notable side effects including inducing irritability and causing tachycardia in some patients.', 'The drug Nabilone is known to have certain side effects such as causing irritability and inducing tachycardia.']"
"[{'source_node': {'name': 'patent blue'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'prazosin'}}, {'source_node': {'name': 'patent blue'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cilostazol'}}, {'source_node': {'name': 'patent blue'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bencyclane'}}, {'source_node': {'name': 'imolamine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the vasodilatory activities '}}, {'source_node': {'name': 'imolamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'patent blue'}}, {'source_node': {'name': 'cilostazol'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the excretion rate '}}]","[{'source_node': {'name': 'patent blue'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cilostazol'}}, {'source_node': {'name': 'patent blue'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bencyclane'}}, {'source_node': {'name': 'imolamine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the vasodilatory activities '}}, {'source_node': {'name': 'imolamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cilostazol'}}, {'source_node': {'name': 'cilostazol'}, 'relation': {'name': 'increase_activity'}, 'target_node': {'name': ' the vasodilatory activities '}}]","[{'type': 'node_removal', 'source': 'ACTIVITY:7', 'target': None, 'metadata': {'node_id': '7', 'node_type': 'ACTIVITY', 'display_name': ' the excretion rate '}}, {'type': 'node_removal', 'source': 'COMPOUND:445', 'target': None, 'metadata': {'node_id': '445', 'node_type': 'COMPOUND', 'display_name': 'prazosin'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:8219', 'target': 'COMPOUND:11806', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:8219', 'target': 'COMPOUND:1146', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1146', 'target': 'ACTIVITY:37', 'metadata': {'predicate': 'increase_activity'}}]",0.4615384615384615,65e9fe81d4254f3bd0c7cf8a11145f0e,9bf4e85b3a3d260f9a8d2650812470c4,[],[]
"[{'source_node': {'name': 'cyclododecane'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'androgen receptor'}}, {'source_node': {'name': 'androgen receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AR'}}]","[{'source_node': {'name': 'cyclododecane'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'androgen receptor'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:38097', 'target': 'GENE:29295', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'GENE:29295', 'target': None, 'metadata': {'node_id': '29295', 'node_type': 'GENE', 'display_name': 'AR'}}]",0.6,f023872c3d5644e4a8062e4e5d421f89,e27cabcf9bcb148cf4ca8b80540041ed,"['Cyclododecane has a specific target known as the androgen receptor. Interestingly, this androgen receptor is a gene product of the AR gene.', 'The chemical compound cyclododecane targets the androgen receptor, which is a gene product of AR.', 'The compound cyclododecane has a target in the form of the androgen receptor which is a gene product of AR.', 'The compound Cyclododecane targets the Androgen receptor. Furthermore, this receptor is a gene product of the AR gene.', 'The substance Cyclododecane has been identified as a target for the Androgen Receptor, which itself is a gene product of the AR gene.']",['The compound cyclododecane has the androgen receptor as its target.']
"[{'source_node': {'name': 'betrixaban'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'turoctocog alfa'}}, {'source_node': {'name': 'cephaloglycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'streptokinase'}}, {'source_node': {'name': 'cephaloglycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'triflusal'}}, {'source_node': {'name': 'cephaloglycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'betrixaban'}}]","[{'source_node': {'name': 'betrixaban'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'turoctocog alfa'}}, {'source_node': {'name': 'betrixaban'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cephaloglycin'}}, {'source_node': {'name': 'betrixaban'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'triflusal'}}, {'source_node': {'name': 'cephaloglycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'streptokinase'}}, {'source_node': {'name': 'cephaloglycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'triflusal'}}, {'source_node': {'name': 'cephaloglycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'betrixaban'}}, {'source_node': {'name': 'cephaloglycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'turoctocog alfa'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:10265', 'target': 'COMPOUND:674', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:10265', 'target': 'COMPOUND:7780', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:674', 'target': 'COMPOUND:8049', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.6666666666666667,3fedec950fad694782c72eb642b5abb1,28e8f74c083ce98c6aa024fb7578ce1a,"['Betrixaban is known to decrease the efficacy of turoctocog alfa. Similarly, cephaloglycin, another drug, tends to decrease the efficacy of both streptokinase and triflusal. It is interesting to note that cephaloglycin also reduces the efficacy of betrixaban, further highlighting the complex interplay between different drugs in a biological system.', 'Betrixaban is a drug known to decrease the efficacy of a medication called Turoctocog alfa. Similarly, Cephaloglycin, another medication, decreases the efficacy of Streptokinase and Triflusal. Interestingly, Cephaloglycin also interferes with Betrixaban, bringing down its effectiveness.', 'The drug Betrixaban has been found to decrease the efficacy of Turoctocog Alfa. Similarly, Cephaloglycin, another drug, is known to decrease the efficacy of several substances, including Streptokinase, Triflusal, and Betrixaban itself. This suggests a complex network of interactions between these substances, which may have implications for treatment strategies.', 'The drug Betrixaban has been found to decrease the efficacy of Turoctocog Alfa. Similarly, Cephaloglycin, another drug, can reduce the efficacy of several other medical substances. Those include Streptokinase, Triflusal, and also Betrixaban. Hence, caution is recommended when combining these substances in treatment.', 'The anticoagulant drug, Betrixaban, has been noted to decrease the efficacy of the clotting factor drug, Turoctocog Alfa. Cephaloglycin, an antibiotic, is also known to reduce the effectiveness of several drugs, including Streptokinase, an agent used to dissolve blood clots; Triflusal, a platelet aggregation inhibitor; and interestingly, it also decreases the efficacy of Betrixaban. As such, it is advisable to consider these interactions when administering these drugs for optimal therapeutic results.']","[""The drug Betrixaban has been observed to decrease the efficacy of several other drugs including Turoctocog Alfa, Cephaloglycin, and Triflusal. On the other hand, Cephaloglycin also reduces the effectiveness of Betrixaban, Turoctocog Alfa, Streptokinase, and Triflusal. Thus, it is important to consider these interactions when prescribing the mentioned drugs concurrently as they could potentially interfere with each other's effectiveness."", 'Betrixaban is a drug known to decrease the efficacy of several other substances such as turoctocog alfa, cephaloglycin, and triflusal. Similarly, the drug cephaloglycin also shows decreased efficacy when taken with substances like streptokinase, triflusal, betrixaban and turoctocog alfa. This complex web of interactions highlights the importance of careful management and review of medication regimens to avoid negative interaction effects.', ""The drug Betrixaban has been observed to decrease the efficacy of several other drugs including Turoctocog Alfa, Cephaloglycin, and Triflusal. In like manner, Cephaloglycin also has a negative impact on the effectiveness of other drugs. It's known to decrease the efficacy of Streptokinase, Triflusal, Betrixaban, and even Turoctocog Alfa. Therefore, caution should be exercised when administering these specific combinations of drugs."", 'The drug Betrixaban is known to decrease the efficacy of several substances including Turoctocog alfa, Cephaloglycin, and Triflusal. Cephaloglycin is another drug that similarly decreases the efficacy of Streptokinase, Triflusal, Betrixaban, and Turoctocog alfa. Therefore, careful consideration should be taken when combining these substances due to their potential interactions.', 'The drug Betrixaban is documented to decrease the efficacy of Turoctocog Alfa, Cephaloglycin, and Triflusal. Similarly, Cephaloglycin, another medication, has also been noted to decrease the efficacy of Streptokinase, Triflusal, Betrixaban, and Turoctocog Alfa. These complex interactions between multiple drugs offer a robust reminder of the criticality in understanding drug-drug interactions in clinical pharmacology.']"
"[{'source_node': {'name': 'prune1-related neurological syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'bilateral talipes equinovarus'}}, {'source_node': {'name': 'prune1-related neurological syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'epileptic spasm'}}]","[{'source_node': {'name': 'prune1-related neurological syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'epileptic spasm'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1290', 'target': None, 'metadata': {'node_id': '1290', 'node_type': 'PHENOTYPE', 'display_name': 'bilateral talipes equinovarus'}}]",0.6,e75695258b92003a95351dd1b32df20f,ffb68b237e43ac65faae58290bebf5e3,"['Prune1-related neurological syndrome is a condition that is characterized by symptoms such as bilateral talipes equinovarus and epileptic spasms.', 'The prune1-related neurological syndrome presents various phenotypes such as bilateral talipes equinovarus and epileptic spasm.', 'Prune1-related neurological syndrome is a condition that manifests with symptoms such as bilateral talipes equinovarus and epileptic spasms.', '""Prune1-related neurological syndrome, a disorder characterized by various phenotypic symptoms, manifests as bilateral talipes equinovarus and epileptic spasms.', 'Prune1-related neurological syndrome, a complex neurological condition, exhibits phenotypes such as bilateral talipes equinovarus and epileptic spasms.']",[]
"[{'source_node': {'name': '2-amino-4-(hydroxymethyl-phosphinyl)butanoic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glutamine synthetase'}}, {'source_node': {'name': 'GLUL'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'glutamine deficiency'}}, {'source_node': {'name': 'GLUL'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glutamate and glutamine metabolism'}}, {'source_node': {'name': 'glutamine synthetase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GLUL'}}, {'source_node': {'name': 'glutamine deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'antenatal onset'}}]","[{'source_node': {'name': 'GLUL'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'glutamine deficiency'}}, {'source_node': {'name': 'GLUL'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glutamate and glutamine metabolism'}}, {'source_node': {'name': 'glutamine synthetase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GLUL'}}, {'source_node': {'name': 'glutamine deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'antenatal onset'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:2516', 'target': 'GENE:28168', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'COMPOUND:2516', 'target': 'DISEASE:14684', 'metadata': {'predicate': 'is_substance_that_treats'}}, {'type': 'node_removal', 'source': 'COMPOUND:2516', 'target': None, 'metadata': {'node_id': '2516', 'node_type': 'COMPOUND', 'display_name': '2-amino-4-(hydroxymethyl-phosphinyl)butanoic acid'}}]",0.8181818181818181,fdfa1cfd7e430762b9ff346067025874,1172674e36c6fee6e9dd4fef46170e91,"['The drug 2-amino-4-(hydroxymethyl-phosphinyl)butanoic acid targets the protein glutamine synthetase. This protein is a gene product of GLUL, which also acts within the pathway of glutamate and glutamine metabolism. Significantly, GLUL is known to cause a condition known as glutamine deficiency. Glutamine deficiency has identifiable aspects, inclusive of an antenatal onset that phenotypically manifests itself early in development.', ""The drug 2-amino-4-(hydroxymethyl-phosphinyl)butanoic acid targets glutamine synthetase. This enzyme is a gene product of GLUL, which is involved in the process of glutamate and glutamine metabolism. When GLUL doesn't function properly, it can lead to a glutamine deficiency, which is characterized by antenatal onset, indicating the symptoms are visible before birth."", 'The compound 2-amino-4-(hydroxymethyl-phosphinyl)butanoic acid has a target, glutamine synthetase. Interestingly, glutamine synthetase is the gene product of GLUL. This same gene, GLUL, also plays a significant role within glutamate and glutamine metabolism. However, dysfunctional GLUL causes a condition known as glutamine deficiency. This deficiency is usually characterized by an antenatal onset.', 'The compound 2-amino-4-(hydroxymethyl-phosphinyl)butanoic acid targets glutamine synthetase. Glutamine synthetase is a gene product of GLUL, a gene which plays a significant role in glutamate and glutamine metabolism and is responsible for causing glutamine deficiency. Notably, glutamine deficiency is characterized by the phenotype of antenatal onset.', 'The drug 2-amino-4-(hydroxymethyl-phosphinyl)butanoic acid has a target, the glutamine synthetase. Interesting enough, glutamine synthetase is a gene product of the GLUL gene, which operates within the glutamate and glutamine metabolism process. GLUL is also known to cause a condition known as glutamine deficiency. Glutamine deficiency presents with a phenotype characterized by antenatal onset.']",['The enzyme glutamine synthetase is a gene product of the protein GLUL which operates within the framework of glutamate and glutamine metabolism. It should be noted that GLUL is implicated as a cause for glutamine deficiency. This specific deficiency is characterized by symptoms with an antenatal onset.']
"[{'source_node': {'name': 'NR1H4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of bile acids and bile salts'}}, {'source_node': {'name': 'nuclear receptor ror-gamma'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RORC'}}, {'source_node': {'name': 'anthranilic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'bile acid receptor'}}, {'source_node': {'name': 'anthranilic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear receptor ror-gamma'}}, {'source_node': {'name': 'anthranilic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hek293'}}, {'source_node': {'name': 'bile acid receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR1H4'}}]","[{'source_node': {'name': 'NR1H4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of bile acids and bile salts'}}, {'source_node': {'name': 'nuclear receptor ror-gamma'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RORC'}}, {'source_node': {'name': 'bile acid receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR1H4'}}, {'source_node': {'name': 'RORC'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of bile acids and bile salts'}}]","[{'type': 'edge_addition', 'source': 'GENE:32371', 'target': 'PATHWAY:687', 'metadata': {'predicate': 'acts_within'}}, {'type': 'edge_addition', 'source': 'COMPOUND:3922', 'target': 'GENE:35769', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'COMPOUND:3922', 'target': None, 'metadata': {'node_id': '3922', 'node_type': 'COMPOUND', 'display_name': 'anthranilic acid'}}]",0.5384615384615384,ed3f02fbd1a327bf5261823ec3fcedd0,bab3d9a4f329fcbeaf4f1cfed176c238,[],[]
"[{'source_node': {'name': 'solute carrier family 28 member 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'breast neoplasms'}}, {'source_node': {'name': 'solute carrier family 28 member 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neutropenia'}}, {'source_node': {'name': 'solute carrier family 28 member 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pancreatic neoplasms'}}, {'source_node': {'name': 'ara-ctp'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'solute carrier family 28 member 1'}}, {'source_node': {'name': 'ara-ctp'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'ctp synthase 1'}}, {'source_node': {'name': 'ara-ctp'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'deoxycytidine kinase'}}, {'source_node': {'name': 'ctp synthase 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'myelosuppression'}}, {'source_node': {'name': 'ctp synthase 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neurotoxicity syndromes'}}]","[{'source_node': {'name': 'ara-ctp'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'deoxycytidine kinase'}}, {'source_node': {'name': 'ctp synthase 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'myelosuppression'}}]","[{'type': 'node_removal', 'source': 'DISEASE:412', 'target': None, 'metadata': {'node_id': '412', 'node_type': 'DISEASE', 'display_name': 'breast neoplasms'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:89690', 'target': 'GENE:19267', 'metadata': None}, {'type': 'node_removal', 'source': 'DISEASE:2401', 'target': None, 'metadata': {'node_id': '2401', 'node_type': 'DISEASE', 'display_name': 'pancreatic neoplasms'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:89690', 'target': 'GENE:4153', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:19267', 'target': None, 'metadata': {'node_id': '19267', 'node_type': 'GENE', 'display_name': 'solute carrier family 28 member 1'}}, {'type': 'node_removal', 'source': 'DISEASE:2256', 'target': None, 'metadata': {'node_id': '2256', 'node_type': 'DISEASE', 'display_name': 'neurotoxicity syndromes'}}]",0.3529411764705882,366779756d6066f40f31c0c6eb5ef070,333a39e289e339d63be2b523c6c7b26b,"['The gene solute carrier family 28 member 1 has been linked to causing several conditions such as breast neoplasms, neutropenia, and pancreatic neoplasms. Interestingly, this gene seems to be affected by ara-ctp, a molecule that also affects ctp synthase 1 and deoxycytidine kinase. In a similar vein, the gene ctp synthase 1 is known to cause conditions like myelosuppression and neurotoxicity syndromes. Thus, it appears there could be an intricate interplay between these genes and molecules in the development and progression of these related conditions.', 'The protein, solute carrier family 28 member 1, has been identified to cause various conditions including breast neoplasms, neutropenia, and pancreatic neoplasms. Similarly, the protein ctp synthase 1 has been found to cause conditions such as myelosuppression and neurotoxicity syndromes. These proteins are known to be affected by Ara-CTP, along with deoxycytidine kinase. Therefore, the relationships indicate that alterations in these proteins may lead to various diseases, demonstrating the complexities of cellular mechanisms and their implications for health.', ""The gene known as solute carrier family 28 member 1 is known to cause several conditions including breast neoplasms, neutropenia, and pancreatic neoplasms. Furthermore, this gene is affected by the compound known as ara-CTP, which also affects other genes such as CTP synthase 1 and deoxycytidine kinase. It's interesting to note that CTP synthase 1 can cause conditions such as myelosuppression and neurotoxicity syndromes."", ""Solute Carrier Family 28 Member 1 is known to contribute to several conditions such as breast neoplasms, neutropenia, and pancreatic neoplasms. Interestingly, this gene is affected by a molecule known as ARA-CTP. This molecular interaction appears to be influential as ARA-CTP also affects a gene known as CTP Synthase 1 and a kinase called Deoxycytidine Kinase.\n\nIn addition to its interactions with Solute Carrier Family 28 Member 1, ARA-CTP's influence extends to CTP Synthase 1, which is also notable for causing several conditions. For example, CTP Synthase 1 can lead to conditions like myelosuppression and neurotoxicity syndromes. Thus, through these complex interactions and relationships, it is clear that these entities are deeply intertwined in both healthy biological function and disease pathology."", 'The Solute Carrier Family 28 Member 1, caused by various conditions, including breast neoplasms, neutropenia, and pancreatic neoplasms. This protein is affected by Ara-CTP, a medication that also impacts other systems such as CTP Synthase 1 and Deoxycytidine Kinase. Unintentional impacts on CTP Synthase 1 may lead to conditions like myelosuppression and neurotoxicity syndromes.']","['The molecule Ara-CTP is affecting the deoxycytidine kinase enzyme. It is important to note that an enzyme called CTP synthase 1 has been identified as a cause of a condition known as myelosuppression, a characteristic decrease in the production of blood cells.', 'The compound Ara-CTP is affecting the activity of an enzyme known as deoxycytidine kinase. In a related context, CTP synthase 1, another enzyme, has been implicated in the cause of a condition known as myelosuppression.', 'The compound Ara-CTP is affecting deoxycytidine kinase. In parallel, enzyme CTP synthase 1 can cause a condition named myelosuppression.']"
"[{'source_node': {'name': 'olsalazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trolamine salicylate'}}, {'source_node': {'name': 'tenoxicam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'olsalazine'}}, {'source_node': {'name': 'tenoxicam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dasiglucagon'}}, {'source_node': {'name': 'tenoxicam'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Agranulocytosis'}}]","[{'source_node': {'name': 'trolamine salicylate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'olsalazine'}}, {'source_node': {'name': 'olsalazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trolamine salicylate'}}, {'source_node': {'name': 'olsalazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tenoxicam'}}, {'source_node': {'name': 'olsalazine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Agranulocytosis'}}, {'source_node': {'name': 'tenoxicam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'olsalazine'}}, {'source_node': {'name': 'tenoxicam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dasiglucagon'}}, {'source_node': {'name': 'tenoxicam'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Agranulocytosis'}}, {'source_node': {'name': 'tenoxicam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trolamine salicylate'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1230', 'target': 'COMPOUND:457', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:457', 'target': 'COMPOUND:9097', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1230', 'target': 'SIDE_EFFECT:545', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'edge_addition', 'source': 'COMPOUND:9097', 'target': 'COMPOUND:1230', 'metadata': {'predicate': 'increase_efficacy'}}]",0.5555555555555556,86a3b4e9661d203359aa308ec8aa3ad3,60dd35d0d4cf78163111795372c6c770,"[""The drug Olsalazine can decrease the efficacy of Trolamine Salicylate. Simultaneously, Tenoxicam can decrease the efficacy of Olsalazine. It's also important to note that Tenoxicam can potentially decrease the efficacy of another drug, known as Dasiglucagon. Moreover, this drug Tenoxicam is associated with a side effect, the condition known as Agranulocytosis."", 'The drug Olsalazine is known to decrease the efficacy of trolamine salicylate. In addition to this, Tenoxicam, another medication, has been reported to decrease the therapeutic effectiveness of Olsalazine. Furthermore, Tenoxicam also reduces the efficacy of an additional drug named Dasiglucagon. It should be taken into account that one of the potential side effects of Tenoxicam is Agranulocytosis, a serious condition that occurs when the body lacks granulocytes, a type of white blood cell.', ""The drug Olsalazine is known to decrease the efficacy of Trolamine Salicylate. Furthermore, Olsalazine's effectiveness is also found to be diminished by Tenoxicam. Interestingly, Tenoxicam not only decreases the efficacy of Olsalazine but it also lowers the efficiency of another drug known as Dasiglucagon. It is notable to mention that one of the probable side effects of Tenoxicam is Agranulocytosis, a serious condition affecting the white blood cells."", ""The drug Olsalazine is known to decrease the efficacy of the therapeutic compound Trolamine Salicylate. Further, Tenoxicam, another drug, similarly decreases the efficacy of Olsalazine. It's worth noting that Tenoxicam does not only affect Olsalazine, but it also decreases the efficacy of Dasiglucagon. In addition to its interference with these drugs, Tenoxicam may lead to a serious side effect known as Agranulocytosis, a condition marked by a severe and dangerous reduction in white blood cells."", 'The drug olsalazine has been observed to decrease the efficacy of trolamine salicylate. Similarly, the drug tenoxicam appears to decrease the efficacy of both olsalazine and dasiglucagon. Moreover, a documented side effect of tenoxicam is Agranulocytosis.']","['The drug Trolamine Salicylate can increase the efficacy of Olsalazine. However, the inverse relation is not true as Olsalazine has been found to decrease the efficacy of Trolamine Salicylate. In addition to its impact on Trolamine Salicylate, Olsalazine can also decrease the efficacy of another drug, Tenoxicam. Unfortunately, Olsalazine has been linked to Agranulocytosis as a side effect. Tenoxicam has a similar pattern of interaction as Olsalazine because it also decreases the efficacy of Olsalazine and Trolamine Salicylate. Furthermore, it reduces the efficacy of Dasiglucagon, a different medication. Just like Olsalazine, Tenoxicam can also produce Agralulocytosis as a side effect. This intricate network of interactions between these three drugs and their associated effects underscore the complexity in drug interactions where efficacy and side effects can be significantly influenced by the presence of other drugs.', ""The drug trolamine salicylate is known to increase the efficacy of olsalazine, thereby enhancing its effects. However, it's a two-way process as olsalazine has also been observed to decrease the efficacy of trolamine salicylate. In addition, olsalazine has been known to reduce the effectiveness of another drug, tenoxicam. An interesting negative effect of olsalazine is that it might lead to Agranulocytosis, a severe and potentially dangerous side effect. Similarly, Tenoxicam not only reduces the efficacy of olsalazine, but it also interferes with the action of dasiglucagon and trolamine salicylate. Furthermore, tenoxicam could induce Agranulocytosis as a side effect as well. Therefore, the interplay and side effects of these drugs should be closely monitored."", 'The drug Trolamine Salicylate enhances the effectiveness of Olsalazine. However, the use of Olsalazine in turn decreases the efficacy of Trolamine Salicylate and Tenoxicam. In addition to its inverse relationship with these two medications, Olsalazine can cause side effects such as Agranulocytosis.\n\nSimilarly, Tenoxicam decreases the effectiveness of not only Olsalazine and Trolamine Salicylate but also of another drug called Dasiglucagon. In addition to negatively impacting the performance of these drugs, Tenoxicam is also noted as having Agranulocytosis as a potential side effect. This complex interaction between these drugs and their effects highlights the intricacy of pharmaceutical interactions and the importance of personalized drug regimen.']"
"[{'source_node': {'name': 'ascorbic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'gamma-butyrobetaine dioxygenase'}}, {'source_node': {'name': 'ascorbic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'erythromycin'}}, {'source_node': {'name': 'ascorbic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'streptomycin'}}, {'source_node': {'name': 'streptomycin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histone-lysine n-methyltransferase'}}, {'source_node': {'name': 'lincomycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ascorbic acid'}}, {'source_node': {'name': 'lincomycin'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'furuncle'}}, {'source_node': {'name': 'lincomycin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Megacolon'}}]","[{'source_node': {'name': 'ascorbic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'gamma-butyrobetaine dioxygenase'}}, {'source_node': {'name': 'ascorbic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'streptomycin'}}, {'source_node': {'name': 'streptomycin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histone-lysine n-methyltransferase'}}, {'source_node': {'name': 'streptomycin'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'furuncle'}}, {'source_node': {'name': 'lincomycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ascorbic acid'}}, {'source_node': {'name': 'lincomycin'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'furuncle'}}, {'source_node': {'name': 'lincomycin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Megacolon'}}, {'source_node': {'name': 'lincomycin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'gamma-butyrobetaine dioxygenase'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1554', 'target': 'PROTEIN:293', 'metadata': {'predicate': 'has_target'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1062', 'target': 'INDICATION:1371', 'metadata': {'predicate': 'has_indication'}}, {'type': 'node_removal', 'source': 'COMPOUND:189', 'target': None, 'metadata': {'node_id': '189', 'node_type': 'COMPOUND', 'display_name': 'erythromycin'}}]",0.7333333333333334,6d6c788dcbc49dcb9b4e7a29da370127,ee4b82cf01c912e500ab27e24130e0a7,"[""The vitamin, ascorbic acid, has target interactions with the enzyme gamma-butyrobetaine dioxygenase. Interestingly, ascorbic acid also decreases the efficacy of two antibiotics: erythromycin and streptomycin. Streptomycin, in turn, targets histone-lysine n-methyltransferase. It should be noted that ascorbic acid's effectiveness can be decreased by the drug lincomycin. Lincomycin is specifically indicated for the treatment of furuncle, a type of skin infection, but one of its side effects can be a condition known as Megacolon."", 'The drug ascorbic acid has a target, gamma-butyrobetaine dioxygenase. However, it is important to note that ascorbic acid decreases the efficacy of other medications such as erythromycin and streptomycin. Specifically, streptomycin has its target as histone-lysine n-methyltransferase. On a related note, the drug lincomycin decreases the efficacy of ascorbic acid. Lincomycin has been indicated for conditions such as furuncle but it may cause side effects including Megacolon.', ""Ascorbic acid, a molecule with numerous functions, has been shown to target the enzyme gamma-butyrobetaine dioxygenase. Interestingly, ascorbic acid can also decrease the efficacy of several antibiotic medications such as erythromycin and streptomycin. Streptomycin, in particular, demonstrates a different target, being able to affect the activity of histone-lysine n-methyltransferase, an enzyme involved in the regulation of gene expression.\n\nOn the other hand, lincomycin, another antibiotic, can actually decrease the efficacy of ascorbic acid. This could potentiate some of lincomycin's clinical uses, as it has been indicated for treatment of skin-related conditions, such as furuncle. However, it is important to keep in mind that lincomycin also comes with its own side effects, one of which includes the condition known as Megacolon, characterized by abnormal dilation of the colon. These specific relationships may provide both challenges and opportunities in clinical applications of these drugs."", 'Ascorbic acid, a key component in many biological processes, interacts with several entities in the body. It has gamma-butyrobetaine dioxygenase as a target, contributing to the regulation of this enzyme. In terms of drug interactions, ascorbic acid has shown to decrease the efficacy of certain antibiotics such as erythromycin and streptomycin. On the other hand, lincomycin decreases the efficacy of ascorbic acid. Streptomycin, apart from its reduced efficacy with ascorbic acid, also targets the histone-lysine n-methyltransferase, an enzyme that affects gene expression. Lincomycin, That affects ascorbic acid efficacy, is indicated for the treatment of furuncle, a type of skin infection, but carries with it the side effect of Megacolon, a potentially serious expansion of the large intestine.']","[""Ascorbic acid, often known for its usefulness in boosting the immune system, has some lesser known functionalities as well. Notably, it has a target in the metabolic enzyme gamma-butyrobetaine dioxygenase, which it interacts with for various biological processes. However, it's important to note that Ascorbic acid decreases the efficacy of Streptomycin, a commonly used antibiotic. Streptomycin, which is often employed to treat various bacterial infections, has a target in the enzyme histone-lysine n-methyltransferase and is indicated for treating conditions such as furuncle, a type of painful skin abscess. \n\nInterestingly, a similar drug called Lincomycin also has an indication for furuncle. However, there is a noteworthy interaction between Lincomycin and Ascorbic acid wherein Lincomycin decreases the efficacy of Ascorbic acid. There is also a known side effect of Lincomycin which is Megacolon, an abnormal dilation of the colon that can cause significant health problems. One more area of overlap between Ascorbic acid and Lincomycin is that both have a target in gamma-butyrobetaine dioxygenase, indicating potentially shared pathways of effect. These intricate interactions and outcomes highlight the complex nature of drug interactions and the importance of understanding them in clinical applications."", 'Ascorbic acid, a known target of the enzyme gamma-butyrobetaine dioxygenase, is noted to decrease the efficacy of the antibiotic Streptomycin. This impairment of functionality given rise by Ascorbic acid is an issue, especially when considering that Streptomycin has essential roles; its targeted attack on the histone-lysine n-methyltransferase and its indication for treating furuncle, a type of skin infection. \n\nIn an interesting interplay of therapeutics, Lincomycin, another antibiotic, has been found to decrease the efficacy of Ascorbic acid. It itself has various roles, aside from it too being a known target of the gamma-butyrobetaine dioxygenase enzyme. It is indicated for the treatment of furuncle and interestingly has a documented side effect of causing Megacolon. This interconnectedness underscores the intricate and delicate balance within pharmacology.']"
"[{'source_node': {'name': 'letaxaban'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cefminox'}}, {'source_node': {'name': 'letaxaban'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'triptolide'}}, {'source_node': {'name': 'letaxaban'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mebutizide'}}, {'source_node': {'name': 'mebutizide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'azapropazone'}}, {'source_node': {'name': 'mebutizide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'tolonidine'}}]","[{'source_node': {'name': 'letaxaban'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cefminox'}}, {'source_node': {'name': 'letaxaban'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'triptolide'}}, {'source_node': {'name': 'mebutizide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'azapropazone'}}, {'source_node': {'name': 'mebutizide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'tolonidine'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:9895', 'target': 'COMPOUND:11284', 'metadata': None}]",0.9090909090909092,4570b5f33710eb01c681b00deeaf8d5d,3868db2fe0a02f6a3276a40b68aa1c22,"['The drug Letaxaban is known to decrease the efficacy of several other drugs such as Cefminox, Triptolide, and Mebutizide. Interestingly, Mebutizide itself can decrease the efficacy of Azapropazone. However, Mebutizide can also increase the efficacy of another medication called Tolonidine.', 'The drug letaxaban is known to decrease the efficacy of several other drugs including cefminox, triptolide, and mebutizide. Interestingly, mebutizide itself is known to decrease the efficacy of the drug azapropazone. However, it is also reported that mebutizide increases the efficacy of another drug known as tolonidine.', 'The drug letaxaban has been found to decrease the efficacy of several other drugs, including cefminox, triptolide, and mebutizide. Interestingly, it has been observed that mebutizide not only has its efficacy decreased by letaxaban, but it also decreases the efficacy of another drug, azapropazone. Contrarily, mebutizide can increase the efficacy of the drug tolonidine.', 'Letaxaban, a highly potent anticoagulant, is known to decrease the efficacy of other drugs including cefminox, an antibiotic, and triptolide, a potent anti-inflammatory and immunosuppressive agent. Additionally, letaxaban also reduces the efficacy of mebutizide, a diuretic medication. Interestingly, mebutizide itself can alter the efficacy of other drugs such as azapropazone, to which it reduces the efficacy, and tolonidine, where it increases its efficacy. Therfore, co-administration of these drugs needs to be done with caution to achieve desired therapeutic effects.', 'The medication Letaxaban has been observed to decrease the efficacy of several other drugs. These include Cefminox, Triptolide, and Mebutizide. Interestingly, Mebutizide itself can also influence the efficacy of other drugs. While it can decrease the therapeutic effectiveness of Azapropazone, it is also known to increase the efficacy of Tolonidine.']","['Letaxaban, a drug used primarily as an anticoagulant, is found to decrease the efficacy of both cefminox and triptolide, which can have significant implications in drug interactions with specific therapeutic regimens. Similarly, another pharmaceutical compound known as mebutizide, also affects the efficacy of multiple therapeutic agents. Research findings suggest it reduces the efficacy of azapropazone, yet interestingly, it is reported to have the opposite effect on tolonidine by significantly enhancing its therapeutic efficacy.', 'Letaxaban, a medication, notably decreases the efficacy of two other pharmaceutical substances, cefminox and triptolide. On the other hand, mebutizide, also a medicinal drug, has an opposite effect on two different chemicals. When interacted with azapropazone, it reduces its efficacy, whereas when combined with tolonidine, it increases its efficacy.', 'Letaxaban, a pharmacological substance, has been shown to decrease the efficacy of both cefminox and triptolide. Meanwhile, mebutizide, another drug, is known to decrease the efficacy of azapropazone while surprisingly, it increases the efficacy of tolonidine. Understanding these interactions is key to preventing counterproductive drug combinations and enhancing the effectiveness of certain drugs.', 'Letaxaban, a commonly prescribed medication, has been found to decrease the efficacy of cefminox and triptolide. Similarly, another drug, mebutizide, also decreases the efficacy of azapropazone. However, interestingly, mebutizide is known to increase the efficacy of tolonidine. This intricate interaction between medications underscores the importance of carefully considering drug interactions in clinical practice.', 'Letaxaban, a drug often utilized for medical purposes, has been shown to decrease the efficacy of cefminox and triptolide. On a similar note, mebutizide has proven to decrease the efficacy of azapropazone. Interestingly, mebutizide is also known to increase the efficacy of tolonidine. In summary, it is important to consider these interactions when prescribing and using these drugs in a clinical setting.']"
"[{'source_node': {'name': 'torasemide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bromocriptine'}}, {'source_node': {'name': 'torasemide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ebselen'}}, {'source_node': {'name': 'torasemide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'suxibuzone'}}, {'source_node': {'name': 'ebselen'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the antihypertensive activities '}}, {'source_node': {'name': 'ebselen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nitrendipine'}}, {'source_node': {'name': 'ebselen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tetrahydropalmatine'}}, {'source_node': {'name': 'suxibuzone'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' renal failure and hypertension '}}, {'source_node': {'name': 'suxibuzone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'xipamide'}}]","[{'source_node': {'name': 'nitrendipine'}, 'relation': {'name': 'decrease_activity'}, 'target_node': {'name': ' the antihypertensive activities '}}, {'source_node': {'name': 'nitrendipine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'suxibuzone'}}, {'source_node': {'name': 'ebselen'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the antihypertensive activities '}}, {'source_node': {'name': 'ebselen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nitrendipine'}}, {'source_node': {'name': 'ebselen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tetrahydropalmatine'}}, {'source_node': {'name': 'suxibuzone'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' renal failure and hypertension '}}, {'source_node': {'name': 'suxibuzone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'xipamide'}}, {'source_node': {'name': 'xipamide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'suxibuzone'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1034', 'target': 'ACTIVITY:14', 'metadata': {'predicate': 'decrease_activity'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11650', 'target': 'COMPOUND:11090', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:204', 'target': None, 'metadata': {'node_id': '204', 'node_type': 'COMPOUND', 'display_name': 'torasemide'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1034', 'target': 'COMPOUND:11090', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.5294117647058824,24bb925e5332a0e0b680e1eae54e48ec,bde9a2b57ae11afbd2c575d5a9df0681,[],[]
"[{'source_node': {'name': 'dosulepin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Blister'}}, {'source_node': {'name': 'dosulepin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Gynaecomastia'}}, {'source_node': {'name': 'dosulepin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Nausea'}}, {'source_node': {'name': 'pitolisant'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methdilazine'}}, {'source_node': {'name': 'pitolisant'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dosulepin'}}, {'source_node': {'name': 'ebastine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the sedative and stimulatory activities '}}, {'source_node': {'name': 'ebastine'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'ebastine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pitolisant'}}]","[{'source_node': {'name': 'dosulepin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Blister'}}, {'source_node': {'name': 'dosulepin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Gynaecomastia'}}, {'source_node': {'name': 'dosulepin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Nausea'}}, {'source_node': {'name': 'dosulepin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'ebastine'}}, {'source_node': {'name': 'pitolisant'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methdilazine'}}, {'source_node': {'name': 'pitolisant'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dosulepin'}}, {'source_node': {'name': 'ebastine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the sedative and stimulatory activities '}}, {'source_node': {'name': 'ebastine'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' adverse effects '}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:9658', 'target': 'COMPOUND:9561', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:8103', 'target': 'COMPOUND:9658', 'metadata': {'predicate': 'increase_efficacy'}}]",0.8823529411764706,286846646da9b0ce7b8109ae1174c262,a69cdcd66008ef4f71c723d67da2ac97,[],[]
"[{'source_node': {'name': 'corticosteroid 11-beta-dehydrogenase isozyme 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HSD11B1'}}, {'source_node': {'name': '3-epimesendanin s'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'corticosteroid 11-beta-dehydrogenase isozyme 1'}}, {'source_node': {'name': 'HSD11B1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'cortisone reductase deficiency 2'}}, {'source_node': {'name': 'HSD11B1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Prednisone ADME'}}]","[{'source_node': {'name': '3-epimesendanin s'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'corticosteroid 11-beta-dehydrogenase isozyme 1'}}]","[{'type': 'node_removal', 'source': 'GENE:28910', 'target': None, 'metadata': {'node_id': '28910', 'node_type': 'GENE', 'display_name': 'HSD11B1'}}]",0.3333333333333333,32a97c873c1dd4b7228c5fc272be9cea,a8d5a6d40352f41c2d8b1c4d7aa95743,[],"['The compound 3-epimesendanin S has corticosteroid 11-beta-dehydrogenase isozyme 1 as its target.', 'The drug 3-epimesendanin S has a specific target, the enzyme known as corticosteroid 11-beta-dehydrogenase isozyme 1.', 'The compound 3-epimesendanin s targets the corticosteroid 11-beta-dehydrogenase isozyme 1.', 'The compound 3-epimesendanin S has a target action on the enzyme known as corticosteroid 11-beta-dehydrogenase isozyme 1.', 'The drug 3-epimesendanin S is known to target the corticosteroid 11-beta-dehydrogenase isozyme 1.']"
"[{'source_node': {'name': 'survival motor neuron protein'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SMN1'}}, {'source_node': {'name': 'nuclear receptor subfamily 1 group i member 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR1I2'}}, {'source_node': {'name': 'e-guggulsterone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear receptor subfamily 1 group i member 2'}}, {'source_node': {'name': 'e-guggulsterone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'survival motor neuron protein'}}, {'source_node': {'name': 'e-guggulsterone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'thyrotropin receptor'}}]","[{'source_node': {'name': 'survival motor neuron protein'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR1I2'}}, {'source_node': {'name': 'nuclear receptor subfamily 1 group i member 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR1I2'}}, {'source_node': {'name': 'e-guggulsterone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear receptor subfamily 1 group i member 2'}}, {'source_node': {'name': 'e-guggulsterone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'survival motor neuron protein'}}, {'source_node': {'name': 'e-guggulsterone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'thyrotropin receptor'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:4843', 'target': 'GENE:34889', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'GENE:32946', 'target': None, 'metadata': {'node_id': '32946', 'node_type': 'GENE', 'display_name': 'SMN1'}}]",0.7272727272727273,c39bac5107c5544513b2a56bec8efbef,100aa68901c7f7cab49985e2e3be28a1,"['The medicinal compound E-guggulsterone primarily targets three distinct entities in the human body. Firstly, it interacts with the nuclear receptor subfamily 1 group i member 2, which is a gene product of NR1I2. Furthermore, it has a target effect on the survival motor neuron protein, a gene product of SMN1. Aside from these two, E-guggulsterone also targets the thyrotropin receptor, which plays a crucial role in the endocrine system.', 'The drug E-guggulsterone has multiple targets, including the survival motor neuron protein, which is a gene product of SMN1, and the nuclear receptor subfamily 1 group i member 2, a gene product of NR1I2. Furthermore, E-guggulsterone also targets the thyrotropin receptor.', 'The drug e-guggulsterone has been identified to target three different proteins, these include the survival motor neuron protein, nuclear receptor subfamily 1 group i member 2, and thyrotropin receptor. The survival motor neuron protein and the nuclear receptor subfamily 1 group i member 2 are gene products of SMN1 and NR1I2 respectively.', 'The drugs E-guggulsterone targets a variety of proteins including the survival motor neuron protein as well as the nuclear receptor subfamily 1 group i member 2 and the thyrotropin receptor. Intriguingly, the survival motor neuron protein is a gene product of SMN1 and the nuclear receptor subfamily 1 group i member 2 is a gene product of NR1I2.', ""The drug E-guggulsterone has several targets, including Survival Motor Neuron Protein, Nuclear Receptor Subfamily 1 group I member 2, and the Thyrotropin Receptor. It's fascinating to note that the Survival Motor Neuron Protein is a gene product of SMN1. Similarly, the Nuclear Receptor Subfamily 1 group I member 2 is a gene product of NR1I2. Thus implying a deep relation of the drug e-guggulsterone with these genes.""]","['The drug e-guggulsterone targets several proteins, including the nuclear receptor subfamily 1 group i member 2 and the survival motor neuron protein. These two proteins are gene products of the gene NR1I2. Furthermore, e-guggulsterone also targets the thyrotropin receptor.', 'Survival motor neuron protein and the nuclear receptor subfamily 1 group i member 2 are both gene products of NR1I2. The drug E-guggulsterone targets several proteins including the survival motor neuron protein, the nuclear receptor subfamily 1 group i member 2 and the thyrotropin receptor.', 'The survival motor neuron protein and nuclear receptor subfamily 1 group i member 2 are both gene products of NR1I2. The compound e-guggulsterone targets several entities, including nuclear receptor subfamily 1 group i member 2, survival motor neuron protein, and the thyrotropin receptor.', 'The survival motor neuron protein and the nuclear receptor subfamily 1 group i member 2 are both gene products of NR1I2. The compound e-guggulsterone targets not only the nuclear receptor subfamily 1 group i member 2 but also the survival motor neuron protein. Additionally, it is observed to target another protein known as the thyrotropin receptor.', 'The drug E-guggulsterone has several targets, including the survival motor neuron protein and nuclear receptor subfamily 1 group I member 2, as well as the thyrotropin receptor. It is interesting to note, the survival motor neuron protein and the nuclear receptor subfamily 1 group I member 2 are gene products of NR1I2.']"
"[{'source_node': {'name': 'g protein subunit alpha q'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'melanoma'}}, {'source_node': {'name': 'melanoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'atypical nevi in non-sun exposed areas'}}, {'source_node': {'name': 'melanoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'numerous nevi'}}, {'source_node': {'name': 'melanoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autosomal dominant inheritance'}}]","[{'source_node': {'name': 'g protein subunit alpha q'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'melanoma'}}, {'source_node': {'name': 'melanoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autosomal dominant inheritance'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:843', 'target': None, 'metadata': {'node_id': '843', 'node_type': 'PHENOTYPE', 'display_name': 'atypical nevi in non-sun exposed areas'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:826', 'target': None, 'metadata': {'node_id': '826', 'node_type': 'PHENOTYPE', 'display_name': 'numerous nevi'}}]",0.5555555555555556,d7b0ae807e497dafdc1b450af1fe75d4,1a4df368ee10bb285b284dc014d04b63,[],"['The G protein subunit alpha q is known to cause a condition known as melanoma. This type of cancer, melanoma, has a characteristic trait, namely, it exhibits autosomal dominant inheritance.', ""The G protein subunit alpha Q, which is implicated as a causative agent in melanoma, also has a link to conditions displaying autosomal dominant inheritance. This suggests that the genetic trait controlling this protein's expression may be inherently susceptible to melanoma."", 'The G protein subunit alpha Q causes a condition known as melanoma, which is characterized by an autosomal dominant inheritance pattern.', 'The G protein subunit alpha q has been identified as a cause of melanoma, a condition that typically exhibits the phenotype of autosomal dominant inheritance.', 'The G protein subunit alpha q is known to cause melanoma. Melanoma, in turn, is characterized by the phenotype of autosomal dominant inheritance.']"
"[{'source_node': {'name': 'moxonidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clozapine'}}, {'source_node': {'name': 'moxonidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ibuprofen'}}, {'source_node': {'name': 'moxonidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'difenpiramide'}}, {'source_node': {'name': 'piroxicam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'metolazone'}}, {'source_node': {'name': 'piroxicam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'moxonidine'}}, {'source_node': {'name': 'piroxicam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'vincamine'}}]","[{'source_node': {'name': 'difenpiramide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'moxonidine'}}, {'source_node': {'name': 'moxonidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clozapine'}}, {'source_node': {'name': 'moxonidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ibuprofen'}}, {'source_node': {'name': 'moxonidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'difenpiramide'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:540', 'target': 'COMPOUND:8177', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:540', 'target': None, 'metadata': {'node_id': '540', 'node_type': 'COMPOUND', 'display_name': 'piroxicam'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11227', 'target': 'COMPOUND:8177', 'metadata': {'predicate': 'increase_efficacy'}}]",0.4615384615384615,adca2d98338ee2e1b2289e2381dc8d3e,60a5e71e7fd9123e0402774afc576c0b,"[""Moxonidine is a drug that is known to decrease the efficacy of various medications including clozapine, ibuprofen, and difenpiramide. In a similar way, piroxicam, another drug, has been observed to reduce the effectiveness of medications like metolazone, moxonidine, and vincamine. It is crucial to be aware of these interactions when prescribing or consuming these drugs to avoid negative consequences on the treatment's effectiveness."", 'The drug moxonidine has been observed to decrease the efficacy of several other pharmaceuticals including clozapine, ibuprofen, and difenpiramide. Simultaneously, piroxicam, an anti-inflammatory agent, can similarly reduce the efficacy of drugs, for instance, metolazone, moxonidine, and vincamine. The intriguing overlap here is moxonidine, a compound that not only diminishes the effectiveness of some drugs but also has its potency decreased by treatment with piroxicam.', ""The drug moxonidine is known to decrease the efficacy of several other medications such as clozapine, ibuprofen, and difenpiramide. Similarly, piroxicam, another medication, can also decrease the efficacy of drugs including metolazone, moxonidine, and vincamine. It's important to consider these relationships when planning a multidrug therapy to ensure optimal efficacy."", 'Moxonidine, a centrally acting therapeutic agent, has been found to decrease the efficacy of several treatments like clozapine, ibuprofen, and difenpiramide. Furthermore, another non-steroidal anti-inflammatory drug known as piroxicam also exhibits similar behavior, decreasing the efficacy of drugs like metolazone, moxonidine, and vincamine.', ""The drug Moxonidine is known to decrease the efficacy of several medications such as Clozapine, Ibuprofen, and Difenpiramide. Similarly, Piroxicam, another drug, is known to reduce the efficacy of Metolazone, Moxonidine, and Vincamine. It's crucial to consider these interactions when prescribing these drugs together as it may impact the overall treatment outcome.""]","['Difenpiramide, a therapeutic agent, is known to increase the efficacy of another drug, moxonidine. However, moxonidine has been noted to decrease the efficacy of several other drugs, with specific examples including clozapine, ibuprofen and surprisingly, difenpiramide itself. The interactions between these therapeutic agents should be carefully considered during the drug prescription and administration process.', 'Difenpiramide is a drug that increases the efficacy of moxonidine. Interestingly, moxonidine, when used, tends to decrease the efficacy of several other drugs, including clozapine, ibuprofen, and even difenpiramide itself. Hence, careful consideration should be given when combining these drugs in a therapeutic regimen.', 'Difenpiramide is a drug that increases the efficacy of another medication, moxonidine. However, moxonidine is known to decrease the efficacy of several other medications, such as clozapine, ibuprofen, and even difenpiramide, the very drug that boosts its effectiveness. This presents a complex interplay between these pharmaceutical agents.', 'The drug difenpiramide has been shown to increase the efficacy of moxonidine. However, moxonidine has an opposite effect on other drugs - it decreases the efficacy of clozapine, ibuprofen, and, interestingly, difenpiramide itself.', 'The drug difenpiramide has been found to increase the efficacy of another medication called moxonidine. However, interestingly, moxonidine then decreases the efficacy of several other drugs including clozapine, ibuprofen, and even difenpiramide itself.']"
"[{'source_node': {'name': 'indenolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'amibegron'}}, {'source_node': {'name': 'indenolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'benfluorex'}}, {'source_node': {'name': 'methylenedioxyethamphetamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nicardipine'}}, {'source_node': {'name': 'methylenedioxyethamphetamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'indenolol'}}, {'source_node': {'name': 'methylenedioxyethamphetamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'moxisylyte'}}, {'source_node': {'name': 'moxisylyte'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tizanidine'}}, {'source_node': {'name': 'moxisylyte'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mephentermine'}}]","[{'source_node': {'name': 'indenolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'amibegron'}}, {'source_node': {'name': 'indenolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'benfluorex'}}, {'source_node': {'name': 'methylenedioxyethamphetamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'indenolol'}}, {'source_node': {'name': 'benfluorex'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'indenolol'}}, {'source_node': {'name': 'amibegron'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'methylenedioxyethamphetamine'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:1496', 'target': 'COMPOUND:8140', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:7967', 'target': 'COMPOUND:7899', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:8140', 'target': None, 'metadata': {'node_id': '8140', 'node_type': 'COMPOUND', 'display_name': 'moxisylyte'}}, {'type': 'node_removal', 'source': 'COMPOUND:608', 'target': None, 'metadata': {'node_id': '608', 'node_type': 'COMPOUND', 'display_name': 'nicardipine'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5004', 'target': 'COMPOUND:1496', 'metadata': {'predicate': 'increase_efficacy'}}]",0.3333333333333333,b67e06da18cd9c8846040087e46fa5ee,3eeb79c0a32e4865bdce96028a4e88ce,"['The drug interaction dynamics among several substances dictate their efficacy. For instance, indenolol decreases the efficacy of amibegron while it increases the efficacy of benfluorex. Further, methylenedioxyethamphetamine also influences the efficacy of several drugs, specifically, it decreases the efficacy of nicardipine, indenolol, and moxisylyte. In a similar vein, moxisylyte further decreases the efficacy of tizanidine and mephentermine. Consequently, the complex interplay among these substances can significantly affect their individual and combined effects.', 'Indenolol, a beta blocker, shows interactions with multiple drugs. Specifically, it has the effect to decrease the efficacy of Amibegron, while at the same time it may increase the efficacy of Benfluorex. Similarly, Methylenedioxyethamphetamine, often used recreationally, is known to decrease the efficacy of multiple drugs such as Nicardipine, Indenolol, and Moxisylyte. Moreover, Moxisylyte is another drug that reduces the efficacy of other agents including Tizanidine and Mephentermine. These findings underline the complex interactions that can occur between evidently disparate drugs, and the need for careful consideration when prescribing medication regimes.', 'Indenolol, a medication, has been found to decrease the efficacy of amibegron, while simultaneously increasing the efficacy of benfluorex. On the other hand, methylenedioxyethamphetamine, a psychoactive drug, decreases the efficacy of several medications, specifically nicardipine, indenolol, and moxisylyte. Moxisylyte, a alpha-adrenergic blocker, has also been reported to decrease the efficacy of other treatments like tizanidine and mephentermine. These interactions highlight the intricate and sometimes antagonistic interplay between various medications.', 'The drug indenolol has been found to decrease the efficacy of amibegron, while simultaneously increasing the efficacy of benfluorex. In a related observation, methylenedioxyethamphetamine, often used recreationally, has been shown to decrease the efficacy of several drugs including nicardipine, indenolol, and moxisylyte. Interestingly, moxisylyte itself has been shown to decrease the efficacy of tizanidine and mephentermine. These interactions highlight the complex and often unpredictable ways in which various pharmaceuticals can interact within the human body.', 'The drug Indenolol has mixed effects on other drugs; it decreases the efficacy of Amibegron, while it increases the efficacy of Benfluorex. Similarly, Methylenedioxyethamphetamine decreases the efficacy of several drugs, including Nicardipine, Indenolol, and Moxisylyte. Moxisylyte, in turn, further decreases the efficacy of Tizanidine and Mephentermine. It portrays a complex interaction network of these drugs where their efficacy is modulated by one another.']","['In the realm of drug interactions, the drug Indenolol decreases the efficacy of Amibegron, but interestingly, it increases the efficacy of Benfluorex. Conversely, Methylenedioxyethamphetamine is known to decrease the efficacy of Indenolol. We also observe that Benfluorex raises the efficacy of Indenolol, while Amibegron enhances the efficacy of Methylenedioxyethamphetamine.', ""Indenolol, a pharmaceutical drug, has a complex network of interactions with other drugs. It decreases the efficacy of amibegron while simultaneously increasing the efficacy of benfluorex. Additionally, the efficacy of indenolol itself is influenced by other drugs. Methylenedioxyethamphetamine, for instance, reduces its efficacy. In contrast, indenolol's efficacy is increased due to its interaction with benfluorex, illustrating the circularity and complexity of drug interplay. Surprisingly, amibegron, which is less effective due to indenolol, contributes to increasing the efficacy of methylenedioxyethamphetamine."", 'The drug Indenolol has a complex interaction with other pharmaceuticals. Specifically, Indenolol decreases the efficacy of Amibegron, but it increases the efficacy of Benfluorex. Conversely, the drug Methylenedioxyethamphetamine has an effect on Indenolol, diminishing its efficacy. Interestingly, Benfluorex further enhances the efficacy of Indenolol, forming a potential synergistic effect. Meanwhile, Amibegron boosts the efficacy of Methylenedioxyethamphetamine, adding complexity to the dynamic pharmacological interplay between these drugs.', ""The drug indenolol is known to decrease the efficacy of amibegron, but interestingly, it increases the efficacy of benfluorex. Indenolol's efficacy can also be influenced by other drugs; for instance, methylenedioxyethamphetamine decreases its efficacy while benfluorex enhances it. In an intertwined relationship, amibegron is also found to increase the efficacy of methylenedioxyethamphetamine."", 'Indenolol, a beta-blocker, can have its therapeutic efficacy affected by different drugs. For instance, methylenedioxyethamphetamine diminishes its effectiveness, which might compromise its therapeutic effects. On the flip side, the presence of benfluorex enhances the efficacy of indenolol, potentially leading to better therapeutic outcomes. Remarkably, indenolol also has an impact on the effectiveness of other medications. Namely, it curbs the efficacy of the adrenergic agonist amibegron yet enhances the action of the anti-hyperlipidemic agent benfluorex. It should be noted that the reciprocal influence also holds true. Namely, amibegron enhances the efficacy of methylenedioxyethamphetamine, despite being negatively impacted by indenolol. These complex interaction dynamics should be considered when planning pharmacological interventions involving these drugs.']"
"[{'source_node': {'name': 'neonectriolide c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'neonectriolide c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sw480'}}]","[{'source_node': {'name': 'neonectriolide c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sw480'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5851', 'target': None, 'metadata': {'node_id': '5851', 'node_type': 'PROTEIN', 'display_name': 'mcf7'}}]",0.6,08ff8623d8e99bfa47948f79c0240ea8,3a10bd85ecf9efc5e573faa722c5132a,"['The compound Neonectriolide C is known to target and interact with both MCF7 and SW480, which are both known as types of human cancer cell lines.', 'Neonectriolide C, a bioactive compound, has notable biological targets which include MCF7 and SW480. These targets correspond to human breast and colon cancer cell lines respectively, outlining the potential therapeutic value of Neonectriolide C in oncology.', 'Neonectriolide C is a compound that has shown to target both MCF7 and SW480, which are two distinct cell lines often used in biological research.', 'The compound Neonectriolide C is known to target both MCF7 and SW480.', 'The compound Neonectriolide C targets both the MCF7 and SW480 cells.']",[]
"[{'source_node': {'name': 'prenalterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'atenolol'}}, {'source_node': {'name': 'prenalterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nadolol'}}, {'source_node': {'name': 'prenalterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nebivolol'}}, {'source_node': {'name': 'atenolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'amiodarone'}}, {'source_node': {'name': 'atenolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mephentermine'}}]","[{'source_node': {'name': 'prenalterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nadolol'}}, {'source_node': {'name': 'prenalterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nebivolol'}}, {'source_node': {'name': 'nadolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nebivolol'}}, {'source_node': {'name': 'atenolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'amiodarone'}}, {'source_node': {'name': 'atenolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mephentermine'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:11624', 'target': 'COMPOUND:324', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:1183', 'target': 'COMPOUND:4577', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.8181818181818181,94df2b495af16d32cf6d55ad60aa060e,fafd6bc953c76327b535981ce72c0f9b,"['The drug prenalterol has been shown to decrease the efficacy of atenolol, nadolol, and nebivolol. Interestingly, the efficacy of the drug amiodarone is increased when taken with atenolol. On the other hand, atenolol decreases the efficacy of mephentermine. So, the effects of prenalterol and atenolol on the performance of these drugs can vary significantly.', ""The medication known as prenalterol has been found to diminish the efficacy of other drugs like atenolol, nadolol, and nebivolol. Interestingly, despite its potential interaction with prenalterol, atenolol simultaneously exhibits an increased efficacy when used with amiodarone. However, atenolol's efficacy is lessened when it interacts with mephentermine. Hence, cautious use of these medications may be required to avoid any potential adverse drug interactions."", ""Prenalterol is a drug that is known to decrease the efficacy of several other drugs including Atenolol, Nadolol, and Nebivolol. However, it's important to note that Atenolol, while having its efficacy decreased by Prenalterol, can increase the efficacy of Amiodarone and actually decrease the efficacy of Mephentermine. This series of effects showcases the complex interactions and impacts that can occur between various pharmaceutical drugs."", 'The drug prenalterol decreases the efficacy of several medications including atenolol, nadolol, and nebivolol. Interestingly, atenolol, whose efficacy is reduced by prenalterol, appears to increase the efficacy of another drug, amiodarone. At the same time, atenolol also decreases the efficacy of mephentermine. This complex series of interactions highlights how multiple medications can interact in unanticipated ways.']","['The drug Prenalterol is known to decrease the efficacy of both Nadolol and Nebivolol. Interestingly, Nadolol itself also contributes to a decrease in the efficacy of Nebivolol. Contrary to these, the drug Atenolol increases the efficacy of Amiodarone but reduces the efficacy of Mephentermine.', 'The drug prenalterol has been shown to decrease the efficacy of both nadolol and nebivolol. Interestingly, nadolol can also reduce the efficacy of nebivolol. On another note, atenolol displays the ability to increase the efficacy of amiodarone but can decrease the efficacy of mephentermine.', 'The drug prenalterol has been found to decrease the efficacy of both nadolol and nebivolol. Interestingly, nadolol also appears to decrease the efficacy of nebivolol independently. On the other hand, atenolol, another commonly used drug, increases the efficacy of amiodarone but decreases the efficacy of mephentermine. The dynamic interplay between these drugs highlights the complexity of pharmaceutical interactions and the importance of personalized medicine.', 'The medication known as prenalterol has been found to diminish the efficacy of other drugs like nadolol and nebivolol. Further, there is a reciprocal decrease in efficacy observed as nadolol also lessens the impacts of nebivolol. On the other hand, other medications, such as atenolol, demonstrate a contrasting interaction pattern. In this case, atenolol is known to enhance the efficacy of amiodarone, yet surprisingly, it lessens the effectiveness of mephentermine. This intricate web of interactions highlights the complexity involved in understanding and predicting drug responses.', ""Prenalterol is a drug that is known to decrease the efficacy of other medications such as nadolol and nebivolol. Interestingly, nadolol also decreases the efficacy of nebivolol. On the other hand, atenolol is a drug that can increase the efficacy of amiodarone but decrease the efficacy of mephentermine. It's important for medical professionals to be aware of these interactions to avoid potential counterproductive effects when prescribing these medications together.""]"
"[{'source_node': {'name': 'eperisone'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hypotensive activities '}}, {'source_node': {'name': 'plecanatide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'aprobarbital'}}, {'source_node': {'name': 'plecanatide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'eperisone'}}, {'source_node': {'name': 'plecanatide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'thonzylamine'}}]","[{'source_node': {'name': 'thonzylamine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hypotensive activities '}}, {'source_node': {'name': 'eperisone'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hypotensive activities '}}, {'source_node': {'name': 'eperisone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'thonzylamine'}}, {'source_node': {'name': 'plecanatide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'aprobarbital'}}, {'source_node': {'name': 'plecanatide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'eperisone'}}, {'source_node': {'name': 'plecanatide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'thonzylamine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:9231', 'target': 'ACTIVITY:17', 'metadata': {'predicate': 'has_activity'}}, {'type': 'edge_addition', 'source': 'COMPOUND:7937', 'target': 'COMPOUND:9231', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.7777777777777778,d73234b0e726e611e0587e1247596d24,1a548bcb41a6348586c51aec51c9c6c6,[],[]
"[{'source_node': {'name': 'cerlapirdine'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'cerlapirdine'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' CNS depression '}}, {'source_node': {'name': 'cerlapirdine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pregabalin'}}]","[{'source_node': {'name': 'cerlapirdine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pregabalin'}}, {'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cerlapirdine'}}]","[{'type': 'node_removal', 'source': 'EFFECT:38', 'target': None, 'metadata': {'node_id': '38', 'node_type': 'EFFECT', 'display_name': ' CNS depression '}}, {'type': 'node_removal', 'source': 'EFFECT:5', 'target': None, 'metadata': {'node_id': '5', 'node_type': 'EFFECT', 'display_name': ' adverse effects '}}, {'type': 'edge_addition', 'source': 'COMPOUND:220', 'target': 'COMPOUND:10133', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.2857142857142857,9ed83fb6b9c58d4aaa6b74b4913142cb,3dc8947950026bc7aa2b2bbaa934db10,[],"['The drug cerlapirdine has been found to increase the efficacy of pregabalin. However, interestingly, pregabalin has a reciprocal effect, in that it decreases the efficacy of cerlapirdine. This suggests a complex interaction between these two drugs.', 'The drug Cerlapirdine is known to increase the efficacy of Pregabalin. However, it is interesting to note that Pregabalin in turns decreases the efficacy of Cerlapirdine.', 'Cerlapirdine, a pharmaceutical drug, has been shown to increase the efficacy of another drug, pregabalin. Conversely, pregabalin has been observed to decrease the efficacy of cerlapirdine. This suggests a complex, bidirectional relationship between these two medications.', ""Cerlapirdine is known to increase the efficacy of pregabalin. However, it's interesting to note that pregabalin simultaneously decreases the efficacy of cerlapirdine, creating a complex interplay between these two drugs."", 'Cerlapirdine and pregabalin interact such that cerlapirdine enhances the efficacy of pregabalin, whereas paradoxically pregabalin is known to decrease the efficacy of cerlapirdine. This intriguing interaction suggests a complex relationship between these two drugs that warrants further investigation.']"
"[{'source_node': {'name': '(7r,8r)-polysphorin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': '(7r,8r)-polysphorin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-ov-3'}}]","[{'source_node': {'name': '(7r,8r)-polysphorin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-ov-3'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5849', 'target': None, 'metadata': {'node_id': '5849', 'node_type': 'PROTEIN', 'display_name': 'a549'}}]",0.6,e9f2d04927086d86a94fbedcd0958f14,f29b32194e6986b94ac5ae59756e38e2,"['The drug (7R,8R)-polysphorin has been identified as having a target interaction with both the A549 and SK-OV-3 cell lines.', 'The compound (7R,8R)-polysphorin has been identified to target both the A549 and SK-OV-3 cell lines.', 'The drug named (7R,8R)-Polysphorin has two primary targets: A549 and SK-OV-3.', 'The compound (7R,8R)-polysphorin targets not only A549 but also SK-OV-3, which indicates its potential therapeutic role in treating conditions associated with these targets.', 'The compound known as (7r,8r)-polysphorin targets two cell lines: A549 and SK-OV-3.']","['The compound (7r,8r)-polysphorin has a target interaction with SK-OV-3.', 'The drug, (7r,8r)-polysphorin, has been identified as having a target in SK-OV-3.']"
"[{'source_node': {'name': 'guadichaudol c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'col2'}}, {'source_node': {'name': 'guadichaudol c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}, {'source_node': {'name': 'guadichaudol c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lu1'}}]","[{'source_node': {'name': 'guadichaudol c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lu1'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5858', 'target': None, 'metadata': {'node_id': '5858', 'node_type': 'PROTEIN', 'display_name': 'kb'}}, {'type': 'node_removal', 'source': 'PROTEIN:5008', 'target': None, 'metadata': {'node_id': '5008', 'node_type': 'PROTEIN', 'display_name': 'col2'}}]",0.4285714285714286,5ba3adcd7ac4f954c9d28f56172939ad,241d295150dbf713af586e3df5fa9e08,"['The compound Guadichaudol C has multiple targets, including proteins COL2, KB, and LU1.', 'The compound guadichaudol c is known to target several proteins, including col2, kb, and lu1.', 'The compound Guadichaudol C targets multiple entities including COL2, KB, and LU1.', 'The compound Guadichaudol C has several targets including Col2, Kb, and Lu1.', 'The compound Guadichaudol C targets several entities, including the Col2, KB, and LU1.']","['The compound guadichaudol C has a target known as LU1.', 'The compound Guadichaudol C has a target interaction with LU1.', 'The compound Guadichaudol C has been found to target LU1.', 'The compound Guadichaudol C interacts with and targets LU1.', 'The compound Guadichaudol C has a direct target interaction with LU1.']"
"[{'source_node': {'name': 'osteosclerotic metaphyseal dysplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'metaphyseal dysplasia'}}, {'source_node': {'name': 'osteosclerotic metaphyseal dysplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'increased bone mineral density'}}]","[{'source_node': {'name': 'osteosclerotic metaphyseal dysplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'increased bone mineral density'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:10716', 'target': None, 'metadata': {'node_id': '10716', 'node_type': 'PHENOTYPE', 'display_name': 'metaphyseal dysplasia'}}]",0.6,1d0a9810dd0b3859ea952214f3cf9b0f,d5c202adc341a9d07d8baf5d96856862,"['Osteosclerotic metaphyseal dysplasia, a bone disorder, is manifested by certain phenotypes such as metaphyseal dysplasia and an increased bone mineral density.', 'Osteosclerotic metaphyseal dysplasia is a condition that exhibits several characteristics including metaphyseal dysplasia and a significant increase in bone mineral density.', 'Osteosclerotic metaphyseal dysplasia is a condition characterized by two distinct phenotypes: metaphyseal dysplasia and increased bone mineral density.', 'Osteosclerotic metaphyseal dysplasia is a condition characterized by several phenotypes including metaphyseal dysplasia and an increased bone mineral density.', 'Osteosclerotic metaphyseal dysplasia is a condition characterized by several phenotypes, notably metaphyseal dysplasia and an increased bone mineral density.']",[]
"[{'source_node': {'name': 'LIN37'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G0 and Early G1'}}, {'source_node': {'name': 'LIN37'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Polo-like kinase mediated events'}}, {'source_node': {'name': 'LIN37'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cyclin A:Cdk2-associated events at S phase entry'}}]","[{'source_node': {'name': 'LIN37'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cyclin A:Cdk2-associated events at S phase entry'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:327', 'target': None, 'metadata': {'node_id': '327', 'node_type': 'PATHWAY', 'display_name': 'G0 and Early G1'}}, {'type': 'node_removal', 'source': 'PATHWAY:743', 'target': None, 'metadata': {'node_id': '743', 'node_type': 'PATHWAY', 'display_name': 'Polo-like kinase mediated events'}}]",0.4285714285714286,19ee2aea57c8014f6a85be8cd0d5a975,4fd260a9fffa946fe72151fccba20afc,[],[]
"[{'source_node': {'name': 'ligraminol a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'ligraminol a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-ov-3'}}, {'source_node': {'name': 'ligraminol a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'huvec'}}]","[{'source_node': {'name': 'ligraminol a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'huvec'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5849', 'target': None, 'metadata': {'node_id': '5849', 'node_type': 'PROTEIN', 'display_name': 'a549'}}, {'type': 'node_removal', 'source': 'PROTEIN:4979', 'target': None, 'metadata': {'node_id': '4979', 'node_type': 'PROTEIN', 'display_name': 'sk-ov-3'}}]",0.4285714285714286,19b5357d84c3f1b57983c2fc5d4a534c,91484c1b628694393490bf3ba9a101eb,"['The molecule Ligraminol A targets multiple entities including A549, SK-OV-3 and HUVEC.', 'The drug Ligraminol A targets several entities, including the A549, SK-OV-3, and HUVEC cells.', 'The compound Ligraminol A exhibits its pharmacological action by targeting several cellular components, namely A549, SK-OV-3, and HUVEC. These targets underline the broad spectrum of biological interactions that Ligraminol A can induce.', 'The compound Ligraminol A targets several different cell types, specifically A549, SK-OV-3, and HUVEC.', 'The compound Ligraminol A targets several cells including A549, SK-OV-3, and HUVEC.']",['The drug Ligraminol A has the cellular component HUVEC as its target.']
"[{'source_node': {'name': 'pyridoxine'}, 'relation': {'name': 'increase_activity'}, 'target_node': {'name': ' the excretion rate '}}, {'source_node': {'name': 'pyridoxine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'retinal dehydrogenase 1'}}, {'source_node': {'name': 'pyridoxine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'plasma'}}]","[{'source_node': {'name': 'pyridoxine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'retinal dehydrogenase 1'}}, {'source_node': {'name': 'pyridoxine'}, 'relation': {'name': 'decrease_activity'}, 'target_node': {'name': ' the excretion rate '}}]","[{'type': 'edge_replacement', 'source': 'COMPOUND:155', 'target': 'ACTIVITY:7', 'metadata': {'predicate': 'decrease_activity'}}, {'type': 'node_removal', 'source': 'PROTEIN:6391', 'target': None, 'metadata': {'node_id': '6391', 'node_type': 'PROTEIN', 'display_name': 'plasma'}}]",0.5714285714285714,1d60d159cfb16e5329159ce37d600155,a8fe49541c0a8017ee8cd66b53bae60b,[],[]
"[{'source_node': {'name': 'sulfaethoxypyridazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'rosiglitazone'}}, {'source_node': {'name': 'sulfaethoxypyridazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'ertugliflozin'}}, {'source_node': {'name': 'sulfaethoxypyridazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'gastric inhibitory polypeptide'}}, {'source_node': {'name': 'gastric inhibitory polypeptide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'acebutolol'}}, {'source_node': {'name': 'gastric inhibitory polypeptide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lanreotide'}}, {'source_node': {'name': 'rosiglitazone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'chlorthalidone'}}, {'source_node': {'name': 'rosiglitazone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'glibornuride'}}, {'source_node': {'name': 'rosiglitazone'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Diabetic Ketoacidosis'}}]","[{'source_node': {'name': 'lanreotide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'chlorthalidone'}}, {'source_node': {'name': 'sulfaethoxypyridazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'ertugliflozin'}}, {'source_node': {'name': 'gastric inhibitory polypeptide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'acebutolol'}}, {'source_node': {'name': 'gastric inhibitory polypeptide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lanreotide'}}, {'source_node': {'name': 'rosiglitazone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'chlorthalidone'}}, {'source_node': {'name': 'rosiglitazone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'glibornuride'}}, {'source_node': {'name': 'rosiglitazone'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Diabetic Ketoacidosis'}}, {'source_node': {'name': 'rosiglitazone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'acebutolol'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:5838', 'target': 'COMPOUND:300', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:9419', 'target': 'COMPOUND:12807', 'metadata': None}, {'type': 'edge_deletion', 'source': 'COMPOUND:9419', 'target': 'COMPOUND:400', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:400', 'target': 'COMPOUND:1173', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7647058823529411,cc1536871ae38ab87ba216696806fa94,98a889799f99534dfc38fc3eb02c3006,"[""The drug Sulfaethoxypyridazine is known to increase the efficacy of several other substances including Rosiglitazone, Ertugliflozin, and the Gastric Inhibitory Polypeptide. Interestingly, the Gastric Inhibitory Polypeptide reciprocally increases the efficacy of Acebutolol but decreases the efficacy of Lanreotide. On the other hand, Rosiglitazone, whose efficacy is boosted by Sulfaethoxypyridazine, decreases the efficacy of Chlorthalidone while enhancing Glibornuride's efficacy. Moreover, Rosiglitazone has an indication for the treatment of Diabetic Ketoacidosis. These intricate, bidirectional interactions among these entities unveil the complex machinery of drug interactions."", 'The drug Sulfaethoxypyridazine has been found to increase the efficacy of not only Rosiglitazone and Ertugliflozin, but also enhances the efficacy of the Gastric Inhibitory Polypeptide. Interestingly, Gastric Inhibitory Polypeptide in turn boosts the effectiveness of Acebutolol but, it reduces the efficacy of Lanreotide. Moreover, Rosiglitazone has a dual effect: it decreases the effectiveness of Chlorthalidone, yet it increases the effectiveness of Glibornuride. Furthermore, Rosiglitazone has indication for use in Diabetic Ketoacidosis.', 'The drug Sulfaethoxypyridazine is reported to increase the efficacy of several compounds, such as Rosiglitazone, Ertugliflozin, and the Gastric Inhibitory Polypeptide. The Gastric Inhibitory Polypeptide, in turn, is known to enhance the effectiveness of Acebutolol but decrease that of Lanreotide. Coincidentally, Rosiglitazone also has variable effects; it reduces the efficacy of Chlorthalidone, but boosts the performance of Glibornuride. Notably, Rosiglitazone is indicated in the treatment of diabetic ketoacidosis. This implies a complex network of interactions and reciprocal impacts among these drugs and compounds.']","['The drug lanreotide can decrease the efficacy of chlorthalidone, while sulfaethoxypyridazine has been found to increase the efficacy of ertugliflozin. The gastric inhibitory polypeptide plays a dual role in that it increases the efficacy of acebutolol but decreases the efficacy of lanreotide. Similarly, the drug rosiglitazone also has multiple impacts. It decreases the efficacy of chlorthalidone and increases the efficacy of glibornuride and acebutolol. Furthermore, rosiglitazone has an indication for a serious metabolic disease known as Diabetic Ketoacidosis.', 'The drug Lanreotide has been observed to decrease the efficacy of Chlorthalidone, while the drug Sulfaethoxypyridazine has shown to increase the efficacy of Ertugliflozin. Strikingly, this is not the only modulatory role played by these drugs. For instance, the hormone gastric inhibitory polypeptide, not only enhances the efficacy of Acebutolol but also decreases the efficiency of Lanreotide. In a similar vein, the drug Rosiglitazone, which is typically indicated for Diabetic Ketoacidosis, has a remarkable role in shaping the efficacy of several other drugs. Specifically, it has been observed to both decrease the efficiency of Chlorthalidone and increase that of Acebutolol and Glibornuride. This wealth of interactions highlights the importance of understanding the ripple effects that a single drug can have across several biochemical pathways and treatments.', 'The drug Lanreotide is known to decrease the efficacy of Chlorthalidone, while Sulfaethoxypyridazine has been observed to increase the efficacy of Ertugliflozin. Interestingly, the gastric inhibitory polypeptide, a hormone in the human body, can both increase and decrease drug efficacy. It increases the effectiveness of Acebutolol but reduces the efficacy of Lanreotide. Another drug, Rosiglitazone, also has a similar duality. It decreases the efficacy of Chlorthalidone but increases the efficacy of both Glibornuride and Acebutolol. Additionally, Rosiglitazone has an indication for Diabetic Ketoacidosis - a serious condition that can occur in patients with diabetes.', 'The application of lanreotide is known to decrease the efficacy of chlorthalidone, whereas the drug rosiglitazone has a similar effect, also decreasing the efficacy of chlorthalidone. On the contrary, sulfaethoxypyridazine works in an opposing way and increases the efficacy of ertugliflozin. Interestingly, rosiglitazone not only influences chlorthalidone but also increases the efficacy of glibornuride and acebutolol. Furthermore, a connection between rosiglitazone and Diabetic Ketoacidosis has been observed as there is an indication for its application in this condition. Gastric inhibitory polypeptide, meanwhile, has a dual role. It increases the efficacy of acebutolol, yet it reduces the efficacy of lanreotide. Taken together, these relationships reflect the complex interplay among different drugs and substances in the body and the need for careful consideration when prescribing combinations.', 'The drug Lanreotide has been found to decrease the efficacy of another drug called Chlorthalidone. Conversely, Sulfaethoxypyridazine increases the efficacy of Ertugliflozin. Interestingly, Gastric Inhibitory Polypeptide serves to increase the efficacy of Acebutolol, but it also decreases the efficacy of Lanreotide. On a similar note, the drug Rosiglitazone decreases the efficacy of Chlorthalidone. However, Rosiglitazone has a positive effect on the efficacy of both Glibornuride and Acebutolol, improving their effectiveness. Furthermore, Rosiglitazone has been indicated in the treatment of a medical condition known as Diabetic Ketoacidosis. These findings highlight the complex and intricate interactions within and between various drug actions and mechanisms.']"
"[{'source_node': {'name': 'sudden cardiac failure'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'myocardial fibrosis'}}, {'source_node': {'name': 'sudden cardiac failure'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'metabolic acidosis'}}]","[{'source_node': {'name': 'sudden cardiac failure'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'metabolic acidosis'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1227', 'target': None, 'metadata': {'node_id': '1227', 'node_type': 'PHENOTYPE', 'display_name': 'myocardial fibrosis'}}]",0.6,750d5a30cfb3faed8e1248449f92c5eb,28d84b62a7174976dee4f8780b6fad20,[],[]
"[{'source_node': {'name': 'folfiri'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'udp glucuronosyltransferase 1 family'}}, {'source_node': {'name': 'folfiri'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'thymidylate synthetase'}}, {'source_node': {'name': 'folfiri'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'overall survival'}}]","[{'source_node': {'name': 'folfiri'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'thymidylate synthetase'}}, {'source_node': {'name': 'folfiri'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'overall survival'}}]","[{'type': 'node_removal', 'source': 'GENE:22981', 'target': None, 'metadata': {'node_id': '22981', 'node_type': 'GENE', 'display_name': 'udp glucuronosyltransferase 1 family'}}]",0.7142857142857143,2693fca351773dc610e08026f327a935,9eef66cbd9a3186db52d7d0f800c478e,[],[]
"[{'source_node': {'name': 'ABCD3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'bile acid synthesis defect'}}, {'source_node': {'name': 'ABCD3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RHOA GTPase cycle'}}, {'source_node': {'name': 'ABCD3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RHOC GTPase cycle'}}, {'source_node': {'name': 'bile acid synthesis defect'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'elevated hepatic transaminase'}}, {'source_node': {'name': 'bile acid synthesis defect'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cirrhosis'}}]","[{'source_node': {'name': 'ABCD3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RHOA GTPase cycle'}}, {'source_node': {'name': 'ABCD3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RHOC GTPase cycle'}}, {'source_node': {'name': 'bile acid synthesis defect'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'elevated hepatic transaminase'}}, {'source_node': {'name': 'bile acid synthesis defect'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cirrhosis'}}]","[{'type': 'edge_deletion', 'source': 'GENE:32142', 'target': 'DISEASE:11505', 'metadata': None}]",0.9090909090909092,a6591b2a39d5a83d06357feb55ed13ac,bf5b398a48ac6bb63e2727d9abe5f256,"['The gene ABCD3 is involved in the RHOA GTPase and RHOC GTPase cycles and is known to cause a condition known as bile acid synthesis defect. This defect is characterized by elevated hepatic transaminase and can progress to cirrhosis.', 'The gene ABCD3 acts within the RHOA GTPase cycle and RHOC GTPase cycle and its malfunction can cause a bile acid synthesis defect. This defect is characterized by conditions like elevated hepatic transaminase and cirrhosis.', 'The gene ABCD3, which acts within the RHOA GTPase cycle and the RHOC GTPase cycle, is known to cause a bile acid synthesis defect. This specific defect is associated with certain phenotypes or symptoms such as elevated hepatic transaminase and cirrhosis.', 'The gene ABCD3, which acts within the RHOA GTPase cycle and the RHOC GTPase cycle, is known to cause a condition known as a bile acid synthesis defect. This defect, in turn, has phenotypes such as elevated hepatic transaminase and cirrhosis.', 'The gene ABCD3 plays a role within both the RHOA GTPase cycle and the RHOC GTPase cycle. Intriguingly, this gene causes a condition known as bile acid synthesis defect. This defect is characterized by certain phenotypes including elevated hepatic transaminase and can even lead to cirrhosis.']","['The gene ABCD3 is a component of the RHOA GTPase cycle and RHOC GTPase cycle. On another note, a disease known as bile acid synthesis defect with specific phenotypes such as elevated hepatic transaminase and cirrhosis, has been documented.', 'The gene ABCD3 acts within the RHOA GTPase cycle and the RHOC GTPase cycle. Meanwhile, bile acid synthesis defect, a medical condition, has the phenotype of elevated hepatic transaminase and cirrhosis. These disease markers are critical indicators of liver health and they demonstrate the functional roles of these pathways.', 'The gene ABCD3 is active within two GTPase cycle pathways, specifically the RHOA GTPase cycle and the RHOC GTPase cycle. Furthermore, bile acid synthesis defect is a medical condition that presents two specific phenotypes, namely elevated hepatic transaminase and cirrhosis.', 'The gene ABCD3 has a role within multiple routes such as the RHOA GTPase cycle and the RHOC GTPase cycle. On another note, the disease known as bile acid synthesis defect presents with several symptoms such as elevated hepatic transaminase and cirrhosis.']"
"[{'source_node': {'name': 'folfox'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'smad family member 7'}}, {'source_node': {'name': 'folfox'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'thymidylate synthetase'}}, {'source_node': {'name': 'folfox'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'neoplasms'}}, {'source_node': {'name': 'smad family member 7'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'overall survival'}}, {'source_node': {'name': 'smad family member 7'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'colorectal neoplasms'}}, {'source_node': {'name': 'smad family member 7'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neoplasm metastasis'}}, {'source_node': {'name': 'thymidylate synthetase'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hyperammonemia'}}, {'source_node': {'name': 'thymidylate synthetase'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'nausea'}}]","[{'source_node': {'name': 'folfox'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'neoplasms'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:90104', 'target': 'GENE:19537', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:19537', 'target': None, 'metadata': {'node_id': '19537', 'node_type': 'GENE', 'display_name': 'smad family member 7'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:90104', 'target': 'GENE:22795', 'metadata': None}, {'type': 'edge_addition', 'source': 'GENE:22795', 'target': 'DISEASE:2199', 'metadata': {'predicate': 'causes_condition'}}, {'type': 'node_removal', 'source': 'GENE:22795', 'target': None, 'metadata': {'node_id': '22795', 'node_type': 'GENE', 'display_name': 'thymidylate synthetase'}}]",0.1764705882352941,a66f05dd389a443e5a2eb5e22e62f2d4,6d1b86a68ede8d9c9df98191a43186c4,[],"['The drug FOLFOX is a substance that is used to treat neoplasms.', 'The chemotherapy regimen commonly referred to as FOLFOX is a substance that is utilized in treating various types of neoplasms.', 'The drug FOLFOX is a substance known to treat various forms of neoplasms.', 'The chemotherapy regimen FOLFOX is a substance that treats various types of neoplasms.', 'The treatment known as FOLFOX is a substance that is used to treat various types of neoplasms.']"
"[{'source_node': {'name': 'thiotepa'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mazaticol'}}, {'source_node': {'name': 'thiotepa'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Agranulocytosis'}}, {'source_node': {'name': 'thiotepa'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Myelosuppression'}}, {'source_node': {'name': 'mazaticol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'haloperidol'}}, {'source_node': {'name': 'mazaticol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nizatidine'}}, {'source_node': {'name': 'mazaticol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pimozide'}}, {'source_node': {'name': 'nizatidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tridihexethyl'}}, {'source_node': {'name': 'nizatidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluocortolone caproate'}}]","[{'source_node': {'name': 'thiotepa'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mazaticol'}}, {'source_node': {'name': 'thiotepa'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Myelosuppression'}}, {'source_node': {'name': 'mazaticol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'haloperidol'}}, {'source_node': {'name': 'nizatidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tridihexethyl'}}, {'source_node': {'name': 'nizatidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluocortolone caproate'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:11301', 'target': 'COMPOUND:571', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:1080', 'target': None, 'metadata': {'node_id': '1080', 'node_type': 'COMPOUND', 'display_name': 'pimozide'}}, {'type': 'edge_addition', 'source': 'COMPOUND:571', 'target': 'SIDE_EFFECT:545', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'node_removal', 'source': 'SIDE_EFFECT:545', 'target': None, 'metadata': {'node_id': '545', 'node_type': 'SIDE_EFFECT', 'display_name': 'Agranulocytosis'}}]",0.7058823529411764,924311ba2fdde0782fc6e66bcdad5b78,4172bfaf2a7fdd6942fb1b8c76304cd9,"['The drug thiotepa has been noted to decrease the efficacy of mazaticol. Moreover, thiotepa brings about some side effects like Agranulocytosis and Myelosuppression. On the other hand, mazaticol also reduces the efficacy of other drugs such as haloperidol, nizatidine, and pimozide. In addition, nizatidine, while in interaction with mazaticol, further reduces the effectiveness of tridihexethyl and fluocortolone caproate. Therefore, consideration should be given when administering these drugs to ensure they do not interact negatively, hence affecting their effectiveness.', 'Thiotepa, a chemotherapy medication, has been found to decrease the efficacy of the drug mazaticol. Moreover, thiotepa usage is associated with several side effects, including Agranulocytosis and Myelosuppression. It should be also noted that mazaticol in turn reduces the effectiveness of several other drugs such as haloperidol, nizatidine, and pimozide. Additionally, the usage of nizatidine can potentially lead to decreased effectiveness of tridihexethyl and fluocortolone caproate. Therefore, caution should be taken when combining these drugs in a treatment plan.', 'The drug Thiotepa is demonstrated to decrease the efficacy of another medication known as Mazaticol. Furthermore, Thiotepa has known side effects that include Agranulocytosis and Myelosuppression. In a similar vein, usage of Mazaticol has been found to decrease the efficacy of several other drugs including Haloperidol, Nizatidine, and Pimozide. This pattern continues with Nizatidine shown to decrease the effectiveness of Tridihexethyl and Fluocortolone caproate. Thus, these interactions emphasize the complexity of drug interactions and the potential for cascading effects in a medicinal regime.', 'Thiotepa is a drug known to cause side effects such as Agranulocytosis and Myelosuppression. Additionally, it has been observed to decrease the efficacy of the drug Mazaticol. Interestingly, Mazaticol in turn reduces the efficacy of several other drugs such as Haloperidol, Nizatidine, and Pimozide. Nizatidine is also implicated in diminishing the efficiency of Tridihexethyl and Fluocortolone Caproate, thereby highlighting a complex interplay of drug interactions.', 'The drug thiotepa has been observed to decrease the efficacy of another drug called mazaticol. Additionally, thiotepa can cause side effects such as agranulocytosis and myelosuppression. Mazaticol is also reported to reduce the efficacy of several other drugs including haloperidol, nizatidine, and pimozide. Moreover, nizatidine can diminish the efficacy of both tridihexethyl and fluocortolone caproate.']","['The drug thiotepa has been known to decrease the efficacy of mazaticol, with a side effect of causing Myelosuppression. Interestingly, mazaticol can also decrease the effectiveness of haloperidol in the body. In a similar manner, nizatidine also exhibits a tendency to reduce the effectiveness of both tridihexethyl and fluocortolone caproate.', ""Thiotepa, a potent chemotherapeutic drug, has been found to decrease the efficacy of mazaticol while presenting a side effect of myelosuppression. Intriguingly, mazaticol's efficacy is also reduced when administered alongside haloperidol, indicating a possible trend of decreased performance with other drugs. Further along these lines of interaction, nizatidine, a commonly used antihistamine, has been shown to decrease the efficacy of both tridihexethyl and fluocortolone caproate. It would seem that careful consideration should be made when administering these substances together, given these observable drug-drug interactions and potential side effects."", 'The drug Thiotepa is known to decrease the efficacy of Mazaticol. Concurrently, Thiotepa has a side effect, Myelosuppression. Additionally, Mazaticol might also suffer in efficacy if used in conjunction with Haloperidol. In a related phenomenon, Nizatidine works similarly by decreasing the efficacy of Tridihexethyl as well as Fluocortolone Caproate.', 'The use of Thiotepa holds notable effects on some other treatments and side effects. It is seen to decrease the efficacy of Mazaticol, an antiparkinsonian agent that in turn is known to decrease the potency of other medications, namely Haloperidol. Thiotepa also presents Myelosuppression as a side-effect. Similarly, the use of Nizatidine, another clinical drug, affects the efficiency of Tridihexethyl and Fluocortolone caproate, decreasing their efficacy and hindering their overall performance during pharmaceutical treatment.', 'The drug Thiotepa has been observed to decrease the efficacy of Mazaticol, while also having a side effect of Myelosuppression. Interestingly, Mazaticol itself also affects the performance of another drug, Haloperidol, by minimising its efficacy. In a somewhat similar vein, Nizatidine acts upon two different chemicals, namely Tridihexethyl and Fluocortolone Caproate, reducing their effectiveness in their respective roles. Thus, there appear to be complex interactions and side effects between these substances that need to be taken into account during treatment planning.']"
"[{'source_node': {'name': 'picosulfuric acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'amiodarone'}}, {'source_node': {'name': 'flurithromycin'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the excretion rate '}}, {'source_node': {'name': 'flurithromycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'picosulfuric acid'}}, {'source_node': {'name': 'flurithromycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vaccine'}}]","[{'source_node': {'name': 'typhoid vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'flurithromycin'}}, {'source_node': {'name': 'typhoid vaccine'}, 'relation': {'name': 'decrease_activity'}, 'target_node': {'name': ' the excretion rate '}}, {'source_node': {'name': 'flurithromycin'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the excretion rate '}}, {'source_node': {'name': 'flurithromycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vaccine'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:8203', 'target': None, 'metadata': {'node_id': '8203', 'node_type': 'COMPOUND', 'display_name': 'picosulfuric acid'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11858', 'target': 'COMPOUND:11194', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11858', 'target': 'ACTIVITY:7', 'metadata': {'predicate': 'decrease_activity'}}]",0.3333333333333333,74da52058f0b0b81ad1674fe8b7a101a,a174b39af7e978b37ea4b1224f678379,[],[]
"[{'source_node': {'name': 'ADORA2B'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (s) signalling events'}}, {'source_node': {'name': 'ADORA2B'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Surfactant metabolism'}}]","[{'source_node': {'name': 'ADORA2B'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Surfactant metabolism'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:424', 'target': None, 'metadata': {'node_id': '424', 'node_type': 'PATHWAY', 'display_name': 'G alpha (s) signalling events'}}]",0.6,4491925f94860e9d895bb2c30521f55e,01b73130ac7daae4d3ff5dc8fa7826f6,"['The gene ADORA2B plays roles in different biological pathways. It acts within the G alpha (s) signalling events, aiding in the communication among molecules in a cell. Moreover, it is also involved in surfactant metabolism, which is crucial for maintaining the health and functioning of lung tissues.', 'The gene ADORA2B, operates within multiple signal pathways. It acts within the G alpha (s) signalling events and also within the mechanism of surfactant metabolism. This suggests that ADORA2B might play a complex role in the regulation of cellular functions.', 'The gene ADORA2B plays a role in several pathways, acting within both the G alpha (s) signalling events and participating in surfactant metabolism.', 'The gene ADORA2B operates within the G alpha (s) signalling events and the surfactant metabolism pathways.', 'The gene ADORA2B is known to function within various pathways, such as the pathway of G alpha (s) signalling events and the process of surfactant metabolism.']","['The gene ADORA2B operates within the sphere of surfactant metabolism.', 'The gene ADORA2B functions within the pathway of surfactant metabolism.']"
"[{'source_node': {'name': 'pimethixene'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'racepinephrine'}}, {'source_node': {'name': 'pimethixene'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'theodrenaline'}}, {'source_node': {'name': 'pimethixene'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'deoxyepinephrine'}}, {'source_node': {'name': 'racepinephrine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'labetalol'}}, {'source_node': {'name': 'racepinephrine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'histapyrrodine'}}, {'source_node': {'name': 'racepinephrine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'flap endonuclease 1'}}]","[{'source_node': {'name': 'pimethixene'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'racepinephrine'}}, {'source_node': {'name': 'pimethixene'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'theodrenaline'}}, {'source_node': {'name': 'pimethixene'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'deoxyepinephrine'}}, {'source_node': {'name': 'pimethixene'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'labetalol'}}, {'source_node': {'name': 'theodrenaline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'labetalol'}}, {'source_node': {'name': 'racepinephrine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'labetalol'}}, {'source_node': {'name': 'racepinephrine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'flap endonuclease 1'}}, {'source_node': {'name': 'racepinephrine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pimethixene'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:11331', 'target': None, 'metadata': {'node_id': '11331', 'node_type': 'COMPOUND', 'display_name': 'histapyrrodine'}}, {'type': 'edge_addition', 'source': 'COMPOUND:10801', 'target': 'COMPOUND:584', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11149', 'target': 'COMPOUND:584', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:9136', 'target': 'COMPOUND:11149', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.6153846153846154,8d0652e098cadb36031d1320cee9cb8d,1ae88cb3c937a7cc8628f5db70c6c309,"['Pimethixene is a medication known to increase the efficacy of certain other drugs such as racepinephrine, theodrenaline, and deoxyepinephrine. Moreover, racepinephrine itself also has the ability to increase the efficacy of medications including labetalol and histapyrrodine. Apart from that, racepinephrine directly targets the particular enzyme known as flap endonuclease 1.', 'The drug pimethixene is known to increase the efficacy of several other drugs including racepinephrine, theodrenaline, and deoxyepinephrine. Furthermore, racepinephrine not only has its efficacy increased by pimethixene but it also increases the efficacy of labetalol and histapyrrodine. An interesting relationship also exists between racepinephrine and flap endonuclease 1, as the former targets the latter.', 'Pimethixene is a drug known to increase the efficacy of several other medications. Specifically, it has been shown to boost the efficacy of racepinephrine, theodrenaline, and deoxyepinephrine. In turn, racepinephrine can further increase the efficacy of labetalol and histapyrrodine. Furthermore, racepinephrine directly targets flap endonuclease 1, a protein involved in DNA repair. Therefore, interactions among these drugs and proteins may provide therapeutic benefits in clinical scenarios.', ""The drug Pimethixene has been identified to increase the efficacy of several drugs including Racepinephrine, Theodrenaline, and Deoxyepinephrine. Furthermore, Racepinephrine also showed an increase in efficacy when combined with Labetalol and Histapyrrodine. It's also notable that Racepinephrine has been found to target the enzyme known as flap endonuclease 1, playing a possible role in the mechanism of action of these drugs."", 'The drug Pimethixene has been found to increase the efficacy of several different substances including Racepinephrine, Theodrenaline, and Deoxyepinephrine. Interestingly, in turn, Racepinephrine itself also augments the effectiveness of drugs like Labetalol and Histapyrrodine. Furthermore, Racepinephrine has been identified to target Flap Endonuclease 1, a key enzyme involved in DNA replication and repair. This intricate network of interactions could open up new avenues in the exploration of novel therapeutics.']","[""Pimethixene is a drug known to increase the efficacy of several others, including Racepinephrine, Theodrenaline, Deoxyepinephrine, and Labetalol. Interestingly, Theodrenaline and Racepinephrine, two of the drugs whose efficacy is increased by Pimethixene, also contribute to the increased efficacy of Labetalol. A unique aspect of Racepinephrine is its targeted action on the protein, flap endonuclease 1. However, while Pimethixene enhances the effect of Racepinephrine, the converse isn't true. In fact, Racepinephrine decreases the efficacy of Pimethixene."", 'The medication pimethixene has been observed to increase the efficacy of several other drugs, including racepinephrine, theodrenaline, deoxyepinephrine, and labetalol. Interestingly, it seems there is a mutual interaction between pimethixene and racepinephrine as it has been reported that racepinephrine can decrease the efficacy of pimethixene. Further, theodrenaline and racepinephrine both seem to synergistically enhance the effectiveness of labetalol which is already boosted by pimethixene. On a molecular level, racepinephrine appears to target flap endonuclease 1, a critical player in the repair of DNA damage, suggesting a possible mechanism for its pharmacological actions.', ""The drug Pimethixene has been known to increase the efficacy of multiple substances including racepinephrine, theodrenaline, deoxyepinephrine, and labetalol. Interestingly, theodrenaline and racepinephrine in turn also improve the efficacy of labetalol. However, it's been observed that racepinephrine decreases the efficacy of pimethixene. Additionally, racepinephrine has a unique property where it targets the flap endonuclease 1, a protein involved in DNA repair."", 'The drug Pimethixene has the ability to bolster the efficacy of several other drugs including Theodrenaline, Deoxyepinephrine, Racepinephrine, and Labetalol, creating a potential synergy in treatment approaches. This effect is mutual as both Theodrenaline and Racepinephrine can also enhance the efficacy of Labetalol. Additionally, Racepinephrine targets the protein known as flap endonuclease 1. Interestingly, while Pimethixene increases the efficacy of Racepinephrine, the latter seems to decrease the efficacy of Pimethixene in a complex interaction between these pharmaceutical agents.', 'The drug Pimethixene is known to increase the efficacy of Racepinephrine, Theodrenaline, Deoxyepinephrine and Labetalol. Interestingly, both Theodrenaline and Racepinephrine themselves can increase the efficacy of Labetalol. Looking deeper into these interactions, it can be seen that Racepinephrine also targets Flap Endonuclease 1. However, it is noteworthy that the efficacy of Pimethixene may decrease when administered alongside Racepinephrine.']"
"[{'source_node': {'name': 'folfox'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'smad family member 7'}}, {'source_node': {'name': 'folfox'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'overall survival'}}, {'source_node': {'name': 'folfox'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'progression-free survival'}}, {'source_node': {'name': 'smad family member 7'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'colorectal neoplasms'}}, {'source_node': {'name': 'smad family member 7'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neoplasm metastasis'}}]","[{'source_node': {'name': 'folfox'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'overall survival'}}, {'source_node': {'name': 'folfox'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'progression-free survival'}}, {'source_node': {'name': 'folfox'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'neoplasm metastasis'}}, {'source_node': {'name': 'smad family member 7'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'colorectal neoplasms'}}, {'source_node': {'name': 'smad family member 7'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neoplasm metastasis'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:90104', 'target': 'GENE:19537', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:90104', 'target': 'DISEASE:2196', 'metadata': {'predicate': 'is_substance_that_treats'}}]",0.8181818181818181,d9f095760d92fb65a0e91d476e47a532,2a0b2b4628588d344b06d1533477f6c2,[],[]
"[{'source_node': {'name': 'bruceine b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-8'}}, {'source_node': {'name': 'bruceine b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'bgc-823'}}, {'source_node': {'name': 'bruceine b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-ov-3'}}]","[{'source_node': {'name': 'bruceine b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-ov-3'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5005', 'target': None, 'metadata': {'node_id': '5005', 'node_type': 'PROTEIN', 'display_name': 'hct-8'}}, {'type': 'node_removal', 'source': 'PROTEIN:5763', 'target': None, 'metadata': {'node_id': '5763', 'node_type': 'PROTEIN', 'display_name': 'bgc-823'}}]",0.4285714285714286,3d9a8f69793fc2f21ba86cba94634614,300c738c6b688f6dc96146e52f3b8b7a,"['Bruceine B is a compound that has been identified to target several entities including HCT-8, BGC-823 and SK-OV-3. These targets play a variety of roles in different biological pathways and systems, contributing further to our understanding of the therapeutic potential of Bruceine B.', 'Bruceine B is a compound that has been found to target several cell lines, including HCT-8, BGC-823, and SK-OV-3.', 'The drug, Bruceine B, is known to target several entities. These include HCT-8, BGC-823, and SK-OV-3.', 'Bruceine B is an active substance that specifically targets multiple cells. These include HCT-8, BGC-823, and SK-OV-3 cells. This reveals the potential of Bruceine B in inhibiting growth of diverse cell types.', 'Bruceine B, a natural compound, targets various entities. It has shown biochemical interactions with HCT-8, a cell line derived from human colon adenocarcinoma. In addition to this, Bruceine B also targets BGC-823, a cell line active in gastric adenocarcinoma research. Moreover, it engages with SK-OV-3, a cell line used in the study of ovarian cancer.']","['The compound Bruceine B has been identified to target SK-OV-3.', 'The compound Bruceine B has a specific target, which is the SK-OV-3.']"
"[{'source_node': {'name': 'geranylgeranyl pyrophosphate synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GGPS1'}}, {'source_node': {'name': 'minodronic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'farnesyl pyrophosphate synthase'}}, {'source_node': {'name': 'minodronic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'geranylgeranyl pyrophosphate synthase'}}]","[{'source_node': {'name': 'geranylgeranyl pyrophosphate synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GGPS1'}}, {'source_node': {'name': 'farnesyl pyrophosphate synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GGPS1'}}, {'source_node': {'name': 'minodronic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'farnesyl pyrophosphate synthase'}}, {'source_node': {'name': 'minodronic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'geranylgeranyl pyrophosphate synthase'}}, {'source_node': {'name': 'minodronic acid'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'GGPS1'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:992', 'target': 'GENE:35452', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5651', 'target': 'GENE:35452', 'metadata': {'predicate': 'is_affecting'}}]",0.7142857142857143,9737bd59f4fd3117805d765a98fc6f1c,f540deafd9550c6194b7a08573edfc05,"['The protein geranylgeranyl pyrophosphate synthase is a gene product of GGPS1. Interestingly, this protein is one of the targets of minodronic acid, a drug which also targets another enzyme known as farnesyl pyrophosphate synthase.', 'The enzyme geranylgeranyl pyrophosphate synthase, which is a gene product of the GGPS1 gene, is a target of the drug minodronic acid. Notably, this drug also targets another enzyme, the farnesyl pyrophosphate synthase. Thus, minodronic acid interacts with these enzymatic pathways via its direct targeting of geranylgeranyl pyrophosphate synthase and farnesyl pyrophosphate synthase.', 'Geranylgeranyl pyrophosphate synthase is a gene product of GGPS1 and is one of the targets of minodronic acid. This drug also targets another enzyme known as farnesyl pyrophosphate synthase.', 'Minodronic Acid, a therapeutic drug, targets both Farnesyl Pyrophosphate Synthase and Geranylgeranyl Pyrophosphate Synthase. The latter is interestingly a gene product of GGPS1.', 'The enzyme geranylgeranyl pyrophosphate synthase, which is a gene product of GGPS1, serves as one of the targets for minodronic acid. Interestingly, minodronic acid also has another target called farnesyl pyrophosphate synthase.']","['The drug minodronic acid targets both geranylgeranyl pyrophosphate synthase and farnesyl pyrophosphate synthase, which are gene products of GGPS1. Besides, minodronic acid also affects the gene GGPS1 directly, indicating a potential mechanism for its therapeutic efficacy.', 'The drug minodronic acid has two molecular targets, geranylgeranyl pyrophosphate synthase and farnesyl pyrophosphate synthase. These enzymes are gene products of GGPS1. Interestingly, minodronic acid also affects GGPS1 directly, indicating a multilayered regulatory interactions facilitated by minodronic acid.']"
"[{'source_node': {'name': 'metocurine iodide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'magnesium sulfate'}}, {'source_node': {'name': 'metocurine iodide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'paromomycin'}}, {'source_node': {'name': 'metocurine iodide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'sulbenicillin'}}]","[{'source_node': {'name': 'metocurine iodide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'magnesium sulfate'}}, {'source_node': {'name': 'metocurine iodide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'paromomycin'}}, {'source_node': {'name': 'paromomycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'magnesium sulfate'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1359', 'target': 'COMPOUND:11540', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:11540', 'target': None, 'metadata': {'node_id': '11540', 'node_type': 'COMPOUND', 'display_name': 'sulbenicillin'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1359', 'target': 'COMPOUND:639', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.5714285714285714,ed7d161f5fd123f3f5a6cbdeff91a970,d1ec669b39791e227d38ffe454f979e4,"['The drug Metocurine Iodide increases the efficacy of several other medicinal compounds. It enhances the effectiveness of Magnesium Sulfate, Paromomycin, and Sulbenicillin.', 'The drug Metocurine Iodide is known to increase the efficacy of several other substances including Magnesium Sulfate, Paromomycin, and Sulbenicillin.', 'The drug metocurine iodide has been shown to increase the efficacy of a few other substances including magnesium sulfate, paromomycin, and sulbenicillin.', 'The medication metocurine iodide is found to increase the efficacy of multiple drugs including magnesium sulfate, paromomycin, and sulbenicillin. This suggests potential for beneficial drug pairings and could influence treatment decisions in clinical practice.', 'The drug metocurine iodide is known to increase the efficacy of several other drugs such as magnesium sulfate, paromomycin, and sulbenicillin.']","['The drug metocurine iodide is found to enhance the efficacy of both magnesium sulfate and paromomycin. Interestingly, paromomycin is then noted to decrease the efficacy of magnesium sulfate.', 'The drug metocurine iodide is known to increase the efficacy of both magnesium sulfate and paromomycin. Interestingly, paromomycin tends to decrease the efficacy of magnesium sulfate.', 'The drug metocurine iodide is known to increase the efficacy of both magnesium sulfate and paromomycin. However, it should be noted that paromomycin may unintentionally decrease the efficacy of magnesium sulfate. Therefore, care should be taken when using these drugs in concert.', 'The drug metocurine iodide has been shown to increase the efficacy of both magnesium sulfate and paromomycin. Interestingly, paromomycin is known to decrease the efficacy of magnesium sulfate. Thus, the relationship between these three drugs appears complex and bidirectional.', 'The drug metocurine iodide is known to increase the efficacy of both magnesium sulfate and paromomycin. Paradoxically, paromomycin is noted to decrease the efficacy of magnesium sulfate. Therefore, the drug interactions between metocurine iodide, paromomycin and magnesium sulfate need to be carefully considered when co-administered.']"
"[{'source_node': {'name': 'formic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna gyrase subunit b'}}, {'source_node': {'name': 'formic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'desmoteplase'}}, {'source_node': {'name': 'formic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'gabexate'}}, {'source_node': {'name': 'desmoteplase'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' hemorrhage '}}, {'source_node': {'name': 'desmoteplase'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'omega-3-carboxylic acids'}}, {'source_node': {'name': 'desmoteplase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'susoctocog alfa'}}]","[{'source_node': {'name': 'formic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'gabexate'}}, {'source_node': {'name': 'formic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'susoctocog alfa'}}, {'source_node': {'name': 'omega-3-carboxylic acids'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'gabexate'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:1841', 'target': 'COMPOUND:4635', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:1841', 'target': 'COMPOUND:9529', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'PROTEIN:1417', 'target': None, 'metadata': {'node_id': '1417', 'node_type': 'PROTEIN', 'display_name': 'dna gyrase subunit b'}}, {'type': 'edge_addition', 'source': 'COMPOUND:8390', 'target': 'COMPOUND:10708', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:4635', 'target': None, 'metadata': {'node_id': '4635', 'node_type': 'COMPOUND', 'display_name': 'desmoteplase'}}]",0.3076923076923077,e42add434ebb234fd6c9bf2a4df73c82,cc25b413e0cefa82dc67a23ce852eb4e,[],"['Formic acid has been found to decrease the effectiveness of both gabexate and susoctocog alfa. Interestingly, the introduction of omega-3-carboxylic acids may increase the efficacy of gabexate.', 'Formic acid is known to decrease the efficacy of certain substances including gabexate and susoctocog alfa. On the other hand, the presence of omega-3-carboxylic acids can increase the efficacy of gabexate. This interaction of substances can help guide the use and combination of these substances in various health-related applications.', 'The presence of formic acid has been found to decrease the efficacy of several therapeutic agents such as gabexate and susoctocog alfa. Interestingly, the beneficial effects of gabexate can however be enhanced by omega-3-carboxylic acids, which are known to increase its efficacy.', 'Formic acid has been found to decrease the efficacy of the drugs Gabexate and Susoctocog Alfa. Meanwhile, Omega-3-Carboxylic acids can potentially increase the efficacy of Gabexate.', 'Formic acid can decrease the efficacy of both gabexate and susoctocog alfa, potentially limiting their therapeutic effects. On the other hand, omega-3-carboxylic acids may enhance the efficacy of gabexate, possibly optimizing its effectiveness as a treatment.']"
"[{'source_node': {'name': 'SLC16A3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Basigin interactions'}}, {'source_node': {'name': 'SLC16A3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Proton-coupled monocarboxylate transport'}}, {'source_node': {'name': 'SLC16A3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pyruvate metabolism'}}, {'source_node': {'name': 'monocarboxylate transporter 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SLC16A3'}}, {'source_node': {'name': '2-oxobutanoic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': '1-aminocyclopropane-1-carboxylate deaminase'}}, {'source_node': {'name': '2-oxobutanoic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'methylmalonyl-coa carboxyltransferase 5s subunit'}}, {'source_node': {'name': '2-oxobutanoic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'monocarboxylate transporter 4'}}]","[{'source_node': {'name': 'SLC16A3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Basigin interactions'}}, {'source_node': {'name': 'SLC16A3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Proton-coupled monocarboxylate transport'}}, {'source_node': {'name': 'SLC16A3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pyruvate metabolism'}}, {'source_node': {'name': 'monocarboxylate transporter 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SLC16A3'}}, {'source_node': {'name': '2-oxobutanoic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': '1-aminocyclopropane-1-carboxylate deaminase'}}, {'source_node': {'name': '2-oxobutanoic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'methylmalonyl-coa carboxyltransferase 5s subunit'}}, {'source_node': {'name': '2-oxobutanoic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'monocarboxylate transporter 4'}}, {'source_node': {'name': '2-oxobutanoic acid'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'SLC16A3'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:4279', 'target': 'GENE:35160', 'metadata': {'predicate': 'is_affecting'}}]",0.9333333333333332,2f6bdcfdca9e7f66d1013e4a679469ef,7f96daac36c9fe40ed4a727359b0ab9b,[],[]
"[{'source_node': {'name': 'alopecia-mental retardation syndrome 4'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'microcephaly'}}, {'source_node': {'name': 'alopecia-mental retardation syndrome 4'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'bilateral cryptorchidism'}}, {'source_node': {'name': 'alopecia-mental retardation syndrome 4'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'neonatal onset'}}]","[{'source_node': {'name': 'alopecia-mental retardation syndrome 4'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'bilateral cryptorchidism'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:211', 'target': None, 'metadata': {'node_id': '211', 'node_type': 'PHENOTYPE', 'display_name': 'microcephaly'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:2585', 'target': None, 'metadata': {'node_id': '2585', 'node_type': 'PHENOTYPE', 'display_name': 'neonatal onset'}}]",0.4285714285714286,9123d83226a42dffa9f1a01731b62083,f1fbd3e347ba953fe34241eb3e518ea0,"['The condition known as alopecia-mental retardation syndrome 4 has several associated phenotypes. These include microcephaly, a reduced head size, neonatal onset indicating an early start of the condition, and bilateral cryptorchidism, which involves the absence of one or both testes from the scrotum.', ""Alopecia-mental retardation syndrome 4 is a medical condition that is characterized by several phenotypes. One of its more notable characteristics is microcephaly, a condition where the individual's head size is significantly smaller than average. Another phenotype that has been observed in people with this syndrome is bilateral cryptorchidism, which is a condition in males where one or both of the testes fail to descend. Furthermore, the syndrome also presents with a neonatal onset, meaning it manifests its symptoms shortly after birth.""]","['The syndrome called Alopecia-mental retardation syndrome 4, also presents a phenotype of bilateral cryptorchidism.']"
"[{'source_node': {'name': 'dihydrocubebin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}, {'source_node': {'name': 'dihydrocubebin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h187'}}]","[{'source_node': {'name': 'dihydrocubebin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h187'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5858', 'target': None, 'metadata': {'node_id': '5858', 'node_type': 'PROTEIN', 'display_name': 'kb'}}]",0.6,d0fc2696b23d549efb744f9167447f66,989257b6f9f9689bb766c86555e3285e,"['The compound dihydrocubebin has been found to target two different entities: KB - a cell line used for drug testing, and NCI-H187 - a type of human lung cancer cell.', 'The compound dihydrocubebin has been identified to target two entities: kb and nci-h187.', 'The compound Dihydrocubebin is known to target both KB and NCI-H187.', 'The compound dihydrocubebin has been identified as having two specific targets, KB and NCI-H187.', 'The compound dihydrocubebin lists two targets; the first being KB and the second being NCI-H187.']",[]
"[{'source_node': {'name': 'sarcrassin e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}, {'source_node': {'name': 'sarcrassin e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}]","[{'source_node': {'name': 'sarcrassin e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:1921', 'target': None, 'metadata': {'node_id': '1921', 'node_type': 'PROTEIN', 'display_name': 'tyrosine-protein phosphatase non-receptor type 1'}}]",0.6,6c00f3c1459859f57899baaee6005c6a,a609d0eb964a8e8afc9b548b078207ff,"['The compound Sarcrassin E targets both KB and Tyrosine-protein phosphatase non-receptor type 1.', 'The compound Sarcrassin E has been found to target several proteins, including KB and Tyrosine-Protein Phosphatase Non-Receptor Type 1.', 'The compound Sarcrassin E has been shown to target both KB and Tyrosine-protein phosphatase non-receptor type 1.', 'The drug Sarcrassin E targets two distinct elements, namely KB and the Tyrosine-protein phosphatase non-receptor type 1.', 'The drug Sarcrassin E is known to target two distinct entities: KB, a cell line derived from human carcinoma of the nasopharynx, and the enzyme known as tyrosine-protein phosphatase non-receptor type 1, which is crucial in cellular signaling processes.']",['The compound sarcrassin e has a target action on kb.']
"[{'source_node': {'name': 'zeaxanthin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}}, {'source_node': {'name': 'zeaxanthin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'androgen receptor'}}, {'source_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TDP1'}}]","[{'source_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TDP1'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:9180', 'target': None, 'metadata': {'node_id': '9180', 'node_type': 'COMPOUND', 'display_name': 'zeaxanthin'}}]",0.4285714285714286,17838837af2b714dab1126d5b74b4d7f,fe2f71cc0ab5abfce1b058ea6a6e5d00,"['Zeaxanthin, a naturally occurring compound in plants and some micro-organisms, targets both tyrosyl-DNA phosphodiesterase 1 and the androgen receptor. Notably, tyrosyl-DNA phosphodiesterase 1 is a gene product of TDP1.', 'Zeaxanthin, a pigment found in many common plants, has been found to target two particular proteins: tyrosyl-DNA phosphodiesterase 1 and the androgen receptor. Interestingly, tyrosyl-DNA phosphodiesterase 1 is actually a gene product of TDP1. This suggests that zeaxanthin may have much deeper biological impacts than just being a simple pigment, potentially influencing gene regulation and human health.', 'The compound zeaxanthin targets both the tyrosyl-DNA phosphodiesterase 1 and androgen receptor. It should be noted that the enzyme tyrosyl-DNA phosphodiesterase 1 is a gene product of TDP1.', 'Zeaxanthin is a substance that targets both the tyrosyl-DNA phosphodiesterase 1 and the androgen receptor. Interestingly, the tyrosyl-DNA phosphodiesterase 1 is a gene product of TDP1.', 'Zeaxanthin, a powerful antioxidant, targets the androgen receptor and tyrosyl-DNA phosphodiesterase 1. Notably, the enzyme tyrosyl-DNA phosphodiesterase 1 is the gene product of TDP1.']",[]
"[{'source_node': {'name': 'osteootohepatoenteric syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'large forehead'}}, {'source_node': {'name': 'osteootohepatoenteric syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'anemia'}}, {'source_node': {'name': 'osteootohepatoenteric syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hydrocephalus'}}]","[{'source_node': {'name': 'osteootohepatoenteric syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'anemia'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:201', 'target': None, 'metadata': {'node_id': '201', 'node_type': 'PHENOTYPE', 'display_name': 'hydrocephalus'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:1466', 'target': None, 'metadata': {'node_id': '1466', 'node_type': 'PHENOTYPE', 'display_name': 'large forehead'}}]",0.4285714285714286,1140a3207a8cb665d5405f68fbb815c5,01d231062d45d085728a06fae53809fe,"['Osteootohepatoenteric syndrome is a medical condition that manifests with several distinct phenotypes. For instance, individuals diagnosed with this syndrome often exhibit a large forehead. They also frequently suffer from anemia, a condition that reduces the quantity of red blood cells or hemoglobin in the body. Moreover, hydrocephalus, characterized by the buildup of fluid in cavities deep within the brain, is another notable symptom associated with osteootohepatoenteric syndrome.', 'Osteootohepatoenteric syndrome, a rare genetic condition, has several distinctive phenotypic features such as a large forehead, anemia, and hydrocephalus.', 'Osteootohepatoenteric syndrome, a complex condition, presents a range of observable phenotypes, including a notably large forehead, anemia, and hydrocephalus.', 'Osteootohepatoenteric syndrome is a condition that manifests several phenotypes, including a large forehead, anemia, and hydrocephalus.', 'Osteootohepatoenteric syndrome is a condition that presents various phenotypes including a large forehead, anemia, and hydrocephalus.']",[]
"[{'source_node': {'name': 'alpha-mannosidosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'synostosis of joints'}}, {'source_node': {'name': 'alpha-mannosidosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'thickened ribs'}}, {'source_node': {'name': 'alpha-mannosidosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'depressed nasal bridge'}}]","[{'source_node': {'name': 'alpha-mannosidosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'thickened ribs'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:3583', 'target': None, 'metadata': {'node_id': '3583', 'node_type': 'PHENOTYPE', 'display_name': 'depressed nasal bridge'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:10701', 'target': None, 'metadata': {'node_id': '10701', 'node_type': 'PHENOTYPE', 'display_name': 'synostosis of joints'}}]",0.4285714285714286,5f52824dd89054002633d4164192402b,dae70969443fca978fc7a188c6f96fd8,"['Alpha-mannosidosis is a condition that presents with several phenotypes such as synostosis of joints, thickened ribs, and a depressed nasal bridge.', 'Alpha-mannosidosis, a disorder of lysosome-related metabolism, manifests a number of phenotypes including synostosis of joints, thickened ribs, and a notably depressed nasal bridge.', 'Alpha-mannosidosis is a disorder characterized by several phenotypes such as synostosis of joints, thickened ribs, and a depressed nasal bridge.', 'Alpha-mannosidosis, a rare genetic disorder, demonstrates several distinct phenotypes including synostosis of joints, thickened ribs and a depressed nasal bridge.', 'Alpha-mannosidosis, a genetic disorder, is characterized by several phenotypic traits such as synostosis of joints, thickened ribs, and a depressed nasal bridge.']",[]
"[{'source_node': {'name': 'phospholipase a2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PLA2G2A'}}, {'source_node': {'name': 'calicoferol h'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'k562'}}, {'source_node': {'name': 'calicoferol h'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'phospholipase a2'}}]","[{'source_node': {'name': 'phospholipase a2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PLA2G2A'}}, {'source_node': {'name': 'calicoferol h'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'phospholipase a2'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4947', 'target': None, 'metadata': {'node_id': '4947', 'node_type': 'PROTEIN', 'display_name': 'k562'}}]",0.7142857142857143,aaec2e1df9ae74c5160d3a7edecc05f0,122b7abf763988f054c0d732efe07778,"['Phospholipase A2, a gene product of PLA2G2A, is targeted by the substance Calicoferol H. Interestingly, Calicoferol H also targets another site named K562.', 'Phospholipase A2, a gene product of PLA2G2A, is a target of the drug Calicoferol H. Notably, this drug also targets another protein known as K562.', 'Phospholipase A2, a gene product of PLA2G2A, acts as a target for the drug Calicoferol H. Interestingly, Calicoferol H also targets K562, a line of human immortalized myelogenous leukemia cells, along with Phospholipase A2, adding to its potential therapeutic applicability.', 'Phospholipase A2, which is a gene product of PLA2G2A, behaves as a target for the drug Calicoferol H. Interestingly, Calicoferol H not only targets Phospholipase A2 but also another substance named K562.', 'The compound Calicoferol H has been found to target both K562, a type of human leukemia cell line, and the key enzyme Phospholipase A2. It is worth noting that Phospholipase A2 is a product of the PLA2G2A gene.']","['Phospholipase A2 is the gene product of PLA2G2A and is targeted by the drug Calicoferol H.', 'The enzyme phospholipase A2, which is a gene product of PLA2G2A, is targeted by the drug calicoferol H.', 'The enzyme phospholipase A2 is a gene product of PLA2G2A. Interestingly, phospholipase A2 is also a target of the drug calicoferol H.', '""The enzyme phospholipase A2 is a gene product of PLA2G2A. Interestingly, the drug Calicoferol H targets this particular gene product, phospholipase A2.', 'The compound calicoferol h targets phospholipase a2, an enzyme that is a gene product of PLA2G2A.']"
"[{'source_node': {'name': 'aurora kinase a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AURKA'}}, {'source_node': {'name': 'alterlactone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'rac-alpha serine/threonine-protein kinase'}}, {'source_node': {'name': 'alterlactone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'aurora kinase a'}}, {'source_node': {'name': 'alterlactone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ephrin type-b receptor 4'}}, {'source_node': {'name': 'rac-alpha serine/threonine-protein kinase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AKT1'}}, {'source_node': {'name': 'ephrin type-b receptor 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'EPHB4'}}]","[{'source_node': {'name': 'alterlactone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'rac-alpha serine/threonine-protein kinase'}}, {'source_node': {'name': 'alterlactone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'aurora kinase a'}}, {'source_node': {'name': 'rac-alpha serine/threonine-protein kinase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AKT1'}}, {'source_node': {'name': 'ephrin type-b receptor 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'EPHB4'}}, {'source_node': {'name': 'ephrin type-b receptor 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AKT1'}}]","[{'type': 'node_removal', 'source': 'GENE:33085', 'target': None, 'metadata': {'node_id': '33085', 'node_type': 'GENE', 'display_name': 'AURKA'}}, {'type': 'edge_addition', 'source': 'PROTEIN:1652', 'target': 'GENE:26810', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:34095', 'target': 'PROTEIN:1652', 'metadata': None}]",0.6923076923076923,91a815fe6c7f9cb2168cb1f7192df9dd,9c547351fc356788d0eb65a4f85353c1,"['The drug Alterlactone has multiple targets in the body including the Rac-alpha serine/threonine-protein kinase, Aurora kinase A, and Ephrin type-B receptor 4. These kinases, in turn, are gene products of several critical genes. The Aurora kinase A is a gene product of the AURKA gene, the Rac-alpha serine/threonine-protein kinase arises from the AKT1 gene, and Ephrin type-B receptor 4 stems from EPHB4 gene.', 'The drug Alterlactone has several target proteins including Aurora Kinase A, Rac-alpha Serine/Threonine-protein Kinase, and Ephrin Type-B Receptor 4. Interestingly, each of these targeted proteins are gene products of specific genes. Aurora Kinase A is a gene product of AURKA, Rac-alpha Serine/Threonine-protein Kinase of AKT1, and Ephrin Type-B Receptor 4 of EPHB4.', 'The drug Alterlactone targets several gene products, including Aurora Kinase A, Rac-Alpha Serine/Threonine-Protein Kinase, and Ephrin Type-B Receptor 4. Aurora Kinase A is a gene product of AURKA, while the Rac-Alpha Serine/Threonine-Protein Kinase and the Ephrin Type-B Receptor 4 are gene products of AKT1 and EPHB4, respectively.', 'The drug alterlactone has numerous targets in the body, including the aurora kinase A protein, rac-alpha serine/threonine-protein kinase and ephrin type-B receptor 4. These proteins are the gene products of their respective genes. Aurora kinase A is the gene product of AURKA, rac-alpha serine/threonine-protein kinase is produced by the AKT1 gene, and EPHB4 is responsible for the formation of ephrin type-B receptor 4.', 'The drug alterlactone targets several proteins such as the rac-alpha serine/threonine-protein kinase, aurora kinase a, and ephrin type-b receptor 4. Interestingly, these proteins are gene products of AKT1, AURKA, and EPHB4 respectively.']","['The drug alterlactone has been found to target both rac-alpha serine/threonine-protein kinase and aurora kinase A. Moreover, rac-alpha serine/threonine-protein kinase is a gene product of AKT1. On the other hand, ephrin type-b receptor 4 is a gene product of both EPHB4 and AKT1. This suggests a potential interplay of these entities in the biological pathways.', 'The drug alterlactone has multiple targets, including the rac-alpha serine/threonine-protein kinase and aurora kinase A. This rac-alpha serine/threonine-protein kinase is a gene product of AKT1. Moreover, ephrin type-b receptor 4 is a gene product of both EPHB4 and AKT1.', 'Alterlactone, a biochemical compound, targets two enzymes: rac-alpha serine/threonine-protein kinase and aurora kinase A. Of these, the rac-alpha serine/threonine-protein kinase is a gene product of the AKT1 gene. This genetic linkage extends to the ephrin type-B receptor 4 as well, which is also a gene product of the AKT1 gene. Interestingly, this receptor is additionally a gene product of another gene, EPHB4. These intricate associations underline the complex interplay of genes and biochemical constituents in biological systems.', 'The drug Alterlactone holds the potential to target two proteins: the rac-alpha serine/threonine-protein kinase and aurora kinase A. Interestingly, the rac-alpha serine/threonine-protein kinase is a gene product of AKT1. Furthermore, AKT1 also stands as the gene which leads to the creation of another protein, the ephrin type-b receptor 4. Interestingly enough, the ephrin type-b receptor 4 also happens to be a gene product of EPHB4. This data reveals intertwined relationships between these pharmaceutical and genetic entities.', 'The drug Alterlactone has been identified to target several proteins including the Rac-alpha serine/threonine-protein kinase and the Aurora kinase A. Interesting to note is that the Rac-alpha serine/threonine-protein kinase is a product of the AKT1 gene. In addition to this, the Ephrin type-B receptor 4 is also a product of the same AKT1 gene. Furthermore, the Ephrin type-B receptor 4 is a gene product of EPHB4. Therefore, the interconnections between these compounds and proteins may provide valuable insight into the action mechanism of Alterlactone and potential therapeutic applications.']"
"[{'source_node': {'name': 'RIMS1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Serotonin Neurotransmitter Release Cycle'}}, {'source_node': {'name': 'RIMS1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Norepinephrine Neurotransmitter Release Cycle'}}, {'source_node': {'name': 'RIMS1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'GABA synthesis, release, reuptake and degradation'}}]","[{'source_node': {'name': 'RIMS1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Serotonin Neurotransmitter Release Cycle'}}, {'source_node': {'name': 'RIMS1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Norepinephrine Neurotransmitter Release Cycle'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:871', 'target': None, 'metadata': {'node_id': '871', 'node_type': 'PATHWAY', 'display_name': 'GABA synthesis, release, reuptake and degradation'}}]",0.7142857142857143,0e6307534cf4f436b5f692d7ba48e26a,c79346b4fe989025a460d17a18a34e73,"['The gene RIMS1 is involved in multiple neurotransmitter release cycles, including the serotonin neurotransmitter release cycle and the norepinephrine neurotransmitter release cycle. Additionally, RIMS1 contributes to the process of GABA synthesis, its release, reuptake, and degradation.', 'The gene RIMS1 has a crucial role in several neurotransmitter release cycles - the serotonin neurotransmitter release cycle, the norepinephrine neurotransmitter release cycle, and also aids in GABA synthesis, release, reuptake, and degradation.', 'The gene RIMS1 engages in several pathways such as the serotonin neurotransmitter release cycle, the norepinephrine neurotransmitter release cycle and also plays a role in GABA synthesis, release, reuptake and degradation.']","['The gene RIMS1 is involved in several neurotransmitter release cycles, including the serotonin neurotransmitter release cycle and the norepinephrine neurotransmitter release cycle.', 'The gene RIMS1 is involved in the neurotransmitter release cycles of both serotonin and norepinephrine.', 'The gene RIMS1 is a crucial component in neurotransmitter release cycles, specifically it acts within the serotonin neurotransmitter release cycle and the norepinephrine neurotransmitter release cycle.']"
"[{'source_node': {'name': 'hypotrichosis 12'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of the nail'}}, {'source_node': {'name': 'hypotrichosis 12'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormal sweat gland morphology'}}]","[{'source_node': {'name': 'hypotrichosis 12'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of the nail'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:760', 'target': None, 'metadata': {'node_id': '760', 'node_type': 'PHENOTYPE', 'display_name': 'abnormal sweat gland morphology'}}]",0.6,e2fda90052d85117902f5eae3a9b5381,26c485597e8509f6ca12b0b1086ff173,"['Hypotrichosis 12 is a medical condition characterized by distinct phenotypes, including an abnormality of the nail and abnormal sweat gland morphology.']",[]
"[{'source_node': {'name': 'tryprostatin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'tryprostatin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'rpmi-8226'}}, {'source_node': {'name': 'tryprostatin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'colo 205'}}]","[{'source_node': {'name': 'tryprostatin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'tryprostatin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'rpmi-8226'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5670', 'target': None, 'metadata': {'node_id': '5670', 'node_type': 'PROTEIN', 'display_name': 'colo 205'}}]",0.7142857142857143,8606733a974d52a9d00cd44c409748cf,7046c85a75a51c5f36e93dc241f0f80f,"['The compound Tryprostatin A is identified to have multiple targets which include MCF7, RPMI-8226, and Colo 205 cells.', 'The compound tryprostatin A is known to target several cell lines, including MCF7, RPMI-8226, and Colo 205.', 'The drug Tryprostatin A has several targets including MCF7, RPMI-8226, and Colo 205.', 'The compound Tryprostatin A targets a range of cells including MCF7, RPMI-8226, and COLO 205.', 'The compound Tryprostatin A has multiple targets including MCF7, RPMI-8226, and Colo 205.']","['The drug Tryprostatin A has multiple target cells, including MCF7 and RPMI-8226.', 'Tryprostatin A is a compound that targets two different types of cells: MCF7 and RPMI-8226.', 'The drug Tryprostatin A has been identified to target various cells, including MCF7 and RPMI-8226.', 'The drug Tryprostatin A has two notable targets: MCF7 and RPMI-8226.', 'The compound Tryprostatin A displays a targeted effect on both the MCF7 and the RPMI-8226 cell lines.']"
"[{'source_node': {'name': 'isocitric acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'isocitrate dehydrogenase [nadp]'}}, {'source_node': {'name': 'isocitric acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'aconitate hydratase'}}, {'source_node': {'name': 'isocitric acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'isocitrate dehydrogenase [nadp] cytoplasmic'}}, {'source_node': {'name': 'aconitate hydratase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACO2'}}, {'source_node': {'name': 'ACO2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Citric acid cycle (TCA cycle)'}}, {'source_node': {'name': 'isocitrate dehydrogenase [nadp] cytoplasmic'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'IDH1'}}, {'source_node': {'name': 'isocitrate dehydrogenase [nadp]'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'IDH2'}}]","[{'source_node': {'name': 'isocitric acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'isocitrate dehydrogenase [nadp]'}}, {'source_node': {'name': 'isocitric acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'aconitate hydratase'}}, {'source_node': {'name': 'isocitric acid'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'IDH2'}}, {'source_node': {'name': 'aconitate hydratase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACO2'}}, {'source_node': {'name': 'ACO2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Citric acid cycle (TCA cycle)'}}, {'source_node': {'name': 'isocitrate dehydrogenase [nadp]'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'IDH2'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1646', 'target': 'GENE:29056', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'PROTEIN:1917', 'target': None, 'metadata': {'node_id': '1917', 'node_type': 'PROTEIN', 'display_name': 'isocitrate dehydrogenase [nadp] cytoplasmic'}}]",0.6666666666666667,b4e3379f36096b44064a0ecbebe08eca,f95db8d0cc1795a3874a6893b5ca9848,"['Isocitric acid targets several enzymes including isocitrate dehydrogenase [nadp], aconitate hydratase, and isocitrate dehydrogenase [nadp] cytoplasmic. Notably, aconitate hydratase is a gene product of ACO2 which acts within the citric acid (TCA) cycle. Furthermore, the isocitrate dehydrogenase [nadp] cytoplasmic is a gene product of IDH1 and isocitrate dehydrogenase [nadp] is a gene product of IDH2.']",[]
"[{'source_node': {'name': 'SLC34A1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'nephrolithiasis/osteoporosis'}}, {'source_node': {'name': 'SLC34A1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'primary fanconi renotubular syndrome'}}, {'source_node': {'name': 'SLC34A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Type II Na+/Pi cotransporters'}}, {'source_node': {'name': 'nephrolithiasis/osteoporosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'renal phosphate wasting'}}]","[{'source_node': {'name': 'SLC34A1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'nephrolithiasis/osteoporosis'}}, {'source_node': {'name': 'SLC34A1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'primary fanconi renotubular syndrome'}}, {'source_node': {'name': 'SLC34A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Type II Na+/Pi cotransporters'}}, {'source_node': {'name': 'nephrolithiasis/osteoporosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'renal phosphate wasting'}}, {'source_node': {'name': 'primary fanconi renotubular syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'renal phosphate wasting'}}]","[{'type': 'edge_addition', 'source': 'DISEASE:7455', 'target': 'PHENOTYPE:101', 'metadata': {'predicate': 'has_phenotype'}}]",0.8888888888888888,1624c44fc1d4e95e81e3f698f701e227,a473dbe92d25ac4ddc8c2e4113155533,"['The gene SLC34A1, which acts within the pathway of Type II Na+/Pi cotransporters, is known to cause two conditions: nephrolithiasis/osteoporosis and primary fanconi renotubular syndrome. Nephrolithiasis/osteoporosis exhibits a phenotype of renal phosphate wasting, highlighting the intricate interplay between these biological entities.', 'The gene SLC34A1, which operates within the pathway of Type II Na+/Pi cotransporters, is known to cause multiple conditions. These ailments include both nephrolithiasis/osteoporosis and primary fanconi renotubular syndrome. The phenotype of renal phosphate wasting is particularly associated with the condition nephrolithiasis/osteoporosis.', 'The gene SLC34A1, which is known to act within the Type II Na+/Pi cotransporters pathway, triggers several medical conditions. It is found to cause nephrolithiasis/osteoporosis, a condition characterized by renal phosphate wasting, and primary fanconi renotubular syndrome.', 'The gene SLC34A1 has been found to cause several conditions such as nephrolithiasis/osteoporosis and primary Fanconi renotubular syndrome. This gene further acts within a pathway known as the type II Na+/Pi cotransporters. Phenotypically, the condition nephrolithiasis/osteoporosis is generally associated with renal phosphate wasting.', 'The gene SLC34A1 is implicated in causing several conditions such as nephrolithiasis/osteoporosis and primary fanconi renotubular syndrome. This gene actively operates within the framework of Type II Na+/Pi cotransporters. Nephrolithiasis/Osteoporosis, one of the conditions triggered by SLC34A1, is characterized by specific phenotypes, including renal phosphate wasting.']","['The gene SLC34A1 contributes to certain conditions, including nephrolithiasis/osteoporosis and primary fanconi renotubular syndrome. In addition, SLC34A1 acts within the pathway for Type II Na+/Pi cotransporters. Both nephrolithiasis/osteoporosis and primary fanconi renotubular syndrome are phenotypically characterized by renal phosphate wasting.', 'The gene SLC34A1, which acts within the Type II Na+/Pi cotransporters pathway, has been found to cause two conditions: nephrolithiasis/osteoporosis and primary fanconi renotubular syndrome. Both conditions present a shared phenotype characterized by renal phosphate wasting.', 'SLC34A1 is a key gene acting within the type II Na+/Pi cotransporters. Interestingly, this gene seems to have multiple implications for health conditions. On one hand, SLC34A1 is known to cause nephrolithiasis/osteoporosis, a condition characterized by the phenotype of renal phosphate wasting. On the other hand, this gene also causes primary Fanconi renotubular syndrome, another disorder associated with renal phosphate wasting. Therefore, understanding the function of the SLC34A1 gene could be of vital importance for unveiling mechanisms underlying these diseases.']"
"[{'source_node': {'name': 'ala-geninthiocin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' bleeding '}}, {'source_node': {'name': 'ala-geninthiocin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'picosulfuric acid'}}, {'source_node': {'name': 'ala-geninthiocin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'estetrol'}}]","[{'source_node': {'name': 'ala-geninthiocin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' bleeding '}}, {'source_node': {'name': 'ala-geninthiocin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'picosulfuric acid'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:10139', 'target': 'COMPOUND:13153', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:10139', 'target': None, 'metadata': {'node_id': '10139', 'node_type': 'COMPOUND', 'display_name': 'estetrol'}}]",0.7142857142857143,4a8f7752d0dcf4fb83ce6fe69d72b6e6,3adf2f4d7c5ace4c6261a1943912db11,[],[]
"[{'source_node': {'name': '2-hydroxy-5-methoxy-3-hexadecyl-1,4-benzoquinone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arachidonate 12-lipoxygenase'}}, {'source_node': {'name': '2-hydroxy-5-methoxy-3-hexadecyl-1,4-benzoquinone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arachidonate 15-lipoxygenase'}}, {'source_node': {'name': '2-hydroxy-5-methoxy-3-hexadecyl-1,4-benzoquinone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'macrophage-expressed gene 1 protein'}}, {'source_node': {'name': 'arachidonate 12-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX12'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15B'}}]","[{'source_node': {'name': '2-hydroxy-5-methoxy-3-hexadecyl-1,4-benzoquinone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arachidonate 12-lipoxygenase'}}, {'source_node': {'name': '2-hydroxy-5-methoxy-3-hexadecyl-1,4-benzoquinone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arachidonate 15-lipoxygenase'}}, {'source_node': {'name': '2-hydroxy-5-methoxy-3-hexadecyl-1,4-benzoquinone'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'ALOX12'}}, {'source_node': {'name': 'arachidonate 12-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX12'}}, {'source_node': {'name': 'arachidonate 12-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15B'}}, {'source_node': {'name': 'arachidonate 12-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15B'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5999', 'target': None, 'metadata': {'node_id': '5999', 'node_type': 'PROTEIN', 'display_name': 'macrophage-expressed gene 1 protein'}}, {'type': 'edge_addition', 'source': 'COMPOUND:19625', 'target': 'GENE:27499', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:5884', 'target': 'GENE:27539', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'PROTEIN:5884', 'target': 'GENE:27532', 'metadata': {'predicate': 'gene_product_of'}}]",0.6153846153846154,fe8e40d5e2e5bbd6a674fb7ceb566e42,ee9fa77c521140de153ca155337b019b,"['The compound 2-hydroxy-5-methoxy-3-hexadecyl-1,4-benzoquinone has notable targets, which include arachidonate 12-lipoxygenase, arachidonate 15-lipoxygenase, and the macrophage-expressed gene 1 protein. Arachidonate 12-lipoxygenase is a gene product of ALOX12, while arachidonate 15-lipoxygenase is a gene product of both ALOX15 and ALOX15B.', 'The compound 2-hydroxy-5-methoxy-3-hexadecyl-1,4-benzoquinone targets several proteins. It specifically targets arachidonate 12-lipoxygenase and arachidonate 15-lipoxygenase, as well as the macrophage-expressed gene 1 protein. Arachidonate 12-lipoxygenase is a gene product of ALOX12, while arachidonate 15-lipoxygenase is a gene product of both the ALOX15 and ALOX15B genes.', 'The compound 2-hydroxy-5-methoxy-3-hexadecyl-1,4-benzoquinone targets several substances. These include the arachidonate 12-lipoxygenase, which is a product of the ALOX12 gene, and the arachidonate 15-lipoxygenase, which is a gene product of both ALOX15 and ALOX15B genes. This compound also targets the macrophage-expressed gene 1 protein.', ""The compound 2-hydroxy-5-methoxy-3-hexadecyl-1,4-benzoquinone targets several proteins including arachidonate 12-lipoxygenase, arachidonate 15-lipoxygenase, and the macrophage-expressed gene 1 protein. It's important to note that arachidonate 12-lipoxygenase is a gene product of ALOX12 while arachidonate 15-lipoxygenase can be the gene product of both ALOX15 and ALOX15B."", ""The compound 2-hydroxy-5-methoxy-3-hexadecyl-1,4-benzoquinone is identified to target several proteins, including arachidonate 12-lipoxygenase, arachidonate 15-lipoxygenase, and macrophage-expressed gene 1 protein. It's interesting to note that arachidonate 12-lipoxygenase and arachidonate 15-lipoxygenase are gene products of ALOX12 and ALOX15, and ALOX15B, respectively.""]","['The compound 2-hydroxy-5-methoxy-3-hexadecyl-1,4-benzoquinone has several targets, including arachidonate 12-lipoxygenase and arachidonate 15-lipoxygenase. Moreover, it is affecting ALOX12 gene expression. The target arachidonate 12-lipoxygenase is a gene product of multiple genes: ALOX12, ALOX15B, and ALOX15. On the other hand, arachidonate 15-lipoxygenase is found to be a gene product of ALOX15 and ALOX15B. These interactions suggest a complex interplay between this compound and several lipogenic genes and enzymes.']"
"[{'source_node': {'name': 'IFNA14'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Interferon alpha/beta signaling'}}, {'source_node': {'name': 'IFNA14'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of IFNA/IFNB signaling'}}, {'source_node': {'name': 'IFNA14'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'TRAF6 mediated IRF7 activation'}}]","[{'source_node': {'name': 'IFNA14'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Interferon alpha/beta signaling'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1001', 'target': None, 'metadata': {'node_id': '1001', 'node_type': 'PATHWAY', 'display_name': 'Regulation of IFNA/IFNB signaling'}}, {'type': 'node_removal', 'source': 'PATHWAY:61', 'target': None, 'metadata': {'node_id': '61', 'node_type': 'PATHWAY', 'display_name': 'TRAF6 mediated IRF7 activation'}}]",0.4285714285714286,b5f5e22414462f354517d1a403e5f458,82ed7680324b30599eba5776cd8b8810,"['The gene IFNA14 is an active component in several molecular pathways. Firstly, it acts within the pathway of Interferon alpha/beta signaling. Secondly, IFNA14 takes part in the regulation of IFNA/IFNB signaling. Lastly, within the context of TRAF6 mediated IRF7 activation, IFNA14 also plays a significant role. In summary, IFNA14 is integral to these specific biological processes.']",[]
"[{'source_node': {'name': 'methacholine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'muscarinic acetylcholine receptor m4'}}, {'source_node': {'name': 'methacholine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'gentamicin'}}, {'source_node': {'name': 'methacholine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'apramycin'}}, {'source_node': {'name': 'muscarinic acetylcholine receptor m4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CHRM4'}}, {'source_node': {'name': 'apramycin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'gallamine'}}, {'source_node': {'name': 'gentamicin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' nephrotoxicity '}}, {'source_node': {'name': 'gentamicin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sulodexide'}}, {'source_node': {'name': 'gentamicin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'telomerase reverse transcriptase'}}]","[{'source_node': {'name': 'methacholine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'muscarinic acetylcholine receptor m4'}}, {'source_node': {'name': 'muscarinic acetylcholine receptor m4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CHRM4'}}, {'source_node': {'name': 'apramycin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'gallamine'}}, {'source_node': {'name': 'apramycin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'sulodexide'}}, {'source_node': {'name': 'gentamicin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' nephrotoxicity '}}, {'source_node': {'name': 'gentamicin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sulodexide'}}, {'source_node': {'name': 'gentamicin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'telomerase reverse transcriptase'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:4347', 'target': 'COMPOUND:5503', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:5760', 'target': 'COMPOUND:781', 'metadata': None}, {'type': 'edge_deletion', 'source': 'COMPOUND:5760', 'target': 'COMPOUND:4347', 'metadata': None}]",0.8235294117647058,6790e845b5f1d24dce49ce21281379e0,a6f39dc547aa1738b445be001faf7062,[],[]
"[{'source_node': {'name': 'dopamine d2 receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DRD2'}}, {'source_node': {'name': 'sodium-dependent serotonin transporter'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SLC6A4'}}, {'source_node': {'name': 'amitifadine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sodium-dependent serotonin transporter'}}, {'source_node': {'name': 'amitifadine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sodium-dependent noradrenaline transporter'}}, {'source_node': {'name': 'amitifadine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dopamine d2 receptor'}}, {'source_node': {'name': 'SLC6A4'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'obsessive-compulsive disorder 1'}}, {'source_node': {'name': 'sodium-dependent noradrenaline transporter'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SLC6A2'}}]","[{'source_node': {'name': 'dopamine d2 receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DRD2'}}, {'source_node': {'name': 'amitifadine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sodium-dependent serotonin transporter'}}, {'source_node': {'name': 'amitifadine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sodium-dependent noradrenaline transporter'}}, {'source_node': {'name': 'amitifadine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dopamine d2 receptor'}}, {'source_node': {'name': 'amitifadine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'DRD2'}}]","[{'type': 'node_removal', 'source': 'GENE:32859', 'target': None, 'metadata': {'node_id': '32859', 'node_type': 'GENE', 'display_name': 'SLC6A2'}}, {'type': 'node_removal', 'source': 'GENE:32861', 'target': None, 'metadata': {'node_id': '32861', 'node_type': 'GENE', 'display_name': 'SLC6A4'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5349', 'target': 'GENE:26576', 'metadata': {'predicate': 'is_affecting'}}]",0.5333333333333333,754886c0d8178cb3664deeec66b88a75,301a436d78c0be8ac2fc712b97386f2c,"['In the complex network of molecular biology, proteins such as the dopamine D2 receptor and the sodium-dependent serotonin transporter are the products of specific genes, namely DRD2 and SLC6A4 respectively. Additionally, the sodium-dependent noradrenaline transporter is a gene product of SLC6A2. Interestingly, a compound called amitifadine shows a fascinating interaction with these proteins. Amitifadine has been found to target not only the sodium-dependent serotonin transporter but also the sodium-dependent noradrenaline transporter and the dopamine D2 receptor. In terms of clinical implications, this is significant as certain conditions such as obsessive-compulsive disorder 1 have been linked to the SLC6A4 gene, indicating potential therapeutic applications for amitifadine.', 'The dopamine D2 receptor, which is the gene product of DRD2, and the Sodium-dependent serotonin transporter, a gene product of SLC6A4 are both targeted by the drug Amitifadine. Amitifadine also targets the sodium-dependent noradrenaline transporter, a gene product of SLC6A2. Notably, mutations in the SLC6A4 gene are reported to be the cause of the Obsessive-compulsive disorder 1.', 'The drug amitifadine targets three receptors: sodium-dependent serotonin transporter, sodium-dependent noradrenaline transporter, and dopamine D2 receptor. These three receptors are gene products of SLC6A4, SLC6A2, and DRD2 respectively. Notably, the gene SLC6A4, synonymous with the sodium-dependent serotonin transporter, has been implicated in causing a condition referred to as obsessive-compulsive disorder 1.', ""The drug Amitifadine targets several sites, including the Sodium-dependent serotonin transporter, Sodium-dependent noradrenaline transporter, and the Dopamine D2 receptor. It's worth noting these target sites are gene products of the genes SLC6A4, SLC6A2 and DRD2 respectively. Interestingly, there are specific disease affiliations for these genes. For example, the SLC6A4 gene, which gives rise to the Sodium-dependent serotonin transporter, is known to cause a condition known as Obsessive-Compulsive Disorder 1."", 'The dopamine D2 receptor and sodium-dependent serotonin transporter are gene products of DRD2 and SLC6A4, respectively. Amitifadine, a drug used for various neural conditions, targets multiple sites, including the sodium-dependent serotonin transporter, the sodium-dependent noradrenaline transporter, and the dopamine D2 receptor. Additionally, the gene SLC6A4 has been known to cause obsessive-compulsive disorder 1 when mutated. Finally, the sodium-dependent noradrenaline transporter is identified as a gene product of SLC6A2. These associations emphasize the complex genetic interactions at play in neurobiological conditions.']",[]
"[{'source_node': {'name': 'glyceraldehyde-3-phosphate dehydrogenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GAPDH'}}, {'source_node': {'name': 'glyceraldehyde-3-phosphate dehydrogenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GAPDHS'}}, {'source_node': {'name': 'GAPDHS'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glycolysis'}}, {'source_node': {'name': 'betanmn'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glyceraldehyde-3-phosphate dehydrogenase'}}]","[{'source_node': {'name': 'GAPDHS'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glycolysis'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:580', 'target': None, 'metadata': {'node_id': '580', 'node_type': 'PROTEIN', 'display_name': 'glyceraldehyde-3-phosphate dehydrogenase'}}]",0.3333333333333333,29e6f691ff8de009591b6ffd288ac2b8,44d4704ca0038062c5e055ee0141a0f9,"['The enzyme glyceraldehyde-3-phosphate dehydrogenase is a gene product of both GAPDH and GAPDHS. Interestingly, GAPDHS acts within the metabolic process called Glycolysis. In an intriguing linkage, the drug betanmn targets glyceraldehyde-3-phosphate dehydrogenase, thereby having an indirect influence on the Glycolysis process itself.', 'The drug Betanmn functions by targeting Glyceraldehyde-3-phosphate dehydrogenase, a protein vital to cellular processes. Intriguingly, this protein is the gene product of both GAPDH and GAPDHS. Further, GAPDHS operates actively within the Glycolysis pathway, attesting to the importance of this pathway in energy production.', 'The substance betanmn targets an enzyme known as glyceraldehyde-3-phosphate dehydrogenase. This enzyme happens to be a gene product of both GAPDH and GAPDHS. Notably, GAPDHS is known to act within the biochemical process of glycolysis.', 'The glyceraldehyde-3-phosphate dehydrogenase, a protein, is a gene product of both GAPDH and GAPDHS. Notably, GAPDHS is also known to act within the pathway of glycolysis. Furthermore, betanmn, a molecule, targets the protein glyceraldehyde-3-phosphate dehydrogenase.']","['The gene GAPDHS functions within the process of Glycolysis.', 'The gene GAPDHS acts within the Glycolysis pathway.', 'The gene GAPDHS acts within the Glycolysis pathway.']"
"[{'source_node': {'name': 'CDH23'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'deafness'}}, {'source_node': {'name': 'CDH23'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'prolactinoma'}}, {'source_node': {'name': 'CDH23'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'usher syndrome type 1'}}]","[{'source_node': {'name': 'CDH23'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'deafness'}}, {'source_node': {'name': 'CDH23'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'usher syndrome type 1'}}]","[{'type': 'node_removal', 'source': 'DISEASE:2667', 'target': None, 'metadata': {'node_id': '2667', 'node_type': 'DISEASE', 'display_name': 'prolactinoma'}}]",0.7142857142857143,c783e83c24aba64ea7f9f98f5154ea5e,0e200e0d5d4cad6ca5e440f98075eba5,"['The gene CDH23 is known to cause several medical conditions. It has been identified as a cause of deafness and prolactinoma. Notably, the CDH23 gene is also linked to usher syndrome type 1, a condition that causes both hearing and vision issues.', 'The gene CDH23 is known to cause several conditions such as deafness, prolactinoma, and Usher Syndrome Type 1.', 'The gene CDH23 is implicated in causing various conditions. It is responsible for causing deafness, prolactinoma - a type of benign tumor in the pituitary gland, and Usher syndrome type 1 - a genetic disorder characterized by progressive vision loss and hearing impairment.', ""The gene CDH23 has been linked to several conditions, as it has been found to cause deafness, contribute to the development of prolactinoma, and also lead to usher syndrome type 1. It's important to note the different roles that just a single gene can play in the health outcomes of an individual.""]","['The gene CDH23 is known to cause several conditions. Specifically, it is responsible for causing deafness and also Usher syndrome type 1.', 'The gene CDH23 is known to cause conditions including both deafness and Usher syndrome type 1.', 'The gene CDH23 is implicated in causing several conditions, namely deafness and Usher syndrome type 1.', 'The gene CDH23 is implicated in causing multiple conditions such as deafness and Usher syndrome type 1.', 'The gene CDH23 is known to cause certain conditions, including deafness and Usher syndrome type 1. This implies a potential genetic link between these two auditory conditions.']"
"[{'source_node': {'name': 'estrogen receptor beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR2'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': 'majusanic acid d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'estrogen receptor alpha'}}, {'source_node': {'name': 'majusanic acid d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'estrogen receptor beta'}}]","[{'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR2'}}, {'source_node': {'name': 'majusanic acid d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'estrogen receptor alpha'}}, {'source_node': {'name': 'majusanic acid d'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'ESR2'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:27340', 'target': 'GENE:26824', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'PROTEIN:942', 'target': None, 'metadata': {'node_id': '942', 'node_type': 'PROTEIN', 'display_name': 'estrogen receptor beta'}}, {'type': 'edge_addition', 'source': 'PROTEIN:943', 'target': 'GENE:26824', 'metadata': {'predicate': 'gene_product_of'}}]",0.4444444444444444,2a6bb682c39a84015efccbe9619dd028,4b7747c34c529baa337143603f1f995b,"['The compound Majusanic Acid D targets both Estrogen Receptor Alpha and Estrogen Receptor Beta. Interestingly, Estrogen Receptor Alpha is a gene product of VHL, while Estrogen Receptor Beta results from the functioning of the ESR2 gene.', 'The chemical compound majusanic acid D targets both estrogen receptor alpha and estrogen receptor beta. The estrogen receptor alpha is a gene product of VHL, whereas estrogen receptor beta is a gene product of ESR2.', 'Estrogen receptor alpha and estrogen receptor beta are gene products of VHL and ESR2 respectively. Furthermore, these receptors are targeted by majusanic acid d. This means, majusanic acid d affects the action of both these receptor proteins that are produced by the VHL and ESR2 genes respectively.', 'Estrogen receptor alpha and estrogen receptor beta are the gene products of VHL and ESR2, respectively. The compound majusanic acid d specifically targets both these receptors.', 'The proteins estrogen receptor alpha and beta, are gene products of VHL and ESR2, respectively. Furthermore, these receptors are targeted by the compound majusanic acid D. This intricate network of interactions represents a key aspect of hormonal signaling and regulation.']","['Estrogen receptor alpha, a gene product of both VHL and ESR2, is targeted by the drug majusanic acid D. In addition to this, majusanic acid D also affects ESR2, thus showing direct and indirect influences on the same gene.', 'Estrogen receptor alpha, a gene product of both VHL and ESR2, is targeted by the substance majusanic acid d. Furthermore, majusanic acid d also has an impact on ESR2, influencing its functionality and processes.', 'Estrogen receptor alpha is a gene product of both VHL and ESR2. The drug Majusanic acid D targets estrogen receptor alpha and affects the activation of ESR2.', 'The protein known as estrogen receptor alpha is a gene product of both VHL and ESR2. Interestingly, it is targeted by a compound named majusanic acid d. Majusanic acid d is also known to affect ESR2, making it a molecule of extreme importance in this gene network.', 'The protein estrogen receptor alpha, which is a gene product of both VHL and ESR2, is the target of majusanic acid D. Furthermore, majusanic acid D also affects the expression of ESR2.']"
"[{'source_node': {'name': 'morphine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'theobromine'}}, {'source_node': {'name': 'morphine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'potassium lactate'}}, {'source_node': {'name': 'morphine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Rectal disorder'}}, {'source_node': {'name': 'theobromine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'alfentanil'}}, {'source_node': {'name': 'theobromine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clotiazepam'}}, {'source_node': {'name': 'theobromine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arylsulfatase a'}}, {'source_node': {'name': 'potassium lactate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'diamorphine'}}, {'source_node': {'name': 'potassium lactate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tilidine'}}]","[{'source_node': {'name': 'theobromine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'alfentanil'}}, {'source_node': {'name': 'theobromine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clotiazepam'}}, {'source_node': {'name': 'theobromine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arylsulfatase a'}}, {'source_node': {'name': 'potassium lactate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'diamorphine'}}, {'source_node': {'name': 'potassium lactate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tilidine'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:285', 'target': 'COMPOUND:8349', 'metadata': None}, {'type': 'edge_deletion', 'source': 'COMPOUND:285', 'target': 'COMPOUND:1351', 'metadata': None}, {'type': 'node_removal', 'source': 'SIDE_EFFECT:1491', 'target': None, 'metadata': {'node_id': '1491', 'node_type': 'SIDE_EFFECT', 'display_name': 'Rectal disorder'}}]",0.7058823529411764,ce941e3e3099090f300ecb8270682f1b,18321aa200486dab7ea47611db5ad07e,"['The drug Morphine is seen to decrease the efficacy of substances like Theobromine and Potassium Lactate and has a side effect of causing Rectal disorder. Interestingly, Theobromine, whose efficacy is decreased by Morphine, can also affect the efficacy of drugs such as Alfentanil and Clotiazepam. Additionally, Theobromine targets arylsulfatase a, a vital enzyme in human metabolic processes. Meanwhile, Potassium Lactate, another substance whose efficacy is lessened by Morphine, can decrease the efficacy of drugs like Diamorphine and Tilidine. Therefore, Morphine not only affects the efficacy of certain substances like Theobromine and Potassium Lactate but can also indirectly impact other drugs and enzymes related to these substances.', 'Morphine, a potent analgesic, has been noted to decrease the efficacy of other substances such as theobromine and potassium lactate. This raises potential concerns for therapeutic interventions utilizing these substances. An unusual side effect of Morphine is also observed, resulting in rectal disorders. Interestingly, theobromine, which is affected by morphine, also has its own influence in decreasing the efficacy of alfentanil and clotiazepam, two other substances commonly used in medical practice. Furthermore, theobromine also targets arylsulfatase a, a type of enzyme. Notably, potassium lactate, another substance under the influence of morphine, is also known to decrease the efficacy of diamorphine and tilidine. The intertwining influences of these chemicals highlight the importance of awareness when it comes to drug interactions and side effects.', 'Morphine, a well-known opioid medication, is known to decrease the efficacy of both theobromine and potassium lactate. This relationship becomes significant as theobromine in particular also reduces the effectiveness of substances such as alfentanil and clotiazepam. Additionally, theobromine targets the enzyme known as arylsulfatase A. On the other hand, morphine also has potential side effects, such as causing rectal disorders. \n\nPotassium lactate, another substance whose efficacy is decreased by morphine, also reduces the effectiveness of specific opioids like diamorphine and tilidine. The interconnected relationships between these substances play a crucial role in understanding their combined impact and side effects in a biological system.', ""Morphine, a strong painkiller, decreases the efficacy of both theobromine and potassium lactate while also having the potential side effect of causing rectal disorder. Theobromine, whose efficacy is reduced by morphine, also decreases the efficacy of alfentanil and clotiazepam. In addition, it has a target with the enzyme arylsulfatase a. On the other hand, potassium lactate's efficacy is not only reduced by morphine but also lowers the efficacy of both diamorphine and tilidine. It is vital for individuals to ensure that they are not inadvertently disrupting the efficacy of these drugs when taking morphine."", 'The opioid drug Morphine decreases the efficacy of Theobromine and Potassium Lactate. This interaction could be linked to the side effects of Morphine which includes various rectal disorders. It is also important to note that Theobromine, aside from being affected by Morphine, also decreases the efficacy of Alfentanil and Clotiazepam. Theobromine further has a target interaction with arylsulfatase A. Potassium Lactate, while affected by Morphine, also decreases the efficacy of Diamorphine and Tilidine. The complex relationship and interaction of these substances could have profound implications in drug efficacy and side effect management. It also highlights the importance of understanding the various drug interactions that happen inside the human body.']","['Theobromine, a compound often found in chocolate and tea, can interact with certain drugs, undermining their efficacy. Specifically, it has been shown to decrease the efficacy of both alfentanil, a powerful opioid, and clotiazepam, a sedative often used to treat anxiety and insomnia. In addition, theobromine targets arylsulfatase A, an enzyme that plays a key role in the metabolism of certain sulfated steroids and lipids. On another note, potassium lactate, a common food additive, can also interact with certain medications, reducing their efficacy. It reduces the effectiveness of diamorphine, commonly known as heroin, and tilidine, an opioid analgesic often employed in treating severe pain. This highlights the notable influence of dietary components on drug interactions and the importance of considering these factors in drug administration and regimen planning.', 'Theobromine, a commonly known compound found in chocolate, actually has the ability to decrease the efficacy of certain drugs. Specifically, it can reduce the effectiveness of both alfentanil, a potent opioid pain medication, and clotiazepam, a sedative for anxiety and seizures. Interestingly, theobromine also has a known target - the enzyme known as arylsulfatase A. Similarly, potassium lactate, often used as a food additive, acts by decreasing the efficacy of the opioid medication diamorphine, and also tilidine, another pain medication. This highlights the need to consider dietary factors when prescribing these medications.', 'The chemical compound theobromine has a complex interaction with several drugs and biological enzymes. It decreases the efficacy of alfentanil and clotiazepam, both potent pain medications, potentially making them less effective. In addition to this, theobromine is known to target the enzyme arylsulfatase A, although the mechanism of this interaction is not completely understood. Potassium lactate, an electrolyte replenisher, also interferes with the effectiveness of certain drugs. It reduces the efficacy of diamorphine and tilidine, two strong analgesics used to treat severe pain. Therefore, careful consideration is needed when taking these drugs with theobromine or potassium lactate, to avoid the risk of reduced drug effectiveness.', 'The compound theobromine has been found to diminish the efficacy of certain substances like alfentanil and clotiazepam. Moreover, it has been identified to target arylsulfatase A. Similarly, potassium lactate is known to decrease the potency of other substances, namely diamorphine and tilidine.', 'Theobromine, a substance commonly found in chocolate and tea, has been found to decrease the efficacy of several drugs, including Alfentanil and Clotiazepam. In addition, it has arylsulfatase A as its target. Furthermore, another substance known as potassium lactate also reduces the efficacy of certain medications, notably Diamorphine and Tilidine.']"
"[{'source_node': {'name': 'maple syrup urine disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cerebral edema'}}, {'source_node': {'name': 'maple syrup urine disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hallucinations'}}, {'source_node': {'name': 'maple syrup urine disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'growth abnormality'}}, {'source_node': {'name': 'DBT'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'maple syrup urine disease'}}, {'source_node': {'name': 'DBT'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glyoxylate metabolism and glycine degradation'}}, {'source_node': {'name': 'DBT'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Branched-chain amino acid catabolism'}}]","[{'source_node': {'name': 'maple syrup urine disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cerebral edema'}}, {'source_node': {'name': 'maple syrup urine disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hallucinations'}}, {'source_node': {'name': 'maple syrup urine disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'growth abnormality'}}, {'source_node': {'name': 'DBT'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glyoxylate metabolism and glycine degradation'}}, {'source_node': {'name': 'DBT'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Branched-chain amino acid catabolism'}}]","[{'type': 'edge_deletion', 'source': 'GENE:26400', 'target': 'DISEASE:13769', 'metadata': None}]",0.9230769230769232,506f245ce5f7d1f0d7432736da2580ce,0774842cf1ab943071d095b055f899df,[],[]
"[{'source_node': {'name': 'chaetoviridin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mgc-803'}}, {'source_node': {'name': 'chaetoviridin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ags'}}]","[{'source_node': {'name': 'chaetoviridin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ags'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5600', 'target': None, 'metadata': {'node_id': '5600', 'node_type': 'PROTEIN', 'display_name': 'mgc-803'}}]",0.6,41eddffb7b5942699f61ae469e053571,9b120d88ead33eba2ecb1cf2d5af2474,"['The compound Chaetoviridin A acts as an inhibitor and targets both MGC-803 and AGS cell lines.', 'The compound Chaetoviridin A targets both MGC-803 and AGS.', 'The molecule Chaetoviridin A has been identified as targeting two specific entities, namely MGC-803 and AGS.', 'The compound Chaetoviridin A is known to target two entities - MGC-803 and AGS.', 'The compound Chaetoviridin A targets both MGC-803 and AGS.']","['The compound Chaetoviridin A has a target interaction with AGS.', 'The compound Chaetoviridin A is known to have AGS as its target.', 'The compound Chaetoviridin A is known to target AGS.', 'The compound Chaetoviridin A has been identified to target AGS.', 'The drug Chaetoviridin A has been found to target AGS.']"
"[{'source_node': {'name': 'neochamaejasmin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lncap'}}, {'source_node': {'name': 'neochamaejasmin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sw-620'}}, {'source_node': {'name': 'neochamaejasmin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'thp-1'}}]","[{'source_node': {'name': 'neochamaejasmin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sw-620'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5854', 'target': None, 'metadata': {'node_id': '5854', 'node_type': 'PROTEIN', 'display_name': 'lncap'}}, {'type': 'node_removal', 'source': 'PROTEIN:5083', 'target': None, 'metadata': {'node_id': '5083', 'node_type': 'PROTEIN', 'display_name': 'thp-1'}}]",0.4285714285714286,acef266c1be118acc3a892478eb2c89d,808e1ee7f3d2d27cc12470742324de65,"['Neochamaejasmin A is a compound that has been observed to target several cell lines, including LNCaP, SW-620, and THP-1.', 'The compound Neochamaejasmin A has several targets, which include the LNCaP, SW-620, and THP-1 cell lines.', 'The compound Neochamaejasmin A demonstrates a broad spectrum of targets such as lncap, sw-620, and thp-1.', 'The compound Neochamaejasmin A selectively targets several cell lines including LNCaP, SW-620, and THP-1.', 'Neochamaejasmin A is a compound known to target several cell lines, including LNCaP, SW-620, and THP-1.']","['The drug Neochamaejasmin A is known to have the cell line SW-620 as its target.', 'Neochamaejasmin A is known to target SW-620.']"
"[{'source_node': {'name': 'xerophilusin x1'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'k562'}}, {'source_node': {'name': 'xerophilusin x1'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mkn-45'}}, {'source_node': {'name': 'xerophilusin x1'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepg2'}}]","[{'source_node': {'name': 'xerophilusin x1'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'k562'}}, {'source_node': {'name': 'xerophilusin x1'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mkn-45'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5817', 'target': None, 'metadata': {'node_id': '5817', 'node_type': 'PROTEIN', 'display_name': 'hepg2'}}]",0.7142857142857143,6ce5b1f4fc1ec0d241efabe4eeee89fc,d8c9b687eb4158cb4a40d55a9bbd3708,"['The chemical compound Xerophilusin X1 targets several entities, including K562, MKN-45, and HepG2 cells.', 'The compound Xerophilusin X1 targets multiple cells including K562, MKN-45, and HepG2.', 'The compound Xerophilusin X1 has been identified to target multiple cell lines. It demonstrates activity against K562, MKN-45, and HepG2 cells, suggesting a potential beneficial effect in therapies targeting these cell types.', 'The substance Xerophilusin X1 has several cellular targets, specifically including K562, MKN-45, and HepG2 cells.', 'The compound Xerophilusin X1 has several targets which include K562, MKN-45, and HepG2 cells. This suggests a considerable role of Xerophilusin X1 in affecting these cell lines.']","['Xerophilusin X1, a known drug, has demonstrated its efficiency by targeting cells such as K562 and MKN-45.', 'The compound Xerophilusin X1 has been found to target two different cell lines, specifically K562 and MKN-45.', ""Xerophilusin X1 is a compound that has been found to target K562 and MKN-45. These are both types of cell lines used in biological research and can provide insight into the compound's potential efficacy in treating certain diseases."", 'The compound Xerophilusin X1 targets two distinct elements, namely K562 and MKN-45.', 'The substance xerophilusin x1 is known to target the k562 and mkn-45.']"
"[{'source_node': {'name': 'smilaside a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}, {'source_node': {'name': 'smilaside a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dld-1'}}, {'source_node': {'name': 'smilaside a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'source_node': {'name': 'smilaside a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dld-1'}}, {'source_node': {'name': 'smilaside a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5858', 'target': None, 'metadata': {'node_id': '5858', 'node_type': 'PROTEIN', 'display_name': 'kb'}}]",0.7142857142857143,5e51c2a124893314288b70ccab26de93,58f9c8739aa76f77ea85254c9bd7e1dd,"['The molecule Smilaside A has been shown to target several entities including KB, DLD-1, and A549.', 'The compound Smilaside A has been identified to target several entities; specifically, it targets KB, DLD-1, and A549.', 'The compound Smilaside A has several targets which include KB, DLD-1, and A549.', 'The compound Smilaside A targets multiple entities including KB, DLD-1, and A549.', 'The drug Smilaside A is known to target several cell lines including KB, DLD-1, and A549.']","['The compound Smilaside A has been identified to target multiple cells, specifically the DLD-1 and A549 cells.', 'The drug Smilaside A has been shown to target two different cellular entities: DLD-1 and A549.', 'The compound Smilaside A has targets that include both DLD-1 and A549 cells.', 'The compound Smilaside A targets two specific cells: DLD-1 and A549.', 'The compound Smilaside A has been shown to target cells like DLD-1 and A549. These interactions indicate potential therapeutic applications for this substance.']"
"[{'source_node': {'name': '8-prenylquercetin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}, {'source_node': {'name': '8-prenylquercetin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': ""cgmp-specific 3',5'-cyclic phosphodiesterase""}}]","[{'source_node': {'name': '8-prenylquercetin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': ""cgmp-specific 3',5'-cyclic phosphodiesterase""}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4976', 'target': None, 'metadata': {'node_id': '4976', 'node_type': 'PROTEIN', 'display_name': 'ht-29'}}]",0.6,801d9c804df5feafd72a468eeb3b367f,5f8d19d37f78ea96c0b038b41d1026d5,[],[]
"[{'source_node': {'name': '(6ar)-roemerine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}, {'source_node': {'name': '(6ar)-roemerine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'pc-3'}}]","[{'source_node': {'name': '(6ar)-roemerine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'pc-3'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4994', 'target': None, 'metadata': {'node_id': '4994', 'node_type': 'PROTEIN', 'display_name': 'hela'}}]",0.6,cbe66236c972b9b6e82db89f234aa355,d09ba8d3ad6a2f27abf6a3e8d870aa92,"['The compound (6ar)-roemerine targets both Hela and PC-3 cell lines.', 'The compound (6ar)-roemerine targets both Hela and PC-3 cell lines.', 'The compound known as (6ar)-roemerine has shown to target certain types of cells like hela and pc-3.', 'The compound, (6ar)-roemerine, has the ability to target two cell types, namely Hela and PC-3.', 'The drug (6ar)-roemerine has targets that include both the HeLa and PC-3 cell lines.']","['The drug (6ar)-roemerine has PC-3 as its target.', 'The drug, (6ar)-roemerine, targets the protein known as PC-3.', 'The drug (6ar)-roemerine has been found to target pc-3.', 'The drug known as (6ar)-roemerine has been identified to target a specific protein called PC-3.', 'The compound (6ar)-roemerine has the cell line PC-3 as its target.']"
"[{'source_node': {'name': 'fusariosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'bronchiectasis'}}, {'source_node': {'name': 'fusariosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'peritonitis'}}, {'source_node': {'name': 'fusariosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'panniculitis'}}]","[{'source_node': {'name': 'fusariosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'panniculitis'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1870', 'target': None, 'metadata': {'node_id': '1870', 'node_type': 'PHENOTYPE', 'display_name': 'peritonitis'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:1554', 'target': None, 'metadata': {'node_id': '1554', 'node_type': 'PHENOTYPE', 'display_name': 'bronchiectasis'}}]",0.4285714285714286,e267fb2f2bd568d44710630f7db9e596,699ff538ef5070a5adc273b44915db4b,"['The disease fusariosis has several associated phenotypes including bronchiectasis, peritonitis and panniculitis. These are all potential manifestations of the disease in affected individuals.', 'Fusariosis is a health condition that presents various phenotypes including bronchiectasis, peritonitis, and panniculitis. Each of these conditions represents a different symptom or manifestation of the disease. For instance, bronchiectasis is a condition where the bronchial tubes of the lungs are permanently damaged, enlarged, and thickened. On the other hand, peritonitis indicates an inflammation of the peritoneum, the thin layer of tissue that covers the inside of the abdomen and most of its organs. Whereas, panniculitis is characterized by inflammation of the fat layer underneath the skin. Thus, each of these phenotypes contributes to the overall clinical picture of fusariosis.', 'Fusariosis, a disease typically affecting the skin, lungs, or blood, has several associated phenotypes. In certain patients, fusariosis has been linked to bronchiectasis, a condition where the bronchial tubes of the lungs are permanently damaged, widened, and thickened. Additionally, individuals with fusariosis often exhibit peritonitis, an inflammation of the peritoneum which is the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs. In some cases, fusariosis also leads to panniculitis, a condition characterized by inflammation of the fatty layer underneath the skin.', '""Fusariosis, a medical condition, has phenotypes that manifest with diverse symptoms such as bronchiectasis - a condition characterized by a chronic, irreversible widening and inflammation of the bronchi and bronchioles, peritonitis - an inflammation of the peritoneum, typically caused by bacterial infection either via the blood or after a rupture of an abdominal organ, and panniculitis, which describes a group of conditions that involve inflammation of the fat layer below the skin.', 'Fusariosis is a condition that is characterized by several phenotypes, some of which include bronchiectasis, peritonitis, and panniculitis.']",[]
"[{'source_node': {'name': 'amegakaryocytic thrombocytopenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'thrombocytopenia'}}, {'source_node': {'name': 'amegakaryocytic thrombocytopenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormal cardiac septum morphology'}}, {'source_node': {'name': 'amegakaryocytic thrombocytopenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'decreased skull ossification'}}]","[{'source_node': {'name': 'amegakaryocytic thrombocytopenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormal cardiac septum morphology'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:3025', 'target': None, 'metadata': {'node_id': '3025', 'node_type': 'PHENOTYPE', 'display_name': 'decreased skull ossification'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:1355', 'target': None, 'metadata': {'node_id': '1355', 'node_type': 'PHENOTYPE', 'display_name': 'thrombocytopenia'}}]",0.4285714285714286,7b53c7de272ce38189ba27e3d892135a,4c598e63258aedd036191100336673f3,[],[]
"[{'source_node': {'name': '1-(2,6-dihydroxy-4-methoxyphenyl)ethanone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'u-251'}}, {'source_node': {'name': '1-(2,6-dihydroxy-4-methoxyphenyl)ethanone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': '786-0'}}, {'source_node': {'name': '1-(2,6-dihydroxy-4-methoxyphenyl)ethanone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-mel-28'}}]","[{'source_node': {'name': '1-(2,6-dihydroxy-4-methoxyphenyl)ethanone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-mel-28'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5664', 'target': None, 'metadata': {'node_id': '5664', 'node_type': 'PROTEIN', 'display_name': '786-0'}}, {'type': 'node_removal', 'source': 'PROTEIN:5629', 'target': None, 'metadata': {'node_id': '5629', 'node_type': 'PROTEIN', 'display_name': 'u-251'}}]",0.4285714285714286,0a3ffe4c59d5d0a1b9dffe50c6088600,2b52b200c41c7bd7fead08923bc9691c,"['The compound 1-(2,6-dihydroxy-4-methoxyphenyl)ethanone targets multiple cell lines including U-251, 786-0, and SK-MEL-28.', 'The chemical compound 1-(2,6-dihydroxy-4-methoxyphenyl)ethanone has been identified to target several cell lines including U-251, 786-0, and SK-MEL-28.', 'The chemical compound 1-(2,6-dihydroxy-4-methoxyphenyl)ethanone has been found to target multiple cell lines, including U-251, 786-0, and SK-MEL-28.', 'The drug 1-(2,6-dihydroxy-4-methoxyphenyl)ethanone targets multiple entities including u-251, 786-0, and sk-mel-28. These targets likely represent different cellular or molecular components, which the drug interacts with in order to exert its effects.', 'The substance 1-(2,6-dihydroxy-4-methoxyphenyl)ethanone has several targets: it targets the cell types U-251, 786-0, and SK-MEL-28.']","['The compound 1-(2,6-dihydroxy-4-methoxyphenyl)ethanone has the ability to target sk-mel-28.']"
"[{'source_node': {'name': 'yangonin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-15'}}, {'source_node': {'name': 'yangonin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h226'}}, {'source_node': {'name': 'yangonin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}]","[{'source_node': {'name': 'yangonin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h226'}}, {'source_node': {'name': 'yangonin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4982', 'target': None, 'metadata': {'node_id': '4982', 'node_type': 'PROTEIN', 'display_name': 'hct-15'}}]",0.7142857142857143,4df16fd54c3e2d799e43e19c5c6ee1a7,f81d8e632387ba7f0f88487516d03d30,"['The compound Yangonin has been identified to target several cancerous cell lines including HCT-15, NCI-H226, as well as HT-29.', 'The compound Yangonin has several targets which include the HCT-15, NCI-H226, and HT-29 cells.', 'The compound Yangonin targets multiple cell lines, specifically HCT-15, NCI-H226, and HT-29.', 'Yangonin, a medicinal compound, has been found to target several cancer cell lines. These include HCT-15, a colon cancer cell line, NCI-H226, a human lung cancer cell line, and HT-29, a colorectal adenocarcinoma line. It suggests that yangonin could potentially be used in therapies for a variety of cancers.', 'Yangonin, a compound with biological activity, has multiple targets including the HCT-15, NCI-H226, and HT-29 cell lines, all of which are commonly used in various medical research studies.']","['Yangonin, a biological molecule, has been identified to target multiple entities including NCI-H226 and HT-29. These targets suggest a potential role for Yangonin in influencing biological processes or pathways related to these entities.', 'The compound yangonin has targets in multiple cells, including nci-h226 and ht-29 cells.', 'The compound yangonin has been identified to target multiple entities, namely the NCI-H226 and HT-29.', 'The compound Yangonin targets two kinds of cells: NCI-H226 and HT-29.', 'The compound Yangonin has been identified to target both NCI-H226 and HT-29 cells.']"
"[{'source_node': {'name': 'cytochrome p450 family 2 subfamily c member 19'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'lupus nephritis'}}, {'source_node': {'name': 'cytochrome p450 family 2 subfamily c member 19'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pain'}}, {'source_node': {'name': 'cytochrome p450 family 2 subfamily c member 19'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hematopoietic stem cell transplantation'}}, {'source_node': {'name': 'norethindrone'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 2 subfamily c member 19'}}]","[{'source_node': {'name': 'cytochrome p450 family 2 subfamily c member 19'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'lupus nephritis'}}, {'source_node': {'name': 'cytochrome p450 family 2 subfamily c member 19'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pain'}}, {'source_node': {'name': 'cytochrome p450 family 2 subfamily c member 19'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hematopoietic stem cell transplantation'}}, {'source_node': {'name': 'norethindrone'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'lupus nephritis'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:90480', 'target': 'DISEASE:1897', 'metadata': {'predicate': 'is_substance_that_treats'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:90480', 'target': 'GENE:4349', 'metadata': None}]",0.7777777777777778,05d6d20e6cf0a824b7eb337bb3787102,73acf00de60211ec4580106fc612fde3,"['The drug Norethindrone affects the activity of the protein Cytochrome P450 family 2 subfamily C member 19. This protein has been found to cause several conditions, such as lupus nephritis, pain, and it has been linked to complications related to hematopoietic stem cell transplantation.']","['The gene Cytochrome P450 Family 2 Subfamily C Member 19 is known to cause several conditions, including lupus nephritis, pain, and complications arising from hematopoietic stem cell transplantation. Interestingly, lupus nephritis, one of the conditions caused by this gene, can be treated with the substance norethindrone.', ""The enzyme Cytochrome P450 family 2 subfamily C member 19 has been implicated in causing several conditions including lupus nephritis, pain, and the complications arising from hematopoietic stem cell transplantation. Interestingly, lupus nephritis can be treated with the hormone Norethindrone, demonstrating an intricate balance within the body's biochemical network."", 'The enzyme Cytochrome P450 family 2 subfamily C member 19 is documented to cause conditions including lupus nephritis, pain and may even trigger a hematopoietic stem cell transplantation. Interestingly, lupus nephritis, one of the ailments caused by this enzyme, can be managed by a substance called Norethindrone.', 'The enzyme cytochrome p450 family 2 subfamily c member 19 is known to cause several conditions, which include lupus nephritis, pain, and hematopoietic stem cell transplantation. Interestingly, lupus nephritis, one of the conditions caused by this enzyme, can be treated by a therapeutic substance, norethindrone.', 'The enzyme Cytochrome P450 Family 2 Subfamily C Member 19 has been implicated in causing various conditions such as lupus nephritis, experience of pain, and issues related to hematopoietic stem cell transplantation. On the other hand, lupus nephritis, a condition caused by Cytochrome P450 Family 2 Subfamily C Member 19, can be treated by the drug Norethindrone.']"
"[{'source_node': {'name': 'FTH1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hemochromatosis'}}, {'source_node': {'name': 'FTH1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}, {'source_node': {'name': 'ferritin heavy chain'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FTH1'}}]","[{'source_node': {'name': 'ferritin heavy chain'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FTH1'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:3', 'target': None, 'metadata': {'node_id': '3', 'node_type': 'PATHWAY', 'display_name': 'Neutrophil degranulation'}}, {'type': 'node_removal', 'source': 'DISEASE:13939', 'target': None, 'metadata': {'node_id': '13939', 'node_type': 'DISEASE', 'display_name': 'hemochromatosis'}}]",0.4285714285714286,4c727e7aaf627516c5d68f8b7a1cf023,74328bf6005b0ec248e855a1d695e636,"['The gene FTH1 is responsible for causing a condition known as hemochromatosis, and it also acts within a biological process referred to as neutrophil degranulation. Furthermore, the gene FTH1 is known to produce a gene product, ferritin heavy chain, which plays an essential role in this complex biological pathway.', 'The gene FTH1, which acts within the pathway of neutrophil degranulation, is responsible for causing the condition known as hemochromatosis. Furthermore, the protein known as ferritin heavy chain is a gene product of FTH1.', 'The gene FTH1, known for its role in neutrophil degranulation, leads to the condition known as hemochromatosis. Interestingly, the gene product of FTH1 is the ferritin heavy chain.', 'The gene FTH1, which acts within the process of neutrophil degranulation, causes a condition known as hemochromatosis. The ferritin heavy chain is a gene product of FTH1.']","['The ferritin heavy chain is a gene product of FTH1.', 'The protein known as ferritin heavy chain is a gene product of FTH1.', 'Ferritin heavy chain is a gene product of the gene FTH1.']"
"[{'source_node': {'name': 'AKR1C3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RA biosynthesis pathway'}}, {'source_node': {'name': 'AKR1C3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Retinoid metabolism and transport'}}, {'source_node': {'name': 'aldo-keto reductase family 1 member c3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AKR1C3'}}]","[{'source_node': {'name': 'AKR1C3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RA biosynthesis pathway'}}, {'source_node': {'name': 'AKR1C3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Retinoid metabolism and transport'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:563', 'target': None, 'metadata': {'node_id': '563', 'node_type': 'PROTEIN', 'display_name': 'aldo-keto reductase family 1 member c3'}}]",0.7142857142857143,64c9160a85ac6407176e8a4bc0be7ec8,2226cae49fd8f09d420ca3ac2874abe5,[],"['The gene AKR1C3 is responsible for functioning within several pathways including RA biosynthesis pathway as well as retinoid metabolism and transport.', 'The gene AKR1C3 functions within multiple processes, specifically the RA biosynthesis pathway and also in retinoid metabolism and transport.', 'The gene AKR1C3 operates within several pathways, more specifically, the RA biosynthesis pathway and the pathway of retinoid metabolism and transport.', 'The gene AKR1C3 is involved in both the RA biosynthesis pathway and the process of retinoid metabolism and transport.', 'The gene AKR1C3 plays a role within several biological processes, including the RA biosynthesis pathway and the process involved in retinoid metabolism and transport.']"
"[{'source_node': {'name': 'SNRPG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'SLBP independent Processing of Histone Pre-mRNAs'}}, {'source_node': {'name': 'SNRPG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'mRNA Splicing - Major Pathway'}}, {'source_node': {'name': 'SNRPG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RNA Polymerase II Transcription Termination'}}]","[{'source_node': {'name': 'SNRPG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RNA Polymerase II Transcription Termination'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1147', 'target': None, 'metadata': {'node_id': '1147', 'node_type': 'PATHWAY', 'display_name': 'SLBP independent Processing of Histone Pre-mRNAs'}}, {'type': 'node_removal', 'source': 'PATHWAY:191', 'target': None, 'metadata': {'node_id': '191', 'node_type': 'PATHWAY', 'display_name': 'mRNA Splicing - Major Pathway'}}]",0.4285714285714286,ff11cd8df49c9280c636fb64fce48d4e,f6576d90b950a6092f83226cd5b6aab0,[],"['The gene SNRPG is known to act within the pathway of RNA Polymerase II transcription termination.', 'The gene SNRPG is known to function within the pathway of RNA Polymerase II transcription termination.', 'The gene SNRPG plays a role within the process of RNA polymerase II transcription termination.', 'The gene SNRPG functions within the pathway of RNA polymerase II transcription termination.', 'The gene SNRPG performs its function within the context of the RNA Polymerase II transcription termination pathway.']"
"[{'source_node': {'name': 'ixekizumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' infection '}}, {'source_node': {'name': 'ixekizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rabies immune globulin'}}, {'source_node': {'name': 'ixekizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'moderna covid-19 vaccine'}}, {'source_node': {'name': 'moderna covid-19 vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'adalimumab'}}, {'source_node': {'name': 'moderna covid-19 vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dactinomycin'}}]","[{'source_node': {'name': 'ixekizumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' infection '}}, {'source_node': {'name': 'ixekizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rabies immune globulin'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:49', 'target': 'COMPOUND:9526', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:9492', 'target': 'COMPOUND:13151', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:49', 'target': None, 'metadata': {'node_id': '49', 'node_type': 'COMPOUND', 'display_name': 'adalimumab'}}, {'type': 'node_removal', 'source': 'COMPOUND:953', 'target': None, 'metadata': {'node_id': '953', 'node_type': 'COMPOUND', 'display_name': 'dactinomycin'}}]",0.4545454545454546,ae3ee7d3455ab7dba7ac1bccab17135b,4f51f7c83b221ba044ef8dfa9c706701,[],[]
"[{'source_node': {'name': 'erb-b2 receptor tyrosine kinase 2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'cardiotoxicity'}}, {'source_node': {'name': 'erb-b2 receptor tyrosine kinase 2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'breast neoplasms'}}, {'source_node': {'name': 'erb-b2 receptor tyrosine kinase 2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'peripheral nervous system diseases'}}, {'source_node': {'name': 'trastuzumab deruxtecan'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' Thrombosis '}}, {'source_node': {'name': 'trastuzumab deruxtecan'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' methemoglobinemia '}}, {'source_node': {'name': 'trastuzumab deruxtecan'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'erb-b2 receptor tyrosine kinase 2'}}]","[{'source_node': {'name': 'erb-b2 receptor tyrosine kinase 2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'cardiotoxicity'}}, {'source_node': {'name': 'erb-b2 receptor tyrosine kinase 2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'breast neoplasms'}}, {'source_node': {'name': 'trastuzumab deruxtecan'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' Thrombosis '}}, {'source_node': {'name': 'trastuzumab deruxtecan'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' methemoglobinemia '}}, {'source_node': {'name': 'trastuzumab deruxtecan'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'cardiotoxicity'}}]","[{'type': 'node_removal', 'source': 'DISEASE:2484', 'target': None, 'metadata': {'node_id': '2484', 'node_type': 'DISEASE', 'display_name': 'peripheral nervous system diseases'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:12613', 'target': 'GENE:5629', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:12613', 'target': 'DISEASE:498', 'metadata': {'predicate': 'is_substance_that_treats'}}]",0.6923076923076923,19bec4e41d9d2d4c53d078b4efd18914,4d825ff1082fbdcd73d5802d3b8db2bc,[],[]
"[{'source_node': {'name': 'CCK'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Peptide ligand-binding receptors'}}, {'source_node': {'name': 'CCK'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (q) signalling events'}}]","[{'source_node': {'name': 'CCK'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Peptide ligand-binding receptors'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:323', 'target': None, 'metadata': {'node_id': '323', 'node_type': 'PATHWAY', 'display_name': 'G alpha (q) signalling events'}}]",0.6,e30597b4032fd311d200b454d7d1ad19,10087d81fc47173933cb26a991445a70,"['The hormone CCK is involved in various biological processes and pathways, working within the peptide ligand-binding receptors and also acting within the G alpha (q) signalling events.', 'The protein CCK, also known as cholecystokinin, operates within several biological mechanisms. Specifically, CCK acts within peptide ligand-binding receptors, facilitating intracellular communication crucial for various cellular functions. In addition, CCK also performs a role in G alpha (q) signalling events, playing a critical part in the transmission of signals within cells.', 'The gene CCK acts within multiple cellular processes, including peptide ligand-binding receptors and G alpha (q) signalling events. This functional diversity underscores the multi-faceted role of CCK in biological systems.', 'The gene CCK operates within various pathways including peptide ligand-binding receptors and G alpha (q) signalling events.', 'The peptide CCK acts within several cellular pathways. Specifically, it is a part of the peptide ligand-binding receptors and is involved in the G alpha (q) signalling events.']","['The peptide hormone, CCK, plays a role within the pathway of peptide ligand-binding receptors.']"
"[{'source_node': {'name': 'PDE4A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'DARPP-32 events'}}, {'source_node': {'name': 'PDE4A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (s) signalling events'}}]","[{'source_node': {'name': 'PDE4A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (s) signalling events'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:420', 'target': None, 'metadata': {'node_id': '420', 'node_type': 'PATHWAY', 'display_name': 'DARPP-32 events'}}]",0.6,72af1e8c735b72bd15735b791954296a,b47b644abe41bbd78f404eb070eeee37,"[""The gene PDE4A is responsible for certain biological actions in the body. It's observed to act within DARPP-32 events and also within G alpha (s) signalling events, enabling normal physiological processes in our system."", 'The gene PDE4A functions within multiple processes, specifically within the DARPP-32 events and also within the G alpha (s) signalling events.', 'The gene known as PDE4A participates in various biological pathways - it acts within DARPP-32 events and G alpha (s) signalling events.', 'The gene PDE4A operates within several pathways, more specifically within the DARPP-32 events and the G alpha (s) signalling events.', 'The gene PDE4A is involved in both the DARPP-32 events and G alpha (s) signalling events pathways.']","['The gene PDE4A is involved in the regulation of G alpha (s) signalling events.', 'The gene PDE4A is known to function within the pathway of G alpha (s) signalling events.', 'The gene PDE4A is known to act within the pathway of G alpha (s) signalling events.', 'The gene PDE4A operates within the framework of G alpha (s) signalling events.']"
"[{'source_node': {'name': 'epratuzumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'epratuzumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' Thrombosis '}}, {'source_node': {'name': 'epratuzumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imlifidase'}}, {'source_node': {'name': 'eptinezumab'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'calcitonin gene-related peptide 2'}}, {'source_node': {'name': 'eptinezumab'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the thrombogenic activities '}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'eptinezumab'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'teclistamab'}}]","[{'source_node': {'name': 'epratuzumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'eptinezumab'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'calcitonin gene-related peptide 2'}}, {'source_node': {'name': 'eptinezumab'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the thrombogenic activities '}}, {'source_node': {'name': 'teclistamab'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'epratuzumab'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'eptinezumab'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'teclistamab'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:13781', 'target': 'COMPOUND:4663', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'EFFECT:7', 'target': None, 'metadata': {'node_id': '7', 'node_type': 'EFFECT', 'display_name': ' Thrombosis '}}, {'type': 'edge_deletion', 'source': 'COMPOUND:4663', 'target': 'COMPOUND:12843', 'metadata': None}]",0.7333333333333334,b37714b45a81ae01945e6fa16e0083f9,b6d16501e1363bf1060fc3630a113336,[],[]
"[{'source_node': {'name': 'pnu177836'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}, {'source_node': {'name': 'PTPN1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'diabetes mellitus'}}, {'source_node': {'name': 'PTPN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Integrin signaling'}}, {'source_node': {'name': 'PTPN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Negative regulation of MET activity'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}, {'source_node': {'name': 'diabetes mellitus'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'severe failure to thrive'}}, {'source_node': {'name': 'diabetes mellitus'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of the kidney'}}, {'source_node': {'name': 'diabetes mellitus'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'neurodevelopmental delay'}}]","[{'source_node': {'name': 'pnu177836'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}, {'source_node': {'name': 'pnu177836'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'PTPN1'}}, {'source_node': {'name': 'PTPN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Integrin signaling'}}, {'source_node': {'name': 'PTPN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Negative regulation of MET activity'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}]","[{'type': 'node_removal', 'source': 'DISEASE:13735', 'target': None, 'metadata': {'node_id': '13735', 'node_type': 'DISEASE', 'display_name': 'diabetes mellitus'}}, {'type': 'edge_addition', 'source': 'COMPOUND:2806', 'target': 'GENE:32076', 'metadata': {'predicate': 'is_affecting'}}]",0.4705882352941176,d980c0eb4d2b088fee4cfb2a6ba3d4bb,6d52bd4d291dd909873112a62e1d53ca,"['The drug PNU177836 has a target known as tyrosine-protein phosphatase non-receptor type 1, a gene product of PTPN1. This particular gene PTPN1 has been known to cause the condition diabetes mellitus. Moreover, PTPN1 actively participates in various biological pathways such as integrin signaling and the negative regulation of MET activity. As a condition, diabetes mellitus can lead to severe phenotypes such as severe failure to thrive, abnormality of the kidney, and neurodevelopmental delay.', 'The drug PNU177836 has a target named Tyrosine-Protein Phosphatase Non-Receptor Type 1. This target is a gene product of PTPN1. Importantly, PTPN1 is known to cause a condition known as Diabetes Mellitus. Moreover, PTPN1 also acts within several pathways including Integrin signaling and the negative regulation of MET activity. Diabetes Mellitus, the condition caused by PTPN1, manifests various phenotypes such as severe failure to thrive, abnormalities of the kidney, and neurodevelopmental delay.', 'The drug PNU177836 targets the tyrosine-protein phosphatase non-receptor type 1, which is identified as a gene product of PTPN1. Notably, PTPN1 functions within various pathways, including both integrin signaling and the negative regulation of MET activity. Furthermore, disruption of PTPN1 is known to cause the condition diabetes mellitus. Diabetes mellitus is characterized by several phenotypes such as severe failure to thrive, abnormalities of the kidney, and neurodevelopmental delay.']","['The drug PNU177836 has multiple biological impacts. Firstly, it targets the tyrosine-protein phosphatase non-receptor type 1, which is a gene product of PTPN1. Additionally, PNU177836 is also found affecting PTPN1. Interestingly, PTPN1 is known to act within several pathways including the integrin signaling and the pathway for negative regulation of MET activity.', 'The substance PNU177836 has a target, namely tyrosine-protein phosphatase non-receptor type 1, which is a gene product of PTPN1. Furthermore, PNU177836 is also directly affecting PTPN1. PTPN1 itself is actively involved in the interactions within two key pathways. It performs roles in integrin signaling and contributes to the negative regulation of MET activity.']"
"[{'source_node': {'name': 'amish nemaline myopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'respiratory insufficiency due to muscle weakness'}}, {'source_node': {'name': 'amish nemaline myopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'intellectual disability'}}, {'source_node': {'name': 'TNNT1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'nemaline myopathy 5'}}, {'source_node': {'name': 'TNNT1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'amish nemaline myopathy'}}]","[{'source_node': {'name': 'nemaline myopathy 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'respiratory insufficiency due to muscle weakness'}}, {'source_node': {'name': 'nemaline myopathy 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'intellectual disability'}}, {'source_node': {'name': 'TNNT1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'nemaline myopathy 5'}}]","[{'type': 'edge_deletion', 'source': 'GENE:33301', 'target': 'DISEASE:12585', 'metadata': None}, {'type': 'edge_addition', 'source': 'DISEASE:14483', 'target': 'PHENOTYPE:1994', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_addition', 'source': 'DISEASE:14483', 'target': 'PHENOTYPE:950', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'node_removal', 'source': 'DISEASE:12585', 'target': None, 'metadata': {'node_id': '12585', 'node_type': 'DISEASE', 'display_name': 'amish nemaline myopathy'}}]",0.6666666666666667,35884236782bf41eb0ca8dfeea8c02ac,63356ce87072761cd15a11501eb6fa2a,"['The genetic mutation in TNNT1 has been associated with several conditions, most notably nemaline myopathy 5 and Amish nemaline myopathy. The latter, Amish nemaline myopathy, is characterized by specific phenotypes such as respiratory insufficiency due to muscle weakness and intellectual disability.', 'The gene TNNT1 is known to cause several conditions including nemaline myopathy 5 and Amish nemaline myopathy. The latter is characterized by some distinctive phenotypes such as respiratory insufficiency due to muscle weakness and intellectual disability.', 'The gene TNNT1 is known to cause two conditions, nemaline myopathy 5 and Amish nemaline myopathy. Amish nemaline myopathy is characterized by two phenotypes - respiratory insufficiency due to muscle weakness and intellectual disability.']",[]
"[{'source_node': {'name': 'ampicillin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pancuronium'}}, {'source_node': {'name': 'ampicillin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna polymerase kappa'}}, {'source_node': {'name': 'ampicillin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}}, {'source_node': {'name': 'pancuronium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pegvisomant'}}, {'source_node': {'name': 'pancuronium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluclorolone'}}]","[{'source_node': {'name': 'ampicillin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pancuronium'}}, {'source_node': {'name': 'ampicillin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna polymerase kappa'}}, {'source_node': {'name': 'ampicillin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}}, {'source_node': {'name': 'fluclorolone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}}, {'source_node': {'name': 'pancuronium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pegvisomant'}}, {'source_node': {'name': 'pancuronium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluclorolone'}}, {'source_node': {'name': 'pegvisomant'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna polymerase kappa'}}, {'source_node': {'name': 'pegvisomant'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluclorolone'}}, {'source_node': {'name': 'pegvisomant'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:77', 'target': 'PROTEIN:4003', 'metadata': {'predicate': 'has_target'}}, {'type': 'edge_addition', 'source': 'COMPOUND:77', 'target': 'COMPOUND:11702', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11702', 'target': 'PROTEIN:3751', 'metadata': {'predicate': 'has_target'}}, {'type': 'edge_addition', 'source': 'COMPOUND:77', 'target': 'PROTEIN:3751', 'metadata': {'predicate': 'has_target'}}]",0.6363636363636364,aab142d1171c8b83355fe10e9a36f3a0,2cf3912ec36f778cd4b4986dc3194287,"['Ampicillin, a commonly used antibiotic, targets and interacts with several proteins, namely, DNA polymerase kappa and DNA-(apurinic or apyrimidinic site) lyase. In addition to this, Ampicillin is known to increase the efficacy of the muscle relaxant drug, Pancuronium. On the other hand, Pancuronium has been found to decrease the efficacy of some drugs, including Pegvisomant and Fluclorolone.', 'The drug Ampicillin targets the DNA polymerase kappa as well as the DNA-(apurinic or apyrimidinic site) lyase. This drug is also known to enhance the efficacy of Pancuronium. However, Pancuronium itself has a reducing effect on the efficacy of both Pegvisomant and Fluclorolone.', 'The use of the antibiotic ampicillin has shown an increase in the efficacy of pancuronium, a muscle relaxant. Additionally, ampicillin targets DNA polymerase kappa and DNA-(apurinic or apyrimidinic site) lyase, which are both crucial enzymes in DNA repair and replication. Furthermore, pancuronium, in contrast, has been observed to decrease the efficacy of both pegvisomant, a growth hormone receptor antagonist, and fluclorolone, a glucocorticoid used for anti-inflammatory and immune-suppressive actions.', 'Ampicillin, a common antibiotic, has been found to increase the efficacy of pancuronium, a muscle relaxant. Interestingly, ampicillin also has targets as diverse as the enzymes DNA polymerase kappa and DNA-(apurinic or apyrimidinic site) lyase. Pancuronium, however, has been shown to decrease the efficacy of other substances such as pegvisomant, a hormone antagonist, and fluclorolone, a corticosteroid. Therefore, the interactions between ampicillin, pancuronium, and other medications should be considered carefully in a pharmaceutical context.', 'The antibiotic ampicillin enhances the efficacy of the muscle relaxant pancuronium, while also demonstrating the ability to target two enzymes: dna polymerase kappa and dna-(apurinic or apyrimidinic site) lyase. However, the efficacy of pancuronium is known to decrease when it is used in conjunction with either pegvisomant or fluclorolone.']","['Ampicillin, a common antibiotic, not only increases the efficacy of the muscle relaxant drug pancuronium but also targets two essential enzymes: DNA polymerase kappa and DNA-(apurinic or apyrimidinic site) lyase. Meanwhile, fluclorolone, a glucocorticoid used to treat skin conditions, also targets DNA-(apurinic or apyrimidinic site) lyase. Interestingly, pancuronium has been noted to decrease the efficacy of both the growth hormone-related drug pegvisomant and fluclorolone. Moreover, pegvisomant shares a targeting profile with ampicillin, as it targets both DNA polymerase kappa and DNA-(apurinic or apyrimidinic site) lyase. Yet despite this, pegvisomant also decreases the efficacy of fluclorolone. This provides a complex interplay of drug interactions and common targets.']"
"[{'source_node': {'name': 'carbonic anhydrase 5a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA5A'}}, {'source_node': {'name': 'endiandrin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'endiandrin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'carbonic anhydrase 5b'}}, {'source_node': {'name': 'endiandrin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'carbonic anhydrase 5a'}}, {'source_node': {'name': 'CA5B'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Reversible hydration of carbon dioxide'}}, {'source_node': {'name': 'carbonic anhydrase 5b'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA5B'}}]","[{'source_node': {'name': 'carbonic anhydrase 5a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA5A'}}, {'source_node': {'name': 'carbonic anhydrase 5a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA5B'}}, {'source_node': {'name': 'endiandrin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'endiandrin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'carbonic anhydrase 5b'}}, {'source_node': {'name': 'endiandrin b'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'CA5B'}}, {'source_node': {'name': 'carbonic anhydrase 5b'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA5B'}}, {'source_node': {'name': 'carbonic anhydrase 5b'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA5A'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:1482', 'target': 'GENE:25375', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:63888', 'target': 'PROTEIN:1482', 'metadata': None}, {'type': 'node_removal', 'source': 'PATHWAY:994', 'target': None, 'metadata': {'node_id': '994', 'node_type': 'PATHWAY', 'display_name': 'Reversible hydration of carbon dioxide'}}, {'type': 'edge_addition', 'source': 'PROTEIN:1483', 'target': 'GENE:33605', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'COMPOUND:63888', 'target': 'GENE:25375', 'metadata': {'predicate': 'is_affecting'}}]",0.5384615384615384,7bbb1efa9871f77d0e04afbd007c8242,63d70601a9536746d370e908f7ae5028,[],[]
"[{'source_node': {'name': 'tyrosinase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TYR'}}, {'source_node': {'name': 'alpha-synuclein'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SNCA'}}, {'source_node': {'name': 'glabridin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'alpha-synuclein'}}, {'source_node': {'name': 'glabridin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosinase'}}, {'source_node': {'name': 'glabridin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'source_node': {'name': 'alpha-synuclein'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SNCA'}}, {'source_node': {'name': 'glabridin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'alpha-synuclein'}}, {'source_node': {'name': 'glabridin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'glabridin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'TYR'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:18396', 'target': 'GENE:33417', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'PROTEIN:655', 'target': None, 'metadata': {'node_id': '655', 'node_type': 'PROTEIN', 'display_name': 'tyrosinase'}}]",0.6363636363636364,518da382b66835fa94168247b00a69b6,63dd14f0e817ae8a6e279c9e819cdb20,"['Tyrosinase is a gene product of TYR, much like alpha-synuclein, which is a gene product of SNCA. Interestingly, glabridin, a compound, targets both these gene products. This means that glabridin has a direct impact on the function of tyrosinase and alpha-synuclein. Further, glabridin also targets A549, a specific cell line, indicating a multifaceted role for this compound.', 'Tyrosinase and alpha-synuclein are gene products of TYR and SNCA respectively. These are targets of glabridin, a compound which also targets a549.', 'The compound glabridin targets a variety of entities such as alpha-synuclein, tyrosinase and A549. Importantly, alpha-synuclein is a gene product of SNCA, while tyrosinase is a gene product of TYR. This implies that glabridin has potential therapeutic effects on conditions associated with these genes and their protein products.', 'Tyrosinase is a gene product of the TYR gene, and alpha-synuclein is a gene product of the SNCA gene. Glabridin is a compound that specifically targets both tyrosinase and alpha-synuclein. Besides this, glabridin also targets the lung cancer cell line, known as A549, indicating a potential role in cancer therapeutics.', 'The compound Glabridin is known to interact with several targets that include Alpha-Synuclein, an important protein that is the gene product of SNCA; Tyrosinase, the gene product of TYR; and cell line A549. This means that Glabridin not only plays a role in interacting with Tyrosinase and Alpha-Synuclein, proteins produced by genes TYR and SNCA respectively, but also influences the A549 cell line.']",[]
"[{'source_node': {'name': '5-hydroxytryptamine receptor 2c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HTR2C'}}, {'source_node': {'name': 'pimavanserin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': '5-hydroxytryptamine receptor 2c'}}, {'source_node': {'name': 'pimavanserin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sigma non-opioid intracellular receptor 1'}}, {'source_node': {'name': 'pimavanserin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'gilteritinib'}}, {'source_node': {'name': 'sigma non-opioid intracellular receptor 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SIGMAR1'}}, {'source_node': {'name': 'gilteritinib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'milnacipran'}}, {'source_node': {'name': 'gilteritinib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'brexpiprazole'}}, {'source_node': {'name': 'gilteritinib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '5-methoxy-n,n-dimethyltryptamine'}}]","[{'source_node': {'name': '5-hydroxytryptamine receptor 2c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HTR2C'}}, {'source_node': {'name': 'pimavanserin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': '5-hydroxytryptamine receptor 2c'}}, {'source_node': {'name': 'pimavanserin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sigma non-opioid intracellular receptor 1'}}, {'source_node': {'name': 'brexpiprazole'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pimavanserin'}}, {'source_node': {'name': 'sigma non-opioid intracellular receptor 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SIGMAR1'}}, {'source_node': {'name': 'gilteritinib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'milnacipran'}}, {'source_node': {'name': 'gilteritinib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'brexpiprazole'}}, {'source_node': {'name': 'gilteritinib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '5-methoxy-n,n-dimethyltryptamine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:8067', 'target': 'COMPOUND:4956', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:4956', 'target': 'COMPOUND:10050', 'metadata': None}]",0.8823529411764706,fd678d10db546d4f991decc610480a6c,71da31182d65f3e541f151d4f020b3ba,"['The drug pimavanserin targets both the 5-hydroxytryptamine receptor 2c and the sigma non-opioid intracellular receptor 1. The 5-hydroxytryptamine receptor 2c is a gene product of HTR2C, while sigma non-opioid intracellular receptor 1 is a gene product of SIGMAR1. Pimavanserin also decreases the efficacy of gilteritinib, which can in turn decrease the efficacy of other drugs such as milnacipran, brexpiprazole, and 5-methoxy-n,n-dimethyltryptamine.', 'The 5-hydroxytryptamine receptor 2c, which is a gene product of HTR2C, is targeted by the drug pimavanserin. Pimavanserin also targets the sigma non-opioid intracellular receptor 1. This sigma receptor is a gene product of SIGMAR1. Interestingly, the efficacy of the cancer drug gilteritinib is reportedly decreased by pimavanserin. Furthermore, gilteritinib is also noted to decrease the efficacy of several other substances including milnacipran, brexpiprazole, and the psychedelic compound 5-methoxy-n,n-dimethyltryptamine.', 'The 5-hydroxytryptamine receptor 2c, one of the gene products of HTR2C, is targeted by the drug Pimavanserin. Pimavanserin also targets the sigma non-opioid intracellular receptor 1, which is a gene product of SIGMAR1. Despite these potential therapeutic effects, Pimavanserin has been found to decrease the efficacy of Gilteritinib. Gilteritinib reciprocally also decreases the efficacy of several other drugs including milnacipran, brexpiprazole, and 5-methoxy-n,n-dimethyltryptamine. This intricate interplay between these drugs and their targets points to the complex interrelationships and potential interactions in pharmacological treatments.', 'The 5-hydroxytryptamine receptor 2c is a gene product of HTR2C and is targeted by the drug pimavanserin. Pimavanserin also targets the sigma non-opioid intracellular receptor 1, another gene product of the gene SIGMAR1. However, pimavanserin decreases the efficacy of another drug, gilteritinib. Gilteritinib, in turn, offsets the efficacy of several additional drugs including milnacipran, brexpiprazole, and the psychedelic 5-methoxy-n,n-dimethyltryptamine.']","['The 5-hydroxytryptamine receptor 2c is a gene product of HTR2C and is a target of the drug pimavanserin. Similarly, pimavanserin also targets the sigma non-opioid intracellular receptor 1, which is a gene product of SIGMAR1. However, the efficiency of pimavanserin may decrease because of the drug brexpiprazole. Also noteworthy is the drug gilteritinib, which can diminish the efficacy of not only brexpiprazole, but also milnacipran and 5-methoxy-n,n-dimethyltryptamine.', ""The 5-hydroxytryptamine receptor 2c is a gene product of HTR2C which is targeted by the drug pimavanserin. Additionally, pimavanserin targets another domain known as the sigma non-opioid intracellular receptor 1, which is a product of the SIGMAR1 gene. However, it has been observed that the effectiveness of pimavanserin can be decreased under the influence of a drug called brexpiprazole. Intriguingly, brexpiprazole's efficacy can also be reduced by yet another medication, gilteritinib. Besides brexpiprazole, gilteritinib diminishes the effectiveness of two other substances, milnacipran and 5-methoxy-n,n-dimethyltryptamine.""]"
"[{'source_node': {'name': 'bosentan'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'methyclothiazide'}}, {'source_node': {'name': 'bosentan'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Pulmonary Veno-Occlusive Disease (disorder)'}}, {'source_node': {'name': 'bosentan'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Hyponatraemia'}}]","[{'source_node': {'name': 'bosentan'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'methyclothiazide'}}, {'source_node': {'name': 'bosentan'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Pulmonary Veno-Occlusive Disease (disorder)'}}, {'source_node': {'name': 'methyclothiazide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'bosentan'}}]","[{'type': 'node_removal', 'source': 'SIDE_EFFECT:595', 'target': None, 'metadata': {'node_id': '595', 'node_type': 'SIDE_EFFECT', 'display_name': 'Hyponatraemia'}}, {'type': 'edge_addition', 'source': 'COMPOUND:222', 'target': 'COMPOUND:545', 'metadata': {'predicate': 'increase_efficacy'}}]",0.5714285714285714,0e5d98cd77adc4916ac44910c4a16956,d68929ea79b3eb79c81cde92d73cf282,[],[]
"[{'source_node': {'name': 'follicle stimulating hormone receptor'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'infertility'}}, {'source_node': {'name': 'urofollitropin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'follicle stimulating hormone receptor'}}, {'source_node': {'name': 'urofollitropin'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Endometrial Carcinoma'}}, {'source_node': {'name': 'urofollitropin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Complication of pregnancy'}}]","[{'source_node': {'name': 'urofollitropin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Complication of pregnancy'}}]","[{'type': 'node_removal', 'source': 'GENE:6728', 'target': None, 'metadata': {'node_id': '6728', 'node_type': 'GENE', 'display_name': 'follicle stimulating hormone receptor'}}, {'type': 'node_removal', 'source': 'INDICATION:593', 'target': None, 'metadata': {'node_id': '593', 'node_type': 'INDICATION', 'display_name': 'Endometrial Carcinoma'}}]",0.3333333333333333,5f1906bc274436f94d474c071837a1a4,b5bb24345cb2459bcd965cfdaf93a8d2,[],"['The fertility drug commonly known as urofollitropin, is known to potentially cause complications during pregnancy as a side effect.', 'The fertility drug, urofollitropin, has been observed to potentially cause complications during pregnancy as a side effect.', 'The drug urofollitropin, often used in assisted reproductive procedures, has been associated with complications of pregnancy as a side effect.', 'The drug urofollitropin has been reported to cause complications of pregnancy as a side effect.', 'The drug urofollitropin has been associated with the side effect of complications in pregnancy.']"
"[{'source_node': {'name': 'collagenase 3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MMP13'}}, {'source_node': {'name': 'MMP13'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'spondyloepimetaphyseal dysplasia'}}, {'source_node': {'name': 'MMP13'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RUNX2 regulates genes involved in cell migration'}}]","[{'source_node': {'name': 'MMP13'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'spondyloepimetaphyseal dysplasia'}}, {'source_node': {'name': 'MMP13'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RUNX2 regulates genes involved in cell migration'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:1389', 'target': None, 'metadata': {'node_id': '1389', 'node_type': 'PROTEIN', 'display_name': 'collagenase 3'}}]",0.7142857142857143,151972d1b9a474ee39de731572742b09,e9a625bd5f50371133ede817c52d0484,"['Collagenase 3 is a gene product of MMP13, which is known to both cause the condition known as spondyloepimetaphyseal dysplasia and to act within the pathway whereby RUNX2 regulates genes involved in cell migration.']",[]
"[{'source_node': {'name': 'maralixibat'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'colestipol'}}, {'source_node': {'name': 'maralixibat'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pitavastatin'}}, {'source_node': {'name': 'maralixibat'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'asunaprevir'}}]","[{'source_node': {'name': 'asunaprevir'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pitavastatin'}}, {'source_node': {'name': 'maralixibat'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pitavastatin'}}, {'source_node': {'name': 'maralixibat'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'asunaprevir'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:364', 'target': 'COMPOUND:9509', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:364', 'target': None, 'metadata': {'node_id': '364', 'node_type': 'COMPOUND', 'display_name': 'colestipol'}}, {'type': 'edge_addition', 'source': 'COMPOUND:9509', 'target': 'COMPOUND:7814', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.5714285714285714,2c9db336e7df47b915b347e66743921d,d3aaca22f0eb04fb91cfb2d0e2379f73,"['The drug maralixibat has been observed to decrease the efficacy of several other drugs including colestipol, pitavastatin, and asunaprevir. As such, it could potentially impact their therapeutic effects.', 'The drug maralixibat has been observed to decrease the efficacy of colestipol, pitavastatin, and asunaprevir. Hence, caution should be exercised when these drugs are administered in combination.', 'The drug Maralixibat is known to decrease the efficacy of Colestipol, Pitavastatin, and Asunaprevir. This interaction may alter the therapeutic effects of these drugs, warranting close monitoring or possible dosage adjustment.', 'The drug maralixibat has been observed to decrease the efficacy of several other medications. These include colestipol, pitavastatin, and asunaprevir. This interaction needs to be considered during co-administration of these drugs with maralixibat.', 'The drug maralixibat has been found to decrease the efficacy of several other medications, including colestipol, pitavastatin, and asunaprevir. It may be advisable to consider alternative medication strategies when maralixibat is also in use.']","['The efficacy of the drug pitavastatin is reduced by two other drugs, asunaprevir and maralixibat. Interestingly, maralixibat also decreases the efficacy of asunaprevir, indicating a complex interplay between these three drugs.', 'The drug Asunaprevir has been reported to decrease the efficacy of another drug, Pitavastatin. Similarly, Maralixibat also impacts Pitavastatin by reducing its efficacy. Interesting to note is that Maralixibat also decreases the efficacy of Asunaprevir. This suggests a complex interaction between these drugs that could be considered when constructing patient treatment plans.', 'The drug Asunaprevir is known to decrease the efficacy of Pitavastatin. Similarly, Maralixibat also lessens the effectiveness of Pitavastatin. Intriguingly, Maralixibat also hampers the efficacy of Asunaprevir.', 'The use of certain drugs such as Asunaprevir and Maralixibat can decrease the efficacy of Pitavastatin. Interestingly, Maralixibat also has the potential to decrease the efficacy of Asunaprevir.', 'The drug Asunaprevir decreases the efficacy of Pitavastatin. Similarly, Maralixibat also undermines the efficacy of Pitavastatin and Asunaprevir. Therefore, care should be taken when these drugs are used in combination to ensure that their effects are not impeded.']"
"[{'source_node': {'name': 'IVD'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'isovaleric acidemia'}}, {'source_node': {'name': 'IVD'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Branched-chain amino acid catabolism'}}, {'source_node': {'name': 'coenzyme a persulfide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'isovaleryl-coa dehydrogenase'}}, {'source_node': {'name': 'isovaleryl-coa dehydrogenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'IVD'}}, {'source_node': {'name': 'isovaleric acidemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ketoacidosis'}}]","[{'source_node': {'name': 'IVD'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'isovaleric acidemia'}}, {'source_node': {'name': 'IVD'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Branched-chain amino acid catabolism'}}, {'source_node': {'name': 'coenzyme a persulfide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'isovaleryl-coa dehydrogenase'}}, {'source_node': {'name': 'isovaleryl-coa dehydrogenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'IVD'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1457', 'target': None, 'metadata': {'node_id': '1457', 'node_type': 'PHENOTYPE', 'display_name': 'ketoacidosis'}}]",0.8181818181818181,43166b11a9036e3b995e71ed11547c32,71350537805f8fff30d89978112f23c0,"['The gene IVD which acts within the branched-chain amino acid catabolism pathway is known to cause isovaleric acidemia, a metabolic disorder characterized by symptoms such as ketoacidosis. Isovaleryl-CoA dehydrogenase, a gene product of IVD, serves as a target for coenzyme A persulfide.', 'The gene IVD implicated in branched-chain amino acid catabolism can cause isovaleric acidemia, a condition marked by phenotypes such as ketoacidosis. Furthermore, isovaleryl-CoA dehydrogenase which is a gene product of IVD, is a potential target for the drug coenzyme A persulfide.', 'The gene IVD, functioning within the branched-chain amino acid catabolism pathway, is implicated in causing the rare metabolic disorder known as isovaleric acidemia. Moreover, the coenzyme a persulfide targets isovaleryl-coa dehydrogenase, which is a gene product of IVD. One distinct phenotype of isovaleric acidemia is a condition called ketoacidosis.', ""The gene IVD, which acts within the branched-chain amino acid catabolism pathway, causes isovaleric acidemia, a medical condition characterized by symptoms such as ketoacidosis. It's worth noting that isovaleryl-coa dehydrogenase, a gene product of IVD, is a target of coenzyme a persulfide."", 'The gene IVD, which acts within the branched-chain amino acid catabolism pathway, causes a condition known as isovaleric acidemia. Isovaleric acidemia, in turn, is characterized by a phenotype that includes the symptom known as ketoacidosis. In the biochemistry at play, coenzyme A persulfide targets isovaleryl-CoA dehydrogenase, which is a gene product of IVD. This illustrates the interplay between biochemical activity, genetic factors, and resulting disease conditions in human metabolism.']","['The gene IVD, which is involved in the branched-chain amino acid catabolism pathway, is linked to the metabolic disorder known as isovaleric acidemia. IVD is identified as the gene product of the enzyme isovaleryl-CoA dehydrogenase. Additionally, coenzyme A persulfide is noted to target isovaleryl-CoA dehydrogenase, further interacting with the IVD gene.', 'The gene IVD is part of the branched-chain amino acid catabolism pathway and is responsible for causing the condition known as isovaleric acidemia. Coenzyme A persulfide targets isovaleryl-CoA dehydrogenase, a protein that is a gene product of IVD.', 'The gene IVD, which actively partakes in the process of branched-chain amino acid catabolism, is known to cause the condition known as isovaleric acidemia. Moreover, isovaleryl-coa dehydrogenase, a gene product of IVD, is targeted by coenzyme a persulfide.', 'The gene IVD is involved in the branched-chain amino acid catabolism. It causes a condition known as isovaleric acidemia. Coenzyme A persulfide targets isovaleryl-CoA dehydrogenase, which is a gene product of IVD.', ""The gene IVD, involved in branched-chain amino acid catabolism, causes the condition known as isovaleric acidemia. It's also noteworthy that IVD is the gene product of isovaleryl-coa dehydrogenase, which is directly targeted by coenzyme A persulfide.""]"
"[{'source_node': {'name': 'heptaethylene glycol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'carbonyl reductase [nadph] 1'}}, {'source_node': {'name': 'heptaethylene glycol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'antihemophilic factor (recombinant)'}}, {'source_node': {'name': 'pegvaliase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pegaptanib'}}, {'source_node': {'name': 'pegvaliase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'peginesatide'}}, {'source_node': {'name': 'pegvaliase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'elapegademase'}}, {'source_node': {'name': 'lipegfilgrastim'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pegvisomant'}}, {'source_node': {'name': 'lipegfilgrastim'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'heptaethylene glycol'}}, {'source_node': {'name': 'lipegfilgrastim'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pegvaliase'}}]","[{'source_node': {'name': 'pegaptanib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'peginesatide'}}, {'source_node': {'name': 'peginesatide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pegvisomant'}}, {'source_node': {'name': 'heptaethylene glycol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'carbonyl reductase [nadph] 1'}}, {'source_node': {'name': 'heptaethylene glycol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'antihemophilic factor (recombinant)'}}, {'source_node': {'name': 'pegvaliase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pegaptanib'}}, {'source_node': {'name': 'pegvaliase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'peginesatide'}}, {'source_node': {'name': 'pegvaliase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'elapegademase'}}, {'source_node': {'name': 'pegvaliase'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pegvisomant'}}, {'source_node': {'name': 'lipegfilgrastim'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pegvisomant'}}, {'source_node': {'name': 'lipegfilgrastim'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'heptaethylene glycol'}}, {'source_node': {'name': 'lipegfilgrastim'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pegvaliase'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:10716', 'target': 'COMPOUND:77', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:4611', 'target': 'COMPOUND:7846', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:7846', 'target': 'COMPOUND:77', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.8235294117647058,9a1c3efcee86fdb5b01da936968c9d2c,4526b3ac47912a90b793e23e840dd3e3,"[""In a complex web of chemical interactions, heptaethylene glycol targets Carbonyl Reductase [NADPH] 1 but can decrease the efficacy of the Antihemophilic Factor (recombinant). Meanwhile, pegvaliase is identified to decrease the efficacy of Pegaptanib, Peginesatide, and Elapegademase. Furthermore, Lipegfilgrastim also plays a significant role in this network by notably reducing the efficacy of substances such as Pegvisomant, the earlier mentioned Heptaethylene Glycol, and Pegvaliase. Clearly, each compound's actions and interactions can significantly influence the efficacy and outcomes of others in this intricate chemical relationship."", 'The drug heptaethylene glycol targets the enzyme carbonyl reductase [NADPH] 1 and demonstrates to decrease the efficacy of the antihemophilic factor (recombinant). In parallel, the drug pegvaliase works similarly by decreasing the efficacy of various medications such as pegaptanib, peginesatide, and elapegademase. Interestingly, another drug called lipegfilgrastim exhibits similar behavior by decreasing the efficacy of pegvisomant as well as the previously mentioned heptaethylene glycol and pegvaliase.', 'The compound heptaethylene glycol has a target known as carbonyl reductase [nadph] 1, but it also decreases the efficacy of the biologic medicine known as antihemophilic factor (recombinant). Similarly, the enzyme pegvaliase lowers the efficacy of three different therapeutics: pegaptanib, peginesatide, and elapegademase. On the other hand, lipegfilgrastim, another enzyme, is responsible for decreasing the efficacy of the hormone analogue pegvisomant, heptaethylene glycol mentioned previously, and also the enzyme pegvaliase. These findings highlight how these substances interact and may influence the effectiveness of various medical treatments.', 'The chemical compound heptaethylene glycol has been identified as a target for the enzyme known as carbonyl reductase [nadph] 1. Interestingly, heptaethylene glycol has also been observed to decrease the efficacy of the antihemophilic factor (recombinant). That implies that this compound can affect some critical biological processes. \n\nOn another note, the drug pegvaliase has a multifaceted nature too. It tends to decrease the efficacy of several other drugs, notably pegaptanib, peginesatide, and elapegademase. This suggests the potential interactions of pegvaliase with these drugs, possibly making them less effective in therapeutic applications.\n\nThere is also the drug lipegfilgrastim, which follows a similar pattern as pegvaliase. It decreases the efficacy of the drug pegvisomant and intriguingly, both heptaethylene glycol and pegvaliase itself. \n\nThus, the complex interactions of these compounds and drugs have shown a decrease in efficacy, which may have serious therapeutic implications. Special care must be taken when these entities interact, as one can affect the functionality of the other.']","['The pharmacological landscape is shaped by various direct and indirect interactions between drugs. The drug pegaptanib decreases the efficacy of peginesatide, another medication. Similarly, peginesatide, following suit, diminishes the effectiveness of pegvisomant. \n\nSimultaneously, there are noteworthy targets for other substances such as heptaethylene glycol, which targets an enzyme named carbonyl reductase [nadph] 1. However, it should be noted that the efficacy of an important clinical substance, antihemophilic factor (recombinant), is reduced when used in conjunction with heptaethylene glycol. \n\nAnother drug, pegvaliase, has a two-pronged effect. On one hand, it reduces the efficacy of medications like pegaptanib, peginesatide, and elapegademase, yet, on the other hand, it increases the efficacy of pegvisomant. \n\nLastly, lipegfilgrastim, another therapeutically relevant drug, is found to decrease the efficacy of pegvisomant and heptaethylene glycol, alongside pegvaliase. Such intricate relationships underline the importance of considering drug interactions in therapeutic contexts.', 'In the complex interplay of pharmaceuticals, both efficacy and targeting play crucial roles. For instance, the drug pegaptanib can decrease the efficacy of another drug called peginesatide. In a similar manner, peginesatide can reduce the efficacy of pegvisomant. The chemical compound heptaethylene glycol has as its target the enzyme known as carbonyl reductase [nadph] 1 and also has potential to decrease the efficacy of antihemophilic factor (recombinant).\n\nAdditionally, the drug pegvaliase might not only decrease the efficacy of pegaptanib, peginesatide, and elapegademase but also increase the efficacy of pegvisomant. On the other hand, the drug lipegfilgrastim has shown to decrease the effectiveness of pegvisomant, heptaethylene glycol, and pegvaliase. These interactions underline the intricate relationships and balancing act within the field of pharmaceuticals.', 'Pegaptanib decreases the efficacy of peginesatide, a drug which in turn decrease the efficacy of pegvisomant. Similarly, pegvaliase also decreases the efficacy of pegaptanib and peginesatide but in contrast, it increases the efficacy of pegvisomant, while decreasing the efficacy of elapegademase. Another drug, lipegfilgrastim, noticeably reduces the effectiveness of pegvisomant, heptaethylene glycol and pegvaliase. Interestingly, heptaethylene glycol targets carbonyl reductase [nadph] 1, but is known to decrease the efficacy of the antihemophilic factor (recombinant). These broad studies convey a deeper understanding of the interactions, effects, and mechanisms of these drugs and substances.', 'The drug pegaptanib can diminish the efficacy of peginesatide, which in turn may also decrease the efficacy of pegvisomant, another pharmaceutical compound. Similarly, heptaethylene glycol, an organic compound, targets carbonyl reductase [nadph] 1 and can undermine the efficacy of antihemophilic factor (recombinant).\n\nPegvaliase, a drug used for phenylketonuria treatment, has a bidirectional effect; it can reduce the effectiveness of pegaptanib, peginesatide, and elapegademase but, on the contrary, it may increase the efficacy of pegvisomant.\n\nLastly, lipegfilgrastim, a drug to increase white blood cell production, might decrease the efficacy of various compounds: pegvisomant, heptaethylene glycol, and pegvaliase. Understanding these complex interactions can guide appropriate drug use and avoid potentially harmful interactions or diminished treatment effectiveness.', 'Pegaptanib is a drug that can decrease the efficacy of peginesatide. Interestingly, peginesatide in turn can reduce the efficacy of another drug known as pegvisomant. On a different note, there is a compound known as heptaethylene glycol that targets carbonyl reductase [nadph] 1. This same compound can reduce the efficacy of antihemophilic factor (recombinant). \n\nMoreover, pegvaliase acts as a double-edge sword in drug efficacy. On one hand, it can decrease the efficacy of drugs like pegaptanib, peginesatide, and elapegademase. Contrarily, it can enhance the efficacy of pegvisomant. \n\nThe drug lipegfilgrastim also exhibits interesting interactions, as it can reduce the efficacy of pegvisomant, heptaethylene glycol, and pegvaliase. As such, these complex interactions underline the need for careful consideration when prescribing or co-administering certain combinations of these drugs.']"
"[{'source_node': {'name': 'flap endonuclease 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FEN1'}}, {'source_node': {'name': 'dna polymerase beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'POLB'}}, {'source_node': {'name': '2-(3,4-dimethoxyphenyl)-n-methylethanamine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna polymerase beta'}}, {'source_node': {'name': '2-(3,4-dimethoxyphenyl)-n-methylethanamine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histone acetyltransferase kat2a'}}, {'source_node': {'name': '2-(3,4-dimethoxyphenyl)-n-methylethanamine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'flap endonuclease 1'}}, {'source_node': {'name': 'histone acetyltransferase kat2a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KAT2A'}}]","[{'source_node': {'name': 'flap endonuclease 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FEN1'}}, {'source_node': {'name': 'flap endonuclease 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KAT2A'}}, {'source_node': {'name': 'dna polymerase beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'POLB'}}, {'source_node': {'name': 'dna polymerase beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'FEN1'}}, {'source_node': {'name': 'dna polymerase beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KAT2A'}}, {'source_node': {'name': '2-(3,4-dimethoxyphenyl)-n-methylethanamine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histone acetyltransferase kat2a'}}, {'source_node': {'name': '2-(3,4-dimethoxyphenyl)-n-methylethanamine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'flap endonuclease 1'}}, {'source_node': {'name': 'histone acetyltransferase kat2a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KAT2A'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:1519', 'target': 'GENE:27020', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:51640', 'target': 'PROTEIN:1519', 'metadata': None}, {'type': 'edge_addition', 'source': 'PROTEIN:1519', 'target': 'GENE:27912', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'PROTEIN:1727', 'target': 'GENE:27912', 'metadata': {'predicate': 'gene_product_of'}}]",0.6923076923076923,3ff88a848ad68063ff1e2b41b19d4029,e88d60f4688bdfc54736c481ded0a1b5,"['The gene product flap endonuclease 1 is derived from the FEN1 gene. Another gene product, dna polymerase beta, originates from the gene POLB. Interestingly, both of these gene products are targeted by the compound 2-(3,4-dimethoxyphenyl)-n-methylethanamine, demonstrating notable interplay in molecular biology. The same compound also has another target, histone acetyltransferase kat2a, which is a gene product of KAT2A. These intricate relationships underscore the complexity of biological systems and the potential effects of compounds such as 2-(3,4-dimethoxyphenyl)-n-methylethanamine.', 'Flap Endonuclease 1 and DNA Polymerase Beta are the gene products of FEN1 and POLB respectively. Furthermore, these two proteins are targeted by the drug 2-(3,4-dimethoxyphenyl)-n-methylethanamine. Additionally, this drug targets another protein, Histone Acetyltransferase Kat2a, which is the gene product of KAT2A.', 'The drug 2-(3,4-dimethoxyphenyl)-n-methylethanamine targets a few specific proteins in its action. Firstly, the DNA polymerase beta, which is a gene product of POLB, is targeted by this drug. Next, the histone acetyltransferase kat2a is also a target and is a gene product of KAT2A. Finally, this drug targets flap endonuclease 1, a gene product of FEN1. In summary, all these targeted proteins are products of genes FEN1, POLB, and KAT2A, respectively.', 'The compound 2-(3,4-dimethoxyphenyl)-n-methylethanamine targets several proteins including DNA polymerase beta, histone acetyltransferase Kat2a, and flap endonuclease 1. DNA polymerase beta, encoded by gene POLB, plays a crucial role in DNA synthesis. Histone acetyltransferase Kat2a, a product of KAT2A gene, plays an essential role in regulating chromatin structure and gene expression by acetylating histones. Flap endonuclease 1, encoded by the gene FEN1, plays a key role in DNA replication and repair.', 'Flap endonuclease 1 and DNA polymerase beta are the gene products of FEN1 and POLB respectively. These two proteins are targeted by the drug 2-(3,4-dimethoxyphenyl)-n-methylethanamine. Additionally, this drug also targets another protein, histone acetyltransferase KAT2A, which is the gene product of KAT2A.']","['Flap endonuclease 1 and DNA polymerase beta are gene products of FEN1 and KAT2A. Interestingly, Flap endonuclease 1 and histone acetyltransferase kat2a are targeted by the drug 2-(3,4-dimethoxyphenyl)-n-methylethanamine. Additionally, DNA polymerase beta is also found to be a gene product of the genes POLB, FEN1, and KAT2A. Further, Histone acetyltransferase kat2a is a gene product of KAT2A. These interconnected relationships imply a potential regulatory mechanism among these entities and provide significant implications for therapeutic targeting.', 'The drug 2-(3,4-dimethoxyphenyl)-n-methylethanamine targets two proteins: flap endonuclease 1 and histone acetyltransferase kat2a. These proteins are gene products of FEN1 and KAT2A respectively, with flap endonuclease 1 also a gene product of KAT2A. Histone acetyltransferase kat2a is a gene product of KAT2A too. Similarly, another protein named DNA polymerase beta is a gene product of three genes namely POLB, FEN1, and KAT2A.']"
"[{'source_node': {'name': 'tiliroside'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepg2'}}, {'source_node': {'name': 'tiliroside'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'carbonic anhydrase 2'}}, {'source_node': {'name': 'tiliroside'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'carbonic anhydrase 7'}}, {'source_node': {'name': 'CA7'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Reversible hydration of carbon dioxide'}}, {'source_node': {'name': 'carbonic anhydrase 7'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA7'}}, {'source_node': {'name': 'carbonic anhydrase 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA2'}}]","[{'source_node': {'name': 'tiliroside'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepg2'}}, {'source_node': {'name': 'tiliroside'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'carbonic anhydrase 2'}}, {'source_node': {'name': 'tiliroside'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'carbonic anhydrase 7'}}, {'source_node': {'name': 'tiliroside'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'CA2'}}, {'source_node': {'name': 'hepg2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA2'}}, {'source_node': {'name': 'CA7'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Reversible hydration of carbon dioxide'}}, {'source_node': {'name': 'carbonic anhydrase 7'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA7'}}, {'source_node': {'name': 'carbonic anhydrase 7'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA2'}}, {'source_node': {'name': 'carbonic anhydrase 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA2'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:1023', 'target': 'GENE:33598', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'PROTEIN:5817', 'target': 'GENE:33598', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'COMPOUND:31936', 'target': 'GENE:33598', 'metadata': {'predicate': 'is_affecting'}}]",0.7692307692307692,b26f6cb0c6059ad185c6b752252ce28b,7b4ae69d4cccfaf0633a7cd05dcabca5,"['The compound Tiliroside targets three different entities: HepG2, Carbonic Anhydrase 2, and Carbonic Anhydrase 7. Both Carbonic Anhydrase 2 and 7 are gene products of CA2 and CA7 respectively. Furthermore, CA7 is known to act within the process of reversible hydration of carbon dioxide.', 'The compound tiliroside targets several enzymes and cell types. These include HepG2, a human liver cancer cell line, as well as two enzymes: Carbonic Anhydrase 2 and Carbonic Anhydrase 7. These enzymes are the product of the genes CA2 and CA7 respectively. Notably, CA7 plays a role in the reversible hydration of carbon dioxide process.', 'Tiliroside, a known pharmacological agent, targets several entities including HepG2, carbonic anhydrase 2, and carbonic anhydrase 7. Notably, carbonic anhydrase 2 and 7 are gene products of the genes CA2 and CA7 respectively. CA7 interestingly acts within the pathway linked to the reversible hydration of carbon dioxide. Therefore, the action of tiliroside on these targets underpins some of its biological effects.', 'Tiliroside, a chemical compound, targets several entities like hepg2, carbonic anhydrase 2, and carbonic anhydrase 7. Carbonic anhydrase 2 is a gene product of CA2, and similarly, carbonic anhydrase 7 is a product of the gene CA7. This gene, CA7, plays an essential role in the reversible hydration of carbon dioxide.', 'The substance tiliroside targets several entities including hepg2, carbonic anhydrase 2, and carbonic anhydrase 7. Carbonic anhydrase 2 and carbonic anhydrase 7 are both gene products. Specifically, carbonic anhydrase 7 is a gene product of CA7, and carbonic anhydrase 2 is a gene product of CA2. Interestingly, CA7 acts within the process of the reversible hydration of carbon dioxide.']",[]
"[{'source_node': {'name': 'GPR143'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'albinism'}}, {'source_node': {'name': 'GPR143'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'nystagmus 6'}}, {'source_node': {'name': 'GPR143'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Amine ligand-binding receptors'}}, {'source_node': {'name': 'albinism'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'exotropia'}}, {'source_node': {'name': 'albinism'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cutaneous melanoma'}}, {'source_node': {'name': 'albinism'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'absent skin pigmentation'}}]","[{'source_node': {'name': 'albinism'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'absent skin pigmentation'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1149', 'target': None, 'metadata': {'node_id': '1149', 'node_type': 'PATHWAY', 'display_name': 'Amine ligand-binding receptors'}}, {'type': 'edge_deletion', 'source': 'GENE:30368', 'target': 'DISEASE:14356', 'metadata': None}, {'type': 'node_removal', 'source': 'PHENOTYPE:446', 'target': None, 'metadata': {'node_id': '446', 'node_type': 'PHENOTYPE', 'display_name': 'exotropia'}}, {'type': 'node_removal', 'source': 'GENE:30368', 'target': None, 'metadata': {'node_id': '30368', 'node_type': 'GENE', 'display_name': 'GPR143'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:8451', 'target': None, 'metadata': {'node_id': '8451', 'node_type': 'PHENOTYPE', 'display_name': 'cutaneous melanoma'}}]",0.2307692307692307,bf457be50c961c34b6fcf76289da1359,14ec84396253a60517221044c4597c4e,"['The gene GPR143, which acts within the amine ligand-binding receptors, can cause multiple conditions such as albinism and nystagmus 6. Albinism itself is characterized by several phenotypes including exotropia, cutaneous melanoma, and absent skin pigmentation.', 'The gene GPR143, which acts within the pathway of amine ligand-binding receptors, is known to cause conditions such as albinism and nystagmus 6. Albinism, a condition characterized by symptoms such as exotropia, cutaneous melanoma, and absent skin pigmentation, is directly linked to abnormalities in the GPR143 gene.']","['Albinism, a genetic condition, has the phenotype of absent skin pigmentation.']"
"[{'source_node': {'name': 'cauloside d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prostaglandin g/h synthase 2'}}, {'source_node': {'name': 'PTGS2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nicotinamide salvaging'}}, {'source_node': {'name': 'PTGS2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of 15-eicosatetraenoic acid derivatives'}}, {'source_node': {'name': 'prostaglandin g/h synthase 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTGS2'}}]","[{'source_node': {'name': 'cauloside d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prostaglandin g/h synthase 2'}}]","[{'type': 'node_removal', 'source': 'GENE:31977', 'target': None, 'metadata': {'node_id': '31977', 'node_type': 'GENE', 'display_name': 'PTGS2'}}]",0.3333333333333333,9adecb8b4eefda359c1cc6768f8bc06a,f07f3be5aa5c2b70125dc5751ce00383,"['Cauloside D, a potent compound, has been found to specifically target Prostaglandin G/H Synthase 2, a gene product of PTGS2. It is interesting to note that PTGS2 also significantly acts within multiple pathways such as Nicotinamide salvaging and the synthesis of 15-eicosatetraenoic acid derivatives.']",['The drug Cauloside D is known to target the enzyme Prostaglandin G/H Synthase 2.']
"[{'source_node': {'name': 'GP1BA'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pseudo-von willebrand disease'}}, {'source_node': {'name': 'GP1BA'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'fetal and neonatal alloimmune thrombocytopenia'}}, {'source_node': {'name': 'GP1BA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Intrinsic Pathway of Fibrin Clot Formation'}}, {'source_node': {'name': 'fetal and neonatal alloimmune thrombocytopenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'melena'}}, {'source_node': {'name': 'fetal and neonatal alloimmune thrombocytopenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'blindness'}}, {'source_node': {'name': 'fetal and neonatal alloimmune thrombocytopenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'subarachnoid hemorrhage'}}]","[{'source_node': {'name': 'fetal and neonatal alloimmune thrombocytopenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'melena'}}, {'source_node': {'name': 'fetal and neonatal alloimmune thrombocytopenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'blindness'}}, {'source_node': {'name': 'fetal and neonatal alloimmune thrombocytopenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'subarachnoid hemorrhage'}}]","[{'type': 'edge_deletion', 'source': 'GENE:28214', 'target': 'DISEASE:9913', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:28214', 'target': None, 'metadata': {'node_id': '28214', 'node_type': 'GENE', 'display_name': 'GP1BA'}}]",0.5384615384615384,b1a1ee28ac2b940d3bcd411e56836702,c5d3a5689ce076f43b58cf9499982604,"['The gene GP1BA acts within the intrinsic pathway of fibrin clot formation and is associated with several medical conditions. It is known to cause pseudo-von Willebrand disease and fetal and neonatal alloimmune thrombocytopenia. Fetal and neonatal alloimmune thrombocytopenia is an illness that presents various phenotypes including melena, a black, tarry stool, blindness, and subarachnoid hemorrhage, a type of stroke caused by bleeding in the space surrounding the brain.', 'The gene GP1BA is critically involved in the intrinsic pathway of fibrin clot formation, playing a causative role in several health conditions. Two such conditions caused by GP1BA are pseudo-von Willebrand disease and fetal and neonatal alloimmune thrombocytopenia. Fetal and neonatal alloimmune thrombocytopenia, a condition caused by GP1BA, is associated with various phenotypic expressions including melena, blindness, and subarachnoid hemorrhage.', 'GP1BA is a gene that acts within the intrinsic pathway of fibrin clot formation, and it has been implicated in causing two conditions; pseudo-von Willebrand disease and fetal and neonatal alloimmune thrombocytopenia. The disease fetal and neonatal alloimmune thrombocytopenia has several phenotypes associated with it, such as melena, blindness, and subarachnoid hemorrhage.', 'The gene GP1BA, which acts within the intrinsic pathway of fibrin clot formation, causes several conditions including pseudo-von Willebrand disease and fetal and neonatal alloimmune thrombocytopenia. Fetal and neonatal alloimmune thrombocytopenia, in particular, has multiple associated phenotypes, which include melena, blindness and even severe conditions like subarachnoid hemorrhage.', 'The gene GP1BA, which acts within the intrinsic pathway of fibrin clot formation, is known to cause two conditions: pseudo-von Willebrand disease and fetal and neonatal alloimmune thrombocytopenia. Distinctively, fetal and neonatal alloimmune thrombocytopenia exhibits symptoms which include melena, blindness, and subarachnoid hemorrhage.']","['Fetal and neonatal alloimmune thrombocytopenia is a condition that presents several phenotypes including melena, blindness, and subarachnoid hemorrhage.', '""Fetal and neonatal alloimmune thrombocytopenia is a condition that has several phenotypes, including melena, blindness, and subarachnoid hemorrhage.']"
"[{'source_node': {'name': 'IL33'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'PIP3 activates AKT signaling'}}, {'source_node': {'name': 'IL33'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ub-specific processing proteases'}}]","[{'source_node': {'name': 'IL33'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'PIP3 activates AKT signaling'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:115', 'target': None, 'metadata': {'node_id': '115', 'node_type': 'PATHWAY', 'display_name': 'Ub-specific processing proteases'}}]",0.6,adc2a425625aab5cefc3a11a061c24a0,fe11d5fdcd62a70f01f90ff84fd9bc30,[],[]
"[{'source_node': {'name': 'PIK3C2A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of PIPs at the early endosome membrane'}}, {'source_node': {'name': 'PIK3C2A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of PIPs at the late endosome membrane'}}, {'source_node': {'name': 'PIK3C2A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Golgi Associated Vesicle Biogenesis'}}]","[{'source_node': {'name': 'PIK3C2A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Golgi Associated Vesicle Biogenesis'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1402', 'target': None, 'metadata': {'node_id': '1402', 'node_type': 'PATHWAY', 'display_name': 'Synthesis of PIPs at the late endosome membrane'}}, {'type': 'node_removal', 'source': 'PATHWAY:1401', 'target': None, 'metadata': {'node_id': '1401', 'node_type': 'PATHWAY', 'display_name': 'Synthesis of PIPs at the early endosome membrane'}}]",0.4285714285714286,5418fbf4d1a4ebaa91d49aa331781ebd,3a36660f06fe296466f43287c1e0ebe7,[],[]
"[{'source_node': {'name': 'AR'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nuclear Receptor transcription pathway'}}, {'source_node': {'name': 'AR'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ub-specific processing proteases'}}, {'source_node': {'name': 'maltol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ekvx'}}, {'source_node': {'name': 'maltol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'uacc-257'}}, {'source_node': {'name': 'maltol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'androgen receptor'}}, {'source_node': {'name': 'androgen receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AR'}}]","[{'source_node': {'name': 'AR'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nuclear Receptor transcription pathway'}}, {'source_node': {'name': 'AR'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ub-specific processing proteases'}}, {'source_node': {'name': 'maltol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ekvx'}}, {'source_node': {'name': 'maltol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'uacc-257'}}, {'source_node': {'name': 'ekvx'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AR'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:5657', 'target': 'GENE:29295', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'PROTEIN:946', 'target': None, 'metadata': {'node_id': '946', 'node_type': 'PROTEIN', 'display_name': 'androgen receptor'}}]",0.7692307692307692,fbcac92d97cd4d5d11dac7ae22644c6e,cb262db7f69be74f0d76813f4db8a0c1,"['The gene AR, acting within both the nuclear receptor transcription pathway and with Ub-specific processing proteases, is known to be the gene product of the androgen receptor. Furthermore, maltol, a compound often used in the food and beverage industry, has shown targeting properties towards the androgen receptor and two other entities, namely ekvx and uacc-257.']",[]
"[{'source_node': {'name': 'bis(2-methylpropyl) benzene-1,2-dicarboxylate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lysine-specific demethylase 4a'}}, {'source_node': {'name': 'bis(2-methylpropyl) benzene-1,2-dicarboxylate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear factor erythroid 2-related factor 2'}}, {'source_node': {'name': 'bis(2-methylpropyl) benzene-1,2-dicarboxylate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'rap guanine nucleotide exchange factor 4'}}, {'source_node': {'name': 'rap guanine nucleotide exchange factor 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RAPGEF4'}}, {'source_node': {'name': 'KDM4A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'HDMs demethylate histones'}}, {'source_node': {'name': 'lysine-specific demethylase 4a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KDM4A'}}]","[{'source_node': {'name': 'bis(2-methylpropyl) benzene-1,2-dicarboxylate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lysine-specific demethylase 4a'}}, {'source_node': {'name': 'bis(2-methylpropyl) benzene-1,2-dicarboxylate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'rap guanine nucleotide exchange factor 4'}}, {'source_node': {'name': 'bis(2-methylpropyl) benzene-1,2-dicarboxylate'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'KDM4A'}}, {'source_node': {'name': 'rap guanine nucleotide exchange factor 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RAPGEF4'}}, {'source_node': {'name': 'KDM4A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'HDMs demethylate histones'}}, {'source_node': {'name': 'lysine-specific demethylase 4a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KDM4A'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:36001', 'target': 'GENE:35605', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'PROTEIN:5907', 'target': None, 'metadata': {'node_id': '5907', 'node_type': 'PROTEIN', 'display_name': 'nuclear factor erythroid 2-related factor 2'}}]",0.7692307692307692,4726c4169c22f93166940db01d2197ee,e7b11b71490d3eeddc826c37ae251bd7,"['The compound bis(2-methylpropyl) benzene-1,2-dicarboxylate targets a number of proteins including lysine-specific demethylase 4a, nuclear factor erythroid 2-related factor 2, and rap guanine nucleotide exchange factor 4. Lysine-specific demethylase 4a is a gene product of KDM4A, which acts within the pathway responsible for demethylating histones, known as HDMs demethylate histones. Additionally, rap guanine nucleotide exchange factor 4 is a gene product of the gene RAPGEF4.']",[]
"[{'source_node': {'name': 'forasartan'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' renal failure, hyperkalemia, and hypertension '}}, {'source_node': {'name': 'forasartan'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' renal failure and hypotension '}}]","[{'source_node': {'name': 'forasartan'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' renal failure, hyperkalemia, and hypertension '}}]","[{'type': 'node_removal', 'source': 'EFFECT:76', 'target': None, 'metadata': {'node_id': '76', 'node_type': 'EFFECT', 'display_name': ' renal failure and hypotension '}}]",0.6,ed8ce634c13415f00c4bef907414e3d2,6ff6cb1c57af0d30f06c793bfaba7df0,[],[]
"[{'source_node': {'name': 'cytochrome p450 19a1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP19A1'}}, {'source_node': {'name': 'microtubule-associated protein tau'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MAPT'}}, {'source_node': {'name': 'dna polymerase kappa'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'POLK'}}, {'source_node': {'name': 'cis-resveratrol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'microtubule-associated protein tau'}}, {'source_node': {'name': 'cis-resveratrol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna polymerase kappa'}}, {'source_node': {'name': 'cis-resveratrol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 19a1'}}]","[{'source_node': {'name': 'cytochrome p450 19a1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP19A1'}}, {'source_node': {'name': 'dna polymerase kappa'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'POLK'}}, {'source_node': {'name': 'cis-resveratrol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'microtubule-associated protein tau'}}, {'source_node': {'name': 'cis-resveratrol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna polymerase kappa'}}, {'source_node': {'name': 'cis-resveratrol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 19a1'}}]","[{'type': 'node_removal', 'source': 'GENE:29856', 'target': None, 'metadata': {'node_id': '29856', 'node_type': 'GENE', 'display_name': 'MAPT'}}]",0.8461538461538461,7ff935183c59a3cc46dc786364785e71,896489917a10d4aa95074e5a3260d383,"['The drug cis-resveratrol interacts with several protein targets including the cytochrome P450 19A1, the microtubule-associated protein tau, and the DNA polymerase kappa. Interestingly, each protein is the output of a specific gene: cytochrome P450 19A1 is the gene product of CYP19A1; the microtubule-associated protein tau arises from the gene MAPT; and DNA polymerase kappa is encoded by the gene POLK.', 'Cytochrome P450 19A1, Microtubule-associated protein tau, and DNA polymerase kappa are all gene products of their respective genes CYP19A1, MAPT, and POLK. Interestingly, these proteins, in turn, are targetted by a compound known as cis-resveratrol. This suggests that cis-resveratrol can influence the activity or function of these proteins by directly interacting with them.', 'The compound cis-resveratrol has been identified to target several key gene products. These include the protein microtubule-associated protein tau which is a product of the MAPT gene, dna polymerase kappa which originates from the POLK gene, and lastly, the protein cytochrome p450 19a1, a product of the CYP19A1 gene.', 'The enzyme cytochrome P450 19A1 is a gene product of CYP19A1 and it acts as a target for the compound cis-resveratrol. Another target for cis-resveratrol is the microtubule-associated protein tau, which is a gene product of MAPT. Adding to this, cis-resveratrol also targets DNA polymerase kappa, a gene product of POLK. These complex interactions exemplify the interconnectedness of genetic and metabolic processes in biological systems.', 'The compound cis-resveratrol interacts with several targets. This includes the microtubule-associated protein tau which is a gene product of MAPT, DNA polymerase kappa which is a gene product of POLK, as well as cytochrome p450 19a1, a gene product of CYP19A1. These targets play important roles in various cellular processes.']","['The drug cis-resveratrol has a multifaceted role as it targets a variety of structures, including the microtubule-associated protein tau, the dna polymerase kappa, and the cytochrome p450 19a1. These targets are not just random proteins but are gene products of important genes. Specifically, the dna polymerase kappa is a gene product of the POLK gene and cytochrome p450 19a1 is synthesized by the CYP19A1 gene. The detailed target profile of cis-resveratrol highlights its potential implications in various biological pathways.', 'Cytochrome P450 19A1 is a gene product of CYP19A1, while DNA polymerase kappa is a gene product of POLK. Both of these proteins are among the targets of cis-resveratrol, a pharmaceutical compound. Another target of cis-resveratrol is the microtubule-associated protein tau, which plays a crucial role in maintaining the structure of nerve cells.', 'The chemical compound cis-resveratrol has several targets including the microtubule-associated protein tau, DNA polymerase kappa, and cytochrome p450 19a1. DNA polymerase kappa is the gene product of POLK, and likewise, cytochrome p450 19a1 is a gene product of CYP19A1.', 'Cytochrome p450 19a1 and DNA Polymerase kappa are gene products of CYP19A1 and POLK respectively. Interestingly, these two proteins are targeted by the molecular compound cis-resveratrol. In addition, cis-resveratrol also targets the microtubule-associated protein tau. This suggests that cis-resveratrol may interact with multiple proteins to exert its biological effects.', 'The compound cis-resveratrol has multiple targets. One of them is microtubule-associated protein tau. Besides, cis-resveratrol also interacts with two proteins that are gene products of specific genes. The first is DNA polymerase kappa, a product of the POLK gene, and the second target is cytochrome P450 19A1, a product of the CYP19A1 gene.']"
"[{'source_node': {'name': '9-methylguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'diazepam'}}, {'source_node': {'name': '9-methylguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'triazolam'}}, {'source_node': {'name': 'brotizolam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '9-methylguanine'}}, {'source_node': {'name': 'brotizolam'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'lofexidine'}}, {'source_node': {'name': 'brotizolam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lisofylline'}}, {'source_node': {'name': 'lisofylline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clonazepam'}}, {'source_node': {'name': 'lisofylline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nitrazepam'}}, {'source_node': {'name': 'lisofylline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'medazepam'}}]","[{'source_node': {'name': '9-methylguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'diazepam'}}, {'source_node': {'name': 'lisofylline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clonazepam'}}, {'source_node': {'name': 'lisofylline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nitrazepam'}}, {'source_node': {'name': 'lisofylline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'medazepam'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:7962', 'target': None, 'metadata': {'node_id': '7962', 'node_type': 'COMPOUND', 'display_name': 'brotizolam'}}, {'type': 'node_removal', 'source': 'COMPOUND:880', 'target': None, 'metadata': {'node_id': '880', 'node_type': 'COMPOUND', 'display_name': 'triazolam'}}]",0.5882352941176471,5583ad6270289a821909d79f6fc2fad9,5e8bfa130ede5a6128c15f94654b1720,"['The drug 9-methylguanine has been noted to decrease the efficacy of both diazepam and triazolam. Interestingly, the efficacy of 9-methylguanine itself is diminished by the drug brotizolam. On the other hand, brotizolam enhances the efficacy of lofexidine but reduces that of lisofylline. Continuing the cycle of interactions, the function of lisofylline in turn, decreases the efficacy of several other drugs including clonazepam, nitrazepam, and medazepam.', 'The substance 9-methylguanine is known to decrease the efficacy of drugs like diazepam and triazolam. Similarly, the drug brotizolam reduces the efficiency of 9-methylguanine, while it increases the efficacy of lofexidine. Strikingly, this same drug, brotizolam, lowers the efficacy of another drug called lisofylline. Lisofylline in turn, appears to decrease the efficacy of several medications such as clonazepam, nitrazepam, and medazepam. This complex interplay between these entities highlights the intricate nature of drug interactions.', 'The compound 9-methylguanine is demonstrated to decrease the efficacy of both diazepam and triazolam. Interestingly enough, the efficacy of 9-methylguanine itself is decreased by a drug known as brotizolam, revealing a complex relationship between these three entities. Brotizolam adds another layer to this interaction as it has been observed to increase the efficacy of lofexidine while also decreasing the efficacy of lisofylline, another drug. This multifaceted interplay goes even further as lisofylline has been shown to decrease the efficacy of multiple drugs; namely clonazepam, nitrazepam, and medazepam. Therefore, the interconnected impact of these substances should be taken into account in pharmacological studies and treatments.', ""The compound 9-methylguanine is known to decrease the efficacy of several drugs including diazepam and triazolam. Interestingly, there is also a feedback loop where the drug brotizolam decreases the efficacy of 9-methylguanine. Brotizolam not only interacts with 9-methylguanine, but also plays a role in increasing the efficacy of the drug lofexidine and decreasing the efficacy of another drug known as lisofylline. Consequently, lisofylline, in turn, impacts the efficacy of other drugs as it decreases the efficacy of clonazepam, nitrazepam, and medazepam. It's important to consider these interactions to avoid potential drug resistance or reduced drug performance."", ""The efficacy of certain drugs is found to be affected by the presence of others. The drug 9-methylguanine has been observed to decrease the efficacy of diazepam and triazolam. Similarly, brotizolam decreases the efficacy of 9-methylguanine but increases the efficacy of lofexidine. Interestingly, brotizolam is also known to decrease the efficacy of lisofylline. Additionally, lisofylline has been found to decrease the efficacy of clonazepam, nitrazepam, and medazepam. The interconnected effects of these drugs on each other's efficacy proposes a complex interaction pattern and presents an opportunity for further exploration in order to optimize drug dosages and combinations.""]","['The influence of different substances on the efficacy of certain medications is quite remarkable. For instance, 9-methylguanine has been found to decrease the efficacy of diazepam. Similarly, the compound lisofylline appears to interact negatively with various substances and can actually decrease the efficacy of drugs such as clonazepam, nitrazepam, and medazepam.', '9-methylguanine and lisofylline are both active substances known to influence the efficiency of some drugs. Specifically, 9-methylguanine is identified to decrease the efficacy of diazepam, a medication used for the treatment of various conditions like anxiety, seizures, and alcohol withdrawal. On the other hand, lisofylline is noted to decrease the efficacy of a range of benzodiazepines, including clonazepam, nitrazepam, and medazepam. These benzodiazepines are predominantly used as sedatives or anticonvulsants. The decrease in efficacy imposed by these active substances could potentially alter the intended effects of these drugs. Therefore, the interactions between them must be carefully considered in pharmaceutical contexts.', 'The chemical compound 9-methylguanine has been shown to decrease the efficacy of the sedative drug, diazepam. Meanwhile, Lisofylline, another compound, is known to decrease the efficacy of several benzodiazepine class drugs including clonazepam, nitrazepam, and medazepam. Therefore, administering these compounds concurrently may result in a reduced therapeutic effect.', 'The compound 9-methylguanine has been observed to decrease the efficacy of the drug diazepam. Similarly, the compound lisofylline has been noted to decrease the efficacy of several benzodiazepines, namely clonazepam, nitrazepam, and medazepam. This illustrates how certain compounds can interfere with the action of various medications, potentially impacting their therapeutic effect.', 'The drug 9-methylguanine has been found to decrease the efficacy of diazepam. Concurrently, lisofylline, another drug is known to reduce the effectiveness of several medication including clonazepam, nitrazepam and medazepam. This decrease in efficacy is significant and should be taken into account when combining these specific drug treatments.']"
"[{'source_node': {'name': '1-hexanol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'thyroid hormone receptor beta'}}, {'source_node': {'name': '1-hexanol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear factor erythroid 2-related factor 2'}}]","[{'source_node': {'name': '1-hexanol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'thyroid hormone receptor beta'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5907', 'target': None, 'metadata': {'node_id': '5907', 'node_type': 'PROTEIN', 'display_name': 'nuclear factor erythroid 2-related factor 2'}}]",0.6,7a6fe93762bb907439a6a6b574431035,c4e9bb212b64ce08a8ee329418d7bb81,"[""1-Hexanol, an organic compound, has two distinct molecular targets: thyroid hormone receptor beta and nuclear factor erythroid 2-related factor 2. These targets play integral roles in cellular regulation and response, contributing to the compound's biological effects in organisms."", 'The compound 1-hexanol has multiple biological targets which include thyroid hormone receptor beta and nuclear factor erythroid 2-related factor 2.', 'The compound 1-hexanol has two significant targets. It targets the thyroid hormone receptor beta, a critical player in thyroid hormone function, and it also interacts with the nuclear factor erythroid 2-related factor 2, a prominent factor in the regulation of oxidative stress response in cells.', 'The chemical compound 1-hexanol has multiple targets. These include both the thyroid hormone receptor beta and the nuclear factor erythroid 2-related factor 2.', 'The compound 1-hexanol targets both the thyroid hormone receptor beta and the nuclear factor erythroid 2-related factor 2.']","['The substance 1-hexanol targets the thyroid hormone receptor beta.', 'The chemical compound 1-hexanol is known to target the thyroid hormone receptor beta.']"
"[{'source_node': {'name': 'nitisinone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Alopecia'}}, {'source_node': {'name': 'nitisinone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Dermatitis exfoliative'}}, {'source_node': {'name': 'nitisinone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Hepatomegaly'}}]","[{'source_node': {'name': 'nitisinone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Hepatomegaly'}}]","[{'type': 'node_removal', 'source': 'SIDE_EFFECT:649', 'target': None, 'metadata': {'node_id': '649', 'node_type': 'SIDE_EFFECT', 'display_name': 'Dermatitis exfoliative'}}, {'type': 'node_removal', 'source': 'SIDE_EFFECT:158', 'target': None, 'metadata': {'node_id': '158', 'node_type': 'SIDE_EFFECT', 'display_name': 'Alopecia'}}]",0.4285714285714286,717f4ca519c319e0afdeb97e68070e0e,94ac8f9db440a5e9936ab81e1cab8cdc,"['The drug Nitisinone is known to have several side effects, including triggering alopecia, causing dermatitis exfoliative, and leading to hepatomegaly.', 'The drug nitisinone is known to have multiple side effects which include alopecia, a condition causing hair loss, dermatitis exfoliative, an inflammation of the skin leading to skin peeling, and hepatomegaly, a condition wherein the liver becomes abnormally enlarged.', 'Nitisinone, a drug used for treating certain medical conditions, can cause several side effects. These include alopecia, a condition characterized by hair loss, dermatitis exfoliative, which is a type of skin inflammation that results in skin peeling, and hepatomegaly, a condition characterized by the enlargement of the liver.', 'The drug nitisinone has been noted for several side effects, including alopecia, exfoliative dermatitis, and hepatomegaly.', 'The medication nitisinone is associated with several side effects including alopecia, exfoliative dermatitis, and hepatomegaly.']","['The drug nitisinone is known to have a side effect of causing Hepatomegaly.', 'The drug nitisinone is known to have hepatomegaly as a side effect.', 'The drug nitisinone is known to have a side effect of causing hepatomegaly.', 'The drug nitisinone has been associated with the side effect of hepatomegaly.', 'The drug nitisinone has a known side effect of causing hepatomegaly.']"
"[{'source_node': {'name': 'levopropoxyphene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trimethadione'}}, {'source_node': {'name': 'levopropoxyphene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'delorazepam'}}, {'source_node': {'name': 'levopropoxyphene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'vinpocetine'}}, {'source_node': {'name': 'vinpocetine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'glycerin'}}]","[{'source_node': {'name': 'levopropoxyphene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trimethadione'}}, {'source_node': {'name': 'levopropoxyphene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'delorazepam'}}, {'source_node': {'name': 'levopropoxyphene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'vinpocetine'}}, {'source_node': {'name': 'levopropoxyphene'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'glycerin'}}, {'source_node': {'name': 'vinpocetine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'glycerin'}}, {'source_node': {'name': 'vinpocetine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'levopropoxyphene'}}, {'source_node': {'name': 'delorazepam'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'glycerin'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:10040', 'target': 'COMPOUND:5840', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1443', 'target': 'COMPOUND:8342', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5840', 'target': 'COMPOUND:8342', 'metadata': {'predicate': 'increase_efficacy'}}]",0.6666666666666667,907c6b8e109c7401457d696338043afd,1b96062bf706ed75de2fa22dcc3ec25d,"['The drug levopropoxyphene is known to decrease the efficacy of various medications including trimethadione, delorazepam, and vinpocetine. Furthermore, it has been observed that vinpocetine can also decrease the efficacy of glycerin. This information is particularly crucial for clinicians to consider when prescribing these medications, to ensure effective treatment outcomes.', 'The administration of levopropoxyphene, a synthetic opioid drug, has been found to decrease the efficacy of several other medications. These include trimethadione, an anticonvulsant, and delorazepam, which is an anxiolytic and sedative. Interestingly, the efficacy of vinpocetine, typically used to improve brain metabolism, is also decreased by levopropoxyphene. Another layer of interaction is observed as vinpocetine in turn decreases the efficacy of glycerin, a compound often used in various pharmaceutical formulations. Thus, careful consideration is required while prescribing these drugs concurrently.', 'The drug Levopropoxyphene is known to decrease the efficacy of several other drugs including Trimethadione, Delorazepam, and Vinpocetine. Moreover, Vinpocetine also has an impact on the effectiveness of Glycerin, as it decreases its efficacy. Therefore, caution should be exercised when combining Levopropoxyphene and Vinpocetine with these particular drugs.', 'The drug levopropoxyphene is known to decrease the efficacy of several other drugs including trimethadione, delorazepam, and vinpocetine. Interestingly, vinpocetine also has a similar effect on glycerin, as it decreases its efficacy.', 'The drug Levopropoxyphene has been found to decrease the efficacy of several other medications including Trimethadione, Delorazepam, and Vinpocetine. Moreover, Vinpocetine itself is known to diminish the effectiveness of Glycerin when administered concurrently. Hence, caution is recommended when combining these substances in a treatment regimen.']","['Levopropoxyphene, a pharmaceutical drug, has been found to decrease the efficacy of several other drugs, namely trimethadione, delorazepam and vinpocetine. Further, it is intriguing to observe that while levopropoxyphene raises the efficacy of glycerin, vinpocetine acts contrarily, reducing the effectiveness of glycerin. Interestingly, vinpocetine also reduces the efficacy of levopropoxyphene. Adding another layer of complexity in these interactions, delorazepam actually bolsters the effectiveness of glycerin. Therefore, these intricate and somewhat paradoxical interactions obligate careful consideration of combinations and sequences when these drugs are administered.', 'The drug Levopropoxyphene is known to decrease the efficacy of Trimethadione, Delorazepam, and Vinpocetine. Interestingly, while Levopropoxyphene reduces the efficacy of Vinpocetine, the drug relationship is mutual as Vinpocetine in return also decreases the efficacy of Levopropoxyphene. Furthermore, Levopropoxyphene contrary to its interactions with these drugs, increases the efficacy of Glycerin. Interestingly this is not the only drug to positively interact with Glycerin, Delorazepam also shows an increased efficacy when interacting with Glycerin. However, the interaction between Vinpocetine and Glycerin is adverse which results in decreased efficacy of Glycerin.', 'Levopropoxyphene, a drug often used in medical treatments, has various interactions that can both decrease and increase the efficacy of other drugs. Specifically, it has been found to decrease the efficacy of trimethadione, delorazepam, and vinpocetine. However, levopropoxyphene has an unusual reaction with glycerin as it unexpectedly increases its efficacy. On the other hand, vinpocetine is known to decrease the efficacy of both glycerin and levopropoxyphene itself. Interestingly, delorazepam, like levopropoxyphene, also increases the efficacy of glycerin. These interactions are crucial in understanding the pharmacodynamics, and caution should be exercised when these drugs are prescribed concurrently.', 'Levopropoxyphene, a medication, has been found to decrease the efficacy of several other drugs like trimethadione, delorazepam, and vinpocetine. This means it may make these drugs less effective, leading to a potential diminishment in treatment outcomes. Interestingly, levopropoxyphene has the opposite effect on glycerin; it has been shown to actually increase the efficacy of glycerin. Vinpocetine, on the other hand, does not only have its efficacy decreased by levopropoxyphene but also has the same diminishing effect on glycerin and even reciprocates the effect on levopropoxyphene itself. Delorazepam is another drug to take note of as it follows a similar pattern to levopropoxyphene, exhibiting an increase in the efficacy of glycerin. These complex interactions underline the delicate balance in multi-drug treatments and the importance of fully understanding medication interactions.', 'Levopropoxyphene, a pharmaceutical drug, exhibits complex interactions with several other drugs. Particularly, it decreases the efficacy of trimethadione, delorazepam, and vinpocetine. Interestingly, while it reduces the efficacy of vinpocetine, vinpocetine also has a similar effect on the efficacy of levopropoxyphene. Nevertheless, levopropoxyphene is observed to increase the efficacy of glycerin, an effect that delorazepam also shares. Vinpocetine, on the other hand, decreases the efficacy of glycerin. These complexities highlight the critical need for constant pharmaceutical review when prescribing combinations of drugs.']"
"[{'source_node': {'name': 'phosphonotyrosine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'proto-oncogene tyrosine-protein kinase src'}}, {'source_node': {'name': 'phosphonotyrosine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mast/stem cell growth factor receptor kit'}}, {'source_node': {'name': 'phosphonotyrosine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 11'}}, {'source_node': {'name': 'proto-oncogene tyrosine-protein kinase src'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SRC'}}, {'source_node': {'name': 'mast/stem cell growth factor receptor kit'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KIT'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 11'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN11'}}, {'source_node': {'name': 'SRC'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Signaling by ALK'}}]","[{'source_node': {'name': 'proto-oncogene tyrosine-protein kinase src'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SRC'}}, {'source_node': {'name': 'mast/stem cell growth factor receptor kit'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KIT'}}, {'source_node': {'name': 'mast/stem cell growth factor receptor kit'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SRC'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 11'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN11'}}, {'source_node': {'name': 'SRC'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Signaling by ALK'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:1860', 'target': None, 'metadata': {'node_id': '1860', 'node_type': 'COMPOUND', 'display_name': 'phosphonotyrosine'}}, {'type': 'edge_addition', 'source': 'PROTEIN:1112', 'target': 'GENE:33030', 'metadata': {'predicate': 'gene_product_of'}}]",0.6666666666666667,5a87de37f4ea728bf90a9ded75d63d13,8e5a13720e6f521e8a2f276ee562ccee,"['The compound phosphonotyrosine has several identified targets: proto-oncogene tyrosine-protein kinase src, mast/stem cell growth factor receptor kit, and the tyrosine-protein phosphatase non-receptor type 11. The proto-oncogene tyrosine-protein kinase src is a gene product of SRC, which is known to act within the signaling by ALK pathway. Similarly, the mast/stem cell growth factor receptor kit is a gene product of KIT. Lastly, the tyrosine-protein phosphatase non-receptor type 11 is a gene product of PTPN11. All these gene products play crucial roles in various cellular pathways.']",[]
"[{'source_node': {'name': '3-octadecanoyloxy-4-(trimethylazaniumyl)butanoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histone-lysine n-methyltransferase'}}, {'source_node': {'name': '3-octadecanoyloxy-4-(trimethylazaniumyl)butanoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ubiquitin carboxyl-terminal hydrolase 1'}}, {'source_node': {'name': '3-octadecanoyloxy-4-(trimethylazaniumyl)butanoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': '78 kda glucose-regulated protein'}}, {'source_node': {'name': 'histone-lysine n-methyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DOT1L'}}, {'source_node': {'name': 'histone-lysine n-methyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'EHMT1'}}, {'source_node': {'name': 'histone-lysine n-methyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'EHMT2'}}]","[{'source_node': {'name': '3-octadecanoyloxy-4-(trimethylazaniumyl)butanoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ubiquitin carboxyl-terminal hydrolase 1'}}, {'source_node': {'name': '3-octadecanoyloxy-4-(trimethylazaniumyl)butanoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': '78 kda glucose-regulated protein'}}, {'source_node': {'name': '3-octadecanoyloxy-4-(trimethylazaniumyl)butanoate'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'DOT1L'}}, {'source_node': {'name': 'histone-lysine n-methyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DOT1L'}}, {'source_node': {'name': '78 kda glucose-regulated protein'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DOT1L'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:59944', 'target': 'PROTEIN:6168', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:33870', 'target': None, 'metadata': {'node_id': '33870', 'node_type': 'GENE', 'display_name': 'EHMT1'}}, {'type': 'node_removal', 'source': 'GENE:25189', 'target': None, 'metadata': {'node_id': '25189', 'node_type': 'GENE', 'display_name': 'EHMT2'}}, {'type': 'edge_addition', 'source': 'PROTEIN:49', 'target': 'GENE:34471', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'COMPOUND:59944', 'target': 'GENE:34471', 'metadata': {'predicate': 'is_affecting'}}]",0.4615384615384615,91353ca47a406d656cfbde8b06479c5e,01c6dde0c9635cfb8d8dc7654ffe41c9,"[""The substance 3-octadecanoyloxy-4-(trimethylazaniumyl)butanoate exhibits targeting properties towards several biochemical entities, which include histone-lysine n-methyltransferase, ubiquitin carboxyl-terminal hydrolase 1, and the 78 kda glucose-regulated protein. It's worth noting that histone-lysine n-methyltransferase is a unique gene product of several genes, namely, DOT1L, EHMT1, and EHMT2."", 'The compound 3-octadecanoyloxy-4-(trimethylazaniumyl)butanoate targets several proteins including the histone-lysine N-methyltransferase, the ubiquitin carboxyl-terminal hydrolase 1, and the 78 kDa glucose-regulated protein. It is further interesting to note that the histone-lysine N-methyltransferase is the gene product of several genes, including DOT1L, EHMT1, and EHMT2.', '3-Octadecanoyloxy-4-(trimethylazaniumyl)butanoate is a substance that targets several biomolecules, specifically histone-lysine N-methyltransferase, ubiquitin carboxyl-terminal hydrolase 1, and the 78 kda glucose-regulated protein. Further, the histone-lysine N-methyltransferase is a gene product of several genes including DOT1L, EHMT1, and EHMT2.', 'The compound 3-octadecanoyloxy-4-(trimethylazaniumyl)butanoate targets multiple proteins including the histone-lysine N-methyltransferase, ubiquitin carboxyl-terminal hydrolase 1, and the 78 kDa glucose-regulated protein. The histone-lysine N-methyltransferase is the gene product of several genes including DOT1L, EHMT1, and EHMT2.', 'The compound 3-octadecanoyloxy-4-(trimethylazaniumyl)butanoate, has several biochemical targets. These include the histone-lysine n-methyltransferase, ubiquitin carboxyl-terminal hydrolase 1, and the 78 kda glucose-regulated protein. Histone-lysine n-methyltransferase is a gene product known to be associated with multiple genes such as DOT1L, EHMT1 and EHMT2.']","['The molecule 3-octadecanoyloxy-4-(trimethylazaniumyl)butanoate targets two entities, namely the ubiquitin carboxyl-terminal hydrolase 1 and the 78 kDa glucose-regulated protein. Interestingly, this glucose-regulated protein is a gene product of DOT1L, just like the histone-lysine N-methyltransferase. In addition, the compound also affects DOT1L directly.', 'The compound, 3-octadecanoyloxy-4-(trimethylazaniumyl)butanoate, targets both the ubiquitin carboxyl-terminal hydrolase 1 and the 78 kda glucose-regulated protein. Interestingly, this compound also appears to affect the function of DOT1L. It should be noted that the 78 kda glucose-regulated protein is a gene product of DOT1L, as is the histone-lysine n-methyltransferase.']"
"[{'source_node': {'name': 'elsahy-waters syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'posteriorly rotated ears'}}, {'source_node': {'name': 'elsahy-waters syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'midface retrusion'}}, {'source_node': {'name': 'elsahy-waters syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'facial asymmetry'}}, {'source_node': {'name': 'teebi hypertelorism syndrome 2'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'delayed eruption of teeth'}}, {'source_node': {'name': 'teebi hypertelorism syndrome 2'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'proptosis'}}, {'source_node': {'name': 'CDH11'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'elsahy-waters syndrome'}}, {'source_node': {'name': 'CDH11'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'teebi hypertelorism syndrome 2'}}, {'source_node': {'name': 'CDH11'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'branchioskeletogenital syndrome'}}]","[{'source_node': {'name': 'elsahy-waters syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'posteriorly rotated ears'}}, {'source_node': {'name': 'elsahy-waters syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'midface retrusion'}}, {'source_node': {'name': 'elsahy-waters syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'facial asymmetry'}}, {'source_node': {'name': 'teebi hypertelorism syndrome 2'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'delayed eruption of teeth'}}, {'source_node': {'name': 'teebi hypertelorism syndrome 2'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'proptosis'}}, {'source_node': {'name': 'CDH11'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'branchioskeletogenital syndrome'}}]","[{'type': 'edge_deletion', 'source': 'GENE:24671', 'target': 'DISEASE:18091', 'metadata': None}, {'type': 'edge_deletion', 'source': 'GENE:24671', 'target': 'DISEASE:4905', 'metadata': None}]",0.8823529411764706,e0a91915b75271662a44c871de0c1c3d,b2d17f88e98a28eaed0b78ce51709652,"['The gene CDH11 is implicated in the causation of several syndromes including Elsahy-Waters syndrome, Teebi Hypertelorism syndrome 2, and Branchioskeletogenital syndrome. Elsahy-Waters syndrome presents diverse phenotypes such as posteriorly rotated ears, midface retrusion and facial asymmetry, whereas Teebi Hypertelorism syndrome 2 is characterized by delayed eruption of teeth and proptosis.', 'The gene CDH11 has been linked to several diverse conditions. Specifically, mutation in CDH11 can lead to Elsahy-Waters syndrome, a rare genetic disorder characterized by symptoms such as facial asymmetry, midface retrusion, and posteriorly rotated ears. In addition, mutations in the same gene can cause Teebi Hypertelorism syndrome 2, a condition characterized by proptosis and delayed eruption of teeth. In a broader scope, CDH11 also plays a causative role in Branchioskeletogenital syndrome symbolizing the diversity of phenotypes that can result from disruption in this single gene.', 'The gene CDH11 is associated with causing several conditions. One of them is the Elsahy-Waters syndrome, a disorder characterized by phenotypes such as posteriorly rotated ears, midface retrusion, and facial asymmetry. Additionally, this gene is also known to cause Teebi Hypertelorism syndrome 2, a condition marked with delayed eruption of teeth and proptosis. Moreover, the CDH11 gene is implicated in causing the Branchioskeletogenital syndrome as well.', 'The gene CDH11 is known to cause several conditions including Elsahy-Waters syndrome, Teebi Hypertelorism Syndrome 2, and Branchioskeletogenital syndrome. The Elsahy-Waters syndrome is characterized by a series of phenotypes such as posteriorly rotated ears, midface retrusion, and facial asymmetry. In the case of Teebi Hypertelorism Syndrome 2, the condition exhibits phenotypes like delayed eruption of teeth and proptosis.', 'The gene CDH11 has been associated with various conditions like elsahy-waters syndrome, teebi hypertelorism syndrome 2, and branchioskeletogenital syndrome. Elsahy-waters syndrome is characterized by phenotypes like posteriorly rotated ears, midface retrusion, and facial asymmetry. Teebi hypertelorism syndrome 2, on the other hand, is identifiable by evidently delayed eruption of teeth and proptosis.']","['Elsahy-waters syndrome is characterized by several distinct phenotypes including posteriorly rotated ears, midface retrusion, and facial asymmetry. Another condition known as Teebi hypertelorism syndrome 2 exhibits a different set of phenotypes such as delayed eruption of teeth and proptosis. The gene CDH11 is also known to cause branchioskeletogenital syndrome, a condition affecting the development of the branchial arches, skeleton, and genitalia.', ""Elsahy-Waters syndrome, a medical condition, displays a phenotype characterized by posteriorly rotated ears, midface retrusion, and facial asymmetry. Another syndrome termed Teebi Hypertelorism syndrome 2, shows its effect through delayed eruption of teeth and proptosis as its noteworthy phenotypic traits. It's also of great significance to note that the gene CDH11 plays a pivotal role in causing a condition known as Branchioskeletogenital syndrome."", 'Elsahy-Waters syndrome and Teebi Hypertelorism syndrome 2 are two conditions with distinct phenotypes. Elsahy-Waters syndrome is characterized by the presence of posteriorly rotated ears, midface retrusion and facial asymmetry. On the other hand, Teebi Hypertelorism syndrome 2 is associated with delayed eruption of teeth and proptosis. Moreover, the gene CDH11 is known to cause a condition known as Branchioskeletogenital syndrome.', 'Elsahy-Waters syndrome and Teebi Hypertelorism syndrome 2 are known diseases with specific attributes. Elsahy-Waters syndrome is characterized by several phenotypes including posteriorly rotated ears, midface retrusion, and facial asymmetry. On the other hand, Teebi Hypertelorism syndrome 2 showcases phenotypes like delayed eruption of teeth and proptosis. Interestingly, the gene CDH11 is known to cause a different condition known as Branchioskeletogenital syndrome.', 'Elsahy-Waters syndrome is a condition characterized by distinct phenotypic features such as posteriorly rotated ears, midface retrusion and facial asymmetry. Similarly, Teebi Hypertelorism syndrome 2 exhibits symptoms which include delayed eruption of teeth and proptosis. On the genetic level, the gene CDH11 has been identified as a cause of Branchioskeletogenital Syndrome, a condition with its own unique set of characteristics.']"
"[{'source_node': {'name': 'ARSG'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'usher syndrome'}}, {'source_node': {'name': 'ARSG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glycosphingolipid metabolism'}}, {'source_node': {'name': 'ARSG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'The activation of arylsulfatases'}}]","[{'source_node': {'name': 'ARSG'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'usher syndrome'}}, {'source_node': {'name': 'ARSG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'The activation of arylsulfatases'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:894', 'target': None, 'metadata': {'node_id': '894', 'node_type': 'PATHWAY', 'display_name': 'Glycosphingolipid metabolism'}}]",0.7142857142857143,24b3da85e87fcdd0ae000a0eb23bc354,4ae5271ddeae648f4b1bf7dc312de44d,"['The gene ARSG, active within the spheres of glycosphingolipid metabolism and in the activation of arylsulfatases, is known to cause a condition known as Usher Syndrome.', 'The gene ARSG plays a role in several biochemical processes. Firstly, it acts within the glycosphingolipid metabolism pathway, which involves the breakdown and synthesis of various cellular components. Additionally, ARSG is also active in the pathway for the activation of arylsulfatases, enzymes that are central to cellular function. Notably, mutations in ARSG are known to cause Usher syndrome, a rare genetic disorder resulting in a combination of hearing loss and visual impairment.']","['The gene ARSG, which functions within the process of arylsulfatases activation, has been found to cause Usher syndrome. Usher syndrome is a range of conditions primarily affecting hearing and vision.']"
"[{'source_node': {'name': 'MSTN'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'muscle hypertrophy'}}, {'source_node': {'name': 'MSTN'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'FOXO-mediated transcription of cell cycle genes'}}, {'source_node': {'name': 'growth/differentiation factor 8'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MSTN'}}]","[{'source_node': {'name': 'growth/differentiation factor 8'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MSTN'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:500', 'target': None, 'metadata': {'node_id': '500', 'node_type': 'PATHWAY', 'display_name': 'FOXO-mediated transcription of cell cycle genes'}}, {'type': 'node_removal', 'source': 'DISEASE:13843', 'target': None, 'metadata': {'node_id': '13843', 'node_type': 'DISEASE', 'display_name': 'muscle hypertrophy'}}]",0.4285714285714286,6b4f49c3636a9274a757f222ec0d394a,9bc02a61e5b7a569e67c814813f2aec4,"['The gene MSTN, also known as growth/differentiation factor 8, participates in the FOXO-mediated transcription of cell cycle genes. Notably, alterations in MSTN are responsible for inducing conditions such as muscle hypertrophy.', 'The gene product of growth/differentiation factor 8 is MSTN, which acts within the FOXO-mediated transcription of cell cycle genes pathway and causes muscle hypertrophy.', 'The gene growth/differentiation factor 8 is a product of MSTN, which is involved in the FOXO-mediated transcription of cell cycle genes. The MSTN gene also leads to a condition known as muscle hypertrophy.', 'The gene MSTN, which is the product of the growth/differentiation factor 8, plays two crucial roles. It acts within the FOXO-mediated transcription of cell cycle genes and also causes muscle hypertrophy - a condition characterized by an abnormal enlargement of muscle cells.']","['The protein known as growth/differentiation factor 8 is a gene product of MSTN.', 'The protein known as growth/differentiation factor 8 is a gene product of MSTN.', 'The protein known as growth/differentiation factor 8 is a gene product of MSTN.', 'The growth/differentiation factor 8 is a gene product of MSTN.']"
"[{'source_node': {'name': '(s)-methadone'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 2 subfamily b member 6'}}, {'source_node': {'name': '(s)-methadone'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}}, {'source_node': {'name': '(s)-methadone'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 3 subfamily a member 4'}}, {'source_node': {'name': 'cytochrome p450 family 3 subfamily a member 4'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'heart transplantation'}}, {'source_node': {'name': 'cytochrome p450 family 3 subfamily a member 4'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'malaria'}}, {'source_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'gastrointestinal neoplasms'}}, {'source_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'depressive disorder'}}, {'source_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'alcoholic psychosis nos'}}]","[{'source_node': {'name': '(s)-methadone'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 3 subfamily a member 4'}}, {'source_node': {'name': 'cytochrome p450 family 3 subfamily a member 4'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'heart transplantation'}}, {'source_node': {'name': 'cytochrome p450 family 3 subfamily a member 4'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'malaria'}}, {'source_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'gastrointestinal neoplasms'}}, {'source_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'depressive disorder'}}, {'source_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'alcoholic psychosis nos'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:90712', 'target': 'GENE:4352', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:4346', 'target': None, 'metadata': {'node_id': '4346', 'node_type': 'GENE', 'display_name': 'cytochrome p450 family 2 subfamily b member 6'}}]",0.8235294117647058,e7d4f72826ba504093092a1550ec0328,aae7904686c1550e0ed9835f180a0442,[],"['The drug (S)-methadone is known to affect the enzyme cytochrome p450 family 3 subfamily a member 4. Interestingly, this enzyme has been linked to the onset of various conditions like heart transplantation and malaria. On a related note, the cytochrome p450 family 2 subfamily d member 6 enzyme is also implicated in several different health issues. Specifically, it has the capability to cause conditions including gastrointestinal neoplasms, depressive disorder and Alcoholic Psychosis NOS. Clearly, these discoveries highlight the integral role of cytochrome P450 enzymes in driving various disease processes and the effect that drugs like (S)-methadone can have on their function.', 'The drug (S)-Methadone is known to affect Cytochrome P450 family 3 subfamily A member 4, which itself is associated with causing conditions such as heart transplantation and malaria. Likewise, another family member, Cytochrome P450 family 2 subfamily D member 6, has been implicated in causing a range of conditions including gastrointestinal neoplasms, depressive disorder, and alcoholic psychosis NOS.']"
"[{'source_node': {'name': 'tripartite motif containing 5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'ovarian neoplasms'}}, {'source_node': {'name': 'tripartite motif containing 5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'overall survival'}}]","[{'source_node': {'name': 'tripartite motif containing 5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'overall survival'}}]","[{'type': 'node_removal', 'source': 'DISEASE:2379', 'target': None, 'metadata': {'node_id': '2379', 'node_type': 'DISEASE', 'display_name': 'ovarian neoplasms'}}]",0.6,31947c7539efe87e9afc73932f79ecf1,400d94dc4d465b4b0525c1adbab0c88a,[],[]
"[{'source_node': {'name': 'basiliximab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rindopepimut'}}, {'source_node': {'name': 'basiliximab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'varicella zoster vaccine (recombinant)'}}, {'source_node': {'name': 'basiliximab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imlifidase'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'adalimumab'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'motavizumab'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'apolizumab'}}]","[{'source_node': {'name': 'adalimumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'apolizumab'}}, {'source_node': {'name': 'basiliximab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rindopepimut'}}, {'source_node': {'name': 'basiliximab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'varicella zoster vaccine (recombinant)'}}, {'source_node': {'name': 'basiliximab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imlifidase'}}, {'source_node': {'name': 'basiliximab'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'apolizumab'}}, {'source_node': {'name': 'basiliximab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'adalimumab'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'adalimumab'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'motavizumab'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'apolizumab'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'varicella zoster vaccine (recombinant)'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:71', 'target': 'COMPOUND:5607', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:49', 'target': 'COMPOUND:5607', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:71', 'target': 'COMPOUND:49', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:12843', 'target': 'COMPOUND:11765', 'metadata': {'predicate': 'increase_efficacy'}}]",0.6923076923076923,724eb802cda5fa9dad0084372ba634ca,a5d84c0ebd2df1473c7597eedc195786,"['The drug basiliximab has been found to decrease the efficacy of other drugs or therapeutic agents like rindopepimut, varicella zoster vaccine (recombinant), and imlifidase. Interestingly, imlifidase itself also reduces the efficacy of certain medications, such as adalimumab, motavizumab, and apolizumab. This decreases the effectiveness of these treatments when combined with either basiliximab or imlifidase, indicating potential contraindications for their concurrent use in treatment regimens.', 'Basiliximab, a known immunosuppressant drug, has an interesting set of interactions with other drugs affecting their efficacy. Specifically, the use of basiliximab has been found to decrease the efficacy of drugs such as rindopepimut, varicella zoster vaccine (recombinant), and imlifidase. Interestingly, imlifidase itself also shows similar inhibitory effects on other pharmaceuticals; it has been found to decrease the efficacy of adalimumab, motavizumab, and apolizumab. These findings underline the need for careful drug interaction studies in therapeutic settings.', 'Basiliximab is a drug that has shown to decrease the efficacy of several other drugs such as rindopepimut, the varicella zoster vaccine (recombinant), and imlifidase. Interestingly, imlifidase also appears to decrease the efficacy of other drugs like adalimumab, motavizumab, and apolizumab. It is crucial to consider these interactions when developing a comprehensive and effective treatment plan.', 'The medication basiliximab has been shown to decrease the efficacy of several other drugs including rindopepimut, varicella zoster vaccine (recombinant), and imlifidase. Similarly, imlifidase, whose efficacy is lowered by basiliximab, also decreases the effectiveness of several other medications such as adalimumab, motavizumab, and apolizumab. It is important to take into account these interactions when co-administering these drugs to avoid decreased therapeutic effects.', 'The drug Basiliximab is known to decrease the efficacy of several other medications like Rindopepimut, the Varicella Zoster Vaccine (recombinant), and Imlifidase. Interestingly, Imlifidase itself also decreases the efficacy of certain medications, including Adalimumab, Motavizumab, and Apolizumab. Thus, care must be taken while administering Basiliximab and Imlifidase in combination with these drugs, to avoid potential reduction in their therapeutic effectiveness.']","['The drug interactions among several pharmaceutical agents highlight contradictions in efficacy. For instance, adalimumab is observed to decrease the efficacy of apolizumab, while basiliximab does the same for rindopepimut, the varicella zoster vaccine (recombinant), imlifidase, and paradoxically, for adalimumab. Considerably, basiliximab distinctly behaves to increase the efficacy of apolizumab. Similarly, the efficacy of adalimumab, motavizumab, and apolizumab are reduced by imlifidase, however, interestingly, the efficacy of the varicella zoster vaccine (recombinant) is increased when paired with imlifidase. These nuanced interactions confirm the complexity of combined pharmaceutical treatments and the need for precision in individual patient care.', 'The administration of several drugs and vaccines can alter the efficacy of others. For instance, adalimumab can decrease the efficacy of apolizumab. Similarly, basiliximab has multiple influences. Firstly, it can decrease the efficacy of rindopepimut, varicella zoster vaccine (recombinant), imlifidase, and adalimumab. Secondly, it can enhance the efficacy of apolizumab. \n\nImlifidase also modulates the performance of other drugs. Although it can lower the efficacy of adalimumab, motavizumab, and apolizumab, it increases the efficacy of the varicella zoster vaccine (recombinant). Thus, the effects of these drugs and vaccines on each other should be considered in creating patient treatment plans.', ""The drugs adalimumab, basiliximab and imlifidase have a complex interconnection network regarding their efficacy in combination with other drugs. Adalimumab is noted to decrease the efficacy of apolizumab, while basiliximab is observed to reduce the efficacy of rindopepimut, imlifidase, varicella zoster vaccine (recombinant) and, interestingly, also adalimumab itself. However, it's worth mentioning that basiliximab increases the efficacy of apolizumab. Lastly, we have imlifidase, which is known to decrease the effectiveness of adalimumab, motavizumab and apolizumab. Nevertheless, it demonstrates an increased efficacy when interacting with varicella zoster vaccine (recombinant).""]"
"[{'source_node': {'name': 'somatostatin receptor type 5'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SSTR5'}}, {'source_node': {'name': 'SSTR5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Peptide ligand-binding receptors'}}, {'source_node': {'name': 'SSTR5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (i) signalling events'}}]","[{'source_node': {'name': 'somatostatin receptor type 5'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SSTR5'}}, {'source_node': {'name': 'SSTR5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (i) signalling events'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:253', 'target': None, 'metadata': {'node_id': '253', 'node_type': 'PATHWAY', 'display_name': 'Peptide ligand-binding receptors'}}]",0.7142857142857143,2836d12f47893107251fae06f3477698,9e3b3bf7d585e82490f94ff27f1a7952,"['Somatostatin receptor type 5 is a gene product of SSTR5. SSTR5 plays a critical role in two pathways, the peptide ligand-binding receptors and G alpha (i) signalling events.', 'The Somatostatin receptor type 5 is a gene product of SSTR5. This gene, SSTR5, acts within several signaling events and pathways, notably within the peptide ligand-binding receptors and G alpha (i) signalling events.', 'The gene product of SSTR5 is the somatostatin receptor type 5. This gene acts within a couple of networks including peptide ligand-binding receptors and G alpha (i) signalling events.']","['The gene SSTR5, which is responsible for the production of the somatostatin receptor type 5, acts within the pathway of G alpha (i) signalling events.', 'The somatostatin receptor type 5 is a gene product of SSTR5. Notably, SSTR5 acts within G alpha (i) signalling events.', 'The somatostatin receptor type 5 is a gene product of the SSTR5 gene. Notably, this SSTR5 gene acts within the pathway of G alpha (i) signalling events.', 'The receptor known as somatostatin receptor type 5 is a gene product of SSTR5. This gene SSTR5 acts within a pathway associated with G alpha (i) signalling events.', 'The somatostatin receptor type 5 is a gene product of SSTR5 which acts within the pathway of G alpha (i) signalling events.']"
"[{'source_node': {'name': 'hydrocortisone probutate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'corticosteroid 11-beta-dehydrogenase isozyme 2'}}, {'source_node': {'name': 'hydrocortisone probutate'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' electrolyte imbalance '}}, {'source_node': {'name': 'hydrocortisone probutate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'allogeneic processed thymus tissue'}}, {'source_node': {'name': 'corticosteroid 11-beta-dehydrogenase isozyme 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HSD11B2'}}, {'source_node': {'name': 'allogeneic processed thymus tissue'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'diflorasone'}}, {'source_node': {'name': 'allogeneic processed thymus tissue'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'vindesine'}}, {'source_node': {'name': 'allogeneic processed thymus tissue'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carfilzomib'}}]","[{'source_node': {'name': 'hydrocortisone probutate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'corticosteroid 11-beta-dehydrogenase isozyme 2'}}, {'source_node': {'name': 'hydrocortisone probutate'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' electrolyte imbalance '}}, {'source_node': {'name': 'vindesine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'allogeneic processed thymus tissue'}}, {'source_node': {'name': 'allogeneic processed thymus tissue'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'diflorasone'}}, {'source_node': {'name': 'allogeneic processed thymus tissue'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'vindesine'}}, {'source_node': {'name': 'allogeneic processed thymus tissue'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carfilzomib'}}, {'source_node': {'name': 'diflorasone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'allogeneic processed thymus tissue'}}, {'source_node': {'name': 'carfilzomib'}, 'relation': {'name': 'decrease_effect'}, 'target_node': {'name': ' electrolyte imbalance '}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:12280', 'target': 'COMPOUND:13820', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:28911', 'target': None, 'metadata': {'node_id': '28911', 'node_type': 'GENE', 'display_name': 'HSD11B2'}}, {'type': 'edge_addition', 'source': 'COMPOUND:213', 'target': 'COMPOUND:13820', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:7841', 'target': 'EFFECT:87', 'metadata': {'predicate': 'decrease_effect'}}, {'type': 'edge_addition', 'source': 'COMPOUND:299', 'target': 'COMPOUND:13820', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.6,441ee6e9af373301b445e2da74807f45,151471e26d43a0e5491e0ec60455f714,[],[]
"[{'source_node': {'name': 'pyridine-2,3-diol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'matrix metalloproteinase-9'}}, {'source_node': {'name': 'pyridine-2,3-diol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'neutrophil collagenase'}}, {'source_node': {'name': 'pyridine-2,3-diol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histone deacetylase 8'}}, {'source_node': {'name': 'histone deacetylase 8'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HDAC8'}}, {'source_node': {'name': 'matrix metalloproteinase-9'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MMP9'}}, {'source_node': {'name': 'neutrophil collagenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MMP8'}}, {'source_node': {'name': 'MMP9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Signaling by SCF-KIT'}}, {'source_node': {'name': 'MMP9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}]","[{'source_node': {'name': 'pyridine-2,3-diol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'matrix metalloproteinase-9'}}, {'source_node': {'name': 'pyridine-2,3-diol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histone deacetylase 8'}}, {'source_node': {'name': 'pyridine-2,3-diol'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'HDAC8'}}, {'source_node': {'name': 'pyridine-2,3-diol'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'MMP8'}}, {'source_node': {'name': 'histone deacetylase 8'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HDAC8'}}, {'source_node': {'name': 'neutrophil collagenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MMP8'}}, {'source_node': {'name': 'neutrophil collagenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HDAC8'}}]","[{'type': 'node_removal', 'source': 'GENE:29965', 'target': None, 'metadata': {'node_id': '29965', 'node_type': 'GENE', 'display_name': 'MMP9'}}, {'type': 'edge_addition', 'source': 'COMPOUND:56207', 'target': 'GENE:31660', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:1386', 'target': 'GENE:31660', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'COMPOUND:56207', 'target': 'GENE:29963', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:56207', 'target': 'PROTEIN:1386', 'metadata': None}]",0.4117647058823529,2e6960ee5c448bc34ba923245bd34727,6b48da50eeb05a068a5298f0aefef40f,"['The chemical compound pyridine-2,3-diol targets a variety of components, including matrix metalloproteinase-9, neutrophil collagenase, and histone deacetylase 8. Interestingly, each of these targets is the gene product of a specific gene: matrix metalloproteinase-9 of MMP9, neutrophil collagenase of MMP8, and histone deacetylase 8 of HDAC8. Furthermore, MMP9 functions within two pathways: the signaling by SCF-KIT and neutrophil degranulation.', 'The molecule pyridine-2,3-diol targets several entities including matrix metalloproteinase-9, neutrophil collagenase, and histone deacetylase 8. The former two, matrix metalloproteinase-9 and neutrophil collagenase, are gene products of MMP9 and MMP8 respectively. MMP9 is known to act within multiple pathways such as signaling by SCF-KIT and neutrophil degranulation. On the other hand, histone deacetylase 8 is a gene product of HDAC8.', 'The compound pyridine-2,3-diol targets a number of proteins including matrix metalloproteinase-9, neutrophil collagenase, and histone deacetylase 8. Matrix metalloproteinase-9 and neutrophil collagenase are gene products of MMP9 and MMP8, respectively. Interestingly, MMP9 acts within several pathways such as signaling by SCF-KIT and neutrophil degranulation. On the other hand, histone deacetylase 8 is a gene product of HDAC8.', 'The chemical compound pyridine-2,3-diol is known to target various biomolecules including matrix metalloproteinase-9, neutrophil collagenase, and histone deacetylase 8. Matrix metalloproteinase-9 is a gene product of MMP9, while neutrophil collagenase is a gene product of MMP8. Both of these gene products play key roles in various biological processes: MMP9 acts within the signaling by SCF-KIT process and is actively involved in neutrophil degranulation. Conversely, histone deacetylase 8, a gene product of HDAC8, has other distinct biological functions.', 'The compound pyridine-2,3-diol targets multiple proteins including matrix metalloproteinase-9, neutrophil collagenase, and histone deacetylase 8. Matrix metalloproteinase-9 is a gene product of MMP9, which acts within various biological processes such as signaling by SCF-KIT and neutrophil degranulation. Similarly, neutrophil collagenase originates from the MMP8 gene. Histone deacetylase 8 is a protein produced by the HDAC8 gene. Therefore, it is clear that the compound pyridine-2,3-diol has multiple targets and is involved in numerous biological pathways.']",[]
"[{'source_node': {'name': 'li-fraumeni syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'leukemia'}}, {'source_node': {'name': 'li-fraumeni syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'acute lymphoblastic leukemia'}}, {'source_node': {'name': 'li-fraumeni syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'prostate cancer'}}]","[{'source_node': {'name': 'li-fraumeni syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'acute lymphoblastic leukemia'}}, {'source_node': {'name': 'li-fraumeni syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'prostate cancer'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1388', 'target': None, 'metadata': {'node_id': '1388', 'node_type': 'PHENOTYPE', 'display_name': 'leukemia'}}]",0.7142857142857143,7255a18283fe3a483c8982ddb7a9cb5d,c115e797f7f244ffd431ba2b63f4370c,"['The Li-Fraumeni Syndrome, a complex disorder, exhibits various phenotypes, such as leukemia, acute lymphoblastic leukemia, and prostate cancer.', '""Li-Fraumeni syndrome, a rare genetic condition, presents several clinical phenotypes, including leukemia, acute lymphoblastic leukemia, and prostate cancer.']","['Li-Fraumeni Syndrome, a rare and complex genetic disorder, is characterized by various symptoms and conditions, including acute lymphoblastic leukemia and prostate cancer.', 'Li-Fraumeni syndrome, a rare inherited disorder, has been associated with multiple phenotypes, notably acute lymphoblastic leukemia and prostate cancer. This suggests that individuals with the syndrome are predisposed to such illnesses.', '""Li-Fraumeni Syndrome, a rare hereditary condition, manifests phenotypes such as acute lymphoblastic leukemia and prostate cancer among those who have been diagnosed with the syndrome.', 'Li-Fraumeni syndrome, a rare hereditary condition, is known to exhibit phenotypes such as acute lymphoblastic leukemia and prostate cancer. These diseases may manifest as part of the range of varied symptoms and conditions associated with this syndrome.', 'Li-Fraumeni syndrome, a rare hereditary disorder, exhibits phenotypes that include ailments such as acute lymphoblastic leukemia and prostate cancer.']"
"[{'source_node': {'name': 'rauwolfia serpentina root'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'diclofenac'}}, {'source_node': {'name': 'rauwolfia serpentina root'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phenylbutazone'}}, {'source_node': {'name': 'oxymetazoline'}, 'relation': {'name': 'increase_activity'}, 'target_node': {'name': ' the hypertensive activities '}}, {'source_node': {'name': 'oxymetazoline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trifluoperazine'}}, {'source_node': {'name': 'oxymetazoline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rauwolfia serpentina root'}}]","[{'source_node': {'name': 'rauwolfia serpentina root'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'diclofenac'}}, {'source_node': {'name': 'oxymetazoline'}, 'relation': {'name': 'increase_activity'}, 'target_node': {'name': ' the hypertensive activities '}}, {'source_node': {'name': 'oxymetazoline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trifluoperazine'}}, {'source_node': {'name': 'oxymetazoline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rauwolfia serpentina root'}}, {'source_node': {'name': 'trifluoperazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'oxymetazoline'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:795', 'target': 'COMPOUND:572', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:918', 'target': 'COMPOUND:795', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:795', 'target': None, 'metadata': {'node_id': '795', 'node_type': 'COMPOUND', 'display_name': 'phenylbutazone'}}, {'type': 'edge_addition', 'source': 'COMPOUND:814', 'target': 'COMPOUND:918', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7272727272727273,9e251124750860a690a08bcfd89802a0,ca447354a1f0e2914d6a480b87cc6f19,[],[]
"[{'source_node': {'name': 'deacetoxyvinzolidine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'calmodulin'}}, {'source_node': {'name': 'calmodulin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CALM1'}}, {'source_node': {'name': 'calmodulin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CALM2'}}, {'source_node': {'name': 'calmodulin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CALM3'}}]","[{'source_node': {'name': 'deacetoxyvinzolidine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'CALM1'}}, {'source_node': {'name': 'deacetoxyvinzolidine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'CALM2'}}, {'source_node': {'name': 'calmodulin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CALM1'}}, {'source_node': {'name': 'calmodulin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CALM2'}}, {'source_node': {'name': 'calmodulin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CALM3'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:2703', 'target': 'GENE:33953', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:2703', 'target': 'PROTEIN:1163', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:2703', 'target': 'GENE:34030', 'metadata': {'predicate': 'is_affecting'}}]",0.6666666666666667,6c53d04d35d349d8e72d34d56d4b83dc,af49e499403ee200696f54a29383762d,"['The chemical compound deacetoxyvinzolidine has calmodulin as its target. Calmodulin, a protein that plays a vital role in numerous cellular processes, is a gene product of not just one but three separate genes: CALM1, CALM2, and CALM3.', 'The drug deacetoxyvinzolidine targets calmodulin, a protein which is a product of several genes including CALM1, CALM2, and CALM3.', 'The drug deacetoxyvinzolidine targets calmodulin, a protein that acts as a gene product of multiple genes, including CALM1, CALM2 and CALM3.', 'The drug deacetoxyvinzolidine targets calmodulin, a protein which is the gene product of several genes including CALM1, CALM2, and CALM3.', 'The molecule deacetoxyvinzolidine has a target in the protein calmodulin. This protein calmodulin is a gene product of several genes including CALM1, CALM2, and CALM3.']",[]
"[{'source_node': {'name': 'itaconate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'androgen receptor'}}, {'source_node': {'name': 'itaconate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor delta'}}, {'source_node': {'name': 'androgen receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AR'}}]","[{'source_node': {'name': 'itaconate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'androgen receptor'}}]","[{'type': 'node_removal', 'source': 'GENE:29295', 'target': None, 'metadata': {'node_id': '29295', 'node_type': 'GENE', 'display_name': 'AR'}}, {'type': 'node_removal', 'source': 'PROTEIN:358', 'target': None, 'metadata': {'node_id': '358', 'node_type': 'PROTEIN', 'display_name': 'peroxisome proliferator-activated receptor delta'}}]",0.4285714285714286,c4bfdcb1fa3ee294a3709d3b75fc60aa,23ba14e1bc718a984c712178c891ecd0,"[""The molecule itaconate targets the androgen receptor and the peroxisome proliferator-activated receptor delta in the body. It's noteworthy that the androgen receptor is a gene product of AR."", 'Itaconate is a substance that targets both the androgen receptor and the peroxisome proliferator-activated receptor delta. Furthermore, the androgen receptor is the gene product of AR.', 'The molecule itaconate targets the androgen receptor and the peroxisome proliferator-activated receptor delta. Notably, the androgen receptor is a gene product of AR.', 'Itaconate is a compound known to target both the androgen receptor and the peroxisome proliferator-activated receptor delta. Interestingly, the androgen receptor is actually a gene product of AR.', 'Itaconate, a metabolic product, prominently targets two receptors: the androgen receptor and the peroxisome proliferator-activated receptor delta. Interestingly, the androgen receptor is a gene product of the AR gene.']",[]
"[{'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'oxybuprocaine'}}, {'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Leukaemoid reaction'}}, {'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Urinary retention'}}, {'source_node': {'name': 'saredutant'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the sedative activities '}}, {'source_node': {'name': 'saredutant'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pregabalin'}}, {'source_node': {'name': 'saredutant'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'lofexidine'}}]","[{'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'oxybuprocaine'}}, {'source_node': {'name': 'pregabalin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Urinary retention'}}, {'source_node': {'name': 'saredutant'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the sedative activities '}}, {'source_node': {'name': 'saredutant'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'lofexidine'}}, {'source_node': {'name': 'saredutant'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Urinary retention'}}, {'source_node': {'name': 'lofexidine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Urinary retention'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:5723', 'target': 'COMPOUND:220', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:4653', 'target': 'SIDE_EFFECT:218', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5723', 'target': 'SIDE_EFFECT:218', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'node_removal', 'source': 'SIDE_EFFECT:3050', 'target': None, 'metadata': {'node_id': '3050', 'node_type': 'SIDE_EFFECT', 'display_name': 'Leukaemoid reaction'}}]",0.6153846153846154,a8baa8e58e3d65520d098e517cd428c0,24473f84a10c148cc9c7e8a62faa3183,[],[]
"[{'source_node': {'name': '5-n-allyl-arginine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nitric oxide synthase'}}, {'source_node': {'name': 'nitric oxide synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NOS2'}}, {'source_node': {'name': 'nitric oxide synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NOS3'}}, {'source_node': {'name': 'nitric oxide synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NOS1'}}, {'source_node': {'name': 'NOS2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nitric oxide stimulates guanylate cyclase'}}]","[{'source_node': {'name': '5-n-allyl-arginine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'NOS2'}}, {'source_node': {'name': 'nitric oxide synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NOS2'}}, {'source_node': {'name': 'nitric oxide synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NOS1'}}, {'source_node': {'name': 'NOS2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nitric oxide stimulates guanylate cyclase'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:3660', 'target': 'GENE:30310', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:3660', 'target': 'PROTEIN:285', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:30311', 'target': None, 'metadata': {'node_id': '30311', 'node_type': 'GENE', 'display_name': 'NOS3'}}]",0.6363636363636364,8df903c8e449bf61cf2dd2b0a27fdd8a,f729c7ab3771a42894c2defc0a6d85b7,"['The compound 5-n-allyl-arginine targets nitric oxide synthase, which is a gene product of three genes: NOS1, NOS2, and NOS3. Moreover, the gene NOS2 is known to act within the pathway in which nitric oxide stimulates guanylate cyclase.', 'The compound 5-n-allyl-arginine has a biological target of nitric oxide synthase. This specific synthase is a gene product of several genes: NOS2, NOS3, and NOS1. Notably, NOS2 acts within the pathway where nitric oxide stimulates guanylate cyclase.', 'The drug 5-n-allyl-arginine targets nitric oxide synthase, which is a gene product of NOS1, NOS2, and NOS3. NOS2, in particular, acts within the pathway of nitric oxide stimulating guanylate cyclase.', 'The drug 5-n-allyl-arginine has the protein nitric oxide synthase as its target. This protein is the gene product of NOS2, NOS3, and NOS1. Furthermore, NOS2 acts within the pathway where nitric oxide stimulates guanylate cyclase.', 'The drug 5-n-allyl-arginine targets nitric oxide synthase. This nitric oxide synthase is a gene product of NOS1, NOS2, and NOS3, indicating it is coded by multiple genes. Particularly, NOS2 acts within a pathway, affecting the process where nitric oxide stimulates guanylate cyclase.']",[]
"[{'source_node': {'name': '5-propyloxolan-2-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 1a2'}}, {'source_node': {'name': 'cytochrome p450 1a2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP1A2'}}]","[{'source_node': {'name': '5-propyloxolan-2-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 1a2'}}]","[{'type': 'node_removal', 'source': 'GENE:26285', 'target': None, 'metadata': {'node_id': '26285', 'node_type': 'GENE', 'display_name': 'CYP1A2'}}]",0.6,58c73ba96a70c836b0fc5ed90b694733,5762635e3a508496e345b51428c456b9,"['The compound 5-propyloxolan-2-one has a known target, cytochrome p450 1a2. This particular cytochrome is actually a gene product of CYP1A2.', ""The compound 5-propyloxolan-2-one has been identified to target cytochrome p450 1a2. It's notable that cytochrome p450 1a2 is a gene product of CYP1A2."", 'The compound 5-propyloxolan-2-one is known to target cytochrome p450 1a2, which is the gene product of CYP1A2.', '5-propyloxolan-2-one is a compound that targets cytochrome p450 1a2. In turn, cytochrome p450 1a2 is a gene product of CYP1A2.', 'The drug 5-propyloxolan-2-one has a target known as cytochrome p450 1a2. Interestingly, this target is a gene product of CYP1A2.']",['The compound 5-propyloxolan-2-one has cytochrome p450 1a2 as its target.']
"[{'source_node': {'name': 'diospyrin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'pbmc'}}, {'source_node': {'name': 'diospyrin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}, {'source_node': {'name': 'diospyrin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a-431'}}]","[{'source_node': {'name': 'diospyrin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}, {'source_node': {'name': 'diospyrin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a-431'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5862', 'target': None, 'metadata': {'node_id': '5862', 'node_type': 'PROTEIN', 'display_name': 'pbmc'}}]",0.7142857142857143,412e4553728628d102a3ca1bea1c0c9c,9e11fad89d2fd51b02d1f7be111334ad,"['The compound Diospyrin has been found to target several cellular types, including PBMC (Peripheral Blood Mononuclear Cell), HL-60 (a human promyelocytic leukemia cell line), and A-431 (an epidermoid carcinoma cell line).', 'The compound Diospyrin has been identified to target several cells; specifically, it targets PBMC, HL-60, and A-431 cells.', ""The compound Diospyrin targets PBMC, HL-60, and A-431. These are all cell lines indicative of the compound's broader therapeutic actions."", 'The compound Diospyrin is known to target several cell lines including PBMC, HL-60, and A-431.', 'Diospyrin, a naturally occurring compound, has been found to target a variety of cellular structures. Among these targets are PBMC (Peripheral Blood Mononuclear Cells), HL-60, a human cell line used in scientific research, and A-431, a cell line derived from epidermoid carcinomas. By specifically interacting with these cell lines, Diospyrin provides a valuable tool in the study of cellular mechanisms and potential therapeutic applications.']","['The compound diospyrin has been identified to target multiple cells, specifically HL-60 and A-431.', 'Diospyrin, a bioactive compound known for its potential medicinal properties, has various cellular targets - among them being HL-60, a human promyelocytic leukemia cell line, and A-431, a human epidermoid carcinoma cell line. This suggests that Diospyrin could have potential therapeutic implications in the treatment of certain types of cancer.', 'The drug diospyrin targets two specific cell lines: HL-60 and A-431.', 'The compound Diospyrin has been identified to target two separate entities, HL-60 and A-431.', 'The compound Diospyrin has been found to target two distinct entities: HL-60, and A-431.']"
"[{'source_node': {'name': ""pyridoxine-5'-phosphate oxidase""}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PNPO'}}, {'source_node': {'name': 'PNPO'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pyridoxamine 5-prime-phosphate oxidase deficiency'}}, {'source_node': {'name': 'PNPO'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Vitamin B6 activation to pyridoxal phosphate'}}]","[{'source_node': {'name': ""pyridoxine-5'-phosphate oxidase""}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PNPO'}}]","[{'type': 'node_removal', 'source': 'DISEASE:10428', 'target': None, 'metadata': {'node_id': '10428', 'node_type': 'DISEASE', 'display_name': 'pyridoxamine 5-prime-phosphate oxidase deficiency'}}, {'type': 'node_removal', 'source': 'PATHWAY:1757', 'target': None, 'metadata': {'node_id': '1757', 'node_type': 'PATHWAY', 'display_name': 'Vitamin B6 activation to pyridoxal phosphate'}}]",0.4285714285714286,a40681bd8e6903c2c6344159d242cfa8,d984efced0ee98c601467edd92e0640a,"[""The enzyme pyridoxine-5'-phosphate oxidase is the gene product of PNPO. This gene PNPO acts within the pathway of Vitamin B6 activation to pyridoxal phosphate, and when mutated it can cause a condition known as pyridoxamine 5-prime-phosphate oxidase deficiency."", ""The enzyme pyridoxine-5'-phosphate oxidase is a gene product of PNPO. This gene acts within a biological pathway responsible for vitamin B6 activation to pyridoxal phosphate. Furthermore, mutations in the PNPO gene can cause a disorder known as pyridoxamine 5-prime-phosphate oxidase deficiency."", ""The enzyme pyridoxine-5'-phosphate oxidase is a gene product of PNPO. This gene, PNPO, operates within the pathway of Vitamin B6 activation to pyridoxal phosphate. Moreover, PNPO is known to be responsible for causing a medical condition called pyridoxamine 5-prime-phosphate oxidase deficiency."", ""The enzyme pyridoxine-5'-phosphate oxidase is a gene product of PNPO. In turn, this gene has been associated with causing a condition known as pyridoxamine 5-prime-phosphate oxidase deficiency. Furthermore, the PNPO gene acts within the process of vitamin B6 activation to pyridoxal phosphate."", ""The enzyme pyridoxine-5'-phosphate oxidase is a gene product of PNPO, which plays a key role within the pathway of Vitamin B6 activation to pyridoxal phosphate. Interestingly, PNPO is known for causing a medical condition known as pyridoxamine 5-prime-phosphate oxidase deficiency.""]",[]
"[{'source_node': {'name': 'talaroflavone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'serine/threonine-protein kinase plk4'}}, {'source_node': {'name': 'talaroflavone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'angiopoietin-1 receptor'}}]","[{'source_node': {'name': 'talaroflavone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'serine/threonine-protein kinase plk4'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:1124', 'target': None, 'metadata': {'node_id': '1124', 'node_type': 'PROTEIN', 'display_name': 'angiopoietin-1 receptor'}}]",0.6,8a431fa9e99dd75d29d3f65469f22955,be5ab8b27844d4310537311ccb60f7e1,"['The drug, Talaroflavone, has been observed to have two key targets: serine/threonine-protein kinase plk4 and angiopoietin-1 receptor.', 'The compound talaroflavone has been found to specifically target serine/threonine-protein kinase PLK4 and angiopoietin-1 receptor.', 'The drug Talaroflavone targets both the serine/threonine-protein kinase PLK4 and the angiopoietin-1 receptor.', 'The compound talaroflavone has been found to target two key proteins: the serine/threonine-protein kinase PLK4 and the angiopoietin-1 receptor.', 'The compound talaroflavone targets the serine/threonine-protein kinase plk4 as well as the angiopoietin-1 receptor.']","['The compound talaroflavone has a target in the serine/threonine-protein kinase PLK4.', 'The compound talaroflavone has the serine/threonine-protein kinase PLK4 as its target.', 'Talaroflavone is a compound that has been identified to target the serine/threonine-protein kinase plk4.', 'The compound Talaroflavone has a target in the Serine/threonine-protein kinase PLK4.']"
"[{'source_node': {'name': 'carbonic anhydrase 7'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA7'}}, {'source_node': {'name': 'aldose reductase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AKR1B1'}}, {'source_node': {'name': 'isoquercetin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'aldose reductase'}}, {'source_node': {'name': 'isoquercetin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}, {'source_node': {'name': 'isoquercetin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'carbonic anhydrase 7'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}]","[{'source_node': {'name': 'carbonic anhydrase 7'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA7'}}, {'source_node': {'name': 'carbonic anhydrase 7'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}, {'source_node': {'name': 'aldose reductase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AKR1B1'}}, {'source_node': {'name': 'isoquercetin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'aldose reductase'}}, {'source_node': {'name': 'isoquercetin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'carbonic anhydrase 7'}}, {'source_node': {'name': 'isoquercetin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'CA7'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA7'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:1921', 'target': 'GENE:33610', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:10549', 'target': 'PROTEIN:1921', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:10549', 'target': 'GENE:33610', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:1023', 'target': 'GENE:32076', 'metadata': {'predicate': 'gene_product_of'}}]",0.6923076923076923,c3f087d632b68b9eda93cc51ef073ee3,d4f801ce9bd2006a957f026958450bec,"['Isoquercetin is a compound that targets several proteins including aldose reductase, tyrosine-protein phosphatase non-receptor type 1 and carbonic anhydrase 7. Aldose reductase is a gene product of AKR1B1, while tyrosine-protein phosphatase non-receptor type 1 and carbonic anhydrase 7 are the gene products of PTPN1 and CA7 respectively.', 'Carbonic anhydrase 7 and aldose reductase are the gene products of CA7 and AKR1B1 respectively. These proteins are targeted by the drug, isoquercetin. This drug also targets another protein, tyrosine-protein phosphatase non-receptor type 1, which is the gene product of PTPN1. Consequently, isoquercetin interacts with these proteins that are vital gene products of their respective genes; CA7, AKR1B1 and PTPN1.', 'The compound isoquercetin interacts with several key biological players. It has been observed to target aldose reductase, a gene product of AKR1B1, as well as tyrosine-protein phosphatase non-receptor type 1, which is a gene product of the PTPN1 gene. Additionally, isoquercetin also has a direct target, named carbonic anhydrase 7, a gene product of the CA7 gene. Consequently, isoquercetin shows broad interaction within the gene product network.', 'The drug isoquercetin targets several proteins including aldose reductase, tyrosine-protein phosphatase non-receptor type 1, and carbonic anhydrase 7. Aldose reductase is a gene product of the AKR1B1 gene, while carbonic anhydrase 7 arises from the CA7 gene. Similarly, the protein tyrosine-protein phosphatase non-receptor type 1 is a product of the PTPN1 gene.', 'Carbonic anhydrase 7 is a gene product of CA7 while aldose reductase is a gene product of AKR1B1. The compound isoquercetin targets both of these gene products as well as the tyrosine-protein phosphatase non-receptor type 1, which, in turn, is a gene product of PTPN1. This shows the integrated network and interplay of these various compounds and proteins.']","['Carbonic anhydrase 7, a gene product of both CA7 and PTPN1, and aldose reductase, which is a gene product of AKR1B1, are two molecular targets of the compound isoquercetin. Isoquercetin also affects the gene CA7. Additionally, the gene product of both PTPN1 and CA7, tyrosine-protein phosphatase non-receptor type 1, is another integral part of this biological network.']"
"[{'source_node': {'name': 'CALM3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'CaM pathway'}}, {'source_node': {'name': 'CALM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Phase 0 - rapid depolarisation'}}, {'source_node': {'name': 'CALM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Loss of phosphorylation of MECP2 at T308'}}, {'source_node': {'name': 'CALM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ion transport by P-type ATPases'}}, {'source_node': {'name': 'calmodulin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CALM1'}}, {'source_node': {'name': 'calmodulin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CALM2'}}, {'source_node': {'name': 'calmodulin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CALM3'}}, {'source_node': {'name': '3-[2-(1,3-benzodioxol-5-yl)ethyl]-5-methoxyphenol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'calmodulin'}}]","[{'source_node': {'name': 'CALM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Phase 0 - rapid depolarisation'}}, {'source_node': {'name': 'CALM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Loss of phosphorylation of MECP2 at T308'}}, {'source_node': {'name': 'CALM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ion transport by P-type ATPases'}}, {'source_node': {'name': 'calmodulin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CALM2'}}, {'source_node': {'name': 'calmodulin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CALM3'}}, {'source_node': {'name': '3-[2-(1,3-benzodioxol-5-yl)ethyl]-5-methoxyphenol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'calmodulin'}}, {'source_node': {'name': 'CALM2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Phase 0 - rapid depolarisation'}}]","[{'type': 'edge_deletion', 'source': 'PROTEIN:1163', 'target': 'GENE:33953', 'metadata': None}, {'type': 'edge_addition', 'source': 'GENE:34030', 'target': 'PATHWAY:1009', 'metadata': {'predicate': 'acts_within'}}, {'type': 'node_removal', 'source': 'PATHWAY:2093', 'target': None, 'metadata': {'node_id': '2093', 'node_type': 'PATHWAY', 'display_name': 'CaM pathway'}}]",0.7647058823529411,3227d01bb6b5f173e6458b22e7290f57,a8f119ead63c44aa185537c0344c5470,"['Calmodulin is a protein that plays a pivotal role in many cellular processes. It is the gene product of three different genes: CALM1, CALM2, and CALM3. Particularly, CALM1 and CALM3 engage in numerous cellular pathways. The gene CALM1 acts within several pathways, including Phase 0 - rapid depolarisation, the Loss of phosphorylation of MECP2 at T308, and Ion transport by P-type ATPases. On the other hand, CALM3 acts within the CaM pathway, a crucial pathway for intracellular signaling. Furthermore, 3-[2-(1,3-benzodioxol-5-yl)ethyl]-5-methoxyphenol, a chemical compound, has calmodulin as its target, signifying the influence of external agents on these biochemical processes. This complicated interplay illustrates the complex nature of molecular biology.']",[]
"[{'source_node': {'name': 'timosaponin aiii'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}, {'source_node': {'name': 'timosaponin aiii'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sw480'}}, {'source_node': {'name': 'timosaponin aiii'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hs68'}}]","[{'source_node': {'name': 'timosaponin aiii'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hs68'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5828', 'target': None, 'metadata': {'node_id': '5828', 'node_type': 'PROTEIN', 'display_name': 'sw480'}}, {'type': 'node_removal', 'source': 'PROTEIN:4976', 'target': None, 'metadata': {'node_id': '4976', 'node_type': 'PROTEIN', 'display_name': 'ht-29'}}]",0.4285714285714286,923bb108d00d55d328ccae75f0e94d9f,89c1da05b98b526c4f49d6b939bc32a5,"['The drug, Timosaponin AIII, targets several entities, including the HT-29, SW480, and HS68 cells. This signifies that Timosaponin AIII interacts specifically with these cell types, perhaps influencing their properties or behaviors.', 'The compound Timosaponin AIII targets various cell lines including HT-29, SW480, and HS68.', 'The drug Timosaponin AIII has multiple targets, including HT-29, SW480, and HS68, highlighting its versatility in interacting with different entities.', 'The compound Timosaponin AIII has proven effective against a range of cellular targets, such as HT-29, SW480 and HS68.', 'The compound Timosaponin AIII has been found to target several entities, specifically the HT-29, SW480, and HS68 cell lines. This suggests a potential role for Timosaponin AIII in therapeutic applications related to these cells.']","['The compound Timosaponin AIII has the HS68 as its target.', 'The compound timosaponin AIII has a target interaction with HS68.', 'The compound Timosaponin AIII has been found to target HS68.']"
"[{'source_node': {'name': 'cycrimine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cisplatin'}}, {'source_node': {'name': 'cycrimine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'posiphen'}}, {'source_node': {'name': 'cycrimine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'senna leaf'}}, {'source_node': {'name': 'prucalopride'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'prucalopride'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'propiomazine'}}, {'source_node': {'name': 'prucalopride'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cycrimine'}}]","[{'source_node': {'name': 'cycrimine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cisplatin'}}, {'source_node': {'name': 'cycrimine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'posiphen'}}, {'source_node': {'name': 'cycrimine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'senna leaf'}}, {'source_node': {'name': 'prucalopride'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'prucalopride'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'propiomazine'}}, {'source_node': {'name': 'prucalopride'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cycrimine'}}, {'source_node': {'name': 'cisplatin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'posiphen'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:501', 'target': 'COMPOUND:12887', 'metadata': {'predicate': 'increase_efficacy'}}]",0.9230769230769232,28c5009aaceff8dd56c2e7181ba7f32c,84a793a101b064ed2d532c729631f860,[],[]
"[{'source_node': {'name': 'ISG15'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'ISG15 antiviral mechanism'}}, {'source_node': {'name': 'ISG15'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Interferon alpha/beta signaling'}}, {'source_node': {'name': 'ISG15'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Negative regulators of DDX58/IFIH1 signaling'}}]","[{'source_node': {'name': 'ISG15'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Negative regulators of DDX58/IFIH1 signaling'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:834', 'target': None, 'metadata': {'node_id': '834', 'node_type': 'PATHWAY', 'display_name': 'ISG15 antiviral mechanism'}}, {'type': 'node_removal', 'source': 'PATHWAY:553', 'target': None, 'metadata': {'node_id': '553', 'node_type': 'PATHWAY', 'display_name': 'Interferon alpha/beta signaling'}}]",0.4285714285714286,9eb315b9b89ff127e74fb993d27a1ee4,f812d27eb5a41e417c50362855b3389c,[],[]
"[{'source_node': {'name': 'B2M'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'DAP12 signaling'}}, {'source_node': {'name': 'B2M'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Interferon gamma signaling'}}, {'source_node': {'name': 'B2M'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Modulation by Mtb of host immune system'}}, {'source_node': {'name': 'beta-2-microglobulin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'B2M'}}]","[{'source_node': {'name': 'B2M'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'DAP12 signaling'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1889', 'target': None, 'metadata': {'node_id': '1889', 'node_type': 'PATHWAY', 'display_name': 'Modulation by Mtb of host immune system'}}, {'type': 'node_removal', 'source': 'PATHWAY:262', 'target': None, 'metadata': {'node_id': '262', 'node_type': 'PATHWAY', 'display_name': 'Interferon gamma signaling'}}, {'type': 'node_removal', 'source': 'PROTEIN:2725', 'target': None, 'metadata': {'node_id': '2725', 'node_type': 'PROTEIN', 'display_name': 'beta-2-microglobulin'}}]",0.3333333333333333,de84ad7478145d6438314cf8c7bce342,1d8897048d726c54bc64bbfa834abe65,[],"['The gene B2M operates within the process known as DAP12 signaling.', 'The gene B2M operates within the process known as DAP12 signaling.', 'The gene B2M operates within the pathway of DAP12 signaling.']"
"[{'source_node': {'name': 'nuclear receptor subfamily 1 group i member 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR1I2'}}, {'source_node': {'name': 'ascochlorin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear receptor subfamily 1 group i member 2'}}, {'source_node': {'name': 'ascochlorin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'estrogen receptor alpha'}}, {'source_node': {'name': 'ascochlorin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'estrogen receptor beta'}}, {'source_node': {'name': 'estrogen receptor beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR2'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR1'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}]","[{'source_node': {'name': 'estrogen receptor beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR2'}}, {'source_node': {'name': 'estrogen receptor beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': 'estrogen receptor beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR1'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR1'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR2'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:48291', 'target': 'PROTEIN:943', 'metadata': None}, {'type': 'edge_addition', 'source': 'PROTEIN:942', 'target': 'GENE:33509', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:48291', 'target': 'PROTEIN:942', 'metadata': None}, {'type': 'node_removal', 'source': 'PROTEIN:682', 'target': None, 'metadata': {'node_id': '682', 'node_type': 'PROTEIN', 'display_name': 'nuclear receptor subfamily 1 group i member 2'}}, {'type': 'edge_addition', 'source': 'PROTEIN:942', 'target': 'GENE:26821', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'PROTEIN:943', 'target': 'GENE:26824', 'metadata': {'predicate': 'gene_product_of'}}]",0.3333333333333333,d2278830fc402e242ded119170312af9,9fd68697d1771e8e4dbfaddf36bc7509,"['The drug ascochlorin targets several receptors including the nuclear receptor subfamily 1 group i member 2, estrogen receptor alpha, and estrogen receptor beta. Interestingly, these receptors are gene products of NR1I2, ESR1, and ESR2 respectively. In addition, estrogen receptor alpha is also a gene product of VHL.', 'The drug ascochlorin targets nuclear receptor subfamily 1 group i member 2, estrogen receptor alpha and estrogen receptor beta. The genomic output of certain genes is responsible for these targets; nuclear receptor subfamily 1 group i member 2 is the gene product of NR1I2, estrogen receptor beta is the product of ESR2, and estrogen receptor alpha is the product of both ESR1 and VHL.', 'The compound ascochlorin targets multiple proteins, including nuclear receptor subfamily 1 group i member 2 and both estrogen receptors, alpha and beta. The nuclear receptor subfamily 1 group i member 2 is a gene product of NR1I2. Furthermore, estrogen receptor alpha is a gene product of both ESR1 and VHL, while estrogen receptor beta is produced by the ESR2 gene.', 'The drug ascochlorin targets several receptors including nuclear receptor subfamily 1 group i member 2, estrogen receptor alpha, and estrogen receptor beta. The nuclear receptor subfamily 1 group i member 2 is a gene product of NR1I2. Similarly, the estrogen receptor alpha and beta are gene products of ESR1 and ESR2 respectively. Additionally, estrogen receptor alpha is also a gene product of VHL.', 'The drug ascochlorin targets several receptors including nuclear receptor subfamily 1 group i member 2, estrogen receptor alpha, and estrogen receptor beta. The nuclear receptor subfamily 1 group i member 2 is a gene product of NR1I2. Similarly, the estrogen receptor beta and alpha are gene products of ESR2 and ESR1 respectively. In addition, the estrogen receptor alpha is also produced by the VHL gene.']","['The estrogen receptor beta is a gene product of ESR2, VHL, and ESR1. Similarly, the estrogen receptor alpha is a product of the genes ESR1, VHL, and ESR2. This intersection of gene products implies a shared functionality across these receptors and their corresponding genes.', 'Estrogen receptor beta and estrogen receptor alpha, two key receptors in endocrine physiology, are gene products of multiple genes, namely ESR2, VHL, and ESR1. Similarly, estrogen receptor alpha also has its genetic origin from genes ESR1, VHL and ESR2. These receptors play a significant role in many physiological roles, especially in reproductive systems.']"
"[{'source_node': {'name': 'SCARB2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'epilepsy'}}, {'source_node': {'name': 'SCARB2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'gaucher disease'}}]","[{'source_node': {'name': 'SCARB2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'epilepsy'}}]","[{'type': 'node_removal', 'source': 'DISEASE:10519', 'target': None, 'metadata': {'node_id': '10519', 'node_type': 'DISEASE', 'display_name': 'gaucher disease'}}]",0.6,8e8600c4d3e6a9b9bb10f6e6e77b0941,6c18aaff921bcb7761a5c0b11c3b030b,"['The gene SCARB2 plays a significant role in the onset of multiple conditions as it is known to cause both epilepsy and Gaucher disease.', 'The gene SCARB2 is known to cause several medical conditions, including epilepsy and Gaucher disease.', 'The gene SCARB2 is known to cause several conditions, including epilepsy and Gaucher disease.', 'The gene SCARB2 is known to cause multiple conditions such as epilepsy and Gaucher disease.', 'The gene SCARB2 is known to cause conditions such as epilepsy and Gaucher disease.']","['The gene SCARB2 has been found to cause epilepsy, a neurological condition.']"
"[{'source_node': {'name': 'ebenfuran vii'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'ebenfuran vii'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'estrogen receptor alpha'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR1'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': 'ESR1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'migraine with or without aura'}}, {'source_node': {'name': 'ESR1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Extra-nuclear estrogen signaling'}}]","[{'source_node': {'name': 'ebenfuran vii'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': 'ESR1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'migraine with or without aura'}}, {'source_node': {'name': 'ESR1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Extra-nuclear estrogen signaling'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:72483', 'target': 'PROTEIN:943', 'metadata': None}, {'type': 'edge_deletion', 'source': 'PROTEIN:943', 'target': 'GENE:26821', 'metadata': None}]",0.8461538461538461,e4c8894b567cf4692c4947cb8d84ba9f,2d03912adb953c52f24070988b55eaf3,"['The compound Ebenfuran VII has multiple targets including the MCF7 protein and the estrogen receptor alpha. The latter is a gene product of not only ESR1, but also VHL. Interestingly, ESR1 is implicated in causing the condition known as migraine with or without aura. Furthermore, ESR1 also functions within the realm of extra-nuclear estrogen signaling. Thus, Ebenfuran VII indirectly influences these biological activities and conditions through its targeting of specific cellular proteins.']","['The compound Ebenfuran VII has a targeted interaction with MCF7. This is particularly noteworthy as there exists an estrogen receptor alpha, a gene product of VHL, which is found within the MCF7 cell lines. Additionally, the gene ESR1, which causes a condition known as migraine with or without aura, acts within a specific pathway termed as extra-nuclear estrogen signaling. This could potentially indicate a role of Ebenfuran VII in estrogen-related cellular signaling and migraine management, but further studies are certainly required to confirm such presumptive connections.']"
"[{'source_node': {'name': '4-iodobenzo[b]thiophene-2-carboxamidine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prothrombin'}}, {'source_node': {'name': '4-iodobenzo[b]thiophene-2-carboxamidine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'trypsin-1'}}, {'source_node': {'name': '4-iodobenzo[b]thiophene-2-carboxamidine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'urokinase-type plasminogen activator'}}, {'source_node': {'name': 'urokinase-type plasminogen activator'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PLAU'}}]","[{'source_node': {'name': 'urokinase-type plasminogen activator'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PLAU'}}, {'source_node': {'name': 'trypsin-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PLAU'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:1851', 'target': 'GENE:31001', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'COMPOUND:2952', 'target': None, 'metadata': {'node_id': '2952', 'node_type': 'COMPOUND', 'display_name': '4-iodobenzo[b]thiophene-2-carboxamidine'}}]",0.3333333333333333,092cf3b705aadabaee8bd724ecd2c654,1c6fc2cb8095d72f4178b74f2d48057d,"['The drug 4-iodobenzo[b]thiophene-2-carboxamidine targets a variety of proteins including prothrombin, trypsin-1 and a urokinase-type plasminogen activator. Notably, the urokinase-type plasminogen activator is actually a gene product of the PLAU gene.', 'The drug 4-iodobenzo[b]thiophene-2-carboxamidine targets several proteins including prothrombin, trypsin-1, and urokinase-type plasminogen activator. The latter is a gene product of PLAU.', 'The chemical compound 4-iodobenzo[b]thiophene-2-carboxamidine targets a variety of proteins, including prothrombin, trypsin-1, and the urokinase-type plasminogen activator. Interestingly, the latter activator is a gene product of PLAU.', 'The drug 4-iodobenzo[b]thiophene-2-carboxamidine targets prothrombin, trypsin-1, and urokinase-type plasminogen activator. It is worth noting that the urokinase-type plasminogen activator is a gene product of PLAU.', 'The drug 4-iodobenzo[b]thiophene-2-carboxamidine targets several proteins including prothrombin, trypsin-1, and urokinase-type plasminogen activator. Interestingly, the urokinase-type plasminogen activator is a gene product of the PLAU gene.']","['The urokinase-type plasminogen activator and trypsin-1 are both gene products of the gene PLAU.', 'The urokinase-type plasminogen activator and trypsin-1 are both gene products of PLAU.', 'The gene known as PLAU is responsible for the production of two critical proteins, urokinase-type plasminogen activator and trypsin-1.', 'The proteins urokinase-type plasminogen activator and trypsin-1 are both gene products of the PLAU gene.', 'The urokinase-type plasminogen activator and trypsin-1 are both gene products of PLAU.']"
"[{'source_node': {'name': 'n-acetyl-alpha-d-glucosamine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'acetylcholinesterase'}}, {'source_node': {'name': 'n-acetyl-alpha-d-glucosamine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucosylceramidase'}}, {'source_node': {'name': 'n-acetyl-alpha-d-glucosamine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sialic acid-binding ig-like lectin 7'}}, {'source_node': {'name': 'GBA1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hereditary late-onset parkinson disease'}}, {'source_node': {'name': 'GBA1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glycosphingolipid metabolism'}}, {'source_node': {'name': 'acetylcholinesterase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACHE'}}, {'source_node': {'name': 'glucosylceramidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GBA1'}}, {'source_node': {'name': 'sialic acid-binding ig-like lectin 7'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SIGLEC7'}}]","[{'source_node': {'name': 'n-acetyl-alpha-d-glucosamine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'acetylcholinesterase'}}, {'source_node': {'name': 'n-acetyl-alpha-d-glucosamine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucosylceramidase'}}, {'source_node': {'name': 'n-acetyl-alpha-d-glucosamine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sialic acid-binding ig-like lectin 7'}}, {'source_node': {'name': 'GBA1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hereditary late-onset parkinson disease'}}, {'source_node': {'name': 'GBA1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glycosphingolipid metabolism'}}, {'source_node': {'name': 'acetylcholinesterase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACHE'}}, {'source_node': {'name': 'acetylcholinesterase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GBA1'}}, {'source_node': {'name': 'glucosylceramidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GBA1'}}]","[{'type': 'node_removal', 'source': 'GENE:28029', 'target': None, 'metadata': {'node_id': '28029', 'node_type': 'GENE', 'display_name': 'SIGLEC7'}}, {'type': 'edge_addition', 'source': 'PROTEIN:273', 'target': 'GENE:27886', 'metadata': {'predicate': 'gene_product_of'}}]",0.8235294117647058,188122f9d166d7d5acae33e6772e516a,1fa175a16d2b2bf5b8e1157487c0a2c2,"[""N-acetyl-alpha-D-glucosamine is a compound known to target several biological entities, including acetylcholinesterase, glucosylceramidase, and sialic acid-binding Ig-like lectin 7. Interestingly, these targets are the gene products of ACHE, GBA1, and SIGLEC7 genes, respectively. Among these genes, GBA1 is particularly notable. It actively participates in the glycosphingolipid metabolism pathway and is linked to a specific health condition, hereditary late-onset Parkinson's disease."", 'The drug N-acetyl-alpha-D-glucosamine has various targets including acetylcholinesterase, glucosylceramidase, and sialic acid-binding Ig-like lectin 7. Noteworthy, acetylcholinesterase is a gene product of ACHE. On the other hand, glucosylceramidase is a gene product of the gene GBA1, which not only causes hereditary late-onset Parkinson disease, but also acts within the glycosphingolipid metabolism pathway. Meanwhile, sialic acid-binding Ig-like lectin 7 is a gene product of SIGLEC7.', ""The molecule N-acetyl-alpha-D-glucosamine has multiple targets, including acetylcholinesterase, glucosylceramidase, and sialic acid-binding Ig-like lectin 7. Acetylcholinesterase is a gene product of ACHE. Moreover, glucosylceramidase is a gene product of GBA1, which is also involved in glycosphingolipid metabolism and known to cause hereditary late-onset Parkinson's disease. Additionally, sialic acid-binding Ig-like lectin 7 is a gene product of SIGLEC7."", 'The molecular compound N-acetyl-alpha-D-glucosamine targets several key proteins, namely acetylcholinesterase, glucosylceramidase, and sialic acid-binding Ig-like lectin 7. Each of these proteins has a corresponding gene. Acetylcholinesterase is a gene product of ACHE while glucoylceramidase and sialic acid-binding Ig-like lectin 7 are respectively the gene products of GBA1 and SIGLEC7. Intriguingly, GBA1 not only codes for the glucosylceramidase protein, it also plays a role in the Glycosphingolipid metabolism pathway, and when mutated, can cause conditions like hereditary late-onset Parkinson disease.', 'The compound N-acetyl-alpha-D-glucosamine targets several entities including acetylcholinesterase, glucosylceramidase, and sialic acid-binding Ig-like lectin 7. Interestingly, acetylcholinesterase is a product derived from the gene ACHE.  \n\nAlso, glucosylceramidase, another target of N-acetyl-alpha-D-glucosamine, is a gene product of GBA1. This gene is involved in the process of glycosphingolipid metabolism and has been linked to causing hereditary late-onset Parkinson disease. \n\nFurthermore, sialic acid-binding Ig-like lectin 7, also targeted by N-acetyl-alpha-D-glucosamine, is product of the gene SIGLEC7. The diverse targets linked to this compound reflect its broad potential in interacting with various biological molecules.']","[""N-acetyl-alpha-D-glucosamine is a compound that has been found to target several entities, including acetylcholinesterase, glucosylceramidase, and sialic acid-binding Ig-like lectin 7. Interestingly, both acetylcholinesterase and glucosylceramidase function as gene products of GBA1, introducing a potential link between these targets. Furthermore, GBA1, which also acts within the glycosphingolipid metabolism pathway, is known to cause hereditary late-onset Parkinson disease. It's important to note as well that acetylcholinesterase, apart from being a product of GBA1, is also a gene product of ACHE. This complex network of interactions reveals significant aspects of how N-acetyl-alpha-D-glucosamine may influence multiple biological processes and conditions."", ""The compound N-acetyl-alpha-D-glucosamine targets several proteins including acetylcholinesterase, glucosylceramidase, and sialic acid-binding Ig-like lectin 7. Acetylcholinesterase is a gene product of both ACHE and GBA1, while glucosylceramidase is a gene product of GBA1. In the context of biochemical pathways, GBA1 acts within the glycosphingolipid metabolism. Additionally, GBA1 is involved in causing conditions like hereditary late-onset Parkinson's disease."", 'N-acetyl-alpha-D-glucosamine is a compound that has several targets, including acetylcholinesterase, glucosylceramidase, and sialic acid-binding Ig-like lectin 7. Acetylcholinesterase is known to be a gene product of two genes, ACHE and GBA1; likewise, glucosylceramidase is a gene product of GBA1. Interestingly, GBA1 acts within the pathway of glycosphingolipid metabolism and is also responsible for causing hereditary late-onset Parkinson disease.']"
"[{'source_node': {'name': 't cell receptor alpha constant'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'leukopenia'}}, {'source_node': {'name': 't cell receptor alpha constant'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'schizophrenia'}}, {'source_node': {'name': 'schizophrenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hallucinations'}}, {'source_node': {'name': 'schizophrenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'social and occupational deterioration'}}, {'source_node': {'name': 'schizophrenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'delusions'}}]","[{'source_node': {'name': 'leukopenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hallucinations'}}]","[{'type': 'edge_addition', 'source': 'DISEASE:1837', 'target': 'PHENOTYPE:575', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:583', 'target': None, 'metadata': {'node_id': '583', 'node_type': 'PHENOTYPE', 'display_name': 'delusions'}}, {'type': 'edge_deletion', 'source': 'GENE:22057', 'target': 'DISEASE:13792', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:22057', 'target': None, 'metadata': {'node_id': '22057', 'node_type': 'GENE', 'display_name': 't cell receptor alpha constant'}}, {'type': 'node_removal', 'source': 'DISEASE:13792', 'target': None, 'metadata': {'node_id': '13792', 'node_type': 'DISEASE', 'display_name': 'schizophrenia'}}]",0.1818181818181817,5cd5b6ea6716a4c05f3ed10fdfa68515,6b0ff4ca8786c2607e50af36151aa207,"['The T cell receptor alpha constant is known to cause certain conditions, including leukopenia and schizophrenia. Schizophrenia, in turn, is characterized by various features such as hallucinations, delusions, and social and occupational deterioration.', 'The T cell receptor alpha constant is known to cause several conditions, such as leukopenia and schizophrenia. Schizophrenia, a serious mental health disorder, is characterized by a range of symptoms including hallucinations, delusions, and social and occupational deterioration.', ""The T cell receptor alpha constant, an important component of the immune system, has been found to cause certain conditions, including leukopenia, a reduction in white blood cells, and schizophrenia. In particular, schizophrenia, a mental disorder, can produce various phenotypes such as hallucinations, social and occupational deterioration, and delusions, impacting various aspects of the patient's life and relationships."", 'The T cell receptor alpha constant is associated with causing several conditions, including leukopenia and schizophrenia. Schizophrenia is a multifaceted disorder manifesting a range of symptoms or phenotypes. Hallucinations, social and occupational deterioration, as well as delusions all correspond to the complex disorder, schizophrenia.']",[]
"[{'source_node': {'name': 'MAPKAPK5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neurocardiofaciodigital syndrome'}}, {'source_node': {'name': 'MAPKAPK5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Oxidative Stress Induced Senescence'}}, {'source_node': {'name': 'MAPKAPK5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'MAPK6/MAPK4 signaling'}}]","[{'source_node': {'name': 'MAPKAPK5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neurocardiofaciodigital syndrome'}}, {'source_node': {'name': 'MAPKAPK5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Oxidative Stress Induced Senescence'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:396', 'target': None, 'metadata': {'node_id': '396', 'node_type': 'PATHWAY', 'display_name': 'MAPK6/MAPK4 signaling'}}]",0.7142857142857143,25af8f1954e550bca0dd54091967dc44,e5a1feb8efa068f5dbd7bbd69a1f8c17,"['The MAPKAPK5 gene has been found to be involved in two key pathways: oxidative stress induced senescence and MAPK6/MAPK4 signaling. Unfortunately, variations within this gene can cause a condition known as neurocardiofaciodigital syndrome.', 'The gene MAPKAPK5, which acts within both the oxidative stress induced senescence and MAPK6/MAPK4 signaling pathways, causes a condition known as neurocardiofaciodigital syndrome.', 'The gene MAPKAPK5, which is active within the Oxidative Stress Induced Senescence and MAPK6/MAPK4 signaling pathways, is known to cause neurocardiofaciodigital syndrome.', 'The gene MAPKAPK5, which operates within both the Oxidative Stress Induced Senescence and the MAPK6/MAPK4 signaling pathways, is known to cause a medical condition known as neurocardiofaciodigital syndrome.']",[]
"[{'source_node': {'name': 'geminin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GMNN'}}, {'source_node': {'name': 'cytochrome p450 3a5'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP3A5'}}, {'source_node': {'name': 'besigomsin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'atp-dependent dna helicase q1'}}, {'source_node': {'name': 'besigomsin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'geminin'}}, {'source_node': {'name': 'besigomsin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 3a5'}}, {'source_node': {'name': 'CYP3A5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hypertension'}}]","[{'source_node': {'name': 'atp-dependent dna helicase q1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GMNN'}}, {'source_node': {'name': 'geminin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GMNN'}}, {'source_node': {'name': 'GMNN'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hypertension'}}, {'source_node': {'name': 'cytochrome p450 3a5'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP3A5'}}, {'source_node': {'name': 'besigomsin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'atp-dependent dna helicase q1'}}, {'source_node': {'name': 'besigomsin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'geminin'}}, {'source_node': {'name': 'besigomsin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 3a5'}}, {'source_node': {'name': 'CYP3A5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hypertension'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:6144', 'target': 'GENE:30558', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'GENE:30558', 'target': 'DISEASE:13810', 'metadata': {'predicate': 'causes_condition'}}]",0.8461538461538461,f78c9205cc9f2f57a46113f1b4d8c190,5f270319a4593a56020ba42a0dadc317,"[""Geminin, the gene product of GMNN, along with Cytochrome P450 3A5, the gene product of CYP3A5, are two significant targets of the drug Besigomsin. Notably, Besigomsin also targets the ATP-dependent DNA helicase Q1. It's important to note that the gene CYP3A5, which produces Cytochrome P450 3A5, is correlated with causing hypertension."", 'The drug Besigomsin has several targets, including the ATP-dependent DNA helicase Q1, Geminin, and Cytochrome P450 3A5. Geminin is a gene product of GMNN, while Cytochrome P450 3A5 is a gene product of CYP3A5. Interestingly, CYP3A5 is known to cause a condition known as hypertension.', 'The drug besigomsin targets several components including the ATP-dependent DNA helicase Q1, geminin, and cytochrome P450 3A5. In turn, geminin is a gene product of GMNN and cytochrome P450 3A5 is a gene product of CYP3A5. Interestingly, CYP3A5 is known to cause hypertension, a chronic condition characterized by high blood pressure levels.', 'Besigomsin, a drug, targets multiple proteins including ATP-dependent DNA helicase Q1, geminin which is a gene product of GMNN, and cytochrome P450 3A5, a gene product of CYP3A5. Interestingly, the activity of CYP3A5 has been linked to causing a health condition, specifically hypertension.', 'Geminin, which is a gene product of the GMNN gene, and Cytochrome P450 3A5, which is a gene product of the CYP3A5 gene, are both targets of the drug Besigomsin. Besigomsin also targets ATP-dependent DNA helicase Q1. Interestingly, the CYP3A5 gene has been implicated in causing hypertension.']","['The drug Besigomsin targets the ATP-dependent DNA helicase Q1, Geminin, and Cytochrome P450 3A5. Both the ATP-dependent DNA helicase Q1 and Geminin are gene products of the GMNN gene. This gene has been linked to the condition of hypertension. Similarly, Cytochrome P450 3A5 is a gene product of the CYP3A5 gene which is also known to cause hypertension.', ""The drug besigomsin targets a trio of proteins: the ATP-dependent DNA helicase Q1, geminin, and cytochrome P450 3A5. Both the ATP-dependent DNA helicase Q1 and geminin are gene products of GMNN, a gene known to cause hypertension. Similarly, cytochrome P450 3A5 is a gene product of CYP3A5, another gene implicated in the development of hypertension. It's interesting to note that these pathways all interlink and culminate in the common medical condition of hypertension."", 'The ATP-dependent DNA helicase Q1 and Geminin are both gene products of the gene GMNN, which is known to cause hypertension. Similarly, Cytochrome P450 3A5 is produced by the gene CYP3A5, another agent that leads to hypertension. The drug Besigomsin targets both ATP-dependent DNA helicase Q1 and Geminin, as well as Cytochrome P450 3A5. These findings might have important implications for the management of hypertension.', 'The drug Besigomsin targets several proteins, including ATP-dependent DNA helicase Q1, Geminin, and Cytochrome P450 3A5. ATP-dependent DNA helicase Q1 and Geminin are products of the GMNN gene, and this gene is known to cause hypertension. Similarly, Cytochrome P450 3A5 is a product of the CYP3A5 gene, which also induces hypertension.', ""The drug besigomsin targets three different proteins, including ATP-dependent DNA helicase Q1, geminin, and cytochrome P450 3A5. The ATP-dependent DNA helicase Q1 and geminin are gene products of the GMNN gene, which is implicated in causing hypertension. Furthermore, cytochrome P450 3A5 is a gene product of the CYP3A5 gene, which is also known to cause hypertension. Therefore, besigomsin's targets are linked to hypertension in a genetic perspective.""]"
"[{'source_node': {'name': 'valdecoxib'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Gastritis'}}, {'source_node': {'name': 'valdecoxib'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Creatinine increased'}}, {'source_node': {'name': 'trichlormethiazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'valdecoxib'}}, {'source_node': {'name': 'trichlormethiazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sulodexide'}}, {'source_node': {'name': 'trichlormethiazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imidazole salicylate'}}]","[{'source_node': {'name': 'valdecoxib'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Gastritis'}}, {'source_node': {'name': 'imidazole salicylate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'valdecoxib'}}, {'source_node': {'name': 'trichlormethiazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sulodexide'}}, {'source_node': {'name': 'trichlormethiazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imidazole salicylate'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:1004', 'target': 'COMPOUND:566', 'metadata': None}, {'type': 'node_removal', 'source': 'SIDE_EFFECT:1317', 'target': None, 'metadata': {'node_id': '1317', 'node_type': 'SIDE_EFFECT', 'display_name': 'Creatinine increased'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11705', 'target': 'COMPOUND:566', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.6363636363636364,6c971336c191e04d10c321cd0ce585c0,651ebefc0b69f9f981279c104362b3d9,[],"['The drug Valdecoxib has a side effect of causing Gastritis. Interestingly, its efficacy is noted to decrease in the presence of another medication, imidazole salicylate. On another note, trichlormethiazide also interacts with a couple of therapeutic agents such as imidazole salicylate and sulodexide, diminishing their efficacy.', 'The drug valdecoxib is known to have side effects, one of which is Gastritis. However, the effectiveness of valdecoxib can be decreased when used in combination with imidazole salicylate. On a similar note, the efficiency of sulodexide can also be undermined when used concurrently with trichlormethiazide. Interestingly, the efficacy of imidazole salicylate, as well, tends to drop when used together with trichlormethiazide. As such, it is important to consider these interactions when prescribing these drugs to patients.', 'The drug valdecoxib has been reported to lead to side effects such as gastritis. Interestingly, its efficacy can be decreased by the presence of imidazole salicylate, another type of medication. Similarly, trichlormethiazide is known to decrease the efficacy of two different drugs: sulodexide as well as the aforementioned imidazole salicylate. Thus, combining these substances in a therapeutic setting requires careful consideration due to their various chemical interactions and potential side effects.', 'The drug valdecoxib, which can cause side effects such as gastritis, has its efficacy decreased by imidazole salicylate. Similarly, the drug trichlormethiazide reduces the efficacy of both sulodexide and imidazole salicylate. Therefore, care should be taken when administering these combinations of drugs.', ""The drug named valdecoxib is known to sometimes cause gastritis as a side effect. However, the efficacy of valdecoxib is decreased when used in conjunction with another drug called imidazole salicylate. Interestingly, the drug imidazole salicylate's overall effectiveness is also decreased when taken alongside trichlormethiazide, another medication. Trichlormethiazide is further observed to decrease the efficacy of yet another substance, sulodexide. This suggests a complex interplay between these drugs, thus necessitating careful consideration while prescribing them in unison.""]"
"[{'source_node': {'name': 'muricin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-mel-2'}}, {'source_node': {'name': 'muricin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'pc-3'}}, {'source_node': {'name': 'muricin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'source_node': {'name': 'muricin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'pc-3'}}, {'source_node': {'name': 'muricin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4980', 'target': None, 'metadata': {'node_id': '4980', 'node_type': 'PROTEIN', 'display_name': 'sk-mel-2'}}]",0.7142857142857143,04e5107dd014933211b6cb49d2bd1e0c,ad64f16009e88af5f52c0bf4f03c4220,"['The drug Muricin A is known to target several entities. These include SK-MEL-2, a human malignant melanoma cell line; PC-3, a human prostate cancer cell line; and A549, a human lung carcinoma cell line. Thus, Muricin A plays a pivotal role in treating various types of cancer.', 'Muricin A is a substance that targets SK-MEL-2, PC-3, and A549 which are types of cancer cell lines. By doing so, it potentially interferes with their function and can serve as a potential treatment strategy.', 'The drug Muricin A has multiple targets including SK-MEL-2 cells, PC-3 cells, and A549 cells.', 'The compound Muricin A has been found to target multiple entities, including SK-MEL-2, PC-3, and A549.', 'Muricin A, a potent drug, exhibits its pharmacological action by targeting several cancer cell lines such as SK-MEL-2, PC-3, and A549.']","['The compound Muricin A has been identified as having two primary targets, specifically the PC-3 and A549 cells.', 'The compound Muricin A targets both PC-3 and A549, functioning as a potential inhibitor and suggesting potential therapeutic applications.', 'The compound Muricin A has been identified to target two specific entities, PC-3 and A549.', 'The drug Muricin A is known to target multiple cell lines including PC-3 and A549.', 'The compound Muricin A has been identified to target two separate entities, namely PC-3 and A549.']"
"[{'source_node': {'name': 'deramciclane'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' neuropsychiatric effects '}}, {'source_node': {'name': 'deramciclane'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'estetrol'}}, {'source_node': {'name': 'ganciclovir'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'deramciclane'}}, {'source_node': {'name': 'ganciclovir'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hff'}}, {'source_node': {'name': 'ganciclovir'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}, {'source_node': {'name': 'estetrol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ipragliflozin'}}]","[{'source_node': {'name': 'deramciclane'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'estetrol'}}, {'source_node': {'name': 'deramciclane'}, 'relation': {'name': 'decrease_effect'}, 'target_node': {'name': ' neuropsychiatric effects '}}, {'source_node': {'name': 'ganciclovir'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hff'}}, {'source_node': {'name': 'ganciclovir'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}, {'source_node': {'name': 'estetrol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ipragliflozin'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:987', 'target': 'COMPOUND:5632', 'metadata': None}, {'type': 'edge_replacement', 'source': 'COMPOUND:5632', 'target': 'EFFECT:41', 'metadata': {'predicate': 'decrease_effect'}}]",0.8461538461538461,20d2b6ab27a8a11019fcbb1228e4fc04,a86575b007bafff7dfc4ba3fc31b9ab7,[],[]
"[{'source_node': {'name': 'isoleucine--trna ligase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'IARS1'}}, {'source_node': {'name': 'mupirocin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'isoleucine--trna ligase'}}, {'source_node': {'name': 'mupirocin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' methemoglobinemia '}}, {'source_node': {'name': 'mupirocin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'estetrol'}}]","[{'source_node': {'name': 'estetrol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'isoleucine--trna ligase'}}, {'source_node': {'name': 'isoleucine--trna ligase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'IARS1'}}, {'source_node': {'name': 'mupirocin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'isoleucine--trna ligase'}}, {'source_node': {'name': 'mupirocin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'estetrol'}}]","[{'type': 'node_removal', 'source': 'EFFECT:8', 'target': None, 'metadata': {'node_id': '8', 'node_type': 'EFFECT', 'display_name': ' methemoglobinemia '}}, {'type': 'edge_addition', 'source': 'COMPOUND:10139', 'target': 'PROTEIN:691', 'metadata': {'predicate': 'has_target'}}]",0.6666666666666667,bb576820e53a7b96d5ff5da00940df04,1a7d6213b19d07107385feadb6971502,[],"[""The drug estetrol has a target of isoleucine--tRNA ligase, which is a gene product of IARS1. Similarly, mupirocin also targets isoleucine--tRNA ligase. However, it's been observed that mupirocin decreases the efficacy of estetrol. So, each of the medications affects the isoleucine--tRNA ligase, but they interact in a way that may affect the overall health outcome for the patient."", 'The drug estetrol targets the enzyme isoleucine--tRNA ligase, which is a gene product of IARS1. This ligase enzyme is also targeted by another drug, mupirocin. Interestingly, mupirocin is known to decrease the efficacy of estetrol, indicating a possible interaction or competition between these two drugs.', 'The drug Estetrol targets the Isoleucine--tRNA ligase, which is a gene product of IARS1. Similarly, Mupirocin also targets the Isoleucine--tRNA ligase but it has been observed to decrease the efficacy of Estetrol.', 'The drug Estetrol targets the Isoleucine--tRNA ligase. Interestingly, Isoleucine--tRNA ligase is also a gene product of IARS1. However, Mupirocin, another drug that also targets the Isoleucine--tRNA ligase, has been seen to decrease the efficacy of Estetrol. This reveals a potentially intricate interaction between these components.', ""The drug Estetrol has a target, the Isoleucine--tRNA ligase. This ligase is the gene product of IARS1. Meanwhile, another drug, Mupirocin, also targets the Isoleucine--tRNA ligase. Interestingly, it's been found that Mupirocin can decrease the efficacy of Estetrol. This implies that these two drugs might interact in the body when given together, potentially affecting the outcome of treatment.""]"
"[{'source_node': {'name': '15-hydroxyprostaglandin dehydrogenase [nad(+)]'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HPGD'}}, {'source_node': {'name': 'olvanil'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': '15-hydroxyprostaglandin dehydrogenase [nad(+)]'}}, {'source_node': {'name': 'olvanil'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'solute carrier family 2'}}, {'source_node': {'name': 'olvanil'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor delta'}}, {'source_node': {'name': 'solute carrier family 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SLC2A2'}}, {'source_node': {'name': 'solute carrier family 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SLC2A1'}}]","[{'source_node': {'name': 'peroxisome proliferator-activated receptor delta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HPGD'}}, {'source_node': {'name': '15-hydroxyprostaglandin dehydrogenase [nad(+)]'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HPGD'}}, {'source_node': {'name': 'olvanil'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': '15-hydroxyprostaglandin dehydrogenase [nad(+)]'}}, {'source_node': {'name': 'olvanil'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor delta'}}, {'source_node': {'name': 'solute carrier family 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SLC2A2'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:83417', 'target': 'PROTEIN:1131', 'metadata': None}, {'type': 'edge_addition', 'source': 'PROTEIN:564', 'target': 'GENE:32834', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'GENE:32834', 'target': None, 'metadata': {'node_id': '32834', 'node_type': 'GENE', 'display_name': 'SLC2A1'}}, {'type': 'edge_addition', 'source': 'PROTEIN:358', 'target': 'GENE:28887', 'metadata': {'predicate': 'gene_product_of'}}]",0.6923076923076923,4d9028a748b17df618e83ae9d9656c58,b566598b8144ccf55d3ca4837e9dba06,"['The substance called Olvanil specifically targets multiple elements including 15-hydroxyprostaglandin dehydrogenase [nad(+)], solute carrier family 2, and peroxisome proliferator-activated receptor delta. Additionally, the 15-hydroxyprostaglandin dehydrogenase [nad(+)] is the gene product of HPGD. On the other hand, solute carrier family 2 is a gene product of both SLC2A2 and SLC2A1.', 'The drug olvanil targets several important proteins and receptors, such as the 15-hydroxyprostaglandin dehydrogenase [NAD(+)], solute carrier family 2, and the peroxisome proliferator-activated receptor delta. Interestingly, 15-hydroxyprostaglandin dehydrogenase [NAD(+)] is a gene product of HPGD. Furthermore, solute carrier family 2 is the gene product of not one, but two genes, namely SLC2A2 and SLC2A1.', ""The molecule olvanil targets several entities within the body, including 15-hydroxyprostaglandin dehydrogenase [NAD(+)], solute carrier family 2, and the peroxisome proliferator-activated receptor delta. Interestingly, 15-hydroxyprostaglandin dehydrogenase [NAD(+)] is a gene product of the HPGD gene. Additionally, the solute carrier family 2 is the gene product of both the SLC2A2 and SLC2A1 genes. These intricate relationships suggest a complex interplay in the body's response to this molecule."", 'The compound Olvanil has been found to target several proteins, including 15-hydroxyprostaglandin dehydrogenase [nad(+)], solute carrier family 2 and peroxisome proliferator-activated receptor delta. These targets, in turn, are gene products of corresponding genes. The 15-hydroxyprostaglandin dehydrogenase [nad(+)] is the gene product of the HPGD gene. Similarly, solute carrier family 2 is known as the gene product of SLC2A1 and SLC2A2 genes.', 'The drug Olvanil has multiple targets, including 15-hydroxyprostaglandin dehydrogenase [nad(+)], solute carrier family 2, and peroxisome proliferator-activated receptor delta. The 15-hydroxyprostaglandin dehydrogenase [nad(+)] is a gene product of the HPGD gene. The solute carrier family 2 is a gene product of both the SLC2A2 and SLC2A1 genes.']","['The drug Olvanil targets two significant gene products - 15-hydroxyprostaglandin dehydrogenase [nad(+)] and peroxisome proliferator-activated receptor delta. These gene products are a result of the HPGD gene. Similarly, the solute carrier family 2 is a gene product of the gene SLC2A2. Therefore, the effect of Olvanil can be linked to these two genes and their corresponding gene products.', 'The drug Olvanil targets both 15-hydroxyprostaglandin dehydrogenase [nad(+)] and peroxisome proliferator-activated receptor delta, which are gene products of HPGD. Similarly, solute carrier family 2 is a gene product of SLC2A2.', 'The drug olvanil targets two proteins: the 15-hydroxyprostaglandin dehydrogenase [nad(+)] and the peroxisome proliferator-activated receptor delta. These target proteins are products of the HPGD gene. Interestingly, the peroxisome proliferator-activated receptor delta and 15-hydroxyprostaglandin dehydrogenase [nad(+)] are gene products of the same HPGD gene. Similarly, the solute carrier family 2 is a gene product of the SLC2A2 gene which shows how diverse genetic material can result in different products.', 'The drug olvanil has targets including 15-hydroxyprostaglandin dehydrogenase [nad(+)] and peroxisome proliferator-activated receptor delta. These targets are gene products of HPGD, similarly like solute carrier family 2, which is a gene product of SLC2A2.', 'The drug olvanil targets the proteins 15-hydroxyprostaglandin dehydrogenase [nad(+)] and peroxisome proliferator-activated receptor delta. Interestingly, these proteins are gene products of the HPGD gene. In addition, the solute carrier family 2 protein is a gene product of the SLC2A2 gene.']"
"[{'source_node': {'name': 'hereditary spherocytosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'extramedullary hematopoiesis'}}, {'source_node': {'name': 'hereditary spherocytosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'restrictive cardiomyopathy'}}, {'source_node': {'name': 'hereditary spherocytosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'gout'}}, {'source_node': {'name': 'SPTB'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'elliptocytosis-3'}}, {'source_node': {'name': 'SPTB'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hereditary spherocytosis'}}, {'source_node': {'name': 'SPTB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'NCAM signaling for neurite out-growth'}}]","[{'source_node': {'name': 'hereditary spherocytosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'extramedullary hematopoiesis'}}, {'source_node': {'name': 'hereditary spherocytosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'restrictive cardiomyopathy'}}, {'source_node': {'name': 'elliptocytosis-3'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'extramedullary hematopoiesis'}}, {'source_node': {'name': 'SPTB'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'elliptocytosis-3'}}, {'source_node': {'name': 'SPTB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'NCAM signaling for neurite out-growth'}}]","[{'type': 'edge_deletion', 'source': 'GENE:33026', 'target': 'DISEASE:6872', 'metadata': None}, {'type': 'edge_addition', 'source': 'DISEASE:14733', 'target': 'PHENOTYPE:1444', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:1461', 'target': None, 'metadata': {'node_id': '1461', 'node_type': 'PHENOTYPE', 'display_name': 'gout'}}]",0.6923076923076923,69b4b4000f6c7001d68536b0aaf32ac5,99a3879e575d02af0f30b73efe2f9681,"['The gene SPTB, which acts within the NCAM signaling for neurite out-growth pathway, is responsible for causing a number of conditions. One of these is hereditary spherocytosis that phenotypically manifests through extramedullary hematopoiesis, restrictive cardiomyopathy, and gout, among other symptoms. Additionally, elliptocytosis-3 is another condition caused by the same gene.', 'Hereditary spherocytosis is a condition caused by the gene SPTB and manifests with several characteristic phenotypes such as extramedullary hematopoiesis, restrictive cardiomyopathy, and gout. SPTB is also known to cause another condition, elliptocytosis-3, and it acts within a biological pathway known as NCAM signaling for neurite out-growth.', 'Hereditary Spherocytosis, a genetic condition caused by the gene SPTB, leads to various phenotypes including extramedullary hematopoiesis, restrictive cardiomyopathy, and gout. In addition to causing Hereditary Spherocytosis, the SPTB gene also leads to a condition called elliptocytosis-3. Furthermore, the actions of SPTB occur within a biological process known as NCAM signaling for neurite out-growth, underscoring its role in both cellular and genetic processes.', 'Hereditary spherocytosis, a condition caused by the gene SPTB, is characterised by appearance of several phenotypes including extramedullary hematopoiesis, restrictive cardiomyopathy, and gout. Besides hereditary spherocytosis, SPTB also triggers another condition known as elliptocytosis-3. Additionally, SPTB is observed to act within the pathway of NCAM signaling for neurite out-growth.']",[]
"[{'source_node': {'name': 'dexbrompheniramine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histamine h1 receptor'}}, {'source_node': {'name': 'dexbrompheniramine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'theodrenaline'}}]","[{'source_node': {'name': 'theodrenaline'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histamine h1 receptor'}}, {'source_node': {'name': 'theodrenaline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'dexbrompheniramine'}}, {'source_node': {'name': 'dexbrompheniramine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histamine h1 receptor'}}, {'source_node': {'name': 'dexbrompheniramine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'theodrenaline'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:10801', 'target': 'PROTEIN:869', 'metadata': {'predicate': 'has_target'}}, {'type': 'edge_addition', 'source': 'COMPOUND:10801', 'target': 'COMPOUND:393', 'metadata': {'predicate': 'increase_efficacy'}}]",0.6,a3d3db56c4f98170d70a056156368113,6be090619c389bf25ca25717301f66e8,"['The drug Dexbrompheniramine targets the Histamine H1 receptor and also increases the efficacy of another drug known as Theodrenaline.', 'The drug Dexbrompheniramine has been known to target the Histamine H1 receptor. Interestingly, it also increases the efficacy of Theodrenaline.', 'Dexbrompheniramine is a medication that targets the histamine H1 receptor. It is known to enhance the efficacy of Theodrenaline, another medication.', 'The drug dexbrompheniramine targets the histamine H1 receptor and can increase the efficacy of another medication known as theodrenaline.', 'The drug Dexbrompheniramine targets the Histamine H1 Receptor and is known to increase the efficacy of Theodrenaline.']","['The drug Theodrenaline targets the histamine H1 receptor and is known to increase the efficacy of another drug known as Dexbrompheniramine. Likewise, Dexbrompheniramine also targets the histamine H1 receptor and increases the efficacy of Theodrenaline. The synergistic actions of these two drugs make them effective in managing certain medical conditions.', ""The drug theodrenaline has been found to target the histamine h1 receptor. In addition to this, theodrenaline can also increase the efficacy of dexbrompheniramine, another drug that targets the histamine h1 receptor. Intriguingly, there is a reciprocal relationship here as dexbrompheniramine can similarly boost the efficacy of theodrenaline. Thus, theodrenaline and dexbrompheniramine appear to work synergistically, enhancing each other's effects on the histamine h1 receptor."", ""Theodrenaline, a drug that has histamine H1 receptor as its target, is found to increase the efficacy of dexbrompheniramine. Interestingly, dexbrompheniramine also targets the same histamine H1 receptor and it, in turn, increases the efficacy of theodrenaline. Therefore, these two drugs seem to work in synergy, enhancing each other's performance in targeting the histamine H1 receptor."", 'Theodrenaline, a drug known to target the histamine H1 receptor, has been shown to increase the efficacy of another drug, dexbrompheniramine. Dexbrompheniramine, which also targets the histamine H1 receptor, in turn increases the efficacy of theodrenaline, creating a beneficial interaction between the two drugs.', ""The drug Theodrenaline targets the Histamine H1 receptor and increases the efficacy of Dexbrompheniramine. Similarly, Dexbrompheniramine also targets the Histamine H1 receptor, and its efficacy is increased by Theodrenaline. So, there exists a mutual interdependency between Theodrenaline and Dexbrompheniramine, working towards a common target, the Histamine H1 receptor, and helping to increase each other's effectiveness.""]"
"[{'source_node': {'name': 'ledipasvir'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the excretion rate '}}, {'source_node': {'name': 'ledipasvir'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'interferon lambda 3'}}, {'source_node': {'name': 'ledipasvir'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'hepatitis c'}}, {'source_node': {'name': 'interferon lambda 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'jaundice'}}, {'source_node': {'name': 'interferon lambda 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'treatment failure'}}]","[{'source_node': {'name': 'ledipasvir'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the excretion rate '}}]","[{'type': 'node_removal', 'source': 'GENE:8531', 'target': None, 'metadata': {'node_id': '8531', 'node_type': 'GENE', 'display_name': 'interferon lambda 3'}}, {'type': 'node_removal', 'source': 'DISEASE:1420', 'target': None, 'metadata': {'node_id': '1420', 'node_type': 'DISEASE', 'display_name': 'hepatitis c'}}]",0.2727272727272727,468a78713f067f24e52edb8cf2087ad8,8990e7a49bd0973810fd430459a64c92,[],[]
"[{'source_node': {'name': 'tecemotide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carboplatin'}}, {'source_node': {'name': 'tecemotide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '2-methoxyethanol'}}, {'source_node': {'name': 'tecemotide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carfilzomib'}}, {'source_node': {'name': 'dasatinib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tiratricol'}}, {'source_node': {'name': 'dasatinib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ingn 225'}}, {'source_node': {'name': 'dasatinib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tecemotide'}}, {'source_node': {'name': 'tiratricol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'foretinib'}}]","[{'source_node': {'name': 'tecemotide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carboplatin'}}, {'source_node': {'name': 'tecemotide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '2-methoxyethanol'}}, {'source_node': {'name': 'tecemotide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carfilzomib'}}, {'source_node': {'name': 'dasatinib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ingn 225'}}, {'source_node': {'name': '2-methoxyethanol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carboplatin'}}, {'source_node': {'name': 'tiratricol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'foretinib'}}, {'source_node': {'name': 'tiratricol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carboplatin'}}, {'source_node': {'name': 'carfilzomib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ingn 225'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:3391', 'target': 'COMPOUND:941', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:1234', 'target': 'COMPOUND:10457', 'metadata': None}, {'type': 'edge_deletion', 'source': 'COMPOUND:1234', 'target': 'COMPOUND:3391', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:2644', 'target': 'COMPOUND:941', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:7841', 'target': 'COMPOUND:4962', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.6666666666666667,c5f00f123ce9413f353c34f280f58d79,a2198fad0c694ba82ac090ed1ba587f1,"['Tecemotide is known to decrease the efficacy of several compounds, including the chemotherapy drug carboplatin, the industrial solvent 2-methoxyethanol, and carfilzomib, a proteasome inhibitor used in cancer treatment. Additionally, the cancer drug dasatinib also has negative interactions with several substances, including a decrease in efficacy when used in conjunction with tecemotide, tiratricol (a synthetic thyroid hormone), and INGN 225, a cancer treatment vaccine. Interestingly, tiratricol also decreases the efficacy of foretinib, a multi-targeted receptor tyrosine kinase inhibitor.', 'The drug tecemotide is known to decrease the efficacy of several other substances including carboplatin, 2-methoxyethanol, and carfilzomib. Similarly, dasatinib also reduces the efficacy of some substances, including tiratricol, ingn 225, and even tecemotide. Interestingly, the efficacy of the substance foretinib is diminished by tiratricol.', 'The drugs tecemotide and dasatinib have been documented to decrease the efficacy of several other substances. Specifically, tecemotide could reduce the effectiveness of carboplatin, 2-methoxyethanol, and carfilzomib. On the other hand, dasatinib is known to hamper the function of tiratricol, ingn 225, and even tecemotide itself. Interestingly, one should also note that tiratricol can decrease the efficacy of foretinib. This information indicates a complex network of interactions and effects among these substances, highlighting the importance of considering potential drug-drug interactions in treatment planning.', 'The therapeutic action of the drug Tecemotide can potentially decrease the efficacy of several other substances, including Carboplatin, 2-Methoxyethanol, and Carfilzomib. In a similar manner, Dasatinib, another medication, is known to reduce the effectiveness of Tiratricol, INGN 225, and interestingly, also Tecemotide. Moreover, it is worth noting that Tiratricol, which has its efficacy reduced by Dasatinib, also has a negative impact on the function of another drug called Foretinib. The implications of these interactions are crucial in the field of pharmacology and can influence the sequence and combinations of medications provided to patients.', 'The drug tecemotide is known to decrease the efficacy of carboplatin, 2-methoxyethanol, and carfilzomib. Similarly, dasatinib, another drug, reduces the effectiveness of tiratricol, ingn 225, and even tecemotide itself. Moreover, tiratricol also has a diminishing effect on the efficacy of foretinib.']","['The drug Tecemotide has been observed to decrease the efficacy of several agents, including Carboplatin, 2-Methoxyethanol, and Carfilzomib. Similarly, another drug, Dasatinib, is also known to lessen the effectiveness of INGN 225. In the same context, 2-Methoxyethanol as well can decrease the potency of Carboplatin, leading to reduced results. Interestingly, the drug Tiratricol, besides causing a decrease in the efficacy of Foretinib, is also said to lower the efficiency of Carboplatin. Likewise, Carfilzomib reduces the efficacy of INGN 225. These decrements in efficiencies between various drugs highlight the complex interactions and possible counter-effects in multi-drug treatments.', 'Tecemotide is a drug that has shown to decrease the efficacy of carboplatin, 2-methoxyethanol, and carfilzomib. Additionally, 2-methoxyethanol also has been observed to decrease the efficacy of carboplatin. On the other hand, dasatinib decreases the efficacy of INGN 225, another drug. Similarly, tiratricol, a thyroid hormone analog, has been reported to decrease the efficacy of foretinib and carboplatin. Carfilzomib, a proteasome inhibitor used for cancer treatment, also has been found to reduce the efficacy of INGN 225.', 'Tecemotide, a molecule often used for therapeutic purposes, is known to decrease the efficacy of certain treatments such as carboplatin, and carfilzomib. Furthermore, it also affects the effectiveness of 2-methoxyethanol. Another interesting interaction is that dasatinib, a commonly used drug in cancer treatments, also lessens the efficacy of INGN 225. Interestingly, 2-methoxyethanol and tiratricol both seem to decrease the efficacy of carboplatin, with tiratricol showing similar effects on foretinib. Furthermore, the drug carfilzomib also appears to have a diminished effectiveness when interacting with INGN 225.', 'The drug tecemotide has been found to diminish the efficacy of other drugs, including carboplatin, 2-methoxyethanol, and carfilzomib. In similar situations, dasatinib and 2-methoxyethanol are also known to reduce the effectiveness of INGN 225 and carboplatin respectively. Furthermore, tiratricol demonstrates this decreasing efficacy effect on both foretinib and carboplatin. Finally, carfilzomib has shown a decrease in the efficiency of INGN 225. These interactions are crucial to be aware of when deciding on a drug treatment plan.', 'The drug Tecemotide is known to decrease the efficacy of several other substances, including Carboplatin, 2-methoxyethanol, and Carfilzomib. In a similar vein, the drug Dasatinib appears to have a diminishing effect on the efficacy of Ingn 225. Interestingly, 2-methoxyethanol has also been noted to reduce the effectiveness of Carboplatin. Among other therapeutics, Tiratricol is another substance that exhibits this capacity to decrease the efficacy of other drugs, including Foretinib and Carboplatin. Finally, Carfilzomib also seems to have a decreasing effect on the efficacy of Ingn 225. These interactions are critical when considering drug combinations and treatment protocols in medical practice.']"
"[{'source_node': {'name': 'isotenuifolide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'du-145'}}, {'source_node': {'name': 'isotenuifolide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lncap'}}]","[{'source_node': {'name': 'isotenuifolide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lncap'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5857', 'target': None, 'metadata': {'node_id': '5857', 'node_type': 'PROTEIN', 'display_name': 'du-145'}}]",0.6,bec42ed5325314fb4c0624a1a04c28a6,c4f279dd439672f4335c29272e2e7a0d,"['The compound Isotenuifolide targets both DU-145 and LNCaP.', 'The compound isotenuifolide is known to target both DU-145 and LNCaP, which are specific cell lines used in cancer research.', 'Isotenuifolide, a bioactive compound, has been identified as a potential therapeutic agent due to its ability to target not only cancer cell DU-145 but also LNCaP.', 'The compound isotenuifolide displays a targeted effect on both DU-145 and LNCaP, which are types of cancer cells.', 'The compound isotenuifolide has been observed to target two specific entities: DU-145 and LNCaP.']",[]
"[{'source_node': {'name': 'bismuth subsalicylate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'thyrotropin alfa'}}, {'source_node': {'name': 'bismuth subsalicylate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'magnesium salicylate'}}, {'source_node': {'name': 'bismuth subsalicylate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'tiratricol'}}, {'source_node': {'name': 'tiratricol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hexestrol'}}, {'source_node': {'name': 'tiratricol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'indenolol'}}, {'source_node': {'name': 'magnesium salicylate'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' hypotension '}}, {'source_node': {'name': 'magnesium salicylate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nicorandil'}}, {'source_node': {'name': 'magnesium salicylate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'prostalene'}}]","[{'source_node': {'name': 'prostalene'}, 'relation': {'name': 'decrease_effect'}, 'target_node': {'name': ' hypotension '}}, {'source_node': {'name': 'bismuth subsalicylate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'thyrotropin alfa'}}, {'source_node': {'name': 'tiratricol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hexestrol'}}, {'source_node': {'name': 'tiratricol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'indenolol'}}, {'source_node': {'name': 'magnesium salicylate'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' hypotension '}}, {'source_node': {'name': 'magnesium salicylate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nicorandil'}}, {'source_node': {'name': 'magnesium salicylate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'prostalene'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:1268', 'target': 'COMPOUND:3391', 'metadata': None}, {'type': 'edge_deletion', 'source': 'COMPOUND:1268', 'target': 'COMPOUND:1338', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:9411', 'target': 'EFFECT:36', 'metadata': {'predicate': 'decrease_effect'}}]",0.8235294117647058,9d156772fed0ad4bf4e436d53d082544,379fb53489e2a0e1176cffbe867d745f,[],[]
"[{'source_node': {'name': 'hypotrichosis 13'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of dental morphology'}}, {'source_node': {'name': 'hypotrichosis 13'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of skin morphology'}}, {'source_node': {'name': 'hypotrichosis 13'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormal sweat gland morphology'}}]","[{'source_node': {'name': 'hypotrichosis 13'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormal sweat gland morphology'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:7536', 'target': None, 'metadata': {'node_id': '7536', 'node_type': 'PHENOTYPE', 'display_name': 'abnormality of skin morphology'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:4232', 'target': None, 'metadata': {'node_id': '4232', 'node_type': 'PHENOTYPE', 'display_name': 'abnormality of dental morphology'}}]",0.4285714285714286,6e266b2f996eaaeb6c2aa22974ead06c,7729255b87e245f55f20b84c5cce4afd,"['Hypotrichosis 13 is a medical condition that is characterized by a range of phenotypes. These include an abnormality of dental morphology, abnormality of skin morphology, as well as an abnormal sweat gland morphology.']",[]
"[{'source_node': {'name': 'tepoxalin'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the antihypertensive activities '}}, {'source_node': {'name': 'tepoxalin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bethanidine'}}, {'source_node': {'name': 'tepoxalin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dexniguldipine'}}, {'source_node': {'name': 'dexniguldipine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hyperkalemic activities '}}, {'source_node': {'name': 'dexniguldipine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ketoprofen'}}, {'source_node': {'name': 'dexniguldipine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'benoxaprofen'}}, {'source_node': {'name': 'bethanidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'droxicam'}}, {'source_node': {'name': 'bethanidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'glycol salicylate'}}]","[{'source_node': {'name': 'benoxaprofen'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'droxicam'}}, {'source_node': {'name': 'tepoxalin'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the antihypertensive activities '}}, {'source_node': {'name': 'tepoxalin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'glycol salicylate'}}, {'source_node': {'name': 'dexniguldipine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ketoprofen'}}, {'source_node': {'name': 'dexniguldipine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'benoxaprofen'}}, {'source_node': {'name': 'bethanidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'droxicam'}}, {'source_node': {'name': 'bethanidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'glycol salicylate'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:9422', 'target': 'COMPOUND:207', 'metadata': None}, {'type': 'edge_deletion', 'source': 'COMPOUND:9422', 'target': 'COMPOUND:11898', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:4528', 'target': 'COMPOUND:8150', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:9422', 'target': 'COMPOUND:9301', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'ACTIVITY:28', 'target': None, 'metadata': {'node_id': '28', 'node_type': 'ACTIVITY', 'display_name': ' the hyperkalemic activities '}}]",0.6470588235294117,0357cf5673b9fa06a10a20ab33d73101,8f02634448ffcfa1df8b3c65178275e1,[],[]
"[{'source_node': {'name': 'dexelvucitabine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rubella virus vaccine'}}, {'source_node': {'name': 'dexelvucitabine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bcg vaccine'}}, {'source_node': {'name': 'dexelvucitabine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'adenovirus type 7 vaccine live'}}]","[{'source_node': {'name': 'dexelvucitabine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rubella virus vaccine'}}, {'source_node': {'name': 'dexelvucitabine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bcg vaccine'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:12391', 'target': None, 'metadata': {'node_id': '12391', 'node_type': 'COMPOUND', 'display_name': 'adenovirus type 7 vaccine live'}}]",0.7142857142857143,6cdacbd497df3c66bb11e03b3439eda1,e0c0666dad325ba7e4074530418db153,"['The drug Dexelvucitabine has been found to decrease the efficacy of several vaccines, including the Rubella virus vaccine, BCG vaccine, and the Adenovirus type 7 live vaccine. Therefore, caution should be exercised when administering these vaccines concurrently with Dexelvucitabine.', 'The drug dexelvucitabine has been observed to decrease the efficacy of several vaccines, including the rubella virus vaccine, bcg vaccine, and the adenovirus type 7 live vaccine. This suggests that individuals undergoing treatment with dexelvucitabine may require alternative vaccination strategies or dosages to achieve effective immunization.', 'The drug Dexelvucitabine has been found to decrease the efficacy of various vaccines including the Rubella virus vaccine, BCG vaccine, and Adenovirus type 7 vaccine live. This may have implications on immunization outcomes and requires careful consideration when administering these vaccines concurrently with Dexelvucitabine.', 'The drug Dexelvucitabine has been shown to decrease the efficacy of several vaccines. Specifically, it diminishes the effectiveness of the Rubella virus vaccine, the BCG vaccine, and the Adenovirus type 7 live vaccine.', 'The drug dexelvucitabine can potentially decrease the efficacy of several vaccines such as the rubella virus vaccine, BCG vaccine, and the adenovirus type 7 live vaccine. This highlights the importance of considering drug interactions when planning vaccination programs.']","['The drug dexelvucitabine is known to decrease the efficacy of some vaccines, notably the rubella virus vaccine and the BCG vaccine.', 'The drug Dexelvucitabine is known to decrease the efficacy of certain vaccines such as the Rubella virus vaccine and BCG vaccine. This could potentially reduce the effectiveness of these vaccines in protecting against their respective diseases. Therefore, caution may be needed when providing these vaccines to patients who are also taking Dexelvucitabine.', 'The drug Dexelvucitabine has been found to decrease the efficacy of certain vaccines including the Rubella virus vaccine and the BCG vaccine.', 'The drug Dexelvucitabine is known to decrease the efficacy of several vaccines, including the Rubella Virus Vaccine and the BCG Vaccine.', 'The drug Dexelvucitabine is known to decrease the efficacy of various vaccines, including the Rubella virus vaccine and the BCG vaccine. This information is important for healthcare providers when considering vaccine administration in patients who are also taking Dexelvucitabine.']"
"[{'source_node': {'name': 'cra_10433'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'trypsin-1'}}, {'source_node': {'name': 'trypsin-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PRSS1'}}]","[{'source_node': {'name': 'cra_10433'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'trypsin-1'}}]","[{'type': 'node_removal', 'source': 'GENE:31747', 'target': None, 'metadata': {'node_id': '31747', 'node_type': 'GENE', 'display_name': 'PRSS1'}}]",0.6,4f575b79ee092bf6136d47cbe95e5bac,3c819a068e18578f3626dbafbe1c7eaf,"['The compound cra_10433 has the protein trypsin-1 as its target. Trypsin-1 is a gene product of PRSS1.', 'The compound cra_10433 is known to target trypsin-1, which is a gene product of PRSS1.', 'The molecule cra_10433 has a target interaction with trypsin-1, which is a gene product of PRSS1.', 'The compound cra_10433 has a target in the form of trypsin-1. The protein trypsin-1 is a gene product of PRSS1.', 'The compound Cra_10433 specifically targets the enzyme Trypsin-1. Notably, this enzyme is an important gene product of the gene PRSS1.']",['The compound cra_10433 has trypsin-1 as its target.']
"[{'source_node': {'name': 'inflatin d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a-375'}}, {'source_node': {'name': 'inflatin d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'inflatin d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hacat'}}]","[{'source_node': {'name': 'inflatin d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'inflatin d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hacat'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4941', 'target': None, 'metadata': {'node_id': '4941', 'node_type': 'PROTEIN', 'display_name': 'a-375'}}]",0.7142857142857143,3bf6eb7f4d87e26b05c1c750cf6ebbe6,9b747573a315886c94a5a2e0af864f38,"['The drug Inflatin D targets several cell lines, including A-375, MCF7, and HaCaT.', 'The drug Inflatin D demonstrates its effect by targeting various entities. These include A-375, MCF7, and HaCaT cells, providing a broad spectrum of targets for influencing cellular processes.', 'The compound Inflatin D has multiple targets, including A-375, MCF7, and HACAT. This highlights the broad impact this compound potentially has in terms of its interactions.', 'The drug Inflatin D has multiple targets, including A-375, MCF7, and HaCaT. These targets represent different cellular entities potentially affected by Inflatin D.', 'The drug Inflatin D has several cellular targets including A-375, MCF7, and HaCaT.']","['The compound Inflatin D has been identified to target multiple cells, specifically MCF7 and HaCaT cells.', 'The drug Inflatin D has been shown to target two different cellular entities: MCF7 and HaCaT.', 'The drug Inflatin D has targets that include both MCF7 and HaCaT cells.', 'The drug Inflatin D is known to target both MCF7, a breast cancer cell line, and HaCaT, a line of human keratinocytes. This range of targets reflects the broad therapeutic potential for Inflatin D in treating conditions related to these cell types.', 'The drug Inflatin D targets both MCF7 and HaCaT cells.']"
"[{'source_node': {'name': 'HMGCL'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': '3-hydroxy-3-methylglutaryl-coa lyase deficiency'}}, {'source_node': {'name': 'HMGCL'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of Ketone Bodies'}}, {'source_node': {'name': 'HMGCL'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Peroxisomal protein import'}}]","[{'source_node': {'name': 'HMGCL'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of Ketone Bodies'}}, {'source_node': {'name': 'HMGCL'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Peroxisomal protein import'}}]","[{'type': 'node_removal', 'source': 'DISEASE:6831', 'target': None, 'metadata': {'node_id': '6831', 'node_type': 'DISEASE', 'display_name': '3-hydroxy-3-methylglutaryl-coa lyase deficiency'}}]",0.7142857142857143,1c24d6d77c3a47fb3d93fc802a417204,32244d488eabcd992c5943a12c84caa2,"['The gene HMGCL, which functions as a key factor in the synthesis of ketone bodies as well as in peroxisomal protein import, is known to cause 3-hydroxy-3-methylglutaryl-coa lyase deficiency.', 'The gene HMGCL which is crucial in the synthesis of ketone bodies and in peroxisomal protein import, can cause a condition known as 3-hydroxy-3-methylglutaryl-coa lyase deficiency.', 'The gene HMGCL, which is actively involved in the Synthesis of Ketone Bodies and peroxisomal protein import, is known to cause a condition known as 3-hydroxy-3-methylglutaryl-CoA lyase deficiency.', 'The HMGCL gene is involved in two important physiological processes, namely the synthesis of ketone bodies and peroxisomal protein import. Interestingly, an abnormal functioning or mutation of the HMGCL gene can lead to the induction of a condition known as 3-hydroxy-3-methylglutaryl-CoA lyase deficiency.', 'The gene HMGCL is notably active within two metabolic pathways: the synthesis of ketone bodies and peroxisomal protein import. Interestingly, mutations in HMGCL cause a condition known as 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency, a rare genetic disorder affecting metabolism.']","['The gene HMGCL operates within multiple biological pathways. One of its significant roles is in the synthesis of ketone bodies and it additionally contributes to peroxisomal protein import.', 'The gene HMGCL is involved in the synthesis of ketone bodies and also acts within the process of peroxisomal protein import.', 'The gene HMGCL plays a critical role in the synthesis of ketone bodies and also acts within the process of peroxisomal protein import.', 'The gene HMGCL, which plays a role in the synthesis of ketone bodies, also acts within the process of peroxisomal protein import.', 'The gene HMGCL is involved in two significant biological processes, namely the synthesis of ketone bodies and the import of peroxisomal proteins.']"
"[{'source_node': {'name': 'gyrosanin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}, {'source_node': {'name': 'gyrosanin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'source_node': {'name': 'gyrosanin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5849', 'target': None, 'metadata': {'node_id': '5849', 'node_type': 'PROTEIN', 'display_name': 'a549'}}]",0.6,f736470b4a39e7f1a97f0c2ffb0adbac,bff12a8299dd47c0da8ec5c7f825e308,"['The compound Gyrosanin A is known to target cells, specifically those identified as HT-29 and A549.', 'The drug Gyrosanin A has been identified to target two specific cell lines: HT-29 and A549.', 'The compound Gyrosanin A targets both HT-29 and A549 cells.', 'The compound Gyrosanin A has been found to target the cell lines HT-29 and A549.', 'Gyrosanin A is a compound known to target certain cell lines, specifically HT-29 and A549 cells. These properties make it potentially beneficial in therapeutic research.']","['The compound Gyrosanin A has been found to target the HT-29 cells.', 'The compound Gyrosanin A has a biological target of HT-29.']"
"[{'source_node': {'name': 'autosomal recessive spastic paraplegia type 25'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'sensorimotor neuropathy'}}, {'source_node': {'name': 'autosomal recessive spastic paraplegia type 25'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'upper limb pain'}}, {'source_node': {'name': 'autosomal recessive spastic paraplegia type 25'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormal lumbar spine morphology'}}]","[{'source_node': {'name': 'autosomal recessive spastic paraplegia type 25'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'sensorimotor neuropathy'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:11146', 'target': None, 'metadata': {'node_id': '11146', 'node_type': 'PHENOTYPE', 'display_name': 'abnormal lumbar spine morphology'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:8898', 'target': None, 'metadata': {'node_id': '8898', 'node_type': 'PHENOTYPE', 'display_name': 'upper limb pain'}}]",0.4285714285714286,97e1560d574f579e5549571fe0dcb21d,74025d28c5aca487bf6ae0cfc2ebecd1,"['Autosomal recessive spastic paraplegia type 25 is a condition that presents with several phenotypic traits, including sensorimotor neuropathy, upper limb pain, and an abnormal lumbar spine morphology. These phenotypes are notable for the overall understanding and management of the disease.', 'Autosomal recessive spastic paraplegia type 25 is a genetic disorder with diverse phenotypic expressions including sensorimotor neuropathy, upper limb pain, and abnormal lumbar spine morphology.', ""Autosomal recessive spastic paraplegia type 25 is a condition that presents a variety of phenotypes, including sensorimotor neuropathy, which affects the person's sensitivity to touch, temperature, and bodily awareness in the limbs and torso. Furthermore, individuals suffering from this condition often report upper limb pain. Additionally, the condition is characterized by an abnormal lumbar spine morphology, which can lead to various back issues.""]",[]
"[{'source_node': {'name': 'tinoridine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'travoprost'}}, {'source_node': {'name': 'tinoridine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'macitentan'}}, {'source_node': {'name': 'tinoridine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'urapidil'}}, {'source_node': {'name': 'travoprost'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nabumetone'}}, {'source_node': {'name': 'travoprost'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Subconjunctival hemorrhage'}}, {'source_node': {'name': 'travoprost'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Urethral disorder'}}]","[{'source_node': {'name': 'urapidil'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Subconjunctival hemorrhage'}}, {'source_node': {'name': 'macitentan'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Urethral disorder'}}, {'source_node': {'name': 'tinoridine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'travoprost'}}, {'source_node': {'name': 'tinoridine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'macitentan'}}, {'source_node': {'name': 'tinoridine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'urapidil'}}, {'source_node': {'name': 'travoprost'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nabumetone'}}, {'source_node': {'name': 'travoprost'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Subconjunctival hemorrhage'}}, {'source_node': {'name': 'travoprost'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Urethral disorder'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:10545', 'target': 'SIDE_EFFECT:3280', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'edge_addition', 'source': 'COMPOUND:7879', 'target': 'SIDE_EFFECT:436', 'metadata': {'predicate': 'has_side_effect'}}]",0.8461538461538461,c6c67d4137812f2ca57c53355f19fdec,7d07c0ce4fcb7aeddecc51584a96b943,"[""The drug Tinoridine is notable for its capacity to decrease the efficacy of several drugs including Travoprost, Macitentan, and Urapidil. Speaking of Travoprost, aside from its efficacy being influenced by Tinoridine, it is known to decrease the efficacy of yet another drug, Nabumetone. Moreover, Travoprost has been associated with certain side effects such as subconjunctival hemorrhage and urethral disorder. It's important to consider these interactions and potential ramifications when prescribing these medications to patients."", 'The drug tinoridine is known to decrease the efficacy of several other medications such as travoprost, macitentan, and urapidil. Interestingly, travoprost also has the potential to decrease the efficacy of another drug called nabumetone. Regarding side effects, travoprost has been linked to certain health concerns including a subconjunctival hemorrhage and urethral disorder.', 'The drug tinoridine has been shown to decrease the efficacy of several other medications including travoprost, macitentan, and urapidil. In turn, travoprost not only has its efficacy reduced by tinoridine but also adversely impacts the efficacy of nabumetone. Beyond these interactions, travoprost has been associated with certain side effects, some of which include Subconjunctival hemorrhage and Urethral disorder.', 'The drug tinoridine has been found to decrease the efficacy of multiple other drugs such as travoprost, macitentan and urapidil. Notably, travoprost itself also plays a similar role by decreasing the efficacy of nabumetone. Furthermore, this drug has been reported to cause a number of side effects including subconjunctival hemorrhage and urethral disorder.', 'The drug Tinoridine is known to decrease the efficacy of several other medications, including Travoprost, Macitentan, and Urapidil. Additionally, Travoprost itself has been observed to diminish the efficacy of Nabumetone. Furthermore, use of Travoprost may lead to some side effects, such as a Subconjunctival hemorrhage or a Urethral disorder. It is important for patients to be mindful of potential drug interactions and side effects when taking these medications.']","['The drug Urapidil has a side effect which can lead to Subconjunctival hemorrhage. Similarly, the drug Macitentan is also associated with a side effect, specifically Urethral disorder. The drug Tinoridine has been found to decrease the efficacy of the drugs Travoprost, Macitentan, and Urapidil. Interestingly, the use of Travoprost can also decrease the efficacy of the drug Nabumetone. In addition to this, Travoprost can lead to side effects such as Subconjunctival hemorrhage and Urethral disorder, similar to Urapidil and Macitentan. These associations suggest a complex interplay between these drugs in terms of their effects and efficiencies.', 'In the field of pharmacology, complex interactions and side-effects exist between different drugs. For instance, Urapidil and Travoprost both have a side effect of causing Subconjunctival hemorrhage. Interestingly, Travoprost has also been known to lead to Urethral disorder, a side effect that it shares with Macitentan. However, these interactions get even more complex when considering the effect of Tinoridine. This drug is found to decrease the efficacy of Travoprost, Macitentan, and Urapidil. Travoprost is further implicated in these intricate interactions, as it has been found to decrease the efficacy of Nabumetone. Therefore, careful consideration is needed when using these drugs in unison, as their interactions could affect treatment effectiveness and patient well-being.', 'The medication Urapidil has been noted to have a side effect of causing Subconjunctival hemorrhage. On another note, the drug Macitentan can result in a side effect, namely Urethral disorder. \n\nMeanwhile, Tinoridine is a medicine that can decrease the efficacy of three drugs. These include Travoprost, Macitentan, and Urapidil. \n\nInterestingly, the efficacy of Nabumetone is reduced by Travoprost. Also, Travoprost has been reported to cause Subconjunctival hemorrhage and Urethral disorder as side effects.']"
"[{'source_node': {'name': 'GPCPD1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Hydrolysis of LPC'}}, {'source_node': {'name': 'GPCPD1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Hydrolysis of LPE'}}]","[{'source_node': {'name': 'GPCPD1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Hydrolysis of LPC'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:2004', 'target': None, 'metadata': {'node_id': '2004', 'node_type': 'PATHWAY', 'display_name': 'Hydrolysis of LPE'}}]",0.6,14ebd139b0f8e556d428c89f22d7d8a3,56757d639f64c85f17e7bc17e12f0e37,"['The gene GPCPD1 plays a role in multiple biological processes including the hydrolysis of LPC and the hydrolysis of LPE.', 'The gene GPCPD1 is involved in functioning within multiple pathways such as the hydrolysis of LPC and the hydrolysis of LPE.', 'The gene GPCPD1 plays a role in several biochemical processes, including the hydrolysis of LPC and the hydrolysis of LPE.', 'The gene GPCPD1 has a role in several pathways, acting within both the hydrolysis of LPC and the hydrolysis of LPE.', 'The gene GPCPD1 plays a role in several processes including the hydrolysis of LPC and LPE.']","['The gene GPCPD1 is known to act within the process of hydrolysis of LPC.', 'The gene GPCPD1 operates within the process of hydrolysis of LPC.', 'The gene GPCPD1 functions within the process known as the hydrolysis of LPC.', 'The gene GPCPD1 acts within the pathway of hydrolysis of LPC.', 'The gene GPCPD1 is known to act within the pathway that facilitates the hydrolysis of LPC.']"
"[{'source_node': {'name': 'bamifylline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'estazolam'}}, {'source_node': {'name': 'bamifylline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pinazepam'}}, {'source_node': {'name': 'bamifylline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'patent blue'}}]","[{'source_node': {'name': 'patent blue'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'estazolam'}}, {'source_node': {'name': 'pinazepam'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'bamifylline'}}, {'source_node': {'name': 'bamifylline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'estazolam'}}, {'source_node': {'name': 'bamifylline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pinazepam'}}, {'source_node': {'name': 'bamifylline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'patent blue'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:11806', 'target': 'COMPOUND:1195', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11191', 'target': 'COMPOUND:11061', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7142857142857143,526ffabd5479be4a8d84dbfc67dd584b,0cb20b553878324854976b39d36c26b4,"['Bamifylline is found to decrease the efficacy of various substances, including estazolam, pinazepam and patent blue. By diminishing the effectiveness of these substances, bamifylline potentially influence the outcomes of therapies or processes they are involved in.', 'The drug bamifylline is known to decrease the efficacy of certain other drugs, including estazolam and pinazepam. Notably, it also lessens the effectiveness of patent blue.', 'The drug bamifylline has the ability to decrease the efficacy of multiple substances, including estazolam, pinazepam, and patent blue.', 'The drug bamifylline is known to decrease the efficacy of several other drugs. It impacts the function of estazolam, pinazepam, and patent blue, reducing their therapeutic effectiveness.', 'The drug Bamifylline is known to decrease the efficacy of several other substances, namely Estazolam, Pinazepam and Patent Blue. Thus, caution should be taken when these substances are administered concurrently with Bamifylline to avoid reduced effectiveness.']","[""The drug Patent Blue is known to increase the efficacy of another medication, Estazolam. Similarly, Pinazepam is observed to bolster the potency of Bamifylline. On the other hand, it's also noted that Bamifylline may decrease the efficacy of multiple medications, including Estazolam, Pinazepam, and even Patent Blue. Such complex interactions among these drugs indicate the necessity of a comprehensive understanding of their combinatorial use in medical treatments."", 'Patent Blue has been found to increase the efficacy of the drug Estazolam. Interestingly, Pinazepam is another drug that can increase the efficacy of Bamifylline. However, Bamifylline seems to have a counteracting effect, as it decreases the efficacy not only of Estazolam but also of Pinazepam and Patent Blue. This intricate interplay among these drugs depicts the complicated nature of biochemistry affecting drug efficacy.', 'The drug Patent Blue is known to increase the efficacy of another drug named Estazolam. Similarly, Pinazepam also increases the efficacy of a different drug called Bamifylline. However, it is important to consider that Bamifylline has been shown to decrease the efficacy of other drugs it interacts with, including Estazolam, Pinazepam, and Patent Blue, thus potentially counteracting their expected effects.', 'The drug Patent Blue enhances the efficacy of another drug named Estazolam. Interestingly, Pinazepam, another drug, also improves the efficacy of a drug named Bamifylline. However, it appears that Bamifylline reduces the effectiveness of several drugs. It is reported to diminish the efficacy of Estazolam, Pinazepam, as well as Patent Blue. Therefore, patients on these medications should be aware of this interaction.', ""The drug Patent Blue is known to increase the efficacy of Estazolam. Similarly, Pinazepam also increases the efficacy of another drug called Bamifylline. However, it's interesting to note that Bamifylline has been found to decrease the efficacy of not just one other drug, but three: it reduces the effectiveness of Estazolam, Pinazepam, and also Patent Blue.""]"
"[{'source_node': {'name': 'xanthine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pinazepam'}}, {'source_node': {'name': 'pentoxifylline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'dermatan sulfate'}}, {'source_node': {'name': 'pentoxifylline'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Leukaemia'}}, {'source_node': {'name': 'pentoxifylline'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Vascular purpura'}}, {'source_node': {'name': 'doxefazepam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dyphylline'}}, {'source_node': {'name': 'doxefazepam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pentoxifylline'}}, {'source_node': {'name': 'doxefazepam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'xanthine'}}]","[{'source_node': {'name': 'xanthine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pinazepam'}}, {'source_node': {'name': 'xanthine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Vascular purpura'}}, {'source_node': {'name': 'pentoxifylline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'dermatan sulfate'}}, {'source_node': {'name': 'pentoxifylline'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Leukaemia'}}, {'source_node': {'name': 'pentoxifylline'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Vascular purpura'}}, {'source_node': {'name': 'pentoxifylline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dyphylline'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:11684', 'target': 'COMPOUND:789', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:2025', 'target': 'SIDE_EFFECT:968', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:11684', 'target': 'COMPOUND:2025', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:789', 'target': 'COMPOUND:637', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:11684', 'target': None, 'metadata': {'node_id': '11684', 'node_type': 'COMPOUND', 'display_name': 'doxefazepam'}}]",0.6,ea6b0c033bdf0e87a40685e4e44c75fc,539f4062c6ec5d68f7b90c510a33d5f8,"['Xanthine is a substance known to decrease the efficacy of the drug Pinazepam. Another drug, Pentoxifylline, is also present in this network, which not only has an increased efficacy with Dermatan sulfate but also has potential side effects. These side effects include Leukaemia and Vascular purpura. \n\nAdditionally, a drug named Doxefazepam reveals interesting interactions within this network. Doxefazepam has a reduced efficacy when it comes into contact with substances such as Dyphylline, Pentoxifylline, and Xanthine. These complex drug interactions highlight the intricate nature of pharmacology and its corresponding effects on drug efficacy and potential side effects.', 'Xanthine decreases the efficacy of pinazepam, a medication used for its sedative properties. Also, a drug called doxefazepam acts similarly, decreasing the efficacy of dyphylline, pentoxifylline, and even xanthine itself. Meanwhile, pentoxifylline exhibits a more complex behavior. Not only does it increase the efficacy of dermatan sulfate, but it also has potential side effects, including the onset of Leukaemia or Vascular purpura. All things considered, the interactions and functions of these substances suggest complex pharmacological dynamics that warrant further research.']","['The drug xanthine is known to decrease the efficacy of pinazepam and may induce a side effect of causing vascular purpura. Meanwhile, the drug pentoxifylline not only increases the efficacy of dermatan sulfate but also brings about a series of side effects. These unwanted outcomes might include conditions such as leukaemia and vascular purpura. Intriguingly, whilst pentoxifylline augments the effect of dermatan sulfate, it actually decreases the efficacy of dyphylline.', ""Xanthine, a compound found in most human body tissues and fluids, can potentially decrease the efficacy of the drug pinazepam, perhaps leading to a diminished therapeutic response. In addition, xanthine may have a side effect known as vascular purpura, which is a condition characterized by the appearance of purple spots on the skin caused by small blood vessels bursting under the skin surface.\n\nInterestingly, pentoxifylline, a drug often used to improve the symptoms of a certain blood flow disorder, may increase the efficacy of dermatan sulfate, a type of molecule that's part of a family of carbohydrates called glycosaminoglycans. This could amplify the therapeutic effects of dermatan sulfate. However, it is important to note that pentoxifylline has been observed to have side effects such as causing leukaemia and the aforementioned vascular purpura. Moreover, pentoxifylline might decrease the efficacy of dyphylline, which is a bronchodilator used to treat asthma and other related breathing problems. This interference could potentially lead to suboptimal treatment outcomes for patients."", 'Xanthine is a substance that is known to decrease the efficacy of the drug pinazepam and also has a side effect of causing Vascular purpura. Similarly, pentoxifylline, another drug, increases the efficacy of dermatan sulfate but unfortunately, has side effects such as causing Leukaemia and Vascular purpura. Furthermore, pentoxifylline also decreases the efficacy of dyphylline. Therefore, careful usage and dosage of these drugs are crucial due to the potential side effects and interaction with other substances.', 'The drug xanthine has been found to decrease the efficacy of pinazepam, and it can also cause a side effect known as vascular purpura. On the other hand, pentoxifylline, another drug, has shown promise in increasing the efficacy of dermatan sulfate. However, pentoxifylline also has some side effects, notably vascular purpura and even leukaemia. Furthermore, pharmaceutical research also suggests that it may decrease the efficacy of dyphylline. Therefore, when prescribing medications, physicians must carefully weigh the potential benefits against the potential side effects and interactions with other drugs.', 'Xanthine, a purine base found in most human body tissues and fluids and in other organisms, is known to decrease the efficacy of pinazepam, a drug typically used for the short-term relief of anxiety. In addition, the intake of Xanthine can lead to a side effect of vascular purpura, a disorder resulting in red or purple discolorations on the skin caused by bleeding underneath the skin. On the other hand, the drug pentoxifylline is noted to increase the efficacy of dermatan sulfate, a kind of glycosaminoglycan, and is reported to have side effects such as leukaemia, a group of cancers that usually begin in the bone marrow and result in high numbers of abnormal white blood cells, and vascular purpura. However, pentoxifylline has been shown to decrease the efficacy of another drug known as dyphylline, a bronchodilator.']"
"[{'source_node': {'name': 'stiff skin syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'strabismus'}}, {'source_node': {'name': 'stiff skin syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'retinal detachment'}}, {'source_node': {'name': 'stiff skin syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'aplasia/hypoplasia of the skin'}}]","[{'source_node': {'name': 'stiff skin syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'strabismus'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:5110', 'target': None, 'metadata': {'node_id': '5110', 'node_type': 'PHENOTYPE', 'display_name': 'aplasia/hypoplasia of the skin'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:415', 'target': None, 'metadata': {'node_id': '415', 'node_type': 'PHENOTYPE', 'display_name': 'retinal detachment'}}]",0.4285714285714286,41c693469f0487882aabb11d983f4e1d,69c6bd994e48a63df8586eb03b4f0a42,"['""Stiff skin syndrome is a health condition characterized by several distinct phenomena inclusive of strabismus and retinal detachment. More notably, the syndrome often results in aplasia/hypoplasia of the skin, which is characterized by underdevelopment or complete absence of the skin.']",[]
"[{'source_node': {'name': 'CYP51A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cholesterol biosynthesis'}}, {'source_node': {'name': 'CYP51A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Endogenous sterols'}}, {'source_node': {'name': 'CYP51A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Activation of gene expression by SREBF (SREBP)'}}]","[{'source_node': {'name': 'CYP51A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cholesterol biosynthesis'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:689', 'target': None, 'metadata': {'node_id': '689', 'node_type': 'PATHWAY', 'display_name': 'Endogenous sterols'}}, {'type': 'node_removal', 'source': 'PATHWAY:682', 'target': None, 'metadata': {'node_id': '682', 'node_type': 'PATHWAY', 'display_name': 'Activation of gene expression by SREBF (SREBP)'}}]",0.4285714285714286,ea090c1c57cdf01868312130e40d84b5,7755fe642f655f1c105d5c15b2140daf,[],"['The enzyme CYP51A1 functions within the pathway responsible for cholesterol biosynthesis.', 'The gene CYP51A1 is known to function as an important player within the cholesterol biosynthesis pathway.', 'The enzyme CYP51A1 plays a crucial role in cholesterol biosynthesis.']"
"[{'source_node': {'name': 'glutamate receptor 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GRIA1'}}, {'source_node': {'name': 'fluciclovine (18f)'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'y+l amino acid transporter 1'}}, {'source_node': {'name': 'fluciclovine (18f)'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glutamate receptor 1'}}, {'source_node': {'name': 'fluciclovine (18f)'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glutamate receptor 4'}}, {'source_node': {'name': 'y+l amino acid transporter 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SLC7A7'}}, {'source_node': {'name': 'glutamate receptor 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GRIA4'}}]","[{'source_node': {'name': 'glutamate receptor 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GRIA1'}}, {'source_node': {'name': 'glutamate receptor 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GRIA4'}}, {'source_node': {'name': 'fluciclovine (18f)'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'y+l amino acid transporter 1'}}, {'source_node': {'name': 'fluciclovine (18f)'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glutamate receptor 1'}}, {'source_node': {'name': 'fluciclovine (18f)'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'GRIA1'}}, {'source_node': {'name': 'y+l amino acid transporter 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SLC7A7'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:424', 'target': 'GENE:28381', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:11013', 'target': 'PROTEIN:424', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:11013', 'target': 'GENE:28381', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:419', 'target': 'GENE:28384', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'PROTEIN:424', 'target': None, 'metadata': {'node_id': '424', 'node_type': 'PROTEIN', 'display_name': 'glutamate receptor 4'}}]",0.6153846153846154,9c9aff23ae57a183f5c220de18399f64,f861e934da81a65b215e3925ae087958,"['Fluciclovine (18F) is a drug with multiple targets including the Y+L amino acid transporter 1, glutamate receptor 1, and glutamate receptor 4. These targets are the gene products of various genes. Specifically, the Y+L amino acid transporter 1 is a gene product of SLC7A7, while the glutamate receptor 1 and glutamate receptor 4 are gene products of GRIA1 and GRIA4, respectively.', ""Glutamate receptor 1, which is a gene product of GRIA1, along with glutamate receptor 4, a gene product of GRIA4, are known targets of the radiopharmaceutical drug, fluciclovine (18F). The Y+L amino acid transporter 1 is another target of fluciclovine (18F) and it's produced by the gene SLC7A7. These targets contribute to the diverse roles and interactive networks that these entities participate within the cellular environment."", 'Glutamate receptor 1 and Glutamate receptor 4 are gene products of GRIA1 and GRIA4 respectively. Similarly, the Y+L amino acid transporter 1 is also a gene product, specifically of SLC7A7. The drug Fluciclovine (18F) targets these receptors and transporter, therefore demonstrating its interaction with Y+L amino acid transporter 1, Glutamate receptor 1, and Glutamate receptor 4. This highlights the integral role of these gene products in processes or reactions instigated by Fluciclovine (18F).', 'The drug Fluciclovine (18F) targets several biological systems, including the Y+L amino acid transporter 1 and glutamate receptors 1 and 4. Interestingly, the glutamate receptor 1 is a gene product of GRIA1, revealing a genetic link in this biological interaction. Similarly, glutamate receptor 4 is a gene product of GRIA4 while Y+L amino acid transporter 1 is a gene product of SLC7A7. This demonstrates the interconnectedness and complexity of biological systems and their interactions with pharmaceutical compounds.', 'The drug Fluciclovine (18F) targets several entities, including Y+L amino acid transporter 1, glutamate receptor 1, and glutamate receptor 4. The Y+L amino acid transporter 1 is a gene product of SLC7A7. Additionally, the glutamate receptor 1 and glutamate receptor 4 are gene products of GRIA1 and GRIA4 respectively.']","['The drug fluciclovine (18f) targets both the y+l amino acid transporter 1 and the glutamate receptor 1. Furthermore, fluciclovine (18f) also influences GRIA1, which is notable as glutamate receptor 1 is the gene product of both GRIA1 and GRIA4. It is also significant to mention that y+l amino acid transporter 1 is the gene product of SLC7A7.', 'The gene glutamate receptor 1 is the product of two separate genes, GRIA1 and GRIA4. The drug Fluciclovine (18F) is known to target this glutamate receptor 1, as well as the Y+L amino acid transporter 1. In addition, it has been observed that Fluciclovine (18F) affects the function of GRIA1. On another note, the Y+L amino acid transporter 1 is the gene product of SLC7A7.', 'The protein Glutamate Receptor 1 is a gene product of both GRIA1 and GRIA4. The drug Fluciclovine (18F) is known to interact with this protein by targeting it and also affecting its associated gene GRIA1. Additionally, Fluciclovine (18F) also targets the Y+L Amino Acid Transporter 1, which is the gene product of SLC7A7.', 'The glutamate receptor 1 is a gene product of both GRIA1 and GRIA4. This receptor is targeted by a drug called fluciclovine (18f), which affects not only the glutamate receptor 1 but also the functionality of GRIA1. Additionally, fluciclovine (18f) targets another protein called y+l amino acid transporter 1, known to be a gene product of SLC7A7.', 'The compound fluciclovine (18f) has been found to target both the glutamate receptor 1 and the y+l amino acid transporter 1. Notably, glutamate receptor 1 is a gene product of GRIA1 and GRIA4, suggesting a direct impact of fluciclovine (18f) on these genes, especially since it is found to affect GRIA1 specifically. Furthermore, y+l amino acid transporter 1 is a gene product of SLC7A7, illuminating further potential paths of influence of fluciclovine (18f) in cellular mechanisms.']"
"[{'source_node': {'name': 'microtubule-associated protein tau'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MAPT'}}, {'source_node': {'name': 'geminin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GMNN'}}, {'source_node': {'name': 'santin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'microtubule-associated protein tau'}}, {'source_node': {'name': 'santin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'geminin'}}, {'source_node': {'name': 'santin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ataxin-2'}}]","[{'source_node': {'name': 'microtubule-associated protein tau'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MAPT'}}, {'source_node': {'name': 'geminin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GMNN'}}, {'source_node': {'name': 'geminin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MAPT'}}, {'source_node': {'name': 'santin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'microtubule-associated protein tau'}}, {'source_node': {'name': 'santin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ataxin-2'}}, {'source_node': {'name': 'santin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'GMNN'}}, {'source_node': {'name': 'santin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'MAPT'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:34015', 'target': 'GENE:30558', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'COMPOUND:34015', 'target': 'GENE:29856', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:5869', 'target': 'GENE:29856', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:34015', 'target': 'PROTEIN:5869', 'metadata': None}]",0.6363636363636364,ebd93235e43e3c9dc3c499626de639cb,4e222eb17a4aeb8d9ea6759aa97bdc03,"['Microtubule-associated protein tau and geminin are gene products with specific mapping to their genetic structures, MAPT and GMNN respectively. The drug santin interacts with a variety of therapeutic targets including these two above-mentioned gene products - microtubule-associated protein tau and geminin - and another protein, ataxin-2. These associations highlight the multi-targeting capability of santin.', 'Microtubule-associated protein tau and geminin are gene products of MAPT and GMNN respectively. These proteins serve as targets for the drug santin. In addition to these, ataxin-2 is also targeted by santin.', 'The drug Santin displays a multi-target action; it has the capability to target microtubule-associated protein tau, geminin, and ataxin-2. Interestingly, the microtubule-associated protein tau is a gene product of MAPT, while geminin is a gene product of GMNN.', ""The microtubule-associated protein tau is a gene product of MAPT and it's targeted by the drug Santin, as is geminin, which is a gene product of GMNN. In addition, Santin also targets ataxin-2. These relationships reveal the role Santin plays in interacting with different gene products."", 'The drug santin is known to target several proteins, such as the microtubule-associated protein tau, geminin, and ataxin-2. The microtubule-associated protein tau and geminin are the gene products of MAPT and GMNN genes, respectively.']","['Microtubule-associated protein tau and geminin are gene products of MAPT and GMNN respectively. Interestingly, geminin also appears to be a gene product of MAPT. The drug Santin focuses its action on microtubule-associated protein tau and ataxin-2, as these are its primary targets. Furthermore, it affects both GMNN and MAPT, crucial genes associated with these proteins. It is clear to see the interconnected nature of these genes, proteins, and the drug Santin in this biological network.', 'The microtubule-associated protein tau and geminin are both gene products of MAPT. Interestingly, geminin is also a gene product of GMNN. These complex relationships are implicated in the pathways affected by the drug Santin. Santin targets several proteins, including the microtubule-associated protein tau, and ataxin-2. It also influences the expressions of genes such as GMNN and MAPT. The interconnected nature of these biomolecules may form the basis for future therapeutic strategies.']"
"[{'source_node': {'name': 'PNP'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}, {'source_node': {'name': 'PNP'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Purine salvage'}}, {'source_node': {'name': 'PNP'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Purine catabolism'}}, {'source_node': {'name': ""guanosine-2',3'-o-ethylidenephosphonate""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'purine nucleoside phosphorylase'}}, {'source_node': {'name': 'purine nucleoside phosphorylase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PNP'}}]","[{'source_node': {'name': 'PNP'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Purine catabolism'}}, {'source_node': {'name': ""guanosine-2',3'-o-ethylidenephosphonate""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'purine nucleoside phosphorylase'}}, {'source_node': {'name': 'purine nucleoside phosphorylase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PNP'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:3', 'target': None, 'metadata': {'node_id': '3', 'node_type': 'PATHWAY', 'display_name': 'Neutrophil degranulation'}}, {'type': 'node_removal', 'source': 'PATHWAY:6', 'target': None, 'metadata': {'node_id': '6', 'node_type': 'PATHWAY', 'display_name': 'Purine salvage'}}]",0.6363636363636364,502bec0551d85dcb4a3fc2ad823d6bee,50265240866bfa4137e96a81370d1878,[],[]
"[{'source_node': {'name': 'prelamin-a/c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'LMNA'}}, {'source_node': {'name': 'histone acetyltransferase kat2a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KAT2A'}}, {'source_node': {'name': 'KAT2A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Formation of paraxial mesoderm'}}, {'source_node': {'name': 'beta carotene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'free radicals'}}, {'source_node': {'name': 'beta carotene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prelamin-a/c'}}, {'source_node': {'name': 'beta carotene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histone acetyltransferase kat2a'}}]","[{'source_node': {'name': 'prelamin-a/c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'LMNA'}}, {'source_node': {'name': 'KAT2A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Formation of paraxial mesoderm'}}, {'source_node': {'name': 'beta carotene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prelamin-a/c'}}, {'source_node': {'name': 'beta carotene'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'LMNA'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:2220', 'target': None, 'metadata': {'node_id': '2220', 'node_type': 'PROTEIN', 'display_name': 'histone acetyltransferase kat2a'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5805', 'target': 'GENE:29744', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'MOLECULE:3878', 'target': None, 'metadata': {'node_id': '3878', 'node_type': 'MOLECULE', 'display_name': 'free radicals'}}]",0.5384615384615384,7551b83e9c72717ec5fe636de2d413d0,7151599efe88fb37db0c1c8860441abd,"['Prelamin-A/C, a protein product of the LMNA gene, and the enzyme Histone Acetyltransferase Kat2A, which is a product of the KAT2A gene, both interact with Beta Carotene. Beta Carotene is known to target free radicals, Prelamin-A/C and Histone Acetyltransferase Kat2A in its actions. Furthermore, the KAT2A gene, which codes for the enzyme Histone Acetyltransferase Kat2A, crucially participates within the process that leads to the formation of paraxial mesoderm.', 'The protein prelamin-a/c is a gene product of LMNA while histone acetyltransferase kat2a is a gene product of KAT2A. KAT2A acts within the formation of paraxial mesoderm. Furthermore, beta carotene acts as a shield, targeting free radicals, prelamin-a/c, and histone acetyltransferase kat2a, illustrating its varied and essential benefits.', 'Prelamin-A/C and histone acetyltransferase KAT2A are gene products of LMNA and KAT2A respectively. Notably, KAT2A plays an important role within the formation of paraxial mesoderm. On the other hand, the compound beta carotene targets several entities including free radicals, prelamin-A/C, and histone acetyltransferase KAT2A.', 'The gene product prelamin-a/c, which originates from the gene LMNA, and the gene product histone acetyltransferase kat2a, emerging from the KAT2A gene, are both targeted by the compound beta carotene. Beta carotene also targets free radicals, demonstrating its wide range of biological activity. Moreover, the gene KAT2A plays a key role within the formation of the paraxial mesoderm pathway, possibly influencing embryogenesis, suggesting the intricate interplay of these entities in varied molecular processes.', 'Prelamin-A/C, a gene product of LMNA, is targeted by Beta Carotene. This is not the only target of Beta Carotene, which also seeks out Free Radicals and Histone Acetyltransferase KAT2A. The latter actually originates from the KAT2A gene, and importantly acts within the formation of the paraxial mesoderm. Therefore, the Beta Carotene compound has interactions with an array of gene products and acts within several biological processes.']","['The substance beta carotene has a target interaction with prelamin-a/c, which is a gene product of LMNA. Furthermore, beta carotene is also affecting LMNA. On another note, the gene KAT2A acts within the formation of paraxial mesoderm, a vital process in developmental biology.']"
"[{'source_node': {'name': 'EGLN1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'erythrocytosis'}}, {'source_node': {'name': 'erythrocytosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'peripheral thrombosis'}}, {'source_node': {'name': 'erythrocytosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'plethora'}}, {'source_node': {'name': 'erythrocytosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypertension'}}]","[{'source_node': {'name': 'EGLN1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'erythrocytosis'}}, {'source_node': {'name': 'erythrocytosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'peripheral thrombosis'}}, {'source_node': {'name': 'erythrocytosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypertension'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:822', 'target': None, 'metadata': {'node_id': '822', 'node_type': 'PHENOTYPE', 'display_name': 'plethora'}}]",0.7777777777777778,821c96222d6d79b78af501151013cadd,0338f8e7e32c437cec6caedff93a9e93,"['The gene EGLN1 causes a condition known as erythrocytosis. This disease, erythrocytosis, has various phenotypes, including peripheral thrombosis, plethora, and hypertension.', 'The gene EGLN1 is known to cause a condition known as erythrocytosis. This condition manifests with several symptoms including peripheral thrombosis, plethora, and hypertension.', 'The gene EGLN1 is known to cause a condition called erythrocytosis. In turn, erythrocytosis often presents with certain phenotypes, including peripheral thrombosis, plethora, and hypertension.', 'The gene EGLN1 is known to cause a condition called erythrocytosis. This condition manifests itself through various symptoms and phenotypes such as peripheral thrombosis, plethora, and hypertension.', 'The gene EGLN1 is responsible for causing the medical condition named erythrocytosis. This condition exhibits several phenotypes, including peripheral thrombosis, plethora, and hypertension.']","['The gene EGLN1 is known to cause a condition referred to as erythrocytosis. This particular condition manifests with certain phenotypes such as peripheral thrombosis and hypertension.', 'The gene EGLN1 can cause a condition known as erythrocytosis. This condition, erythrocytosis, can exhibit several phenotypes such as peripheral thrombosis and hypertension.', 'The gene EGLN1 causes the condition known as erythrocytosis, which is characterized by an increased amount of red blood cells. Erythrocytosis has phenotypes which may include conditions such as peripheral thrombosis and hypertension.', 'The gene EGLN1 is known to cause erythrocytosis, a condition that can manifest in the form of peripheral thrombosis and hypertension.', 'The gene EGLN1 is known to cause a condition known as erythrocytosis. This condition is characterized by symptoms such as peripheral thrombosis and hypertension.']"
"[{'source_node': {'name': 'pemigatinib'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' Thrombosis '}}, {'source_node': {'name': 'pemigatinib'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' methemoglobinemia '}}, {'source_node': {'name': 'pemigatinib'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'fibroblast growth factor receptor 1'}}]","[{'source_node': {'name': 'pemigatinib'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' Thrombosis '}}]","[{'type': 'node_removal', 'source': 'EFFECT:8', 'target': None, 'metadata': {'node_id': '8', 'node_type': 'EFFECT', 'display_name': ' methemoglobinemia '}}, {'type': 'node_removal', 'source': 'GENE:6376', 'target': None, 'metadata': {'node_id': '6376', 'node_type': 'GENE', 'display_name': 'fibroblast growth factor receptor 1'}}]",0.4285714285714286,2fb652a9cc8182d97d2d590f7a9f9c3e,a268096bf7290accab876d8c0ba24eda,[],[]
"[{'source_node': {'name': 'cra_1144'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'trypsin-1'}}, {'source_node': {'name': 'cra_1144'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'serine protease hepsin'}}]","[{'source_node': {'name': 'cra_1144'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'serine protease hepsin'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:1851', 'target': None, 'metadata': {'node_id': '1851', 'node_type': 'PROTEIN', 'display_name': 'trypsin-1'}}]",0.6,983bb30a20e3cb6e120cf7d65d91fb77,e288de542ec5af646a147f746d4f870a,"['The compound cra_1144 acts as an inhibitor which targets both trypsin-1 and the serine protease hepsin molecule in biological interactions.', 'The compound cra_1144 targets both trypsin-1 and the serine protease hepsin.', 'The molecule cra_1144 has been identified as targeting two critical proteins, trypsin-1 and serine protease hepsin.', 'The compound cra_1144 is known to target two specific enzymes: trypsin-1 and the serine protease hepsin.', 'The compound cra_1144 targets both trypsin-1 and the enzyme known as serine protease hepsin.']","['The compound Cra_1144 has a target interaction with the serine protease hepsin.', 'The compound cra_1144 has the protein serine protease hepsin as its target.', 'The compound Cra_1144 has been identified as having serine protease hepsin as its target.']"
"[{'source_node': {'name': 'cathepsin b'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CTSB'}}, {'source_node': {'name': 'tokaramide a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cathepsin b'}}]","[{'source_node': {'name': 'cathepsin b'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CTSB'}}, {'source_node': {'name': 'tokaramide a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cathepsin b'}}, {'source_node': {'name': 'tokaramide a'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'CTSB'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:83030', 'target': 'GENE:26227', 'metadata': {'predicate': 'is_affecting'}}]",0.8,5b931253cecbc62f3c913a4c28da9f10,146a4cb33fb528614c9aa7f911ebdf69,"['Cathepsin B is a gene product of CTSB, and it is targeted by the drug Tokaramide A.', 'The drug tokaramide A primarily targets cathepsin B, which interestingly is a gene product of the CTSB gene.', 'The drug Tokaramide A targets Cathepsin B, which is a gene product of CTSB.', 'The protein cathepsin B, which is the gene product of CTSB, is the target of the drug Tokaramide A.', 'The compound Tokaramide A targets the protein Cathepsin B, which is a gene product of CTSB.']","['Cathepsin B, a gene product of CTSB, is targeted by Tokaramide A. In addition to this interaction, Tokaramide A also directly affects CTSB. This suggests that Tokaramide A potentially influence the function of CTSB by interacting with its gene product.']"
"[{'source_node': {'name': 'opioid receptor mu 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'methamphetamine dependence'}}, {'source_node': {'name': 'opioid receptor mu 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'sleep apnea syndromes'}}, {'source_node': {'name': 'modafinil'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'opioid receptor mu 1'}}, {'source_node': {'name': 'modafinil'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Hypersomnia'}}, {'source_node': {'name': 'modafinil'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Anaemia'}}]","[{'source_node': {'name': 'opioid receptor mu 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'sleep apnea syndromes'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:729', 'target': None, 'metadata': {'node_id': '729', 'node_type': 'COMPOUND', 'display_name': 'modafinil'}}, {'type': 'node_removal', 'source': 'DISEASE:2026', 'target': None, 'metadata': {'node_id': '2026', 'node_type': 'DISEASE', 'display_name': 'methamphetamine dependence'}}]",0.2727272727272727,21d07e97cae5fcd419fb7062bace148e,3ddaa06e592ddf01a3b516f20cca6a7a,"['The drug modafinil, which is often indicated for treating Hypersomnia, can have side effects like Anaemia. Interestingly, modafinil is known to affect the opioid receptor mu 1. The activation of the opioid receptor mu 1 itself has been shown to cause conditions such as methamphetamine dependence and sleep apnea syndromes.']",[]
"[{'source_node': {'name': 'survival motor neuron protein'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SMN2'}}, {'source_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'APEX1'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15B'}}, {'source_node': {'name': 'estragole'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'survival motor neuron protein'}}, {'source_node': {'name': 'estragole'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arachidonate 15-lipoxygenase'}}, {'source_node': {'name': 'estragole'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}}]","[{'source_node': {'name': 'survival motor neuron protein'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SMN2'}}, {'source_node': {'name': 'survival motor neuron protein'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15B'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SMN2'}}, {'source_node': {'name': 'estragole'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'survival motor neuron protein'}}, {'source_node': {'name': 'estragole'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arachidonate 15-lipoxygenase'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:4843', 'target': 'GENE:27532', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'PROTEIN:3751', 'target': 'GENE:27532', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'PROTEIN:2703', 'target': 'GENE:32947', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'PROTEIN:3751', 'target': None, 'metadata': {'node_id': '3751', 'node_type': 'PROTEIN', 'display_name': 'dna-(apurinic or apyrimidinic site) lyase'}}]",0.6,eb28e7719bc07f9889bddd2e00eefbbc,85a388ae50b9a12d5674a8e445c6edca,"['The drug Estragole targets several proteins, including the survival motor neuron protein, DNA-(apurinic or apyrimidinic site) lyase, and arachidonate 15-lipoxygenase. The survival motor neuron protein is a gene product of SMN2, while DNA-(apurinic or apyrimidinic site) lyase is a gene product of APEX1. Arachidonate 15-lipoxygenase is a gene product of both ALOX15 and ALOX15B.', 'The genomic output of certain genes has been identified to be targeted by the chemical compound Estragole. For instance, Survival motor neuron protein, a gene product of SMN2, is one of the targets of Estragole. Conversely, DNA-(apurinic or apyrimidinic site) lyase, which is produced from the APEX1 gene, is also targeted by the same compound. Additionally, Arachidonate 15-lipoxygenase, a gene product of both the ALOX15 and ALOX15B genes, is another target of Estragole. All in all, these findings highlight the profound impact that chemical compounds like Estragole can have on the functioning and symbolization of genomic products.', 'The compound estragole has multi-target effects on several proteins. Firstly, the survival motor neuron protein, which is a gene product of SMN2. Secondly, arachidonate 15-lipoxygenase, a gene product of both ALOX15 and ALOX15B. Lastly, it interacts with dna-(apurinic or apyrimidinic site) lyase, also known as a gene product of APEX1.', 'The compound estragole interacts with several targets including the survival motor neuron protein, arachidonate 15-lipoxygenase, and the dna-(apurinic or apyrimidinic site) lyase. The survival motor neuron protein is derived from the gene SMN2. In addition, dna-(apurinic or apyrimidinic site) lyase is a gene product of APEX1. Interestingly, arachidonate 15-lipoxygenase is produced by two genes namely ALOX15 and ALOX15B.', 'Survival Motor Neuron Protein, a gene product of SMN2, is targeted by the organic compound, estragole. Estragole also has targeting effects on Arachidonate 15-Lipoxygenase, another protein which can be derived from two genes named ALOX15 and ALOX15B. Another target of estragole is DNA-(apurinic or apyrimidinic site) lyase, which is a product of the gene APEX1.']","['Survival Motor Neuron Protein and Arachidonate 15-lipoxygenase are both gene products of multiple genes: the former is produced by SMN2 and ALOX15, whereas the latter can be produced by ALOX15, ALOX15B and SMN2. Interestingly, both these proteins are targeted by the chemical Estragole.', 'The proteins survival motor neuron protein and arachidonate 15-lipoxygenase share intriguing relationships with several genes and compounds. Both survival motor neuron protein and arachidonate 15-lipoxygenase are gene products of SMN2. Additionally, survival motor neuron protein is specifically produced by the gene ALOX15. Uniquely, arachidonate 15-lipoxygenase is not just the result of SMN2, but is also a product of ALOX15 and ALOX15B. Additionally, the compound estragole targets both proteins, specifically the survival motor neuron protein and the arachidonate 15-lipoxygenase.', ""The survival motor neuron protein, which is a gene product of both SMN2 and ALOX15, as well as the arachidonate 15-lipoxygenase, which is a gene product of ALOX15, ALOX15B, and again SMN2, are both targeted by the compound estragole. These complex interactions show the genetic and chemical intricacies involved in biochemistry, revealing the interconnected networks that drive life's processes."", 'The survival motor neuron protein, which has estragole as a target, is a gene product of several genes, specifically SMN2 and ALOX15. Similarly, arachidonate 15-lipoxygenase, another target of estragole, is also a gene product of multiple genes, namely ALOX15, ALOX15B, and SMN2.', 'The survival motor neuron protein, a gene product of both SMN2 and ALOX15, along with the arachidonate 15-lipoxygenase, which is a gene product of ALOX15, ALOX15B, and SMN2, are both targeted by the compound estragole. This intricate web of interactions demonstrates the complex nature of biological systems and the importance of specific target molecules in shaping physiological responses.']"
"[{'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}, {'source_node': {'name': '15-oxolabd-8(17)-en-19-oic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}]","[{'source_node': {'name': '15-oxolabd-8(17)-en-19-oic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:84126', 'target': 'GENE:32076', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'GENE:32076', 'target': None, 'metadata': {'node_id': '32076', 'node_type': 'GENE', 'display_name': 'PTPN1'}}]",0.6,7ac837ffe21f2670d6dbf869d931f60f,d17e31ded58d6d3c4aa7db5dbea5f2b2,"['The molecule 15-oxolabd-8(17)-en-19-oic acid has a target known as tyrosine-protein phosphatase non-receptor type 1. This protein is a gene product of PTPN1.', 'The compound 15-oxolabd-8(17)-en-19-oic acid has a target known as tyrosine-protein phosphatase non-receptor type 1. Notably, this specific protein is a gene product of PTPN1.', 'The compound 15-oxolabd-8(17)-en-19-oic acid targets Tyrosine-protein phosphatase non-receptor type 1, which is a gene product of PTPN1.', 'The compound 15-oxolabd-8(17)-en-19-oic acid has a target known as tyrosine-protein phosphatase non-receptor type 1, which is the gene product of the PTPN1 gene.', 'The drug 15-oxolabd-8(17)-en-19-oic acid targets the tyrosine-protein phosphatase non-receptor type 1, which is a gene product of PTPN1.']","['The compound 15-oxolabd-8(17)-en-19-oic acid has been identified to target tyrosine-protein phosphatase non-receptor type 1.', 'The compound 15-oxolabd-8(17)-en-19-oic acid has tyrosine-protein phosphatase non-receptor type 1 as its target.', 'The compound 15-oxolabd-8(17)-en-19-oic acid has a target known as the tyrosine-protein phosphatase non-receptor type 1.', 'The compound 15-oxolabd-8(17)-en-19-oic acid targets the tyrosine-protein phosphatase non-receptor type 1.', 'The molecule 15-oxolabd-8(17)-en-19-oic acid has a target interaction with tyrosine-protein phosphatase non-receptor type 1.']"
"[{'source_node': {'name': 'flavonol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arachidonate 15-lipoxygenase'}}, {'source_node': {'name': 'flavonol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'gtp-binding nuclear protein ran'}}, {'source_node': {'name': 'flavonol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ataxin-2'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15B'}}, {'source_node': {'name': 'gtp-binding nuclear protein ran'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RAN'}}, {'source_node': {'name': 'ALOX15'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of Leukotrienes (LT) and Eoxins (EX)'}}]","[{'source_node': {'name': 'flavonol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ataxin-2'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:88164', 'target': 'PROTEIN:2703', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:27539', 'target': None, 'metadata': {'node_id': '27539', 'node_type': 'GENE', 'display_name': 'ALOX15B'}}, {'type': 'edge_addition', 'source': 'PROTEIN:3525', 'target': 'GENE:27532', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'GENE:27532', 'target': None, 'metadata': {'node_id': '27532', 'node_type': 'GENE', 'display_name': 'ALOX15'}}, {'type': 'node_removal', 'source': 'PROTEIN:3525', 'target': None, 'metadata': {'node_id': '3525', 'node_type': 'PROTEIN', 'display_name': 'gtp-binding nuclear protein ran'}}]",0.1999999999999999,a96e2e3ccebc575f263eff0ae939ea9a,cbccb3b3a4604bc707a15fc9a5058bab,"['Flavonol, a class of flavonoids, targets three different proteins: arachidonate 15-lipoxygenase, GTP-binding nuclear protein Ran, and ataxin-2. Arachidonate 15-lipoxygenase is a gene product of both ALOX15 and ALOX15B. Interestingly, ALOX15 acts within the pathway for the synthesis of leukotrienes (LT) and eoxins (EX), substances involved in inflammatory response. On the other hand, GTP-binding nuclear protein Ran is a gene product of the gene RAN, which implies a broader biological impact.', 'The compound flavonol targets three different entities: arachidonate 15-lipoxygenase, gtp-binding nuclear protein ran, and ataxin-2. Arachidonate 15-lipoxygenase is a gene product of both ALOX15 and ALOX15B, while gtp-binding nuclear protein ran is a gene product of RAN. Furthermore, ALOX15 acts within the synthesis of leukotrienes (LT) and eoxins (EX) pathway.', 'The bioactive compound flavonol targets multiple proteins, including arachidonate 15-lipoxygenase, GTP-binding nuclear protein ran, and ataxin-2. Interestingly, arachidonate 15-lipoxygenase is the gene product of both ALOX15 and ALOX15B, while GTP-binding nuclear protein ran is the gene product of RAN. Specifically, ALOX15 functions within the synthesis of Leukotrienes (LT) and Eoxins (EX).', 'The compound flavonol is known to target several proteins, including arachidonate 15-lipoxygenase, GTP-binding nuclear protein ran, and ataxin-2. Arachidonate 15-lipoxygenase is a gene product of both ALOX15 and ALOX15B. On the other hand, the GTP-binding nuclear protein ran is a gene product of RAN. Particularly interesting is ALOX15, which acts within the pathway responsible for the synthesis of leukotrienes (LT) and eoxins (EX).', 'Flavonol, a type of compound, targets several proteins such as arachidonate 15-lipoxygenase, gtp-binding nuclear protein ran, and ataxin-2. The protein arachidonate 15-lipoxygenase is the gene product of ALOX15 and ALOX15B. Furthermore, the gtp-binding nuclear protein ran is a gene product of RAN. Notably, ALOX15 plays a vital role within the pathway responsible for the synthesis of leukotrienes (LT) and eoxins (EX).']",['The compound flavonol has a target known as ataxin-2.']
"[{'source_node': {'name': 'dragonamide c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'u2os'}}, {'source_node': {'name': 'dragonamide c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}, {'source_node': {'name': 'dragonamide c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}}, {'source_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TDP1'}}, {'source_node': {'name': 'spinocerebellar ataxia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'pes cavus'}}, {'source_node': {'name': 'TDP1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'spinocerebellar ataxia'}}, {'source_node': {'name': 'TDP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nonhomologous End-Joining (NHEJ)'}}]","[{'source_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TDP1'}}, {'source_node': {'name': 'spinocerebellar ataxia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'pes cavus'}}, {'source_node': {'name': 'TDP1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'spinocerebellar ataxia'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:63730', 'target': None, 'metadata': {'node_id': '63730', 'node_type': 'COMPOUND', 'display_name': 'dragonamide c'}}, {'type': 'node_removal', 'source': 'PATHWAY:270', 'target': None, 'metadata': {'node_id': '270', 'node_type': 'PATHWAY', 'display_name': 'Nonhomologous End-Joining (NHEJ)'}}]",0.4666666666666667,2e8f07dc9302d2730987b916f25f228d,e8782a6e6fa0ab1c1f621c4cde9cef55,"['The drug Dragonamide C is known to target U2OS and HT-29 cellular structures as well as the enzyme Tyrosyl-DNA phosphodiesterase 1. This specific enzyme is a gene product of TDP1, a gene that functions within the pathway of Nonhomologous End-Joining (NHEJ). The gene TDP1 can also induce conditions such as Spinocerebellar Ataxia, a disorder characterized by the presence of certain phenotypes like Pes Cavus.']","['Tyrosyl-DNA phosphodiesterase 1, a gene product of TDP1, has been identified as a potential culprit in the development of spinocerebellar ataxia. The disorder is further characterized by a distinctive phenotype known as pes cavus. Thus, it could be deduced that TDP1 plays a role in causing this specific condition.', 'Tyrosyl-DNA phosphodiesterase 1 is a gene product of TDP1. Interestingly, TDP1 has been identified to cause a condition known as spinocerebellar ataxia. This particular disease presents a range of physical manifestations, one of them being Pes cavus, a condition characterized by an abnormally high arch of the foot.', 'Tyrosyl-DNA phosphodiesterase 1 is a gene product of TDP1. The gene TDP1 can cause a condition known as spinocerebellar ataxia which presents with various clinical features including pes cavus, a high-arched foot deformity.', 'Tyrosyl-DNA phosphodiesterase 1 is the gene product of TDP1, a gene implicated in causing spinocerebellar ataxia. Notably, spinocerebellar ataxia, a neurodegenerative disorder, often manifests the phenotype known as pes cavus, a condition resulting in high-arched feet.', 'Tyrosyl-DNA phosphodiesterase 1 is a gene product of TDP1. Interestingly, it has been observed that this gene TDP1 can cause a condition known as spinocerebellar ataxia. This condition exhibits a phenotype marked by pes cavus, a high-arched foot deformity often seen in patients.']"
"[{'source_node': {'name': 'acute bilirubin encephalopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypernatremia'}}, {'source_node': {'name': 'acute bilirubin encephalopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'neonatal sepsis'}}]","[{'source_node': {'name': 'acute bilirubin encephalopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypernatremia'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:10321', 'target': None, 'metadata': {'node_id': '10321', 'node_type': 'PHENOTYPE', 'display_name': 'neonatal sepsis'}}]",0.6,73fc214c809be27e80ce19c36975e80c,6784a7b27998a1e51902377d6e4e2f26,"['Acute bilirubin encephalopathy, a severe neurological condition, exhibits phenotypes such as hypernatremia and neonatal sepsis.', 'Acute bilirubin encephalopathy, a complex medical condition, exhibits phenotypes such as hypernatremia and neonatal sepsis.', 'Acute bilirubin encephalopathy is a condition that presents various phenotypes including hypernatremia and neonatal sepsis.', 'Acute bilirubin encephalopathy, a potentially life-threatening condition, has critical phenotypes including hypernatremia and neonatal sepsis.', 'Acute bilirubin encephalopathy, a condition affecting the brain, presents with multiple symptoms such as hypernatremia and is also associated with neonatal sepsis.']",[]
"[{'source_node': {'name': 'carbinoxamine'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Angioedema'}}, {'source_node': {'name': 'carbinoxamine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Diarrhoea'}}, {'source_node': {'name': 'carbinoxamine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Agitation'}}]","[{'source_node': {'name': 'carbinoxamine'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Angioedema'}}, {'source_node': {'name': 'carbinoxamine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Agitation'}}]","[{'type': 'node_removal', 'source': 'SIDE_EFFECT:20', 'target': None, 'metadata': {'node_id': '20', 'node_type': 'SIDE_EFFECT', 'display_name': 'Diarrhoea'}}]",0.7142857142857143,320d0413727e01e47de2a94ccd539203,7f03fc0d07c0ea22574d5f080ee80e00,"['The drug carbinoxamine is indicated for the treatment of angioedema, a medical condition characterized by swelling beneath the skin. However, it should be taken with caution as it carries potential side effects such as diarrhoea and agitation.', 'The drug, carbinoxamine, is indicated for treating Angioedema, a disorder which involves swelling in the deep layers of the skin. However, it should be noted that the use of carbinoxamine can result in certain side effects such as Diarrhoea and Agitation.', 'The medication carbinoxamine is indicated for the treatment of angioedema, a condition characterised by rapid swelling below the skin. However, potential side effects of carbinoxamine include diarrhoea and agitation.', ""Carbinoxamine, a therapeutic agent commonly used in the clinic, has several implications and side effects. It is typically indicated for treating conditions such as Angioedema. Meanwhile, it might also cause side effects such as Diarrhoea and Agitation. It's important for clinicians and patients to be aware of these potential side effects when considering carbinoxamine for treatment."", 'Carbinoxamine is a medication that is indicated for the treatment of Angioedema. However, it is important to note that the use of Carbinoxamine may be accompanied by side effects such as Diarrhoea and Agitation.']","['Carbinoxamine is a drug commonly used for the indication of angioedema, a condition characterized by intense swelling beneath the skin. However, a noted side effect of this medication is agitation, which users should be aware of when taking this treatment.', 'The drug Carbinoxamine has multiple known consequences after use. It has been indicated for the treatment of Angioedema, a serious condition characterized by swelling in the deeper layers of the skin. Additionally, user have reported experiencing Agitation as a side effect of Carbinoxamine.', 'The drug Carbinoxamine is indicated for the treatment of Angioedema, an allergic reaction characterized by swelling of the skin. However, it may have a side effect causing Agitation in some patients.', 'Carbinoxamine is a medication that has an indication for treating Angioedema. However, it is important to note that Carbinoxamine may also induce a side effect, such as Agitation, in some patients.', 'The drug carbinoxamine is indicated for the treatment of Angioedema, a condition involving the rapid onset of swelling beneath the skin or mucosa. However, it is important to note that one of the potential side effects of taking this medication is agitation.']"
"[{'source_node': {'name': 'docusate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clevidipine'}}, {'source_node': {'name': 'prifinium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'magnesium carbonate'}}, {'source_node': {'name': 'prifinium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'docusate'}}, {'source_node': {'name': 'prifinium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'potassium sulfate'}}]","[{'source_node': {'name': 'potassium sulfate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'docusate'}}, {'source_node': {'name': 'docusate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clevidipine'}}, {'source_node': {'name': 'prifinium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'magnesium carbonate'}}, {'source_node': {'name': 'prifinium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'docusate'}}, {'source_node': {'name': 'prifinium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'potassium sulfate'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:12238', 'target': 'COMPOUND:9105', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.8888888888888888,56217367705485845fa19a04a2ff39ca,f0c3c55ff8986551c2a004ac04481f5e,"['The drug docusate has been found to decrease the efficacy of clevidipine. Similarly, prifinium, another drug, lowers the efficacy of magnesium carbonate, docusate and potassium sulfate. This means with concurrent usage, prifinium may interfere with the therapeutic effects of these substances, thus careful consideration is required in drug administration.', 'Docusate, a stool softener, is known to reduce the effectiveness of the blood pressure medication, clevidipine. Similarly, the antimuscarinic drug, prifinium, shows a reduced efficacy when taken in conjunction with magnesium carbonate, commonly used for heartburn and indigestion, or potassium sulfate, often prescribed for low potassium levels. Interestingly, prifinium also exhibits decreased efficacy when taken with docusate. Therefore, caution should be taken when these medications are prescribed together to avoid potential adverse effects.', ""The drug docusate has been shown to decrease the efficacy of clevidipine. Similarly, prifinium also exhibits a decrease in efficacy when introduced to multiple substances. Specifically, prifinium's effectiveness is known to be reduced with the presence of magnesium carbonate, docusate, and potassium sulfate. The interaction between these drugs and substances is highly critical in drug administration and combination therapy as it affects the overall effectiveness."", 'Prifinium is a medication that has been noted to decrease the efficacy of several other drugs, such as docusate, magnesium carbonate, and potassium sulfate. Interestingly, docusate has also been found to decrease the efficacy of clevidipine, creating a complex interplay of interactions that could impact drug effectiveness. Careful coordination and monitoring of these drugs is needed to ensure optimal medical benefits.', 'Docusate, a commonly used medication, has been found to decrease the efficacy of the drug clevidipine. In a similar vein, prifinium, another medication, is known to decrease the efficacy of several compounds such as magnesium carbonate, docusate, and potassium sulfate. This suggests that careful consideration is necessary when using these medications in conjunction, as the desired medicinal impacts may be dampened.']","['Potassium sulfate has been found to decrease the efficacy of the drug, docusate. Concurrently, docusate can also reduce the efficacy of another medication, clevidipine. On another note, the drug prifinium plays a significant role in diminishing the efficacy of magnesium carbonate, docusate and potassium sulfate. This means that if taken alongside prifinium, these compounds may not perform their therapeutic function as effectively as they could. Careful consideration is needed when these substances need to be administered together.', 'The chemical compound potassium sulfate has been found to decrease the efficacy of the drug docusate. Similarly, docusate itself is known to lessen the effectiveness of clevidipine when administered together. Prifinium, another pharmaceutical, is also observed to have negative impacts on the efficacy of not only one but three different substances: magnesium carbonate, docusate, and potassium sulfate. In other words, the presence of prifinium reduces the effectiveness of these minerals and drugs.', 'The efficacy of certain substances is known to be decreased by others, suggesting complex interactions in context of drug utilization. Potassium sulfate, for instance, is known to decrease the efficacy of docusate. Interestingly, docusate also reduces the efficiency of clevidipine. However, it is not just docusate that is impacted. Prifinium, another substance, is found to lower the efficacy of magnesium carbonate, docusate as well as potassium sulfate. Such interconnected efficacy relationships could have implications in drug dosage and scheduling for optimum therapeutic outcomes.', 'The efficacy of several medications can be decreased by certain substances. For instance, the efficacy of docusate is known to decrease in the presence of potassium sulfate. This lower efficacy of docusate can also result in a decrease in the efficacy of clevidipine. Another substance, prifinium, demonstrates similar behaviors in its negative impact on the efficacy of medications. Prifinium leads to decreased efficacy of magnesium carbonate as well as the aforementioned docusate and potassium sulfate.', 'Potassium sulfate has been found to decrease the efficacy of docusate. This diminished effectiveness also occurs between docusate and clevidipine. Similarly, prifinium can decrease the efficacy of both magnesium carbonate and potassium sulfate. Furthermore, prifinium also lowers the effectiveness of docusate. Therefore, caution should be exercised when coadministering these pairs of drugs.']"
"[{'source_node': {'name': 'phosphoglycerate mutase'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'rhabdomyolysis'}}, {'source_node': {'name': 'phosphoglycerate mutase'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'myopathy'}}, {'source_node': {'name': 'phosphoglycerate mutase'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'exercise intolerance'}}]","[{'source_node': {'name': 'phosphoglycerate mutase'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'exercise intolerance'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:2307', 'target': None, 'metadata': {'node_id': '2307', 'node_type': 'PHENOTYPE', 'display_name': 'rhabdomyolysis'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:2304', 'target': None, 'metadata': {'node_id': '2304', 'node_type': 'PHENOTYPE', 'display_name': 'myopathy'}}]",0.4285714285714286,554a4684d1500e70f3783752b0a118a9,032064fbd1248dbd3433f1304f8649b0,"['The enzyme phosphoglycerate mutase is associated with several phenotypes, such as rhabdomyolysis, myopathy, and exercise intolerance.', 'The enzyme phosphoglycerate mutase is associated with several phenotypes including rhabdomyolysis, myopathy, and exercise intolerance. These are all conditions with potential muscular implications that can severely impact physical abilities and overall health.', 'The enzyme phosphoglycerate mutase is associated with several clinical phenotypes such as rhabdomyolysis, a rapid breakdown of muscle tissue, myopathy, a neuromuscular disorder, and exercise intolerance, an unusual sensitivity to physical exercise.']","['The enzyme phosphoglycerate mutase exhibits a specific phenotype characterized by inducing exercise intolerance.', 'The enzyme phosphoglycerate mutase has a phenotype that is associated with exercise intolerance.', 'The enzyme phosphoglycerate mutase exhibits a phenotype of causing exercise intolerance.']"
"[{'source_node': {'name': 'bilirubin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prelamin-a/c'}}, {'source_node': {'name': 'bilirubin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'udp glucuronosyltransferase 1 family'}}]","[{'source_node': {'name': 'prelamin-a/c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'udp glucuronosyltransferase 1 family'}}, {'source_node': {'name': 'bilirubin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prelamin-a/c'}}, {'source_node': {'name': 'bilirubin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'udp glucuronosyltransferase 1 family'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:6154', 'target': 'GENE:22981', 'metadata': {'predicate': 'gene_product_of'}}]",0.8,29ae7581369b50c8fe80e453b3d615a9,36db78f29020d3ed857442836317a643,"['The compound bilirubin has been identified as having a target interaction with prelamin-a/c and is affecting the UDP glucuronosyltransferase 1 family, which is an enzyme group known for their role in detoxification processes.', 'Bilirubin, a yellow compound found in the body, targets prelamin-A/C, a protein involved in the structure of the cell nucleus. Additionally, it plays a crucial role in affecting the UDP glucuronosyltransferase 1 family, a collection of enzymes responsible for the detoxification of various drugs, bilirubin included.']","['The compound bilirubin has a target, prelamin-a/c, which is a gene product of the UDP glucuronosyltransferase 1 family. Furthermore, bilirubin is known to affect the UDP glucuronosyltransferase 1 family as well.', 'The compound bilirubin targets prelamin-a/c and affects the UDP glucuronosyltransferase 1 family. Interestingly, prelamin-a/c is a gene product of the UDP glucuronosyltransferase 1 family.']"
"[{'source_node': {'name': 'dna polymerase iota'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'POLI'}}, {'source_node': {'name': '6-methoxy-1-methyl-2-phenylquinolin-4-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'retinal dehydrogenase 1'}}, {'source_node': {'name': '6-methoxy-1-methyl-2-phenylquinolin-4-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna polymerase iota'}}, {'source_node': {'name': '6-methoxy-1-methyl-2-phenylquinolin-4-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hek293'}}]","[{'source_node': {'name': 'retinal dehydrogenase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'POLI'}}, {'source_node': {'name': '6-methoxy-1-methyl-2-phenylquinolin-4-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'retinal dehydrogenase 1'}}, {'source_node': {'name': '6-methoxy-1-methyl-2-phenylquinolin-4-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hek293'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:579', 'target': 'GENE:25358', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'PROTEIN:6323', 'target': None, 'metadata': {'node_id': '6323', 'node_type': 'PROTEIN', 'display_name': 'dna polymerase iota'}}]",0.6666666666666667,6e8c0755ec0f632cdcce92d549ff9e18,7c291a6029f998d211f50d178d78219b,"[""The DNA Polymerase iota, known as a gene product of POLI, along with the protein retinal dehydrogenase 1 and the HEK293 cell line represent the primary target points for the drug, 6-methoxy-1-methyl-2-phenylquinolin-4-one. These various entities represent the key chemical and biological components manipulated by this drug's activity.""]","['The drug 6-methoxy-1-methyl-2-phenylquinolin-4-one targets both the retinal dehydrogenase 1 and hek293. Retinal dehydrogenase 1 is a gene product of POLI, with specific functions within the genetic structures.', 'Retinal dehydrogenase 1, which is a gene product of POLI, is notably targeted by the drug 6-methoxy-1-methyl-2-phenylquinolin-4-one. This same drug also targets HEK293, a widely-used cell line in biological research.', 'The compound 6-methoxy-1-methyl-2-phenylquinolin-4-one targets both the retinal dehydrogenase 1 enzyme and the cellular model known as HEK293. Interestingly, the enzyme retinal dehydrogenase 1 is a gene product of POLI.', 'Retinal dehydrogenase 1 is a gene product of POLI and it is targeted by the compound called 6-methoxy-1-methyl-2-phenylquinolin-4-one. This same compound also targets another entity, hek293. In essence, the mechanisms of 6-methoxy-1-methyl-2-phenylquinolin-4-one extend to both retinal dehydrogenase 1 and hek293 in the biological spectrum.', 'The compound 6-methoxy-1-methyl-2-phenylquinolin-4-one has active targets, specifically retinal dehydrogenase 1 and the cell line known as hek293. The enzyme retinal dehydrogenase 1 is a gene product of the POLI gene.']"
"[{'source_node': {'name': 'LPL'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hyperlipidemia'}}, {'source_node': {'name': 'LPL'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Retinoid metabolism and transport'}}, {'source_node': {'name': 'tyloxapol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lipoprotein lipase'}}, {'source_node': {'name': 'lipoprotein lipase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'LPL'}}]","[{'source_node': {'name': 'LPL'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hyperlipidemia'}}, {'source_node': {'name': 'LPL'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Retinoid metabolism and transport'}}, {'source_node': {'name': 'tyloxapol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lipoprotein lipase'}}, {'source_node': {'name': 'tyloxapol'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'LPL'}}, {'source_node': {'name': 'lipoprotein lipase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'LPL'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:5589', 'target': 'GENE:29777', 'metadata': {'predicate': 'is_affecting'}}]",0.8888888888888888,a05572dfbb5224bc3831ed6c547fa4e8,195e2ebad7b1771d8ec28a58706a121f,"['The gene LPL, which has a role within the retinoid metabolism and transport pathway, is known to cause hyperlipidemia, a condition often associated with high levels of lipids in the blood. The drug tyloxapol targets lipoprotein lipase, which is a gene product of LPL.', 'The gene LPL acts within the process of retinoid metabolism and transport and it is known to cause a condition known as hyperlipidemia. Furthermore, LPL is the gene product of lipoprotein lipase, which is the target of the drug tyloxapol.', 'The gene LPL acts within the retinoid metabolism and transport pathway and is responsible for causing hyperlipidemia. Interestingly, LPL is also the gene product of the lipoprotein lipase enzyme. Further, this enzyme happens to be the known target of the drug, Tyloxapol.', 'The gene LPL, which functions within the pathway of retinoid metabolism and transport, has been connected to the condition of hyperlipidemia. The drug tyloxapol has lipoprotein lipase as a target, and interestingly, lipoprotein lipase is a gene product of the aforementioned LPL.', 'The gene LPL, which contributes to retinoid metabolism and transport, is known to cause hyperlipidemia. The drug tyloxapol targets lipoprotein lipase, a product of this gene.']","[""The gene LPL acts within the pathway of retinoid metabolism and transport and is known to cause a condition known as hyperlipidemia. It should be noted that LPL is the gene product of lipoprotein lipase, which is targeted by a drug named tyloxapol. Interestingly, tyloxapol is also known to affect LPL directly. Therefore, both tyloxapol's direct and indirect effects on LPL could be significant in the context of treating hyperlipidemia."", 'The gene LPL, which functions within the retinoid metabolism and transport pathway, is capable of causing the condition known as hyperlipidemia. This gene is the result of the gene product of lipoprotein lipase. The drug Tyloxapol targets lipoprotein lipase and also affects LPL.']"
"[{'source_node': {'name': 'abdominal obesity-metabolic syndrome 3'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'stroke'}}, {'source_node': {'name': 'abdominal obesity-metabolic syndrome 3'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hyperglycemia'}}, {'source_node': {'name': 'abdominal obesity-metabolic syndrome 3'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'young adult onset'}}]","[{'source_node': {'name': 'abdominal obesity-metabolic syndrome 3'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'young adult onset'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:2214', 'target': None, 'metadata': {'node_id': '2214', 'node_type': 'PHENOTYPE', 'display_name': 'hyperglycemia'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:985', 'target': None, 'metadata': {'node_id': '985', 'node_type': 'PHENOTYPE', 'display_name': 'stroke'}}]",0.4285714285714286,2ed60ee26897c1f4dd08a973af40578b,6fedb7f0fdac3a8c1d024d7d789f406b,"['Abdominal obesity-metabolic syndrome 3, a health condition influencing metabolic processes, exhibits several pathophysiological manifestations. Among these phenotypes are stroke, characterized by disruption in blood supply to the brain, and hyperglycemia, where an elevated level of glucose circulates in the blood. Additionally, this syndrome can be exhibited at an early age, as is evident from its phenotype of young adult onset.']",[]
"[{'source_node': {'name': 'wrr-99'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cathepsin f'}}, {'source_node': {'name': 'wrr-99'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cruzipain'}}, {'source_node': {'name': 'CTSF'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'ceroid lipofuscinosis'}}, {'source_node': {'name': 'CTSF'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'MHC class II antigen presentation'}}, {'source_node': {'name': 'cathepsin f'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CTSF'}}, {'source_node': {'name': 'ceroid lipofuscinosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'intellectual disability'}}, {'source_node': {'name': 'ceroid lipofuscinosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'premature closure of fontanelles'}}]","[{'source_node': {'name': 'wrr-99'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cathepsin f'}}, {'source_node': {'name': 'wrr-99'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cruzipain'}}, {'source_node': {'name': 'ceroid lipofuscinosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'intellectual disability'}}, {'source_node': {'name': 'ceroid lipofuscinosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'premature closure of fontanelles'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:3363', 'target': 'GENE:34797', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'GENE:34797', 'target': None, 'metadata': {'node_id': '34797', 'node_type': 'GENE', 'display_name': 'CTSF'}}]",0.6666666666666667,d62c44758801e615449fe8850afcea7a,1524b92a89d5ff098652eb8541849adf,[],"['The compound wrr-99 targets both cathepsin f and cruzipain. In a related observation, ceroid lipofuscinosis, a disease much studied in the medical community, shows phenotypes such as intellectual disability and premature closure of fontanelles. Our knowledge about the interrelated biochemical pathways and their impact on diseases is growing with each research.', 'The drug WRR-99 targets proteins such as Cathepsin F and Cruzipain. The disease Ceroid Lipofuscinosis, which is characterized by phenotypes including intellectual disability and premature closure of fontanelles, could potentially be linked to these target protein interactions.', 'The compound WRR-99 targets both cathepsin F and cruzipain. Notably, cathepsin F is associated with ceroid lipofuscinosis, a condition with various phenotypes including intellectual disability and premature closure of fontanelles.', 'The drug WRR-99 targets two particular proteins, namely Cathepsin F and Cruzipain. Meanwhile, Ceroid Lipofuscinosis, a neurodegenerative disorder, presents certain physiological characteristics or phenotypes which include intellectual disability and the premature closure of fontanelles.', 'The agent known as WRR-99 has been identified to target two particular proteins, cathepsin F and cruzipain. On a separate note, the condition called Ceroid Lipofuscinosis is associated with phenotypes including intellectual disability and premature closure of fontanelles.']"
"[{'source_node': {'name': 'wiedemann-rautenstrauch syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'gynecomastia'}}, {'source_node': {'name': 'wiedemann-rautenstrauch syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'atlantoaxial abnormality'}}]","[{'source_node': {'name': 'wiedemann-rautenstrauch syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'atlantoaxial abnormality'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:602', 'target': None, 'metadata': {'node_id': '602', 'node_type': 'PHENOTYPE', 'display_name': 'gynecomastia'}}]",0.6,accfce94476fec1453d28f03606bb89e,35da6cc9cae4d9ed1ac5a4fb6960c2d4,"['Wiedemann-Rautenstrauch Syndrome, a rare genetic disorder, presents itself with several distinguishing characteristics, most notably gynecomastia and atlantoaxial abnormality. These phenotypic traits are integral in identifying and diagnosing the syndrome.', 'Wiedemann-Rautenstrauch syndrome is characterized by certain conditions such as gynecomastia and an atlantoaxial abnormality.', '""Wiedemann-Rautenstrauch syndrome, a rare genetic disorder, manifests certain phenotypes including gynecomastia, which is the enlargement or swelling of breast tissue in males, and atlantoaxial abnormality, a condition causing instability between the first and second bones in the neck.', 'Wiedemann-Rautenstrauch syndrome, a rare genetic disorder, exhibits various phenotypes including gynecomastia and atlantoaxial abnormality.']",[]
"[{'source_node': {'name': '3-phosphono-d-alanine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'phosphoserine phosphatase'}}, {'source_node': {'name': 'phosphoserine phosphatase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PSPH'}}]","[{'source_node': {'name': '3-phosphono-d-alanine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'phosphoserine phosphatase'}}, {'source_node': {'name': '3-phosphono-d-alanine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'PSPH'}}, {'source_node': {'name': 'phosphoserine phosphatase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PSPH'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:3102', 'target': 'GENE:31941', 'metadata': {'predicate': 'is_affecting'}}]",0.8,25f190f7cda4faaacd7f4507939150dc,78c334c92a4168a18e4e2faac298a067,"['The compound 3-phosphono-d-alanine has a target known as phosphoserine phosphatase. This particular molecule, phosphoserine phosphatase, is the gene product of the PSPH gene.', 'The compound 3-phosphono-d-alanine has a target, specifically the phosphoserine phosphatase enzyme. This enzyme is a gene product of PSPH.', 'The compound 3-phosphono-d-alanine targets the enzyme phosphoserine phosphatase, which is a gene product of PSPH.', 'The chemical compound 3-phosphono-d-alanine targets phosphoserine phosphatase. In turn, this enzyme is a gene product of the PSPH gene.', 'The compound 3-phosphono-d-alanine targets phosphoserine phosphatase, which is a gene product of PSPH.']","['The compound 3-phosphono-d-alanine has a target known as phosphoserine phosphatase, and also affects the gene PSPH. Interestingly, phosphoserine phosphatase is also a gene product of PSPH.', 'The compound 3-phosphono-d-alanine targets phosphoserine phosphatase and affects the PSPH gene. Interestingly, phosphoserine phosphatase is a gene product of PSPH.', 'The compound 3-phosphono-d-alanine has a target called phosphoserine phosphatase, which interestingly, is a gene product of PSPH. Moreover, 3-phosphono-d-alanine is also known to affect PSPH directly. This establishes a significant link between the compound 3-phosphono-d-alanine and the gene PSPH, since it interacts with both the gene directly and indirectly through one of its gene products, phosphoserine phosphatase.', 'The compound 3-phosphono-d-alanine has a target, specifically phosphoserine phosphatase. This compound is also known to affect PSPH. It is worth noting that phosphoserine phosphatase is a gene product of PSPH.']"
"[{'source_node': {'name': 'trismethoxyresveratrol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-mel-5'}}, {'source_node': {'name': 'trismethoxyresveratrol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h23'}}, {'source_node': {'name': 'trismethoxyresveratrol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sr'}}]","[{'source_node': {'name': 'trismethoxyresveratrol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h23'}}, {'source_node': {'name': 'trismethoxyresveratrol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sr'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5621', 'target': None, 'metadata': {'node_id': '5621', 'node_type': 'PROTEIN', 'display_name': 'sk-mel-5'}}]",0.7142857142857143,07792056452b6eb80ca4ac961adb4144,8209890d4a8c2b261a3db4615326498d,"['The drug Trismethoxyresveratrol has been identified to target several entities, notably Sk-Mel-5, NCI-H23, and SR.', 'The compound trismethoxyresveratrol has multiple targets, including SK-MEL-5, NCI-H23, and SR.', 'The drug trismethoxyresveratrol is found to target three elements: SK-MEL-5, NCI-H23, and SR.', 'The compound trismethoxyresveratrol has been found to target various cellular entities - specifically, it targets SK-MEL-5 and NCI-H23 cell lines, as well as something referred to as SR.', 'The compound trismethoxyresveratrol has several targets, namely SK-MEL-5, NCI-H23, and SR. These targets may be involved in various biological processes and interactions affected by trismethoxyresveratrol.']","['The drug trismethoxyresveratrol targets two particular entities, one being the NCI-H23, and the other being SR.', 'The compound known as trismethoxyresveratrol targets both NCI-H23 and SR.', 'Trismethoxyresveratrol, a pharmacologically active compound, has been identified to target cells referred to as NCI-H23.  Furthermore, this compound also targets another receptor known as SR. These interactions illustrate the cellular efficacy of trismethoxyresveratrol and its potential in biological contexts.', 'The compound trismethoxyresveratrol has been identified to target both NCI-H23, a cell line used in cancer research, and SR.', 'The compound trismethoxyresveratrol has been identified to target two different entities, namely NCI-H23 and SR.']"
"[{'source_node': {'name': 'pmf'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'p-glycoprotein 1'}}, {'source_node': {'name': 'p-glycoprotein 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ABCB1'}}]","[{'source_node': {'name': 'p-glycoprotein 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ABCB1'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:51075', 'target': None, 'metadata': {'node_id': '51075', 'node_type': 'COMPOUND', 'display_name': 'pmf'}}]",0.6,4279868603d4ffb620c2a44ad4099500,5eed2855af778ec05264c855c7be66c6,"['The drug PMF targets p-glycoprotein 1 which is a gene product of ABCB1.', 'The drug PMF targets P-glycoprotein 1, and P-glycoprotein 1 is a gene product of the gene ABCB1.', 'The substance PMF targets P-glycoprotein 1, which is known to be a gene product of ABCB1.', 'The compound PMF has a target known as P-glycoprotein 1. Furthermore, P-glycoprotein 1 is the gene product of ABCB1.', 'The drug pmf has a target known as p-glycoprotein 1. Interestingly, p-glycoprotein 1 is the gene product of the ABCB1 gene.']",[]
"[{'source_node': {'name': 'theodrenaline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'dimenhydrinate'}}, {'source_node': {'name': 'theodrenaline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'oxaprotiline'}}, {'source_node': {'name': 'theodrenaline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'epanolol'}}, {'source_node': {'name': 'clemastine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'ephedrine'}}, {'source_node': {'name': 'clemastine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'racepinephrine'}}, {'source_node': {'name': 'clemastine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'theodrenaline'}}]","[{'source_node': {'name': 'epanolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'racepinephrine'}}, {'source_node': {'name': 'theodrenaline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'dimenhydrinate'}}, {'source_node': {'name': 'theodrenaline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'oxaprotiline'}}, {'source_node': {'name': 'theodrenaline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'epanolol'}}, {'source_node': {'name': 'clemastine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'ephedrine'}}, {'source_node': {'name': 'clemastine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'racepinephrine'}}, {'source_node': {'name': 'clemastine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'dimenhydrinate'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:11604', 'target': 'COMPOUND:9136', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:273', 'target': 'COMPOUND:10801', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:273', 'target': 'COMPOUND:968', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7692307692307692,d0da943d45de6901ed7e9609df90f90f,973b8cd4bbacf52468b58512891dc065,"['The drug theodrenaline is known to increase the efficacy of several other medications, including dimenhydrinate, oxaprotiline, and epanolol. Similarly, clemastine also increases the efficacy of a few drugs which are ephedrine, racepinephrine, and notably theodrenaline. This interconnected relationship highlights the potential therapeutic benefits of drug combinations, where drugs such as theodrenaline and clemastine can enhance the effects of other specific medications.', 'Theodrenaline is a potent drug known to increase the efficacy of other medications. Specifically, it enhances the performance of dimenhydrinate, oxaprotiline, and epanolol. Similarly, clemastine is another agent known to increase the efficacy of specific drugs, in this case, ephedrine, racepinephrine, and even Theodrenaline itself. This interconnected relationship highlights their potential combinative effect in medical treatments.', 'Theodrenaline is known to increase the efficacy of several drugs including dimenhydrinate, oxaprotiline, and epanolol. Similarly, clemastine enhances the effectiveness of ephedrine, racepinephrine, and even theodrenaline itself. Hence, these combinations could potentially offer improved therapeutic outcomes.', 'Theodrenaline, a highly potent drug, is known to increase the efficacy of dimenhydrinate, oxaprotiline, and epanolol. Similarly, clemastine, another therapeutic drug, is observed to enhance the efficacy of certain drugs such as ephedrine, racepinephrine, and interestingly, even theodrenaline. These combined associations contribute to the potential synergistic treatment strategies in complex diseases.', 'The drugs Theodrenaline and Clemastine are responsible for increasing the efficacy of several other therapeutic agents. Specifically, Theodrenaline has been found to amplify the effects of Dimenhydrinate, Oxaprotiline, and Epanolol. Meanwhile, Clemastine exhibits a positive interactive effect on the potency of Ephedrine, Racepinephrine, and, interestingly, even Theodrenaline itself, contributing to its intensified impact on the aforementioned drugs. These interactions hint at the complex ways these drugs could potentially be combined in clinical settings to enhance their overall effectiveness.']","[""The drug epanolol decreases the efficacy of another drug, racepinephrine. On the other hand, theodrenaline enhances the efficacy of three other substances: dimenhydrinate, oxaprotiline, and interestingly, epanolol. It seems that theodrenaline and epanolol can modify each other's effectiveness. Simultaneously, another drug, clemastine, increases the efficacy of ephedrine, racepinephrine, and dimenhydrinate. Interestingly, clemastine and epanolol have contrary effects on the efficacy of racepinephrine. Such complex interplay of drug efficacy shows the intricate mechanics of drug therapy."", 'The drug Epanolol is known to decrease the efficacy of Racepinephrine. Conversely, Theodrenaline can increase the efficacy of three other drugs: Dimenhydrinate, Oxaprotiline, and even Epanolol itself. Additionally, Clemastine is another drug that has the capacity to increase the efficacy of several drugs, specifically Ephedrine, Racepinephrine, and Dimenhydrinate. The interactions between these drugs illustrate the delicate balances within pharmacology and medication regimens.', ""The drug epanolol has been found to decrease the efficacy of racepinephrine, implying that it could potentially hinder racepinephrine's primary function. In contrast, theodrenaline seems to increase the efficacy of several drugs such as dimenhydrinate, oxaprotiline, and epanolol, implying that it could boost their primary functions. Additionally, clemastine behaves similarly to theodrenaline, exhibiting an increase in efficacy when interacted with drugs like ephedrine, racepinephrine, and dimenhydrinate. These findings could be crucial in understanding drug-drug interactions and optimizing pharmacological therapies."", 'The efficacy of several drugs can be modified by the presence of other drugs. For instance, epanolol has been found to decrease the efficacy of racepinephrine. Concurrently, theodrenaline increases the efficacy of dimenhydrinate, oxaprotiline, and even epanolol, creating a complex interplay of drug interactions. Furthermore, clemastine is another drug that augments the efficacy of a group of drugs, namely ephedrine, racepinephrine, and dimenhydrinate. Thus, these drugs exhibit interconnected and dynamic relationships that influence their therapeutic effects.', 'The drug Epanolol is shown to decrease the efficacy of Racepinephrine. In contrast, Theodrenaline is a pharmaceutical that increases the efficacy of several other drugs such as Dimenhydrinate, Oxaprotiline, and even Epanolol itself. Interestingly, Clemastine is another drug that positively impacts the efficacy of several others, including Ephedrine, Racepinephrine, and Dimenhydrinate. Thus, the interactions between these drugs can have varying effects on their respective efficacies.']"
"[{'source_node': {'name': 'cytochrome p450 2a13'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP2A13'}}, {'source_node': {'name': '4-(dimethylamino)benzaldehyde'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 2a6'}}, {'source_node': {'name': '4-(dimethylamino)benzaldehyde'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 2a13'}}, {'source_node': {'name': '4-(dimethylamino)benzaldehyde'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear factor erythroid 2-related factor 2'}}, {'source_node': {'name': 'CYP2A13'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Aflatoxin activation and detoxification'}}, {'source_node': {'name': 'cytochrome p450 2a6'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP2A6'}}]","[{'source_node': {'name': 'cytochrome p450 2a13'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP2A13'}}, {'source_node': {'name': '4-(dimethylamino)benzaldehyde'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 2a6'}}, {'source_node': {'name': '4-(dimethylamino)benzaldehyde'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 2a13'}}, {'source_node': {'name': '4-(dimethylamino)benzaldehyde'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear factor erythroid 2-related factor 2'}}, {'source_node': {'name': 'CYP2A13'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Aflatoxin activation and detoxification'}}, {'source_node': {'name': 'cytochrome p450 2a6'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP2A13'}}]","[{'type': 'node_removal', 'source': 'GENE:26290', 'target': None, 'metadata': {'node_id': '26290', 'node_type': 'GENE', 'display_name': 'CYP2A6'}}, {'type': 'edge_addition', 'source': 'PROTEIN:3690', 'target': 'GENE:26302', 'metadata': {'predicate': 'gene_product_of'}}]",0.7692307692307692,8e9094b05d6dbec38a13e28fd5699d87,3f328566a592e8a8a4bfa4f0c2f51f8c,[],"['The compound 4-(dimethylamino)benzaldehyde has multiple targets including cytochrome p450 2a6, cytochrome p450 2a13, and nuclear factor erythroid 2-related factor 2. Of interest, cytochrome p450 2a6 and cytochrome p450 2a13 are both gene products of CYP2A13. Furthermore, CYP2A13 acts within the pathway of aflatoxin activation and detoxification. This complex interweaving of reactions reveals a multifaceted relationship that underlies various biochemical processes.', 'The compound 4-(dimethylamino)benzaldehyde primarily targets three biological factors, namely cytochrome p450 2a6, cytochrome p450 2a13, and nuclear factor erythroid 2-related factor 2. The cytochrome P450 2A6 and cytochrome P450 2A13 are gene products of the common gene CYP2A13. Interestingly, this shared gene, CYP2A13, acts within the biochemical pathway responsible for aflatoxin activation and detoxification. Overall, the interactions exhibited between 4-(dimethylamino)benzaldehyde and these biological factors form a complex network indicative of potential biochemical mechanisms.', 'The compound 4-(dimethylamino)benzaldehyde targets cytochrome p450 2a6, cytochrome p450 2a13 as well as the nuclear factor erythroid 2-related factor 2. Interestingly, cytochrome p450 2a6 and cytochrome p450 2a13 are both gene products of CYP2A13. Additionally, CYP2A13 acts within the pathway of aflatoxin activation and detoxification. The interplay between these elements suggest complex pharmacological interactions that warrant further research.', 'The compound 4-(dimethylamino)benzaldehyde has targets including Cytochrome P450 2A6, Cytochrome P450 2A13, and the Nuclear Factor Erythroid 2-Related Factor 2. Interestingly, both Cytochrome P450 2A6 and Cytochrome P450 2A13 are gene products of the CYP2A13 gene. Furthermore, CYP2A13 has been shown to act within the pathway of Aflatoxin activation and detoxification, indicating potential health implications of these gene-product and target relationships.', 'The drug 4-(dimethylamino)benzaldehyde targets three different molecules, namely cytochrome p450 2a6, cytochrome p450 2a13 and nuclear factor erythroid 2-related factor 2. Both cytochrome p450 2a6 and cytochrome p450 2a13 are gene products of CYP2A13. Furthermore, CYP2A13 acts within the pathway of Aflatoxin activation and detoxification.']"
"[{'source_node': {'name': 'homovanillic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histone-lysine n-methyltransferase'}}, {'source_node': {'name': 'homovanillic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'atpase family aaa domain-containing protein 5'}}, {'source_node': {'name': 'homovanillic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'udp-glucuronosyltransferase 1-6'}}, {'source_node': {'name': 'histone-lysine n-methyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DOT1L'}}, {'source_node': {'name': 'histone-lysine n-methyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'EHMT1'}}, {'source_node': {'name': 'histone-lysine n-methyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'EHMT2'}}, {'source_node': {'name': 'EHMT2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of TP53 Activity through Methylation'}}, {'source_node': {'name': 'udp-glucuronosyltransferase 1-6'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'UGT1A6'}}]","[{'source_node': {'name': 'homovanillic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'atpase family aaa domain-containing protein 5'}}, {'source_node': {'name': 'homovanillic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'udp-glucuronosyltransferase 1-6'}}, {'source_node': {'name': 'histone-lysine n-methyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'EHMT1'}}, {'source_node': {'name': 'histone-lysine n-methyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'EHMT2'}}, {'source_node': {'name': 'EHMT2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of TP53 Activity through Methylation'}}, {'source_node': {'name': 'udp-glucuronosyltransferase 1-6'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'UGT1A6'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:48396', 'target': 'PROTEIN:6168', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:34471', 'target': None, 'metadata': {'node_id': '34471', 'node_type': 'GENE', 'display_name': 'DOT1L'}}]",0.8235294117647058,78232560968cc49d8540ea160f24cc05,9235c32d004f096b03c976457c361946,"['The compound homovanillic acid targets multiple proteins including the histone-lysine n-methyltransferase, the ATPase family AAA domain-containing protein 5 and the UDP-glucuronosyltransferase 1-6. The histone-lysine n-methyltransferase is a gene product of several genes, including DOT1L, EHMT1, and EHMT2. Specifically, EHMT2 acts within the regulation of TP53 activity through methylation pathway. Moreover, UDP-glucuronosyltransferase 1-6 is a gene product of UGT1A6.', 'Homovanillic acid targets several proteins, including histone-lysine n-methyltransferase, ATPase family AAA domain-containing protein 5, and UDP-glucuronosyltransferase 1-6. Histone-lysine n-methyltransferase is a gene product of several genes, namely DOT1L, EHMT1, and EHMT2. Notably, EHMT2 acts within the pathway known as the regulation of TP53 activity through methylation. Meanwhile, UDP-glucuronosyltransferase 1-6 is a gene product of UGT1A6.', 'Homovanillic acid targets several proteins including the histone-lysine n-methyltransferase, the ATPase family AAA domain-containing protein 5, and the UDP-glucuronosyltransferase 1-6. The histone-lysine n-methyltransferase is a gene product of several genes including DOT1L, EHMT1, and EHMT2. Furthermore, EHMT2 is involved in the process of the regulation of TP53 activity through methylation. The protein, UDP-glucuronosyltransferase 1-6, is a gene product of UGT1A6.', 'The compound homovanillic acid targets three different molecules - the histone-lysine n-methyltransferase, the ATPase family AAA domain-containing protein 5, and the UDP-glucuronosyltransferase 1-6. Moreover, this histone-lysine n-methyltransferase, targeted by homovanillic acid, is the gene product of several genes including DOT1L, EHMT1, and EHMT2. Interestingly, the EHMT2 gene acts within the regulation of TP53 activity through methylation. On the other hand, UDP-glucuronosyltransferase 1-6, another target of homovanillic acid, is a gene product of UGT1A6.', 'The compound homovanillic acid targets a variety of proteins, including the histone-lysine n-methyltransferase, the ATPase family AAA domain-containing protein 5, and UDP-glucuronosyltransferase 1-6. The histone-lysine n-methyltransferase is actually a gene product of several genes such as DOT1L, EHMT1, and EHMT2. Interestingly, EHMT2 actively functions within a biological network known as the regulation of TP53 activity through methylation. UDP-glucuronosyltransferase 1-6 is also noteworthy, as it is the gene product of UGT1A6.']","['The compound homovanillic acid targets not only the atpase family aaa domain-containing protein 5 but also udp-glucuronosyltransferase 1-6. The enzyme udp-glucuronosyltransferase 1-6, in fact, is a gene product of UGT1A6. Moreover, histone-lysine n-methyltransferase is a gene product of both EHMT1 and EHMT2. Importantly, EHMT2 has been found to act within the regulation of TP53 activity through methylation pathway, a mechanism vital for controlling cell growth and division.', 'The compound homovanillic acid targets two different proteins, ATPase family AAA domain-containing protein 5 and UDP-glucuronosyltransferase 1-6. UDP-glucuronosyltransferase 1-6 is a gene product of UGT1A6. On the other side, the histone-lysine N-methyltransferase is the gene product of two different genes, EHMT1 and EHMT2. Notably, EHMT2 acts within a special biological pathway which is termed as the regulation of TP53 activity through methylation.', 'The drug homovanillic acid targets two proteins: the ATPase family AAA domain-containing protein 5 and UDP-glucuronosyltransferase 1-6. Interestingly, the second protein is a gene product of UGT1A6. Meanwhile, histone-lysine N-methyltransferase, another important protein in the cell, is a gene product of two other genes, EHMT1 and EHMT2. Of these, EHMT2 acts within the pathway for regulation of TP53 activity through methylation. This illustrates how these compounds and proteins interact in complex ways within cellular pathways.', 'Homovanillic acid is a compound that targets a range of proteins, such as the ATPase family AAA domain-containing protein 5 and the UDP-glucuronosyltransferase 1-6. Furthermore, UDP-glucuronosyltransferase 1-6 is the gene product of UGT1A6. Histone-lysine N-methyltransferase plays a role in this process as it is a gene product of both EHMT1 and EHMT2. Additionally, EHMT2 acts within the process of regulation of the TP53 Activity through methylation. This elaborate network of interactions forms a sophisticated pathway of regulatory and target activities.', 'Homovanillic acid, a chemical compound often used in medical diagnosis, targets two proteins: the ATPase family AAA domain-containing protein 5 and UDP-glucuronosyltransferase 1-6. The latter is a gene product of UGT1A6. Additionally, the enzyme Histone-lysine N-methyltransferase is produced by two genes, EHMT1 and EHMT2. Importantly, EHMT2 acts within a specific biological pathway, regulation of TP53 activity through methylation, which is an essential process for maintaining the integrity of DNA sequences and controlling gene expression.']"
"[{'source_node': {'name': 'antiaroside f'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'caki-1'}}, {'source_node': {'name': 'antiaroside f'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}]","[{'source_node': {'name': 'antiaroside f'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'caki-1'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5851', 'target': None, 'metadata': {'node_id': '5851', 'node_type': 'PROTEIN', 'display_name': 'mcf7'}}]",0.6,06c74001563c1dbcb427c14e39414281,6c919bfc258a4af820e1d7e85b8d8cc5,"['The compound Antiaroside F has multiple targets, specifically the proteins Caki-1 and MCF7.', 'The compound Antiaroside F is known to target two different types of cells: CAKI-1 and MCF7.', 'The drug Antiaroside F has been found to target two different cell lines, namely Caki-1 and MCF7.', 'The drug Antiaroside F targets both the Caki-1 and MCF7 cells.', 'The compound Antiaroside F has been identified to target two specific entities, namely CAKI-1 and MCF7.']",[]
"[{'source_node': {'name': 'thymine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'thymidine phosphorylase'}}, {'source_node': {'name': 'thymine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ccrf-cem'}}, {'source_node': {'name': 'thymine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'atpase family aaa domain-containing protein 2'}}, {'source_node': {'name': 'TYMP'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pyrimidine salvage'}}, {'source_node': {'name': 'TYMP'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pyrimidine catabolism'}}, {'source_node': {'name': 'atpase family aaa domain-containing protein 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ATAD2'}}, {'source_node': {'name': 'thymidine phosphorylase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TYMP'}}]","[{'source_node': {'name': 'TYMP'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pyrimidine salvage'}}, {'source_node': {'name': 'TYMP'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pyrimidine catabolism'}}, {'source_node': {'name': 'thymidine phosphorylase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TYMP'}}]","[{'type': 'edge_addition', 'source': 'GENE:28414', 'target': 'PATHWAY:1264', 'metadata': {'predicate': 'acts_within'}}, {'type': 'node_removal', 'source': 'GENE:28414', 'target': None, 'metadata': {'node_id': '28414', 'node_type': 'GENE', 'display_name': 'ATAD2'}}, {'type': 'node_removal', 'source': 'COMPOUND:3264', 'target': None, 'metadata': {'node_id': '3264', 'node_type': 'COMPOUND', 'display_name': 'thymine'}}]",0.4666666666666667,ae9b8216934d1be2836b66965db5e777,b3d5500c53a7a3a677ed4775b91cf831,"['The compound thymine targets several entities including thymidine phosphorylase, ccrf-cem, and atpase family aaa domain-containing protein 2. Thymidine phosphorylase is a gene product of TYMP, which acts within two pathways: pyrimidine salvage and pyrimidine catabolism. Moreover, atpase family aaa domain-containing protein 2 is the gene product of ATAD2.', 'Thymine, a fundamental component of DNA, targets three distinct entities: thymidine phosphorylase, CCRF-CEM, and ATPase family AAA domain-containing protein 2. The Thymidine phosphorylase itself is a gene product of TYMP, a gene that crucially acts within the pyrimidine salvage and the pyrimidine catabolism processes. Similarly, ATPase family AAA domain-containing protein 2 is a gene product of the ATAD2 gene.', 'The compound Thymine targets several entities including thymidine phosphorylase, CCRF-CEM, and ATPase family AAA domain-containing protein 2. Thymidine phosphorylase and ATPase family AAA domain-containing protein 2 are gene products of TYMP and ATAD2 respectively. TYMP is notable as it acts within the pyrimidine salvage and pyrimidine catabolism pathways.', 'The compound thymine targets a range of proteins including thymidine phosphorylase, CCRF-CEM, and ATPase family AAA domain-containing protein 2. Thymidine phosphorylase is the gene product of TYMP, a gene that also acts within the pyrimidine salvage and pyrimidine catabolism pathways. On the other hand, the ATPase family AAA domain-containing protein 2 is a gene product of ATAD2.', 'The compound thymine has various targets. These include thymidine phosphorylase, ccrf-cem, and the atpase family aaa domain-containing protein 2. Thymidine phosphorylase is the gene product of TYMP. Similarly, the atpase family aaa domain-containing protein 2 is the gene product of ATAD2. This implicates both TYMP and ATAD2 in the function of thymine. Interestingly, TYMP not only contributes to the production of thymidine phosphorylase but also acts within the pyrimidine salvage and pyrimidine catabolism metabolic pathways.']","['The gene TYMP acts within the pyrimidine salvage and pyrimidine catabolism pathways. Additionally, thymidine phosphorylase is found to be the gene product of TYMP.', 'The gene TYMP is active within two biological pathways: Pyrimidine salvage and Pyrimidine catabolism. Furthermore, TYMP is responsible for the formation of the gene product known as thymidine phosphorylase.', 'The gene TYMP, which is known to act within several biochemical pathways, including the pyrimidine salvage and pyrimidine catabolism, is responsible for the production of the gene product thymidine phosphorylase.']"
"[{'source_node': {'name': 'callystatin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'achn'}}, {'source_node': {'name': 'callystatin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mda-mb-231'}}, {'source_node': {'name': 'callystatin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h522'}}]","[{'source_node': {'name': 'callystatin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mda-mb-231'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5690', 'target': None, 'metadata': {'node_id': '5690', 'node_type': 'PROTEIN', 'display_name': 'nci-h522'}}, {'type': 'node_removal', 'source': 'PROTEIN:5617', 'target': None, 'metadata': {'node_id': '5617', 'node_type': 'PROTEIN', 'display_name': 'achn'}}]",0.4285714285714286,fec811602d608dd4537c14ee69ef728b,8484487a41bfc0223bed7a14a22e2d3e,"['Callystatin A is a potent drug that has various targets, including ACHN, MDA-MB-231, and NCI-H522, demonstrating its potential use in varied therapeutic applications.', 'The compound Callystatin A has several targets which include ACHN, MDA-MB-231, and NCI-H522.', 'Callystatin A is a compound that has been identified as targeting several cancer cells, including ACHN, MDA-MB-231, and NCI-H522. Its effectiveness may vary based on the specific characteristics of these individual cancer types.', 'The drug Callystatin A has been found to target a variety of entities, including ACHN, MDA-MB-231, and NCI-H522.', 'The drug Callystatin A is known to target several entities, specifically ACHN, MDA-MB-231, and NCI-H522.']","['The drug Callystatin A has been identified to have the MDA-MB-231 as its target.', 'The compound Callystatin A has a target interaction with the human cancer cell line MDA-MB-231.', 'The compound Callystatin A has a target in MDA-MB-231.', 'The drug Callystatin A has the cancer cell line MDA-MB-231 as its target.', 'The drug Callystatin A has been found to target MDA-MB-231.']"
"[{'source_node': {'name': 'lofentanil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'amiloride'}}, {'source_node': {'name': 'gluconic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nylidrin'}}, {'source_node': {'name': 'gluconic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lofentanil'}}, {'source_node': {'name': 'gluconic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'win 55212-2'}}]","[{'source_node': {'name': 'lofentanil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'amiloride'}}, {'source_node': {'name': 'lofentanil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'gluconic acid'}}, {'source_node': {'name': 'gluconic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nylidrin'}}, {'source_node': {'name': 'gluconic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lofentanil'}}, {'source_node': {'name': 'gluconic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'win 55212-2'}}, {'source_node': {'name': 'gluconic acid'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'amiloride'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:11044', 'target': 'COMPOUND:580', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:8110', 'target': 'COMPOUND:11044', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.7777777777777778,2d40c21a157eceda53ad5d417907194e,7d47b64d47fb4bffa241f670843806db,"['The drug Lofentanil is known to decrease the efficacy of another drug called Amiloride. Meanwhile, Gluconic Acid can decrease the efficacy of three different compounds - Nylidrin, Lofentanil, and Win 55212-2. This suggests a complex network of interactions between these substances, which may have implications for their combined use in medical treatments.']","[""The drug Lofentanil has been found to decrease the efficacy of both Amiloride and Gluconic acid. Interestingly, Gluconic acid appears to have a complex interaction with other substances: it can decrease the efficacy of Nylidrin, Lofentanil, and Win 55212-2, but it also increases the efficacy of Amiloride. It's a fascinating display of how complex drug interactions can be."", 'The drug Lofentanil has been found to decrease the efficacy of both Amiloride and Gluconic acid. Interestingly, Gluconic acid also has a similar inhibitory effect on the efficacy of Nylidrin, Lofentanil, and Win 55212-2. However, in contrast to its suppressive interactions with other drugs, Gluconic acid is known to increase the efficacy of Amiloride.', 'Lofentanil, an opioid analgesic, is observed to decrease the efficacy of amiloride, a diuretic medication, and gluconic acid, a carboxylic acid. Interestingly, gluconic acid also interacts with several other substances. It diminishes the efficacy of nylidrin, a drug used primarily in the treatment of vascular diseases, lofentanil, and a synthetic cannabinoid named win 55212-2. Additionally, it plays an opposing role in the efficacy of amiloride by increasing its efficiency. The interactions between these drugs could play an important role in the effectiveness of medications and should be highly regarded when considering drug combinations.', 'The drug lofentanil is noted to decrease the efficacy of both amiloride and gluconic acid. In turn, gluconic acid has been found to also decrease the efficacy of several drugs, including nylidrin, lofentanil, and win 55212-2. Interestingly, while it reduces the effectiveness of some substances, gluconic acid is able to increase the efficacy of amiloride, a substance that it itself is negatively affected by lofentanil. This presents an unusual reciprocal relationship between these involved drugs.', ""The compound lofentanil has been found to decrease the efficacy of both amiloride and gluconic acid. Interestingly, gluconic acid itself also has a similar effect on a variety of compounds including nylidrin, lofentanil, and win 55212-2. However, gluconic acid is also known to increase the efficacy of amiloride. It appears these compounds interact in complex ways to influence each other's efficacy.""]"
"[{'source_node': {'name': 'xenon'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'etomidate'}}, {'source_node': {'name': 'xenon'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'phenoperidine'}}, {'source_node': {'name': 'xenon'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'medical cannabis'}}]","[{'source_node': {'name': 'etomidate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phenoperidine'}}, {'source_node': {'name': 'xenon'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'etomidate'}}, {'source_node': {'name': 'xenon'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'phenoperidine'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:11846', 'target': None, 'metadata': {'node_id': '11846', 'node_type': 'COMPOUND', 'display_name': 'medical cannabis'}}, {'type': 'edge_addition', 'source': 'COMPOUND:282', 'target': 'COMPOUND:11453', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.5714285714285714,9e86047b6b7901c61d55f3734a67fcd8,18c6e8383723ecc217d2fd558e1b7a7c,"['Xenon, a noble gas, has been observed to increase the efficacy of several substances, including etomidate, a short-acting intravenous anaesthetic medication, phenoperidine, a powerful opioid analgesic, and medical cannabis, a broad term used to describe products derived from the Cannabis plant for medical uses.', 'Xenon is known to increase the efficacy of several medicinal substances such as etomidate, phenoperidine, as well as medical cannabis, essentially ramping up their effectiveness in their respective applications.', 'The compound Xenon is known to increase the efficacy of several other substances. This includes the anesthetic drug Etomidate, the opioid Phenoperidine, and medical cannabis. Thus, using Xenon in combination with these substances may augment their therapeutic effects.', 'The noble gas, xenon, is noted for its capability to increase the efficacy of a number of substances. Specifically, it has been observed to enhance the effectiveness of etomidate, a potent anesthetic. In addition, phenoperidine, a highly potent opioid analgesic, also demonstrates increased potency when used in conjunction with xenon. Even medical cannabis, widely used for a variety of therapeutic purposes, shows an increased efficacy when combined with xenon.', 'The noble gas xenon has been found to increase the efficacy of several drugs. Specifically, it enhances the effectiveness of etomidate, phenoperidine, and medical cannabis. This suggests a considerable role for xenon in potentially augmenting the impacts of these drugs for better therapeutic outcomes.']","['The drug Etomidate can decrease the efficacy of Phenoperidine. However, the presence of Xenon increases the efficacy of both Etomidate and Phenoperidine. Therefore, using Etomidate and Xenon together could potentially improve the effectiveness of Phenoperidine.', 'The drug, etomidate, is known to decrease the efficacy of phenoperidine. Interestingly, the presence of xenon can potentially reverse this effect by increasing the efficacy of etomidate itself. Moreover, xenon also directly enhances the efficacy of phenoperidine, providing dual amelioration of the negative impacts posed by etomidate.', 'The drug etomidate is known to decrease the efficacy of phenoperidine. Interestingly, xenon is found to increase the effectiveness of both etomidate and phenoperidine. Hence, xenon might have a potential beneficial effect in therapies involving either of these drugs.', ""Etomidate and Phenoperidine are both efficacious drugs; however, the former decreases the efficacy of the latter. Conversely, Xenon, another drug, increases the efficacy of both Etomidate and Phenoperidine, toning down any possible negative impact of Etomidate on Phenoperidine's efficacy."", 'In the field of pharmacology, certain substances can alter the efficacy of others. For instance, the drug etomidate has decreased efficacy when coupled with phenoperidine. In contrast, xenon, a chemical element used in various applications, is known to increase the efficacy of both etomidate and phenoperidine. These interactions highlight the complex nature of drug interactions and their potential impact on drug effectiveness.']"
"[{'source_node': {'name': 'IGF1R'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'insulin-like growth factor i'}}, {'source_node': {'name': 'IGF1R'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'SHC-related events triggered by IGF1R'}}, {'source_node': {'name': 'cixutumumab'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'insulin-like growth factor 1 receptor'}}, {'source_node': {'name': 'cixutumumab'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the thrombogenic activities '}}, {'source_node': {'name': 'cixutumumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'insulin-like growth factor 1 receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'IGF1R'}}]","[{'source_node': {'name': 'IGF1R'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'insulin-like growth factor i'}}, {'source_node': {'name': 'IGF1R'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'SHC-related events triggered by IGF1R'}}, {'source_node': {'name': 'cixutumumab'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'IGF1R'}}, {'source_node': {'name': 'cixutumumab'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'insulin-like growth factor i'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:10154', 'target': 'GENE:29135', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'PROTEIN:62', 'target': None, 'metadata': {'node_id': '62', 'node_type': 'PROTEIN', 'display_name': 'insulin-like growth factor 1 receptor'}}, {'type': 'node_removal', 'source': 'EFFECT:5', 'target': None, 'metadata': {'node_id': '5', 'node_type': 'EFFECT', 'display_name': ' adverse effects '}}, {'type': 'edge_addition', 'source': 'COMPOUND:10154', 'target': 'DISEASE:10530', 'metadata': {'predicate': 'is_substance_that_treats'}}, {'type': 'node_removal', 'source': 'ACTIVITY:2', 'target': None, 'metadata': {'node_id': '2', 'node_type': 'ACTIVITY', 'display_name': ' the thrombogenic activities '}}]",0.3076923076923077,15112b73750c155c3bdc0edf30500334,13339186838128fbf5a1b1d8d2c2e44e,[],"['The gene IGF1R is known to cause a condition known as insulin-like growth factor I. IGF1R is also involved in processes within the SHC-related events triggered by IGF1R pathway. Cixutumumab, a therapeutic substance, impacts the IGF1R gene and is found to treat conditions like insulin-like growth factor I.', 'The gene IGF1R, which acts within the pathway of SHC-related events triggered by IGF1R, causes a condition known as insulin-like growth factor I. Moreover, this gene is affected by the drug Cixutumumab, which also treats the condition insulin-like growth factor I. This suggests an interconnected role of IGF1R and Cixutumumab in managing therapeutic outcomes.']"
"[{'source_node': {'name': 'ME1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'PPARA activates gene expression'}}, {'source_node': {'name': 'ME1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pyruvate metabolism'}}, {'source_node': {'name': 'ME1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'NFE2L2 regulating TCA cycle genes'}}]","[{'source_node': {'name': 'ME1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'NFE2L2 regulating TCA cycle genes'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:39', 'target': None, 'metadata': {'node_id': '39', 'node_type': 'PATHWAY', 'display_name': 'PPARA activates gene expression'}}, {'type': 'node_removal', 'source': 'PATHWAY:1307', 'target': None, 'metadata': {'node_id': '1307', 'node_type': 'PATHWAY', 'display_name': 'Pyruvate metabolism'}}]",0.4285714285714286,f549d426a4c9bb7d360ea55557ccc59d,72bac69ef6b1e6081c3dd2dcd7495ec2,"['The gene ME1 is involved in multiple biological pathways. It acts within the pathway where PPARA activates gene expression and plays a role in pyruvate metabolism. Additionally, ME1 acts within the process where NFE2L2 regulates TCA cycle genes.']",[]
"[{'source_node': {'name': 'retinoic acid receptor rxr-alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RXRA'}}, {'source_node': {'name': 'thyrotropin receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TSHR'}}, {'source_node': {'name': 'cellular tumor antigen p53'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TP53'}}, {'source_node': {'name': 'benzene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'thyrotropin receptor'}}, {'source_node': {'name': 'benzene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cellular tumor antigen p53'}}, {'source_node': {'name': 'benzene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'retinoic acid receptor rxr-alpha'}}]","[{'source_node': {'name': 'retinoic acid receptor rxr-alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RXRA'}}, {'source_node': {'name': 'retinoic acid receptor rxr-alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TP53'}}, {'source_node': {'name': 'thyrotropin receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TSHR'}}, {'source_node': {'name': 'cellular tumor antigen p53'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TP53'}}, {'source_node': {'name': 'benzene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'thyrotropin receptor'}}, {'source_node': {'name': 'benzene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cellular tumor antigen p53'}}, {'source_node': {'name': 'benzene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'retinoic acid receptor rxr-alpha'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:360', 'target': 'GENE:33312', 'metadata': {'predicate': 'gene_product_of'}}]",0.9230769230769232,b2c77953e321fd1fd1204c9abf613905,f7e256db01545c312dde3c8e9333dc96,"['The compound Benzene targets several biological entities such as the Thyrotropin receptor, the Cellular tumor antigen p53 and the Retinoic acid receptor RXR-alpha. These targeted entities are gene products of respective genes: the Thyrotropin receptor is a gene product of TSHR, the Cellular tumor antigen p53 is a gene product of TP53 and the Retinoic acid receptor RXR-alpha is a gene product of RXRA.', 'Benzene is a chemical compound which targets multiple cellular components including the thyrotropin receptor, cellular tumor antigen p53, and retinoic acid receptor RXR-alpha. Each of these receptors are gene products of distinct genes; the thyrotropin receptor emerges from the gene TSHR, the cellular tumor antigen p53 is the genomic output of TP53 and lastly, the retinoic acid receptor RXR-alpha is a gene product of RXRA.', 'The compound benzene is known to interact with several biological targets. Notably, it binds to the thyrotropin receptor, which is a product of the TSHR gene. Another target of benzene is the cellular tumor antigen p53, a protein encoded by the TP53 gene. In addition to these, benzene interacts with the retinoic acid receptor rxr-alpha, a protein product of the RXRA gene. These interactions raise implications for the broad range of biological processes that benzene could potentially influence.', 'The compound benzene targets several proteins such as the thyrotropin receptor, cellular tumor antigen p53, and retinoic acid receptor RXR-alpha. These proteins are the gene products of the TSHR, TP53, and RXRA genes respectively.', 'The compound benzene affects a variety of cellular components and processes by targeting key proteins such as the thyrotropin receptor, cellular tumor antigen p53, and retinoic acid receptor RXR-alpha. Each of these proteins are a gene product of specific genes. Mainly, the thyrotropin receptor is a gene product of the TSHR gene, where the cellular tumor antigen p53 is a product of the TP53 gene, and lastly, the retinoic acid receptor RXR-alpha is a gene product of the RXRA gene.\n']","['The drug benzene targets several receptors including the retinoic acid receptor rxr-alpha, thyrotropin receptor and cellular tumor antigen p53. The retinoic acid receptor rxr-alpha is a gene product of both RXRA and TP53 genes. The thyrotropin receptor is a gene product of the TSHR gene. Furthermore, the cellular tumor antigen p53 is produced by the TP53 gene.', 'The drug benzene targets several proteins including the retinoic acid receptor RXR-alpha, thyrotropin receptor, and the cellular tumor antigen p53. The retinoic acid receptor RXR-alpha is a product of two different genes, RXRA and TP53. The thyrotropin receptor, too, is a gene product of the TSHR gene. Additionally, the cellular tumor antigen p53 is a gene product of the TP53 gene.', 'The chemical compound Benzene has a broad range of targets including the Thyrotropin Receptor, Cellular Tumor Antigen p53, and Retinoic Acid Receptor Rxr-alpha. Interestingly, these targets are also gene products, where the Retinoic Acid Receptor Rxr-alpha is produced by both the RXRA and TP53 genes, the Cellular Tumor Antigen p53 is a product of the TP53 gene, and the Thyrotropin Receptor is a result of the TSHR gene expression.', 'The chemical compound benzene targets several receptors and antigens, including the thyrotropin receptor, cellular tumor antigen p53, and retinoic acid receptor rxr-alpha. The retinoic acid receptor rxr-alpha is a gene product of both the RXRA and TP53 genes, and similarly, the cellular tumor antigen p53 is also a product of the TP53 gene. The thyrotropin receptor, on the other hand, is a gene product of the TSHR gene. This gives an indication of the range of biological processes that benzene can impact and consequently, provides insight into the various health risks associated with this compound.', 'The chemical compound benzene targets multiple entities including the retinoic acid receptor RXR-alpha, the thyrotropin receptor, and the cellular tumor antigen p53. The retinoic acid receptor RXR-alpha, specifically, is a gene product of both RXRA and TP53 genes. While, the thyrotropin receptor is a gene product of the TSHR gene and the cellular tumor antigen p53 is produced by the TP53 gene.']"
"[{'source_node': {'name': 'VHL'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'erythrocytosis'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR1'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': 'paeoniflorin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'n9'}}, {'source_node': {'name': 'paeoniflorin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'estrogen receptor alpha'}}]","[{'source_node': {'name': 'VHL'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'erythrocytosis'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ESR1'}}, {'source_node': {'name': 'estrogen receptor alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'VHL'}}, {'source_node': {'name': 'paeoniflorin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'n9'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:52592', 'target': 'PROTEIN:943', 'metadata': None}]",0.9090909090909092,02d8df5f2b03e9d61321e6193bec0a84,a1d871160003a13ac88b7f3473c3281d,"['The gene VHL is known to cause a condition known as erythrocytosis. The estrogen receptor alpha, which is a gene product of both ESR1 and VHL, plays a significant role in this process. In pharmacological studies, it has been found that the compound paeoniflorin targets a protein called n9, as well as the estrogen receptor alpha. Such mechanism of action suggests a potential therapeutic significance of paeoniflorin in conditions related to these proteins and genes.']","['The gene VHL causes the condition known as erythrocytosis. Interestingly, this gene VHL is one of the gene products of estrogen receptor alpha along with ESR1. Furthermore, the substance paeoniflorin has been identified to target the gene product, n9, belonging to the estrogen receptor alpha.', 'The VHL gene is known to cause a condition called erythrocytosis. Estrogen receptor alpha is the gene product of both ESR1 and VHL genes. Additionally, paeoniflorin, a significant compound, has proven to target a gene referred to as n9.', 'The gene VHL is associated with causing a condition known as erythrocytosis. Additionally, the estrogen receptor alpha is a gene product of both ESR1 and VHL. Lastly, a compound known as paeoniflorin targets a molecule identified as n9.']"
"[{'source_node': {'name': 'n-phenyl-1h-pyrazole-3-carboxamide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cyclin-dependent kinase 2'}}, {'source_node': {'name': 'CDK2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Processing of DNA double-strand break ends'}}, {'source_node': {'name': 'CDK2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G2 Phase'}}, {'source_node': {'name': 'CDK2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'CDK-mediated phosphorylation and removal of Cdc6'}}, {'source_node': {'name': 'cyclin-dependent kinase 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CDK2'}}]","[{'source_node': {'name': 'CDK2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G2 Phase'}}, {'source_node': {'name': 'CDK2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'CDK-mediated phosphorylation and removal of Cdc6'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:7136', 'target': None, 'metadata': {'node_id': '7136', 'node_type': 'COMPOUND', 'display_name': 'n-phenyl-1h-pyrazole-3-carboxamide'}}, {'type': 'node_removal', 'source': 'PATHWAY:272', 'target': None, 'metadata': {'node_id': '272', 'node_type': 'PATHWAY', 'display_name': 'Processing of DNA double-strand break ends'}}, {'type': 'node_removal', 'source': 'PROTEIN:2085', 'target': None, 'metadata': {'node_id': '2085', 'node_type': 'PROTEIN', 'display_name': 'cyclin-dependent kinase 2'}}]",0.4545454545454546,fd844e0d9ec5af0db873a1e535f9dbca,5cd0d282f4966a9cd4cfe1085b36936a,"['The drug called n-phenyl-1h-pyrazole-3-carboxamide targets cyclin-dependent kinase 2. This kinase is a gene product of CDK2 which acts within several processes, such as the processing of DNA double-strand break ends, activity during the G2 phase, and CDK-mediated phosphorylation and removal of Cdc6.']",[]
"[{'source_node': {'name': 'chlormadinone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cyclacillin'}}, {'source_node': {'name': 'chlormadinone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'amoxicillin'}}, {'source_node': {'name': 'chlormadinone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'temocillin'}}, {'source_node': {'name': 'cyclacillin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'metocurine'}}, {'source_node': {'name': 'cyclacillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cyproterone acetate'}}]","[{'source_node': {'name': 'chlormadinone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cyclacillin'}}, {'source_node': {'name': 'chlormadinone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'temocillin'}}, {'source_node': {'name': 'chlormadinone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'cyproterone acetate'}}, {'source_node': {'name': 'cyclacillin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'metocurine'}}, {'source_node': {'name': 'cyclacillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cyproterone acetate'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:1040', 'target': None, 'metadata': {'node_id': '1040', 'node_type': 'COMPOUND', 'display_name': 'amoxicillin'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11379', 'target': 'COMPOUND:4555', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7272727272727273,4b30edc885b14c3bbef6f4fca73c99da,e9367af873fe674bb0cc3018612ee6ed,"['Chlormadinone, a medication, is known for decreasing the efficacy of several antibiotics, namely, cyclacillin, amoxicillin, and temocillin. On the other hand, cyclacillin displays the ability to increase the efficacy of metocurine, a muscle relaxant. However, cyclacillin shows a diminishing effect on the efficacy of another drug, cyproterone acetate.', 'The efficacy of the drug cyclacillin is known to be decreased by chlormadinone. However, cyclacillin has been found to increase the efficacy of another drug, metocurine. On the other hand, the administration of cyclacillin reduces the efficacy of cyproterone acetate. Furthermore, chlormadinone also negatively affects the effectiveness of the antibiotics amoxicillin and temocillin.', 'Chlormadinone, a potent medication, decreases the efficacy of several others, including cyclacillin, amoxicillin, and temocillin. Interestingly, cyclacillin, while having its efficacy decreased by chlormadinone, can increase the efficacy of yet another drug, metocurine. However, cyclacillin also decreases the efficacy of cyproterone acetate, creating a complex interaction network among these drugs.', 'The drug Chlormadinone has been found to diminish the efficacy of several antibiotics including Cyclacillin, Amoxicillin and Temocillin. In addition, Cyclacillin plays a dual role. On one hand, it enhances the efficacy of Metocurine, other hand, reduces that of Cyproterone Acetate. Consequently, caution should be used when prescribing these combinations.', 'Chlormadinone decreases the efficacy of several drugs including Cyclacillin, Amoxicillin, and Temocillin. However, Cyclacillin is known to increase the efficacy of Metocurine and decrease the efficacy of Cyproterone Acetate. Thus, it is critical to consider these interactions when co-administering these medications.']","['The drug Chlormadinone has been found to decrease the efficacy of Cyclacillin and Temocillin, but interestingly, it increases the efficacy of Cyproterone Acetate. On the other hand, Cyclacillin, despite its efficacy being reduced by Chlormadinone, increases the efficacy of Metocurine. However, Cyclacillin also decreases the efficacy of Cyproterone Acetate. Thus, these drugs need to be administered carefully taking into account their complex interactions and efficacy modulations.', 'The drug chlormadinone has been found to decrease the efficacy of both cyclacillin and temocillin. Interestingly, while it hampers the efficacy of cyclacillin, this drug, in turn, is known to increase the efficacy of metocurine but decrease the efficacy of cyproterone acetate. Alongside these interactions, chlormadinone is noted to increase the efficacy of cyproterone acetate. This intricate interplay of drug interactions highlights the complexity of pharmacological effects and potential complications in polypharmacy.', 'The use of the drug Chlormadinone can decrease the efficacy of Cyclacillin and Temocillin, but conversely, it may increase the efficacy of Cyproterone Acetate. In relation to other drugs, Cyclacillin could potentially increase the efficacy of Metocurine, but decrease the efficacy of Cyproterone Acetate, highlighting a complex network of drug interactions.', 'The drug chlormadinone has complex interactions with other drugs. It is known to decrease the efficacy of both cyclacillin and temocillin. Interestingly, while it reduces the effectivity of cyclacillin, Chlormadinone also simultaneously increases the efficacy of cyproterone acetate. Cyclacillin itself also plays a role in modulating the efficacy of other drugs - it increases the effectiveness of metocurine but decreases that of cyproterone acetate. Thus, careful consideration must be given when these drugs are administered in combination.', 'The drug chlormadinone has been observed to decrease the efficacy of cyclacillin and temocillin. Conversely, chlormadinone is observed to increase the efficacy of cyproterone acetate. Cyclacillin, on the other hand, is known to both increase the efficacy of metocurine and decrease the efficacy of cyproterone acetate.']"
"[{'source_node': {'name': 'SOAT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'LDL clearance'}}, {'source_node': {'name': 'ilekudinoside f'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sterol o-acyltransferase 1'}}, {'source_node': {'name': 'sterol o-acyltransferase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SOAT1'}}]","[{'source_node': {'name': 'SOAT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'LDL clearance'}}, {'source_node': {'name': 'sterol o-acyltransferase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SOAT1'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:46021', 'target': 'GENE:32981', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'COMPOUND:46021', 'target': None, 'metadata': {'node_id': '46021', 'node_type': 'COMPOUND', 'display_name': 'ilekudinoside f'}}]",0.7142857142857143,cbcfce0c8cebd8130270b9105f1aa817,60e6458d7636a80feafddde8176fca89,"['The drug Ilekudinoside F targets sterol O-acyltransferase 1, commonly known as SOAT1, which in itself acts within the process of LDL clearance. Notably, the protein sterol O-acyltransferase 1 is a gene product of SOAT1.', 'The compound Ilekudinoside F has sterol O-acyltransferase 1 as its target. Sterol O-acyltransferase 1 is specifically a gene product of SOAT1. Moreover, SOAT1 plays a significant role within the pathway of LDL clearance.', 'The compound ilekudinoside f has sterol o-acyltransferase 1 as its target. Sterol o-acyltransferase 1 is a product of the gene SOAT1. SOAT1, in turn, acts within the pathway responsible for LDL clearance.', 'The compound ilekudinoside f targets sterol o-acyltransferase 1, which is a gene product of SOAT1. This gene, SOAT1, plays a functional role acting within the pathway responsible for LDL clearance.']","['The gene product of sterol O-acyltransferase 1, also known as SOAT1, acts within the pathway responsible for LDL clearance.']"
"[{'source_node': {'name': 'enviomycin'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the neuromuscular blocking activities '}}, {'source_node': {'name': 'enviomycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vaccine'}}, {'source_node': {'name': 'enviomycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'vibrio cholerae cvd 103-hgr strain live antigen'}}, {'source_node': {'name': 'vibrio cholerae cvd 103-hgr strain live antigen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ganciclovir'}}]","[{'source_node': {'name': 'enviomycin'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the neuromuscular blocking activities '}}, {'source_node': {'name': 'enviomycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'vibrio cholerae cvd 103-hgr strain live antigen'}}, {'source_node': {'name': 'enviomycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ganciclovir'}}, {'source_node': {'name': 'vibrio cholerae cvd 103-hgr strain live antigen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ganciclovir'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:7938', 'target': 'COMPOUND:987', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:11858', 'target': None, 'metadata': {'node_id': '11858', 'node_type': 'COMPOUND', 'display_name': 'typhoid vaccine'}}]",0.6666666666666667,ac9f0f45ca7fceeb0afc2b92abdcb9d7,a15591faccafd751bb62836f020bd363,[],[]
"[{'source_node': {'name': 'alemtuzumab'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'campath-1 antigen'}}, {'source_node': {'name': 'alemtuzumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pertussis vaccine'}}, {'source_node': {'name': 'alemtuzumab'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'c-x-c motif chemokine ligand 12'}}, {'source_node': {'name': 'campath-1 antigen'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CD52'}}]","[{'source_node': {'name': 'alemtuzumab'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'campath-1 antigen'}}, {'source_node': {'name': 'campath-1 antigen'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CD52'}}]","[{'type': 'node_removal', 'source': 'GENE:4215', 'target': None, 'metadata': {'node_id': '4215', 'node_type': 'GENE', 'display_name': 'c-x-c motif chemokine ligand 12'}}, {'type': 'node_removal', 'source': 'COMPOUND:12857', 'target': None, 'metadata': {'node_id': '12857', 'node_type': 'COMPOUND', 'display_name': 'pertussis vaccine'}}]",0.5555555555555556,cfab841e3c21c911b73774aeff00bf29,d948aa2ccfc7afb20f07f9a649ffb251,"['The drug Alemtuzumab, targets the Campath-1 antigen. Interestingly, the Campath-1 antigen is a gene product of CD52. It is worth noting that Alemtuzumab affects the c-x-c motif chemokine ligand 12. Moreover, this drug has an impact on the efficacy of certain vaccines, such as the pertussis vaccine, by decreasing its effectiveness.', 'Alemtuzumab, a drug used in medical treatments, functions by targeting the Campath-1 antigen. Interestingly, the Campath-1 antigen is the gene product of CD52, hence, creating a direct relationship between Alemtuzumab and CD52. Furthermore, Alemtuzumab may negatively impact the efficacy of the pertussis vaccine. Additionally, it is known to affect the C-X-C motif chemokine ligand 12, adding a further dimension to its therapeutic and biological roles.', 'The drug Alemtuzumab targets the Campath-1 antigen, which is a gene product of CD52. Alemtuzumab also affects the C-X-C motif chemokine ligand 12. Interestingly, Alemtuzumab is noted to decrease the efficacy of the pertussis vaccine.', 'The drug Alemtuzumab targets the Campath-1 antigen, which is a gene product of CD52. Moreover, Alemtuzumab is known to affect the C-X-C motif chemokine ligand 12. Interestingly, it also has an effect on the efficacy of the pertussis vaccine, diminishing its effectiveness.', 'The drug Alemtuzumab targets the Campath-1 antigen, which is a gene product of CD52. However, Alemtuzumab is known to decrease the efficacy of the Pertussis vaccine. Additionally, it also affects the release of the C-X-C motif chemokine ligand 12.']","['The drug alemtuzumab has a target known as campath-1 antigen, which is a gene product of CD52.', 'The drug Alemtuzumab is known to target the Campath-1 antigen. Interestingly, this antigen is a gene product of CD52.', 'The drug alemtuzumab has a target known as the campath-1 antigen. This antigen is a gene product of CD52.', 'The drug alemtuzumab has a specific target, the Campath-1 antigen. Interestingly, the Campath-1 antigen is a gene product of CD52.', 'The drug alemtuzumab specifically targets the campath-1 antigen. This antigen is a gene product of CD52.']"
"[{'source_node': {'name': 'fms related tyrosine kinase 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'carcinoma'}}, {'source_node': {'name': 'fms related tyrosine kinase 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'progression-free survival'}}, {'source_node': {'name': 'imatinib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pev3a'}}, {'source_node': {'name': 'imatinib'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'epidermal growth factor receptor'}}, {'source_node': {'name': 'imatinib'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'fms related tyrosine kinase 1'}}]","[{'source_node': {'name': 'fms related tyrosine kinase 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'carcinoma'}}, {'source_node': {'name': 'fms related tyrosine kinase 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'progression-free survival'}}, {'source_node': {'name': 'imatinib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pev3a'}}]","[{'type': 'node_removal', 'source': 'GENE:5342', 'target': None, 'metadata': {'node_id': '5342', 'node_type': 'GENE', 'display_name': 'epidermal growth factor receptor'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:605', 'target': 'GENE:6454', 'metadata': None}]",0.7272727272727273,fc3961198bcfe41af05bd2e94395416d,fee4b60fc93528f3305bc54d43297c0a,[],[]
"[{'source_node': {'name': 'antcin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'antcin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}, {'source_node': {'name': 'antcin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'source_node': {'name': 'antcin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}, {'source_node': {'name': 'antcin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5851', 'target': None, 'metadata': {'node_id': '5851', 'node_type': 'PROTEIN', 'display_name': 'mcf7'}}]",0.7142857142857143,fc664060c3acf49913bd8a7eb9e43c27,cff5b81a6f0189256efde1fc3d04b68b,"['The drug Antcin A targets several cell lines including MCF7, KB, and A549.', 'The compound Antcin A has been identified to target multiple cell lines including MCF7, KB, and A549.', 'The compound Antcin A is known to target several cells, including MCF7, KB, and A549.', 'The compound Antcin A is known to target several cell lines, including MCF7, KB, and A549.', 'The compound Antcin A has been found to target several cells including MCF7, KB, and A549.']","['The compound Antcin A targets two specific components, KB and A549.', 'The drug Antcin A targets both KB and A549 cells.', 'The drug Antcin A targets both KB and A549.', 'The compound Antcin A targets both KB and A549.', 'The compound Antcin A targets both KB and A549 cells.']"
"[{'source_node': {'name': 'F2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Platelet Aggregation (Plug Formation)'}}, {'source_node': {'name': 'prothrombin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'F2'}}, {'source_node': {'name': '4-iodobenzo[b]thiophene-2-carboxamidine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prothrombin'}}, {'source_node': {'name': '4-iodobenzo[b]thiophene-2-carboxamidine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'trypsin-1'}}, {'source_node': {'name': '4-iodobenzo[b]thiophene-2-carboxamidine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'urokinase-type plasminogen activator'}}, {'source_node': {'name': 'urokinase-type plasminogen activator'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PLAU'}}, {'source_node': {'name': 'trypsin-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PRSS1'}}]","[{'source_node': {'name': '4-iodobenzo[b]thiophene-2-carboxamidine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prothrombin'}}, {'source_node': {'name': '4-iodobenzo[b]thiophene-2-carboxamidine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'urokinase-type plasminogen activator'}}, {'source_node': {'name': 'urokinase-type plasminogen activator'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PLAU'}}, {'source_node': {'name': 'trypsin-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PRSS1'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:1851', 'target': 'GENE:26852', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:2952', 'target': 'PROTEIN:1851', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:2952', 'target': 'GENE:26852', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'GENE:26852', 'target': None, 'metadata': {'node_id': '26852', 'node_type': 'GENE', 'display_name': 'F2'}}]",0.6666666666666667,8ecdb0e0b996cab768dc396d5c198172,aa538bf3ce6e79210d97f4fbf1c3d722,[],"['The compound 4-iodobenzo[b]thiophene-2-carboxamidine has a specific interaction with the targets prothrombin and urokinase-type plasminogen activator. The urokinase-type plasminogen activator is a gene product of PLAU. Additionally, trypsin-1 serves as a gene product of PRSS1.', 'The compound 4-iodobenzo[b]thiophene-2-carboxamidine has targets that include prothrombin and the urokinase-type plasminogen activator. The latter is a gene product of PLAU. Another notable mention is trypsin-1, which is a gene product of PRSS1.', 'The compound 4-iodobenzo[b]thiophene-2-carboxamidine has been identified as a target for both prothrombin and the urokinase-type plasminogen activator. Interestingly, the urokinase-type plasminogen activator is a gene product of PLAU. Similarly, trypsin-1 is a product of the PRSS1 gene.', 'The compound 4-iodobenzo[b]thiophene-2-carboxamidine has a dual target mechanism of action. It targets prothrombin, as well as the urokinase-type plasminogen activator. The latter is interestingly a gene product of PLAU. In a related note, trypsin-1, an enzymatic protein involved in digestive processes, is a gene product of PRSS1.', 'The compound 4-iodobenzo[b]thiophene-2-carboxamidine targets two key proteins: prothrombin and urokinase-type plasminogen activator. Notably, urokinase-type plasminogen activator is a gene product of PLAU. Furthermore, we also observe that trypsin-1 is a gene product of PRSS1.']"
"[{'source_node': {'name': 'pf-00356231'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'macrophage metalloelastase'}}, {'source_node': {'name': 'macrophage metalloelastase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MMP12'}}, {'source_node': {'name': 'MMP12'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Collagen degradation'}}, {'source_node': {'name': 'MMP12'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Degradation of the extracellular matrix'}}]","[{'source_node': {'name': 'pf-00356231'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'macrophage metalloelastase'}}, {'source_node': {'name': 'pf-00356231'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'MMP12'}}, {'source_node': {'name': 'macrophage metalloelastase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MMP12'}}, {'source_node': {'name': 'MMP12'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Degradation of the extracellular matrix'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:3174', 'target': 'GENE:29969', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'PATHWAY:411', 'target': None, 'metadata': {'node_id': '411', 'node_type': 'PATHWAY', 'display_name': 'Collagen degradation'}}]",0.6666666666666667,797f805e0cd489ccbec191706623b7b6,306b11bde83c478c660afb97be8a83e4,"['The drug PF-00356231 targets a protein known as macrophage metalloelastase. Macrophage metalloelastase is a gene product of MMP12. MMP12 acts within several pathways, two of which are the collagen degradation and degradation of the extracellular matrix pathways.', 'PF-00356231 directly targets macrophage metalloelastase. This molecule is actually a gene product of MMP12. MMP12 acts within multiple biological pathways such as collagen degradation and degradation of the extracellular matrix.', 'The drug PF-00356231 targets an enzyme known as macrophage metalloelastase. Interestingly, this enzyme is the gene product of MMP12, a gene that is vital to certain processes within the body, as it acts within pathways responsible for collagen degradation and the broader process of the degradation of the extracellular matrix.', 'The drug PF-00356231 has a specific target known as macrophage metalloelastase. Macrophage metalloelastase is actually a gene product of a gene called MMP12. Interestingly, this gene MMP12 not only acts within a process known as collagen degradation, but it also participates in the degradation of the extracellular matrix.', 'The drug PF-00356231 targets the macrophage metalloelastase which is a gene product of MMP12. MMP12 acts within several biochemical pathways including collagen degradation and degradation of the extracellular matrix.']",[]
"[{'source_node': {'name': 'leukoencephalopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'renal insufficiency'}}, {'source_node': {'name': 'leukoencephalopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'bowel incontinence'}}, {'source_node': {'name': 'leukoencephalopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'myoclonus'}}, {'source_node': {'name': 'EIF2AK1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'leukoencephalopathy'}}, {'source_node': {'name': 'EIF2AK1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Response of EIF2AK1 (HRI) to heme deficiency'}}]","[{'source_node': {'name': 'leukoencephalopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'bowel incontinence'}}, {'source_node': {'name': 'leukoencephalopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'myoclonus'}}, {'source_node': {'name': 'EIF2AK1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Response of EIF2AK1 (HRI) to heme deficiency'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:77', 'target': None, 'metadata': {'node_id': '77', 'node_type': 'PHENOTYPE', 'display_name': 'renal insufficiency'}}, {'type': 'edge_deletion', 'source': 'GENE:28054', 'target': 'DISEASE:17980', 'metadata': None}]",0.7272727272727273,5c1a6f73551d426bfc55707222be7ead,575578d3820e58ad9625960112b04ca1,"['The gene EIF2AK1 is known to act within the biochemical pathway responding to heme deficiency, more specifically the Response of EIF2AK1 (HRI) to heme deficiency. This gene is also responsible for causing the medical condition known as leukoencephalopathy. This condition is characterized by a variety of phenotypes including renal insufficiency, bowel incontinence, and myoclonus among others.', 'Leukoencephalopathy, a condition caused by the gene EIF2AK1, exhibits several notable phenotypes. These include renal insufficiency, bowel incontinence, and myoclonus. Moreover, EIF2AK1 also acts within a specific pathway, known as the response of EIF2AK1 (HRI) to heme deficiency.', 'The gene EIF2AK1, which operates within the response of EIF2AK1 (HRI) to heme deficiency, is known to cause leukoencephalopathy. This condition, leukoencephalopathy, presents various symptoms such as renal insufficiency, bowel incontinence, and myoclonus.', 'The gene EIF2AK1, which acts within the biological process of the response of EIF2AK1 (HRI) to heme deficiency, causes a condition known as leukoencephalopathy. This condition, leukoencephalopathy, has various phenotypes including renal insufficiency, bowel incontinence, and myoclonus.']","['The disease Leukoencephalopathy is characterized by various symptoms including bowel incontinence and myoclonus. Moreover, the gene EIF2AK1 is known to act within the pathway that oversees the response of EIF2AK1 (HRI) to heme deficiency.']"
"[{'source_node': {'name': 'dipyridamole'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'malathion'}}, {'source_node': {'name': 'dipyridamole'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'olive oil'}}, {'source_node': {'name': 'dipyridamole'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Eye pain'}}, {'source_node': {'name': 'malathion'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'malathion'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Chemical burn'}}, {'source_node': {'name': 'malathion'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Burns second degree'}}]","[{'source_node': {'name': 'dipyridamole'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Eye pain'}}, {'source_node': {'name': 'malathion'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Chemical burn'}}, {'source_node': {'name': 'malathion'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Burns second degree'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:958', 'target': 'COMPOUND:756', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:8389', 'target': None, 'metadata': {'node_id': '8389', 'node_type': 'COMPOUND', 'display_name': 'olive oil'}}, {'type': 'edge_replacement', 'source': 'COMPOUND:756', 'target': 'EFFECT:5', 'metadata': {'predicate': 'decrease_effect'}}, {'type': 'node_removal', 'source': 'EFFECT:5', 'target': None, 'metadata': {'node_id': '5', 'node_type': 'EFFECT', 'display_name': ' adverse effects '}}]",0.6153846153846154,b3b9952d5087bb794564ed3fefa5925f,f81e750cfa5073d439016a9c1cae75df,[],"['The drug dipyridamole carries a side effect of causing eye pain. Similarly, another compound known as malathion has reported side effects that include causing both chemical burns and second degree burns.', 'The medication Dipyridamole can potentially have a side effect of causing eye pain to the user. Similarly, the chemical compound Malathion, often used as an insecticide, carries side effects such as causing chemical burns and second degree burns. Thus, when using these substances, individuals must be carefully monitored for any adverse reactions.', 'The drugs dipyridamole and malathion may have significant side effects on the users. Dipyridamole can cause eye pain, a discomfort that may vary from mild to severe. On the other hand, malathion has been documented to cause both chemical burns and second degree burns, which can be quite serious if not handled immediately and properly.', 'The drug dipyridamole is known to occasionally cause side effects such as eye pain. Similarly, the insecticide malathion can potentially cause severe adverse effects which include chemical burns and burns of the second degree.', 'The drug dipyridamole has a known side effect of causing eye pain in some users. Similarly, exposure to the chemical substance malathion can result in side effects such as chemical burns and second degree burns in serious cases.']"
"[{'source_node': {'name': 'patritumab'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the thrombogenic activities '}}, {'source_node': {'name': 'patritumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}]","[{'source_node': {'name': 'patritumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}]","[{'type': 'node_removal', 'source': 'ACTIVITY:2', 'target': None, 'metadata': {'node_id': '2', 'node_type': 'ACTIVITY', 'display_name': ' the thrombogenic activities '}}]",0.6,7d0a23d45135c301115e217cd1989202,559e291b994f6f9a1c33e24f9e44b1b4,[],[]
"[{'source_node': {'name': 'nuclear factor nf-kappa-b p105 subunit'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NFKB1'}}, {'source_node': {'name': 'HSPB1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Extra-nuclear estrogen signaling'}}, {'source_node': {'name': 'heat shock protein beta-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HSPB1'}}, {'source_node': {'name': 'methyl 3,7-dimethyloct-6-enoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'heat shock protein beta-1'}}, {'source_node': {'name': 'methyl 3,7-dimethyloct-6-enoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear factor nf-kappa-b p105 subunit'}}, {'source_node': {'name': 'methyl 3,7-dimethyloct-6-enoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'transcription factor ap-1'}}, {'source_node': {'name': 'transcription factor ap-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'JUN'}}]","[{'source_node': {'name': 'HSPB1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Extra-nuclear estrogen signaling'}}, {'source_node': {'name': 'heat shock protein beta-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HSPB1'}}, {'source_node': {'name': 'heat shock protein beta-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'JUN'}}, {'source_node': {'name': 'methyl 3,7-dimethyloct-6-enoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'heat shock protein beta-1'}}, {'source_node': {'name': 'methyl 3,7-dimethyloct-6-enoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'transcription factor ap-1'}}, {'source_node': {'name': 'transcription factor ap-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'JUN'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:1408', 'target': None, 'metadata': {'node_id': '1408', 'node_type': 'PROTEIN', 'display_name': 'nuclear factor nf-kappa-b p105 subunit'}}, {'type': 'edge_addition', 'source': 'PROTEIN:3873', 'target': 'GENE:29344', 'metadata': {'predicate': 'gene_product_of'}}]",0.6666666666666667,3c83e9ceb6dfc3395202513f835b1d78,51789c5ee394f06c6aa624baa36ad77a,"['The drug methyl 3,7-dimethyloct-6-enoate targets multiple factors, including heat shock protein beta-1 and the nuclear factor nf-kappa-b p105 subunit, as well as transcription factor ap-1. The heat shock protein beta-1 is produced as a gene product of HSPB1, which also acts within the complex biological process known as extra-nuclear estrogen signaling. Meanwhile, the nuclear factor nf-kappa-b p105 subunit is a gene product of NFKB1. Interestingly, the transcription factor ap-1 is a gene product of the JUN gene.']","['The gene HSPB1 acts within the extra-nuclear estrogen signaling pathway. This gene produces a product known as heat shock protein beta-1, which is also the result of another gene, JUN. The compound methyl 3,7-dimethyloct-6-enoate targets this heat shock protein. Additionally, the same compound targets another product of the JUN gene, known as transcription factor ap-1.', 'The molecule HSPB1 acts within a signal pathway known as extra-nuclear estrogen signaling. Heat shock protein beta-1 is a gene product of HSPB1 and also of a gene known as JUN. Additionally, a compound called methyl 3,7-dimethyloct-6-enoate targets heat shock protein beta-1. Interestingly, this same drug also targets another gene product of JUN, the transcription factor AP-1. Consequently, both the heat shock protein beta-1 and the transcription factor AP-1 are intertwined in their interactions with the compound methyl 3,7-dimethyloct-6-enoate and are gene products of the JUN gene, with the former also being linked to HSPB1 and the extra-nuclear estrogen signaling pathway.', 'Heat shock protein beta-1, a gene product of both HSPB1 and JUN, is targeted by the compound methyl 3,7-dimethyloct-6-enoate. Moreover, HSPB1 is active within the pathway of extra-nuclear estrogen signaling. This pharmaceutical compound also targets transcription factor ap-1, another gene product of JUN. It signifies an intricate relationship between these compounds and proteins, implicating them in broader biological processes and potential therapeutic regimes.']"
"[{'source_node': {'name': 'eflornithine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ornithine decarboxylase'}}, {'source_node': {'name': 'ornithine decarboxylase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ODC1'}}, {'source_node': {'name': 'ODC1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of ornithine decarboxylase (ODC)'}}, {'source_node': {'name': 'ODC1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Metabolism of polyamines'}}]","[{'source_node': {'name': 'eflornithine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ornithine decarboxylase'}}, {'source_node': {'name': 'eflornithine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'ODC1'}}, {'source_node': {'name': 'ornithine decarboxylase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ODC1'}}, {'source_node': {'name': 'ODC1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Metabolism of polyamines'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:380', 'target': None, 'metadata': {'node_id': '380', 'node_type': 'PATHWAY', 'display_name': 'Regulation of ornithine decarboxylase (ODC)'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5483', 'target': 'GENE:30384', 'metadata': {'predicate': 'is_affecting'}}]",0.6666666666666667,e3f8e794fd72d004588ed96cc7b9c3d0,7e29588b54c54e4c657510247ccc24fa,"['Eflornithine, an active substance often used in medications, targets the protein known as ornithine decarboxylase. This protein is the gene product of ODC1. The gene ODC1 plays a critical role within two metabolic pathways: the regulation of ornithine decarboxylase (ODC), and the metabolism of polyamines, both of which are vital for various biological processes.']","['The drug Eflornithine has a target known as ornithine decarboxylase, which is a gene product of ODC1. In addition to this, the drug affects ODC1, which is known to act within a biological pathway involved in the metabolism of polyamines.', 'Eflornithine, a pharmacological agent, interacts with ornithine decarboxylase, which is a gene product of ODC1, an essential gene involved in the metabolism of polyamines. Furthermore, eflornithine is also known for affecting the function of ODC1.']"
"[{'source_node': {'name': 'petrocortyne e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'k562'}}, {'source_node': {'name': 'petrocortyne e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'phospholipase a2'}}, {'source_node': {'name': 'PLA2G2A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Acyl chain remodelling of PE'}}, {'source_node': {'name': 'phospholipase a2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PLA2G2A'}}, {'source_node': {'name': 'phospholipase a2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PLA2G1B'}}]","[{'source_node': {'name': 'petrocortyne e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'k562'}}, {'source_node': {'name': 'petrocortyne e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'phospholipase a2'}}]","[{'type': 'node_removal', 'source': 'GENE:30995', 'target': None, 'metadata': {'node_id': '30995', 'node_type': 'GENE', 'display_name': 'PLA2G1B'}}, {'type': 'edge_addition', 'source': 'PROTEIN:4947', 'target': 'GENE:30996', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'GENE:30996', 'target': None, 'metadata': {'node_id': '30996', 'node_type': 'GENE', 'display_name': 'PLA2G2A'}}]",0.4545454545454546,4702750eab8eaadde1627bd846e9c7a0,60048c5fe8ee3a143e651f2a06bb026a,"['Petrocortyne E, a substance of interest in scientific research, has been identified to target K562, a human leukemia cell line, and phospholipase a2, an enzyme involved in the regulation of the inflammatory response. This phospholipase a2 is the gene product of both PLA2G2A and PLA2G1B. Interestingly, PLA2G2A is known to act within the process of acyl chain remodelling of PE, a lipid signalling pathway that can potentially influence health and disease outcomes.', 'The compound petrocortyne E is known to target K562 and phospholipase A2. Phospholipase A2 is a gene product of both PLA2G2A and PLA2G1B. Moreover, PLA2G2A acts within the acyl chain remodelling of PE pathway.', 'Petrocortyne E has two targets: K562 and phospholipase A2. Phospholipase A2 is the gene product of both PLA2G2A and PLA2G1B. Furthermore, PLA2G2A acts within the Acyl chain remodelling of PE pathway.', 'The drug Petrocortyne E has several molecular targets. Firstly, it targets K562. It also targets Phospholipase A2, a gene product of both PLA2G2A and PLA2G1B. Interestingly, PLA2G2A acts within the biochemical pathway known as acyl chain remodelling of PE.']","['The compound Petrocortyne E targets both K562, a type of human leukemia cell, and the enzyme Phospholipase A2.', 'The compound Petrocortyne E targets both K562, a human immortalised myelogenous leukemia cell line, and an enzyme known as Phospholipase A2.', 'The compound Petrocortyne E has been identified to target both K562, a type of leukemia cell line, and Phospholipase A2, an enzyme crucial for various cellular processes.', 'The compound Petrocortyne E targets both K562, a human immortalised myelogenous leukemia cell line, and the enzyme phospholipase A2.', 'The compound Petrocortyne E has targets that include both K562, a human leukemia cell line, and Phospholipase A2, an enzyme involved in inflammation and other cellular processes.']"
"[{'source_node': {'name': 'epihematoxin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'proto-oncogene tyrosine-protein kinase src'}}, {'source_node': {'name': 'epihematoxin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'epidermal growth factor receptor'}}, {'source_node': {'name': 'epihematoxin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepatocyte growth factor receptor'}}, {'source_node': {'name': 'hepatocyte growth factor receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MET'}}, {'source_node': {'name': 'proto-oncogene tyrosine-protein kinase src'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SRC'}}]","[{'source_node': {'name': 'epihematoxin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'proto-oncogene tyrosine-protein kinase src'}}, {'source_node': {'name': 'epihematoxin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'epidermal growth factor receptor'}}, {'source_node': {'name': 'epihematoxin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepatocyte growth factor receptor'}}, {'source_node': {'name': 'epihematoxin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'MET'}}, {'source_node': {'name': 'hepatocyte growth factor receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MET'}}, {'source_node': {'name': 'proto-oncogene tyrosine-protein kinase src'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SRC'}}, {'source_node': {'name': 'epidermal growth factor receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SRC'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:70758', 'target': 'GENE:29917', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:2', 'target': 'GENE:33030', 'metadata': {'predicate': 'gene_product_of'}}]",0.8181818181818181,a9fda34e14c18fc71382d0bcee1458e4,57f3aa9ef4788a603ad51b374e69cf2b,"['The compound epihematoxin has multiple targets which include the proto-oncogene tyrosine-protein kinase src, the epidermal growth factor receptor, and the hepatocyte growth factor receptor. In the context of genetic products, the proto-oncogene tyrosine-protein kinase src is a product of the SRC gene while the hepatocyte growth factor receptor is a product of the MET gene.', 'The drug epihematoxin has multiple targets, which include the proto-oncogene tyrosine-protein kinase src, the epidermal growth factor receptor, and the hepatocyte growth factor receptor. Interestingly, the proto-oncogene tyrosine-protein kinase src and hepatocyte growth factor receptor are gene products of SRC and MET, respectively.', 'The drug epihematoxin targets several proteins, including the proto-oncogene tyrosine-protein kinase src, the epidermal growth factor receptor, and the hepatocyte growth factor receptor. The hepatocyte growth factor receptor is a gene product of MET, while the proto-oncogene tyrosine-protein kinase src is a gene product of SRC.', 'The drug epihematoxin has multiple targets, including the proto-oncogene tyrosine-protein kinase src, the epidermal growth factor receptor, and the hepatocyte growth factor receptor. The proto-oncogene tyrosine-protein kinase src is a gene product of SRC, while the hepatocyte growth factor receptor is a gene product of MET.', 'The drug epihematoxin targets several proteins, including the proto-oncogene tyrosine-protein kinase src, epidermal growth factor receptor, and the hepatocyte growth factor receptor. Further, it is important to note that the hepatocyte growth factor receptor is the gene product of the MET gene and the proto-oncogene tyrosine-protein kinase src is a gene product of the SRC gene.']",[]
"[{'source_node': {'name': 'butanilicaine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the neuromuscular blocking activities '}}, {'source_node': {'name': 'butanilicaine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' effectiveness '}}, {'source_node': {'name': 'butanilicaine'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}]","[{'source_node': {'name': 'butanilicaine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the neuromuscular blocking activities '}}, {'source_node': {'name': 'butanilicaine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' effectiveness '}}]","[{'type': 'node_removal', 'source': 'EFFECT:5', 'target': None, 'metadata': {'node_id': '5', 'node_type': 'EFFECT', 'display_name': ' adverse effects '}}]",0.7142857142857143,0c467a98ece310006e447523fd272565,73d6768ccf11093085f6050f29e1aaa1,[],[]
"[{'source_node': {'name': 'phenoxymethylpenicillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'doxycycline'}}, {'source_node': {'name': 'phenoxymethylpenicillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lymecycline'}}, {'source_node': {'name': 'phenoxymethylpenicillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'eravacycline'}}, {'source_node': {'name': 'doxycycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dicloxacillin'}}, {'source_node': {'name': 'doxycycline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pyrantel'}}, {'source_node': {'name': 'doxycycline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'letibotulinumtoxina'}}, {'source_node': {'name': 'eravacycline'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hepatotoxic activities '}}, {'source_node': {'name': 'eravacycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sultamicillin'}}]","[{'source_node': {'name': 'doxycycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dicloxacillin'}}, {'source_node': {'name': 'doxycycline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pyrantel'}}, {'source_node': {'name': 'doxycycline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'letibotulinumtoxina'}}, {'source_node': {'name': 'doxycycline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'sultamicillin'}}, {'source_node': {'name': 'eravacycline'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hepatotoxic activities '}}, {'source_node': {'name': 'eravacycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sultamicillin'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:405', 'target': 'COMPOUND:10230', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:244', 'target': 'COMPOUND:10036', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:405', 'target': 'COMPOUND:244', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:246', 'target': None, 'metadata': {'node_id': '246', 'node_type': 'COMPOUND', 'display_name': 'lymecycline'}}]",0.6470588235294117,0da9b71d1fdc8b4a018c75a592824205,8d6e187a636abc42aa33c14aed83e7f1,[],[]
"[{'source_node': {'name': 'gallamine triethiodide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'piperacillin'}}, {'source_node': {'name': 'gallamine triethiodide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'azlocillin'}}, {'source_node': {'name': 'gallamine triethiodide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'carindacillin'}}, {'source_node': {'name': 'oxyphenisatin acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trihexyphenidyl'}}, {'source_node': {'name': 'oxyphenisatin acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'gallamine triethiodide'}}, {'source_node': {'name': 'oxyphenisatin acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fendiline'}}, {'source_node': {'name': 'fendiline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carboxymethylcellulose'}}, {'source_node': {'name': 'fendiline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'calcium polycarbophil'}}]","[{'source_node': {'name': 'gallamine triethiodide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'azlocillin'}}, {'source_node': {'name': 'gallamine triethiodide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'carindacillin'}}, {'source_node': {'name': 'oxyphenisatin acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trihexyphenidyl'}}, {'source_node': {'name': 'fendiline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carboxymethylcellulose'}}, {'source_node': {'name': 'fendiline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'calcium polycarbophil'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:309', 'target': None, 'metadata': {'node_id': '309', 'node_type': 'COMPOUND', 'display_name': 'piperacillin'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:12333', 'target': 'COMPOUND:7925', 'metadata': None}, {'type': 'edge_deletion', 'source': 'COMPOUND:12333', 'target': 'COMPOUND:471', 'metadata': None}]",0.7647058823529411,8e8303b4d29c4d96acc1a3f1377cde6d,dba8b5bafeeee1d674960a5e526f1204,"['The drug gallamine triethiodide has been found to increase the efficacy of several other drugs, including piperacillin, azlocillin, and carindacillin, amplifying their effects. In contrast, the pharmaceutical compound oxyphenisatin acetate diminishes the efficacy of drugs like trihexyphenidyl and fendiline, while also reducing the effectiveness of gallamine triethiodide. Notably, fendiline also decreases the efficacy of two substances: carboxymethylcellulose and calcium polycarbophil.', ""Gallamine triethiodide is known to increase the efficacy of various antibiotics like piperacillin, azlocillin, and carindacillin. Concurrently, another drug, oxyphenisatin acetate, functions to decrease the efficacy of gallamine triethiodide, along with decreasing the efficacy of trihexyphenidyl and fendiline. Interestingly, fendiline also has a similar effect of decreasing the efficacy on other substances, including carboxymethylcellulose and calcium polycarbophil. With this in mind, it's crucial to consider the potential interactions and influence on efficacy when these substances are present together.""]","['The drug Gallamine Triethiodide has been shown to increase the efficacy of both Azlocillin and Carindacillin. In contrast, Oxyphenisatin Acetate can decrease the efficacy of Trihexyphenidyl. Similarly, Fendiline has been found to reduce the effectiveness of Carboxymethylcellulose and Calcium Polycarbophil.', 'Gallamine triethiodide is known to increase the efficacy of the antibiotics azlocillin and carindacillin. On the other hand, the use of oxyphenisatin acetate reduces the effectiveness of trihexyphenidyl. Furthermore, fendiline is observed to decrease the efficacy of both carboxymethylcellulose and calcium polycarbophil. These interactions, illustrating the interplay between different pharmaceutical substances, highlight the complexity of drug interactions and their impacts on treatment efficacy.', 'The drug gallamine triethiodide is known to increase the efficacy of certain other medications, such as azlocillin and carindacillin. On the other hand, oxyphenisatin acetate has been observed to decrease the efficacy of trihexyphenidyl. Similarly, fendiline, another medication, appears to reduce the efficacy of both carboxymethylcellulose and calcium polycarbophil.', 'Gallamine triethiodide is known to increase the efficacy of two drugs: azlocillin and carindacillin. On the other hand, oxyphenisatin acetate may decrease the efficacy of trihexyphenidyl. Similarly, fendiline can also decrease the efficacy of certain substances. Specifically, it can lessen the efficacy of carboxymethylcellulose and calcium polycarbophil.', 'The compound gallamine triethiodide is known to increase the efficacy of both azlocillin and carindacillin. However, the compound fendiline exhibits a contrasting effect on the efficacy of carboxymethylcellulose and calcium polycarbophil, resulting in a decreased effectiveness. Interestingly, oxyphenisatin acetate is noted to decrease the efficacy of trihexyphenidyl.']"
"[{'source_node': {'name': '2-methoxyethanol'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the neutropenic activities '}}, {'source_node': {'name': '2-methoxyethanol'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' myelosuppression '}}, {'source_node': {'name': '2-methoxyethanol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'vibrio cholerae cvd 103-hgr strain live antigen'}}]","[{'source_node': {'name': '2-methoxyethanol'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the neutropenic activities '}}, {'source_node': {'name': '2-methoxyethanol'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' myelosuppression '}}]","[{'type': 'node_removal', 'source': 'COMPOUND:12210', 'target': None, 'metadata': {'node_id': '12210', 'node_type': 'COMPOUND', 'display_name': 'vibrio cholerae cvd 103-hgr strain live antigen'}}]",0.7142857142857143,b25b7e38d244103a9289da4b4f3d78f6,641b65a22386133fbd8fb5561c2f7527,[],[]
"[{'source_node': {'name': 'NISCH'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RAC1 GTPase cycle'}}, {'source_node': {'name': 'NISCH'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RND3 GTPase cycle'}}, {'source_node': {'name': 'NISCH'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RND2 GTPase cycle'}}, {'source_node': {'name': 'nischarin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NISCH'}}]","[{'source_node': {'name': 'NISCH'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RAC1 GTPase cycle'}}, {'source_node': {'name': 'nischarin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NISCH'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:827', 'target': None, 'metadata': {'node_id': '827', 'node_type': 'PATHWAY', 'display_name': 'RND2 GTPase cycle'}}, {'type': 'node_removal', 'source': 'PATHWAY:690', 'target': None, 'metadata': {'node_id': '690', 'node_type': 'PATHWAY', 'display_name': 'RND3 GTPase cycle'}}]",0.5555555555555556,591a6c8bafafc94d55a3524af4ea4345,43b997670f475e74742bdb7f1bf7badc,[],"['The gene NISCH, known for its action within the RAC1 GTPase cycle, produces a product known as nischarin.']"
"[{'source_node': {'name': 'rottlerin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histone-lysine n-methyltransferase'}}, {'source_node': {'name': 'rottlerin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sw-620'}}, {'source_node': {'name': 'rottlerin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'uacc-62'}}, {'source_node': {'name': 'histone-lysine n-methyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DOT1L'}}, {'source_node': {'name': 'histone-lysine n-methyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'EHMT1'}}, {'source_node': {'name': 'histone-lysine n-methyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'EHMT2'}}, {'source_node': {'name': 'EHMT2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Senescence-Associated Secretory Phenotype (SASP)'}}, {'source_node': {'name': 'EHMT2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of TP53 Activity through Methylation'}}]","[{'source_node': {'name': 'rottlerin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sw-620'}}, {'source_node': {'name': 'rottlerin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'uacc-62'}}, {'source_node': {'name': 'rottlerin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'DOT1L'}}, {'source_node': {'name': 'rottlerin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'EHMT2'}}, {'source_node': {'name': 'histone-lysine n-methyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DOT1L'}}, {'source_node': {'name': 'histone-lysine n-methyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'EHMT1'}}, {'source_node': {'name': 'EHMT2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of TP53 Activity through Methylation'}}, {'source_node': {'name': 'DOT1L'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of TP53 Activity through Methylation'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:44025', 'target': 'PROTEIN:6168', 'metadata': None}, {'type': 'edge_deletion', 'source': 'PROTEIN:6168', 'target': 'GENE:25189', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:44025', 'target': 'GENE:34471', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'GENE:34471', 'target': 'PATHWAY:639', 'metadata': {'predicate': 'acts_within'}}, {'type': 'edge_addition', 'source': 'COMPOUND:44025', 'target': 'GENE:25189', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'PATHWAY:332', 'target': None, 'metadata': {'node_id': '332', 'node_type': 'PATHWAY', 'display_name': 'Senescence-Associated Secretory Phenotype (SASP)'}}]",0.5882352941176471,f09f1f189a0dfd510a0d7ffe424d1f42,8b82cab7b2af7887c8ed9b55aa66a916,"['The drug Rottlerin targets multiple entities, including the histone-lysine N-methyltransferase, SW-620, and UACC-62. Notably, histone-lysine N-methyltransferase is a gene product of several genes, such as DOT1L, EHMT1, and EHMT2. The gene EHMT2 plays a role within pathways like the Senescence-Associated Secretory Phenotype (SASP) and the Regulation of TP53 Activity through Methylation.', 'The molecule rottlerin has several key targets that include histone-lysine n-methyltransferase, and the cell lines SW-620 and UACC-62. Histone-lysine n-methyltransferase is a gene product of three separate genes, namely DOT1L, EHMT1, and EHMT2. EHMT2 particularly plays a distinct role acting within two biological pathways. These are the Senescence-Associated Secretory Phenotype (SASP) and Regulation of TP53 Activity through Methylation pathway.', 'The drug Rottlerin targets several entities including histone-lysine N-methyltransferase, SW-620, and UACC-62. Histone-lysine N-methyltransferase is a gene product of several genes such as DOT1L, EHMT1, and EHMT2. Notably, EHMT2 is implicated in acting within several biological pathways such as Senescence-Associated Secretory Phenotype (SASP) and the Regulation of TP53 Activity through Methylation.']",[]
"[{'source_node': {'name': 'oxymetazoline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nimodipine'}}, {'source_node': {'name': 'oxymetazoline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'telmisartan'}}, {'source_node': {'name': 'oxymetazoline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'deslanoside'}}]","[{'source_node': {'name': 'deslanoside'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oxymetazoline'}}, {'source_node': {'name': 'deslanoside'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'nimodipine'}}, {'source_node': {'name': 'telmisartan'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'oxymetazoline'}}, {'source_node': {'name': 'oxymetazoline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nimodipine'}}, {'source_node': {'name': 'oxymetazoline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'telmisartan'}}, {'source_node': {'name': 'oxymetazoline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'deslanoside'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1058', 'target': 'COMPOUND:918', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1058', 'target': 'COMPOUND:381', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:949', 'target': 'COMPOUND:918', 'metadata': {'predicate': 'increase_efficacy'}}]",0.5714285714285714,c21f50c850a67529709101a5aee9e07e,ff41cf2bd8a414cfaf34194e613a56e2,"[""Oxymetazoline, a commonly used decongestant, has been shown to decrease the efficacy of multiple drugs. This includes nimodipine, a medication typically used to prevent cerebral vasospasm and alleviate ischemic pain, telmisartan, a medication often prescribed for controlling high blood pressure, and deslanoside, a medication used to treat specific heart conditions. It's important to consider the impact of oxymetazoline when taking these medications to ensure optimal medical treatment."", 'The drug Oxymetazoline is known to decrease the efficacy of several other medications including Nimodipine, Telmisartan, and Deslanoside. This implies that these drugs may not work as effectively when used concurrently with Oxymetazoline.', 'The drug oxymetazoline is known to decrease the efficacy of certain other medicines, such as nimodipine, telmisartan, and deslanoside. Therefore, individuals using oxymetazoline should do so with caution if they are also on medication involving these specific drugs.', 'The drug oxymetazoline has been shown to decrease the efficacy of several other drugs including nimodipine, telmisartan, and deslanoside. This implies that the therapeutic effectiveness of these latter drugs may be reduced when used concomitantly with oxymetazoline.', 'The drug Oxymetazoline is known to decrease the efficacy of Nimodipine, Telmisartan, and Deslanoside. This implies that when these drugs are taken in combination with Oxymetazoline, their potential therapeutic effects could be lessened.']","['The drug deslanoside is known to decrease the efficacy of oxymetazoline, while simultaneously increasing the efficacy of nimodipine. On the other hand, telmisartan has been observed to increase the efficacy of oxymetazoline. However, it is important to note that oxymetazoline potentially decreases the efficacy of a variety of medications, including nimodipine, telmisartan, and deslanoside. Therefore, careful consideration is required when these drugs are used in combination due to their complex interactions.', 'The drug deslanoside is known to decrease the efficacy of oxymetazoline while simultaneously increasing the efficacy of nimodipine. Similarly, telmisartan also seems to boost the efficacy of oxymetazoline. However, oxymetazoline has an inhibiting effect on a few drugs; it decreases the efficacy of nimodipine, telmisartan, and deslanoside. This network of drug interactions indicates a complex pharmacological interplay.', 'The drug deslanoside has a therapeutic complex, as it decreases the efficacy of oxymetazoline, yet increases the efficacy of nimodipine. Conversely, Telmisartan interacts differently, it increases the efficacy of oxymetazoline. Interestingly, oxymetazoline seems to have a general dampening effect on other drugs, as it decreases the efficacy of nimodipine, telmisartan, and deslanoside. These interrelated effects underscore the importance of considering potential drug interactions in treatment plans.', 'Deslanoside, a cardiac medication, has a complex interplay with other medications, as it is known to decrease the efficacy of Oxymetazoline, a nasal decongestant, while also increasing the efficacy of Nimodipine, a calcium channel blocker. Conversely, Telmisartan, an anti-hypertensive medication, is found to enhance the efficacy of Oxymetazoline. However, the interplay is further complicated by Oxymetazoline, which not only has its effectiveness decreased by Deslanoside and Telmisartan, but also has inverse effects on Nimodipine and Telmisartan, as it lessens their efficacies. Lastly, Oxymetazoline also decreases the efficacy of Deslanoside, highlighting the intricate interactions and potential considerations when prescribing these medications.']"
"[{'source_node': {'name': 'prelamin-a/c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'LMNA'}}, {'source_node': {'name': 'acrylic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'beta-lactamase shv-1'}}, {'source_node': {'name': 'acrylic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prelamin-a/c'}}, {'source_node': {'name': 'acrylic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histone-lysine n-methyltransferase'}}]","[{'source_node': {'name': 'acrylic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'beta-lactamase shv-1'}}, {'source_node': {'name': 'acrylic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prelamin-a/c'}}, {'source_node': {'name': 'acrylic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histone-lysine n-methyltransferase'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:1819', 'target': 'GENE:29744', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'COMPOUND:2438', 'target': 'GENE:29744', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'GENE:29744', 'target': None, 'metadata': {'node_id': '29744', 'node_type': 'GENE', 'display_name': 'LMNA'}}]",0.7777777777777778,96b69da72f81403c593567e439b5b5a1,cf6790fc2c1874c53a7abc03441b923c,"['Prelamin-A/C, a gene product of LMNA, is one of the targets of the drug acrylic acid. This drug also interacts with the beta-lactamase SHV-1 enzyme and the histone-lysine N-methyltransferase enzyme. These interactions allow acrylic acid to intervene in various biological processes and biochemical reactions taking place in the human body.', ""Prelamin-A/C is a gene product of LMNA. On the other hand, acrylic acid functions by targeting various biomolecules and proteins such as beta-lactamase shv-1, prelamin-a/c, and histone-lysine n-methyltransferase. Specifically, it's notable that acrylic acid targets prelamin-a/c, creating an interesting link between these elements."", ""Prelamin-A/C is a gene product of the LMNA gene. It's interesting to note that Prelamin-A/C is targeted by acrylic acid, as is the beta-lactamase SHV-1 and the histone-lysine N-methyltransferase. This suggests that acrylic acid may have wide-ranging effects on these molecular targets."", 'The compound acrylic acid is found to target several entities such as the beta-lactamase shv-1, prelamin-a/c and the histone-lysine n-methyltransferase. Prelamin-a/c, in particular, is interesting as it is a gene product of LMNA, indicating a potential indirect interaction between acrylic acid and the LMNA gene.', ""The substance known as acrylic acid has several target interactions with substances such as the beta-lactamase SHV-1, prelamin-A/C, and the enzyme histone-lysine N-methyltransferase. It's worth noting that prelamin-A/C is a gene product of LMNA.""]","['The compound acrylic acid is known to target multiple proteins. These include beta-lactamase SHV-1, prelamin-A/C, and histone-lysine N-methyltransferase. Therefore, acrylic acid could potentially affect several biological pathways that involve these protein targets.', 'The compound acrylic acid notably targets several proteins including the beta-lactamase SHV-1, prelamin-A/C and the histone-lysine N-methyltransferase.', 'The chemical compound acrylic acid is known to target several proteins which include beta-lactamase SHV-1, prelamin-A/C, and the enzyme histone-lysine N-methyltransferase.', 'Acrylic acid is a substance with multiple targets. These include the beta-lactamase SHV-1, which is an enzyme responsible for antibiotic resistance. Additionally, acrylic acid also targets Prelamin-A/C, a type of protein precursor that plays a crucial role in nuclear structure. Lastly, the substance also interacts with the histone-lysine N-methyltransferase, an enzyme that modifies proteins by adding a methyl group. This diverse range of targets demonstrates the broad activity spectrum of acrylic acid.', 'The compound acrylic acid has multiple biological targets including beta-lactamase SHV-1, prelamin-A/C and histone-lysine N-methyltransferase. These targets are part of the actions that acrylic acid can possibly enact within an organism.']"
"[{'source_node': {'name': 'insulin glargine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Hypotension'}}, {'source_node': {'name': 'insulin glargine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Redness'}}, {'source_node': {'name': 'esterified estrogens'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'insulin glargine'}}, {'source_node': {'name': 'esterified estrogens'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'liothyronine'}}, {'source_node': {'name': 'esterified estrogens'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'furosemide'}}]","[{'source_node': {'name': 'insulin glargine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Hypotension'}}, {'source_node': {'name': 'insulin glargine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Redness'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:8305', 'target': 'COMPOUND:45', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:8305', 'target': 'SIDE_EFFECT:459', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'node_removal', 'source': 'COMPOUND:8305', 'target': None, 'metadata': {'node_id': '8305', 'node_type': 'COMPOUND', 'display_name': 'esterified estrogens'}}]",0.4545454545454546,7ca761b6e57f709733b30b08318bd956,86ee56e6b8f3ff814f815584f32e88d0,"[""The drug insulin glargine has been associated with various side effects such as hypotension and redness. It's also important to note that its efficacy can be significantly reduced when combined with certain medications, such as esterified estrogens. Additionally, esterified estrogens may also decrease the effectiveness of other drugs such as liothyronine and furosemide. Hence, the usage of these drugs needs to be carefully monitored to prevent their adverse effects."", ""The drug insulin glargine has been reported to have side effects such as hypotension and redness. The efficacy of insulin glargine, however, can be decreased by esterified estrogens. It's important to note that esterified estrogens also lessen the efficacy of other drugs such as liothyronine and furosemide."", 'Insulin glargine is a medication that can have side effects such as hypotension and redness. However, the efficacy of insulin glargine can be decreased when combined with esterified estrogens, which could also decrease the efficacy of other medications, namely liothyronine and furosemide.', 'The diabetes medication insulin glargine has been noted to cause several side effects, including hypotension and redness. Interestingly, the efficacy of insulin glargine seems to be decreased by the hormone treatment esterified estrogens. Moreover, esterified estrogens are not only limited to insulin glargine, but they also appear to decrease the efficacy of the thyroid hormone liothyronine and the diuretic medication furosemide.', ""The drug insulin glargine has documented side effects such as hypotension and redness. However, it's important to note that its efficacy could be decreased by the use of esterified estrogens. This same substance, esterified estrogens, is also known to reduce the efficacy of other medications like liothyronine and furosemide. Therefore, caution must be taken when combining such drugs due to their potential drug-drug interactions.""]","['The drug insulin glargine has been associated with side effects like hypotension - an abnormally low blood pressure condition, and redness, which may cause skin irritation or discomfort.']"
"[{'source_node': {'name': 'prelamin-a/c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'LMNA'}}, {'source_node': {'name': '1,4-dichlorobenzene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 2a6'}}, {'source_node': {'name': '1,4-dichlorobenzene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prelamin-a/c'}}, {'source_node': {'name': 'cytochrome p450 2a6'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP2A6'}}]","[{'source_node': {'name': 'prelamin-a/c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'LMNA'}}, {'source_node': {'name': 'prelamin-a/c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP2A6'}}, {'source_node': {'name': '1,4-dichlorobenzene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 2a6'}}, {'source_node': {'name': '1,4-dichlorobenzene'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'CYP2A6'}}, {'source_node': {'name': 'cytochrome p450 2a6'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP2A6'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:30045', 'target': 'GENE:26290', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:6154', 'target': 'GENE:26290', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:30045', 'target': 'PROTEIN:6154', 'metadata': None}]",0.6666666666666667,d394c4eef9387202e984313731d9a2bb,23a7962024341cd005ee75844ff46c54,"['The compound 1,4-dichlorobenzene targets two different molecules, one of which is cytochrome p450 2a6, a gene product of CYP2A6. It also targets prelamin-a/c, which itself is a gene product of the gene LMNA.', 'The compound 1,4-dichlorobenzene targets two proteins, namely cytochrome p450 2a6 and prelamin-a/c. Interestingly, these proteins are gene products of CYP2A6 and LMNA respectively. It suggests that 1,4-dichlorobenzene may influence the genetic pathways related to these genes.', 'The compound 1,4-dichlorobenzene has two main targets, prelamin-a/c and cytochrome p450 2a6. The protein prelamin-a/c is a gene product of LMNA, a gene known for its role in structural function of the cell. On the other hand, cytochrome p450 2a6, a critical enzyme in drug metabolism, is a gene product of CYP2A6.', 'The chemical compound 1,4-dichlorobenzene targets both the cytochrome P450 2A6 and prelamin-A/C, exerting its biological action. Cytochrome P450 2A6 is a gene product of CYP2A6, and prelamin-A/C is a gene product of the LMNA gene. These interactions help us better understand therapeutic targets and drug pathways.', 'Prelamin-A/C, a gene product of LMNA, is a target of the chemical 1,4-dichlorobenzene. This substance also targets cytochrome P450 2A6, a protein that functions as a gene product of CYP2A6. This shows a complex network of relationships that contribute to the broader understanding of how these biological and chemical entities interact.']","['The protein prelamin-A/C is a gene product of both LMNA and CYP2A6. The compound 1,4-dichlorobenzene targets the cytochrome p450 2a6 and affects CYP2A6, both of which are gene products of CYP2A6 itself.', ""Prelamin-A/C is a gene product of both LMNA and CYP2A6. Moreover, the compound 1,4-dichlorobenzene targets cytochrome p450 2a6 and affects CYP2A6. It's important to note that cytochrome p450 2a6 is a gene product of CYP2A6. Thus, these connections indicate a complex interplay between these genes and compounds."", 'Prelamin-A/C is a gene product of two different genes, LMNA and CYP2A6. Furthermore, 1,4-dichlorobenzene is a chemical that targets cytochrome P450 2A6, another gene product of CYP2A6. Additionally, it has been found that 1,4-dichlorobenzene affects the gene CYP2A6 directly. This illustrates the complex relationships between these biological entities.', 'Prelamin-A/C is a gene product of two different genes, LMNA and CYP2A6. Interestingly, 1,4-dichlorobenzene, is known to target cytochrome p450 2a6, which is also a gene product of CYP2A6. Furthermore, 1,4-dichlorobenzene is found to affect CYP2A6 itself. This implies a complex interaction between prelamin-A/C, CYP2A6, and 1,4-dichlorobenzene via the medium of cytochrome p450 2a6.', ""Prelamin-A/C is a gene product of both LMNA and CYP2A6. Interestingly, the substance 1,4-dichlorobenzene targets Cytochrome P450 2A6 and also affects CYP2A6. It's worth noting that Cytochrome P450 2A6 is a gene product of CYP2A6 as well.""]"
"[{'source_node': {'name': '9-deazaguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'delorazepam'}}, {'source_node': {'name': '9-deazaguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cinolazepam'}}, {'source_node': {'name': '9-deazaguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'remimazolam'}}, {'source_node': {'name': 'cinolazepam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '6-o-benzylguanine'}}, {'source_node': {'name': 'remimazolam'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the sedative activities '}}, {'source_node': {'name': 'remimazolam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'peldesine'}}, {'source_node': {'name': 'remimazolam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'doxofylline'}}]","[{'source_node': {'name': '9-deazaguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'delorazepam'}}, {'source_node': {'name': '9-deazaguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cinolazepam'}}, {'source_node': {'name': '9-deazaguanine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': '6-o-benzylguanine'}}, {'source_node': {'name': 'cinolazepam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '6-o-benzylguanine'}}, {'source_node': {'name': 'cinolazepam'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': '9-deazaguanine'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:4099', 'target': 'COMPOUND:10304', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:2428', 'target': 'COMPOUND:10304', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:10304', 'target': None, 'metadata': {'node_id': '10304', 'node_type': 'COMPOUND', 'display_name': 'remimazolam'}}, {'type': 'edge_addition', 'source': 'COMPOUND:4099', 'target': 'COMPOUND:9831', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1523', 'target': 'COMPOUND:4099', 'metadata': {'predicate': 'increase_efficacy'}}]",0.3333333333333333,b303a5beb331a2320b353cd7f40416f6,c846fec29107d4bdb7854863512a9ced,[],"['The drug 9-deazaguanine is known to have contrasting effects on other substances. It decreases the efficacy of certain benzodiazepines, specifically delorazepam and cinolazepam. On the other hand, it increases the efficacy of another drug known as 6-o-benzylguanine. Interestingly, cinolazepam itself also has a similar two-fold interaction. It decreases the efficacy of 6-o-benzylguanine and intriguingly, it is capable of increasing the efficacy of 9-deazaguanine. Further research is needed to understand this complex web of drug interactions.', 'The compound 9-deazaguanine has varying interactions with other substances. Firstly, it has been found to decrease the efficacy of both delorazepam and cinolazepam. Additionally, it is also known to increase the efficacy of 6-o-benzylguanine. Intriguingly, there are also interactions between 6-o-benzylguanine and cinolazepam where 6-o-benzylguanine sees decreased efficacy when cinolazepam is involved. Yet, 9-deazaguanine experiences an increase in its efficacy when cinolazepam is present. These complex interactions show how specific compounds can affect one another in diverse ways.', '9-Deazaguanine is a compound which interestingly decreases the efficacy of both delorazepam and cinolazepam, but also increases the efficacy of 6-o-benzylguanine. Conversely, cinolazepam seems to have a mechanism which reduces the efficacy of 6-o-benzylguanine but increases the efficacy of 9-deazaguanine. This evidences complex interactions between these substances, and suggests careful consideration should be given when prescribing combinations of these drugs.', 'The compound 9-deazaguanine has varying effects on different medications. While it decreases the effectiveness of delorazepam and cinolazepam, it enhances the efficacy of 6-o-benzylguanine. On the other hand, cinolazepam interactions result in a decreased efficacy of 6-o-benzylguanine, but interestingly increase the effectiveness of 9-deazaguanine. These intricate relationships underline the importance of understanding drug interactions and the role of specific compounds such as 9-deazaguanine.', 'The compound 9-deazaguanine has been shown to decrease the efficacy of certain drugs such as delorazepam and cinolazepam. Despite this, 9-deazaguanine interestingly, enhances the efficacy of another compound named 6-O-benzylguanine. On the other hand, cinolazepam behaves in a similar manner, reducing the efficacy of 6-O-benzylguanine but interestingly enhancing that of 9-deazaguanine. This complex interplay of interactions suggests a complicated pharmacological landscape that requires further investigation.']"
"[{'source_node': {'name': 'AR'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nuclear Receptor transcription pathway'}}, {'source_node': {'name': 'calusterone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'androgen receptor'}}, {'source_node': {'name': 'calusterone'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the excretion rate '}}, {'source_node': {'name': 'calusterone'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' edema formation '}}, {'source_node': {'name': 'androgen receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AR'}}]","[{'source_node': {'name': 'calusterone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'androgen receptor'}}]","[{'type': 'node_removal', 'source': 'EFFECT:86', 'target': None, 'metadata': {'node_id': '86', 'node_type': 'EFFECT', 'display_name': ' edema formation '}}, {'type': 'node_removal', 'source': 'GENE:29295', 'target': None, 'metadata': {'node_id': '29295', 'node_type': 'GENE', 'display_name': 'AR'}}, {'type': 'node_removal', 'source': 'ACTIVITY:7', 'target': None, 'metadata': {'node_id': '7', 'node_type': 'ACTIVITY', 'display_name': ' the excretion rate '}}]",0.2727272727272727,6e63b5d7f3a79f9584f3c1503aed1e0f,6307349323cb46f9f5299c8fb1073800,[],"['The drug Calusterone has been identified to target the androgen receptor.', 'The drug calusterone has a target action on the androgen receptor.']"
"[{'source_node': {'name': 'dasabuvir'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nonstructural protein 5b (ns5b)'}}, {'source_node': {'name': 'dasabuvir'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' neutropenia '}}, {'source_node': {'name': 'dasabuvir'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'anthrax vaccine'}}, {'source_node': {'name': 'adenovirus type 7 vaccine live'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pleconaril'}}, {'source_node': {'name': 'adenovirus type 7 vaccine live'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dasabuvir'}}, {'source_node': {'name': 'adenovirus type 7 vaccine live'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ruzasvir'}}]","[{'source_node': {'name': 'dasabuvir'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nonstructural protein 5b (ns5b)'}}, {'source_node': {'name': 'dasabuvir'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' neutropenia '}}, {'source_node': {'name': 'dasabuvir'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'anthrax vaccine'}}, {'source_node': {'name': 'adenovirus type 7 vaccine live'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pleconaril'}}, {'source_node': {'name': 'adenovirus type 7 vaccine live'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ruzasvir'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:12391', 'target': 'COMPOUND:8118', 'metadata': None}]",0.9230769230769232,ac06a8760c78876b9fee74f394478fdc,05e9fd2334a9dac943707e7d51b38eb3,[],[]
"[{'source_node': {'name': 'PPARD'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Carnitine shuttle'}}, {'source_node': {'name': 'PPARD'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nuclear Receptor transcription pathway'}}, {'source_node': {'name': 'PPARD'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Signaling by Retinoic Acid'}}]","[{'source_node': {'name': 'PPARD'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Carnitine shuttle'}}, {'source_node': {'name': 'PPARD'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Signaling by Retinoic Acid'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:42', 'target': None, 'metadata': {'node_id': '42', 'node_type': 'PATHWAY', 'display_name': 'Nuclear Receptor transcription pathway'}}]",0.7142857142857143,1b69e37aa66826bb663faa6d604dfc88,683f1289d1023058557f23224e459777,"['The gene PPARD is active within several biological pathways. It operates within the carnitine shuttle, a key system for transporting fatty acids into the mitochondria for oxidation. Moreover, PPARD also acts within the nuclear receptor transcription pathway, a key component in gene expression and cellular function. Additionally, it plays a role within retinoic acid signaling, a crucial aspect of various cellular processes, including cell growth and differentiation.', 'The gene PPARD operates within multiple pathways such as the carnitine shuttle, the nuclear receptor transcription pathway, and the signaling by retinoic acid.', 'The gene PPARD is known to act within several pathways. Firstly, it has an effect on the carnitine shuttle, a system involved in the transport of fatty acids into the mitochondria for beta-oxidation. Secondly, it has a role within the nuclear receptor transcription pathway, which is crucial for the regulation of gene expression. Lastly, PPARD also acts within the signaling by retinoic acid process, a mechanism that modulates cell growth and differentiation.']",[]
"[{'source_node': {'name': 'KAT2A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ub-specific processing proteases'}}, {'source_node': {'name': 'KAT2A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cardiogenesis'}}, {'source_node': {'name': 'KAT2A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Formation of paraxial mesoderm'}}, {'source_node': {'name': 'androgen receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AR'}}, {'source_node': {'name': 'histone acetyltransferase kat2a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KAT2A'}}, {'source_node': {'name': 'arachidonoyl glycine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histone acetyltransferase kat2a'}}, {'source_node': {'name': 'arachidonoyl glycine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ubiquitin carboxyl-terminal hydrolase 1'}}, {'source_node': {'name': 'arachidonoyl glycine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'androgen receptor'}}]","[{'source_node': {'name': 'AR'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ub-specific processing proteases'}}, {'source_node': {'name': 'KAT2A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ub-specific processing proteases'}}, {'source_node': {'name': 'KAT2A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cardiogenesis'}}, {'source_node': {'name': 'androgen receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AR'}}, {'source_node': {'name': 'arachidonoyl glycine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ubiquitin carboxyl-terminal hydrolase 1'}}, {'source_node': {'name': 'arachidonoyl glycine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'androgen receptor'}}, {'source_node': {'name': 'arachidonoyl glycine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'AR'}}, {'source_node': {'name': 'arachidonoyl glycine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'KAT2A'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:2220', 'target': None, 'metadata': {'node_id': '2220', 'node_type': 'PROTEIN', 'display_name': 'histone acetyltransferase kat2a'}}, {'type': 'edge_addition', 'source': 'COMPOUND:60303', 'target': 'GENE:29295', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'COMPOUND:60303', 'target': 'GENE:27912', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'GENE:29295', 'target': 'PATHWAY:115', 'metadata': {'predicate': 'acts_within'}}, {'type': 'node_removal', 'source': 'PATHWAY:141', 'target': None, 'metadata': {'node_id': '141', 'node_type': 'PATHWAY', 'display_name': 'Formation of paraxial mesoderm'}}]",0.5294117647058824,c62c4c2e080d936eaf242877b95c8702,bfd30fc15817e6b00b30348c3cc47f99,[],[]
"[{'source_node': {'name': 'ticagrelor'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cefpiramide'}}, {'source_node': {'name': 'ticagrelor'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'turoctocog alfa'}}, {'source_node': {'name': 'ticagrelor'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ceftobiprole medocaril'}}, {'source_node': {'name': 'cefpiramide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tenecteplase'}}, {'source_node': {'name': 'ceftobiprole medocaril'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'alteplase'}}, {'source_node': {'name': 'ceftobiprole medocaril'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'defibrotide'}}, {'source_node': {'name': 'ceftobiprole medocaril'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ferulic acid'}}]","[{'source_node': {'name': 'ticagrelor'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cefpiramide'}}, {'source_node': {'name': 'ticagrelor'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'turoctocog alfa'}}, {'source_node': {'name': 'cefpiramide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tenecteplase'}}, {'source_node': {'name': 'ceftobiprole medocaril'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'alteplase'}}, {'source_node': {'name': 'ceftobiprole medocaril'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'defibrotide'}}, {'source_node': {'name': 'ceftobiprole medocaril'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ferulic acid'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:7782', 'target': 'COMPOUND:12434', 'metadata': None}]",0.9333333333333332,f45be4dc0324788fee7eaa3eaf9070ba,a3c0cdf60ab9d51f800c0750299b4bce,"[""The drug Ticagrelor is known to decrease the efficacy of cefpiramide, turoctocog alfa, and ceftobiprole medocaril. Interestingly, cefpiramide also has a similar effect on the effectiveness of tenecteplase. Additionally, it has been found that ceftobiprole medocaril negatively impacts the efficacy of alteplase, defibrotide, and ferulic acid. This chain of effects emphasizes the complex ways in which different drugs can interact and potentially influence each other's therapeutic action."", 'The drug Ticagrelor is known to decrease the efficacy of several other drugs, including Cefpiramide, Turoctocog Alfa, and Ceftobiprole Medocaril. In a similar manner, Cefpiramide has an influence on reducing the effectiveness of Tenecteplase. Furthermore, Ceftobiprole Medocaril also exhibits effects that diminish the efficacy of Alteplase, Defibrotide, and Ferulic Acid. These interactions are important considerations when these drugs are prescribed in combination, potentially necessitating dosage adjustments.', 'The drug ticagrelor is known to decrease the efficacy of several other medications including cefpiramide, turoctocog alfa, and ceftobiprole medocaril. Interestingly, cefpiramide and ceftobiprole medocaril also have similar effects on other drugs. Specifically, cefpiramide can decrease the efficacy of tenecteplase, a drug commonly used to treat certain acute myocardial infarctions. Similarly, ceftobiprole medocaril also decreases the efficacy of alteplase, defibrotide and ferulic acid. Alteplase is a tissue plasminogen activator used to treat acute ischemic stroke, while defibrotide is a medication used to treat certain liver diseases and ferulic acid has been researched for its anti-aging and anti-inflammatory effects. Therefore, it is important to consider these interactions when prescribing these medications.', 'The drug ticagrelor is known to decrease the efficacy of several different substances, including cefpiramide, turoctocog alfa, and ceftobiprole medocaril. Further, cefpiramide is identified to magnify this effect by reducing the efficacy of tenecteplase. Similarly, ceftobiprole medocaril has been shown to compromise the performance of alteplase, defibrotide, and ferulic acid. Consequently, these interactive effects should be taken into account when administering these drugs concurrently.', 'The drug Ticagrelor has been found to decrease the efficacy of several drugs including Cefpiramide, Turoctocog alfa and Ceftobiprole medocaril. The efficacy of Tenecteplase is also reduced by Cefpiramide. In a similar vein, Ceftobiprole medocaril shows a decreasing effect on the efficacy of drugs such as Alteplase, Defibrotide, and Ferulic acid. Therefore, these interactions should be considered when co-administrating these drugs.']","['Ticagrelor, a medication used to prevent thrombotic events such as stroke or heart attack, is known to decrease the efficacy of other drugs such as cefpiramide and turoctocog alfa. Cefpiramide is a third-generation cephalosporin antibiotic and it also reduces the efficacy of tenecteplase, a clot-busting drug. Moreover, ceftobiprole medocaril, a broad-spectrum cephalosporin antibiotic, is also found to decrease the efficacy of several drugs including alteplase, a thrombolytic medication; defibrotide, an antithrombotic agent; as well as ferulic acid, a plant-derived antioxidant. It is crucial to bear all of these interactions in mind when prescribing treatments in order to ensure optimal patient outcomes.', 'The drug Ticagrelor has been known to decrease the efficacy of several other drugs such as Cefpiramide and Turoctocog Alfa. Similarly, it has been reported that Cefpiramide may also reduce the effectiveness of Tenecteplase. Another drug, Ceftobiprole Medocaril, is associated with a decreased efficacy of Alteplase, Defibrotide, and Ferulic Acid. It is crucial to consider these interactions when prescribing medications to ensure appropriate clinical outcomes.', 'The medication ticagrelor is known to decrease the efficacy of both cefpiramide and turoctocog alfa, which could potentially influence the desired effects of these other drugs. Similarly, the substance cefpiramide also decreases the efficacy of tenecteplase. In a related matter, ceftobiprole medocaril, an antibiotic, lessens the efficacy of alteplase, defibrotide, and ferulic acid. Consequently, caution should be taken when pairing these compounds to prevent diminished therapeutic effects.', 'Ticagrelor is a drug noted to decrease the efficacy of cefpiramide and turoctocog alfa. Similarly, cefpiramide has been observed to decrease the efficacy of tenecteplase. Likewise, the drug ceftobiprole medocaril reduces the efficacy of alteplase, defibrotide, and ferulic acid. Collectively, these findings highlight the potential for drug-drug interactions and call for careful consideration when prescribing and combining these medications.', 'The drug Ticagrelor has been found to decrease the efficacy of both Cefpiramide and Turoctocog alfa. Interestingly, Cefpiramide itself is known to reduce the efficacy of Tenecteplase. Adding to this chain, the drug Ceftobiprole medocaril is also noted to decrease the efficacy of several compounds including Alteplase, Defibrotide and Ferulic acid. In this complex network, the magnifying effect of these drug interactions should be carefully considered in clinical scenarios to avoid potential drug inefficacy.']"
"[{'source_node': {'name': 'FLOT2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RIPK1-mediated regulated necrosis'}}, {'source_node': {'name': 'FLOT2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RHOB GTPase cycle'}}, {'source_node': {'name': 'FLOT2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RHOC GTPase cycle'}}]","[{'source_node': {'name': 'FLOT2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RHOB GTPase cycle'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:92', 'target': None, 'metadata': {'node_id': '92', 'node_type': 'PATHWAY', 'display_name': 'RIPK1-mediated regulated necrosis'}}, {'type': 'node_removal', 'source': 'PATHWAY:432', 'target': None, 'metadata': {'node_id': '432', 'node_type': 'PATHWAY', 'display_name': 'RHOC GTPase cycle'}}]",0.4285714285714286,f67e4fa831aab73303b48d29328b7a3c,20f8a1cd1612f46d6828efbd704a0c85,"['The protein FLOT2 plays a role in various biological processes, acting within pathways such as RIPK1-mediated regulated necrosis, RHOB GTPase cycle, and RHOC GTPase cycle.', 'The gene FLOT2 is involved in several cellular processes. Specifically, it acts within the pathway of RIPK1-mediated regulated necrosis. Moreover, it is also part of the RHOB GTPase cycle and the RHOC GTPase cycle, contributing to important functions within these mechanisms.']",[]
"[{'source_node': {'name': 'anomanolide d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepg2'}}, {'source_node': {'name': 'anomanolide d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'anomanolide d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'source_node': {'name': 'anomanolide d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepg2'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5849', 'target': None, 'metadata': {'node_id': '5849', 'node_type': 'PROTEIN', 'display_name': 'a549'}}, {'type': 'node_removal', 'source': 'PROTEIN:5851', 'target': None, 'metadata': {'node_id': '5851', 'node_type': 'PROTEIN', 'display_name': 'mcf7'}}]",0.4285714285714286,4dce3559eb0ac19af3979f68145bf079,186938828640330e365ad6424fc9850c,"['The compound Anomanolide D has been found to target several cell lines, including HepG2 and MCF7, as well as A549.', 'Anomanolide D is a compound that has been found to target several cell types, including HepG2, MCF7, and A549 cells.', 'Anomanolide D is an active substance that specifically targets multiple cell types including HepG2, MCF7, and A549.', 'The compound Anomanolide D has been found to target a variety of cells, including HepG2, MCF7, and A549 cells.', 'Anomanolide D is a compound that has target interactions with several cell lines including HepG2, MCF7, and A549.']",[]
"[{'source_node': {'name': '3beta-o-trans-coumaroyl-betulinic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'col2'}}, {'source_node': {'name': '3beta-o-trans-coumaroyl-betulinic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lncap'}}]","[{'source_node': {'name': '3beta-o-trans-coumaroyl-betulinic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lncap'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5008', 'target': None, 'metadata': {'node_id': '5008', 'node_type': 'PROTEIN', 'display_name': 'col2'}}]",0.6,368529abd41727071ff6252e3c84def4,5bfb46065de310d030c9e1b9cffcbd9b,"['The compound, 3beta-o-trans-coumaroyl-betulinic acid, targets both col2 and lncap.', 'The compound 3beta-o-trans-coumaroyl-betulinic acid has been shown to target both COL2 and LNCaP.', 'The compound 3beta-o-trans-coumaroyl-betulinic acid has been found to target both col2 and lncap.', 'The compound 3beta-o-trans-coumaroyl-betulinic acid targets both col2 and lncap.', 'The compound 3beta-o-trans-coumaroyl-betulinic acid has been found to target both col2 and lncap.']",['The compound 3beta-o-trans-coumaroyl-betulinic acid has a target interaction with lncap.']
"[{'source_node': {'name': 'metachromin u'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sf-268'}}, {'source_node': {'name': 'metachromin u'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h460'}}, {'source_node': {'name': 'metachromin u'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}]","[{'source_node': {'name': 'metachromin u'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h460'}}, {'source_node': {'name': 'metachromin u'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5658', 'target': None, 'metadata': {'node_id': '5658', 'node_type': 'PROTEIN', 'display_name': 'sf-268'}}]",0.7142857142857143,efd8eb693c3a1300880ec952c7677738,91700423724b2cad2e6df33ac8bcdf4a,"['The drug Metachromin U has multiple targets including SF-268, NCI-H460, and HT-29. It appears to be effective in targeting these specific cells and tissues, which are commonly studied in biomedical research.', 'The drug Metachromin U has multiple targets including SF-268, NCI-H460, and HT-29.', 'The drug, Metachromin U, targets several cellular entities, including SF-268, NCI-H460 and HT-29. This signifies that Metachromin U has a broad range of cellular targets in its action.', 'The substance metachromin U is found to target several cells including SF-268, NCI-H460, and HT-29.', 'The drug Metachromin U prominently targets cancer cells such as SF-268, NCI-H460, and HT-29.']","['The compound Metachromin U has been identified to target specific cells, namely NCI-H460 and HT-29.', 'The compound metachromin U is known to target two different types of human cells: NCI-H460 and HT-29.', 'The drug metachromin U has been found to target two different cell lines, namely NCI-H460 and HT-29.', 'The drug Metachromin U targets both NCI-H460 and HT-29, demonstrating its potential therapeutic abilities.', 'The drug Metachromin U has been identified to target two specific cell lines: NCI-H460 and HT-29.']"
"[{'source_node': {'name': 'cardiomyopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'seizure'}}, {'source_node': {'name': 'cardiomyopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'babinski sign'}}, {'source_node': {'name': 'CAV3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'creatine phosphokinase'}}, {'source_node': {'name': 'CAV3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'cardiomyopathy'}}, {'source_node': {'name': 'CAV3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'romano-ward syndrome'}}, {'source_node': {'name': 'romano-ward syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'sudden cardiac death'}}, {'source_node': {'name': 'romano-ward syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ventricular arrhythmia'}}, {'source_node': {'name': 'romano-ward syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of prenatal development or birth'}}]","[{'source_node': {'name': 'cardiomyopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'seizure'}}, {'source_node': {'name': 'cardiomyopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'babinski sign'}}, {'source_node': {'name': 'CAV3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'creatine phosphokinase'}}, {'source_node': {'name': 'CAV3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'cardiomyopathy'}}, {'source_node': {'name': 'CAV3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'romano-ward syndrome'}}, {'source_node': {'name': 'romano-ward syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'sudden cardiac death'}}, {'source_node': {'name': 'romano-ward syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ventricular arrhythmia'}}, {'source_node': {'name': 'creatine phosphokinase'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ventricular arrhythmia'}}, {'source_node': {'name': 'creatine phosphokinase'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'babinski sign'}}, {'source_node': {'name': 'creatine phosphokinase'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'sudden cardiac death'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:926', 'target': None, 'metadata': {'node_id': '926', 'node_type': 'PHENOTYPE', 'display_name': 'abnormality of prenatal development or birth'}}, {'type': 'edge_addition', 'source': 'DISEASE:13845', 'target': 'PHENOTYPE:3007', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_addition', 'source': 'DISEASE:13845', 'target': 'PHENOTYPE:2513', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_addition', 'source': 'DISEASE:13845', 'target': 'PHENOTYPE:1197', 'metadata': {'predicate': 'has_phenotype'}}]",0.7058823529411764,a4ca47935bb6f27ebb315ba63c9f6815,da4a34385297c37fa7538a6df772b180,[],"['The gene CAV3 is linked to several conditions and contributes to the understanding of the relationship between cardiomyopathy, Romano-Ward syndrome and abnormal creatine phosphokinase levels. It is understood that CAV3 influences the development of cardiomyopathy, a disease that often presents symptoms of seizures and the Babinski sign - a reflex movement of the big toe upwards instead of downwards when the sole of the foot is stimulated, commonly used as an indicator of neurological conditions. Similarly, CAV3 also triggers the condition creatine phosphokinase, which is associated with phenotypes such as ventricular arrhythmia, the Babinski sign, and sudden cardiac death. \n\nCAV3 also induces Romano-Ward syndrome, a condition known for its association with sudden cardiac death and ventricular arrhythmia. Therefore, we may say that the CAV3 gene plays a significant role in the manifestation of these overlapping phenotype associations within these medical conditions.', 'The gene CAV3 is known to cause several conditions including cardiomyopathy, creatine phosphokinase, and Romano-Ward Syndrome. Cardiomyopathy, a condition often linked with the phenotypes such as seizure and Babinski sign. Creatine phosphokinase is also associated with numerous phenotypes such as ventricular arrhythmia, Babinski sign, and sudden cardiac death. Romano-Ward Syndrome, another condition associated with CAV3, is phenotypically characterized by sudden cardiac death and ventricular arrhythmia.']"
"[{'source_node': {'name': 'ononin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'raji'}}, {'source_node': {'name': 'ononin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ras-related protein rab-9a'}}, {'source_node': {'name': 'ononin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear factor erythroid 2-related factor 2'}}]","[{'source_node': {'name': 'ononin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'raji'}}, {'source_node': {'name': 'ononin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear factor erythroid 2-related factor 2'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:3523', 'target': None, 'metadata': {'node_id': '3523', 'node_type': 'PROTEIN', 'display_name': 'ras-related protein rab-9a'}}]",0.7142857142857143,592b1038c553705c41395ec8b1d68b04,0212bc43f9abbe732280291ed21299db,"['The chemical compound ononin exhibits targeting activity towards several entities including raji, as well as the ras-related protein rab-9a. Moreover, ononin also targets nuclear factor erythroid 2-related factor 2.', 'The substance Ononin targets several entities including the Raji, a variety of protein, namely the Ras-related protein Rab-9A and the Nuclear factor erythroid 2-related factor 2.', 'Ononin, a bioactive compound, targets several proteins including Raji, a human cell line used in biological research, the Ras-related protein Rab-9A, and the Nuclear Factor Erythroid 2-Related Factor 2, a key regulator of oxidative stress.', 'The compound Ononin targets several proteins including Raji, the Ras-related protein Rab-9A, and the Nuclear Factor Erythroid 2-Related Factor 2. It acts by influencing their functionalities and corresponding biological activities.', ""The compound Ononin has distinct targets including Raji, a B lymphocyte cell line, Ras-related protein Rab-9A which is essential for protein transport, and Nuclear Factor Erythroid 2-related Factor 2 that plays a pivotal role in cell's response to oxidative stress.""]","['The compound Ononin has multiple target interactions. It targets Raji, a type of lymphocyte cell line and also interacts with Nuclear factor erythroid 2-related factor 2, a protein involved in cellular response to oxidative stress.', 'The drug Ononin is known to target multiple factors, such as the nuclear factor erythroid 2-related factor 2 and Raji. These are both crucial targets affected by the drug intervention.', 'The compound Ononin has two notable targets: Raji and nuclear factor erythroid 2-related factor 2.', 'The compound ononin is known to target both raji and the nuclear factor erythroid 2-related factor 2.', 'Ononin, a naturally occurring substance, acts by targeting multiple entities. It targets Raji, a cancer cell line used in biomedical research. In addition to this, Ononin also targets a protein named Nuclear Factor Erythroid 2-Related Factor 2, which plays a key role in regulating the expression of antioxidant proteins that protect against oxidative damage triggered by injury and inflammation.']"
"[{'source_node': {'name': 'medical cannabis'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glycine receptor subunit alpha-1'}}, {'source_node': {'name': 'nitrous oxide'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the neuromuscular blocking activities '}}, {'source_node': {'name': 'nitrous oxide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'medical cannabis'}}, {'source_node': {'name': 'nitrous oxide'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Dizziness'}}]","[{'source_node': {'name': 'medical cannabis'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glycine receptor subunit alpha-1'}}, {'source_node': {'name': 'medical cannabis'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'nitrous oxide'}}, {'source_node': {'name': 'medical cannabis'}, 'relation': {'name': 'decrease_activity'}, 'target_node': {'name': ' the neuromuscular blocking activities '}}, {'source_node': {'name': 'nitrous oxide'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the neuromuscular blocking activities '}}, {'source_node': {'name': 'nitrous oxide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'medical cannabis'}}]","[{'type': 'node_removal', 'source': 'SIDE_EFFECT:21', 'target': None, 'metadata': {'node_id': '21', 'node_type': 'SIDE_EFFECT', 'display_name': 'Dizziness'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11846', 'target': 'COMPOUND:5741', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11846', 'target': 'ACTIVITY:13', 'metadata': {'predicate': 'decrease_activity'}}]",0.5555555555555556,dab8cab5add520924c31af897f6407d4,bab1137946587640262a1977399d3bc1,[],[]
"[{'source_node': {'name': 'bilateral frontal polymicrogyria'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hemiparesis'}}, {'source_node': {'name': 'bilateral frontal polymicrogyria'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'eeg abnormality'}}, {'source_node': {'name': 'bilateral frontal polymicrogyria'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'pseudobulbar signs'}}]","[{'source_node': {'name': 'bilateral frontal polymicrogyria'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hemiparesis'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1725', 'target': None, 'metadata': {'node_id': '1725', 'node_type': 'PHENOTYPE', 'display_name': 'eeg abnormality'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:1619', 'target': None, 'metadata': {'node_id': '1619', 'node_type': 'PHENOTYPE', 'display_name': 'pseudobulbar signs'}}]",0.4285714285714286,083c6cef25239a94b0e1256fc207c913,dff4ed7b925305f9b2791fff493ac432,[],[]
"[{'source_node': {'name': 'APOH'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Platelet degranulation '}}, {'source_node': {'name': 'beta-2-glycoprotein 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'APOH'}}, {'source_node': {'name': 'ljp 1082'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'beta-2-glycoprotein 1'}}]","[{'source_node': {'name': 'beta-2-glycoprotein 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'APOH'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:2', 'target': None, 'metadata': {'node_id': '2', 'node_type': 'PATHWAY', 'display_name': 'Platelet degranulation '}}, {'type': 'node_removal', 'source': 'COMPOUND:5049', 'target': None, 'metadata': {'node_id': '5049', 'node_type': 'COMPOUND', 'display_name': 'ljp 1082'}}]",0.4285714285714286,73c7fe58d99e9e02c9056082f7cd47e7,5d5b0f1b6cc6d1e1a1966f4e3fea1745,"['The drug LJP 1082 primarily targets Beta-2-glycoprotein 1, which is found to be the gene product of APOH. Interestingly, APOH is found to be actively involved in the process of platelet degranulation. This series of interactions links the drug LJP 1082 to the biological process of platelet degranulation.', 'The drug named LJP 1082 targets the protein known as beta-2-glycoprotein 1. This protein actually represents the gene product of APOH. Moreover, APOH is known to notably act within the process of platelet degranulation.', 'The drug ljp 1082 targets beta-2-glycoprotein 1, which is a gene product of APOH. Notably, APOH acts within the pathway of platelet degranulation.', 'The drug ljp 1082 targets beta-2-glycoprotein 1, which is the gene product of APOH. Interestingly, APOH is known to act within the process of platelet degranulation.', 'The drug ljp 1082 targets beta-2-glycoprotein 1, which is a gene product of APOH. Furthermore, APOH acts within the process of platelet degranulation.']","['The protein beta-2-glycoprotein 1 is a gene product of APOH.', 'The protein beta-2-glycoprotein 1 is a gene product of APOH.']"
"[{'source_node': {'name': 'pinusolidic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'pinusolidic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'smmc-7721'}}, {'source_node': {'name': 'pinusolidic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}]","[{'source_node': {'name': 'pinusolidic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'smmc-7721'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4951', 'target': None, 'metadata': {'node_id': '4951', 'node_type': 'PROTEIN', 'display_name': 'hl-60'}}, {'type': 'node_removal', 'source': 'PROTEIN:5849', 'target': None, 'metadata': {'node_id': '5849', 'node_type': 'PROTEIN', 'display_name': 'a549'}}]",0.4285714285714286,17a3c46debab0edd99e93af8897a9c83,86cae43477b3788d603e023726301679,"['The compound pinusolidic acid has been identified to target several cell lines, including A549, SMMC-7721, and HL-60.', 'The compound pinusolidic acid has been found to target several cell lines, including the A549, SMMC-7721, and HL-60.', 'The compound pinusolidic acid is known to target A549, SMMC-7721, and HL-60 cell lines.', 'The compound pinusolidic acid prominently targets a variety of cells including A549, SMMC-7721, and HL-60.', 'The compound known as pinusolidic acid demonstrates a notable biological activity as it has the ability to target a variety of cell lines. This includes the A549, SMMC-7721, and HL-60 lines, suggesting a potential for broad-spectrum effectiveness.']",[]
"[{'source_node': {'name': 'GSR'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Detoxification of Reactive Oxygen Species'}}, {'source_node': {'name': 'GSR'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'TP53 Regulates Metabolic Genes'}}, {'source_node': {'name': 'cationic amino acid transporter 3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SLC7A3'}}, {'source_node': {'name': 'SLC7A3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Amino acid transport across the plasma membrane'}}, {'source_node': {'name': 'glutathione reductase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GSR'}}, {'source_node': {'name': 'lysine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cationic amino acid transporter 4'}}, {'source_node': {'name': 'lysine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cationic amino acid transporter 3'}}, {'source_node': {'name': 'lysine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glutathione reductase'}}]","[{'source_node': {'name': 'GSR'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Detoxification of Reactive Oxygen Species'}}, {'source_node': {'name': 'GSR'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'TP53 Regulates Metabolic Genes'}}, {'source_node': {'name': 'cationic amino acid transporter 3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SLC7A3'}}, {'source_node': {'name': 'SLC7A3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Amino acid transport across the plasma membrane'}}, {'source_node': {'name': 'glutathione reductase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GSR'}}, {'source_node': {'name': 'glutathione reductase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SLC7A3'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:115', 'target': None, 'metadata': {'node_id': '115', 'node_type': 'COMPOUND', 'display_name': 'lysine'}}, {'type': 'edge_addition', 'source': 'PROTEIN:432', 'target': 'GENE:34582', 'metadata': {'predicate': 'gene_product_of'}}]",0.6470588235294117,ba0dc33fbea1636c0fddc8bc11361028,ecacbb4d421e0de87a4c2cfa28504c26,[],[]
"[{'source_node': {'name': 'apramycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pilocarpine'}}, {'source_node': {'name': 'apramycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'acetylcholine'}}]","[{'source_node': {'name': 'pilocarpine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'acetylcholine'}}, {'source_node': {'name': 'apramycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pilocarpine'}}, {'source_node': {'name': 'apramycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'acetylcholine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1065', 'target': 'COMPOUND:2945', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.8,0f095faace250db489d149fa31840931,8ae88af2aa682ebd30bdf5672f8b4b2c,"['The drug apramycin has been found to decrease the efficacy of both pilocarpine and acetylcholine.', 'The drug apramycin is known to decrease the efficacy of both pilocarpine and acetylcholine.', 'The drug apramycin has been known to decrease the efficacy of both pilocarpine and acetylcholine. This interaction might impact the effectiveness of treatments where these two drugs are used.', 'The drug apramycin has been found to decrease the efficacy of both pilocarpine and acetylcholine. This means that the usage of apramycin may reduce the effectiveness of these drugs.', 'The drug apramycin is known to decrease the efficacy of both pilocarpine and acetylcholine, possibly influencing their therapeutic outcomes.']","['The drug Apramycin has been observed to decrease the efficacy of Pilocarpine and Acetylcholine. Interestingly, Pilocarpine also leads to a decrease in the effectiveness of Acetylcholine. Therefore, suggests a complex interaction between Apramycin, Pilocarpine and Acetylcholine.', ""The drug apramycin is known to reduce the effectiveness of both pilocarpine and acetylcholine. Concurrently, the efficacy of acetylcholine is also diminished by pilocarpine. Thus, when these substances interact, they negatively affect each other's potency."", 'The drug Apramycin is known to decrease the efficacy of both Acetylcholine and Pilocarpine. In turn, Pilocarpine also lessens the effectiveness of Acetylcholine. Therefore, the combined use of these drugs may lead to reduced therapeutic impact.', ""The drug apramycin has been noted for its ability to decrease the efficacy of other substances, including both pilocarpine and acetylcholine. Similarly, pilocarpine also decreases the efficacy of acetylcholine. It's an intriguing complex where the interaction of these substances leads to a reduced overall effect."", 'The drug apramycin is known to decrease the efficacy of both pilocarpine and acetylcholine. Furthermore, pilocarpine also has its efficacy decreased when interacting with acetylcholine. This interconnected relationship between apramycin, pilocarpine, and acetylcholine needs to be considered in drug interaction studies.']"
"[{'source_node': {'name': 'man1b1-cdg'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cerebellar hypoplasia'}}, {'source_node': {'name': 'man1b1-cdg'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'long eyebrows'}}, {'source_node': {'name': 'man1b1-cdg'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'long eyelashes'}}]","[{'source_node': {'name': 'man1b1-cdg'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'long eyelashes'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1000', 'target': None, 'metadata': {'node_id': '1000', 'node_type': 'PHENOTYPE', 'display_name': 'cerebellar hypoplasia'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:3158', 'target': None, 'metadata': {'node_id': '3158', 'node_type': 'PHENOTYPE', 'display_name': 'long eyebrows'}}]",0.4285714285714286,a39a90539dd5ead2c89d73cfc3840576,b684fd11c9d773aa1348730779c39cc6,"['The condition known as MAN1B1-CDG presents several phenotypes such as cerebellar hypoplasia, long eyebrows, and long eyelashes.', 'The disorder man1b1-cdg has various phenotypes associated with it, including cerebellar hypoplasia, long eyebrows, and long eyelashes.', 'The genetic disorder known as MAN1B1-CDG presents with several distinguishing phenotypes, including cerebellar hypoplasia, long eyebrows, and long eyelashes.', 'The condition known as MAN1B1-CDG exhibits phenotypes including cerebellar hypoplasia, long eyebrows, and long eyelashes.']",['The genetic disorder known as MAN1B1-CDG is characterized by several phenotypes including the distinctive physical trait of long eyelashes.']
"[{'source_node': {'name': 'tubulin beta-6 chain'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TUBB6'}}, {'source_node': {'name': 'combretastatin a-1'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h460'}}, {'source_node': {'name': 'combretastatin a-1'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hop-62'}}, {'source_node': {'name': 'combretastatin a-1'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tubulin beta-6 chain'}}, {'source_node': {'name': 'TUBB6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Gap junction assembly'}}, {'source_node': {'name': 'TUBB6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Activation of AMPK downstream of NMDARs'}}, {'source_node': {'name': 'TUBB6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Aggrephagy'}}]","[{'source_node': {'name': 'tubulin beta-6 chain'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TUBB6'}}, {'source_node': {'name': 'hop-62'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TUBB6'}}, {'source_node': {'name': 'combretastatin a-1'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h460'}}, {'source_node': {'name': 'combretastatin a-1'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hop-62'}}, {'source_node': {'name': 'combretastatin a-1'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tubulin beta-6 chain'}}, {'source_node': {'name': 'TUBB6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Gap junction assembly'}}, {'source_node': {'name': 'TUBB6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Activation of AMPK downstream of NMDARs'}}, {'source_node': {'name': 'TUBB6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Aggrephagy'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:5627', 'target': 'GENE:34506', 'metadata': {'predicate': 'gene_product_of'}}]",0.9333333333333332,6bbb673ed3854ef58b5a729ce3e95b9f,135c1b8adbbcb6677b2e3b1df3f75ef0,"['The drug Combretastatin A-1 has several targets that include NCI-H460, HOP-62, and Tubulin Beta-6 Chain. Meanwhile, the Tubulin Beta-6 Chain is a gene product of TUBB6, a gene which exhibits its activity within several biochemical pathways like the Gap Junction Assembly, Aggrephagy, and the Activation of AMPK downstream of NMDARs part of cell signalling mechanism. This provides a compelling interconnected network of chemical, genetic, and signalling pathway interactions.', 'The Tubulin beta-6 chain is a protein, which is the gene product of TUBB6. This gene is involved in several processes such as Gap junction assembly, activation of AMPK downstream of NMDARs, and Aggrephagy. Interestingly, the drug Combretastatin A-1 targets diverse entities, including the Tubulin beta-6 chain itself, but also extends its action towards certain strains of cancer cells like NCI-H460 and HOP-62.', 'The drug Combretastatin A-1 targets NCI-H460, HOP-62, and tubulin beta-6 chain. The tubulin beta-6 chain is a gene product of TUBB6, which acts within several pathways. These pathways include, the assembly of gap junctions, the activation of AMPK downstream of NMDARs, and aggrephagy.', 'The drug called Combretastatin A-1 targets the NCI-H460, HOP-62, and Tubulin Beta-6 Chain, contributing to its role in cancer therapy. The Tubulin Beta-6 Chain is a gene product of TUBB6, a gene which acts within various pathways such as the gap junction assembly, the activation of AMPK downstream of NMDARs, and aggrephagy. This shows the complex interactions and functions of genes and drugs within the cell.\n', 'The molecule combretastatin a-1 targets a variety entities including the NCI-H460, HOP-62, and the tubulin beta-6 chain. This tubulin beta-6 chain molecule is a gene product of TUBB6. Interestingly, TUBB6 is involved in several crucial biological processes including gap junction assembly, the activation of AMPK downstream of NMDARs, and the process of aggrephagy.']","['The Tubulin beta-6 chain and HOP-62 are gene products of TUBB6. TUBB6 operates within certain pathways, facilitating functions such as the assembly of gap junctions, the activation of AMPK downstream of NMDARs, and the process known as Aggrephagy. Strikingly, this is linked with the action of the drug Combretastatin A-1, which targets not only the Tubulin beta-6 chain and HOP-62 but also another entity known as NCI-H460. Hence, a network of interactions can be traced, starting from the genetic expressions of TUBB6 to its metabolic activities and eventually its drug interactions.', 'The molecule tubulin beta-6 chain is a gene product of TUBB6, which also produces the gene product known as hop-62. TUBB6 is involved in various pathways such as the assembly of gap junctions, activation of AMPK downstream of NMDARs, and aggrephagy. The drug Combretastatin A-1 targets multiple entities including NCI-H460, hop-62 and the tubulin beta-6 chain.', 'The drug, combretastatin a-1, targets multiple paths including the nci-h460, hop-62 and the tubulin beta-6 chain. Both the tubulin beta-6 chain and the hop-62 are gene products of TUBB6. Furthermore, TUBB6 acts within several pathways such as the gap junction assembly, the activation of AMPK downstream of NMDARs and aggrephagy.', 'The Tubulin beta-6 chain and Hop-62 are both gene products of TUBB6. This gene acts within several pathways such as gap junction assembly, activation of AMPK downstream of NMDARs, and aggrephagy. Furthermore, the drug Combretastatin A-1 has multiple targets, including NCI-H460, Hop-62, and the Tubulin beta-6 chain.', 'The proteins tubulin beta-6 chain and hop-62 are gene products of TUBB6, a gene that acts within various pathways, notably the gap junction assembly, the activation of AMPK downstream of NMDARs, and aggrephagy. Interestingly, the drug combretastatin a-1 targets a range of entities including nci-h460, hop-62, and the tubulin beta-6 chain. By interacting with these targets, combretastatin a-1 adopts a pivotal role in molecular biology.']"
"[{'source_node': {'name': 'LYZ'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}, {'source_node': {'name': 'LYZ'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Antimicrobial peptides'}}, {'source_node': {'name': 'lysozyme c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'LYZ'}}]","[{'source_node': {'name': 'LYZ'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}, {'source_node': {'name': 'LYZ'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Antimicrobial peptides'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:331', 'target': None, 'metadata': {'node_id': '331', 'node_type': 'PROTEIN', 'display_name': 'lysozyme c'}}]",0.7142857142857143,e9266694f10dc4c87a6c2e4b91f18109,33173c75ebaaeb2332d2f567dffb9db6,[],"['The enzyme LYZ performs a key role in various biological processes, functioning within processes such as neutrophil degranulation and acting within the mechanism of antimicrobial peptides.']"
"[{'source_node': {'name': 'darglitazone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor gamma'}}, {'source_node': {'name': 'peroxisome proliferator-activated receptor gamma'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PPARG'}}, {'source_node': {'name': 'PPARG'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'congenital generalized lipodystrophy'}}, {'source_node': {'name': 'PPARG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'SUMOylation of intracellular receptors'}}, {'source_node': {'name': 'PPARG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'MECP2 regulates transcription factors'}}]","[{'source_node': {'name': 'darglitazone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor gamma'}}, {'source_node': {'name': 'darglitazone'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'congenital generalized lipodystrophy'}}, {'source_node': {'name': 'peroxisome proliferator-activated receptor gamma'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PPARG'}}, {'source_node': {'name': 'PPARG'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'congenital generalized lipodystrophy'}}, {'source_node': {'name': 'PPARG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'SUMOylation of intracellular receptors'}}, {'source_node': {'name': 'PPARG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'MECP2 regulates transcription factors'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:11867', 'target': 'DISEASE:4374', 'metadata': {'predicate': 'is_substance_that_treats'}}]",0.9090909090909092,4b92aa563c0185ebad758ed303f06a0a,20eaf7e9ac10617e876eac7b3bb416be,"['The drug Darglitazone has a target, the peroxisome proliferator-activated receptor gamma. This receptor is a gene product of PPARG, which is known to cause a condition called congenital generalized lipodystrophy. Additionally, PPARG acts within certain pathways, specifically the SUMOylation of intracellular receptors pathway and the pathway where MECP2 regulates transcription factors.']","['The drug darglitazone targets the peroxisome proliferator-activated receptor gamma and is used to treat congenital generalized lipodystrophy. This receptor is the gene product of PPARG, which also causes congenital generalized lipodystrophy. PPARG is active within both the SUMOylation of intracellular receptors and MECP2 regulates transcription factors pathways.']"
"[{'source_node': {'name': 'lethal congenital contracture syndrome 7'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cerebral atrophy'}}, {'source_node': {'name': 'lethal congenital contracture syndrome 7'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypoplasia of the corpus callosum'}}, {'source_node': {'name': 'lethal congenital contracture syndrome 7'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'paralysis'}}]","[{'source_node': {'name': 'lethal congenital contracture syndrome 7'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypoplasia of the corpus callosum'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:2505', 'target': None, 'metadata': {'node_id': '2505', 'node_type': 'PHENOTYPE', 'display_name': 'paralysis'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:1510', 'target': None, 'metadata': {'node_id': '1510', 'node_type': 'PHENOTYPE', 'display_name': 'cerebral atrophy'}}]",0.4285714285714286,cd3e45ce6a5055cd1f99650963026100,aee756ba36c5f6410243fb381ca0df04,"['""Lethal congenital contracture syndrome 7, a medical condition, presents several phenotypes. These include cerebral atrophy, a degenerative process that can impair cognitive ability and hypoplasia of the corpus callosum, affecting its size and development. Another phenomenon associated with this syndrome is paralysis, which may restrict body mobility.', '""Lethal congenital contracture syndrome 7 is a disease with multiple phenotypes including cerebral atrophy, hypoplasia of the corpus callosum, and paralysis.', 'The lethal congenital contracture syndrome 7 manifests several phenotypes. These include cerebral atrophy and hypoplasia of the corpus callosumbrain conditions that lead to reduced brain size and incomplete or underdevelopment of the corpus callosum, respectively. Furthermore, paralysis, a total loss of muscle function for one or more muscle groups, is also a phenotype of this syndrome.']",[]
"[{'source_node': {'name': 'moxifloxacin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'rosiglitazone'}}, {'source_node': {'name': 'moxifloxacin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'gliquidone'}}, {'source_node': {'name': 'moxifloxacin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'voglibose'}}, {'source_node': {'name': 'rosiglitazone'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Diabetic'}}, {'source_node': {'name': 'rosiglitazone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Dizziness'}}]","[{'source_node': {'name': 'gliquidone'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Diabetic'}}, {'source_node': {'name': 'moxifloxacin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'gliquidone'}}, {'source_node': {'name': 'moxifloxacin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'voglibose'}}, {'source_node': {'name': 'rosiglitazone'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Diabetic'}}, {'source_node': {'name': 'rosiglitazone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Dizziness'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1231', 'target': 'INDICATION:402', 'metadata': {'predicate': 'has_indication'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:208', 'target': 'COMPOUND:400', 'metadata': None}]",0.8181818181818181,3d862fafa64f7ff047e75d47d668cce1,b3fa2d5d6fcb4fc1566820e1ee11decf,[],[]
"[{'source_node': {'name': 'isradipine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oxymetazoline'}}, {'source_node': {'name': 'isradipine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phenolphthalein'}}, {'source_node': {'name': 'magnesium acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'isradipine'}}, {'source_node': {'name': 'magnesium acetate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'rocuronium'}}, {'source_node': {'name': 'magnesium acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'flunarizine'}}]","[{'source_node': {'name': 'isradipine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oxymetazoline'}}, {'source_node': {'name': 'isradipine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phenolphthalein'}}, {'source_node': {'name': 'isradipine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'rocuronium'}}, {'source_node': {'name': 'magnesium acetate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'rocuronium'}}, {'source_node': {'name': 'magnesium acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'flunarizine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:260', 'target': 'COMPOUND:713', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:11834', 'target': 'COMPOUND:260', 'metadata': None}]",0.8181818181818181,21279f513d1f66cff13ff87ab2f663d6,f944ea173ee1cf086fa968ab15e56428,"['The drug Isradipine decreases the efficacy of both Oxymetazoline and Phenolphthalein. However, the effectiveness of Isradipine can be reduced by the impact of Magnesium Acetate. It is also noteworthy to mention that Magnesium Acetate plays a dual role as it both decreases and increases the effectiveness of certain drugs. For instance, it enhances the efficacy of Rocuronium and simultaneously diminishes that of Flunarizine.', 'The drug Isradipine has been observed to decrease the efficacy of not only Oxymetazoline but also Phenolphthalein. Interestingly, another drug, Magnesium Acetate, is known to decrease the efficacy of Isradipine itself. Moreover, Magnesium Acetate also has a role in the modification of the efficacy of other drugs. For instance, it increases the efficacy of Rocuronium while, on the other hand, decreases the efficacy of Flunarizine. Thus, caution should be exercised when these drugs are used in combination.', 'Isradipine, a pharmaceutical drug, is known to decrease the efficacy of other medications such as oxymetazoline and phenolphthalein. Another compound, magnesium acetate also displays interesting interactions with drugs. It is reported to decrease the efficacy of isradipine while increasing the efficacy of rocuronium. However, just like isradipine, magnesium acetate also has the effect of decreasing the efficacy of flunarizine. These interactions should be considered in pharmacological management and drug co-administration scenarios.', ""The drug isradipine is known to decrease the efficacy of other treatments such as oxymetazoline and phenolphthalein. This interaction is bidirectional with isradipine's own efficacy being decreased by substances like magnesium acetate. Interestingly, magnesium acetate not only interacts with isradipine, but it also decreases the efficacy of flunarizine while increasing the efficacy of rocuronium. This complex interplay of substances shows how careful consideration must be given when prescribing or administering multiple treatments concurrently."", ""The drug isradipine is known to decrease the efficacy of both oxymetazoline and phenolphthalein. Interestingly, isradipine's efficacy is also decreased by magnesium acetate. Along with this, magnesium acetate tends to increase the efficacy of rocuronium while simultaneously decreasing the efficacy of flunarizine.""]","['The drug Isradipine has been shown to decrease the efficacy of both Oxymetazoline and Phenolphthalein, while it has been known to increase the efficacy of Rocuronium. Magnesium Acetate, on the other hand, also boosts the effectiveness of Rocuronium, however, its interaction with Flunarizine results in a decreased efficacy of the latter.', 'The drug Isradipine decreases the efficacy of Oxymetazoline and Phenolphthalein, but increases the efficacy of Rocuronium. Similarly, Magnesium Acetate also increases the efficacy of Rocuronium but decreases the efficacy of Flunarizine.', 'The drug Isradipine has a varied impact on the efficacy of several other medications. Specifically, it has been found to decrease the efficacy of Oxymetazoline and Phenolphthalein. On the other hand, it enhances the efficacy of Rocuronium. Similarly, Magnesium Acetate also influences drug efficacy. It enhances the effectiveness of Rocuronium, similar to Isradipine, while reducing the efficacy of Flunarizine.', 'The drug Isradipine decreases the efficacy of both Oxymetazoline and Phenolphthalein, while it increases the efficacy of Rocuronium. Additionally, Magnesium Acetate also increases the efficacy of Rocuronium, but on the other hand, it is known to reduce the performance of Flunarizine.', 'The drug Isradipine has been found to decrease the efficacy of drugs such as Oxymetazoline and Phenolphthalein, but interestingly, it increases the efficacy of Rocuronium. In a similar vein, Magnesium Acetate amplifies the effectiveness of Rocuronium but depresses that of Flunarizine.']"
"[{'source_node': {'name': 'pentobarbital'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pyridostigmine'}}, {'source_node': {'name': 'pentobarbital'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methdilazine'}}, {'source_node': {'name': 'pentobarbital'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Hepatocellular injury'}}, {'source_node': {'name': 'methdilazine'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' seizure '}}, {'source_node': {'name': 'methdilazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phenobarbital'}}, {'source_node': {'name': 'methdilazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'theodrenaline'}}, {'source_node': {'name': 'pyridostigmine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Increased bronchial secretion'}}]","[{'source_node': {'name': 'pentobarbital'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pyridostigmine'}}, {'source_node': {'name': 'pentobarbital'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Hepatocellular injury'}}, {'source_node': {'name': 'methdilazine'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' seizure '}}, {'source_node': {'name': 'methdilazine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phenobarbital'}}, {'source_node': {'name': 'pyridostigmine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Increased bronchial secretion'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:10801', 'target': None, 'metadata': {'node_id': '10801', 'node_type': 'COMPOUND', 'display_name': 'theodrenaline'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:302', 'target': 'COMPOUND:885', 'metadata': None}]",0.8,b25d3a4f3a53982252bd4e160c983dc5,eb4f5d16f7e2a56d3de8b0989a053a4b,[],[]
"[{'source_node': {'name': 'quisqualic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'metabotropic glutamate receptor 5'}}, {'source_node': {'name': 'quisqualic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}}, {'source_node': {'name': 'quisqualic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'm-phase phosphoprotein 8'}}, {'source_node': {'name': 'GRM5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (q) signalling events'}}, {'source_node': {'name': 'GRM5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neurexins and neuroligins'}}, {'source_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TDP1'}}, {'source_node': {'name': 'metabotropic glutamate receptor 5'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GRM5'}}]","[{'source_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TDP1'}}, {'source_node': {'name': 'TDP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (q) signalling events'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:6169', 'target': 'GENE:28456', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:2827', 'target': 'PROTEIN:6169', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:2827', 'target': None, 'metadata': {'node_id': '2827', 'node_type': 'COMPOUND', 'display_name': 'quisqualic acid'}}, {'type': 'edge_addition', 'source': 'GENE:31610', 'target': 'PATHWAY:323', 'metadata': {'predicate': 'acts_within'}}, {'type': 'node_removal', 'source': 'GENE:28456', 'target': None, 'metadata': {'node_id': '28456', 'node_type': 'GENE', 'display_name': 'GRM5'}}]",0.1999999999999999,7fa9cfa6a0252a87f486a587ac01fe15,1fcbf7fd65256a6b9f3a91ddbf4a7673,"['Quisqualic acid is a substance that targets various proteins such as the metabotropic glutamate receptor 5, tyrosyl-DNA phosphodiesterase 1, and M-phase phosphoprotein 8. Notably, metabotropic glutamate receptor 5 is a gene product of GRM5, which acts within the pathways of G alpha (q) signalling events as well as neurexins and neuroligins. Additionally, tyrosyl-DNA phosphodiesterase 1 is a gene product of TDP1.', 'The compound quisqualic acid targets several entities including metabotropic glutamate receptor 5, tyrosyl-dna phosphodiesterase 1 and m-phase phosphoprotein 8. The metabotropic glutamate receptor 5 is a gene product of GRM5, which acts within pathways such as the G alpha (q) signalling events and neurexins and neuroligins. Meanwhile, the tyrosyl-dna phosphodiesterase 1 is a gene product of TDP1.', 'Quisqualic acid, a chemical substance, targets several entities including the metabotropic glutamate receptor 5, tyrosyl-DNA phosphodiesterase 1, and M-phase phosphoprotein 8. Interestingly, the metabotropic glutamate receptor 5 is a product of the gene GRM5 which also acts within pathways like G alpha (q) signalling events and Neurexins and neuroligins. Similarly, tyrosyl-dna phosphodiesterase 1 is also a gene product, specifically that of TDP1.', 'Quisqualic acid targets several entities including metabotropic glutamate receptor 5, tyrosyl-DNA phosphodiesterase 1, and M-phase phosphoprotein 8. Metabotropic glutamate receptor 5 is the gene product of GRM5 which also acts within pathways such as G alpha (q) signalling events and neurexins and neuroligins. Tyrosyl-DNA phosphodiesterase 1 is the gene product of TDP1.', 'The compound quisqualic acid acts as a target for several entities including metabotropic glutamate receptor 5, tyrosyl-DNA phosphodiesterase 1, and M-phase phosphoprotein 8. Metabotropic glutamate receptor 5 is a gene product of GRM5, which is an actor within pathways such as G alpha (q) signalling events and Neurexins and neuroligins. Furthermore, tyrosyl-DNA phosphodiesterase 1 is known to be a gene product of TDP1.']","['Tyrosyl-DNA phosphodiesterase 1 is a gene product of TDP1. TDP1 then acts within G alpha (q) signalling events.', 'Tyrosyl-DNA phosphodiesterase 1 is a gene product of TDP1. TDP1 acts within the pathway of G alpha (q) signalling events.', 'Tyrosyl-DNA phosphodiesterase 1 is a gene product of TDP1. In turn, TDP1 acts within the G alpha (q) signalling events pathway.']"
"[{'source_node': {'name': 'anomalin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'aurora kinase b'}}, {'source_node': {'name': 'anomalin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'focal adhesion kinase 1'}}, {'source_node': {'name': 'anomalin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'vascular endothelial growth factor receptor 2'}}, {'source_node': {'name': 'vascular endothelial growth factor receptor 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KDR'}}, {'source_node': {'name': 'AURKB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RHO GTPases Activate Formins'}}, {'source_node': {'name': 'aurora kinase b'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AURKB'}}, {'source_node': {'name': 'focal adhesion kinase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTK2'}}]","[{'source_node': {'name': 'anomalin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'aurora kinase b'}}, {'source_node': {'name': 'anomalin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'focal adhesion kinase 1'}}, {'source_node': {'name': 'anomalin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'vascular endothelial growth factor receptor 2'}}, {'source_node': {'name': 'anomalin a'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'AURKB'}}, {'source_node': {'name': 'vascular endothelial growth factor receptor 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KDR'}}, {'source_node': {'name': 'vascular endothelial growth factor receptor 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTK2'}}, {'source_node': {'name': 'AURKB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RHO GTPases Activate Formins'}}, {'source_node': {'name': 'aurora kinase b'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AURKB'}}, {'source_node': {'name': 'focal adhesion kinase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTK2'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:33715', 'target': 'GENE:35248', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:1110', 'target': 'GENE:31990', 'metadata': {'predicate': 'gene_product_of'}}]",0.8666666666666667,34915a3063e9e3f6d185f49b96dbec29,7b5ea809a84654b190584407e8a7cbc3,"['Anomalin A, a compound of interest, is known to target several proteins including Aurora Kinase B, Focal Adhesion Kinase 1 and Vascular Endothelial Growth Factor Receptor 2. Interestingly, these targeted proteins are the gene products of AURKB, PTK2, and KDR genes respectively. The AURKB gene plays a crucial role within the RHO GTPases Activate Formins pathway.', 'The compound Anomalin A has multiple targets including Aurora kinase B, Focal Adhesion Kinase 1, and Vascular Endothelial Growth Factor Receptor 2. Aurora kinase B is a gene product of AURKB, which operates within the pathway of RHO GTPases activating Formins. Moreover, Focal Adhesion Kinase 1 is a gene product of PTK2. Lastly, Vascular Endothelial Growth Factor Receptor 2 is a gene product of KDR.']","['The compound Anomalin A has multiple targets, including Aurora kinase B, Focal adhesion kinase 1, and Vascular endothelial growth factor receptor 2. Anomalin A also affects AURKB. Aurora kinase B is a gene product of AURKB while Vascular endothelial growth factor receptor 2 is a gene product of both KDR and PTK2. Focal adhesion kinase 1 is also a gene product of PTK2. AURKB is known to act within the RHO GTPases Activate Formins pathway.', 'Anomalin A, a potent molecule, targets several proteins including Aurora Kinase B, Focal Adhesion Kinase 1, and Vascular Endothelial Growth Factor Receptor 2. Specifically, Anomalin A exhibits activity affecting the protein AURKB which in turn acts within the pathway known as RHO GTPases activate formins. Further expanding on its breadth of influence, the drug Anomalin A links with Vascular Endothelial Growth Factor Receptor 2, which is a gene product of both KDR and PTK2. Aurora Kinase B is also found to be a gene product of AURKB, while Focal Adhesion Kinase 1 is a gene product of PTK2. Together, these complex relationships underscore the numerous biological pathways and entities within which Anomalin A operates.']"
"[{'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 11'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN11'}}, {'source_node': {'name': 'PTPN11'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RET signaling'}}, {'source_node': {'name': 'PTPN11'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of IFNA/IFNB signaling'}}, {'source_node': {'name': 'PTPN11'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'FLT3 Signaling'}}, {'source_node': {'name': 'dodecyltrimethylammonium'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 11'}}]","[{'source_node': {'name': 'PTPN11'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RET signaling'}}, {'source_node': {'name': 'PTPN11'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'FLT3 Signaling'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:2757', 'target': None, 'metadata': {'node_id': '2757', 'node_type': 'PROTEIN', 'display_name': 'tyrosine-protein phosphatase non-receptor type 11'}}, {'type': 'node_removal', 'source': 'PATHWAY:1001', 'target': None, 'metadata': {'node_id': '1001', 'node_type': 'PATHWAY', 'display_name': 'Regulation of IFNA/IFNB signaling'}}]",0.4545454545454546,02664577ee9481a6be6e61cf6e75304b,e5b5cb3391f78be608e6525c1c4afae5,"['The compound known as dodecyltrimethylammonium specifically targets an enzyme called tyrosine-protein phosphatase non-receptor type 11. This enzyme is a gene product of PTPN11. This particular gene is instrumental as it acts within different pathways such as RET signaling, regulation of IFNA/IFNB signaling, and FLT3 signaling. Such interactions hint at the complex interplay of genetic elements and their role in various biological processes.', 'The drug dodecyltrimethylammonium has a target known as tyrosine-protein phosphatase non-receptor type 11. This protein is a gene product of PTPN11, which acts within multiple pathways including RET signaling, regulation of IFNA/IFNB signaling, and FLT3 signaling.', 'The drug, dodecyltrimethylammonium, targets the tyrosine-protein phosphatase non-receptor type 11, which is a gene product of PTPN11. The gene PTPN11 acts within multiple pathways, such as RET signaling, regulation of IFNA/IFNB signaling, and FLT3 signaling.', 'The drug dodecyltrimethylammonium targets the tyrosine-protein phosphatase non-receptor type 11. Tyrosine-protein phosphatase non-receptor type 11 is a gene product of PTPN11. PTPN11 acts within several signaling pathways such as RET signaling, Regulation of IFNA/IFNB signaling, and FLT3 signaling.', 'The compound Dodecyltrimethylammonium targets the tyrosine-protein phosphatase non-receptor type 11, which is a gene product of PTPN11. This gene PTPN11 plays a role within various pathways such as RET signaling, the regulation of IFNA/IFNB signaling, and FLT3 signaling.']","['The gene PTPN11 plays a crucial role within multiple signaling pathways, including the RET signaling and FLT3 signaling pathways.', 'The gene PTPN11 operates within several pathways, specifically within RET signaling and FLT3 signaling.']"
"[{'source_node': {'name': 'PTPN1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'diabetes mellitus'}}, {'source_node': {'name': 'PTPN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Integrin signaling'}}, {'source_node': {'name': 'PTPN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Growth hormone receptor signaling'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}, {'source_node': {'name': 'ohioensin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}, {'source_node': {'name': 'ohioensin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}, {'source_node': {'name': 'ohioensin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}]","[{'source_node': {'name': 'PTPN1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'diabetes mellitus'}}, {'source_node': {'name': 'PTPN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Growth hormone receptor signaling'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}, {'source_node': {'name': 'ohioensin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}, {'source_node': {'name': 'ohioensin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}, {'source_node': {'name': 'ohioensin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'ht-29'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:4976', 'target': 'GENE:32076', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'PATHWAY:298', 'target': None, 'metadata': {'node_id': '298', 'node_type': 'PATHWAY', 'display_name': 'Integrin signaling'}}]",0.8,9fa0fda54ed437f63f5b70999dedd89f,38bf68ca2d23736b7de02f350c42e743,"['The gene PTPN1 is linked to the development of diabetes mellitus and is found to act within two key signalling pathways, namely integrin signalling and growth hormone receptor signalling. Tyrosine-protein phosphatase non-receptor type 1 is a gene product of PTPN1. The drug Ohioensin A specifically targets tyrosine-protein phosphatase non-receptor type 1 and also interacts with HT-29 and MCF7, both of which further illustrate the effects of PTPN1 in complex biological networks.', 'The gene PTPN1 is known to act within the Integrin signaling and Growth hormone receptor signaling pathways, and it can cause the disease condition known as diabetes mellitus. An interesting fact about this gene is that the protein it expresses, known as tyrosine-protein phosphatase non-receptor type 1, is targeted by the compound ohioensin a. Moreover, ohioensin a also targets two other entities, namely ht-29 and mcf7.', 'The molecule Ohioensin A targets multiple entities, including the Tyrosine-protein phosphatase non-receptor type 1 and human tumour cell lines HT-29 and MCF7. This molecule, Tyrosine-protein phosphatase non-receptor type 1, is actually a product of the gene PTPN1. Interestingly, the gene PTPN1 can cause a condition known as diabetes mellitus. Furthermore, PTPN1 actively functions within various cellular pathways such as Integrin signaling and growth hormone receptor signaling.']","['The gene PTPN1 is linked to the development of diabetes mellitus and is involved in the process of Growth hormone receptor signaling. The specific gene product is tyrosine-protein phosphatase non-receptor type 1. It is interesting to note that this protein is a target of the compound ohioensin a, which also targets the HT-29 and MCF7 cells. The HT-29 cells are another gene product of the PTPN1 gene, reinforcing the integral role of PTPN1 in different biochemical processes and disease conditions.']"
"[{'source_node': {'name': 'beta-glucosidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GBA2'}}, {'source_node': {'name': 'GBA2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'spastic paraplegia 46'}}, {'source_node': {'name': 'GBA2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'autosomal recessive spastic paraplegia type 46'}}]","[{'source_node': {'name': 'beta-glucosidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GBA2'}}, {'source_node': {'name': 'GBA2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'spastic paraplegia 46'}}]","[{'type': 'node_removal', 'source': 'DISEASE:7866', 'target': None, 'metadata': {'node_id': '7866', 'node_type': 'DISEASE', 'display_name': 'autosomal recessive spastic paraplegia type 46'}}]",0.7142857142857143,049a534857ce019f1414a43b2f1c6979,c06e9a9d4ca75402d29daba31678c2ba,"['The protein beta-glucosidase is a gene product of GBA2. Notably, the gene GBA2 is known to cause several conditions. Among those are spastic paraplegia 46, as well as a specific variety of this disease known as autosomal recessive spastic paraplegia type 46.', 'Beta-glucosidase is a gene product of GBA2. This gene, GBA2, is known to cause certain medical conditions, specifically spastic paraplegia 46 and autosomal recessive spastic paraplegia type 46.', 'Beta-Glucosidase, a gene product of GBA2, is implicated in two related conditions. GBA2 is known to cause spastic paraplegia 46, an inherited neurological disorder that leads to progressive spasticity and weakness of the legs. Notably, GBA2 is also found to cause autosomal recessive spastic paraplegia type 46, a more specific categorization of the aforementioned condition.', 'Beta-glucosidase is a gene product of GBA2. Notably, GBA2 is associated with various medical conditions. It specifically causes spastic paraplegia 46 and another form of the same disease known as autosomal recessive spastic paraplegia type 46.', 'The enzyme beta-glucosidase is a gene product of GBA2. The gene GBA2 has been found to cause two conditions: spastic paraplegia 46 and autosomal recessive spastic paraplegia type 46.']","['Beta-glucosidase is a gene product of GBA2. Notably, GBA2 is known to cause a condition referred to as spastic paraplegia 46.', 'Beta-glucosidase is a gene product of GBA2 which is known to cause spastic paraplegia 46, a rare neurodegenerative disorder.', ""Beta-glucosidase is a gene product of GBA2. Notably, GBA2 is associated with spastic paraplegia 46, a neurodegenerative condition it's known to cause."", 'Beta-glucosidase is a gene product of GBA2 which in turn causes a condition known as spastic paraplegia 46.', 'The enzyme beta-glucosidase, produced by the gene GBA2, can be associated with the development of a rare neurodegenerative disorder called spastic paraplegia 46.']"
"[{'source_node': {'name': 'ferric derisomaltose'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hemoglobin subunit alpha'}}, {'source_node': {'name': 'ferric derisomaltose'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'transferrin receptor'}}, {'source_node': {'name': 'hemoglobin subunit alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HBA1'}}, {'source_node': {'name': 'hemoglobin subunit alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HBA2'}}]","[{'source_node': {'name': 'ferric derisomaltose'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hemoglobin subunit alpha'}}, {'source_node': {'name': 'ferric derisomaltose'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'transferrin receptor'}}, {'source_node': {'name': 'ferric derisomaltose'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'HBA2'}}, {'source_node': {'name': 'hemoglobin subunit alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HBA1'}}, {'source_node': {'name': 'hemoglobin subunit alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HBA2'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:13122', 'target': 'GENE:28625', 'metadata': {'predicate': 'is_affecting'}}]",0.8888888888888888,88932479eeb1f0cfc0640470c4c5fa5b,d2da6cc6f8fef3cd8f90505d22b7cb42,"['The drug Ferric derisomaltose has targets that include both hemoglobin subunit alpha and the transferrin receptor. Hemoglobin subunit alpha is a gene product of both HBA1 and HBA2.', 'The drug ferric derisomaltose targets both the hemoglobin subunit alpha and the transferrin receptor. The hemoglobin subunit alpha is a gene product of both HBA1 and HBA2.', 'The drug Ferric derisomaltose has targets which include hemoglobin subunit alpha and the transferrin receptor. The hemoglobin subunit alpha is a gene product of the genes HBA1 and HBA2.', 'The drug Ferric Derisomaltose targets multiple proteins including Hemoglobin Subunit Alpha and the Transferrin Receptor. Interestingly, Hemoglobin Subunit Alpha is a gene product of both HBA1 and HBA2 genes, highlighting a comprehensive network of interactions between these biological entities.', 'The drug ferric derisomaltose targets both the hemoglobin subunit alpha and the transferrin receptor. It should be noted that the hemoglobin subunit alpha is the gene product of both HBA1 and HBA2.']","['Ferric derisomaltose targets two specific molecules, hemoglobin subunit alpha and transferrin receptor. This medication also affects the gene HBA2. Hemoglobin subunit alpha itself is a gene product of both HBA1 and HBA2.', 'The drug ferric derisomaltose has multiple targets, including the hemoglobin subunit alpha and the transferrin receptor. It is notable that ferric derisomaltose affects the HBA2 gene. Interestingly, the hemoglobin subunit alpha is a gene product of both HBA1 and HBA2.', 'Ferric derisomaltose is a compound that targets two protein molecules - hemoglobin subunit alpha and the transferrin receptor. In particular, it has been found to affect the gene HBA2. Interestingly, hemoglobin subunit alpha is the gene product of both HBA1 and HBA2, indicating that ferric derisomaltose plays a crucial role in this genetic process.', 'The drug ferric derisomaltose holds the capacity to target two key components, hemoglobin subunit alpha and the transferrin receptor. This targeting ability affects the HBA2 gene. Furthermore, it should be noted that hemoglobin subunit alpha is a gene product of two other genes, namely HBA1 and HBA2.', 'The substance ferric derisomaltose has multiple targets, including hemoglobin subunit alpha and the transferrin receptor. Furthermore, ferric derisomaltose also affects the gene HBA2. The hemoglobin subunit alpha, which ferric derisomaltose targets, is a gene product of both HBA1 and HBA2.']"
"[{'source_node': {'name': '1-o-acetylterricolyne'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}, {'source_node': {'name': '1-o-acetylterricolyne'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}]","[{'source_node': {'name': '1-o-acetylterricolyne'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5851', 'target': None, 'metadata': {'node_id': '5851', 'node_type': 'PROTEIN', 'display_name': 'mcf7'}}]",0.6,76df13224b9bdfe28bc74c88137fb02d,78554f9f756897ce96f0d65d03fea546,"['The compound 1-O-acetylterricolyne has multiple biological targets which include HeLa and MCF7 cells.', 'The compound 1-O-acetylterricolyne has been identified to target two different cell lines, specifically HeLa and MCF7.', 'The compound 1-O-acetylterricolyne has multiple targets including HeLa and MCF7 cells.', 'The compound 1-O-acetylterricolyne has been identified as having a target effect on two types of cells: HeLa and MCF7.', 'The compound 1-O-acetylterricolyne targets both HeLa and MCF7 cell lines.']",[]
"[{'source_node': {'name': 'prelamin-a/c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'LMNA'}}, {'source_node': {'name': 'sodium lauryl sulfate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prelamin-a/c'}}, {'source_node': {'name': 'sodium lauryl sulfate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ubiquitin carboxyl-terminal hydrolase 1'}}, {'source_node': {'name': 'sodium lauryl sulfate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-116'}}]","[{'source_node': {'name': 'prelamin-a/c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'LMNA'}}, {'source_node': {'name': 'ubiquitin carboxyl-terminal hydrolase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'LMNA'}}, {'source_node': {'name': 'sodium lauryl sulfate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prelamin-a/c'}}, {'source_node': {'name': 'sodium lauryl sulfate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ubiquitin carboxyl-terminal hydrolase 1'}}, {'source_node': {'name': 'sodium lauryl sulfate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-116'}}, {'source_node': {'name': 'sodium lauryl sulfate'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'LMNA'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:6121', 'target': 'GENE:29744', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'COMPOUND:798', 'target': 'GENE:29744', 'metadata': {'predicate': 'is_affecting'}}]",0.7777777777777778,9754843a8a2201788d02e6bf072cb7a6,871b1b71eb9f56afc611806251f35d82,"[""The compound sodium lauryl sulfate targets several entities including prelamin-a/c, ubiquitin carboxyl-terminal hydrolase 1, and hct-116. It's interesting to note that the prelamin-a/c is a gene product of the LMNA gene."", ""The drug sodium lauryl sulfate targets several entities including prelamin-a/c, ubiquitin carboxyl-terminal hydrolase 1, and hct-116. Prelamin-a/c is a gene product of LMNA. It's an intricate web of relationships that showcase the interconnected biochemical pathways taking place in the human body."", 'The compound Sodium Lauryl Sulfate targets several molecules including Prelamin-A/C, Ubiquitin Carboxyl-Terminal Hydrolase 1, and HCT-116. Notably, Prelamin-A/C is a gene product of LMNA, implying a possible interaction between LMNA-encoded products and Sodium Lauryl Sulfate.', 'The substance called sodium lauryl sulfate has several biological targets, including Prelamin-A/C, ubiquitin carboxyl-terminal hydrolase 1, and HCT-116. Prelamin-A/C is worth noting because it holds the distinction of being the gene product of the LMNA gene.', 'The substance sodium lauryl sulfate interacts with several targets, including prelamin-a/c, ubiquitin carboxyl-terminal hydrolase 1, and the cell line hct-116. Prelamin-a/c is a gene product of LMNA.']","['Prelamin-A/C and Ubiquitin Carboxyl-Terminal Hydrolase 1 are both gene products of LMNA. Sodium Lauryl Sulfate is a compound that has these two proteins as targets, along with another entity known as HCT-116. This compound also affects the gene LMNA, which is responsible for producing Prelamin-A/C and Ubiquitin Carboxyl-Terminal Hydrolase 1. Therefore, Sodium Lauryl Sulfate has a significant relationship with the gene LMNA and its products.', ""Prelamin-A/C and ubiquitin carboxyl-terminal hydrolase 1 are two gene products of the gene LMNA. There is a bioactive compound called sodium lauryl sulfate which, interestingly, targets both prelamin-A/C and ubiquitin carboxyl-terminal hydrolase 1. Furthermore, this compound targets an entity known as HCT-116. It's worth noting that sodium lauryl sulfate also influences the activity of the gene LMNA."", 'The substance Sodium Lauryl Sulfate is known to interact with multiple targets including Prelamin-A/C, Ubiquitin Carboxyl-Terminal Hydrolase 1, and the cellular entity HCT-116. Both Prelamin-A/C and Ubiquitin Carboxyl-Terminal Hydrolase 1 are gene products of LMNA - a gene that is also affected by Sodium Lauryl Sulfate.', 'The substance known as sodium lauryl sulfate targets several entities: prelamin-a/c, ubiquitin carboxyl-terminal hydrolase 1, and hct-116. Interestingly, sodium lauryl sulfate also does affect the gene LMNA. Both prelamin-a/c and ubiquitin carboxyl-terminal hydrolase 1 are gene products of LMNA. This establishes a complex interaction network revolving around the substance sodium lauryl sulfate.', 'Prelamin-A/C and Ubiquitin Carboxyl-Terminal Hydrolase 1 are both gene products of LMNA. Interestingly, the compound Sodium Lauryl Sulfate targets these two proteins, Prelamin-A/C and Ubiquitin Carboxyl-Terminal Hydrolase 1, as well as HCT-116. Furthermore, Sodium Lauryl Sulfate also affects the gene LMNA itself.']"
"[{'source_node': {'name': '3-o-[(s)-2-methylbutyroyl]pinobanksin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-1080'}}, {'source_node': {'name': '3-o-[(s)-2-methylbutyroyl]pinobanksin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': '3-o-[(s)-2-methylbutyroyl]pinobanksin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}]","[{'source_node': {'name': '3-o-[(s)-2-methylbutyroyl]pinobanksin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-1080'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5849', 'target': None, 'metadata': {'node_id': '5849', 'node_type': 'PROTEIN', 'display_name': 'a549'}}, {'type': 'node_removal', 'source': 'PROTEIN:4994', 'target': None, 'metadata': {'node_id': '4994', 'node_type': 'PROTEIN', 'display_name': 'hela'}}]",0.4285714285714286,edb33dab8eea51b7160f024b01bcfdb7,7444baaef0f231b0d8c82d634bdd863b,"['The compound 3-O-[(S)-2-methylbutyroyl]pinobanksin targets several cell lines. These include HT-1080, A549, and HeLa.', 'The chemical compound 3-O-[(S)-2-Methylbutyroyl]pinobanksin exhibits targeted activity towards several cell lines including HT-1080, A549, and HeLa.', 'The compound 3-O-[(S)-2-methylbutyroyl]pinobanksin targets a variety of cell lines. These include but are not limited to, HT-1080, A549, and HeLa cells.', 'The compound 3-O-[(S)-2-methylbutyroyl]pinobanksin has several targets. It is particularly effective against the HT-1080, A549, and Hela cell lines.', 'The compound 3-O-[(S)-2-methylbutyroyl]pinobanksin has potential therapeutic effects as it targets several human cancer cell lines, including HT-1080, A549, and HeLa.']","['The compound 3-O-[(S)-2-methylbutyroyl]pinobanksin has HT-1080 as its target.', 'The compound 3-O-[(S)-2-methylbutyroyl]pinobanksin has the cellular target HT-1080.', 'The compound 3-O-[(S)-2-methylbutyroyl]pinobanksin has a target interaction with HT-1080.', 'The compound 3-O-[(S)-2-methylbutyroyl]pinobanksin has HT-1080 as its target.', 'The compound 3-O-[(S)-2-methylbutyroyl]pinobanksin has a target interaction with HT-1080.']"
"[{'source_node': {'name': 'pipecuronium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trilostane'}}, {'source_node': {'name': 'pipecuronium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'betaine'}}, {'source_node': {'name': 'pipecuronium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'konjac mannan'}}, {'source_node': {'name': 'lynestrenol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'motretinide'}}, {'source_node': {'name': 'amdinocillin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pipecuronium'}}, {'source_node': {'name': 'amdinocillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nomegestrol'}}, {'source_node': {'name': 'amdinocillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lynestrenol'}}]","[{'source_node': {'name': 'pipecuronium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trilostane'}}, {'source_node': {'name': 'pipecuronium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'betaine'}}, {'source_node': {'name': 'pipecuronium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'konjac mannan'}}, {'source_node': {'name': 'lynestrenol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'motretinide'}}, {'source_node': {'name': 'lynestrenol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'konjac mannan'}}, {'source_node': {'name': 'betaine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trilostane'}}, {'source_node': {'name': 'amdinocillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nomegestrol'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:1143', 'target': 'COMPOUND:1296', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:10371', 'target': 'COMPOUND:12614', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5806', 'target': 'COMPOUND:1088', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:1143', 'target': 'COMPOUND:10371', 'metadata': None}]",0.7333333333333334,e7d2893bfc2a21ae8e533eb2e3b9d395,b3802b07d5d20ecc59438ef9e7b2eb22,"['The drug Pipecuronium decreases the efficacy of several other drugs, including Trilostane, Betaine, and Konjac Mannan. Similarly, Lynestrenol is known to decrease the efficacy of Motretinide. Interestingly, Amdinocillin has mixed effects on other drugs. It increases the efficacy of Pipecuronium but decreases the efficacy of both Nomegestrol and Lynestrenol. Therefore, the interactions of these substances must be carefully considered in a pharmaceutical context.', 'The drug Pipecuronium has been observed to decrease the efficacy of several substances, including Trilostane, Betaine, and Konjac Mannan. Similarly, Lynestrenol, another drug, has a similar effect on Motretinidedecreasing its efficacy.\n\nOn the other hand, Amdinocillin shows an opposite effect on Pipecuronium, actually increasing its efficacy. However, similar to Pipecuronium and Lynestrenol, Amdinocillin also decreases the efficacy of certain substances. In this case, Nomegestrol and Lynestrenol become less effective in the presence of Amdinocillin.', ""The interactions between several drugs demonstrate their complex efficacy relationships. For instance, pipecuronium, a neuromuscular blocking agent, is shown to decrease the efficacy of trilostane, betaine, and konjac mannan. Furthermore, it appears that pipecuronium's efficacy is increased by the antimicrobial drug amdinocillin. \n\nIn a similar vein, lynestrenol, a progestin medication, has its efficacy decreased by amdinocillin, while also limiting the efficacy of motretinide, a retinoic acid derivative. Amdinocillin further compounds this interaction network by decreasing the effectiveness of nomegestrol, a synthetic progestogen. The various effects these drugs have on each other underline the need for detailed understanding when combining medications."", 'The drug Pipecuronium has been noted to decrease the efficacy of several other compounds including Trilostane, Betaine and Konjac Mannan. Lynestrenol, another drug, also exhibits a similar effect by decreasing the efficacy of Motretinide. Interestingly, Amdinocillin seems to have conflicting effects. While it can decrease the efficacy of Nomegestrol and Lynestrenol, it has an increasing effect on the efficacy of Pipecuronium.', 'The drug Pipecuronium is known to decrease the efficacy of a few entities including Trilostane, Betaine, and Konjac Mannan. On the other hand, Lynestrenol decreased the efficacy of Motretinide. Amdinocillin presents a dual behaviour by increasing the efficacy of Pipecuronium, while it reduces the efficacy of Nomegestrol and Lynestrenol.']","[""The drug Pipecuronium has been observed to decrease the efficacy of Trilostane, Betaine, and Konjac Mannan. Similarly, Lynestrenol also decreases the efficacy of both Motretinide and Konjac Mannan. Interestingly, Betaine's effectiveness is also diminished when introduced to Trilostane. Amdinocillin has been found to lower the efficacy of Nomegestrol as well."", ""The use of Pipecuronium decreases the efficacy of several substances including, Trilostane, Betaine, and Konjac Mannan. Similarly, Lynestrenol is known to significantly decrease the efficacy of Motretinide and Konjac Mannan. It's important to note that Betaine also has an effect that diminishes the efficacy of Trilostane. Lastly, the drug Amdinocillin is reported to decrease the effectiveness of Nomegestrol."", 'The drugs Pipecuronium, Lynestrenol, Betaine, and Amdinocillin can decrease the efficacy of several other substances. For instance, Pipecuronium can reduce the efficacy of Trilostane, Betaine, and Konjac Mannan. Likewise, Lynestrenol can hamper the function of Motretinide and Konjac Mannan. Similarly, Betaine can decrease the effectiveness of Trilostane, while Amdinocillin diminishes the efficiency of Nomegestrol. Overall, this describes the complex interactions and impacts these drugs can have on the potency of other substances.', 'The drugs pipecuronium, lynestrenol, betaine, and amdinocillin play a significant role in decreasing the efficacy of certain other drugs. For instance, pipecuronium has been shown to decrease the efficacy of trilostane, betaine, and konjac mannan which is a type of dietary fiber. Similarly, lynestrenol also decreases the efficacy of motretinide and konjac mannan. Notably, lynestrenol shares this effect on konjac mannan with pipecuronium. Furthermore, betaine also decreases the efficacy of trilostane, an effect it shares with pipecuronium. Additionally, amdinocillin, another drug, has an efficacy decreasing effect on nomegestrol, a hormonal drug. This knowledge of interaction between different drugs is crucial in understanding their combined usage in therapies.', 'The drugs Pipecuronium and Lynestrenol have been observed to decrease the efficacy of multiple substances. Specifically, Pipecuronium can reduce the effectiveness of Trilostane, Betaine, and Konjac Mannan. Similarly, Lynestrenol has shown to decrease the efficacy of Motretinide and also Konjac Mannan. Interestingly, Betaine itself can adversely affect the effectiveness of Trilostane, resulting in a complex interplay of drug interactions. Amdinocillin is another drug that has been found to decrease the efficacy of Nomegestrol. Users or prescribers of these substances should be aware of their potential interactions and adjust treatment plans accordingly.']"
"[{'source_node': {'name': '1-(pyrrolidin-1-yl)dodeca-2,4-dien-1-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': '1-(pyrrolidin-1-yl)dodeca-2,4-dien-1-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-br-3'}}, {'source_node': {'name': '1-(pyrrolidin-1-yl)dodeca-2,4-dien-1-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}]","[{'source_node': {'name': '1-(pyrrolidin-1-yl)dodeca-2,4-dien-1-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-br-3'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5858', 'target': None, 'metadata': {'node_id': '5858', 'node_type': 'PROTEIN', 'display_name': 'kb'}}, {'type': 'node_removal', 'source': 'PROTEIN:5849', 'target': None, 'metadata': {'node_id': '5849', 'node_type': 'PROTEIN', 'display_name': 'a549'}}]",0.4285714285714286,30ff0a97cf4fe10d1b8dd18f2055927e,bfc81f7b74c0e72ba8819db5d11c6459,"['The compound 1-(pyrrolidin-1-yl)dodeca-2,4-dien-1-one has multiple targets including the A549, SK-BR-3 and KB cells.', 'The compound 1-(pyrrolidin-1-yl)dodeca-2,4-dien-1-one has multiple targets such as A549, SK-BR-3, and KB, suggesting potential applications in targeting these specific cellular entities.', 'The chemical compound 1-(pyrrolidin-1-yl)dodeca-2,4-dien-1-one targets a number of cell lines which includes A549, SK-BR-3, and KB.', 'The drug 1-(pyrrolidin-1-yl)dodeca-2,4-dien-1-one targets multiple cell lines, including A549, SK-BR-3, and KB.', 'The compound 1-(pyrrolidin-1-yl)dodeca-2,4-dien-1-one has been identified to target multiple cell lines, including A549, SK-BR-3, and KB.']",[]
"[{'source_node': {'name': 'MPL'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'primary myelofibrosis'}}, {'source_node': {'name': 'MPL'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'polycythemia vera'}}, {'source_node': {'name': 'MPL'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Platelet Aggregation (Plug Formation)'}}, {'source_node': {'name': 'primary myelofibrosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'portal hypertension'}}, {'source_node': {'name': 'primary myelofibrosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'venous thrombosis'}}, {'source_node': {'name': 'primary myelofibrosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autoimmune antibody positivity'}}]","[{'source_node': {'name': 'MPL'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'polycythemia vera'}}, {'source_node': {'name': 'primary myelofibrosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'venous thrombosis'}}, {'source_node': {'name': 'primary myelofibrosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autoimmune antibody positivity'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1059', 'target': None, 'metadata': {'node_id': '1059', 'node_type': 'PHENOTYPE', 'display_name': 'portal hypertension'}}, {'type': 'edge_deletion', 'source': 'GENE:29988', 'target': 'DISEASE:9704', 'metadata': None}, {'type': 'node_removal', 'source': 'PATHWAY:1127', 'target': None, 'metadata': {'node_id': '1127', 'node_type': 'PATHWAY', 'display_name': 'Platelet Aggregation (Plug Formation)'}}]",0.6153846153846154,9e03917a1f2986d49a262b08c8523853,9ad66a55f8156c4aa463947af3860ce2,[],"['The MPL gene has been identified as a cause of the medical condition known as polycythemia vera. Primary myelofibrosis, another haematological disease, exhibits phenotypes such as venous thrombosis and autoimmune antibody positivity. These characteristics emphasize the intricate pathophysiology associated with both conditions.', 'MPL is a gene that is known to cause a condition called polycythemia vera, a type of blood cancer. Likewise, primary myelofibrosis, another type of blood disorder, is associated with various phenotypes, notably venous thrombosis and autoimmune antibody positivity. These complex relationships demonstrate the intricate links between genetics and disease phenotypes.', 'The gene MPL is responsible for causing a condition known as polycythemia vera. Additionally, primary myelofibrosis, a disorder of the bone marrow, is characterized by certain phenotypes including venous thrombosis and autoimmune antibody positivity.', 'The gene MPL is known to cause a condition known as polycythemia vera. On another note, primary myelofibrosis, a type of cancer that affects the bone marrow, can present phenotypes such as venous thrombosis and autoimmune antibody positivity.', 'The gene MPL is responsible for causing the condition known as polycythemia vera. In a related vein, the disease primary myelofibrosis presents with two distinct phenotypes, autoimmune antibody positivity and venous thrombosis.']"
"[{'source_node': {'name': 'HAGH'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'glyoxalase ii deficiency'}}, {'source_node': {'name': 'HAGH'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pyruvate metabolism'}}, {'source_node': {'name': 'hydroxyacylglutathione hydrolase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HAGH'}}]","[{'source_node': {'name': 'HAGH'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'glyoxalase ii deficiency'}}, {'source_node': {'name': 'HAGH'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pyruvate metabolism'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:463', 'target': None, 'metadata': {'node_id': '463', 'node_type': 'PROTEIN', 'display_name': 'hydroxyacylglutathione hydrolase'}}]",0.7142857142857143,9a05f53d718bd70adbef041dd469d75d,cbd8db4d9ed4070a527de8addcdd3f0c,[],"['The gene HAGH, which is involved in pyruvate metabolism and contributes to the occurrence of glyoxalase II deficiency, a rare genetic metabolic disorder.', 'The gene HAGH, which acts within the pyruvate metabolism pathway, is known to cause the condition known as glyoxalase II deficiency.', 'The gene HAGH, which acts within the pyruvate metabolism pathway, is known to cause a condition known as Glyoxalase II deficiency.', 'The gene HAGH, which operates within the pyruvate metabolism pathway, is known to cause Glyoxalase II deficiency.', 'The gene HAGH, which plays a role within the pyruvate metabolism pathway, can cause a condition known as glyoxalase II deficiency.']"
"[{'source_node': {'name': 'ULK1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of TNFR1 signaling'}}, {'source_node': {'name': 'ULK1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'TBC/RABGAPs'}}, {'source_node': {'name': 'ULK1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RAB GEFs exchange GTP for GDP on RABs'}}]","[{'source_node': {'name': 'ULK1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'TBC/RABGAPs'}}, {'source_node': {'name': 'ULK1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RAB GEFs exchange GTP for GDP on RABs'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:304', 'target': None, 'metadata': {'node_id': '304', 'node_type': 'PATHWAY', 'display_name': 'Regulation of TNFR1 signaling'}}]",0.7142857142857143,71c96e72d32f9568d1e7fc801edc7d6e,471ef51b87e37af009e6655dae5770ae,"['The gene ULK1 acts within several biological pathways which include the regulation of TNFR1 signaling, TBC/RABGAPs, and the pathway where RAB GEFs exchange GTP for GDP on RABs.']",['The gene ULK1 operates within several pathways - it acts within the TBC/RABGAPs and is also involved in the RAB GEFs exchange of GTP for GDP on RABs pathway. The role of ULK1 in these pathways is essential for their normal function and efficient operation.']
"[{'source_node': {'name': 'epicorazine a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mgc-803'}}, {'source_node': {'name': 'epicorazine a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'k562'}}, {'source_node': {'name': 'epicorazine a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-116'}}]","[{'source_node': {'name': 'epicorazine a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-116'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5600', 'target': None, 'metadata': {'node_id': '5600', 'node_type': 'PROTEIN', 'display_name': 'mgc-803'}}, {'type': 'node_removal', 'source': 'PROTEIN:4947', 'target': None, 'metadata': {'node_id': '4947', 'node_type': 'PROTEIN', 'display_name': 'k562'}}]",0.4285714285714286,69bfde5c31405b388e94b0ac9e36cc3a,52ed3384c7cc0451cd8b4a7fae93ce8b,"['The drug Epicorazine A has been identified to target multiple elements, including MGC-803, K562 and HCT-116.', 'Epicorazine A is a compound known to target several biological entities including MGC-803, K562, and HCT-116.', 'The drug Epicorazine A targets multiple entities including MGC-803, K562, and HCT-116.', 'The drug Epicorazine A has several targets including MGC-803, K562, and HCT-116.', 'The drug Epicorazine A targets several entities, including the MGC-803, K562, and HCT-116. This indicates a potential therapeutic role for Epicorazine A in conditions associated with these targets.']","['The drug Epicorazine A has been identified to target HCT-116.', 'Epicorazine A has the cellular line HCT-116 as its target.']"
"[{'source_node': {'name': 'n-hydroxy-phip'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'udp-glucuronosyltransferase 1-7'}}, {'source_node': {'name': 'n-hydroxy-phip'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'udp-glucuronosyltransferase 1-9'}}, {'source_node': {'name': 'n-hydroxy-phip'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'udp-glucuronosyltransferase 1-1'}}, {'source_node': {'name': 'UGT1A9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glucuronidation'}}, {'source_node': {'name': 'udp-glucuronosyltransferase 1-7'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'UGT1A7'}}, {'source_node': {'name': 'udp-glucuronosyltransferase 1-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'UGT1A1'}}, {'source_node': {'name': 'udp-glucuronosyltransferase 1-9'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'UGT1A9'}}]","[{'source_node': {'name': 'n-hydroxy-phip'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'udp-glucuronosyltransferase 1-7'}}, {'source_node': {'name': 'n-hydroxy-phip'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'udp-glucuronosyltransferase 1-9'}}, {'source_node': {'name': 'n-hydroxy-phip'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'udp-glucuronosyltransferase 1-1'}}, {'source_node': {'name': 'UGT1A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glucuronidation'}}, {'source_node': {'name': 'UGT1A9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glucuronidation'}}, {'source_node': {'name': 'udp-glucuronosyltransferase 1-7'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'UGT1A7'}}, {'source_node': {'name': 'udp-glucuronosyltransferase 1-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'UGT1A1'}}, {'source_node': {'name': 'udp-glucuronosyltransferase 1-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'UGT1A7'}}, {'source_node': {'name': 'udp-glucuronosyltransferase 1-9'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'UGT1A9'}}]","[{'type': 'edge_addition', 'source': 'GENE:31198', 'target': 'PATHWAY:825', 'metadata': {'predicate': 'acts_within'}}, {'type': 'edge_addition', 'source': 'PROTEIN:4607', 'target': 'GENE:31181', 'metadata': {'predicate': 'gene_product_of'}}]",0.8666666666666667,03388b4d920c395a6242bd5977e8c587,98551686b1eb10701d69272c9bbef16c,"['The chemical compound N-Hydroxy-PHIP targets UDP-Glucuronosyltransferase 1-7, 1-9, and 1-1, which are gene products of UGT1A7, UGT1A9 and UGT1A1 respectively. Notably, UGT1A9 also participates within the domain of glucuronidation, a pathway that is crucial to the metabolism of many substances in the human body.', 'The compound N-Hydroxy-PHIP has multiple target enzymes, namely, UDP-glucuronosyltransferase 1-7, UDP-glucuronosyltransferase 1-9, and UDP-glucuronosyltransferase 1-1. These enzymes are gene products of UGT1A7, UGT1A9, and UGT1A1, respectively. Particularly, UGT1A9 acts within the metabolic process known as Glucuronidation.', ""The compound N-hydroxy-PHIP has various known targets such as UDP-glucuronosyltransferase 1-7, UDP-glucuronosyltransferase 1-9 and UDP-glucuronosyltransferase 1-1. It's interesting to note here that UDP-glucuronosyltransferase 1-7 is a gene product of UGT1A7, while UDP-glucuronosyltransferase 1-1 is a gene product of UGT1A1, and UDP-glucuronosyltransferase 1-9 is a gene product of UGT1A9. Additionally, UGT1A9 also acts within a process known as Glucuronidation adding more complexity to the relationships."", 'The compound N-Hydroxy-PHIP is known to target several proteins, namely UDP-glucuronosyltransferase 1-7, UDP-glucuronosyltransferase 1-9, and UDP-glucuronosyltransferase 1-1. Each of these proteins are gene products of different genes: UDP-glucuronosyltransferase 1-7 is a product of the UGT1A7 gene, UDP-glucuronosyltransferase 1-9 is a product of the UGT1A9 gene, and UDP-glucuronosyltransferase 1-1 is a product of the UGT1A1 gene. Additionally, the UGT1A9 gene acts within the biological process known as glucuronidation, a crucial part of drug metabolism in the human body.']","['N-hydroxy-PHIP is a compound that targets three different enzymes such as Udp-glucuronosyltransferase 1-7, Udp-glucuronosyltransferase 1-9, and Udp-glucuronosyltransferase 1-1. These enzymes are gene products of UGT1A7, UGT1A9, and UGT1A1 respectively. Interestingly, UGT1A1 and UGT1A9 play a significant role in glucuronidation, a key metabolic pathway in the body. Notably, Udp-glucuronosyltransferase 1-1 is a gene product of both UGT1A1 and UGT1A7.', 'The compound N-Hydroxy-PHIP is identified to target multiple enzymes including UDP-glucuronosyltransferase 1-7, UDP-glucuronosyltransferase 1-9, and UDP-glucuronosyltransferase 1-1. These enzymes are the gene products of the genes UGT1A7, UGT1A1, and UGT1A9, respectively. Notably, UGT1A1 and UGT1A9 are involved in the biological process of glucuronidation, a crucial pathway for drug and toxin metabolism in the body. Interestingly, UDP-glucuronosyltransferase 1-1 acts as the gene product of both UGT1A1 and UGT1A7, highlighting the overlapping genetic foundations of these key metabolic enzymes.', ""The compound N-Hydroxy-PHIP targets several enzymes including UDP-glucuronosyltransferase 1-7, UDP-glucuronosyltransferase 1-9, and UDP-glucuronosyltransferase 1-1. These enzymes are gene products of UGT1A7, UGT1A1, and UGT1A9 respectively. Interestingly, both UGT1A1 and UGT1A9 are known to act within the process of Glucuronidation. It's noteworthy that UDP-glucuronosyltransferase 1-1, a target for N-Hydroxy-PHIP, is a gene product not just of UGT1A1, but also UGT1A7. This complex interaction presents a potential pathway for the action of N-Hydroxy-PHIP.""]"
"[{'source_node': {'name': 'pipecuronium'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' reduced gastrointestinal motility '}}, {'source_node': {'name': 'pipecuronium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'aprotinin'}}, {'source_node': {'name': 'pipecuronium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'plantago seed'}}, {'source_node': {'name': 'plantago seed'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clidinium'}}, {'source_node': {'name': 'aprotinin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bevonium'}}, {'source_node': {'name': 'aprotinin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dihexyverine'}}, {'source_node': {'name': 'aprotinin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Pericarditis'}}]","[{'source_node': {'name': 'pipecuronium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'aprotinin'}}, {'source_node': {'name': 'plantago seed'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clidinium'}}, {'source_node': {'name': 'aprotinin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dihexyverine'}}, {'source_node': {'name': 'aprotinin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Pericarditis'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:9113', 'target': 'EFFECT:98', 'metadata': {'predicate': 'has_effect'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:1296', 'target': 'COMPOUND:9113', 'metadata': None}, {'type': 'node_removal', 'source': 'EFFECT:98', 'target': None, 'metadata': {'node_id': '98', 'node_type': 'EFFECT', 'display_name': ' reduced gastrointestinal motility '}}, {'type': 'node_removal', 'source': 'COMPOUND:11393', 'target': None, 'metadata': {'node_id': '11393', 'node_type': 'COMPOUND', 'display_name': 'bevonium'}}]",0.6666666666666667,f38045164d30273667619492736d9318,2f4a047d4c6c2297cb5468d075a1bd65,[],"['The drug Pipecuronium has been found to decrease the efficacy of Aprotinin. Similarly, Plantago seed also impacts the efficacy of Clidinium by reducing it. Furthermore, Aprotinin, besides having its efficacy decreased by Pipecuronium, also reduces the efficacy of Dihexyverine. Interestingly, Aprotinin has been associated with a side effect, causing Pericarditis in some cases.', 'Pipecuronium, a neuromuscular blocking agent, can decrease the efficacy of aprotinin, a medication used to reduce bleeding during complex surgery. Similarly, plantago seed, a medicinal herb, can reduce the efficacy of clidinium, a medication for gastrointestinal disorders. Intriguingly, the reduced efficacy of aprotinin can extend to dihexyverine, a muscle relaxant. Furthermore, aprotinin may lead to pericarditis, a potential side effect which causes inflammation of the lining around the heart.', 'Pipecuronium and Plantago seed are known to decrease the efficacy of aprotinin and clidinium respectively. Notably, aprotinin has also been observed to decrease the efficacy of dihexyverine. One should be cautious of combining these compounds or medicaments due to these interactions. Moreover, aprotinin could potentially have a side effect of Pericarditis, a condition which causes inflammation of the pericardium, the thin sac-like membrane surrounding your heart.']"
"[{'source_node': {'name': '10alpha-cucurbitadienol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-mel-1'}}, {'source_node': {'name': '10alpha-cucurbitadienol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': '10alpha-cucurbitadienol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}]","[{'source_node': {'name': '10alpha-cucurbitadienol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5861', 'target': None, 'metadata': {'node_id': '5861', 'node_type': 'PROTEIN', 'display_name': 'sk-mel-1'}}, {'type': 'node_removal', 'source': 'PROTEIN:5851', 'target': None, 'metadata': {'node_id': '5851', 'node_type': 'PROTEIN', 'display_name': 'mcf7'}}]",0.4285714285714286,cdeac5765893ef78ae6dff4648b6b9eb,54ea40aa0026a2bd98ce8473d2ac2283,"['The compound 10alpha-cucurbitadienol has been identified to target multiple cell lines including SK-MEL-1, MCF7, and HeLa.', 'The compound 10alpha-cucurbitadienol targets various cells such as SK-MEL-1, MCF7 and HeLa.', 'The compound 10alpha-cucurbitadienol targets several cell lines including SK-MEL-1, MCF7, and HeLa.', 'The compound 10alpha-cucurbitadienol targets several cells namely, the SK-MEL-1, MCF7 and HeLa cells.', 'The compound 10alpha-cucurbitadienol targets several cell lines, including SK-MEL-1, MCF7, and HeLA.']","['The compound 10alpha-cucurbitadienol has the human cancer cell line, HeLa, as its target.', 'The compound 10alpha-cucurbitadienol has Hela, a human cell line, as its target.']"
"[{'source_node': {'name': 'metocurine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'demecarium'}}, {'source_node': {'name': 'metocurine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'prucalopride'}}, {'source_node': {'name': 'atracurium besylate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'magnesium cation'}}, {'source_node': {'name': 'atracurium besylate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pivmecillinam'}}, {'source_node': {'name': 'atracurium besylate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lactitol'}}, {'source_node': {'name': 'magnesium acetate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'atracurium besylate'}}, {'source_node': {'name': 'magnesium acetate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'metocurine'}}, {'source_node': {'name': 'magnesium acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ethylmorphine'}}]","[{'source_node': {'name': 'ethylmorphine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lactitol'}}, {'source_node': {'name': 'atracurium besylate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pivmecillinam'}}, {'source_node': {'name': 'atracurium besylate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lactitol'}}, {'source_node': {'name': 'demecarium'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pivmecillinam'}}, {'source_node': {'name': 'magnesium acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ethylmorphine'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:11834', 'target': 'COMPOUND:1294', 'metadata': None}, {'type': 'edge_deletion', 'source': 'COMPOUND:11834', 'target': 'COMPOUND:716', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:1326', 'target': None, 'metadata': {'node_id': '1326', 'node_type': 'COMPOUND', 'display_name': 'magnesium cation'}}, {'type': 'edge_addition', 'source': 'COMPOUND:927', 'target': 'COMPOUND:1533', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1402', 'target': 'COMPOUND:10815', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:1294', 'target': None, 'metadata': {'node_id': '1294', 'node_type': 'COMPOUND', 'display_name': 'metocurine'}}]",0.4117647058823529,82cd5a2088db95cbc00bbdbb394d9c76,9af900fcf9140c0ff1699288b200328b,"['The drug metocurine decreases the efficacy of both demecarium and prucalopride. On the other hand, atracurium besylate increases the efficacy of magnesium cation and pivmecillinam but decreases the efficacy of lactitol. Interestingly, the efficacy of both atracurium besylate and metocurine is increased by magnesium acetate. However, magnesium acetate has a negative effect on ethylmorphine as it decreases its efficacy.', ""The effects of various compounds are interlinked and can modify each other's efficacy. For instance, metocurine is known to decrease the efficacy of certain substances such as demecarium and prucalopride. On the other hand, atracurium besylate enhances the efficacy of magnesium cation and pivmecillinam while decreasing the efficacy of lactitol. Meanwhile, magnesium acetate increases the efficacy of both atracurium besylate and metocurine and decreases the efficacy of ethylmorphine. Understanding these interactions could have important implications in clinical settings, as the efficacy of a drug can be influenced by the presence of others."", 'The drug metocurine is known to decrease the efficacy of both demecarium and prucalopride. In contrast, the drug atracurium besylate demonstrates the capability to increase the efficacy of magnesium cation and pivmecillinam, however, it also decreases the efficacy of lactitol. On the other hand, magnesium acetate not only enhances the efficacy of both atracurium besylate and metocurine, but it also reduces the efficacy of ethylmorphine. Therefore, the interactions and efficacy between these drugs should be thoroughly taken into account in a clinical setting to avoid any unintended effects or adverse reactions.', ""The drug metocurine has the effect of decreasing the efficacy of both demecarium and prucalopride. In contrast, atracurium besylate works differently; it increases the efficacy of magnesium cation and pivmecillinam. However, it's important to note that atracurium besylate also decreases the efficacy of lactitol. Similarly, magnesium acetate is known to increase the efficacy of atracurium besylate and metocurine. Yet, it has the opposite effect on ethylmorphine; it decreases its efficacy."", 'The drug Metocurine has been found to decrease the efficacy of Demecarium and Prucalopride. On the other hand, Atracurium Besylate is known to increase the efficacy of Magnesium Cation and Pivmecillinam, but reduces the efficacy of Lactitol. Furthermore, Magnesium Acetate is found to enhance the efficacy of Atracurium Besylate and Metocurine but reduces the effectiveness of Ethylmorphine.']","['Ethylmorphine, a potent drug, has been found to decrease the efficacy of lactitol. Interestingly, the medication atracurium besylate has a dichotomous effect on drug efficacy; while it has been shown to increase the efficacy of pivmecillinam, it simultaneously decreases the efficacy of lactitol. Similarly, the drug demecarium is also noted to increase the efficacy of pivmecillinam. However, another important interaction to consider is that of magnesium acetate and ethylmorphine, where the former decreases the efficacy of the latter. This highlighted network of drug interactions is essential to consider when prescribing these treatment regimens.', 'The efficacy of various drugs can be influenced by their interaction with other drugs. For example, the efficacy of lactitol can be decreased by ethylmorphine and atracurium besylate. Notably, the effectiveness of ethylmorphine itself could be diminished by magnesium acetate. Conversely, the potency of pivmecillinam can be enhanced when used concurrently with atracurium besylate and demecarium. Careful consideration of these interactions is essential to ensure optimal drug efficiency.', 'The use of ethylmorphine has been found to decrease the efficacy of lactitol. Conversely, the application of atracurium besylate appears to have contrasting results on different drugs; it enhances the efficacy of pivmecillinam, yet decreases the efficacy of lactitol. Similarly, demecarium increases the efficacy of pivmecillinam. Lastly, the use of magnesium acetate decreases the efficacy of ethylmorphine.', 'Ethylmorphine is a substance that has been found to decrease the efficacy of lactitol. In contrast, the drug atracurium besylate both increases the efficacy of pivmecillinam and decreases the efficacy of lactitol. Similarly, demecarium also increases the efficacy of pivmecillinam. On the other hand, magnesium acetate has an opposite effect on ethylmorphine, as it decreases its efficacy. In summary, the interactions between these substances are complex and affect their efficacy in different ways.', 'The drug ethylmorphine has been noted to decrease the efficacy of lactitol, a substance which has its efficacy decreased as well by atracurium besylate. This same drug, atracurium besylate, can conversely increase the efficacy of pivmecillinam, a reaction also observed when pivmecillinam is treated with demecarium. Interestingly, the efficacy of ethylmorphine itself is lessened when it is combined with magnesium acetate.']"
"[{'source_node': {'name': 'glioma susceptibility 3'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'astrocytoma'}}, {'source_node': {'name': 'glioma susceptibility 3'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 't-cell acute lymphoblastic leukemias'}}, {'source_node': {'name': 'glioma susceptibility 3'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'medulloblastoma'}}]","[{'source_node': {'name': 'glioma susceptibility 3'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'astrocytoma'}}, {'source_node': {'name': 'glioma susceptibility 3'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 't-cell acute lymphoblastic leukemias'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:2089', 'target': None, 'metadata': {'node_id': '2089', 'node_type': 'PHENOTYPE', 'display_name': 'medulloblastoma'}}]",0.7142857142857143,79ec93b245acfd4e43ebe2baee747923,265797217855cd28a6a8f12edfff77e8,"['The condition known as Glioma Susceptibility 3 has various phenotypes which are linked to multiple forms of cancer. Some of these include astrocytoma, T-cell acute lymphoblastic leukemias, and medulloblastoma.', '""Glioma Susceptibility 3, a genetic variant, has been associated with several phenotypic manifestations including cancers like astrocytoma, t-cell acute lymphoblastic leukemias, and medulloblastoma.']","['The gene known as glioma susceptibility 3 presents two distinct phenotypes, astrocytoma and T-cell acute lymphoblastic leukemias. These phenotypes signify different types of cancers that can potentially be triggered by this gene.', 'Glioma susceptibility 3, a genetic trait, has been found to be associated with two cancer phenotypes:  astrocytoma, which is a common type of brain tumor, and T-cell acute lymphoblastic leukemias, a type of leukemia characterized by the overproduction of T cell lymphocytes.']"
"[{'source_node': {'name': '8(14)-podocarpen-13-on-18-oic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': '72 kda type iv collagenase'}}, {'source_node': {'name': 'MMP2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'multicentric osteolysis'}}, {'source_node': {'name': 'MMP2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Degradation of the extracellular matrix'}}, {'source_node': {'name': 'MMP2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Extra-nuclear estrogen signaling'}}, {'source_node': {'name': '72 kda type iv collagenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MMP2'}}, {'source_node': {'name': 'multicentric osteolysis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'short stature'}}, {'source_node': {'name': 'multicentric osteolysis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'delayed closure of the anterior fontanelle'}}]","[{'source_node': {'name': 'MMP2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Degradation of the extracellular matrix'}}, {'source_node': {'name': 'MMP2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Extra-nuclear estrogen signaling'}}]","[{'type': 'edge_deletion', 'source': 'GENE:29960', 'target': 'DISEASE:14398', 'metadata': None}, {'type': 'node_removal', 'source': 'DISEASE:14398', 'target': None, 'metadata': {'node_id': '14398', 'node_type': 'DISEASE', 'display_name': 'multicentric osteolysis'}}, {'type': 'node_removal', 'source': 'PROTEIN:1383', 'target': None, 'metadata': {'node_id': '1383', 'node_type': 'PROTEIN', 'display_name': '72 kda type iv collagenase'}}]",0.3333333333333333,3aebf1578d5f4776c8129107386003ea,e3d07fb99e61c014776dda3d27981b65,"[""The drug 8(14)-podocarpen-13-on-18-oic acid has a target, known as the 72 kda type iv collagenase. This collagenase is a gene product of the gene MMP2. Interestingly, MMP2 acts within several physiological processes, including the degradation of the extracellular matrix and extra-nuclear estrogen signaling. Consequently, MMP2 is known to cause multicentric osteolysis, a condition associated with phenotypes such as short stature and delayed closure of the anterior fontanelle. Therefore, there's a clear chain of causative and correlative relationships between the action of this drug, the functioning of a specific gene, and the manifestation of certain physical attributes."", 'The compound 8(14)-podocarpen-13-on-18-oic acid has a target known as the 72 kDa type IV collagenase. This collagenase is a gene product of MMP2, a gene that operates within diverse pathways, including the degradation of the extracellular matrix and extra-nuclear estrogen signaling. Furthermore, the MMP2 gene has been linked to the development of a condition characterized as multicentric osteolysis. Those afflicted with multicentric osteolysis often exhibit symptoms such as short stature and delayed closure of the anterior fontanelle.', 'The 8(14)-podocarpen-13-on-18-oic acid targets the 72 kda type iv collagenase, which is a gene product of MMP2. This gene, MMP2, is known to act within two pathways - the degradation of the extracellular matrix and extra-nuclear estrogen signaling. In addition, MMP2 is responsible for causing a condition known as multicentric osteolysis. This disease is characterized by a series of phenotypes, including short stature and a delayed closure of the anterior fontanelle.', ""The compound 8(14)-podocarpen-13-on-18-oic acid targets a biological structure called 72 kda type iv collagenase. This collagenase is the gene product of MMP2 which acts within various pathways such as degradation of the extracellular matrix and extra-nuclear estrogen signaling. Within this context, it's worth mentioning that MMP2 is capable of causing a condition called multicentric osteolysis. This disease is characterized by various phenotypes, most notably short stature and a delayed closure of the anterior fontanelle."", 'The compound 8(14)-podocarpen-13-on-18-oic acid has a specific target, the 72 kDa type IV collagenase. This enzyme is the gene product of MMP2, a gene which acts within numerous pathways, specifically the degradation of the extracellular matrix and extra-nuclear estrogen signaling. Aberrations in the behavior of MMP2 can lead to multicentric osteolysis. Such a health condition is characterized by phenotypical symptoms like short stature and delayed closure of the anterior fontanelle.']","['The gene MMP2 operates within multiple biological pathways. One of its significant roles is in the degradation of the extracellular matrix, aiding the breakdown and recycling of tissue structures. Additionally, MMP2 acts within the extra-nuclear estrogen signaling process, which is crucial for transmitting hormone responses.', 'The molecule MMP2 plays a critical role in multiple biological processes. It acts within the pathway for degradation of the extracellular matrix, ultimately impacting the structural integrity of tissues. Moreover, it also acts within the pathway for extra-nuclear estrogen signaling, which has significant implications for hormonal regulation and cellular responses.', 'The gene MMP2 acts within the degradation of the extracellular matrix and extra-nuclear estrogen signaling pathways.', 'The gene MMP2 is known to act within several pathways, including the degradation of the extracellular matrix and extra-nuclear estrogen signaling.', 'The gene MMP2 acts within several pathways. It plays a role in the degradation of the extracellular matrix and is involved in extra-nuclear estrogen signaling.']"
"[{'source_node': {'name': 'nuclear receptor subfamily 1 group d member 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR1D2'}}, {'source_node': {'name': 'nuclear receptor subfamily 1 group d member 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR1D1'}}, {'source_node': {'name': 'NR1D1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'PPARA activates gene expression'}}, {'source_node': {'name': 'NR1D1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nuclear Receptor transcription pathway'}}, {'source_node': {'name': 'sr-9009'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear receptor subfamily 1 group d member 1'}}, {'source_node': {'name': 'sr-9009'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear receptor subfamily 1 group d member 2'}}]","[{'source_node': {'name': 'nuclear receptor subfamily 1 group d member 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR1D2'}}, {'source_node': {'name': 'nuclear receptor subfamily 1 group d member 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR1D1'}}, {'source_node': {'name': 'NR1D2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'PPARA activates gene expression'}}, {'source_node': {'name': 'NR1D1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'PPARA activates gene expression'}}, {'source_node': {'name': 'sr-9009'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear receptor subfamily 1 group d member 1'}}, {'source_node': {'name': 'sr-9009'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear receptor subfamily 1 group d member 2'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:42', 'target': None, 'metadata': {'node_id': '42', 'node_type': 'PATHWAY', 'display_name': 'Nuclear Receptor transcription pathway'}}, {'type': 'edge_addition', 'source': 'GENE:35772', 'target': 'PATHWAY:39', 'metadata': {'predicate': 'acts_within'}}]",0.7692307692307692,7b00dbfb484a79001e9cb1d0b4b60ecf,3afd3662860713403494c90a514fcdb5,[],[]
"[{'source_node': {'name': 'norgestimate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phenoxymethylpenicillin'}}, {'source_node': {'name': 'norgestimate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'repaglinide'}}, {'source_node': {'name': 'norgestimate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'meticillin'}}, {'source_node': {'name': 'phenoxymethylpenicillin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' methemoglobinemia '}}, {'source_node': {'name': 'phenoxymethylpenicillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ormeloxifene'}}]","[{'source_node': {'name': 'repaglinide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ormeloxifene'}}, {'source_node': {'name': 'norgestimate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'repaglinide'}}, {'source_node': {'name': 'norgestimate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'meticillin'}}, {'source_node': {'name': 'norgestimate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ormeloxifene'}}, {'source_node': {'name': 'ormeloxifene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phenoxymethylpenicillin'}}, {'source_node': {'name': 'phenoxymethylpenicillin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' methemoglobinemia '}}, {'source_node': {'name': 'phenoxymethylpenicillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ormeloxifene'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:940', 'target': 'COMPOUND:11166', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:895', 'target': 'COMPOUND:11166', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:940', 'target': 'COMPOUND:405', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:11166', 'target': 'COMPOUND:405', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.6363636363636364,00034729699aae44bab690adb89343ea,21bc1c24b147365f8def9b8f9967d962,[],[]
"[{'source_node': {'name': 'carteolol'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hypotensive activities '}}, {'source_node': {'name': 'carteolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'cyclothiazide'}}, {'source_node': {'name': 'carteolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'cyclopenthiazide'}}, {'source_node': {'name': 'cyclopenthiazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'etodolac'}}, {'source_node': {'name': 'cyclopenthiazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ibuprofen'}}]","[{'source_node': {'name': 'carteolol'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hypotensive activities '}}, {'source_node': {'name': 'carteolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'cyclothiazide'}}, {'source_node': {'name': 'carteolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'cyclopenthiazide'}}, {'source_node': {'name': 'carteolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'etodolac'}}, {'source_node': {'name': 'cyclothiazide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'ibuprofen'}}, {'source_node': {'name': 'cyclopenthiazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'etodolac'}}, {'source_node': {'name': 'cyclopenthiazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ibuprofen'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:592', 'target': 'COMPOUND:1031', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:507', 'target': 'COMPOUND:733', 'metadata': {'predicate': 'increase_efficacy'}}]",0.8181818181818181,5f2b0d32dbaf50b5e08ec98066749cad,0860fccbe197236a612c4f486f350775,[],[]
"[{'source_node': {'name': 'deslorelin'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' effectiveness '}}, {'source_node': {'name': 'deslorelin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'corifollitropin alfa'}}, {'source_node': {'name': 'corifollitropin alfa'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'leuprolide'}}, {'source_node': {'name': 'corifollitropin alfa'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'goserelin'}}, {'source_node': {'name': 'corifollitropin alfa'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'histrelin'}}]","[{'source_node': {'name': 'deslorelin'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' effectiveness '}}, {'source_node': {'name': 'corifollitropin alfa'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'leuprolide'}}, {'source_node': {'name': 'corifollitropin alfa'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'histrelin'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:14', 'target': None, 'metadata': {'node_id': '14', 'node_type': 'COMPOUND', 'display_name': 'goserelin'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:9453', 'target': 'COMPOUND:8006', 'metadata': None}]",0.7272727272727273,b99fe4f575c4e2c40fe235391edea4fd,0519429b3d61a29164cfb7858307a15f,[],[]
"[{'source_node': {'name': 'melphalan'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tick-borne encephalitis vaccine (whole virus'}}, {'source_node': {'name': 'melphalan'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Muscle atrophy'}}, {'source_node': {'name': 'melphalan'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Hepatobiliary disease'}}, {'source_node': {'name': 'tick-borne encephalitis vaccine (whole virus'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'difluocortolone'}}]","[{'source_node': {'name': 'melphalan'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Muscle atrophy'}}, {'source_node': {'name': 'melphalan'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Hepatobiliary disease'}}, {'source_node': {'name': 'melphalan'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'difluocortolone'}}, {'source_node': {'name': 'tick-borne encephalitis vaccine (whole virus'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'difluocortolone'}}, {'source_node': {'name': 'tick-borne encephalitis vaccine (whole virus'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Hepatobiliary disease'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1023', 'target': 'COMPOUND:8035', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:13745', 'target': 'SIDE_EFFECT:134', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:1023', 'target': 'COMPOUND:13745', 'metadata': None}]",0.6666666666666667,4b6f87caa659059db5e233b6308fe573,298b232d5a05f22a073349fa4646bff3,[],[]
"[{'source_node': {'name': 'remurin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hsc-2'}}, {'source_node': {'name': 'remurin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hsc-4'}}]","[{'source_node': {'name': 'remurin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hsc-4'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5860', 'target': None, 'metadata': {'node_id': '5860', 'node_type': 'PROTEIN', 'display_name': 'hsc-2'}}]",0.6,0f381503c3344b07a280257b70306bc4,45d729dc9f3d41f45897f1ec72a47126,"['The drug Remurin A is known to target both HSC-2 and HSC-4.', 'The compound Remurin A targets both HSC-2 and HSC-4.', 'The compound remurin a targets both hsc-2 and hsc-4.', 'The drug Remurin A has targets including the proteins HSC-2 and HSC-4.', 'The drug Remurin A has multiple cellular targets, including HSC-2 and HSC-4.']",['The drug Remurin A has been found to target HSC-4.']
"[{'source_node': {'name': 'nitric oxide synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NOS2'}}, {'source_node': {'name': 'nitric oxide synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NOS3'}}, {'source_node': {'name': 'nitric oxide synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NOS1'}}, {'source_node': {'name': 'NOS1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nitric oxide stimulates guanylate cyclase'}}, {'source_node': {'name': '2-aminothiazoline'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nitric oxide synthase'}}]","[{'source_node': {'name': 'nitric oxide synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NOS2'}}, {'source_node': {'name': 'nitric oxide synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NOS3'}}, {'source_node': {'name': 'nitric oxide synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NOS1'}}, {'source_node': {'name': '2-aminothiazoline'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'NOS2'}}]","[{'type': 'edge_addition', 'source': 'GENE:30310', 'target': 'PATHWAY:1725', 'metadata': {'predicate': 'acts_within'}}, {'type': 'edge_addition', 'source': 'COMPOUND:2210', 'target': 'GENE:30310', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:2210', 'target': 'PROTEIN:285', 'metadata': None}, {'type': 'node_removal', 'source': 'PATHWAY:1725', 'target': None, 'metadata': {'node_id': '1725', 'node_type': 'PATHWAY', 'display_name': 'Nitric oxide stimulates guanylate cyclase'}}]",0.6363636363636364,17d2a9ea3f363f78227ca403fe89698a,3ec9b9bb30e7d6be2f99879bc3fc6fa0,"['Nitric oxide synthase is a gene product of NOS1, NOS2, and NOS3. Particularly, NOS1 acts within the pathway in which nitric oxide stimulates guanylate cyclase. Furthermore, the compound 2-aminothiazoline specifically targets nitric oxide synthase.', 'The enzyme nitric oxide synthase is a gene product of NOS1, NOS2, and NOS3. Among these, NOS1 acts within the pathway where nitric oxide stimulates guanylate cyclase. Additionally, 2-aminothiazoline directly targets nitric oxide synthase.']",[]
"[{'source_node': {'name': 'tipranavir'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Haemorrhage intracranial'}}, {'source_node': {'name': 'atoltivimab'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'envelope glycoprotein'}}, {'source_node': {'name': 'atoltivimab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'atoltivimab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vaccine live'}}, {'source_node': {'name': 'typhoid vaccine live'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'betamethasone'}}, {'source_node': {'name': 'typhoid vaccine live'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tipranavir'}}, {'source_node': {'name': 'typhoid vaccine live'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'abacavir'}}]","[{'source_node': {'name': 'tipranavir'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Haemorrhage intracranial'}}, {'source_node': {'name': 'atoltivimab'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'envelope glycoprotein'}}, {'source_node': {'name': 'atoltivimab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'typhoid vaccine live'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tipranavir'}}, {'source_node': {'name': 'typhoid vaccine live'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'abacavir'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:13278', 'target': 'COMPOUND:9074', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:431', 'target': None, 'metadata': {'node_id': '431', 'node_type': 'COMPOUND', 'display_name': 'betamethasone'}}]",0.8,da12c604baae4f80f939dd63fab1f739,976bc3362bfe0aa8d50030540e28b10e,[],[]
"[{'source_node': {'name': 'trimipramine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nylidrin'}}, {'source_node': {'name': 'trimipramine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'synephrine'}}, {'source_node': {'name': 'trimipramine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 1 subfamily a member 2'}}]","[{'source_node': {'name': 'synephrine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trimipramine'}}, {'source_node': {'name': 'trimipramine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nylidrin'}}, {'source_node': {'name': 'trimipramine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'synephrine'}}, {'source_node': {'name': 'trimipramine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 1 subfamily a member 2'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:8138', 'target': 'COMPOUND:711', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.8571428571428572,8a51d1b6aadb846b62bf817b2d3ea35e,a9e93fd6f2f0d56a89e9156aaca73d98,"['Trimipramine, a widely used medication, has been shown to decrease the efficacy of multiple agents, such as nylidrin and synephrine. Concurrently, trimipramine also affects the function of a specific enzyme called cytochrome P450 family 1 subfamily A member 2. This knowledge suggests that the overall therapeutic effectiveness of nylidrin and synephrine may be adversely affected when used in conjunction with trimipramine due to its capability to modulate this relevant enzyme. This interaction requires further investigation to clarify the potential clinical implications.', 'The drug trimipramine has been observed to decrease the efficacy of nylidrin and synephrine. Moreover, it seems to affect the cytochrome p450 family 1 subfamily a member 2. This suggests that caution may be required when prescribing trimipramine in conjunction with either nylidrin or synephrine, particularly in patients with specific cytochrome p450 configurations.', 'The drug Trimipramine has several impacts on the body. Not only does it decrease the efficacy of Nylidrin and Synephrine, two other medications, but it also affects the Cytochrome P450 family 1 subfamily A member 2, a group of enzymes involved in drug metabolism in the body. This could potentially put patients at risk if they are taking these medications in combination with Trimipramine, as their effectiveness may be reduced.', 'The drug trimipramine is known to decrease the efficacy of both nylidrin and synephrine. Additionally, it has been found to affect the enzyme, cytochrome p450 family 1 subfamily a member 2.', 'The drug Trimipramine has been observed to decrease the efficacy of both Nylidrin and Synephrine. Additionally, Trimipramine is known to affect the function of the enzyme Cytochrome P450 Family 1 Subfamily A Member 2.']","['The drug synephrine is known to decrease the efficacy of trimipramine, which in turn, decreases the efficacy of both nylidrin and synephrine itself. It is interesting to note that trimipramine affects the function of an important enzyme, cytochrome p450 family 1 subfamily a member 2, further complicating the drug interactions.', 'The use of Synephrine, a naturally occurring alkaloid, has been found to decrease the efficacy of Trimipramine, an antidepressant medication. Intriguingly, the converse is also true: Trimipramine can decrease the efficacy of both Nylidrin, a medication used to treat blood vessel disorders, and Synephrine. The effects of Trimipramine are also noteworthy as it influences the enzyme Cytochrome P450 Family 1 Subfamily A Member 2, implicated in drug metabolism. Therefore, it seems there is a complex interplay between the effects of these drugs and their effect on biological systems.', 'The compound synephrine can decrease the efficacy of the drug trimipramine. Interestingly, trimipramine has a similar impact on two other substances, namely nylidrin and synephrine itself. Trimipramine also has the ability to influence the cytochrome P450 family 1 subfamily A member 2.', 'The compound synephrine has been shown to decrease the efficacy of trimipramine. Coincidentally, findings also point to trimipramine reducing the efficacy of nylidrin and reciprocally, synephrine. In addition to these interactions, trimipramine directly affects the function of a specific enzyme known as the cytochrome p450 family 1 subfamily a member 2.']"
"[{'source_node': {'name': 'lyngbyastatin 7'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'neutrophil elastase'}}, {'source_node': {'name': 'lyngbyastatin 7'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'beas-2b'}}, {'source_node': {'name': 'ELANE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Degradation of the extracellular matrix'}}, {'source_node': {'name': 'ELANE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}, {'source_node': {'name': 'neutrophil elastase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ELANE'}}]","[{'source_node': {'name': 'beas-2b'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ELANE'}}, {'source_node': {'name': 'lyngbyastatin 7'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'neutrophil elastase'}}, {'source_node': {'name': 'lyngbyastatin 7'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'beas-2b'}}, {'source_node': {'name': 'lyngbyastatin 7'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'ELANE'}}, {'source_node': {'name': 'ELANE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Degradation of the extracellular matrix'}}, {'source_node': {'name': 'ELANE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}, {'source_node': {'name': 'neutrophil elastase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ELANE'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:46336', 'target': 'GENE:26709', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:6544', 'target': 'GENE:26709', 'metadata': {'predicate': 'gene_product_of'}}]",0.8181818181818181,72d1f1a285e8d92afb5ec7ffab365d15,b28ea746087e16d602cfa15b89ddb2b8,"['The drug Lyngbyastatin 7 targets both neutrophil elastase and BEAS-2B. Notably, neutrophil elastase is a gene product of ELANE. ELANE acts within two notable pathways, namely the degradation of the extracellular matrix and neutrophil degranulation.', 'Lyngbyastatin 7, a potent biochemical element, has multiple targets including neutrophil elastase and BEAS-2B. More specifically, neutrophil elastase is a gene product of ELANE - a significant entity that plays a role in several biological processes. ELANE is known to act within two primary systems, thereby contributing to the degradation of the extracellular matrix and also encouraging neutrophil degranulation. This intricate network of interactions and functions forms the foundation of several essential functions within cellular biology.', 'Lyngbyastatin 7 is a compound that has been shown to target both neutrophil elastase and a cell type known as beas-2b. Interestingly, neutrophil elastase is a gene product of ELANE, a gene implicated in several biological pathways. More specifically, ELANE acts within two pathways: degradation of the extracellular matrix and neutrophil degranulation. This intricate web of interactions highlights the complexity of cellular and molecular processes.', 'The drug Lyngbyastatin 7 targets both the neutrophil elastase and beas-2b. Neutrophil elastase is a gene product of ELANE, which acts within several processes such as degradation of the extracellular matrix and neutrophil degranulation.', 'The drug Lyngbyastatin 7 targets both the Neutrophil Elastase and BEAS-2B. Neutrophil Elastase is a protein that is a gene product of the ELANE gene. The ELANE gene typically acts within two processes in the body, including the degradation of the extracellular matrix and neutrophil degranulation.']","['Beas-2b is a gene product of ELANE, a gene that acts within both the degradation of the extracellular matrix and neutrophil degranulation processes. Interestingly, LYNGBYASTATIN 7 is a compound that targets beas-2b and also neutrophil elastase, another gene product of ELANE. Notably, the effect of lyngbyastatin 7 extends even to influencing ELANE itself, creating a complex network of interactions.']"
"[{'source_node': {'name': '3,5-diiodotyrosine'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' Cardiac Arrhythmia '}}, {'source_node': {'name': '3,5-diiodotyrosine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trazodone'}}, {'source_node': {'name': '3,5-diiodotyrosine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'entrectinib'}}, {'source_node': {'name': 'saracatinib'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' Thrombosis '}}, {'source_node': {'name': 'saracatinib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '3,5-diiodotyrosine'}}, {'source_node': {'name': 'saracatinib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'teriparatide'}}]","[{'source_node': {'name': '3,5-diiodotyrosine'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' Cardiac Arrhythmia '}}, {'source_node': {'name': '3,5-diiodotyrosine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trazodone'}}, {'source_node': {'name': 'saracatinib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '3,5-diiodotyrosine'}}, {'source_node': {'name': 'saracatinib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'teriparatide'}}]","[{'type': 'node_removal', 'source': 'EFFECT:7', 'target': None, 'metadata': {'node_id': '7', 'node_type': 'EFFECT', 'display_name': ' Thrombosis '}}, {'type': 'node_removal', 'source': 'COMPOUND:9897', 'target': None, 'metadata': {'node_id': '9897', 'node_type': 'COMPOUND', 'display_name': 'entrectinib'}}]",0.6923076923076923,7345042b7994ab22d19c52579bcc042b,18ac6bbf9f5bce55874c4a6838e91215,[],[]
"[{'source_node': {'name': 'pontocerebellar hypoplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'oligohydramnios'}}, {'source_node': {'name': 'pontocerebellar hypoplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'high palate'}}, {'source_node': {'name': 'pontocerebellar hypoplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'low anterior hairline'}}, {'source_node': {'name': 'EXOSC9'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pontocerebellar hypoplasia'}}, {'source_node': {'name': 'EXOSC9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': ""mRNA decay by 3' to 5' exoribonuclease""}}, {'source_node': {'name': 'EXOSC9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'KSRP (KHSRP) binds and destabilizes mRNA'}}]","[{'source_node': {'name': 'pontocerebellar hypoplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'oligohydramnios'}}, {'source_node': {'name': 'pontocerebellar hypoplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'high palate'}}, {'source_node': {'name': 'pontocerebellar hypoplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'low anterior hairline'}}, {'source_node': {'name': 'EXOSC9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'KSRP (KHSRP) binds and destabilizes mRNA'}}]","[{'type': 'edge_deletion', 'source': 'GENE:31071', 'target': 'DISEASE:17169', 'metadata': None}, {'type': 'node_removal', 'source': 'PATHWAY:847', 'target': None, 'metadata': {'node_id': '847', 'node_type': 'PATHWAY', 'display_name': ""mRNA decay by 3' to 5' exoribonuclease""}}]",0.7692307692307692,785e6962a9bf07c1bf473b16bc294d4d,467a2a884a01fc0366941e6992162160,[],"['Pontocerebellar hypoplasia, a neurological condition, has various phenotypical expressions, such as oligohydramnios, which is a low level of amniotic fluid, a high palate, and a distinctive low anterior hairline. Furthermore, the gene EXOSC9 is active within the biological pathway where KSRP (KHSRP) binds and destabilizes mRNA, contributing to the overall understanding of this complex disease.', 'Pontocerebellar hypoplasia is a condition associated with several phenotypes including oligohydramnios, a high palate, and a low anterior hairline. Meanwhile, the gene EXOSC9 is known to function within the pathway in which KSRP (KHSRP) binds and destabilizes mRNA.', 'Pontocerebellar hypoplasia, a neurological condition, has several phenotypes that include oligohydramnios, a condition characterized by low levels of amniotic fluid, a high palate, and a low anterior hairline. Furthermore, the gene EXOSC9 is known to act within the pathway where KSRP (KHSRP) binds and destabilizes mRNA, potentially influencing the manifestation of these symptoms.']"
"[{'source_node': {'name': 'prednisolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mefloquine'}}, {'source_node': {'name': 'prednisolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ingn 225'}}, {'source_node': {'name': 'prednisolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'durvalumab'}}, {'source_node': {'name': 'mefloquine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clonazepam'}}, {'source_node': {'name': 'mefloquine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'flavoxate'}}, {'source_node': {'name': 'mefloquine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'difemerine'}}, {'source_node': {'name': 'ingn 225'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dacarbazine'}}, {'source_node': {'name': 'ingn 225'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '2-methoxyethanol'}}]","[{'source_node': {'name': 'prednisolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ingn 225'}}, {'source_node': {'name': 'prednisolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'durvalumab'}}, {'source_node': {'name': 'mefloquine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clonazepam'}}, {'source_node': {'name': 'mefloquine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'flavoxate'}}, {'source_node': {'name': 'mefloquine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'difemerine'}}, {'source_node': {'name': 'difemerine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'durvalumab'}}, {'source_node': {'name': 'ingn 225'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dacarbazine'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:843', 'target': 'COMPOUND:347', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:2644', 'target': 'COMPOUND:843', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:2644', 'target': None, 'metadata': {'node_id': '2644', 'node_type': 'COMPOUND', 'display_name': '2-methoxyethanol'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11236', 'target': 'COMPOUND:9633', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.7647058823529411,cef6a274752de8e6da274950cd023fda,a4bd0104aa77f89294b7b244c64754df,"['Prednisolone, an often-prescribed medication, has been found to decrease the efficacy of several other drugs including mefloquine, ingn 225, and durvalumab. Similarly, mefloquine also lessens the efficacy of certain medications such as clonazepam, flavoxate, and difemerine. Interestingly, ingn 225 as well appears to lower the efficacy of certain drugs, specifically dacarbazine and 2-methoxyethanol. This intricate web of drug interactions underscores the importance of considering potential pharmaceutical interactions when prescribing medications.', 'Prednisolone is a drug known to decrease the efficacy of other treatment agents such as mefloquine, ingn 225, and durvalumab. Similarly, mefloquine also has the potential to decrease the effectiveness of certain medications like clonazepam, flavoxate, and difemerine. The influence of ingn 225 is observed on the effectiveness of other drugs as well; it can decrease the efficacy of dacarbazine and 2-methoxyethanol. All these interactions should be taken into consideration while prescribing a combination therapy involving any of these drugs.', 'The drug prednisolone has been found to decrease the efficacy of several other drugs, specifically mefloquine, ingn 225, and durvalumab. Similarly, mefloquine also has been observed to decrease the efficacy of certain drugs including clonazepam, flavoxate, and difemerine. Owing to its nature of decreasing drug efficacy, ingn 225 is also associated with reduced effectiveness of dacarbazine and 2-methoxyethanol.', 'Prednisolone is a medication that has been found to diminish the efficacy of other drugs, including mefloquine, INGN 225, and durvalumab. Similarly, mefloquine also reduces the effectiveness of certain medications such as clonazepam, flavoxate, and difemerine. Dacarbazine and 2-methoxyethanol, on the other hand, have decreased efficacy due to the presence of INGN 225. Hence, any clinical use of these drugs must consider potential interactions with prednisolone, mefloquine and INGN 225.', 'The drug Prednisolone has been observed to decrease the efficacy of several other substances, including Mefloquine, Ingn 225, and Durvalumab. Interestingly, this effect is not limited to Prednisolone. Mefloquine, in turn, has the same decreasing efficacy effect on Clonazepam, Flavoxate, and Difemerine. Similarly, Ingn 225 also shows a decrease in efficacy when interacting with Dacarbazine and 2-Methoxyethanol. This cascading reduction in effectiveness underscores the complex interactions that can occur between different drugs and compounds within the body.']","['The drug prednisolone is known to decrease the efficacy of both INGN 225 and durvalumab. Another drug, mefloquine, also has a similar impact, leading to decreased efficacy of clonazepam, flavoxate and difemerine. Interestingly, difemerine, in turn decreases the efficacy of durvalumab, demonstrating a complex interplay of these drugs. Furthermore, INGN 225 has an impact on dacarbazine, as it reduces its efficacy, adding another layer to the intricate interactions among these compounds.', ""The medication prednisolone has been found to decrease the efficacy of both INGN 225 and durvalumab. Additionally, mefloquine is known to impair the outcomes of clonazepam, flavoxate, and difemerine. Surprisingly, difemerine also has a similar dampening effect on the efficiency of durvalumab. Lastly, INGN 225 lowers the success rate of dacarbazine. It's clear there are intricate interplays between these medications and the need for careful consideration when they are prescribed in combination."", ""Prednisolone, a widely used corticosteroid, is known to decrease the efficacy of certain medications including INGN 225 and Durvalumab, which are both used as immunotherapy drugs in the treatment of cancer. Likewise, the antimalarial drug Mefloquine, not only reduces the efficacy of Clonazepam, a well-known medication for seizure disorders, and Flavoxate, used for urinary bladder disorders, but it also decreases the effectiveness of Difemerine. It's important to note that Difemerine in turn has been found to compromise the efficacy of Durvalumab. Interestingly, INGN 225 also appears to affect the performance of Dacarbazine, a chemotherapy drug used for treating various types of cancer. These interactions underline the importance of taking drug interactions into account in clinical practice."", ""The drugs prednisolone and mefloquine decrease the efficacy of several other medications. Prednisolone impacts INGN 225 and durvalumab, potentially reducing their effectiveness. Similarly, mefloquine is also known to reduce the efficacy of clonazepam, flavoxate, and difemerine. Interestingly, difemerine might exhibit decreased efficacy when exposed to mefloquine and also durvalumab. Furthermore, INGN 225's efficacy can diminish when it interacts with prednisolone or dacarbazine."", ""The medications prednisolone and mefloquine share a property where they decrease the efficacy of other drugs. Prednisolone tends to decrease the potency of both INGN 225 and durvalumab. On the other hand, mefloquine can diminish the efficacy of clonazepam, flavoxate, and difemerine. Interestingly, the drug difemerine also has the potential to reduce the efficacy of durvalumab. Furthermore, INGN 225 is found to limit the effectiveness of dacarbazine. It's critical to take these interactions into account when prescribing or combining these medications to ensure optimal therapeutic effects.""]"
"[{'source_node': {'name': 'alpha-conidendrin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-1080'}}, {'source_node': {'name': 'alpha-conidendrin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 2d6'}}, {'source_node': {'name': 'alpha-conidendrin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}]","[{'source_node': {'name': 'alpha-conidendrin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 2d6'}}, {'source_node': {'name': 'alpha-conidendrin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5689', 'target': None, 'metadata': {'node_id': '5689', 'node_type': 'PROTEIN', 'display_name': 'ht-1080'}}]",0.7142857142857143,73349a848af5182454fdd4484f23a714,9f37241deb3fd1ed65a8027751a5d818,[],"['The compound alpha-conidendrin is known to target cytochrome p450 2d6, an enzyme that plays an important role in drug metabolism. Additionally, alpha-conidendrin also targets hela, a lineage of cells widely used in scientific research.', 'Alpha-Conidendrin, a biomolecule, targets both Cytochrome P450 2D6, which is an important enzyme in metabolism, and HeLa, a cell line widely used for biomedical research.', 'The compound alpha-conidendrin targets both the enzyme cytochrome P450 2D6 and HeLa, a prevalent cell line used in scientific research.', 'The compound alpha-conidendrin has been identified as a target for both cytochrome p450 2d6, a key protein implicated in drug metabolism, and hela, a cell line used widely in scientific research.', 'Alpha-conidendrin, a pharmacologically active compound, has been identified to target two key components within human biological makeup; cytochrome P450 2D6, an enzyme known for its role in drug metabolism, and HeLa, a type of immortal cell line that is widely used in scientific research.']"
"[{'source_node': {'name': 'nuclear factor nf-kappa-b p105 subunit'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NFKB1'}}, {'source_node': {'name': 'heat shock protein beta-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HSPB1'}}, {'source_node': {'name': 'HSPB1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neuronopathy'}}, {'source_node': {'name': 'methyl 3,7-dimethyloct-6-enoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'heat shock protein beta-1'}}, {'source_node': {'name': 'methyl 3,7-dimethyloct-6-enoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor delta'}}, {'source_node': {'name': 'methyl 3,7-dimethyloct-6-enoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear factor nf-kappa-b p105 subunit'}}, {'source_node': {'name': 'peroxisome proliferator-activated receptor delta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PPARD'}}]","[{'source_node': {'name': 'nuclear factor nf-kappa-b p105 subunit'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NFKB1'}}, {'source_node': {'name': 'heat shock protein beta-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HSPB1'}}, {'source_node': {'name': 'HSPB1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neuronopathy'}}, {'source_node': {'name': 'methyl 3,7-dimethyloct-6-enoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'heat shock protein beta-1'}}, {'source_node': {'name': 'methyl 3,7-dimethyloct-6-enoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor delta'}}, {'source_node': {'name': 'methyl 3,7-dimethyloct-6-enoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear factor nf-kappa-b p105 subunit'}}, {'source_node': {'name': 'peroxisome proliferator-activated receptor delta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PPARD'}}, {'source_node': {'name': 'peroxisome proliferator-activated receptor delta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HSPB1'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:358', 'target': 'GENE:28930', 'metadata': {'predicate': 'gene_product_of'}}]",0.9333333333333332,e61c4531230f7aa7430c6bd651a41738,3a7ec71b89531ce94060ca7e6936049e,"['The nuclear factor nf-kappa-b p105 subunit is a gene product of NFKB1, and another gene product is the heat shock protein beta-1 which is produced by the HSPB1 gene. Interestingly, the HSPB1 gene can cause a condition called neuronopathy. The compound named methyl 3,7-dimethyloct-6-enoate has multiple targets: heat shock protein beta-1, peroxisome proliferator-activated receptor delta, and the nuclear factor nf-kappa-b p105 subunit. The gene product of the PPARD gene is the peroxisome proliferator-activated receptor delta, which is another target of methyl 3,7-dimethyloct-6-enoate.', 'The drug methyl 3,7-dimethyloct-6-enoate interacts with several proteins, including heat shock protein beta-1, nuclear factor nf-kappa-b p105 subunit, and peroxisome proliferator-activated receptor delta. Diving deeper, the heat shock protein beta-1 is a gene product of HSPB1, which is known to cause a condition called neuronopathy. On the other hand, the nuclear factor nf-kappa-b p105 subunit is a gene product of NFKB1. Lastly, the peroxisome proliferator-activated receptor delta is a gene product of PPARD. Hence, the drug demonstrates connections to multiple important biological entities and processes.', 'The drug known as methyl 3,7-dimethyloct-6-enoate targets several proteins in the body, including heat shock protein beta-1 and nuclear factor nf-kappa-b p105 subunit, as well as the peroxisome proliferator-activated receptor delta. Interestingly, these proteins are the products of specific genes. The heat shock protein beta-1 is a gene product of HSPB1, which has been shown to cause neuronopathy, a serious neurological condition. Similarly, the nuclear factor nf-kappa-b p105 subunit is a gene product of NFKB1. On the other hand, the peroxisome proliferator-activated receptor delta is a gene product of PPARD. Therefore, it is essential to understand the impacts of methyl 3,7-dimethyloct-6-enoate and how it interacts with these genes and proteins to improve therapeutic strategies.', 'Heat shock protein beta-1 and nuclear factor nf-kappa-b p105 subunit are respective gene products of HSPB1 and NFKB1. HSPB1 is known to cause a condition called neuronopathy. Meanwhile, the drug methyl 3,7-dimethyloct-6-enoate targets multiple molecules, including the heat shock protein beta-1 and the nuclear factor nf-kappa-b p105 subunit. This drug also targets the peroxisome proliferator-activated receptor delta, which is a gene product of PPARD.', 'The drug, methyl 3,7-dimethyloct-6-enoate, targets several proteins including heat shock protein beta-1, peroxisome proliferator-activated receptor delta, and nuclear factor nf-kappa-b p105 subunit. Interestingly, these targeted proteins are gene products of HSPB1, PPARD, and NFKB1 genes respectively. Studies have indicated that the abnormal functioning or deformation of heat shock protein beta-1, a gene product of HSPB1, can cause a medical condition called neuronopathy. Therefore, understanding these interactions might significantly contribute to improving health outcomes for those suffering from disorders related to these gene products.']","['The compound methyl 3,7-dimethyloct-6-enoate targets a number of unique proteins. Namely it targets the nuclear factor nf-kappa-b p105 subunit which is a gene product of NFKB1. Similarly, it also targets the heat shock protein beta-1, notably a gene product of HSPB1, as well as the peroxisome proliferator-activated receptor delta, which interestingly is a gene product of not only PPARD but also HSPB1. This is significant as HSPB1 is known to cause neuronopathy, a debilitating disease affecting the neurons. The interaction between methyl 3,7-dimethyloct-6-enoate and these proteins could have significant implications for future treatment methodologies.', 'The drug methyl 3,7-dimethyloct-6-enoate has several targets including heat shock protein beta-1, peroxisome proliferator-activated receptor delta, and nuclear factor nf-kappa-b p105 subunit. Heat shock protein beta-1 is a gene product of HSPB1 which is known to cause neuronopathy. The peroxisome proliferator-activated receptor delta is a gene product of genes PPARD and HSPB1. In the same vein, the nuclear factor nf-kappa-b p105 subunit is the gene product of NFKB1.']"
"[{'source_node': {'name': 'HTR2C'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Serotonin receptors'}}, {'source_node': {'name': 'HTR2C'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (q) signalling events'}}, {'source_node': {'name': '5-hydroxytryptamine receptor 2c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HTR2C'}}]","[{'source_node': {'name': 'HTR2C'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (q) signalling events'}}, {'source_node': {'name': '5-hydroxytryptamine receptor 2c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HTR2C'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1779', 'target': None, 'metadata': {'node_id': '1779', 'node_type': 'PATHWAY', 'display_name': 'Serotonin receptors'}}]",0.7142857142857143,970d6415051e16ce374b8821011fff18,58f9518139a0dcbfeae43a688b47cb1c,"['The gene symbol HTR2C, which acts within the serotonin receptors and G alpha (q) signalling events, represents the gene product of the gene named 5-hydroxytryptamine receptor 2c.']","['The gene HTR2C, which is the product of the 5-hydroxytryptamine receptor 2c, acts within the G alpha (q) signalling events pathway.', 'The HTR2C gene acts within the G alpha (q) signalling events. HTR2C also produces the gene product known as 5-hydroxytryptamine receptor 2c.', 'The gene HTR2C, which acts within the pathway of G alpha (q) signalling events, is associated with the production of the 5-hydroxytryptamine receptor 2c.', 'The gene HTR2C, which acts within the G alpha (q) signalling events pathway, is the gene product of the 5-hydroxytryptamine receptor 2c.', 'The 5-hydroxytryptamine receptor 2c is a gene product of HTR2C. Furthermore, HTR2C acts within the G alpha (q) signalling events, playing a crucial role in this biological pathway.']"
"[{'source_node': {'name': 'SCN10A'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'episodic pain syndrome'}}, {'source_node': {'name': 'SCN10A'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'brugada syndrome 1'}}, {'source_node': {'name': 'SCN10A'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'erythermalgia'}}, {'source_node': {'name': 'proparacaine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sodium channel protein type 10 subunit alpha'}}, {'source_node': {'name': 'proparacaine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Haemoglobin'}}, {'source_node': {'name': 'proparacaine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Pain'}}, {'source_node': {'name': 'sodium channel protein type 10 subunit alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SCN10A'}}]","[{'source_node': {'name': 'proparacaine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sodium channel protein type 10 subunit alpha'}}, {'source_node': {'name': 'proparacaine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Haemoglobin'}}, {'source_node': {'name': 'proparacaine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Pain'}}]","[{'type': 'node_removal', 'source': 'DISEASE:15936', 'target': None, 'metadata': {'node_id': '15936', 'node_type': 'DISEASE', 'display_name': 'episodic pain syndrome'}}, {'type': 'node_removal', 'source': 'GENE:32532', 'target': None, 'metadata': {'node_id': '32532', 'node_type': 'GENE', 'display_name': 'SCN10A'}}]",0.4666666666666667,14934e2727e2492c5941f30f6ecf099e,196502c0c9db71360c9af3fb9e1f145f,"['The gene SCN10A is known to cause several conditions such as episodic pain syndrome, Brugada syndrome 1, and erythermalgia. An interesting point to note is that the sodium channel protein type 10 subunit alpha is a gene product of SCN10A. Proparacaine, a medication used in ophthalmology, has this particular protein as its target. Furthermore, it has been observed that proparacaine may have side effects, impacting Haemoglobin levels and potentially causing pain.']","['Proparacaine, a commonly used local anesthetic, has a characteristic target which is the sodium channel protein type 10 subunit alpha. However, it has been observed that the usage of proparacaine can exert certain side effects. Notably, it may affect haemoglobin, a protein in red blood cells responsible for delivering oxygen to body tissues. Moreover, despite being an anesthetic, it can paradoxically cause pain as a side effect to some extent in certain cases.']"
"[{'source_node': {'name': 'tnf superfamily member 13b'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'breast neoplasms'}}, {'source_node': {'name': 'tnf superfamily member 13b'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neutropenia'}}, {'source_node': {'name': 'tnf superfamily member 13b'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'leukopenia'}}, {'source_node': {'name': 'neutropenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'acute lymphoblastic leukemia'}}, {'source_node': {'name': 'neutropenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'short stature'}}, {'source_node': {'name': 'neutropenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'sensorineural hearing impairment'}}]","[{'source_node': {'name': 'tnf superfamily member 13b'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'breast neoplasms'}}, {'source_node': {'name': 'neutropenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'acute lymphoblastic leukemia'}}, {'source_node': {'name': 'neutropenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'short stature'}}, {'source_node': {'name': 'neutropenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'sensorineural hearing impairment'}}]","[{'type': 'edge_deletion', 'source': 'GENE:21889', 'target': 'DISEASE:14592', 'metadata': None}, {'type': 'node_removal', 'source': 'DISEASE:1837', 'target': None, 'metadata': {'node_id': '1837', 'node_type': 'DISEASE', 'display_name': 'leukopenia'}}]",0.7692307692307692,e9cab518746d3035f7013ed11aa74fbe,9ec2af4f3796eb01c7912296392509af,"['The TNF superfamily member 13B is known to cause several health conditions, including breast neoplasms and two types of blood disorders: neutropenia and leukopenia. Particularly in neutropenia, associated phenotypes or features can be observed such as acute lymphoblastic leukemia, short stature, and sensorineural hearing impairment.', 'The protein TNF Superfamily Member 13B is implicated in causing several conditions, including breast neoplasms, neutropenia and leukopenia. The condition of neutropenia, caused by the TNF Superfamily Member 13B, is characterised by several phenotypic features such as acute lymphoblastic leukemia, short stature and sensorineural hearing impairment.', 'The protein TNF superfamily member 13B is responsible for causing a series of medical conditions including breast neoplasms, neutropenia, and leukopenia. Particularly, neutropenia is a condition characterized by several phenotypes such as acute lymphoblastic leukemia, short stature, and sensorineural hearing impairment.', 'TNF Superfamily Member 13B is a gene that results in several conditions, such as breast neoplasms, leukopenia and especially neutropenia. Strikingly, neutropenia is itself a disease with several characteristic symptoms. People with neutropenia often suffer from acute lymphoblastic leukemia and sensorineural hearing impairment, and may also reveal a short stature. Thus, TNF Superfamily Member 13B plays a substantial role in health and disease prevalence.', 'The protein TNF superfamily member 13B has been identified as a cause of multiple conditions including breast neoplasms, neutropenia, and leukopenia. Interestingly, neutropenia, one of the conditions caused by TNF superfamily member 13B, is further associated with several phenotypes, such as acute lymphoblastic leukemia, short stature, and sensorineural hearing impairment.']","['The TNF superfamily member 13B, a protein that is known to cause breast neoplasms, operates within the same biological context as neutropenia. Neutropenia, on the other hand, is a condition that manifests a range of symptoms, which can include acute lymphoblastic leukemia, short stature, and sensorineural hearing impairment. This interconnectedness of conditions and their underlying biological factors forms a complex network that helps us better understand disease mechanisms and potential treatments.', 'The gene known as TNF superfamily member 13b has been found to cause a condition known as breast neoplasms. Another condition, neutropenia, has been associated with several phenotypes, such as acute lymphoblastic leukemia and short stature. In addition to these phenotypes, neutropenia is also tied to sensorineural hearing impairment.', 'The protein TNF superfamily member 13B is known to cause a condition such as breast neoplasms. On a related note, there is an associated condition known as neutropenia, which has various symptoms or phenotypes, one of them being acute lymphoblastic leukemia. Other phenotypes of neutropenia include short stature and sensorineural hearing impairment. These interconnected relations highlight the complexity of biological systems and their potential health implications.', 'The protein TNF superfamily member 13b causes a condition known as breast neoplasms. Meanwhile, neutropenia is a condition characterized by various symptoms, such as association with acute lymphoblastic leukemia, short stature, and sensorineural hearing impairment. These characteristics are phenotypes that are observable in individuals with neutropenia.', 'The TNF superfamily member 13b, a biological entity, is known to cause the condition of breast neoplasms. In a different context, we observe neutropenia, a condition often associated with various phenotypes. These include acute lymphoblastic leukemia, short stature, and sensorineural hearing impairment. Please note that these relationships are based on available scientific data and the actual causative agents could involve numerous other factors.']"
"[{'source_node': {'name': 'SLC27A2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Alpha-oxidation of phytanate'}}, {'source_node': {'name': 'SLC27A2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}, {'source_node': {'name': 'SLC27A2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Peroxisomal protein import'}}]","[{'source_node': {'name': 'SLC27A2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Alpha-oxidation of phytanate'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:49', 'target': None, 'metadata': {'node_id': '49', 'node_type': 'PATHWAY', 'display_name': 'Peroxisomal protein import'}}, {'type': 'node_removal', 'source': 'PATHWAY:3', 'target': None, 'metadata': {'node_id': '3', 'node_type': 'PATHWAY', 'display_name': 'Neutrophil degranulation'}}]",0.4285714285714286,88b57ac6e1f1b8051c70d9237292e16f,38482bc37f63f8fe7efffa02c20dcbaf,"['The gene SLC27A2 acts within several biological processes, including the alpha-oxidation of phytanate, neutrophil degranulation, and the import of peroxisomal proteins.', 'The gene SLC27A2 is crucial in several important biological processes. It acts within the alpha-oxidation of phytanate, contributing to the breakdown of this compound in our body. SLC27A2 also plays a role in neutrophil degranulation, which is a critical component of our immune response against bacterial and fungal infections. In addition, the SLC27A2 gene contributes to peroxisomal protein import, which is crucial for the proper functioning of peroxisomes, tiny cell organs that detoxify harmful substances.', 'The gene SLC27A2 functions within several biological processes, including the alpha-oxidation of phytanate, neutrophil degranulation, and peroxisomal protein import.', 'The gene SLC27A2 is involved in several biological processes. It acts within the alpha-oxidation of phytanate, a metabolic pathway crucial for fat metabolism. Apart from that, SLC27A2 also has a functional role in neutrophil degranulation, which is a key step in the immune response of the body against infections. Furthermore, it is a vital player in the peroxisomal protein import, a pathway responsible for the transportation of proteins into the peroxisome.', 'The gene SLC27A2 is known to act within several biological processes. These include alpha-oxidation of phytanate, neutrophil degranulation, and peroxisomal protein import. These activities signify its crucial role in various cellular reactions and pathways.']",[]
"[{'source_node': {'name': 'methyclothiazide'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' granulocytopenia '}}, {'source_node': {'name': 'valsartan'}, 'relation': {'name': 'decrease_activity'}, 'target_node': {'name': ' the excretion rate '}}, {'source_node': {'name': 'valsartan'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'methyclothiazide'}}, {'source_node': {'name': 'valsartan'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'benzthiazide'}}, {'source_node': {'name': 'benzthiazide'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' Cardiac Arrhythmia '}}, {'source_node': {'name': 'benzthiazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ditazole'}}, {'source_node': {'name': 'benzthiazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'benzhydrocodone'}}]","[{'source_node': {'name': 'methyclothiazide'}, 'relation': {'name': 'decrease_effect'}, 'target_node': {'name': ' granulocytopenia '}}, {'source_node': {'name': 'valsartan'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'methyclothiazide'}}, {'source_node': {'name': 'valsartan'}, 'relation': {'name': 'increase_activity'}, 'target_node': {'name': ' the excretion rate '}}, {'source_node': {'name': 'benzhydrocodone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'benzthiazide'}}, {'source_node': {'name': 'benzthiazide'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' Cardiac Arrhythmia '}}, {'source_node': {'name': 'benzthiazide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'benzhydrocodone'}}]","[{'type': 'edge_replacement', 'source': 'COMPOUND:222', 'target': 'EFFECT:120', 'metadata': {'predicate': 'decrease_effect'}}, {'type': 'edge_replacement', 'source': 'COMPOUND:167', 'target': 'ACTIVITY:7', 'metadata': {'predicate': 'increase_activity'}}, {'type': 'node_removal', 'source': 'COMPOUND:7939', 'target': None, 'metadata': {'node_id': '7939', 'node_type': 'COMPOUND', 'display_name': 'ditazole'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:167', 'target': 'COMPOUND:548', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:12999', 'target': 'COMPOUND:548', 'metadata': {'predicate': 'increase_efficacy'}}]",0.6,c08c38ca2c90a2dff4c6115c57407ce1,fe168236ccd645c721c486650d5ef11d,[],[]
"[{'source_node': {'name': 'ATR'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'seckel syndrome'}}, {'source_node': {'name': 'dna-dependent protein kinase catalytic subunit'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PRKDC'}}, {'source_node': {'name': 'schisandrin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'menin/histone-lysine n-methyltransferase mll'}}, {'source_node': {'name': 'schisandrin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'serine/threonine-protein kinase atr'}}, {'source_node': {'name': 'schisandrin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna-dependent protein kinase catalytic subunit'}}, {'source_node': {'name': 'serine/threonine-protein kinase atr'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ATR'}}]","[{'source_node': {'name': 'ATR'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'seckel syndrome'}}, {'source_node': {'name': 'dna-dependent protein kinase catalytic subunit'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PRKDC'}}, {'source_node': {'name': 'schisandrin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'menin/histone-lysine n-methyltransferase mll'}}, {'source_node': {'name': 'schisandrin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna-dependent protein kinase catalytic subunit'}}, {'source_node': {'name': 'PRKDC'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'seckel syndrome'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4886', 'target': None, 'metadata': {'node_id': '4886', 'node_type': 'PROTEIN', 'display_name': 'serine/threonine-protein kinase atr'}}, {'type': 'edge_addition', 'source': 'GENE:31676', 'target': 'DISEASE:4267', 'metadata': {'predicate': 'causes_condition'}}]",0.6923076923076923,cc26463e18f49f5d2e12006ff1fc99c3,cdbe149e797b5110506392653113cdb2,"['The gene ATR, which causes Seckel syndrome, is a product of the serine/threonine-protein kinase ATR. This kinase is a target of schisandrin B, a compound that also targets the DNA-dependent protein kinase catalytic subunit and the menin/histone-lysine n-methyltransferase MLL. The DNA-dependent protein kinase catalytic subunit is also a product of the gene PRKDC.', 'The drug Schisandrin B targets several proteins, including Menin/Histone-lysine N-methyltransferase MLL, Serine/Threonine-protein kinase ATR, and DNA-dependent protein kinase catalytic subunit. This DNA-dependent protein kinase catalytic subunit is a gene product of PRKDC. Similarly, the Serine/Threonine-protein kinase ATR is a gene product of the gene named ATR. Furthermore, this particular gene, ATR has been identified as a cause of Seckel syndrome, a rare genetic disorder.', 'The compound Schisandrin B targets several entities including Menin/histone-lysine N-methyltransferase MLL, Serine/threonine-protein kinase ATR, and DNA-dependent protein kinase catalytic subunit. The Serine/threonine-protein kinase ATR is a gene product of ATR, which is also associated with Schisandrin B and causes the condition known as Seckel syndrome. Moreover, the DNA-dependent protein kinase catalytic subunit is a gene product of PRKDC and it too is a target of Schisandrin B.', 'The drug Schisandrin B targets multiple proteins including Menin/Histone-lysine N-methyltransferase MLL, the DNA-Dependent Protein Kinase Catalytic Subunit, and the Serine/Threonine-Protein Kinase ATR. The Serine/Threonine-Protein Kinase ATR is a gene product of ATR, which causes the condition known as Seckel Syndrome. Additionally, the DNA-Dependent Protein Kinase Catalytic Subunit is a gene product of PRKDC.', ""Schisandrin B is a potent compound that targets multiple proteins including Menin/histone-lysine N-methyltransferase MLL, serine/threonine-protein kinase ATR, and DNA-dependent protein kinase catalytic subunit. It's interesting to note that the serine/threonine-protein kinase ATR and the DNA-dependent protein kinase catalytic subunit are gene products of ATR and PRKDC respectively. The ATR gene is implicated in causing a medical condition known as Seckel syndrome.""]","['The drug Schisandrin B targets both Menin/histone-lysine N-methyltransferase MLL and DNA-Dependent Protein Kinase Catalytic Subunit. This latter protein is a gene product of PRKDC, which causes Seckel syndrome, a genetically inherited disorder. Moreover, the gene ATR also plays a role in the onset of Seckel syndrome.', 'The gene ATR has been identified as a causative agent of Seckel syndrome, a clinically distinct disorder. This gene is in line with DNA-dependent protein kinase catalytic subunit, which is a gene product of PRKDC. On the other hand, Schisandrin B, a potential drug target, has marked Menin/histone-lysine N-methyltransferase MLL and DNA-dependent protein kinase catalytic subunit as its targets. Notably, PRKDC, can also cause Seckel syndrome, underscoring the complex network of interactions in this condition.', 'The ATR gene and PRKDC are known to cause Seckel syndrome, a severe form of primordial dwarfism. PRKDC, specifically, is the gene product of dna-dependent protein kinase catalytic subunit, and this particular genetic entity is a target of the compound schisandrin B. In an analogous manner, menin/histone-lysine n-methyltransferase mll also serves as a target for schisandrin B. Thus implying a potential relation of these entities in the pathogenesis and possible treatment methods for Seckel syndrome.', 'The ATR gene is known to cause a condition known as Seckel syndrome. Similarly, PRKDC, another gene which is the product of the DNA-dependent protein kinase catalytic subunit, also causes Seckel syndrome. The compound schisandrin B targets the Menin/histone-lysine N-methyltransferase MLL, and intriguingly, also targets the DNA-dependent protein kinase catalytic subunit, showing an intricate network of interactions within biological systems.', 'The gene ATR is known to cause Seckel Syndrome, a rare genetic disorder. This gene is also linked to the DNA-dependent protein kinase catalytic subunit, a gene product of PRKDC. PRKDC also results in Seckel Syndrome. In the pharmacological context, Schisandrin B is a compound that targets both menin/histone-lysine N-methyltransferase MLL and the DNA-dependent protein kinase catalytic subunit. These findings suggest a intertwined set of genetic and pharmacological interactions associated with Seckel Syndrome.']"
"[{'source_node': {'name': 'idelalisib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tecemotide'}}, {'source_node': {'name': 'valoctocogene roxaparvovec'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trastuzumab emtansine'}}, {'source_node': {'name': 'valoctocogene roxaparvovec'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'regorafenib'}}, {'source_node': {'name': 'valoctocogene roxaparvovec'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'idelalisib'}}]","[{'source_node': {'name': 'valoctocogene roxaparvovec'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'trastuzumab emtansine'}}, {'source_node': {'name': 'valoctocogene roxaparvovec'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'regorafenib'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:5219', 'target': 'COMPOUND:10457', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:10457', 'target': None, 'metadata': {'node_id': '10457', 'node_type': 'COMPOUND', 'display_name': 'tecemotide'}}, {'type': 'node_removal', 'source': 'COMPOUND:7995', 'target': None, 'metadata': {'node_id': '7995', 'node_type': 'COMPOUND', 'display_name': 'idelalisib'}}]",0.5555555555555556,883816e1ee602a82d1ea3f4596e3e109,b13101d0caab5cfe1163442338cfdc19,"['The drug idelalisib has been found to decrease the efficacy of the cancer vaccine tecemotide. Similarly, another drug, valoctocogene roxaparvovec, reduces the efficacy of a few other agents. It impacts the effectiveness of the targeted cancer drug trastuzumab emtansine, the cancer medication regorafenib and even idelalisib, the drug aforementioned. Please consider these interactions when formulating a therapeutic treatment plan.', 'The drug idelalisib is known to decrease the efficacy of tecemotide. Similarly, valoctocogene roxaparvovec, a medicinal substance, is reported to lessen the effectiveness of several drugs including trastuzumab emtansine, regorafenib, and idelalisib itself. Therefore, it is cautious when these drugs are used in combination due to their potential interactions that might compromise their therapeutic performance.', 'The drug idelalisib is known to decrease the efficacy of tecemotide. Similarly, valoctocogene roxaparvovec has shown to potentially decrease the efficacy of several drugs including trastuzumab emtansine, regorafenib, and even idelalisib. Thus, caution must be exercised when considering co-administration of these drugs.', 'The efficacy of various drugs can be decreased by other medications. For instance, Idelalisib, a medication used in the treatment of certain cancers, tends to decrease the efficacy of Tecemotide, a cancer vaccine undergoing clinical trials. Valoctocogene Roxaparvovec, a genetic therapy for hemophilia, appears to decrease the therapeutic efficacy of several drugs such as Trastuzumab Emtansine, an antibody used in breast cancer treatment, as well as Regorafenib, a medication used for treating colorectal cancer. Surprisingly, it also decreases the efficacy of Idelalisib, further complicating potential drug interactions.', 'The drug idelalisib is known to decrease the efficacy of tecemotide. Meanwhile, another drug, valoctocogene roxaparvovec, has similar effects on multiple drugs: it is found to decrease the efficacy of trastuzumab emtansine, regorafenib, and even idelalisib itself. This suggests a complex interplay of efficacy between these medications, which may have implications on their combined use in treatment plans.']","['The use of valoctocogene roxaparvovec, a gene therapy medication, has been found to decrease the efficacy of other drugs, specifically trastuzumab emtansine and regorafenib. Therefore, caution should be exercised when these drugs are used in combination.', 'The drug valoctocogene roxaparvovec is known to decrease the efficacy of both trastuzumab emtansine and regorafenib, limiting their potential therapeutic benefits.', 'The drug valoctocogene roxaparvovec has been found to decrease the efficacy of both trastuzumab emtansine and regorafenib. This interaction could potentially limit therapeutic outcomes when these drugs are used in combination.', 'Valoctocogene roxaparvovec, a gene therapy, may decrease the efficacy of some drugs, including trastuzumab emtansine and regorafenib. This implies that using these treatments concurrently could reduce the effectiveness of the prescribed therapies in tackling the diseases they are meant to address.', 'The drug valoctocogene roxaparvovec reduces the efficacy of both trastuzumab emtansine and regorafenib.']"
"[{'source_node': {'name': 'neurodevelopmental disorder with seizures'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'gray matter heterotopia'}}, {'source_node': {'name': 'neurodevelopmental disorder with seizures'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'atrial septal defect'}}, {'source_node': {'name': 'GRM7'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neurodevelopmental disorder with seizures'}}, {'source_node': {'name': 'GRM7'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'early infantile epileptic encephalopathy'}}, {'source_node': {'name': 'GRM7'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (i) signalling events'}}, {'source_node': {'name': 'metabotropic glutamate receptor 7'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GRM7'}}]","[{'source_node': {'name': 'GRM7'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neurodevelopmental disorder with seizures'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:389', 'target': None, 'metadata': {'node_id': '389', 'node_type': 'PROTEIN', 'display_name': 'metabotropic glutamate receptor 7'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:1676', 'target': None, 'metadata': {'node_id': '1676', 'node_type': 'PHENOTYPE', 'display_name': 'gray matter heterotopia'}}, {'type': 'node_removal', 'source': 'DISEASE:4216', 'target': None, 'metadata': {'node_id': '4216', 'node_type': 'DISEASE', 'display_name': 'early infantile epileptic encephalopathy'}}, {'type': 'node_removal', 'source': 'PATHWAY:109', 'target': None, 'metadata': {'node_id': '109', 'node_type': 'PATHWAY', 'display_name': 'G alpha (i) signalling events'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:1184', 'target': None, 'metadata': {'node_id': '1184', 'node_type': 'PHENOTYPE', 'display_name': 'atrial septal defect'}}]",0.2307692307692307,73c4465f72d4cbe2efffeb20a4487fa9,ef6468495fd0bd86a5a119c5200833e7,"['The neurodevelopmental disorder with seizures, which is caused by the gene GRM7, has two major phenotypes; gray matter heterotopia and atrial septal defect. This gene is known to act within the pathway known as G alpha (i) signalling events. Moreover, GRM7 is also responsible for causing another condition known as early infantile epileptic encephalopathy. It is worth noting that GRM7 is the gene product of metabotropic glutamate receptor 7.', 'The gene product of metabotropic glutamate receptor 7, which is otherwise known as GRM7, acts within the pathway of G alpha (i) signalling events. This gene, GRM7, has been implicated as the cause of certain conditions including neurodevelopmental disorder with seizures, and early infantile epileptic encephalopathy. The neurodevelopmental disorder with seizures is characterized by phenotypes such as gray matter heterotopia and atrial septal defect.', 'The Metabotropic Glutamate Receptor 7 is a gene product of GRM7. GRM7 is involved in the G alpha (i) signalling events pathway. Mainly, GRM7 is known to cause neurodevelopmental disorders with seizures and early infantile epileptic encephalopathy. As such disorders are examined further, it is observed that phenotypic expressions include gray matter heterotopia and atrial septal defects in individuals affected by neurodevelopmental disorder with seizures.', 'The gene product of metabotropic glutamate receptor 7, or GRM7, is integral to the regulation of G alpha (i) signalling events. Dysfunction of GRM7 can result in several medical conditions such as the neurodevelopmental disorder with seizures and early infantile epileptic encephalopathy. The neurodevelopmental disorder with seizures is often characterized by physiological abnormalities like gray matter heterotopia and atrial septal defects.']",['The gene GRM7 is known to cause a condition known as neurodevelopmental disorder with seizures.']
"[{'source_node': {'name': 'pyrogallol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}, {'source_node': {'name': 'pyrogallol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'e-selectin'}}]","[{'source_node': {'name': 'pyrogallol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'e-selectin'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4951', 'target': None, 'metadata': {'node_id': '4951', 'node_type': 'PROTEIN', 'display_name': 'hl-60'}}]",0.6,5405524ca873d13b2aab7c0a1ad612af,fc97b79f07525aa58b41cedd4a75afbf,"['The compound Pyrogallol has been identified to target multiple entities, specifically HL-60 - a human promyelocytic leukemia cell line, and E-Selectin, a cell adhesion molecule expressed only on endothelial cells activated by cytokines.', 'The chemical compound pyrogallol is known to target two different entities: HL-60, and E-selectin.', 'The compound pyrogallol has targets that include both HL-60, a type of human promyelocytic leukemia cell, and E-selectin, a cell adhesion molecule expressed only on endothelial cells activated by cytokines.', 'The compound Pyrogallol serves as a target for both HL-60, a human leukemia cell line, and E-selectin, a cell adhesion molecule expressed only on endothelial cells activated by cytokines.', 'The compound Pyrogallol targets both HL-60, a human leukemia cell line, and E-selectin, a cell adhesion molecule expressed only on endothelial cells activated by cytokines.']","['The compound pyrogallol is known to target e-selectin.', 'The drug pyrogallol has a noted target of e-selectin.']"
"[{'source_node': {'name': 'lipoyl synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'LIAS'}}, {'source_node': {'name': 'hyperglycinemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cerebral atrophy'}}, {'source_node': {'name': 'hyperglycinemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'leukodystrophy'}}, {'source_node': {'name': 'LIAS'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hyperglycinemia'}}, {'source_node': {'name': 'LIAS'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glyoxylate metabolism and glycine degradation'}}]","[{'source_node': {'name': 'hyperglycinemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cerebral atrophy'}}, {'source_node': {'name': 'hyperglycinemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'leukodystrophy'}}]","[{'type': 'node_removal', 'source': 'GENE:25249', 'target': None, 'metadata': {'node_id': '25249', 'node_type': 'GENE', 'display_name': 'LIAS'}}]",0.4545454545454546,053b68746c5ecea884e93b4fd791afe6,0918f3e5840accd48543dc816388686c,"['Lipoyl synthase is a gene product of LIAS which acts within the pathway known as glyoxylate metabolism and glycine degradation. The LIAS gene has been linked to the medical condition hyperglycinemia. This condition is associated with several phenotypes, including cerebral atrophy and leukodystrophy.', 'Lipoyl synthase is a gene product of the LIAS gene, which acts within the pathway of glyoxylate metabolism and glycine degradation. This gene can cause a condition known as hyperglycinemia, a disease characterized by certain phenotypes like cerebral atrophy and leukodystrophy.', 'Lipoyl synthase is a gene product of the gene named LIAS, which operates within a metabolic pathway known as glyoxylate metabolism and glycine degradation. Mutations in this gene can result in a condition known as hyperglycinemia. Hyperglycinemia, in turn, has phenotypes, or observable characteristics, like cerebral atrophy and leukodystrophy, which are serious brain disorders.', 'Lipoyl synthase is a gene product of the gene LIAS, which is involved in several biological processes. Particularly, it acts within the pathway concerned with glyoxylate metabolism and glycine degradation. Notably, LIAS is known to cause a condition known as hyperglycinemia. Hyperglycinemia is characterized by specific phenotypes including cerebral atrophy and leukodystrophy. Therefore, understanding the role of lipoyl synthase and LIAS in these pathways may offer insights into hyperglycinemia and its associated symptoms.', 'Lipoyl synthase is the gene product of LIAS, which not only acts within the process of glyoxylate metabolism and glycine degradation, but also causes a certain condition known as hyperglycinemia. This condition, hyperglycinemia, is characterized by phenotypes such as cerebral atrophy and leukodystrophy.']","['Hyperglycinemia, a metabolic disorder, exhibits several notable phenotypes which include cerebral atrophy and leukodystrophy. Both these conditions are characterized by progressive deterioration or loss of functions of the brain.', 'Hyperglycinemia, a medical condition, manifests phenotypes such as cerebral atrophy and leukodystrophy. These phenotypes are clinical features associated with the disease and can contribute to the diagnostic process.', 'Hyperglycinemia, a metabolic disorder, presents with multiple phenotypes including cerebral atrophy and leukodystrophy.', ""Hyperglycinemia, a metabolic disorder, is associated with certain phenotypes such as cerebral atrophy and leukodystrophy. These are severe conditions that lead to abnormal changes in the brain's white matter and an overall reduction in brain size, respectively."", 'Hyperglycinemia, a metabolic disorder, manifests certain phenotypes or symptoms. These include cerebral atrophy, a condition where the brain tissues and cells degenerate and die, leading to a array of neurological issues. Leukodystrophy, another associated phenotype, refers to a group of disorders characterized by progressive degeneration of the white matter in the brain. Overall, patients diagnosed with hyperglycinemia typically experience these drastic neurological changes.']"
"[{'source_node': {'name': 'noonan syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'failure to thrive in infancy'}}, {'source_node': {'name': 'noonan syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'patent ductus arteriosus'}}, {'source_node': {'name': 'noonan syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'intellectual disability'}}]","[{'source_node': {'name': 'noonan syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'failure to thrive in infancy'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:950', 'target': None, 'metadata': {'node_id': '950', 'node_type': 'PHENOTYPE', 'display_name': 'intellectual disability'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:1195', 'target': None, 'metadata': {'node_id': '1195', 'node_type': 'PHENOTYPE', 'display_name': 'patent ductus arteriosus'}}]",0.4285714285714286,544abc5101a6733906bbd087271801ec,900bd2872c3cd6970d3b1cc6ac714749,"['Noonan Syndrome 1 is a medical condition associated with several phenotypes such as a failure to thrive in infancy, the presence of patent ductus arteriosus, and intellectual disability.']",[]
"[{'source_node': {'name': 'polyethylene glycol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mecamylamine'}}, {'source_node': {'name': 'polyethylene glycol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dicyclomine'}}, {'source_node': {'name': 'polyethylene glycol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'loperamide'}}, {'source_node': {'name': 'cepeginterferon alfa-2b'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'polyethylene glycol'}}, {'source_node': {'name': 'cepeginterferon alfa-2b'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rotavirus vaccine'}}, {'source_node': {'name': 'cepeginterferon alfa-2b'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'elapegademase'}}, {'source_node': {'name': 'elapegademase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'peginterferon alfa-2b'}}, {'source_node': {'name': 'elapegademase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pegloticase'}}]","[{'source_node': {'name': 'polyethylene glycol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mecamylamine'}}, {'source_node': {'name': 'polyethylene glycol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dicyclomine'}}, {'source_node': {'name': 'polyethylene glycol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'loperamide'}}, {'source_node': {'name': 'cepeginterferon alfa-2b'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'elapegademase'}}, {'source_node': {'name': 'cepeginterferon alfa-2b'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'mecamylamine'}}, {'source_node': {'name': 'elapegademase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'peginterferon alfa-2b'}}, {'source_node': {'name': 'elapegademase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pegloticase'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:10692', 'target': 'COMPOUND:643', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:8397', 'target': None, 'metadata': {'node_id': '8397', 'node_type': 'COMPOUND', 'display_name': 'rotavirus vaccine'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:10692', 'target': 'COMPOUND:8222', 'metadata': None}]",0.7647058823529411,762be34abbeb6e83fb05ab41ef7f0bc2,116c7670c76f1af855cc328910e59ef6,"[""The compound polyethylene glycol has been found to decrease the efficacy of certain medications such as mecamylamine, dicyclomine, and loperamide. In turn, Polyethylene glycol's efficacy is reduced by the action of cepeginterferon alfa-2b. Also, cepeginterferon alfa-2b can decrease the effectiveness of other treatments such as the rotavirus vaccine and elapegademase. The repercussions are such that elapegademase can diminish the efficacy of drugs like peginterferon alfa-2b and pegloticase. Hence, the interactions and implications of these substances need to be considered in the context of therapeutic applications."", 'Polyethylene glycol has been found to decrease the efficacy of several drugs including mecamylamine, dicyclomine, and loperamide. Furthermore, its efficacy is decreased by the influence of cepeginterferon alfa-2b. Continuing the cycle of decreasing efficacy, this drug, cepeginterferon alfa-2b, in turn lowers the efficiency of the rotavirus vaccine and elapegademase. Elapegademase is not free from this chain interference as it also exhibits a decrease in efficacy for peginterferon alfa-2b and pegloticase. Therefore, it is evident that these drugs are interconnected through this dynamic of efficacy reduction.', ""Polyethylene glycol, a commonly used substance, can decrease the efficacy of several medications, including mecamylamine, dicyclomine, and loperamide. Additionally, this substance's efficacy can be reduced by cepeginterferon alfa-2b. Interestingly, cepeginterferon alfa-2b can also diminish the efficacy of the rotavirus vaccine and elapegademase. Adding to the complexity, elapegademase, in turn, can reduce the efficacy of the drug peginterferon alfa-2b and pegloticase. These interactions highlight the intricate nature of pharmacological effects and suggest that medication efficacy can sometimes be influenced by interactions with other substances."", 'The substance polyethylene glycol is known to decrease the efficacy of several drugs, including mecamylamine, dicyclomine, and loperamide. However, the efficacy of polyethylene glycol itself is reduced by cepeginterferon alfa-2b. This latter medication also lowers the efficacy of both the rotavirus vaccine and elapegademase. Interestingly, the efficiency of peginterferon alfa-2b and pegloticase is lessened when they interact with elapegademase.', 'Polyethylene glycol is known to decrease the efficacy of several drugs, including mecamylamine, dicyclomine, and loperamide. Similarly, cepeginterferon alfa-2b also decreases the efficacy of certain substances such as polyethylene glycol, rotavirus vaccine, and elapegademase. Interestingly, there seems to be a reciprocal relationship in some cases, as elapegademase has also been found to decrease the efficacy of peginterferon alfa-2b and pegloticase. These interactions are important to consider in pharmacological therapy to avoid potential negative effects on drug efficacy.']","['The substance polyethylene glycol is known to decrease the efficacy of several medications including mecamylamine, dicyclomine, and loperamide. On the other hand, cepeginterferon alfa-2b not only decreases the efficacy of elapegademase, but conversely, increases the efficacy of mecamylamine. A complex relationship further exists with elapegademase, as it in turn decreases the efficacy of peginterferon alfa-2b and pegloticase. This intricate web of interactions can have significant implications for effective medication management.', 'Polyethylene glycol, a common compound found in a variety of medicinal and cosmetic applications, has been found to decrease the efficacy of certain drugs. Specifically, it has been found that the effectiveness of mecamylamine, dicyclomine, and loperamide are reduced in the presence of polyethylene glycol. In contrast, the drug cepeginterferon alfa-2b not only decreases the efficacy of elapegademase but also enhances the efficacy of mecamylamine. Surprisingly, elapegademase, in turn, lessens the efficacy of both peginterferon alfa-2b and pegloticase. These complex interactions underscore the importance of evaluating potential drug-drug interactions for the effective management of drug regimen.', ""The chemical compound, polyethylene glycol, has been found to decrease the efficacy of several drugs, including mecamylamine, dicyclomine, and loperamide. On the other hand, cepeginterferon alfa-2b has a similar decreased efficacy effect on elapegademase but interestingly, it has an opposite effect on mecamylamine, where it actually increases its efficacy. It's important to note that elapegademase itself decreases the efficacy of specific drugs like peginterferon alfa-2b and pegloticase."", 'The substance polyethylene glycol is known to decrease the efficacy of several different compounds, including mecamylamine, dicyclomine, and loperamide. Similarly, cepeginterferon alfa-2b can decrease the efficacy of elapegademase but increase the efficacy of mecamylamine. Furthermore, elapegademase can decrease the efficacy of both peginterferon alfa-2b and pegloticase. Therefore, understanding these interactions is critical when using these substances in tandem.', 'Polyethylene glycol, a compound widely used in various industrial applications, appears to diminish the efficacy of certain drugs such as mecamylamine, dicyclomine, and loperamide. The drug cepeginterferon alfa-2b, on the other hand, is observed to decrease the efficacy of elapegademase, while simultaneously increasing the efficacy of mecamylamine. Interestingly, elapegademase is known to lessen the effectiveness of both peginterferon alfa-2b and pegloticase. This intertwined network of reactions underlines the complexity of drug interactions and the potential for unintended side effects.']"
"[{'source_node': {'name': 'ciprofloxacin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'ipragliflozin'}}, {'source_node': {'name': 'ciprofloxacin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}}, {'source_node': {'name': 'ciprofloxacin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'smmc-7721'}}, {'source_node': {'name': 'ipragliflozin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'hydroxyfasudil'}}, {'source_node': {'name': 'ipragliflozin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'sulfachlorpyridazine'}}, {'source_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TDP1'}}]","[{'source_node': {'name': 'ciprofloxacin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'ipragliflozin'}}, {'source_node': {'name': 'ciprofloxacin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}}, {'source_node': {'name': 'ciprofloxacin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'smmc-7721'}}, {'source_node': {'name': 'ipragliflozin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'sulfachlorpyridazine'}}, {'source_node': {'name': 'ipragliflozin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ciprofloxacin'}}, {'source_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TDP1'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:9617', 'target': 'COMPOUND:523', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:4425', 'target': 'PROTEIN:5826', 'metadata': {'predicate': 'has_target'}}, {'type': 'node_removal', 'source': 'COMPOUND:4425', 'target': None, 'metadata': {'node_id': '4425', 'node_type': 'COMPOUND', 'display_name': 'hydroxyfasudil'}}]",0.7692307692307692,267c4765ad9f70fd00a80bd593db5a24,b1c7de10f309ced5ad34ec9b9b6f5a78,"['Ciprofloxacin, a common antibiotic, has several important interactions. Notably, it has been found to increase the efficacy of ipragliflozin, a drug used in the treatment of diabetes. Moreover, ciprofloxacin targets tyrosyl-DNA phosphodiesterase 1 and SMMC-7721. Interestingly, tyrosyl-DNA phosphodiesterase 1 is a gene product of TDP1. Ipragliflozin also has other interactions; it increases the efficacy of both hydroxyfasudil and sulfachlorpyridazine, which are used for the treatment of diverse medical conditions. This illustrates the complex network of interactions and dependencies that exist between various drugs, targets and pathways.', 'Ciprofloxacin, an antibiotic known to target two major entities - the enzyme Tyrosyl-DNA phosphodiesterase 1 and the liver cancer cell, SMMC-7721, also enhances the efficacy of the antidiabetic drug, Ipragliflozin. Notably, Ipragliflozin elevates the efficacy of Hydroxyfasudil, a drug with vasodilatory effects, and Sulfachlorpyridazine, an antimicrobial agent. It is important to note that Tyrosyl-DNA phosphodiesterase 1 is the gene product of TDP1.', 'The antibiotic ciprofloxacin is known to increase the efficacy of the drug ipragliflozin. Besides, ciprofloxacin also has targets such as tyrosyl-DNA phosphodiesterase 1 and SMMC-7721. Interestingly, ipragliflozin also increases the efficacy of drugs like hydroxyfasudil and sulfachlorpyridazine. Moreover, tyrosyl-DNA phosphodiesterase 1 is a gene product of the gene TDP1.', 'The antibiotic drug Ciprofloxacin targets Tyrosyl-DNA phosphodiesterase 1, a gene product of TDP1, and SMMC-7721. In addition to these interactions, Ciprofloxacin also enhances the efficacy of Ipragliflozin, which itself further increases the efficacy of Hydroxyfasudil and Sulfachlorpyridazine. Thus, the interplay between these drugs and their targets showcases a complex pharmacological network.', ""Ciprofloxacin is a versatile drug that targets different entities, including tyrosyl-DNA phosphodiesterase 1, a gene product of TDP1, and smmc-7721. Fascinatingly, it also increases the efficacy of several other medications. One instance is ipragliflozin, which in turn boosts the performance of hydroxyfasudil and sulfachlorpyridazine. Thus, ciprofloxacin's indirect influence magnifies the therapeutic effects of a variety of drugs.""]","['The antibiotic ciprofloxacin not only increases the efficacy of the antidiabetic drug ipragliflozin, but also targets tyrosyl-DNA phosphodiesterase 1 and SMMC-7721. Interestingly, the compound tyrosyl-DNA phosphodiesterase 1 is a gene product of TDP1. In contrast, ipragliflozin boosts the efficacy of the antimicrobial drug sulfachlorpyridazine, whereas it decreases the efficacy of ciprofloxacin.', 'Ciprofloxacin, a drug, targets both tyrosyl-DNA phosphodiesterase 1 and SMMC-7721. Tyrosyl-DNA phosphodiesterase 1 is a gene product of TDP1. Interestingly, Ciprofloxacin also interacts with another drug, Ipragliflozin, and increases its efficacy. However, Ipragliflozin, in return, decreases the efficacy of ciprofloxacin. Further, Ipragliflozin also has a positive effect on the efficacy of another drug, Sulfachlorpyridazine. Therefore, the interaction and effects of these drugs are complex and interrelated.', 'The medication ciprofloxacin targets both tyrosyl-DNA phosphodiesterase 1 and SMMC-7721. Tyrosyl-DNA phosphodiesterase 1 is a gene product of TDP1. The effectiveness of ciprofloxacin increases the efficacy of ipragliflozin, a drug which in turn increases the efficacy of sulfachlorpyridazine. However, it should be noted that the efficacy of ciprofloxacin is decreased by ipragliflozin.', 'Ciprofloxacin is a potent drug which increases the efficacy of Ipragliflozin, a diabetes medication. Ciprofloxacin also targets two important biomolecules - tyrosyl-DNA phosphodiesterase 1 and SMMC-7721. The enzyme tyrosyl-DNA phosphodiesterase 1 in fact, is the gene product of TDP1. On the other hand, Ipragliflozin not only has its efficacy increased by Ciprofloxacin, but it also increases the efficacy of another drug called Sulfachlorpyridazine. Interestingly, even though Ciprofloxacin enhances the efficacy of Ipragliflozin, the latter is found to decrease the efficacy of Ciprofloxacin. This circular relationship signifies the complex interactions between these drugs.', 'The drug ciprofloxacin targets both tyrosyl-dna phosphodiesterase 1 and smmc-7721. Interestingly, tyrosyl-dna phosphodiesterase 1 is a gene product of TDP1. Furthermore, ciprofloxacin increases the efficacy of the drug ipragliflozin, which in turn is responsible for increasing the efficacy of sulfachlorpyridazine. Nevertheless, it should be noted that ipragliflozin decreases the efficacy of ciprofloxacin, indicating a complex interplay between these drugs.']"
"[{'source_node': {'name': 'ADK'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ribavirin ADME'}}, {'source_node': {'name': 'adenosine kinase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ADK'}}]","[{'source_node': {'name': 'ADK'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ribavirin ADME'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:342', 'target': None, 'metadata': {'node_id': '342', 'node_type': 'PROTEIN', 'display_name': 'adenosine kinase'}}]",0.6,ccc1a005d221afde35e219b53f1df2e2,999b0495ec6aba42047d4f2746b32d64,[],"['The gene ADK acts within the pathway known as Ribavirin ADME.', 'The gene ADK is known to act within the metabolic pathway of Ribavirin ADME.', 'The gene ADK plays a role within the pathway of Ribavirin ADME.']"
"[{'source_node': {'name': 'maternally expressed 3 (non-protein coding)'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'lung neoplasms'}}, {'source_node': {'name': 'maternally expressed 3 (non-protein coding)'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'dermatitis'}}, {'source_node': {'name': 'maternally expressed 3 (non-protein coding)'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'thrombocytopenia'}}, {'source_node': {'name': 'thrombocytopenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'impaired ristocetin-induced platelet aggregation'}}, {'source_node': {'name': 'thrombocytopenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'bruising susceptibility'}}, {'source_node': {'name': 'thrombocytopenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'epistaxis'}}]","[{'source_node': {'name': 'maternally expressed 3 (non-protein coding)'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'lung neoplasms'}}, {'source_node': {'name': 'maternally expressed 3 (non-protein coding)'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'dermatitis'}}, {'source_node': {'name': 'maternally expressed 3 (non-protein coding)'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'thrombocytopenia'}}, {'source_node': {'name': 'thrombocytopenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'bruising susceptibility'}}, {'source_node': {'name': 'thrombocytopenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'epistaxis'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:8267', 'target': None, 'metadata': {'node_id': '8267', 'node_type': 'PHENOTYPE', 'display_name': 'impaired ristocetin-induced platelet aggregation'}}]",0.8461538461538461,2dee9191addb330887730073b767add5,8aff8b5eccfe74bb5e00aacbeb8b66a6,[],[]
"[{'source_node': {'name': 'mitochondrial complex iv deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'bilateral tonic-clonic seizure'}}, {'source_node': {'name': 'mitochondrial complex iv deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'proteinuria'}}, {'source_node': {'name': 'mitochondrial complex iv deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'renal fanconi syndrome'}}, {'source_node': {'name': 'NDUFA4'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'mitochondrial complex iv deficiency'}}, {'source_node': {'name': 'NDUFA4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'TP53 Regulates Metabolic Genes'}}, {'source_node': {'name': 'NDUFA4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Respiratory electron transport'}}]","[{'source_node': {'name': 'mitochondrial complex iv deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'bilateral tonic-clonic seizure'}}, {'source_node': {'name': 'mitochondrial complex iv deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'proteinuria'}}, {'source_node': {'name': 'mitochondrial complex iv deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'renal fanconi syndrome'}}, {'source_node': {'name': 'NDUFA4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'TP53 Regulates Metabolic Genes'}}, {'source_node': {'name': 'NDUFA4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Respiratory electron transport'}}]","[{'type': 'edge_deletion', 'source': 'GENE:30214', 'target': 'DISEASE:10172', 'metadata': None}]",0.9230769230769232,d718ba13f3d29ce8ea1d61fe298f6316,5ecc164071ba6402445662a4741ac8ce,"['The gene NDUFA4 has a critical role in two significant pathways - TP53 regulates metabolic genes and respiratory electron transport. It is known to cause a disease named mitochondrial complex IV deficiency. This disease manifests itself through several phenotypic traits, including bilateral tonic-clonic seizure, proteinuria, and renal Fanconi syndrome.', 'The gene NDUFA4, which acts within the pathway of TP53 regulating metabolic genes and is also involved in respiratory electron transport, has been implicated in causing the condition called mitochondrial complex IV deficiency. This condition is known to have several phenotypes, including bilateral tonic-clonic seizures, proteinuria, and renal Fanconi syndrome.']",[]
"[{'source_node': {'name': 'mitomycin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'em-2'}}, {'source_node': {'name': 'mitomycin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hucct-1'}}, {'source_node': {'name': 'mitomycin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Rash'}}]","[{'source_node': {'name': 'mitomycin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'em-2'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5498', 'target': None, 'metadata': {'node_id': '5498', 'node_type': 'PROTEIN', 'display_name': 'hucct-1'}}, {'type': 'node_removal', 'source': 'SIDE_EFFECT:25', 'target': None, 'metadata': {'node_id': '25', 'node_type': 'SIDE_EFFECT', 'display_name': 'Rash'}}]",0.4285714285714286,c0ba6d822eed0f64ad0b1576bf9fe407,5347781811d5880e06f894f9d5958230,"['The pharmaceutical drug Mitomycin targets not only EM-2 but also HUCCT-1. However, it should be noted that a potential side effect of using Mitomycin is the development of Rash.', 'The drug Mitomycin targets both EM-2 and HUCCT-1. However, a notable side effect of Mitomycin is the development of a rash.', 'The drug Mitomycin is known to target two different proteins, EM-2 and HUCCT-1. As a consequence, rash is a recognized side effect of the drug.', 'The drug mitomycin is known to target two proteins, EM-2 and HUCCT-1. However, a notable side effect of using mitomycin is that it may cause the skin condition known as Rash.', 'The drug Mitomycin is known to target EM-2 and HUCCT-1. A notable side effect of Mitomycin is the occurrence of a rash.']",['The drug Mitomycin has been identified to target EM-2.']
"[{'source_node': {'name': '20(s)-hydroxycholesterol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'oxysterols receptor lxr-alpha'}}, {'source_node': {'name': '20(s)-hydroxycholesterol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear receptor ror-gamma'}}]","[{'source_node': {'name': '20(s)-hydroxycholesterol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'oxysterols receptor lxr-alpha'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5873', 'target': None, 'metadata': {'node_id': '5873', 'node_type': 'PROTEIN', 'display_name': 'nuclear receptor ror-gamma'}}]",0.6,53683e7ed1f29a34a28262dd3b33aa58,31e506a7487deff9b695b480ebfbdb18,"['The compound 20(s)-hydroxycholesterol targets two distinct receptors: the oxysterols receptor lxr-alpha and the nuclear receptor ror-gamma.', 'The compound 20(s)-hydroxycholesterol targets two specific receptors: the oxysterols receptor lxr-alpha and the nuclear receptor ror-gamma.', 'The compound 20(S)-hydroxycholesterol targets two distinct receptors in the body, the oxysterols receptor LXR-alpha and the nuclear receptor ROR-gamma.', 'The compound 20(s)-hydroxycholesterol displays its biological effects by targeting two primary sites. The first is the oxysterols receptor lxr-alpha and the second is the nuclear receptor ror-gamma.', 'The compound 20(s)-hydroxycholesterol targets two specific receptors: the oxysterols receptor lxr-alpha and the nuclear receptor ror-gamma.']","['The compound 20(s)-hydroxycholesterol has a targeted interaction with the oxysterols receptor lxr-alpha.', 'The compound 20(s)-hydroxycholesterol has a target interaction with the oxysterols receptor lxr-alpha.', 'The compound 20(s)-hydroxycholesterol has the oxysterols receptor LXR-alpha as its target.', 'The compound 20(s)-hydroxycholesterol has a target interaction with the oxysterols receptor lxr-alpha.', 'The compound 20(s)-hydroxycholesterol has been identified as having the oxysterols receptor lxr-alpha as its target.']"
"[{'source_node': {'name': '4,5-dicaffeoylquinic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'amyloid beta a4 protein'}}, {'source_node': {'name': '4,5-dicaffeoylquinic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'u-251'}}, {'source_node': {'name': '4,5-dicaffeoylquinic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}]","[{'source_node': {'name': '4,5-dicaffeoylquinic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'amyloid beta a4 protein'}}, {'source_node': {'name': '4,5-dicaffeoylquinic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'u-251'}}]","[{'type': 'node_removal', 'source': 'GENE:32076', 'target': None, 'metadata': {'node_id': '32076', 'node_type': 'GENE', 'display_name': 'PTPN1'}}, {'type': 'node_removal', 'source': 'PROTEIN:1921', 'target': None, 'metadata': {'node_id': '1921', 'node_type': 'PROTEIN', 'display_name': 'tyrosine-protein phosphatase non-receptor type 1'}}]",0.5555555555555556,18eae881e07e5b10c7d62bae3e23f5cb,4222042fe6a8a14d030412efa2b0451c,"['The compound 4,5-dicaffeoylquinic acid is known to target several molecules and cells, such as the amyloid beta a4 protein, a cell line named u-251, and the tyrosine-protein phosphatase non-receptor type 1. Interestingly, this latter target is a gene product of the PTPN1 gene.', 'The compound 4,5-dicaffeoylquinic acid targets several elements, including the amyloid beta a4 protein, u-251, and the tyrosine-protein phosphatase non-receptor type 1. It is also noteworthy to mention that tyrosine-protein phosphatase non-receptor type 1 is a gene product of PTPN1.', 'The compound 4,5-dicaffeoylquinic acid targets several entities including the amyloid beta a4 protein, u-251, and tyrosine-protein phosphatase non-receptor type 1. Interestingly, the tyrosine-protein phosphatase non-receptor type 1 is a gene product of PTPN1.']","['The compound 4,5-dicaffeoylquinic acid targets both the amyloid beta a4 protein and U-251.']"
"[{'source_node': {'name': 'nor-3s,14s-petrocortyne a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'nor-3s,14s-petrocortyne a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-ov-3'}}, {'source_node': {'name': 'nor-3s,14s-petrocortyne a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'xf498'}}]","[{'source_node': {'name': 'nor-3s,14s-petrocortyne a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'xf498'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4979', 'target': None, 'metadata': {'node_id': '4979', 'node_type': 'PROTEIN', 'display_name': 'sk-ov-3'}}, {'type': 'node_removal', 'source': 'PROTEIN:5849', 'target': None, 'metadata': {'node_id': '5849', 'node_type': 'PROTEIN', 'display_name': 'a549'}}]",0.4285714285714286,5f6dc707beb1edf24fc1504db7d9f532,8a66585c57621980991ef652f22d8d1a,"['The compound nor-3s,14s-petrocortyne A has several biological targets. It specifically targets A549, SK-OV-3, and XF498.', 'The compound nor-3s,14s-petrocortyne A acts on multiple targets including the A549, SK-OV-3, and XF498 cancer cell lines.', 'The drug Nor-3s,14s-petrocortyne A has multiple targets which include A549, SK-OV-3, and XF498.', 'The drug nor-3s,14s-petrocortyne A has been identified to target a variety of entities including A549, SK-OV-3, and XF498.', 'The compound Nor-3s,14s-petrocortyne A is observed to have specific targets which are A549, SK-OV-3, and XF498.']","['The compound nor-3s,14s-petrocortyne A has the molecular target known as XF498.', 'The compound nor-3s,14s-petrocortyne A has a target interaction with XF498.', 'The compound nor-3s,14s-petrocortyne A is seen to have a target association with xf498.', 'The compound nor-3s,14s-petrocortyne A has a target that is identified as XF498.', 'The drug nor-3s,14s-petrocortyne A is known to target the protein, XF498.']"
"[{'source_node': {'name': 'HNRNPH2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'mental retardation'}}, {'source_node': {'name': 'HNRNPH2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'mRNA Splicing - Major Pathway'}}, {'source_node': {'name': 'HNRNPH2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Processing of Capped Intron-Containing Pre-mRNA'}}]","[{'source_node': {'name': 'HNRNPH2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Processing of Capped Intron-Containing Pre-mRNA'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:191', 'target': None, 'metadata': {'node_id': '191', 'node_type': 'PATHWAY', 'display_name': 'mRNA Splicing - Major Pathway'}}, {'type': 'node_removal', 'source': 'DISEASE:4510', 'target': None, 'metadata': {'node_id': '4510', 'node_type': 'DISEASE', 'display_name': 'mental retardation'}}]",0.4285714285714286,ed10c3911d8fc71a06a031214aab858c,720be79ede6ec23bc37668c4e98d50b7,"['The gene HNRNPH2 is found to act within several biological processes such as the mRNA splicing - major pathway and the processing of capped intron-containing pre-mRNA. Furthermore, anomalies in HNRNPH2 are known to cause conditions like mental retardation.']",[]
"[{'source_node': {'name': ""2'-methoxyformonetin""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 't47d'}}, {'source_node': {'name': ""2'-methoxyformonetin""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': '3-hydroxyacyl-coa dehydrogenase type-2'}}, {'source_node': {'name': ""2'-methoxyformonetin""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'retinal dehydrogenase 1'}}]","[{'source_node': {'name': ""2'-methoxyformonetin""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 't47d'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:534', 'target': None, 'metadata': {'node_id': '534', 'node_type': 'PROTEIN', 'display_name': '3-hydroxyacyl-coa dehydrogenase type-2'}}, {'type': 'node_removal', 'source': 'PROTEIN:579', 'target': None, 'metadata': {'node_id': '579', 'node_type': 'PROTEIN', 'display_name': 'retinal dehydrogenase 1'}}]",0.4285714285714286,f5d9ff5163e1c67ed2e99c5ae6d8b4ee,3ae98c3e48f45d10c65e9fd3d50c1209,"[""The compound 2'-methoxyformonetin targets several proteins and cell structures - specifically, it targets T47D, a type of breast cancer cell line, the protein 3-Hydroxyacyl-CoA Dehydrogenase Type-2, and Retinal Dehydrogenase 1. It is worth noting that these targets are involved in various cellular processes and metabolic pathways, potentially indicating multiple modes of action or effects for this compound."", ""The compound 2'-methoxyformonetin targets several entities including T47D, 3-hydroxyacyl-CoA dehydrogenase type-2, and retinal dehydrogenase 1."", ""The compound 2'-methoxyformonetin primarily targets T47D, the enzyme 3-hydroxyacyl-CoA dehydrogenase type-2, and retinal dehydrogenase 1. It exhibits its various therapeutic effects through interactions with these targets."", ""The compound 2'-methoxyformonetin targets several entities, namely T47D, the enzyme 3-hydroxyacyl-coa dehydrogenase type-2, and retinal dehydrogenase 1."", ""The compound 2'-methoxyformonetin targets several entities including T47D, a subtype of breast cancer cells, as well as two enzymes: 3-hydroxyacyl-CoA dehydrogenase type-2 and retinal dehydrogenase 1.""]","[""The drug 2'-methoxyformonetin has been shown to target T47D, a human breast cancer cell line used in cancer research."", ""The chemical compound 2'-methoxyformonetin has a biochemical interaction with T47D."", ""The compound 2'-methoxyformonetin has been found to target T47D."", ""The substance known as 2'-methoxyformonetin acts on a specific target, T47D."", ""The substance known as 2'-methoxyformonetin is understood to have the cell line T47D as its target.""]"
"[{'source_node': {'name': 'neurodegeneration with brain iron accumulation 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'neurodegeneration'}}, {'source_node': {'name': 'neurodegeneration with brain iron accumulation 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'tremor'}}, {'source_node': {'name': 'WDR45'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neurodegeneration with brain iron accumulation 5'}}, {'source_node': {'name': 'WDR45'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'albinism'}}, {'source_node': {'name': 'WDR45'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'infantile spasms syndrome'}}, {'source_node': {'name': 'albinism'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'strabismus'}}, {'source_node': {'name': 'albinism'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autosomal recessive inheritance'}}, {'source_node': {'name': 'albinism'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'partial albinism'}}]","[{'source_node': {'name': 'neurodegeneration with brain iron accumulation 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'neurodegeneration'}}, {'source_node': {'name': 'neurodegeneration with brain iron accumulation 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'tremor'}}, {'source_node': {'name': 'neurodegeneration with brain iron accumulation 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'partial albinism'}}, {'source_node': {'name': 'neurodegeneration with brain iron accumulation 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autosomal recessive inheritance'}}, {'source_node': {'name': 'albinism'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autosomal recessive inheritance'}}, {'source_node': {'name': 'albinism'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'partial albinism'}}, {'source_node': {'name': 'albinism'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'neurodegeneration'}}]","[{'type': 'node_removal', 'source': 'GENE:25327', 'target': None, 'metadata': {'node_id': '25327', 'node_type': 'GENE', 'display_name': 'WDR45'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:371', 'target': None, 'metadata': {'node_id': '371', 'node_type': 'PHENOTYPE', 'display_name': 'strabismus'}}, {'type': 'edge_addition', 'source': 'DISEASE:15582', 'target': 'PHENOTYPE:4760', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_addition', 'source': 'DISEASE:14356', 'target': 'PHENOTYPE:1603', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_addition', 'source': 'DISEASE:15582', 'target': 'PHENOTYPE:6', 'metadata': {'predicate': 'has_phenotype'}}]",0.4117647058823529,76b35ccabac9b7e398623821592aa46c,f1a47c91a42fa7d6cfff0aac4655bb5c,"['The gene WDR45 is known to cause several conditions. One of these is neurodegeneration with brain iron accumulation 5, a disease notable for phenotypes such as neurodegeneration and tremor. WDR45 also causes albinism, which is characterized by phenotypes including strabismus, autosomal recessive inheritance, and partial albinism. Furthermore, WDR45 also causes the infantile spasms syndrome. So, all three conditions - neurodegeneration with brain iron accumulation 5, albinism, and infantile spasms syndrome - can be associated with the gene WDR45.', 'The gene WDR45 is implicated in causing several conditions including neurodegeneration with brain iron accumulation 5, albinism and infantile spasms syndrome. Neurodegeneration with brain iron accumulation 5 exhibits phenotypes like neurodegeneration and tremor. Similarly, albinism, which is another condition caused by WDR45, is characterized by phenotypes including strabismus, autosomal recessive inheritance, and partial albinism. Therefore, we see a pattern of neurodegeneration, movement disorders, and skin and eye related changes associated with the mutation of the WDR45 gene symbol.', 'The gene WDR45 is responsible for causing various conditions, such as neurodegeneration with brain iron accumulation 5, albinism, and infantile spasms syndrome. Neurodegeneration with brain iron accumulation 5 encompasses phenotypes such as neurodegeneration and tremor. On the other hand, albinism exhibits characteristics such as strabismus, autosomal recessive inheritance, and partial albinism.', 'The gene WDR45 is responsible for causing a variety of conditions, including neurodegeneration with brain iron accumulation 5, albinism, and infantile spasms syndrome. Neurodegeneration with brain iron accumulation 5 typically presents with phenotypical characteristics such as neurodegeneration and tremors. On the other hand, albinism, another disorder caused by WDR45, is commonly associated with specific phenotypes like strabismus, autosomal recessive inheritance, and partial albinism.', 'The gene WDR45 is known to cause several conditions such as neurodegeneration with brain iron accumulation 5, albinism, and infantile spasms syndrome. Neurodegeneration with brain iron accumulation 5 is characterized by neurodegeneration and tremor. On the other hand, albinism shows various phenotypes such as strabismus, autosomal recessive inheritance, and partial albinism.']","['Neurodegeneration with brain iron accumulation 5 is a condition that is characterized by several symptoms, including neurodegeneration, tremors, partial albinism and follows an autosomal recessive inheritance pattern. Similarly, albinism is another genetically influenced condition, which also has traits such as partial albinism and autosomal recessive inheritance, in addition to neurodegeneration.', 'The diseases neurodegeneration with brain iron accumulation 5 and albinism exhibit several common phenotypes such as neurodegeneration, partial albinism, and autosomal recessive inheritance. Interestingly, the affliction known as neurodegeneration with brain iron accumulation 5 further demonstrates a unique presentation of tremors as part of its phenotype.', 'Neurodegeneration with brain iron accumulation 5 is a condition that exhibits multiple phenotypes such as neurodegeneration, tremor, partial albinism and follows autosomal recessive inheritance. Albinism is another condition associated with phenotypes including autosomal recessive inheritance, partial albinism, and neurodegeneration. Noticeably, partial albinism is a common characteristic of both conditions.']"
"[{'source_node': {'name': 'burttinone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}]","[{'source_node': {'name': 'burttinone'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'PTPN1'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:36018', 'target': 'GENE:32076', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'PROTEIN:1921', 'target': None, 'metadata': {'node_id': '1921', 'node_type': 'PROTEIN', 'display_name': 'tyrosine-protein phosphatase non-receptor type 1'}}]",0.1999999999999999,2b257687529f76d9ef46ab2fb73f1e4a,1344ad0cbdd685a52f1b254278303908,"['The compound Burttinone targets tyrosine-protein phosphatase non-receptor type 1. This protein is a gene product of PTPN1.', 'Burttinone is a drug that has a target known as tyrosine-protein phosphatase non-receptor type 1. This specific protein is a gene product of PTPN1.', 'The compound Burttinone acts by targeting the tyrosine-protein phosphatase non-receptor type 1, which is a gene product of the PTPN1 gene.', 'The compound burttinone has been identified to target a specific protein called tyrosine-protein phosphatase non-receptor type 1. This protein is a gene product of PTPN1.', 'The compound known as Burttinone has a target known as tyrosine-protein phosphatase non-receptor type 1. This particular protein is a gene product of PTPN1.']",['The compound burttinone is known to affect the enzyme PTPN1.']
"[{'source_node': {'name': 'transcription factor p65'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RELA'}}, {'source_node': {'name': '11alpha,13-dihydrohelenalinmethacrylate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'transcription factor p65'}}, {'source_node': {'name': 'RELA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'NF-kB is activated and signals survival'}}, {'source_node': {'name': 'RELA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Interleukin-1 processing'}}, {'source_node': {'name': 'RELA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'The NLRP3 inflammasome'}}]","[{'source_node': {'name': 'transcription factor p65'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RELA'}}, {'source_node': {'name': '11alpha,13-dihydrohelenalinmethacrylate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'transcription factor p65'}}, {'source_node': {'name': '11alpha,13-dihydrohelenalinmethacrylate'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'RELA'}}, {'source_node': {'name': 'RELA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'NF-kB is activated and signals survival'}}, {'source_node': {'name': 'RELA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Interleukin-1 processing'}}, {'source_node': {'name': 'RELA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'The NLRP3 inflammasome'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:43300', 'target': 'GENE:32288', 'metadata': {'predicate': 'is_affecting'}}]",0.9090909090909092,4de7e5c4d2ead296d53311a42f874a1b,3f95141c0960b17b5088cbc1650a1493,[],[]
"[{'source_node': {'name': 'LPG1G2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'FCGR3A-mediated IL10 synthesis'}}, {'source_node': {'name': 'LPG1G2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'FCGR3A-mediated phagocytosis'}}]","[{'source_node': {'name': 'LPG1G2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'FCGR3A-mediated IL10 synthesis'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:56', 'target': None, 'metadata': {'node_id': '56', 'node_type': 'PATHWAY', 'display_name': 'FCGR3A-mediated phagocytosis'}}]",0.6,11eb0b610c0b0f012657044bddafdac1,13a9bab1f4ab3919f66adb970e4b78eb,"['The gene LPG1G2 is involved in both the FCGR3A-mediated IL10 synthesis and FCGR3A-mediated phagocytosis pathways.', 'The gene LPG1G2 is involved in several processes such as the FCGR3A-mediated IL10 synthesis and FCGR3A-mediated phagocytosis.', 'The gene LPG1G2 operates within several pathways such as FCGR3A-mediated IL10 synthesis and FCGR3A-mediated phagocytosis.', 'The gene LPG1G2 acts within the FCGR3A-mediated IL10 synthesis and the FCGR3A-mediated phagocytosis pathways. This role of LPG1G2 helps in understanding its part in crucial cellular processes.', 'The gene LPG1G2 plays an active role within two processes, FCGR3A-mediated IL10 synthesis and FCGR3A-mediated phagocytosis.']","['The gene LPG1G2 is active within the pathway of FCGR3A-mediated IL10 synthesis.', 'The gene LPG1G2 functions within the process of FCGR3A-mediated IL10 synthesis.', 'The gene LPG1G2 operates within the pathway responsible for FCGR3A-mediated IL10 synthesis.', 'The gene LPG1G2 operates within the pathway of FCGR3A-mediated IL10 synthesis.']"
"[{'source_node': {'name': 'rubiyunnanin g'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepg2'}}, {'source_node': {'name': 'rubiyunnanin g'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'pc-3'}}, {'source_node': {'name': 'rubiyunnanin g'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'bgc-823'}}]","[{'source_node': {'name': 'rubiyunnanin g'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'pc-3'}}, {'source_node': {'name': 'rubiyunnanin g'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'bgc-823'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5817', 'target': None, 'metadata': {'node_id': '5817', 'node_type': 'PROTEIN', 'display_name': 'hepg2'}}]",0.7142857142857143,ff4ae137b7a9c934f987a73f78f1f663,890f6cf7be4feed1204009c6bd5b55f3,"['Rubiyunnanin G, a biologically active compound, targets several cancer cell lines in order to exert its medicinal effects. These include HepG2, PC-3, and BGC-823 cells. Each target presents different challenges and opportunities for treatment, and Rubiyunnanin G appears to interact effectively with all of them.', 'The compound Rubiyunnanin G exhibits targeting activity towards several cells including HepG2, PC-3, and BGC-823.', 'The compound rubiyunnanin G specifically targets multiple cells, such as HepG2, PC-3, and BGC-823.', 'Rubiyunnanin G is a drug that has multiple targets, including HepG2, PC-3, and BGC-823 cell lines. These cell lines are commonly used in biomedical research to study the effects of various substances on their growth and survival.', 'Rubiyunnanin G, a known compound, has several cellular targets, specifically HepG2, PC-3, and BGC-823 cells. The mechanism of action of Rubiyunnanin G involves interference with these specific cell lines, indicating its potential effectiveness in impacting cells like HepG2, PC-3 and BGC-823.']","['The compound Rubiyunnanin G is known to target and interact with both PC-3 and BGC-823 cells.', 'The compound Rubiyunnanin G targets two different cells, specifically the PC-3 and BGC-823 cells.', 'The molecule Rubiyunnanin G is known to target various cells, including PC-3 and BGC-823.', 'The compound Rubiyunnanin G has specific targets, which include PC-3 and BGC-823 cells.', 'The compound Rubiyunnanin G is known to target both PC-3 and BGC-823.']"
"[{'source_node': {'name': 'piperrolein b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'intercellular adhesion molecule 1'}}, {'source_node': {'name': 'intercellular adhesion molecule 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ICAM1'}}]","[{'source_node': {'name': 'piperrolein b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'intercellular adhesion molecule 1'}}, {'source_node': {'name': 'piperrolein b'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'ICAM1'}}, {'source_node': {'name': 'intercellular adhesion molecule 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ICAM1'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:38263', 'target': 'GENE:28986', 'metadata': {'predicate': 'is_affecting'}}]",0.8,d76306e0e545e0f075b187ed24a5d0cb,ad338df594482181e692839b42704909,"['The compound piperrolein b has a target, the intercellular adhesion molecule 1, which is a gene product of ICAM1.', 'The compound Piperrolein B has been found to target the Intercellular Adhesion Molecule 1 (ICAM1). This molecule is the gene product of the ICAM1 gene.', 'The compound piperrolein b has a target interaction with the intercellular adhesion molecule 1, which is a gene product of ICAM1.', 'The drug, piperrolein b, has a specific target, which is the intercellular adhesion molecule 1. This molecule is a gene product of ICAM1.', 'The compound piperrolein b targets the protein known as intercellular adhesion molecule 1. This molecule is a product of the gene ICAM1.']","['The drug Piperrolein B is known to target the Intercellular Adhesion Molecule 1. In addition, Piperrolein B is also affecting ICAM1. It is also noteworthy that Intercellular Adhesion Molecule 1 is a gene product of ICAM1.']"
"[{'source_node': {'name': 'myxoid/round cell liposarcoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abdominal pain'}}, {'source_node': {'name': 'myxoid/round cell liposarcoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'gastrointestinal dysmotility'}}, {'source_node': {'name': 'tremor'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'vocal tremor'}}, {'source_node': {'name': 'FUS'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'tremor'}}, {'source_node': {'name': 'FUS'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'myxoid/round cell liposarcoma'}}, {'source_node': {'name': 'FUS'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Processing of Capped Intron-Containing Pre-mRNA'}}]","[{'source_node': {'name': 'myxoid/round cell liposarcoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abdominal pain'}}, {'source_node': {'name': 'myxoid/round cell liposarcoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'gastrointestinal dysmotility'}}, {'source_node': {'name': 'myxoid/round cell liposarcoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'vocal tremor'}}, {'source_node': {'name': 'tremor'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'vocal tremor'}}, {'source_node': {'name': 'tremor'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'gastrointestinal dysmotility'}}]","[{'type': 'node_removal', 'source': 'GENE:27557', 'target': None, 'metadata': {'node_id': '27557', 'node_type': 'GENE', 'display_name': 'FUS'}}, {'type': 'edge_addition', 'source': 'DISEASE:15542', 'target': 'PHENOTYPE:1864', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_addition', 'source': 'DISEASE:1858', 'target': 'PHENOTYPE:8862', 'metadata': {'predicate': 'has_phenotype'}}]",0.4615384615384615,482296e16fef315fe9b45c2c18cfa50d,7227cc5a88806503f5eb206225edbf18,"['The gene FUS, which acts within the processing of capped intron-containing pre-mRNA pathway, is known to cause both tremor and myxoid/round cell liposarcoma. The tremor condition is typically characterized by symptoms such as vocal tremor. On the other hand, myxoid/round cell liposarcoma is often associated with phenotypes like abdominal pain and gastrointestinal dysmotility.', 'The gene FUS, which acts within the pathway for the processing of capped intron-containing pre-mRNA, is known to be involved in the onset of several conditions, including tremor and myxoid/round cell liposarcoma. The condition tremor is often characterized by symptoms such as vocal tremor. On the other hand, myxoid/round cell liposarcoma, a type of cancer, often presents with phenotypes such as abdominal pain and gastrointestinal dysmotility among patients.', 'The gene FUS acts within the pathway of Processing of Capped Intron-Containing Pre-mRNA and is known to cause both myxoid/round cell liposarcoma and tremor. Myxoid/round cell liposarcoma is a rare disease that can present symptoms such as abdominal pain and gastrointestinal dysmotility. On the other hand, the disorder tremor that FUS can cause, can exhibit the unique phenotype of vocal tremor.', 'The gene FUS plays a significant role within the Processing of Capped Intron-Containing Pre-mRNA pathway and is known to cause a number of conditions. These include tremor, which exhibits vocal tremor as a symptom, and the disease myxoid/round cell liposarcoma. Patients diagnosed with myxoid/round cell liposarcoma often complain about having abdominal pain and experiencing gastrointestinal dysmotility.', 'The gene FUS, which operates within the pathway of Processing of Capped Intron-Containing Pre-mRNA, causes several conditions including tremor and myxoid/round cell liposarcoma. Tremors are characterized by symptoms such as a recognisable vocal tremor. Meanwhile, myxoid/round cell liposarcoma is associated with phenotypes like abdominal pain and gastrointestinal dysmotility.']","['Myxoid/round cell liposarcoma, a form of cancer, has associated phenotypes including abdominal pain, gastrointestinal dysmotility, and vocal tremor. These symptoms manifest differently across individuals, for instance, trending towards severity in gastrointestinal dysmotility and a subtle onset in the case of vocal tremor. Moreover, the condition of tremor also has phenotypes namely vocal tremor and gastrointestinal dysmotility. This illustrates how similar symptoms can be shared across different conditions and diseases.', 'The disease known as myxoid/round cell liposarcoma has multiple symptoms, or phenotypes, including abdominal pain, problems in digestive tract movement commonly referred to as gastrointestinal dysmotility, and a condition known as vocal tremor. Tremor, a general term for uncontrolled and rhythmic shaking, can manifest as specific phenotypes, such as the aforementioned vocal tremor and gastrointestinal dysmotility. These symptoms collectively define the condition and present revealing information about the disease.', 'The disease known as myxoid/round cell liposarcoma is characterized by symptoms including abdominal pain, gastrointestinal dysmotility and vocal tremor. It is interesting to note that tremor, another condition, also shares the symptoms of vocal tremor and gastrointestinal dysmotility.', ""Myxoid/round cell liposarcoma, a type of cancer, manifests with a range of symptoms including abdominal pain, gastrointestinal dysmotility, and vocal tremor. It's interesting to note that these last two symptoms are also associated with a condition called tremor, indicating a possible linkage in their pathological pathways."", 'Myxoid/round cell liposarcoma, a rare type of cancer, has several associated phenotypes such as abdominal pain, gastrointestinal dysmotility, and vocal tremor. Interestingly, tremor itself has phenotypes that include vocal tremor and gastrointestinal dysmotility, which overlap with the symptoms of myxoid/round cell liposarcoma.']"
"[{'source_node': {'name': 'pyrantel'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Anorexia'}}, {'source_node': {'name': 'magnesium oxide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'secobarbital'}}, {'source_node': {'name': 'magnesium oxide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'homatropine methylbromide'}}, {'source_node': {'name': 'magnesium oxide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pyrantel'}}]","[{'source_node': {'name': 'homatropine methylbromide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'magnesium oxide'}}, {'source_node': {'name': 'pyrantel'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Anorexia'}}, {'source_node': {'name': 'magnesium oxide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'secobarbital'}}, {'source_node': {'name': 'magnesium oxide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'homatropine methylbromide'}}, {'source_node': {'name': 'magnesium oxide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pyrantel'}}, {'source_node': {'name': 'secobarbital'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pyrantel'}}, {'source_node': {'name': 'secobarbital'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Anorexia'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:710', 'target': 'COMPOUND:1325', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:406', 'target': 'COMPOUND:9165', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:406', 'target': 'SIDE_EFFECT:6', 'metadata': {'predicate': 'has_side_effect'}}]",0.6666666666666667,95451e57f22a5b227e789b298246cf70,24e6617714a73dd23df33a75bb80dac1,"['The drug Pyrantel is known to potentially induce side effects such as Anorexia. Simultaneously, its efficacy can be enhanced by Magnesium Oxide. However, Magnesium Oxide with its ability to alter the effectiveness of drugs, is known to decrease the efficacy of Secobarbital and Homatropine Methylbromide. Thus, users should be aware of these potential interactions and impact on drug effectiveness.', ""The drug Pyrantel can sometimes have Anorexia as a side effect. Meanwhile, Magnesium oxide can adversely affect the efficacy of certain drugs, leading to decreased efficiency of Secobarbital and Homatropine methylbromide. However, it is also reported to increase the effectiveness of Pyrantel. It's essential to keep these interactions in mind when considering a combination of these medicinal compounds."", 'The drug Pyrantel, which has a known side effect of causing Anorexia, is impacted by the substance Magnesium Oxide. This interaction can both increase the efficacy of Pyrantel, and decrease the efficacy of other substances such as Secobarbital and Homatropine Methylbromide.', ""Pyrantel, an anthelmintic drug, is known to cause side effects like Anorexia. Further, its efficacy increases when used in conjunction with magnesium oxide. However, it's noteworthy that magnesium oxide, while positively affecting the potency of pyrantel, tends to decrease the efficacy of secobarbital and homatropine methylbromide. These interactions must be kept in mind when curating a drug regimen for a patient."", 'Pyrantel, a medication used for treating a variety of parasitic worm infections, has been noted to sometimes cause the side effect of anorexia. However, the efficacy of Pyrantel can be increased through concomitant use with Magnesium Oxide. Conversely, Magnesium Oxide has been shown to decrease the efficacy of secobarbital and homatropine methylbromide, two other medications. Therefore, the combined usage of these drugs should be considered with caution.']","['Homatropine methylbromide is a drug known to decrease the efficacy of magnesium oxide. Simultaneously, magnesium oxide lessens the effectiveness of secobarbital and homatropine methylbromide. Interestingly, magnesium oxide also shows an increased efficacy when taken with pyrantel. \n\nOn the other hand, pyrantel, a common antiparasitic drug, has been reported to have a side effect of anorexia. Notably, the drug secobarbital not only increases the efficacy of pyrantel when combined but also demonstrates the same side effect, anorexia. These interactions are important considerations when these drugs are prescribed in combination.', 'The drug homatropine methylbromide has been observed to decrease the efficacy of magnesium oxide. Additionally, magnesium oxide not only decreases the efficacy of homatropine methylbromide but also reduces the efficacy of secobarbital. However, interestingly, magnesium oxide seems to increase the efficacy of pyrantel, a drug which is known to have anorexia as a side effect. Similarly, secobarbital also enhances the efficacy of pyrantel but carries the same side effect of anorexia. Therefore, caution is advised when these drugs are used in combination due to the various interactions that can influence their efficacy and potential side effects.', 'The drug homatropine methylbromide is documented to decrease the efficacy of magnesium oxide. Magnesium oxide, on the other hand, has a diverse interaction pattern. It decreases the efficacy of both secobarbital and homatropine methylbromide, while it substantially increases the efficacy of pyrantel. Pyrantel, a drug commonly used for treating infections caused by worms, may however induce Anorexia as a side-effect. Moreover, this efficacy of pyrantel is escalated by secobarbital, which itself can also lead to anorexia as a side-effect. Thus, care should be taken while using these drugs in combination to avoid adverse interactions or side effects.']"
"[{'source_node': {'name': 'STX16'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pseudohypoparathyroidism'}}, {'source_node': {'name': 'STX16'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pseudohypoparathyroidism type 1b'}}, {'source_node': {'name': 'STX16'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Retrograde transport at the Trans-Golgi-Network'}}]","[{'source_node': {'name': 'STX16'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pseudohypoparathyroidism'}}, {'source_node': {'name': 'STX16'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pseudohypoparathyroidism type 1b'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:313', 'target': None, 'metadata': {'node_id': '313', 'node_type': 'PATHWAY', 'display_name': 'Retrograde transport at the Trans-Golgi-Network'}}]",0.7142857142857143,b90c56f555eeb40212fe1377f043c4df,68aca28c4c5544888aee282842e96d60,"['The gene STX16, which acts within the retrograde transport at the trans-Golgi-network pathway, is known to cause two related conditions: pseudohypoparathyroidism and pseudohypoparathyroidism type 1b.', 'The gene STX16, which acts within the context of the retrograde transport at the Trans-Golgi-Network, is known to cause two specific medical conditions: pseudohypoparathyroidism and pseudohypoparathyroidism type 1b.', 'The gene STX16, which is active within the retrograde transport at the Trans-Golgi-Network pathway, has been found to cause two conditions: pseudohypoparathyroidism and pseudohypoparathyroidism type 1b.']","['The gene STX16 is known to cause the condition pseudohypoparathyroidism, a type of hormonal disorder. Furthermore, this gene is also responsible for causing a specific form of the disease termed as pseudohypoparathyroidism type 1b.', 'The gene STX16 is known to cause two conditions: pseudohypoparathyroidism and its subtype, pseudohypoparathyroidism type 1b.', 'The gene STX16 is known to cause the condition pseudohypoparathyroidism. Interestingly, it also specifically triggers a variant of the disease known as pseudohypoparathyroidism type 1b.', 'The gene STX16 has been found to cause two specific conditions: pseudohypoparathyroidism and pseudohypoparathyroidism type 1b.', 'The gene STX16 is associated with causing several conditions. Notably, it is known to cause pseudohypoparathyroidism and a specific variant of the disorder known as pseudohypoparathyroidism type 1b.']"
"[{'source_node': {'name': 'barber-say syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'gingival overgrowth'}}, {'source_node': {'name': 'TWIST2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'barber-say syndrome'}}, {'source_node': {'name': 'TWIST2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'focal facial dermal dysplasia type iii'}}, {'source_node': {'name': 'TWIST2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Transcriptional regulation by RUNX2'}}, {'source_node': {'name': 'focal facial dermal dysplasia type iii'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'strabismus'}}, {'source_node': {'name': 'focal facial dermal dysplasia type iii'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'downslanted palpebral fissures'}}, {'source_node': {'name': 'focal facial dermal dysplasia type iii'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypopigmented skin patches'}}]","[{'source_node': {'name': 'barber-say syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'gingival overgrowth'}}, {'source_node': {'name': 'barber-say syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'downslanted palpebral fissures'}}, {'source_node': {'name': 'TWIST2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'barber-say syndrome'}}, {'source_node': {'name': 'TWIST2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Transcriptional regulation by RUNX2'}}, {'source_node': {'name': 'focal facial dermal dysplasia type iii'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'strabismus'}}, {'source_node': {'name': 'focal facial dermal dysplasia type iii'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'downslanted palpebral fissures'}}, {'source_node': {'name': 'focal facial dermal dysplasia type iii'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypopigmented skin patches'}}]","[{'type': 'edge_deletion', 'source': 'GENE:25586', 'target': 'DISEASE:5163', 'metadata': None}, {'type': 'edge_addition', 'source': 'DISEASE:4653', 'target': 'PHENOTYPE:377', 'metadata': {'predicate': 'has_phenotype'}}]",0.8666666666666667,abcaf470d9e143be1005a9577ebc49da,d3280349631b33a61b86264bcee48631,"['The gene TWIST2 is involved in the pathway of transcriptional regulation by RUNX2. It is responsible for causing two distinct conditions, Barber-Say syndrome and Focal facial dermal dysplasia type III. Barber-Say syndrome has phenotypic characteristics including gingival overgrowth. Focal facial dermal dysplasia type III manifests diverse symptoms such as strabismus, downslanted palpebral fissures, and hypopigmented skin patches.', 'The gene TWIST2, which operates within the context of transcriptional regulation by RUNX2, is responsible for causing two conditions: Barber-Say syndrome and focal facial dermal dysplasia type III. Barber-Say syndrome is characterized by a phenotype that includes gingival overgrowth, whereas focal facial dermal dysplasia type III manifests as strabismus, downslanted palpebral fissures, and hypopigmented skin patches among its symptoms.', 'The gene TWIST2 is connected to several conditions and operates within a specific biological pathway. It acts within the transcriptional regulation by RUNX2, a process that aids in gene expression within cells. This gene causes two conditions: Barber-Say syndrome and Focal Facial Dermal Dysplasia Type III. Barber-Say syndrome demonstrates the observable phenotypic characteristic of gingival overgrowth. On the other hand, Focal Facial Dermal Dysplasia Type III exhibits several phenotypes, such as strabismus, downslanted palpebral fissures, and hypopigmented skin patches.', 'The gene TWIST2, which acts within the pathway of transcriptional regulation by RUNX2, is associated with causing several conditions, including Barber-Say syndrome and focal facial dermal dysplasia type III. Barber-Say syndrome is characterized by unique features like gingival overgrowth while focal facial dermal dysplasia type III exhibits phenotypical traits such as strabismus, downslanted palpebral fissures, and hypopigmented skin patches.', 'The gene TWIST2, which acts within the transcriptional regulation by RUNX2 pathway, is responsible for causing a number of conditions, including Barber-Say syndrome and focal facial dermal dysplasia type III. Barber-Say syndrome is characterised by symptoms like gingival overgrowth. On the other hand, focal facial dermal dysplasia type III manifests as strabismus, downslanted palpebral fissures, and hypopigmented skin patches.']","['The gene TWIST2, which acts within the pathway of transcriptional regulation by RUNX2, causes Barber-Say syndrome. Barber-Say syndrome exhibits certain phenotypes, including gingival overgrowth and downslanted palpebral fissures. On another note, Focal Facial Dermal Dysplasia Type III, which is characterized by strabismus, downslanted palpebral fissures, and hypopigmented skin patches as its unique phenotypes.', ""Barber-Say Syndrome and Focal Facial Dermal Dysplasia Type III are two distinct medical conditions with unique presentations. Barber-Say Syndrome presents with symptoms such as gingival overgrowth and downslanted palpebral fissures. This condition is caused by the gene TWIST2, which also acts within the pathway responsible for transcriptional regulation by RUNX2. On the other hand, Focal Facial Dermal Dysplasia Type III exhibits symptoms that include strabismus, downslanted palpebral fissures, and hypopigmented skin patches. It's significant to notice that both these disorders present the symptom of downslanted palpebral fissures, yet they symbolize different genomic interference and clinical manifestations.""]"
"[{'source_node': {'name': 'rabdokunmin d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nb-4'}}, {'source_node': {'name': 'rabdokunmin d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'rabdokunmin d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sw480'}}]","[{'source_node': {'name': 'rabdokunmin d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nb-4'}}, {'source_node': {'name': 'rabdokunmin d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sw480'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5849', 'target': None, 'metadata': {'node_id': '5849', 'node_type': 'PROTEIN', 'display_name': 'a549'}}]",0.7142857142857143,3f24a268c34c98993c58a05b25fb9814,6fd53b8be13575e98aa74ec6b4f5f63b,"['The drug Rabdokunmin D is identified to have multiple targets which include NB-4, a human cell line commonly used in cancer research, A549, a model cell line for pulmonary toxicity and drug safety testing, and SW480, another cell line often used for colorectal cancer studies.', 'Rabdokunmin D is known to target several cell lines including NB-4, A549, and SW480.', 'The drug, Rabdokunmin D, targets several entities, including NB-4 which is a type of leukemia cell, as well as A549 and SW480, which are both types of cancer cell lines.', 'The substance Rabdokunmin D targets a number of cells including NB-4, A549, and SW480.', 'Rabdokunmin D is a compound that has several biological targets, including NB-4, A549, and SW480 cells.']","['The compound Rabdokunmin D has been found to target both NB-4 and SW480 cells.', 'The compound Rabdokunmin D is known to target both NB-4 and SW480.', 'The drug Rabdokunmin D has been identified to target both NB-4 and SW480.', 'The drug Rabdokunmin D has two distinct targets: NB-4 and SW480.', 'The drug Rabdokunmin D has been observed to target both NB-4 and SW480.']"
"[{'source_node': {'name': 'psammocinin a2'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'psammocinin a2'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'xf498'}}, {'source_node': {'name': 'psammocinin a2'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-15'}}]","[{'source_node': {'name': 'psammocinin a2'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'xf498'}}, {'source_node': {'name': 'psammocinin a2'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-15'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5849', 'target': None, 'metadata': {'node_id': '5849', 'node_type': 'PROTEIN', 'display_name': 'a549'}}]",0.7142857142857143,b12143ca84161f039b3beca75372ddfb,c7f53fbcc8016bd89667a3742591652b,"['The compound Psammocinin A2 has been found to target several cells, including A549, XF498 and HCT-15.', 'The compound Psammocinin A2 targets several cell lines including A549, XF498, and HCT-15.', 'The drug Psammocinin A2 has several targets which include A549, XF498, and HCT-15.', 'The compound Psammocinin A2 has multiple targets. Notably, it has impacts on A549, XF498, and HCT-15 cell lines.', 'The compound psammocinin a2 has been identified as having several cellular targets. These include A549, XF498, and HCT-15 cells. This suggests that psammocinin a2 may have diverse biological effects across different cellular contexts.']","['The drug Psammocinin A2 targets both XF498 and HCT-15.', 'The compound Psammocinin A2 targets both XF498 and HCT-15.', 'The drug Psammocinin A2 operates by targeting two different entities: XF498 and HCT-15.', 'The drug Psammocinin A2 has multiple targets, specifically XF498 and HCT-15.', 'The drug Psammocinin A2 has been identified to target both XF498 and HCT-15, which suggests its potential therapeutic applications in treating diseases associated with these targets.']"
"[{'source_node': {'name': 'sipholenol k'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'p-glycoprotein 1'}}, {'source_node': {'name': 'p-glycoprotein 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ABCB1'}}]","[{'source_node': {'name': 'sipholenol k'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'p-glycoprotein 1'}}, {'source_node': {'name': 'sipholenol k'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'ABCB1'}}, {'source_node': {'name': 'p-glycoprotein 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ABCB1'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:87735', 'target': 'GENE:30941', 'metadata': {'predicate': 'is_affecting'}}]",0.8,613795e5b334f1f403985df093246d1f,c06c014adfe090a98f20a08e30452ccb,"['The compound Sipholenol K is known to target P-glycoprotein 1. Upon further investigation, it was found that P-glycoprotein 1 is the gene product of the ABCB1 gene.', 'The compound sipholenol k has been identified as a target of p-glycoprotein 1. P-glycoprotein 1 is, in turn, a gene product of ABCB1.', 'The compound Sipholenol K has been found to target a protein known as P-Glycoprotein 1. This protein is known to be a gene product of ABCB1.', 'The drug Sipholenol K has been identified as having a target interaction with P-glycoprotein 1. This protein is known to be a gene product of the ABCB1 gene.', 'The compound Sipholenol K targets P-glycoprotein 1, which is a gene product of ABCB1.']","['The compound Sipholenol K targets P-glycoprotein 1 and affects the ABCB1 gene. Additionally, P-glycoprotein 1 is noted as a gene product of the aforementioned ABCB1.', 'Sipholenol K targets the protein known as P-glycoprotein 1 and affects a gene called ABCB1. Interestingly, P-glycoprotein 1 is also a gene product of ABCB1, which represents a fascinating interplay of genetic expression and targeting.', 'Sipholenol K, a bioactive compound, has a target known as P-glycoprotein 1 and also affects the gene ABCB1. The P-glycoprotein 1 is interestingly a gene product of ABCB1.', 'The compound sipholenol k has been found to target p-glycoprotein 1, which in turn is a gene product of ABCB1. Moreover, sipholenol k is also known to affect ABCB1 directly.', 'Sipholenol K is a compound known to target a specific protein, p-glycoprotein 1. Interestingly, p-glycoprotein 1 is also identified as a gene product of ABCB1. With further effects, Sipholenol K is shown to affect ABCB1 as well. Hence, there is a close functional interplay happening among Sipholenol K, p-glycoprotein 1, and ABCB1.']"
"[{'source_node': {'name': 'ADRA1A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Adrenoceptors'}}, {'source_node': {'name': 'ADRA1A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (q) signalling events'}}, {'source_node': {'name': 'ADRA1A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (12/13) signalling events'}}]","[{'source_node': {'name': 'ADRA1A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Adrenoceptors'}}, {'source_node': {'name': 'ADRA1A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (q) signalling events'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:114', 'target': None, 'metadata': {'node_id': '114', 'node_type': 'PATHWAY', 'display_name': 'G alpha (12/13) signalling events'}}]",0.7142857142857143,8dc6dd3d1c30c6e854674c2c058006da,b299313cb73d8c7c5ef8493c02da4b77,"['The gene ADRA1A is known to act within several pathways. These pathways include adrenoceptors, G alpha (q) signalling events, and G alpha (12/13) signalling events. Each of these pathways play crucial roles in a variety of biological responses, and thorough understanding of their interplay is essential for our understanding of the complex mechanisms at work in our bodies.', 'The gene ADRA1A acts within multiple molecular pathways. These include adrenoceptors and G alpha (q) signalling events, as well as G alpha (12/13) signalling events.', 'The gene ADRA1A is known to act within several pathways. It plays a role in the operation of Adrenoceptors and actively participates in G alpha (q) signalling events. Additionally, ADRA1A is also an integral part of G alpha (12/13) signalling events.', 'The gene ADRA1A plays a significant role within several biochemical pathways. It acts within the adrenoceptors, the G alpha (q) signalling events, and the G alpha (12/13) signalling events.']","['The gene ADRA1A plays a role in several biological mechanisms and pathways. This includes acting within the adrenoceptors and also within the G alpha (q) signalling events.', 'The gene ADRA1A is known to act within multiple processes, such as adrenoceptors and G alpha (q) signalling events.', 'The gene ADRA1A operates within several biological pathways such as adrenoceptors and G alpha (q) signalling events.', 'The gene ADRA1A is involved in two crucial signaling processes. Firstly, it acts within adrenoceptors, a class of G protein-coupled receptors involved in various physiological responses. Secondly, it participates in G alpha (q) signalling events, an essential pathway associated with numerous cellular responses.']"
"[{'source_node': {'name': 'sulindac'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cloprostenol'}}, {'source_node': {'name': 'sulindac'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Haemolytic anaemia'}}, {'source_node': {'name': 'limaprost'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sulindac'}}, {'source_node': {'name': 'limaprost'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'diflunisal'}}, {'source_node': {'name': 'limaprost'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'firocoxib'}}]","[{'source_node': {'name': 'sulindac'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Haemolytic anaemia'}}, {'source_node': {'name': 'sulindac'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'limaprost'}}, {'source_node': {'name': 'limaprost'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sulindac'}}, {'source_node': {'name': 'limaprost'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'diflunisal'}}, {'source_node': {'name': 'limaprost'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'firocoxib'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:9451', 'target': None, 'metadata': {'node_id': '9451', 'node_type': 'COMPOUND', 'display_name': 'cloprostenol'}}, {'type': 'edge_addition', 'source': 'COMPOUND:591', 'target': 'COMPOUND:8146', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.7272727272727273,28edfe4e97e70ddd8c7d01218823fdd2,c5b7932aa5321f292f4cb36afaa21fa3,"['The drug Sulindac has a potential to decrease the efficacy of Cloprostenol. In addition, Sulindac has been reported to have the side effect of causing Haemolytic anaemia. On a similar note, another drug, Limaprost, may decrease the efficacy of Sulindac as well as that of Diflunisal and Firocoxib. Thereby, careful consideration should be given while co-administering these drugs.', 'The drug Sulindac is known to decrease the efficacy of Cloprostenol and is reported to cause a side effect of Haemolytic anaemia. Interestingly, the efficacy of Sulindac itself is decreased by Limaprost. The efficacy of two other drugs, Diflunisal and Firocoxib, is also decreased by Limaprost. Therefore, it is important to consider these interactions before prescribing these drugs in combination.', ""The use of sulindac, a non-steroidal anti-inflammatory drug, can potentially decrease the efficacy of cloprostenol, a drug often used in veterinary medicine. Furthermore, one possible side effect of sulindac usage is the development of Haemolytic anaemia, an autoimmune disease where the body's immune system attacks its own red blood cells. On the other hand, the drug limaprost has been found to decrease the efficacy of not only sulindac, but also of other drugs such as diflunisal and firocoxib. Therefore, caution should be taken when using these combinations of drugs together as it may potentially interfere with their effectiveness."", 'The drug sulindac has been observed to decrease the efficacy of cloprostenol, while also presenting a side effect of haemolytic anaemia. On the other hand, the drug limaprost decreases the efficacy of several drugs including sulindac, diflunisal, and firocoxib. Hence, potential interaction effects should be carefully considered when these drugs are prescribed together.', 'The drug Sulindac has been found to diminish the efficacy of Cloprostenol, suggesting a potential interaction between the two. Interestingly, Sulindac also has a potential harmful side effect, namely Haemolytic anaemia, which should be taken into consideration during treatment decisions. Another drug, Limaprost, has been found to decrease the effectivity of Sulindac, as well as that of other drugs such as Diflunisal and Firocoxib. Thus, if Sulindac and Limaprost are given in conjunction, the overall decreased efficacy could make Sulindac less effective for the condition being treated. This complex interaction between these therapies demonstrates the necessity of in-depth knowledge and careful consideration when designing treatment plans.']","['The drug Sulindac has been known to exhibit a side effect of Haemolytic anaemia. Interestingly, Sulindac and Limaprost interact in a bidirectional manner, where each decrease the efficacy of the other. Furthermore, Limaprost also interferes with the action of other drugs such as Diflunisal and Firocoxib by decreasing their efficacy.', ""Sulindac, a potent medication, has been found to have a side effect of leading to Haemolytic anaemia. In addition, it has been studied that sulindac decreases the efficacy of limaprost. It's important to note that this diminished effectiveness is mutual, as limaprost also has an adverse effect on the efficiency of sulindac. Furthermore, limaprost has also been observed to decrease the efficacy of other medications like diflunisal and firocoxib.""]"
"[{'source_node': {'name': 'propafenone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'liotrix'}}, {'source_node': {'name': 'propafenone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'tofogliflozin'}}, {'source_node': {'name': 'propafenone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Erectile dysfunction'}}]","[{'source_node': {'name': 'liotrix'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'tofogliflozin'}}, {'source_node': {'name': 'tofogliflozin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'propafenone'}}, {'source_node': {'name': 'propafenone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'liotrix'}}, {'source_node': {'name': 'propafenone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'tofogliflozin'}}, {'source_node': {'name': 'propafenone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Erectile dysfunction'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:9739', 'target': 'COMPOUND:1162', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1513', 'target': 'COMPOUND:9739', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7142857142857143,5dac62dbffea11aea456a5488f35f967,05d33bd3f3a96129c0d90a03b951526b,"[""The medication propafenone has varying effects on different drugs; it lessens the efficacy of liotrix while simultaneously enhancing the efficacy of tofogliflozin. However, it's important to note that the use of propafenone might lead to some side effects such as erectile dysfunction."", ""The drug Propafenone presents a complex drug interaction profile. On one side, it is found to decrease the efficacy of Liotrix. On the other side, it surprisingly increases the efficacy of Tofogliflozin. However, it's also important to note that the use of Propafenone is associated with the side effect of erectile dysfunction. This interaction potential should be considered when prescribing a treatment involving these drugs."", 'The drug Propafenone interacts with other medications in various ways. Specifically, its administration can decrease the efficacy of Liotrix and can amplify the efficacy of Tofogliflozin. However, propafenone does have reported side-effects, notably it can possibly lead to erectile dysfunction.', 'The drug propafenone has various interactions with other drugs and effects on the body. For instance, its use can decrease the efficacy of liotrix while simultaneously increasing the efficacy of another drug called tofogliflozin. Notably, a common side effect of using propafenone is the occurrence of erectile dysfunction.', 'The drug propafenone has varying effects on the efficacy of other drugs and can also lead to undesirable side effects. Specifically, it has been observed to decrease the efficacy of liotrix and simultaneously increase the efficacy of tofogliflozin. Additionally, a side effect associated with the use of propafenone is erectile dysfunction.']","['The drug liotrix has been shown to increase the efficacy of another drug, tofogliflozin. Interestingly, tofogliflozin in turn appears to decrease the efficacy of a third drug, propafenone, which also reduces the efficacy of liotrix. However, propafenone can actually enhance the efficacy of tofogliflozin. Use of propafenone may have a side effect, as it has been linked to erectile dysfunction. Such interplay among these three drugs suggests complex pharmacological interactions that can influence their therapeutic effects and potential side effects.', 'Liotrix is known to increase the efficacy of tofogliflozin. However, it is crucial to note that the administration of tofogliflozin can decrease the efficacy of Propafenone. In return, Propafenone also decreases the effectiveness of liotrix, forming an intricate relationship among these medications. Interestingly, Propafenone has been observed to increase the efficacy of tofogliflozin. A noteworthy side effect of the use of Propafenone is erectile dysfunction.', ""The drug liotrix can increase the efficacy of another medication, tofogliflozin. However, tofogliflozin is shown to decrease the efficacy of a different drug, propafenone. Interestingly, propafenone also decreases the efficacy of liotrix, while at the same time it increases the efficacy of tofogliflozin. Moreover, one of the side effects that has been observed with the usage of propafenone is erectile dysfunction. This complex interaction and potential side effects must be taken into careful consideration when prescribing these medications, as they can affect each other's efficacy."", 'Liotrix is known to increase the efficacy of the drug tofogliflozin. However, tofogliflozin can decrease the efficacy of the drug propafenone. Interestingly, propafenone in turn decreases the efficacy of liotrix and increases the therapeutic efficacy of tofogliflozin. In some cases, propafenone has been associated with side effects such as erectile dysfunction.', 'The drug Liotrix has been shown to increase the efficacy of Tofogliflozin. However, Tofogliflozin might lower the efficacy of Propafenone. In return, Propafenone decreases the efficacy of Liotrix while it simultaneously enhances the efficacy of Tofogliflozin. An important note is that the use of Propafenone has been linked to the side effect of Erectile Dysfunction.']"
"[{'source_node': {'name': 'recurrent respiratory papillomatosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'respiratory insufficiency'}}, {'source_node': {'name': 'recurrent respiratory papillomatosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'tachypnea'}}, {'source_node': {'name': 'recurrent respiratory papillomatosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'wheezing'}}]","[{'source_node': {'name': 'recurrent respiratory papillomatosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'respiratory insufficiency'}}, {'source_node': {'name': 'recurrent respiratory papillomatosis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'tachypnea'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:10079', 'target': None, 'metadata': {'node_id': '10079', 'node_type': 'PHENOTYPE', 'display_name': 'wheezing'}}]",0.7142857142857143,75b828db130f1240cebb1db8d5fe5188,741e96d23620f12b78a33dc15af8937a,"[""Recurrent respiratory papillomatosis is a condition characterized by several phenotypes, including respiratory insufficiency, tachypnea, and wheezing. These symptoms collectively suggests a significant impact on the patient's respiratory health.""]",[]
"[{'source_node': {'name': 'cytochrome p450 family 2 subfamily c member 19'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'atrial fibrillation'}}, {'source_node': {'name': 'cytochrome p450 family 2 subfamily c member 19'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'metabolic syndrome'}}, {'source_node': {'name': 'cytochrome p450 family 2 subfamily c member 19'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'mycoses'}}, {'source_node': {'name': 'atrial fibrillation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'permanent atrial fibrillation'}}, {'source_node': {'name': '3-cyano-7-ethoxycoumarin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 2 subfamily c member 19'}}]","[{'source_node': {'name': 'atrial fibrillation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'permanent atrial fibrillation'}}]","[{'type': 'node_removal', 'source': 'GENE:4349', 'target': None, 'metadata': {'node_id': '4349', 'node_type': 'GENE', 'display_name': 'cytochrome p450 family 2 subfamily c member 19'}}]",0.2727272727272727,71c0aa7eaa7e26cb1bd9529c7f4e003f,fe472c7800487e6d37be77285bc3d549,"['The enzyme cytochrome p450 family 2 subfamily c member 19 is known to cause several health conditions including atrial fibrillation, metabolic syndrome, and mycoses. Atrial fibrillation, one of the conditions caused by this enzyme, is characterized by permanent atrial fibrillation. Moreover, it is observed that this enzyme is affected by the compound known as 3-cyano-7-ethoxycoumarin.', 'The enzyme Cytochrome P450 family 2 subfamily c member 19 is known to cause several conditions including atrial fibrillation, metabolic syndrome, and mycoses. Of these, atrial fibrillation has a characteristic phenotype of leading to permanent atrial fibrillation. Interestingly, this enzyme is affected by the compound 3-cyano-7-ethoxycoumarin.', ""The gene named cytochrome p450 family 2 subfamily c member 19 has been associated with the onset of various conditions, namely atrial fibrillation, metabolic syndrome, and mycoses. Atrial fibrillation, one of these conditions, exhibits a phenotype of permanent atrial fibrillation. Meanwhile, the compound 3-cyano-7-ethoxycoumarin is known to affect the functioning of the cytochrome p450 family 2 subfamily c member 19 gene. This intricate interaction within the genetic and metabolic landscape showcases the complexity of the human body's biological processes.""]",[]
"[{'source_node': {'name': 'vtp-27999'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' renal failure, hypotension, and hyperkalemia '}}, {'source_node': {'name': 'vtp-27999'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' nephrotoxicity '}}]","[{'source_node': {'name': 'vtp-27999'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' renal failure, hypotension, and hyperkalemia '}}]","[{'type': 'node_removal', 'source': 'EFFECT:48', 'target': None, 'metadata': {'node_id': '48', 'node_type': 'EFFECT', 'display_name': ' nephrotoxicity '}}]",0.6,8e44d9db574639ac0e4a133f40d239ca,8d29dc22694e5cb31f3375392556989a,[],[]
"[{'source_node': {'name': 'brevipolide b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'brevipolide b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}, {'source_node': {'name': 'brevipolide b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear factor nf-kappa-b p105 subunit'}}, {'source_node': {'name': 'nuclear factor nf-kappa-b p105 subunit'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NFKB1'}}, {'source_node': {'name': 'NFKB1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'FCERI mediated NF-kB activation'}}, {'source_node': {'name': 'NFKB1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Interleukin-1 processing'}}, {'source_node': {'name': 'NFKB1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'HCMV Early Events'}}]","[{'source_node': {'name': 'brevipolide b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'brevipolide b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}, {'source_node': {'name': 'brevipolide b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear factor nf-kappa-b p105 subunit'}}, {'source_node': {'name': 'nuclear factor nf-kappa-b p105 subunit'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NFKB1'}}, {'source_node': {'name': 'NFKB1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'FCERI mediated NF-kB activation'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:318', 'target': None, 'metadata': {'node_id': '318', 'node_type': 'PATHWAY', 'display_name': 'HCMV Early Events'}}, {'type': 'node_removal', 'source': 'PATHWAY:1260', 'target': None, 'metadata': {'node_id': '1260', 'node_type': 'PATHWAY', 'display_name': 'Interleukin-1 processing'}}]",0.7333333333333334,4af60f51c0483099702a057fa0916382,f60edd4ab22044e0306903b868d005ce,"['The compound brevipolide b targets multiple entities including MCF7, HT-29, and the nuclear factor NF-kappa-B p105 subunit. Notably, the nuclear factor NF-kappa-B p105 subunit is the gene product of NFKB1. This gene operates within several processes like FCERI mediated NF-kB activation, Interleukin-1 processing, and HCMV early events, revealing the interconnected networks of these biological entities and processes.\n', 'The substance Brevipolide B targets several elements, which include MCF7, HT-29, and the Nuclear Factor NF-kappa-B p105 subunit. This nuclear factor is a gene product of NFKB1, a gene that acts within several biochemical pathways. These pathways include the FCERI mediated NF-kB activation, Interleukin-1 processing, and HCMV early events.']","['The drug Brevipolide B targets several entities such as MCF7, HT-29, and the Nuclear Factor NF-kappa-B P105 subunit. Interestingly, the Nuclear Factor NF-kappa-B P105 subunit is a gene product of NFKB1. Moreover, NFKB1 is known to act within the pathway of FCERI mediated NF-kB activation.', 'The compound Brevipolide B has been found to target several cellular structures including the MCF7 and HT-29. In addition to these, it also targets the nuclear factor NF-kappa-B p105 subunit. This subunit is a gene product of NFKB1 which acts within the pathway of FCERI mediated NF-kB activation.', 'The compound Brevipolide B is known to target several entities, including MCF7, HT-29, and the nuclear factor NF-kappa-B p105 subunit. Intriguingly, this nuclear factor is a gene product of NFKB1. Moreover, NFKB1 is known to act within a specific pathway called FCERI mediated NF-kB activation. Thus, Brevipolide B, through its various targets, can potentially affect a variety of biological processes.', 'Brevipolide B, a molecule with potential therapeutic properties, targets several biomolecules including MCF7, a widely studied cancer cell line, and HT-29, another cell line utilized in cancer research. In addition, Brevipolide B also targets the Nuclear Factor NF-Kappa-B p105 Subunit, a core component of the NF-Kappa-B protein complex. This particular subunit is a gene product of the NFKB1 gene. NFKB1, in turn, acts within the pathway of FCERI-mediated NF-kB activation, which is an important pathway involved in immunity and inflammation.', 'Brevipolide B is a compound that target several entities including MCF7, HT-29, and the nuclear factor NF-kappa-B p105 subunit. The nuclear factor NF-kappa-B p105 subunit is a gene product of NFKB1. Furthermore, NFKB1 is known to act within the pathway of FCERI mediated NF-kB activation.']"
"[{'source_node': {'name': 'succinic semialdehyde dehydrogenase deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'delayed cns myelination'}}, {'source_node': {'name': 'succinic semialdehyde dehydrogenase deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cerebellar atrophy'}}, {'source_node': {'name': 'succinic semialdehyde dehydrogenase deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypotonia'}}]","[{'source_node': {'name': 'succinic semialdehyde dehydrogenase deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'delayed cns myelination'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:969', 'target': None, 'metadata': {'node_id': '969', 'node_type': 'PHENOTYPE', 'display_name': 'cerebellar atrophy'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:953', 'target': None, 'metadata': {'node_id': '953', 'node_type': 'PHENOTYPE', 'display_name': 'hypotonia'}}]",0.4285714285714286,636bd6d57a01886e8f615d1f4572527f,509b08342516b107af98e8c7cb40a98a,[],[]
"[{'source_node': {'name': 'ACHE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neurotransmitter clearance'}}, {'source_node': {'name': 'stemocurtisinol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'acetylcholinesterase'}}, {'source_node': {'name': 'acetylcholinesterase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACHE'}}]","[{'source_node': {'name': 'ACHE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neurotransmitter clearance'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:82744', 'target': None, 'metadata': {'node_id': '82744', 'node_type': 'COMPOUND', 'display_name': 'stemocurtisinol'}}, {'type': 'node_removal', 'source': 'PROTEIN:273', 'target': None, 'metadata': {'node_id': '273', 'node_type': 'PROTEIN', 'display_name': 'acetylcholinesterase'}}]",0.4285714285714286,59cfda529f8c8b5b4dbcc3a7f9fbec81,dcdda46b37bc2250b63026afaf8b4d63,[],[]
"[{'source_node': {'name': 'pyruvate dehydrogenase deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'trigonocephaly'}}, {'source_node': {'name': 'pyruvate dehydrogenase deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'frontal bossing'}}, {'source_node': {'name': 'pyruvate dehydrogenase deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ventriculomegaly'}}]","[{'source_node': {'name': 'pyruvate dehydrogenase deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'trigonocephaly'}}, {'source_node': {'name': 'pyruvate dehydrogenase deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'frontal bossing'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1557', 'target': None, 'metadata': {'node_id': '1557', 'node_type': 'PHENOTYPE', 'display_name': 'ventriculomegaly'}}]",0.7142857142857143,e33d0b8da65563610e53b0ef00610d29,6f8460bcf684a5fa4dd7314c11a03ed7,"[""Pyruvate dehydrogenase deficiency, a serious metabolic disorder, is characterized by several prominent phenotypes. Among these are trigonocephaly, a condition marked by a triangularly shaped head, frontal bossing, where the forehead appears abnormally prominent or large, and ventriculomegaly, characterized by an increase in the size of the brain's ventricular system."", 'The disorder known as pyruvate dehydrogenase deficiency has several characteristic phenotypes which include trigonocephaly, frontal bossing and ventriculomegaly.', ""Pyruvate dehydrogenase deficiency, a metabolic disorder, manifests various phenotypic traits. This includes trigonocephaly, characterized by a triangular shape of the head, frontal bossing, characterized by an unusually pronounced forehead, and ventriculomegaly, a condition where the brain's ventricles are enlarged."", ""Pyruvate dehydrogenase deficiency is a condition with various phenotypes including trigonocephaly, which results in a triangularly shaped forehead, frontal bossing characterized by a prominent, protruding forehead, and ventriculomegaly, an abnormal enlargement of the brain's ventricles."", '""Pyruvate dehydrogenase deficiency is a condition that presents with various phenotypes including trigonocephaly, frontal bossing, and ventriculomegaly.']","['Pyruvate dehydrogenase deficiency is a medical condition that exhibits multiple phenotypes such as trigonocephaly and frontal bossing.', 'Pyruvate dehydrogenase deficiency, a metabolic disorder, exhibits various phenotypes including trigonocephaly and frontal bossing.']"
"[{'source_node': {'name': 'carbamoyl phosphate synthetase i deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'stroke'}}, {'source_node': {'name': 'carbamoyl phosphate synthetase i deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ataxia'}}, {'source_node': {'name': 'carbamoyl phosphate synthetase i deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'coma'}}]","[{'source_node': {'name': 'carbamoyl phosphate synthetase i deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'coma'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:952', 'target': None, 'metadata': {'node_id': '952', 'node_type': 'PHENOTYPE', 'display_name': 'ataxia'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:985', 'target': None, 'metadata': {'node_id': '985', 'node_type': 'PHENOTYPE', 'display_name': 'stroke'}}]",0.4285714285714286,7bfc26855482f3c5c9c55d58f4c5f804,722d69f650e96668726cf4c65fc87440,"['Carbamoyl phosphate synthetase I deficiency is a medical condition that manifests with several phenotypes such as stroke, ataxia, and coma.', 'Carbamoyl phosphate synthetase I deficiency, a metabolic disorder, exhibits phenotypes which include stroke, ataxia, and even coma.']",[]
"[{'source_node': {'name': 'acetyldigitoxin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' Cardiac Arrhythmia '}}, {'source_node': {'name': 'acetyldigitoxin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'acetyldigitoxin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oxymetazoline'}}, {'source_node': {'name': 'oxymetazoline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'reserpine'}}, {'source_node': {'name': 'oxymetazoline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'paliperidone'}}, {'source_node': {'name': 'oxymetazoline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imidapril'}}]","[{'source_node': {'name': 'acetyldigitoxin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' Cardiac Arrhythmia '}}, {'source_node': {'name': 'acetyldigitoxin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'reserpine'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'reserpine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oxymetazoline'}}, {'source_node': {'name': 'oxymetazoline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'reserpine'}}, {'source_node': {'name': 'oxymetazoline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'paliperidone'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:497', 'target': 'COMPOUND:918', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:196', 'target': 'EFFECT:5', 'metadata': {'predicate': 'has_effect'}}, {'type': 'node_removal', 'source': 'COMPOUND:9699', 'target': None, 'metadata': {'node_id': '9699', 'node_type': 'COMPOUND', 'display_name': 'imidapril'}}, {'type': 'edge_addition', 'source': 'COMPOUND:196', 'target': 'COMPOUND:918', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.6153846153846154,e4b31a4542b187a152dfcfa9d5176cae,d21e39c4f7fa9761a118972874a6efb3,[],[]
"[{'source_node': {'name': 'congenital myasthenic syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'weak cry'}}, {'source_node': {'name': 'congenital myasthenic syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'poor head control'}}]","[{'source_node': {'name': 'congenital myasthenic syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'weak cry'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1768', 'target': None, 'metadata': {'node_id': '1768', 'node_type': 'PHENOTYPE', 'display_name': 'poor head control'}}]",0.6,0dc5768441c76b0cb456d8ca6809a84f,fe2787bbab644830a0e90fdc4c15c748,"['Congenital myasthenic syndrome, a complex neuromuscular disorder, presents several characteristic phenotypes, including a weak cry and poor head control.', 'Congenital myasthenic syndrome is a medical condition characterized by distinct phenotypes, such as a weak cry and poor head control.', 'Congenital myasthenic syndrome is a condition characterized by certain symptoms such as a weak cry and poor head control.']",[]
"[{'source_node': {'name': 'pazopanib'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the immunosuppressive activities '}}, {'source_node': {'name': 'pazopanib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'potassium iodide'}}, {'source_node': {'name': 'pazopanib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'thyrotropin'}}, {'source_node': {'name': 'potassium iodide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cediranib'}}, {'source_node': {'name': 'potassium iodide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'capmatinib'}}]","[{'source_node': {'name': 'pazopanib'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the immunosuppressive activities '}}, {'source_node': {'name': 'pazopanib'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'potassium iodide'}}, {'source_node': {'name': 'potassium iodide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cediranib'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:12847', 'target': None, 'metadata': {'node_id': '12847', 'node_type': 'COMPOUND', 'display_name': 'thyrotropin'}}, {'type': 'node_removal', 'source': 'COMPOUND:9707', 'target': None, 'metadata': {'node_id': '9707', 'node_type': 'COMPOUND', 'display_name': 'capmatinib'}}]",0.6363636363636364,b3605621e56a27d373f0b1973ad81434,03942254e709f7d40749bd1a8464b671,[],[]
"[{'source_node': {'name': 'GNG11'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G-protein activation'}}, {'source_node': {'name': 'GNG11'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Presynaptic function of Kainate receptors'}}, {'source_node': {'name': 'GNG11'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'GPER1 signaling'}}]","[{'source_node': {'name': 'GNG11'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G-protein activation'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:783', 'target': None, 'metadata': {'node_id': '783', 'node_type': 'PATHWAY', 'display_name': 'GPER1 signaling'}}, {'type': 'node_removal', 'source': 'PATHWAY:779', 'target': None, 'metadata': {'node_id': '779', 'node_type': 'PATHWAY', 'display_name': 'Presynaptic function of Kainate receptors'}}]",0.4285714285714286,63da31805e725272f984483cce438e4b,d03edd9011beeacefe1af6bd830d83ae,"['The gene GNG11 operates prominently within several biological processes. These include the activation of G-proteins, playing a role in the presynaptic function of Kainate receptors, and contributing to the signaling of GPER1.']","['The gene GNG11 plays a role in the activation of G-proteins.', 'The gene GNG11 operates within the process of G-protein activation.', 'The gene GNG11 operates within the process of G-protein activation.', 'The gene GNG11 operates within the pathway responsible for G-protein activation.', 'The gene GNG11 plays a role in the process of G-protein activation.']"
"[{'source_node': {'name': 'prelamin-a/c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'LMNA'}}, {'source_node': {'name': 'LMNA'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'mandibuloacral dysplasia'}}, {'source_node': {'name': 'LMNA'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'restrictive dermopathy 1'}}, {'source_node': {'name': '(4-methylphenyl) acetate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prelamin-a/c'}}]","[{'source_node': {'name': 'LMNA'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'mandibuloacral dysplasia'}}, {'source_node': {'name': 'LMNA'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'restrictive dermopathy 1'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:6154', 'target': None, 'metadata': {'node_id': '6154', 'node_type': 'PROTEIN', 'display_name': 'prelamin-a/c'}}]",0.5555555555555556,0f676b526e21398ec2ee2a3abc140f3d,a9a6ee9f8bcefe04716d68839c3b1795,"['The protein prelamin-A/C is a gene product of LMNA. This gene, LMNA, is known to cause various conditions including mandibuloacral dysplasia and restrictive dermopathy 1. Additionally, the (4-methylphenyl) acetate substance targets prelamin-A/C as part of its physiological effects.', 'Prelamin-A/C, a gene product of LMNA, is targeted by the compound known as (4-Methylphenyl) Acetate. The gene LMNA is known to be associated with several medical conditions, specifically the cause of mandibuloacral dysplasia and restrictive dermopathy 1.', 'The protein prelamin-A/C, which is a gene product of LMNA, is targeted by the compound (4-methylphenyl) acetate. The LMNA gene is known to cause conditions such as Mandibuloacral dysplasia and restrictive dermopathy 1.', 'The protein prelamin-a/c, a gene product of LMNA, is implicated in conditions such as mandibuloacral dysplasia and restrictive dermopathy 1. Interestingly, the chemical compound (4-methylphenyl) acetate has been shown to target prelamin-a/c specifically.', 'Prelamin-A/C, a gene product of LMNA, is targeted by the substance known as (4-methylphenyl) acetate. The gene LMNA is also associated with causing two conditions: mandibuloacral dysplasia and restrictive dermopathy 1.']","['The gene LMNA is known to cause multiple conditions. Notably, it is responsible for the development of mandibuloacral dysplasia, a rare genetic disorder characterized by skeletal abnormalities. Additionally, LMNA also causes restrictive dermopathy 1, a severe skin condition often present from birth.', 'The gene LMNA is known to cause multiple conditions, such as mandibuloacral dysplasia and restrictive dermopathy 1.', 'The gene LMNA causes conditions known as mandibuloacral dysplasia and restrictive dermopathy 1.', 'The gene LMNA has been identified as the cause of several conditions, including mandibuloacral dysplasia and restrictive dermopathy 1.', 'The gene LMNA is known to cause several conditions, including mandibuloacral dysplasia and restrictive dermopathy 1. These conditions are directly linked to mutations or disruptions within the LMNA gene.']"
"[{'source_node': {'name': 'H4C5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'HCMV Early Events'}}, {'source_node': {'name': 'H4C5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Defective pyroptosis'}}]","[{'source_node': {'name': 'H4C5'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'HCMV Early Events'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:525', 'target': None, 'metadata': {'node_id': '525', 'node_type': 'PATHWAY', 'display_name': 'Defective pyroptosis'}}]",0.6,42f38b770fa3eba0e335d950f997b975,60d6f87475156769b1717b76b529da0a,"['The gene H4C5 has a role in both HCMV early events and defective pyroptosis. This indicates that this gene takes action within these processes, potentially influencing their outcomes.']",[]
"[{'source_node': {'name': 'classical-like ehlers-danlos syndrome type 2'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'inguinal hernia'}}, {'source_node': {'name': 'classical-like ehlers-danlos syndrome type 2'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'tooth malposition'}}, {'source_node': {'name': 'classical-like ehlers-danlos syndrome type 2'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'bilateral ptosis'}}]","[{'source_node': {'name': 'classical-like ehlers-danlos syndrome type 2'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'tooth malposition'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1104', 'target': None, 'metadata': {'node_id': '1104', 'node_type': 'PHENOTYPE', 'display_name': 'bilateral ptosis'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:21', 'target': None, 'metadata': {'node_id': '21', 'node_type': 'PHENOTYPE', 'display_name': 'inguinal hernia'}}]",0.4285714285714286,141b3e6e3cc163be2458c6b223af1355,0f4feb40308b551963bfc64798330949,"['Classical-like Ehlers-Danlos Syndrome Type 2, a genetic disorder, displays symptoms including an inguinal hernia, tooth malposition, and bilateral ptosis.', 'Classical-like Ehlers-Danlos syndrome type 2 is a condition characterized by several phenotypes, including inguinal hernia, tooth malposition and bilateral ptosis. These manifestations can vary greatly amongst affected individuals, but are typical signs of the syndrome.', 'Classical-like Ehlers-Danlos syndrome type 2 is a condition that has several associated phenotypes, including inguinal hernia, tooth malposition, and bilateral ptosis.', 'Classical-like Ehlers-Danlos syndrome type 2, a genetic condition, manifests certain phenotypes, including an inguinal hernia, tooth malposition, and bilateral ptosis. This syndrome encompasses various complications such as soft tissues normally found inside the groin region pushing into the inguinal canal, misalignment of the teeth, and drooping of both eyelids, respectively.', 'Classical-like Ehlers-Danlos syndrome type 2 is a condition that manifests several physical phenotypes including an inguinal hernia, tooth malposition, and bilateral ptosis.']",[]
"[{'source_node': {'name': 'thorectandrol a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ovcar-3'}}, {'source_node': {'name': 'thorectandrol a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'colo 205'}}]","[{'source_node': {'name': 'thorectandrol a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'colo 205'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5625', 'target': None, 'metadata': {'node_id': '5625', 'node_type': 'PROTEIN', 'display_name': 'ovcar-3'}}]",0.6,d85ee19f02b08ee2d49795e112008491,b311e84a2830b87e35be7fda9408a723,"['The compound Thorectandrol A is known to target and affect various cancer cells including OVCAR-3 and COLO 205.', 'The compound Thorectandrol A targets two different types of cells: OVCAR-3 and COLO 205.', 'The molecule Thorectandrol A targets both OVCAR-3 and COLO 205 cells.', 'Thorectandrol A has been identified as a potential therapeutic agent that targets multiple types of cancer cells such as OVCAR-3 and COLO 205.', 'The compound Thorectandrol A is known to target both OVCAR-3 and COLO 205, prevalent cell lines used in cancer research.']",['The drug Thorectandrol A is designed to target a specific cancer cell line known as Colo 205.']
"[{'source_node': {'name': 'ras-related protein rab-6a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RAB6A'}}, {'source_node': {'name': 'RAB6A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}, {'source_node': {'name': 'RAB6A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'TBC/RABGAPs'}}, {'source_node': {'name': 'RAB6A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RAB GEFs exchange GTP for GDP on RABs'}}]","[{'source_node': {'name': 'RAB6A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}, {'source_node': {'name': 'RAB6A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'TBC/RABGAPs'}}, {'source_node': {'name': 'RAB6A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RAB GEFs exchange GTP for GDP on RABs'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:6726', 'target': None, 'metadata': {'node_id': '6726', 'node_type': 'PROTEIN', 'display_name': 'ras-related protein rab-6a'}}]",0.7777777777777778,1e7f0d29ad16c561859704849c180b54,f283dad9d4a4cdff8fda064e32093e83,"['The ras-related protein rab-6a is a gene product of RAB6A. This particular gene, RAB6A, is instrumental within several biological mechanisms such as neutrophil degranulation and TBC/RABGAPs. Interestingly, RAB6A is also known to function within the pathway RAB GEFs exchange GTP for GDP on RABs, highlighting its importance in diverse cellular processes.']","['The gene RAB6A participates in various biological processes, notably neutrophil degranulation, and the operation of TBC/RABGAPs. Furthermore, RAB6A also acts within the pathway where RAB GEFs exchange GTP for GDP on RABs, playing a key role in these processes.', 'The gene RAB6A is known to act within several pathways such as neutrophil degranulation, TBC/RABGAPs, and RAB GEFs exchange GTP for GDP on RABs. These pathways play a crucial role in different cellular processes including the normal function of immune cells and the regulation of intracellular trafficking.', 'The protein RAB6A plays a role in various biological processes such as neutrophil degranulation, and acts within the pathway of TBC/RABGAPs. In addition, it also participates in the pathway where RAB GEFs exchange GTP for GDP on RABs.', 'The gene RAB6A acts within several processes including neutrophil degranulation, TBC/RABGAPs, and the process where RAB GEFs exchange GTP for GDP on RABs.']"
"[{'source_node': {'name': 'clorazepic acid'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' liver damage '}}, {'source_node': {'name': 'clorazepic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mianserin'}}, {'source_node': {'name': '9-deazaguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clorazepic acid'}}, {'source_node': {'name': '9-deazaguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'estazolam'}}, {'source_node': {'name': '9-deazaguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cinazepam'}}]","[{'source_node': {'name': 'clorazepic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mianserin'}}, {'source_node': {'name': 'clorazepic acid'}, 'relation': {'name': 'decrease_effect'}, 'target_node': {'name': ' liver damage '}}, {'source_node': {'name': 'mianserin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'cinazepam'}}, {'source_node': {'name': '9-deazaguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clorazepic acid'}}, {'source_node': {'name': '9-deazaguanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cinazepam'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:614', 'target': 'COMPOUND:1195', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:1195', 'target': None, 'metadata': {'node_id': '1195', 'node_type': 'COMPOUND', 'display_name': 'estazolam'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5414', 'target': 'COMPOUND:12417', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_replacement', 'source': 'COMPOUND:614', 'target': 'EFFECT:25', 'metadata': {'predicate': 'decrease_effect'}}]",0.6363636363636364,9b5dfa80148c1f5a70ecfda4dad6255c,2a622438c2edd35d5bb8249e808615ff,[],[]
"[{'source_node': {'name': 'nitric oxide synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NOS2'}}, {'source_node': {'name': 'nitric oxide synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NOS3'}}, {'source_node': {'name': 'nitric oxide synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NOS1'}}, {'source_node': {'name': 'NOS2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Inhibition of nitric oxide production'}}, {'source_node': {'name': 's-isopropyl-isothiourea'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nitric oxide synthase'}}]","[{'source_node': {'name': 'nitric oxide synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NOS2'}}, {'source_node': {'name': 'nitric oxide synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NOS3'}}, {'source_node': {'name': 'nitric oxide synthase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NOS1'}}, {'source_node': {'name': 'NOS1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Inhibition of nitric oxide production'}}, {'source_node': {'name': 'NOS2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Inhibition of nitric oxide production'}}, {'source_node': {'name': 's-isopropyl-isothiourea'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nitric oxide synthase'}}]","[{'type': 'edge_addition', 'source': 'GENE:30309', 'target': 'PATHWAY:1849', 'metadata': {'predicate': 'acts_within'}}]",0.9090909090909092,55aafe52908c09744b42165b9ae67239,bad53bd2d1f02955426fb5e9a61a81dd,"['The enzyme called nitric oxide synthase is a gene product of NOS1, NOS2, and NOS3. Interestingly, NOS2 acts within a biological process known as the inhibition of nitric oxide production. The drug s-isopropyl-isothiourea targets this very enzyme, nitric oxide synthase.', 'Nitric oxide synthase is a gene product of NOS1, NOS2 and NOS3. Interestingly, NOS2 acts within the process of inhibition of nitric oxide production. The drug S-isopropyl-isothiourea targets nitric oxide synthase, which adds an intriguing layer to our understanding of its activity.', 'Nitric oxide synthase, a protein targeted by the s-isopropyl-isothiourea, is a gene product of three genes: NOS2, NOS3, and NOS1. Moreover, NOS2 plays an active role within the process known as inhibition of nitric oxide production.', 'Nitric oxide synthase, an essential enzyme, is a gene product of not just one, but three different genes - NOS1, NOS2, and NOS3. Among these, NOS2 is particularly intriguing as it operates within the pathway focused on the inhibition of nitric oxide production. On the other hand, the molecule s-isopropyl-isothiourea specifically targets the enzyme nitric oxide synthase, indicating a probable mechanism by which it mediates biochemical processes.', 'Nitric oxide synthase, a key enzyme involved in nitric oxide production, is a gene product of several genes including NOS2, NOS3, and NOS1. Notably, NOS2 acts within the pathway that leads to the inhibition of nitric oxide production, regulating the levels of this important molecule. The biochemical molecule s-isopropyl-isothiourea is known to target nitric oxide synthase, impacting its activity and thereby influencing the overall production of nitric oxide.']","[""Nitric oxide synthase, the protein product of the genes NOS1, NOS2 and NOS3, serves as a crucial player in the mechanism of multiple processes. Notably, both NOS1 and NOS2 act within the context of the inhibition of nitric oxide production. Furthermore, the substance S-isopropyl-isothiourea is known to target nitric oxide synthase, potentially influencing this protein's involvement in the aforementioned pathway."", 'Nitric oxide synthase, a protein involved in generating nitric oxide in organisms, is the gene product of NOS1, NOS2, and NOS3. Both NOS1 and NOS2 are involved in the pathway known as inhibition of nitric oxide production. In this context, s-isopropyl-isothiourea, a compound known for its bioactivity, specifically targets nitric oxide synthase.', 'Nitric oxide synthase, a enzyme responsible for producing nitric oxide in the body, is a gene product of NOS1, NOS2, and NOS3. Interestingly, NOS1 and NOS2 both participate within the process known as inhibition of nitric oxide production, suggesting a negative feedback mechanism in nitric oxide production where the enzyme limits its own production. Furthermore, the chemical compound known as S-isopropyl-isothiourea has been found to target nitric oxide synthase in various biological experiments signifying another level of possible regulatory control.', 'Nitric oxide synthase is a gene product of several genes, namely NOS1, NOS2, and NOS3. These genes act within a pathway known as inhibition of nitric oxide production. Specifically, NOS1 and NOS2 have been identified to play significant roles in this process. Additionally, a chemical compound known as S-isopropyl-isothiourea targets nitric oxide synthase.']"
"[{'source_node': {'name': 'polyphillin c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'panc-1'}}, {'source_node': {'name': 'polyphillin c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}]","[{'source_node': {'name': 'polyphillin c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5707', 'target': None, 'metadata': {'node_id': '5707', 'node_type': 'PROTEIN', 'display_name': 'panc-1'}}]",0.6,bfacc89d22f59eb0b340b28ba7326f8f,b5539275a42788ba2788cd51189f8732,"['The drug Polyphillin C has been identified to target multiple cell lines, including Panc-1 and MCF7.', 'The drug Polyphillin C is designed with specific targets in mind, including the Panc-1 and MCF7 cancer cell lines. This illustrates the increasingly personalized approach being taken in drug development, focusing on individual cellular or molecular targets for maximum effect.', 'The drug Polyphillin C is known to target both Panc-1 and MCF7 cells.', 'The compound Polyphillin C has been identified to target two types of cells, one being Panc-1 and the other being MCF7.', 'The drug, Polyphillin C, targets two distinct cells: Panc-1 and MCF7.']",['The drug polyphillin C has been noted to specifically target MCF7.']
"[{'source_node': {'name': 'tranexamic acid'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Haemophilia'}}, {'source_node': {'name': 'tranexamic acid'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Nausea'}}, {'source_node': {'name': 'tranexamic acid'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Sinus congestion'}}]","[{'source_node': {'name': 'tranexamic acid'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Haemophilia'}}]","[{'type': 'node_removal', 'source': 'SIDE_EFFECT:777', 'target': None, 'metadata': {'node_id': '777', 'node_type': 'SIDE_EFFECT', 'display_name': 'Sinus congestion'}}, {'type': 'node_removal', 'source': 'SIDE_EFFECT:44', 'target': None, 'metadata': {'node_id': '44', 'node_type': 'SIDE_EFFECT', 'display_name': 'Nausea'}}]",0.4285714285714286,668be5512e3e5fa067ee49bcd1353223,2725d0ca33e6f17c9acf9b679a791ae0,"[""Tranexamic acid is indicated for use in the management of Haemophilia, a medical condition that affects the body's ability to clot blood. However, there are potential side effects to consider when taking this medication, which include both Nausea and Sinus congestion."", 'The drug Tranexamic Acid is indicated for the treatment of Haemophilia. However, it is important to note that its usage may lead to some side effects including Nausea and Sinus congestion.', ""Tranexamic acid is a medication that has an indication for treating Haemophilia, a health condition characterized by the body's inability to make blood clots. While beneficial, it comes with potential side effects including nausea and sinus congestion."", ""Tranexamic acid, a medication used widely, has the indication for the treatment of Haemophilia, a genetic disorder that impairs the body's ability to form blood clots. However, the administration of tranexamic acid can potentially lead to side effects such as nausea and sinus congestion."", ""Tranexamic acid is a medication that is indicated for the treatment of Haemophilia, a genetic disorder that affects the body's ability to make blood clots. However, the use of tranexamic acid may lead to side effects such as nausea and sinus congestion.""]","['The drug Tranexamic acid has been indicated for the treatment of Haemophilia.', 'The drug tranexamic acid has an indication for the treatment of Haemophilia.', 'The medication, tranexamic acid, has been indicated for use in the treatment of Haemophilia.', 'Tranexamic acid is indicated for the treatment of Haemophilia.']"
"[{'source_node': {'name': 'KAT2A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pre-NOTCH Transcription and Translation'}}, {'source_node': {'name': 'KAT2A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RNA Polymerase I Transcription Initiation'}}, {'source_node': {'name': 'KAT2A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cardiogenesis'}}, {'source_node': {'name': 'histone acetyltransferase kat2a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KAT2A'}}, {'source_node': {'name': 'methyl nicotinate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'homo sapiens'}}, {'source_node': {'name': 'methyl nicotinate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'skin'}}, {'source_node': {'name': 'methyl nicotinate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histone acetyltransferase kat2a'}}]","[{'source_node': {'name': 'homo sapiens'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KAT2A'}}, {'source_node': {'name': 'skin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KAT2A'}}, {'source_node': {'name': 'KAT2A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cardiogenesis'}}, {'source_node': {'name': 'methyl nicotinate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'homo sapiens'}}, {'source_node': {'name': 'methyl nicotinate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'skin'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:6390', 'target': 'GENE:27912', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'PATHWAY:135', 'target': None, 'metadata': {'node_id': '135', 'node_type': 'PATHWAY', 'display_name': 'Pre-NOTCH Transcription and Translation'}}, {'type': 'node_removal', 'source': 'PATHWAY:449', 'target': None, 'metadata': {'node_id': '449', 'node_type': 'PATHWAY', 'display_name': 'RNA Polymerase I Transcription Initiation'}}, {'type': 'edge_addition', 'source': 'PROTEIN:6337', 'target': 'GENE:27912', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'PROTEIN:2220', 'target': None, 'metadata': {'node_id': '2220', 'node_type': 'PROTEIN', 'display_name': 'histone acetyltransferase kat2a'}}]",0.4666666666666667,005b0fd84efab3cf948f93424869ec08,f1c8466d44fab89123f2d024cfca304e,[],[]
"[{'source_node': {'name': 'psammocinin a2'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-mel-2'}}, {'source_node': {'name': 'psammocinin a2'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-15'}}]","[{'source_node': {'name': 'psammocinin a2'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-mel-2'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4982', 'target': None, 'metadata': {'node_id': '4982', 'node_type': 'PROTEIN', 'display_name': 'hct-15'}}]",0.6,4cda6472c09819857162ef7be7b92b56,94aacdaf39a4c0e86a8e7ee0d6022a83,"['The drug Psammocinin A2 targets both SK-MEL-2 and HCT-15.', 'The compound psammocinin a2 has been found to target two different cell lines, specifically SK-MEL-2 and HCT-15.', 'The compound Psammocinin A2 has been shown to target both SK-MEL-2 and HCT-15.', 'Psammocinin A2, a potent cytotoxic agent, is known to target several cell lines. Specifically, it has been observed to target both SK-MEL-2 and HCT-15 cancer cell lines in drug resistance studies.', 'Psammocinin A2 is a chemical compound known to interact with targets such as SK-MEL-2 and HCT-15.']","['The compound Psammocinin A2 has the cell line SK-MEL-2 as its target.', 'The drug Psammocinin A2 has as its target the protein SK-MEL-2.', 'The drug Psammocinin A2 has been identified to target SK-MEL-2.']"
"[{'source_node': {'name': ""(2s)-3',4'-dihydroxy-5,7-dimethoxyflavan""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h187'}}, {'source_node': {'name': ""(2s)-3',4'-dihydroxy-5,7-dimethoxyflavan""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': ""(2s)-3',4'-dihydroxy-5,7-dimethoxyflavan""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'kb'}}]","[{'source_node': {'name': ""(2s)-3',4'-dihydroxy-5,7-dimethoxyflavan""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h187'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5851', 'target': None, 'metadata': {'node_id': '5851', 'node_type': 'PROTEIN', 'display_name': 'mcf7'}}, {'type': 'node_removal', 'source': 'PROTEIN:5858', 'target': None, 'metadata': {'node_id': '5858', 'node_type': 'PROTEIN', 'display_name': 'kb'}}]",0.4285714285714286,04790d0c7ba8d43ab1287c3b239a0eac,ba0524c6d02cd612abe2a93a84364dc5,[],[]
"[{'source_node': {'name': 'GSTZ1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'maleylacetoacetate isomerase deficiency'}}, {'source_node': {'name': 'GSTZ1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glutathione conjugation'}}, {'source_node': {'name': 'GSTZ1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Tyrosine catabolism'}}, {'source_node': {'name': 'maleylacetoacetate isomerase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GSTZ1'}}]","[{'source_node': {'name': 'GSTZ1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glutathione conjugation'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:446', 'target': None, 'metadata': {'node_id': '446', 'node_type': 'PROTEIN', 'display_name': 'maleylacetoacetate isomerase'}}, {'type': 'node_removal', 'source': 'DISEASE:14032', 'target': None, 'metadata': {'node_id': '14032', 'node_type': 'DISEASE', 'display_name': 'maleylacetoacetate isomerase deficiency'}}, {'type': 'node_removal', 'source': 'PATHWAY:1459', 'target': None, 'metadata': {'node_id': '1459', 'node_type': 'PATHWAY', 'display_name': 'Tyrosine catabolism'}}]",0.3333333333333333,173e43a581dea15033f9a2345cc1d412,7d4569f554476fdd5b1115b798aff01f,"['The gene GSTZ1, which is involved in the processes of glutathione conjugation and tyrosine catabolism, is known to cause the condition known as maleylacetoacetate isomerase deficiency. Interestingly, the protein known as maleylacetoacetate isomerase is a gene product of GSTZ1.']","['The gene GSTZ1 functions within the process of glutathione conjugation.', 'The enzyme GSTZ1 operates within the process of glutathione conjugation.']"
"[{'source_node': {'name': 'salvianolic acid a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'carbonic anhydrase 4'}}, {'source_node': {'name': 'salvianolic acid a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'carbonic anhydrase 7'}}, {'source_node': {'name': 'salvianolic acid a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mv4-11'}}, {'source_node': {'name': 'carbonic anhydrase 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA4'}}]","[{'source_node': {'name': 'salvianolic acid a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'carbonic anhydrase 4'}}, {'source_node': {'name': 'salvianolic acid a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'carbonic anhydrase 7'}}, {'source_node': {'name': 'salvianolic acid a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mv4-11'}}, {'source_node': {'name': 'carbonic anhydrase 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA4'}}, {'source_node': {'name': 'carbonic anhydrase 7'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CA4'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:1023', 'target': 'GENE:33600', 'metadata': {'predicate': 'gene_product_of'}}]",0.8888888888888888,b71c54bf944c0fe1e496d4a31bbd5df7,938df69b0f52cd7790474ca398a35533,"['Salvianolic acid A targets three different entities: carbonic anhydrase 4, carbonic anhydrase 7, and mv4-11. Interesting to note is that carbonic anhydrase 4 is actually a gene product of another gene called CA4.', 'Salvianolic acid A is a compound that has multiple targets - one of which is carbonic anhydrase 4, which is a gene product of CA4. Other notable targets of Salvianolic acid A include carbonic anhydrase 7 and mv4-11.', 'Salvianolic acid A is known to target multiple entities, such as carbonic anhydrase 4, carbonic anhydrase 7, and MV4-11. Interestingly, carbonic anhydrase 4 is a gene product of CA4.', 'The drug Salvianolic Acid A has multiple targets. These include Carbonic Anhydrase 4 and Carbonic Anhydrase 7. Additionally, MV4-11 is also a target of this drug. It should be noted that Carbonic Anhydrase 4 is a gene product of CA4.', 'The compound salvianolic acid A targets several proteins including carbonic anhydrase 4, carbonic anhydrase 7, and mv4-11. Interestingly, Carbonic anhydrase 4 is a gene product of the CA4 gene.']","['Salvianolic Acid A is known to target various entities including Carbonic Anhydrase 4, Carbonic Anhydrase 7, and MV4-11. Interestingly, both Carbonic Anhydrase 4 and Carbonic Anhydrase 7 are gene products of CA4.', 'The drug Salvianolic Acid A has been found to target a few proteins, including Carbonic Anhydrase 4 and Carbonic Anhydrase 7. In addition to these, it also targets the MV4-11 protein. Carbonic Anhydrase 4 and Carbonic Anhydrase 7 are interestingly the gene products of the same CA4 gene.', ""Salvianolic acid A is an active biological component that notably targets several entities: carbonic anhydrase 4, carbonic anhydrase 7, and mv4-11. It's interesting to note that both carbonic anhydrase 4 and carbonic anhydrase 7 are gene products of CA4."", 'The drug Salvianolic Acid A targets several molecules, including Carbonic Anhydrase 4, Carbonic Anhydrase 7, and Mv4-11. Interestingly, Carbonic Anhydrase 4 and Carbonic Anhydrase 7 are gene products of the same gene CA4.', 'Salvianolic Acid A targets Carbonic Anhydrase 4, Carbonic Anhydrase 7, and MV4-11. Interestingly, both Carbonic Anhydrase 4 and Carbonic Anhydrase 7 are gene products of CA4.']"
"[{'source_node': {'name': 'aloe-emodin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'intestinal-type alkaline phosphatase'}}, {'source_node': {'name': 'aloe-emodin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'rxf 631'}}, {'source_node': {'name': 'aloe-emodin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mcf7'}}, {'source_node': {'name': 'ALPI'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of PA'}}, {'source_node': {'name': 'ALPI'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Digestion'}}, {'source_node': {'name': 'intestinal-type alkaline phosphatase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALPI'}}]","[{'source_node': {'name': 'aloe-emodin'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'ALPI'}}, {'source_node': {'name': 'ALPI'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis of PA'}}, {'source_node': {'name': 'ALPI'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Digestion'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4829', 'target': None, 'metadata': {'node_id': '4829', 'node_type': 'PROTEIN', 'display_name': 'intestinal-type alkaline phosphatase'}}, {'type': 'edge_addition', 'source': 'COMPOUND:83801', 'target': 'GENE:27541', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:5851', 'target': 'GENE:27541', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'PROTEIN:5851', 'target': None, 'metadata': {'node_id': '5851', 'node_type': 'PROTEIN', 'display_name': 'mcf7'}}, {'type': 'node_removal', 'source': 'PROTEIN:5787', 'target': None, 'metadata': {'node_id': '5787', 'node_type': 'PROTEIN', 'display_name': 'rxf 631'}}]",0.3846153846153846,ddb82834a5140cc1679302743a3afeb8,610aea0c5ee18102f67b969dcb494ea7,"['The compound aloe-emodin has several targets, including intestinal-type alkaline phosphatase, rxf 631, and mcf7. The intestinal-type alkaline phosphatase is a gene product of ALPI, which further acts within two biological processes: the synthesis of PA and digestion.', 'The compound aloe-emodin has been identified as targeting several enzymes and proteins, including intestinal-type alkaline phosphatase, rxf 631, and mcf7. The intestinal-type alkaline phosphatase is a gene product of ALPI, which is a gene that acts within two pathways, namely the synthesis of PA and digestion.', 'Aloe-emodin targets several entities namely intestinal-type alkaline phosphatase, RXF 631, and MCF7. Notably, the intestinal-type alkaline phosphatase is a gene product of ALPI. The gene ALPI contributes to certain vital biological processes including the synthesis of PA and digestion.', 'The drug aloe-emodin has the ability to target various entities such as the intestinal-type alkaline phosphatase, rxf 631, and mcf7. In particular, the intestinal-type alkaline phosphatase is the gene product of ALPI. ALPI is known to act within two different processes, one being the synthesis of PA, and the other being digestion.', 'The compound aloe-emodin has a variety of targets. For one, it targets the intestinal-type alkaline phosphatase, a gene product of ALPI, which acts within the synthesis of PA process and the digestion process. Besides that, aloe-emodin also targets entities rxf 631 and mcf7.']","['The compound aloe-emodin is known for affecting ALPI, an enzyme which performs essential roles within the pathway for the synthesis of PA. Furthermore, ALPI is also crucial in the process of digestion.', 'Aloe-emodin, a naturally occurring substance, is affecting ALPI. ALPI plays a significant role within two distinct metabolic processes, the synthesis of PA and the digestion.']"
"[{'source_node': {'name': 'vibrio cholerae cvd 103-hgr strain live antigen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'afelimomab'}}, {'source_node': {'name': 'vibrio cholerae cvd 103-hgr strain live antigen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'elvitegravir'}}, {'source_node': {'name': 'vibrio cholerae cvd 103-hgr strain live antigen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'onasemnogene abeparvovec'}}]","[{'source_node': {'name': 'vibrio cholerae cvd 103-hgr strain live antigen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'afelimomab'}}, {'source_node': {'name': 'vibrio cholerae cvd 103-hgr strain live antigen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'elvitegravir'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:13047', 'target': 'COMPOUND:8041', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:13047', 'target': None, 'metadata': {'node_id': '13047', 'node_type': 'COMPOUND', 'display_name': 'onasemnogene abeparvovec'}}]",0.7142857142857143,159913c6b072c3a6f6b2a115c0af4851,dd5e9af0f9e319c95033b3dcba2b2d02,"['The Vibrio cholerae CVD 103-Hgr strain live antigen decreases the efficacy of several drugs including Afelimomab, Elvitegravir, and Onasemnogene Abeparvovec.']",[]
"[{'source_node': {'name': 'potassium'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hyperkalemic activities '}}, {'source_node': {'name': 'potassium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'butorphanol'}}, {'source_node': {'name': 'potassium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'remifentanil'}}, {'source_node': {'name': 'butorphanol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dapagliflozin'}}, {'source_node': {'name': 'butorphanol'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Drug withdrawal syndrome'}}]","[{'source_node': {'name': 'potassium'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hyperkalemic activities '}}, {'source_node': {'name': 'potassium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'remifentanil'}}, {'source_node': {'name': 'butorphanol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dapagliflozin'}}, {'source_node': {'name': 'butorphanol'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Drug withdrawal syndrome'}}, {'source_node': {'name': 'remifentanil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dapagliflozin'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:12239', 'target': 'COMPOUND:597', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:882', 'target': 'COMPOUND:5516', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.8181818181818181,ca980b6ab9ffd3ac94bd7b670448d641,c1792ae7af63ae6c5aa4f53edb8bd419,[],[]
"[{'source_node': {'name': 'corticobasal syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'aphasia'}}, {'source_node': {'name': 'corticobasal syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'speech apraxia'}}, {'source_node': {'name': 'corticobasal syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of movement'}}]","[{'source_node': {'name': 'corticobasal syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'aphasia'}}, {'source_node': {'name': 'corticobasal syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of movement'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:7514', 'target': None, 'metadata': {'node_id': '7514', 'node_type': 'PHENOTYPE', 'display_name': 'speech apraxia'}}]",0.7142857142857143,cfcfd6b3cbcba7cd4f27ec21e98cf18e,e4ca27d9ecc4e8b8b43fb15d79934fb4,"[""Corticobasal syndrome, a neurological disorder, presents with various phenotypes, notably aphasia and speech apraxia, both indicating impairment in communication skills. In addition to these symptoms, the disorder also manifests as an abnormality of movement, further compounding the patient's daily life challenges."", 'Corticobasal syndrome, a neurological disorder, exhibits several phenotypes including aphasia, speech apraxia and abnormality of movement. Aphasia involves difficulties in language comprehension and expression, speech apraxia refers to the loss of ability to perform learned purposeful movements, and abnormality of movement encompasses various movement disorders.', 'Corticobasal syndrome, a neurological disorder, has several phenotypic manifestations such as aphasia, speech apraxia, and abnormality of movement. The individuals affected by this disease struggle with language comprehension due to aphasia, have difficulties in planning, coordinating and executing motor movements resulting in speech apraxia, and show signs of abnormality of movement.', 'Corticobasal syndrome is a neurological disorder characterized by a variety of phenotypes including aphasia, which is a difficulty in comprehending or formulating language; speech apraxia, a motor disorder causing difficulty in moving the muscles required for speaking; and general abnormalities of movement.', ""Corticobasal syndrome, a neurological disorder, exhibits several phenotypes including aphasia, speech apraxia, and an abnormality of movement. Aphasia refers to an impaired ability to understand or produce speech, whereas speech apraxia is a motor speech disorder that makes it difficult to speak correctly. Lastly, an abnormality of movement can range from tremors to involuntary muscle contractions, severely impairing the patient's ability to execute coordinated movements.""]","['Corticobasal syndrome, a neurological disorder, presents with various phenotypes such as aphasia, a loss of speech, and an abnormality of movement, which are noted as defining characteristics of this condition.', ""Corticobasal syndrome is a neurological disorder that reflects certain phenotypes such as aphasia, a condition that affects the ability to communicate, and abnormalities of movement, affecting an individual's ability to control their physical actions."", 'Corticobasal syndrome, a neurological disorder, has specific phenotypes including aphasia, a language impairment, and abnormality of movement. Thus, individuals suffering from corticobasal syndrome may experience difficulties with language and show irregular movement patterns.']"
"[{'source_node': {'name': 'AURKA'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'colorectal cancer'}}, {'source_node': {'name': 'AURKA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'SUMOylation of DNA replication proteins'}}, {'source_node': {'name': 'AURKA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'AURKA Activation by TPX2'}}, {'source_node': {'name': 'aurora kinase a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AURKA'}}]","[{'source_node': {'name': 'AURKA'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'colorectal cancer'}}, {'source_node': {'name': 'AURKA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'AURKA Activation by TPX2'}}, {'source_node': {'name': 'aurora kinase a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AURKA'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:627', 'target': None, 'metadata': {'node_id': '627', 'node_type': 'PATHWAY', 'display_name': 'SUMOylation of DNA replication proteins'}}]",0.7777777777777778,a386454073e6b89950fb20f23ddbdbbb,09f34f6bf5efed91634a6e4b7beb39ec,"['AURKA, which is the gene product of aurora kinase a, plays an active role in a couple of pathways. These pathways include SUMOylation of DNA replication proteins and the activation of AURKA by TPX2. Importantly, it is worth noting that AURKA is associated with causing colorectal cancer.', 'The Aurora kinase A, a gene product of AURKA, acts within several pathways including SUMOylation of DNA replication proteins and AURKA activation by TPX2. Notably, AURKA is known to cause colorectal cancer.', 'Aurora kinase A, a gene product of AURKA, plays an active role in several biological processes including SUMOylation of DNA replication proteins and Aurka activation by TPX2. Notably, AURKA is also known to cause colorectal cancer.', 'Aurora kinase A, a gene product of AURKA, operates within several key pathways. These include the SUMOylation of DNA replication proteins and the AURKA Activation by TPX2 pathways. Additionally, AURKA is known to cause colorectal cancer.']","['The gene product known as Aurora Kinase A is produced by the gene AURKA. This gene AURKA acts within a biological pathway known as AURKA Activation by TPX2, and is known to cause the condition referred to as colorectal cancer.']"
"[{'source_node': {'name': 'ABCC6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pseudoxanthoma elasticum'}}, {'source_node': {'name': 'ABCC6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'arterial calcification'}}, {'source_node': {'name': 'ABCC6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'ABC-family proteins mediated transport'}}, {'source_node': {'name': 'multidrug resistance-associated protein 6'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ABCC6'}}]","[{'source_node': {'name': 'ABCC6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'ABC-family proteins mediated transport'}}]","[{'type': 'node_removal', 'source': 'DISEASE:15335', 'target': None, 'metadata': {'node_id': '15335', 'node_type': 'DISEASE', 'display_name': 'arterial calcification'}}, {'type': 'node_removal', 'source': 'DISEASE:14739', 'target': None, 'metadata': {'node_id': '14739', 'node_type': 'DISEASE', 'display_name': 'pseudoxanthoma elasticum'}}, {'type': 'node_removal', 'source': 'PROTEIN:700', 'target': None, 'metadata': {'node_id': '700', 'node_type': 'PROTEIN', 'display_name': 'multidrug resistance-associated protein 6'}}]",0.3333333333333333,a18b3614a2cadedffd29a346a7ec1e85,218cf124b8bfca2a7d1468fe54c89b6a,"['The gene ABCC6 is known to cause two conditions: pseudoxanthoma elasticum and arterial calcification. This gene also acts within the pathway of ABC-family proteins mediated transport. Multidrug resistance-associated protein 6 is identified as a gene product of ABCC6.', 'The gene ABCC6, which is crucial in ABC-family proteins mediated transport, is also known for causing conditions like pseudoxanthoma elasticum and arterial calcification. Interestingly, the multidrug resistance-associated protein 6 is a gene product of ABCC6.', 'The ABCC6 gene, which acts within the ABC-family proteins mediated transport pathway, is responsible for causing conditions like pseudoxanthoma elasticum and arterial calcification. Further, this gene also produces the multidrug resistance-associated protein 6.']","['The gene ABCC6 functions within the process of transport mediated by ABC-family proteins.', 'The gene ABCC6 is known to act within a specific biological process, specifically the transport mediated by ABC-family proteins.', 'The gene ABCC6 acts within the pathway of transport mediated by ABC-family proteins.', 'The gene ABCC6 acts within the pathway of transport mediated by ABC-family proteins.', 'The gene ABCC6 is known to function within the pathway of transport mediated by proteins from the ABC-family.']"
"[{'source_node': {'name': 'levothyroxine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sorafenib'}}, {'source_node': {'name': 'levothyroxine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'glibornuride'}}, {'source_node': {'name': 'levothyroxine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cortisone'}}, {'source_node': {'name': 'glibornuride'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'desogestrel'}}, {'source_node': {'name': 'glibornuride'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'bosentan'}}, {'source_node': {'name': 'glibornuride'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'nadolol'}}]","[{'source_node': {'name': 'cortisone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sorafenib'}}, {'source_node': {'name': 'levothyroxine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sorafenib'}}, {'source_node': {'name': 'levothyroxine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'glibornuride'}}, {'source_node': {'name': 'levothyroxine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cortisone'}}, {'source_node': {'name': 'glibornuride'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'desogestrel'}}, {'source_node': {'name': 'glibornuride'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'bosentan'}}, {'source_node': {'name': 'glibornuride'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'nadolol'}}, {'source_node': {'name': 'glibornuride'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'levothyroxine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:12387', 'target': 'COMPOUND:386', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:7908', 'target': 'COMPOUND:439', 'metadata': {'predicate': 'increase_efficacy'}}]",0.8461538461538461,8d145eec77cae25f0086aa66b68f020b,3b5cf1a95825186814669cb36fa0d297,"['Levothyroxine, a commonly prescribed medication, is known to decrease the efficacy of several drugs including sorafenib, glibornuride, and cortisone. Interestingly, glibornuride, one of the drugs that levothyroxine affects, also has several other interactions. It is known to decrease the efficacy of another medication, desogestrel. However, on the other hand, glibornuride could potentially increase the efficacy of some other drugs including bosentan and nadolol. These drug interactions might influence the effectiveness of the treatment and therefore clinicians must consider them during their prescription writing process.', 'The drug levothyroxine is known to decrease the efficacy of other drugs such as sorafenib, glibornuride, and cortisone. Interestingly, glibornuride also decreases the efficacy of another drug namely, desogestrel, but enhances the efficacy of bosentan and nadolol. This underlines the multifaceted and potentially complex interactions of these drugs within the human body.', 'The drug Levothyroxine is noted to decrease the efficacy of Sorafenib, Glibornuride, and Cortisone. Furthermore, Glibornuride itself has also been found to adversely affect the efficacy of Desogestrel. On the other hand, Bosentan and Nadolol show increased efficacy in the presence of Glibornuride. This indicates the complex interplay between these medications and the need for careful management when used in combination.', ""The drug levothyroxine has been observed to decrease the efficacy of several other drugs, including sorafenib, glibornuride, and cortisone. Interestingly, glibornuride - one of the drugs impacted by levothyroxine - is also involved in modifying the efficacy of other drugs, decreasing the efficacy of desogestrel, while actually increasing the efficacy of bosentan and nadolol. It's crucial to consider these interactions when prescribing and combining these medications."", 'The drug levothyroxine has been observed to decrease the efficacy of several other medications, including sorafenib, glibornuride and cortisone. Meanwhile, glibornuride itself has an interesting dual effect on other drugs. While it decreases the efficacy of desogestrel, it actually increases the efficacy of bosentan and nadolol. This illustrates the complex interactions that can occur between medications.']","['The drug cortisone has been found to decrease the efficacy of sorafenib. Similarly, levothyroxine also decreases the efficacy of sorafenib. Additionally, levothyroxine decreases the efficacy of glibornuride and cortisone. On the other hand, glibornuride has multiple effects on other drugs. It decreases the efficacy of desogestrel while increasing the efficacy of bosentan, nadolol, and levothyroxine. Therefore, these complex drug interactions must be thoroughly understood and considered for effective medical treatment and medication management.', 'Cortisone and levothyroxine both decrease the efficacy of sorafenib. Similarly, levothyroxine also reduces the efficacy of glibornuride and cortisone. Glibornuride, on the other hand, not only decreases the efficacy of desogestrel but also significantly increases the efficacy of bosentan, nadolol, and levothyroxine. It is important to consider these interactions since they could alter the therapeutic effects of these medications.', ""The drugs cortisone and levothyroxine have been found to decrease the efficacy of sorafenib. Levothyroxine not only has this effect on sorafenib, but it also decreases the efficacy of glibornuride and cortisone. On the other hand, glibornuride shows varied drug interactions; it has been observed to decrease the efficacy of desogestrel while increasing the efficacy of drugs like bosentan, nadolol and levothyroxine. It's important to consider these interactions and their potential effects on drug performance."", 'The efficacy of several drugs can be decreased by certain other drugs. For instance, cortisone and levothyroxine have been observed to decrease the efficacy of sorafenib. Similarly, levothyroxine can also decrease the efficacy of glibornuride and cortisone. On the other hand, glibornuride plays a dual role in this complex drug interaction network. While it decreases the efficacy of desogestrel, it increases the efficacy of bosentan, nadolol, and levothyroxine. Hence, understanding these interactions is crucial for effective medication management.', ""The drug cortisone has been found to diminish the effectiveness of sorafenib, which is a concern because levothyroxine can also reduce the efficacy of sorafenib. Moreover, levothyroxine is capable of decreasing the efficacy of glibornuride and cortisone. In addition to this, glibornuride also reduces the effectiveness of desogestrel. However, it's interesting to note that glibornuride increases the efficacy of drugs such as bosentan, nadolol, and levothyroxine. These complex interactions may have important implications for drug therapies and patient outcomes.""]"
"[{'source_node': {'name': 'PTPN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Negative regulation of MET activity'}}, {'source_node': {'name': 'PTPN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of IFNA/IFNB signaling'}}, {'source_node': {'name': 'PTPN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Growth hormone receptor signaling'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}, {'source_node': {'name': 'barbinervic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}]","[{'source_node': {'name': 'PTPN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of IFNA/IFNB signaling'}}, {'source_node': {'name': 'PTPN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Growth hormone receptor signaling'}}, {'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:486', 'target': None, 'metadata': {'node_id': '486', 'node_type': 'PATHWAY', 'display_name': 'Negative regulation of MET activity'}}, {'type': 'node_removal', 'source': 'COMPOUND:31765', 'target': None, 'metadata': {'node_id': '31765', 'node_type': 'COMPOUND', 'display_name': 'barbinervic acid'}}]",0.6363636363636364,08a977f9e1c72077e3f77fe0369209f8,6490bf958260ac975fb3d27be42392dc,"['The drug barbinervic acid is known to target tyrosine-protein phosphatase non-receptor type 1, which is a gene product of the PTPN1 gene. This gene, PTPN1, plays a role within several regulatory pathways. These include the negative regulation of MET activity, regulation of IFNA/IFNB signaling, and growth hormone receptor signaling.', 'The drug barbinervic acid targets tyrosine-protein phosphatase non-receptor type 1, which is a gene product of PTPN1. Notably, PTPN1 plays an extensive role within multiple pathways, such as negative regulation of MET activity, regulation of IFNA/IFNB signaling, and growth hormone receptor signaling.', 'The molecule, barbinervic acid, specifically targets tyrosine-protein phosphatase non-receptor type 1, which is a gene product of PTPN1. Significantly, PTPN1 has been found to act within several pathways such as negative regulation of MET activity, regulation of IFNA/IFNB signaling, and growth hormone receptor signaling.', 'The compound barbinervic acid targets the tyrosine-protein phosphatase non-receptor type 1, which is a gene product of PTPN1. The gene PTPN1 further acts within multiple pathways including negative regulation of MET activity, regulation of IFNA/IFNB signaling, and growth hormone receptor signaling.']","['The gene protein PTPN1, which is a product of the gene tyrosine-protein phosphatase non-receptor type 1, acts within two key pathways: the regulation of IFNA/IFNB signaling, and the growth hormone receptor signaling.']"
"[{'source_node': {'name': 'zuclopenthixol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'etomidate'}}, {'source_node': {'name': 'zuclopenthixol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mazaticol'}}, {'source_node': {'name': 'zuclopenthixol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'amidephrine'}}, {'source_node': {'name': 'dobutamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'zuclopenthixol'}}, {'source_node': {'name': 'dobutamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'orm-12741'}}, {'source_node': {'name': 'dobutamine'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Cardiac index'}}, {'source_node': {'name': 'orm-12741'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ritodrine'}}, {'source_node': {'name': 'orm-12741'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'arformoterol'}}]","[{'source_node': {'name': 'zuclopenthixol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mazaticol'}}, {'source_node': {'name': 'zuclopenthixol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'amidephrine'}}, {'source_node': {'name': 'zuclopenthixol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'orm-12741'}}, {'source_node': {'name': 'dobutamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'orm-12741'}}, {'source_node': {'name': 'dobutamine'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Cardiac index'}}, {'source_node': {'name': 'orm-12741'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ritodrine'}}, {'source_node': {'name': 'orm-12741'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'arformoterol'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:824', 'target': 'COMPOUND:1551', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:1551', 'target': 'COMPOUND:9967', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:282', 'target': None, 'metadata': {'node_id': '282', 'node_type': 'COMPOUND', 'display_name': 'etomidate'}}]",0.7647058823529411,a2cc62dd12dc181f80a9eaba7a351da0,7aed89051b201ca36acf7836e6675be1,"['The drug Zuclopenthixol is known to decrease the efficacy of several other compounds, namely Etomidate, Mazaticol, and Amidephrine. Another drug, Dobutamine, can decrease the effectiveness of Zuclopenthixol as well as a compound known as ORM-12741. Interestingly, Dobutamine has an indication for improving the Cardiac Index, suggesting a potential role in cardiovascular health. ORM-12741 also has interactions with other compounds, as it can decrease the efficacy of Ritodrine and Arformoterol. These intricate relationships highlight the complex interplay of these compounds within the body.\n', 'The drug zuclopenthixol has been known to decrease the efficacy of several other drugs, including etomidate, mazaticol, and amidephrine. Similarly, dobutamine also decreases the effectiveness of certain drugs, such as zuclopenthixol and orm-12741. However, dobutamine also has an indication to improve the cardiac index, a measurement of cardiac performance. On the other hand, orm-12741 seems to diminish the effectiveness of ritodrine and arformoterol.', 'The drug Zuclopenthixol decreases the efficacy of several other drugs including Etomidate, Mazaticol, and Amidephrine. Conversely, there is also a reported decrease in the efficacy of Zuclopenthixol when Dobutamine is introduced. Dobutamine has implications beyond Zuclopenthixol, as it also decreases the efficacy of ORM-12741, a drug used to reduce the effectiveness of Ritodrine and Arformoterol. Notably, Dobutamine has an indication for the cardiac index, an essential measurement in cardiovascular health.', ""The drug Zuclopenthixol has been found to decrease the efficacy of other drugs including Etomidate, Mazaticol, and Amidephrine. Similarly, Dobutamine can also decrease the efficacy of certain drugs, specifically Zuclopenthixol and ORM-12741. However, it's interesting to note that Dobutamine has an indication in improving the Cardiac Index. On the other hand, the drug ORM-12741 could potentially decrease the efficacy of Ritodrine and Arformoterol. Thus, their interactions need to be carefully considered when co-prescribing these drugs."", 'The drug zuclopenthixol has been shown to decrease the efficacy of several drugs, including etomidate, mazaticol, and amidephrine. The drug dobutamine not only decreases the efficacy of zuclopenthixol but also decreases the efficacy of orm-12741, which in turn causes a decline in the efficacy of the drugs ritodrine and arformoterol. Notably, dobutamine has been indicated for use in improving the cardiac index.']","['The drug Zuclopenthixol is known to decrease the efficacy of other drugs such as Mazaticol, Amidephrine and ORM-12741. Similarly, Dobutamine also reduces the effectiveness of ORM-12741. However, Dobutamine has an indication for increasing the Cardiac index. ORM-12741, on the other hand, can lower the efficacy of drugs like Ritodrine and Arformoterol. Therefore, the interactions and interconnected implications of these drugs need to be carefully considered in pharmaceutical and medical scenarios.', 'Zuclopenthixol is a drug known to decrease the efficacy of several other medications such as mazaticol, amidephrine, and orm-12741. Similarly, dobutamine also decreases the efficacy of orm-12741 but interestingly, it also has an indication for improving the Cardiac index, a measure of heart function. On the other hand, orm-12741 can decrease the efficacy of ritodrine and arformoterol, which may further complicate its application in particular therapeutic settings. Understanding these drug interactions is critical for the appropriate use and management of these pharmaceutical agents.', 'The drug zuclopenthixol has been observed to decrease the efficacy of several other drugs including mazaticol, amidephrine, and orm-12741. Similarly, the drug dobutamine also decreases the efficacy of orm-12741, a drug that itself decreases the efficacy of ritodrine and arformoterol. However, dobutamine has a medical indication for improving the Cardiac Index, a measure of heart function.', 'The drug zuclopenthixol decreases the efficacy of several other medications including mazaticol, amidephrine, and orm-12741. Additionally, the drug dobutamine also lowers the efficacy of orm-12741. However, while these drugs might weak the effect of orm-12741, dobutamine nonetheless has an indication for improving the Cardiac index. In a similar fashion, orm-12741 also decreases the efficacy of ritodrine and arformoterol. Therefore, careful consideration should be given when these drugs are to be used in combination as their interactions may potentially impact the overall effectiveness of the treatments.', 'Zuclopenthixol, a clinical drug, is known to decrease the efficacy of several other drugs such as Mazaticol, Amidephrine, and ORM-12741. Similarly, Dobutamine, another medical compound, also decreases the efficacy of ORM-12741 which is in turn associated with reduced efficacy when used in conjunction with Ritodrine and Arformoterol. Interestingly, Dobutamine is commonly indicated to improve the Cardiac Index, a significant clinical metric used in the diagnosis and treatment of cardiac diseases.']"
"[{'source_node': {'name': 'metabotropic glutamate receptor 7'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GRM7'}}, {'source_node': {'name': 'GRM7'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'neurodevelopmental disorder with seizures'}}, {'source_node': {'name': 'GRM7'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'early infantile epileptic encephalopathy'}}]","[{'source_node': {'name': 'metabotropic glutamate receptor 7'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GRM7'}}, {'source_node': {'name': 'GRM7'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'early infantile epileptic encephalopathy'}}]","[{'type': 'node_removal', 'source': 'DISEASE:17571', 'target': None, 'metadata': {'node_id': '17571', 'node_type': 'DISEASE', 'display_name': 'neurodevelopmental disorder with seizures'}}]",0.7142857142857143,22a6545d0e3226fb7dfcf9273f3cb88b,6d024c570d36958535a76fe3098d9688,"['The metabotropic glutamate receptor 7 is a gene product of GRM7. This gene GRM7 is known to cause various conditions including the neurodevelopmental disorder with seizures and early infantile epileptic encephalopathy.', 'The metabotropic glutamate receptor 7, is a gene product of GRM7. Notably, GRM7 is associated with various health conditions. It specifically causes neurodevelopmental disorder with seizures and early infantile epileptic encephalopathy.', 'The Metabotropic Glutamate Receptor 7 is a gene product of GRM7. The gene GRM7 has been found to cause several neurological conditions. These include a neurodevelopmental disorder with seizures and an early infantile epileptic encephalopathy.', 'The gene metabotropic glutamate receptor 7 is a product of the GRM7 gene. The GRM7 gene is responsible for causing conditions such as neurodevelopmental disorder with seizures and early infantile epileptic encephalopathy.', 'The gene product of GRM7 is the metabotropic glutamate receptor 7. The gene GRM7 can result in various conditions, two of which are a neurodevelopmental disorder with seizures and early infantile epileptic encephalopathy.']","['Metabotropic glutamate receptor 7 is a gene product of GRM7, which is known to cause a condition known as early infantile epileptic encephalopathy.', 'The metabotropic glutamate receptor 7 is a gene product of GRM7. This gene, GRM7, plays a significant role in the causation of early infantile epileptic encephalopathy.', 'The metabotropic glutamate receptor 7, which is a gene product of GRM7, has been identified as a cause of early infantile epileptic encephalopathy.', 'The protein, metabotropic glutamate receptor 7, is a gene product of GRM7. In turn, GRM7 is associated with causing a condition known as early infantile epileptic encephalopathy.', 'The metabotropic glutamate receptor 7 is a gene product of GRM7, a gene that is known to trigger a condition referred to as early infantile epileptic encephalopathy.']"
"[{'source_node': {'name': 'retinitis pigmentosa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'constriction of peripheral visual field'}}, {'source_node': {'name': 'retinitis pigmentosa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hyperreflexia'}}, {'source_node': {'name': 'retinitis pigmentosa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'type ii diabetes mellitus'}}, {'source_node': {'name': 'PRPF31'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'retinitis pigmentosa 11'}}, {'source_node': {'name': 'PRPF31'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'retinitis pigmentosa'}}, {'source_node': {'name': 'PRPF31'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'mRNA Splicing - Major Pathway'}}, {'source_node': {'name': 'retinitis pigmentosa 11'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'macular degeneration'}}, {'source_node': {'name': 'retinitis pigmentosa 11'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'macular atrophy'}}]","[{'source_node': {'name': 'retinitis pigmentosa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'constriction of peripheral visual field'}}, {'source_node': {'name': 'retinitis pigmentosa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hyperreflexia'}}, {'source_node': {'name': 'retinitis pigmentosa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'type ii diabetes mellitus'}}, {'source_node': {'name': 'retinitis pigmentosa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'macular atrophy'}}, {'source_node': {'name': 'retinitis pigmentosa 11'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'macular degeneration'}}, {'source_node': {'name': 'retinitis pigmentosa 11'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'macular atrophy'}}, {'source_node': {'name': 'retinitis pigmentosa 11'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hyperreflexia'}}, {'source_node': {'name': 'retinitis pigmentosa 11'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'type ii diabetes mellitus'}}, {'source_node': {'name': 'retinitis pigmentosa 11'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'constriction of peripheral visual field'}}]","[{'type': 'edge_deletion', 'source': 'GENE:27813', 'target': 'DISEASE:14229', 'metadata': None}, {'type': 'edge_addition', 'source': 'DISEASE:14229', 'target': 'PHENOTYPE:1020', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_addition', 'source': 'DISEASE:14229', 'target': 'PHENOTYPE:3969', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_deletion', 'source': 'GENE:27813', 'target': 'DISEASE:2810', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:27813', 'target': None, 'metadata': {'node_id': '27813', 'node_type': 'GENE', 'display_name': 'PRPF31'}}, {'type': 'edge_addition', 'source': 'DISEASE:2810', 'target': 'PHENOTYPE:4730', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_addition', 'source': 'DISEASE:14229', 'target': 'PHENOTYPE:887', 'metadata': {'predicate': 'has_phenotype'}}]",0.4705882352941176,1c2abf1eb08b8e6fc7c42cdfd2901536,dbbd9a595d9b7cd18fc32987e3ea559d,"['Retinitis Pigmentosa and Retinitis Pigmentosa 11 are eye conditions caused by the PRPF31 gene, which operates within the mRNA Splicing - Major Pathway. Both conditions have various phenotypes. For instance, Retinitis Pigmentosa is characterized by symptoms like constriction of peripheral visual field, hyperreflexia and it may also be linked to type II diabetes mellitus. On the other hand, Retinitis Pigmentosa 11 manifests as macular degeneration and macular atrophy.', 'The gene PRPF31 acts within the mRNA Splicing - Major Pathway and is known to cause both retinitis pigmentosa 11 and retinitis pigmentosa, conditions that are characterized by several significant phenotypes. Retinitis pigmentosa, for instance, is associated with the constriction of the peripheral visual field, hyperreflexia, and even Type II diabetes mellitus. On the other hand, retinitis pigmentosa 11 typically manifests as macular degeneration and macular atrophy.']","['Retinitis Pigmentosa, a degenerative eye disorder, manifests various phenotypes including constriction of the peripheral visual field, hyperreflexia, type II diabetes mellitus, and macular atrophy. Likewise, a specific form of the disorder, Retinitis Pigmentosa 11, is associated with a similar range of phenotypes encompassing macular degeneration, macular atrophy, hyperreflexia, type II diabetes mellitus, and constriction of the peripheral visual field.', 'The symptoms of retinitis pigmentosa, a degenerative eye disorder, include constriction of peripheral visual field, hyperreflexia, type II diabetes mellitus, and macular atrophy. A particular form of the disease, retinitis pigmentosa 11, manifests similar phenotypes. Its symptoms include not just macular atrophy and hyperreflexia, but also macular degeneration, type II diabetes mellitus and constriction of peripheral visual field.', 'Retinitis Pigmentosa is a genetic disorder that has several phenotypes or symptoms, which include the constriction of the peripheral visual field, hyperreflexia, type II diabetes mellitus, and macular atrophy. Similarly, Retinitis Pigmentosa 11, a subtype of this disease, is also associated with a number of phenotypes that include macular degeneration and atrophy, hyperreflexia, type II diabetes mellitus, and a constriction of the peripheral visual field. Therefore, it is essential to understand the complexities of these diseases and their various manifestations in order to provide the most effective treatment plan for patients.', 'Retinitis pigmentosa is a genetic disorder characterized by a host of phenotypes including constriction of the peripheral visual field, hyperreflexia, type II diabetes mellitus and macular atrophy. Similarly, a specific subtype of the disease, Retinitis pigmentosa 11 also shows similar symptoms along with the added phenotype of macular degeneration.', 'Retinitis pigmentosa and retinitis pigmentosa 11 are conditions associated with a range of phenotypes. Commonly observed phenotypes in those suffering from retinitis pigmentosa include constriction of the peripheral visual field, hyperreflexia, type II diabetes mellitus, and macular atrophy. Similarly, retinitis pigmentosa 11 is characterized by symptoms such as macular degeneration, macular atrophy, hyperreflexia, type II diabetes mellitus, and constriction of the peripheral visual field.']"
"[{'source_node': {'name': 'DEPDC5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'epilepsy'}}, {'source_node': {'name': 'DEPDC5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'familial focal epilepsy with variable foci'}}, {'source_node': {'name': 'familial focal epilepsy with variable foci'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'multifocal epileptiform discharges'}}, {'source_node': {'name': 'epilepsy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'periorbital fullness'}}, {'source_node': {'name': 'epilepsy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cerebellar vermis hypoplasia'}}, {'source_node': {'name': 'epilepsy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'psychosis'}}]","[{'source_node': {'name': 'DEPDC5'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'familial focal epilepsy with variable foci'}}, {'source_node': {'name': 'familial focal epilepsy with variable foci'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'multifocal epileptiform discharges'}}, {'source_node': {'name': 'epilepsy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'periorbital fullness'}}, {'source_node': {'name': 'epilepsy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cerebellar vermis hypoplasia'}}, {'source_node': {'name': 'epilepsy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'psychosis'}}]","[{'type': 'edge_deletion', 'source': 'GENE:35604', 'target': 'DISEASE:15008', 'metadata': None}]",0.9230769230769232,e081aa294ca1ccca05698d20cfa8d77a,9ffdd294c98fc57cb38a6903aea7513e,"['The gene DEPDC5 is known to cause certain medical conditions, including epilepsy and a specific type of epilepsy known as familial focal epilepsy with variable foci. This specialized form of epilepsy is typically characterized by multifocal epileptiform discharges, a specific type of irregular brain activity. \n\nOn the other hand, epilepsy in general can manifest diverse phenotypes including periorbital fullness, a condition where there is excessive swelling around the eyes. Epilepsy can also lead to cerebellar vermis hypoplasia, a condition marked by underdevelopment of certain structures in the brain. In some cases, epilepsy might even result in psychosis, a severe mental disorder characterized by a disconnection from reality.', 'The gene DEPDC5 has been linked to various neurological conditions. Specifically, it has been identified as the root cause of epilepsy, a condition marked by symptoms such as periorbital fullness, cerebellar vermis hypoplasia, and even psychosis. In a more specific context, DEPDC5 also causes familial focal epilepsy with variable foci - a specific type of epilepsy that is often characterized by multifocal epileptiform discharges.', 'The gene DEPDC5 has been found to cause both epilepsy and a specific form of epilepsy called familial focal epilepsy with variable foci. Both of these conditions are associated with certain phenotypes. Epilepsy is typically characterized by symptoms such as periorbital fullness, cerebellar vermis hypoplasia, and even psychosis. Familial focal epilepsy with variable foci, on the other hand, is characterized by the phenotype of multifocal epileptiform discharges.', 'The gene DEPDC5 is known to cause two types of conditions, epilepsy and familial focal epilepsy with variable foci. Epilepsy is a broad term for neurological disorders that are characterized by recurring seizures. Certain phenotypes, or observable traits, often associated with epilepsy include periorbital fullness, cerebellar vermis hypoplasia, and also psychosis, which are all types of neurological disparities. On the other hand, familial focal epilepsy with variable foci is a more specific form of epilepsy, marked by the phenotype of multifocal epileptiform discharges, suggesting the presence of multiple areas in the brain from where seizures may originate.', 'The gene DEPDC5 is known to cause epilepsy as well as familial focal epilepsy with variable foci. Notably, familial focal epilepsy with variable foci is characterized by the phenotype of multifocal epileptiform discharges. On the other hand, epilepsy is related to several phenotypes like periorbital fullness, cerebellar vermis hypoplasia, and even psychosis.']","['The gene DEPDC5 is a cause of familial focal epilepsy with variable foci, a form of epilepsy that exhibits the phenotype of multifocal epileptiform discharges. Epilepsy, as a broader disease category, can manifest in various ways, including symptoms such as periorbital fullness, cerebellar vermis hypoplasia, and even psychosis.', 'DEPDC5 is a gene known to cause a condition known as familial focal epilepsy with variable foci. This form of epilepsy is characterized by multifocal epileptiform discharges. On a broader scale, epilepsy can manifest several phenotypes such as periorbital fullness, cerebellar vermis hypoplasia, and even psychosis.', 'The gene DEPDC5 causes a condition known as familial focal epilepsy with variable foci, which has a phenotype characterized by multifocal epileptiform discharges. The condition epilepsy, on the other hand, displays phenotypes such as periorbital fullness, cerebellar vermis hypoplasia, and psychosis.', 'The gene DEPDC5 is known to cause a condition called familial focal epilepsy with variable foci. This specific type of epilepsy is characterized by a phenotype of multifocal epileptiform discharges. Broadly speaking, epilepsy can be associated with various symptoms or phenotypes such as periorbital fullness, cerebellar vermis hypoplasia, and notably, psychosis.', 'The gene DEPDC5 is known to cause the condition familial focal epilepsy with variable foci. This particular kind of epilepsy is characterized by symptoms such as multifocal epileptiform discharges. Furthermore, epilepsy as a broader condition can manifest in a variety of phenotypes including periorbital fullness, cerebellar vermis hypoplasia, and even psychosis.']"
"[{'source_node': {'name': 'proprotein convertase 1/3 deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'diarrhea'}}, {'source_node': {'name': 'proprotein convertase 1/3 deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'malabsorption'}}, {'source_node': {'name': 'proprotein convertase 1/3 deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'primary amenorrhea'}}, {'source_node': {'name': 'PCSK1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'proprotein convertase 1/3 deficiency'}}, {'source_node': {'name': 'PCSK1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Peptide hormone biosynthesis'}}, {'source_node': {'name': 'PCSK1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Synthesis, secretion, and deacylation of Ghrelin'}}]","[{'source_node': {'name': 'proprotein convertase 1/3 deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'diarrhea'}}, {'source_node': {'name': 'proprotein convertase 1/3 deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'malabsorption'}}]","[{'type': 'edge_deletion', 'source': 'GENE:30647', 'target': 'DISEASE:14103', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:30647', 'target': None, 'metadata': {'node_id': '30647', 'node_type': 'GENE', 'display_name': 'PCSK1'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:611', 'target': None, 'metadata': {'node_id': '611', 'node_type': 'PHENOTYPE', 'display_name': 'primary amenorrhea'}}]",0.3846153846153846,f1f1f031d37fd862b81431204d3611d7,11191387c6cb16e7280617e24280371b,"['The gene PCSK1 is active within two crucial pathways: peptide hormone biosynthesis and the Synthesis, secretion, and deacylation of Ghrelin. This gene is known to cause a condition known as proprotein convertase 1/3 deficiency. This rare endocrine disorder presents several distinctive symptoms like diarrhea, malabsorption, and primary amenorrhea.', 'The PCSK1 gene serves a crucial role within two biological pathways. It is not only involved in the peptide hormone biosynthesis process but also in the synthesis, secretion, and deacylation of Ghrelin. Mutation or malfunctions in the PCSK1 gene have been linked to a medical condition known as proprotein convertase 1/3 deficiency. The symptoms or phenotypes of proprotein convertase 1/3 deficiency are quite diverse and include diarrhea, malabsorption and primary amenorrhea.', 'Proprotein convertase 1/3 deficiency, caused by PCSK1, is a condition which results in a number of significant phenotypes including diarrhea, malabsorption, and primary amenorrhea. PCSK1, the gene responsible for the condition, operates within peptide hormone biosynthesis as well as the process of synthesis, secretion, and deacylation of Ghrelin.', 'The gene PCSK1 plays vital roles within various processes, including peptide hormone biosynthesis and the synthesis, secretion, and deacylation of Ghrelin. Importantly, this gene is implicated in causing a condition known as proprotein convertase 1/3 deficiency. This particular deficiency is characterized by several phenotypes, such as diarrhea, malabsorption, and primary amenorrhea.', 'The gene PCSK1 is involved in several functions and pathways, including Peptide hormone biosynthesis and the synthesis, secretion, and deacylation of Ghrelin. An important role this gene plays is causing the condition known as proprotein convertase 1/3 deficiency. This deficiency has a range of phenotypes, leading to conditions such as diarrhea, malabsorption, and primary amenorrhea.']","['Proprotein convertase 1/3 deficiency is a condition that has symptoms or phenotypes such as diarrhea and malabsorption.', 'Proprotein convertase 1/3 deficiency, a medical condition, manifests with various phenotypes including diarrhea and malabsorption.']"
"[{'source_node': {'name': 'warburg micro syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'osteoporosis'}}, {'source_node': {'name': 'warburg micro syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hyperreflexia'}}, {'source_node': {'name': 'warburg micro syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'seizure'}}, {'source_node': {'name': 'RAB3GAP1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'warburg micro syndrome 1'}}, {'source_node': {'name': 'RAB3GAP1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'martsolf syndrome 1'}}, {'source_node': {'name': 'RAB3GAP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'COPI-independent Golgi-to-ER retrograde traffic'}}, {'source_node': {'name': 'martsolf syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'talipes equinovarus'}}]","[{'source_node': {'name': 'warburg micro syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hyperreflexia'}}, {'source_node': {'name': 'warburg micro syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'talipes equinovarus'}}, {'source_node': {'name': 'RAB3GAP1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'warburg micro syndrome 1'}}, {'source_node': {'name': 'RAB3GAP1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'martsolf syndrome 1'}}, {'source_node': {'name': 'RAB3GAP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'COPI-independent Golgi-to-ER retrograde traffic'}}, {'source_node': {'name': 'martsolf syndrome 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'talipes equinovarus'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:951', 'target': None, 'metadata': {'node_id': '951', 'node_type': 'PHENOTYPE', 'display_name': 'seizure'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:735', 'target': None, 'metadata': {'node_id': '735', 'node_type': 'PHENOTYPE', 'display_name': 'osteoporosis'}}, {'type': 'edge_addition', 'source': 'DISEASE:5930', 'target': 'PHENOTYPE:1281', 'metadata': {'predicate': 'has_phenotype'}}]",0.6666666666666667,e254f2a79b359e7168ef439629b29d55,b5c2d5a8eb774ef82c12ac3c61c6227e,"['Warburg Micro Syndrome 1 and Martsolf Syndrome 1 are two medical conditions that are caused by the gene RAB3GAP1. Specifically, RAB3GAP1 acts within the pathway of COPI-independent Golgi-to-ER retrograde traffic, which contributes to the onset of these conditions. Warburg Micro Syndrome 1 manifests various phenotypes including osteoporosis, hyperreflexia, and seizures. Additionally, Martsolf Syndrome 1 also presents distinct characteristics, such as the condition talipes equinovarus.', 'Warburg Micro Syndrome 1, a disease caused by the gene RAB3GAP1, is characterized by various symptoms including osteoporosis, hyperreflexia, and seizures. Interestingly, the very same RAB3GAP1 gene also causes Martsolf Syndrome 1, another condition that presents with symptoms such as talipes equinovarus. In addition to its role in causing conditions, RAB3GAP1 is also known to act within a biological pathway known as the COPI-independent Golgi-to-ER retrograde traffic.', 'Warburg Micro syndrome 1, a condition caused by the gene RAB3GAP1, is characterized by osteoporosis, hyperreflexia, and seizures. RAB3GAP1 is also known to cause another condition, Martsolf syndrome 1, which has talipes equinovarus as a phenotype. Additionally, the RAB3GAP1 gene acts within the pathway of COPI-independent Golgi-to-ER retrograde traffic.', ""The gene RAB3GAP1 plays a role in several mechanisms and conditions. It acts within the pathway of COPI-independent Golgi-to-ER retrograde traffic, impacting how cells recycle material from their surface. This gene also causes two conditions: Warburg Micro syndrome 1 and Martsolf syndrome 1.\n\nWarburg Micro syndrome 1 has phenotypes including osteoporosis, hyperreflexia, and seizures. This means that individuals with this condition may exhibit weak and brittle bones (osteoporosis), overactive reflexes (hyperreflexia), and may also experience seizures.\n\nOn the other hand, Martsolf syndrome 1 has a phenotype of talipes equinovarus, commonly known as clubfoot, which is a deformity in which the foot appears twisted and may even look as if it's upside down. This indicates that the foot is unable to extend fully in a typical upward direction."", 'Warburg Micro Syndrome 1 and Martsolf Syndrome 1 are both conditions caused by the gene RAB3GAP1. Additionally, RAB3GAP1 is known to act within the COPI-independent Golgi-to-ER retrograde traffic pathway. Warburg Micro Syndrome 1 shows several phenotypes including osteoporosis, hyperreflexia, and seizures. On the other hand, Martsolf Syndrome 1 is characterized by the phenotype of talipes equinovarus.']","['The gene RAB3GAP1 plays multiple roles in various pathways and conditions. It operates within the pathway of COPI-independent Golgi-to-ER retrograde traffic. It is also known to cause two rare genomic disorders - Warburg Micro Syndrome 1 and Martsolf Syndrome 1. Patients with Warburg Micro Syndrome 1 usually exhibit physical symptoms such as hyperreflexia and talipes equinovarus (commonly known as clubfoot). Interestingly, talipes equinovarus is also a common symptom in patients suffering from Martsolf Syndrome 1.']"
"[{'source_node': {'name': 'streptokinase'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'plasminogen'}}, {'source_node': {'name': 'streptokinase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'menadione bisulfite'}}, {'source_node': {'name': 'turoctocog alfa pegol'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'turoctocog alfa pegol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'anistreplase'}}, {'source_node': {'name': 'turoctocog alfa pegol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'streptokinase'}}]","[{'source_node': {'name': 'streptokinase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'menadione bisulfite'}}, {'source_node': {'name': 'streptokinase'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'turoctocog alfa pegol'}}, {'source_node': {'name': 'turoctocog alfa pegol'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'turoctocog alfa pegol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'anistreplase'}}, {'source_node': {'name': 'turoctocog alfa pegol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'streptokinase'}}, {'source_node': {'name': 'turoctocog alfa pegol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'menadione bisulfite'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:22', 'target': None, 'metadata': {'node_id': '22', 'node_type': 'PROTEIN', 'display_name': 'plasminogen'}}, {'type': 'edge_addition', 'source': 'COMPOUND:12439', 'target': 'COMPOUND:13323', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:80', 'target': 'COMPOUND:12439', 'metadata': {'predicate': 'increase_efficacy'}}]",0.6363636363636364,91bdea881138f32924c9ed9914d4b44f,bee8bee62011bb74c6f36e13e54f8ddb,[],[]
"[{'source_node': {'name': 'phloretic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine phenol-lyase'}}, {'source_node': {'name': 'phloretic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prephenate dehydrogenase'}}, {'source_node': {'name': 'phloretic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'pi3-kinase p110-alpha/p85-alpha'}}]","[{'source_node': {'name': 'phloretic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prephenate dehydrogenase'}}, {'source_node': {'name': 'phloretic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'pi3-kinase p110-alpha/p85-alpha'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:3288', 'target': None, 'metadata': {'node_id': '3288', 'node_type': 'PROTEIN', 'display_name': 'tyrosine phenol-lyase'}}]",0.7142857142857143,c145cd2e7b764ee549048408a76b707a,9a82648366326978a7c0b146bea8e79e,"['Phloretic acid, a biochemical compound, targets multiple proteins including tyrosine phenol-lyase, prephenate dehydrogenase, and the subunits pi3-kinase p110-alpha/p85-alpha. These interactions suggest varied biochemical impacts of phloretic acid.', 'The compound phloretic acid is known to target several biological enzymes such as tyrosine phenol-lyase, prephenate dehydrogenase, and pi3-kinase p110-alpha/p85-alpha.', 'The compound phloretic acid is known to target multiple enzymes. These include the tyrosine phenol-lyase and the prephenate dehydrogenase. In addition, phloretic acid also specifically targets the cellular component pi3-kinase p110-alpha/p85-alpha.', 'The compound phloretic acid targets several enzymes such as tyrosine phenol-lyase, prephenate dehydrogenase and pi3-kinase p110-alpha/p85-alpha.', 'The substance phloretic acid has multiple targets including tyrosine phenol-lyase, prephenate dehydrogenase, and pi3-kinase p110-alpha/p85-alpha.']","['Phloretic acid is noted to have targets in two distinct areas: the prephenate dehydrogenase and the pi3-kinase p110-alpha/p85-alpha.', 'Phloretic acid, a compound often found in plant-based substances, is known to interact with prephenate dehydrogenase and also with a kinase complex known as PI3-kinase P110-alpha/P85-alpha. These substances are relevant in various biological pathways and interactions.', 'The compound phloretic acid has several targets, including prephenate dehydrogenase and the PI3-kinase P110-alpha/P85-alpha.', 'The chemical compound known as phloretic acid targets both prephenate dehydrogenase and the enzyme complex pi3-kinase p110-alpha/p85-alpha.', 'Phloretic acid, a biochemical agent, has targets that include prephenate dehydrogenase and PI3-kinase p110-alpha/p85-alpha. These enzymes play critical roles in various biochemical pathways and cellular functions.']"
"[{'source_node': {'name': 'renal-hepatic-pancreatic dysplasia 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'dandy-walker malformation'}}, {'source_node': {'name': 'renal-hepatic-pancreatic dysplasia 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'enlarged kidney'}}, {'source_node': {'name': 'renal-hepatic-pancreatic dysplasia 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ureteral atresia'}}]","[{'source_node': {'name': 'renal-hepatic-pancreatic dysplasia 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'dandy-walker malformation'}}, {'source_node': {'name': 'renal-hepatic-pancreatic dysplasia 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ureteral atresia'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:93', 'target': None, 'metadata': {'node_id': '93', 'node_type': 'PHENOTYPE', 'display_name': 'enlarged kidney'}}]",0.7142857142857143,1a17767710cb25e5a1d528e3853c8774,25bac52c955b00ef9e4e7a001356d83d,"['Renal-hepatic-pancreatic dysplasia 1 is a condition that is characterized by several phenotypes including Dandy-Walker malformation, an enlarged kidney, and ureteral atresia.', 'Renal-hepatic-pancreatic dysplasia 1 is a complex condition which has several associated phenotypes including a Dandy-Walker malformation, which is a specific type of brain malformation, as well enlarged kidney. In some severe cases, it may even lead to ureteral atresia, a condition characterized by the absence or closure of one or both ureters.', 'The disease known as renal-hepatic-pancreatic dysplasia 1 has various phenotypes including dandy-walker malformation, an enlarged kidney, and ureteral atresia. These are all symptoms associated with this multidimensional health disorder.', 'Renal-hepatic-pancreatic dysplasia 1, a complex medical condition, exhibits various phenotypes including Dandy-Walker malformation, an enlarged kidney, and ureteral atresia. Each of these conditions represent different manifestations of the disease, indicating the extensive impact of Renal-hepatic-pancreatic dysplasia 1 on multiple organ systems in the body.', 'Renal-hepatic-pancreatic dysplasia 1, a complex and serious condition, has several observable phenotypes, which include distinct abnormalities like Dandy-Walker malformation, enlarged kidney, and ureteral atresia. These manifestations give insight into the extensive effects of the disease on various organ systems including the kidneys, liver, and pancreas.']","['Renal-hepatic-pancreatic dysplasia 1 is a condition that has phenotypes including Dandy-Walker malformation, a congenital brain malformation involving the cerebellum and the fluid filled spaces around it, and ureteral atresia, a condition characterized by the absence or severe narrowing of a part of the ureter.', 'Renal-hepatic-pancreatic dysplasia 1, a multifaceted disorder, shows several phenotypes. Among these, two prominent manifestations are Dandy-Walker malformation, a congenital brain malformation involving the area at the back of the brain that coordinates movement, and ureteral atresia, a condition that occurs when one or both of the tubes (ureters) that carry urine from the kidneys to the bladder do not develop normally.', 'Renal-hepatic-pancreatic dysplasia 1 is a condition characterized by several phenotypes, including Dandy-Walker malformation and ureteral atresia.', 'Renal-hepatic-pancreatic dysplasia 1, a rare genetic disorder, exhibits a variety of phenotypes including Dandy-Walker malformation, a congenital brain malformation, and ureteral atresia, a condition characterized by the absence or closure of one or both ureters.', 'Renal-hepatic-pancreatic dysplasia 1 is a condition that presents several phenotypes, such as dandy-walker malformation and ureteral atresia.']"
"[{'source_node': {'name': 'folfox'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'caudal type homeobox 2'}}, {'source_node': {'name': 'folfox'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'dihydropyrimidine dehydrogenase'}}, {'source_node': {'name': 'folfox'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'smad family member 7'}}, {'source_node': {'name': 'dihydropyrimidine dehydrogenase'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'rectal neoplasms'}}, {'source_node': {'name': 'dihydropyrimidine dehydrogenase'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'precursor cell lymphoblastic leukemia-lymphoma'}}, {'source_node': {'name': 'dihydropyrimidine dehydrogenase'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'cardiomyopathies'}}]","[{'source_node': {'name': 'folfox'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'caudal type homeobox 2'}}, {'source_node': {'name': 'folfox'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'dihydropyrimidine dehydrogenase'}}, {'source_node': {'name': 'folfox'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'smad family member 7'}}, {'source_node': {'name': 'folfox'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'precursor cell lymphoblastic leukemia-lymphoma'}}, {'source_node': {'name': 'smad family member 7'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'precursor cell lymphoblastic leukemia-lymphoma'}}, {'source_node': {'name': 'smad family member 7'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'rectal neoplasms'}}, {'source_node': {'name': 'dihydropyrimidine dehydrogenase'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'rectal neoplasms'}}, {'source_node': {'name': 'dihydropyrimidine dehydrogenase'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'precursor cell lymphoblastic leukemia-lymphoma'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:90104', 'target': 'DISEASE:2631', 'metadata': {'predicate': 'is_substance_that_treats'}}, {'type': 'edge_addition', 'source': 'GENE:19537', 'target': 'DISEASE:2631', 'metadata': {'predicate': 'causes_condition'}}, {'type': 'node_removal', 'source': 'DISEASE:492', 'target': None, 'metadata': {'node_id': '492', 'node_type': 'DISEASE', 'display_name': 'cardiomyopathies'}}, {'type': 'edge_addition', 'source': 'GENE:19537', 'target': 'DISEASE:2762', 'metadata': {'predicate': 'causes_condition'}}]",0.6153846153846154,88d18b8c310a04dcdf3e179ad605e531,1ceb90584c0b2bfe30a3f31f658c2741,"[""FOLFOX, a therapeutic treatment, is known to affect several aspects including the caudal type homeobox 2 (a DNA-binding transcription factor), dihydropyrimidine dehydrogenase (an enzyme), and SMAD family member 7, which plays a role in cell signaling. Intriguingly, the affected dihydropyrimidine dehydrogenase has been linked to numerous conditions, including rectal neoplasms, precursor cell lymphoblastic leukemia-lymphoma, and cardiomyopathies. Thus, the drug's interactions might contribute to its broad effectiveness in managing various conditions."", 'The drug FOLFOX is found to affect several entities including the caudal type homeobox 2, dihydropyrimidine dehydrogenase, and the smad family member 7. Particularly, the dihydropyrimidine dehydrogenase is notable for causing various conditions such as rectal neoplasms, precursor cell lymphoblastic leukemia-lymphoma, and cardiomyopathies.', 'The chemotherapy treatment FOLFOX is known to affect several entities including the Caudal Type Homeobox 2, Dihydropyrimidine Dehydrogenase, and SMAD Family Member 7. Dihydropyrimidine Dehydrogenase, in particular, has been linked to several serious conditions such as rectal neoplasms, precursor cell lymphoblastic leukemia-lymphoma, and cardiomyopathies.', 'FOLFOX, a chemotherapy drug regimen, is noted to affect several key proteins in the body, including the Caudal Type Homeobox 2, Dihydropyrimidine Dehydrogenase, and SMAD Family Member 7. Particularly, the action on Dihydropyrimidine Dehydrogenase reveals its crucial role in the pathogenesis of certain conditions, such as Rectal Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, and varied forms of Cardiomyopathies.', 'FOLFOX, a treatment regimen, is known to affect several proteins and enzymes including caudal type homeobox 2, dihydropyrimidine dehydrogenase, and SMAD family member 7. The dihydropyrimidine dehydrogenase, which is affected by FOLFOX, has been linked to several conditions such as rectal neoplasms, precursor cell lymphoblastic leukemia-lymphoma, and cardiomyopathies.']","[""FOLFOX, a mixture of chemotherapy drugs, is shown to influence a variety of different biological entities including the caudal type homeobox 2 gene, dihydropyrimidine dehydrogenase enzyme and the SMAD family member 7 protein. Remarkably, FOLFOX is recognized as a therapeutic substance for treating precursor cell lymphoblastic leukemia-lymphoma, a malignant disease typically characterized by an overcrowded number of immature white blood cells in the blood and marrow. In connection with that, it's worth noting that both SMAD family member 7 and dihydropyrimidine dehydrogenase, which are affected by FOLFOX, have been implicated in the onset of this leukemia condition. Furthermore, both of these biological elements are also linked to the pathological formation of rectal neoplasms, thus hinting at their pivotal contribution to cancer development.""]"
"[{'source_node': {'name': 'valoctocogene roxaparvovec'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nevirapine'}}, {'source_node': {'name': 'valoctocogene roxaparvovec'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lapatinib'}}, {'source_node': {'name': 'valoctocogene roxaparvovec'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'idelalisib'}}]","[{'source_node': {'name': 'idelalisib'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'valoctocogene roxaparvovec'}}, {'source_node': {'name': 'valoctocogene roxaparvovec'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nevirapine'}}, {'source_node': {'name': 'valoctocogene roxaparvovec'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lapatinib'}}, {'source_node': {'name': 'valoctocogene roxaparvovec'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'idelalisib'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:7995', 'target': 'COMPOUND:13078', 'metadata': {'predicate': 'increase_efficacy'}}]",0.8571428571428572,f151f6761bebfe558949c57cf6b9650c,ed75bf1d33c14634097c01a49355372d,"['The drug valoctocogene roxaparvovec decreases the efficacy of a number of other drugs, including nevirapine, lapatinib, and idelalisib. This indicates that usage of valoctocogene roxaparvovec might render these other drugs less effective, a fact that healthcare providers should take into account when designing a treatment plan.', 'Valoctocogene roxaparvovec, a gene therapy treatment, has been identified to decrease the efficacy of several drugs. These include Nevirapine, an antiretroviral medication, Lapatinib, used for the treatment of breast cancer, and Idelalisib, a therapy used for certain types of blood cancer. Therefore, caution should be practiced when combining Valoctocogene roxaparvovec with these drugs.', 'The drug valoctocogene roxaparvovec has been observed to decrease the efficacy of several other medications including nevirapine, lapatinib, and idelalisib. This insight is crucial in developing medication plans, as the lowered efficacy could significantly impact the expected treatment outcomes.', 'The drug valoctocogene roxaparvovec is known to decrease the efficacy of certain other drugs, including nevirapine, lapatinib, and idelalisib. This decrease in efficacy may potentially impact the overall effectiveness of these drugs when used in combination with valoctocogene roxaparvovec.', 'The efficacy of several drugs, including nevirapine, lapatinib, and idelalisib, is known to be reduced by valoctocogene roxaparvovec. This suggests that care should be taken when administering these drugs together, as valoctocogene roxaparvovec might compromise their therapeutic effects.']","['The drug idelalisib is known to increase the efficacy of another drug, valoctocogene roxaparvovec. However, when applying valoctocogene roxaparvovec, it has been observed to decrease the efficacy of several other drugs, including nevirapine, lapatinib, and intriguingly, idelalisib itself.', 'The drug Idelalisib is known to increase the efficacy of Valoctocogene Roxaparvovec. However, Valoctocogene Roxaparvovec has been found to decrease the efficacy of several other drugs including Nevirapine, Lapatinib, and interestingly, also Idelalisib itself. It suggests that the relationship between Idelalisib and Valoctocogene Roxaparvovec might be complex and needs to be carefully examined before co-administration.', 'The drug Idelalisib increases the efficacy of Valoctocogene Roxaparvovec. However, it is important to note that Valoctocogene Roxaparvovec decreases the efficacy of several other drugs. It has a diminishing effect on Nevirapine, Lapatinib, and interestingly on Idelalisib itself, thereby creating a complex network of drug interactions to consider in treatment plans.', 'The drug idelalisib is suggested to increase the efficacy of valoctocogene roxaparvovec, another medication. However, the use of valoctocogene roxaparvovec has been found to decrease the efficacy of several other drugs, namely nevirapine, lapatinib, and ironically, idelalisib itself. This implies an intricate interaction network among these substances that can significantly influence treatment outcomes.', ""The drug idelalisib is known to increase the efficacy of valoctocogene roxaparvovec. However, it's noteworthy that valoctocogene roxaparvovec has been observed to decrease the efficacy of several other drugs namely nevirapine, lapatinib, and interestingly, idelalisib itself.""]"
"[{'source_node': {'name': 'aerothionin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'aerothionin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-29'}}, {'source_node': {'name': 'aerothionin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}]","[{'source_node': {'name': 'aerothionin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4976', 'target': None, 'metadata': {'node_id': '4976', 'node_type': 'PROTEIN', 'display_name': 'ht-29'}}, {'type': 'node_removal', 'source': 'PROTEIN:4994', 'target': None, 'metadata': {'node_id': '4994', 'node_type': 'PROTEIN', 'display_name': 'hela'}}]",0.4285714285714286,3f50a1549cbd428d13accf82daaaefb5,88bd6e49bc4ad8b831fa0e3a99e1bf6e,"['The compound Aerothionin is known to target various cell lines including A549, HT-29, and Hela as part of its biological interactions.', 'The drug aerothionin has the ability to target several types of cells. These include, but are not limited to, A549, HT-29 and HeLa cells.', 'The drug aerothionin has shown to have multiple biological targets. It has an affinity for A549, HT-29, and HeLa - all prominent cell lines often studied in cancer research.', ""The compound Aerothionin has been found to target several cancer cell lines. These include A549, a lung cancer cell line, HT-29, a colon cancer cell line, and HeLa, the world's first immortal human cell line, originating from cervical cancer."", 'The compound aerothionin targets multiple cell lines including A549, HT-29, and HeLa.']","['The drug aerothionin has a target interaction with the A549 cell line.', 'The compound aerothionin has a549 as a target.']"
"[{'source_node': {'name': 'PKD2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'autosomal dominant polycystic kidney disease'}}, {'source_node': {'name': 'PKD2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'VxPx cargo-targeting to cilium'}}, {'source_node': {'name': 'autosomal dominant polycystic kidney disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'aortic root aneurysm'}}, {'source_node': {'name': 'autosomal dominant polycystic kidney disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'pyelonephritis'}}, {'source_node': {'name': 'autosomal dominant polycystic kidney disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'arachnoid cyst'}}]","[{'source_node': {'name': 'autosomal dominant polycystic kidney disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'aortic root aneurysm'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:747', 'target': None, 'metadata': {'node_id': '747', 'node_type': 'PATHWAY', 'display_name': 'VxPx cargo-targeting to cilium'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:11136', 'target': None, 'metadata': {'node_id': '11136', 'node_type': 'PHENOTYPE', 'display_name': 'arachnoid cyst'}}, {'type': 'node_removal', 'source': 'GENE:30989', 'target': None, 'metadata': {'node_id': '30989', 'node_type': 'GENE', 'display_name': 'PKD2'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:8720', 'target': None, 'metadata': {'node_id': '8720', 'node_type': 'PHENOTYPE', 'display_name': 'pyelonephritis'}}]",0.2727272727272727,806b48c1adf7a6313181702fef1f79b0,c2033622c2443e6b52e0bcf772c15868,"['The gene PKD2, which acts within the pathway known as VxPx cargo-targeting to cilium, is a known cause of autosomal dominant polycystic kidney disease. This disease presents various phenotypes such as arachnoid cyst, pyelonephritis, and indeed aortic root aneurysm.', 'The gene PKD2, which acts within the VxPx cargo-targeting to cilium pathway, is known to cause autosomal dominant polycystic kidney disease. This disease is characterized by various symptoms including aortic root aneurysm, pyelonephritis, and arachnoid cyst.']",[]
"[{'source_node': {'name': 'gallamine triethiodide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'neuronal acetylcholine receptor subunit alpha-2'}}, {'source_node': {'name': 'gallamine triethiodide'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' constipation '}}, {'source_node': {'name': 'gallamine triethiodide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'domperidone'}}, {'source_node': {'name': 'doxycycline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'gallamine triethiodide'}}, {'source_node': {'name': 'doxycycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bcg vaccine'}}, {'source_node': {'name': 'doxycycline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'cloricromen'}}]","[{'source_node': {'name': 'gallamine triethiodide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'neuronal acetylcholine receptor subunit alpha-2'}}, {'source_node': {'name': 'gallamine triethiodide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'domperidone'}}, {'source_node': {'name': 'gallamine triethiodide'}, 'relation': {'name': 'decrease_effect'}, 'target_node': {'name': ' constipation '}}, {'source_node': {'name': 'gallamine triethiodide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'cloricromen'}}, {'source_node': {'name': 'cloricromen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'doxycycline'}}, {'source_node': {'name': 'doxycycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bcg vaccine'}}, {'source_node': {'name': 'doxycycline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'cloricromen'}}, {'source_node': {'name': 'doxycycline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'domperidone'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:244', 'target': 'COMPOUND:471', 'metadata': None}, {'type': 'edge_replacement', 'source': 'COMPOUND:471', 'target': 'EFFECT:100', 'metadata': {'predicate': 'decrease_effect'}}, {'type': 'edge_addition', 'source': 'COMPOUND:471', 'target': 'COMPOUND:11223', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11223', 'target': 'COMPOUND:244', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:244', 'target': 'COMPOUND:1164', 'metadata': {'predicate': 'increase_efficacy'}}]",0.6153846153846154,9f3b5e5261e2e65b52868dbf11ceafc5,3ba25155438cf16d588e36e9492447c1,[],[]
"[{'source_node': {'name': 'cytochrome p450 2a6'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP2A6'}}, {'source_node': {'name': 'CYP2A6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'coumarin resistance'}}, {'source_node': {'name': '1,7-dimethylnaphthalene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 1a2'}}, {'source_node': {'name': '1,7-dimethylnaphthalene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 2a6'}}, {'source_node': {'name': 'cytochrome p450 1a2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP1A2'}}]","[{'source_node': {'name': 'cytochrome p450 2a6'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP2A6'}}, {'source_node': {'name': 'CYP2A6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'coumarin resistance'}}, {'source_node': {'name': '1,7-dimethylnaphthalene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 1a2'}}, {'source_node': {'name': '1,7-dimethylnaphthalene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 2a6'}}, {'source_node': {'name': 'cytochrome p450 1a2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP2A6'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:1507', 'target': 'GENE:26290', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'GENE:26285', 'target': None, 'metadata': {'node_id': '26285', 'node_type': 'GENE', 'display_name': 'CYP1A2'}}]",0.7272727272727273,c39d5f3f527489f5b114b33dde914109,aab5bf88b6b8ff5e6d9e9b57f5d51cdc,"['The molecule 1,7-dimethylnaphthalene targets a couple of cytochrome P450 enzymes, specifically cytochrome p450 1a2 and cytochrome p450 2a6. Noteworthy, cytochrome p450 1a2 is a gene product of CYP1A2. On the other hand, cytochrome p450 2a6 is a gene product of another gene, CYP2A6, which is known to cause a condition known as coumarin resistance.', 'The drug 1,7-dimethylnaphthalene targets two specific cytochrome P450 enzymes: cytochrome p450 1a2 and cytochrome p450 2a6. Cytochrome p450 1a2 is a gene product of CYP1A2. Similarly, Cytochrome p450 2a6 is a gene product of CYP2A6, and interestingly, CYP2A6 is known to cause a condition known as coumarin resistance.', 'The drug 1,7-dimethylnaphthalene targets both the enzymes cytochrome p450 1a2 and cytochrome p450 2a6. Cytochrome p450 1a2 is a gene product of the gene CYP1A2. Similarly, cytochrome p450 2a6 is the gene product of CYP2A6, which is known to cause a condition known as coumarin resistance.', 'Cytochrome P450 2A6 is a gene product of CYP2A6, a gene that can cause a condition known as coumarin resistance. This genetic protein, along with Cytochrome P450 1A2, which is a gene product of CYP1A2, are both targeted by the compound 1,7-dimethylnaphthalene.', 'The compound 1,7-dimethylnaphthalene interacts with two key enzymes, cytochrome p450 1a2 and cytochrome p450 2a6. The former enzyme is a gene product of CYP1A2. Interestingly, the second enzyme, cytochrome p450 2a6, is a gene product of CYP2A6 which is linked to the condition of coumarin resistance.']","['The molecule 1,7-dimethylnaphthalene targets a pair of closely related enzymes, cytochrome p450 2a6 and cytochrome p450 1a2. These enzymes are gene products of the gene CYP2A6 which is known to cause a condition known as coumarin resistance.', 'Cytochrome P450 2A6 is a gene product of CYP2A6, a gene that can cause a condition known as coumarin resistance. This genetic protein, along with Cytochrome P450 1A2, are targetted by 1,7-dimethylnaphthalene. Cytochrome P450 1A2 is also a gene product of CYP2A6, implying a potential synchronistic biochemical interaction in the presence of 1,7-dimethylnaphthalene.', 'The compound 1,7-dimethylnaphthalene interacts with two key enzymes, cytochrome p450 1a2 and cytochrome p450 2a6. The gene CYP2A6 produces both of these proteins. Furthermore, the gene CYP2A6 has been linked to the medical condition of coumarin resistance.', ""The compound 1,7-dimethylnaphthalene targets two major entities: the cytochrome p450 1a2 and the cytochrome p450 2a6. Intriguingly, both cytochromes are gene products of CYP2A6. This relationship is particularly critical in the context of CYP2A6's understood influence on health, as it has been linked to the development of coumarin resistance."", ""The enzyme Cytochrome P450 2A6 is a gene product of the CYP2A6 gene. An interesting characteristic of CYP2A6 is that it is known to cause a condition known as Coumarin resistance. On the other hand, 1,7-dimethylnaphthalene, a chemical compound, acts on two targets: Cytochrome P450 1A2 and Cytochrome P450 2A6. It's also important to note that Cytochrome P450 1A2 is another gene product of CYP2A6. Therefore, both these enzymes, which are targeted by 1,7-dimethylnaphthalene, originate from the CYP2A6 gene.""]"
"[{'source_node': {'name': 'protokylol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methotrimeprazine'}}, {'source_node': {'name': 'protokylol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'clenbuterol'}}, {'source_node': {'name': 'protokylol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pizotifen'}}, {'source_node': {'name': 'pizotifen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bitolterol'}}, {'source_node': {'name': 'pizotifen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'regramostim'}}]","[{'source_node': {'name': 'pizotifen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bitolterol'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1342', 'target': 'COMPOUND:5857', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:5857', 'target': None, 'metadata': {'node_id': '5857', 'node_type': 'COMPOUND', 'display_name': 'protokylol'}}, {'type': 'node_removal', 'source': 'COMPOUND:4997', 'target': None, 'metadata': {'node_id': '4997', 'node_type': 'COMPOUND', 'display_name': 'regramostim'}}]",0.2727272727272727,05a5d0151c15ca79d7b3698863aebcd2,f41f7b8c924e5184a0588dcf38cf6cd2,"['The drug protokylol has diverse effects on the efficacy of other drugs. It is observed to decrease the efficacy of drugs like methotrimeprazine and pizotifen, yet increase the efficacy of clenbuterol. It is also of note that pizotifen has a detrimental effect on the efficacy of both bitolterol and regramostim.', 'The drug protokylol has been observed to have varying impacts on the efficacy of different drugs. It enhances the efficacy of clenbuterol but it decreases the efficacy of methotrimeprazine and pizotifen. Interestingly, pizotifen, which sees its efficacy decreased by protokylol, also reduces the efficacy of other drugs like bitolterol and regramostim.', 'The drug protokylol interacts with several other medications, altering their effectiveness. Specifically, it decreases the efficacy of methotrimeprazine and pizotifen. However, it increases the efficacy of clenbuterol. Interestingly, pizotifen also modulates the effectiveness of other drugs; it decreases the efficacy of both bitolterol and regramostim.', 'The drug Protokylol has a unique impact on the efficacy of several other medications. It decreases the efficacy of Methotrimeprazine and Pizotifen, while increasing the efficacy of Clenbuterol. Interestingly, Pizotifen, although having its own efficacy decreased by Protokylol, is also responsible for lowering the efficacy of Bitolterol and Regramostim. The complex interactions among these drugs may have profound implications for treatment outcomes.', 'The drug protokylol has been identified to alter the efficacy of several other medications. Notably, it reduces the efficacy of methotrimeprazine and pizotifen. Conversely, protokylol enhances the effectiveness of clenbuterol. Interestingly, pizotifen itself, while reduced in efficacy by protokylol, is also noted to decrease the efficacy of bitolterol and regramostim.']","['The efficacy of the drug bitolterol is decreased by pizotifen.', 'The efficacy of the drug bitolterol is decreased by pizotifen.', 'The drug pizotifen is known to decrease the efficacy of bitolterol.', 'The drug Pizotifen may decrease the efficacy of Bitolterol.']"
"[{'source_node': {'name': 'intellectual disability'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'tongue fasciculations'}}, {'source_node': {'name': 'intellectual disability'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'limited elbow flexion/extension'}}, {'source_node': {'name': 'intellectual disability'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'motor axonal neuropathy'}}]","[{'source_node': {'name': 'intellectual disability'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'motor axonal neuropathy'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:992', 'target': None, 'metadata': {'node_id': '992', 'node_type': 'PHENOTYPE', 'display_name': 'tongue fasciculations'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:3439', 'target': None, 'metadata': {'node_id': '3439', 'node_type': 'PHENOTYPE', 'display_name': 'limited elbow flexion/extension'}}]",0.4285714285714286,c29ae01be7458278ade16e83523f4b95,dce380747f65b4474de237c56db55021,"['Intellectual disability is a condition characterized by several distinctive phenotypes. Among these are tongue fasciculations and limited elbow flexion/extension. Additionally, it is associated with motor axonal neuropathy.', 'People with intellectual disability often exhibit various physical phenotypes, including tongue fasciculations, limited elbow flexion/extension, and motor axonal neuropathy.', 'Intellectual disability, a condition often characterized by a range of phenotypes such as tongue fasciculations, limited elbow flexion/extension, and motor axonal neuropathy, reveals the diverse manifestation of symptoms tied to this impairment.', 'Intellectual disability, a neurological disorder, exhibits several phenotypes including tongue fasciculations, limited elbow flexion/extension, and motor axonal neuropathy.', '""Intellectual disability is a condition characterized by several phenotypes including tongue fasciculations, limited elbow flexion/extension, and motor axonal neuropathy.']",[]
"[{'source_node': {'name': 'HSPA2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Meiotic synapsis'}}, {'source_node': {'name': 'HSPA2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of HSF1-mediated heat shock response'}}, {'source_node': {'name': 'HSPA2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Attenuation phase'}}]","[{'source_node': {'name': 'HSPA2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of HSF1-mediated heat shock response'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:829', 'target': None, 'metadata': {'node_id': '829', 'node_type': 'PATHWAY', 'display_name': 'Attenuation phase'}}, {'type': 'node_removal', 'source': 'PATHWAY:510', 'target': None, 'metadata': {'node_id': '510', 'node_type': 'PATHWAY', 'display_name': 'Meiotic synapsis'}}]",0.4285714285714286,60b10a03a3b74dd0b135223d42af6644,73642cd24ab1408aa46c7130facf8734,[],[]
"[{'source_node': {'name': 'carbromal'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' sedation and somnolence '}}, {'source_node': {'name': 'carbromal'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'lofexidine'}}]","[{'source_node': {'name': 'lofexidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carbromal'}}, {'source_node': {'name': 'lofexidine'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' sedation and somnolence '}}, {'source_node': {'name': 'carbromal'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' sedation and somnolence '}}, {'source_node': {'name': 'carbromal'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'lofexidine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:4653', 'target': 'COMPOUND:11664', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:4653', 'target': 'EFFECT:91', 'metadata': {'predicate': 'increase_effect'}}]",0.6,ab3add1e78b74cb28388e7486efeb898,41054f84b686f6f4d8968b3fb3b67b54,[],[]
"[{'source_node': {'name': '12,13-dihydroxybakuchiol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': '12,13-dihydroxybakuchiol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'k562'}}]","[{'source_node': {'name': '12,13-dihydroxybakuchiol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4947', 'target': None, 'metadata': {'node_id': '4947', 'node_type': 'PROTEIN', 'display_name': 'k562'}}]",0.6,182396d2559f67df0306231e90bf447a,6ceb0617c0513eb21cdbba30b28cf462,"['The compound 12,13-dihydroxybakuchiol has been observed to have specific cellular targets, namely the A549 and K562 cell lines.', 'The compound 12,13-dihydroxybakuchiol targets both A549 and K562 cells.', 'The compound 12,13-dihydroxybakuchiol interacts or has a target relationship with not just one, but two distinct cell lines: a549 and k562. This suggests a possible effect on these cellular structures worthy of further explorations in scientific research.', 'The compound 12,13-dihydroxybakuchiol targets cells such as A549 and K562.', 'The compound 12,13-dihydroxybakuchiol has been found to target two specific cell lines: A549 and K562.']","['The compound 12,13-dihydroxybakuchiol has a549 as its target.', 'The compound 12,13-dihydroxybakuchiol has A549 as its target.', 'The compound 12,13-dihydroxybakuchiol has A549 as a target.']"
"[{'source_node': {'name': '5,6,7-trimethoxy-2,3-dihydroinden-1-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'flap endonuclease 1'}}, {'source_node': {'name': '5,6,7-trimethoxy-2,3-dihydroinden-1-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ataxin-2'}}, {'source_node': {'name': '5,6,7-trimethoxy-2,3-dihydroinden-1-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}}]","[{'source_node': {'name': '5,6,7-trimethoxy-2,3-dihydroinden-1-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'flap endonuclease 1'}}, {'source_node': {'name': '5,6,7-trimethoxy-2,3-dihydroinden-1-one'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna-(apurinic or apyrimidinic site) lyase'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:6151', 'target': None, 'metadata': {'node_id': '6151', 'node_type': 'PROTEIN', 'display_name': 'ataxin-2'}}]",0.7142857142857143,847e25730c6773f65da217de30b650c6,288cec234fc40856c7bf0659fccbbaf4,"['The compound 5,6,7-trimethoxy-2,3-dihydroinden-1-one targets several specific entities including flap endonuclease 1, ataxin-2, and dna-(apurinic or apyrimidinic site) lyase.', 'The drug called 5,6,7-trimethoxy-2,3-dihydroinden-1-one has multiple targets. These targets include the flap endonuclease 1, a critical enzyme involved in the repair of damaged DNA, ataxin-2, a protein linked with various neurological disorders, and dna-(apurinic or apyrimidinic site) lyase, an enzyme essential for the repair of DNA molecules.', 'The compound 5,6,7-trimethoxy-2,3-dihydroinden-1-one targets multiple processes within the body, specifically those involving flap endonuclease 1 and ataxin-2. In addition, it also plays a significant role in the process associated with DNA-(apurinic or apyrimidinic site) lyase.', 'The compound 5,6,7-trimethoxy-2,3-dihydroinden-1-one has multiple targets. It interacts with flap endonuclease 1 and ataxin-2. Additionally, it targets dna-(apurinic or apyrimidinic site) lyase. These interactions present a comprehensive image of its therapeutic potential.', 'The compound 5,6,7-trimethoxy-2,3-dihydroinden-1-one has several targets including flap endonuclease 1, ataxin-2, and dna-(apurinic or apyrimidinic site) lyase.']","['The compound 5,6,7-trimethoxy-2,3-dihydroinden-1-one exerts its effect by targeting two key proteins: flap endonuclease 1 and DNA-(apurinic or apyrimidinic site) lyase.', 'The compound 5,6,7-trimethoxy-2,3-dihydroinden-1-one has been identified as targeting several proteins including flap endonuclease 1 and DNA-(apurinic or apyrimidinic site) lyase.', 'The compound 5,6,7-trimethoxy-2,3-dihydroinden-1-one is known to target two different entities: flap endonuclease 1 and DNA-(apurinic or apyrimidinic site) lyase.', 'The compound 5,6,7-trimethoxy-2,3-dihydroinden-1-one has multiple targets, specifically flap endonuclease 1 and DNA-(apurinic or apyrimidinic site) lyase, indicating its potential effectiveness in influencing these enzymes.', 'The compound 5,6,7-trimethoxy-2,3-dihydroinden-1-one has targets the key proteins flap endonuclease 1 and dna-(apurinic or apyrimidinic site) lyase in its action mechanism.']"
"[{'source_node': {'name': 'rifabutin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lactulose'}}, {'source_node': {'name': 'rifabutin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Pain'}}]","[{'source_node': {'name': 'rifabutin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'lactulose'}}, {'source_node': {'name': 'lactulose'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rifabutin'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:567', 'target': 'SIDE_EFFECT:45', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'edge_addition', 'source': 'COMPOUND:567', 'target': 'COMPOUND:601', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'SIDE_EFFECT:45', 'target': None, 'metadata': {'node_id': '45', 'node_type': 'SIDE_EFFECT', 'display_name': 'Pain'}}]",0.4,9ecb14427215b95b7cf9900e41f5fb88,43cbeaf482665eb138ea6e96f3366488,"['Rifabutin, a commonly used medication, has been found to decrease the efficacy of lactulose, a therapeutic drug aiding in the treatment of several health conditions. Additionally, the use of Rifabutin is also associated with certain side effects, with pain being a notable consequence reported by some patients.', 'The drug rifabutin has been found to decrease the efficacy of lactulose. In addition, the use of rifabutin might have some side effects, one of which could include pain.', 'The drug Rifabutin has been known to decrease the efficacy of lactulose, which may compromise its effectiveness. Additionally, a side effect of rifabutin includes pain.', 'The drug Rifabutin has been noted to decrease the efficacy of Lactulose. Additionally, one of the potential side effects associated with the use of Rifabutin is experiencing pain.', 'The drug Rifabutin may decrease the efficacy of the medication Lactulose. Additionally, when taken, Rifabutin might have the side effect of inducing pain.']","[""Rifabutin, a known drug, has been observed to decrease the efficacy of lactulose. Conversely, lactulose also reduces the effectiveness of rifabutin. Thus, these two drugs show a two-way interaction influencing each other's potency."", 'The drug rifabutin has been found to decrease the efficacy of lactulose. Conversely, lactulose also decreases the efficacy of rifabutin. This bi-directional effect indicates an intricate relationship between these two compounds.', 'The drug Rifabutin has been found to decrease the efficacy of Lactulose. Similarly, when Lactulose is administered, it may also reduce the effectiveness of Rifabutin. This highlights the potential for drug interaction between these two medications.', 'The drug rifabutin is known to decrease the efficacy of lactulose. Conversely, lactulose also reduces the effectiveness of rifabutin.', 'The drug rifabutin decreases the efficacy of lactulose. Similarly, lactulose also diminishes the efficacy of rifabutin. It suggests a mutual antagonistic interaction exists between these two drugs.']"
"[{'source_node': {'name': 'homatropine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'magnesium hydroxide'}}, {'source_node': {'name': 'homatropine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'polycarbophil'}}, {'source_node': {'name': 'homatropine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Eye oedema'}}, {'source_node': {'name': 'polycarbophil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'diphenidol'}}]","[{'source_node': {'name': 'homatropine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'magnesium hydroxide'}}]","[{'type': 'node_removal', 'source': 'SIDE_EFFECT:2139', 'target': None, 'metadata': {'node_id': '2139', 'node_type': 'SIDE_EFFECT', 'display_name': 'Eye oedema'}}, {'type': 'node_removal', 'source': 'COMPOUND:8245', 'target': None, 'metadata': {'node_id': '8245', 'node_type': 'COMPOUND', 'display_name': 'polycarbophil'}}]",0.3333333333333333,f84f6f1b0de203d2399f2d5f9609f7c1,7d4d3124e88015ff6e9e7a4cd72f14db,"['The drug Homatropine has several interactions and effects. Notably, it decreases the efficacy of magnesium hydroxide and polycarbophil. A side effect of Homatropine usage can be Eye oedema. Furthermore, polycarbophil, when influenced by Homatropine, decreases the efficacy of another drug, diphenidol. This interconnected decrease in efficacy and impact on side effects is crucial to consider when coordinating treatments involving these drugs.', 'Homatropine, a drug used for dilating the pupil and relaxing eye muscles, adversely affects the efficacy of other drugs, such as magnesium hydroxide and polycarbophil. Notably, homatropine can also have a side effect leading to eye oedema. Interestingly, polycarbophil, one of the drugs whose efficacy is decreased by homatropine, also reduces the effectiveness of another drug, diphenidol. It is therefore essential for clinicians to consider these interactions when prescribing a combination of these drugs.', 'The drug homatropine is observed to decrease the efficacy of both magnesium hydroxide and polycarbophil. An additional concern is that homatropine may also cause a side effect of eye oedema. Interestingly, polycarbophil, whose efficacy is reduced by homatropine, can in turn decrease the efficacy of diphenidol. Thus, the interactions among these drugs and their potential side effects need careful monitoring.', 'The drug Homatropine is known to decrease the efficacy of magnesium hydroxide and polycarbophil. Interestingly, Homatropine can also cause side effects such as eye oedema. Further complicating its interactions, the efficacy of diphenidol is decreased by polycarbophil, a compound whose efficacy is already compromised by Homatropine.', ""The drug homatropine is known to decrease the efficacy of both magnesium hydroxide and polycarbophil. Additionally, homatropine may cause side effects such as Eye oedema. It's worth noting that the efficacy of diphenidol could be decreased by the use of polycarbophil.""]","['The commonly used drug homatropine may decrease the efficacy of magnesium hydroxide.', 'The drug Homatropine is known to decrease the efficacy of Magnesium Hydroxide.', 'The drug homatropine can decrease the efficacy of magnesium hydroxide.', 'The drug homatropine is known to decrease the efficacy of magnesium hydroxide.', 'The efficacy of magnesium hydroxide is decreased by homatropine.']"
"[{'source_node': {'name': 'adrenoceptor beta 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hypertriglyceridemia'}}, {'source_node': {'name': 'adrenoceptor beta 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'schizophrenia'}}, {'source_node': {'name': 'adrenoceptor beta 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'essential hypertension'}}, {'source_node': {'name': 'schizophrenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hallucinations'}}, {'source_node': {'name': 'schizophrenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'social and occupational deterioration'}}, {'source_node': {'name': 'schizophrenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'delusions'}}, {'source_node': {'name': 'hypertriglyceridemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autosomal dominant inheritance'}}]","[{'source_node': {'name': 'schizophrenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hallucinations'}}, {'source_node': {'name': 'schizophrenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'social and occupational deterioration'}}, {'source_node': {'name': 'schizophrenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'delusions'}}, {'source_node': {'name': 'hypertriglyceridemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autosomal dominant inheritance'}}, {'source_node': {'name': 'hypertriglyceridemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'social and occupational deterioration'}}]","[{'type': 'edge_addition', 'source': 'DISEASE:17723', 'target': 'PHENOTYPE:4576', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_deletion', 'source': 'GENE:432', 'target': 'DISEASE:13792', 'metadata': None}, {'type': 'edge_deletion', 'source': 'GENE:432', 'target': 'DISEASE:17723', 'metadata': None}, {'type': 'node_removal', 'source': 'DISEASE:1069', 'target': None, 'metadata': {'node_id': '1069', 'node_type': 'DISEASE', 'display_name': 'essential hypertension'}}]",0.6,7e3264ff64a61f6c17bd87f9cc5057ed,820ec68b596b6b0255bc81f2efccb197,"['Adrenoceptor beta 3 has been found to cause several medical conditions such as hypertriglyceridemia, schizophrenia and essential hypertension. Specific to schizophrenia, the sufferers typically have phenotypes encompassing hallucinations, social and occupational deterioration, as well as delusions. Meanwhile, a phenotype of hypertriglyceridemia is the trait of autosomal dominant inheritance.', 'The gene known as adrenoceptor beta 3 causes several conditions, including hypertriglyceridemia, schizophrenia, and essential hypertension. In particular, individuals with schizophrenia may experience symptoms such as hallucinations, delusions, and social and occupational deterioration. Hypertriglyceridemia, another condition caused by adrenoceptor beta 3, can often exhibit a phenotype of autosomal dominant inheritance.', 'The Adrenoceptor Beta 3 is known to cause several conditions such as Essential Hypertension, Hypertriglyceridemia and Schizophrenia. Hypertriglyceridemia, characterized by its autosomal dominant inheritance, is one of the health issues linked to this receptor. Furthermore, Adrenoceptor Beta 3 involvement is evident in Schizophrenia, a debilitating mental health disorder. Phenotypes or signs and symptoms of this disorder typically encompass hallucinations, delusions, as well as social and occupational deterioration.', ""The appearance of adrenoceptor beta 3 could potentially lead to several health conditions including hypertriglyceridemia, schizophrenia, and essential hypertension. \n\nIt's crucial to take into account the distinct traits of these medical conditions. Schizophrenia, for example, is typically characterized by several phenomena, such as hallucinations, social and occupational deterioration, and even delusions.\n\nAnother condition caused by adrenoceptor beta 3 is hypertriglyceridemia, which often has the phenotype of autosomal dominant inheritance. This implies that the condition can be passed on to future generations, making it important for the affected individuals to be aware of.""]","['Schizophrenia, a severe mental disorder, is characterized by various phenotypes such as hallucinations, delusions, and noticeable social and occupational deterioration. Similarly, hypertriglyceridemia, a condition that elevates the level of triglycerides in the blood, also shows phenotypes such as autosomal dominant inheritance, where a single copy of the disease-associated mutation is enough to cause the disease, and it too can lead to social and occupational deterioration.', 'Schizophrenia, a mental disorder, exhibits various phenotypes including hallucinations, delusions and social and occupational deterioration. On the other hand, hypertriglyceridemia, a condition characterized by an excess of triglycerides in the bloodstream, is known for its phenotypic characteristics such as autosomal dominant inheritance and it can also lead to social and occupational deterioration.']"
"[{'source_node': {'name': 'BGN'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'meester-loeys syndrome'}}, {'source_node': {'name': 'BGN'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Defective B4GALT7 causes EDS, progeroid type'}}, {'source_node': {'name': 'BGN'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Defective B3GAT3 causes JDSSDHD'}}, {'source_node': {'name': 'meester-loeys syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'umbilical hernia'}}]","[{'source_node': {'name': 'BGN'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Defective B4GALT7 causes EDS, progeroid type'}}, {'source_node': {'name': 'BGN'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Defective B3GAT3 causes JDSSDHD'}}]","[{'type': 'node_removal', 'source': 'DISEASE:16678', 'target': None, 'metadata': {'node_id': '16678', 'node_type': 'DISEASE', 'display_name': 'meester-loeys syndrome'}}]",0.5555555555555556,79f2e66eab6a274978e93b8c6af4a38b,5ac8f09ac603baefb034ac6c43b76ec8,[],[]
"[{'source_node': {'name': 'TPH2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'attention deficit-hyperactivity disorder'}}, {'source_node': {'name': 'TPH2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'major depressive disorder'}}, {'source_node': {'name': 'TPH2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Serotonin and melatonin biosynthesis'}}, {'source_node': {'name': 'tryptophan 5-hydroxylase 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TPH2'}}, {'source_node': {'name': 'attention deficit-hyperactivity disorder'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'global developmental delay'}}]","[{'source_node': {'name': 'TPH2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'major depressive disorder'}}, {'source_node': {'name': 'TPH2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Serotonin and melatonin biosynthesis'}}, {'source_node': {'name': 'major depressive disorder'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'global developmental delay'}}]","[{'type': 'edge_addition', 'source': 'DISEASE:13799', 'target': 'PHENOTYPE:961', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'node_removal', 'source': 'PROTEIN:4773', 'target': None, 'metadata': {'node_id': '4773', 'node_type': 'PROTEIN', 'display_name': 'tryptophan 5-hydroxylase 2'}}, {'type': 'node_removal', 'source': 'DISEASE:14019', 'target': None, 'metadata': {'node_id': '14019', 'node_type': 'DISEASE', 'display_name': 'attention deficit-hyperactivity disorder'}}]",0.5454545454545454,3f0e5a91ecd4e64c6fb8e4417dda570a,2626023b9152506a54c491c8ff4e3617,[],"['The gene TPH2, which is integral in the serotonin and melatonin biosynthesis process, is known to cause major depressive disorder. This disorder commonly presents symptoms such as global developmental delay.', 'The gene TPH2, which acts within the serotonin and melatonin biosynthesis pathway, has been shown to cause major depressive disorder. This mental health condition is often characterized by various phenotypes, including global developmental delay.', 'The gene TPH2, which plays a role within the serotonin and melatonin biosynthesis pathway, is known to cause major depressive disorder. This disorder, in turn, often presents with a condition characterized by a global developmental delay.', 'The gene TPH2, which plays a key role in the serotonin and melatonin biosynthesis pathway, has been found to cause the major depressive disorder. This disorder often exhibits a phenotype characterized by global developmental delay.']"
"[{'source_node': {'name': 'eyes absent homolog 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'EYA2'}}, {'source_node': {'name': 'geminin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GMNN'}}, {'source_node': {'name': 'picein'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'eyes absent homolog 2'}}, {'source_node': {'name': 'picein'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'geminin'}}, {'source_node': {'name': 'GMNN'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Switching of origins to a post-replicative state'}}]","[{'source_node': {'name': 'EYA2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Switching of origins to a post-replicative state'}}, {'source_node': {'name': 'eyes absent homolog 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'EYA2'}}, {'source_node': {'name': 'eyes absent homolog 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GMNN'}}, {'source_node': {'name': 'geminin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GMNN'}}, {'source_node': {'name': 'geminin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'EYA2'}}, {'source_node': {'name': 'picein'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'eyes absent homolog 2'}}, {'source_node': {'name': 'picein'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'geminin'}}, {'source_node': {'name': 'picein'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'EYA2'}}, {'source_node': {'name': 'GMNN'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Switching of origins to a post-replicative state'}}]","[{'type': 'edge_addition', 'source': 'GENE:26848', 'target': 'PATHWAY:1878', 'metadata': {'predicate': 'acts_within'}}, {'type': 'edge_addition', 'source': 'PROTEIN:5879', 'target': 'GENE:30558', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'PROTEIN:5869', 'target': 'GENE:26848', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'COMPOUND:50913', 'target': 'GENE:26848', 'metadata': {'predicate': 'is_affecting'}}]",0.6363636363636364,ebb35e60a8cfec87fc0ef5b5ab55731c,602379d41cc35ec00ead9779e85824a7,"['The molecules eyes absent homolog 2 and geminin are gene products of EYA2 and GMNN respectively. The compound picein has been found to target both eyes absent homolog 2 and geminin. Furthermore, GMNN plays a crucial role within a biological process known as the switching of origins to a post-replicative state.', 'The drug picein targets two proteins, eyes absent homolog 2 and geminin. These proteins are gene products of EYA2 and GMNN respectively. Additionally, GMNN plays a role within a cellular process called the switching of origins to a post-replicative state.']",[]
"[{'source_node': {'name': 'nelarabine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Hypocalcaemia'}}, {'source_node': {'name': 'nelarabine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Blood magnesium decreased'}}]","[{'source_node': {'name': 'nelarabine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Blood magnesium decreased'}}]","[{'type': 'node_removal', 'source': 'SIDE_EFFECT:575', 'target': None, 'metadata': {'node_id': '575', 'node_type': 'SIDE_EFFECT', 'display_name': 'Hypocalcaemia'}}]",0.6,4b566193ad74186266caec91d0c7a1ea,734f105fe4f71ea0d183a7bd36baa0ae,[],[]
"[{'source_node': {'name': 'carfecillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'norelgestromin'}}, {'source_node': {'name': 'carfecillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'norgestrel'}}, {'source_node': {'name': 'minocycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'carfecillin'}}, {'source_node': {'name': 'minocycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'metampicillin'}}, {'source_node': {'name': 'minocycline'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glutaminase kidney isoform'}}]","[{'source_node': {'name': 'carfecillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'norgestrel'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:1000', 'target': None, 'metadata': {'node_id': '1000', 'node_type': 'COMPOUND', 'display_name': 'minocycline'}}, {'type': 'node_removal', 'source': 'COMPOUND:5764', 'target': None, 'metadata': {'node_id': '5764', 'node_type': 'COMPOUND', 'display_name': 'norelgestromin'}}]",0.2727272727272727,a7243680017fb2a0536411cd58fb2fda,3d00144313d6706872bd482b31f37518,"['The drug Carfecillin is known to decrease the efficacy of both Norelgestromin and Norgestrel. On the other hand, Minocycline, another medication, decreases the efficacy of Carfecillin and Metampicillin. In addition, Minocycline has been found to target glutaminase kidney isoform.', 'The drug carfecillin is known to decrease the efficacy of two compounds, norelgestromin and norgestrel. Meanwhile, another drug, minocycline, reduces the effectiveness of carfecillin and metampicillin. Interestingly, minocycline also targets the glutaminase kidney isoform.', 'The use of certain drugs can impact the efficacy of others. For instance, the drug carfecillin can decrease the efficacy of both norelgestromin and norgestrel. Similarly, the drug minocycline has been shown to decrease the efficacy of carfecillin and metampicillin. In addition, minocycline has a known target of glutaminase kidney isoform. This could potentially add to the interactions and effects observed when these drugs are combined in a treatment plan.', 'The antibiotic drug carfecillin is known to decrease the efficacy of both norelgestromin and norgestrel, which are commonly used in hormonal contraceptives. Additionally, minocycline, another antibiotic, might decrease the efficacy of carfecillin itself as well as metampicillin. Interestingly, minocycline also works by targeting the kidney enzyme known as glutaminase kidney isoform. As these drugs might affect one anothers performance, it does bring about questions for careful consideration while suggesting a combination therapy.', 'The drug carfecillin is known to decrease the efficacy of norelgestromin and norgestrel. On the other hand, minocycline can reduce the effectiveness of carfecillin as well as metampicillin. Interestingly, one of the known targets of minocycline is the glutaminase kidney isoform.']","['The drug Carfecillin has been found to decrease the efficacy of Norgestrel.', 'The efficacy of the drug norgestrel is decreased by carfecillin.', 'The drug carfecillin can decrease the efficacy of norgestrel.', 'The drug Carfecillin has been observed to decrease the efficacy of Norgestrel.', 'The drug carfecillin has been found to decrease the efficacy of norgestrel.']"
"[{'source_node': {'name': '17q21.31 microdeletion syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'recurrent urinary tract infections'}}, {'source_node': {'name': '17q21.31 microdeletion syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'underdeveloped nasal alae'}}, {'source_node': {'name': '17q21.31 microdeletion syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cervical spinal canal stenosis'}}]","[{'source_node': {'name': '17q21.31 microdeletion syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'underdeveloped nasal alae'}}, {'source_node': {'name': '17q21.31 microdeletion syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cervical spinal canal stenosis'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:9', 'target': None, 'metadata': {'node_id': '9', 'node_type': 'PHENOTYPE', 'display_name': 'recurrent urinary tract infections'}}]",0.7142857142857143,d8fbb7c1bfcd1b83a4e5f1cc34bd20ae,0e03c3996023ebdc3435a54f7f453e86,"['""17q21.31 microdeletion syndrome is a genetic condition that exhibits several phenotypes such as recurrent urinary tract infections, underdeveloped nasal alae, and cervical spinal canal stenosis.', '17q21.31 microdeletion syndrome, a genetic disorder, can present with several phenotypic manifestations including recurrent urinary tract infections, underdeveloped nasal alae, and cervical spinal canal stenosis.']","['The 17q21.31 microdeletion syndrome, a genetic disorder, is characterized by certain phenotypic traits, including underdeveloped nasal alae and cervical spinal canal stenosis.', 'The genetic condition known as 17q21.31 microdeletion syndrome is characterized by certain phenotypes which include underdeveloped nasal alae and cervical spinal canal stenosis.', 'The 17q21.31 microdeletion syndrome, a rare genetic disorder, has several physical manifestations, such as underdeveloped nasal alae and cervical spinal canal stenosis.', 'The 17q21.31 microdeletion syndrome has various phenotypes, including underdeveloped nasal alae and cervical spinal canal stenosis.', 'The 17q21.31 microdeletion syndrome, a genetic disorder, exhibits various phenotypes including both an underdeveloped nasal alae and cervical spinal canal stenosis.']"
"[{'source_node': {'name': 'meprednisone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'ethotoin'}}, {'source_node': {'name': 'meprednisone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rubella virus vaccine'}}, {'source_node': {'name': 'eldecalcitol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'desoximetasone'}}, {'source_node': {'name': 'eldecalcitol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'meprednisone'}}, {'source_node': {'name': 'eldecalcitol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clocortolone acetate'}}]","[{'source_node': {'name': 'meprednisone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'ethotoin'}}, {'source_node': {'name': 'meprednisone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rubella virus vaccine'}}, {'source_node': {'name': 'meprednisone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'eldecalcitol'}}, {'source_node': {'name': 'ethotoin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'meprednisone'}}, {'source_node': {'name': 'eldecalcitol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'desoximetasone'}}, {'source_node': {'name': 'eldecalcitol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'meprednisone'}}, {'source_node': {'name': 'eldecalcitol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clocortolone acetate'}}, {'source_node': {'name': 'eldecalcitol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rubella virus vaccine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:738', 'target': 'COMPOUND:8307', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:8307', 'target': 'COMPOUND:4938', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:4938', 'target': 'COMPOUND:8425', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.7272727272727273,b5beb94565e9fdd28f613da1a1f871f6,2a333d3458079000cd8a63bec93899bc,"[""The drug meprednisone increases the efficacy of ethotoin and simultaneously decreases the efficacy of the rubella virus vaccine. On the other hand, eldecalcitol, another drug, is known to decrease the efficacy not only of desoximetasone and clocortolone acetate but also of meprednisone itself. This highlights the complex interplay of drug interactions and effects on each other's performance."", 'The drug meprednisone is observed to increase the efficacy of another drug known as ethotoin. However, its use has been found to decrease the efficacy of the rubella virus vaccine. Another drug, eldecalcitol, is also noted for its ability to decrease the efficacy of certain treatments. Specifically, it lowers the efficacy of desoximetasone, meprednisone, and clocortolone acetate. Careful consideration and management of these drugs is advisible to maximize their benefits and minimize potential drawbacks.', 'The drug meprednisone is known to increase the efficacy of ethotoin, while paradoxically decreasing the efficacy of the rubella virus vaccine. On the other hand, eldecalcitol can potentially decrease the efficacy of several drugs including desoximetasone, meprednisone, and clocortolone acetate. Thus, it is essential to understand the interplay between these drugs while administering them in tandem.', ""Meprednisone, a drug known to influence the efficacy of other drugs, has a diverse impact on its target agents. It increases the efficacy of ethotoin, which may benefit patients who rely on this medication for seizure control. However, meprednisone decreases the efficacy of the rubella virus vaccine, possibly hampering the vaccine's preventive abilities against the rubella virus. \n\nOn another note, eldecalcitol, another drug that can alter the efficacy of various agents, detrimentally affects several drugs. It decreases the efficacy of desoximetasone, meprednisone, and clocortolone acetate which could potentially lead to less than expected results in treating inflammatory skin disorders, arthritis, allergies, and other medical conditions these drugs are usually prescribed for. This shows the complex interactions in drug efficacy, highlighting the need for prescribers to be aware of these interactions when combining treatments."", 'The drug meprednisone has been found to increase the efficacy of ethotoin. However, it simultaneously decreases the efficacy of the rubella virus vaccine. Another drug, eldecalcitol, generally decreases the efficacy of other drugs it interacts with. Specifically, it has been noted to decrease the efficacy of desoximetasone, meprednisone, and clocortolone acetate.']","['The drug meprednisone has multiple effects on other compounds. It can increase the efficacy of substances like ethotoin and eldecalcitol. However, it also has the potential to decrease the efficacy of the rubella virus vaccine. A reciprocal relationship exists between meprednisone and ethotoin in that ethotoin can also increase the efficacy of meprednisone. Interestingly, the effects of meprednisone and eldecalcitol are not reciprocal. While meprednisone enhances the efficacy of eldecalcitol, eldecalcitol can decrease the efficacy of meprednisone. Additionally, eldecalcitol can decrease the efficacy of other substances like the rubella virus vaccine, desoximetasone, and clocortolone acetate. This complex web of interactions is key to understanding the potential impacts and side effects of these compounds when used in combination.', ""The drug meprednisone has multiple effects on drug and vaccine efficacy. It is noted to increase the efficacy of both ethotoin and eldecalcitol. However, its interaction with the rubella virus vaccine demonstrates a decrease in efficacy. Further interactions with ethotoin exhibits an increase in meprednisone's effectiveness. Yet, eldecalcitol too displays a complex relationship with multiple elements, where it decreases the efficacy of not only meprednisone but also desoximetasone, clocortolone acetate, and the rubella virus vaccine. Strikingly, these drug-drug and drug-vaccine interactions highlight how multifaceted medication efficacy can be, and the caution required during the prescription process."", 'The drug meprednisone demonstrated a potential to increase the efficacy of the anti-seizure medication ethotoin and the medication eldecalcitol. Conversely, it may decrease the efficacy of the rubella virus vaccine. Interestingly, in a reciprocal interaction, ethotoin was also found to increase the efficacy of meprednisone.\n\nOn the other hand, examining eldecalcitols interactions showed that it tends to decrease the efficacy of multiple drugs, including meprednisone, the anti-inflammatory medication desoximetasone, and yet another medication named clocortolone acetate. The efficacy of the rubella virus vaccine showed a similar decline when exposed to eldecalcitol.', 'Meprednisone, a medication known for its diverse effects, increases the efficacy of ethotoin and eldecalcitol while decreasing the efficacy of the rubella virus vaccine. Interestingly, this relationship between meprednisone and ethotoin is reciprocal as ethotoin also enhances the efficacy of meprednisone. Conversely, eldecalcitol has a complex role as it not only reduces the efficacy of meprednisone, but also decreases the effectiveness of desoximetasone, clocortolone acetate, and rubella virus vaccine. These various interactions underline the multifaceted interactions between these pharmaceutical agents and underscore the importance of carefully managing drug combinations.', 'The drug meprednisone can increase the efficacy of both ethotoin and eldecalcitol. However, it has been noted to decrease the efficacy of the rubella virus vaccine. On the flipside, ethotoin can reciprocally increase the efficacy of meprednisone. In contrast, eldecalcitol has a complicated relationship with other substances. It can decrease the efficacy of desoximetasone, meprednisone, clocortolone acetate, as well as the rubella virus vaccine. These interplays emphasize the need for careful consideration when mixing drugs and vaccines, to avoid threats to patient safety and to maximize the efficacy of treatments.']"
"[{'source_node': {'name': 'caspase-4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CASP4'}}, {'source_node': {'name': 'CASP4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'NOD1/2 Signaling Pathway'}}]","[{'source_node': {'name': 'CASP4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'NOD1/2 Signaling Pathway'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:3894', 'target': None, 'metadata': {'node_id': '3894', 'node_type': 'PROTEIN', 'display_name': 'caspase-4'}}]",0.6,bba73873f283cf0d013afa749b198781,1c869f3a7b3a8fcb6bc5b718482fa8e2,"['The protein caspase-4 is a gene product of the gene CASP4, which is known to act within the NOD1/2 signaling pathway.']","['The gene CASP4 operates within the NOD1/2 signaling pathway.', 'The gene CASP4 is known to function within the NOD1/2 signaling pathway.', 'The gene CASP4 operates within the framework of the NOD1/2 Signaling Pathway.', 'The gene CASP4 is known to act within the NOD1/2 signaling pathway.']"
"[{'source_node': {'name': 'flavin containing dimethylaniline monoxygenase 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'cardiotoxicity'}}, {'source_node': {'name': 'flavin containing dimethylaniline monoxygenase 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'liver transplantation'}}, {'source_node': {'name': 'flavin containing dimethylaniline monoxygenase 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'coronary artery disease'}}, {'source_node': {'name': 'coronary artery disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'impaired glucose tolerance'}}, {'source_node': {'name': 'coronary artery disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'diabetes mellitus'}}, {'source_node': {'name': 'coronary artery disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'obesity'}}]","[{'source_node': {'name': 'liver transplantation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'diabetes mellitus'}}, {'source_node': {'name': 'flavin containing dimethylaniline monoxygenase 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'cardiotoxicity'}}, {'source_node': {'name': 'flavin containing dimethylaniline monoxygenase 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'liver transplantation'}}, {'source_node': {'name': 'coronary artery disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'impaired glucose tolerance'}}, {'source_node': {'name': 'coronary artery disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'diabetes mellitus'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1118', 'target': None, 'metadata': {'node_id': '1118', 'node_type': 'PHENOTYPE', 'display_name': 'obesity'}}, {'type': 'edge_deletion', 'source': 'GENE:6471', 'target': 'DISEASE:14798', 'metadata': None}, {'type': 'edge_addition', 'source': 'DISEASE:1873', 'target': 'PHENOTYPE:637', 'metadata': {'predicate': 'has_phenotype'}}]",0.6923076923076923,92c00c98dd4dbff4e4a3eab56d8d0508,1d0776d384da27d54b3e5e0e57350b25,"['The enzyme called flavin containing dimethylaniline monoxygenase 3 is responsible for causing several conditions such as cardiotoxicity, the necessity for liver transplantation, and coronary artery disease. Notably, coronary artery disease exhibits several phenotypes including impaired glucose tolerance, diabetes mellitus, and obesity.', 'The enzyme flavin containing dimethylaniline monoxygenase 3 is implicated in causing several conditions, including cardiotoxicity, necessitating liver transplantation, and even coronary artery disease. This particular coronary artery disease is characterized by various phenotypes, such as impaired glucose tolerance, diabetes mellitus, and obesity.', 'The enzyme known as flavin containing dimethylaniline monoxygenase 3 is implicated in several medical conditions. It has been found to cause cardiotoxicity, necessitate liver transplantation, and even trigger the onset of coronary artery disease. This coronary artery disease may present itself through various phenotypes such as impaired glucose tolerance, diabetes mellitus, and obesity.', 'The flavin containing dimethylaniline monoxygenase 3 can cause several conditions including cardiotoxicity, liver transplantation, and coronary artery disease. Interestingly, coronary artery disease typically presents with several phenotypes such as impaired glucose tolerance, diabetes mellitus, and obesity.', 'The enzyme flavin containing dimethylaniline monoxygenase 3 is associated with multiple adverse conditions including cardiotoxicity, the need for liver transplantation, and coronary artery disease. In particular, coronary artery disease often manifests with related phenotypes such as impaired glucose tolerance, diabetes mellitus, and obesity.']",[]
"[{'source_node': {'name': 'PGK2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glycolysis'}}, {'source_node': {'name': 'PGK2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Gluconeogenesis'}}]","[{'source_node': {'name': 'PGK2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Gluconeogenesis'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:57', 'target': None, 'metadata': {'node_id': '57', 'node_type': 'PATHWAY', 'display_name': 'Glycolysis'}}]",0.6,1b3d6c872792a075214cd36e1bac327d,a5e17bb0b526aafbddef64dcfd511db3,"['The gene PGK2 plays a significant role in the metabolic processes of Glycolysis and Gluconeogenesis.', 'The gene PGK2 is involved in multiple metabolic processes, acting within pathways of glycolysis and gluconeogenesis.', 'The gene PGK2 is involved in multiple metabolic processes, acting within both the glycolysis and gluconeogenesis pathways.', 'The gene PGK2 is known to act within several metabolic pathways, particularly those of glycolysis and gluconeogenesis.', 'The gene PGK2 plays a role within multiple metabolic processes, including glycolysis and gluconeogenesis.']","['The gene PGK2 acts within the pathway known as gluconeogenesis.', 'The gene PGK2 operates within the process of Gluconeogenesis.', 'The gene PGK2 is involved in the metabolic process known as gluconeogenesis.', 'The gene PGK2 operates within the pathway of gluconeogenesis.', 'The gene PGK2 plays a role within the pathway of gluconeogenesis.']"
"[{'source_node': {'name': 'fluperolone'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' tendinopathy '}}, {'source_node': {'name': 'fluperolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ginkgo biloba'}}, {'source_node': {'name': 'fluperolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pev3a'}}]","[{'source_node': {'name': 'fluperolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ginkgo biloba'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:4822', 'target': None, 'metadata': {'node_id': '4822', 'node_type': 'COMPOUND', 'display_name': 'pev3a'}}, {'type': 'node_removal', 'source': 'EFFECT:84', 'target': None, 'metadata': {'node_id': '84', 'node_type': 'EFFECT', 'display_name': ' tendinopathy '}}]",0.4285714285714286,cc4dc79aea54e0abd9929247718e6cbc,f658ad2542a5836d0b98bd25c94efdd4,[],"['The drug fluperolone is found to decrease the efficacy of ginkgo biloba.', 'The drug fluperolone has been shown to decrease the efficacy of ginkgo biloba.', 'The drug Fluperolone is known to decrease the efficacy of Ginkgo Biloba.', 'The drug Fluperolone is known to decrease the efficacy of Ginkgo Biloba.', 'The drug fluperolone may decrease the efficacy of ginkgo biloba.']"
"[{'source_node': {'name': 'patent blue'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'isosorbide mononitrate'}}, {'source_node': {'name': 'patent blue'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'molsidomine'}}, {'source_node': {'name': 'patent blue'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'naftopidil'}}, {'source_node': {'name': 'naftopidil'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the arrhythmogenic activities '}}, {'source_node': {'name': 'naftopidil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '2,5-dimethoxy-4-ethylthioamphetamine'}}, {'source_node': {'name': 'imolamine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the vasodilatory activities '}}, {'source_node': {'name': 'imolamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'patent blue'}}]","[{'source_node': {'name': 'patent blue'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'isosorbide mononitrate'}}, {'source_node': {'name': 'patent blue'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'naftopidil'}}, {'source_node': {'name': 'naftopidil'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the arrhythmogenic activities '}}, {'source_node': {'name': 'naftopidil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '2,5-dimethoxy-4-ethylthioamphetamine'}}, {'source_node': {'name': 'imolamine'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the vasodilatory activities '}}, {'source_node': {'name': 'imolamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'patent blue'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:10002', 'target': 'COMPOUND:8217', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:8217', 'target': None, 'metadata': {'node_id': '8217', 'node_type': 'COMPOUND', 'display_name': 'molsidomine'}}]",0.8666666666666667,088e5f17f03b676a732724fddbf82c77,d4da61aa41f3f43f5dfc8a1e30fd26a5,[],[]
"[{'source_node': {'name': 'nalmefene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'butorphanol'}}, {'source_node': {'name': 'nalmefene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ketobemidone'}}, {'source_node': {'name': 'nalmefene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phenoperidine'}}]","[{'source_node': {'name': 'nalmefene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'butorphanol'}}, {'source_node': {'name': 'nalmefene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ketobemidone'}}, {'source_node': {'name': 'nalmefene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phenoperidine'}}, {'source_node': {'name': 'ketobemidone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'butorphanol'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:5788', 'target': 'COMPOUND:597', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.8571428571428572,6c289205e533e797f343cb4b7fb288d7,45de2bd1c18bb9ecc75d308bcb9eb23b,"['The drug Nalmefene has been found to decrease the efficacy of several other medications, namely Butorphanol, Ketobemidone, and Phenoperidine. This means patients using Nalmefene alongside these medications may find their treatments less effective than expected.', 'Nalmefene, a known substance, decreases the efficacy of several drugs including butorphanol, ketobemidone, and phenoperidine. This implies that simultaneous administration of these drugs with nalmefene may lead to reduced effectiveness.', 'The drug nalmefene is known to decrease the efficacy of several substances including butorphanol, ketobemidone, and phenoperidine. Thus, it is important to be cautious of potential interactions when these substances are used together.', 'Nalmefene is a pharmaceutical substance that has been found to decrease the efficacy of several other drugs. These include butorphanol, ketobemidone, and phenoperidine. Therefore, caution should be exercised when Nalmefene is used in conjunction with these medications.', 'The medication nalmefene has been found to decrease the efficacy of several other drugs, including butorphanol, ketobemidone, and phenoperidine. This means that when nalmefene is administered concurrently with these drugs, their potential therapeutic effects could be lessened.']","['The drug nalmefene has been found to decrease the efficacy of several other substances including butorphanol, ketobemidone, and phenoperidine. Interestingly, ketobemidone has also demonstrated a similar effect on butorphanol, decreasing its efficacy.', 'The drug Nalmefene has been shown to decrease the efficacy of several medications, including but not limited to Butorphanol, Ketobemidone, and Phenoperidine. Interestingly, it was also found that Ketobemidone, one of the affected medications, can likewise decrease the efficacy of Butorphanol.', 'The drug Nalmefene has been observed to decrease the efficacy of several opioids including butorphanol, ketobemidone, and phenoperidine. Furthermore, ketobemidone, another opioid, is also found to decrease the efficacy of butorphanol. This interplay and cross activity between these opioids can impact the effectiveness of pain relief strategies.', 'The drug nalmefene is associated with decreased efficacy of several medications, including butorphanol, ketobemidone, and phenoperidine. Intriguingly, ketobemidone also has the potential to decrease the effectiveness of butorphanol. This implies a complex network of drug interactions, necessitating careful consideration in medical treatments.', 'The drug nalmefene has been observed to decrease the efficacy of several other substances including butorphanol, ketobemidone, and phenoperidine. Interestingly, ketobemidone itself has also been found to reciprocally decrease the efficacy of butorphanol. It is crucial to consider this complex interplay when prescribing the above-mentioned drugs.']"
"[{'source_node': {'name': 'enokizumab'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the thrombogenic activities '}}, {'source_node': {'name': 'enokizumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'enokizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imlifidase'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'adalimumab'}}]","[{'source_node': {'name': 'enokizumab'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the thrombogenic activities '}}, {'source_node': {'name': 'enokizumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'enokizumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imlifidase'}}, {'source_node': {'name': 'adalimumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'adalimumab'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'enokizumab'}}, {'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'adalimumab'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:49', 'target': 'EFFECT:5', 'metadata': {'predicate': 'has_effect'}}, {'type': 'edge_addition', 'source': 'COMPOUND:49', 'target': 'COMPOUND:5127', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7777777777777778,1359168eca3fe588d5337b85110ba4b3,7cc5f5a911739a453d041801ebdf22fc,[],[]
"[{'source_node': {'name': 'VRK1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pontocerebellar hypoplasia type 1a'}}, {'source_node': {'name': 'VRK1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nuclear Envelope Breakdown'}}, {'source_node': {'name': 'VRK1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Initiation of Nuclear Envelope (NE) Reformation'}}, {'source_node': {'name': 'pontocerebellar hypoplasia type 1a'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cerebral cortical atrophy'}}, {'source_node': {'name': 'pontocerebellar hypoplasia type 1a'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'arthrogryposis multiplex congenita'}}]","[{'source_node': {'name': 'VRK1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Initiation of Nuclear Envelope (NE) Reformation'}}, {'source_node': {'name': 'pontocerebellar hypoplasia type 1a'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cerebral cortical atrophy'}}, {'source_node': {'name': 'pontocerebellar hypoplasia type 1a'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'arthrogryposis multiplex congenita'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1406', 'target': None, 'metadata': {'node_id': '1406', 'node_type': 'PATHWAY', 'display_name': 'Nuclear Envelope Breakdown'}}, {'type': 'edge_deletion', 'source': 'GENE:33519', 'target': 'DISEASE:7053', 'metadata': None}]",0.7272727272727273,4045b23fc98ce1f8d2b139e97e4d256f,85700e1af96b1e47797722b04770b579,"['The VRK1 gene is implicated in various biological processes, as it acts within the mechanisms of nuclear envelope breakdown and the initiation of Nuclear Envelope (NE) reformation. Aberrations in VRK1 are known to cause pontocerebellar hypoplasia type 1a, a condition characterized by cerebral cortical atrophy and arthrogryposis multiplex congenita.', 'The gene VRK1, which causes the condition pontocerebellar hypoplasia type 1a, acts within the nuclear envelope breakdown and initiation of nuclear envelope (NE) reformation processes. Pontocerebellar hypoplasia type 1a is a condition characterized by phenotypes such as cerebral cortical atrophy and arthrogryposis multiplex congenita.', 'The gene VRK1, known to act within the pathways of nuclear envelope breakdown and initiation of nuclear envelope (NE) reformation, has been linked to the condition of pontocerebellar hypoplasia type 1a. This condition in turn, presents distressing phenotypes such as cerebral cortical atrophy and arthrogryposis multiplex congenita.']","['The gene VRK1 is known to act within the process of initiation of Nuclear Envelope (NE) reformation. On a separate note, the disease pontocerebellar hypoplasia type 1a is associated with certain phenotypes including cerebral cortical atrophy and arthrogryposis multiplex congenita, which are indicators of this neurological condition.']"
"[{'source_node': {'name': 'benzyl (e)-2-methylbut-2-enoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'heat shock protein beta-1'}}, {'source_node': {'name': 'benzyl (e)-2-methylbut-2-enoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor delta'}}, {'source_node': {'name': 'benzyl (e)-2-methylbut-2-enoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear factor nf-kappa-b p105 subunit'}}, {'source_node': {'name': 'nuclear factor nf-kappa-b p105 subunit'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NFKB1'}}, {'source_node': {'name': 'peroxisome proliferator-activated receptor delta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PPARD'}}]","[{'source_node': {'name': 'benzyl (e)-2-methylbut-2-enoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'heat shock protein beta-1'}}, {'source_node': {'name': 'benzyl (e)-2-methylbut-2-enoate'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'NFKB1'}}, {'source_node': {'name': 'peroxisome proliferator-activated receptor delta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PPARD'}}, {'source_node': {'name': 'peroxisome proliferator-activated receptor delta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NFKB1'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:358', 'target': 'GENE:30277', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:28448', 'target': 'PROTEIN:358', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:28448', 'target': 'GENE:30277', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'PROTEIN:1408', 'target': None, 'metadata': {'node_id': '1408', 'node_type': 'PROTEIN', 'display_name': 'nuclear factor nf-kappa-b p105 subunit'}}]",0.4545454545454546,4040d9e797fbd0aa89c983cd467a7285,45c974b9eabafe3c4d0206a09b6aded9,"['Benzyl (E)-2-methylbut-2-enoate has been shown to interact with several proteins including the heat shock protein beta-1, the peroxisome proliferator-activated receptor delta, and the nuclear factor NF-kappa-B p105 subunit. The peroxisome proliferator-activated receptor delta, in fact, is a gene product of PPARD. Similarly, the nuclear factor NF-kappa-B p105 subunit is a gene product of NFKB1.', 'Benzyl (E)-2-methylbut-2-enoate, a chemical compound, has several targets including heat shock protein beta-1, peroxisome proliferator-activated receptor delta, and nuclear factor nf-kappa-b p105 subunit. Notably, the Nuclear factor nf-kappa-b p105 subunit is a gene product of NFKB1. Similarly, the peroxisome proliferator-activated receptor delta is a gene product of PPARD.', ""The chemical agent benzyl (e)-2-methylbut-2-enoate targets several biological molecules. This includes the heat shock protein beta-1, the peroxisome proliferator-activated receptor delta, and the nuclear factor nf-kappa-b p105 subunit. It's essential to note that the peroxisome proliferator-activated receptor delta is a gene product of PPARD and the nuclear factor nf-kappa-b p105 subunit is a gene product of NFKB1."", ""Benzyl (E)-2-methylbut-2-enoate is a compound that targets various proteins, including heat shock protein beta-1, peroxisome proliferator-activated receptor delta, and the nuclear factor NF-kappa-B p105 subunit. It's important to note that the nuclear factor NF-kappa-B p105 subunit is a gene product of NFKB1. Similarly, the peroxisome proliferator-activated receptor delta is also a gene product of PPARD. This demonstrates the interconnected role that these targets and gene products play in a myriad of biological pathways and responses."", 'The compound benzyl (e)-2-methylbut-2-enoate has been found to target three distinct proteins: heat shock protein beta-1, peroxisome proliferator-activated receptor delta and nuclear factor NF-kappa-B p105 subunit. The peroxisome proliferator-activated receptor delta is a gene product of PPARD, while the nuclear factor NF-kappa-B p105 subunit is a gene product of NFKB1.']",[]
"[{'source_node': {'name': 'ADRB2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (s) signalling events'}}, {'source_node': {'name': 'beta-2 adrenergic receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ADRB2'}}, {'source_node': {'name': 'befunolol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'beta-2 adrenergic receptor'}}, {'source_node': {'name': 'befunolol'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the sympathomimetic activities '}}, {'source_node': {'name': 'befunolol'}, 'relation': {'name': 'increase_activity'}, 'target_node': {'name': ' the bradycardic activities '}}]","[{'source_node': {'name': 'befunolol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'beta-2 adrenergic receptor'}}, {'source_node': {'name': 'befunolol'}, 'relation': {'name': 'increase_activity'}, 'target_node': {'name': ' the bradycardic activities '}}]","[{'type': 'node_removal', 'source': 'ACTIVITY:55', 'target': None, 'metadata': {'node_id': '55', 'node_type': 'ACTIVITY', 'display_name': ' the sympathomimetic activities '}}, {'type': 'node_removal', 'source': 'PATHWAY:424', 'target': None, 'metadata': {'node_id': '424', 'node_type': 'PATHWAY', 'display_name': 'G alpha (s) signalling events'}}, {'type': 'node_removal', 'source': 'GENE:26277', 'target': None, 'metadata': {'node_id': '26277', 'node_type': 'GENE', 'display_name': 'ADRB2'}}]",0.4545454545454546,c56209e82b3a50b64133be3a5d0090d2,fdea8b36a030545c769cde64355fcad0,[],[]
"[{'source_node': {'name': 'rivoglitazone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'progesterone'}}, {'source_node': {'name': 'rivoglitazone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'norfloxacin'}}, {'source_node': {'name': 'rivoglitazone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'enrofloxacin'}}]","[{'source_node': {'name': 'progesterone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'rivoglitazone'}}, {'source_node': {'name': 'progesterone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'norfloxacin'}}, {'source_node': {'name': 'rivoglitazone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'progesterone'}}, {'source_node': {'name': 'rivoglitazone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'norfloxacin'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:384', 'target': 'COMPOUND:8135', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:9370', 'target': None, 'metadata': {'node_id': '9370', 'node_type': 'COMPOUND', 'display_name': 'enrofloxacin'}}, {'type': 'edge_addition', 'source': 'COMPOUND:384', 'target': 'COMPOUND:1039', 'metadata': {'predicate': 'increase_efficacy'}}]",0.4285714285714286,9f36a09580bd892b12f61c0e8c546ef1,4d4b754ce69bf4b690dbe51fdabe84cf,"['The drug rivoglitazone can affect the efficacy of several other drugs and substances. Specifically, it has been shown to decrease the efficacy of progesterone. On the other hand, rivoglitazone can actually increase the efficacy of both norfloxacin and enrofloxacin.', 'The drug rivoglitazone has varied effects on the efficacy of other substances. Notably, it decreases the efficacy of progesterone, a hormone involved in the female menstrual cycle. On the other hand, rivoglitazone increases the efficacy of two antibiotics, norfloxacin and enrofloxacin, which are commonly used for treating bacterial infections.', 'The drug Rivoglitazone is known to interact differently with various other substances. For instance, it causes a decrease in the efficacy of Progesterone. On the other hand, Rivoglitazone can enhance the efficacy of certain antibiotics, specifically Norfloxacin and Enrofloxacin.', 'The drug rivoglitazone has been observed to decrease the efficacy of progesterone while simultaneously increasing the efficacy of both norfloxacin and enrofloxacin.', 'The drug Rivoglitazone is known to both enhance and dimish the efficiency of certain substances. Specifically, it decreases the efficacy of progesterone, which might potentially alter its hormonal effects. Conversely, Rivoglitazone increases the efficacy of both norfloxacin and enrofloxacin, suggesting it could potentially boost the therapeutic effects of these antibiotics. Consequently, careful consideration should be given when combining Rivoglitazone with these agents due to the varying impacts on their efficacy.']","[""The hormone progesterone is known to enhance the efficacy of certain drugs, including rivoglitazone and norfloxacin. However, it should be noted that although progesterone boosts the effectiveness of rivoglitazone, rivoglitazone in return decreases the efficacy of progesterone. Interestingly, this conversely paired interaction does not impede rivoglitazone's ability to further heighten the efficacy of norfloxacin."", 'The hormone progesterone is known to increase the efficacy of both rivoglitazone and norfloxacin. Interestingly, rivoglitazone, while having its efficacy increased by progesterone, can decrease the efficacy of the hormone itself. Additionally, rivoglitazone is found to enhance the efficacy of norfloxacin.', 'Progesterone, a naturally occurring steroid hormone, has been shown to increase the efficacy of both Rivoglitazone and Norfloxacin. However, the effectiveness of Progesterone itself may decrease when used in combination with Rivoglitazone. Interestingly, Rivoglitazone can also amplify the efficacy of Norfloxacin. This intricate interplay illustrates the careful balance needed when combining these drugs for therapeutic purposes.', 'Progesterone, a hormonal substance, has been found to increase the efficacy of both rivoglitazone and norfloxacin. Intriguingly, rivoglitazone, influenced by progesterone, reciprocates by not only decreasing the efficacy of progesterone but also enhancing the efficacy of norfloxacin. This dynamic interplay suggests a complex interaction between these substances potentially influencing treatment outcomes.', 'Progesterone, a hormone, significantly increases the efficacy of drugs like Rivoglitazone and Norfloxacin. Interestingly, Rivoglitazone surprisingly reciprocates this interaction by decreasing the efficacy of Progesterone while paradoxically enhancing the effectiveness of Norfloxacin. This complex interplay could have important implications for medication management in patients prescribed any combination of these drugs.']"
"[{'source_node': {'name': 'idiopathic congenital hypothyroidism'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'lethargy'}}, {'source_node': {'name': 'idiopathic congenital hypothyroidism'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'depressed nasal bridge'}}]","[{'source_node': {'name': 'idiopathic congenital hypothyroidism'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'depressed nasal bridge'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:954', 'target': None, 'metadata': {'node_id': '954', 'node_type': 'PHENOTYPE', 'display_name': 'lethargy'}}]",0.6,405ffb7d66b56b5e17b27846e3cd9ff4,d0d18e2f541b19f9847afdfa64d37153,"['Idiopathic congenital hypothyroidism is a condition that manifests with several phenotypes including lethargy and a depressed nasal bridge.', 'Idiopathic congenital hypothyroidism, a condition that typically presents phenotypes such as lethargy and a depressed nasal bridge, is characterized by low levels of thyroid hormones from birth with no known cause.', 'Idiopathic congenital hypothyroidism, a medical condition, manifests with various phenotypes including lethargy and a depressed nasal bridge.', 'Idiopathic congenital hypothyroidism, a medical condition, has several phenotypes including lethargy and a depressed nasal bridge.', 'Idiopathic congenital hypothyroidism, a condition that manifests in various ways, includes symptoms such as lethargy and a distinct physical characteristic, namely a depressed nasal bridge.']",[]
"[{'source_node': {'name': 'methyl pyrrolidone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'creb-binding protein'}}, {'source_node': {'name': 'methyl pyrrolidone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'bromodomain-containing protein 4'}}, {'source_node': {'name': 'methyl pyrrolidone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'BRD4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Potential therapeutics for SARS'}}, {'source_node': {'name': 'creb-binding protein'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CREBBP'}}, {'source_node': {'name': 'bromodomain-containing protein 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'BRD4'}}]","[{'source_node': {'name': 'methyl pyrrolidone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'creb-binding protein'}}, {'source_node': {'name': 'methyl pyrrolidone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'a549'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CREBBP'}}, {'source_node': {'name': 'creb-binding protein'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CREBBP'}}, {'source_node': {'name': 'CREBBP'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Potential therapeutics for SARS'}}, {'source_node': {'name': 'bromodomain-containing protein 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CREBBP'}}]","[{'type': 'edge_addition', 'source': 'GENE:25983', 'target': 'PATHWAY:173', 'metadata': {'predicate': 'acts_within'}}, {'type': 'edge_addition', 'source': 'PROTEIN:5964', 'target': 'GENE:25983', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'PROTEIN:5849', 'target': 'GENE:25983', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:10413', 'target': 'PROTEIN:5964', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:27388', 'target': None, 'metadata': {'node_id': '27388', 'node_type': 'GENE', 'display_name': 'BRD4'}}]",0.5384615384615384,afb8f181323701ce61f570cb7b7063a1,19df7e1019de4b31865a69b3e4ed4005,"['The compound methyl pyrrolidone targets several molecules which include the creb-binding protein, bromodomain-containing protein 4, and a549. Notably, the creb-binding protein is a gene product of CREBBP. Similarly, bromodomain-containing protein 4 is a gene product of BRD4, a gene that acts within the potential therapeutics for SARS.', 'The drug Methyl Pyrrolidone targets several entities including the CREB-binding protein, Bromodomain-containing protein 4, and A549. Specifically, the CREB-binding protein is a gene product of CREBBP. Simultaneously, Bromodomain-containing protein 4 is a gene product of BRD4, which is known to act within the potential therapeutics for SARS, contributing to its effectiveness.', 'The compound methyl pyrrolidone targets a range of proteins including the creb-binding protein, bromodomain-containing protein 4, and interactions with an A549. The creb-binding protein is the gene product of CREBBP. Similarly, bromodomain-containing protein 4 is the gene product of BRD4, which is known to act within potential therapeutics for SARS.', 'The compound, methyl pyrrolidone, is known to target multiple entities like the CREB-binding protein, the bromodomain-containing protein 4, and A549. An interesting fact is that the CREB-binding protein is a gene product of CREBBP and the bromodomain-containing protein 4 is a gene product of BRD4. Moreover, BRD4 acts within the pathway of potential therapeutics for SARS, indicating a potential therapeutic role for methyl pyrrolidone in SARS treatment via its interaction with these targets.']","['The drug methyl pyrrolidone targets both the creb-binding protein and a549. It is fascinating to note that both a549 and creb-binding protein are gene products of CREBBP. Moreover, CREBBP acts within a crucial pathway identified as potential therapeutics for SARS. Interestingly, CREBBP does not only relate to creb-binding protein and a549, but also to the bromodomain-containing protein 4, as it is a gene product of CREBBP.', ""The drug Methyl pyrrolidone is known to target the creb-binding protein and A549. Interestingly, both A549 and creb-binding protein are gene products of CREBBP. Furthermore, CREBBP is known to act within the Potential therapeutics for SARS pathway. It's worth noting that bromodomain-containing protein 4 is also a gene product of CREBBP.""]"
"[{'source_node': {'name': 'diamond-blackfan anemia 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'global developmental delay'}}, {'source_node': {'name': 'diamond-blackfan anemia 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'macrocytic anemia'}}, {'source_node': {'name': 'diamond-blackfan anemia 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypospadias'}}]","[{'source_node': {'name': 'diamond-blackfan anemia 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'global developmental delay'}}, {'source_node': {'name': 'diamond-blackfan anemia 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypospadias'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1438', 'target': None, 'metadata': {'node_id': '1438', 'node_type': 'PHENOTYPE', 'display_name': 'macrocytic anemia'}}]",0.7142857142857143,87501d386adbc7951d1f174a1526a738,f43ff89861c0021e5aefe5c63513a1c8,"['Diamond-Blackfan anemia 5 is a variant of anemia that manifests with a range of phenotypes including global developmental delay, macrocytic anemia, and hypospadias.']","['Diamond-Blackfan anemia 5, a severe blood disorder, is characterized by certain conditions such as global developmental delay and hypospadias, a birth defect in boys where the opening of the urethra is on the underside of the penis.', 'Diamond-Blackfan Anemia 5 is a medical condition that features distinct phenotypes, including global developmental delay and hypospadias.']"
"[{'source_node': {'name': 'congenital enterovirus infection'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'neutropenia'}}, {'source_node': {'name': 'congenital enterovirus infection'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypotension'}}]","[{'source_node': {'name': 'congenital enterovirus infection'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'neutropenia'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1892', 'target': None, 'metadata': {'node_id': '1892', 'node_type': 'PHENOTYPE', 'display_name': 'hypotension'}}]",0.6,54bf5283d4b88fd3a9f71c33ef8609ad,56751c3f549124f61142697911b430a1,"['Congenital enterovirus infection, a condition usually contracted at birth, is characterized by certain conditions such as neutropenia, a deficiency in the amount of neutrophils in the blood, as well as hypotension, more commonly known as low blood pressure.', 'Congenital enterovirus infection, a medical condition often seen in newborns, is associated with several phenotypes including neutropenia, a decrease in the number of neutrophils in the blood, and hypotension, abnormally low blood pressure.']",[]
"[{'source_node': {'name': 'bavachinin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'menin/histone-lysine n-methyltransferase mll'}}, {'source_node': {'name': 'bavachinin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': '78 kda glucose-regulated protein'}}, {'source_node': {'name': 'bavachinin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor gamma'}}, {'source_node': {'name': '78 kda glucose-regulated protein'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HSPA5'}}]","[{'source_node': {'name': 'bavachinin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'menin/histone-lysine n-methyltransferase mll'}}, {'source_node': {'name': 'bavachinin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor gamma'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:49', 'target': None, 'metadata': {'node_id': '49', 'node_type': 'PROTEIN', 'display_name': '78 kda glucose-regulated protein'}}]",0.5555555555555556,b87067e32e82c5ff48f31e652821fcc6,5de676ffca24fc84ffbe1e50e002e04b,"['Bavachinin A is known to target multiple proteins including the menin/histone-lysine n-methyltransferase MLL, the 78 kDa glucose-regulated protein, and the peroxisome proliferator-activated receptor gamma. It is noteworthy to mention that the 78 kDa glucose-regulated protein is a gene product of HSPA5.', 'The compound Bavachinin A targets several proteins including Menin/histone-lysine N-methyltransferase MLL, 78 kDa glucose-regulated protein, and peroxisome proliferator-activated receptor gamma. Interestingly, the 78 kDa glucose-regulated protein is a gene product of HSPA5.', ""The compound Bavachinin A has multiple targets. It interacts with Menin/Histone-lysine N-methyltransferase MLL, with the 78 kDa glucose-regulated protein, and with Peroxisome proliferator-activated receptor gamma. It's worth noting that the 78 kDa glucose-regulated protein is a gene product of HSPA5."", 'The compound Bavachinin A targets several proteins including the menin/histone-lysine N-methyltransferase MLL, the 78 kDa glucose-regulated protein, and the peroxisome proliferator-activated receptor gamma. Interestingly, the 78 kDa glucose-regulated protein is a gene product of the HSPA5 gene.', ""Bavachinin A is a compound known to target several proteins. These include Menin/Histone-Lysine N-Methyltransferase MLL, the 78 KDa Glucose-Regulated Protein, and the Peroxisome Proliferator-Activated Receptor Gamma. It's interesting to note that the 78 KDa Glucose-Regulated Protein is actually a gene product of HSPA5.""]","['The compound Bavachinin A targets both Menin/Histone-Lysine N-Methyltransferase MLL and the Peroxisome Proliferator-Activated Receptor Gamma.', 'The compound Bavachinin A targets both the Menin/Histone-Lysine N-Methyltransferase MLL and the Peroxisome Proliferator-Activated Receptor Gamma.', 'The substance Bavachinin A has been shown to target both the Menin/Histone-Lysine N-Methyltransferase MLL and the Peroxisome Proliferator-Activated Receptor Gamma.', 'The compound Bavachinin A displays its biological effects by targeting two primary sites. The first is the Menin/histone-lysine N-methyltransferase MLL, and the second is the Peroxisome proliferator-activated receptor gamma.', 'The drug Bavachinin A targets both the Menin/Histone-Lysine N-Methyltransferase MLL and the Peroxisome Proliferator-Activated Receptor Gamma.']"
"[{'source_node': {'name': 'demecarium'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the neuromuscular blocking activities '}}, {'source_node': {'name': 'demecarium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hyoscyamine'}}, {'source_node': {'name': 'demecarium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'atracurium besylate'}}, {'source_node': {'name': 'atracurium besylate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'tobramycin'}}]","[{'source_node': {'name': 'hyoscyamine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'demecarium'}}, {'source_node': {'name': 'demecarium'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the neuromuscular blocking activities '}}, {'source_node': {'name': 'demecarium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hyoscyamine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:412', 'target': 'COMPOUND:716', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:716', 'target': 'COMPOUND:927', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:716', 'target': None, 'metadata': {'node_id': '716', 'node_type': 'COMPOUND', 'display_name': 'atracurium besylate'}}, {'type': 'edge_addition', 'source': 'COMPOUND:412', 'target': 'COMPOUND:927', 'metadata': {'predicate': 'increase_efficacy'}}]",0.4444444444444444,341bc17e80790dd992f5ba70f15d41cc,5faf5fdd3f04e25625df1675c5c7109f,[],[]
"[{'source_node': {'name': 'CYP2A6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'coumarin resistance'}}, {'source_node': {'name': 'CYP2A6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'CYP2E1 reactions'}}, {'source_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TDP1'}}, {'source_node': {'name': 'cytochrome p450 1a2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP1A2'}}, {'source_node': {'name': '2-methylnaphthalene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 1a2'}}, {'source_node': {'name': '2-methylnaphthalene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 2a6'}}, {'source_node': {'name': '2-methylnaphthalene'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}}, {'source_node': {'name': 'cytochrome p450 2a6'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP2A6'}}]","[{'source_node': {'name': 'CYP2A6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'coumarin resistance'}}, {'source_node': {'name': 'CYP2A6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'CYP2E1 reactions'}}, {'source_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TDP1'}}, {'source_node': {'name': 'cytochrome p450 2a6'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP2A6'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:48224', 'target': None, 'metadata': {'node_id': '48224', 'node_type': 'COMPOUND', 'display_name': '2-methylnaphthalene'}}, {'type': 'node_removal', 'source': 'GENE:26285', 'target': None, 'metadata': {'node_id': '26285', 'node_type': 'GENE', 'display_name': 'CYP1A2'}}]",0.5882352941176471,652ffdb1e6c8cac4086a93f775770363,41b446eb323b2367246436fe39ea2069,"['The compound 2-methylnaphthalene targets several proteins in the body, including cytochrome p450 1a2, cytochrome p450 2a6, and tyrosyl-dna phosphodiesterase 1. The protein cytochrome p450 1a2 is a gene product of CYP1A2. Similarly, cytochrome p450 2a6 is a gene product of CYP2A6, which not only acts within CYP2E1 reactions but is also responsible for causing a condition known as coumarin resistance. On the other hand, tyrosyl-dna phosphodiesterase 1 is a gene product of TDP1.', 'The compound 2-methylnaphthalene interacts with several biological targets including cytochrome p450 1a2, cytochrome p450 2a6 and tyrosyl-dna phosphodiesterase 1. Both cytochrome p450 1a2 and 2a6 are gene products of CYP1A2 and CYP2A6 respectively. Interestingly, CYP2A6 acts within the metabolic pathway known as CYP2E1 reactions and has been implicated in causing a condition of coumarin resistance. The enzyme tyrosyl-dna phosphodiesterase 1 on the other hand, is the gene product of TDP1.', 'The drug, 2-methylnaphthalene, targets several proteins including cytochrome p450 1a2, cytochrome p450 2a6 and tyrosyl-dna phosphodiesterase 1. Interestingly, these proteins have close relations with certain genes. For instance, cytochrome p450 1a2 is the gene product of CYP1A2, while tyrosyl-dna phosphodiesterase 1 is the gene product of TDP1. Similarly, cytochrome p450 2a6 is a gene product of CYP2A6. \n\nCYP2A6, apart from being associated with cytochrome p450 2a6, also acts within CYP2E1 reactions and is known to cause a condition called coumarin resistance. Such intricate connections demonstrate the complex relationships within these biological entities and pathways.', 'The compound 2-methylnaphthalene has numerous targets, interacting with the proteins cytochrome p450 1a2, cytochrome p450 2a6, and tyrosyl-dna phosphodiesterase 1. Cytochrome p450 1a2 is a gene product of CYP1A2, while cytochrome p450 2a6 is a gene product of CYP2A6. On the other hand, tyrosyl-dna phosphodiesterase 1 is a gene product of TDP1. Furthermore, CYP2A6, in addition to producing cytochrome p450 2a6, also acts within the pathway of CYP2E1 reactions and causes the medical condition known as coumarin resistance.', 'The gene CYP2A6, which acts within the pathway of CYP2E1 reactions, has been identified as a cause of condition known as coumarin resistance. On the other hand, the compound 2-methylnaphthalene targets several proteins including cytochrome p450 1a2, cytochrome p450 2a6 and tyrosyl-dna phosphodiesterase 1. Of note, cytochrome p450 1a2 and cytochrome p450 2a6 are gene products of CYP1A2 and CYP2A6, respectively, while tyrosyl-dna phosphodiesterase 1 is a gene product of TDP1.']",[]
"[{'source_node': {'name': 'levallorphan'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dextropropoxyphene'}}, {'source_node': {'name': 'levallorphan'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'diphenoxylate'}}, {'source_node': {'name': 'levallorphan'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phenoperidine'}}, {'source_node': {'name': 'phenoperidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pegvisomant'}}, {'source_node': {'name': 'phenoperidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sorbitol'}}, {'source_node': {'name': 'phenoperidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nalorphine'}}, {'source_node': {'name': 'dextropropoxyphene'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Myopathy'}}]","[{'source_node': {'name': 'levallorphan'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dextropropoxyphene'}}, {'source_node': {'name': 'levallorphan'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'diphenoxylate'}}, {'source_node': {'name': 'phenoperidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pegvisomant'}}, {'source_node': {'name': 'phenoperidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nalorphine'}}, {'source_node': {'name': 'diphenoxylate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phenoperidine'}}, {'source_node': {'name': 'diphenoxylate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'nalorphine'}}, {'source_node': {'name': 'dextropropoxyphene'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Myopathy'}}, {'source_node': {'name': 'pegvisomant'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Myopathy'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:492', 'target': 'COMPOUND:11453', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:1564', 'target': None, 'metadata': {'node_id': '1564', 'node_type': 'COMPOUND', 'display_name': 'sorbitol'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1061', 'target': 'COMPOUND:11453', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:77', 'target': 'SIDE_EFFECT:1105', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1061', 'target': 'COMPOUND:9440', 'metadata': {'predicate': 'increase_efficacy'}}]",0.6,a4edd62487d0cc5b8f1e1225c1291cf7,448fc7da8d3ae4c8a69f7de6dc2843c6,"['Levallorphan, a known drug, has been found to decrease the efficacy of several other medications. These include dextropropoxyphene, diphenoxylate, and phenoperidine. It is also notable that the drug phenoperidine itself reduces the effectiveness of pegvisomant, sorbitol, and nalorphine. Furthermore, usage of dextropropoxyphene has been linked to side effects such as Myopathy. This interconnected network of drug interactions and side effects showcases the complexity of pharmacological therapy, emphasizing the importance of personalized medicine.', 'Levallorphan, a drug commonly used in pain management, acts by decreasing the efficacy of several other drugs like dextropropoxyphene, diphenoxylate, and phenoperidine. This decrease in efficacy might have several implications on treatment options. For instance, dextropropoxyphene, a mild painkiller and cough suppressant, may also cause a side effect, Myopathy. \n\nPhenoperidine, another drug whose efficacy is reduced by Levallorphan, also has a diminishing effect on the efficiency of some other drugs such as pegvisomant, sorbitol, and nalorphine. Combining these drugs may potentially influence their therapeutic impacts. All these interactions, highlighting the complex interplay between different medications, underscore the importance for healthcare providers to consider drug interactions when prescribing pain management treatments.', ""The drug Levallorphan decreases the efficacy of several other drugs, including Dextropropoxyphene, Diphenoxylate, and Phenoperidine. Phenoperidine, in turn, decreases the efficacy of Pegvisomant, Sorbitol, and Nalorphine. It's also noteworthy to mention that Dextropropoxyphene has a side effect of causing Myopathy. Therefore, caution should be exercised when using these drugs in combination due to the potential for reduced effectiveness and the possibility of adverse side effects."", 'The drug Levallorphan decreases the efficacy of several other drugs such as Dextropropoxyphene, Diphenoxylate, and Phenoperidine. On the other hand, Phenoperidine is found to reduce the effectiveness of Pegvisomant, Sorbitol, and Nalorphine. Interestingly, the use of Dextropropoxyphene has been associated with a side effect, Myopathy.', 'The drug Levallorphan may decrease the efficacy of several medications, including Dextropropoxyphene, Diphenoxylate, and Phenoperidine. This decreased efficacy could have significant effects on patient treatment plans. Furthermore, it appears that Phenoperidine can also substantially decrease the efficacy of medications like Pegvisomant, Sorbitol, and Nalorphine, which could further complicate treatment. An essential point to mention is that Dextropropoxyphene has a known side effect of potentially causing Myopathy, a muscle disorder. Therefore, caution should be exercised when prescribing these drugs concurrently.']","['The drug Levallorphan can decrease the efficacy of other specific drugs such as Dextropropoxyphene and Diphenoxylate. Dextropropoxyphene, despite its decreased efficacy when combined with Levallorphan, is known to have a side effect of causing Myopathy. \n\nOn the other hand, Phenoperidine, another drug, can reduce the efficacy of Pegvisomant and Nalorphine. Interestingly, Diphenoxylate can also decrease the efficacy of Phenoperidine, while conversely increasing the efficacy of Nalorphine. \n\nMoreover, use of Pegvisomant, still being affected by Phenoperidine, can lead to the occurrence of Myopathy as a side effect. In summary, it is vital to consider these interactions and potential side effects when prescribing and combining these drugs.', 'Levallorphan, a pharmaceutical drug, is known to decrease the efficacy of other medications, namely dextropropoxyphene and diphenoxylate. Similarly, phenoperidine also decreases the efficacy of certain drugs such as pegvisomant and nalorphine. However, diphenoxylate has a different relationship with these drugs. While it decreases the efficacy of phenoperidine, it surprisingly increases the efficacy of nalorphine. Moreover, dextropropoxyphene and pegvisomant, despite their lowered efficacy due to other drugs, carry side effects such as myopathy.', 'Levallorphan, a medicinal drug, has been noted to decrease the efficacy of both Dextropropoxyphene and Diphenoxylate. Furthermore, Phenoperidine, another drug, also decreases the efficacy of Pegvisomant and Nalorphine. Interestingly, Diphenoxylate can have opposing effects as it not only decreases the efficacy of Phenoperidine but also increases the efficacy of Nalorphine. It is important to note that usage of both Dextropropoxyphene and Pegvisomant might result in an undesired side effect known as Myopathy, a disease affecting muscle fibers.', 'In the network of pharmacological interactions, levallorphan is demonstrated to decrease the efficacy of both dextropropoxyphene and diphenoxylate. Likewise, phenoperidine also diminishes the effectiveness of pegvisomant and nalorphine. Interestingly, diphenoxylate not only lowers the efficacy of phenoperidine but also enhances the effectiveness of nalorphine. As per the side effect profile, myopathy has been linked with both dextropropoxyphene and pegvisomant.', 'The pharmaceutical Levallorphan has been observed to decrease the efficacy of both Dextropropoxyphene and Diphenoxylate. It is important to note that Dextropropoxyphene has a known side effect of causing Myopathy. Similarly, Diphenoxylate decreases the efficacy of Phenoperidine but interestingly increases the efficacy of Nalorphine. On the other hand, Phenoperidine is found to decrease the efficacy of drugs Pegvisomant and Nalorphine. Pegvisomant, like Dextropropoxyphene, carries the risk of having Myopathy as a side effect.']"
"[{'source_node': {'name': 'ITGAL'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cell surface interactions at the vascular wall'}}, {'source_node': {'name': 'cucurbitacin l'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'jy'}}, {'source_node': {'name': 'cucurbitacin l'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'integrin alpha-l'}}, {'source_node': {'name': 'integrin alpha-l'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ITGAL'}}]","[{'source_node': {'name': 'ITGAL'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Cell surface interactions at the vascular wall'}}, {'source_node': {'name': 'integrin alpha-l'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ITGAL'}}, {'source_node': {'name': 'jy'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ITGAL'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:5676', 'target': 'GENE:29309', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'COMPOUND:70837', 'target': None, 'metadata': {'node_id': '70837', 'node_type': 'COMPOUND', 'display_name': 'cucurbitacin l'}}]",0.5555555555555556,1acacbfb639e4a55ca9972214fc8efbd,a008d6837bb1734ef29fc203d4d3e05e,"['The gene ITGAL plays a significant role within cell surface interactions at the vascular wall. Interestingly, the drug cucurbitacin l has been observed to target both the gene product known as integrin alpha-l and JY with specific relation to this. Integrin alpha-l is known to be a gene product of ITGAL reinforcing its crucial involvement in these interactions.', 'The gene ITGAL acts within the pathway of cell surface interactions at the vascular wall. Interestingly, the compound cucurbitacin l targets both jy and integrin alpha-l, the latter being a gene product of ITGAL. Hence, there is a direct functional intersection between ITGAL and cucurbitacin l through the involvement of integrin alpha-l.', 'The gene ITGAL plays a vital role within cell surface interactions at the vascular wall. Cucurbitacin L is a substance which has been found to target integrin alpha-l, and coincidentally, integrin alpha-l is a gene product of ITGAL. In addition to integrin alpha-l, cucurbitacin l also targets JY, another important compound in this interconnected system.', 'The gene ITGAL, known to act within cell surface interactions at the vascular wall, produces the protein integrin alpha-l. This protein is targeted by the drug cucurbitacin l, which has been found to also target jy.', 'The gene ITGAL is known to act within the biological pathway of cell surface interactions at the vascular wall. Also, interestingly, the compound cucurbitacin l targets both the protein jy and another protein known as integrin alpha-l. This protein integrin alpha-l is actually a gene product of the aforementioned gene ITGAL, connecting these disparate entities into an intriguing biological network.']",['The gene ITGAL acts within the pathway of cell surface interactions at the vascular wall. This gene produces two gene products: integrin alpha-l and jy.']
"[{'source_node': {'name': 'cefcapene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'urokinase'}}, {'source_node': {'name': 'cefcapene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'parnaparin'}}]","[{'source_node': {'name': 'urokinase'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cefcapene'}}, {'source_node': {'name': 'cefcapene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'urokinase'}}, {'source_node': {'name': 'cefcapene'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'parnaparin'}}, {'source_node': {'name': 'parnaparin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'urokinase'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:8195', 'target': 'COMPOUND:13', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:13', 'target': 'COMPOUND:11313', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.6,86bfacf31d31cdcd7f8a0f6b8d37014d,3319f20ccdef5ec527607196aed46884,"['The drug Cefcapene is known to decrease the efficacy of both Urokinase and Parnaparin.', 'The drug cefcapene is known to decrease the efficacy of both urokinase and parnaparin.', 'The drug Cefcapene decreases the efficacy of both Urokinase and Parnaparin.', 'The drug cefcapene has been shown to decrease the efficacy of both urokinase and parnaparin. This suggests that caution should be exercised when administering cefcapene in conjunction with these agents, as it may compromise their therapeutic benefits.', 'The drug cefcapene has been found to decrease the efficacy of both urokinase, an enzyme, and parnaparin, an anticoagulant medication.']","['The drug urokinase can decrease the efficacy of cefcapene, a medicine that is also found to reduce the efficacy of urokinase itself. Moreover, cefcapene can also decrease the efficacy of another drug named parnaparin. In turn, parnaparin is known to reduce the efficacy of urokinase. Therefore, it appears that there is a complex interplay between the effects of these drugs, and their effectiveness can be influenced by each other.', 'The drug urokinase is known to decrease the efficacy of cefcapene, a pharmaceutical agent. Interestingly, this interaction is reciprocal as cefcapene also diminishes the efficacy of urokinase. Furthermore, cefcapene impairs the performance of another drug called parnaparin. This network of efficacy reduction comes full circle, as in turn, parnaparin weakens the potency of urokinase. Thus, caution must be exercised when co-administering these medicines due to their interconnected diminishing effects on each other.', 'The drug urokinase has been shown to decrease the efficacy of cefcapene. Similarly, cefcapene can decrease the efficacy of urokinase, creating a two-way negative interaction between the drugs. Additionally, cefcapene decreases the efficacy of another drug, parnaparin. To complicate matters further, parnaparin also reduces the efficacy of urokinase. These interconnected relationships highlight the importance of considering potential drug interactions in treatment plans.', 'Urokinase is a substance that has been found to decrease the efficacy of the drug cefcapene. Similarly, cefcapene has also shown to decrease the efficacy of urokinase. It should also be noted that cefcapene decreases the efficacy of the medication parnaparin. In turn, parnaparin also lessens the efficacy of urokinase. This highlights a complex network of interactions and potential interference when these drugs are used concurrently.', 'In certain medical scenarios, different drugs can counteract the efficacy of each other. For instance, the drug Urokinase has been found to decrease the efficacy of another medication, Cefcapene. Similarly, Cefcapene also reduces the effectiveness of Urokinase. Further, it has been observed that Cefcapene diminishes the performance of another drug, Parnaparin. In turn, Parnaparin exhibits a detrimental effect on the effectiveness of Urokinase, reducing its therapeutic impact. This revolving cycle of decreased efficacy among Urokinase, Cefcapene and Parnaparin is noteworthy. It emphasizes the need for careful consideration and management when these drugs are administered together, in order to ensure optimal therapeutic effect.']"
"[{'source_node': {'name': 'hemifacial microsomia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'partial duplication of thumb phalanx'}}, {'source_node': {'name': 'hemifacial microsomia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'coarctation of aorta'}}, {'source_node': {'name': 'hemifacial microsomia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ptosis'}}, {'source_node': {'name': 'SF3B2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hemifacial microsomia'}}, {'source_node': {'name': 'SF3B2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'mRNA Splicing - Major Pathway'}}, {'source_node': {'name': 'SF3B2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'mRNA Splicing - Minor Pathway'}}]","[{'source_node': {'name': 'hemifacial microsomia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'coarctation of aorta'}}, {'source_node': {'name': 'hemifacial microsomia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ptosis'}}]","[{'type': 'node_removal', 'source': 'GENE:25235', 'target': None, 'metadata': {'node_id': '25235', 'node_type': 'GENE', 'display_name': 'SF3B2'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:6415', 'target': None, 'metadata': {'node_id': '6415', 'node_type': 'PHENOTYPE', 'display_name': 'partial duplication of thumb phalanx'}}]",0.3846153846153846,fe95bda208d95389f950aa26f97b4653,b50b393f6a6af4ddb96b0067219451b0,"['Hemifacial microsomia, a condition caused by the gene SF3B2, manifests with several characteristic phenotypes such as partial duplication of thumb phalanx, coarctation of aorta, and ptosis. This gene, SF3B2, functions within two specific cellular pathways, namely the mRNA Splicing - Major Pathway and the mRNA Splicing - Minor Pathway.', 'Hemifacial microsomia, a condition caused by the gene SF3B2, which acts within both the mRNA splicing - major pathway and the mRNA splicing - minor pathway, exhibits several phenotypes. These include a partial duplication of thumb phalanx, coarctation of the aorta and ptosis.']","['Hemifacial microsomia, a medical condition, is characterized by various phenotypes including coarctation of aorta and ptosis.', 'Hemifacial microsomia, a condition characterised by developmental anomalies, includes symptoms such as coarctation of the aorta and ptosis.', 'Hemifacial microsomia, a medical condition, embodies various phenotypes such as coarctation of the aorta and ptosis.', 'Hemifacial microsomia, a congenital disorder, is characterized by phenotypes such as coarctation of the aorta and ptosis.', 'Hemifacial microsomia, a medical condition, presents with several phenotypic characteristics including coarctation of the aorta and ptosis.']"
"[{'source_node': {'name': 'DDR2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'spondylometaepiphyseal dysplasia'}}, {'source_node': {'name': 'DDR2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Non-integrin membrane-ECM interactions'}}]","[{'source_node': {'name': 'DDR2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Non-integrin membrane-ECM interactions'}}]","[{'type': 'node_removal', 'source': 'DISEASE:12260', 'target': None, 'metadata': {'node_id': '12260', 'node_type': 'DISEASE', 'display_name': 'spondylometaepiphyseal dysplasia'}}]",0.6,602d548f46653088cdf276b79ccdcfa2,c3f8cd79d1816ba5f03b5c96a824703b,"['The gene DDR2, which acts within the realm of non-integrin membrane-ECM interactions, is known to cause a condition called spondylometaepiphyseal dysplasia.', 'The gene DDR2, which plays a critical role in Non-integrin membrane-ECM interactions, is known to cause a condition known as spondylometaepiphyseal dysplasia.', 'The gene DDR2 acts within the non-integrin membrane-ECM interactions pathway and is known to cause a range of conditions, including spondylometaepiphyseal dysplasia.', 'The gene DDR2, which acts within the pathway of non-integrin membrane-ECM interactions, is known to cause a condition called spondylometaepiphyseal dysplasia.', 'The gene DDR2, which acts within the pathway involving non-integrin membrane-ECM interactions, has been found to cause the condition known as spondylometaepiphyseal dysplasia.']","['The gene DDR2 operates within the pathway of non-integrin membrane-ECM interactions.', 'The gene DDR2 operates within the context of non-integrin membrane-ECM interactions.', 'The gene DDR2 functions within non-integrin membrane-ECM interactions.']"
"[{'source_node': {'name': 'TSPOAP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Norepinephrine Neurotransmitter Release Cycle'}}, {'source_node': {'name': 'TSPOAP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pregnenolone biosynthesis'}}, {'source_node': {'name': 'TSPOAP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glutamate Neurotransmitter Release Cycle'}}]","[{'source_node': {'name': 'TSPOAP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pregnenolone biosynthesis'}}, {'source_node': {'name': 'TSPOAP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Glutamate Neurotransmitter Release Cycle'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:676', 'target': None, 'metadata': {'node_id': '676', 'node_type': 'PATHWAY', 'display_name': 'Norepinephrine Neurotransmitter Release Cycle'}}]",0.7142857142857143,310431f3204b535138ac034c132c256a,0bf6ea40f644fc0c84f783d1849970b9,"['The gene TSPOAP1 operates within several pathways. These include the norepinephrine neurotransmitter release cycle and the glutamate neurotransmitter release cycle which are both essential parts of the nervous system function. Additionally, it is involved in the pregnenolone biosynthesis process, crucial for the creation of steroid hormones.', 'The gene TSPOAP1 is involved in several biological processes, including the norepinephrine neurotransmitter release cycle, pregnenolone biosynthesis, and the glutamate neurotransmitter release cycle. This active participation plays a critical role in the functioning and regulation of these significant pathways.', 'The gene TSPOAP1 plays a role in various pathways including the norepinephrine neurotransmitter release cycle, pregnenolone biosynthesis, and the glutamate neurotransmitter release cycle.', 'The gene TSPOAP1 is notably active within various metabolic and neurotransmitter pathways. This includes the norepinephrine neurotransmitter release cycle and the glutamate neurotransmitter release cycle. Alongside these, TSPOAP1 also acts within the process of pregnenolone biosynthesis, highlighting its multifaceted role within the cellular system.', 'The gene TSPOAP1 is involved in multiple pathways. It acts within the norepinephrine neurotransmitter release cycle, which is fundamental for the nerve signal transmission in the brain. Furthermore, TSPOAP1 also plays a role in pregnenolone biosynthesis, which is crucial for the production of steroid hormones. Last but not least, this gene is a part of the glutamate neurotransmitter release cycle, which is vitally important for normal brain function and neurological health.']","['The gene TSPOAP1 operates within multiple pathways, including the pregnenolone biosynthesis and glutamate neurotransmitter release cycle.', 'The gene TSPOAP1 has been found to act within two crucial pathways: Pregnenolone biosynthesis and the Glutamate Neurotransmitter Release Cycle. This suggests a significant role in both hormonal and neurotransmitter processes.', 'The gene TSPOAP1 participates in various biological pathways - it acts within the pregnenolone biosynthesis process and is also involved in the glutamate neurotransmitter release cycle.', 'The gene TSPOAP1 is known to act within multiple biochemical pathways. One of these pathways is pregnenolone biosynthesis, a crucial process for the production of steroid hormones. TSPOAP1 also performs a role in the glutamate neurotransmitter release cycle, playing a part in the release of the neurotransmitter glutamate within the nervous system.']"
"[{'source_node': {'name': '3,7,11,15-tetramethylhexadec-1-en-3-ol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'androgen receptor'}}, {'source_node': {'name': '3,7,11,15-tetramethylhexadec-1-en-3-ol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'interleukin-8'}}]","[{'source_node': {'name': '3,7,11,15-tetramethylhexadec-1-en-3-ol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'androgen receptor'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:3836', 'target': None, 'metadata': {'node_id': '3836', 'node_type': 'PROTEIN', 'display_name': 'interleukin-8'}}]",0.6,0956a0194c0aee66de1b6bf8ddb2a8d8,294d4cf76021b248ab12748a62f01659,"['The compound 3,7,11,15-tetramethylhexadec-1-en-3-ol targets both the androgen receptor and interleukin-8, implicating potential influences in hormone-related and immune response mechanisms.', 'The compound 3,7,11,15-tetramethylhexadec-1-en-3-ol has multiple targets, including the androgen receptor and interleukin-8.', 'The compound 3,7,11,15-tetramethylhexadec-1-en-3-ol has a dual-targeted action, affecting both the androgen receptor and interleukin-8.', 'The compound 3,7,11,15-tetramethylhexadec-1-en-3-ol targets both the androgen receptor and the interleukin-8. These two targets are critical in various bodily functions including hormone regulation and immune response respectively.', 'The chemical compound 3,7,11,15-tetramethylhexadec-1-en-3-ol targets both the androgen receptor and interleukin-8. The targeting of these two proteins can have a significant biological impact, considering the vital role they play in hormonal function and immune response, respectively.\n']","['The compound 3,7,11,15-tetramethylhexadec-1-en-3-ol has the androgen receptor as its target.', 'The compound 3,7,11,15-tetramethylhexadec-1-en-3-ol targets the androgen receptor.', 'The compound 3,7,11,15-tetramethylhexadec-1-en-3-ol has the androgen receptor as its target.', 'The compound 3,7,11,15-tetramethylhexadec-1-en-3-ol is known to target the androgen receptor.', 'The compound 3,7,11,15-tetramethylhexadec-1-en-3-ol has a specific target which is the androgen receptor.']"
"[{'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15B'}}, {'source_node': {'name': 'heat shock protein beta-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HSPB1'}}, {'source_node': {'name': 'HSPB1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'VEGFA-VEGFR2 Pathway'}}, {'source_node': {'name': 'cumene hydroperoxide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arachidonate 15-lipoxygenase'}}, {'source_node': {'name': 'cumene hydroperoxide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sh-sy5y'}}, {'source_node': {'name': 'cumene hydroperoxide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'heat shock protein beta-1'}}]","[{'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15B'}}, {'source_node': {'name': 'heat shock protein beta-1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HSPB1'}}, {'source_node': {'name': 'HSPB1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'VEGFA-VEGFR2 Pathway'}}, {'source_node': {'name': 'sh-sy5y'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': 'sh-sy5y'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HSPB1'}}, {'source_node': {'name': 'cumene hydroperoxide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arachidonate 15-lipoxygenase'}}, {'source_node': {'name': 'cumene hydroperoxide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sh-sy5y'}}, {'source_node': {'name': 'cumene hydroperoxide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'heat shock protein beta-1'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:5749', 'target': 'GENE:27532', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'PROTEIN:5749', 'target': 'GENE:28930', 'metadata': {'predicate': 'gene_product_of'}}]",0.8666666666666667,f86550335edc5bf444c6d7f204a78018,1f756b88dee5919d8df16b479cc2d381,[],"['Arachidonate 15-lipoxygenase is a gene product of both ALOX15 and ALOX15B. Another gene product of ALOX15 is sh-sy5y. Cumene hydroperoxide, a chemical compound, targets arachidonate 15-lipoxygenase as well as sh-sy5y. The heat shock protein beta-1, on the other hand, is the gene product of HSPB1 and also a target of cumene hydroperoxide. Interestingly, HSPB1, which produces heat shock protein beta-1, acts within the VEGFA-VEGFR2 Pathway. Additionally, sh-sy5y is also a gene product of HSPB1. Thus, ALOX15, ALOX15B, and HSPB1 are interconnected through their gene products and the actions of cumene hydroperoxide.', 'The enzyme arachidonate 15-lipoxygenase is a gene product of both ALOX15 and ALOX15B. This enzyme, along with the protein heat shock protein beta-1a gene product of HSPB1, form part of the target points for cumene hydroperoxide. SH-SY5Y, a gene product of both ALOX15 and HSPB1, is also targeted by cumene hydroperoxide. Furthermore, HSPB1 is known to act within the VEGFA-VEGFR2 pathway, providing a potential link between these various molecular interactions.', 'Arachidonate 15-lipoxygenase is the gene product of both ALOX15 and ALOX15B. Similarly, heat shock protein beta-1 is a gene product of HSPB1. Furthermore, HSPB1 is known to act within the VEGFA-VEGFR2 pathway. SH-SY5Y, another gene product, is derived from both ALOX15 and HSPB1. On the other hand, cumene hydroperoxide targets multiple entities such as arachidonate 15-lipoxygenase, sh-sy5y, and heat shock protein beta-1.']"
"[{'source_node': {'name': 'normethadone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bendroflumethiazide'}}, {'source_node': {'name': 'normethadone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fenquizone'}}]","[{'source_node': {'name': 'normethadone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bendroflumethiazide'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:11555', 'target': 'COMPOUND:9532', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:11555', 'target': None, 'metadata': {'node_id': '11555', 'node_type': 'COMPOUND', 'display_name': 'fenquizone'}}]",0.6,d8327620aa69d077a3e0c401417578f6,7f1c01fefefb1af80ccdff741a70c3e2,"['Normethadone, an opioid medication, is known to decrease the efficacy of certain drugs including bendroflumethiazide, a diuretic medication, and fenquizone, a drug used primarily in Europe for pain and inflammation. If taken concurrently with normethadone, the beneficial effects of these drugs might be significantly reduced.', 'Normethadone, a well-known medication, has been found to decrease the efficacy of other drugs such as bendroflumethiazide and fenquizone. This means that the effectiveness of bendroflumethiazide and fenquizone may be reduced when administered together with normethadone. Therefore, clinicians should carefully consider the usage of these drugs together.', 'Normethadone, a synthetic opioid, is known to decrease the efficacy of certain drugs, including bendroflumethiazide, a thiazide diuretic used for hypertension and edema treatment, and fenquizone, an anti-inflammatory. It is therefore crucial to consider potential drug interactions when using these medications in combination with normethadone.', 'Normethadone, a known medication, can decrease the efficacy of both bendroflumethiazide and fenquizone. This suggests that caution may be required when these drugs are administered concurrently with normethadone.', 'Normethadone, a pharmaceutical drug, has been found to decrease the efficacy of both bendroflumethiazide and fenquizone. Therefore care should be taken when these drugs are administered together or within close time frames.']","['The drug Normethadone is known to decrease the efficacy of another medication known as Bendroflumethiazide.', 'The drug normethadone may decrease the efficacy of bendroflumethiazide.', 'The drug normethadone may decrease the efficacy of bendroflumethiazide.', 'The drug normethadone is known to decrease the efficacy of another drug, bendroflumethiazide.', 'Normethadone is known to decrease the efficacy of the drug bendroflumethiazide.']"
"[{'source_node': {'name': 'liotrix'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'entrectinib'}}, {'source_node': {'name': 'liotrix'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mepindolol'}}, {'source_node': {'name': 'liotrix'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'choline salicylate'}}, {'source_node': {'name': 'colesevelam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'liotrix'}}, {'source_node': {'name': 'colesevelam'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Back pain'}}, {'source_node': {'name': 'colesevelam'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Nasopharyngitis'}}]","[{'source_node': {'name': 'liotrix'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'entrectinib'}}, {'source_node': {'name': 'liotrix'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mepindolol'}}, {'source_node': {'name': 'liotrix'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'choline salicylate'}}, {'source_node': {'name': 'liotrix'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'colesevelam'}}, {'source_node': {'name': 'liotrix'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Nasopharyngitis'}}, {'source_node': {'name': 'mepindolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'choline salicylate'}}, {'source_node': {'name': 'mepindolol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'entrectinib'}}, {'source_node': {'name': 'colesevelam'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'liotrix'}}, {'source_node': {'name': 'colesevelam'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Back pain'}}, {'source_node': {'name': 'colesevelam'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Nasopharyngitis'}}, {'source_node': {'name': 'colesevelam'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'choline salicylate'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1513', 'target': 'COMPOUND:913', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11381', 'target': 'COMPOUND:11843', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1513', 'target': 'SIDE_EFFECT:704', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11381', 'target': 'COMPOUND:9897', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:913', 'target': 'COMPOUND:11843', 'metadata': {'predicate': 'increase_efficacy'}}]",0.6153846153846154,a3caec85db1e27f2d2ca4af0408ccf76,d221e187c78b3d8291e5f145ec0d847b,"[""The medication liotrix has been shown to have differing effects on the efficacy of other drugs. Specifically, it decreases the efficacy of two drugs, entrectinib and mepindolol, while it has been found to increase the efficacy of choline salicylate. However, the interaction is bi-directional as liotrix's efficacy itself is decreased when used in conjunction with another drug, colesevelam. Notably, colesevelam has been linked with specific side effects, including back pain and nasopharyngitis."", 'The drug Liotrix has been observed to decrease the efficacy of both Entrectinib and Mepindolol. Interestingly, the efficacy of Choline Salicylate is known to increase when acted upon by Liotrix. However, the efficacy of Liotrix itself is decreased by the drug Colesevelam. Taking Colesevelam can also lead to a couple of noteworthy side effects, including back pain and nasopharyngitis.', ""The drug liotrix has been noted to decrease the efficacy of both entrectinib and mepindolol, but interestingly, it increases the efficacy of choline salicylate. However, it's important to note that another drug, colesevelam, can decrease the effectiveness of liotrix. Additionally, users of colesevelam may experience side effects such as back pain and nasopharyngitis."", 'Liotrix, a thyroid hormone, has a complex interplay with multiple drugs. It is known to decrease the efficacy of entrectinib and mepindolol, which implies caution while patients are prescribed these medications together. Interestingly, liotrix can increase the efficacy of choline salicylate. \n\nAnother significant relation to note is the interference of Colesevelam with liotrix. Colesevelam, a bile acid sequestrant, decreases the efficacy of liotrix, thereby necessitating the consideration of their simultaneous administration. Colesevelam also has reported side effects that include back pain and nasopharyngitis, which patients need to be informed about when this drug is prescribed.', 'Liotrix, a frequently prescribed drug, exhibits a distinct interaction with a range of other drugs. For instance, its consumption can decrease the efficacy of both entrectinib and mepindolol. Conversely, it is able to enhance the efficacy of choline salicylate. Yet, it should be noted that the drug colesevelam can reduce the efficacy of liotrix. Colesevelam may also produce side effects, including back pain and nasopharyngitis. As a result, caution should be exercised when co-administering these medications due to their potential interactions and side effects.']","['The drug Liotrix has varying interactions with a number of other pharmaceuticals and may lead to the side effect of Nasopharyngitis. Specifically, Liotrix has been found to decrease the efficacy of entrectinib and mepindolol, while simultaneously increasing the efficacy of choline salicylate and colesevelam. Interactions between Liotrix and these other drugs are bidirectional - for instance, colesevelam also affects the efficacy of Liotrix, decreasing it, and can lead to side effects such as back pain and Nasopharyngitis. Additionally, colesevelam also interacts with another drug by increasing the efficacy of choline salicylate. On the other hand, mepindolol positively influences the efficacy of choline salicylate and entrectinib. The complex interplay between these drugs illustrates the importance of considering all potential drug interactions in pharmaceutical protocols.']"
"[{'source_node': {'name': 'gtp-binding nuclear protein ran'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RAN'}}, {'source_node': {'name': 'lysine-specific demethylase 4a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KDM4A'}}, {'source_node': {'name': 'tumor susceptibility gene 101 protein'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TSG101'}}, {'source_node': {'name': 'methylmalonic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lysine-specific demethylase 4a'}}, {'source_node': {'name': 'methylmalonic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tumor susceptibility gene 101 protein'}}, {'source_node': {'name': 'methylmalonic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'gtp-binding nuclear protein ran'}}, {'source_node': {'name': 'TSG101'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Budding and maturation of HIV virion'}}, {'source_node': {'name': 'TSG101'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Late endosomal microautophagy'}}]","[{'source_node': {'name': 'gtp-binding nuclear protein ran'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RAN'}}, {'source_node': {'name': 'gtp-binding nuclear protein ran'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KDM4A'}}, {'source_node': {'name': 'lysine-specific demethylase 4a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KDM4A'}}, {'source_node': {'name': 'tumor susceptibility gene 101 protein'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TSG101'}}, {'source_node': {'name': 'methylmalonic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lysine-specific demethylase 4a'}}, {'source_node': {'name': 'methylmalonic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tumor susceptibility gene 101 protein'}}, {'source_node': {'name': 'TSG101'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Budding and maturation of HIV virion'}}, {'source_node': {'name': 'TSG101'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Late endosomal microautophagy'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:3525', 'target': 'GENE:35605', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:3938', 'target': 'PROTEIN:3525', 'metadata': None}]",0.8823529411764706,39a64ea970b0d3e74115d5f611f8dfd4,731de22e39adad0afe93fd01051fedfe,"['The GTP-binding nuclear protein Ran, which is a gene product of RAN, the lysine-specific demethylase 4a which comes from KDM4A, and the tumor susceptibility gene 101 protein that is a product of TSG101, are all targets of methylmalonic acid. Furthermore, TSG101 acts within two processes: budding and maturation of the HIV virion, as well as late endosomal microautophagy.']","['The GTP-binding nuclear protein RAN is a gene product of both RAN and KDM4A. Similarly, the lysine-specific demethylase 4A is another gene product of KDM4A. The drug, methylmalonic acid, targets these proteins, specifically lysine-specific demethylase 4A and the tumor susceptibility gene 101 protein. This tumor susceptibility gene 101 protein is a gene product of TSG101, a gene known to act within pathways such as budding and maturation of HIV virion as well as late endosomal microautophagy.', 'The gtp-binding nuclear protein ran is a gene product of both RAN and KDM4A. Furthermore, the lysine-specific demethylase 4a, is a gene product of KDM4A. Meanwhile, the tumor susceptibility gene 101 protein is a gene product of TSG101. Interestingly, the compound methylmalonic acid targets both the lysine-specific demethylase 4a and the tumor susceptibility gene 101 protein. Moreover, TSG101 is involved in both the process of the budding and maturation of HIV virion and the late endosomal microautophagy.\n', 'The GTP-binding nuclear protein RAN is a gene product of both RAN and KDM4A. Similarly, Lysine-specific demethylase 4A is a gene product of KDM4A. Another protein, the tumor susceptibility gene 101 protein, is a gene product of TSG101. Interestingly, methylmalonic acid targets both lysine-specific demethylase 4A and tumor susceptibility gene 101 protein in its function. TSG101, on its part, acts within several biochemical processes, including budding and maturation of HIV virion and late endosomal microautophagy.', 'GTP-binding nuclear protein Ran is a gene product of both RAN and KDM4A genes. Another gene product of KDM4A is lysine-specific demethylase 4a. On the other hand, tumor susceptibility gene 101 protein is a gene product of TSG101. Interestingly, both lysine-specific demethylase 4a and tumor susceptibility gene 101 protein are targeted by methylmalonic acid. Furthermore, TSG101 has essential roles in two key biological processes: budding and maturation of HIV virion and late endosomal microautophagy.']"
"[{'source_node': {'name': 'muscarinic acetylcholine receptor m3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CHRM3'}}, {'source_node': {'name': 'noccardimicin e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'muscarinic acetylcholine receptor m3'}}]","[{'source_node': {'name': 'muscarinic acetylcholine receptor m3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CHRM3'}}, {'source_node': {'name': 'noccardimicin e'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'muscarinic acetylcholine receptor m3'}}, {'source_node': {'name': 'noccardimicin e'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'CHRM3'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:73593', 'target': 'GENE:25420', 'metadata': {'predicate': 'is_affecting'}}]",0.8,d54b0ce2188b7e5f841a038cf6c37c54,deef9e7b079391f02198c607dd8f06a6,"['The drug Noccardimicin E targets the Muscarinic Acetylcholine Receptor M3, which is a gene product of the CHRM3 gene.', 'The drug Noccardimicin E specifically targets the muscarinic acetylcholine receptor M3, which is the gene product of CHRM3.', 'The muscarinic acetylcholine receptor m3 is a gene product of CHRM3. Interestingly, it has been found that this receptor is a target for the drug Noccardimicin E.', 'The drug noccardimicin E targets the muscarinic acetylcholine receptor M3. This receptor is a gene product of CHRM3.', 'The drug Noccardimicin E targets the muscarinic acetylcholine receptor M3, which is a gene product of CHRM3.']","[""Muscarinic acetylcholine receptor M3, a gene product of CHRM3, is targeted by the drug noccardimicin E. Furthermore, CHRM3 is also affected by noccardimicin E, highlighting the drug's complex interaction with this specific gene and its product."", 'The drug Noccardimicin E has a direct target, which is the Muscarinic Acetylcholine Receptor M3. This receptor is a gene product of CHRM3. Furthermore, Noccardimicin E is known to affect CHRM3, adding to the complex relationship between the drug, the receptor, and the gene.', 'The drug noccardimicin E targets the muscarinic acetylcholine receptor M3, which is a gene product of CHRM3. Moreover, noccardimicin E also affects the functioning of CHRM3.', 'The compound noccardimicin e targets the muscarinic acetylcholine receptor m3, which is a gene product of CHRM3. Additionally, noccardimicin e is known to affect the CHRM3 gene directly.']"
"[{'source_node': {'name': '(-)-gracilioether c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor gamma'}}, {'source_node': {'name': 'PPARG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nuclear Receptor transcription pathway'}}, {'source_node': {'name': 'peroxisome proliferator-activated receptor gamma'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PPARG'}}]","[{'source_node': {'name': '(-)-gracilioether c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor gamma'}}, {'source_node': {'name': '(-)-gracilioether c'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'PPARG'}}, {'source_node': {'name': 'PPARG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nuclear Receptor transcription pathway'}}, {'source_node': {'name': 'peroxisome proliferator-activated receptor gamma'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PPARG'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:66806', 'target': 'GENE:31205', 'metadata': {'predicate': 'is_affecting'}}]",0.8571428571428572,69fb5a0399d25ade29bded191225c334,ea823213a002eadb2a0be212b61debc0,"['The compound (-)-gracilioether c has a target known as the peroxisome proliferator-activated receptor gamma. This receptor is a gene product of PPARG which in turn acts within the Nuclear Receptor transcription pathway.', 'The compound known as (-)-gracilioether c targets peroxisome proliferator-activated receptor gamma, which is a product of the gene PPARG. Furthermore, PPARG is known to act within the nuclear receptor transcription pathway.', 'The compound (-)-gracilioether C has a target in the peroxisome proliferator-activated receptor gamma. This receptor, in turn, is the gene product of PPARG. Furthermore, PPARG acts within the nuclear receptor transcription pathway, suggesting a potential cellular mechanism for the actions of (-)-gracilioether C.', 'The compound (-)-gracilioether c targets peroxisome proliferator-activated receptor gamma, which is a gene product of PPARG. This gene, PPARG, functions within the nuclear receptor transcription pathway.', 'The compound (-)-gracilioether C has peroxisome proliferator-activated receptor gamma as its target. This receptor is a gene product of PPARG, which acts within the nuclear receptor transcription pathway.']","[""The compound (-)-gracilioether C targets the peroxisome proliferator-activated receptor gamma and affects PPARG. It's notable that PPARG acts within the nuclear receptor transcription pathway. Moreover, the peroxisome proliferator-activated receptor gamma is a gene product of PPARG."", 'The active ingredient (-)-gracilioether C functions by targeting the peroxisome proliferator-activated receptor gamma. This receptor is a gene product of the PPARG gene, which itself is influenced by (-)-gracilioether C. The PPARG gene operates within the nuclear receptor transcription pathway.']"
"[{'source_node': {'name': 'hypertriglyceridemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autosomal dominant inheritance'}}, {'source_node': {'name': 'hypertriglyceridemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'atheroeruptive xanthoma'}}, {'source_node': {'name': 'hypertriglyceridemia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'glucose intolerance'}}, {'source_node': {'name': 'glucokinase regulator'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hypertriglyceridemia'}}, {'source_node': {'name': 'glucokinase regulator'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'stomach neoplasms'}}, {'source_node': {'name': 'glucokinase regulator'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'overall survival'}}]","[{'source_node': {'name': 'glucokinase regulator'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'overall survival'}}, {'source_node': {'name': 'overall survival'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'glucose intolerance'}}]","[{'type': 'edge_deletion', 'source': 'GENE:7014', 'target': 'DISEASE:17723', 'metadata': None}, {'type': 'edge_addition', 'source': 'DISEASE:2380', 'target': 'PHENOTYPE:1420', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'node_removal', 'source': 'DISEASE:3058', 'target': None, 'metadata': {'node_id': '3058', 'node_type': 'DISEASE', 'display_name': 'stomach neoplasms'}}, {'type': 'node_removal', 'source': 'DISEASE:17723', 'target': None, 'metadata': {'node_id': '17723', 'node_type': 'DISEASE', 'display_name': 'hypertriglyceridemia'}}]",0.3076923076923077,a7d4bb500b732a0234ec252eac7d52ab,22e9701d512363f40dae9a9a3a12c3fe,"['The gene glucokinase regulator is accountable for causing several conditions, including hypertriglyceridemia, stomach neoplasms and impacting overall survival. Hypertriglyceridemia in particular is further characterized by distinct phenotypes such as possessing autosomal dominant inheritance patterns, presenting with atheroeruptive xanthoma, and manifesting with glucose intolerance.']",[]
"[{'source_node': {'name': 'nimesulide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'calcium glubionate anhydrous'}}, {'source_node': {'name': 'ambrisentan'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nimesulide'}}, {'source_node': {'name': 'ambrisentan'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Nocturia'}}, {'source_node': {'name': 'ambrisentan'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Pulmonary veno-occlusive disease'}}]","[{'source_node': {'name': 'ambrisentan'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nimesulide'}}, {'source_node': {'name': 'ambrisentan'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Nocturia'}}, {'source_node': {'name': 'ambrisentan'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Pulmonary veno-occlusive disease'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:11009', 'target': 'SIDE_EFFECT:708', 'metadata': {'predicate': 'has_side_effect'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11009', 'target': 'COMPOUND:5568', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11009', 'target': 'COMPOUND:4460', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:11009', 'target': None, 'metadata': {'node_id': '11009', 'node_type': 'COMPOUND', 'display_name': 'calcium glubionate anhydrous'}}]",0.7777777777777778,06b78ace3a762c0281293b55eb15523a,13c4ba02428dd97a7b351fd7e8f538a2,"['The administration of nimesulide has been found to decrease the efficacy of calcium glubionate anhydrous. Interestingly, the efficacy of nimesulide itself can be reduced by the use of another drug called ambrisentan. In addition to its interactions with other drugs, ambrisentan is also known for causing certain side effects. Particularly noteworthy among these are nocturia and pulmonary veno-occlusive disease.', ""The drug Nimesulide has been observed to decrease the efficacy of another medication known as Calcium Glubionate Anhydrous. Interestingly, the drug Ambrisentan may decrease the efficacy of Nimesulide. However, it's worth noting that Ambrisentan has been associated with a variety of side effects. These include nocturia, a condition characterized by excess urination during the night, and Pulmonary Veno-Occlusive Disease, a rare form of pulmonary hypertension."", 'The drug nimesulide has shown to decrease the efficacy of calcium glubionate anhydrous. This is particularly noteworthy because another drug, ambrisentan, has been observed to decrease the efficacy of nimesulide. Additionally, ambrisentan has been associated with certain side effects including nocturia and pulmonary veno-occlusive disease. Thus, understanding these complex relationships is key for assessing potential drug interactions and side effects.', 'The active ingredient nimesulide, that can be found in some pharmaceutical drugs, has been found to decrease the efficacy of calcium glubionate anhydrous. Interestingly, another substance, ambrisentan, can also reduce the effectiveness of nimesulide. Ambrisentan is associated with various side effects including Nocturia, a condition that frequently interrupts sleep due to excessive urination at night, and Pulmonary veno-occlusive disease, a condition that affects the small veins and capillaries within the lungs.', 'The drug nimesulide is known to decrease the efficacy of calcium glubionate anhydrous. Moreover, the drug ambrisentan has been found to decrease the efficacy of nimesulide. Notably, ambrisentan has certain side effects including nocturia and pulmonary veno-occlusive disease.']","['The drug ambrisentan has been known to decrease the efficacy of nimesulide. Additionally, it has certain side effects, such as nocturia, a condition characterized by excessive urination at night, and pulmonary veno-occlusive disease, a rare form of pulmonary hypertension.', 'The drug ambrisentan has been identified to decrease the efficacy of nimesulide. In addition, ambrisentan has been linked to certain side effects including nocturia and pulmonary veno-occlusive disease.', 'The drug ambrisentan can decrease the efficacy of nimesulide. Furthermore, side effects of ambrisentan usage include nocturia and pulmonary veno-occlusive disease.', 'The drug ambrisentan has been known to decrease the efficacy of nimesulide while also producing side effects such as nocturia and pulmonary veno-occlusive disease.', 'The drug Ambrisentan is known to decrease the efficacy of Nimesulide. Additionally, Ambrisentan has been associated with side effects such as Nocturia and Pulmonary veno-occlusive disease.']"
"[{'source_node': {'name': 'norclozapine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'muscarinic acetylcholine receptor m1'}}, {'source_node': {'name': 'norclozapine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dopamine d2 receptor'}}, {'source_node': {'name': 'norclozapine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dopamine d3 receptor'}}, {'source_node': {'name': 'dopamine d2 receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DRD2'}}, {'source_node': {'name': 'DRD3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Dopamine receptors'}}, {'source_node': {'name': 'dopamine d3 receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DRD3'}}]","[{'source_node': {'name': 'muscarinic acetylcholine receptor m1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DRD2'}}, {'source_node': {'name': 'muscarinic acetylcholine receptor m1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DRD3'}}, {'source_node': {'name': 'norclozapine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dopamine d2 receptor'}}, {'source_node': {'name': 'dopamine d2 receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DRD2'}}, {'source_node': {'name': 'DRD3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Dopamine receptors'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:920', 'target': None, 'metadata': {'node_id': '920', 'node_type': 'PROTEIN', 'display_name': 'dopamine d3 receptor'}}, {'type': 'edge_addition', 'source': 'PROTEIN:799', 'target': 'GENE:26576', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'PROTEIN:799', 'target': 'GENE:26577', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:5213', 'target': 'PROTEIN:799', 'metadata': None}]",0.6153846153846154,43c9c8145037803cb6da0fdf29dd2ba8,7a5fe1809eeabc967e74ab9a300ea6e6,"['The drug Norclozapine targets several receptors including the muscarinic acetylcholine receptor m1, dopamine d2 receptor, and dopamine d3 receptor. The dopamine d2 receptor and dopamine d3 receptor are gene products of DRD2 and DRD3 respectively. Moreover, DRD3 acts within the pathway of dopamine receptors.']","['The Muscarinic Acetylcholine Receptor M1 is a gene product of both DRD2 and DRD3. This receptor has a connection to the drug Norclozapine, which has the Dopamine D2 receptor as its target. This Dopamine D2 receptor is also a gene product of DRD2. Furthermore, DRD3 acts within the realm of dopamine receptors.', ""The muscarinic acetylcholine receptor m1 is a gene product of both DRD2 and DRD3. Interestingly, norclozapine has been found to target the dopamine d2 receptor, which is another gene product of DRD2. Additionally, it's worth noting that DRD3 acts within the larger framework of Dopamine receptors, highlighting the interconnected nature of these gene products and pathways."", 'The muscarinic acetylcholine receptor M1 is a gene product of DRD2 and DRD3. Norclozapine has a target in the dopamine D2 receptor, which is itself a gene product of DRD2. Intriguingly, DRD3 acts within the system of dopamine receptors. This interplay of genes and receptors draws a complex map of drug-genomic interactions.', 'The muscarinic acetylcholine receptor M1 is a gene product of both DRD2 and DRD3. Interestingly, Norclozapine targets the dopamine d2 receptor, which in turn is a gene product of DRD2. Moreover, DRD3 acts within a group of dopamine receptors, cementing the intricate interplay between these elements.', 'The muscarinic acetylcholine receptor M1 is a gene product of both DRD2 and DRD3. The gene DRD3 also acts within Dopamine receptors. The drug norclozapine targets dopamine D2 receptor, which is a gene product of DRD2. This implies a complex web of interactions, where genes create products that are then targeted by certain substances, thus impacting the internal signaling pathway.']"
"[{'source_node': {'name': 'IDH1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'glioma susceptibility 1'}}, {'source_node': {'name': 'IDH1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'NADPH regeneration'}}, {'source_node': {'name': 'IDH1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Peroxisomal protein import'}}, {'source_node': {'name': 'isocitrate dehydrogenase [nadp] cytoplasmic'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'IDH1'}}]","[{'source_node': {'name': 'IDH1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'NADPH regeneration'}}, {'source_node': {'name': 'isocitrate dehydrogenase [nadp] cytoplasmic'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'IDH1'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:49', 'target': None, 'metadata': {'node_id': '49', 'node_type': 'PATHWAY', 'display_name': 'Peroxisomal protein import'}}, {'type': 'node_removal', 'source': 'DISEASE:13716', 'target': None, 'metadata': {'node_id': '13716', 'node_type': 'DISEASE', 'display_name': 'glioma susceptibility 1'}}]",0.5555555555555556,4188004ef8a241408f0d39fed2a2014e,75d0d758213ada35d18312c3c37ca104,"['The gene IDH1 acts within several biological processes including NADPH regeneration and peroxisomal protein import and is known to cause a condition known as glioma susceptibility 1. The enzyme isocitrate dehydrogenase [nadp] cytoplasmic is a gene product of IDH1.', 'The gene IDH1, which plays a critical role within the NADPH regeneration and peroxisomal protein import pathways, causes a condition known as glioma susceptibility 1. Furthermore, isocitrate dehydrogenase [nadp] cytoplasmic is identified as the gene product of IDH1.']","['The gene known as isocitrate dehydrogenase [NADP] cytoplasmic, is a product of the gene IDH1. IDH1 plays a crucial role within the metabolic process of NADPH regeneration in the cell.', 'The enzyme isocitrate dehydrogenase [NADP] cytoplasmic is a gene product of IDH1. Furthermore, IDH1 acts within the pathway of NADPH regeneration.', 'The gene product called isocitrate dehydrogenase [nadp] cytoplasmic is derived from the IDH1 gene. This IDH1 gene is known to act within the metabolic process of NADPH regeneration.', 'The enzyme isocitrate dehydrogenase [nadp] cytoplasmic is a gene product of IDH1, which in turn acts within the pathway of NADPH regeneration.', 'The enzyme isocitrate dehydrogenase [nadp] cytoplasmic, is a gene product of IDH1. This gene, IDH1, acts within the pathway of NADPH regeneration.']"
"[{'source_node': {'name': 'tolazoline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'trichlormethiazide'}}, {'source_node': {'name': 'tolazoline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'norfenefrine'}}, {'source_node': {'name': 'tolazoline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mofebutazone'}}]","[{'source_node': {'name': 'tolazoline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'trichlormethiazide'}}, {'source_node': {'name': 'tolazoline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'norfenefrine'}}, {'source_node': {'name': 'norfenefrine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'trichlormethiazide'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:11234', 'target': 'COMPOUND:1004', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11234', 'target': 'COMPOUND:11477', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:11477', 'target': None, 'metadata': {'node_id': '11477', 'node_type': 'COMPOUND', 'display_name': 'mofebutazone'}}]",0.5714285714285714,f773a5a66f68f4537784e98615a77250,226cb2c687de27b76cccb2ef35721591,"['The drug Tolazoline has been found to increase the effectiveness of Trichlormethiazide. Conversely, the same drug, Tolazoline, is known to decrease the efficacy of Norfenefrine and Mofebutazone. This highlights the importance of understanding drug-drug interactions when prescribing multiple treatment options.', 'The drug tolazoline is known to increase the efficacy of trichlormethiazide. However, it decreases the efficacy of both norfenefrine and mofebutazone.', 'The drug tolazoline has been observed to increase the efficacy of trichlormethiazide. However, the same drug, tolazoline, has also been reported to decrease the efficacy of both norfenefrine and mofebutazone. This suggests that the potential interactions between these various drugs should be carefully considered in a clinical setting.', 'The drug tolazoline has been found to increase the efficacy of trichlormethiazide. However, tolazoline may decrease the efficacy of other substances such as norfenefrine and mofebutazone.', 'The drug tolazoline has various impacts on other substances. It is known to increase the efficacy of trichlormethiazide. Conversely, the presence of tolazoline tends to decrease the efficacy of mofebutazone and norfenefrine.\n']","['The drug Tolazoline has been shown to increase the efficacy of Trichlormethiazide and decrease the efficacy of Norfenefrine. Interestingly, Norfenefrine also has the propensity to amplify the efficacy of Trichlormethiazide. Therefore, interplay of these medications can result in complex drug interactions.', 'The drug tolazoline is known to increase the efficacy of trichlormethiazide while decreasing the efficacy of norfenefrine. Interestingly, norfenefrine itself is known to increase the efficacy of trichlormethiazide.', 'The drug tolazoline has been shown to increase the efficacy of trichlormethiazide while simultaneously decreasing the efficacy of norfenefrine. Intriguingly, norfenefrine itself can increase the efficacy of trichlormethiazide, suggesting a complex interplay of drug actions.', 'Tolazoline has a dual-action with regard to different substances. On one hand, it has been shown to increase the efficacy of trichlormethiazide. On the other hand, tolazoline tends to decrease the efficacy of norfenefrine. Interestingly, norfenefrine itself has been found to increase the efficacy of trichlormethiazide.', 'The drug tolazoline demonstrates a dual effect by increasing the efficacy of trichlormethiazide while concurrently decreasing the efficacy of norfenefrine. Interestingly, norfenefrine also appears to enhance the efficacy of trichlormethiazide, suggesting a complex interplay between these three drugs.']"
"[{'source_node': {'name': 'dirithromycin'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the QTc-prolonging activities '}}, {'source_node': {'name': 'dirithromycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bcg vaccine'}}]","[{'source_node': {'name': 'dirithromycin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bcg vaccine'}}, {'source_node': {'name': 'bcg vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dirithromycin'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:10650', 'target': 'COMPOUND:937', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:10650', 'target': 'ACTIVITY:5', 'metadata': {'predicate': 'decrease_activity'}}, {'type': 'node_removal', 'source': 'ACTIVITY:5', 'target': None, 'metadata': {'node_id': '5', 'node_type': 'ACTIVITY', 'display_name': ' the QTc-prolonging activities '}}]",0.4,d0d9000c8118a5153d3f323aad16db74,7b82f610649e9522d246b020b27723b0,[],"['The drug Dirithromycin may decrease the efficacy of the BCG Vaccine, and conversely, the BCG Vaccine may also reduce the efficacy of Dirithromycin. This mutual interplay indicates a complex interaction between these two pharmaceutical agents.', 'Dirithromycin is known to decrease the efficacy of the BCG vaccine. However, it is also interesting to note that this relationship appears to be bidirectional as BCG vaccine can also reduce the potency of dirithromycin.', 'The drug Dirithromycin has been found to decrease the efficacy of the BCG Vaccine. Conversely, the BCG Vaccine also appears to decrease the efficacy of Dirithromycin. This indicates a complex interaction between these two treatments.', 'The drug dirithromycin is known to decrease the efficacy of the BCG vaccine. Conversely, the BCG vaccine can also reduce the effectiveness of dirithromycin.', 'The drug Dirithromycin has been observed to decrease the efficacy of the BCG Vaccine. Interestingly, the BCG Vaccine also has a similar effect on Dirithromycin, decreasing its efficacy as well. Therefore, it appears there is a mutual diminishing interaction between Dirithromycin and the BCG Vaccine.']"
"[{'source_node': {'name': 'quinine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'bivalirudin'}}, {'source_node': {'name': 'quinine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'anistreplase'}}, {'source_node': {'name': 'triptolide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'chlorpropamide'}}, {'source_node': {'name': 'triptolide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'triptolide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mda-mb-435'}}, {'source_node': {'name': 'phenindione'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'quinine'}}, {'source_node': {'name': 'phenindione'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'miconazole'}}, {'source_node': {'name': 'phenindione'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'triptolide'}}]","[{'source_node': {'name': 'quinine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'bivalirudin'}}, {'source_node': {'name': 'anistreplase'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'anistreplase'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'triptolide'}}, {'source_node': {'name': 'triptolide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'chlorpropamide'}}, {'source_node': {'name': 'triptolide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'triptolide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mda-mb-435'}}, {'source_node': {'name': 'phenindione'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'quinine'}}, {'source_node': {'name': 'phenindione'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'miconazole'}}, {'source_node': {'name': 'phenindione'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'triptolide'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:28', 'target': 'PROTEIN:5849', 'metadata': {'predicate': 'has_target'}}, {'type': 'edge_addition', 'source': 'COMPOUND:28', 'target': 'COMPOUND:9936', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:456', 'target': 'COMPOUND:28', 'metadata': None}]",0.8235294117647058,b9c93bd117d2f0c0688f610ce530d175,6f81409dc2a37c6e47709ce778d5bb80,"[""The efficacy of various drugs can be influenced by other substances. For example, quinine is known to increase the efficacy of bivalirudin and anistreplase. On the other hand, triptolide can decrease the effectiveness of another drug, chlorpropamide. Furthermore, triptolide has shown target interactions with certain cell lines, such as those of A549 and MDA-MB-435.\n\nMeanwhile, phenindione has a role in enhancing the potency of other substances. It's been observed to boost the efficacy of quinine and miconazole. However, phenindione has also been found to reduce the efficacy of triptolide. The complexity of these interactions underscores the manifold effects of substances on the human body and the importance of understanding these relationships in pharmacology and disease treatment strategies."", 'The drugs quinine and phenindione interact in a positive-feedback loop, where phenindione increases the efficacy of quinine, and quinine in return enhances the treatment potencies of anticoagulant bivalirudin and clot-busting agent anistreplase. The drug triptolide, however, has a negative influence on the efficacy of the antidiabetic drug chlorpropamide. Interestingly, triptolide also demonstrates interactions with specific cell lines, exhibited by its targeting of the lung cancer cell line A549 and breast cancer cell line MDA-MB-435. Notwithstanding, phenindione diminishes the efficacy of triptolide. Additionally, phenindione symbolises potential beneficial interference with antifungal treatment as it escalates the efficacy of miconazole.', 'The drug quinine can increase the efficacy of both bivalirudin and anistreplase. On the other hand, triptolide has been shown to decrease the efficacy of chlorpropamide but it targets cells such as a549 and mda-mb-435. Notably, phenindione can enhance the efficacy of quinine and miconazole but it decreases the efficacy of triptolide.', 'The drug quinine has been found to increase the efficacy of both bivalirudin and anistreplase. On the other hand, triptolide, another drug, is known to decrease the efficacy of chlorpropamide. Notably, triptolide targets both A549 and MDA-MB-435 cellular components. Interestingly, phenindione, a third drug, increases the efficacy of quinine, making it more potent, while also enhancing the efficacy of miconazole. However, phenindione also decreases the efficacy of triptolide, perhaps offsetting some of its potential interactions with its targets.', 'Quinine, a widely used drug, has been found to increase the efficacy of bivalirudin and anistreplase, thus boosting their effectiveness. In contrast, another drug, triptolide, is known to decrease the efficacy of chlorpropamide, while also targeting a549 and mda-mb-435, two crucial components in drug development. Furthermore, phenindione increases the efficacy of both quinine and miconazole, potent anti-malarial and antifungal drugs, respectively. However, phenindione seems to carry a complex role as it also decreases the efficacy of triptolide, demonstrating the intricate interplay of drug actions and interactions.']","[""Quinine and phenindione are two drugs that form an interesting interaction network. Quinine is known to increase the efficacy of bivalirudin. On the other hand, phenindione increases the efficacy of quinine, which creates a potential for synergistic effects. However, it must be noted that phenindione also increases the efficacy of miconazole and decreases the efficacy of triptolide.\n\nIn a separate connection, anistreplase targets a549, a commonly used cell line in biological research. It also increases the efficacy of triptolide, suggesting potential combined therapeutic applications. However, the relationship with triptolide is more complex as it's known to reduce the efficacy of chlorpropamide.\n\nLastly, triptolide itself is not just a passive recipient in this network. Besides having its efficacy altered by anistreplase and phenindione, it also actively targets not one, but two cell lines - a549 and mda-mb-435. This indicates its potential as a broadly effective therapeutic agent."", 'Quinine is known to increase the efficacy of bivalirudin, and its efficacy is likewise increased by phenindione. Interestingly, phenindione also increases the efficacy of miconazole, but it decreases the efficacy of triptolide. Triptolide plays a significant role in this network, as it targets both a549 and mda-mb-435, and decreases the efficacy of chlorpropamide. Coincidentally, anistreplase also targets a549 and it increases the efficacy of triptolide. This interconnected relationship underscores the complexity and preciseness of these medicinal interactions.', 'The efficacy of several drugs is interconnected within a complex system of interactions. Quinine, known for its antimalarial properties, is observed to increase the efficacy of bivalirudin, an anticoagulant drug. Similarly, phenindione, an anticoagulant, increases the efficacy of not only quinine but also miconazole, an antifungal medication.\n\nIn another series of interactions, Anistreplase, a thrombolytic agent, targets a549, a human lung cancer cell line. Additionally, Anistreplase increases the efficacy of triptolide, a potent immunosuppressive and anti-inflammatory agent derived from a Chinese herb.\n\nHowever, the usage of triptolide shows a decrease in efficacy when used in conjunction with chlorpropamide, an antidiabetic drug. Instead, triptolide appears to have better outcomes when targeting a549 cancer cells and mda-mb-435, a breast cancer cell line.\n\nInterestingly, phenindione shows decreased efficacy when used alongside triptolide, suggesting a negative interaction between the two substances. Such complex drug interactions hold key implications for personalized medicine and highlight the necessity of a comprehensive understanding of drug efficacy relationships.']"
"[{'source_node': {'name': 'p-glycoprotein 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ABCB1'}}, {'source_node': {'name': 'tuckeyanol a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'p-glycoprotein 1'}}]","[{'source_node': {'name': 'p-glycoprotein 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ABCB1'}}, {'source_node': {'name': 'tuckeyanol a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'p-glycoprotein 1'}}, {'source_node': {'name': 'tuckeyanol a'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'ABCB1'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:71534', 'target': 'GENE:30941', 'metadata': {'predicate': 'is_affecting'}}]",0.8,3355c49ea04301963703a34ba0a47c1d,04672bf135eb082f4023716551799556,"['The compound Tuckeyanol A targets P-glycoprotein 1, a product of the ABCB1 gene.', 'The compound Tuckeyanol A has a target known as P-glycoprotein 1, which is a gene product of the ABCB1 gene.', 'The compound Tuckeyanol A has a biological target - p-glycoprotein 1, which is a gene product of the ABCB1 gene.', 'The drug Tuckeyanol A has been identified as targeting P-glycoprotein 1. Interestingly, P-glycoprotein 1 is the gene product of ABCB1.', 'The drug Tuckeyanol A has a target known as P-glycoprotein 1, which is a gene product of ABCB1.']","['The compound Tuckeyanol A targets P-glycoprotein 1 and also directly affects ABCB1. Additionally, P-glycoprotein 1 is a gene product of ABCB1.']"
"[{'source_node': {'name': 'ADORA1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (i) signalling events'}}, {'source_node': {'name': 'adenosine receptor a1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ADORA1'}}, {'source_node': {'name': 'tecadenoson'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'adenosine receptor a1'}}]","[{'source_node': {'name': 'adenosine receptor a1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ADORA1'}}, {'source_node': {'name': 'tecadenoson'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'adenosine receptor a1'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:109', 'target': None, 'metadata': {'node_id': '109', 'node_type': 'PATHWAY', 'display_name': 'G alpha (i) signalling events'}}]",0.7142857142857143,42cdece8a4fa15a19d454e212ab2513a,baa919184af4f8e596d924eb6c5795e0,"['Tecadenoson is a pharmaceutical drug that primarily targets the adenosine receptor a1. This particular receptor is found to be the gene product of the gene ADORA1. The ADORA1 gene interestingly, is also known to act within the G alpha (i) signalling events pathway.', 'The drug known as tecadenoson primarily targets the adenosine receptor A1, which is a gene product of ADORA1. Notably, ADORA1 plays a critical part within a network of G alpha (i) signalling events.', 'The gene ADORA1 works within the G alpha (i) signalling events pathway, whose gene product is the adenosine receptor a1. Additionally, Tecadenoson, a pharmaceutical drug, targets this specific receptor, adenosine receptor a1.', 'Tecadenoson acts on its target, the adenosine receptor A1. Furthermore, the adenosine receptor A1 is the gene product of ADORA1, which acts within G alpha (i) signalling events.', 'Tecadenoson, a drug with a known target of the adenosine receptor A1, plays a significant role in scientific studies. The adenosine receptor A1 is a gene product of ADORA1. This gene notably acts within the G alpha (i) signalling events, contributing to a variety of cellular pathways and processes.']","['Adenosine receptor A1 is a gene product of ADORA1 and is targeted by the drug Tecadenoson.', 'The adenosine receptor A1, functioning as a gene product of ADORA1, is specifically targeted by the drug Tecadenoson.', 'The drug tecadenoson specifically targets the adenosine receptor A1, which is a gene product of ADORA1.', 'The drug Tecadenoson specifically targets the Adenosine Receptor A1 which is a gene product of the gene ADORA1.', 'Adenosine receptor A1 is the gene product of ADORA1. Additionally, this receptor serves as the target for tecadenoson.']"
"[{'source_node': {'name': '2,3,6,7-tethrahydroxyxanthone'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'angiotensin-converting enzyme'}}, {'source_node': {'name': 'renal tubular dysgenesis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'microcephaly'}}, {'source_node': {'name': 'renal tubular dysgenesis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autosomal recessive inheritance'}}, {'source_node': {'name': 'renal tubular dysgenesis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'respiratory insufficiency'}}, {'source_node': {'name': 'ACE'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'renal tubular dysgenesis'}}, {'source_node': {'name': 'ACE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Metabolism of Angiotensinogen to Angiotensins'}}, {'source_node': {'name': 'angiotensin-converting enzyme'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACE'}}]","[{'source_node': {'name': 'renal tubular dysgenesis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'microcephaly'}}, {'source_node': {'name': 'renal tubular dysgenesis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autosomal recessive inheritance'}}, {'source_node': {'name': 'renal tubular dysgenesis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'respiratory insufficiency'}}, {'source_node': {'name': 'ACE'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'renal tubular dysgenesis'}}, {'source_node': {'name': 'angiotensin-converting enzyme'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACE'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:321', 'target': None, 'metadata': {'node_id': '321', 'node_type': 'PATHWAY', 'display_name': 'Metabolism of Angiotensinogen to Angiotensins'}}, {'type': 'node_removal', 'source': 'COMPOUND:34776', 'target': None, 'metadata': {'node_id': '34776', 'node_type': 'COMPOUND', 'display_name': '2,3,6,7-tethrahydroxyxanthone'}}]",0.7333333333333334,5adb24d9733784eb3f68434791858a1f,f60e15e4027ea257dee0f466f027fc62,"['The compound 2,3,6,7-tethrahydroxyxanthone has a targeted impact on the angiotensin-converting enzyme which is a gene product of ACE. ACE acts within the metabolism of angiotensinogen to angiotensins pathway and it is notable for causing a condition known as renal tubular dysgenesis. Renal tubular dysgenesis is characterized by several interconnected phenotypes including microcephaly, autosomal recessive inheritance, and respiratory insufficiency.', 'The compound 2,3,6,7-tethrahydroxyxanthone has a specific target, the angiotensin-converting enzyme. This enzyme is a gene product of ACE, which acts within a particular metabolic mechanism known as Metabolism of Angiotensinogen to Angiotensins and it is known to cause a certain condition referred to as renal tubular dysgenesis. This condition comes with several phenotypes including microcephaly, autosomal recessive inheritance, and respiratory insufficiency.']","[""Renal tubular dysgenesis, a condition caused by the gene ACE, manifests several symptoms, namely microcephaly, autosomal recessive inheritance, and respiratory insufficiency. Additionally, the angiotensin-converting enzyme is a product of the ACE gene, further linking the enzyme's role to this condition."", 'Renal tubular dysgenesis, a condition caused by the gene ACE, exhibits several phenotypes, including microcephaly, autosomal recessive inheritance, and respiratory insufficiency. Furthermore, the angiotensin-converting enzyme is a gene product of ACE, strengthening the connection between these genes and the condition.', 'Renal tubular dysgenesis, a condition caused by the gene ACE, holds various phenotypes including microcephaly, autosomal recessive inheritance, and respiratory insufficiency. This ACE gene is a product of the angiotensin-converting enzyme. This details a therapeutic outline, relating various symptoms and their genetic origins, and can be vital in understanding and treating the disease at its root.', 'Renal tubular dysgenesis, a condition caused by the gene ACE, has several associated phenotypes including microcephaly, autosomal recessive inheritance, and respiratory insufficiency. ACE, specifically, is the gene product of angiotensin-converting enzyme which directly influences the occurrence of renal tubular dysgenesis, a disorder characterized by underdevelopment of the renal tubules.', 'Renal tubular dysgenesis is a condition caused by the gene ACE, which is the gene product of angiotensin-converting enzyme. This disease exhibits several phenotypes such as microcephaly, autosomal recessive inheritance, as well as respiratory insufficiency.']"
"[{'source_node': {'name': 'pyrithione'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'dicoumarol'}}, {'source_node': {'name': 'pyrithione'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'phenprocoumon'}}, {'source_node': {'name': 'pyrithione'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'tioclomarol'}}, {'source_node': {'name': 'dicoumarol'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' bleeding and hemorrhage '}}, {'source_node': {'name': 'dicoumarol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'ofloxacin'}}, {'source_node': {'name': 'dicoumarol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cloprostenol'}}, {'source_node': {'name': 'tioclomarol'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the anticoagulant activities '}}]","[{'source_node': {'name': 'pyrithione'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'dicoumarol'}}, {'source_node': {'name': 'pyrithione'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'phenprocoumon'}}, {'source_node': {'name': 'phenprocoumon'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'dicoumarol'}}, {'source_node': {'name': 'dicoumarol'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' bleeding and hemorrhage '}}, {'source_node': {'name': 'dicoumarol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cloprostenol'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:929', 'target': 'COMPOUND:256', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:1145', 'target': None, 'metadata': {'node_id': '1145', 'node_type': 'COMPOUND', 'display_name': 'ofloxacin'}}, {'type': 'node_removal', 'source': 'COMPOUND:11303', 'target': None, 'metadata': {'node_id': '11303', 'node_type': 'COMPOUND', 'display_name': 'tioclomarol'}}]",0.5333333333333333,3e2448f7d539382785990f4f9523ce8a,e4a5d2165b6ec8a9ab7ba87173e0b335,[],[]
"[{'source_node': {'name': 'collagenase clostridium histolyticum'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'collagen alpha-1(ii) chain'}}, {'source_node': {'name': 'collagenase clostridium histolyticum'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clomocycline'}}]","[{'source_node': {'name': 'clomocycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'collagenase clostridium histolyticum'}}, {'source_node': {'name': 'collagenase clostridium histolyticum'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clomocycline'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:93', 'target': None, 'metadata': {'node_id': '93', 'node_type': 'PROTEIN', 'display_name': 'collagen alpha-1(ii) chain'}}, {'type': 'edge_addition', 'source': 'COMPOUND:441', 'target': 'COMPOUND:46', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.4,5489153b0a0553218166922475ab5a1a,cb0b74e08151acbbd9eb3af619e19e2f,"['Collagenase Clostridium Histolyticum, a drug used in the treatment of various diseases, acts primarily by targeting the collagen alpha-1(II) chain. However, it is also known to decrease the efficacy of another drug, Clomocycline, leading to potential implications for treatment plans involving these two drugs.', 'The drug collagenase clostridium histolyticum has a dual role. It targets the collagen alpha-1(ii) chain specifically, but it also lessens the efficacy of the drug clomocycline.', 'The drug collagenase clostridium histolyticum has been found to target collagen alpha-1(ii) chain. Additionally, its efficacy is reported to decrease when used in conjunction with clomocycline.', 'The drug Collagenase Clostridium Histolyticum targets collagen alpha-1(II) chain and interestingly, it has been noted to decrease the efficacy of Clomocycline.', 'The drug collagenase clostridium histolyticum has collagen alpha-1(ii) chain as its target. Meanwhile, collagenase clostridium histolyticum has also been found to decrease the efficacy of another drug, clomocycline.']","[""The efficacy of the drug clomocycline is decreased by collagenase clostridium histolyticum. In a similar way, the efficacy of collagenase clostridium histolyticum is decreased when in presence of clomocycline. This points to a mutual antagonistic relationship where each drug decreases the other's efficacy."", 'The drug clomocycline is known to decrease the efficacy of another drug named collagenase clostridium histolyticum. Interestingly, the influence is reciprocal, as collagenase clostridium histolyticum in turn decreases the efficacy of clomocycline. This suggests a mutual interplay between these two drugs that could potentially affect the treatment outcomes.', ""The drug clomocycline and collagenase clostridium histolyticum have a reciprocal relationship where they decrease each other's efficacy. This means that if one is present, the effect of the other tends to be diminished."", ""The drug clomocycline has been found to decrease the efficacy of collagenase clostridium histolyticum. Moreover, it is important to note that collagenase clostridium histolyticum can also decrease the efficacy of clomocycline. This suggests that both drugs can potentially interfere with each other's ability to function effectively."", ""The drug Clomocycline is known to decrease the efficacy of another drug known as Collagenase Clostridium Histolyticum. However, it should also be noted that the efficacy of Clomocycline itself is reduced by Collagenase Clostridium Histolyticum. The functioning and effectiveness of these two drugs are interconnected, influencing each other's overall effect when used for treatments.""]"
"[{'source_node': {'name': 'fluocortolone'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' hyperglycemia '}}, {'source_node': {'name': 'fluocortolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rabies immune globulin'}}, {'source_node': {'name': 'fluocortolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'previtamin d(3)'}}, {'source_node': {'name': 'fenthion'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'anisotropine methylbromide'}}, {'source_node': {'name': 'fenthion'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluocortolone'}}, {'source_node': {'name': 'fenthion'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'diphemanil'}}, {'source_node': {'name': 'anisotropine methylbromide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cisplatin'}}, {'source_node': {'name': 'anisotropine methylbromide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dichlorvos'}}]","[{'source_node': {'name': 'dichlorvos'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'rabies immune globulin'}}, {'source_node': {'name': 'fluocortolone'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' hyperglycemia '}}, {'source_node': {'name': 'fluocortolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rabies immune globulin'}}, {'source_node': {'name': 'fluocortolone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'previtamin d(3)'}}, {'source_node': {'name': 'fenthion'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'diphemanil'}}, {'source_node': {'name': 'anisotropine methylbromide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cisplatin'}}, {'source_node': {'name': 'anisotropine methylbromide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dichlorvos'}}, {'source_node': {'name': 'cisplatin'}, 'relation': {'name': 'decrease_effect'}, 'target_node': {'name': ' hyperglycemia '}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:9376', 'target': 'COMPOUND:503', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:501', 'target': 'EFFECT:29', 'metadata': {'predicate': 'decrease_effect'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:9376', 'target': 'COMPOUND:7917', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:9365', 'target': 'COMPOUND:9526', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7647058823529411,17d3ba133f2824cbf430de1230a95562,d0225f39d0dd0738c9d56ab163e499fa,[],[]
"[{'source_node': {'name': 'buflomedil'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the antiplatelet activities '}}, {'source_node': {'name': 'buflomedil'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' hypertension '}}, {'source_node': {'name': 'buflomedil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'phentermine'}}, {'source_node': {'name': 'phentermine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'netoglitazone'}}, {'source_node': {'name': 'phentermine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'luseogliflozin'}}, {'source_node': {'name': 'phentermine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Abdominal cramps'}}, {'source_node': {'name': 'netoglitazone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'chlorthalidone'}}]","[{'source_node': {'name': 'phentermine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'netoglitazone'}}, {'source_node': {'name': 'phentermine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'luseogliflozin'}}, {'source_node': {'name': 'phentermine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Abdominal cramps'}}, {'source_node': {'name': 'phentermine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'chlorthalidone'}}, {'source_node': {'name': 'chlorthalidone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'netoglitazone'}}, {'source_node': {'name': 'netoglitazone'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'chlorthalidone'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:11361', 'target': 'COMPOUND:181', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:181', 'target': 'COMPOUND:300', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:8134', 'target': 'ACTIVITY:21', 'metadata': {'predicate': 'has_activity'}}, {'type': 'node_removal', 'source': 'ACTIVITY:21', 'target': None, 'metadata': {'node_id': '21', 'node_type': 'ACTIVITY', 'display_name': ' the antiplatelet activities '}}, {'type': 'node_removal', 'source': 'COMPOUND:11361', 'target': None, 'metadata': {'node_id': '11361', 'node_type': 'COMPOUND', 'display_name': 'buflomedil'}}, {'type': 'edge_addition', 'source': 'COMPOUND:300', 'target': 'COMPOUND:8134', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.4666666666666667,a6ad3d18c81164e0714f50e43bad00d7,c589b428c7b857372a7b47bdaa0e8594,[],"[""The drug Phentermine is noted to increase the efficacy of both Netoglitazone and Luseogliflozin. However, it is also recognized to have side effects such as abdominal cramps, and decreases the efficacy of another drug, Chlorthalidone. It's worth mentioning that Chlorthalidone also decreases the efficacy of Netoglitazone, which in turn decreases the efficacy of Chlorthalidone, forming a loop of diminished effectiveness between the two medications."", 'The drug phentermine has been shown to increase the efficacy of other drugs, netoglitazone and luseogliflozin. However, it is also important to note that phentermine has certain side effects, such as causing abdominal cramps. Interestingly, the effectiveness of phentermine seems to reduce the efficacy of chlorthalidone, another medication. In a similar vein, chlorthalidone has been demonstrated to lower the efficacy of netoglitazone. There also appears to be a reciprocal relationship, with netoglitazone affecting the functionality of chlorthalidone, decreasing its efficacy in return. What these findings imply is that the interaction among these drugs and their effectiveness could vary significantly, a factor that may become increasingly important in the context of polypharmacy.', 'The drug Phentermine has been identified to increase therapeutic efficacy of certain drugs such as Netoglitazone and Luseogliflozin. However, it should be noted that Phentermine may also come with a side effect such as abdominal cramps. Interestingly, it has been noticed that Phentermine might decrease the efficacy of Chlorthalidone, a commonly used pharmaceutical agent. Likewise, it has been found that Chlorthalidone could decrease the efficacy of Netoglitazone. In a parallel observation, Netoglitazone itself could also potentially reduce the efficacy of Chlorthalidone. Hence, a careful scrutiny of the combined administration of these drugs may be warranted.', ""The medication phentermine has been found to increase the efficacy of certain drugs, specifically netoglitazone and luseogliflozin. However, it is important to note that phentermine may also have side effects, such as triggering abdominal cramps. Furthermore, the administration of phentermine tends to decrease the efficacy of the drug chlorthalidone. Interestingly, chlorthalidone and netoglitazone appear to have a reciprocal diminishing effect on each other's efficacy."", 'The drug Phentermine is known to increase the efficacy of specific drugs such as Netoglitazone and Luseogliflozin. However, it should be noted that the use of Phentermine also leads to side effects including abdominal cramps. Interestingly, while Phentermine enhances the performance of Netoglitazone, it concurrently decreases the efficacy of another drug, Chlorthalidone. Moreover, Chlorthalidone itself exhibits a decreasing efficacy when used in conjunction with Netoglitazone and vice versa. Hence, care should be taken while administering these medications together.']"
"[{'source_node': {'name': 'amitriptyline'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Endogenous depression'}}, {'source_node': {'name': 'r,s-warfarin alcohol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'tramadol'}}, {'source_node': {'name': 'r,s-warfarin alcohol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'amitriptyline'}}, {'source_node': {'name': 'r,s-warfarin alcohol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'levofloxacin'}}]","[{'source_node': {'name': 'amitriptyline'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Endogenous depression'}}, {'source_node': {'name': 'amitriptyline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'r,s-warfarin alcohol'}}, {'source_node': {'name': 'tramadol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'r,s-warfarin alcohol'}}, {'source_node': {'name': 'levofloxacin'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Endogenous depression'}}, {'source_node': {'name': 'r,s-warfarin alcohol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'tramadol'}}, {'source_node': {'name': 'r,s-warfarin alcohol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'amitriptyline'}}, {'source_node': {'name': 'r,s-warfarin alcohol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'levofloxacin'}}, {'source_node': {'name': 'r,s-warfarin alcohol'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Endogenous depression'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:183', 'target': 'COMPOUND:7705', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:311', 'target': 'COMPOUND:7705', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1117', 'target': 'INDICATION:899', 'metadata': {'predicate': 'has_indication'}}, {'type': 'edge_addition', 'source': 'COMPOUND:7705', 'target': 'INDICATION:899', 'metadata': {'predicate': 'has_indication'}}]",0.5555555555555556,ab45bd71f6725787c9f50769df9bbfad,8924420d369948f2768166a5d02efb9e,"['The drug Amitriptyline is indicated for the treatment of Endogenous depression. Interestingly, its efficacy can be decreased by the presence of R,S-warfarin alcohol. On the other hand, R,S-warfarin alcohol can also increase the efficacy of Tramadol and Levofloxacin.', 'The drug amitriptyline has been indicated for the treatment of endogenous depression. It should be noted, however, that the effectiveness of amitriptyline can be reduced by the intake of R,S-warfarin alcohol. Conversely, the same substance, R,S-warfarin alcohol, enhances the efficacy of two other drugs, tramadol and levofloxacin. Consequently, care should be taken when administering these drugs concurrently or in close proximity.', 'The drug Amitriptyline is typically indicated for the treatment of endogenous depression. However, its efficacy decreases when combined with R,S-warfarin alcohol. Interestingly, R,S-warfarin alcohol can increase the efficacy of two other drugs: Tramadol and Levofloxacin. This reflects how precise drug combinations can impact health outcomes and treatment effectiveness.', 'Amitriptyline, a commonly used medication, has been indicated for the treatment of endogenous depression. However, it is noteworthy that the efficacy of Amitriptyline can be decreased by the intake of r,s-warfarin alcohol. Conversely, the same r,s-warfarin alcohol can also increase the efficacy of certain other medications like Tramadol and Levofloxacin. This understanding of the interplay of these drugs can greatly guide therapeutic choices, prevent unwanted side-effects and maximize treatment efficacy.', 'Amitriptyline, a commonly prescribed medication, has an indication for the treatment of endogenous depression. However, its efficacy decreases if used in tandem with the substance r,s-warfarin alcohol. Conversely, the same substance, r,s-warfarin alcohol, is known to increase the efficacy of other drugs such as tramadol and levofloxacin. Thus, care must be taken when prescribing these medications in combination.']",[]
"[{'source_node': {'name': 'IRF8'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'immunodeficiency 32a'}}, {'source_node': {'name': 'IRF8'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'immunodeficiency 32b'}}, {'source_node': {'name': 'IRF8'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Interferon gamma signaling'}}]","[{'source_node': {'name': 'IRF8'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'immunodeficiency 32b'}}, {'source_node': {'name': 'IRF8'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Interferon gamma signaling'}}]","[{'type': 'node_removal', 'source': 'DISEASE:15814', 'target': None, 'metadata': {'node_id': '15814', 'node_type': 'DISEASE', 'display_name': 'immunodeficiency 32a'}}]",0.7142857142857143,151803a26302ba1e30519955e208e9a2,020b96b7b326c5153877edb6cbf781e2,"['The gene IRF8, which is a crucial player in interferon gamma signaling, is known to be responsible for causing certain conditions such as immunodeficiency 32a and immunodeficiency 32b.']","['The gene IRF8, which functions within the framework of Interferon gamma signaling, is known to cause a condition known as Immunodeficiency 32B.', 'The gene IRF8 is involved in Interferon gamma signaling and can cause a condition known as immunodeficiency 32b.', 'The gene IRF8, which functions within the pathway of interferon gamma signaling, has been identified as a cause of the disease Immunodeficiency 32b.', 'The gene IRF8 is known to cause a condition known as immunodeficiency 32b. Additionally, IRF8 acts within the pathway of interferon gamma signaling.', 'The gene IRF8 is involved in the process of interferon gamma signaling and is known to cause a condition known as immunodeficiency 32b.']"
"[{'source_node': {'name': 'pivampicillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'norethindrone enanthate'}}, {'source_node': {'name': 'atracurium besylate'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' Cardiac Arrhythmia '}}, {'source_node': {'name': 'atracurium besylate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'magnesium sulfate'}}, {'source_node': {'name': 'atracurium besylate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dehydrocholic acid'}}, {'source_node': {'name': 'oxytetracycline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'atracurium besylate'}}, {'source_node': {'name': 'oxytetracycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pivampicillin'}}, {'source_node': {'name': 'oxytetracycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'epicillin'}}]","[{'source_node': {'name': 'pivampicillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'norethindrone enanthate'}}, {'source_node': {'name': 'pivampicillin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'atracurium besylate'}}, {'source_node': {'name': 'norethindrone enanthate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'dehydrocholic acid'}}, {'source_node': {'name': 'atracurium besylate'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' Cardiac Arrhythmia '}}, {'source_node': {'name': 'atracurium besylate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'magnesium sulfate'}}, {'source_node': {'name': 'atracurium besylate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dehydrocholic acid'}}, {'source_node': {'name': 'oxytetracycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'epicillin'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:1532', 'target': 'COMPOUND:716', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:581', 'target': 'COMPOUND:1532', 'metadata': None}, {'type': 'edge_deletion', 'source': 'COMPOUND:581', 'target': 'COMPOUND:716', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:12384', 'target': 'COMPOUND:9543', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7333333333333334,a477345ab8045a3e898db5a39e41b263,d2798dfca5d658db421c35d870b68e1a,[],[]
"[{'source_node': {'name': 'NR1I2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nuclear Receptor transcription pathway'}}, {'source_node': {'name': 'NR1I2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'SUMOylation of intracellular receptors'}}, {'source_node': {'name': 'chenodeoxycholic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear receptor subfamily 1 group i member 2'}}, {'source_node': {'name': 'chenodeoxycholic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'k562'}}, {'source_node': {'name': 'chenodeoxycholic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tk-10'}}, {'source_node': {'name': 'nuclear receptor subfamily 1 group i member 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR1I2'}}]","[{'source_node': {'name': 'NR1I2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nuclear Receptor transcription pathway'}}, {'source_node': {'name': 'NR1I2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'SUMOylation of intracellular receptors'}}, {'source_node': {'name': 'chenodeoxycholic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear receptor subfamily 1 group i member 2'}}, {'source_node': {'name': 'chenodeoxycholic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'k562'}}, {'source_node': {'name': 'chenodeoxycholic acid'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'NR1I2'}}, {'source_node': {'name': 'k562'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR1I2'}}, {'source_node': {'name': 'nuclear receptor subfamily 1 group i member 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR1I2'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5633', 'target': None, 'metadata': {'node_id': '5633', 'node_type': 'PROTEIN', 'display_name': 'tk-10'}}, {'type': 'edge_addition', 'source': 'PROTEIN:4947', 'target': 'GENE:34889', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5825', 'target': 'GENE:34889', 'metadata': {'predicate': 'is_affecting'}}]",0.6923076923076923,cb190ffc9f69c12964ae6163e768fc0e,83243ea531a68bc2936a9972f4819954,"['The gene NR1I2 acts within several pathways including the nuclear receptor transcription pathway and the sumoylation of intracellular receptors. The compound chenodeoxycholic acid has multiple targets. It targets nuclear receptor subfamily 1 group i member 2, which is a gene product of NR1I2. Additionally, chenodeoxycholic acid targets the K562 and TK-10 cell lines.']",[]
"[{'source_node': {'name': 'lipoid congenital adrenal hyperplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'adrenogenital syndrome'}}, {'source_node': {'name': 'lipoid congenital adrenal hyperplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'macroorchidism'}}, {'source_node': {'name': 'lipoid congenital adrenal hyperplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'breast carcinoma'}}]","[{'source_node': {'name': 'lipoid congenital adrenal hyperplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'breast carcinoma'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1504', 'target': None, 'metadata': {'node_id': '1504', 'node_type': 'PHENOTYPE', 'display_name': 'macroorchidism'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:655', 'target': None, 'metadata': {'node_id': '655', 'node_type': 'PHENOTYPE', 'display_name': 'adrenogenital syndrome'}}]",0.4285714285714286,7e2df5bb8e2c3f336a9ee0b9ecfbe4e3,fccdffebd6b33ab373fc68ea485f450a,"['Lipoid congenital adrenal hyperplasia is a condition that manifests various phenotypes including adrenogenital syndrome, macroorchidism, and even breast carcinoma.']",[]
"[{'source_node': {'name': 'tarsal-carpal coalition syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hearing abnormality'}}, {'source_node': {'name': 'tarsal-carpal coalition syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cubitus valgus'}}, {'source_node': {'name': 'tarsal-carpal coalition syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'distal symphalangism of hands'}}, {'source_node': {'name': 'NOG'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'tarsal-carpal coalition syndrome'}}, {'source_node': {'name': 'NOG'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'brachydactyly'}}, {'source_node': {'name': 'NOG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Signaling by BMP'}}, {'source_node': {'name': 'brachydactyly'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'short metatarsal'}}]","[{'source_node': {'name': 'NOG'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Signaling by BMP'}}]","[{'type': 'edge_addition', 'source': 'DISEASE:12274', 'target': 'PHENOTYPE:287', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_deletion', 'source': 'GENE:35270', 'target': 'DISEASE:12274', 'metadata': None}, {'type': 'node_removal', 'source': 'DISEASE:4834', 'target': None, 'metadata': {'node_id': '4834', 'node_type': 'DISEASE', 'display_name': 'tarsal-carpal coalition syndrome'}}, {'type': 'node_removal', 'source': 'DISEASE:12274', 'target': None, 'metadata': {'node_id': '12274', 'node_type': 'DISEASE', 'display_name': 'brachydactyly'}}]",0.1999999999999999,489a9beab61c693f537b0ea1c3e7d2fa,626afe5bf234655c3edba79921ece07c,[],[]
"[{'source_node': {'name': 'nahuoic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'n-lysine methyltransferase setd8'}}, {'source_node': {'name': 'n-lysine methyltransferase setd8'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KMT5A'}}]","[{'source_node': {'name': 'nahuoic acid'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'KMT5A'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:54549', 'target': 'GENE:29533', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'PROTEIN:6244', 'target': None, 'metadata': {'node_id': '6244', 'node_type': 'PROTEIN', 'display_name': 'n-lysine methyltransferase setd8'}}]",0.1999999999999999,a400fb50debb5c472bcc53c8d754f171,ec9567c38568ed1dd576e9b48e163f40,"['Nahuoic acid is a compound that has a target known as n-lysine methyltransferase SETD8. Notably, the n-lysine methyltransferase SETD8 is the gene product of KMT5A.', 'Nahuoic acid has been identified to target n-lysine methyltransferase SETD8. This specific methyltransferase is known to be a gene product of KMT5A.', 'The drug nahuoic acid specifically targets n-lysine methyltransferase setd8, which is a known gene product of KMT5A.', 'Nahuoic acid is known to target the protein n-lysine methyltransferase setd8. Interestingly, this protein is the gene product of KMT5A.', 'Nahuoic acid has a specific target, the N-lysine methyltransferase SETD8. This methyltransferase is a gene product of KMT5A.']",[]
"[{'source_node': {'name': 'toloxatone'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the orthostatic hypotensive activities '}}, {'source_node': {'name': 'toloxatone'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the serotonergic activities '}}, {'source_node': {'name': 'toloxatone'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hypoglycemic activities '}}]","[{'source_node': {'name': 'toloxatone'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the serotonergic activities '}}, {'source_node': {'name': 'toloxatone'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hypoglycemic activities '}}]","[{'type': 'node_removal', 'source': 'ACTIVITY:18', 'target': None, 'metadata': {'node_id': '18', 'node_type': 'ACTIVITY', 'display_name': ' the orthostatic hypotensive activities '}}]",0.7142857142857143,0b5f5b3e6e9998fca06bf1365ba42dff,14b799c4b8f4f5265d47ab389164197b,[],[]
"[{'source_node': {'name': 'JMJD1C'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': '22q11.2 deletion syndrome'}}, {'source_node': {'name': '22q11.2 deletion syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'short philtrum'}}, {'source_node': {'name': '22q11.2 deletion syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormal dental enamel morphology'}}, {'source_node': {'name': '22q11.2 deletion syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'bowel incontinence'}}]","[{'source_node': {'name': '22q11.2 deletion syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'bowel incontinence'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:531', 'target': None, 'metadata': {'node_id': '531', 'node_type': 'PHENOTYPE', 'display_name': 'abnormal dental enamel morphology'}}, {'type': 'node_removal', 'source': 'GENE:26970', 'target': None, 'metadata': {'node_id': '26970', 'node_type': 'GENE', 'display_name': 'JMJD1C'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:261', 'target': None, 'metadata': {'node_id': '261', 'node_type': 'PHENOTYPE', 'display_name': 'short philtrum'}}]",0.3333333333333333,e45470a37c9af8d43fecdb34b717d91d,4f110c047a31bc24298c8d5c572274e1,"['The gene JMJD1C has been identified as a cause of the 22q11.2 deletion syndrome. This condition manifests with several distinguishing attributes including a short philtrum, an abnormal dental enamel morphology, and bowel incontinence.', 'The gene JMJD1C is known to cause a condition known as 22q11.2 deletion syndrome. This syndrome is characterized by several phenotypic traits, some of which include a short philtrum, abnormal dental enamel morphology, and bowel incontinence.', 'The gene JMJD1C is known to cause the 22q11.2 deletion syndrome. This syndrome is linked with a variety of phenotypes like a short philtrum, abnormal dental enamel morphology, and bowel incontinence.', 'The gene JMJD1C is known to cause a condition known as 22q11.2 deletion syndrome. This syndrome exhibits several phenotypic characteristics such as a short philtrum, abnormal dental enamel morphology, and bowel incontinence.', 'The gene JMJD1C is known to cause the condition 22q11.2 deletion syndrome. This condition has various associated phenotypes, including a short philtrum, abnormal dental enamel morphology and bowel incontinence.']",[]
"[{'source_node': {'name': 'DCP2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': ""mRNA decay by 5' to 3' exoribonuclease""}}, {'source_node': {'name': 'DCP2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'KSRP (KHSRP) binds and destabilizes mRNA'}}]","[{'source_node': {'name': 'DCP2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'KSRP (KHSRP) binds and destabilizes mRNA'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:970', 'target': None, 'metadata': {'node_id': '970', 'node_type': 'PATHWAY', 'display_name': ""mRNA decay by 5' to 3' exoribonuclease""}}]",0.6,41196a100b7896b247a8427122a96436,134c98d356e74ecde0f6c64f8125fd17,[],[]
"[{'source_node': {'name': 'SARM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'MyD88-independent TLR4 cascade '}}, {'source_node': {'name': 'SARM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Toll Like Receptor 3 (TLR3) Cascade'}}, {'source_node': {'name': 'SARM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'IKK complex recruitment mediated by RIP1'}}, {'source_node': {'name': 'nad(+) hydrolase sarm1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SARM1'}}, {'source_node': {'name': 'acetylcholinesterase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACHE'}}, {'source_node': {'name': 'berberine chloride'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'acetylcholinesterase'}}, {'source_node': {'name': 'berberine chloride'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ekvx'}}, {'source_node': {'name': 'berberine chloride'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nad(+) hydrolase sarm1'}}]","[{'source_node': {'name': 'ACHE'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'MyD88-independent TLR4 cascade '}}, {'source_node': {'name': 'SARM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'MyD88-independent TLR4 cascade '}}, {'source_node': {'name': 'SARM1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Toll Like Receptor 3 (TLR3) Cascade'}}, {'source_node': {'name': 'ekvx'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACHE'}}, {'source_node': {'name': 'nad(+) hydrolase sarm1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SARM1'}}, {'source_node': {'name': 'acetylcholinesterase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ACHE'}}, {'source_node': {'name': 'berberine chloride'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'acetylcholinesterase'}}, {'source_node': {'name': 'berberine chloride'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ekvx'}}, {'source_node': {'name': 'berberine chloride'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nad(+) hydrolase sarm1'}}, {'source_node': {'name': 'berberine chloride'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'SARM1'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:51286', 'target': 'GENE:27201', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'PATHWAY:127', 'target': None, 'metadata': {'node_id': '127', 'node_type': 'PATHWAY', 'display_name': 'IKK complex recruitment mediated by RIP1'}}, {'type': 'edge_addition', 'source': 'PROTEIN:5657', 'target': 'GENE:29952', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'GENE:29952', 'target': 'PATHWAY:123', 'metadata': {'predicate': 'acts_within'}}]",0.7058823529411764,20b84ac9a2abb5395e6931b710b79531,9ae21030e20992746bff2a8cc637c624,[],"['The drug Berberine chloride targets several biochemical components namely Acetylcholinesterase, Ekvx, and Nad(+) hydrolase SARM1. Furthermore, it also affects the function of SARM1. Both Acetylcholinesterase and Nad(+) hydrolase SARM1 are gene products of ACHE and SARM1 respectively, while Ekvx is a gene product of ACHE as well. Interestingly, these gene products have their specific roles in several biochemical implications. ACHE acts within the MyD88-independent TLR4 cascade, a pathway that is also influenced by SARM1. SARM1 also plays a pivotal role in the Toll Like Receptor 3 (TLR3) Cascade. These intricate interplays demarcate the broad spectrum of effects that berberine chloride might exert on biological systems.', 'The drug berberine chloride has multiple targets including acetylcholinesterase, ekvx, and nad(+) hydrolase sarm1. These targets are orchestrated by different genes. Acetylcholinesterase is a gene product of ACHE; moreover, ekvx is also a gene product of ACHE. Additionally, nad(+) hydrolase sarm1 is a gene product of SARM1. \n\nFurthermore, ACHE acts within the MyD88-independent TLR4 cascade, a pathway involved in immune response. Likewise, SARM1 has multiple areas of activity, acting within the MyD88-independent TLR4 cascade and the Toll Like Receptor 3 (TLR3) Cascade, suggesting a role in various immune response pathways. Interestingly, berberine chloride is also affecting SARM1, giving indications of a potential pharmacological pathway interaction.']"
"[{'source_node': {'name': 'melengestrol acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dexpanthenol'}}, {'source_node': {'name': 'insulin argine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'estrone'}}, {'source_node': {'name': 'insulin argine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rolofylline'}}, {'source_node': {'name': 'insulin argine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'melengestrol acetate'}}, {'source_node': {'name': 'glucocorticoid receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR3C1'}}, {'source_node': {'name': 'desonide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucocorticoid receptor'}}, {'source_node': {'name': 'desonide'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'desonide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'insulin argine'}}]","[{'source_node': {'name': 'glucocorticoid receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR3C1'}}, {'source_node': {'name': 'desonide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucocorticoid receptor'}}, {'source_node': {'name': 'desonide'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'NR3C1'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:1239', 'target': 'COMPOUND:9491', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:9491', 'target': None, 'metadata': {'node_id': '9491', 'node_type': 'COMPOUND', 'display_name': 'insulin argine'}}, {'type': 'node_removal', 'source': 'COMPOUND:8289', 'target': None, 'metadata': {'node_id': '8289', 'node_type': 'COMPOUND', 'display_name': 'dexpanthenol'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1239', 'target': 'GENE:28425', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'EFFECT:5', 'target': None, 'metadata': {'node_id': '5', 'node_type': 'EFFECT', 'display_name': ' adverse effects '}}]",0.2352941176470588,037ee2c99ba6e90969a4b185dddddadb,94f6f7ce0c1d0520e7f8e8557992292a,[],"['The drug desonide targets the glucocorticoid receptor, a gene product of NR3C1. Interestingly, desonide also directly affects the functioning of the NR3C1 gene.', 'Desonide is a medicinal compound that notably targets the glucocorticoid receptor, as well as having an affect on NR3C1. Notably, the glucocorticoid receptor is a gene product of NR3C1.', 'The drug desonide has a target known as the glucocorticoid receptor, which is a gene product of NR3C1. Additionally, desonide affects NR3C1 directly.', 'The drug desonide specifically targets the glucocorticoid receptor and affects the gene NR3C1. Interestingly, the glucocorticoid receptor is a gene product of NR3C1 itself.', 'The medication Desonide has a target interaction with the glucocorticoid receptor, which is a gene product of NR3C1. Additionally, Desonide is known to affect NR3C1 directly as well.']"
"[{'source_node': {'name': 'darier-white disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'intellectual disability'}}, {'source_node': {'name': 'darier-white disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ridged nail'}}, {'source_node': {'name': 'darier-white disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'skin vesicle'}}, {'source_node': {'name': 'ATP2A2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'darier-white disease'}}, {'source_node': {'name': 'ATP2A2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pre-NOTCH Processing in Golgi'}}, {'source_node': {'name': 'ATP2A2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ion transport by P-type ATPases'}}]","[{'source_node': {'name': 'darier-white disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'intellectual disability'}}, {'source_node': {'name': 'darier-white disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ridged nail'}}, {'source_node': {'name': 'darier-white disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'skin vesicle'}}, {'source_node': {'name': 'ATP2A2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pre-NOTCH Processing in Golgi'}}, {'source_node': {'name': 'ATP2A2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Ion transport by P-type ATPases'}}]","[{'type': 'edge_deletion', 'source': 'GENE:30329', 'target': 'DISEASE:3723', 'metadata': None}]",0.9230769230769232,1f708486611f35f452690e612412f148,917759c4f0ef5ec5ade0f7ea1a42522b,"['Darier-White Disease, caused by the ATP2A2 gene, often exhibits several phenotypes including intellectual disability, ridged nail, and skin vesicle. The ATP2A2 gene is active within a couple of biological processes, notably pre-NOTCH processing in the Golgi and ion transport by P-type ATPases.', 'The ATP2A2 gene acts within the pre-NOTCH processing in Golgi and ion transport by P-type ATPases pathways, and it is a known cause of Darier-White disease. This disease is characterized by several phenotypes, notably intellectual disability, the presence of ridged nails, and the occurrence of skin vesicles.', 'Darier-White Disease, which is caused by the gene ATP2A2, is characterized by several phenotypes including intellectual disability, ridged nails, and skin vesicles. The ATP2A2 gene plays roles in several pathways, notably the Pre-NOTCH Processing in Golgi and Ion transport by P-type ATPases.', 'The gene ATP2A2, which plays a crucial role in the pathways of Pre-NOTCH Processing in Golgi and ion transport by P-type ATPases, is known to cause Darier-White disease. Darier-White disease is a condition that exhibits several phenotypes including intellectual disability, ridged nail, and skin vesicle.', 'Darier-White disease, caused by the ATP2A2 gene, exhibits several phenotypes like intellectual disability, ridged nail, and skin vesicle. Additionally, ATP2A2 functions within specific cellular pathways. It is involved in pre-NOTCH processing in Golgi and also plays a role in ion transport through P-type ATPases.']",[]
"[{'source_node': {'name': 'violapyrone d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-116'}}, {'source_node': {'name': 'violapyrone d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepg2'}}]","[{'source_node': {'name': 'violapyrone d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-116'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5817', 'target': None, 'metadata': {'node_id': '5817', 'node_type': 'PROTEIN', 'display_name': 'hepg2'}}]",0.6,89c40c80d580da55c159568e17fa2b62,8f1f107fed4a12bb88fb0d6470b43e22,"['The compound Violapyrone D is known to target HCT-116, a human colorectal carcinoma cell line. Additionally, it also targets HepG2, a human liver cancer cell line.', 'The drug Violapyrone D targets both HCT-116 and HEPG2 cells.', 'The compound Violapyrone D is known to target both HCT-116 and HepG2 cells.', 'The compound Violapyrone D targets multiple entities including cells like HCT-116 and HepG2.', 'The compound violapyrone D has been found to target multiple cell lines, specifically HCT-116 and HepG2.']","['The compound Violapyrone D has been identified to target HCT-116.', 'The compound Violapyrone D has a specific target, which is the HCT-116 cell.']"
"[{'source_node': {'name': 'succinyl coa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ketonuria'}}, {'source_node': {'name': 'succinyl coa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'vomiting'}}, {'source_node': {'name': 'succinyl coa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'tachypnea'}}, {'source_node': {'name': 'succinyl-coa'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'OXCT1'}}, {'source_node': {'name': 'OXCT1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'succinyl coa'}}, {'source_node': {'name': 'OXCT1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Utilization of Ketone Bodies'}}]","[{'source_node': {'name': 'succinyl coa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ketonuria'}}, {'source_node': {'name': 'succinyl coa'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'vomiting'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:2721', 'target': None, 'metadata': {'node_id': '2721', 'node_type': 'PROTEIN', 'display_name': 'succinyl-coa'}}, {'type': 'node_removal', 'source': 'GENE:30424', 'target': None, 'metadata': {'node_id': '30424', 'node_type': 'GENE', 'display_name': 'OXCT1'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:2019', 'target': None, 'metadata': {'node_id': '2019', 'node_type': 'PHENOTYPE', 'display_name': 'tachypnea'}}]",0.3846153846153846,242b21420f462b14915522a8c7a63290,c70ea259f4a38d5b2a28f02a35794455,[],"['The molecule succinyl coa is associated with certain phenotypes, including the presence of ketones in urine (ketonuria), and causing episodes of vomiting.', 'The molecule succinyl coa is associated with various phenotypes such as ketonuria and vomiting.']"
"[{'source_node': {'name': 'alternating hemiplegia of childhood 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'developmental regression'}}, {'source_node': {'name': 'alternating hemiplegia of childhood 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'headache'}}, {'source_node': {'name': 'ATP1A2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'migraine'}}, {'source_node': {'name': 'ATP1A2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'alternating hemiplegia of childhood 1'}}, {'source_node': {'name': 'ATP1A2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'fetal akinesia'}}, {'source_node': {'name': 'migraine'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'intellectual disability'}}, {'source_node': {'name': 'migraine'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'episodic ataxia'}}]","[{'source_node': {'name': 'fetal akinesia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'episodic ataxia'}}, {'source_node': {'name': 'alternating hemiplegia of childhood 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'developmental regression'}}, {'source_node': {'name': 'alternating hemiplegia of childhood 1'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'headache'}}, {'source_node': {'name': 'ATP1A2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'fetal akinesia'}}, {'source_node': {'name': 'migraine'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'intellectual disability'}}, {'source_node': {'name': 'migraine'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'episodic ataxia'}}]","[{'type': 'edge_deletion', 'source': 'GENE:30263', 'target': 'DISEASE:15568', 'metadata': None}, {'type': 'edge_deletion', 'source': 'GENE:30263', 'target': 'DISEASE:14092', 'metadata': None}, {'type': 'edge_addition', 'source': 'DISEASE:17951', 'target': 'PHENOTYPE:1563', 'metadata': {'predicate': 'has_phenotype'}}]",0.8,3fbb747ad4d8b3936ebeee6081b682e5,5d8aa2ddbfab9ef7c189c4fa42404f42,"['Alternating hemiplegia of childhood 1 is a rare condition that causes certain symptoms and phenotypes such as developmental regression and headaches. This condition, along with others like migraine and fetal akinesia, are caused by mutations in the gene ATP1A2. Migraines, specifically, can also lead to other phenotypes like intellectual disability and episodic ataxia. It should be noted that this information is derived from a complex knowledge graph that lays out the connections between various genes, phenotypes, conditions and their resulting symptoms.', 'The gene ATP1A2 has been shown to cause several conditions, including migraine, fetal akinesia and alternating hemiplegia of childhood 1. The latter is characterized by phenotypes such as developmental regression and headache. Interestingly, the affliction known as migraine also has diverse phenotypes, including intellectual disability and episodic ataxia.', 'Alternating Hemiplegia of Childhood 1, a condition caused by the ATP1A2 gene, presents with several phenotypes such as developmental regression and headaches. Interestingly, ATP1A2 is also implicated in causing other conditions like migraine and fetal akinesia. Speaking of migraines, it is worth noting that people suffering from migraines, a condition also caused by ATP1A2, may experience additional symptoms such as intellectual disability and episodic ataxia.']","['Fetal akinesia, a condition caused by the ATP1A2 gene, has characteristics such as episodic ataxia. Simultaneously, a condition known as alternating hemiplegia of childhood 1 presents with phenotypes like developmental regression and headaches. Furthermore, migraine, another condition clinically linked to episodic ataxia, also demonstrates intellectual disability as one of its primary phenotypes.', 'Fetal akinesia, a condition caused by the ATP1A2 gene, is known to have the phenotype of episodic ataxia. Similarly, another disease alternating hemiplegia of childhood 1, has various phenotypical expressions such as developmental regression and headache. Moreover, migraine, another condition, has multiple symptoms including intellectual disability and episodic ataxia.', 'Fetal akinesia is a condition caused by the ATP1A2 gene and is characterized by the phenotype of episodic ataxia. Alternating hemiplegia of childhood 1 is another condition that exhibits the phenotypes of developmental regression and headaches. Meanwhile, migraine is a condition associated with the phenotypes of intellectual disability and episodic ataxia.', 'Fetal akinesia, a condition caused by the ATP1A2 gene, has a phenotype which presents as episodic ataxia. Interestingly, a similar phenotype is also observed in cases of migraine, along with intellectual disability. On another note, the condition known as alternating hemiplegia of childhood 1 exhibits symptoms such as developmental regression and headaches, contributing to its diverse symptomatology.', 'The gene ATP1A2 is known to cause fetal akinesia, a condition which exhibits the phenotype of episodic ataxia. Additionally, the condition termed alternating hemiplegia of childhood 1 also shows the phenotypic characteristics of developmental regression and headaches. Meanwhile, migraine, which is yet another condition, presents phenotypes of intellectual disability and episodic ataxia. This uncovers a complex interplay between these conditions and their respective symptoms.']"
"[{'source_node': {'name': 'meticillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'estetrol'}}, {'source_node': {'name': 'rocuronium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'terbutaline'}}, {'source_node': {'name': 'rocuronium'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'hygromycin b'}}, {'source_node': {'name': 'rocuronium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'macimorelin'}}, {'source_node': {'name': 'metacycline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'rocuronium'}}, {'source_node': {'name': 'metacycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'meticillin'}}, {'source_node': {'name': 'metacycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'picosulfuric acid'}}]","[{'source_node': {'name': 'estetrol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'picosulfuric acid'}}, {'source_node': {'name': 'estetrol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'metacycline'}}, {'source_node': {'name': 'meticillin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'estetrol'}}, {'source_node': {'name': 'rocuronium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'terbutaline'}}, {'source_node': {'name': 'rocuronium'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'hygromycin b'}}, {'source_node': {'name': 'rocuronium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'macimorelin'}}, {'source_node': {'name': 'metacycline'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'rocuronium'}}, {'source_node': {'name': 'metacycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'meticillin'}}, {'source_node': {'name': 'metacycline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'picosulfuric acid'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:10139', 'target': 'COMPOUND:8203', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:10139', 'target': 'COMPOUND:914', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.8666666666666667,492e13a45ff58076b9329499e365dffe,1d578010a34add9e003162e7a84b39bc,"['The antibiotic drug meticillin has been observed to decrease the efficacy of another drug, estetrol. Another muscle relaxant drug, rocuronium, also shows various interactions; it decreases the efficacy of terbutaline and macimorelin, but it increases the efficacy of hygromycin b. Moreover, the drug metacycline interacts with these drugs in opposite ways. It increases the efficacy of rocuronium, but it decreases the efficacy of meticillin and picosulfuric acid. These interactions highlight the interconnected nature of drug efficacy and the implications of drug co-administration for therapeutic outcomes.', 'The antibiotic drug meticillin is known to decrease the efficacy of estetrol, while the neuromuscular-blocking drug rocuronium decreases the efficacy of terbutaline and macimorelin, but interestingly, increases the efficacy of hygromycin b. Conversely, the antibiotic metacycline plays a complex role by enhancing the efficacy of rocuronium, but also reduces the efficacy of both meticillin and picosulfuric acid. Therefore, these drugs may have varying impacts on the efficacy of others, highlighting the importance of considering potential drug interactions in medical treatments.', 'The drug Meticillin is known to decrease the efficacy of Estetrol. Another drug, Rocuronium, provides interesting interactions - it has the capacity to decrease the efficacy of Terbutaline and Macimorelin, while conversely, increasing the efficacy of Hygromycin B. Metacycline is another drug, which interestingly increases the efficacy of Rocuronium, but decreases the efficacy of both Meticillin and Picosulfuric Acid.', 'The antibiotics meticillin and metacycline have been shown to interact with other drugs. Notably, meticillin decreases the efficacy of the hormone estetrol. On the other hand, metacycline increases the efficacy of the muscle relaxant rocuronium but decreases the efficacy of meticillin and the laxative picosulfuric acid.\n\nRocuronium has an interesting set of interactions. It decreases the efficacy of terbutaline, typically used for respiratory conditions, and macimorelin, a diagnostic agent. However, the effectiveness of the antibacterial agent hygromycin B is increased when used with rocuronium. These findings highlight the importance of understanding drug interactions in medical treatments.', 'The use of certain drugs can impact the effectiveness of others, leading to an increase or decrease in efficacy. Meticillin, for example, has been found to decrease the efficacy of estetrol. Similarly, rocuronium can decrease the efficacy of terbutaline and macimorelin, while simultaneously increasing the efficacy of hygromycin b. Interestingly, metacycline can both decrease and increase the efficacy of certain drugs. It decreases the efficacy of meticillin and picosulfuric acid but increases that of rocuronium. Therefore, careful consideration of drug interactions is crucial in patient management to ensure optimal therapeutic outcomes.']",[]
"[{'source_node': {'name': 'mizoribine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'g17dt'}}, {'source_node': {'name': 'mizoribine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'srp 299'}}, {'source_node': {'name': 'mizoribine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bordetella pertussis toxoid antigen (formaldehyde'}}]","[{'source_node': {'name': 'srp 299'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'g17dt'}}, {'source_node': {'name': 'mizoribine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'g17dt'}}, {'source_node': {'name': 'mizoribine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'srp 299'}}, {'source_node': {'name': 'mizoribine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bordetella pertussis toxoid antigen (formaldehyde'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:5043', 'target': 'COMPOUND:4627', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.8571428571428572,ff6fc2d2ba0a56735402d05cdc764ed7,797cc3224fa7e2c533d91610bca47757,[],[]
"[{'source_node': {'name': 'EXOSC3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pontocerebellar hypoplasia type 1a'}}, {'source_node': {'name': 'EXOSC3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': ""mRNA decay by 3' to 5' exoribonuclease""}}, {'source_node': {'name': 'EXOSC3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'KSRP (KHSRP) binds and destabilizes mRNA'}}]","[{'source_node': {'name': 'EXOSC3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': ""mRNA decay by 3' to 5' exoribonuclease""}}, {'source_node': {'name': 'EXOSC3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'KSRP (KHSRP) binds and destabilizes mRNA'}}]","[{'type': 'node_removal', 'source': 'DISEASE:7053', 'target': None, 'metadata': {'node_id': '7053', 'node_type': 'DISEASE', 'display_name': 'pontocerebellar hypoplasia type 1a'}}]",0.7142857142857143,7021e73d7abf4a539a961f256c58e888,0acbdaba6f14e20d180ca3bffc73bae9,[],[]
"[{'source_node': {'name': 'NDUFS3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Complex I biogenesis'}}, {'source_node': {'name': 'NDUFS3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RHOG GTPase cycle'}}]","[{'source_node': {'name': 'NDUFS3'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'RHOG GTPase cycle'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1112', 'target': None, 'metadata': {'node_id': '1112', 'node_type': 'PATHWAY', 'display_name': 'Complex I biogenesis'}}]",0.6,8aad96d9c1953928b937be442556751b,2da56cae6e3b024e795369e43c23873c,"['The gene NDUFS3 is involved in several pathways, working within the process of Complex I biogenesis and acting within the RHOG GTPase cycle.', ""The gene NDUFS3, which operates within multiple pathways like Complex I biogenesis and the RHOG GTPase cycle, plays an integral role in the body's cellular processes."", 'The gene NDUFS3 is involved in the processes of both Complex I biogenesis and the RHOG GTPase cycle.', 'The gene NDUFS3 is involved in the process of Complex I biogenesis and also acts within the RHOG GTPase cycle.', 'The gene NDUFS3 is involved in two crucial processes: Complex I biogenesis and the RHOG GTPase cycle. It plays an influential role within these pathways, contributing to their normal functioning and homeostasis.']",[]
"[{'source_node': {'name': 'HIBCH'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': '3-hydroxyisobutryl-coa hydrolase deficiency'}}, {'source_node': {'name': 'HIBCH'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Branched-chain amino acid catabolism'}}, {'source_node': {'name': '3-hydroxyisobutryl-coa hydrolase deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'aminoaciduria'}}, {'source_node': {'name': '3-hydroxyisobutryl-coa hydrolase deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'respiratory insufficiency'}}]","[{'source_node': {'name': '3-hydroxyisobutryl-coa hydrolase deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'aminoaciduria'}}, {'source_node': {'name': '3-hydroxyisobutryl-coa hydrolase deficiency'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'respiratory insufficiency'}}]","[{'type': 'edge_deletion', 'source': 'GENE:27875', 'target': 'DISEASE:11057', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:27875', 'target': None, 'metadata': {'node_id': '27875', 'node_type': 'GENE', 'display_name': 'HIBCH'}}]",0.5555555555555556,45dd1be4b61bb511f9fc0904c517f447,394462b072dab76b124db68efdb33be4,"['The gene HIBCH, which acts within the pathway of branched-chain amino acid catabolism, is known to cause a medical condition termed 3-hydroxyisobutryl-CoA hydrolase deficiency. This deficiency is characterized by symptoms such as aminoaciduria and respiratory insufficiency.', 'The gene HIBCH, which operates within the branched-chain amino acid catabolism pathway, is known to cause the condition known as 3-hydroxyisobutryl-CoA hydrolase deficiency. This deficiency is characterized by specific phenotypes including aminoaciduria and respiratory insufficiency.', 'The gene HIBCH, which is active within the pathway of branched-chain amino acid catabolism, can cause a condition known as 3-hydroxyisobutryl-CoA hydrolase deficiency. This deficiency is characterized by certain phenotypes, such as aminoaciduria and respiratory insufficiency.', 'The gene HIBCH, which acts within the pathway of branched-chain amino acid catabolism, is known to cause a condition called 3-hydroxyisobutryl-coa hydrolase deficiency. This condition, 3-hydroxyisobutryl-coa hydrolase deficiency, manifests with phenotypes including aminoaciduria and respiratory insufficiency.', 'The gene known as HIBCH, which acts within the process of branched-chain amino acid catabolism, has been linked to a condition known as 3-hydroxyisobutryl-CoA hydrolase deficiency. This condition manifests phenotypes such as aminoaciduria and respiratory insufficiency.']","['3-Hydroxyisobutryl-CoA hydrolase deficiency is a medical condition characterized by several phenotypes including aminoaciduria and respiratory insufficiency.', '3-Hydroxyisobutryl-CoA hydrolase deficiency is a metabolic disorder which presents certain phenotypes including aminoaciduria, a condition characterized by the excess presence of amino acids in urine, and respiratory insufficiency, which denotes a condition where the respiratory system fails in one or both of its gas exchange functions: oxygenation and carbon dioxide elimination.', '3-hydroxyisobutryl-CoA hydrolase deficiency, a metabolic condition, has several associated phenotypes such as aminoaciduria, an abnormal presence of amino acids in urine, and respiratory insufficiency, a condition where the body cannot take in enough oxygen or remove enough carbon dioxide.', '3-Hydroxyisobutryl-CoA hydrolase deficiency is a condition that is characterized by certain phenotypes, including aminoaciduria and respiratory insufficiency.', '3-Hydroxyisobutryl-CoA hydrolase deficiency, a metabolic disorder, exhibits several phenotypes including aminoaciduria, which is characterized by the presence of amino acids in urine, and respiratory insufficiency, a condition where the body is unable to adequately fill the lungs with oxygen.']"
"[{'source_node': {'name': 'pseudoachondroplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'limited elbow extension'}}, {'source_node': {'name': 'pseudoachondroplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormal femoral epiphysis morphology'}}, {'source_node': {'name': 'cartilage oligomeric matrix protein'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'COMP'}}, {'source_node': {'name': 'COMP'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pseudoachondroplasia'}}, {'source_node': {'name': 'COMP'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Integrin cell surface interactions'}}, {'source_node': {'name': 'COMP'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'ECM proteoglycans'}}]","[{'source_node': {'name': 'pseudoachondroplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'limited elbow extension'}}, {'source_node': {'name': 'pseudoachondroplasia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormal femoral epiphysis morphology'}}]","[{'type': 'node_removal', 'source': 'GENE:25874', 'target': None, 'metadata': {'node_id': '25874', 'node_type': 'GENE', 'display_name': 'COMP'}}]",0.3846153846153846,7412004cbaded33973956ef10cb624ff,d69ed4d896111540a105e9e4f9829cc1,"['The condition pseudoachondroplasia, caused by the gene COMP, is characterized by several clinical features including limited elbow extension and abnormal femoral epiphysis morphology. The gene COMP not only causes pseudoachondroplasia but also acts within several pathways such as the integrin cell surface interactions and ECM proteoglycans. Notably, COMP is the gene product of the cartilage oligomeric matrix protein.']",[]
"[{'source_node': {'name': 'RELB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'CD209 (DC-SIGN) signaling'}}, {'source_node': {'name': 'RELB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'NIK-->noncanonical NF-kB signaling'}}]","[{'source_node': {'name': 'RELB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'CD209 (DC-SIGN) signaling'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:394', 'target': None, 'metadata': {'node_id': '394', 'node_type': 'PATHWAY', 'display_name': 'NIK-->noncanonical NF-kB signaling'}}]",0.6,df0c391c759f98fbe88a5663ea763b5c,0438c5d6762aa591e0002687d65e7587,[],[]
"[{'source_node': {'name': 'dipotassium phosphate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tolterodine'}}, {'source_node': {'name': 'dipotassium phosphate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pipenzolate'}}]","[{'source_node': {'name': 'pipenzolate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tolterodine'}}, {'source_node': {'name': 'dipotassium phosphate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tolterodine'}}, {'source_node': {'name': 'dipotassium phosphate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pipenzolate'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:11691', 'target': 'COMPOUND:1018', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.8,d8d4025092e8622fcfea50adca2acb54,5ade229b9edafbbd071c54b856ffe5d1,"['The compound dipotassium phosphate is known to decrease the efficacy of various pharmaceuticals such as tolterodine and pipenzolate. Hence, caution must be exercised when using these medications in combination with dipotassium phosphate.', 'The compound dipotassium phosphate has been found to decrease the efficacy of certain medications including tolterodine and pipenzolate.', 'The chemical compound dipotassium phosphate has been shown to decrease the efficacy of certain drugs, including tolterodine and pipenzolate.', 'The compound dipotassium phosphate is known to decrease the efficacy of certain drugs, particularly tolterodine and pipenzolate. Thus, when taking these medications, one should take caution with the consumption of foods or products containing dipotassium phosphate to avoid potentially decreasing the effect of the medication.', 'The compound dipotassium phosphate has been observed to decrease the efficacy of several drugs, namely tolterodine and pipenzolate.']","['The drugs Pipenzolate and Dipotassium Phosphate are known to decrease the efficacy of Tolterodine. Furthermore, Dipotassium Phosphate also reduces the efficacy of Pipenzolate.', 'The use of pipenzolate has been found to decrease the efficacy of tolterodine. Similarly, dipotassium phosphate has also been observed to reduce the effectiveness of tolterodine. Notably, dipotassium phosphate can also decrease the efficacy of pipenzolate, suggesting a complex interaction between these substances.', 'The use of the drug Pipenzolate and Dipotassium Phosphate decreases the efficacy of another drug named Tolterodine. Interestingly, Dipotassium Phosphate also diminishes the efficacy of Pipenzolate, indicating a complex interplay between these substances.', 'The use of the drug pipenzolate is known to decrease the efficacy of tolterodine. Similarly, dipotassium phosphate also reduces the effectiveness of tolterodine. Furthermore, dipotassium phosphate is seen to decrease the efficacy of pipenzolate.']"
"[{'source_node': {'name': 'COPS6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'DNA Damage Recognition in GG-NER'}}, {'source_node': {'name': 'COPS6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Formation of TC-NER Pre-Incision Complex'}}, {'source_node': {'name': 'COPS6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neddylation'}}]","[{'source_node': {'name': 'COPS6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Formation of TC-NER Pre-Incision Complex'}}, {'source_node': {'name': 'COPS6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neddylation'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:132', 'target': None, 'metadata': {'node_id': '132', 'node_type': 'PATHWAY', 'display_name': 'DNA Damage Recognition in GG-NER'}}]",0.7142857142857143,30b7d869dfdd3f064b1e682dc4e8e19c,fe2677b42405913d0a334303eb68a712,[],"['The gene COPS6 acts within several biological processes, including the formation of the TC-NER pre-incision complex and the process of neddylation.']"
"[{'source_node': {'name': 'coumarin resistance'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of blood and blood-forming tissues'}}, {'source_node': {'name': 'coumarin resistance'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autosomal dominant inheritance'}}, {'source_node': {'name': '6-bromo-1h-indole-3-carbaldehyde'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 2a6'}}, {'source_node': {'name': 'CYP2A6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'lung cancer'}}, {'source_node': {'name': 'CYP2A6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'coumarin resistance'}}, {'source_node': {'name': 'CYP2A6'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'CYP2E1 reactions'}}, {'source_node': {'name': 'cytochrome p450 2a6'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP2A6'}}]","[{'source_node': {'name': 'coumarin resistance'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of blood and blood-forming tissues'}}, {'source_node': {'name': 'coumarin resistance'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autosomal dominant inheritance'}}, {'source_node': {'name': '6-bromo-1h-indole-3-carbaldehyde'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cytochrome p450 2a6'}}, {'source_node': {'name': 'lung cancer'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormality of blood and blood-forming tissues'}}, {'source_node': {'name': 'lung cancer'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autosomal dominant inheritance'}}, {'source_node': {'name': 'CYP2A6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'coumarin resistance'}}, {'source_node': {'name': 'cytochrome p450 2a6'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP2A6'}}]","[{'type': 'edge_addition', 'source': 'DISEASE:13721', 'target': 'PHENOTYPE:1353', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_addition', 'source': 'DISEASE:13721', 'target': 'PHENOTYPE:5', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'node_removal', 'source': 'PATHWAY:1279', 'target': None, 'metadata': {'node_id': '1279', 'node_type': 'PATHWAY', 'display_name': 'CYP2E1 reactions'}}, {'type': 'edge_deletion', 'source': 'GENE:26290', 'target': 'DISEASE:13721', 'metadata': None}]",0.6666666666666667,1976c215728abf2d3c425c8ec255070a,3d149ba4f4b62454eb965645d2c8d545,"['The condition known as Coumarin resistance exhibits phenotypes such as abnormalities in blood and blood-forming tissues and often exhibits autosomal dominant inheritance. This resistance is caused by the gene CYP2A6. CYP2A6 is also associated with a higher risk of lung cancer. It is interesting to note that the gene CYP2A6 acts within multiple pathways, such as CYP2E1 reactions. Cytochrome p450 2a6, a gene product of CYP2A6 is targeted by the compound 6-bromo-1h-indole-3-carbaldehyde.']",[]
"[{'source_node': {'name': 'DAGLA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Arachidonate production from DAG'}}, {'source_node': {'name': 'sn1-specific diacylglycerol lipase alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DAGLA'}}, {'source_node': {'name': 'cannabigerolic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sn1-specific diacylglycerol lipase alpha'}}, {'source_node': {'name': 'cannabigerolic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'n-acylethanolamine-hydrolyzing acid amidase'}}, {'source_node': {'name': 'n-acylethanolamine-hydrolyzing acid amidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NAAA'}}, {'source_node': {'name': 'NAAA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neurotransmitter release cycle'}}]","[{'source_node': {'name': 'DAGLA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Arachidonate production from DAG'}}, {'source_node': {'name': 'sn1-specific diacylglycerol lipase alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DAGLA'}}, {'source_node': {'name': 'cannabigerolic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sn1-specific diacylglycerol lipase alpha'}}, {'source_node': {'name': 'cannabigerolic acid'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'DAGLA'}}, {'source_node': {'name': 'n-acylethanolamine-hydrolyzing acid amidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NAAA'}}, {'source_node': {'name': 'n-acylethanolamine-hydrolyzing acid amidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DAGLA'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1679', 'target': None, 'metadata': {'node_id': '1679', 'node_type': 'PATHWAY', 'display_name': 'Neurotransmitter release cycle'}}, {'type': 'edge_addition', 'source': 'PROTEIN:4316', 'target': 'GENE:33532', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'COMPOUND:63560', 'target': 'GENE:33532', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:63560', 'target': 'PROTEIN:4316', 'metadata': None}]",0.6153846153846154,b48d90b2458b91d4262f881e2e888f27,aee253a1935c733545857705439adcf9,[],[]
"[{'source_node': {'name': '1-naphthaleneacetic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 's-phase kinase-associated protein 1'}}, {'source_node': {'name': '1-naphthaleneacetic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'thyroid hormone receptor beta'}}, {'source_node': {'name': '1-naphthaleneacetic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor gamma'}}, {'source_node': {'name': 'peroxisome proliferator-activated receptor gamma'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PPARG'}}, {'source_node': {'name': 's-phase kinase-associated protein 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SKP1'}}, {'source_node': {'name': 'thyroid hormone receptor beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'THRB'}}]","[{'source_node': {'name': '1-naphthaleneacetic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'thyroid hormone receptor beta'}}, {'source_node': {'name': '1-naphthaleneacetic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor gamma'}}, {'source_node': {'name': 'peroxisome proliferator-activated receptor gamma'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'THRB'}}, {'source_node': {'name': 's-phase kinase-associated protein 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SKP1'}}, {'source_node': {'name': 's-phase kinase-associated protein 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'THRB'}}, {'source_node': {'name': 'thyroid hormone receptor beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'THRB'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:1924', 'target': 'GENE:33248', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'PROTEIN:1924', 'target': 'GENE:31205', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:1667', 'target': 'PROTEIN:1924', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:31205', 'target': None, 'metadata': {'node_id': '31205', 'node_type': 'GENE', 'display_name': 'PPARG'}}, {'type': 'edge_addition', 'source': 'PROTEIN:359', 'target': 'GENE:33248', 'metadata': {'predicate': 'gene_product_of'}}]",0.6153846153846154,338133da9c4b9499189308bf846b88d5,438e34e37b72d96f1a5b236a0a3e156d,"['The drug 1-naphthaleneacetic acid targets three proteins - s-phase kinase-associated protein 1, thyroid hormone receptor beta, and peroxisome proliferator-activated receptor gamma. These proteins are the gene products of SKP1, THRB, and PPARG respectively.', 'The compound 1-naphthaleneacetic acid targets several proteins including the s-phase kinase-associated protein 1, thyroid hormone receptor beta, and peroxisome proliferator-activated receptor gamma. The s-phase kinase-associated protein 1 is a gene product of SKP1, while the thyroid hormone receptor beta is a gene product of THRB. The peroxisome proliferator-activated receptor gamma is in turn a gene product of PPARG.', 'The compound 1-naphthaleneacetic acid targets several proteins such as the s-phase kinase-associated protein 1, thyroid hormone receptor beta, and peroxisome proliferator-activated receptor gamma. These proteins are the gene products of their respective genes: SKP1, THRB, and PPARG. Therefore, 1-naphthaleneacetic acid may influence the genetic activities associated with these genes.', 'The compound 1-naphthaleneacetic acid has been found to target several proteins, including the S-phase kinase-associated protein 1, thyroid hormone receptor beta, and peroxisome proliferator-activated receptor gamma. These proteins are gene products of SKP1, THRB, and PPARG, respectively.', 'The compound 1-naphthaleneacetic acid has multiple targets, including the S-phase kinase-associated protein 1, thyroid hormone receptor beta, and peroxisome proliferator-activated receptor gamma. The S-phase kinase-associated protein 1 is a gene product of SKP1, while thyroid hormone receptor beta is a gene product of THRB. Furthermore, the peroxisome proliferator-activated receptor gamma is a gene product of the gene PPARG.']","['The compound 1-naphthaleneacetic acid has two targets, thyroid hormone receptor beta and peroxisome proliferator-activated receptor gamma. Thyroid hormone receptor beta, in turn, is a gene product that arises from the gene THRB. Similarly, peroxisome proliferator-activated receptor gamma also results from the gene THRB. Additionally, the s-phase kinase-associated protein 1, derived from genes SKP1 and THRB, is another meaningful gene product in this context.', 'The compound 1-naphthaleneacetic acid targets two key entities, thyroid hormone receptor beta and the peroxisome proliferator-activated receptor gamma. Interestingly, both receptors are gene products of the gene THRB. Additionally, the protein known as s-phase kinase-associated protein 1 is a gene product of both SKP1 and THRB genes. In essence, the network reveals a shared genetic basis in THRB for the targets of 1-naphthaleneacetic acid and the origins of s-phase kinase-associated protein 1.', 'The chemical substance 1-naphthaleneacetic acid targets two receptors, specifically the thyroid hormone receptor beta and the peroxisome proliferator-activated receptor gamma. Interestingly, both receptors are gene products of THRB. Another gene product of THRB is the thyroid hormone receptor beta, revealing a closely interconnected system. On a different note, s-phase kinase-associated protein 1 is a gene product of both SKP1 and THRB, suggesting it plays a role in the pathways of these genes.', 'The compound 1-naphthaleneacetic acid targets two specific receptors: thyroid hormone receptor beta and peroxisome proliferator-activated receptor gamma. These receptors are gene products of THRB; in other words, the THRB gene plays a primary role in the synthesis of both receptors. Fascinatingly, the protein known as s-phase kinase-associated protein 1, which is a gene product of both SKP1 and THRB genes, shares this relationship with the thyroid hormone receptor beta. In this complex web of interactions, one can see the intricate and interconnected nature of biological systems.', 'The drug 1-naphthaleneacetic acid has been observed to target both thyroid hormone receptor beta and peroxisome proliferator-activated receptor gamma. In the context of genetic association, the peroxisome proliferator-activated receptor gamma is shown to be a gene product of THRB. On the other hand, the s-phase kinase-associated protein 1, being a gene product of both SKP1 and THRB, establishes its relevance to the aforementioned receptors. Interestingly, thyroid hormone receptor beta is also noted to be a gene product of THRB, creating a complex network of interactions and affiliations within the genetic landscape.']"
"[{'source_node': {'name': 'prelamin-a/c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'LMNA'}}, {'source_node': {'name': 'adipic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prelamin-a/c'}}, {'source_node': {'name': 'adipic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histone acetyltransferase kat2a'}}, {'source_node': {'name': 'adipic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'peroxisome proliferator-activated receptor delta'}}, {'source_node': {'name': 'histone acetyltransferase kat2a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KAT2A'}}, {'source_node': {'name': 'peroxisome proliferator-activated receptor delta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PPARD'}}]","[{'source_node': {'name': 'adipic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prelamin-a/c'}}, {'source_node': {'name': 'adipic acid'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'histone acetyltransferase kat2a'}}, {'source_node': {'name': 'histone acetyltransferase kat2a'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'KAT2A'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:358', 'target': None, 'metadata': {'node_id': '358', 'node_type': 'PROTEIN', 'display_name': 'peroxisome proliferator-activated receptor delta'}}, {'type': 'node_removal', 'source': 'GENE:29744', 'target': None, 'metadata': {'node_id': '29744', 'node_type': 'GENE', 'display_name': 'LMNA'}}]",0.5384615384615384,735fda2b6f473fdd8577453296113543,0f2332b4cc92655ef9dbd43cd7a1dd8f,"['Prelamin-A/C is a gene product of LMNA and is targeted by adipic acid. Similarly, adipic acid also targets histone acetyltransferase kat2a and peroxisome proliferator-activated receptor delta. Histone acetyltransferase kat2a is a gene product of KAT2A, while peroxisome proliferator-activated receptor delta is a gene product of PPARD.', 'The drug adipic acid interacts with various targets, namely prelamin-a/c, histone acetyltransferase kat2a, and peroxisome proliferator-activated receptor delta. Intriguingly, these targets are the gene products of different genes. For instance, prelamin-a/c is a product of the gene LMNA, histone acetyltransferase kat2a emanates from the gene KAT2A, and peroxisome proliferator-activated receptor delta is a gene product of PPARD. This intricately woven network of interactions forms the basis for understanding the multifaceted influence of adipic acid in different biological pathways.', 'Prelamin-A/C, a gene product of LMNA, is one of the targets of adipic acid. Adipic acid also targets other entities such as histone acetyltransferase KAT2A, a gene product of KAT2A, and peroxisome proliferator-activated receptor delta, a gene product of PPARD.', 'The molecule adipic acid targets several entities including prelamin-a/c, which is a gene product of LMNA, histone acetyltransferase kat2a, a gene product of KAT2A, and the peroxisome proliferator-activated receptor delta, a gene product of PPARD.', 'The chemical compound adipic acid targets several proteins including prelamin-a/c, histone acetyltransferase kat2a, and peroxisome proliferator-activated receptor delta. The protein prelamin-a/c is a gene product of LMNA. Similarly, histone acetyltransferase kat2a and peroxisome proliferator-activated receptor delta are gene products of KAT2A and PPARD respectively.']","['Adipic acid, a compound commonly used in biochemistry, has specific targets that include prelamin-A/C and histone acetyltransferase kat2a. Noteworthy to mention, histone acetyltransferase kat2a is a gene product of the gene symbolized as KAT2A.', 'Adipic acid, a commonly used molecule in various industries, has been identified to target both Prelamin-A/C and the Histone Acetyltransferase KAT2A protein. Interestingly, Histone Acetyltransferase KAT2A is a gene product of KAT2A gene, hence establishing a linkage between these entities.', 'The chemical compound adipic acid targets several proteins, including prelamin-A/C and histone acetyltransferase KAT2A. Interestingly, histone acetyltransferase KAT2A is a gene product of KAT2A.', 'Adipic acid, a chemical compound, targets two entities: prelamin-a/c and histone acetyltransferase kat2a. Interestingly, the latter is a gene product of KAT2A.', 'The compound adipic acid targets both prelamin-a/c and the protein histone acetyltransferase kat2a. Furthermore, the protein histone acetyltransferase kat2a is a gene product of KAT2A.']"
"[{'source_node': {'name': 'ambrein'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'widr'}}, {'source_node': {'name': 'ambrein'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'source_node': {'name': 'ambrein'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4957', 'target': None, 'metadata': {'node_id': '4957', 'node_type': 'PROTEIN', 'display_name': 'widr'}}]",0.6,26480db893cce3f5731f191dd0e53a86,a362e5fb1a9a2d0d3dbf6f7a6e3c1c81,"['The compound Ambrein is known to target two specific types of cells - WiDr and A549.', 'The compound Ambrein has been identified to target two cell lines, namely WiDr and A549.', 'The compound Ambrein targets two different entities: WiDR and A549.', 'The compound ambrein targets both Widr and A549.', 'The compound Ambrein has been found to target two specific cell lines: WiDr and A549.']","['The compound Ambrein has been identified to target A549.', 'The compound Ambrein has a specific target, namely the lung epithelial cell line known as A549.']"
"[{'source_node': {'name': 'mental retardation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cerebellar vermis atrophy'}}, {'source_node': {'name': 'mental retardation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypoglycemia'}}, {'source_node': {'name': 'mental retardation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'thick lower lip vermilion'}}]","[{'source_node': {'name': 'mental retardation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypoglycemia'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:155', 'target': None, 'metadata': {'node_id': '155', 'node_type': 'PHENOTYPE', 'display_name': 'thick lower lip vermilion'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:4462', 'target': None, 'metadata': {'node_id': '4462', 'node_type': 'PHENOTYPE', 'display_name': 'cerebellar vermis atrophy'}}]",0.4285714285714286,925cf1a10840da8b16ae05fceb04bb34,c4d20bcee9a53238d144040ab983f45f,"['The condition of mental retardation is characterized by several distinct phenotypes. It often presents with cerebellar vermis atrophy, a particular kind of brain degradation. Additionally, individuals with mental retardation frequently exhibit hypoglycemia, a condition where blood sugar levels are significantly lower than normal. Another typical physical manifestation is a thick lower lip vermilion, where the border of the lip appears noticeably fuller.']",[]
"[{'source_node': {'name': 'arachidonate 15-lipoxygenase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ALOX15'}}, {'source_node': {'name': ""o,o'-dimethylcaffeic acid""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-1080'}}, {'source_node': {'name': ""o,o'-dimethylcaffeic acid""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'lysine-specific demethylase 4d-like'}}, {'source_node': {'name': ""o,o'-dimethylcaffeic acid""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'arachidonate 15-lipoxygenase'}}]","[{'source_node': {'name': ""o,o'-dimethylcaffeic acid""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'ht-1080'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:6153', 'target': None, 'metadata': {'node_id': '6153', 'node_type': 'PROTEIN', 'display_name': 'lysine-specific demethylase 4d-like'}}, {'type': 'node_removal', 'source': 'PROTEIN:2703', 'target': None, 'metadata': {'node_id': '2703', 'node_type': 'PROTEIN', 'display_name': 'arachidonate 15-lipoxygenase'}}]",0.3333333333333333,c64b9b3a6784dfa3139644e6278c335f,bf79ddda97222743a69bea515e7d840e,"[""Arachidonate 15-lipoxygenase is a gene product of ALOX15 and is one of the targets of o,o'-dimethylcaffeic acid. This drug also targets two other elements, namely HT-1080 and lysine-specific demethylase 4d-like."", ""Arachidonate 15-lipoxygenase is a gene product of ALOX15. O,O'-Dimethylcaffeic acid, a chemical compound, holds the potential to target several entities including HT-1080, a cell line used in biological and medical research, lysine-specific demethylase 4D-like, an enzyme that plays a vital role in modulating chromatin architecture and gene expression, and intriguingly, it also targets arachidonate 15-lipoxygenase."", ""Arachidonate 15-lipoxygenase is a gene product of ALOX15. The compound o,o'-dimethylcaffeic acid has multiple targets, including the cell line HT-1080, a protein known as the lysine-specific demethylase 4D-like, and also the aforementioned gene product, arachidonate 15-lipoxygenase.""]","[""The compound commonly referred to as O,O'-Dimethylcaffeic Acid has HT-1080 as its target."", ""The compound O,O'-dimethylcaffeic acid has a target interaction with HT-1080, a human fibrosarcoma cell line.""]"
"[{'source_node': {'name': 'taurochenodeoxycholic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'norethisterone'}}, {'source_node': {'name': 'bezafibrate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'taurochenodeoxycholic acid'}}, {'source_node': {'name': 'bezafibrate'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Atheroma'}}, {'source_node': {'name': 'bezafibrate'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Infection'}}]","[{'source_node': {'name': 'taurochenodeoxycholic acid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'norethisterone'}}, {'source_node': {'name': 'taurochenodeoxycholic acid'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'bezafibrate'}}, {'source_node': {'name': 'taurochenodeoxycholic acid'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Atheroma'}}, {'source_node': {'name': 'bezafibrate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'taurochenodeoxycholic acid'}}, {'source_node': {'name': 'bezafibrate'}, 'relation': {'name': 'has_indication'}, 'target_node': {'name': 'Atheroma'}}, {'source_node': {'name': 'bezafibrate'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Infection'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:7794', 'target': 'COMPOUND:1334', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:7794', 'target': 'INDICATION:2466', 'metadata': {'predicate': 'has_indication'}}]",0.7777777777777778,f4f0df3296680d5b8aa65701d0285169,4be6e3c28345e12e59be1c9065cfe560,[],"['Taurochenodeoxycholic acid, a molecule often used in therapy, shows varied interactive characteristics with different substances. It is known to decrease the efficacy of a medicament called norethisterone, while simultaneously increasing the efficacy of another drug, bezafibrate. Interestingly, taurochenodeoxycholic acid itself has an indication for the treatment of a condition known as Atheroma. \n\nBezafibrate, which exhibits enhanced efficacy due to taurochenodeoxycholic acid, has a reciprocal action and can lower the efficacy of taurochenodeoxycholic acid in return. Like taurochenodeoxycholic acid, bezafibrate too, is indicated for the treatment of Atheroma, although it can potentially cause infections as a side effect, something that those administering it need to be aware of.\n', 'Taurochenodeoxycholic acid, a substance known to decrease the efficacy of norethisterone, interestingly increases the efficacy of another drug called bezafibrate. Both taurochenodeoxycholic acid and bezafibrate have a common indication and are used in the treatment of atheroma, a type of artery wall lump. However, bezafibrate must be carefully administered as it may decrease the efficacy of taurochenodeoxycholic acid and can potentially cause infections as a side effect.', 'The drug taurochenodeoxycholic acid is notable for its interaction with several substances. It decreases the efficacy of norethisterone, while it boosts the efficacy of another drug known as bezafibrate. Interestingly, this increase in potency is reciprocal as bezafibrate, in turn, diminishes the effectiveness of taurochenodeoxycholic acid. Both taurochenodeoxycholic acid and bezafibrate share the indication of treating the health condition known as atheroma. However, usage of bezafibrate has a potential side effect, as it has been associated with infections.', 'The compound taurochenodeoxycholic acid has been indicated for treating atheroma. Furthermore, this compound has been observed to decrease the efficacy of the drug norethisterone, while it can increase the efficacy of another drug, bezafibrate. However, bezafibrate could also decrease the efficacy of taurochenodeoxycholic acid, demonstrating a complex interaction between these two compounds. Moreover, bezafibrate has been indicated not only for the treatment of atheroma like taurochenodeoxycholic acid, but additionally has been documented to have a side effect of causing infections.', 'Taurochenodeoxycholic acid demonstrates varying effects on different drugs. On the one hand, it decreases the efficacy of norethisterone. On the other hand, it boosts the efficacy of bezafibrate. Moreover, taurochenodeoxycholic acid has been indicated for the treatment of atheroma. Interestingly, bezafibrate, which sees an increase in efficacy due to taurochenodeoxycholic acid, simultaneously decreases the efficacy of taurochenodeoxycholic acid and causes a side effect, namely infection. Bezafibrate, like taurochenodeoxycholic acid, is also used in the treatment of atheroma.']"
"[{'source_node': {'name': 'muscular dystrophy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'scapular winging'}}, {'source_node': {'name': 'muscular dystrophy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'respiratory insufficiency'}}, {'source_node': {'name': 'muscular dystrophy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'reduced left ventricular ejection fraction'}}, {'source_node': {'name': 'miyoshi myopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'decreased/absent ankle reflexes'}}, {'source_node': {'name': 'miyoshi myopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'foot dorsiflexor weakness'}}, {'source_node': {'name': 'DYSF'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'muscular dystrophy'}}, {'source_node': {'name': 'DYSF'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'miyoshi myopathy'}}, {'source_node': {'name': 'DYSF'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Smooth Muscle Contraction'}}]","[{'source_node': {'name': 'muscular dystrophy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'scapular winging'}}, {'source_node': {'name': 'muscular dystrophy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'respiratory insufficiency'}}, {'source_node': {'name': 'muscular dystrophy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'reduced left ventricular ejection fraction'}}, {'source_node': {'name': 'miyoshi myopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'foot dorsiflexor weakness'}}, {'source_node': {'name': 'miyoshi myopathy'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'scapular winging'}}, {'source_node': {'name': 'DYSF'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Smooth Muscle Contraction'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:11439', 'target': None, 'metadata': {'node_id': '11439', 'node_type': 'PHENOTYPE', 'display_name': 'decreased/absent ankle reflexes'}}, {'type': 'edge_deletion', 'source': 'GENE:34212', 'target': 'DISEASE:4224', 'metadata': None}, {'type': 'edge_addition', 'source': 'DISEASE:10817', 'target': 'PHENOTYPE:2619', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_deletion', 'source': 'GENE:34212', 'target': 'DISEASE:10817', 'metadata': None}]",0.7058823529411764,88d3f34a01dabd0e7a14f3af621a0d13,fdf13a99fe2fc4c13aa275263f7443dc,[],"['Muscular dystrophy, a genetic disorder, is characterized by phenotypes such as scapular winging, respiratory insufficiency, and reduced left ventricular ejection fraction. Similarly, Miyoshi myopathy is also associated with foot dorsiflexor weakness and scapular winging. Moreover, DYSF, a protein, is known to act within the pathway of smooth muscle contraction. The manifestations of these diseases speak to the complex interplay between genetic factors and physiological pathways.', ""Muscular dystrophy, a progressive disease that causes muscle weakness, has multiple phenotypes such as scapular winging, characterized by an unusual protrusion of the shoulder blades, respiratory insufficiency, which reflects a deficiency in the exchange of oxygen and carbon dioxide, and a reduced left ventricular ejection fraction, indicating a decrease in the heart's ability to pump blood. Similarly, miyoshi myopathy, another muscle disorder, has phenotypes that include foot dorsiflexor weakness, causing difficulty in lifting the front part of the foot, and scapular winging. The gene DYSF acts within the pathway responsible for smooth muscle contraction, a process that is disrupted in these muscle disorders."", 'Muscular dystrophy and Miyoshi myopathy are two conditions that manifest different phenotypes. Muscular dystrophy exhibits a range of symptoms including scapular winging, respiratory insufficiency, and reduced left ventricular ejection fraction. On the other hand, Miyoshi myopathy leads to phenomenons such as foot dorsiflexor weakness and scapular winging. The gene DYSF acts within the pathway of smooth muscle contraction and is believed to play a role in how these conditions develop.']"
"[{'source_node': {'name': 'NAMPT'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nicotinamide salvaging'}}, {'source_node': {'name': 'gmx1777'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nicotinamide phosphoribosyltransferase'}}, {'source_node': {'name': 'nicotinamide phosphoribosyltransferase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NAMPT'}}]","[{'source_node': {'name': 'gmx1777'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nicotinamide phosphoribosyltransferase'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:311', 'target': None, 'metadata': {'node_id': '311', 'node_type': 'PATHWAY', 'display_name': 'Nicotinamide salvaging'}}, {'type': 'node_removal', 'source': 'GENE:24710', 'target': None, 'metadata': {'node_id': '24710', 'node_type': 'GENE', 'display_name': 'NAMPT'}}]",0.4285714285714286,889195481ab5e0f2f33630cc4d7d4129,7cacc2e74326e1a10fe71af40149a64f,[],[]
"[{'source_node': {'name': 'alfacalcidol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluticasone propionate'}}, {'source_node': {'name': 'alfacalcidol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'budesonide'}}, {'source_node': {'name': 'fluocortin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'alfacalcidol'}}, {'source_node': {'name': 'fluocortin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rabies immune globulin'}}, {'source_node': {'name': 'fluocortin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ipidacrine'}}]","[{'source_node': {'name': 'alfacalcidol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'budesonide'}}, {'source_node': {'name': 'ipidacrine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'rabies immune globulin'}}, {'source_node': {'name': 'fluocortin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'alfacalcidol'}}, {'source_node': {'name': 'fluocortin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rabies immune globulin'}}, {'source_node': {'name': 'fluocortin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ipidacrine'}}, {'source_node': {'name': 'fluocortin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'budesonide'}}, {'source_node': {'name': 'budesonide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'alfacalcidol'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:574', 'target': None, 'metadata': {'node_id': '574', 'node_type': 'COMPOUND', 'display_name': 'fluticasone propionate'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11081', 'target': 'COMPOUND:1202', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:11515', 'target': 'COMPOUND:9526', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1202', 'target': 'COMPOUND:1374', 'metadata': {'predicate': 'increase_efficacy'}}]",0.5454545454545454,c5f0ac810916091acde1a334874ea528,41a46942a09a0aaf32323046eaeab705,"['Alfacalcidol, a form of vitamin D, is known to decrease the efficacy of certain drugs including fluticasone propionate and budesonide. Similarly, the drug fluocortin also interferes with the effectiveness of alfacalcidol as well as other substances such as rabies immune globulin and ipidacrine. Thus, it is crucial to take into account potential drug interactions when these substances are prescribed together.', 'The medications alfacalcidol and fluocortin interact with various other drugs, often resulting in decreased efficacy. Specifically, alfacalcidol reduces the effectiveness of both fluticasone propionate and budesonide. On the other hand, fluocortin diminishes the efficacy of alfacalcidol, along with that of rabies immune globulin and ipidacrine. This interaction could have implications for treatment plans where these drugs are used concurrently.', ""The drug alfacalcidol is known to decrease the efficacy of other drugs, specifically budesonide and fluticasone propionate. On the other hand, the efficacy of alfacalcidol is diminished by fluocortin, which also reduces the performance of rabies immune globulin and ipidacrine. It's important that medical professionals are aware of these interactions to avoid potential complications in treatment plans."", 'The drug alfacalcidol is known to diminish the efficacy of both fluticasone propionate and budesonide. Conversely, the drug fluocortin negatively affects the efficacy of alfacalcidol itself. Furthermore, fluocortin also decreases the efficacy of rabies immune globulin and ipidacrine. Therefore, interactions between these drugs should be considered when developing treatment strategies.', 'The drug alfacalcidol is known to decrease the efficacy of both fluticasone propionate and budesonide. However, this effect is not unilateral, as fluocortin also decreases the efficacy of alfacalcidol. Additionally, fluocortin is observed to decrease the effectiveness of rabies immune globulin and ipidacrine as well.']","[""Alfacalcidol and budesonide are two drugs that interact in complex ways. While alfacalcidol tends to decrease the efficacy of budesonide, budesonide paradoxically increases the efficacy of alfacalcidol. On the other hand, fluocortin, another type of drug, has a tendency to reduce the efficacy of both alfacalcidol and budesonide. Meanwhile, the drug ipidacrine focuses its actions on amplifying the effectiveness of rabies immune globulin, a crucial element in treating and controlling rabies. Yet the function of ipidacrine is compromised by the presence of fluocortin, which reduces its efficacy. The same negative effect applies to fluocortin's relationship with rabies immune globulin, resulting in a decreased effectiveness. This intricate network of interactions showcases the complex interplay of drugs in the body."", 'The use of various drugs can impact the efficacy of others. For instance, the drug alfacalcidol decreases the efficacy of budesonide. An interesting counteracting effect is observed, because budesonide itself increases the efficacy of alfacalcidol. On the other hand, ipidacrine is known to increase the efficacy of rabies immune globulin, a critical factor in the treatment of rabies. However, the efficacy of both alfacalcidol and rabies immune globulin along with ipidacrine and budesonide can be reduced by the drug fluocortin. These complex interactions indicate the need for caution and careful coordination when using these drugs in therapeutic applications.', 'The drug alfacalcidol decreases the efficacy of budesonide, while budesonide, in turn, increases the efficacy of alfacalcidol. In contrast, the drug ipidacrine is found to enhance the efficacy of the rabies immune globulin. Fluocortin, however, seems to decrease the efficacy of several drugs including alfacalcidol, rabies immune globulin, ipidacrine, and budesonide. These complex interactions between drugs can inform potential combination therapies and advise on potent drug interactions to avoid.', ""The relationships between several drugs and their effects on each other are complex and interconnected. The drug Alfacalcidol, often used to treat low calcium levels, is impacted in efficacy by other drugs. For instance, its effectiveness decreases when combined with Budesonide, a medication commonly prescribed for asthma and non-infectious rhinitis, while it shows an increase in efficacy when partnered with Budesonide.\n\nFurthermore, the drug Fluocortin influences the efficacy of alfacalcidol, ipidacrine, rabies immune globulin, and budesonide by reducing their effectiveness. On the other hand, the drug Ipidacrine, which is primarily used for treating myasthenia gravis and Alzheimer's disease, can increase the effectiveness of Rabies immune globulin, which is administered for rabies post-exposure prophylaxis."", 'The drug alfacalcidol has an interesting relationship with other medications. Its efficacy is known to decrease when in combination with budesonide, however, the efficacy of budesonide itself increases in the presence of alfacalcidol. Another drug, fluocortin, tends to decrease the efficacy of numerous substances including alfacalcidol, rabies immune globulin, ipidacrine, and budesonide. On a more optimistic note, ipidacrine has the capacity to increase the efficacy of the rabies immune globulin which is a constructive effect in medical treatments.']"
"[{'source_node': {'name': 'plasminogen activator inhibitor 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'SERPINE1'}}, {'source_node': {'name': 'SERPINE1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'plasminogen activator inhibitor-1 deficiency'}}, {'source_node': {'name': 'SERPINE1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'ECM proteoglycans'}}, {'source_node': {'name': 'SERPINE1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Dissolution of Fibrin Clot'}}]","[{'source_node': {'name': 'SERPINE1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'ECM proteoglycans'}}]","[{'type': 'node_removal', 'source': 'DISEASE:9918', 'target': None, 'metadata': {'node_id': '9918', 'node_type': 'DISEASE', 'display_name': 'plasminogen activator inhibitor-1 deficiency'}}, {'type': 'node_removal', 'source': 'PROTEIN:25', 'target': None, 'metadata': {'node_id': '25', 'node_type': 'PROTEIN', 'display_name': 'plasminogen activator inhibitor 1'}}, {'type': 'node_removal', 'source': 'PATHWAY:1738', 'target': None, 'metadata': {'node_id': '1738', 'node_type': 'PATHWAY', 'display_name': 'Dissolution of Fibrin Clot'}}]",0.3333333333333333,6b0287276e4a212ea1d711a782912d0e,88e18238a415e0f1a8e2d9af5c414717,"['The gene SERPINE1, which acts within both the ECM proteoglycans and the dissolution of fibrin clot pathways, causes a specific condition known as plasminogen activator inhibitor-1 deficiency. Plasminogen activator inhibitor 1 is identified as a gene product of this same gene, SERPINE1.']","['The gene SERPINE1 is known to be active within the pathway of ECM proteoglycans.', 'The gene SERPINE1 is known to act within the pathway of ECM proteoglycans.', 'The gene SERPINE1 operates within the framework of ECM proteoglycans.']"
"[{'source_node': {'name': 'bufexamac'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'bufexamac'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' bleeding '}}, {'source_node': {'name': 'bufexamac'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nitroaspirin'}}, {'source_node': {'name': 'nitroaspirin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fenoldopam'}}, {'source_node': {'name': 'nitroaspirin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tafluprost'}}, {'source_node': {'name': 'nitroaspirin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hexamethonium'}}, {'source_node': {'name': 'hexamethonium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methylcellulose'}}]","[{'source_node': {'name': 'bufexamac'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'bufexamac'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nitroaspirin'}}, {'source_node': {'name': 'nitroaspirin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fenoldopam'}}, {'source_node': {'name': 'nitroaspirin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tafluprost'}}, {'source_node': {'name': 'nitroaspirin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hexamethonium'}}, {'source_node': {'name': 'hexamethonium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methylcellulose'}}, {'source_node': {'name': 'tafluprost'}, 'relation': {'name': 'decrease_effect'}, 'target_node': {'name': ' adverse effects '}}]","[{'type': 'node_removal', 'source': 'EFFECT:4', 'target': None, 'metadata': {'node_id': '4', 'node_type': 'EFFECT', 'display_name': ' bleeding '}}, {'type': 'edge_addition', 'source': 'COMPOUND:7784', 'target': 'EFFECT:5', 'metadata': {'predicate': 'decrease_effect'}}]",0.8,60c5d6c40036b02e0afd7c44d5c313d7,39d577de5d0062a0ca94309800ed801c,[],[]
"[{'source_node': {'name': '13-deoxydoxorubicin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna topoisomerase 2-alpha'}}, {'source_node': {'name': '13-deoxydoxorubicin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna'}}]","[{'source_node': {'name': '13-deoxydoxorubicin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna topoisomerase 2-alpha'}}]","[{'type': 'node_removal', 'source': 'MOLECULE:10', 'target': None, 'metadata': {'node_id': '10', 'node_type': 'MOLECULE', 'display_name': 'dna'}}]",0.6,01248128f6c21e8c7e2fe677300e500f,74703cfeb0a008c1964c8b39f25a0b10,"['The compound 13-deoxydoxorubicin is observed to target two distinct entities: DNA topoisomerase 2-alpha, a type of enzyme, and DNA, the genetic material found in all living organisms.', 'The drug 13-deoxydoxorubicin targets both DNA topoisomerase 2-alpha and DNA.', 'The drug 13-deoxydoxorubicin targets both DNA and the enzyme DNA topoisomerase 2-alpha.', 'The drug 13-deoxydoxorubicin targets both DNA topoisomerase 2-alpha and DNA itself.', 'The drug 13-deoxydoxorubicin has multiple targets. Specifically, it targets DNA topoisomerase 2-alpha, a crucial enzyme involved in DNA transcription, and it also prominently interacts with the DNA itself.']",['The drug 13-deoxydoxorubicin targets DNA topoisomerase 2-alpha.']
"[{'source_node': {'name': 'oxycodone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Glossitis'}}, {'source_node': {'name': 'ularitide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oxycodone'}}, {'source_node': {'name': 'ularitide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dextromoramide'}}, {'source_node': {'name': 'ularitide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oliceridine'}}]","[{'source_node': {'name': 'oxycodone'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Glossitis'}}, {'source_node': {'name': 'oxycodone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'oliceridine'}}, {'source_node': {'name': 'ularitide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oxycodone'}}, {'source_node': {'name': 'ularitide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dextromoramide'}}, {'source_node': {'name': 'ularitide'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oliceridine'}}, {'source_node': {'name': 'dextromoramide'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Glossitis'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:485', 'target': 'COMPOUND:12545', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1459', 'target': 'SIDE_EFFECT:516', 'metadata': {'predicate': 'has_side_effect'}}]",0.7777777777777778,a1e0d71b32d44a1fe7d606505bbc4eac,bd31f48584cbf4c5888de63f7550b47e,"['The drug oxycodone presents side effects such as Glossitis. However, its efficacy can be reduced by the drug ularitide. In addition, ularitide also has been known to decrease the efficacy of other drugs including dextromoramide and oliceridine.', 'The drug Oxycodone, known for its side effect of causing Glossitis, has decreased efficacy when interacted with Ularitide. In addition to Oxycodone, Ularitide also decreases the efficacy of two other drugs: Dextromoramide and Oliceridine.', ""The drug Oxycodone, commonly used for pain management, presents glossitis as potential side-effect. Meanwhile, Ularitide, another medication, is known to decrease the efficacy of Oxycodone. Nonetheless, Ularitide isn't specific in its actions, it also tends to diminish the potency of other analgesics such as Dextromoramide and Oliceridine."", 'The drug Oxycodone has a side effect known as Glossitis. Another drug, Ularitide, is known to decrease the efficacy of Oxycodone. Ularitide also reduces the effectiveness of other drugs such as Dextromoramide and Oliceridine.', 'The drug oxycodone is known to have certain side effects, including Glossitis. This effect, however, might be altered by the presence of other medications. For instance, the compound ularitide is found to decrease the efficacy of oxycodone. In addition to oxycodone, ularitide also reduces the effectiveness of both dextromoramide and oliceridine drugs.']","[""Oxycodone, a widely used opioid medication, has been linked to the side effect of Glossitis, a condition characterized by tongue inflammation. Interestingly, the efficacy of Oxycodone is shown to increase when used in conjunction with Oliceridine, a potent pain reliever. However, the drug interaction with Ularitide, a heart failure treatment medication, is clinically significant. Administration of Ularitide reduces the efficacy of Oxycodone, as well as another painkiller, Dextromoramide. Parallely, Ularitide's interaction with Oliceridine also results in decreased efficacy of the latter. Moreover, it is worth noting that Dextromoramide, too, has been associated with the onset of Glossitis. These findings point out a complex network of interactions and side effects that medical practitioners should consider when prescribing these medications."", 'Oxycodone, a potent opioid pain medication, has been linked to the side effect of Glossitis, a condition characterized by an inflammation or swelling of the tongue. Additionally, it has been found that Oxycodone may have its efficacy increased by Oliceridine, a drug of the same class. However, the administration of another drug, Ularitide, is noted to decrease the efficacy of Oxycodone. Interestingly, the same effects of Ularitide have also been observed for Dextromoramide and Oliceridine, both opioid analgesics. Similar to Oxycodone, Dextromoramide too has the potential side effect of Glossitis. Thus, patients under treatment with these opioid drugs should be monitored for signs of Glossitis, and the impact of the co-administration of Ularitide should be carefully considered.', ""The drug oxycodone is known to have side effects, one of which is Glossitis. Additionally, it is observed that the efficacy of oxycodone increases when used in conjunction with oliceridine. However, it's important to note that another drug, ularitide, can decrease the effectiveness of oxycodone. The same substance, ularitide, is also known to reduce the efficacy of two other drugs, dextromoramide and oliceridine. Moreover, similar to oxycodone, dextromoramide has been linked to the same side effect of Glossitis."", 'The painkiller oxycodone has been found to have a side effect of Glossitis, an inflammation of the tongue. Interestingly, oxycodone also appears to increase the efficacy of another pain medication, oliceridine. However, the drug ularitide seems to have an opposite interaction with oxycodone and oliceridine, as it has been observed to decrease their efficacy. Ularitide also shows a decrease in the efficacy of dextromoramide. Like oxycodone, dextromoramide has the side effect of Glossitis. This suggests that medication regimens need to consider these interactions in order to optimize therapeutic effects and minimize side effects.', ""The drug Oxycodone, known for its potential side effect of Glossitis, has been shown to increase the efficacy of Oliceridine. However, its efficacy can be decreased by Ularitide. Interestingly, Ularitide also decreases the efficacy of Dextromoramide and Oliceridine. It's noteworthy that Dextromoramide, like Oxycodone, has a side-effect of Glossitis.""]"
"[{'source_node': {'name': 'gsk-1059615'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'serine/threonine-protein kinase mtor'}}, {'source_node': {'name': 'serine/threonine-protein kinase mtor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RPTOR'}}, {'source_node': {'name': 'serine/threonine-protein kinase mtor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MAPKAP1'}}]","[{'source_node': {'name': 'gsk-1059615'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'serine/threonine-protein kinase mtor'}}, {'source_node': {'name': 'gsk-1059615'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'MAPKAP1'}}, {'source_node': {'name': 'serine/threonine-protein kinase mtor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'RPTOR'}}, {'source_node': {'name': 'serine/threonine-protein kinase mtor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MAPKAP1'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:9873', 'target': 'GENE:33730', 'metadata': {'predicate': 'is_affecting'}}]",0.8571428571428572,c5262737dc21a8b76d32463e2dea0d0a,a103fcc1792a5aba859b48b9722bfadf,"['The drug GSK-1059615 targets the serine/threonine-protein kinase mTOR. This protein kinase mTOR is a gene product of both RPTOR and MAPKAP1.', 'The drug GSK-1059615 has a target of the serine/threonine-protein kinase MTOR. This protein is a gene product of both RPTOR and MAPKAP1.', 'The drug GSK-1059615 targets serine/threonine-protein kinase mTOR, which is a gene product of both RPTOR and MAPKAP1.', 'The compound GSK-1059615 has been identified as a target for the serine/threonine-protein kinase MTOR. This protein kinase is the gene product of both RPTOR and MAPKAP1.', 'The drug GSK-1059615 targets the Serine/Threonine-protein kinase mTOR, which is a gene product of both RPTOR and MAPKAP1.']","[""The drug GSK-1059615 targets the serine/threonine-protein kinase MTOR and affects MAPKAP1. It's interesting to note that the serine/threonine-protein kinase MTOR is a gene product of both RPTOR and MAPKAP1."", 'The drug GSK-1059615 targets the serine/threonine-protein kinase mTOR and is also affecting MAPKAP1. Interestingly, serine/threonine-protein kinase mTOR is a gene product of RPTOR and MAPKAP1.', 'The drug, GSK-1059615, has a target action on the serine/threonine-protein kinase MTOR and it also affects MAPKAP1. Serine/threonine-protein kinase MTOR is a gene product of two different entities - RPTOR and MAPKAP1.', 'The drug GSK-1059615 targets the serine/threonine-protein kinase MTOR and affects MAPKAP1. The kinase, serine/threonine-protein kinase MTOR, is a gene product of both RPTOR and MAPKAP1, thereby establishing a potential linkage between the drug and these genes.', 'The drug GSK-1059615 has the capability to target Serine/Threonine-protein kinase mTOR and affect MAPKAP1. The Serine/Threonine-protein kinase mTOR acts as the gene product of both RPTOR and MAPKAP1.']"
"[{'source_node': {'name': 'chromosome 20q11-q12 deletion syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'brachydactyly'}}, {'source_node': {'name': 'chromosome 20q11-q12 deletion syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'adducted thumb'}}]","[{'source_node': {'name': 'chromosome 20q11-q12 deletion syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'adducted thumb'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:904', 'target': None, 'metadata': {'node_id': '904', 'node_type': 'PHENOTYPE', 'display_name': 'brachydactyly'}}]",0.6,fba6150b57172f9a9057c120a7ef3f26,1eeaff6c848a0357e5c7c468273be104,[],[]
"[{'source_node': {'name': 'fingolimod'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rindopepimut'}}, {'source_node': {'name': 'fingolimod'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hepatitis b vaccine (recombinant)'}}, {'source_node': {'name': 'fingolimod'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tick-borne encephalitis vaccine (whole virus'}}]","[{'source_node': {'name': 'fingolimod'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hepatitis b vaccine (recombinant)'}}, {'source_node': {'name': 'fingolimod'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tick-borne encephalitis vaccine (whole virus'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:9547', 'target': 'COMPOUND:4989', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:4989', 'target': None, 'metadata': {'node_id': '4989', 'node_type': 'COMPOUND', 'display_name': 'rindopepimut'}}]",0.7142857142857143,50e66beb7816a307b6475a4e6a38b079,b717c9d5893a844d4cd1dce0aea1b475,[],[]
"[{'source_node': {'name': 'triprolidine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'epinephrine'}}, {'source_node': {'name': 'triprolidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'betahistine'}}]","[{'source_node': {'name': 'triprolidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'betahistine'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:653', 'target': None, 'metadata': {'node_id': '653', 'node_type': 'COMPOUND', 'display_name': 'epinephrine'}}]",0.6,1b23cfc01ee0979e6896a678d1952bf5,0b21a9c40a108b18903697d2c1005222,"['Triprolidine is a medication that impacts the effectiveness of certain other drugs in the body. Its use has shown to increase the efficacy of epinephrine, empowering its effects. However, the same drug, triprolidine, also tends to decrease the efficacy of betahistine, dampening its effectiveness.', 'The drug triprolidine is known to have variable effects on different substances. It has been found to increase the efficacy of epinephrine, making it more potent. On the contrary, triprolidine tends to decrease the efficacy of betahistine, essentially reducing its potency as a drug.', 'The drug triprolidine has been found to increase the efficacy of epinephrine. However, it seems to decrease the efficacy of another drug, betahistine.', 'The drug triprolidine can impact the efficacy of certain other drugs. Specifically, it has been shown to increase the efficacy of epinephrine, thereby enhancing its effects. On the other hand, triprolidine reduces the efficacy of betahistine, potentially lessening its therapeutic effect.', 'The drug triprolidine is known to increase the efficacy of epinephrine. However, it can decrease the efficacy of another medication known as betahistine.']","['The drug triprolidine can decrease the efficacy of betahistine.', 'The drug triprolidine may decrease the efficacy of betahistine.', 'The drug triprolidine can decrease the efficacy of betahistine.', 'The drug triprolidine has been observed to decrease the efficacy of betahistine.', 'The drug triprolidine is known to decrease the efficacy of another medication, betahistine.']"
"[{'source_node': {'name': 'glymidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'darunavir'}}, {'source_node': {'name': 'glymidine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'buformin'}}, {'source_node': {'name': 'glymidine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'sulfameter'}}, {'source_node': {'name': 'buformin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ethynodiol diacetate'}}, {'source_node': {'name': 'buformin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pseudoephedrine'}}, {'source_node': {'name': 'buformin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cyproterone acetate'}}]","[{'source_node': {'name': 'glymidine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'darunavir'}}, {'source_node': {'name': 'glymidine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'sulfameter'}}, {'source_node': {'name': 'buformin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ethynodiol diacetate'}}, {'source_node': {'name': 'buformin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'cyproterone acetate'}}, {'source_node': {'name': 'sulfameter'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'buformin'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:5863', 'target': 'COMPOUND:4546', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:835', 'target': None, 'metadata': {'node_id': '835', 'node_type': 'COMPOUND', 'display_name': 'pseudoephedrine'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:1329', 'target': 'COMPOUND:4546', 'metadata': None}]",0.6923076923076923,18a059991359dda8cc6d33651a1aca9e,034989cd721742fb8adcd2e7fcd824eb,"['The drug Glymidine displays diverse effects on other drug efficacies. It decreases the efficacy of Darunavir while concurrently increasing the efficacy of drugs like Buformin and Sulfameter. Similarly, Buformin is linked to reduced efficacy of other drugs, for instance, Ethynodiol Diacetate, Pseudoephedrine, and Cyproterone Acetate.', 'The drug glymidine is known to have varying effects on the efficacy of other drugs. It diminishes the efficacy of darunavir, whilst bolstering the efficacy of both buformin and sulfameter. Buformin, while having its efficacy increased by glymidine, is also known to dampen the efficacy of several drugs including ethynodiol diacetate, pseudoephedrine, and cyproterone acetate.', 'The drug glymidine has differential effects on the efficacy of various other medications. For instance, it is known to decrease the efficacy of darunavir but works to increase the efficacy of both buformin and sulfameter. However, buformin, though positively influenced by glymidine, itself decreases the efficacy of other drugs such as ethynodiol diacetate, pseudoephedrine, and cyproterone acetate.', 'The drug glymidine has been found to decrease the efficacy of darunavir while increasing the efficacy of both buformin and sulfameter. Notably, buformin itself appears to decrease the efficacy of several other drugs, including ethynodiol diacetate, pseudoephedrine, and cyproterone acetate.', 'The drug glymidine has varying effects on different substances. It reduces the efficacy of darunavir, while it increases the efficacy of buformin and sulfameter. On the other hand, buformin, whose effectiveness is increased by glymidine, decreases the efficacy of several substances namely ethynodiol diacetate, pseudoephedrine, and cyproterone acetate.']","['In pharmacological studies, various drugs have been shown to interact in a way that affects their efficacy. For instance, the drug Glymidine has been observed to decrease the efficacy of Darunavir while at the same time increasing the efficacy of Sulfameter. Similarly, Buformin has been shown to decrease the efficacy of both Ethynodiol Diacetate and Cyproterone Acetate. Interestingly, Sulfameter, whose efficacy is boosted by Glymidine, is found to decrease the efficacy of Buformin in a reciprocal manner. These insights reveal a complex interplay of drug efficacy modulation in pharmacological treatments.', 'The drug Glymidine is known to decrease the efficacy of Darunavir, but increases the efficacy of Sulfameter. On the other hand, Buformin is known to decrease the efficacy of both Ethynodiol Diacetate and Cyproterone Acetate. Interestingly, the efficacy of Buformin itself is decreased by Sulfameter.', ""The drug glymidine decreases the efficacy of darunavir but increases the efficacy of sulfameter. Conversely, the medication buformin reduces the efficacy of ethynodiol diacetate and cyproterone acetate. Interestingly, it's also evident that sulfameter diminishes the effectiveness of buformin, thereby forming a complex interplay of medication interactions."", 'The drug glymidine is known to decrease the efficacy of darunavir, while at the same time, it increases the efficacy of sulfameter. In contrast, buformin tends to decrease the potency of both ethynodiol diacetate and cyproterone acetate. Interestingly, sulfameter also decreases the efficacy of buformin. This intricate web of drug interactions represents a complex balancing act in pharmacology.', 'The drug Glymidine affects the efficacy of several compounds. It tends to decrease the efficacy of Darunavir, a medication used in the treatment and prevention of HIV/AIDS, while increasing the efficacy of Sulfameter, an antibacterial agent. Similarly, Buformin, an antidiabetic drug, has been found to decrease the efficacy of Ethynodiol diacetate, a hormonal medication used in some types of birth control pills, and Cyproterone acetate, often used to treat androgen-related conditions such as acne and hirsutism. However, intriguingly, Sulfameter has also been shown to decrease the efficacy of Buformin. These examples illustrate the complex interconnected dynamics and potential interactions that may occur among various drugs and therapeutic agents.']"
"[{'source_node': {'name': 'pasakbumin c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'pasakbumin c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}]","[{'source_node': {'name': 'pasakbumin c'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4994', 'target': None, 'metadata': {'node_id': '4994', 'node_type': 'PROTEIN', 'display_name': 'hela'}}]",0.6,b03d2ac4546ef4b1adf2b3209e1c0e73,436701be7b933dccfa6b055484363840,"['The drug Pasakbumin C is designed with specific targets in mind, including A549 and HeLa.', 'The compound Pasakbumin C targets both A549 and Hela cells.', 'The drug Pasakbumin C is known to target both A549 and HeLa cells.', 'Pasakbumin C, a pharmacologically active compound, has been identified to target and potentially interact with two specific human cell lines, namely A549 and HeLa.', 'The drug Pasakbumin C has been found to target two distinct types of cells, A549 and HeLa.']","['The drug Pasakbumin C has the A549 cell line as its targeted action site.', 'The drug Pasakbumin C has the cellular A549 as its target.', 'Pasakbumin C has A549 as its target.']"
"[{'source_node': {'name': 'coptisine chloride'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sf-539'}}, {'source_node': {'name': 'coptisine chloride'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h522'}}, {'source_node': {'name': 'coptisine chloride'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'km12'}}]","[{'source_node': {'name': 'coptisine chloride'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nci-h522'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5622', 'target': None, 'metadata': {'node_id': '5622', 'node_type': 'PROTEIN', 'display_name': 'sf-539'}}, {'type': 'node_removal', 'source': 'PROTEIN:5640', 'target': None, 'metadata': {'node_id': '5640', 'node_type': 'PROTEIN', 'display_name': 'km12'}}]",0.4285714285714286,92dd981516318dcf1e27b6eba7af19ec,d669b00ebafc9be8b686b6226c768647,"['The compound coptisine chloride has been identified as having multiple targets, which include SF-539, NCI-H522 and KM12.', 'The drug Coptisine Chloride has multiple targets including SF-539, NCI-H522, and KM12.', 'Coptisine chloride, a compound of interest in pharmaceutical research, has multiple targets. These targets include SF-539, NCI-H522 and KM12 cell lines which are often utilized in various experimental settings. This suggests that coptisine chloride may interact with these cell lines in its modes of action.', 'The drug Coptisine Chloride prominently targets a variety of entities including SF-539, NCI-H522, and KM12.', 'The compound coptisine chloride exhibits its pharmacological action by targeting several entities including SF-539, NCI-H522, and KM12.']",['The drug coptisine chloride has been found to target NCI-H522.']
"[{'source_node': {'name': 'nadph oxidase 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hyperthyroidism'}}, {'source_node': {'name': 'nadph oxidase 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'agranulocytosis'}}, {'source_node': {'name': 'hyperthyroidism'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'pretibial myxedema'}}]","[{'source_node': {'name': 'nadph oxidase 3'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'agranulocytosis'}}]","[{'type': 'node_removal', 'source': 'DISEASE:13544', 'target': None, 'metadata': {'node_id': '13544', 'node_type': 'DISEASE', 'display_name': 'hyperthyroidism'}}]",0.4285714285714286,95592ca2a2015f1615524c4560ebea69,b1cd5e549396b76da65d3ca654996b1d,"['The enzyme NADPH oxidase 3 is capable of causing several conditions, notably hyperthyroidism and agranulocytosis. Hyperthyroidism, one of those conditions, is characterized by certain phenotypic traits, such as pretibial myxedema.', 'The enzyme NADPH oxidase 3 has been linked to causing certain conditions such as hyperthyroidism and agranulocytosis. Specifically, hyperthyroidism, a disease caused by NADPH oxidase 3, is known to manifest a phenotype known as pretibial myxedema.', 'The enzyme NADPH oxidase 3 is found to cause conditions such as hyperthyroidism and agranulocytosis. Notably, a phenotypic manifestation of hyperthyroidism is pretibial myxedema.', 'The enzyme NADPH oxidase 3 is responsible for causing two separate conditions: hyperthyroidism and agranulocytosis. Interestingly, one of the phenotypic manifestations of hyperthyroidism is pretibial myxedema, a skin condition characterized by swelling on the front of the lower legs.', 'The gene NADPH oxidase 3 is known to cause several conditions, namely hyperthyroidism and agranulocytosis. In the case of hyperthyroidism, one notable characteristic or phenotype of the condition is the development of pretibial myxedema.']","['The enzyme NADPH oxidase 3 is known to cause a medical condition called agranulocytosis.', 'The enzyme NADPH oxidase 3 has been found to cause the medical condition known as agranulocytosis.', 'The enzyme NADPH oxidase 3 is known to cause the medical condition agranulocytosis.', 'The enzyme NADPH oxidase 3 has been found to cause the medical condition known as agranulocytosis.', 'The protein NADPH oxidase 3 is known to cause a medical condition called agranulocytosis.']"
"[{'source_node': {'name': 'cinchophen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methyclothiazide'}}, {'source_node': {'name': 'cinchophen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'benzthiazide'}}, {'source_node': {'name': 'cinchophen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hydrochlorothiazide'}}]","[{'source_node': {'name': 'cinchophen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'benzthiazide'}}, {'source_node': {'name': 'cinchophen'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hydrochlorothiazide'}}, {'source_node': {'name': 'benzthiazide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'cinchophen'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:548', 'target': 'COMPOUND:11402', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:222', 'target': None, 'metadata': {'node_id': '222', 'node_type': 'COMPOUND', 'display_name': 'methyclothiazide'}}]",0.5714285714285714,b42384553e6a012cccb3a98f9462cd25,ebf397fe069b13a0d2973b26745405e5,"['The drug Cinchophen is known to decrease the efficacy of several others, notably Methyclothiazide, Benzthiazide, and Hydrochlorothiazide. Users of these medications should therefore exercise caution when considering the concurrent use of Cinchophen.', 'Cinchophen, a pharmaceutical drug, is reported to decrease the efficacy of several other medications including methyclothiazide, benzthiazide, and hydrochlorothiazide. Care should be taken when administering these drugs concurrently.', 'The drug cinchophen is known to decrease the efficacy of various medications such as methyclothiazide, benzthiazide and hydrochlorothiazide.', 'The drug cinchophen has been found to decrease the efficacy of several medications including methyclothiazide, benzthiazide, and hydrochlorothiazide. This implies that the therapeutic properties of these drugs may be reduced when used in conjunction with cinchophen.', 'The drug cinchophen has been observed to decrease the efficacy of several other drugs, including methyclothiazide, benzthiazide, and hydrochlorothiazide. This information is vital as it provides insights into potential drug interactions and aids in determining the best treatment methods.']","['Cinchophen has been found to decrease the effectiveness of both benzthiazide and hydrochlorothiazide. Interestingly, benzthiazide in turn increases the efficacy of cinchophen.', 'The drug cinchophen has an effect on both benzthiazide and hydrochlorothiazide by decreasing their efficacy. Interestingly, benzthiazide reciprocally increases the efficacy of cinchophen.', 'The drug Cinchophen has been observed to decrease the efficacy of Benzthiazide and Hydrochlorothiazide. Interestingly, in the case of Benzthiazide, it also appears to increase the efficacy of Cinchophen, indicating a complex, bidirectional interplay between these two drugs.', 'The drug cinchophen has been observed to decrease the efficacy of both benzthiazide and hydrochlorothiazide. Intriguingly, in a reciprocal manner, benzthiazide has been shown to increase the efficacy of cinchophen.\n', 'The drug cinchophen is known to decrease the efficacy of both benzthiazide and hydrochlorothiazide. Interestingly, benzthiazide is reported to reciprocally increase the efficacy of cinchophen. Therefore, the interaction and efficacy changes between these drugs should be considered in treatment plans.']"
"[{'source_node': {'name': 'ozenoxacin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna gyrase subunit a'}}, {'source_node': {'name': 'ozenoxacin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna topoisomerase 4 subunit a'}}, {'source_node': {'name': 'ozenoxacin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'estetrol'}}, {'source_node': {'name': 'estetrol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'obeticholic acid'}}, {'source_node': {'name': 'estetrol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dulaglutide'}}, {'source_node': {'name': 'estetrol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '25-desacetylrifapentine'}}, {'source_node': {'name': 'dulaglutide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'sulfamethizole'}}]","[{'source_node': {'name': 'estetrol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'obeticholic acid'}}, {'source_node': {'name': 'estetrol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dulaglutide'}}, {'source_node': {'name': 'estetrol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': '25-desacetylrifapentine'}}, {'source_node': {'name': 'estetrol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sulfamethizole'}}, {'source_node': {'name': 'dulaglutide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'sulfamethizole'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:10139', 'target': 'COMPOUND:562', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:10798', 'target': 'COMPOUND:10139', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:10798', 'target': 'COMPOUND:562', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:10798', 'target': None, 'metadata': {'node_id': '10798', 'node_type': 'COMPOUND', 'display_name': 'ozenoxacin'}}]",0.5333333333333333,37bdb89d8e05255f98fa527bd4d06c11,e128ce8a6f18860e629b80687a8c150d,"[""The medication Ozenoxacin targets two specific elements: DNA Gyrase subunit A and DNA topoisomerase 4 subunit A. However, it also affects the efficacy of another drug, Estetrol, by decreasing its capability. Estetrol, in turn, has a similar decreasing efficacy effect on Obeticholic Acid, Dulaglutide, and 25-Desacetylrifapentine. Yet, it appears there's a distinctive dynamic with Dulaglutide, in that this medication actually increases the efficacy of Sulfamethizole. This intricate web shows the interconnected mechanics of these various substances and their potential impacts when administered in tandem."", 'Ozenoxacin, an antibiotic, primarily targets two enzymes: DNA gyrase subunit A and DNA topoisomerase 4 subunit A. It is also noted that ozenoxacin can reduce the efficacy of estetrol. Estetrol, a steroid hormone, also has an effect on the efficacy of several other substances. For instance, it decreases the efficacy of obeticholic acid and dulaglutide, but also 25-desacetylrifapentine, an antibiotic primarily used for treating tuberculosis. \nInterestingly, the efficacy of sulfamethizole, an antibiotic, is increased in the presence of dulaglutide. All these interactions, suggesting a complex network of drug interactions and potential therapeutic effects or side effects.\n', 'The drug Ozenoxacin has been found to target two specific functions within cellular structures, namely DNA gyrase subunit A and DNA topoisomerase 4 subunit A. However, Ozenoxacin has a dampening effect on the efficacy of Estetrol. Estetrol, in turn, decreases the efficacy of other compounds, such as Obeticholic acid, Dulaglutide, and 25-desacetylrifapentine. Conversely, the performance of Sulfamethizole is found to be boosted by Dulaglutide.', 'The drug Ozenoxacin targets two critical enzymes: DNA gyrase subunit A and DNA topoisomerase 4 subunit A. However, Ozenoxacin has been shown to decrease the efficacy of Estetrol. Interestingly, Estetrol has the effect of decreasing the efficacy of three different substances: Obeticholic acid, Dulaglutide, and 25-desacetylrifapentine. Despite its decreased efficacy by Estetrol, Dulaglutide is known to increase the efficacy of Sulfamethizole.', 'The drug Ozenoxacin targets both DNA gyrase subunit A and DNA topoisomerase 4 subunit A. Ozenoxacin is known to decrease the efficacy of Estetrol. Estetrol, in turn, can decrease the efficacy of multiple other drugs including Obeticholic Acid, Dulaglutide, and 25-desacetylrifapentine. Interestingly, while the efficacy of Dulaglutide is decreased by Estetrol, it has been found to increase the efficacy of Sulfamethizole. These interlinked drug interactions highlight the complex nature of pharmacology.']","[""The drug Estetrol has been observed to decrease the efficacy of multiple other therapeutic agents such as Obeticholic Acid, Dulaglutide, 25-Desacetylrifapentine, and Sulfamethizole. Interestingly, Dulaglutide shows an interactive effect with Sulfamethizole whereby it is known to increase the antibiotic's therapeutic efficacy. This suggests a potential counteracting interaction that could be explored for maximized therapeutic benefit. It highlights the nuanced relationships that exist between multiple drugs and their potential interactions in pharmacological settings."", ""Estetrol, a human hormone, is known to decrease the efficacy of several medications including obeticholic acid, dulaglutide, 25-desacetylrifapentine, and sulfamethizole. It's worth noting here that dulaglutide, even though its efficacy is decreased by estetrol, interestingly, is found to increase the efficacy of sulfamethizole, illustrating the complex interactions and pathways among these compounds."", ""The drug estetrol has been observed to potentially decrease the efficacy of several other substances. Specifically, its use could lessen the effectiveness of obeticholic acid, dulaglutide, 25-desacetylrifapentine, and sulfamethizole. Interestingly, dulaglutide itself can actually increase the efficacy of sulfamethizole. This underlines the complex nature of drug interactions, as one substance's effect can vary depending on what else it is administrated with."", 'The hormone Estetrol has been found to decrease the efficacy of several medications, including Obeticholic Acid, Dulaglutide, 25-Desacetylrifapentine, and Sulfamethizole. Interesting to note is that Dulaglutide, whose efficacy gets impacted negatively by Estetrol, paradoxically increases the efficacy of Sulfamethizole.', 'The drug estetrol holds the potential to decrease the efficacy of several other drugs, such as obeticholic acid, dulaglutide, 25-desacetylrifapentine, and sulfamethizole. This suggests that patients taking these drugs should avoid concurrent administration of estetrol to prevent potential treatment complications. Interestingly, while estetrol can reduce its effectiveness, dulaglutide may actually increase the efficacy of sulfamethizole. This beneficial interaction might be used to enhance treatment results when dulaglutide and sulfamethizole are administered in combination.']"
"[{'source_node': {'name': ""bis(adenosine)-5'-pentaphosphate""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'adenylate kinase 8'}}, {'source_node': {'name': ""bis(adenosine)-5'-pentaphosphate""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'purinergic receptor p2y1'}}]","[{'source_node': {'name': ""bis(adenosine)-5'-pentaphosphate""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'adenylate kinase 8'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:6070', 'target': None, 'metadata': {'node_id': '6070', 'node_type': 'PROTEIN', 'display_name': 'purinergic receptor p2y1'}}]",0.6,25920b6da985a88ef2b24fb6d918c876,8c1e4f767d5e28638d32bcaaf9f45c02,"[""The compound bis(adenosine)-5'-pentaphosphate has several targets, among which are adenylate kinase 8 and the purinergic receptor p2y1."", ""The compound bis(adenosine)-5'-pentaphosphate has been identified to target both the enzyme adenylate kinase 8 and the purinergic receptor p2y1."", ""The compound bis(adenosine)-5'-pentaphosphate has two known targets. Firstly, it targets adenylate kinase 8, an important enzyme involved in energy metabolism. Furthermore, it also targets the purinergic receptor p2y1, which plays a key role in numerous cellular functions."", ""The compound bis(adenosine)-5'-pentaphosphate is known to target both adenylate kinase 8 and the purinergic receptor p2y1. These targets can be found across several cellular pathways and are crucial to numerous cell signaling processes."", ""The compound Bis(adenosine)-5'-pentaphosphate is known to target both Adenylate Kinase 8 and the Purinergic Receptor P2Y1.""]","[""The compound bis(adenosine)-5'-pentaphosphate has a target interaction with adenylate kinase 8."", ""The compound bis(adenosine)-5'-pentaphosphate has adenylate kinase 8 as its target."", ""The compound bis(adenosine)-5'-pentaphosphate targets adenylate kinase 8."", ""The compound bis(adenosine)-5'-pentaphosphate has adenylate kinase 8 as its target.""]"
"[{'source_node': {'name': 'TAP1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'bare lymphocyte syndrome'}}, {'source_node': {'name': 'TAP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'ER-Phagosome pathway'}}, {'source_node': {'name': 'bare lymphocyte syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'recurrent lower respiratory tract infections'}}, {'source_node': {'name': 'bare lymphocyte syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'failure to thrive'}}, {'source_node': {'name': 'bare lymphocyte syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormal facial shape'}}]","[{'source_node': {'name': 'bare lymphocyte syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'recurrent lower respiratory tract infections'}}, {'source_node': {'name': 'bare lymphocyte syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'failure to thrive'}}]","[{'type': 'edge_deletion', 'source': 'GENE:33152', 'target': 'DISEASE:6818', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:33152', 'target': None, 'metadata': {'node_id': '33152', 'node_type': 'GENE', 'display_name': 'TAP1'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:1463', 'target': None, 'metadata': {'node_id': '1463', 'node_type': 'PHENOTYPE', 'display_name': 'abnormal facial shape'}}]",0.4545454545454546,aba2ef92754f1218485ecb2d7513cfc8,9d78902c53c792ad06f58eaa507eb2f4,"['The gene TAP1, which acts within the ER-Phagosome pathway, is known to cause a condition known as bare lymphocyte syndrome. This particular syndrome is characterized by numerous phenotypes, including a failure to thrive, recurrent lower respiratory tract infections, and an abnormal facial shape.', 'The gene TAP1, integral to the ER-Phagosome pathway, is implicated in causing a rare genetic disorder known as bare lymphocyte syndrome. This syndrome is characterized by several phenotypic presentations including recurrent lower respiratory tract infections, failure to thrive, and an abnormal facial shape.', 'The gene TAP1, which functions within the ER-Phagosome pathway, causes a condition known as bare lymphocyte syndrome. This syndrome is identified by a variety of phenotypes, including recurrent lower respiratory tract infections, failure to thrive, as well as an abnormal facial shape.', 'The gene TAP1, which plays a pivotal role within the ER-Phagosome pathway, is known to cause a condition called bare lymphocyte syndrome. Bare lymphocyte syndrome exhibits several phenotypes, including recurrent lower respiratory tract infections, failure to thrive, and an abnormal facial shape.', 'The gene TAP1, which is involved in the ER-Phagosome pathway, has been identified as a cause of bare lymphocyte syndrome. This syndrome comes with various phenotypes including an abnormal facial shape, failure to thrive, and recurrent lower respiratory tract infections.']","['Bare lymphocyte syndrome, a medical condition, manifests phenotypes such as recurrent lower respiratory tract infections and failure to thrive.', 'Bare lymphocyte syndrome, a complex medical condition, is characterized by two primary phenotypes: recurrent lower respiratory tract infections and failure to thrive. In individuals with this syndrome, their growth and development is hindered, resulting in the failure to thrive, while their immune system struggles to ward off regular infections especially within the lower respiratory tract.', 'Bare lymphocyte syndrome, a type of disease, often manifests phenotypes like recurrent lower respiratory tract infections and failure to thrive. These symptoms provide key insights into the nature and condition of the disease.', 'Bare lymphocyte syndrome, a medical condition, presents with two significant phenotypes namely recurrent lower respiratory tract infections and failure to thrive.', '""Bare lymphocyte syndrome, a disorder affecting the immune system, manifests several key symptoms including a failure to thrive and recurrent lower respiratory tract infections.']"
"[{'source_node': {'name': 'POLI'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Translesion synthesis by POLI'}}, {'source_node': {'name': 'POLI'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Termination of translesion DNA synthesis'}}, {'source_node': {'name': 'geminin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'GMNN'}}, {'source_node': {'name': '(r)-3-hydroxybutanoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna polymerase iota'}}, {'source_node': {'name': '(r)-3-hydroxybutanoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna polymerase kappa'}}, {'source_node': {'name': '(r)-3-hydroxybutanoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'geminin'}}, {'source_node': {'name': 'dna polymerase kappa'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'POLK'}}, {'source_node': {'name': 'dna polymerase iota'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'POLI'}}]","[{'source_node': {'name': 'POLI'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Translesion synthesis by POLI'}}, {'source_node': {'name': 'POLI'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Termination of translesion DNA synthesis'}}, {'source_node': {'name': '(r)-3-hydroxybutanoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna polymerase iota'}}, {'source_node': {'name': '(r)-3-hydroxybutanoate'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dna polymerase kappa'}}, {'source_node': {'name': '(r)-3-hydroxybutanoate'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'POLI'}}, {'source_node': {'name': 'dna polymerase iota'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'POLI'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:5869', 'target': 'GENE:25358', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:42888', 'target': 'PROTEIN:5869', 'metadata': None}, {'type': 'node_removal', 'source': 'PROTEIN:5869', 'target': None, 'metadata': {'node_id': '5869', 'node_type': 'PROTEIN', 'display_name': 'geminin'}}, {'type': 'edge_addition', 'source': 'GENE:30739', 'target': 'PATHWAY:806', 'metadata': {'predicate': 'acts_within'}}, {'type': 'node_removal', 'source': 'GENE:30739', 'target': None, 'metadata': {'node_id': '30739', 'node_type': 'GENE', 'display_name': 'POLK'}}, {'type': 'edge_addition', 'source': 'COMPOUND:42888', 'target': 'GENE:25358', 'metadata': {'predicate': 'is_affecting'}}]",0.5882352941176471,a22fe3097807b3e5f5f84d0f607b1c2d,0add3fe61a51b77b3f393f7043e408a3,"['The gene POLI actively participates within diverse biological pathways, specifically the pathway of translesion synthesis by POLI, and the termination of translesion DNA synthesis. This gene is the source of the protein dna polymerase iota. Another protein, geminin, is also considered in this context. It is a gene product of GMNN and constitutes a target for the compound (r)-3-hydroxybutanoate. \nSimilarly, the compound acts upon two more targets: dna polymerase iota and dna polymerase kappa. The latter proteins are gene products of the POLI and POLK genes, respectively.', 'The POLI gene acts within two key pathways: the translesion synthesis by POLI and termination of translesion DNA synthesis. Geminin is a gene product of GMNN and is targeted by the molecule (r)-3-hydroxybutanoate. Importantly, (r)-3-hydroxybutanoate also targets DNA polymerase iota and DNA polymerase kappa. DNA polymerase iota and DNA polymerase kappa are gene products of POLI and POLK, respectively. Thus, POLI not only forms a crucial part of DNA synthesis but also links with other genes and molecules for essential biological activities.', 'The gene POLI acts within different pathways, such as the pathway for translesion synthesis by POLI and the pathway for termination of translesion DNA synthesis. Geminin is a gene product of GMNN. The compound (r)-3-hydroxybutanoate has multiple targets including DNA polymerase iota, DNA polymerase kappa, and geminin. DNA polymerase kappa is a gene product of POLK, and DNA polymerase iota is a gene product of POLI.']",[]
"[{'source_node': {'name': 'glutathione s-transferase pi 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'ovarian neoplasms'}}, {'source_node': {'name': 'glutathione s-transferase pi 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'osteosarcoma'}}]","[{'source_node': {'name': 'glutathione s-transferase pi 1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'osteosarcoma'}}]","[{'type': 'node_removal', 'source': 'DISEASE:2379', 'target': None, 'metadata': {'node_id': '2379', 'node_type': 'DISEASE', 'display_name': 'ovarian neoplasms'}}]",0.6,a87a89bc1c35295a0edb10889cee821a,b463fe1b886dedad1959a1be5240171b,"['The enzyme glutathione s-transferase pi 1 is known to cause certain medical conditions, including ovarian neoplasms and osteosarcoma.', 'The glutathione s-transferase pi 1, an enzyme involved in cellular detoxification, is associated with the causation of several conditions such as ovarian neoplasms and osteosarcoma.', 'The protein glutathione S-transferase pi 1 is associated with certain conditions as it can cause both ovarian neoplasms and osteosarcoma.', 'The protein known as glutathione S-transferase pi 1 is implicated in causing several conditions, particularly ovarian neoplasms and osteosarcoma.', 'The enzyme glutathione S-transferase pi 1 has been associated with causing several conditions, notably ovarian neoplasms and osteosarcoma.']",[]
"[{'source_node': {'name': 'pitt-hopkins-like syndrome 2'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'broad-based gait'}}, {'source_node': {'name': 'NRXN1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pitt-hopkins-like syndrome 2'}}, {'source_node': {'name': 'NRXN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Non-integrin membrane-ECM interactions'}}, {'source_node': {'name': 'NRXN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neurexins and neuroligins'}}]","[{'source_node': {'name': 'NRXN1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pitt-hopkins-like syndrome 2'}}, {'source_node': {'name': 'NRXN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neurexins and neuroligins'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1568', 'target': None, 'metadata': {'node_id': '1568', 'node_type': 'PHENOTYPE', 'display_name': 'broad-based gait'}}, {'type': 'node_removal', 'source': 'PATHWAY:564', 'target': None, 'metadata': {'node_id': '564', 'node_type': 'PATHWAY', 'display_name': 'Non-integrin membrane-ECM interactions'}}]",0.5555555555555556,7e7bd9412018d1c23dcff092134b5ac2,c0ba723e16c2ebb2117bb4cb27b6aa7e,"[""The gene NRXN1 plays a significant role in several pathways, most notably, Non-integrin membrane-ECM interactions, and Neurexins and neuroligins. This gene's effects cause a condition known as Pitt-Hopkins-like syndrome 2, a disorder characterized by several symptoms, including a broad-based gait."", 'The gene NRXN1, which is active within two main processes: Non-integrin membrane-ECM interactions and Neurexins and neuroligins, is responsible for causing a condition known as Pitt-Hopkins-like syndrome 2. This syndrome is characterized by certain noticeable phenotypes, one of which includes a broad-based gait.', 'The NRXN1 gene is known to act within two pathways: the non-integrin membrane-ECM interactions pathway and the Neurexins and neuroligins pathway. This gene is also associated with causing a condition known as Pitt-Hopkins-like syndrome 2. One of the notable phenotypes of Pitt-Hopkins-like syndrome 2 is a broad-based gait.', 'The gene NRXN1 is involved in the mechanism of the Non-integrin membrane-ECM interactions and also in the interactions of Neurexins and Neuroligins. This gene causes a condition known as Pitt-Hopkins-like syndrome 2, which manifests a prominent phenotype characterized by a broad-based gait.', 'The gene NRXN1, which acts within the pathways of non-integrin membrane-ECM interactions and Neurexins and neuroligins, is known to cause a condition known as Pitt-Hopkins-like syndrome 2. This syndrome is characterised by distinctive phenotypes including a broad-based gait among other symptoms.']","['The gene NRXN1, known to cause Pitt-Hopkins-like syndrome 2, operates within the pathway of neurexins and neuroligins.', 'The gene NRXN1, which acts within the pathway of neurexins and neuroligins, is known to cause a condition known as Pitt-Hopkins-like syndrome 2.']"
"[{'source_node': {'name': 'neurodevelopmental disorder with gait disturbance'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypermetropia'}}, {'source_node': {'name': 'neurodevelopmental disorder with gait disturbance'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'developmental regression'}}, {'source_node': {'name': 'neurodevelopmental disorder with gait disturbance'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ankle clonus'}}]","[{'source_node': {'name': 'neurodevelopmental disorder with gait disturbance'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'ankle clonus'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:414', 'target': None, 'metadata': {'node_id': '414', 'node_type': 'PHENOTYPE', 'display_name': 'hypermetropia'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:1743', 'target': None, 'metadata': {'node_id': '1743', 'node_type': 'PHENOTYPE', 'display_name': 'developmental regression'}}]",0.4285714285714286,17a13b1c443e7de49402f18fcc9494b8,3db8f69e870bbe353126f3f66f208aa4,"['The neurodevelopmental disorder with gait disturbance manifests various phenotypes including hypermetropia, developmental regression, and ankle clonus.', 'Neurodevelopmental disorder with gait disturbance exhibits several phenotypes, including hypermetropia, developmental regression, and ankle clonus. These are characteristic symptoms observed in patients diagnosed with this disorder.']",[]
"[{'source_node': {'name': 'hydroxychloroquine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Abdominal cramps'}}, {'source_node': {'name': 'dapagliflozin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'temafloxacin'}}, {'source_node': {'name': 'dapagliflozin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'hydroxychloroquine'}}, {'source_node': {'name': 'dapagliflozin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'sulfaquinoxaline'}}]","[{'source_node': {'name': 'dapagliflozin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'hydroxychloroquine'}}, {'source_node': {'name': 'dapagliflozin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'sulfaquinoxaline'}}]","[{'type': 'node_removal', 'source': 'SIDE_EFFECT:1', 'target': None, 'metadata': {'node_id': '1', 'node_type': 'SIDE_EFFECT', 'display_name': 'Abdominal cramps'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1539', 'target': 'COMPOUND:1344', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:1344', 'target': None, 'metadata': {'node_id': '1344', 'node_type': 'COMPOUND', 'display_name': 'temafloxacin'}}]",0.5555555555555556,d5c0e042ba2f5946f237795ce4f4c453,ed16cc46700106d56c2d50286d6e729a,"['Hydroxychloroquine is a drug known to cause side effects such as abdominal cramps. Interestingly, the efficacy of hydroxychloroquine, along with two other drugs, temafloxacin and sulfaquinoxaline, can be increased by another drug known as dapagliflozin. Thus, it could be interesting to explore further how dapagliflozin might potentially affect the occurrence of these side effects.', 'The drug Hydroxychloroquine, is known to have the side effect of causing abdominal cramps in some patients. Interestingly, the use of the drug Dapagliflozin has been shown to increase the efficacy of several other drugs including Temafloxacin, Hydroxychloroquine, and Sulfaquinoxaline. This potentially implies that Dapagliflozin could enhance the therapeutic effectiveness of these medications, although consequent side-effects such as abdominal cramps from Hydroxychloroquine need to be taken into consideration.', 'The medication Hydroxychloroquine has been known to cause side effects like abdominal cramps. On the other hand, the drug called Dapagliflozin has been shown to enhance the efficacy of several other medications. Specifically, Dapagliflozin increases the efficacy of Temafloxacin, Hydroxychloroquine, and Sulfaquinoxaline. Therefore, the enhanced efficacy of Hydroxychloroquine through Dapagliflozin might be beneficial; however, one should also take into account the potential side effects such as the aforementioned abdominal cramps.']","['The drug dapagliflozin is known to increase the efficacy of both hydroxychloroquine and sulfaquinoxaline.', 'The drug dapagliflozin is known to increase the efficacy of other pharmaceuticals such as hydroxychloroquine and sulfaquinoxaline.', 'Dapagliflozin has been found to increase the efficacy of both hydroxychloroquine and sulfaquinoxaline.', 'The drug Dapagliflozin has been found to increase the efficacy of both Hydroxychloroquine and Sulfaquinoxaline.', 'The drug dapagliflozin has been noted to increase the efficacy of other medicinal agents. Specifically, it is known to enhance the effects of hydroxychloroquine and sulfaquinoxaline. This suggests that dapagliflozin could potentially be used in combination therapies with these drugs for improved outcomes.']"
"[{'source_node': {'name': 'sculponin d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'k562'}}, {'source_node': {'name': 'sculponin d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'sculponin d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepg2'}}]","[{'source_node': {'name': 'sculponin d'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4947', 'target': None, 'metadata': {'node_id': '4947', 'node_type': 'PROTEIN', 'display_name': 'k562'}}, {'type': 'node_removal', 'source': 'PROTEIN:5817', 'target': None, 'metadata': {'node_id': '5817', 'node_type': 'PROTEIN', 'display_name': 'hepg2'}}]",0.4285714285714286,becca257704709102570ae0b06ec1ba3,5da83c1f97fecbde9aff72c166f57703,"['The compound Sculponin D has several notable biological targets. These include K562, a human immature myeloblast cell line, commonly used in leukaemia research. Moreover, Sculponin D also targets A549, a carcinoma cell line which is notably resistant to drugs and radiation, and HepG2, a cell line used extensively to study drug metabolism and liver disease.', 'The drug Sculponin D has multiple targets, including K562, A549, and HepG2 which are types of cancer cell lines.', 'The compound Sculponin D has several targets including the cancer cell lines K562, A549, and HepG2.', 'The compound Sculponin D is known to target K562, A549, and HepG2 cells.', 'The compound sculponin d has several targets including K562, A549, and HepG2 cell lines.']",['The drug Sculponin D has the cellular A549 as its target.']
"[{'source_node': {'name': 'F2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pregnancy loss'}}, {'source_node': {'name': 'F2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Peptide ligand-binding receptors'}}, {'source_node': {'name': 'F2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Defective F8 cleavage by thrombin'}}, {'source_node': {'name': 'prothrombin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'F2'}}, {'source_node': {'name': 'cochinchinenin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prothrombin'}}, {'source_node': {'name': 'cochinchinenin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dipeptidyl peptidase 4'}}, {'source_node': {'name': 'dipeptidyl peptidase 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DPP4'}}]","[{'source_node': {'name': 'F2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pregnancy loss'}}, {'source_node': {'name': 'F2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Defective F8 cleavage by thrombin'}}, {'source_node': {'name': 'prothrombin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DPP4'}}, {'source_node': {'name': 'DPP4'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Defective F8 cleavage by thrombin'}}, {'source_node': {'name': 'cochinchinenin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prothrombin'}}, {'source_node': {'name': 'cochinchinenin b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dipeptidyl peptidase 4'}}, {'source_node': {'name': 'dipeptidyl peptidase 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DPP4'}}]","[{'type': 'edge_addition', 'source': 'GENE:26567', 'target': 'PATHWAY:1440', 'metadata': {'predicate': 'acts_within'}}, {'type': 'node_removal', 'source': 'PATHWAY:253', 'target': None, 'metadata': {'node_id': '253', 'node_type': 'PATHWAY', 'display_name': 'Peptide ligand-binding receptors'}}, {'type': 'edge_addition', 'source': 'PROTEIN:1', 'target': 'GENE:26567', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'PROTEIN:1', 'target': 'GENE:26852', 'metadata': None}]",0.6666666666666667,409fd6507cb60c6a0c31666e0a366b83,b3130dbeddf2d3bb551fba72cc9daaf7,"['The drug cochinchinenin b targets both prothrombin and dipeptidyl peptidase 4. Prothrombin is a gene product of F2, and dipeptidyl peptidase 4 is a gene product of DPP4. The gene F2 is active within both peptide ligand-binding receptors and within the process of defective F8 cleavage by thrombin. Importantly, F2 is known to cause pregnancy loss.', 'The drug Cochinchinenin B targets both Prothrombin and Dipeptidyl Peptidase 4. Interestingly, both these targets have gene origins. Prothrombin is a gene product of F2, which also acts within the Peptide ligand-binding receptors and the defective F8 cleavage by thrombin pathways. Likewise, Dipeptidyl Peptidase 4 is a gene product of DPP4. Notably, F2 is known to cause a condition termed pregnancy loss.', 'The gene F2, which is known to cause pregnancy loss, acts within several pathways, namely the peptide ligand-binding receptors and defective F8 cleavage by thrombin. This gene is responsible for producing prothrombin, a key player in the clotting process. The drug cochinchinenin b targets prothrombin, affecting its functionality. Interestingly, cochinchinenin b also targets dipeptidyl peptidase 4, a protein which is the gene product of DPP4. In this complex interaction network, we see how drugs, proteins, and genes are intricately linked and can influence a variety of physiological conditions.']",[]
"[{'source_node': {'name': 'albusomatropin'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hypoglycemic activities '}}, {'source_node': {'name': 'albusomatropin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'macimorelin'}}, {'source_node': {'name': 'macimorelin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pirenzepine'}}, {'source_node': {'name': 'macimorelin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluticasone furoate'}}, {'source_node': {'name': 'macimorelin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'revefenacin'}}]","[{'source_node': {'name': 'albusomatropin'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the hypoglycemic activities '}}, {'source_node': {'name': 'albusomatropin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'macimorelin'}}, {'source_node': {'name': 'albusomatropin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pirenzepine'}}, {'source_node': {'name': 'macimorelin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pirenzepine'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:9770', 'target': None, 'metadata': {'node_id': '9770', 'node_type': 'COMPOUND', 'display_name': 'revefenacin'}}, {'type': 'edge_addition', 'source': 'COMPOUND:10823', 'target': 'COMPOUND:655', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'node_removal', 'source': 'COMPOUND:7858', 'target': None, 'metadata': {'node_id': '7858', 'node_type': 'COMPOUND', 'display_name': 'fluticasone furoate'}}]",0.5454545454545454,11aaf0edfa34b6d5f94f9af9c19b46b8,46ec782f757a3d90525bb8faaf39dc50,[],[]
"[{'source_node': {'name': 'telomerase reverse transcriptase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TERT'}}, {'source_node': {'name': 'gamma-rubromycin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'telomerase reverse transcriptase'}}, {'source_node': {'name': 'gamma-rubromycin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'gamma-rubromycin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'pc-3'}}, {'source_node': {'name': 'TERT'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'pulmonary fibrosis and/or bone marrow failure'}}, {'source_node': {'name': 'TERT'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'meningioma'}}]","[{'source_node': {'name': 'telomerase reverse transcriptase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TERT'}}, {'source_node': {'name': 'gamma-rubromycin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'telomerase reverse transcriptase'}}, {'source_node': {'name': 'gamma-rubromycin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'gamma-rubromycin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'pc-3'}}, {'source_node': {'name': 'TERT'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'meningioma'}}]","[{'type': 'node_removal', 'source': 'DISEASE:16415', 'target': None, 'metadata': {'node_id': '16415', 'node_type': 'DISEASE', 'display_name': 'pulmonary fibrosis and/or bone marrow failure'}}]",0.8461538461538461,a8e2c43747f60ad810cb1505e50c7d02,5d8eb92a5c0565573ac55dd1787dc3cf,[],"['Gamma-rubromycin targets several elements including telomerase reverse transcriptase, a549, and pc-3. Telomerase reverse transcriptase is a gene product of TERT, a gene which when mutated can lead to conditions such as meningioma. Thus, the drug Gamma-rubromycin could potentially play a role in the treatment of certain conditions caused by TERT mutations.', 'The drug gamma-rubromycin is known to target several entities, including telomerase reverse transcriptase, a549, and pc-3. Interestingly, telomerase reverse transcriptase is a gene product of TERT. Furthermore, TERT has been implicated in causing the condition known as meningioma.', 'The drug gamma-rubromycin is known to target three entities: telomerase reverse transcriptase, a549, and pc-3. Telomerase reverse transcriptase is a gene product of TERT, which is recognised for causing a condition called meningioma. Thus, gamma-rubromycin is indirectly linked to the cause of meningioma via its target, telomerase reverse transcriptase.', 'Gamma-rubromycin, a pharmaceutical agent, targets several entities including a549 and pc-3 cells, as well as the telomerase reverse transcriptase, which is a gene product of TERT. Interestingly, mutations in the gene TERT are known to cause the condition meningioma, a typically benign type of brain tumor.', 'The drug gamma-rubromycin has multiple targets, including telomerase reverse transcriptase, A549, and PC-3. Telomerase reverse transcriptase is a gene product of TERT, which is implicated in causing a medical condition named meningioma.']"
"[{'source_node': {'name': 'calaspargase pegol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'norethisterone'}}, {'source_node': {'name': 'calaspargase pegol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'norethynodrel'}}, {'source_node': {'name': 'calaspargase pegol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'demegestone'}}]","[{'source_node': {'name': 'calaspargase pegol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'norethynodrel'}}, {'source_node': {'name': 'calaspargase pegol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'demegestone'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:702', 'target': None, 'metadata': {'node_id': '702', 'node_type': 'COMPOUND', 'display_name': 'norethisterone'}}]",0.7142857142857143,2060e40bb2c9c0db78fd91b9d20909b5,5233a7eed3c63321947872994bff5924,"['The drug Calaspargase pegol has been found to decrease the efficacy of multiple hormones including Norethisterone, Norethynodrel, and Demegestone. Therefore, caution should be exercised when administrating Calaspargase pegol alongside these substances.', 'The drug calaspargase pegol has been found to decrease the efficacy of several other pharmaceuticals, including norethisterone, norethynodrel, and demegestone. This is particularly important to consider when prescribing medications, as drug interactions may reduce treatment effectiveness.', 'The drug Calaspargase Pegol has been observed to decrease the efficacy of several other drugs, such as Norethisterone, Norethynodrel, and Demegestone. Therefore, it may be prudent to consider this likelihood if Calaspargase Pegol and any of these other medications are to be administered in combination.', ""The drug Calaspargase pegol has been shown to decrease the efficacy of several other substances. These include Norethisterone and Norethynodrel, both of which are used in hormone therapies, as well as Demegestone, a synthetic progestogen. It's important to understand these interactions in order to avoid potential unintended decrease in efficacy."", 'The drug Calaspargase Pegol is known to decrease the efficacy of several substances. These include Norethisterone and Norethynodrel, both of which are synthetic progestins with some important medical applications, as well as Demegestone, a more potent synthetic progestin. This interaction represents a noteworthy fact to consider in the medical field, especially in treatments combining these compounds.']","['The drug Calaspargase Pegol is known to decrease the efficacy of norethynodrel and demegestone.', 'The drug calaspargase pegol has been observed to decrease the efficacy of certain substances. Specifically, its impact has been noticed on norethynodrel and demegestone. Therefore, it is important to consider the interactions of calaspargase pegol with these compounds while formulating pharmaceutical therapies.', 'The drug calaspargase pegol is known to decrease the efficacy of both norethynodrel and demegestone. Therefore, it is advisable to consider this drug interaction when prescribing these medications.', 'The medication Calaspargase Pegol is known to decrease the efficacy of certain drugs, including Norethynodrel and Demegestone. Therefore, care should be taken when co-administering these substances to ensure optimal health outcomes.', 'The drug calaspargase pegol can potentially decrease the efficacy of both norethynodrel and demegestone. It suggests that when combined, calaspargase pegol might reduce the expected effects of these drugs, resulting in less optimal outcomes.']"
"[{'source_node': {'name': 'diarrhea 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'small for gestational age'}}, {'source_node': {'name': 'diarrhea 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'arthritis'}}]","[{'source_node': {'name': 'diarrhea 5'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'small for gestational age'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1032', 'target': None, 'metadata': {'node_id': '1032', 'node_type': 'PHENOTYPE', 'display_name': 'arthritis'}}]",0.6,4457bcfd5e3f6594d6ef12752ebc8455,46a7dbf34943a4044e1c4eefe58f9f8e,"['The condition Diarrhea 5 is known to have several phenotypes, one of which includes being small for gestational age. Another phenotype associated with this condition is arthritis.']",[]
"[{'source_node': {'name': 'labetalol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'isoprenaline'}}, {'source_node': {'name': 'labetalol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'tulobuterol'}}, {'source_node': {'name': 'labetalol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'balaglitazone'}}, {'source_node': {'name': 'tulobuterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'periciazine'}}, {'source_node': {'name': 'tulobuterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bucindolol'}}, {'source_node': {'name': 'isoprenaline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'thioridazine'}}]","[{'source_node': {'name': 'labetalol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'isoprenaline'}}, {'source_node': {'name': 'labetalol'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'balaglitazone'}}, {'source_node': {'name': 'tulobuterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'periciazine'}}, {'source_node': {'name': 'tulobuterol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'bucindolol'}}, {'source_node': {'name': 'isoprenaline'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'thioridazine'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:584', 'target': 'COMPOUND:10152', 'metadata': None}]",0.9230769230769232,9dd503436501e7f9126f2391f3b1bde4,c773341bd97a9ab7a9e23cee7048d169,"['The drug labetalol is known to decrease the efficacy of both isoprenaline and tulobuterol, while simultaneously increasing the efficacy of balaglitazone. Interestingly, tulobuterol is also known to decrease the efficacy of both periciazine and bucindolol. Furthermore, isoprenaline is noteworthy for its ability to reduce the efficacy of thioridazine. Therefore, the interactions between these drugs need to be carefully considered during treatment to avoid any unexpected effects or adverse reactions.', 'Labetalol, a pharmaceutical drug, is known to decrease the efficacy of both isoprenaline and tulobuterol. However, it can also increase the efficacy of balaglitazone. On the other hand, tulobuterol, when used, can decrease the efficacy of periciazine and bucindolol. In a similar vein, isoprenaline also has the effect of reducing the efficacy of thioridazine when used together.', 'The drug labetalol is known to decrease the efficacy of isoprenaline and tulobuterol, but interestingly it can also increase the efficacy of balaglitazone. Tulobuterol further decreases the efficacy of periciazine and bucindolol. Lastly, isoprenaline is reported to decrease the efficacy of thioridazine. Therefore, these interactions should be considered when prescribing these medications to avoid potential adverse events or poor therapeutic outcomes.', 'The drug labetalol has a therapeutic complex, as it decreases the efficacy of other drugs such as isoprenaline and tulobuterol, while it increases the efficacy of balaglitazone. Interestingly, tulobuterol, whose efficacy is decreased by labetalol, further decreases the efficacy of periciazine and bucindolol. Furthermore, isoprenaline, another drug whose efficacy is decreased by labetalol, is known to reduce the efficacy of thioridazine. It is crucial to take into account these interactions when using these drugs for therapeutic purposes to avoid unforeseen consequences.', 'The drug labetalol decreases the efficacy of both isoprenaline and tulobuterol while increasing the efficacy of balaglitazone. Additionally, tulobuterol also decreases the efficacy of periciazine and bucindolol. Interestingly, the efficacy of thioridazine is reduced when it interacts with isoprenaline.']","['The drug labetalol is known for its dual functionality where it decreases the efficacy of the drug isoprenaline while increasing the efficacy of another drug balaglitazone. On the other hand, tulobuterol has a different effect on drugs; it decreases the efficacy of periciazine and bucindolol. In a different chain of drug interactions, isoprenaline decreases the efficacy of thioridazine. Such interplay among these drugs can significantly influence treatment outcomes and require careful assessment in pharmaceutical planning.', 'The drug labetalol is known to influence the efficacy of other drugs: it decreases the efficacy of isoprenaline but increases the efficacy of balaglitazone. Similarly, tulobuterol, another drug, also modulates the efficacy of some drugs, causing a decrease in the efficacy of both periciazine and bucindolol. Interestingly, isoprenaline, which has its efficacy reduced by labetalol, also decreases the efficacy of another drug called thioridazine.', 'The drug labetalol is known to increase the efficacy of balaglitazone, but conversely decrease the efficacy of isoprenaline. Similarly, the drug tulobuterol decreases the efficacy of both periciazine and bucindolol. Furthermore, the efficacy of thioridazine is decreased by isoprenaline.', 'The drug labetalol is known to decrease the efficacy of isoprenaline, indicating that patients taking isoprenaline might see a reduction in its effects if labetalol is also being administered. Interestingly, labetalol also increases the efficacy of balaglitazone, suggesting a potential synergistic effect when these two medications are taken together. On the other hand, the drug tulobuterol is reported to decrease the efficacy of both periciazine and bucindolol, which might have implications on their combined use in therapeutic settings. Similarly, isoprenaline, the drug that is affected by labetalol, is also noted to decrease the efficacy of thioridazine. This intertwined network of drug interactions highlights the importance of understanding comprehensive drug-drug relationships when considering combination therapies.', 'The drug labetalol has the dual effect of reducing the efficacy of isoprenaline while increasing the efficacy of balaglitazone. Another drug, tulobuterol, exhibits similar behavior as it decreases the efficacy of both periciazine and bucindolol. Interestingly, isoprenaline, whose effectiveness is diminished by labetalol, is also shown to decrease the efficacy of thioridazine.']"
"[{'source_node': {'name': 'salsalate'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the neuroexcitatory activities '}}, {'source_node': {'name': 'salsalate'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' nephrotoxicity '}}, {'source_node': {'name': 'salsalate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sulfasalazine'}}, {'source_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'beta-thalassemia'}}, {'source_node': {'name': 'debrisoquine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'salsalate'}}, {'source_node': {'name': 'debrisoquine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'parecoxib'}}, {'source_node': {'name': 'debrisoquine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}}]","[{'source_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'beta-thalassemia'}}, {'source_node': {'name': 'debrisoquine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'parecoxib'}}, {'source_node': {'name': 'debrisoquine'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'cytochrome p450 family 2 subfamily d member 6'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:4556', 'target': 'COMPOUND:1339', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:1339', 'target': None, 'metadata': {'node_id': '1339', 'node_type': 'COMPOUND', 'display_name': 'salsalate'}}]",0.4666666666666667,b3afc19f2dcde6c658e8d32e793d52b0,810b8ce1b05289045ece890f0e006509,[],"['The gene known as cytochrome p450 family 2 subfamily d member 6 has been found to cause beta-thalassemia, a severe hereditary blood disorder. In addition, this gene is affected by the drug debrisoquine, which interestingly also decreases the efficacy of parecoxib, a nonsteroidal anti-inflammatory drug used for pain management. Therefore, there is a complex interplay between these entities, bringing in aspects of drug efficacy, disease causation, and pharmacogenomics.', ""The gene known as cytochrome p450 family 2 subfamily d member 6 is known to cause a condition known as beta-thalassemia. This gene's function is affected by a compound called debrisoquine. Furthermore, debrisoquine is also known to decrease the efficacy of a drug known as parecoxib."", ""The enzyme cytochrome P450 family 2 subfamily D member 6 is known to cause a genetic condition known as beta-thalassemia. Debrisoquine, a drug, has been found to affect the function of this enzyme. Further, it's also associated with decreased efficacy of parecoxib, another type of medication."", 'The gene known as Cytochrome P450 family 2 subfamily D member 6, has been associated with causing the condition beta-thalassemia. In related research, it has also been found that the drug Debrisoquine affects the function of this Cytochrome P450 enzyme. Interestingly, Debrisoquine has also been noted to decrease the efficacy of another drug, Parecoxib. These interwoven relations remind us of the complexity of drug interaction and pharmacogenomics.', 'The drug debrisoquine both affects the cytochrome p450 family 2 subfamily d member 6 and decreases the efficacy of parecoxib. Alarmingly, the aforementioned cytochrome p450 has been identified as a cause of the genetic disorder beta-thalassemia.']"
"[{'source_node': {'name': 'sessiloside'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'pancreatic triacylglycerol lipase'}}, {'source_node': {'name': 'pancreatic triacylglycerol lipase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PNLIP'}}]","[{'source_node': {'name': 'sessiloside'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'pancreatic triacylglycerol lipase'}}]","[{'type': 'node_removal', 'source': 'GENE:31081', 'target': None, 'metadata': {'node_id': '31081', 'node_type': 'GENE', 'display_name': 'PNLIP'}}]",0.6,f11d317c697d4a79949646170aa5e8ee,a725d239f7f812f2dff8684c04091ff3,"['The compound sessiloside has pancreatic triacylglycerol lipase as its target. This pancreatic triacylglycerol lipase, interestingly, is the gene product of PNLIP.', 'The compound sessiloside has as its target the pancreatic triacylglycerol lipase enzyme. This enzyme is a gene product of the PNLIP gene.', 'The compound sessiloside has a target interaction with pancreatic triacylglycerol lipase. This lipase is a gene product of PNLIP.', 'The bioactive compound sessiloside is known to target pancreatic triacylglycerol lipase. This specific lipase is a gene product of the gene PNLIP.', 'The compound sessiloside has been identified as having a target, which is the pancreatic triacylglycerol lipase. Notably, this pancreatic triacylglycerol lipase is the gene product of PNLIP.']",[]
"[{'source_node': {'name': 'oltipraz'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' Thrombosis '}}, {'source_node': {'name': 'oltipraz'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' methemoglobinemia '}}]","[{'source_node': {'name': 'oltipraz'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' Thrombosis '}}]","[{'type': 'node_removal', 'source': 'EFFECT:8', 'target': None, 'metadata': {'node_id': '8', 'node_type': 'EFFECT', 'display_name': ' methemoglobinemia '}}]",0.6,5593b46866ed29a4843685482a913170,2af8ad7bd45794586a8edf61d78370dd,[],[]
"[{'source_node': {'name': 'trabectedin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rotavirus vaccine'}}, {'source_node': {'name': 'trabectedin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'astrazeneca covid-19 vaccine'}}]","[{'source_node': {'name': 'trabectedin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'rotavirus vaccine'}}, {'source_node': {'name': 'trabectedin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'astrazeneca covid-19 vaccine'}}, {'source_node': {'name': 'rotavirus vaccine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'trabectedin'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:8397', 'target': 'COMPOUND:4787', 'metadata': {'predicate': 'increase_efficacy'}}]",0.8,93ca351f9c36929ef6cb0f58b2a2c076,38359a878f368f98d253efeecf37003d,"['The drug Trabectedin is known to decrease the efficacy of multiple vaccines such as the Rotavirus vaccine and the AstraZeneca Covid-19 vaccine. This interplay between Trabectedin and vaccinations is an important consideration in medical and pharmaceutical practices.', 'The drug Trabectedin has been found to decrease the efficacy of some vaccines. Specifically, studies have shown it lessens the effectiveness of both the Rotavirus vaccine and the AstraZeneca COVID-19 vaccine.', 'The drug Trabectedin has been shown to decrease the efficacy of several vaccines, including the Rotavirus vaccine and the AstraZeneca COVID-19 vaccine.', 'The drug Trabectedin has been found to decrease the efficacy of several vaccines such as the Rotavirus vaccine and the AstraZeneca Covid-19 vaccine.', 'The drug Trabectedin decreases the efficacy of certain vaccines. Specifically, it has an effect on the rotavirus vaccine as well as the AstraZeneca Covid-19 vaccine. This decrease in efficacy highlights the importance of considering drug interactions when prescribing vaccines.']","['The drug Trabectedin has been found to decrease the efficacy of both the Rotavirus vaccine and the AstraZeneca Covid-19 vaccine. Interestingly, the efficacy of Trabectedin itself is increased by the Rotavirus vaccine.', 'The drug Trabectedin is known to decrease the efficacy of both the Rotavirus vaccine and the AstraZeneca Covid-19 vaccine. Interestingly, it was also found that the Rotavirus vaccine could increase the efficacy of Trabectedin. This points to a complex interplay between drug and vaccine efficacy.', 'The drug Trabectedin has been found to decrease the efficacy of both the Rotavirus vaccine and the AstraZeneca Covid-19 vaccine. Conversely, the Rotavirus vaccine seems to boost the efficacy of Trabectedin. This unexpected interaction suggests a complex relationship between these drugs and vaccines that merits further investigation.', 'Trabectedin is known to decrease the efficacy of both the Rotavirus vaccine and the AstraZeneca COVID-19 vaccine. Interestingly, the Rotavirus vaccine is reported to increase the efficacy of Trabectedin, suggesting a complex relationship between these therapeutics.', 'The drug trabectedin has been found to decrease the efficacy of both the rotavirus vaccine and the AstraZeneca COVID-19 vaccine. Conversely, the rotavirus vaccine has been shown to increase the efficacy of trabectedin.']"
"[{'source_node': {'name': 'varicella zoster vaccine (recombinant)'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nilotinib'}}, {'source_node': {'name': 'varicella zoster vaccine (recombinant)'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluclorolone'}}, {'source_node': {'name': 'estramustine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'varicella zoster vaccine (recombinant)'}}, {'source_node': {'name': 'estramustine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vaccine'}}, {'source_node': {'name': 'estramustine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Leukopenia'}}, {'source_node': {'name': 'typhoid vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hetacillin'}}, {'source_node': {'name': 'typhoid vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'teprotumumab'}}, {'source_node': {'name': 'typhoid vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'enrofloxacin'}}]","[{'source_node': {'name': 'varicella zoster vaccine (recombinant)'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nilotinib'}}, {'source_node': {'name': 'varicella zoster vaccine (recombinant)'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fluclorolone'}}, {'source_node': {'name': 'typhoid vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hetacillin'}}, {'source_node': {'name': 'typhoid vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'teprotumumab'}}, {'source_node': {'name': 'typhoid vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'enrofloxacin'}}, {'source_node': {'name': 'nilotinib'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'enrofloxacin'}}, {'source_node': {'name': 'teprotumumab'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'typhoid vaccine'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:1176', 'target': None, 'metadata': {'node_id': '1176', 'node_type': 'COMPOUND', 'display_name': 'estramustine'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5542', 'target': 'COMPOUND:11858', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:4584', 'target': 'COMPOUND:9370', 'metadata': {'predicate': 'increase_efficacy'}}]",0.5882352941176471,8dec2cef38007a5a31c1ed92c7b66696,ba403332437b53a0349a9e63fb1a1d33,"['The varicella zoster vaccine (recombinant) is known to decrease the efficacy of certain drugs, such as nilotinib and fluclorolone. Conversely, the drug estramustine can also decrease the efficacy of vaccines such as varicella zoster vaccine (recombinant) and typhoid vaccine. In addition to this, estramustine poses the side effect of inducing Leukopenia. Similarly, typhoid vaccines, too, can decrease the efficacy of specific medications including hetacillin, teprotumumab and enrofloxacin. This interconnected nature of effects and interactions signifies the complexity of biological systems and the careful considerations that need to be made in drug and vaccine administration.', 'The efficacy of certain drugs is known to be decreased by the interaction with specific vaccines. Notably, the varicella zoster vaccine (recombinant) decreases the efficacy of nilotinib and fluclorolone. Similarly, the efficacy of the varicella zoster vaccine (recombinant) is also reduced when in combination with estramustine. \n\nEstramustine is also known to decrease the effectiveness of the typhoid vaccine. On a separate note, estramustine has been associated with the side effect of Leukopenia, a condition characterized by a decrease in the number of white blood cells. \n\nThe typhoid vaccine, in addition to interacting with estramustine, has its efficacy diminished when combined with hetacillin, teprotumumab, and enrofloxacin. These interactions can drastically affect the effectiveness of these drugs and vaccines. Health professionals and patients should be aware of these interactions for optimal therapeutic results.']","['The varicella zoster vaccine (recombinant) decreases the efficacy of nilotinib and fluclorolone treatment. In contrast, nilotinib when introduced, increases the efficacy of the drug enrofloxacin. On the other hand, the typhoid vaccine also reduces the efficacy of hetacillin, teprotumumab, and enrofloxacin treatments. Interestingly, teprotumumab appears to increase the efficacy of the typhoid vaccine. Thus, the interactions and effectiveness of these vaccines and drugs are interconnected and can vary depending on the given combinations.', 'The varicella zoster vaccine (recombinant) has been observed to decrease the efficacy of certain drugs like nilotinib and fluclorolone. Similarly, the typhoid vaccine also has an impact on drug efficacy. It decreases the efficacy of hetacillin, teprotumumab, and enrofloxacin. Interestingly, the interaction is not only one-way. For instance, nilotinib is known to increase the efficacy of enrofloxacin and teprotumumab also increases the efficacy of the typhoid vaccine. These interactions underline the complex interplay between vaccines and drugs, which influence their respective efficacies.', ""The efficacy of certain vaccines and drugs can be influenced by the presence of other substances. For instance, the varicella zoster vaccine (recombinant) demonstrated a decrease in efficacy when combined with the drugs nilotinib and fluclorolone. Likewise, the efficacy of the typhoid vaccine was observed to decrease when administered with hetacillin, teprotumumab, and enrofloxacin.\n\nHowever, it's important to note that drug interactions may also lead to an increase in efficacy. In the case of nilotinib, it was shown to actually increase the efficacy of enrofloxacin, and similarly, the efficacy of the typhoid vaccine was seen to improve in the presence of teprotumumab. These findings underscore the complex relationships that exist in drug and vaccine interactions."", 'The use of the varicella zoster vaccine (recombinant) is found to decrease the efficacy of two drugs: nilotinib and fluclorolone. Similarly, the typhoid vaccine also exhibits efficacy issues. It is known to decrease the efficacy of three other drugs: hetacillin, teprotumumab, and enrofloxacin. Interestingly, nilotinib, which has its efficacy decreased by the varicella zoster vaccine (recombinant), is known to increase the efficacy of enrofloxacin, a drug whose efficacy is decreased by the typhoid vaccine. Furthermore, teprotumumab, another drug with decreased efficacy when combined with the typhoid vaccine, is shown to increase the efficacy of the typhoid vaccine itself.', ""The varicella zoster vaccine (recombinant) has been found to decrease the efficacy of certain drugs, including nilotinib and fluclorolone, suggesting that there may be interactions to consider in a clinical context. Similarly, the typhoid vaccine is reported to decrease the efficacy of hetacillin, teprotumumab, and enrofloxacin. However, it's also relevant to note that some drugs, such as nilotinib and teprotumumab, have been found to boost the efficacy of others. In particular, nilotinib can increase the efficacy of enrofloxacin, while teprotumumab strengthens the efficacy of typhoid vaccine. The complex web of interactions between these pharmaceuticals indicates the need for careful management in treatments to ensure optimal outcomes.""]"
"[{'source_node': {'name': ""2-geranyl-2',3,4,4'-tetrahydroxydihyrochalcone""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cathepsin k'}}, {'source_node': {'name': ""2-geranyl-2',3,4,4'-tetrahydroxydihyrochalcone""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'du-145'}}]","[{'source_node': {'name': ""2-geranyl-2',3,4,4'-tetrahydroxydihyrochalcone""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'du-145'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:2041', 'target': None, 'metadata': {'node_id': '2041', 'node_type': 'PROTEIN', 'display_name': 'cathepsin k'}}]",0.6,eab32e67fe920123fcd3cf51def7faf2,6c42b20adddf22541b7ac46ecdc3c7b2,[],[]
"[{'source_node': {'name': 'g17dt'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ibritumomab tiuxetan'}}, {'source_node': {'name': 'g17dt'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'risankizumab'}}, {'source_node': {'name': 'pertussis vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'brequinar'}}, {'source_node': {'name': 'pertussis vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'vedolizumab'}}, {'source_node': {'name': 'pertussis vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'acteoside'}}, {'source_node': {'name': 'interferon alfacon-1'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'g17dt'}}, {'source_node': {'name': 'interferon alfacon-1'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vi polysaccharide vaccine'}}, {'source_node': {'name': 'interferon alfacon-1'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pertussis vaccine'}}]","[{'source_node': {'name': 'g17dt'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ibritumomab tiuxetan'}}, {'source_node': {'name': 'g17dt'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'risankizumab'}}, {'source_node': {'name': 'acteoside'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pertussis vaccine'}}, {'source_node': {'name': 'pertussis vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'brequinar'}}, {'source_node': {'name': 'pertussis vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'vedolizumab'}}, {'source_node': {'name': 'pertussis vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'acteoside'}}, {'source_node': {'name': 'interferon alfacon-1'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'g17dt'}}, {'source_node': {'name': 'interferon alfacon-1'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vi polysaccharide vaccine'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:66', 'target': 'COMPOUND:12857', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:10868', 'target': 'COMPOUND:12857', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.8823529411764706,34db83ad2f37dfd6fd8cc5fc8b8a1eb8,168e32110f9a7e62df854737fe71509d,"['The drug G17DT has been found to decrease the efficacy of other medications including Ibritumomab Tiuxetan and Risankizumab. Similarly, the Pertussis Vaccine has shown to decrease the efficacy of several other compounds, such as Brequinar, Vedolizumab, and Acteoside. Also, Interferon Alfacon-1 has been observed to decrease the efficacy of a variety of substances, including G17DT, the Typhoid VI Polysaccharide Vaccine, and the Pertussis Vaccine. Therefore, careful consideration should be taken when combining these substances in treatment strategies.', 'The efficacy of certain drugs and vaccines can be decreased by the influence of other substances and pharmaceutical products. In particular, G17DT can decrease the efficacy of Ibritumomab Tiuxetan and Risankizumab. Similarly, the Pertussis Vaccine can decrease the efficacy of Brequinar, Vedolizumab, and Acteoside. Moreover, Interferon Alfacon-1 can reduce the efficiency of G17DT, the Typhoid VI Polysaccharide Vaccine, and the Pertussis Vaccine. Therefore, the interaction among these drugs, vaccines, and compounds should be carefully considered in the clinical environment to ensure effective treatment.', 'The compound G17DT has been shown to decrease the efficacy of several agents, including the therapeutic antibody Ibritumomab Tiuxetan and the medicine Risankizumab. Similarly, the Pertussis Vaccine can also significantly lower the effectiveness of other drugs, such as Brequinar, Vedolizumab, and Acteoside. These interactions should be handled with care as they could alter patient outcomes. Moreover, Interferon Alfacon-1, another significant drug, is known to decrease the efficacy of G17DT as well as various vaccines such as the Typhoid Vi Polysaccharide Vaccine and the Pertussis Vaccine. These relationships highlight the importance of careful drug scheduling to avoid potential negative drug-drug interactions, which could hinder treatment effectiveness.', 'The efficacy of several drugs is decreased due to interactions with other substances or medications. The drug G17DT, for instance, is observed to decrease the efficacy of Ibritumomab Tiuxetan and Risankizumab. The Pertussis vaccine, popularly used to combat whooping cough, also shows a decrease in efficacy when exposed to certain substances. It is seen to be less effective in the presence of Brequinar, Vedolizumab, and Acteoside. Finally, Interferon Alfacon-1, a bioengineered product derived from natural alpha interferons, is known to decrease the efficacy of G17DT, Typhoid Vi Polysaccharide Vaccine, and the Pertussis Vaccine. These interactions point towards the importance of monitoring drug-drug interactions to ensure the optimal efficiency of medical treatments.', 'The drug G17DT, an immunotherapeutic device, is known to decrease the efficacy of other drugs including Ibritumomab Tiuxetan, a radiolabelled monoclonal antibody used to treat lymphoma, and Risankizumab, an antibody used to treat psoriasis. A similar drug with the capacity to decrease efficacy is the Pertussis Vaccine, a standard immunization shot for whooping cough. It decreases the efficacy of a broad spectrum of drugs such as Brequinar, used for organ transplant rejection, Vedolizumab, used to treat inflammatory bowel disease, and Acteoside, an anti-inflammatory drug. In a reverse interaction, the efficacy of G17DT as well as the Typhoid vi Polysaccharide Vaccine and previous mentioned Pertussis Vaccine are observed to diminish when Interferon Alfacon-1 is present, a medication used to treat hepatitis C.']","['The drug G17DT has been found to decrease the efficacy of Ibritumomab Tiuxetan and Risankizumab. Similarly, Acteoside, an active compound, is noted for reducing the efficacy of the Pertussis vaccine. Interestingly, the efficacy of Brequinar, Vedolizumab, and Acteoside itself are found to be diminished by the Pertussis vaccine. Furthermore, Interferon Alfacon-1 also decreases the efficacy of G17DT and Typhoid VI Polysaccharide vaccine. This interconnected web of interactions sheds light on potential drug incompatibilities and the complex behavior of these compounds within the human body.', 'The compound G17DT is known to decrease the efficacy of certain medications and treatments, including Ibritumomab Tiuxetan and Risankizumab. Similarly, Acteoside is understood to decrease the efficacy of the Pertussis Vaccine. Noteworthy, Pertussis Vaccine itself can also reduce the efficacy of several other compounds, such as Brequinar, Vedolizumab, and, interestingly, Acteoside. Furthermore, Interferon Alfacon-1 has been shown to decrease the efficacy of G17DT and Typhoid Vi Polysaccharide Vaccine. This interconnected network of interactions highlights the complexity of pharmacological responses and the importance of considering potential interactions when prescribing treatments.', 'The application of certain substances has been found to decrease efficacy in various drugs and vaccines. For instance, G17DT decreases the efficacy of Ibritumomab Tiuxetan and Risankizumab. Similarly, Acteoside reduces the effectiveness of the Pertussis vaccine. Interestingly, the efficacy of Brequinar, Vedolizumab, and Acteoside also decreases when in combination with the Pertussis vaccine. Lastly, Interferon Alfacon-1 lowers the efficacy of both G17DT and the Typhoid VI Polysaccharide Vaccine. These complex interrelationships exhibit the intricate nature of pharmaceutical interactions and their outcomes on drug effectiveness.', 'The drug G17DT is known to decrease efficacy of both Ibritumomab Tiuxetan and Risankizumab. Acteoside, a chemical compound, can have similar effects on the Pertussis Vaccine, resulting in decreased efficacy. Interestingly, the Pertussis Vaccine has also been reported to limit the effectiveness of Brequinar, Vedolizumab and even Acteoside itself. Moreover, Interferon Alfacon-1, a protein often used in the treatment of various diseases, could potentially decrease the efficacy of G17DT and Typhoid Vi Polysaccharide Vaccine. Clearly, these interactions underline the complex interplay between multiple medications and substances that could influence their overall effectiveness.', 'The drug G17DT has been observed to decrease the efficacy of certain treatments such as the drugs Ibritumomab Tiuxetan and Risankizumab. Conversely, the efficacy of G17DT has been found to be decreased by Interferon Alfacon-1. Another interesting interaction to note is with Acteoside, which is reported to decrease the efficacy of Pertussis Vaccine. Moreover, this same vaccine curiously also has a decreasing effect on the efficacy of Acteoside. The Pertussis Vaccine has additional interactions where it decreases efficacy, specifically with the drugs Brequinar and Vedolizumab. Lastly, the efficacy of the Typhoid Vi Polysaccharide Vaccine also appears to be decreased by Interferon Alfacon-1. These complex interactions highlight the precision needed when considering drug interactions and combinations.']"
"[{'source_node': {'name': 'centella asiatica'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oxcarbazepine'}}, {'source_node': {'name': 'centella asiatica'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'doramectin'}}]","[{'source_node': {'name': 'doramectin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'oxcarbazepine'}}, {'source_node': {'name': 'centella asiatica'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'oxcarbazepine'}}, {'source_node': {'name': 'centella asiatica'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'doramectin'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:9368', 'target': 'COMPOUND:760', 'metadata': {'predicate': 'increase_efficacy'}}]",0.8,65a9216f5d57653db86bfcb0600c8f56,6213c1944fbc9b6711d8beeba376afc2,"['The plant Centella Asiatica may decrease the efficacy of certain drugs such as Oxcarbazepine and Doramectin.', 'Centella asiatica, a medicinal herb, lowers the efficacy of treatment drugs such as oxcarbazepine and doramectin. This implies that individuals taking these medications should exercise caution when considering the concurrent usage of centella asiatica.', 'The herbal extract, centella asiatica, is known to decrease the efficacy of certain medications. Specifically, it has a diminishing effect on the drugs oxcarbazepine and doramectin.', 'Centella Asiatica, a medicinal herb, has been known to decrease the efficacy of certain drugs such as Oxcarbazepine and Doramectin. It is therefore important to monitor the use of Centella Asiatica in patients who have been prescribed these medications.', 'The herb Centella asiatica is known to decrease the efficacy of several drugs, including Oxcarbazepine and Doramectin.']","['Doramectin, an antiparasitic agent, is known to increase the efficacy of the anticonvulsant drug, Oxcarbazepine. In contrast, the traditional medicinal plant Centella Asiatica is shown to decrease the efficacy of both Oxcarbazepine and Doramectin.', 'The drug Doramectin is known to increase the efficacy of Oxcarbazepine. On the other hand, Centella Asiatica can decrease the efficacy of both Oxcarbazepine and Doramectin. Thus, the effectiveness of these drugs might be influenced by the use of Doramectin or Centella Asiatica.', 'The drug Doramectin increases the efficacy of another medication, Oxcarbazepine. However, the usage of the plant Centella Asiatica is known to decrease the efficacy of not only Oxcarbazepine but also Doramectin.', 'The drug Doramectin enhances the efficacy of another medication called Oxcarbazepine. However, the use of the herb Centella Asiatica can diminish the effectiveness of both Doramectin and Oxcarbazepine.', 'The drug doramectin increases the efficacy of oxcarbazepine, while Centella asiatica, a medicinal herb, is known to decrease the efficacy of both doramectin and oxcarbazepine. Therefore, usage of these substances should be carefully monitored to ensure optimal therapeutic effect.']"
"[{'source_node': {'name': 'mody'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'intrauterine growth retardation'}}, {'source_node': {'name': 'mody'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hepatocellular adenoma'}}, {'source_node': {'name': 'mody'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'acanthosis nigricans'}}, {'source_node': {'name': 'hepatocyte nuclear factor 4-alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HNF4A'}}, {'source_node': {'name': 'diabetes mellitus'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autoimmune antibody positivity'}}, {'source_node': {'name': 'HNF4A'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'diabetes mellitus'}}, {'source_node': {'name': 'HNF4A'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'mody'}}, {'source_node': {'name': 'HNF4A'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of gene expression in beta cells'}}]","[{'source_node': {'name': 'mody'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'acanthosis nigricans'}}, {'source_node': {'name': 'hepatocyte nuclear factor 4-alpha'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'HNF4A'}}, {'source_node': {'name': 'diabetes mellitus'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'autoimmune antibody positivity'}}, {'source_node': {'name': 'HNF4A'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'diabetes mellitus'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1117', 'target': None, 'metadata': {'node_id': '1117', 'node_type': 'PHENOTYPE', 'display_name': 'intrauterine growth retardation'}}, {'type': 'edge_deletion', 'source': 'GENE:28847', 'target': 'DISEASE:9501', 'metadata': None}, {'type': 'node_removal', 'source': 'PATHWAY:1471', 'target': None, 'metadata': {'node_id': '1471', 'node_type': 'PATHWAY', 'display_name': 'Regulation of gene expression in beta cells'}}, {'type': 'node_removal', 'source': 'PHENOTYPE:8423', 'target': None, 'metadata': {'node_id': '8423', 'node_type': 'PHENOTYPE', 'display_name': 'hepatocellular adenoma'}}]",0.5882352941176471,892bfdcc97ddcb35a6e38302c8528a0f,519ca958c8af61f5092a4b84933bba80,[],"['The disorder known as MODY manifests with a characteristic phenotype, such as acanthosis nigricans. This condition is tied to the function of the protein, hepatocyte nuclear factor 4-alpha, which is actually a gene product of HNF4A. Interestingly, HNF4A is known to cause another significant medical condition, diabetes mellitus. Diabetes mellitus, on the other hand, displays the phenotype of autoimmune antibody positivity. In this way, these entities connect to form a complex web of relationships, from molecular genetics to clinical manifestation.']"
"[{'source_node': {'name': 'levallorphan'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'naltrexone'}}, {'source_node': {'name': 'levallorphan'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'diphenoxylate'}}, {'source_node': {'name': 'levallorphan'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'alphaprodine'}}, {'source_node': {'name': 'meptazinol'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' hypotension and CNS depression '}}, {'source_node': {'name': 'meptazinol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'levallorphan'}}, {'source_node': {'name': 'meptazinol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sorbitol'}}]","[{'source_node': {'name': 'levallorphan'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'diphenoxylate'}}, {'source_node': {'name': 'levallorphan'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'alphaprodine'}}, {'source_node': {'name': 'levallorphan'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' hypotension and CNS depression '}}, {'source_node': {'name': 'diphenoxylate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'meptazinol'}}, {'source_node': {'name': 'diphenoxylate'}, 'relation': {'name': 'decrease_effect'}, 'target_node': {'name': ' hypotension and CNS depression '}}, {'source_node': {'name': 'meptazinol'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' hypotension and CNS depression '}}, {'source_node': {'name': 'meptazinol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sorbitol'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:11330', 'target': 'COMPOUND:492', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:689', 'target': None, 'metadata': {'node_id': '689', 'node_type': 'COMPOUND', 'display_name': 'naltrexone'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1061', 'target': 'COMPOUND:11330', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:492', 'target': 'EFFECT:134', 'metadata': {'predicate': 'increase_effect'}}, {'type': 'edge_addition', 'source': 'COMPOUND:1061', 'target': 'EFFECT:134', 'metadata': {'predicate': 'decrease_effect'}}]",0.5384615384615384,56c0ce35ab0b89117451aa4d2bf9966c,3685c1eb42bd5ecb701bd7332fada73b,[],[]
"[{'source_node': {'name': 'F2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (q) signalling events'}}, {'source_node': {'name': 'cochinchinenene a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prothrombin'}}, {'source_node': {'name': 'cochinchinenene a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dipeptidyl peptidase 4'}}, {'source_node': {'name': 'dipeptidyl peptidase 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DPP4'}}, {'source_node': {'name': 'prothrombin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'F2'}}]","[{'source_node': {'name': 'F2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'G alpha (q) signalling events'}}, {'source_node': {'name': 'cochinchinenene a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prothrombin'}}, {'source_node': {'name': 'cochinchinenene a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'dipeptidyl peptidase 4'}}, {'source_node': {'name': 'dipeptidyl peptidase 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'DPP4'}}, {'source_node': {'name': 'dipeptidyl peptidase 4'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'F2'}}, {'source_node': {'name': 'prothrombin'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'F2'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:1568', 'target': 'GENE:26852', 'metadata': {'predicate': 'gene_product_of'}}]",0.9090909090909092,0322824a2fab011b9ddcf497437c4c7b,bcd6901ec20a22f0b38f79a446870dfc,"['The gene F2 plays an active role within the G alpha (q) signalling events and serves as a precursor for the formation of prothrombin. Cochinchinenene A, a drug, has been shown to target prothrombin along with dipeptidyl peptidase 4, thereby affecting multiple elements in the biochemical map. Furthermore, both prothrombin and dipeptidyl peptidase 4 stand as gene products of F2 and DPP4, respectively. This highlights a potential interplay between these entities and potentially contributes to our understanding of drug mechanisms.']","['F2, a gene of interest, is known to act within G alpha (q) signalling events. The compound cochinchinenene A targets two significant proteins: prothrombin and dipeptidyl peptidase 4. Intriguingly, both of these target proteins are gene products of F2. Dipeptidyl peptidase 4 also happens to be a gene product of another gene, DPP4.']"
"[{'source_node': {'name': 'seizures-scoliosis-macrocephaly syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'microcephaly'}}, {'source_node': {'name': 'seizures-scoliosis-macrocephaly syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'atrial septal defect'}}, {'source_node': {'name': 'seizures-scoliosis-macrocephaly syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'exostoses'}}]","[{'source_node': {'name': 'seizures-scoliosis-macrocephaly syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'microcephaly'}}, {'source_node': {'name': 'seizures-scoliosis-macrocephaly syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'exostoses'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1184', 'target': None, 'metadata': {'node_id': '1184', 'node_type': 'PHENOTYPE', 'display_name': 'atrial septal defect'}}]",0.7142857142857143,d61fd7c8f7d73503f043515d1f38f5fe,c00f4776f6ba7b89758e61469706aa61,"['Seizures-scoliosis-macrocephaly syndrome is a condition characterized by several symptoms including microcephaly, atrial septal defect, and exostoses.']",[]
"[{'source_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'TDP1'}}, {'source_node': {'name': 'moxestrol'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the thrombogenic activities '}}, {'source_node': {'name': 'moxestrol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'glimepiride'}}, {'source_node': {'name': 'moxestrol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hyaluronidase'}}, {'source_node': {'name': 'liothyronine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'indalpine'}}, {'source_node': {'name': 'liothyronine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'moxestrol'}}, {'source_node': {'name': 'liothyronine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}}, {'source_node': {'name': 'indalpine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'potassium iodide'}}]","[{'source_node': {'name': 'moxestrol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'glimepiride'}}, {'source_node': {'name': 'moxestrol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'hyaluronidase'}}, {'source_node': {'name': 'hyaluronidase'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}}, {'source_node': {'name': 'liothyronine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'indalpine'}}, {'source_node': {'name': 'liothyronine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}}, {'source_node': {'name': 'indalpine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'potassium iodide'}}, {'source_node': {'name': 'potassium iodide'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'hyaluronidase'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:12441', 'target': 'ACTIVITY:2', 'metadata': {'predicate': 'has_activity'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:269', 'target': 'COMPOUND:11273', 'metadata': None}, {'type': 'node_removal', 'source': 'GENE:31610', 'target': None, 'metadata': {'node_id': '31610', 'node_type': 'GENE', 'display_name': 'TDP1'}}, {'type': 'edge_addition', 'source': 'COMPOUND:5766', 'target': 'COMPOUND:12441', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'ACTIVITY:2', 'target': None, 'metadata': {'node_id': '2', 'node_type': 'ACTIVITY', 'display_name': ' the thrombogenic activities '}}, {'type': 'edge_addition', 'source': 'COMPOUND:12441', 'target': 'PROTEIN:6169', 'metadata': {'predicate': 'has_target'}}]",0.5882352941176471,90289b8545d1cddfd67acaf2bd0ee21d,a6c9e8fbfd0da703cc27e9c5fa0ed8e1,[],"['Moxestrol acts as a suppressant, decreasing the efficacy of both glimepiride and hyaluronidase. Hyaluronidase, in turn, targets the enzymatic protein tyrosyl-DNA phosphodiesterase 1. Furthermore, Liothyronine plays a crucial role in two pathways. It targets tyrosyl-DNA phosphodiesterase 1 and also decreases the efficacy of indalpine. Interestingly, indalpine has a similar dampening effect on the compound potassium iodide. However, the latter increases the efficacy of hyaluronidase, making a complex network of influence and action between these substances.', ""Moxestrol, a synthetic nonsteroidal estrogen, has been found to reduce the efficacy of both glimepiride, an anti-diabetic drug, and hyaluronidase, an enzyme that catalyzes the degradation of hyaluronic acid. Hyaluronidase also targets tyrosyl-dna phosphodiesterase 1, an enzyme associated with DNA repair. On the other hand, liothyronine, a form of thyroid hormone, is known to decrease the efficacy of indalpine, an antidepressant drug, and interestingly, liothyronine also targets tyrosyl-dna phosphodiesterase 1. Indalpine itself, however, reduces the efficacy of potassium iodide, a compound used for a range of medical treatments. Interestingly, potassium iodide has an inverse relationship with hyaluronidase, where it increases the latter's efficacy. In the interconnected world of pharmacology, these complex interactions illuminate the cascading effects of drug action and implications on treatment efficiency."", 'The drug Moxestrol is known to decrease the efficacy of both Glimepiride and Hyaluronidase. Hyaluronidase, interestingly also acts as a target for the Tyrosyl-DNA phosphodiesterase 1. Similarly, Liothyronine can decrease the efficacy of Indalpine and targets Tyrosyl-DNA phosphodiesterase 1. However, Indalpine can decrease the efficacy of Potassium Iodide, which in turn can increase the efficacy of Hyaluronidase. Thus, a complex interplay exists between these drugs and biological entities.', 'The substance moxestrol decreases the efficacy of both glimepiride and hyaluronidase. Hyaluronidase, in turn, has the enzyme tyrosyl-DNA phosphodiesterase 1, as its target. On the other hand, liothyronine, a thyroid hormone, also decreases the efficacy of the antidepressant drug indalpine, while it targets the same enzyme as hyaluronidase, the tyrosyl-DNA phosphodiesterase 1. The drug indalpine reduces the efficacy of potassium iodide which, interestingly, increases the efficacy of hyaluronidase.', 'The compound moxestrol has been found to decrease the efficacy of glimepiride and hyaluronidase. This reduction in efficacy is particularly significant for hyaluronidase as it has been identified as a target of tyrosyl-dna phosphodiesterase 1. Another compound, liothyronine, also exhibits a decrease in efficacy when acting upon indalpine, and similarly to hyaluronidase, liothyronine has been shown to have tyrosyl-dna phosphodiesterase 1 as a target. This phenomenon continues with indalpine, which in turn decreases the efficacy of potassium iodide. However, in a break from the trend, potassium iodide has been observed to increase the efficacy of hyaluronidase, a stark contrast to the responses observed with moxestrol and indalpine. This intricate web of interactions illustrates the complex dynamics in the realm of biochemistry and drug design.']"
"[{'source_node': {'name': 'cefamandole nafate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'heparin'}}, {'source_node': {'name': 'cefamandole nafate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ancrod'}}, {'source_node': {'name': 'cefamandole nafate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'danaparoid'}}, {'source_node': {'name': 'danaparoid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fibrinogen human'}}, {'source_node': {'name': 'danaparoid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'plazomicin'}}]","[{'source_node': {'name': 'cefamandole nafate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ancrod'}}, {'source_node': {'name': 'fibrinogen human'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'plazomicin'}}, {'source_node': {'name': 'danaparoid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fibrinogen human'}}, {'source_node': {'name': 'danaparoid'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'plazomicin'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:12426', 'target': 'COMPOUND:5804', 'metadata': None}, {'type': 'node_removal', 'source': 'COMPOUND:1089', 'target': None, 'metadata': {'node_id': '1089', 'node_type': 'COMPOUND', 'display_name': 'heparin'}}, {'type': 'edge_addition', 'source': 'COMPOUND:8157', 'target': 'COMPOUND:10501', 'metadata': {'predicate': 'decrease_efficacy'}}]",0.6363636363636364,47f16e23035988ede3c70f40aeaeb227,1e8ec4055b6b81d68179334781ecc358,"['The drug Cefamandole Nafate is known to decrease the efficacy of Heparin, Ancrod, and Danaparoid. Moreover, the impact of Cefamandole Nafate on Danaparoid indirectly affect its efficiency on Fibrinogen Human and Plazomicin. Thus, the therapeutic impact of these medicaments could be significantly compromised in the presence of Cefamandole Nafate.', 'The drug cefamandole nafate is known to decrease the efficacy of several other substances including heparin, ancrod, and danaparoid. Interestingly, danaparoid itself has a similar effect on other substances, specifically fibrinogen human and plazomicin. Therefore, the use of these substances in combination may have limited effectiveness due to this mutual decrease in efficacy.', 'The drug cefamandole nafate has been shown to decrease the efficacy of heparin, ancrod, and danaparoid. Furthermore, danaparoid has been shown to decrease the efficacy of fibrinogen human and plazomicin. Therefore, caution should be exercised when using these combinations of medication.', 'The drug Cefamandole Nafate is known to decrease the efficacy of Heparin, Ancrod, and Danaparoid. Among those, Danaparoid, in turn, reduces the efficacy of Fibrinogen Human and Plazomicin. Hence, potential interaction effects should be carefully considered when patients are prescribed a combination of these drugs.', 'The drug Cefamandole Nafate has been found to decrease the efficacy of several other substances, including Heparin, Ancrod, and Danaparoid. Interestingly, Danaparoid itself can also decrease the efficacy of Fibrinogen Human and Plazomicin. Therefore, caution should be exercised when using these drugs in combination due to the potential for reduced effectiveness.']","[""Cefamandole nafate, a type of drug, has been reported to decrease the efficacy of ancrod. Moreover, the efficacy of plazomicin, another therapeutic agent, appears to be decreased by the substance fibrinogen human and the drug danaparoid. Danaparoid, in parallel, has also been noticed to lower the efficacy of fibrinogen human. Therefore, care should be taken when using these medications together as they can interfere with each other's effectiveness."", 'The drug cefamandole nafate has been found to decrease the efficacy of the clotting agent ancrod. Similarly, danaparoid, an anticoagulant, also diminishes the effectiveness of fibrinogen human, a clotting factor in blood coagulation and plazomicin, an antibiotic. Interestingly, fibrinogen human itself can also lessen the curative power of plazomicin.', 'The effectiveness of Ancrod can be decreased by the drug Cefamandole Nafate. Similarly, the efficacy of Plazomicin can be diminished by the presence of Fibrinogen Human. Moreover, Danaparoid has been found to decrease the efficacy of both Plazomicin and Fibrinogen Human.']"
"[{'source_node': {'name': 'eosinophilic fasciitis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'weight loss'}}, {'source_node': {'name': 'eosinophilic fasciitis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'paresthesia'}}]","[{'source_node': {'name': 'eosinophilic fasciitis'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'paresthesia'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:1323', 'target': None, 'metadata': {'node_id': '1323', 'node_type': 'PHENOTYPE', 'display_name': 'weight loss'}}]",0.6,5fb3551eed899b8e3f5780783d3d3e7a,b87453f3f2bdc880ad19bb289ae6b338,"['""Eosinophilic fasciitis, a medical condition, embodies various phenotypes such as weight loss and paresthesia. The presence of these symptoms may indicate an individual is suffering from eosinophilic fasciitis.']",[]
"[{'source_node': {'name': 'dersalazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'thyrotropin alfa'}}, {'source_node': {'name': 'dersalazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'liotrix'}}, {'source_node': {'name': 'etodolac'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'remikiren'}}, {'source_node': {'name': 'etodolac'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dersalazine'}}, {'source_node': {'name': 'etodolac'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'pinacidil'}}, {'source_node': {'name': 'pinacidil'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' orthostatic hypotension and dizziness '}}, {'source_node': {'name': 'pinacidil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'zaltoprofen'}}, {'source_node': {'name': 'pinacidil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'robenacoxib'}}]","[{'source_node': {'name': 'dersalazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'liotrix'}}, {'source_node': {'name': 'etodolac'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'remikiren'}}, {'source_node': {'name': 'etodolac'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'dersalazine'}}, {'source_node': {'name': 'zaltoprofen'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'dersalazine'}}, {'source_node': {'name': 'pinacidil'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' orthostatic hypotension and dizziness '}}, {'source_node': {'name': 'pinacidil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'zaltoprofen'}}, {'source_node': {'name': 'pinacidil'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'robenacoxib'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:23', 'target': None, 'metadata': {'node_id': '23', 'node_type': 'COMPOUND', 'display_name': 'thyrotropin alfa'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:733', 'target': 'COMPOUND:5811', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:5787', 'target': 'COMPOUND:5490', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7647058823529411,5ccfcf5bcb462e5cb2a7be41879119b1,cf66381273ce853e1fc290aa92cbf36c,[],[]
"[{'source_node': {'name': 'pterolinus j'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'pterolinus j'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mda-mb-231'}}, {'source_node': {'name': 'pterolinus j'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepg2'}}]","[{'source_node': {'name': 'pterolinus j'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mda-mb-231'}}, {'source_node': {'name': 'pterolinus j'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hepg2'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5849', 'target': None, 'metadata': {'node_id': '5849', 'node_type': 'PROTEIN', 'display_name': 'a549'}}]",0.7142857142857143,6a1ae78deed0bb5a97db2e299f4d4e0b,38d65e02553ec4421636b521c3e1d764,"['The compound Pterolinus J has been found to target several cell lines, including A549, MDA-MB-231 and HepG2.', 'The compound pterolinus J targets several biological entities. These include A549, a human lung carcinoma cell line, MDA-MB-231, a human breast cancer cell line, and HepG2, a liver cancer cell line.', 'The compound Pterolinus J is noted for having multiple targets. It has an affinity for A549, MDA-MB-231, and HepG2 cell lines. These varying targets suggest potential applications in different types of biological research and therapies.', 'The compound Pterolinus J has several cellular targets, which include A549, MDA-MB-231, and HepG2.', 'The compound Pterolinus J has multiple targets including A549, MDA-MB-231, and HepG2, which are all significant in cancer research.']","['The compound Pterolinus J has been identified to target both MDA-MB-231 and HepG2 cells.', 'The compound Pterolinus J is known to target two different types of cells: MDA-MB-231 and HepG2.', 'The drug Pterolinus J has been found to target two different cell lines, namely MDA-MB-231 and HepG2.', 'The drug Pterolinus J targets both MDA-MB-231 and HepG2 cells.', 'The chemical compound Pterolinus J has been observed to target both the MDA-MB-231 breast cancer cell line and the HepG2 liver cancer cell line.']"
"[{'source_node': {'name': 'ganolucidic acid b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'aldose reductase'}}, {'source_node': {'name': 'aldose reductase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AKR1B1'}}, {'source_node': {'name': 'AKR1B1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pregnenolone biosynthesis'}}, {'source_node': {'name': 'AKR1B1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Fructose biosynthesis'}}]","[{'source_node': {'name': 'ganolucidic acid b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'aldose reductase'}}, {'source_node': {'name': 'ganolucidic acid b'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'AKR1B1'}}, {'source_node': {'name': 'aldose reductase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AKR1B1'}}, {'source_node': {'name': 'AKR1B1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Pregnenolone biosynthesis'}}, {'source_node': {'name': 'AKR1B1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Fructose biosynthesis'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:88513', 'target': 'GENE:27202', 'metadata': {'predicate': 'is_affecting'}}]",0.8888888888888888,dc95f4b55643526113860e83271bdfb8,e1a05c2c63ff7b94768d8bd02a84cea4,"['The compound Ganolucidic Acid B is known to target Aldose Reductase. Interestingly, Aldose Reductase is a gene product of the gene AKR1B1. This gene, AKR1B1, plays significant roles in two pathways: it acts within both the Pregnenolone biosynthesis and the Fructose biosynthesis pathways.', 'The compound ganolucidic acid b targets the enzyme aldose reductase, which in itself is a gene product of AKR1B1. Interestingly, the AKR1B1 gene acts within two specific biological pathways: pregnenolone biosynthesis and fructose biosynthesis.', 'The compound ganolucidic acid B targets the protein aldose reductase which is a gene product of AKR1B1. This gene, AKR1B1, acts within both the pregnenolone biosynthesis and fructose biosynthesis pathways.', 'The compound ganolucidic acid b targets aldose reductase. This enzyme aldose reductase is the gene product of AKR1B1. The gene AKR1B1 is known to function within various biosynthesis pathways, such as pregnenolone biosynthesis and fructose biosynthesis.', 'Ganolucidic acid B targets aldose reductase, which is a gene product of AKR1B1. AKR1B1 plays a significant role within several biosynthesis pathways, that include pregnenolone biosynthesis and fructose biosynthesis.']","['Ganolucidic Acid B is known to target Aldose Reductase, which is a gene product of AKR1B1. In addition to this, the action of Ganolucidic Acid B is also affecting AKR1B1 directly. AKR1B1 is participating in various biochemical pathways such as pregnenolone biosynthesis and fructose biosynthesis.']"
"[{'source_node': {'name': 'granulatamide b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'du-145'}}, {'source_node': {'name': 'granulatamide b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-mel-28'}}, {'source_node': {'name': 'granulatamide b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'panc-1'}}]","[{'source_node': {'name': 'granulatamide b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-mel-28'}}, {'source_node': {'name': 'granulatamide b'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'panc-1'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5857', 'target': None, 'metadata': {'node_id': '5857', 'node_type': 'PROTEIN', 'display_name': 'du-145'}}]",0.7142857142857143,6ca92391b032ba3c8f79ad71118897aa,daf96d14a9974dd32c1c9a1009c1fc88,"['Granulatamide B is a compound that has multiple targets including DU-145, SK-MEL-28 and PANC-1. It exerts its effect by interacting with these targets.', 'The drug Granulatamide B is known to target several cancer cell lines including DU-145, SK-MEL-28, and PANC-1.', 'Granulatamide B is a compound that is known to target DU-145, SK-MEL-28, and PANC-1. These are cell lines often used in various types of cancer research.', 'Granulatamide B is a compound known for its multiple target interactions. It specifically targets DU-145, SK-MEL-28, and PANC-1, which are all considered important targets in various studies.', 'The compound Granulatamide B has been found to target a variety of entities, including DU-145, SK-MEL-28, and PANC-1. These are noteworthy as they are often used as cell lines in different types of cancer research.']","['The compound granulatamide B targets multiple cells, including SK-MEL-28 and PANC-1.', 'The compound Granulatamide B targets both SK-MEL-28 and PANC-1, which are specific cell lines used in cancer research.', 'The molecule Granulatamide B operates by targeting specific cells. Its known targets include the SK-MEL-28 cell line, commonly used in melanoma research, and PANC-1, a pancreatic cancer cell line.', 'The compound granulatamide b has been identified as having targeted effects on specific cancer cells, specifically the SK-MEL-28 and PANC-1 cells.', 'The compound Granulatamide B has been identified to target SK-MEL-28 and PANC-1.']"
"[{'source_node': {'name': 'tyrothricin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'betamethasone'}}, {'source_node': {'name': 'tyrothricin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'amantadine'}}, {'source_node': {'name': 'tyrothricin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'etanautine'}}]","[{'source_node': {'name': 'tyrothricin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'betamethasone'}}, {'source_node': {'name': 'tyrothricin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'amantadine'}}, {'source_node': {'name': 'tyrothricin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'etanautine'}}, {'source_node': {'name': 'amantadine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'tyrothricin'}}, {'source_node': {'name': 'amantadine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'etanautine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:898', 'target': 'COMPOUND:11354', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:898', 'target': 'COMPOUND:11484', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7142857142857143,3f1d12b223ac3eab5ebb9b2c86a6863e,edb6e1b7a366b195eea8184cd15dcbb9,"[""The antibiotic tyrothricin has been observed to decrease the efficacy of several drugs. It can affect betamethasone - a medication typically used for a variety of skin conditions, as well as amantadine, which is often used in the treatment of influenzas. Moreover, it has been noted to reduce the effectiveness of etanautine, another therapeutic drug. It's important to consider the impact tyrothricin can have on the efficacy of these therapeutic agents before starting an antibiotic treatment."", 'The medication Tyrothricin can decrease the efficacy of various drugs such as Betamethasone, Amantadine, and Etanautine. It is essential to understand these interactions to ensure appropriate and effective treatment strategies.', 'The antibiotic Tyrothricin has been observed to decrease the efficacy of several medicines including Betamethasone, a topical corticosteroid, Amantadine, an antiviral and antiparkinson agent, and Etanautine, a histamine receptor antagonist used to treat various conditions such as anxiety and sleep disorders.', 'Tyrothricin, a notable antibiotic, has been observed to decrease the efficacy of several drugs, including betamethasone, a well-known steroid, as well as amantadine and etanautine, both of which possess diverse therapeutic applications. This significant interaction indicates the need for caution when combining these treatments.', 'The drug Tyrothricin is known to decrease the efficacy of several other medications, including Betamethasone, Amantadine, and Etanautine. This means that when Tyrothricin is administered in conjunction with any of these drugs, their ability to treat or manage certain conditions may be diminished.']","[""Tyrothricin, a natural antibiotic, is known to decrease the efficacy of multiple therapeutic agents such as betamethasone, amantadine, and etanautine. Interestingly, amantadine, one of the affected drugs by tyrothricin, shows a reciprocal relationship with it: amantadine not only has its potency reduced by tyrothricin but also increases the efficacy of both tyrothricin and etanautine. Thus, tyrothricin and amantadine's interplay appears crucial in determining drug interactions and outcomes in pharmacological settings."", 'The antibiotic Tyrothricin has been found to decrease the efficacy of several drugs including Betamethasone, Amantadine, and Etanautine. Interestingly, while Tyrothricin reduces the efficacy of Amantadine, the latter has been found to increase the efficacy of Tyrothricin. Furthermore, Amantadine is also known to enhance the efficacy of Etanautine, illustrating a complex interplay between these drugs.\n', 'Tyrothricin is a substance known to decrease the efficacy of drugs such as betamethasone and etanautine. It also decreases the efficacy of amantadine, however, interestingly, amantadine in turn increases the efficacy of tyrothricin and etanautine. This demonstrates a complex interaction map within the body where substances can modulate the efficiency of one another.', 'The antibiotic tyrothricin is known to decrease the efficacy of various drugs such as betamethasone, amantadine, and etanautine. Interestingly, amantadine, while having its efficacy decreased by tyrothricin, reciprocally has an amplifying effect on the efficacy of tyrothricin and etanautine. Therefore, prescribers should be aware of these interactions when administering these drugs together.', 'The drug tyrothricin is known to decrease the efficacy of other drugs such as betamethasone, amantadine, and etanautine. Interestingly, the relationship is reciprocal with amantadine, as amantadine has been reported to increase the efficacy of tyrothricin. Furthermore, amantadine also increases the efficacy of etanautine. This intricate network of drug interactions emphasizes the importance of careful drug administration considerations.']"
"[{'source_node': {'name': 'midomafetamine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'protriptyline'}}, {'source_node': {'name': 'midomafetamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nadolol'}}, {'source_node': {'name': 'midomafetamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'orm-12741'}}, {'source_node': {'name': 'protriptyline'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Fatigue'}}, {'source_node': {'name': 'protriptyline'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Psychotic disorder'}}]","[{'source_node': {'name': 'midomafetamine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'protriptyline'}}, {'source_node': {'name': 'midomafetamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'nadolol'}}, {'source_node': {'name': 'midomafetamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'orm-12741'}}, {'source_node': {'name': 'protriptyline'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Fatigue'}}, {'source_node': {'name': 'protriptyline'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Psychotic disorder'}}, {'source_node': {'name': 'orm-12741'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'midomafetamine'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:9967', 'target': 'COMPOUND:1391', 'metadata': {'predicate': 'increase_efficacy'}}]",0.9090909090909092,9de4000efdc62dfc76755e71764f57e1,7808ebd4cebecf4f474d2489d790d4bb,"[""Midomafetamine, a substance known in pharmacology, showcases diverse interactions with various drugs and substances. In detail, it increases the efficacy of protriptyline, a medication widely prescribed for the treatment of depression and anxiety. Despite the enhanced efficacy, protriptyline may present side effects such as fatigue and in rare cases, psychotic disorder. Moreover, midomafetamine also demonstrates a depreciating effect where it decreases the efficacy of nadolol and orm-12741, other medications used in the medical setting. It highlights the nuanced impact of midomafetamine's interactions, playing both a positive and negative role depending on its counterpart."", 'Midomafetamine is a compound known to interact with multiple drugs, including protriptyline and nadolol. Interestingly, its administration can differentially impact the efficacy of these drugs. Midomafetamine can increase the efficacy of protriptyline, a medication used in depression treatment, potentially amplifying its therapeutic potential. However, it decreases the efficacy of nadolol and ORM-12741, thereby possibly undermining their therapeutic applications. Of note, protriptyline has been associated with certain side effects including fatigue and psychotic disorder, factors that need to be considered when assessing its augmented usage with midomafetamine.', ""The drug Midomafetamine has a dichotomous effect on the efficacy of other drugs, leading to an increase in the efficacy of Protriptyline but a decrease in the efficacy of both Nadolol and ORM-12741. It's important to note, however, that the use of Protriptyline has been associated with certain side effects including Fatigue and Psychotic disorder. Thus, one must handle Midomafetamine with care due its potential wide-reaching effects on other drugs and associated side effects."", ""The substance midomafetamine is known to interact differently with other substances. Its administration has been found to increase the efficacy of protriptyline. However, it can diminish the efficacy of nadolol and orm-12741. It's worth noting that the enhanced use of protriptyline, facilitated by midomafetamine, can lead to side effects such as fatigue and even a psychotic disorder."", ""Midomafetamine, a psychoactive drug, plays a significant role in modulating the efficacy of other medications. It enhances the effectiveness of protriptyline, a tricyclic antidepressant. However, it also decreases the efficacy of both nadolol, a beta-blocker used to treat high blood pressure, and orm-12741, a drug used in Alzheimer's treatment. It is important to note that protriptyline, while potentially augmented by midomafetamine, has been associated with side effects such as fatigue and the onset of psychotic disorders.""]","['The drug midomafetamine can have differing effects on the efficacy of other medications. Specifically, it has been found to increase the efficacy of protriptyline, yet it decreases the efficacy of both nadolol and orm-12741. Protriptyline, on the other hand, has been linked to side effects such as fatigue and psychotic disorder. Interestingly, orm-12741 has been observed to increase the efficacy of midomafetamine, suggesting a complex interplay between these substances.', 'Midomafetamine is a complex drug whose efficacy impacts other treatments. For instance, it increases the efficacy of protriptyline, but conversely, decreases the efficacy of both nadolol and orm-12741. Protriptyline, meanwhile, while its efficacy can be enhanced by midomafetamine, has potential side effects, including fatigue and psychotic disorders. Interestingly, orm-12741, which sees its efficacy reduced by midomafetamine, can, in turn, increase the efficacy of midomafetamine, establishing a mutual and interactive influence between these two drugs.', 'The drug midomafetamine is known to have varying effects on different drugs. It increases the efficacy of protriptyline, while decreasing the efficacy of nadolol and orm-12741. Furthermore, protriptyline has been associated with side effects such as fatigue and psychotic disorder. Interestingly, orm-12741 has the potential to increase the efficacy of midomafetamine.', 'The drug midomafetamine has a complex therapeutic profile since it can increase the efficacy of protriptyline while it may decrease the efficacy of nadolol and orm-12741. Protriptyline, boosted by midomafetamine, is known to have side effects such as fatigue and psychotic disorder. Interestingly, while midomafetamine lowers the potency of orm-12741, orm-12741 in turn can increase the efficacy of midomafetamine, suggesting a complex interaction between these two substances.', 'Midomafetamine is noted to increase the efficacy of protriptyline, while conversely decreasing the efficacy of both nadolol and orm-12741. Notably, protriptyline use can lead to side effects such as fatigue and psychotic disorders. Interestingly, orm-12741 shows potential to increase the efficacy of midomafetamine, presenting a complex interplay between these compounds.']"
"[{'source_node': {'name': 'goserelin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sulfadiazine'}}, {'source_node': {'name': 'goserelin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'insulin degludec'}}, {'source_node': {'name': 'goserelin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Anaemia'}}, {'source_node': {'name': 'sulfadiazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'hydroxyfasudil'}}, {'source_node': {'name': 'sulfadiazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'celiprolol'}}, {'source_node': {'name': 'sulfadiazine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Depression'}}]","[{'source_node': {'name': 'goserelin'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'sulfadiazine'}}, {'source_node': {'name': 'goserelin'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Anaemia'}}, {'source_node': {'name': 'sulfadiazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'hydroxyfasudil'}}, {'source_node': {'name': 'sulfadiazine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'celiprolol'}}, {'source_node': {'name': 'sulfadiazine'}, 'relation': {'name': 'has_side_effect'}, 'target_node': {'name': 'Depression'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:8388', 'target': None, 'metadata': {'node_id': '8388', 'node_type': 'COMPOUND', 'display_name': 'insulin degludec'}}]",0.8461538461538461,4092a46dea211ddf7dfc72e54004afc3,6b1c9a97fbad7a821ad8aeb8eee4c074,"[""The medication goserelin is known to reduce the efficacy of both sulfadiazine and insulin degludec. Interestingly, sulfadiazine can in turn increase the efficacy of two other drugs, namely hydroxyfasudil and celiprolol. Furthermore, it's important to note that both goserelin and sulfadiazine have been associated with clinically significant side effects. Goserelin may induce Anaemia, whereas sulfadiazine can lead to Depression. Therefore, any treatment plan involving these medications should weigh these potential impacts against the benefits offered by the particular drug combination."", 'Goserelin is a medication that is observed to decrease the efficacy of both Sulfadiazine and Insulin Degludec. Furthermore, Goserelin might also have the side effect of instigating Anaemia in some patients. On the other hand, Sulfadiazine interestingly has been shown to increase the efficacy of Hydroxyfasudil and Celiprolol. It should be noted, however, that the use of Sulfadiazine can potentially lead to Depression as a side effect.', 'Goserelin, a hormonal treatment, has been shown to decrease the efficacy of certain medications such as sulfadiazine and insulin degludec. Furthermore, potential side effects of goserelin treatment include conditions like anaemia. Interestingly, sulfadiazine, while weakened by the effects of goserelin, independently increases the efficacy of some other drugs such as hydroxyfasudil and celiprolol. However, it should also be noted that taking sulfadiazine can lead to the onset of depression, which is a notable side effect. Therefore, careful consideration must be taken when these drugs are prescribed in combination due to their nuanced interactions and potential side effects.', 'The drug goserelin is known to decrease the efficacy of both sulfadiazine and insulin degludec. Furthermore, goserelin is also associated with a side effect of causing anaemia. On the other hand, sulfadiazine interacts differently with other drugs; it increases the efficacy of both hydroxyfasudil and celiprolol. However, sulfadiazine has its side effects as well, one of which includes causing depression in some cases.', 'The drug goserelin has been found to decrease the efficacy of both sulfadiazine and insulin degludec. Additionally, goserelin may have side effects, one of which includes anaemia. On the other hand, the antibiotic sulfadiazine has the potential to increase the efficacy of hydroxyfasudil and celiprolol. However, similar to goserelin, sulfadiazine also has its own side effects, such as depression. Hence, the administration of these drugs needs to be carefully monitored to avoid potential drug interactions and side effects.']","['The drug Goserelin is known to decrease the efficacy of another medication, Sulfadiazine, as well as cause a side effect of Anaemia. Furthermore, it has been observed that Sulfadiazine, despite the impact from Goserelin, can increase the efficacy of both Hydroxyfasudil and Celiprolol drugs. However, Sulfadiazine usage also carries a risk of a side effect which manifests as Depression.', 'The medication goserelin has been observed to decrease the efficacy of another drug called sulfadiazine. In addition to this interaction, goserelin can unfortunately lead to anaemia as a side effect. Interestingly, sulfadiazine, the drug whose efficacy is hampered by goserelin, has been found to enhance the effectiveness of two other drugs known as hydroxyfasudil and celiprolol. However, a cautionary note must be made as sulfadiazine could have depression as a side effect.', 'The drug goserelin is known to decrease the efficacy of sulfadiazine and it also has a side effect of causing anaemia. Sulfadiazine, on the other hand, is found to increase the efficacy of both hydroxyfasudil and celiprolol, but it can also lead to depression as a potential side effect.', 'The drug goserelin has been observed to decrease the efficacy of sulfadiazine and can bring about the side effect of anaemia. On the other hand, sulfadiazine is noted to enhance the efficacy of both hydroxyfasudil and celiprolol. However, use of sulfadiazine may prompt depression as an adverse effect.', 'Goserelin, a drug commonly administered to treat hormone-sensitive cancers, has been observed to decrease the efficacy of sulfadiazine, another medication often prescribed in the treatment of bacterial and parasitic infections. Concurrently, goserelin has been associated with side effects, such as Anaemia. Interestingly, sulfadiazine appears to enhance the efficacy of both hydroxyfasudil, a vasodilator, and celiprolol, a beta blocker medication used to manage hypertension and heart diseases. However, a notable side effect related to sulfadiazine usage includes Depression.']"
"[{'source_node': {'name': 'BBIP1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'bardet-biedl syndrome 18'}}, {'source_node': {'name': 'BBIP1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'bardet-biedl syndrome'}}, {'source_node': {'name': 'BBIP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'BBSome-mediated cargo-targeting to cilium'}}, {'source_node': {'name': 'bardet-biedl syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'cryptorchidism'}}, {'source_node': {'name': 'bardet-biedl syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'nephrotic syndrome'}}, {'source_node': {'name': 'bardet-biedl syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'skeletal muscle atrophy'}}]","[{'source_node': {'name': 'BBIP1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'bardet-biedl syndrome 18'}}, {'source_node': {'name': 'BBIP1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'BBSome-mediated cargo-targeting to cilium'}}, {'source_node': {'name': 'bardet-biedl syndrome 18'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'nephrotic syndrome'}}, {'source_node': {'name': 'bardet-biedl syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'nephrotic syndrome'}}, {'source_node': {'name': 'bardet-biedl syndrome'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'skeletal muscle atrophy'}}]","[{'type': 'edge_addition', 'source': 'DISEASE:15788', 'target': 'PHENOTYPE:90', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_deletion', 'source': 'GENE:35275', 'target': 'DISEASE:326', 'metadata': None}, {'type': 'node_removal', 'source': 'PHENOTYPE:26', 'target': None, 'metadata': {'node_id': '26', 'node_type': 'PHENOTYPE', 'display_name': 'cryptorchidism'}}]",0.6923076923076923,5c77b25ca1057154125d83ed7b246a69,2e6865cfa472d5aeb463e94d343b1e0e,"['The gene BBIP1, which acts within the pathway of BBSome-mediated cargo-targeting to cilium, is known to cause both Bardet-Biedl syndrome 18 and Bardet-Biedl syndrome. Bardet-Biedl syndrome itself manifests with various phenotypes including cryptorchidism, nephrotic syndrome, and skeletal muscle atrophy.', 'The gene BBIP1 is implicated in the pathogenesis of several conditions, including Bardet-Biedl syndrome 18 and Bardet-Biedl syndrome. This gene operates within the mechanism of BBSome-mediated cargo-targeting to cilium, a process essential for cellular function. Bardet-Biedl syndrome is noteworthy for presenting with a diverse range of symptoms, including cryptorchidism, nephrotic syndrome, and skeletal muscle atrophy.', 'The gene BBIP1 is accountable for causing conditions like Bardet-Biedl syndrome 18 and Bardet-Biedl syndrome and it operates within the pathway responsible for BBSome-mediated cargo-targeting to the cilium. Bardet-Biedl syndrome is characterised by several phenotypes including cryptorchidism, nephrotic syndrome, and skeletal muscle atrophy.', 'The gene BBIP1 is known to cause conditions like Bardet-Biedl syndrome 18 and Bardet-Biedl syndrome. This gene acts within a particular pathway called BBSome-mediated cargo-targeting to cilium. Bardet-Biedl syndrome manifests with several phenotypes including cryptorchidism, nephrotic syndrome, and skeletal muscle atrophy.']","['The gene BBIP1, which acts within the pathway of BBSome-mediated cargo-targeting to the cilium, causes Bardet-Biedl Syndrome 18. This condition, Bardet-Biedl Syndrome 18, results in a phenotype that includes nephrotic syndrome. Similarly, Bardet-Biedl Syndrome is also characterized by phenotypes such as nephrotic syndrome and skeletal muscle atrophy.']"
"[{'source_node': {'name': 'magnesium sulfate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'cyclizine'}}, {'source_node': {'name': 'magnesium sulfate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pridinol'}}, {'source_node': {'name': 'fencamfamin'}, 'relation': {'name': 'has_activity'}, 'target_node': {'name': ' the sedative activities '}}, {'source_node': {'name': 'fencamfamin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' sedation '}}, {'source_node': {'name': 'fencamfamin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'magnesium sulfate'}}]","[{'source_node': {'name': 'magnesium sulfate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'cyclizine'}}, {'source_node': {'name': 'magnesium sulfate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'pridinol'}}, {'source_node': {'name': 'magnesium sulfate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'fencamfamin'}}, {'source_node': {'name': 'fencamfamin'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' sedation '}}, {'source_node': {'name': 'fencamfamin'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'magnesium sulfate'}}]","[{'type': 'node_removal', 'source': 'ACTIVITY:20', 'target': None, 'metadata': {'node_id': '20', 'node_type': 'ACTIVITY', 'display_name': ' the sedative activities '}}, {'type': 'edge_addition', 'source': 'COMPOUND:639', 'target': 'COMPOUND:1399', 'metadata': {'predicate': 'increase_efficacy'}}]",0.7272727272727273,155bb6b22f6f6094619f7f2529249bc8,e0423664c69303dc8c4dba72644d31ab,[],[]
"[{'source_node': {'name': 'extracellular calcium-sensing receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CASR'}}, {'source_node': {'name': 'etelcalcetide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'extracellular calcium-sensing receptor'}}, {'source_node': {'name': 'CASR'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hyperparathyroidism'}}]","[{'source_node': {'name': 'extracellular calcium-sensing receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CASR'}}, {'source_node': {'name': 'CASR'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'hyperparathyroidism'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:10742', 'target': 'GENE:34502', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'COMPOUND:10742', 'target': None, 'metadata': {'node_id': '10742', 'node_type': 'COMPOUND', 'display_name': 'etelcalcetide'}}]",0.7142857142857143,cc479519d2edd2396009128274421aa7,fb5a420677aa83ea2a8002ef31b761a3,"['The drug Etelcalcetide targets the Extracellular Calcium-Sensing Receptor, which is a gene product of CASR. Mutations in the CASR gene have been known to cause hyperparathyroidism, a condition characterized by an overactive parathyroid gland.', 'Etelcalcetide, a drug specifically designed to target the extracellular calcium-sensing receptor, works by interacting with this receptor, which is the gene product of CASR. Abnormalities in CASR can cause conditions such as hyperparathyroidism.', 'The drug etelcalcetide acts on the extracellular calcium-sensing receptor, which is a gene product of CASR. In turn, CASR is known to cause a condition known as hyperparathyroidism.', 'The drug etelcalcetide targets the extracellular calcium-sensing receptor, which is a gene product of CASR. Notably, the CASR gene has been identified as a cause of hyperparathyroidism.', 'The drug Etelcalcetide specifically targets the extracellular calcium-sensing receptor, which is the gene product of CASR. Abnormalities in CASR are known to cause hyperparathyroidism, a condition associated with malfunctions of the parathyroid glands.']","['The extracellular calcium-sensing receptor is a gene product of CASR. Notably, CASR is known to cause a condition known as hyperparathyroidism.', 'The extracellular calcium-sensing receptor is a gene product of CASR, which is known to cause hyperparathyroidism.', 'The extracellular calcium-sensing receptor, which is a gene product of CASR, is implicated in causing a condition known as hyperparathyroidism.', ""The extracellular calcium-sensing receptor is a gene product of CASR. It's critical to note that the gene CASR is associated with causing the condition known as hyperparathyroidism."", 'The extracellular calcium-sensing receptor is a gene product of CASR. Mutations in CASR can lead to conditions such as hyperparathyroidism.']"
"[{'source_node': {'name': 'dalfampridine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'menin/histone-lysine n-methyltransferase mll'}}, {'source_node': {'name': 'dalfampridine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'rap guanine nucleotide exchange factor 3'}}, {'source_node': {'name': 'dalfampridine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear factor nf-kappa-b p105 subunit'}}]","[{'source_node': {'name': 'dalfampridine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'menin/histone-lysine n-methyltransferase mll'}}, {'source_node': {'name': 'dalfampridine'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear factor nf-kappa-b p105 subunit'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:6126', 'target': None, 'metadata': {'node_id': '6126', 'node_type': 'PROTEIN', 'display_name': 'rap guanine nucleotide exchange factor 3'}}]",0.7142857142857143,b10606085c08605e44147023512704d0,7a42350eb0458346102f7bcccea68357,"['The drug Dalfampridine has several targets including the Menin/Histone-Lysine N-Methyltransferase MLL, the RAP Guanine Nucleotide Exchange Factor 3, and the Nuclear factor NF-kappa-B p105 subunit.', 'The drug dalfampridine primarily targets three key proteins: the menin/histone-lysine N-methyltransferase MLL, the Rap guanine nucleotide exchange factor 3, and the nuclear factor NF-kappa-B p105 subunit. These proteins are all vital to various processes within the body, hence making them significant targets for dalfampridine.', 'The drug Dalfampridine has several targets including the Menin/Histone-Lysine N-Methyltransferase MLL, the Rap Guanine Nucleotide Exchange Factor 3, and the Nuclear Factor NF-Kappa-B P105 Subunit.', 'The drug dalfampridine targets several proteins, including the menin/histone-lysine N-methyltransferase mll, the rap guanine nucleotide exchange factor 3, and the nuclear factor NF-kappa-B P105 subunit.', 'The drug Dalfampridine targets several molecular entities, including the Menin/Histone-Lysine N-Methyltransferase MLL, the Rap Guanine Nucleotide Exchange Factor 3, and the Nuclear Factor NF-kappa-B P105 subunit.']","['The drug Dalfampridine has multiple targets, including both the menin/histone-lysine N-methyltransferase MLL and the nuclear factor NF-kappa-B p105 subunit.', 'The drug Dalfampridine has several targets including the Menin/Histone-Lysine N-Methyltransferase MLL and the Nuclear Factor NF-Kappa-B P105 Subunit.', 'The drug dalfampridine targets both the menin/histone-lysine N-methyltransferase MLL and the nuclear factor NF-kappa-B p105 subunit.', 'The drug Dalfampridine has been identified to target both the Menin/histone-lysine N-methyltransferase MLL and the Nuclear factor NF-kappa-B p105 subunit, revealing its multifaceted pharmacological actions.', 'Dalfampridine is a drug that targets two distinct components: the Menin/Histone-Lysine N-Methyltransferase MLL, and the Nuclear Factor NF-kappa-B P105 Subunit. These targets play essential roles in various biological processes and are important in understanding the drug action of Dalfampridine.']"
"[{'source_node': {'name': 'n-(4-methoxyphenyl)acetamide'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cholesterol 24-hydroxylase'}}, {'source_node': {'name': 'CYP46A1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Endogenous sterols'}}, {'source_node': {'name': 'cholesterol 24-hydroxylase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP46A1'}}]","[{'source_node': {'name': 'cholesterol 24-hydroxylase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'CYP46A1'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:689', 'target': None, 'metadata': {'node_id': '689', 'node_type': 'PATHWAY', 'display_name': 'Endogenous sterols'}}, {'type': 'node_removal', 'source': 'COMPOUND:45367', 'target': None, 'metadata': {'node_id': '45367', 'node_type': 'COMPOUND', 'display_name': 'n-(4-methoxyphenyl)acetamide'}}]",0.4285714285714286,0272168efb1111c82115469088e6e178,191bab7002477fcb9db031c167604a13,"['The drug N-(4-methoxyphenyl)acetamide has a particular target, cholesterol 24-hydroxylase, a gene product of CYP46A1. CYP46A1, in turn, operates within the pathway of endogenous sterols.', 'The drug N-(4-methoxyphenyl)acetamide has a target known as cholesterol 24-hydroxylase. Interestingly, cholesterol 24-hydroxylase is the gene product of CYP46A1. Further investigation reveals that CYP46A1 actively operates within the pathway of endogenous sterols.', 'The drug N-(4-methoxyphenyl)acetamide targets cholesterol 24-hydroxylase, which is a gene product of CYP46A1. It is interesting to note that CYP46A1 acts within the pathway of endogenous sterols.', 'The drug N-(4-methoxyphenyl)acetamide targets cholesterol 24-hydroxylase, which is a gene product of CYP46A1. Furthermore, CYP46A1 acts within endogenous sterols.', 'The drug known as N-(4-methoxyphenyl)acetamide targets cholesterol 24-hydroxylase which is a gene product of CYP46A1. Further, CYP46A1 is known to act within the broader biochemical framework of endogenous sterols.']",[]
"[{'source_node': {'name': 'fruticoside a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}, {'source_node': {'name': 'fruticoside a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'smmc-7721'}}]","[{'source_node': {'name': 'fruticoside a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'smmc-7721'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4951', 'target': None, 'metadata': {'node_id': '4951', 'node_type': 'PROTEIN', 'display_name': 'hl-60'}}]",0.6,8899856af7677525127b2ab35e28613f,9457633948c8123dfda99317e4b5521e,"['Fruticoside A, a bioactive compound, targets two different cell lines: HL-60 and SMMC-7721. This implies it may interact with these cells inducing a certain biological response.', 'The compound Fruticoside A is known to target both HL-60 and SMMC-7721 cells.', 'The compound Fruticoside A has been identified to target various cell lines, including HL-60 and SMMC-7721.', 'The drug Fruticoside A has two notable targets: HL-60 and SMMC-7721.', 'The compound Fruticoside A is known to target both HL-60 and SMMC-7721 cells.']",['Fruticoside A has been identified as having a target of SMMC-7721.']
"[{'source_node': {'name': 'congenital disorder of glycosylation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'amelogenesis imperfecta'}}, {'source_node': {'name': 'congenital disorder of glycosylation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'exotropia'}}, {'source_node': {'name': 'SLC35A2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'congenital disorder of glycosylation'}}, {'source_node': {'name': 'SLC35A2'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'slc35a2-cdg'}}, {'source_node': {'name': 'SLC35A2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Transport of nucleotide sugars'}}, {'source_node': {'name': 'slc35a2-cdg'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormal heart morphology'}}, {'source_node': {'name': 'slc35a2-cdg'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'metatarsus adductus'}}, {'source_node': {'name': 'slc35a2-cdg'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypoplasia of the corpus callosum'}}]","[{'source_node': {'name': 'congenital disorder of glycosylation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'amelogenesis imperfecta'}}, {'source_node': {'name': 'congenital disorder of glycosylation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'exotropia'}}, {'source_node': {'name': 'congenital disorder of glycosylation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypoplasia of the corpus callosum'}}, {'source_node': {'name': 'congenital disorder of glycosylation'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormal heart morphology'}}, {'source_node': {'name': 'SLC35A2'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Transport of nucleotide sugars'}}, {'source_node': {'name': 'slc35a2-cdg'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'abnormal heart morphology'}}, {'source_node': {'name': 'slc35a2-cdg'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'metatarsus adductus'}}, {'source_node': {'name': 'slc35a2-cdg'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypoplasia of the corpus callosum'}}, {'source_node': {'name': 'slc35a2-cdg'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'amelogenesis imperfecta'}}]","[{'type': 'edge_addition', 'source': 'DISEASE:8166', 'target': 'PHENOTYPE:548', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_deletion', 'source': 'GENE:33459', 'target': 'DISEASE:11598', 'metadata': None}, {'type': 'edge_deletion', 'source': 'GENE:33459', 'target': 'DISEASE:8166', 'metadata': None}, {'type': 'edge_addition', 'source': 'DISEASE:11598', 'target': 'PHENOTYPE:1529', 'metadata': {'predicate': 'has_phenotype'}}, {'type': 'edge_addition', 'source': 'DISEASE:11598', 'target': 'PHENOTYPE:1182', 'metadata': {'predicate': 'has_phenotype'}}]",0.7058823529411764,a40a03190d5eb9f07b78c8240cc8d476,d3acacb88253a7e2f95e1a075ba0b830,"['The gene SLC35A2, which acts within the transport of nucleotide sugars, is known to cause conditions such as congenital disorder of glycosylation and SLC35A2-CDG. The condition congenital disorder of glycosylation presents several phenotypes including but not limited to amelogenesis imperfecta, a dental enamel defect, and exotropia, a type of eye misalignment.\n\nAs for SLC35A2-CDG, it is associated with a number of phenotypes that include abnormal heart morphology, metatarsus adductus, a foot deformity often present at birth, and hypoplasia of the corpus callosum, which is the underdevelopment or absence of the part of the brain that connects the two cerebral hemispheres.']","['Congenital disorder of glycosylation, a genetic condition, shows various phenotypes, which include amelogenesis imperfecta, exotropia, hypoplasia of the corpus callosum and abnormal heart morphology. Similarly, slc35a2-cdg, another variant disorder, exhibits symptoms such as abnormal heart morphology, metatarsus adductus, hypoplasia of the corpus callosum and amelogenesis imperfecta. The gene SLC35A2, which is known to act within the transport of nucleotide sugars pathway, most likely plays a significant role in these conditions.']"
"[{'source_node': {'name': 'ret proto-oncogene'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'carcinoma'}}, {'source_node': {'name': 'ret proto-oncogene'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'gastrointestinal stromal tumor'}}, {'source_node': {'name': 'ret proto-oncogene'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'thyroid neoplasms'}}, {'source_node': {'name': 'gastrointestinal stromal tumor'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'neurofibroma'}}, {'source_node': {'name': 'gastrointestinal stromal tumor'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'neoplasm of the rectum'}}]","[{'source_node': {'name': 'carcinoma'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'neurofibroma'}}, {'source_node': {'name': 'ret proto-oncogene'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'carcinoma'}}, {'source_node': {'name': 'ret proto-oncogene'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'gastrointestinal stromal tumor'}}, {'source_node': {'name': 'ret proto-oncogene'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'thyroid neoplasms'}}, {'source_node': {'name': 'gastrointestinal stromal tumor'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'neurofibroma'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:11171', 'target': None, 'metadata': {'node_id': '11171', 'node_type': 'PHENOTYPE', 'display_name': 'neoplasm of the rectum'}}, {'type': 'edge_addition', 'source': 'DISEASE:477', 'target': 'PHENOTYPE:837', 'metadata': {'predicate': 'has_phenotype'}}]",0.7272727272727273,64506c68aea6b8077406307aee2018c4,8cb39c946c9090da57a51a1d28ac33a8,"['The ret proto-oncogene, a specific gene, has been linked with causing a variety of conditions including carcinoma, gastrointestinal stromal tumors and thyroid neoplasms. A gastrointestinal stromal tumor, apart from being a condition caused by the ret proto-oncogene, also exhibits certain phenotypes or characteristics such as neurofibroma and a neoplasm of the rectum.', 'The ret proto-oncogene is known to cause several conditions, including carcinoma, gastrointestinal stromal tumor, and thyroid neoplasms. More specifically, the gastrointestinal stromal tumor, which is one of the conditions caused by the ret proto-oncogene, is characterized by phenotypes such as neurofibroma and neoplasm of the rectum.', 'The ret proto-oncogene is known to cause several conditions, including carcinoma, gastrointestinal stromal tumor and thyroid neoplasms. Interestingly, those suffering from a gastrointestinal stromal tumor, caused by the ret proto-oncogene, often exhibit certain phenotypes such as neurofibroma and neoplasm of the rectum.', ""The ret proto-oncogene is directly implicated in causing several conditions such as carcinoma, gastrointestinal stromal tumor, and thyroid neoplasms. Moreover, the gastrointestinal stromal tumor, which is partly a result of the ret proto-oncogene's activity, has been associated with several phenotypic manifestations such as neurofibroma and a specific form of cancer known as a neoplasm of the rectum."", 'The RET proto-oncogene is a potent factor in the genesis of several conditions. It is responsible for causing carcinoma, gastrointestinal stromal tumor, and thyroid neoplasms. The gastrointestinal stromal tumor, which is one of the conditions caused by the RET proto-oncogene, is characterized by various phenotypes like neurofibroma and neoplasm of the rectum.']","['The ret proto-oncogene is known to cause conditions such as carcinoma, gastrointestinal stromal tumor, and thyroid neoplasms. Both carcinoma and gastrointestinal stromal tumor, as a consequence, have the phenotype of neurofibroma, a type of benign nerve sheath tumor.', 'The ret proto-oncogene causes several conditions including carcinoma, gastrointestinal stromal tumor, and thyroid neoplasms. Carcinoma and gastrointestinal stromal tumor, both caused by the ret proto-oncogene, share a common phenotype: neurofibroma. Thus, both these conditions may result in neurofibroma due to the pathological effects of the ret proto-oncogene.', 'The ret proto-oncogene is known to cause several conditions including carcinoma, gastrointestinal stromal tumor, and thyroid neoplasms. Both carcinoma and gastrointestinal stromal tumor are associated with the phenotype of neurofibroma.', 'The ret proto-oncogene is known to cause a number of conditions, including carcinoma, gastrointestinal stromal tumors, and thyroid neoplasms. Interestingly, both the carcinoma and the gastrointestinal stromal tumor have a shared phenotype: neurofibroma. This gives us a deeper understanding of the mutual characteristics that these conditions possess.', 'The RET proto-oncogene is implicated in causing several conditions, such as carcinoma, gastrointestinal stromal tumor, and thyroid neoplasms. Notably, carcinoma and gastrointestinal stromal tumor both exhibit the phenotype of neurofibroma.']"
"[{'source_node': {'name': 'buerger disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hyperhidrosis'}}, {'source_node': {'name': 'buerger disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'insomnia'}}]","[{'source_node': {'name': 'buerger disease'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hyperhidrosis'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:11210', 'target': None, 'metadata': {'node_id': '11210', 'node_type': 'PHENOTYPE', 'display_name': 'insomnia'}}]",0.6,42725de4705816a8767ed5a8655f3419,e31562711788ed67d686f782d37ac1b7,"['Buerger disease, a medical condition, manifests several symptoms among which are hyperhidrosis and insomnia.', 'Buerger disease is a condition typified by several associated features or phenotypes and these include hyperhidrosis and insomnia.', 'The condition known as Buerger disease, often manifests phenotypes like hyperhidrosis - an excessive sweating condition, and insomnia - a common sleep disorder.', 'Buerger Disease, a serious condition characterized by symptoms such as excessive sweating often referred to as hyperhidrosis, is also noted for causing insomnia in patients.', 'Buerger disease, a disorder with symptoms such as hyperhidrosis, also manifests as insomnia in many patients.']",[]
"[{'source_node': {'name': 'major histocompatibility complex'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'heparin-induced thrombocytopenia'}}, {'source_node': {'name': 'major histocompatibility complex'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'carcinoma'}}, {'source_node': {'name': 'heparin-induced thrombocytopenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'stroke'}}, {'source_node': {'name': 'protein tyrosine phosphatase non-receptor type 22'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'arthritis'}}, {'source_node': {'name': 'protein tyrosine phosphatase non-receptor type 22'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'drug-induced liver injury'}}, {'source_node': {'name': 'clavulanate'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'major histocompatibility complex'}}, {'source_node': {'name': 'clavulanate'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'protein tyrosine phosphatase non-receptor type 22'}}, {'source_node': {'name': 'clavulanate'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'drug toxicity'}}]","[{'source_node': {'name': 'major histocompatibility complex'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'heparin-induced thrombocytopenia'}}, {'source_node': {'name': 'major histocompatibility complex'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'arthritis'}}, {'source_node': {'name': 'heparin-induced thrombocytopenia'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'stroke'}}, {'source_node': {'name': 'protein tyrosine phosphatase non-receptor type 22'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'arthritis'}}, {'source_node': {'name': 'protein tyrosine phosphatase non-receptor type 22'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'drug-induced liver injury'}}, {'source_node': {'name': 'clavulanate'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'major histocompatibility complex'}}, {'source_node': {'name': 'clavulanate'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'protein tyrosine phosphatase non-receptor type 22'}}, {'source_node': {'name': 'clavulanate'}, 'relation': {'name': 'is_substance_that_treats'}, 'target_node': {'name': 'drug toxicity'}}]","[{'type': 'edge_addition', 'source': 'GENE:8028', 'target': 'DISEASE:265', 'metadata': {'predicate': 'causes_condition'}}, {'type': 'node_removal', 'source': 'DISEASE:477', 'target': None, 'metadata': {'node_id': '477', 'node_type': 'DISEASE', 'display_name': 'carcinoma'}}]",0.8235294117647058,bb0b4f873143eab7cb0ee6adae8e7e92,d193b6fad4b75e55e3cba66e00461776,"['The major histocompatibility complex and the protein tyrosine phosphatase non-receptor type 22 are reported to be involved in the pathology of several conditions. Specifically, the major histocompatibility complex leads to both heparin-induced thrombocytopenia and carcinoma. Interestingly, stroke is a common phenotype associated with heparin-induced thrombocytopenia. On the other hand, protein tyrosine phosphatase non-receptor type 22 contributes to the occurrence of arthritis and drug-induced liver injury. In this complex web of interactions, the drug clavulanate has a significant impact. It affects both the major histocompatibility complex and the protein tyrosine phosphatase non-receptor type 22. Furthermore, it is also recognized as a substance that treats drug toxicity. Therefore, a possible interplay between these molecules and conditions can provide insightful information about disease mechanisms and potential therapeutic approaches.', 'The major histocompatibility complex, an essential part of the immune system, has been identified as a cause of certain conditions like heparin-induced thrombocytopenia and carcinoma. Diving deeper, heparin-induced thrombocytopenia, a condition commonly associated with the use of the drug heparin, has a known phenotype of stroke. \n\nOn the other hand, the enzyme protein tyrosine phosphatase non-receptor type 22 also causes conditions such as arthritis and drug-induced liver injury. \n\nInterestingly, an antibiotic substance, clavulanate, appears to interact with both the major histocompatibility complex and protein tyrosine phosphatase non-receptor type 22. Moreover, clavulanate is also known to treat conditions related to drug toxicity. \n\nThis web of interconnections signifies how conditions, proteins, and substances can interact in complex ways within the physiological system.', 'The major histocompatibility complex has been identified as a cause for both, heparin-induced thrombocytopenia and carcinoma. Interestingly, heparin-induced thrombocytopenia displays a phenotype of stroke. Concurrently, the protein tyrosine phosphatase non-receptor type 22 is another complex that can cause arthritis and even drug-induced liver injury.  \nRemarkably, the drug clavulanate affects both the major histocompatibility complex and the protein tyrosine phosphatase non-receptor type 22, suggesting a potential influence on these related conditions. Furthermore, clavulanate has been identified as a substance that can treat drug toxicity. Combining these pieces of information provides a picture of an intricate interaction network suggesting possible shared pathogenetic processes among these conditions.', 'The major histocompatibility complex, a crucial part of our immune system, is known to cause specific conditions such as heparin-induced thrombocytopenia and carcinoma. Notably, individuals with heparin-induced thrombocytopenia may exhibit the phenotype of stroke. Another important protein known as the protein tyrosine phosphatase non-receptor type 22, also causes conditions such as arthritis and drug-induced liver injury. Interestingly, these two proteins can be affected by the drug clavulanate. In addition to its impact on these proteins, clavulanate also treats drug toxicity, emphasizing its multifaceted role in disease treatment and management.']","['The major histocompatibility complex has been linked to causing conditions such as heparin-induced thrombocytopenia and arthritis. Heparin-induced thrombocytopenia can present with a phenotype such as stroke. Meanwhile, the protein tyrosine phosphatase non-receptor type 22 also contributes to the incidence of arthritis as well as drug-induced liver injury. Interestingly, both major histocompatibility complex and protein tyrosine phosphatase non-receptor type 22 can be affected by the substance clavulanate. Further, clavulanate is a substance known to treat drug toxicity.', 'The Major Histocompatibility Complex, a key component in the immune response, can cause various conditions such as Heparin-Induced Thrombocytopenia and Arthritis. Particularly, Heparin-Induced Thrombocytopenia can present a phenotype such as Stroke. Additionally, Protein Tyrosine Phosphatase Non-Receptor Type 22, another important protein in the body, also causes conditions like Arthritis and Drug-Induced Liver Injury. Intriguingly, a compound called Clavulanate is known to affect both Major Histocompatibility Complex and Protein Tyrosine Phosphatase Non-Receptor Type 22. Apart from that, it acts as a substance that treats Drug Toxicity, which could be a connection to its effect on these proteins most commonly associated with various conditions.', 'The Major Histocompatibility Complex, affected by the use of Clavulanate, is known to cause conditions such as Heparin-Induced Thrombocytopenia and arthritis. Heparin-Induced Thrombocytopenia has the phenotype of stroke. On the other hand, Protein Tyrosine Phosphatase Non-Receptor Type 22, which is also influenced by Clavulanate, causes conditions such as arthritis and Drug-Induced Liver Injury. Clavulanate, aside from affecting these two proteins, is a substance that is known to treat drug toxicity.', 'The major histocompatibility complex is known to cause conditions such as heparin-induced thrombocytopenia and arthritis. Heparin-induced thrombocytopenia can present with various phenotypes, including stroke. Another major contributory factor to arthritis is the protein tyrosine phosphatase non-receptor type 22. This protein is also linked to causing drug-induced liver injury. Interestingly, both the major histocompatibility complex and the protein tyrosine phosphatase non-receptor type 22 are affected by clavulanate. Importantly, clavulanate also holds potential as a substance that can treat drug toxicity.', 'The Major Histocompatibility Complex and the Protein Tyrosine Phosphatase non-receptor type 22 significantly affect our health by causing various conditions. The Major Histocompatibility Complex is known to cause both Heparin-induced thrombocytopenia and arthritis. Similarly, the Protein Tyrosine Phosphatase non-receptor type 22 is implicated in causing arthritis and drug-induced liver injury. Clavulanate, a treatment substance, affects both the Major Histocompatibility Complex and Protein Tyrosine Phosphatase non-receptor type 22 and is used in treating drug toxicity. Notably, Heparin-induced thrombocytopenia, one of the conditions caused by the Major Histocompatibility Complex, has a phenotype that includes the occurrence of strokes. The diverse health implications underline the need for continued investigation into these health conditions and treatments.']"
"[{'source_node': {'name': 'rocuronium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fenthion'}}, {'source_node': {'name': 'colistimethate'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' nephrotoxicity '}}, {'source_node': {'name': 'colistimethate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'rocuronium'}}, {'source_node': {'name': 'colistimethate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'rapacuronium'}}]","[{'source_node': {'name': 'rocuronium'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'fenthion'}}, {'source_node': {'name': 'rocuronium'}, 'relation': {'name': 'increase_effect'}, 'target_node': {'name': ' nephrotoxicity '}}, {'source_node': {'name': 'colistimethate'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' nephrotoxicity '}}, {'source_node': {'name': 'colistimethate'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'rapacuronium'}}, {'source_node': {'name': 'fenthion'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' nephrotoxicity '}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:9376', 'target': 'EFFECT:48', 'metadata': {'predicate': 'has_effect'}}, {'type': 'edge_addition', 'source': 'COMPOUND:713', 'target': 'EFFECT:48', 'metadata': {'predicate': 'increase_effect'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:1091', 'target': 'COMPOUND:713', 'metadata': None}]",0.6666666666666667,d2d256d1e3d28a3f13cf8ad864bf062b,8afe107106ac9680ad965996df629250,[],[]
"[{'source_node': {'name': 'milatuzumab'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}, {'source_node': {'name': 'milatuzumab'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'imlifidase'}}]","[{'source_node': {'name': 'imlifidase'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' adverse effects '}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:12843', 'target': 'EFFECT:5', 'metadata': {'predicate': 'has_effect'}}, {'type': 'node_removal', 'source': 'COMPOUND:10816', 'target': None, 'metadata': {'node_id': '10816', 'node_type': 'COMPOUND', 'display_name': 'milatuzumab'}}]",0.4,ede09a1e712e2e98eebb07faffbb3647,5d1276fbd13d414452ef7bde272386a6,[],[]
"[{'source_node': {'name': '4-methylesculetin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'xanthine dehydrogenase/oxidase'}}, {'source_node': {'name': '4-methylesculetin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'aldose reductase'}}, {'source_node': {'name': '4-methylesculetin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'thyroid hormone receptor beta'}}, {'source_node': {'name': 'aldose reductase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'AKR1B1'}}, {'source_node': {'name': 'THRB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nuclear Receptor transcription pathway'}}, {'source_node': {'name': 'xanthine dehydrogenase/oxidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'XDH'}}, {'source_node': {'name': 'thyroid hormone receptor beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'THRB'}}]","[{'source_node': {'name': '4-methylesculetin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'xanthine dehydrogenase/oxidase'}}, {'source_node': {'name': '4-methylesculetin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'aldose reductase'}}, {'source_node': {'name': '4-methylesculetin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'thyroid hormone receptor beta'}}, {'source_node': {'name': 'THRB'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Nuclear Receptor transcription pathway'}}, {'source_node': {'name': 'xanthine dehydrogenase/oxidase'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'XDH'}}, {'source_node': {'name': 'thyroid hormone receptor beta'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'THRB'}}]","[{'type': 'edge_addition', 'source': 'PROTEIN:1142', 'target': 'GENE:27202', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'node_removal', 'source': 'GENE:27202', 'target': None, 'metadata': {'node_id': '27202', 'node_type': 'GENE', 'display_name': 'AKR1B1'}}]",0.8666666666666667,742e050d0d432d2906cb62e9cd4a5f2d,59c48ada30fcab8ed444ae69363d1494,[],"['The drug 4-methylesculetin is known to target several biomolecules, including xanthine dehydrogenase/oxidase, aldose reductase, and thyroid hormone receptor beta. \nXanthine dehydrogenase/oxidase is a gene product of XDH. Additionally, thyroid hormone receptor beta, another target of 4-methylesculetin, is the gene product of THRB.\nTHRB also acts within a biochemical process known as the nuclear receptor transcription pathway.', 'The compound 4-methylesculetin targets several proteins including xanthine dehydrogenase/oxidase, aldose reductase and thyroid hormone receptor beta. Xanthine dehydrogenase/oxidase is a gene product of XDH, while the thyroid hormone receptor beta is a product of the THRB gene. It is also important to note that the THRB gene is known to act within the Nuclear Receptor transcription pathway.', 'The compound 4-methylesculetin has been identified to target a series of enzymes and receptors, such as xanthine dehydrogenase/oxidase, aldose reductase, and thyroid hormone receptor beta. Interestingly, xanthine dehydrogenase/oxidase is a gene product of the XDH gene and thyroid hormone receptor beta is a gene product of the THRB gene. Further, the THRB gene, which encodes for thyroid hormone receptor beta, plays a significant role within the nuclear receptor transcription pathway.', 'The compound 4-methylesculetin has been found to target xanthine dehydrogenase/oxidase, aldose reductase, and thyroid hormone receptor beta. Interestingly, both xanthine dehydrogenase/oxidase and thyroid hormone receptor beta are gene products, produced by XDH and THRB respectively. The THRB gene itself is known to act within the nuclear receptor transcription pathway, elucidating a crucial interplay of enzymes, gene products, and biological pathways.', 'The compound 4-methylesculetin targets various enzymes and receptors, such as xanthine dehydrogenase/oxidase, aldose reductase, and thyroid hormone receptor beta. The latter is a gene product of THRB, which plays a significant role in the nuclear receptor transcription pathway. Similarly, xanthine dehydrogenase/oxidase is a gene product of XDH.']"
"[{'source_node': {'name': 'podocarpusflavone a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'cathepsin k'}}, {'source_node': {'name': 'podocarpusflavone a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'podocarpusflavone a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mda-mb-231'}}]","[{'source_node': {'name': 'podocarpusflavone a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'mda-mb-231'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:5849', 'target': None, 'metadata': {'node_id': '5849', 'node_type': 'PROTEIN', 'display_name': 'a549'}}, {'type': 'node_removal', 'source': 'PROTEIN:2041', 'target': None, 'metadata': {'node_id': '2041', 'node_type': 'PROTEIN', 'display_name': 'cathepsin k'}}]",0.4285714285714286,9211b94e18a4a06f32c3c812f16468ab,a2e2e72004305438ea6ec2ce8a5f62f7,"['The compound Podocarpusflavone A has been found to target multiple entities. It exerts its effect on both the Cathepsin K enzyme and certain cell lines including A549 and MDA-MB-231.', 'The compound Podocarpusflavone A has multiple targets, including the protease enzyme Cathepsin K, as well as the cell lines A549 and MDA-MB-231.', 'The compound Podocarpusflavone A targets several entities including Cathepsin K, A549, and MDA-MB-231. This highlights its diverse range of interactions, potentially playing a significant role in various biological processes.', 'The compound Podocarpusflavone A has multiple targets including Cathepsin K, A549, and MDA-MB-231.', 'The compound podocarpusflavone A has several targets, including cathepsin K, A549, and MDA-MB-231.']",[]
"[{'source_node': {'name': 'gamma-glutamyl hydrolase'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'toxic liver disease'}}, {'source_node': {'name': 'gamma-glutamyl hydrolase'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'thrombocytopenia'}}]","[{'source_node': {'name': 'gamma-glutamyl hydrolase'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'toxic liver disease'}}]","[{'type': 'node_removal', 'source': 'DISEASE:15575', 'target': None, 'metadata': {'node_id': '15575', 'node_type': 'DISEASE', 'display_name': 'thrombocytopenia'}}]",0.6,f39cf7f9a88219e4d599339169aeadd6,51b58ea750067bb1d8d1456c6720e531,"['The enzyme gamma-glutamyl hydrolase is known to cause certain conditions, specifically toxic liver disease and thrombocytopenia.', 'The enzyme gamma-glutamyl hydrolase is linked to causing certain medical conditions such as toxic liver disease and thrombocytopenia.', 'The enzyme gamma-glutamyl hydrolase is known to cause certain conditions such as toxic liver disease and thrombocytopenia.', 'The enzyme gamma-glutamyl hydrolase is associated with causing certain conditions such as toxic liver disease and thrombocytopenia.', 'The enzyme gamma-glutamyl hydrolase is known to cause certain conditions such as toxic liver disease and thrombocytopenia.']",['The enzyme gamma-glutamyl hydrolase is known to cause toxic liver disease.']
"[{'source_node': {'name': 'isoflurophate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'homatropine methylbromide'}}, {'source_node': {'name': 'isoflurophate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clobetasol propionate'}}, {'source_node': {'name': 'isoflurophate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'umeclidinium'}}, {'source_node': {'name': 'janssen covid-19 vaccine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'mitomycin'}}, {'source_node': {'name': 'hydrocortisone acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'isoflurophate'}}, {'source_node': {'name': 'hydrocortisone acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vi polysaccharide vaccine'}}, {'source_node': {'name': 'hydrocortisone acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'janssen covid-19 vaccine'}}]","[{'source_node': {'name': 'isoflurophate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'homatropine methylbromide'}}, {'source_node': {'name': 'isoflurophate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clobetasol propionate'}}, {'source_node': {'name': 'isoflurophate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'umeclidinium'}}, {'source_node': {'name': 'hydrocortisone acetate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'typhoid vi polysaccharide vaccine'}}, {'source_node': {'name': 'clobetasol propionate'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'isoflurophate'}}]","[{'type': 'node_removal', 'source': 'COMPOUND:13256', 'target': None, 'metadata': {'node_id': '13256', 'node_type': 'COMPOUND', 'display_name': 'janssen covid-19 vaccine'}}, {'type': 'edge_addition', 'source': 'COMPOUND:996', 'target': 'COMPOUND:662', 'metadata': {'predicate': 'decrease_efficacy'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:12276', 'target': 'COMPOUND:662', 'metadata': None}]",0.6,91f448ff2ac62c5285ed72e39d30de80,6d82fbcf0c85a977ba35294124d6b02c,"['Isoflurophate, a widely used medication, has been found to decrease the efficacy of certain other drugs. Specifically, it decreases the effectiveness of homatropine methylbromide, clobetasol propionate, and umeclidinium. Interestingly, the decrease in efficacy is not limited to isoflurophate. The Janssen COVID-19 vaccine is also known to cause a decrease in the efficacy of mitomycin. Furthermore, the drug hydrocortisone acetate also diminishes the efficacy of several medications, including isoflurophate and the typhoid vi polysaccharide vaccine. It has also been found to lessen the effectiveness of the Janssen COVID-19 vaccine. This information sheds critical light on the complex interactions between medications, which could aid healthcare professionals and patients in customized medication planning.', 'The drug isoflurophate is known to decrease the efficacy of several other compounds including homatropine methylbromide, clobetasol propionate, and umeclidinium. Similarly, hydrocortisone acetate has been found to reduce the efficacy of not only isoflurophate but also the typhoid vi polysaccharide vaccine and the Janssen COVID-19 vaccine. Additionally, it has been observed that the Janssen COVID-19 vaccine may evidently decrease the efficacy of the chemotherapy drug mitomycin.', 'The drug isoflurophate has been observed to decrease the efficacy of multiple other drugs, including homatropine methylbromide, clobetasol propionate, and umeclidinium. Interestingly, this phenomenon is not unidirectional as hydrocortisone acetate has been shown to likewise decrease the efficacy of isoflurophate. The effects of hydrocortisone acetate are not limited to isoflurophate as it also diminishes the efficacy of the typhoid vi polysaccharide vaccine as well as the Janssen covid-19 vaccine. Of note is the potential interaction between the Janssen covid-19 vaccine and mitomycin, with the efficacy of the latter being reduced when administered in combination. As such, careful consideration must be given to the usage of these drugs in tandem to minimize the risk of reduced efficacy.']","['The drug isoflurophate is known to decrease the efficacy of multiple other drugs, including homatropine methylbromide, clobetasol propionate, and umeclidinium. Concurrently, the drug hydrocortisone acetate is reported to decrease the efficacy of the typhoid vi polysaccharide vaccine. Moreover, a reciprocal effect has been observed where clobetasol propionate is capable of decreasing the efficacy of isoflurophate. The implication of these findings on clinical drug usage and treatment regimens warrants further investigation.', 'The medication Isoflurophate is known to decrease the efficacy of three other medications namely Homatropine Methylbromide, Clobetasol Propionate, and Umeclidinium. Interestingly, Clobetasol Propionate also decreases the efficacy of Isoflurophate, indicating some level of bi-directionality in their relationship.  Meanwhile, Hydrocortisone Acetate can similarly reduce the effectiveness of the Typhoid VI Polysaccharide Vaccine. Thus, care must be taken when these medications are prescribed concurrently.', ""Isoflurophate is observed to decrease the efficacy of several substances including homatropine methylbromide, clobetasol propionate and umeclidinium. Similarly, the drug hydrocortisone acetate is known to decrease the efficacy of the typhoid vi polysaccharide vaccine. Interestingly, it's noted that clobetasol propionate also decreases the efficacy of isoflurophate, suggesting a complex interaction between these substances."", 'Isoflurophate, a commonly used drug, has been found to decrease the efficacy of several other medications including homatropine methylbromide, clobetasol propionate, and umeclidinium. Simultaneously, hydrocortisone acetate, another widely used drug, has been shown to decrease the efficacy of the typhoid vi polysaccharide vaccine. Interestingly, clobetasol propionate also similarly decreases the efficacy of isoflurophate indicating a potential reciprocal relationship. This interplay between medications demonstrates the complex interactions in drug therapies.', 'The drug isoflurophate has been found to decrease the efficacy of several medications, including homatropine methylbromide, clobetasol propionate, and umeclidinium. Interestingly, the drug clobetasol propionate also decreases the efficacy of isoflurophate. Meanwhile, the medication hydrocortisone acetate reduces the effectiveness of the typhoid vi polysaccharide vaccine.']"
"[{'source_node': {'name': 'epiestriol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'udp-glucuronosyltransferase 2b7'}}, {'source_node': {'name': 'epiestriol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'liver microsome'}}, {'source_node': {'name': 'epiestriol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'udp-glucuronosyltransferase 1-3'}}, {'source_node': {'name': 'udp-glucuronosyltransferase 2b7'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'UGT2B7'}}, {'source_node': {'name': 'udp-glucuronosyltransferase 1-3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'UGT1A3'}}, {'source_node': {'name': 'UGT2B7'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Aspirin ADME'}}, {'source_node': {'name': 'UGT2B7'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Prednisone ADME'}}]","[{'source_node': {'name': 'epiestriol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'udp-glucuronosyltransferase 2b7'}}, {'source_node': {'name': 'epiestriol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'liver microsome'}}, {'source_node': {'name': 'epiestriol'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'UGT1A3'}}, {'source_node': {'name': 'udp-glucuronosyltransferase 2b7'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'UGT2B7'}}, {'source_node': {'name': 'udp-glucuronosyltransferase 1-3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'UGT1A3'}}, {'source_node': {'name': 'udp-glucuronosyltransferase 1-3'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'UGT2B7'}}, {'source_node': {'name': 'UGT2B7'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Aspirin ADME'}}, {'source_node': {'name': 'UGT2B7'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Prednisone ADME'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:22670', 'target': 'GENE:31199', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'PROTEIN:6312', 'target': 'GENE:33464', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_deletion', 'source': 'COMPOUND:22670', 'target': 'PROTEIN:6312', 'metadata': None}]",0.8,04c2147b1d5cae2f5a065fd6128d7ce9,bbf9e652d215a1d4fbdf33fa6a6608c9,"['The drug epiestriol targets several key components including udp-glucuronosyltransferase 2b7, liver microsome, and udp-glucuronosyltransferase 1-3. The protein udp-glucuronosyltransferase 2b7 is a gene product of UGT2B7, which acts within different medication-related pathways such as Aspirin ADME and Prednisone ADME. Similarly, the protein udp-glucuronosyltransferase 1-3 is a gene product of UGT1A3.', 'The estrogen steroid hormone Epiestriol targets several components including the UDP-glucuronosyltransferase 2B7, liver microsome, and UDP-glucuronosyltransferase 1-3. Interestingly, these UDP-glucuronosyltransferases are gene products of UGT2B7 and UGT1A3 respectively. Furthermore, UGT2B7 is known to act within multiple metabolic pathways, notably the Aspirin ADME and Prednisone ADME.', 'The hormone epiestriol has several molecular targets, specifically UDP-glucuronosyltransferase 2B7 (UGT2B7) and UDP-glucuronosyltransferase 1-3 (UGT1A3), as well as liver microsomes. Both UGT2B7 and UGT1A3 are gene products of their respective genes, UGT2B7 and UGT1A3. Furthermore, UGT2B7 acts within various metabolic pathways including aspirin ADME and prednisone ADME, possibly influencing their pharmacokinetics.', 'Epiestriol, a form of estrogen, targets several entities including the enzymes UDP-glucuronosyltransferase 2B7 and UDP-glucuronosyltransferase 1-3, as well as liver microsome, a collection of enzymes that play a key role in the metabolism of drugs. The enzyme UDP-glucuronosyltransferase 2B7 is a gene product of UGT2B7, while UDP-glucuronosyltransferase 1-3 is produced by the gene UGT1A3. Interestingly, UGT2B7 acts within two key drug metabolism pathways: Aspirin ADME and Prednisone ADME. These pathways are involved in the absorption, distribution, metabolism, and excretion (ADME) of drugs like aspirin and prednisone.', 'The compound epiestriol targets several entities, including udp-glucuronosyltransferase 2b7, liver microsome, and udp-glucuronosyltransferase 1-3. The protein udp-glucuronosyltransferase 2b7 is a gene product of UGT2B7, as is udp-glucuronosyltransferase 1-3 of UGT1A3. The gene UGT2B7 acts within two important pathways relevant for drug metabolism and excretion: the Aspirin ADME and Prednisone ADME pathways.']","['Epiestriol, a compound of interest, has multiple targets within the body which include udp-glucuronosyltransferase 2b7, a gene product of UGT2B7, and liver microsomes. Furthermore, epiestriol is also known to affect UGT1A3. Interestingly, UGT2B7 actively functions within two primary pathways, namely Aspirin ADME and Prednisone ADME. It is also pertinent to mention that UGT1A3 is indirectly associated to epiestriol via the intermediary of udp-glucuronosyltransferase 1-3, which happens to be another gene product of UGT2B7 as well as that of UGT1A3. Consequently, udp-glucuronosyltransferase 1-3 acts as a link between UGT1A3 and epiestriol, thereby completing the cycle of interaction.']"
"[{'source_node': {'name': 'guanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'adinazolam'}}, {'source_node': {'name': 'guanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'midazolam'}}]","[{'source_node': {'name': 'adinazolam'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'guanine'}}, {'source_node': {'name': 'adinazolam'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'midazolam'}}, {'source_node': {'name': 'guanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'adinazolam'}}, {'source_node': {'name': 'guanine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'midazolam'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:532', 'target': 'COMPOUND:2250', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'edge_addition', 'source': 'COMPOUND:532', 'target': 'COMPOUND:668', 'metadata': {'predicate': 'increase_efficacy'}}]",0.6,a2ebfb7a90c11002e77064bce4a51292,d9c160077266e646a056b27dac5367ba,"['Guanine has been observed to decrease the efficacy of certain drugs. Notable among these are adinazolam and midazolam, both of which experience reduced effectiveness in the presence of guanine.', 'The compound guanine has been observed to decrease the efficacy of certain drugs like adinazolam and midazolam.', 'The compound guanine is known to decrease the efficacy of certain drugs. Specifically, it can lessen the impact of both adinazolam and midazolam, which implies that it can interfere with the effectiveness of these medications.', 'The presence of guanine has been found to decrease the efficacy of some drugs, including adinazolam and midazolam.', 'The compound guanine is known to decrease the efficacy of certain drugs, including adinazolam and midazolam.']","['The drug adinazolam has been found to increase the efficacy of both guanine and midazolam. However, interestingly, when guanine is administered, it can decrease the efficacy of not only adinazolam but also midazolam.', 'Adinazolam, a well-known medication, notably increases the efficacy of both guanine and midazolam. Interestingly, this occurs despite guanine being known to actually decrease the efficacy of adinazolam and midazolam, indicating the complicated and intricate relationship these substances have with one another.', 'The drug adinazolam is involved in a complex relationship where it increases the efficacy of both guanine and midazolam. Counterintuitively, guanine, instead of enhancing the action of adinazolam, ends up decreasing its efficacy, as well as that of midazolam. This showcases an intricate and paradoxical interplay where an agent could both augment and undermine the efficacy of other components within the same pathway.', 'The drug adinazolam has been shown to increase the efficacy of both guanine and midazolam. However, it is important to note that guanine can decrease the efficacy of adinazolam and midazolam, indicating a complex interaction between these substances.', 'Adinazolam, a pharmaceutical compound, has been found to increase the efficacy of both guanine and midazolam. However, interestingly, guanine then decreases the efficacy of both adinazolam and midazolam, illustrating a complex relationship among these substances.']"
"[{'source_node': {'name': 'microsomal glutathione s-transferase 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'MGST1'}}, {'source_node': {'name': 'MGST1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}]","[{'source_node': {'name': 'MGST1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Neutrophil degranulation'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:455', 'target': None, 'metadata': {'node_id': '455', 'node_type': 'PROTEIN', 'display_name': 'microsomal glutathione s-transferase 1'}}]",0.6,d86dcf3b44b0ec4a61db1c4d4142bb35,0191cb9ce51c40c1f6d125f12b023d0c,"['The enzyme microsomal glutathione s-transferase 1 is a gene product of MGST1. Furthermore, MGST1 operates within the biological pathway of neutrophil degranulation.', 'The protein, microsomal glutathione s-transferase 1, is a gene product of MGST1. Furthermore, MGST1 is known to act within the process of neutrophil degranulation.', 'Microsomal glutathione s-transferase 1 is a gene product of the MGST1 gene. This MGST1 gene operates within the biological process of neutrophil degranulation.', 'The enzyme known as microsomal glutathione s-transferase 1 is a gene product of MGST1. This gene further acts within the process of neutrophil degranulation.']",[]
"[{'source_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'PTPN1'}}, {'source_node': {'name': ""abyssinone-iv-4'-o-methyl ether""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}, {'source_node': {'name': 'PTPN1'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Growth hormone receptor signaling'}}]","[{'source_node': {'name': ""abyssinone-iv-4'-o-methyl ether""}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosine-protein phosphatase non-receptor type 1'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:1054', 'target': None, 'metadata': {'node_id': '1054', 'node_type': 'PATHWAY', 'display_name': 'Growth hormone receptor signaling'}}, {'type': 'node_removal', 'source': 'GENE:32076', 'target': None, 'metadata': {'node_id': '32076', 'node_type': 'GENE', 'display_name': 'PTPN1'}}]",0.4285714285714286,25642c6fbf06c4783943cd590accd260,6c6e26fb8ddfadd0d370da19b4381fd5,[],[]
"[{'source_node': {'name': 'propranolol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}}, {'source_node': {'name': 'iofetamine i-123'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' hypertension '}}, {'source_node': {'name': 'iofetamine i-123'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'metoprolol'}}, {'source_node': {'name': 'iofetamine i-123'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'propranolol'}}, {'source_node': {'name': 'metoprolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ubidecarenone'}}, {'source_node': {'name': 'metoprolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'calcium gluconate'}}, {'source_node': {'name': 'metoprolol'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'sorting nexin 9'}}]","[{'source_node': {'name': 'ubidecarenone'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'metoprolol'}}, {'source_node': {'name': 'propranolol'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'tyrosyl-dna phosphodiesterase 1'}}, {'source_node': {'name': 'iofetamine i-123'}, 'relation': {'name': 'has_effect'}, 'target_node': {'name': ' hypertension '}}, {'source_node': {'name': 'iofetamine i-123'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'propranolol'}}, {'source_node': {'name': 'metoprolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'ubidecarenone'}}, {'source_node': {'name': 'metoprolol'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'calcium gluconate'}}]","[{'type': 'edge_deletion', 'source': 'COMPOUND:8347', 'target': 'COMPOUND:254', 'metadata': None}, {'type': 'edge_addition', 'source': 'COMPOUND:9138', 'target': 'GENE:20159', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'COMPOUND:8205', 'target': 'GENE:20159', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'edge_addition', 'source': 'COMPOUND:8205', 'target': 'COMPOUND:254', 'metadata': {'predicate': 'increase_efficacy'}}, {'type': 'node_removal', 'source': 'GENE:20159', 'target': None, 'metadata': {'node_id': '20159', 'node_type': 'GENE', 'display_name': 'sorting nexin 9'}}]",0.7333333333333334,08befd4b511b3f7bc2c5a9f750f23ed1,bdd3e4370c5378aa1ee84a40325b686b,[],[]
"[{'source_node': {'name': 'tretamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'paroxetine'}}, {'source_node': {'name': 'tretamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methylprednisolone hemisuccinate'}}, {'source_node': {'name': 'tretamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clocortolone acetate'}}]","[{'source_node': {'name': 'tretamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'paroxetine'}}, {'source_node': {'name': 'tretamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'methylprednisolone hemisuccinate'}}, {'source_node': {'name': 'tretamine'}, 'relation': {'name': 'decrease_efficacy'}, 'target_node': {'name': 'clocortolone acetate'}}, {'source_node': {'name': 'paroxetine'}, 'relation': {'name': 'increase_efficacy'}, 'target_node': {'name': 'clocortolone acetate'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:700', 'target': 'COMPOUND:12358', 'metadata': {'predicate': 'increase_efficacy'}}]",0.8571428571428572,374f55159ac00adbc93ddf74a95db161,4cc5d8eb4b72f4eaca02d6afb9117c44,"['The drug tretamine is known to decrease the efficacy of several others, notably paroxetine, methylprednisolone hemisuccinate, and clocortolone acetate. This suggests that interactions between tretamine and these medications could result in less effective treatment outcomes. Therefore, caution is recommended when co-administering these drugs.', 'The drug tretamine decreases the efficacy of several other substances, including paroxetine, methylprednisolone hemisuccinate, and clocortolone acetate. Thus, when these substances are administered in conjunction with tretamine, their expected effects may be reduced.', 'The drug Tretamine is known to decrease the efficacy of various other medications, including Paroxetine, Methylprednisolone Hemisuccinate, and Clocortolone Acetate.', 'The medication Tretamine has been found to decrease the efficacy of several other drugs. Notably, it lessens the effectiveness of Paroxetine, Methylprednisolone Hemisuccinate, and Clocortolone Acetate.', 'The drug tretamine is known to decrease the efficacy of several other medications. Specifically, it reduces the effectiveness of paroxetine, methylprednisolone hemisuccinate, and clocortolone acetate.']","['The drug tretamine is known to decrease the efficacy of paroxetine, methylprednisolone hemisuccinate, and clocortolone acetate. Interestingly, while tretamine reduces the effectiveness of clocortolone acetate, paroxetine actually increases the efficacy of clocortolone acetate.', ""The drug Tretamine has been found to decrease the efficacy of several other medications, including Paroxetine, Methylprednisolone Hemisuccinate, and Clocortolone Acetate. Interestingly, despite tretamine's influence, Paroxetine can in turn increase the efficacy of Clocortolone Acetate. This illustrates the complex dynamics and interactions that can occur between various medications."", 'The drug Tretamine is known to decrease the efficacy of several other drugs. Specifically, it reduces the effectiveness of Paroxetine, Methylprednisolone Hemisuccinate, and Clocortolone Acetate. Interestingly, there is a unique interaction between these drugs. The decreased efficacy of Paroxetine due to Tretamine, remarkably increases the efficacy of Clocortolone Acetate. Thus, the presence of Tretamine influences the complex interaction and performance of these drugs in the body.', 'The drug called tretamine is found to decrease the efficacy of several medications including paroxetine, methylprednisolone hemisuccinate, and clocortolone acetate. However, paradoxically, paroxetine, despite experiencing decrease efficacy from tretamine, has been observed to increase the efficacy of clocortolone acetate.', 'The drug Tretamine is known to decrease the effectiveness of Paroxetine, Methylprednisolone Hemisuccinate, and Clocortolone Acetate. Interestingly, although Tretamine reduces the efficacy of Paroxetine, Paroxetine conversely tends to increase the efficacy of Clocortolone Acetate.']"
"[{'source_node': {'name': 'taccabulin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-ov-3'}}, {'source_node': {'name': 'taccabulin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hela'}}]","[{'source_node': {'name': 'taccabulin a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'sk-ov-3'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4994', 'target': None, 'metadata': {'node_id': '4994', 'node_type': 'PROTEIN', 'display_name': 'hela'}}]",0.6,93de33f6f3180fab6efe04478ce78e9f,e096f9305384f573b531c0b04c2ad060,"['The compound Taccabulin A is known to target SK-OV-3 and HeLa cell lines.', 'The drug Taccabulin A targets both SK-OV-3 and HeLa cells.', 'The drug Taccabulin A has been identified to target two specific cell lines: SK-OV-3 and HeLa.', 'The compound Taccabulin A has been found to target SK-OV-3 and HeLa cell lines.', 'The drug Taccabulin A has been identified as having SK-OV-3 and HeLa cells as targets.']",['The drug Taccabulin A has the cancer cell line SK-OV-3 as a target.']
"[{'source_node': {'name': 'CHD9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Activation of gene expression by SREBF (SREBP)'}}, {'source_node': {'name': 'CHD9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of lipid metabolism by PPARalpha'}}, {'source_node': {'name': 'CHD9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Circadian Clock'}}]","[{'source_node': {'name': 'CHD9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Activation of gene expression by SREBF (SREBP)'}}, {'source_node': {'name': 'CHD9'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Regulation of lipid metabolism by PPARalpha'}}]","[{'type': 'node_removal', 'source': 'PATHWAY:526', 'target': None, 'metadata': {'node_id': '526', 'node_type': 'PATHWAY', 'display_name': 'Circadian Clock'}}]",0.7142857142857143,914623219eccc63cc2228b121ecf16b2,6010bea7d27c2c6b8d53b33506a86800,[],"['The gene CHD9 is observed to act within multiple mechanisms, including the activation of gene expression by SREBF (SREBP), as well as the regulation of lipid metabolism by PPARalpha.', 'The gene CHD9 acts within various biological pathways including the activation of gene expression by SREBF (SREBP) and the regulation of lipid metabolism by PPARalpha.', 'The gene CHD9 plays critical roles within multiple pathways such as the activation of gene expression by SREBF (SREBP) and the regulation of lipid metabolism by PPARalpha.', 'The gene CHD9 plays a role in several metabolic processes. It acts within the process of gene expression activation by SREBF (SREBP) and is also found to contribute to the regulation of lipid metabolism by PPARalpha.', 'The gene CHD9 participates in the activation of gene expression by SREBF (SREBP) and also functions within the regulation of lipid metabolism by PPARalpha.']"
"[{'source_node': {'name': 'cardiac'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypertonia'}}, {'source_node': {'name': 'cardiac'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hearing impairment'}}, {'source_node': {'name': 'cardiac'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'infantile onset'}}]","[{'source_node': {'name': 'cardiac'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'hypertonia'}}, {'source_node': {'name': 'cardiac'}, 'relation': {'name': 'has_phenotype'}, 'target_node': {'name': 'infantile onset'}}]","[{'type': 'node_removal', 'source': 'PHENOTYPE:288', 'target': None, 'metadata': {'node_id': '288', 'node_type': 'PHENOTYPE', 'display_name': 'hearing impairment'}}]",0.7142857142857143,a9b347036f0b74bdfb73411e94bf3f92,5b9619fa766c37bde8dbab7f363b95f2,[],[]
"[{'source_node': {'name': 'prelamin-a/c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'LMNA'}}, {'source_node': {'name': 'LMNA'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'lipodystrophy'}}, {'source_node': {'name': 'LMNA'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'emery-dreifuss muscular dystrophy'}}, {'source_node': {'name': 'LMNA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Initiation of Nuclear Envelope (NE) Reformation'}}, {'source_node': {'name': 'triacetin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'prelamin-a/c'}}, {'source_node': {'name': 'triacetin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'glucocorticoid receptor'}}, {'source_node': {'name': 'triacetin'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'nuclear factor erythroid 2-related factor 2'}}, {'source_node': {'name': 'glucocorticoid receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR3C1'}}]","[{'source_node': {'name': 'prelamin-a/c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'LMNA'}}, {'source_node': {'name': 'prelamin-a/c'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR3C1'}}, {'source_node': {'name': 'nuclear factor erythroid 2-related factor 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'LMNA'}}, {'source_node': {'name': 'LMNA'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'lipodystrophy'}}, {'source_node': {'name': 'LMNA'}, 'relation': {'name': 'acts_within'}, 'target_node': {'name': 'Initiation of Nuclear Envelope (NE) Reformation'}}, {'source_node': {'name': 'glucocorticoid receptor'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'NR3C1'}}, {'source_node': {'name': 'NR3C1'}, 'relation': {'name': 'causes_condition'}, 'target_node': {'name': 'lipodystrophy'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:13383', 'target': 'GENE:29744', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'DISEASE:2121', 'target': None, 'metadata': {'node_id': '2121', 'node_type': 'DISEASE', 'display_name': 'emery-dreifuss muscular dystrophy'}}, {'type': 'edge_addition', 'source': 'PROTEIN:5907', 'target': 'GENE:29744', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'COMPOUND:13383', 'target': 'GENE:28425', 'metadata': {'predicate': 'is_affecting'}}, {'type': 'node_removal', 'source': 'COMPOUND:13383', 'target': None, 'metadata': {'node_id': '13383', 'node_type': 'COMPOUND', 'display_name': 'triacetin'}}, {'type': 'edge_addition', 'source': 'PROTEIN:6154', 'target': 'GENE:28425', 'metadata': {'predicate': 'gene_product_of'}}, {'type': 'edge_addition', 'source': 'GENE:28425', 'target': 'DISEASE:14867', 'metadata': {'predicate': 'causes_condition'}}]",0.4705882352941176,e608779c93e19af189e18e021a452d6a,149d096590806a0c715157874e8acff1,[],"['The protein prelamin-a/c is a gene product of both the LMNA and NR3C1 genes. Similarly, the nuclear factor erythroid 2-related factor 2 is a gene product of LMNA, while the glucocorticoid receptor is a gene product of NR3C1. Interestingly, LMNA is known to cause a condition known as lipodystrophy and it acts within the process of initiation of nuclear envelope (NE) reformation. In parallel, NR3C1 is also associated with the cause of lipodystrophy. These associations reveal intricate relationships between these genes and proteins and how they may contribute to the development of lipodystrophy.']"
"[{'source_node': {'name': 'ustusolate a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}, {'source_node': {'name': 'ustusolate a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hl-60'}}]","[{'source_node': {'name': 'ustusolate a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'a549'}}]","[{'type': 'node_removal', 'source': 'PROTEIN:4951', 'target': None, 'metadata': {'node_id': '4951', 'node_type': 'PROTEIN', 'display_name': 'hl-60'}}]",0.6,ab25dd898f9e87d901e14000a9aab927,13791608ff8a35a1c56ba6aabcaaacd5,"['The compound Ustusolate A has been shown to target two human cell lines: A549 and HL-60.', 'Ustusolate A, a molecule of interest in pharmaceutical research, has been identified as having a number of significant biological targets. It targets A549, a human lung carcinoma cell line commonly used in cancer research. Another target of Ustusolate A is HL-60, a human promyelocytic leukemia cell line used in research on acute promyelocytic leukemia.', 'The compound ustusolate A is known to target multiple cell lines including A549 and HL-60.', 'The compound Ustusolate A targets two specific cell lines, A549 and HL-60.', 'The substance Ustusolate A has been shown to target cells like A549 and HL-60.']",[]
"[{'source_node': {'name': 'botryllamide a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-116'}}, {'source_node': {'name': 'botryllamide a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'atp-binding cassette sub-family g member 2'}}, {'source_node': {'name': 'atp-binding cassette sub-family g member 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ABCG2'}}]","[{'source_node': {'name': 'botryllamide a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'hct-116'}}, {'source_node': {'name': 'botryllamide a'}, 'relation': {'name': 'has_target'}, 'target_node': {'name': 'atp-binding cassette sub-family g member 2'}}, {'source_node': {'name': 'botryllamide a'}, 'relation': {'name': 'is_affecting'}, 'target_node': {'name': 'ABCG2'}}, {'source_node': {'name': 'atp-binding cassette sub-family g member 2'}, 'relation': {'name': 'gene_product_of'}, 'target_node': {'name': 'ABCG2'}}]","[{'type': 'edge_addition', 'source': 'COMPOUND:35884', 'target': 'GENE:35432', 'metadata': {'predicate': 'is_affecting'}}]",0.8571428571428572,7b7e3de99ee72774a8a6181d4e307d4f,314bd09df372fa90276ac3cab7af7566,"['The compound Botryllamide A targets ATP-binding cassette sub-family G member 2 and HCT-116. Furthermore, the ATP-binding cassette sub-family G member 2 is the gene product of ABCG2.', 'The drug Botryllamide A has as its targets not only the HCT-116, but also the ATP-binding cassette sub-family G member 2. Further into its function, it is found that the ATP-binding cassette sub-family G member 2 is actually a gene product of ABCG2.', 'The compound Botryllamide A has been shown to target HCT-116 and ATP-binding cassette sub-family G member 2. Interestingly, the ATP-binding cassette sub-family G member 2 is known to be a gene product of ABCG2.', 'The compound Botryllamide A has targeted effects on both HCT-116 and the ATP-binding cassette sub-family G member 2. The latter, also known as ABCG2, is a gene product of ABCG2.', ""The compound Botryllamide A targets both the HCT-116 and the ATP-Binding Cassette Sub-Family G Member 2. It's important to note that the ATP-Binding Cassette Sub-Family G Member 2 is a gene product of ABCG2.""]","['The compound Botryllamide A targets multiple entities, such as HCT-116 and the ATP-binding cassette sub-family G member 2. Interestingly, Botryllamide A is also known to affect the function of ABCG2, of which the ATP-binding cassette sub-family G member 2 is a gene product.', 'The compound botryllamide A interacts specifically with HCT-116 and the ATP-binding cassette sub-family G member 2. Moreover, botryllamide A also influences the physiological processes mediated by ABCG2. Notably, the ATP-binding cassette sub-family G member 2 is a product of the gene ABCG2.']"
